assay_type,assay_cell_type,cell_id,assay_test_type,assay_category,tissue_id,assay_strain,confidence_score,assay_tax_id,tid,src_id,curated_by,src_assay_id,variant_id,assay_id,assay_subcellular_fraction,doc_id,relationship_type,chembl_id,bao_format,assay_tissue,description,assay_organism
B,,,,,,,8,,12052,1,Autocuration,,,1,,11087,H,CHEMBL615117,BAO_0000019,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,
F,,,,,,,0,,22226,1,Autocuration,,,2,,684,U,CHEMBL615118,BAO_0000219,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,
B,,,,,,,0,,22226,1,Autocuration,,,3,,15453,U,CHEMBL615119,BAO_0000019,,,
B,,,,,,,4,9913.0,104729,1,Autocuration,,,4,,17841,H,CHEMBL615120,BAO_0000249,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,Bos taurus
F,143B,163.0,,,,,1,9606.0,80001,1,Intermediate,,,5,,17430,N,CHEMBL615121,BAO_0000219,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Homo sapiens
F,143B,163.0,,,,,1,9606.0,80001,1,Intermediate,,,6,,17430,N,CHEMBL615122,BAO_0000219,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Homo sapiens
F,143B,163.0,,,,,1,10090.0,80001,1,Intermediate,,,7,,13799,N,CHEMBL615123,BAO_0000219,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,Mus musculus
F,143B,163.0,,,,,1,9606.0,80001,1,Expert,,,8,,17774,N,CHEMBL615124,BAO_0000219,,In vitro cell cytotoxicity was determined against 143B cell line,Homo sapiens
F,143B,163.0,,,,,1,9606.0,80001,1,Intermediate,,,9,,3801,N,CHEMBL615125,BAO_0000219,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,Homo sapiens
F,143B,163.0,,,,,1,9606.0,80001,1,Intermediate,,,10,,17430,N,CHEMBL615126,BAO_0000219,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Homo sapiens
F,143B,163.0,,,,,1,9606.0,80001,1,Intermediate,,,11,,17430,N,CHEMBL615127,BAO_0000219,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Homo sapiens
F,143B,163.0,,,,,1,9606.0,80001,1,Expert,,,12,,17774,N,CHEMBL615128,BAO_0000219,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,Homo sapiens
F,,,,,,,1,1280.0,50185,1,Intermediate,,,13,,11324,N,CHEMBL857900,BAO_0000218,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus
F,,,,,,,1,1280.0,50185,1,Intermediate,,,14,,11324,N,CHEMBL615129,BAO_0000218,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus
F,,,,,,,1,1280.0,50185,1,Intermediate,,,15,,11324,N,CHEMBL615130,BAO_0000218,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus
F,,,,,,,1,1280.0,50185,1,Intermediate,,,16,,11324,N,CHEMBL615131,BAO_0000218,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus
A,,,,,,,9,10116.0,100122,1,Expert,,,17,,11347,D,CHEMBL884521,BAO_0000357,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,Rattus norvegicus
B,,,,,,,8,,12054,1,Autocuration,,,18,,16474,H,CHEMBL615132,BAO_0000357,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),
B,,,,,,,8,,12054,1,Autocuration,,,19,,10091,H,CHEMBL615133,BAO_0000019,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,
B,,,,,,,8,,12054,1,Autocuration,,,20,,16474,H,CHEMBL615134,BAO_0000357,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),
B,,,,,,,8,,12054,1,Autocuration,,,21,,16474,H,CHEMBL615135,BAO_0000357,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),
B,,,,,,,8,,12054,1,Autocuration,,,22,,16474,H,CHEMBL615136,BAO_0000357,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),
B,,,,,,,8,,12054,1,Autocuration,,,23,,16474,H,CHEMBL615137,BAO_0000357,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,
B,,,,,,,8,,12054,1,Autocuration,,,24,,16474,H,CHEMBL615138,BAO_0000357,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,
B,,,,,,,0,,22226,1,Autocuration,,,25,,14352,U,CHEMBL836324,BAO_0000219,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",
B,,,,,,,8,9986.0,12054,1,Autocuration,,,26,,5646,H,CHEMBL615139,BAO_0000357,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,Oryctolagus cuniculus
B,,,,,,,8,9986.0,12054,1,Autocuration,,,27,,5646,H,CHEMBL615140,BAO_0000357,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),Oryctolagus cuniculus
B,,,,,,,8,,12426,1,Autocuration,,,28,,10997,H,CHEMBL615141,BAO_0000219,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,
B,,,,,,,8,3847.0,12054,1,Autocuration,,,29,,6309,H,CHEMBL615142,BAO_0000357,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,soya bean
B,,,,,,,8,3847.0,12054,1,Autocuration,,,30,,167,H,CHEMBL615143,BAO_0000357,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,Glycine max
B,,,,,,,8,3847.0,12054,1,Autocuration,,,31,,167,H,CHEMBL615144,BAO_0000357,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,Glycine max
B,,,,,,,8,3847.0,12054,1,Autocuration,,,32,,11087,H,CHEMBL872867,BAO_0000357,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,Glycine max
B,,,,,,,8,3847.0,12054,1,Autocuration,,,33,,11087,H,CHEMBL615145,BAO_0000357,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,Glycine max
B,,,,,,,8,3847.0,12054,1,Autocuration,,,34,,13622,H,CHEMBL615146,BAO_0000357,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,Glycine max
B,,,,,,,8,3847.0,12054,1,Autocuration,,,35,,13622,H,CHEMBL615147,BAO_0000357,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,Glycine max
A,,,,,,,0,10116.0,22226,1,Autocuration,,,36,,11347,U,CHEMBL615148,BAO_0000019,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,Rattus norvegicus
B,,,,,,,0,562.0,22226,1,Autocuration,,,37,,5926,U,CHEMBL615149,BAO_0000019,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,Escherichia coli
B,,,,,,,0,,22226,1,Autocuration,,,38,,4567,U,CHEMBL615150,BAO_0000019,,Dissociation constant with dimeric 16S rRNA RNA construct B,
B,,,,,,,3,,22222,1,Intermediate,,,39,,3782,M,CHEMBL615151,BAO_0000225,,Dissociation constant towards 16S rRNA construct A,
B,,,,,,,3,,22222,1,Intermediate,,,40,,3782,M,CHEMBL615152,BAO_0000225,,Dissociation constant towards 16S rRNA construct B,
B,,,,,,,3,562.0,100263,1,Expert,,,41,,4466,M,CHEMBL615153,BAO_0000225,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,Escherichia coli
B,,,,,,,3,562.0,100263,1,Expert,,,42,,6592,M,CHEMBL615154,BAO_0000225,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,Escherichia coli
B,,,,,,,8,,13053,1,Autocuration,,,43,,898,H,CHEMBL615155,BAO_0000019,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),
B,,,,,,,8,,13053,1,Autocuration,,,44,,898,H,CHEMBL615156,BAO_0000019,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),
B,,,,,,,8,9606.0,20001,1,Autocuration,,,45,,13163,H,CHEMBL615157,BAO_0000019,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Homo sapiens
B,,,,,,,8,9606.0,20001,1,Autocuration,,,46,,13163,H,CHEMBL615158,BAO_0000019,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Homo sapiens
B,,,,,,,9,10116.0,12971,1,Expert,,,47,,10691,D,CHEMBL615159,BAO_0000019,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Rattus norvegicus
B,,,,,,,9,10116.0,12971,1,Expert,,,48,,10691,D,CHEMBL615172,BAO_0000019,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Rattus norvegicus
B,,,,,,,9,10116.0,12971,1,Expert,,,49,,10691,D,CHEMBL615173,BAO_0000019,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Rattus norvegicus
B,,,,,,,9,10116.0,12971,1,Expert,,,50,,10691,D,CHEMBL615174,BAO_0000019,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Rattus norvegicus
B,,,,,,,8,,13053,1,Autocuration,,,51,,898,H,CHEMBL884518,BAO_0000019,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),
B,,,,,,,8,,11512,1,Autocuration,,,52,,912,H,CHEMBL615175,BAO_0000357,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),
B,,,,,,,8,,11512,1,Autocuration,,,53,,912,H,CHEMBL615176,BAO_0000357,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,
B,,,,,,,8,,11512,1,Autocuration,,,54,,912,H,CHEMBL615177,BAO_0000357,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,
B,,,,,,,5,10116.0,104740,1,Autocuration,,,55,Membranes,15103,D,CHEMBL615178,BAO_0000249,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Rattus norvegicus
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,56,,5116,N,CHEMBL615179,BAO_0000219,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,Homo sapiens
F,Oocytes,,,,,,7,10116.0,104835,1,Autocuration,,,57,,14578,D,CHEMBL615180,BAO_0000219,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,Rattus norvegicus
F,Oocytes,,,,,,7,10116.0,104821,1,Autocuration,,,58,,14578,D,CHEMBL615181,BAO_0000219,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,Rattus norvegicus
F,Oocytes,,,,,,7,10116.0,104848,1,Autocuration,,,59,,14578,D,CHEMBL615182,BAO_0000219,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,Rattus norvegicus
F,1A9,506.0,,,,,1,9606.0,80002,1,Expert,,,60,,4787,N,CHEMBL615183,BAO_0000219,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,61,,4787,N,CHEMBL615184,BAO_0000219,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,62,,3547,N,CHEMBL615185,BAO_0000219,,Cytotoxic activity against human ovarian cancer (1A9) cell line,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,63,,3547,N,CHEMBL615186,BAO_0000219,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,64,,6726,N,CHEMBL615187,BAO_0000219,,Effective dose of compound against replication of 1A9 cell line was evaluated,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Expert,,,65,,3455,N,CHEMBL885343,BAO_0000219,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,66,,5726,N,CHEMBL615188,BAO_0000219,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,67,,5726,N,CHEMBL615189,BAO_0000219,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,68,,5726,N,CHEMBL615190,BAO_0000219,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,69,,3395,N,CHEMBL615191,BAO_0000219,,Inhibitory activity against Taxol resistant 1A9 cell lines,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Expert,,,70,,3415,N,CHEMBL615192,BAO_0000219,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Expert,,,71,,3415,N,CHEMBL827083,BAO_0000219,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Expert,,,72,,17099,N,CHEMBL615193,BAO_0000219,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,73,,17099,N,CHEMBL615194,BAO_0000219,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,74,,17099,N,CHEMBL615195,BAO_0000219,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,Homo sapiens
F,1A9,506.0,,,,,1,9606.0,80002,1,Intermediate,,,75,,17099,N,CHEMBL615196,BAO_0000219,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,Homo sapiens
F,Jurkat,503.0,,,,,1,9606.0,81072,1,Intermediate,,,76,,17721,N,CHEMBL615197,BAO_0000219,,Inhibitory concentration against Jurkat cells,Homo sapiens
F,,,,,,,0,,22226,1,Intermediate,,,77,,1229,U,CHEMBL615198,BAO_0000019,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,
A,,,,,,,9,10116.0,100121,1,Expert,,,78,,11347,D,CHEMBL615199,BAO_0000357,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,Rattus norvegicus
B,,,,,,,8,,11231,1,Expert,,,79,,17117,H,CHEMBL615200,BAO_0000357,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",
B,,,,,,,8,,11231,1,Expert,,,80,,17117,H,CHEMBL615201,BAO_0000357,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",
B,,,,,,,8,,11231,1,Expert,,,81,,17117,H,CHEMBL615202,BAO_0000357,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",
B,,,,,,,8,5476.0,11231,1,Autocuration,,,82,Microsomes,11375,H,CHEMBL615203,BAO_0000251,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Candida albicans
B,,,,,,,8,5476.0,11231,1,Autocuration,,,83,Microsomes,11375,H,CHEMBL615204,BAO_0000251,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Candida albicans
B,,,,,,,8,4932.0,11231,1,Autocuration,,,84,Microsomes,11375,H,CHEMBL615205,BAO_0000251,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Saccharomyces cerevisiae
B,,,,,,,8,4932.0,11231,1,Autocuration,,,85,Microsomes,11375,H,CHEMBL615206,BAO_0000251,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Saccharomyces cerevisiae
B,,,,,2107.0,,8,9823.0,12083,1,Autocuration,,,86,Microsomes,11375,H,CHEMBL615207,BAO_0000251,Liver,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Sus scrofa
B,,,,,,,8,10116.0,11231,1,Autocuration,,,87,,791,H,CHEMBL827084,BAO_0000019,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",Rattus norvegicus
B,,,,,,,8,10116.0,11231,1,Autocuration,,,88,,791,H,CHEMBL615208,BAO_0000019,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",Rattus norvegicus
B,,,,,,,8,10116.0,11231,1,Autocuration,,,89,,791,H,CHEMBL615209,BAO_0000019,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12083,1,Autocuration,,,90,Microsomes,11375,D,CHEMBL615210,BAO_0000251,Liver,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12083,1,Autocuration,,,91,Microsomes,11375,D,CHEMBL615211,BAO_0000251,Liver,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12083,1,Autocuration,,,92,Microsomes,153,D,CHEMBL615212,BAO_0000251,Liver,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Rattus norvegicus
B,,,,,,,8,,11377,1,Expert,,,93,,8269,H,CHEMBL615213,BAO_0000357,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),
B,,,,,,,8,,11377,1,Expert,,,94,,8269,H,CHEMBL615273,BAO_0000357,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,
F,HepG2,726.0,,,,,1,9606.0,81020,1,Expert,,,95,,17653,N,CHEMBL615274,BAO_0000219,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Homo sapiens
F,HepG2,726.0,,,,,1,9606.0,81020,1,Intermediate,,,96,,14277,N,CHEMBL615275,BAO_0000219,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,Homo sapiens
F,HepG2,726.0,,,,,1,9606.0,81020,1,Intermediate,,,97,,1717,N,CHEMBL615276,BAO_0000219,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,Homo sapiens
F,HepG2,726.0,,,,,1,9606.0,81020,1,Intermediate,,,98,,14091,N,CHEMBL615277,BAO_0000219,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,Homo sapiens
F,HepG2,726.0,,,,,1,9606.0,81020,1,Intermediate,,,99,,14091,N,CHEMBL615326,BAO_0000219,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,Homo sapiens
F,,,,,,,1,10407.0,50606,1,Expert,,,100,,17653,N,CHEMBL883130,BAO_0000218,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Hepatitis B virus
F,HepG2,726.0,,,,,1,9606.0,81020,1,Intermediate,,,101,,13105,N,CHEMBL884519,BAO_0000219,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,Homo sapiens
F,HepG2,726.0,,,,,1,9606.0,81020,1,Intermediate,,,102,,1717,N,CHEMBL615327,BAO_0000219,,Concentration required to inhibit 50% of 2.2.15 cell line,Homo sapiens
A,HepG2,726.0,,,,,1,9606.0,81020,1,Intermediate,,,103,,13105,N,CHEMBL615328,BAO_0000219,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,Homo sapiens
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,104,,13600,N,CHEMBL615329,BAO_0000218,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,Homo sapiens
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,105,,13467,N,CHEMBL615330,BAO_0000218,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,Homo sapiens
F,2.2.15,,,,,,1,10407.0,50606,1,Expert,,,106,,17477,N,CHEMBL615331,BAO_0000218,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",Hepatitis B virus
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,107,,1593,N,CHEMBL615332,BAO_0000218,,In vitro anti-HBV activity in 2.2.15 cells,Homo sapiens
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,108,,1593,N,CHEMBL615333,BAO_0000218,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,Homo sapiens
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,109,,15089,N,CHEMBL615334,BAO_0000218,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,Homo sapiens
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,110,,15089,N,CHEMBL615335,BAO_0000218,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,Homo sapiens
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,111,,1593,N,CHEMBL615336,BAO_0000218,,Cytotoxicity in 2.2.15 cells,Homo sapiens
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,112,,1593,N,CHEMBL615337,BAO_0000218,,Cytotoxicity in 2.2.15 cells; Not determined,Homo sapiens
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,113,,13600,N,CHEMBL615338,BAO_0000218,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,Homo sapiens
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,114,,13467,N,CHEMBL615339,BAO_0000218,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,Homo sapiens
F,2.2.15,,,,,,1,9606.0,50587,1,Intermediate,,,115,,13467,N,CHEMBL615340,BAO_0000218,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,Homo sapiens
F,HepG2,726.0,,,,,1,9606.0,81020,1,Intermediate,,,116,,14764,N,CHEMBL615341,BAO_0000219,,Antiviral activity against HBV was determined in 2.215 cell line,Homo sapiens
B,,,,,,,0,9606.0,22226,1,Autocuration,,,117,Microsomes,6531,U,CHEMBL615342,BAO_0000251,,Inhibition of 20-HETE synthesis in human renal microsomes,Homo sapiens
B,,,,,,,0,,22226,1,Autocuration,,,118,,17322,U,CHEMBL615343,BAO_0000019,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,
F,2008,388.0,,,,,1,9606.0,80612,1,Intermediate,,,119,,17072,N,CHEMBL615344,BAO_0000219,,Inhibitory concentration against 2008 (ovarian) cells,Homo sapiens
F,2008,388.0,,,,,1,9606.0,80612,1,Intermediate,,,120,,16936,N,CHEMBL615345,BAO_0000219,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,Homo sapiens
F,2008,388.0,,,,,1,9606.0,80612,1,Intermediate,,,121,,16936,N,CHEMBL615346,BAO_0000219,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),Homo sapiens
F,2008,388.0,,,,,1,9606.0,80612,1,Intermediate,,,122,,17146,N,CHEMBL615347,BAO_0000219,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,Homo sapiens
F,2008,388.0,,,,,1,9606.0,80612,1,Intermediate,,,123,,17146,N,CHEMBL615348,BAO_0000219,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,Homo sapiens
F,2008/R,561.0,,,,,1,9606.0,80613,1,Intermediate,,,124,,10797,N,CHEMBL827085,BAO_0000219,,In vitro inhibition of 2008/R ovarian cancer cell line,Homo sapiens
F,2008/R,561.0,,,,,1,9606.0,80613,1,Intermediate,,,125,,10797,N,CHEMBL615349,BAO_0000219,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,Homo sapiens
F,2008/S,389.0,,,,,1,9606.0,80614,1,Intermediate,,,126,,10797,N,CHEMBL615350,BAO_0000219,,In vitro inhibition of 2008/S ovarian cancer cell line,Homo sapiens
F,2008/S,389.0,,,,,1,9606.0,80614,1,Intermediate,,,127,,10797,N,CHEMBL615351,BAO_0000219,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,Homo sapiens
B,,,,,,,2,9606.0,100256,1,Expert,,,128,,4823,S,CHEMBL615352,BAO_0000220,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,Homo sapiens
B,,,,,,,2,9606.0,100256,1,Intermediate,,,129,,12912,S,CHEMBL615353,BAO_0000220,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,Homo sapiens
B,,,,,,,2,,100256,1,Expert,,,130,,2957,S,CHEMBL615354,BAO_0000220,,Inhibition of chymotrypsin-like activity of 20S proteasome,
B,,,,,,,2,,100256,1,Expert,,,131,,2957,S,CHEMBL615355,BAO_0000220,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,
B,,,,,,,2,,100256,1,Intermediate,,,132,,3260,S,CHEMBL615356,BAO_0000220,,Inhibitory activity against 20S proteosome,
B,,,,,,,0,9606.0,22226,1,Autocuration,,,133,,3451,U,CHEMBL615357,BAO_0000019,,Compound was tested for inhibitory activity against tryptase,Homo sapiens
F,HepG2,726.0,,,,,1,9606.0,81020,1,Intermediate,,,134,,13885,N,CHEMBL615358,BAO_0000219,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,Homo sapiens
F,HepG2,726.0,,,,,1,9606.0,81020,1,Intermediate,,,135,,13885,N,CHEMBL827086,BAO_0000219,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,Homo sapiens
B,,,,,,,0,,22226,1,Autocuration,,,136,,3676,U,CHEMBL615359,BAO_0000019,,Compound was tested for the inhibition of Alpha-glucosidase,
B,,,,,,,8,,235,1,Autocuration,,,137,,6043,H,CHEMBL615360,BAO_0000357,,Inhibitory concentration against human neutrophil elastase (HNE),
F,,,,,948.0,,0,10116.0,22226,1,Autocuration,,,138,,11140,U,CHEMBL615361,BAO_0000218,Heart,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Rattus norvegicus
F,,,,,,,8,,19640,1,Autocuration,,,139,,10543,H,CHEMBL615362,BAO_0000019,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,
F,,,,,,,8,,19640,1,Expert,,,140,,10543,H,CHEMBL615363,BAO_0000019,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,
B,,,,,,,8,,19640,1,Autocuration,,,141,,10543,H,CHEMBL615364,BAO_0000357,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,
F,,,,,,,8,,19640,1,Expert,,,142,,10543,H,CHEMBL615365,BAO_0000019,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,
F,P338,524.0,,,,,1,10090.0,80360,1,Intermediate,,,143,,11365,N,CHEMBL615366,BAO_0000219,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,Mus musculus
F,P338,524.0,,,,,1,10090.0,80360,1,Intermediate,,,144,,11365,N,CHEMBL615367,BAO_0000219,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,Mus musculus
F,PBL,554.0,,,,,1,9606.0,80384,1,Intermediate,,,145,,11803,N,CHEMBL615368,BAO_0000219,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,Homo sapiens
F,,,,,,,0,9940.0,22226,1,Autocuration,,,146,,11803,U,CHEMBL615369,BAO_0000019,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,Ovis aries
F,,,,,,,0,9940.0,22226,1,Autocuration,,,147,,11803,U,CHEMBL615370,BAO_0000019,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,Ovis aries
B,,,,,,,8,,191,1,Autocuration,,,148,,12278,H,CHEMBL615673,BAO_0000357,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),
F,,,,,,,0,9606.0,22226,1,Autocuration,,,149,,8249,U,CHEMBL615674,BAO_0000019,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,Homo sapiens
F,,,,,,,0,9606.0,22226,1,Autocuration,,,150,,8249,U,CHEMBL615675,BAO_0000019,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,Homo sapiens
F,CCRF-CEM,635.0,,,,,0,9606.0,22226,1,Autocuration,,,151,,8249,U,CHEMBL615676,BAO_0000219,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,Homo sapiens
F,CCRF-CEM,635.0,,,,,0,9606.0,22226,1,Autocuration,,,152,,8249,U,CHEMBL615677,BAO_0000219,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,Homo sapiens
F,CCRF-CEM,635.0,,,,,0,9606.0,22226,1,Autocuration,,,153,,8249,U,CHEMBL615678,BAO_0000219,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,Homo sapiens
F,CCRF-CEM,635.0,,,,,0,9606.0,22226,1,Autocuration,,,154,,8249,U,CHEMBL615679,BAO_0000219,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,Homo sapiens
F,,,,,,,0,9606.0,22226,1,Autocuration,,,155,,8249,U,CHEMBL615680,BAO_0000019,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,Homo sapiens
F,,,,,,,0,9606.0,22226,1,Autocuration,,,156,,8249,U,CHEMBL615681,BAO_0000019,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,Homo sapiens
B,,,,,,,6,,104290,1,Autocuration,,,157,,16992,H,CHEMBL857972,BAO_0000249,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,
F,,,,,,,1,1314.0,50264,1,Intermediate,,,158,,10543,N,CHEMBL857899,BAO_0000218,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,Streptococcus pyogenes
F,,,,,,,1,10335.0,50527,1,Intermediate,,,159,,17833,N,CHEMBL615371,BAO_0000218,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),Human herpesvirus 3
F,HEL,468.0,,,,,1,10335.0,50527,1,Expert,,,160,,17290,N,CHEMBL615372,BAO_0000218,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,vericilla zoster virus
F,,,,,,,1,10335.0,50527,1,Intermediate,,,161,,17290,N,CHEMBL615373,BAO_0000218,,Antiviral activity against 07/1 strain of VZV; ND: No data,vericilla zoster virus
F,,,,,,,1,10335.0,50527,1,Intermediate,,,162,,17290,N,CHEMBL615374,BAO_0000218,,Antiviral activity against 07/1 strain of VZV; ND=No data,vericilla zoster virus
F,,,,,,,1,561.0,50145,1,Intermediate,,,163,,10932,N,CHEMBL615375,BAO_0000218,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",escherichia cloac
B,,,,,,,0,,22226,1,Autocuration,,,164,,9707,U,CHEMBL615376,BAO_0000019,,Ratio of Ki at A2 to Ki at A1 receptors,
B,,,,,,,8,5476.0,11143,1,Expert,,,165,,2346,H,CHEMBL615377,BAO_0000249,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",Candida albicans
B,,,,,,,8,284593.0,18077,1,Expert,,,166,,2205,H,CHEMBL615378,BAO_0000357,,"Inhibition of 1,3-beta-glucan synthase",Candida glabrata CBS 138
F,1-87 tumor cell line,832.0,,,,,1,9606.0,80609,1,Intermediate,,,167,,11900,N,CHEMBL615379,BAO_0000219,,Inhibition of growth of 1-87 human tumor cell line,Homo sapiens
B,,,,,,,9,10116.0,12166,1,Expert,,,168,,14864,D,CHEMBL615380,BAO_0000219,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,Rattus norvegicus
B,,,,,,,9,3847.0,100171,1,Autocuration,,,169,,16474,D,CHEMBL615381,BAO_0000357,,Inhibitory activity against soybean 1-lipoxygenase (SLO),Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,170,,16474,D,CHEMBL615382,BAO_0000357,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,171,,16474,D,CHEMBL615383,BAO_0000357,,% inhibition against soybean 1-lipoxygenase (SLO),Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,172,,16474,D,CHEMBL615384,BAO_0000357,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,173,,3094,D,CHEMBL615385,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,174,,3094,D,CHEMBL615386,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,175,,3094,D,CHEMBL615387,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,176,,3094,D,CHEMBL615388,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,177,,3094,D,CHEMBL615214,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,178,,3094,D,CHEMBL827087,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,179,,3094,D,CHEMBL615215,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,180,,3094,D,CHEMBL615216,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,181,,3094,D,CHEMBL615217,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,182,,3094,D,CHEMBL615218,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,Glycine max
B,,,,,,,9,3847.0,100171,1,Autocuration,,,183,,3094,D,CHEMBL615219,BAO_0000357,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,Glycine max
B,,,,,,,0,10090.0,22226,1,Autocuration,,,184,,10413,U,CHEMBL615220,BAO_0000019,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,Mus musculus
F,C3H 10T1/2,294.0,,,,,1,10090.0,80049,1,Intermediate,,,185,,16929,N,CHEMBL615221,BAO_0000219,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),Mus musculus
F,,,,,,,0,,22226,1,Intermediate,,,186,,1229,U,CHEMBL615222,BAO_0000019,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,
B,,,,,,,8,,11489,1,Autocuration,,,187,,16587,H,CHEMBL615223,BAO_0000357,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),
B,,,,,,,8,,11862,1,Autocuration,,,188,,16587,H,CHEMBL615224,BAO_0000357,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),
B,,,,,,,8,,11862,1,Autocuration,,,189,,16587,H,CHEMBL615225,BAO_0000357,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,
B,,,,,,,8,,11489,1,Autocuration,,,190,,16587,H,CHEMBL615226,BAO_0000357,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,
B,,,,,,,8,,11862,1,Autocuration,,,191,,16587,H,CHEMBL615227,BAO_0000357,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,
F,,,,,,,9,9913.0,12347,1,Expert,,,192,,8058,D,CHEMBL615228,BAO_0000019,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,Bos taurus
B,,,,,,,9,10116.0,100120,1,Expert,,,193,,9065,D,CHEMBL615229,BAO_0000357,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,Rattus norvegicus
B,,,,,2369.0,,9,10116.0,100120,1,Expert,,,194,,8865,D,CHEMBL615230,BAO_0000357,Adrenal gland,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Rattus norvegicus
B,,,,,,,9,10116.0,100120,1,Expert,,,195,,9066,D,CHEMBL615231,BAO_0000357,,Inhibition of rat adrenal 11-beta-hydroxylase,Rattus norvegicus
B,,,,,,,9,10116.0,100120,1,Expert,,,196,,8394,D,CHEMBL884520,BAO_0000357,,Inhibition of rat adrenal 11-beta-hydroxylase,Rattus norvegicus
B,,,,,,,9,10116.0,100120,1,Expert,,,197,,8394,D,CHEMBL615232,BAO_0000357,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,Rattus norvegicus
B,,,,,,,8,,10328,1,Autocuration,,,198,,6431,H,CHEMBL615233,BAO_0000019,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,
B,,,,,,,8,,11490,1,Autocuration,,,199,,6431,H,CHEMBL827088,BAO_0000357,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,
B,,,,,,,8,,11490,1,Autocuration,,,200,,6431,H,CHEMBL615234,BAO_0000357,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,
F,,,,,,,8,,11134,1,Autocuration,,,201,,9295,H,CHEMBL615235,BAO_0000019,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,
B,,,,,,,8,,12052,1,Autocuration,,,202,,10193,H,CHEMBL615236,BAO_0000019,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,
B,,,,,,,8,,11134,1,Autocuration,,,203,,13622,H,CHEMBL615237,BAO_0000019,,Compound was tested in vitro for inhibition of 12-LO human platelet,
F,,,,,,,8,,11134,1,Autocuration,,,204,,12079,H,CHEMBL615238,BAO_0000019,,Inhibitory concentration against human platelet 12-lipoxygenase,
B,,,,,,,8,,11134,1,Autocuration,,,205,,13622,H,CHEMBL615239,BAO_0000019,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,
F,,,,,,,9,9606.0,11134,1,Autocuration,,,206,,12079,D,CHEMBL615240,BAO_0000019,,Inhibitory concentration against human platelet 12-lipoxygenase,Homo sapiens
B,,,,,,,8,,11835,1,Expert,,,207,,13500,H,CHEMBL615241,BAO_0000019,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,
B,,,,,,,8,,11601,1,Expert,,,208,,13723,H,CHEMBL615242,BAO_0000357,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,
B,,,,,,,8,,11134,1,Autocuration,,,209,,16474,H,CHEMBL615243,BAO_0000019,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),
B,,,,,,,8,,11134,1,Autocuration,,,210,,1630,H,CHEMBL615244,BAO_0000019,,Inhibitory activity against human platelet 12-lipoxygenase,
B,,,,,,,8,,11134,1,Autocuration,,,211,,167,H,CHEMBL615245,BAO_0000019,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,
B,,,,,,,8,,11134,1,Autocuration,,,212,,16474,H,CHEMBL615246,BAO_0000019,,% inhibition against human platelet 12-lipoxygenase (12-HLO),
B,,,,,,,8,,11134,1,Autocuration,,,213,,167,H,CHEMBL615247,BAO_0000019,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,
B,,,,,,,8,,11134,1,Autocuration,,,214,,16474,H,CHEMBL615248,BAO_0000019,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,
B,,,,,,,8,,11601,1,Autocuration,,,215,,10091,H,CHEMBL615249,BAO_0000357,,Inhibitory activity towards porcine 12-lipoxygenase,
B,,,,,,,8,,11601,1,Autocuration,,,216,,11966,H,CHEMBL615250,BAO_0000357,,Tested for inhibition against porcine 12-LO,
B,,,,,,,8,,12052,1,Autocuration,,,217,,951,H,CHEMBL615251,BAO_0000019,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,
B,,,,,,,8,,12052,1,Autocuration,,,218,,10997,H,CHEMBL615252,BAO_0000019,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,
B,,,,,,,8,,12052,1,Expert,,,219,,10193,H,CHEMBL828340,BAO_0000019,,In vitro inhibition of rat platelet 12-lipoxygenase,
B,,,,,,,8,,12052,1,Autocuration,,,220,,10193,H,CHEMBL615253,BAO_0000019,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,
B,,,,,,,8,,12052,1,Autocuration,,,221,,10193,H,CHEMBL615254,BAO_0000019,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,
B,,,,,,,8,,12052,1,Autocuration,,,222,,10193,H,CHEMBL615255,BAO_0000019,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,
B,,,,,,,8,,12052,1,Autocuration,,,223,,10193,H,CHEMBL615256,BAO_0000019,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,
B,,,,,,,8,,12052,1,Autocuration,,,224,,10193,H,CHEMBL615257,BAO_0000019,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,
B,,,,,,,8,,12052,1,Autocuration,,,225,,11087,H,CHEMBL615258,BAO_0000019,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,
F,41M,621.0,,,,,1,9606.0,80007,1,Intermediate,,,226,,15569,N,CHEMBL615259,BAO_0000219,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,Homo sapiens
F,41M,621.0,,,,,1,9606.0,80007,1,Expert,,,227,,12989,N,CHEMBL615260,BAO_0000219,,In vitro antitumor activity against 41M cell line.,Homo sapiens
F,41M,621.0,,,,,1,9606.0,80007,1,Intermediate,,,228,,16745,N,CHEMBL615261,BAO_0000219,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,Homo sapiens
F,41M,621.0,,,,,1,9606.0,80007,1,Intermediate,,,229,,15569,N,CHEMBL615262,BAO_0000219,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,Homo sapiens
F,41M,621.0,,,,,1,9606.0,80007,1,Expert,,,230,,12989,N,CHEMBL615263,BAO_0000219,,In vitro antitumor activity against 41McisR cell line.,Homo sapiens
F,41M,621.0,,,,,1,9606.0,80007,1,Expert,,,231,,12989,N,CHEMBL838393,BAO_0000219,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,Homo sapiens
F,41M,621.0,,,,,1,9606.0,80007,1,Intermediate,,,232,,16745,N,CHEMBL615264,BAO_0000219,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,Homo sapiens
B,,,,,,,9,9606.0,84,1,Expert,,,233,,6210,D,CHEMBL615265,BAO_0000357,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),Homo sapiens
B,,,,,,,9,9606.0,68,1,Expert,,,234,,6210,D,CHEMBL615266,BAO_0000357,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Homo sapiens
B,,,,,,,8,,68,1,Expert,,,235,,6226,H,CHEMBL615267,BAO_0000357,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),
B,,,,,,,8,,10201,1,Expert,,,236,,17855,H,CHEMBL615268,BAO_0000357,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,
B,,,,,,,8,,10201,1,Expert,,,237,,17855,H,CHEMBL615269,BAO_0000357,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,
B,,,,,,,8,,10201,1,Expert,,,238,,17855,H,CHEMBL615270,BAO_0000357,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,
B,,,,,,,8,,12220,1,Autocuration,,,239,,10413,H,CHEMBL615271,BAO_0000357,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",
B,,,,,,,8,562.0,11303,1,Autocuration,,,240,,10413,H,CHEMBL615272,BAO_0000357,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Escherichia coli
B,,,,,,,8,562.0,11303,1,Autocuration,,,241,,10413,H,CHEMBL615103,BAO_0000357,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Escherichia coli
B,,,,,,,8,562.0,11303,1,Autocuration,,,242,,10413,H,CHEMBL615104,BAO_0000357,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",Escherichia coli
B,,,,,,,8,,12220,1,Autocuration,,,243,,10413,H,CHEMBL615105,BAO_0000357,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",
B,,,,,,,8,,12220,1,Autocuration,,,244,,10413,H,CHEMBL872866,BAO_0000357,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",
B,,,,,,,8,9823.0,11303,1,Autocuration,,,245,,7587,H,CHEMBL615106,BAO_0000357,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,246,,7587,H,CHEMBL615107,BAO_0000019,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,247,,7587,H,CHEMBL615108,BAO_0000357,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,248,,7587,H,CHEMBL615109,BAO_0000357,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,249,,7587,H,CHEMBL615110,BAO_0000357,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,250,,7587,H,CHEMBL840105,BAO_0000019,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,251,,7587,H,CHEMBL615111,BAO_0000019,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,252,,7587,H,CHEMBL615112,BAO_0000019,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,253,,7587,H,CHEMBL615113,BAO_0000019,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,254,,7587,H,CHEMBL615114,BAO_0000019,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,255,,7587,H,CHEMBL615115,BAO_0000357,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa
B,,,,,,,8,9823.0,11303,1,Autocuration,,,256,,7587,H,CHEMBL615116,BAO_0000019,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Sus scrofa
B,,,,,,,8,,11303,1,Autocuration,,,257,,7323,H,CHEMBL615698,BAO_0000357,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",
B,,,,,,,0,9823.0,22226,1,Autocuration,,,258,,7587,U,CHEMBL615699,BAO_0000019,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",Sus scrofa
B,,,,,,,0,9823.0,22226,1,Autocuration,,,259,,7587,U,CHEMBL615700,BAO_0000019,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",Sus scrofa
B,,,,,,,8,4932.0,100249,1,Expert,,,260,,13750,H,CHEMBL615701,BAO_0000357,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,Saccharomyces cerevisiae
B,,,,,,,0,10116.0,22226,1,Autocuration,,,261,,7662,U,CHEMBL615702,BAO_0000019,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Rattus norvegicus
B,,,,,,,0,10116.0,22226,1,Autocuration,,,262,,7662,U,CHEMBL615703,BAO_0000019,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Rattus norvegicus
B,,,,,,,0,10116.0,22226,1,Autocuration,,,263,,7662,U,CHEMBL615704,BAO_0000019,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",Rattus norvegicus
F,,,,,,,6,,104698,1,Autocuration,,,264,,12211,H,CHEMBL615705,BAO_0000019,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",
F,,,,,,,6,,104698,1,Autocuration,,,265,,12211,H,CHEMBL615706,BAO_0000019,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,266,,12211,D,CHEMBL615707,BAO_0000221,Ileum,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Cavia porcellus
F,,,,,,,8,,10623,1,Expert,,,267,,12211,H,CHEMBL615708,BAO_0000019,,Stimulatory activity of intragastric pressure was tested in the rat,
B,,,,,,,8,,121,1,Autocuration,,,268,,15453,H,CHEMBL615709,BAO_0000357,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,
F,,,,,,,0,10116.0,22226,1,Autocuration,,,269,,11884,U,CHEMBL615710,BAO_0000218,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),Rattus norvegicus
F,,,,,,,8,,12688,1,Autocuration,,,270,,7185,H,CHEMBL615711,BAO_0000019,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,
B,,,,,,,9,9606.0,121,1,Expert,,,271,,6876,D,CHEMBL615712,BAO_0000357,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,Homo sapiens
B,,,,,,,9,9606.0,121,1,Expert,,,272,,6876,D,CHEMBL836325,BAO_0000357,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,Homo sapiens
F,,,,,,,8,,12198,1,Autocuration,,,273,,11863,H,CHEMBL615713,BAO_0000019,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,
B,,,,,,,8,,12198,1,Autocuration,,,274,,11863,H,CHEMBL615714,BAO_0000357,,Inhibition constant of high-affinity 5-HT uptake,
F,,,,,,,8,,12198,1,Autocuration,,,275,,11863,H,CHEMBL615715,BAO_0000019,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,
F,,,,,,,8,,12198,1,Autocuration,,,276,,11863,H,CHEMBL615716,BAO_0000019,,Maximum rate was determined for high affinity transport of 5-HT,
F,,,,,,,4,,104714,1,Autocuration,,,277,,4639,H,CHEMBL615717,BAO_0000019,,Compound was tested for agonistic activity against 5-HT uptake,
B,,,,,,,8,,10577,1,Expert,,,278,,15796,H,CHEMBL881818,BAO_0000019,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,
B,,,,,,,8,9913.0,105,1,Expert,,,279,,15796,H,CHEMBL884540,BAO_0000357,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,Bos taurus
B,,,,,,,5,10116.0,104744,1,Autocuration,,,280,,12801,D,CHEMBL615718,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Rattus norvegicus
B,,,,,,,4,,104744,1,Autocuration,,,281,,12801,H,CHEMBL615719,BAO_0000224,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,
B,,,,,,,4,,104744,1,Autocuration,,,282,Membranes,12120,H,CHEMBL615720,BAO_0000249,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,
B,,,,,,,4,,104744,1,Autocuration,,,283,Membranes,12120,H,CHEMBL615721,BAO_0000249,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,
B,,,,,,,4,,104744,1,Autocuration,,,284,,11963,H,CHEMBL615722,BAO_0000019,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,
F,,,,,,,8,,51,1,Autocuration,,,285,,11701,H,CHEMBL615723,BAO_0000019,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,286,,9995,H,CHEMBL615724,BAO_0000221,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,287,,9995,H,CHEMBL615725,BAO_0000221,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,288,,9995,H,CHEMBL615726,BAO_0000221,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,
F,,,In vivo,,,,8,,10576,1,Autocuration,,,289,,16394,H,CHEMBL615727,BAO_0000218,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),
F,,,,,,,9,10141.0,105570,1,Intermediate,,,290,,11574,D,CHEMBL615728,BAO_0000019,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,Cavia porcellus
B,CHO,449.0,,,,,8,,279,1,Autocuration,,,291,,15779,H,CHEMBL857971,BAO_0000219,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,
B,,,,,,,8,,107,1,Autocuration,,,292,,15363,H,CHEMBL615729,BAO_0000357,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,
F,,,,,,,9,10116.0,12687,1,Expert,,,293,,15363,D,CHEMBL615730,BAO_0000019,,Efficacy against 5-hydroxytryptamine 2A receptor,Rattus norvegicus
F,,,,,,,8,,12687,1,Expert,,,294,,15329,H,CHEMBL615731,BAO_0000019,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,
F,,,,,,,8,,12687,1,Expert,,,295,,15329,H,CHEMBL615732,BAO_0000019,,Relative potency towards 5-HT2A receptor of rat tail artery,
F,,,,,,,8,,12687,1,Expert,,,296,,15329,H,CHEMBL615733,BAO_0000019,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,
F,,,,,,,8,,12687,1,Expert,,,297,,15329,H,CHEMBL615734,BAO_0000019,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,
F,,,,,,,8,,12687,1,Autocuration,,,298,,15329,H,CHEMBL615735,BAO_0000019,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,
F,,,,,,,8,,12687,1,Expert,,,299,,15329,H,CHEMBL615736,BAO_0000019,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,300,,273,D,CHEMBL615737,BAO_0000221,Ileum,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,301,,273,D,CHEMBL615738,BAO_0000221,Ileum,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,302,,273,D,CHEMBL615739,BAO_0000221,Ileum,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus
B,,,,,,,8,,10623,1,Autocuration,,,303,,12092,H,CHEMBL615278,BAO_0000357,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,
F,,,,,,,9,10116.0,10623,1,Expert,,,304,,1317,D,CHEMBL615279,BAO_0000019,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Rattus norvegicus
B,,,,,,,8,,168,1,Expert,,,305,,12409,H,CHEMBL615280,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 4 receptor,
B,,,,,,,0,9031.0,22226,1,Autocuration,,,306,,11126,U,CHEMBL615281,BAO_0000019,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,Gallus gallus
F,,,,,,,0,9606.0,22226,1,Autocuration,,,307,,11126,U,CHEMBL615282,BAO_0000019,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,Homo sapiens
F,,,,,,,0,9606.0,22226,1,Autocuration,,,308,,11126,U,CHEMBL615283,BAO_0000019,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,Homo sapiens
B,HL-60,649.0,,,,,1,9606.0,80156,1,Autocuration,,,309,,11126,N,CHEMBL615284,BAO_0000219,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,Homo sapiens
B,,,,,,,0,9606.0,22226,1,Autocuration,,,310,,11126,U,CHEMBL615285,BAO_0000019,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,Homo sapiens
B,,,,,,,0,9606.0,22226,1,Autocuration,,,311,,11126,U,CHEMBL615286,BAO_0000019,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,Homo sapiens
B,Oocytes,,,,,,7,9606.0,104703,1,Autocuration,,,312,,17807,D,CHEMBL615287,BAO_0000219,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,Homo sapiens
F,,,,,,,2,,100256,1,Intermediate,,,313,,16575,S,CHEMBL615288,BAO_0000220,,Chymotryptic inhibitory activity against 26S proteasome,
B,,,,,,,2,,100256,1,Intermediate,,,314,,15407,S,CHEMBL615289,BAO_0000220,,Inhibitory activity against 26S proteasome degradation of IkB,
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,315,,10797,N,CHEMBL615290,BAO_0000219,,In vitro inhibition of 2780/DOX ovarian cancer cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,316,,10797,N,CHEMBL884522,BAO_0000219,,In vitro inhibition of 2780/S ovarian cancer cell line,Homo sapiens
F,,,,,,,0,9606.0,22226,1,Autocuration,,,317,,3469,U,CHEMBL615291,BAO_0000019,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,Homo sapiens
B,,,,,,,3,,22222,1,Intermediate,,,318,,16037,M,CHEMBL615292,BAO_0000225,,Association constant for binding to AATT 28-mer AATT hairpin,
B,,,,,,,3,,22222,1,Intermediate,,,319,,16037,M,CHEMBL615293,BAO_0000225,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,
B,,,,,,,3,,22222,1,Intermediate,,,320,,16037,M,CHEMBL615294,BAO_0000225,,Reaction Rate Parameter for 28-mer AATT hairpin,
B,,,,,,,3,,22222,1,Intermediate,,,321,,16037,M,CHEMBL615295,BAO_0000225,,Reaction Rate Parameter for 28-mer AATT hairpin,
F,,,,,,,0,9606.0,22226,1,Autocuration,,,322,,16524,U,CHEMBL825021,BAO_0000019,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),Homo sapiens
F,,,,,,,0,9606.0,22226,1,Autocuration,,,323,,16524,U,CHEMBL615296,BAO_0000019,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),Homo sapiens
F,,,,,,,0,9606.0,22226,1,Autocuration,,,324,,16524,U,CHEMBL615297,BAO_0000019,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,Homo sapiens
F,,,,,,,0,10029.0,22226,1,Autocuration,,,325,,16758,U,CHEMBL615298,BAO_0000019,,Cytotoxicity against cell line 2SC/20 determined by MTT test,Cricetulus griseus
F,,,,,,,0,10029.0,22226,1,Autocuration,,,326,,16758,U,CHEMBL615299,BAO_0000019,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,Cricetulus griseus
F,,,,,,,0,10029.0,22226,1,Autocuration,,,327,,16758,U,CHEMBL615300,BAO_0000019,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Cricetulus griseus
B,,,,,,,8,,241,1,Autocuration,,,328,,14360,H,CHEMBL615301,BAO_0000357,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,
B,,,,,,,9,9606.0,241,1,Expert,,,329,,14360,D,CHEMBL615302,BAO_0000357,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,Homo sapiens
B,,,,,,,0,10116.0,22226,1,Autocuration,,,330,,9964,U,CHEMBL615303,BAO_0000019,,Selectivity ratio of ID50 in liver and heart,Rattus norvegicus
B,,,,,,,8,,12132,1,Autocuration,,,331,,9964,H,CHEMBL615304,BAO_0000019,,"Selectivity, ratio of relative ID50 in liver and heart",
B,,,,,,,8,,12132,1,Autocuration,,,332,,9964,H,CHEMBL615305,BAO_0000019,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,
B,,,,,,,8,,12132,1,Autocuration,,,333,,9964,H,CHEMBL615306,BAO_0000218,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",
B,,,,,,,8,,12132,1,Autocuration,,,334,,9964,H,CHEMBL615307,BAO_0000218,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",
B,,,In vivo,,,,8,,12132,1,Autocuration,,,335,,9964,H,CHEMBL615308,BAO_0000218,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",
F,,,In vivo,,,,8,,12132,1,Autocuration,,,336,,9964,H,CHEMBL615309,BAO_0000218,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",
B,,,,,,,0,,22226,1,Autocuration,,,337,,9964,U,CHEMBL615310,BAO_0000019,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",
B,,,,,,,8,,12132,1,Autocuration,,,338,,9964,H,CHEMBL615311,BAO_0000019,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,
B,,,,,,,0,9606.0,22226,1,Autocuration,,,339,,9964,U,CHEMBL615312,BAO_0000019,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",Homo sapiens
B,,,,,,,8,,12132,1,Autocuration,,,340,,9964,H,CHEMBL615313,BAO_0000019,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,
F,,,,,,,8,,12132,1,Autocuration,,,341,,9964,H,CHEMBL615314,BAO_0000019,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,
B,,,,,,,8,,12132,1,Autocuration,,,342,,9964,H,CHEMBL615315,BAO_0000019,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",
B,,,,,,,0,10116.0,22226,1,Autocuration,,,343,,9964,U,CHEMBL615316,BAO_0000218,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",Rattus norvegicus
B,,,In vivo,,,,8,,12132,1,Autocuration,,,344,,9964,H,CHEMBL615317,BAO_0000218,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,
B,,,,,,,8,,12132,1,Autocuration,,,345,,9964,H,CHEMBL615318,BAO_0000218,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",
B,,,,,,,0,10116.0,22226,1,Autocuration,,,346,,9964,U,CHEMBL615319,BAO_0000218,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",Rattus norvegicus
B,,,,,,,8,,12132,1,Autocuration,,,347,,9964,H,CHEMBL615320,BAO_0000019,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",
F,,,,,,,8,,12132,1,Autocuration,,,348,,9964,H,CHEMBL615321,BAO_0000019,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",
B,,,,,,,0,10116.0,22226,1,Autocuration,,,349,,3796,U,CHEMBL615322,BAO_0000019,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",Rattus norvegicus
B,,,,,,,8,562.0,19690,1,Autocuration,,,350,,4251,H,CHEMBL615323,BAO_0000357,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Escherichia coli
B,,,,,,,8,562.0,19690,1,Autocuration,,,351,,4251,H,CHEMBL615407,BAO_0000357,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Escherichia coli
B,,,,,,,8,562.0,19690,1,Autocuration,,,352,,4251,H,CHEMBL857267,BAO_0000357,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Escherichia coli
B,,,,,,,8,562.0,19690,1,Autocuration,,,353,,4251,H,CHEMBL615408,BAO_0000357,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Escherichia coli
B,,,,,,,8,,19690,1,Autocuration,,,354,,166,H,CHEMBL615409,BAO_0000357,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,
B,,,,,,,8,,19690,1,Autocuration,,,355,,17861,H,CHEMBL615410,BAO_0000357,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,
B,,,,,,,8,,19690,1,Autocuration,,,356,,166,H,CHEMBL615411,BAO_0000357,,Inhibition constant against 3-dehydroquinate synthase,
B,,,,,,,8,,19690,1,Autocuration,,,357,,166,H,CHEMBL615412,BAO_0000357,,Association rate constant against 3-dehydroquinate synthase,
B,,,,,,,8,,19690,1,Autocuration,,,358,,166,H,CHEMBL615413,BAO_0000357,,Rate constant against 3-dehydroquinate synthase,
B,,,,,,,0,,22226,1,Autocuration,,,359,,3548,U,CHEMBL615414,BAO_0000019,,Inhibitory activity against fuc-TVII,
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,360,Microsomes,9877,D,CHEMBL615415,BAO_0000251,Liver,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,361,Microsomes,9877,D,CHEMBL615416,BAO_0000251,Liver,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,362,Microsomes,9877,D,CHEMBL615417,BAO_0000251,Liver,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,363,Microsomes,9877,D,CHEMBL615418,BAO_0000251,Liver,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,364,Microsomes,9877,D,CHEMBL615419,BAO_0000251,Liver,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,365,Microsomes,9877,D,CHEMBL615420,BAO_0000251,Liver,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,366,Microsomes,9877,D,CHEMBL615421,BAO_0000251,Liver,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,367,Microsomes,9877,D,CHEMBL615422,BAO_0000251,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,368,Microsomes,9877,D,CHEMBL615423,BAO_0000251,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,369,Microsomes,9877,D,CHEMBL872868,BAO_0000251,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Rattus norvegicus
B,,,,,2107.0,,9,10116.0,12236,1,Autocuration,,,370,Microsomes,9877,D,CHEMBL615424,BAO_0000251,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Rattus norvegicus
B,,,,,,,4,,104832,1,Autocuration,,,371,,3003,H,CHEMBL825022,BAO_0000224,,Inhibitory activity against 3-phosphoglycerate kinase.,
B,,,,,,,4,,104832,1,Autocuration,,,372,,3003,H,CHEMBL615425,BAO_0000224,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,
B,,,,,,,4,,104832,1,Autocuration,,,373,,3003,H,CHEMBL615426,BAO_0000224,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",
B,,,,,,,9,9606.0,10612,1,Expert,,,374,,17185,D,CHEMBL615427,BAO_0000357,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,Homo sapiens
F,3677 melanoma cell line,844.0,,,,,1,9606.0,80616,1,Intermediate,,,375,,6072,N,CHEMBL615428,BAO_0000219,,Cytotoxicity on 3677 melanoma cells,Homo sapiens
F,3677 melanoma cell line,844.0,,,,,1,9606.0,80616,1,Intermediate,,,376,,6072,N,CHEMBL615429,BAO_0000219,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,Homo sapiens
F,MC-38,700.0,,,,,1,10090.0,80617,1,Intermediate,,,377,,5018,N,CHEMBL615430,BAO_0000219,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,Mus musculus
F,,,,,,,0,9606.0,22226,1,Intermediate,,,378,,2852,U,CHEMBL615431,BAO_0000019,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,Homo sapiens
F,B16,798.0,,,,,0,,22226,1,Autocuration,,,379,,8663,U,CHEMBL615432,BAO_0000218,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,
F,B16,798.0,,,,,0,,22226,1,Autocuration,,,380,,8663,U,CHEMBL615433,BAO_0000218,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,
F,,,,,,,9,12131.0,12464,1,Expert,,,381,,3245,D,CHEMBL615434,BAO_0000019,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,Human rhinovirus 14
F,,,,,,,1,169066.0,50085,1,Intermediate,,,382,,3245,N,CHEMBL615435,BAO_0000218,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,Human rhinovirus sp.
F,,,,,,,1,169066.0,50679,1,Intermediate,,,383,,3877,N,CHEMBL615436,BAO_0000218,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,human rhinovirus type 14
F,,,,,,,1,169066.0,50679,1,Intermediate,,,384,,3877,N,CHEMBL615437,BAO_0000218,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,human rhinovirus type 14
F,,,,,,,9,12131.0,12464,1,Expert,,,385,,5861,D,CHEMBL615438,BAO_0000019,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14
F,,,,,,,9,12131.0,12464,1,Expert,,,386,,5861,D,CHEMBL615439,BAO_0000019,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14
F,,,,,,,9,12131.0,12464,1,Expert,,,387,,5861,D,CHEMBL615440,BAO_0000019,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14
F,,,,,,,9,12131.0,12464,1,Expert,,,388,,5861,D,CHEMBL615441,BAO_0000019,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,Human rhinovirus 14
F,,,,,,,1,12059.0,50665,1,Intermediate,,,389,,13748,N,CHEMBL615641,BAO_0000218,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,Enterovirus
F,,,,,,,1,12059.0,50665,1,Intermediate,,,390,,13748,N,CHEMBL872065,BAO_0000218,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,Enterovirus
F,,,,,,,1,12059.0,50665,1,Intermediate,,,391,,13748,N,CHEMBL825023,BAO_0000218,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,Enterovirus
F,,,,,,,1,12059.0,50665,1,Intermediate,,,392,,13748,N,CHEMBL615642,BAO_0000218,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,Enterovirus
B,,,,,,,8,147712.0,12464,1,Expert,,,393,,13748,H,CHEMBL615643,BAO_0000357,,Inhibition of human rhinovirus 3C protease,Human rhinovirus B
B,,,,,,,0,9606.0,22226,1,Autocuration,,,394,,17699,U,CHEMBL615644,BAO_0000019,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,Homo sapiens
F,3EM 37,833.0,,,,,1,10090.0,80619,1,Intermediate,,,395,,7145,N,CHEMBL615645,BAO_0000218,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),Mus musculus
F,3EM 37,833.0,,,,,1,10090.0,80619,1,Intermediate,,,396,,7145,N,CHEMBL615646,BAO_0000218,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),Mus musculus
F,3EM 37,833.0,,,,,1,10090.0,80619,1,Intermediate,,,397,,7145,N,CHEMBL615647,BAO_0000218,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),Mus musculus
F,3EM 37,833.0,,,,,1,10090.0,80619,1,Intermediate,,,398,,7145,N,CHEMBL615648,BAO_0000218,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),Mus musculus
F,3EM 37,833.0,,,,,1,10090.0,80619,1,Intermediate,,,399,,7145,N,CHEMBL615649,BAO_0000218,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,Mus musculus
F,3EM 37,833.0,,,,,1,10090.0,80619,1,Intermediate,,,400,,7145,N,CHEMBL615650,BAO_0000218,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,401,,5325,N,CHEMBL615651,BAO_0000218,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,402,,5325,N,CHEMBL615652,BAO_0000218,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Expert,,,403,,5325,N,CHEMBL615653,BAO_0000218,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,404,,16169,N,CHEMBL615654,BAO_0000219,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,405,,16169,N,CHEMBL615655,BAO_0000219,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,406,,16169,N,CHEMBL825024,BAO_0000219,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,407,,16169,N,CHEMBL615656,BAO_0000219,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,408,,16169,N,CHEMBL615657,BAO_0000219,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,409,,16169,N,CHEMBL615658,BAO_0000219,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,410,,16169,N,CHEMBL615659,BAO_0000219,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,411,,16169,N,CHEMBL615660,BAO_0000219,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,412,,16169,N,CHEMBL615661,BAO_0000219,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,413,,16169,N,CHEMBL615662,BAO_0000219,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,414,,16169,N,CHEMBL615663,BAO_0000219,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,415,,16169,N,CHEMBL615664,BAO_0000219,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,416,,16169,N,CHEMBL615665,BAO_0000219,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,417,,16169,N,CHEMBL615666,BAO_0000219,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,418,,16169,N,CHEMBL615667,BAO_0000219,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,419,,16169,N,CHEMBL615668,BAO_0000219,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,420,,16169,N,CHEMBL615669,BAO_0000219,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,421,,16169,N,CHEMBL615670,BAO_0000219,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,422,,16169,N,CHEMBL836739,BAO_0000219,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,423,,16169,N,CHEMBL615671,BAO_0000219,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,424,,16169,N,CHEMBL615672,BAO_0000219,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,425,,16169,N,CHEMBL615791,BAO_0000219,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,426,,16169,N,CHEMBL615792,BAO_0000219,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,427,,16169,N,CHEMBL615793,BAO_0000219,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,428,,16169,N,CHEMBL615794,BAO_0000219,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus
F,3LL cell line,847.0,,,,,1,10090.0,80620,1,Intermediate,,,429,,16169,N,CHEMBL615795,BAO_0000219,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus
F,3LLD122,971.0,,,,,1,9606.0,80621,1,Intermediate,,,430,,15547,N,CHEMBL615590,BAO_0000219,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,Homo sapiens
F,,,,,,,0,,22226,1,Autocuration,,,431,,8663,U,CHEMBL615591,BAO_0000218,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,
F,,,,,,,0,,22226,1,Autocuration,,,432,,8663,U,CHEMBL615592,BAO_0000218,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,
F,,,,,,,0,,22226,1,Autocuration,,,433,,8663,U,CHEMBL615593,BAO_0000218,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,
F,,,,,,,0,,22226,1,Autocuration,,,434,,8663,U,CHEMBL615594,BAO_0000218,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,435,,4504,N,CHEMBL615595,BAO_0000219,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,436,,4504,N,CHEMBL615596,BAO_0000219,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Mus musculus
F,NIH3T3,723.0,,,,,8,,11169,1,Expert,,,437,,12695,H,CHEMBL615597,BAO_0000219,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,438,,12695,N,CHEMBL615598,BAO_0000219,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,439,,12695,N,CHEMBL615599,BAO_0000219,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,440,,17642,N,CHEMBL615600,BAO_0000219,,Effective dose against murine 3T3 fibroblasts cells,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,441,,17642,N,CHEMBL615601,BAO_0000219,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,442,,12340,N,CHEMBL615602,BAO_0000219,,Cytotoxic effect on 3T3 cells,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,443,,12340,N,CHEMBL615603,BAO_0000219,,Cytotoxic effect on 3T3 cells,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,444,,12716,N,CHEMBL615604,BAO_0000219,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,445,,6277,N,CHEMBL615605,BAO_0000219,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,446,,6277,N,CHEMBL615606,BAO_0000219,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,447,,6277,N,CHEMBL884526,BAO_0000219,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,448,,6277,N,CHEMBL615607,BAO_0000219,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,449,,6277,N,CHEMBL615608,BAO_0000219,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,450,,6277,N,CHEMBL615609,BAO_0000219,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,451,,6277,N,CHEMBL615682,BAO_0000219,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,452,,6277,N,CHEMBL615683,BAO_0000219,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,453,,17780,N,CHEMBL615684,BAO_0000218,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,Mus musculus
F,,,,,,,7,10090.0,104860,1,Autocuration,,,454,,12751,D,CHEMBL615685,BAO_0000219,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,455,,12380,N,CHEMBL615686,BAO_0000219,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,456,,14892,N,CHEMBL615687,BAO_0000219,,Inhibitory activity against 3T3 cell line,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,457,,12695,N,CHEMBL884523,BAO_0000219,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,Mus musculus
F,,,,,,,8,,11169,1,Expert,,,458,,12695,H,CHEMBL615688,BAO_0000019,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,459,,12695,N,CHEMBL615689,BAO_0000219,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,460,,12695,N,CHEMBL615690,BAO_0000219,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,Mus musculus
F,,,,,,,8,,11169,1,Expert,,,461,,12695,H,CHEMBL615691,BAO_0000019,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,
F,,,,,,,8,,11169,1,Expert,,,462,,12695,H,CHEMBL615692,BAO_0000019,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,463,,6277,N,CHEMBL615693,BAO_0000219,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,464,,6277,N,CHEMBL615324,BAO_0000219,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,Mus musculus
F,NIH3T3,723.0,,,,,9,9606.0,9,1,Expert,,,465,,4959,D,CHEMBL615325,BAO_0000219,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Homo sapiens
F,NIH3T3,723.0,,,,,9,9606.0,9,1,Expert,,,466,,4959,D,CHEMBL615490,BAO_0000219,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),Homo sapiens
F,NIH3T3,723.0,,,,,9,9606.0,188,1,Expert,,,467,,4959,D,CHEMBL615491,BAO_0000219,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,Homo sapiens
F,NIH3T3,723.0,,,,,9,9606.0,188,1,Expert,,,468,,4959,D,CHEMBL615492,BAO_0000219,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),Homo sapiens
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,469,,12082,N,CHEMBL615493,BAO_0000219,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,470,,12082,N,CHEMBL615494,BAO_0000219,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,471,,12082,N,CHEMBL615495,BAO_0000219,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,472,,12082,N,CHEMBL615496,BAO_0000219,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,473,,2643,N,CHEMBL615497,BAO_0000219,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,474,,11926,N,CHEMBL615498,BAO_0000219,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,Mus musculus
A,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,475,,15204,N,CHEMBL615499,BAO_0000219,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,476,,15992,N,CHEMBL835522,BAO_0000219,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,477,,16279,N,CHEMBL615500,BAO_0000219,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,478,,16279,N,CHEMBL615501,BAO_0000219,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,479,,16279,N,CHEMBL615502,BAO_0000219,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,480,,16279,N,CHEMBL615503,BAO_0000219,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,481,,16279,N,CHEMBL615504,BAO_0000219,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,482,,16279,N,CHEMBL615505,BAO_0000219,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Expert,,,483,,12831,N,CHEMBL615506,BAO_0000219,,Inhibition of swiss 3T3 mouse fibroblast proliferation,Mus musculus
F,NIH3T3,723.0,,,,,1,10090.0,80951,1,Intermediate,,,484,,13497,N,CHEMBL615507,BAO_0000219,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,Mus musculus
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,485,,13715,N,CHEMBL615508,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Intermediate,,,486,,13618,N,CHEMBL615509,BAO_0000219,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Intermediate,,,487,,11902,N,CHEMBL615510,BAO_0000219,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Intermediate,,,488,,11902,N,CHEMBL615511,BAO_0000219,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Intermediate,,,489,,11902,N,CHEMBL615512,BAO_0000219,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Intermediate,,,490,,14840,N,CHEMBL615513,BAO_0000218,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Intermediate,,,491,,14840,N,CHEMBL615514,BAO_0000218,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",Mus musculus
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,492,,13715,N,CHEMBL615515,BAO_0000219,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,493,,13715,N,CHEMBL615516,BAO_0000219,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,494,,13715,N,CHEMBL615517,BAO_0000219,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,495,,13715,N,CHEMBL615518,BAO_0000219,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,496,,13715,N,CHEMBL615519,BAO_0000219,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,497,,13715,N,CHEMBL615520,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,498,,13715,N,CHEMBL615521,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,499,,13715,N,CHEMBL615522,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,500,,13715,N,CHEMBL615523,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Expert,,,501,,13715,N,CHEMBL615524,BAO_0000218,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Expert,,,502,,13715,N,CHEMBL615525,BAO_0000218,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,503,,13715,N,CHEMBL615526,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,504,,13715,N,CHEMBL615527,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,505,,13715,N,CHEMBL615528,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Expert,,,506,,13715,N,CHEMBL615529,BAO_0000218,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Expert,,,507,,13715,N,CHEMBL615530,BAO_0000218,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Expert,,,508,,13715,N,CHEMBL615531,BAO_0000218,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,509,,13715,N,CHEMBL615532,BAO_0000219,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,510,,13715,N,CHEMBL615533,BAO_0000219,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,511,,13715,N,CHEMBL615534,BAO_0000219,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,512,,13715,N,CHEMBL615535,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,513,,13715,N,CHEMBL615536,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,514,,13715,N,CHEMBL615537,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,515,,13715,N,CHEMBL615538,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,
F,3T3-L1,620.0,,,,,1,,80006,1,Intermediate,,,516,,13715,N,CHEMBL836166,BAO_0000218,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,
F,3T3-L1,620.0,,,,,8,,11214,1,Expert,,,517,,6411,H,CHEMBL615539,BAO_0000219,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Intermediate,,,518,,6411,N,CHEMBL615540,BAO_0000219,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,Mus musculus
F,3T3-L1,620.0,,,,,8,,11214,1,Expert,,,519,,6411,H,CHEMBL615541,BAO_0000219,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Expert,,,520,,3966,N,CHEMBL615542,BAO_0000219,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Intermediate,,,521,,3966,N,CHEMBL615543,BAO_0000219,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Expert,,,522,,15556,N,CHEMBL615544,BAO_0000219,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Expert,,,523,,5845,N,CHEMBL615545,BAO_0000219,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Expert,,,524,,14422,N,CHEMBL615546,BAO_0000219,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Expert,,,525,,5845,N,CHEMBL615547,BAO_0000219,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Expert,,,526,,14508,N,CHEMBL615548,BAO_0000219,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Expert,,,527,,14508,N,CHEMBL615549,BAO_0000219,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,Mus musculus
F,3T3-L1,620.0,,,,,1,10090.0,80006,1,Expert,,,528,,14508,N,CHEMBL615550,BAO_0000219,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,Mus musculus
F,3Y1 cell line,1118.0,,,,,1,10116.0,80622,1,Intermediate,,,529,,6349,N,CHEMBL615551,BAO_0000219,,Inhibitory activity against rat fibroblast (3Y1) cell line,Rattus norvegicus
F,3Y1 cell line,1118.0,,,,,1,10116.0,80622,1,Expert,,,530,,15899,N,CHEMBL615552,BAO_0000219,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,Rattus norvegicus
F,3Y1 cell line,1118.0,,,,,1,10116.0,80622,1,Expert,,,531,,15899,N,CHEMBL615553,BAO_0000219,,Cytotoxicity in 3Y1 cells.,Rattus norvegicus
F,3Y1 cell line,1118.0,,,,,1,10116.0,80622,1,Expert,,,532,,15899,N,CHEMBL615554,BAO_0000219,,Cytostatic effect in 3Y1 cells.,Rattus norvegicus
F,3Y1 cell line,1118.0,,,,,1,10116.0,80622,1,Intermediate,,,533,,15899,N,CHEMBL615555,BAO_0000219,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",Rattus norvegicus
F,3Y1 cell line,1118.0,,,,,1,10116.0,80622,1,Expert,,,534,,17038,N,CHEMBL615556,BAO_0000219,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,Rattus norvegicus
B,,,,,,,0,,22226,1,Autocuration,,,535,,12421,U,CHEMBL615557,BAO_0000019,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,
B,,,,,,,0,,22226,1,Autocuration,,,536,,12947,U,CHEMBL615558,BAO_0000019,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,
B,,,,,,,0,,22226,1,Autocuration,,,537,,12947,U,CHEMBL872066,BAO_0000019,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,
B,,,,,,,9,9823.0,11607,1,Expert,,,538,,4896,D,CHEMBL615559,BAO_0000019,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,Sus scrofa
B,,,,,,,8,,11607,1,Autocuration,,,539,,6148,H,CHEMBL615560,BAO_0000019,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,
B,,,,,,,8,,11607,1,Autocuration,,,540,,16432,H,CHEMBL615561,BAO_0000019,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,
B,,,,,,,8,,11607,1,Expert,,,541,,4978,H,CHEMBL857062,BAO_0000019,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,
B,,,,,,,8,,11607,1,Expert,,,542,,4978,H,CHEMBL615562,BAO_0000019,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),
B,,,,,,,8,,11607,1,Autocuration,,,543,,3723,H,CHEMBL615563,BAO_0000019,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,
B,,,,,,,8,,11607,1,Autocuration,,,544,,3518,H,CHEMBL615564,BAO_0000357,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),
B,,,,,,,8,,11607,1,Autocuration,,,545,,4164,H,CHEMBL615565,BAO_0000019,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,
B,,,,,,,8,,11607,1,Autocuration,,,546,,3518,H,CHEMBL615566,BAO_0000019,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,
B,,,,,,,9,9823.0,11607,1,Expert,,,547,,4164,D,CHEMBL615567,BAO_0000019,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,Sus scrofa
B,,,,,,,8,,11607,1,Autocuration,,,548,,3518,H,CHEMBL615568,BAO_0000019,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,
B,,,,,,,8,,11607,1,Autocuration,,,549,,3518,H,CHEMBL615569,BAO_0000357,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),
B,,,,,,,8,,11607,1,Autocuration,,,550,,4978,H,CHEMBL615570,BAO_0000019,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,
B,,,,,,,8,,11607,1,Autocuration,,,551,,4978,H,CHEMBL615571,BAO_0000019,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),
B,,,,,,,4,,104733,1,Autocuration,,,552,,6455,H,CHEMBL615572,BAO_0000224,,Binding affinity against melatonin (MT1) receptor (pC1),
B,,,,,,,0,,22226,1,Autocuration,,,553,,2222,U,CHEMBL615573,BAO_0000019,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,
B,,,,,,,0,,22226,1,Autocuration,,,554,,13020,U,CHEMBL615574,BAO_0000019,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,
B,,,,,,,0,,22226,1,Autocuration,,,555,,13021,U,CHEMBL615575,BAO_0000019,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,
B,,,,,,,8,,10619,1,Autocuration,,,556,,14532,H,CHEMBL615576,BAO_0000357,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,
B,,,,,,,8,,10619,1,Autocuration,,,557,,14118,H,CHEMBL615577,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,558,,11884,H,CHEMBL615578,BAO_0000221,Hippocampus,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,
B,,,,,,,8,,51,1,Expert,,,559,,13969,H,CHEMBL615579,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Expert,,,560,,13392,H,CHEMBL615580,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Expert,,,561,,14430,H,CHEMBL615581,BAO_0000019,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,562,,12248,H,CHEMBL615582,BAO_0000221,Hippocampus,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,563,,12249,H,CHEMBL615583,BAO_0000221,Hippocampus,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,564,,9995,H,CHEMBL615584,BAO_0000221,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,565,,9995,H,CHEMBL833691,BAO_0000221,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,566,,9995,H,CHEMBL615585,BAO_0000221,Hippocampus,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,567,,9995,H,CHEMBL615586,BAO_0000221,Hippocampus,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,568,,9995,H,CHEMBL884524,BAO_0000221,Hippocampus,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,569,,12249,H,CHEMBL615587,BAO_0000221,Hippocampus,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,570,,11799,H,CHEMBL615588,BAO_0000221,Hippocampus,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",
B,,,,,,,9,10116.0,10576,1,Expert,,,571,Membranes,14331,D,CHEMBL615589,BAO_0000249,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Rattus norvegicus
B,,,,,10000000.0,,8,9913.0,51,1,Expert,,,572,,11884,H,CHEMBL615442,BAO_0000221,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Bos taurus
B,,,,,10000000.0,,8,,51,1,Autocuration,,,573,,14331,H,CHEMBL615443,BAO_0000221,Hippocampus,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,574,,11701,H,CHEMBL615444,BAO_0000221,Hippocampus,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Expert,,,575,,11701,H,CHEMBL615445,BAO_0000221,Hippocampus,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,576,,12248,H,CHEMBL615446,BAO_0000221,Hippocampus,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,577,,12248,H,CHEMBL615447,BAO_0000219,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,
B,,,,,10000000.0,,8,,51,1,Expert,,,578,,12248,H,CHEMBL615448,BAO_0000221,Hippocampus,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Expert,,,579,,12249,H,CHEMBL615449,BAO_0000221,Hippocampus,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,580,,12248,H,CHEMBL615450,BAO_0000219,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,
B,,,,,10000000.0,,8,,51,1,Expert,,,581,,11799,H,CHEMBL615451,BAO_0000221,Hippocampus,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",
B,,,,,,,8,,51,1,Autocuration,,,582,,634,H,CHEMBL615452,BAO_0000357,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,583,,9995,H,CHEMBL615453,BAO_0000221,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,584,,9995,H,CHEMBL615454,BAO_0000221,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,585,,9995,H,CHEMBL615455,BAO_0000221,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,586,,9995,H,CHEMBL615456,BAO_0000221,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,587,,9995,H,CHEMBL615457,BAO_0000221,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,
B,,,,,10000000.0,,8,,51,1,Expert,,,588,,12210,H,CHEMBL615458,BAO_0000218,Hippocampus,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,
B,,,,,10000000.0,,8,,51,1,Expert,,,589,,13311,H,CHEMBL615459,BAO_0000221,Hippocampus,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,
B,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,590,,2331,D,CHEMBL615460,BAO_0000219,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",Homo sapiens
F,,,,,,,8,10141.0,51,1,Autocuration,,,591,,1375,H,CHEMBL615461,BAO_0000019,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,Cavia porcellus
F,,,,,,,8,10141.0,51,1,Autocuration,,,592,,1375,H,CHEMBL615462,BAO_0000019,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,Cavia porcellus
F,,,,,10000000.0,,8,10141.0,51,1,Autocuration,,,593,,11574,H,CHEMBL615463,BAO_0000221,Hippocampus,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Cavia porcellus
B,,,,,2116.0,,8,10141.0,51,1,Autocuration,,,594,,12867,H,CHEMBL615464,BAO_0000221,Ileum,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Cavia porcellus
B,,,,,2116.0,,8,10141.0,51,1,Autocuration,,,595,,12867,H,CHEMBL615465,BAO_0000221,Ileum,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus
B,,,,,2116.0,,8,10141.0,51,1,Autocuration,,,596,,12867,H,CHEMBL615466,BAO_0000221,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Cavia porcellus
B,,,,,2116.0,,8,10141.0,51,1,Autocuration,,,597,,12867,H,CHEMBL615467,BAO_0000221,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus
B,,,,,2116.0,,8,10141.0,51,1,Autocuration,,,598,,12867,H,CHEMBL615468,BAO_0000221,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus
B,,,,,2116.0,,8,10141.0,51,1,Autocuration,,,599,,12867,H,CHEMBL615469,BAO_0000221,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Cavia porcellus
B,,,,,,,8,10141.0,51,1,Autocuration,,,600,,11574,H,CHEMBL615470,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor,Cavia porcellus
B,,,,,,,8,10141.0,51,1,Autocuration,,,601,,13114,H,CHEMBL615471,BAO_0000357,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,Cavia porcellus
B,,,,,,,8,10141.0,51,1,Autocuration,,,602,,13181,H,CHEMBL615472,BAO_0000357,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,Cavia porcellus
B,,,,,10000000.0,,8,10141.0,106,1,Autocuration,,,603,,10639,H,CHEMBL883242,BAO_0000221,Hippocampus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Cavia porcellus
F,,,,,10000000.0,,8,10141.0,106,1,Autocuration,,,604,,10639,H,CHEMBL615473,BAO_0000221,Hippocampus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Cavia porcellus
B,CHO,449.0,,,,,8,10029.0,11863,1,Autocuration,,,605,,11883,H,CHEMBL615474,BAO_0000218,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Cricetulus griseus
B,,,,,,,8,,51,1,Autocuration,,,606,,17785,H,CHEMBL615475,BAO_0000357,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,
F,HeLa,308.0,,,,,8,,51,1,Autocuration,,,607,,1558,H,CHEMBL615476,BAO_0000219,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,
F,HeLa,308.0,,,,,8,,51,1,Autocuration,,,608,,1558,H,CHEMBL615477,BAO_0000219,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,
F,,,,,,,8,,51,1,Autocuration,,,609,,15740,H,CHEMBL615478,BAO_0000019,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,610,,17624,H,CHEMBL615160,BAO_0000219,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,
F,CHO,449.0,,,,,8,,51,1,Expert,,,611,,17624,H,CHEMBL615161,BAO_0000219,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,612,,17624,H,CHEMBL615162,BAO_0000219,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,613,,17624,H,CHEMBL615163,BAO_0000219,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,
B,CHO,449.0,,,,,8,,51,1,Expert,,,614,,17624,H,CHEMBL615164,BAO_0000219,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,
B,CHO,449.0,,,,,8,,51,1,Expert,,,615,,17624,H,CHEMBL615165,BAO_0000219,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,616,,17624,H,CHEMBL615166,BAO_0000219,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,
F,,,,,,,8,,51,1,Autocuration,,,617,,14256,H,CHEMBL615167,BAO_0000219,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,
B,HeLa,308.0,,,,,9,9606.0,51,1,Expert,,,618,,3445,D,CHEMBL615168,BAO_0000219,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Homo sapiens
B,HeLa,308.0,,,,,9,9606.0,51,1,Expert,,,619,,3445,D,CHEMBL615169,BAO_0000219,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,Homo sapiens
B,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,620,,17200,D,CHEMBL615170,BAO_0000219,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens
B,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,621,,17200,D,CHEMBL615171,BAO_0000219,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,Homo sapiens
F,,,,,,,8,,51,1,Autocuration,,,622,,15180,H,CHEMBL615694,BAO_0000019,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,
F,,,,,,,8,,51,1,Autocuration,,,623,,15180,H,CHEMBL615695,BAO_0000019,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,
F,,,,,,,8,,51,1,Autocuration,,,624,,16026,H,CHEMBL615696,BAO_0000019,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,625,,2759,H,CHEMBL615697,BAO_0000219,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,
F,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,626,,2759,D,CHEMBL859410,BAO_0000219,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Homo sapiens
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,627,,2759,H,CHEMBL615841,BAO_0000219,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),
F,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,628,,2759,D,CHEMBL615842,BAO_0000219,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Homo sapiens
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,629,,2759,H,CHEMBL835003,BAO_0000219,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,630,,2759,H,CHEMBL615843,BAO_0000219,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),
F,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,631,,2759,D,CHEMBL615979,BAO_0000219,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Homo sapiens
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,632,,2759,H,CHEMBL615980,BAO_0000219,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),
F,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,633,,2759,D,CHEMBL615981,BAO_0000219,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,634,,3445,D,CHEMBL615982,BAO_0000019,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,635,,5272,D,CHEMBL615983,BAO_0000019,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,636,,5272,D,CHEMBL615984,BAO_0000019,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,637,,5272,D,CHEMBL615985,BAO_0000019,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,638,,17624,H,CHEMBL615986,BAO_0000219,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,639,,17624,H,CHEMBL615987,BAO_0000219,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,640,,17624,H,CHEMBL615988,BAO_0000219,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,
F,CHO,449.0,,,,,8,,51,1,Expert,,,641,,17624,H,CHEMBL615989,BAO_0000219,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,642,,17624,H,CHEMBL615990,BAO_0000219,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,643,,17624,H,CHEMBL615991,BAO_0000219,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,644,,17624,H,CHEMBL615992,BAO_0000219,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,645,,17624,H,CHEMBL615993,BAO_0000219,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,
F,CHO,449.0,,,,,8,,51,1,Expert,,,646,,17624,H,CHEMBL615994,BAO_0000219,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,647,,17624,H,CHEMBL615995,BAO_0000219,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,648,,17624,H,CHEMBL615996,BAO_0000219,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,649,,17624,H,CHEMBL615997,BAO_0000219,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,
F,,,,,,,8,,51,1,Autocuration,,,650,,6563,H,CHEMBL615998,BAO_0000019,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",
F,,,,,,,8,,51,1,Autocuration,,,651,,6563,H,CHEMBL615999,BAO_0000019,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",
F,,,,,,,8,,51,1,Autocuration,,,652,,6563,H,CHEMBL616000,BAO_0000019,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,
F,HEK293,722.0,,,,,8,,51,1,Autocuration,,,653,,17296,H,CHEMBL616001,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,
F,,,,,,,9,9606.0,51,1,Expert,,,654,,6876,D,CHEMBL616002,BAO_0000019,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",Homo sapiens
F,,,,,,,8,,51,1,Expert,,,655,,6876,H,CHEMBL616003,BAO_0000019,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",
F,,,,,,,9,9606.0,51,1,Expert,,,656,,5272,D,CHEMBL616004,BAO_0000019,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,657,,5272,D,CHEMBL616005,BAO_0000019,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,Homo sapiens
F,,,,,,,8,,51,1,Autocuration,,,658,,5548,H,CHEMBL616006,BAO_0000019,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",
F,,,,,,,8,,51,1,Expert,,,659,,5548,H,CHEMBL616007,BAO_0000019,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",
F,,,,,,,8,,51,1,Autocuration,,,660,,5548,H,CHEMBL616008,BAO_0000019,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",
F,,,,,,,8,,51,1,Autocuration,,,661,,5548,H,CHEMBL616009,BAO_0000019,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",
F,,,,,,,8,,51,1,Expert,,,662,,5929,H,CHEMBL616010,BAO_0000019,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",
F,,,,,,,9,9606.0,51,1,Expert,,,663,,5929,D,CHEMBL616011,BAO_0000019,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,664,,5929,D,CHEMBL615740,BAO_0000019,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",Homo sapiens
F,,,,,,,8,,51,1,Autocuration,,,665,,16245,H,CHEMBL615741,BAO_0000019,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",
F,,,,,,,8,,51,1,Expert,,,666,,5640,H,CHEMBL615742,BAO_0000019,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",
F,,,,,,,8,,51,1,Autocuration,,,667,,5640,H,CHEMBL615743,BAO_0000019,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,668,,14509,H,CHEMBL615744,BAO_0000219,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,
F,CHO,449.0,,,,,8,,51,1,Expert,,,669,,14509,H,CHEMBL615745,BAO_0000219,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,
B,,,,,,,8,,51,1,Autocuration,,,670,,15331,H,CHEMBL615746,BAO_0000357,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,
B,,,,,,,8,,51,1,Autocuration,,,671,,15331,H,CHEMBL615747,BAO_0000357,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,
F,,,,,,,8,,51,1,Autocuration,,,672,,6563,H,CHEMBL615748,BAO_0000019,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",
F,,,,,,,8,,51,1,Autocuration,,,673,,6563,H,CHEMBL615749,BAO_0000019,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",
F,,,,,,,8,,51,1,Autocuration,,,674,,6563,H,CHEMBL615750,BAO_0000019,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,
F,,,,,,,9,9606.0,51,1,Expert,,,675,,6563,D,CHEMBL616259,BAO_0000019,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,Homo sapiens
F,,,,,,,8,,51,1,Autocuration,,,676,,6563,H,CHEMBL616260,BAO_0000019,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",
F,,,,,,,9,9606.0,51,1,Expert,,,677,,5272,D,CHEMBL616261,BAO_0000019,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,678,,5272,D,CHEMBL616262,BAO_0000019,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,679,,5272,D,CHEMBL616263,BAO_0000019,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,680,,5272,D,CHEMBL616264,BAO_0000019,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,681,,5272,D,CHEMBL616265,BAO_0000019,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,682,,5272,D,CHEMBL616266,BAO_0000019,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,683,,5272,D,CHEMBL616267,BAO_0000019,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,684,,5272,D,CHEMBL616268,BAO_0000019,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,Homo sapiens
B,,,,,,,9,9606.0,51,1,Expert,,,685,,16146,D,CHEMBL616269,BAO_0000357,,Inhibition of human 5-hydroxytryptamine 1A receptor,Homo sapiens
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,686,,17624,H,CHEMBL884528,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,
B,HEK293,722.0,,,,,9,,105,1,Expert,,,687,,13706,D,CHEMBL616270,BAO_0000219,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,688,,15250,H,CHEMBL616271,BAO_0000219,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,689,,17624,H,CHEMBL616272,BAO_0000219,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Expert,,,690,,6861,H,CHEMBL616273,BAO_0000357,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,
B,,,,,,,9,9606.0,51,1,Expert,,,691,,17200,D,CHEMBL616274,BAO_0000357,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,692,,17624,H,CHEMBL616275,BAO_0000219,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,693,,17624,H,CHEMBL616276,BAO_0000219,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,694,,12058,U,CHEMBL616277,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,695,,12058,U,CHEMBL616278,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,696,,12058,U,CHEMBL616279,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,697,,12058,U,CHEMBL616280,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,698,,12058,U,CHEMBL616281,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,699,,12058,U,CHEMBL616282,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,700,,12058,U,CHEMBL616283,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,701,,12058,U,CHEMBL616284,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,702,,12058,U,CHEMBL616285,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,703,,12058,U,CHEMBL616286,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,704,,12058,U,CHEMBL616287,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,705,,12058,U,CHEMBL616288,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,706,,12058,U,CHEMBL616289,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,707,,12058,U,CHEMBL615610,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,708,,12058,U,CHEMBL615611,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,709,,12058,U,CHEMBL615612,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,710,,12058,U,CHEMBL615613,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,711,,12058,U,CHEMBL615614,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,Rattus norvegicus
F,,,In vivo,,,,0,10116.0,22226,1,Autocuration,,,712,,12058,U,CHEMBL615615,BAO_0000218,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Rattus norvegicus
B,,,,,,,4,,105093,1,Autocuration,,,713,,11440,H,CHEMBL615616,BAO_0000019,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,
B,,,,,1898.0,,8,,11923,1,Autocuration,,,714,,6238,H,CHEMBL615617,BAO_0000249,Hypothalamus,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,
B,,,,,,,8,,10577,1,Autocuration,,,715,,10046,H,CHEMBL615618,BAO_0000019,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,
B,,,,,,,8,,10577,1,Autocuration,,,716,,10046,H,CHEMBL615619,BAO_0000019,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,
B,,,,,,,8,,10577,1,Expert,,,717,,10046,H,CHEMBL615620,BAO_0000019,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,
B,,,,,,,8,,55,1,Autocuration,,,718,,167,H,CHEMBL615621,BAO_0000357,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",
B,,,,,,,8,,55,1,Autocuration,,,719,,167,H,CHEMBL615622,BAO_0000357,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",
F,,,,,,,8,,12166,1,Autocuration,,,720,,11520,H,CHEMBL615623,BAO_0000019,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),
F,,,,,,,8,,12166,1,Autocuration,,,721,,11520,H,CHEMBL615624,BAO_0000019,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,
F,,,,,,,8,,12166,1,Autocuration,,,722,,11520,H,CHEMBL615625,BAO_0000019,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,
F,,,,,,,8,,12166,1,Autocuration,,,723,,11520,H,CHEMBL767045,BAO_0000019,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,
F,,,,,,,8,10141.0,55,1,Autocuration,,,724,,135,H,CHEMBL615626,BAO_0000019,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,Cavia porcellus
F,,,,,,,8,10141.0,55,1,Autocuration,,,725,,135,H,CHEMBL615627,BAO_0000019,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,726,,11311,H,CHEMBL615628,BAO_0000019,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,727,,10193,H,CHEMBL615629,BAO_0000357,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Cavia porcellus
B,,,,,,,9,9606.0,55,1,Expert,,,728,,12281,D,CHEMBL615630,BAO_0000357,,Inhibitory concentration against 5-lipoxygenase from human whole blood,Homo sapiens
B,,,,,,,8,,55,1,Autocuration,,,729,,11311,H,CHEMBL615631,BAO_0000219,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],
F,,,,,,,8,,17087,1,Autocuration,,,730,,12576,H,CHEMBL615632,BAO_0000218,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,
B,,,,,,,8,,17087,1,Autocuration,,,731,,12281,H,CHEMBL615633,BAO_0000357,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,
F,,,,,,,8,,17087,1,Autocuration,,,732,,12576,H,CHEMBL615634,BAO_0000218,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,
B,,,,,,,8,9823.0,55,1,Expert,,,733,,11089,H,CHEMBL615635,BAO_0000019,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,Sus scrofa
B,,,,,,,8,,12166,1,Expert,,,734,,11006,H,CHEMBL615636,BAO_0000357,,In vitro inhibition of rat 5-Lipoxygenase,
B,,,,,,,9,10116.0,12166,1,Expert,,,735,,11481,D,CHEMBL615637,BAO_0000357,,Inhibitory activity against 5-Lipoxygenase,Rattus norvegicus
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,736,,10864,H,CHEMBL615638,BAO_0000219,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,737,,3595,H,CHEMBL615639,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,738,,11311,H,CHEMBL615640,BAO_0000219,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,
B,,,,,,,8,,12166,1,Autocuration,,,739,,11311,H,CHEMBL615796,BAO_0000019,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,
B,,,,,,,8,,12166,1,Autocuration,,,740,,11311,H,CHEMBL615845,BAO_0000219,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],
B,,,,,,,8,,12166,1,Autocuration,,,741,,11006,H,CHEMBL615846,BAO_0000357,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,742,,3595,H,CHEMBL615847,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,
B,,,,,,,8,,12166,1,Autocuration,,,743,,11311,H,CHEMBL615848,BAO_0000357,,The compound was tested for inhibition of isolated 5-Lipoxygenase,
B,,,,,,,0,10116.0,22226,1,Autocuration,,,744,,11481,U,CHEMBL615849,BAO_0000019,,Ratio of IC50 against 5-LO and COX,Rattus norvegicus
B,,,,,,,8,,12166,1,Autocuration,,,745,,11006,H,CHEMBL615850,BAO_0000357,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,
B,,,,,,,8,,12166,1,Autocuration,,,746,,11006,H,CHEMBL615851,BAO_0000357,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,
B,,,,,,,8,,12166,1,Autocuration,,,747,,11311,H,CHEMBL615852,BAO_0000219,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,
F,,,,,,,8,,12166,1,Autocuration,,,748,,11006,H,CHEMBL615853,BAO_0000019,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,
B,,,,,2367.0,,8,,120,1,Autocuration,,,749,,4288,H,CHEMBL884527,BAO_0000357,Prostate gland,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,
B,,,,,,,0,8932.0,22226,1,Autocuration,,,750,,7587,U,CHEMBL872871,BAO_0000019,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,Columba livia
B,,,,,,,0,8932.0,22226,1,Autocuration,,,751,,7587,U,CHEMBL615854,BAO_0000019,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,Columba livia
B,,,,,,,0,8932.0,22226,1,Autocuration,,,752,,7587,U,CHEMBL767046,BAO_0000019,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,Columba livia
B,,,,,,,8,,10732,1,Autocuration,,,753,,11249,H,CHEMBL615855,BAO_0000357,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,
F,,,,,,,9,10116.0,12198,1,Expert,,,754,,8003,D,CHEMBL615856,BAO_0000019,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,Rattus norvegicus
F,,,,,,,9,10116.0,12198,1,Expert,,,755,,8003,D,CHEMBL615857,BAO_0000019,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Rattus norvegicus
F,,,,,,,9,10116.0,12198,1,Expert,,,756,,8003,D,CHEMBL615858,BAO_0000019,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Expert,,,757,,12416,H,CHEMBL615859,BAO_0000221,Hippocampus,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,
B,,,,,,,8,,51,1,Autocuration,,,758,,16293,H,CHEMBL615860,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,
B,,,,,,,0,9986.0,22226,1,Autocuration,,,759,,13047,U,CHEMBL615861,BAO_0000019,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus
B,,,,,,,0,9986.0,22226,1,Autocuration,,,760,,13047,U,CHEMBL615862,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus
B,,,,,,,0,9986.0,22226,1,Autocuration,,,761,,13047,U,CHEMBL615863,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus
B,,,,,,,0,9986.0,22226,1,Autocuration,,,762,,13047,U,CHEMBL615864,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus
B,,,,,10000000.0,,4,,104744,1,Autocuration,,,763,,10085,H,CHEMBL615865,BAO_0000221,Hippocampus,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,
B,,,,,10000000.0,,4,,104744,1,Autocuration,,,764,,10085,H,CHEMBL615866,BAO_0000221,Hippocampus,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,
B,,,,,10000000.0,,4,,104744,1,Autocuration,,,765,,10085,H,CHEMBL615867,BAO_0000221,Hippocampus,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,
B,,,,,,,4,,104744,1,Autocuration,,,766,Membranes,9841,H,CHEMBL615868,BAO_0000249,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,
B,,,,,,,5,10116.0,104744,1,Autocuration,,,767,,8822,D,CHEMBL615869,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,Rattus norvegicus
B,,,,,,,5,10116.0,104744,1,Autocuration,,,768,,9806,D,CHEMBL615870,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,Rattus norvegicus
B,,,,,,,5,10116.0,104744,1,Autocuration,,,769,,9806,D,CHEMBL615871,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,Rattus norvegicus
B,,,,,,,4,,104744,1,Autocuration,,,770,,8868,H,CHEMBL615872,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,
B,,,,,10000000.0,,4,,104744,1,Autocuration,,,771,,9036,H,CHEMBL833492,BAO_0000221,Hippocampus,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,
B,,,,,10000000.0,,4,,104744,1,Autocuration,,,772,,11374,H,CHEMBL615873,BAO_0000221,Hippocampus,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,
B,,,,,,,4,,104744,1,Autocuration,,,773,,10881,H,CHEMBL615479,BAO_0000224,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,
B,,,,,,,4,,104744,1,Autocuration,,,774,,8822,H,CHEMBL615480,BAO_0000019,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,
B,,,,,,,5,10116.0,104744,1,Autocuration,,,775,,9806,D,CHEMBL615481,BAO_0000249,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,Rattus norvegicus
B,,,,,,,4,,104744,1,Autocuration,,,776,,15463,H,CHEMBL872869,BAO_0000019,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,
B,,,,,,,4,,104744,1,Autocuration,,,777,,15463,H,CHEMBL615482,BAO_0000019,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,
B,,,,,955.0,,4,,104744,1,Autocuration,,,778,,14542,H,CHEMBL615483,BAO_0000221,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,
B,,,,,955.0,,4,,104744,1,Autocuration,,,779,,14542,H,CHEMBL615484,BAO_0000221,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,
B,,,,,,,4,,104744,1,Autocuration,,,780,,8569,H,CHEMBL615485,BAO_0000019,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,
B,,,,,,,5,10116.0,104744,1,Autocuration,,,781,,10062,D,CHEMBL615486,BAO_0000224,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,Rattus norvegicus
B,,,,,,,4,,104744,1,Autocuration,,,782,,4771,H,CHEMBL615487,BAO_0000224,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,
B,,,,,,,4,,104744,1,Autocuration,,,783,,10062,H,CHEMBL615488,BAO_0000224,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,
B,,,,,,,4,,104744,1,Autocuration,,,784,,10062,H,CHEMBL615489,BAO_0000224,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,
B,,,,,,,4,,104744,1,Autocuration,,,785,,10062,H,CHEMBL615389,BAO_0000224,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,
B,,,,,,,4,,104744,1,Autocuration,,,786,,15463,H,CHEMBL615390,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,
B,,,,,,,4,,104744,1,Autocuration,,,787,,15463,H,CHEMBL615391,BAO_0000019,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,
B,,,,,,,4,,104744,1,Autocuration,,,788,,9098,H,CHEMBL615392,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,
B,,,,,,,0,10116.0,22226,1,Autocuration,,,789,,3070,U,CHEMBL615393,BAO_0000019,,Affinity for 5-hydroxytryptamine 1 receptor,Rattus norvegicus
B,,,,,955.0,,4,,104744,1,Autocuration,,,790,,14542,H,CHEMBL615394,BAO_0000221,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,
B,,,,,955.0,,4,,104744,1,Autocuration,,,791,,14542,H,CHEMBL615395,BAO_0000221,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,
B,,,,,,,4,,104744,1,Autocuration,,,792,,6398,H,CHEMBL615396,BAO_0000224,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,
B,,,,,955.0,,4,,104744,1,Autocuration,,,793,,1344,H,CHEMBL615397,BAO_0000221,Brain,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,
B,,,,,,,4,,104744,1,Autocuration,,,794,,11963,H,CHEMBL615398,BAO_0000019,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,
B,,,,,,,0,10116.0,22226,1,Autocuration,,,795,,8908,U,CHEMBL615399,BAO_0000019,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,Rattus norvegicus
B,,,,,,,4,,104744,1,Autocuration,,,796,,9098,H,CHEMBL615400,BAO_0000019,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,
B,,,,,,,5,10116.0,104744,1,Autocuration,,,797,,8841,D,CHEMBL615401,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,Rattus norvegicus
B,,,,,,,0,10116.0,22226,1,Autocuration,,,798,,8814,U,CHEMBL615402,BAO_0000019,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,Rattus norvegicus
B,,,,,,,4,,104744,1,Autocuration,,,799,,11752,H,CHEMBL615403,BAO_0000019,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,
B,,,,,955.0,,4,,104744,1,Autocuration,,,800,,11642,H,CHEMBL615404,BAO_0000221,Brain,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,
B,,,,,,,4,,104744,1,Autocuration,,,801,,11642,H,CHEMBL615781,BAO_0000019,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,
B,,,,,955.0,,4,,104744,1,Autocuration,,,802,,9231,H,CHEMBL615782,BAO_0000220,Brain,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,
B,,,,,955.0,,4,,104744,1,Autocuration,,,803,,11351,H,CHEMBL615783,BAO_0000221,Brain,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,
B,,,,,,,0,,22226,1,Autocuration,,,804,,4639,U,CHEMBL873481,BAO_0000019,,Compound was tested for binding affinity against 5-HT1 receptor,
B,,,,,,,0,,22226,1,Autocuration,,,805,,1205,U,CHEMBL615784,BAO_0000019,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,
B,,,,,,,8,,10576,1,Expert,,,806,,10025,H,CHEMBL615785,BAO_0000357,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,
F,,,,,,,8,,10576,1,Autocuration,,,807,,13241,H,CHEMBL615786,BAO_0000249,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",
F,,,In vivo,,,,8,,10576,1,Autocuration,,,808,,16245,H,CHEMBL615787,BAO_0000218,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,
F,,,In vivo,,,,8,,10576,1,Autocuration,,,809,,16245,H,CHEMBL615788,BAO_0000218,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,
F,,,,,,,8,,10576,1,Autocuration,,,810,,12438,H,CHEMBL767044,BAO_0000019,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,
F,,,In vivo,,,,8,,10576,1,Autocuration,,,811,,16245,H,CHEMBL615789,BAO_0000218,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,
F,,,In vivo,,,,8,,10576,1,Autocuration,,,812,,16245,H,CHEMBL615790,BAO_0000218,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,
F,,,,,,,8,,10576,1,Autocuration,,,813,,15740,H,CHEMBL615813,BAO_0000019,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,
F,,,,,,,8,,10576,1,Autocuration,,,814,,15535,H,CHEMBL615814,BAO_0000219,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,
F,,,,,,,8,,51,1,Expert,,,815,,15535,H,CHEMBL615815,BAO_0000219,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,
F,,,,,,,8,,10576,1,Autocuration,,,816,,15535,H,CHEMBL615816,BAO_0000219,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,
B,,,,,,,8,,10576,1,Expert,,,817,,9888,H,CHEMBL615817,BAO_0000249,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,818,,10085,H,CHEMBL615818,BAO_0000221,Hippocampus,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,819,,10085,H,CHEMBL615819,BAO_0000221,Hippocampus,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,
B,,,,,,,8,,10576,1,Expert,,,820,Membranes,17331,H,CHEMBL615820,BAO_0000249,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,821,,10845,D,CHEMBL615821,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Rattus norvegicus
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,822,,10845,D,CHEMBL615822,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Expert,,,823,,10845,H,CHEMBL615823,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,824,,10845,D,CHEMBL615824,BAO_0000221,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Rattus norvegicus
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,825,,10845,D,CHEMBL615825,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Rattus norvegicus
B,,,,,,,8,,10576,1,Expert,,,826,,13730,H,CHEMBL615826,BAO_0000357,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,10576,1,Expert,,,827,,13508,H,CHEMBL615827,BAO_0000249,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Expert,,,828,,13508,H,CHEMBL615828,BAO_0000249,Hippocampus,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Expert,,,829,,12073,H,CHEMBL615829,BAO_0000221,Hippocampus,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,830,,4671,H,CHEMBL615830,BAO_0000221,Hippocampus,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Expert,,,831,,13631,H,CHEMBL615831,BAO_0000221,Hippocampus,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,
B,,,,,,,8,,10576,1,Autocuration,,,832,,12438,H,CHEMBL615832,BAO_0000357,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Autocuration,,,833,,10483,H,CHEMBL615833,BAO_0000019,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,834,,10483,H,CHEMBL615834,BAO_0000221,Hippocampus,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,
B,,,,,,,8,,10576,1,Intermediate,,,835,,12352,H,CHEMBL615835,BAO_0000249,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,836,,14732,H,CHEMBL615836,BAO_0000249,Hippocampus,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,
B,,,,,,,9,10116.0,10576,1,Expert,,,837,,11049,D,CHEMBL615837,BAO_0000019,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Rattus norvegicus
B,,,,,,,9,10116.0,10576,1,Expert,,,838,,11049,D,CHEMBL615838,BAO_0000019,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,Rattus norvegicus
B,,,,,,,8,,10576,1,Expert,,,839,,13657,H,CHEMBL615839,BAO_0000249,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",
B,,,,,,,8,,10576,1,Autocuration,,,840,,11473,H,CHEMBL884525,BAO_0000019,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,
B,,,,,,,8,,10576,1,Autocuration,,,841,,2014,H,CHEMBL615840,BAO_0000249,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,
B,,,,,10000000.0,,8,,10576,1,Expert,,,842,,3086,H,CHEMBL615405,BAO_0000221,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,
B,,,,,,,8,,10576,1,Expert,,,843,,15854,H,CHEMBL615406,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,
B,,,,,10000000.0,,8,,10576,1,Expert,,,844,,10922,H,CHEMBL615900,BAO_0000221,Hippocampus,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,
B,,,,,10000000.0,,8,,10576,1,Expert,,,845,,13346,H,CHEMBL615901,BAO_0000221,Hippocampus,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,
B,,,,,,,8,,10576,1,Expert,,,846,,15311,H,CHEMBL615902,BAO_0000357,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,847,,10922,H,CHEMBL615903,BAO_0000221,Hippocampus,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,
B,,,,,,,8,,10576,1,Autocuration,,,848,,10025,H,CHEMBL615904,BAO_0000357,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,
B,,,,,,,8,,10576,1,Expert,,,849,,10025,H,CHEMBL615905,BAO_0000357,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,
B,,,,,,,8,,10576,1,Autocuration,,,850,,9742,H,CHEMBL615906,BAO_0000019,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,
F,,,,,,,8,,10576,1,Autocuration,,,851,,9742,H,CHEMBL615907,BAO_0000019,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,
B,,,,,,,8,,10576,1,Expert,,,852,,12304,H,CHEMBL615908,BAO_0000019,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,853,,15789,H,CHEMBL615909,BAO_0000221,Hippocampus,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,
B,,,,,,,8,,10576,1,Autocuration,,,854,,9912,H,CHEMBL615910,BAO_0000019,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",
B,,,,,,,8,,10576,1,Autocuration,,,855,,9912,H,CHEMBL615911,BAO_0000019,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",
B,,,,,,,8,,10576,1,Autocuration,,,856,,9912,H,CHEMBL615912,BAO_0000019,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",
B,,,,,,,8,,10576,1,Expert,,,857,,16693,H,CHEMBL615913,BAO_0000019,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,10576,1,Expert,,,858,,13276,H,CHEMBL615914,BAO_0000357,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,859,,12678,H,CHEMBL615915,BAO_0000221,Hippocampus,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,
B,,,,,,,8,,10576,1,Autocuration,,,860,,11825,H,CHEMBL615916,BAO_0000357,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,
B,,,,,,,8,,10576,1,Expert,,,861,,12443,H,CHEMBL615917,BAO_0000357,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,
B,,,,,,,8,,10576,1,Expert,,,862,,13830,H,CHEMBL615918,BAO_0000357,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,
B,,,,,10000000.0,,8,,10576,1,Expert,,,863,,14286,H,CHEMBL615919,BAO_0000249,Hippocampus,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,864,,14356,D,CHEMBL615920,BAO_0000221,Hippocampus,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,865,,15306,H,CHEMBL615921,BAO_0000357,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Expert,,,866,,15306,H,CHEMBL615922,BAO_0000357,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),
F,,,,,,,9,10116.0,10576,1,Expert,,,867,,16616,D,CHEMBL881290,BAO_0000249,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,868,,3651,H,CHEMBL615923,BAO_0000221,Hippocampus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",
F,,,,,10000000.0,,8,,10576,1,Autocuration,,,869,,14331,H,CHEMBL615924,BAO_0000221,Hippocampus,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,
F,,,,,10000000.0,,8,,10576,1,Autocuration,,,870,,14331,H,CHEMBL615925,BAO_0000221,Hippocampus,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,
B,,,,,,,9,10116.0,10576,1,Expert,,,871,,14178,D,CHEMBL615926,BAO_0000357,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,Rattus norvegicus
B,,,,,,,9,10116.0,10576,1,Expert,,,872,,10639,D,CHEMBL615927,BAO_0000019,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,873,,12306,H,CHEMBL615928,BAO_0000221,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,
B,,,,,,,9,10116.0,10576,1,Expert,,,874,,1348,D,CHEMBL615929,BAO_0000357,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,875,,13605,H,CHEMBL615930,BAO_0000221,Hippocampus,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,876,,17624,H,CHEMBL615931,BAO_0000219,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,877,,17624,H,CHEMBL615932,BAO_0000219,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,878,,17624,H,CHEMBL615933,BAO_0000219,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,879,,15267,H,CHEMBL615934,BAO_0000357,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,880,,16532,H,CHEMBL615935,BAO_0000357,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,
F,,,,,,,8,,51,1,Autocuration,,,881,,6563,H,CHEMBL615936,BAO_0000019,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,882,,4751,H,CHEMBL615937,BAO_0000219,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,
B,,,,,,,8,,51,1,Autocuration,,,883,,15463,H,CHEMBL615938,BAO_0000357,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,884,,3805,H,CHEMBL615797,BAO_0000357,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),
B,,,,,,,8,,51,1,Autocuration,,,885,,5640,H,CHEMBL615798,BAO_0000357,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,886,,6563,H,CHEMBL872870,BAO_0000357,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,
B,,,,,,,8,,51,1,Autocuration,,,887,,5548,H,CHEMBL615799,BAO_0000357,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,
B,,,,,,,8,,51,1,Autocuration,,,888,,6347,H,CHEMBL615800,BAO_0000357,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,
F,HEK293,722.0,,,,,8,,51,1,Autocuration,,,889,,17296,H,CHEMBL615801,BAO_0000219,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,
B,,,,,,,8,,51,1,Autocuration,,,890,,13047,H,CHEMBL615802,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,
B,,,,,,,8,,51,1,Autocuration,,,891,,15740,H,CHEMBL615803,BAO_0000357,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,
F,,,,,,,8,,51,1,Expert,,,892,,5640,H,CHEMBL835002,BAO_0000019,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",
F,,,,,,,8,,51,1,Autocuration,,,893,,5640,H,CHEMBL615804,BAO_0000019,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",
B,HeLa,308.0,,,,,8,,51,1,Expert,,,894,,17211,H,CHEMBL615805,BAO_0000219,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,895,,4751,H,CHEMBL615806,BAO_0000219,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,
B,,,,,,,9,9606.0,51,1,Expert,,,896,,6491,D,CHEMBL615807,BAO_0000357,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,Homo sapiens
B,,,,,,,8,,51,1,Autocuration,,,897,,4707,H,CHEMBL615808,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,
B,,,,,,,9,9606.0,51,1,Expert,,,898,,13910,D,CHEMBL615809,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor,Homo sapiens
B,HeLa,308.0,,,,,8,,51,1,Autocuration,,,899,,16190,H,CHEMBL615810,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,
B,,,,,,,8,,51,1,Autocuration,,,900,,16633,H,CHEMBL615811,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,901,,11898,H,CHEMBL615812,BAO_0000219,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,902,,11898,H,CHEMBL615751,BAO_0000219,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,
B,,,,,,,8,,51,1,Autocuration,,,903,,14331,H,CHEMBL615752,BAO_0000357,,Binding affinity against human 5-hydroxytryptamine 1A receptor,
B,CHO,449.0,,,,,8,,51,1,Expert,,,904,,17624,H,CHEMBL615753,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,905,,17624,H,CHEMBL615754,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,
B,,,,,,,8,,51,1,Autocuration,,,906,,3307,H,CHEMBL615755,BAO_0000357,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,
B,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,907,,6563,D,CHEMBL615756,BAO_0000219,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Homo sapiens
B,,,,,,,8,,51,1,Autocuration,,,908,,14165,H,CHEMBL615757,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,909,,5732,H,CHEMBL615758,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,
B,,,,,,,8,,51,1,Expert,,,910,,13366,H,CHEMBL615759,BAO_0000357,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,
B,,,,,,,8,,51,1,Autocuration,,,911,,17626,H,CHEMBL615760,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,
B,HeLa,308.0,,,,,8,,51,1,Expert,,,912,,6588,H,CHEMBL615761,BAO_0000219,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,
B,,,,,,,8,,51,1,Autocuration,,,913,,16209,H,CHEMBL872104,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,914,,15463,H,CHEMBL615762,BAO_0000357,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,915,,15463,H,CHEMBL615763,BAO_0000357,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,916,,14770,H,CHEMBL615764,BAO_0000357,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,
B,Cell line,1167.0,,,,,8,,51,1,Autocuration,,,917,,16245,H,CHEMBL615765,BAO_0000219,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),
B,,,,,,,8,,51,1,Autocuration,,,918,,16245,H,CHEMBL615766,BAO_0000019,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),
B,,,,,,,8,,51,1,Autocuration,,,919,,5548,H,CHEMBL615767,BAO_0000357,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Expert,,,920,,5548,H,CHEMBL615768,BAO_0000357,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,921,,5548,H,CHEMBL615769,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Expert,,,922,,6876,H,CHEMBL615770,BAO_0000357,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,
B,,,,,,,8,,51,1,Autocuration,,,923,,2598,H,CHEMBL615771,BAO_0000357,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Expert,,,924,,17785,H,CHEMBL615772,BAO_0000357,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,925,,6013,H,CHEMBL615773,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Expert,,,926,,5929,H,CHEMBL615774,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,927,,16633,H,CHEMBL615775,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,928,,1558,H,CHEMBL615776,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,
B,,,,,,,8,,51,1,Expert,,,929,,16026,H,CHEMBL615777,BAO_0000357,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,930,,12469,H,CHEMBL615778,BAO_0000219,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,
B,,,,,,,9,9606.0,51,1,Expert,,,931,,15874,D,CHEMBL615779,BAO_0000357,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Homo sapiens
B,,,,,,,8,,51,1,Autocuration,,,932,,15874,H,CHEMBL615780,BAO_0000357,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,
B,,,,,,,8,,51,1,Autocuration,,,933,,3935,H,CHEMBL616298,BAO_0000357,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,934,,15818,H,CHEMBL616299,BAO_0000357,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,
B,CHO-K1,485.0,,,,,8,,51,1,Autocuration,,,935,,13706,H,CHEMBL616300,BAO_0000219,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,
F,CHO-K1,485.0,,,,,8,,51,1,Expert,,,936,,13729,H,CHEMBL616301,BAO_0000219,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,
B,,,,,,,8,,51,1,Autocuration,,,937,,15413,H,CHEMBL616302,BAO_0000019,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,938,,15413,H,CHEMBL616117,BAO_0000019,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),
B,,,,,,,8,,51,1,Autocuration,,,939,,15413,H,CHEMBL616118,BAO_0000019,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),
B,,,,,,,8,,51,1,Autocuration,,,940,,15413,H,CHEMBL616119,BAO_0000019,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,
B,HeLa,308.0,,,,,9,9606.0,51,1,Expert,,,941,,3445,D,CHEMBL616120,BAO_0000219,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Homo sapiens
B,,,,,,,8,,51,1,Autocuration,,,942,,15740,H,CHEMBL616121,BAO_0000357,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,943,,15740,H,CHEMBL616122,BAO_0000357,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,
B,,,,,,,8,,51,1,Autocuration,,,944,,17626,H,CHEMBL616123,BAO_0000357,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,
B,,,,,,,9,9606.0,51,1,Expert,,,945,,4234,D,CHEMBL616124,BAO_0000357,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,Homo sapiens
B,,,,,,,8,,51,1,Expert,,,946,,5640,H,CHEMBL616125,BAO_0000357,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,
B,,,,,,,8,10116.0,51,1,Expert,,,947,,5272,H,CHEMBL616126,BAO_0000357,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,Rattus norvegicus
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,948,,4622,H,CHEMBL616127,BAO_0000219,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Expert,,,949,,17085,H,CHEMBL616128,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,950,,3025,H,CHEMBL616129,BAO_0000357,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,
B,,,,,,,8,,51,1,Expert,,,951,,15315,H,CHEMBL616130,BAO_0000357,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,952,,15267,H,CHEMBL616131,BAO_0000357,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,
B,HeLa,308.0,,,,,8,,51,1,Autocuration,,,953,,17158,H,CHEMBL616132,BAO_0000219,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,
B,HeLa,308.0,,,,,9,9606.0,51,1,Expert,,,954,,14214,D,CHEMBL616133,BAO_0000219,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,Homo sapiens
B,,,,,,,8,,51,1,Autocuration,,,955,,17133,H,CHEMBL616134,BAO_0000357,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,956,,16532,H,CHEMBL616135,BAO_0000357,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,
B,,,,,,,9,9606.0,51,1,Expert,,,957,,2391,D,CHEMBL616136,BAO_0000357,,Affinity for 5-hydroxytryptamine 1A receptor subtype,Homo sapiens
B,,,,,,,8,,51,1,Autocuration,,,958,,14447,H,CHEMBL616137,BAO_0000019,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,
B,,,,,,,8,,51,1,Autocuration,,,959,,14447,H,CHEMBL872105,BAO_0000019,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,
B,,,,,,,8,,51,1,Autocuration,,,960,,15086,H,CHEMBL616138,BAO_0000357,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,
B,,,,,,,9,9606.0,51,1,Expert,,,961,,13051,D,CHEMBL616139,BAO_0000357,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens
F,,,,,,,8,,51,1,Autocuration,,,962,,16026,H,CHEMBL616140,BAO_0000019,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",
B,,,,,,,8,,51,1,Expert,,,963,,17085,H,CHEMBL616141,BAO_0000019,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,
B,,,,,,,8,,51,1,Autocuration,,,964,,17133,H,CHEMBL616142,BAO_0000357,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Autocuration,,,965,,17133,H,CHEMBL616143,BAO_0000357,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,
B,HeLa,308.0,,,,,8,,51,1,Autocuration,,,966,,17211,H,CHEMBL616144,BAO_0000219,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,
B,HeLa,308.0,,,,,8,,51,1,Autocuration,,,967,,17211,H,CHEMBL616145,BAO_0000219,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,
B,HeLa,308.0,,,,,8,,51,1,Autocuration,,,968,,17211,H,CHEMBL616012,BAO_0000219,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,
B,HeLa,308.0,,,,,8,,51,1,Autocuration,,,969,,17211,H,CHEMBL616013,BAO_0000219,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,
F,,,,,,,8,,51,1,Autocuration,,,970,,16394,H,CHEMBL616014,BAO_0000019,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",
F,,,,,,,8,,51,1,Autocuration,,,971,,16394,H,CHEMBL616015,BAO_0000019,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",
F,,,,,,,8,,51,1,Autocuration,,,972,,16394,H,CHEMBL616016,BAO_0000019,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",
F,,,In vivo,,,,8,,51,1,Autocuration,,,973,,16394,H,CHEMBL616017,BAO_0000218,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,
B,,,,,,,8,,51,1,Autocuration,,,974,,16394,H,CHEMBL616018,BAO_0000019,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,
F,,,,,,,8,,51,1,Autocuration,,,975,,15740,H,CHEMBL616019,BAO_0000019,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,
F,,,,,,,8,,51,1,Autocuration,,,976,,15740,H,CHEMBL616020,BAO_0000019,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,
B,,,,,,,8,,51,1,Autocuration,,,977,,15740,H,CHEMBL858018,BAO_0000357,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,
F,HEK293,722.0,,,,,8,,51,1,Autocuration,,,978,,17296,H,CHEMBL616021,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,
F,,,,,,,8,,51,1,Expert,,,979,,5640,H,CHEMBL616022,BAO_0000019,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",
F,,,,,,,8,,51,1,Autocuration,,,980,,5640,H,CHEMBL616023,BAO_0000019,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",
F,,,,,,,8,,51,1,Autocuration,,,981,,5640,H,CHEMBL616024,BAO_0000019,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",
F,,,,,,,8,,51,1,Autocuration,,,982,,5640,H,CHEMBL616025,BAO_0000019,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,983,,2759,H,CHEMBL616026,BAO_0000219,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,
F,,,,,,,8,,51,1,Autocuration,,,984,,16394,H,CHEMBL616027,BAO_0000019,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",
F,,,,,,,9,9606.0,51,1,Expert,,,985,,16394,D,CHEMBL616028,BAO_0000019,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,986,,3445,D,CHEMBL616029,BAO_0000019,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,Homo sapiens
B,CHO,449.0,,,,,8,,51,1,Expert,,,987,,4316,H,CHEMBL616030,BAO_0000219,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,
B,,,,,,,8,,51,1,Expert,,,988,,4316,H,CHEMBL616031,BAO_0000019,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,
F,,,,,,,9,9606.0,51,1,Expert,,,989,,15180,D,CHEMBL616032,BAO_0000019,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,990,,15180,D,CHEMBL616033,BAO_0000019,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Homo sapiens
F,,,,,,,8,,51,1,Autocuration,,,991,,15042,H,CHEMBL616034,BAO_0000019,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,
F,,,,,,,8,,51,1,Autocuration,,,992,,15042,H,CHEMBL616035,BAO_0000019,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,
F,,,,,,,8,,51,1,Autocuration,,,993,,15042,H,CHEMBL616036,BAO_0000019,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,
F,,,,,,,8,,51,1,Autocuration,,,994,,15042,H,CHEMBL616037,BAO_0000019,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,
F,,,,,,,8,,51,1,Autocuration,,,995,,15042,H,CHEMBL616038,BAO_0000019,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,
F,,,,,,,8,,51,1,Autocuration,,,996,,15042,H,CHEMBL616039,BAO_0000019,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,
F,,,,,,,8,,51,1,Autocuration,,,997,,15042,H,CHEMBL616040,BAO_0000019,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,
F,HeLa,308.0,,,,,9,9606.0,51,1,Expert,,,998,,15180,D,CHEMBL616041,BAO_0000219,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens
F,HeLa,308.0,,,,,9,9606.0,51,1,Expert,,,999,,15180,D,CHEMBL616042,BAO_0000219,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens
F,HeLa,308.0,,,,,9,9606.0,51,1,Expert,,,1000,,15180,D,CHEMBL616043,BAO_0000219,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens
F,,,,,,,8,,51,1,Autocuration,,,1001,,16245,H,CHEMBL616044,BAO_0000019,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",
F,,,,,,,8,,51,1,Autocuration,,,1002,,16026,H,CHEMBL616045,BAO_0000019,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",
F,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1003,,17296,H,CHEMBL616046,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,1004,,2759,H,CHEMBL616047,BAO_0000219,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,1005,,2759,H,CHEMBL616048,BAO_0000219,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,
F,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,1006,,2759,D,CHEMBL616049,BAO_0000219,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),Homo sapiens
F,CHO,449.0,,,,,8,,51,1,Autocuration,,,1007,,2759,H,CHEMBL616050,BAO_0000219,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),
F,,,,,,,8,,51,1,Expert,,,1008,,15419,H,CHEMBL616051,BAO_0000219,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,
F,,,,,,,8,,51,1,Autocuration,,,1009,,15419,H,CHEMBL616212,BAO_0000219,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,
F,,,,,,,8,,51,1,Autocuration,,,1010,,16026,H,CHEMBL616213,BAO_0000019,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",
B,,,In vitro,,,,8,,51,1,Expert,,,1011,,1414,H,CHEMBL616214,BAO_0000219,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,
B,,,In vitro,,,,8,,51,1,Expert,,,1012,,1414,H,CHEMBL616215,BAO_0000219,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,
B,,,,,,,8,,51,1,Autocuration,,,1013,,12861,H,CHEMBL616216,BAO_0000357,,Binding activity radioligand.,
B,,,,,,,8,,51,1,Autocuration,,,1014,,12861,H,CHEMBL616217,BAO_0000019,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,
B,,,,,,,8,,51,1,Autocuration,,,1015,,5104,H,CHEMBL616218,BAO_0000357,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,1016,,5105,H,CHEMBL616219,BAO_0000357,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,1017,,16312,H,CHEMBL616220,BAO_0000357,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,
B,,,,,,,9,9606.0,51,1,Expert,,,1018,,15180,D,CHEMBL833493,BAO_0000357,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,Homo sapiens
B,,,,,,,8,,51,1,Autocuration,,,1019,,5033,H,CHEMBL616221,BAO_0000357,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,
B,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,1020,,16909,D,CHEMBL616222,BAO_0000219,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Homo sapiens
F,,,,,,,8,,51,1,Autocuration,,,1021,,2590,H,CHEMBL616223,BAO_0000019,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,
F,,,,,,,8,,51,1,Autocuration,,,1022,,2590,H,CHEMBL616224,BAO_0000019,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,
B,,,,,,,8,,51,1,Expert,,,1023,,16394,H,CHEMBL616225,BAO_0000019,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,
B,HEK293,722.0,,,,,9,9606.0,51,1,Expert,,,1024,,4540,D,CHEMBL616226,BAO_0000219,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,Homo sapiens
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1025,,17296,H,CHEMBL616227,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1026,,17296,H,CHEMBL616228,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1027,,15779,H,CHEMBL616229,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1028,,15779,H,CHEMBL616230,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1029,,15779,H,CHEMBL616231,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,
B,,,,,,,8,,51,1,Autocuration,,,1030,,6166,H,CHEMBL616232,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1031,,15779,H,CHEMBL616233,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1032,,4199,H,CHEMBL857973,BAO_0000219,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,
B,,,,,,,8,,51,1,Autocuration,,,1033,,15316,H,CHEMBL616234,BAO_0000219,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,
B,,,,,,,8,,51,1,Autocuration,,,1034,,14875,H,CHEMBL616235,BAO_0000357,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,
B,HeLa,308.0,,,,,8,,51,1,Expert,,,1035,,14727,H,CHEMBL616236,BAO_0000219,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,
B,,,,,,,8,,51,1,Expert,,,1036,,14727,H,CHEMBL616237,BAO_0000019,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1037,,15146,H,CHEMBL616238,BAO_0000219,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1038,,5213,H,CHEMBL616239,BAO_0000219,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,
B,,,,,,,8,,51,1,Autocuration,,,1039,,16429,H,CHEMBL616240,BAO_0000219,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,
B,HeLa,308.0,,,,,9,9606.0,51,1,Expert,,,1040,,15042,D,CHEMBL616241,BAO_0000219,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,Homo sapiens
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1041,,14818,H,CHEMBL616242,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,
B,HEK293,722.0,,,,,8,,51,1,Autocuration,,,1042,,4829,H,CHEMBL616243,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",
B,,,,,,,9,,51,1,Expert,,,1043,,17200,D,CHEMBL616244,BAO_0000357,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,
B,,,,,,,9,9606.0,51,1,Autocuration,,,1044,,13051,D,CHEMBL616245,BAO_0000357,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens
B,,,,,,,8,,106,1,Autocuration,,,1045,,5486,H,CHEMBL616246,BAO_0000357,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,
B,,,,,,,8,,105,1,Autocuration,,,1046,,5254,H,CHEMBL616247,BAO_0000357,,Binding affinity against 5-HT1D receptor,
B,,,,,,,8,,105,1,Autocuration,,,1047,,5254,H,CHEMBL616248,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,107,1,Autocuration,,,1048,,15331,H,CHEMBL616249,BAO_0000357,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,
B,,,,,,,8,9606.0,10576,1,Autocuration,,,1049,,13506,H,CHEMBL616250,BAO_0000357,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Homo sapiens
B,,,,,,,8,,51,1,Autocuration,,,1050,,15267,H,CHEMBL616251,BAO_0000357,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,
F,,,In vivo,,,,8,,11863,1,Autocuration,,,1051,,16616,H,CHEMBL616252,BAO_0000218,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,
F,,,In vivo,,,,8,,11863,1,Autocuration,,,1052,,16616,H,CHEMBL616253,BAO_0000218,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,
F,,,In vivo,,,,8,,11863,1,Autocuration,,,1053,,16616,H,CHEMBL616254,BAO_0000218,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,
F,,,,,,,9,10090.0,11863,1,Expert,,,1054,,16616,D,CHEMBL616255,BAO_0000218,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,Mus musculus
F,,,,,,,9,10090.0,11863,1,Expert,,,1055,,16616,D,CHEMBL832872,BAO_0000218,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,Mus musculus
F,,,,,,,9,10090.0,11863,1,Expert,,,1056,,16616,D,CHEMBL616256,BAO_0000218,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,Mus musculus
F,,,,,,,9,10090.0,11863,1,Expert,,,1057,,16616,D,CHEMBL616257,BAO_0000218,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,Mus musculus
F,,,,,,,9,10090.0,11863,1,Expert,,,1058,,16616,D,CHEMBL616258,BAO_0000218,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,Mus musculus
F,,,,,,,9,10090.0,11863,1,Expert,,,1059,,16616,D,CHEMBL616384,BAO_0000218,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,Mus musculus
B,,,,,10000000.0,,8,,11863,1,Autocuration,,,1060,,10297,H,CHEMBL616385,BAO_0000221,Hippocampus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,
B,,,,,,,8,,11863,1,Expert,,,1061,,13704,H,CHEMBL616386,BAO_0000357,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,
B,,,,,10000000.0,,9,10090.0,11863,1,Expert,,,1062,,10297,D,CHEMBL616387,BAO_0000221,Hippocampus,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Mus musculus
B,,,,,10000000.0,,8,,11863,1,Autocuration,,,1063,,10297,H,CHEMBL616388,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,
B,,,,,10000000.0,,9,10090.0,11863,1,Expert,,,1064,,10297,D,CHEMBL616389,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Mus musculus
B,,,,,10000000.0,,8,,11863,1,Autocuration,,,1065,,10297,H,CHEMBL616390,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,
B,,,,,,,8,,11863,1,Autocuration,,,1066,,217,H,CHEMBL616391,BAO_0000357,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,
B,,,,,10000000.0,,9,10090.0,11863,1,Expert,,,1067,,10297,D,CHEMBL616392,BAO_0000221,Hippocampus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Mus musculus
B,,,,,,,8,9823.0,51,1,Autocuration,,,1068,,4921,H,CHEMBL616393,BAO_0000357,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,Sus scrofa
B,,,,,,,8,9823.0,51,1,Autocuration,,,1069,,4921,H,CHEMBL616394,BAO_0000357,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,Sus scrofa
B,,,,,,,8,9823.0,51,1,Autocuration,,,1070,,4996,H,CHEMBL616395,BAO_0000019,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,Sus scrofa
B,,,,,,,8,9823.0,51,1,Autocuration,,,1071,,12918,H,CHEMBL616396,BAO_0000357,,Compound was evaluated for the binding affinity at 5- HT1A receptor,Sus scrofa
B,,,,,,,8,9823.0,51,1,Autocuration,,,1072,,5333,H,CHEMBL872907,BAO_0000019,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Sus scrofa
B,,,,,,,8,9823.0,51,1,Autocuration,,,1073,,4437,H,CHEMBL616397,BAO_0000019,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Sus scrofa
B,,,,,,,8,9823.0,51,1,Autocuration,,,1074,,1742,H,CHEMBL616398,BAO_0000019,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,Sus scrofa
B,,,,,,,8,9823.0,51,1,Expert,,,1075,,16688,H,CHEMBL616399,BAO_0000357,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,Sus scrofa
B,,,,,,,8,9823.0,51,1,Autocuration,,,1076,,12861,H,CHEMBL857065,BAO_0000357,,Binding activity radioligand.,Sus scrofa
B,,,,,,,8,9823.0,51,1,Expert,,,1077,,12861,H,CHEMBL616400,BAO_0000019,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Sus scrofa
B,,,,,,,8,9823.0,51,1,Autocuration,,,1078,,12861,H,CHEMBL616401,BAO_0000019,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Sus scrofa
B,,,,,,,8,,10624,1,Expert,,,1079,,12490,H,CHEMBL616402,BAO_0000019,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,
B,,,,,,,8,9823.0,51,1,Expert,,,1080,,11828,H,CHEMBL616403,BAO_0000019,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,Sus scrofa
B,,,,,10000000.0,,8,9823.0,51,1,Autocuration,,,1081,,11866,H,CHEMBL616404,BAO_0000221,Hippocampus,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Sus scrofa
B,,,,,,,8,9823.0,51,1,Autocuration,,,1082,,12827,H,CHEMBL616405,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,Sus scrofa
B,,,,,,,8,9823.0,51,1,Autocuration,,,1083,,12918,H,CHEMBL616406,BAO_0000019,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,Sus scrofa
F,,,,,,,8,9823.0,51,1,Expert,,,1084,,12919,H,CHEMBL616407,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,Sus scrofa
B,,,,,,,8,9986.0,51,1,Autocuration,,,1085,,13047,H,CHEMBL616408,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,Oryctolagus cuniculus
B,,,,,,,9,10116.0,10576,1,Expert,,,1086,,15796,D,CHEMBL616409,BAO_0000249,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,Rattus norvegicus
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1087,,3651,D,CHEMBL616410,BAO_0000221,Hippocampus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1088,,188,H,CHEMBL616411,BAO_0000357,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,
F,,,,,,,9,10116.0,10576,1,Expert,,,1089,Membranes,16616,D,CHEMBL616412,BAO_0000249,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Rattus norvegicus
F,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1090,Membranes,16616,D,CHEMBL616413,BAO_0000249,Hippocampus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1091,,12306,H,CHEMBL616414,BAO_0000221,Hippocampus,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1092,,17167,D,CHEMBL616415,BAO_0000221,Hippocampus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1093,,14776,H,CHEMBL616416,BAO_0000019,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,
B,,,,,,,8,,10576,1,Expert,,,1094,,12158,H,CHEMBL616417,BAO_0000357,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,
B,,,,,,,8,,10576,1,Autocuration,,,1095,,13481,H,CHEMBL616418,BAO_0000357,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,
B,,,In vitro,,,,8,,10576,1,Autocuration,,,1096,,13427,H,CHEMBL616419,BAO_0000219,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,
B,,,,,,,8,,10576,1,Autocuration,,,1097,,10210,H,CHEMBL616420,BAO_0000357,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,
B,,,,,,,8,,10576,1,Autocuration,,,1098,Membranes,10205,H,CHEMBL616421,BAO_0000249,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,
B,,,,,,,8,,10576,1,Autocuration,,,1099,Membranes,10205,H,CHEMBL616422,BAO_0000249,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,
B,,,,,,,8,,10576,1,Expert,,,1100,Membranes,10205,H,CHEMBL616423,BAO_0000249,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,
B,,,,,,,9,10116.0,10576,1,Expert,,,1101,,12280,D,CHEMBL616424,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,Rattus norvegicus
B,,,,,,,8,,10576,1,Expert,,,1102,,17386,H,CHEMBL616425,BAO_0000357,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Expert,,,1103,,13654,H,CHEMBL616426,BAO_0000357,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1104,,14423,H,CHEMBL616427,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1105,,15412,H,CHEMBL616428,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1106,,12073,H,CHEMBL616290,BAO_0000221,Hippocampus,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,
B,,,,,,,9,10116.0,10576,1,Expert,,,1107,,4101,D,CHEMBL616052,BAO_0000357,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1108,,10062,H,CHEMBL616053,BAO_0000357,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Autocuration,,,1109,,6238,H,CHEMBL616054,BAO_0000249,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,10576,1,Autocuration,,,1110,,16273,H,CHEMBL616055,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Autocuration,,,1111,,11139,H,CHEMBL616056,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,
B,,,,,,,8,,10576,1,Expert,,,1112,,16796,H,CHEMBL616057,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,
B,,,,,955.0,,9,10116.0,10576,1,Expert,,,1113,,9548,D,CHEMBL616058,BAO_0000221,Brain,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Rattus norvegicus
B,,,,,955.0,,8,,10576,1,Autocuration,,,1114,,10381,H,CHEMBL616059,BAO_0000221,Brain,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,
B,,,,,,,8,,10576,1,Autocuration,,,1115,,13408,H,CHEMBL616060,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1116,,13825,D,CHEMBL616061,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Expert,,,1117,,11147,H,CHEMBL616062,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,
B,,,,,,,8,,10576,1,Autocuration,,,1118,,10552,H,CHEMBL616063,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,
B,,,,,2435.0,,8,,10576,1,Autocuration,,,1119,,10552,H,CHEMBL616064,BAO_0000249,Striatum,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",
B,,,,,,,9,10116.0,10576,1,Expert,,,1120,Membranes,17136,D,CHEMBL616065,BAO_0000249,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Rattus norvegicus
B,,,,,,,9,10116.0,10576,1,Expert,,,1121,Membranes,5778,D,CHEMBL616066,BAO_0000249,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1122,,13481,H,CHEMBL616067,BAO_0000221,Hippocampus,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1123,,13481,H,CHEMBL616068,BAO_0000221,Hippocampus,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,
B,,,,,10000000.0,,8,,10576,1,Intermediate,,,1124,,13630,H,CHEMBL616069,BAO_0000221,Hippocampus,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,10576,1,Expert,,,1125,,16245,H,CHEMBL616070,BAO_0000249,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1126,,14509,H,CHEMBL616071,BAO_0000221,Hippocampus,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1127,,14509,H,CHEMBL616072,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1128,,14509,H,CHEMBL616073,BAO_0000221,Hippocampus,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1129,,14509,H,CHEMBL616074,BAO_0000221,Hippocampus,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,
B,,,,,,,8,,10576,1,Expert,,,1130,,14256,H,CHEMBL616075,BAO_0000019,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,
B,,,,,,,8,,10576,1,Autocuration,,,1131,,11139,H,CHEMBL616076,BAO_0000357,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,
B,,,,,,,9,10116.0,10576,1,Expert,,,1132,,11047,D,CHEMBL616077,BAO_0000019,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,Rattus norvegicus
B,,,,,,,9,10116.0,10576,1,Expert,,,1133,,11047,D,CHEMBL616078,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,Rattus norvegicus
B,,,,,,,9,10116.0,10576,1,Expert,,,1134,,11047,D,CHEMBL616079,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,Rattus norvegicus
B,CHO-K1,485.0,,,,,9,10116.0,10576,1,Expert,,,1135,,2395,D,CHEMBL616080,BAO_0000219,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1136,,9699,H,CHEMBL616081,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1137,,12028,D,CHEMBL616082,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1138,,12028,H,CHEMBL616083,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,
B,,,,,,,8,,10576,1,Autocuration,,,1139,,5815,H,CHEMBL616084,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,
B,,,,,,,8,,10576,1,Expert,,,1140,,16616,H,CHEMBL616085,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,
B,,,,,,,8,,10576,1,Autocuration,,,1141,,5815,H,CHEMBL616086,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1142,,2761,H,CHEMBL616087,BAO_0000221,Hippocampus,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",
B,,,,,,,8,,10576,1,Expert,,,1143,,13133,H,CHEMBL616088,BAO_0000357,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,
B,,,,,,,8,,10576,1,Autocuration,,,1144,,10444,H,CHEMBL616089,BAO_0000019,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,
B,,,,,,,9,10116.0,10576,1,Expert,,,1145,,13278,D,CHEMBL616090,BAO_0000357,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1146,,15874,H,CHEMBL616091,BAO_0000357,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,
B,,,,,2435.0,,8,,10576,1,Autocuration,,,1147,Membranes,10552,H,CHEMBL616092,BAO_0000249,Striatum,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",
B,,,,,,,8,,10576,1,Autocuration,,,1148,,11130,H,CHEMBL616093,BAO_0000357,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),
B,,,In vivo,,,,8,,10576,1,Autocuration,,,1149,,11130,H,CHEMBL616094,BAO_0000218,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),
B,,,,,955.0,,8,,10576,1,Autocuration,,,1150,,14542,H,CHEMBL616095,BAO_0000221,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,
B,,,,,,,9,10116.0,10576,1,Expert,,,1151,,13670,D,CHEMBL616096,BAO_0000357,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Rattus norvegicus
B,,,,,,,8,,10576,1,Expert,,,1152,,9888,H,CHEMBL616097,BAO_0000249,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,
B,,,,,,,9,10116.0,10576,1,Expert,,,1153,Membranes,3678,D,CHEMBL616098,BAO_0000249,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1154,,11332,H,CHEMBL616099,BAO_0000221,Hippocampus,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1155,,11332,H,CHEMBL616100,BAO_0000221,Hippocampus,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,10576,1,Expert,,,1156,,1185,H,CHEMBL616101,BAO_0000357,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Expert,,,1157,,2014,H,CHEMBL616102,BAO_0000249,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,
B,,,,,,,8,,10576,1,Autocuration,,,1158,,1185,H,CHEMBL616103,BAO_0000357,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Expert,,,1159,,14429,H,CHEMBL616104,BAO_0000019,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,
B,,,,,,,8,,10576,1,Expert,,,1160,,16288,H,CHEMBL616105,BAO_0000019,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",
B,,,,,,,9,10116.0,10576,1,Expert,,,1161,,5432,D,CHEMBL616106,BAO_0000019,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1162,,14429,H,CHEMBL616107,BAO_0000019,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,
B,,,,,,,8,,10576,1,Expert,,,1163,,13672,H,CHEMBL616108,BAO_0000357,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1164,,11296,H,CHEMBL616109,BAO_0000221,Hippocampus,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,
B,,,,,,,8,,10576,1,Autocuration,,,1165,,11296,H,CHEMBL616110,BAO_0000357,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,
B,CHO,449.0,,,,,8,,10576,1,Expert,,,1166,,14749,H,CHEMBL616111,BAO_0000219,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,
B,,,,,,,8,,10576,1,Expert,,,1167,,15086,H,CHEMBL616112,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1168,,13462,H,CHEMBL616113,BAO_0000221,Hippocampus,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,
B,,,,,,,8,,10576,1,Autocuration,,,1169,,15363,H,CHEMBL616114,BAO_0000019,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Autocuration,,,1170,,15363,H,CHEMBL616115,BAO_0000019,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Autocuration,,,1171,,10796,H,CHEMBL616116,BAO_0000357,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,
B,,,,,955.0,,8,,10576,1,Expert,,,1172,,12816,H,CHEMBL615844,BAO_0000221,Brain,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1173,,13542,H,CHEMBL615939,BAO_0000221,Hippocampus,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Expert,,,1174,,13308,H,CHEMBL615940,BAO_0000019,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1175,,13541,H,CHEMBL615941,BAO_0000221,Hippocampus,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1176,,10058,H,CHEMBL615942,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1177,,10058,H,CHEMBL615943,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1178,,10058,H,CHEMBL615944,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1179,,10058,H,CHEMBL615945,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1180,,10058,H,CHEMBL615946,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1181,,10058,H,CHEMBL615947,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1182,,10058,H,CHEMBL615948,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1183,,10058,H,CHEMBL615949,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1184,,10058,H,CHEMBL615950,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1185,,10058,H,CHEMBL615951,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1186,,10058,H,CHEMBL615952,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1187,,10058,H,CHEMBL615953,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1188,,10058,H,CHEMBL615954,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1189,,10058,D,CHEMBL615955,BAO_0000221,Hippocampus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1190,,10058,H,CHEMBL615956,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1191,,10058,H,CHEMBL615957,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,
B,,,,,,,8,,10576,1,Expert,,,1192,,12879,H,CHEMBL615958,BAO_0000019,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,
B,,,,,,,8,,10576,1,Expert,,,1193,,11964,H,CHEMBL615959,BAO_0000019,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,
B,,,,,,,8,,10576,1,Autocuration,,,1194,,11964,H,CHEMBL615960,BAO_0000019,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),
B,,,,,,,8,,10576,1,Autocuration,,,1195,,11964,H,CHEMBL615961,BAO_0000019,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),
B,,,,,955.0,,8,,10576,1,Expert,,,1196,,9548,H,CHEMBL615962,BAO_0000221,Brain,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,
B,,,,,,,8,,10576,1,Expert,,,1197,,9098,H,CHEMBL615963,BAO_0000019,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,
B,,,,,,,8,,10576,1,Autocuration,,,1198,,9098,H,CHEMBL615964,BAO_0000019,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,
B,,,,,,,8,,10576,1,Autocuration,,,1199,,9098,H,CHEMBL615965,BAO_0000019,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,
B,CHO,449.0,,,,,8,,10576,1,Expert,,,1200,,13248,H,CHEMBL615966,BAO_0000219,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,
B,,,,,,,8,,10576,1,Expert,,,1201,,3147,H,CHEMBL615967,BAO_0000249,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,
B,,,,,,,8,,10576,1,Expert,,,1202,,13949,H,CHEMBL615968,BAO_0000019,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,
B,CHO,449.0,,,,,8,,10576,1,Autocuration,,,1203,,11883,H,CHEMBL615969,BAO_0000218,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),
B,,,,,,,8,,10576,1,Autocuration,,,1204,,11883,H,CHEMBL615970,BAO_0000218,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),
B,,,,,,,9,10116.0,10576,1,Expert,,,1205,,11883,D,CHEMBL615971,BAO_0000357,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,Rattus norvegicus
B,,,,,,,8,,10576,1,Expert,,,1206,Membranes,15535,H,CHEMBL615972,BAO_0000249,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,
B,,,,,,,8,,10576,1,Autocuration,,,1207,,15535,H,CHEMBL615973,BAO_0000249,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,
B,,,,,,,8,,10576,1,Autocuration,,,1208,,15535,H,CHEMBL615974,BAO_0000249,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,
B,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,1209,,16372,D,CHEMBL615975,BAO_0000219,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Homo sapiens
B,,,,,,,8,,10576,1,Expert,,,1210,,14608,H,CHEMBL615976,BAO_0000249,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1211,,4795,D,CHEMBL872106,BAO_0000221,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1212,,13863,H,CHEMBL615977,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,10576,1,Autocuration,,,1213,,13863,H,CHEMBL615978,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,
B,,,,,,,8,,10576,1,Autocuration,,,1214,,13863,H,CHEMBL616166,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,
B,,,,,,,8,,10576,1,Autocuration,,,1215,,13863,H,CHEMBL616167,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,
B,,,,,,,8,,10576,1,Autocuration,,,1216,,13863,H,CHEMBL616168,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,
B,,,,,,,8,,10576,1,Autocuration,,,1217,,13863,H,CHEMBL616169,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,
B,,,,,,,8,,10576,1,Autocuration,,,1218,,13863,H,CHEMBL616170,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,
B,,,,,,,8,,10576,1,Autocuration,,,1219,,13863,H,CHEMBL616171,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,
B,,,,,,,8,,10576,1,Autocuration,,,1220,,13863,H,CHEMBL616172,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,
B,,,,,,,8,,10576,1,Autocuration,,,1221,,13863,H,CHEMBL616173,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,
B,,,,,,,8,,10576,1,Autocuration,,,1222,,13863,H,CHEMBL616174,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,
B,,,,,,,8,,10576,1,Autocuration,,,1223,,13863,H,CHEMBL616175,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,
B,,,,,,,8,,10576,1,Autocuration,,,1224,,13863,H,CHEMBL616176,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,
B,,,,,,,8,,10576,1,Autocuration,,,1225,,13863,H,CHEMBL616177,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,
B,,,,,,,8,,10576,1,Autocuration,,,1226,,13863,H,CHEMBL616178,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,
B,,,,,,,8,,10576,1,Autocuration,,,1227,,9742,H,CHEMBL616179,BAO_0000019,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,
B,,,,,,,8,,10576,1,Autocuration,,,1228,,12073,H,CHEMBL616180,BAO_0000357,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Autocuration,,,1229,,4101,H,CHEMBL616181,BAO_0000357,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,
B,,,,,,,8,,10576,1,Autocuration,,,1230,,15360,H,CHEMBL616182,BAO_0000019,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1231,,11576,H,CHEMBL616183,BAO_0000221,Hippocampus,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Expert,,,1232,,5834,H,CHEMBL615874,BAO_0000019,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,
B,CHO-K1,485.0,,,,,9,10116.0,10576,1,Expert,,,1233,,2395,D,CHEMBL615875,BAO_0000219,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1234,,1375,H,CHEMBL615876,BAO_0000019,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,
B,,,,,,,8,,10576,1,Autocuration,,,1235,,1375,H,CHEMBL615877,BAO_0000019,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,
B,,,,,,,8,,10576,1,Autocuration,,,1236,,3967,H,CHEMBL615878,BAO_0000357,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),
B,,,,,,,8,,10576,1,Expert,,,1237,,12884,H,CHEMBL615879,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,
B,,,,,,,8,,10576,1,Expert,,,1238,,2343,H,CHEMBL615880,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,
B,,,,,,,8,,10576,1,Autocuration,,,1239,,11511,H,CHEMBL615881,BAO_0000019,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",
B,,,,,,,9,10116.0,10576,1,Expert,,,1240,,11511,D,CHEMBL615882,BAO_0000019,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Rattus norvegicus
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1241,,16394,H,CHEMBL615883,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1242,,16394,H,CHEMBL615884,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1243,,16394,H,CHEMBL615885,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1244,,16394,H,CHEMBL615886,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1245,,16394,H,CHEMBL615887,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1246,,16394,H,CHEMBL615888,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1247,,16394,H,CHEMBL615889,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1248,,16394,H,CHEMBL615890,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1249,,16394,H,CHEMBL615891,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1250,,16394,H,CHEMBL615892,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1251,,16394,H,CHEMBL615893,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1252,,16394,H,CHEMBL615894,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1253,,16394,H,CHEMBL615895,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1254,,16394,H,CHEMBL615896,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),
F,,,In vivo,,,,8,,10576,1,Autocuration,,,1255,,16394,H,CHEMBL615897,BAO_0000218,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,
F,,,,,,,9,10116.0,10576,1,Expert,,,1256,Membranes,16616,D,CHEMBL615898,BAO_0000249,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1257,,16796,H,CHEMBL615899,BAO_0000019,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,
B,,,,,,,8,,10576,1,Autocuration,,,1258,,16796,H,CHEMBL616291,BAO_0000019,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,
B,,,,,,,8,,10576,1,Autocuration,,,1259,,15629,H,CHEMBL616292,BAO_0000357,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,
F,,,,,,,8,,10576,1,Autocuration,,,1260,,13241,H,CHEMBL616293,BAO_0000249,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",
B,,,,,10000000.0,,8,,10576,1,Expert,,,1261,,12073,H,CHEMBL616294,BAO_0000221,Hippocampus,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1262,,14286,H,CHEMBL616295,BAO_0000249,Hippocampus,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,
B,,,,,955.0,,8,,10576,1,Autocuration,,,1263,,14542,H,CHEMBL616296,BAO_0000221,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,
F,,,,,,,8,,10576,1,Autocuration,,,1264,,13630,H,CHEMBL616297,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,
F,,,,,,,8,,10576,1,Autocuration,,,1265,,13630,H,CHEMBL616605,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,
F,,,,,,,8,,10576,1,Autocuration,,,1266,,13630,H,CHEMBL616606,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,
F,,,,,,,8,,10576,1,Autocuration,,,1267,,13630,H,CHEMBL616607,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,
F,,,,,,,8,,10576,1,Expert,,,1268,,13630,H,CHEMBL616608,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,
F,,,,,,,8,,10576,1,Autocuration,,,1269,,13630,H,CHEMBL616609,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,
F,,,,,,,9,10116.0,10576,1,Expert,,,1270,,13630,D,CHEMBL616610,BAO_0000019,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,Rattus norvegicus
F,,,,,,,8,,10576,1,Autocuration,,,1271,,13630,H,CHEMBL616611,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,
F,,,,,,,8,,10576,1,Expert,,,1272,,13630,H,CHEMBL616612,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,
F,,,,,,,8,,10576,1,Autocuration,,,1273,,13630,H,CHEMBL616613,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,
F,,,,,,,8,,10576,1,Expert,,,1274,,13630,H,CHEMBL616614,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,
F,,,,,,,8,,10576,1,Autocuration,,,1275,,13630,H,CHEMBL616615,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,
F,,,,,,,8,,10576,1,Expert,,,1276,,13630,H,CHEMBL616616,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,
F,,,,,,,8,,10576,1,Autocuration,,,1277,,13630,H,CHEMBL616617,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,
F,,,,,,,8,,10576,1,Autocuration,,,1278,,13630,H,CHEMBL616618,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,
F,,,,,,,8,,10576,1,Autocuration,,,1279,,13630,H,CHEMBL616619,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,
F,,,,,,,8,,10576,1,Expert,,,1280,,13630,H,CHEMBL616620,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,
F,,,,,,,8,,10576,1,Expert,,,1281,,13630,H,CHEMBL616621,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,
F,,,,,,,8,,10576,1,Autocuration,,,1282,,13630,H,CHEMBL616622,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,
F,,,,,,,8,,10576,1,Expert,,,1283,,13630,H,CHEMBL616146,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,
F,,,,,,,8,,10576,1,Autocuration,,,1284,,13630,H,CHEMBL832873,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,
F,,,,,,,8,,10576,1,Autocuration,,,1285,,13630,H,CHEMBL616147,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,
F,,,,,,,8,,10576,1,Autocuration,,,1286,,13630,H,CHEMBL872872,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,
F,,,,,,,8,,10576,1,Autocuration,,,1287,,13630,H,CHEMBL616148,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1288,,9783,H,CHEMBL616149,BAO_0000221,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1289,,9783,H,CHEMBL616150,BAO_0000221,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,
B,,,,,,,9,10116.0,10576,1,Expert,,,1290,Membranes,14331,D,CHEMBL616151,BAO_0000249,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Expert,,,1291,,15260,H,CHEMBL872873,BAO_0000221,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1292,,15260,H,CHEMBL616670,BAO_0000221,Hippocampus,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1293,,15260,H,CHEMBL616671,BAO_0000221,Hippocampus,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,
F,,,,,,,9,10116.0,10576,1,Expert,,,1294,,16616,D,CHEMBL884861,BAO_0000249,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1295,,15629,H,CHEMBL616672,BAO_0000357,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,
B,,,,,,,8,,10576,1,Autocuration,,,1296,,15086,H,CHEMBL616673,BAO_0000019,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,
F,,,,,,,8,,10576,1,Expert,,,1297,,5717,H,CHEMBL616674,BAO_0000019,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,
B,,,,,,,8,,10576,1,Autocuration,,,1298,,12652,H,CHEMBL616675,BAO_0000357,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1299,,14608,H,CHEMBL616676,BAO_0000221,Hippocampus,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1300,,12306,H,CHEMBL616677,BAO_0000221,Hippocampus,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1301,,12306,H,CHEMBL616678,BAO_0000221,Hippocampus,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,
B,,,,,,,9,10116.0,10576,1,Expert,,,1302,,15247,D,CHEMBL616679,BAO_0000357,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Expert,,,1303,,17529,H,CHEMBL616680,BAO_0000221,Hippocampus,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1304,,14826,H,CHEMBL616681,BAO_0000221,Hippocampus,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1305,,14826,H,CHEMBL616682,BAO_0000221,Hippocampus,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1306,,13241,H,CHEMBL616683,BAO_0000221,Hippocampus,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1307,,14093,H,CHEMBL616684,BAO_0000221,Hippocampus,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1308,,14093,H,CHEMBL616685,BAO_0000221,Hippocampus,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,
B,,,,,955.0,,8,,10576,1,Autocuration,,,1309,,14442,H,CHEMBL616686,BAO_0000221,Brain,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,
B,,,,,,,8,,10576,1,Autocuration,,,1310,,9919,H,CHEMBL616687,BAO_0000357,,Affinity for 5-hydroxytryptamine 1A receptor site,
B,,,,,,,8,,10576,1,Autocuration,,,1311,,9919,H,CHEMBL616688,BAO_0000357,,Affinity for 5-hydroxytryptamine 1A receptor site,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1312,,11440,H,CHEMBL616689,BAO_0000221,Hippocampus,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,
B,,,,,,,8,,10576,1,Autocuration,,,1313,,11257,H,CHEMBL616690,BAO_0000357,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,
B,,,,,,,8,,10576,1,Expert,,,1314,,10330,H,CHEMBL616691,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1315,,17331,D,CHEMBL616692,BAO_0000221,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Rattus norvegicus
B,,,,,,,8,,10576,1,Expert,,,1316,,16567,H,CHEMBL616693,BAO_0000249,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,
B,,,,,,,9,10116.0,10576,1,Expert,,,1317,,12058,D,CHEMBL616694,BAO_0000019,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1318,,9699,H,CHEMBL616695,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,
B,,,,,,,8,,10576,1,Autocuration,,,1319,,9547,H,CHEMBL616696,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,
B,,,,,,,8,,10576,1,Autocuration,,,1320,,10330,H,CHEMBL616697,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,
B,,,,,,,8,,10576,1,Autocuration,,,1321,,14331,H,CHEMBL616698,BAO_0000357,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,
B,,,,,,,9,10116.0,10576,1,Expert,,,1322,,14060,D,CHEMBL616949,BAO_0000019,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1323,,14744,H,CHEMBL616950,BAO_0000221,Hippocampus,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,
B,,,,,,,8,,10576,1,Autocuration,,,1324,,13506,H,CHEMBL832875,BAO_0000357,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,
B,,,,,955.0,,8,,10576,1,Expert,,,1325,,10862,H,CHEMBL616951,BAO_0000221,Brain,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,
B,,,,,955.0,,8,,10576,1,Expert,,,1326,,10862,H,CHEMBL616952,BAO_0000221,Brain,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,
B,,,,,,,8,,10576,1,Expert,,,1327,,10062,H,CHEMBL616953,BAO_0000357,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,
B,,,,,,,8,,10576,1,Autocuration,,,1328,,12073,H,CHEMBL616954,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,
B,,,,,,,8,,106,1,Autocuration,,,1329,,14875,H,CHEMBL616955,BAO_0000357,,GTPgammaS radioligand binding assay,
B,,,,,,,8,,106,1,Autocuration,,,1330,,2391,H,CHEMBL616956,BAO_0000357,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,
F,,,,,,,8,,106,1,Autocuration,,,1331,,2391,H,CHEMBL616957,BAO_0000019,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,
F,,,,,,,8,,106,1,Autocuration,,,1332,,2391,H,CHEMBL616958,BAO_0000019,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,
B,,,,,,,8,,106,1,Autocuration,,,1333,,2391,H,CHEMBL616959,BAO_0000357,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Autocuration,,,1334,,2391,H,CHEMBL616960,BAO_0000357,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,
F,,,,,,,8,,106,1,Autocuration,,,1335,,2391,H,CHEMBL616961,BAO_0000019,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,
B,HeLa,308.0,,,,,8,,106,1,Expert,,,1336,,17211,H,CHEMBL616962,BAO_0000219,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,
B,HeLa,308.0,,,,,8,,106,1,Autocuration,,,1337,,17211,H,CHEMBL616963,BAO_0000219,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,
B,,,,,,,9,9606.0,106,1,Expert,,,1338,,6491,D,CHEMBL616524,BAO_0000357,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,Homo sapiens
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1339,,16190,H,CHEMBL616525,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,
B,,,,,,,8,,106,1,Autocuration,,,1340,,14165,H,CHEMBL872908,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,
B,,,,,,,8,,106,1,Autocuration,,,1341,,14165,H,CHEMBL616526,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,
B,,,,,,,9,9606.0,106,1,Expert,,,1342,,4234,D,CHEMBL616527,BAO_0000357,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,Homo sapiens
B,,,,,,,8,,106,1,Expert,,,1343,,6328,H,CHEMBL616528,BAO_0000219,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,
B,,,,,,,8,,106,1,Autocuration,,,1344,,14770,H,CHEMBL616529,BAO_0000357,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,
B,,,,,,,8,,106,1,Autocuration,,,1345,,2598,H,CHEMBL616530,BAO_0000357,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,
B,,,,,,,8,,106,1,Expert,,,1346,,6897,H,CHEMBL616531,BAO_0000357,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Autocuration,,,1347,,6897,H,CHEMBL616532,BAO_0000357,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Autocuration,,,1348,,6013,H,CHEMBL616533,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Expert,,,1349,,5843,H,CHEMBL616534,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Expert,,,1350,,14454,H,CHEMBL616535,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,
B,,,,,,,8,,106,1,Autocuration,,,1351,,16209,H,CHEMBL616536,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,
B,,,,,,,8,,106,1,Autocuration,,,1352,,3935,H,CHEMBL616537,BAO_0000357,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,
F,CHO-K1,485.0,,,,,8,,106,1,Expert,,,1353,,13729,H,CHEMBL616538,BAO_0000219,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,
F,,,,,,,8,,106,1,Expert,,,1354,,14251,H,CHEMBL616539,BAO_0000019,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Expert,,,1355,,17085,H,CHEMBL616540,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Autocuration,,,1356,,3025,H,CHEMBL616429,BAO_0000357,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,
B,,,,,,,8,,106,1,Expert,,,1357,,15315,H,CHEMBL616430,BAO_0000357,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,
B,,,,,,,9,9606.0,106,1,Expert,,,1358,,14214,D,CHEMBL616431,BAO_0000219,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,Homo sapiens
B,,,,,,,9,9606.0,106,1,Expert,,,1359,,3804,D,CHEMBL616432,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Homo sapiens
B,,,,,,,9,9606.0,106,1,Expert,,,1360,,2391,D,CHEMBL616433,BAO_0000357,,Affinity for 5-hydroxytryptamine 1B receptor subtype,Homo sapiens
B,,,,,,,9,9606.0,106,1,Expert,,,1361,,4175,D,CHEMBL616434,BAO_0000357,,Binding affinity for human 5-hydroxytryptamine 1B receptor,Homo sapiens
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1362,,17296,H,CHEMBL616435,BAO_0000219,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,
B,,,,,,,8,,106,1,Expert,,,1363,,17085,H,CHEMBL616436,BAO_0000019,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,
B,HeLa,308.0,,,,,8,,106,1,Autocuration,,,1364,,17211,H,CHEMBL616437,BAO_0000219,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,
B,HeLa,308.0,,,,,8,,106,1,Autocuration,,,1365,,17211,H,CHEMBL616438,BAO_0000219,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,
B,HeLa,308.0,,,,,8,,106,1,Autocuration,,,1366,,17211,H,CHEMBL616439,BAO_0000219,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,
B,,,,,,,9,9606.0,106,1,Expert,,,1367,,15926,D,CHEMBL616440,BAO_0000357,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,Homo sapiens
B,CHO-K1,485.0,,,,,8,,106,1,Autocuration,,,1368,,16312,H,CHEMBL616441,BAO_0000219,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,
B,,,,,,,8,,106,1,Expert,,,1369,,5843,H,CHEMBL616442,BAO_0000357,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,
B,,,,,,,8,,106,1,Autocuration,,,1370,,5843,H,CHEMBL616443,BAO_0000357,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,
B,CHO-K1,485.0,,,,,8,,106,1,Expert,,,1371,,16312,H,CHEMBL616444,BAO_0000219,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,
B,,,,,,,9,9606.0,106,1,Expert,,,1372,,15926,D,CHEMBL616445,BAO_0000357,,Binding activity against human 5-hydroxytryptamine 1B receptor,Homo sapiens
B,,,,,,,9,9606.0,106,1,Expert,,,1373,,15926,D,CHEMBL616446,BAO_0000357,,Binding activity against human 5-hydroxytryptamine 1B receptor,Homo sapiens
B,CHO,449.0,,,,,9,9606.0,106,1,Expert,,,1374,,4540,D,CHEMBL616447,BAO_0000219,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Homo sapiens
B,,,,,,,8,,106,1,Autocuration,,,1375,,6166,H,CHEMBL616448,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1376,,17296,H,CHEMBL616449,BAO_0000219,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1377,,17296,H,CHEMBL616450,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1378,,17296,H,CHEMBL857974,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1379,,15779,H,CHEMBL616451,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1380,,15779,H,CHEMBL616452,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1381,,15779,H,CHEMBL616453,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1382,,4199,H,CHEMBL616454,BAO_0000219,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,
B,,,,,,,9,9606.0,106,1,Expert,,,1383,,14875,D,CHEMBL616455,BAO_0000357,,Binding affinity for human 5-hydroxytryptamine 1B receptor,Homo sapiens
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1384,,15146,H,CHEMBL616456,BAO_0000219,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,
B,,,,,,,8,,106,1,Autocuration,,,1385,,5213,H,CHEMBL616457,BAO_0000357,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1386,,14818,H,CHEMBL616458,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,1387,,4829,H,CHEMBL616459,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",
F,,,,,,,8,,106,1,Expert,,,1388,,14454,H,CHEMBL616460,BAO_0000019,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,
F,,,,,,,8,,106,1,Expert,,,1389,,14454,H,CHEMBL616461,BAO_0000019,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,
F,CHO,449.0,,,,,8,,106,1,Autocuration,,,1390,,14875,H,CHEMBL616462,BAO_0000219,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",
F,CHO,449.0,,,,,8,,106,1,Autocuration,,,1391,,14875,H,CHEMBL616463,BAO_0000219,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",
F,,,,,,,8,,105,1,Autocuration,,,1392,,15250,H,CHEMBL616464,BAO_0000019,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1393,,15250,H,CHEMBL616465,BAO_0000219,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,
B,,,,,,,8,,17105,1,Autocuration,,,1394,,15086,H,CHEMBL832874,BAO_0000357,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,
F,,,,,,,8,9986.0,106,1,Autocuration,,,1395,,3025,H,CHEMBL616184,BAO_0000019,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,Oryctolagus cuniculus
B,,,,,,,8,9986.0,106,1,Autocuration,,,1396,,14998,H,CHEMBL616185,BAO_0000019,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,Oryctolagus cuniculus
B,,,,,,,8,9986.0,106,1,Intermediate,,,1397,,14998,H,CHEMBL616186,BAO_0000019,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",Oryctolagus cuniculus
B,,,,,,,8,9986.0,106,1,Autocuration,,,1398,,14998,H,CHEMBL616187,BAO_0000019,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,Oryctolagus cuniculus
B,,,,,,,8,,10577,1,Expert,,,1399,,13969,H,CHEMBL616188,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,
B,,,,,,,9,,10577,1,Intermediate,,,1400,,13392,D,CHEMBL873475,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1B receptor,
B,,,,,2435.0,,9,10116.0,10577,1,Expert,,,1401,,3651,D,CHEMBL616189,BAO_0000019,Striatum,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Rattus norvegicus
B,,,,,,,8,,10577,1,Expert,,,1402,,10025,H,CHEMBL616190,BAO_0000357,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,
B,,,,,,,8,,10576,1,Autocuration,,,1403,,13863,H,CHEMBL616191,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,
B,,,,,,,8,,10576,1,Autocuration,,,1404,,13863,H,CHEMBL616192,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,
B,,,,,,,8,,10576,1,Autocuration,,,1405,,13863,H,CHEMBL616193,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,
B,,,,,,,8,,10576,1,Autocuration,,,1406,,13863,H,CHEMBL616194,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,
B,,,,,,,8,,10576,1,Autocuration,,,1407,,13863,H,CHEMBL616195,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,
B,,,,,,,8,,10576,1,Autocuration,,,1408,,13863,H,CHEMBL616196,BAO_0000357,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1409,,4622,H,CHEMBL616197,BAO_0000249,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,
B,,,,,,,8,,10576,1,Intermediate,,,1410,,14911,H,CHEMBL616198,BAO_0000019,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1411,,12678,H,CHEMBL616199,BAO_0000221,Hippocampus,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1412,,12678,H,CHEMBL616200,BAO_0000221,Hippocampus,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1413,,14235,H,CHEMBL616201,BAO_0000221,Hippocampus,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1414,,14949,H,CHEMBL616202,BAO_0000221,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1415,,14949,H,CHEMBL616203,BAO_0000221,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1416,,14949,H,CHEMBL616204,BAO_0000221,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1417,,14949,H,CHEMBL616205,BAO_0000221,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1418,,14949,H,CHEMBL616206,BAO_0000221,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,
B,,,,,,,8,,10576,1,Expert,,,1419,,16118,H,CHEMBL616207,BAO_0000249,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,
B,,,,,,,8,,10576,1,Autocuration,,,1420,,3268,H,CHEMBL616208,BAO_0000249,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,
B,,,,,,,8,,10576,1,Autocuration,,,1421,,3268,H,CHEMBL616209,BAO_0000249,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,
B,,,,,,,8,,10576,1,Expert,,,1422,,16117,H,CHEMBL616210,BAO_0000357,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1423,,9783,H,CHEMBL616211,BAO_0000221,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1424,,9783,H,CHEMBL616504,BAO_0000221,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1425,,14356,D,CHEMBL616505,BAO_0000221,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Rattus norvegicus
F,,,,,,,8,,10576,1,Autocuration,,,1426,,15740,H,CHEMBL616506,BAO_0000019,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1427,,12306,H,CHEMBL872107,BAO_0000221,Hippocampus,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1428,,13348,D,CHEMBL616507,BAO_0000221,Hippocampus,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1429,,10394,H,CHEMBL616303,BAO_0000249,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1430,,15260,H,CHEMBL616304,BAO_0000221,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1431,,10046,H,CHEMBL616305,BAO_0000221,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,
F,,,,,10000000.0,,8,,10576,1,Intermediate,,,1432,,15260,H,CHEMBL616306,BAO_0000221,Hippocampus,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Autocuration,,,1433,,12851,H,CHEMBL616307,BAO_0000357,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1434,,2148,D,CHEMBL881829,BAO_0000221,Hippocampus,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Rattus norvegicus
B,,,,,,,8,,10576,1,Expert,,,1435,,13134,H,CHEMBL616308,BAO_0000357,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,
B,,,,,,,8,,10576,1,Autocuration,,,1436,,12462,H,CHEMBL616309,BAO_0000019,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,
B,,,,,,,8,,10576,1,Expert,,,1437,,12462,H,CHEMBL616310,BAO_0000019,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,
B,CHO,449.0,,,,,8,,10576,1,Autocuration,,,1438,,12462,H,CHEMBL616311,BAO_0000219,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,
B,,,,,,,8,,10576,1,Expert,,,1439,,11933,H,CHEMBL616312,BAO_0000357,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,10576,1,Autocuration,,,1440,,11933,H,CHEMBL616313,BAO_0000357,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1441,,403,D,CHEMBL616314,BAO_0000221,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1442,,15538,H,CHEMBL616315,BAO_0000221,Hippocampus,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1443,,15538,H,CHEMBL616567,BAO_0000221,Hippocampus,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1444,,15538,H,CHEMBL616568,BAO_0000221,Hippocampus,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,
B,,,,,,,8,,10576,1,Intermediate,,,1445,,12464,H,CHEMBL616569,BAO_0000019,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,
B,,,,,,,8,,10576,1,Expert,,,1446,,1455,H,CHEMBL616570,BAO_0000357,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,
B,,,,,,,8,,10576,1,Autocuration,,,1447,,12652,H,CHEMBL616571,BAO_0000357,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1448,,12639,H,CHEMBL616572,BAO_0000221,Hippocampus,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,
B,,,,,,,8,,10576,1,Expert,,,1449,,13949,H,CHEMBL616573,BAO_0000249,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,
B,,,,,,,9,10116.0,10576,1,Expert,,,1450,,12463,D,CHEMBL616574,BAO_0000357,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Expert,,,1451,,14829,H,CHEMBL616575,BAO_0000221,Hippocampus,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1452,,14829,H,CHEMBL872108,BAO_0000221,Hippocampus,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,
B,,,,,,,8,,10576,1,Autocuration,,,1453,,12092,H,CHEMBL616576,BAO_0000357,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,
B,,,,,,,8,,10576,1,Autocuration,,,1454,,403,H,CHEMBL616577,BAO_0000249,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,
B,,,,,,,8,,10576,1,Autocuration,,,1455,,403,H,CHEMBL616578,BAO_0000249,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,
B,,,,,,,8,,10576,1,Expert,,,1456,,3967,H,CHEMBL616579,BAO_0000357,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,
B,,,,,,,9,10116.0,10576,1,Expert,,,1457,,12771,D,CHEMBL616580,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1458,,15086,H,CHEMBL616581,BAO_0000019,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1459,,14909,H,CHEMBL616582,BAO_0000221,Hippocampus,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1460,,14949,H,CHEMBL616583,BAO_0000221,Hippocampus,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1461,,2309,D,CHEMBL616584,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Rattus norvegicus
B,,,,,,,8,,10576,1,Expert,,,1462,,4170,H,CHEMBL616585,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1463,,11642,D,CHEMBL616586,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1464,,11642,H,CHEMBL616587,BAO_0000221,Hippocampus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1465,,12953,H,CHEMBL616588,BAO_0000221,Hippocampus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1466,,12953,H,CHEMBL616589,BAO_0000221,Hippocampus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1467,,12953,H,CHEMBL616590,BAO_0000221,Hippocampus,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,
B,CHO,449.0,,,,,8,,10576,1,Expert,,,1468,,12903,H,CHEMBL616591,BAO_0000219,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",
B,,,,,,,8,,10576,1,Expert,,,1469,,12536,H,CHEMBL616592,BAO_0000357,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Autocuration,,,1470,,10058,H,CHEMBL616593,BAO_0000357,,The inhibition activity of 5-HT1A at 1 uM,
B,CHO-K1,485.0,,,,,8,,10576,1,Expert,,,1471,,12902,H,CHEMBL616594,BAO_0000219,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",
B,,,,,,,8,,10576,1,Expert,,,1472,,14057,H,CHEMBL616595,BAO_0000249,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,
B,,,,,,,8,,10576,1,Autocuration,,,1473,,11296,H,CHEMBL616596,BAO_0000357,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1474,,11296,H,CHEMBL616597,BAO_0000221,Hippocampus,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,
B,,,,,10000000.0,,8,,10576,1,Expert,,,1475,,11296,H,CHEMBL616598,BAO_0000221,Hippocampus,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,
F,,,,,,,9,10116.0,10576,1,Expert,,,1476,Membranes,16616,D,CHEMBL616599,BAO_0000249,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Rattus norvegicus
F,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1477,Membranes,16616,D,CHEMBL616600,BAO_0000249,Hippocampus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1478,,16567,H,CHEMBL616601,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,
B,,,,,,,8,,10576,1,Autocuration,,,1479,,16567,H,CHEMBL616602,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,
B,,,,,,,8,,10576,1,Autocuration,,,1480,,16567,H,CHEMBL616603,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,
B,,,,,,,8,,10576,1,Autocuration,,,1481,,16567,H,CHEMBL616604,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,
B,,,,,,,8,,10576,1,Autocuration,,,1482,,17136,H,CHEMBL616316,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,
B,,,,,,,8,,10576,1,Autocuration,,,1483,,17136,H,CHEMBL616317,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,
B,,,,,,,9,10116.0,10576,1,Expert,,,1484,,16616,D,CHEMBL616318,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1485,,17331,H,CHEMBL616319,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1486,,17331,H,CHEMBL616320,BAO_0000221,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1487,,17167,D,CHEMBL616321,BAO_0000221,Hippocampus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Rattus norvegicus
F,,,,,,,8,,10576,1,Autocuration,,,1488,,15740,H,CHEMBL616322,BAO_0000019,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,
F,,,,,,,8,,10576,1,Autocuration,,,1489,,15740,H,CHEMBL616323,BAO_0000019,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,
B,,,,,,,8,,10576,1,Autocuration,,,1490,,4671,H,CHEMBL616324,BAO_0000357,,Ratio of binding affinity to 5-HT 1A and D2 receptor,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1491,,10058,H,CHEMBL616325,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1492,,10058,H,CHEMBL616326,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1493,,10058,H,CHEMBL616327,BAO_0000221,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,
B,,,,,,,8,,10576,1,Autocuration,,,1494,,12073,H,CHEMBL616328,BAO_0000357,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,10576,1,Autocuration,,,1495,,2759,H,CHEMBL858110,BAO_0000249,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),
F,,,,,,,8,,10576,1,Autocuration,,,1496,,2759,H,CHEMBL616329,BAO_0000249,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),
B,,,,,,,8,,10576,1,Autocuration,,,1497,,2759,H,CHEMBL616330,BAO_0000249,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),
F,,,,,,,8,,10576,1,Autocuration,,,1498,,2759,H,CHEMBL616331,BAO_0000249,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),
F,,,,,,,8,,10576,1,Autocuration,,,1499,,2759,H,CHEMBL616332,BAO_0000249,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,
B,,,,,955.0,,8,,10576,1,Autocuration,,,1500,,9737,H,CHEMBL857063,BAO_0000249,Brain,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,
B,,,,,,,8,,10576,1,Autocuration,,,1501,,9737,H,CHEMBL616333,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,
F,,,,,,,8,,10576,1,Expert,,,1502,,5717,H,CHEMBL616334,BAO_0000019,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1503,,12253,H,CHEMBL616335,BAO_0000221,Hippocampus,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,
B,,,,,,,8,,10576,1,Autocuration,,,1504,,14025,H,CHEMBL616336,BAO_0000019,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,
B,,,,,,,8,,10576,1,Expert,,,1505,,10425,H,CHEMBL616337,BAO_0000249,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,
B,,,,,,,8,,10576,1,Autocuration,,,1506,,14998,H,CHEMBL616338,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1507,,13694,H,CHEMBL616339,BAO_0000221,Hippocampus,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1508,,13694,H,CHEMBL616340,BAO_0000221,Hippocampus,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,
B,,,,,,,8,,10576,1,Autocuration,,,1509,,4342,H,CHEMBL616341,BAO_0000357,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,
B,,,,,,,9,10116.0,10576,1,Expert,,,1510,,12936,D,CHEMBL616342,BAO_0000357,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Rattus norvegicus
B,,,,,,,9,10116.0,10576,1,Expert,,,1511,,13144,D,CHEMBL616343,BAO_0000019,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,Rattus norvegicus
B,,,,,,,8,,10576,1,Expert,,,1512,,13343,H,CHEMBL616344,BAO_0000019,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,
B,,,,,,,8,,10576,1,Expert,,,1513,,12132,H,CHEMBL616345,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,
B,,,,,,,8,,10576,1,Expert,,,1514,,15419,H,CHEMBL616346,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1515,,1479,H,CHEMBL616347,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,
B,,,,,,,8,,10576,1,Expert,,,1516,,14287,H,CHEMBL616348,BAO_0000019,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,
B,,,,,,,8,,10576,1,Expert,,,1517,,13116,H,CHEMBL616349,BAO_0000357,,Binding affinity at 5-hydroxytryptamine 1A receptor,
B,,,,,,,9,10116.0,10576,1,Expert,,,1518,Membranes,2759,D,CHEMBL616152,BAO_0000249,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Rattus norvegicus
B,,,,,,,8,,10576,1,Autocuration,,,1519,,2759,H,CHEMBL616153,BAO_0000249,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,
B,,,,,,,8,,10576,1,Expert,,,1520,,14748,H,CHEMBL616154,BAO_0000019,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",
B,,,,,,,8,,10576,1,Autocuration,,,1521,,12304,H,CHEMBL616155,BAO_0000019,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1522,,12409,D,CHEMBL616156,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Rattus norvegicus
B,,,,,10000000.0,,9,10116.0,10576,1,Expert,,,1523,,12409,D,CHEMBL616157,BAO_0000221,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Rattus norvegicus
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,1524,,13267,H,CHEMBL616158,BAO_0000221,Hippocampus,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,
B,,,,,,,8,,10576,1,Autocuration,,,1525,,15194,H,CHEMBL616159,BAO_0000357,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,
B,,,,,,,8,,10576,1,Expert,,,1526,,14256,H,CHEMBL616160,BAO_0000357,,pKi value against rat 5-hydroxytryptamine 1A receptor.,
B,,,,,,,8,,10576,1,Autocuration,,,1527,,16567,H,CHEMBL616161,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,
F,,,,,,,8,,10576,1,Autocuration,,,1528,,15740,H,CHEMBL616162,BAO_0000019,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,
B,,,,,,,9,10116.0,12687,1,Expert,,,1529,,13278,D,CHEMBL616163,BAO_0000357,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Rattus norvegicus
B,,,,,,,8,,10626,1,Expert,,,1530,Membranes,1970,H,CHEMBL616164,BAO_0000249,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,
B,,,,,955.0,,8,,10576,1,Autocuration,,,1531,,10034,H,CHEMBL616165,BAO_0000221,Brain,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,
B,,,,,,,8,10116.0,51,1,Autocuration,,,1532,,13348,H,CHEMBL616355,BAO_0000019,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,Rattus norvegicus
F,,,,,,,8,,10576,1,Autocuration,,,1533,,13630,H,CHEMBL616356,BAO_0000019,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,
B,,,,,955.0,,8,,10576,1,Autocuration,,,1534,,10862,H,CHEMBL616357,BAO_0000221,Brain,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,
B,,,,,,,8,,10576,1,Autocuration,,,1535,,12058,H,CHEMBL616358,BAO_0000019,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",
B,,,,,,,8,,51,1,Autocuration,,,1536,,4639,H,CHEMBL616359,BAO_0000357,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Expert,,,1537,,15453,H,CHEMBL616360,BAO_0000357,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,
B,,,,,,,8,,51,1,Expert,,,1538,,4820,H,CHEMBL616361,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,1539,,1089,H,CHEMBL616362,BAO_0000357,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,1540,Brain membranes,386,H,CHEMBL616363,BAO_0000249,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,
B,,,,,,,8,,51,1,Autocuration,,,1541,,6011,H,CHEMBL616364,BAO_0000357,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,
B,,,,,,,8,,51,1,Autocuration,,,1542,,5014,H,CHEMBL616365,BAO_0000357,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Expert,,,1543,,4402,H,CHEMBL616366,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,51,1,Expert,,,1544,,17066,H,CHEMBL872906,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,1545,,17515,H,CHEMBL616367,BAO_0000357,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,
B,,,,,,,8,,51,1,Autocuration,,,1546,,2474,H,CHEMBL616368,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,51,1,Autocuration,,,1547,,4775,H,CHEMBL616369,BAO_0000357,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,
B,,,,,,,9,9606.0,51,1,Expert,,,1548,,14294,D,CHEMBL616370,BAO_0000357,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,Homo sapiens
B,,,,,,,9,9606.0,51,1,Expert,,,1549,,14294,D,CHEMBL616371,BAO_0000357,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,Homo sapiens
B,CHO,449.0,,,,,8,,51,1,Autocuration,,,1550,,12249,H,CHEMBL616372,BAO_0000219,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,
B,,,,,,,8,,51,1,Expert,,,1551,,11376,H,CHEMBL616373,BAO_0000219,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,
B,,,In vivo,,,,8,,51,1,Autocuration,,,1552,,2474,H,CHEMBL616374,BAO_0000218,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
B,,,,,10000000.0,,8,,51,1,Autocuration,,,1553,,13311,H,CHEMBL616375,BAO_0000221,Hippocampus,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,
B,,,,,,,8,,51,1,Autocuration,,,1554,,4373,H,CHEMBL616376,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,
B,,,,,,,8,,51,1,Expert,,,1555,,1633,H,CHEMBL857064,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,
B,,,,,,,8,,51,1,Autocuration,,,1556,,11866,H,CHEMBL616377,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,
B,,,,,,,8,,51,1,Autocuration,,,1557,,4373,H,CHEMBL616378,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,
B,,,,,,,8,,51,1,Autocuration,,,1558,,4687,H,CHEMBL616379,BAO_0000357,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,11863,1,Autocuration,,,1559,,16946,H,CHEMBL616380,BAO_0000357,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,11863,1,Autocuration,,,1560,,13291,H,CHEMBL616381,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,
B,,,,,,,8,,11863,1,Autocuration,,,1561,,14159,H,CHEMBL616382,BAO_0000357,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,11863,1,Autocuration,,,1562,,10812,H,CHEMBL616383,BAO_0000357,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,
B,CHO,449.0,,,,,9,10090.0,11863,1,Expert,,,1563,,3032,D,CHEMBL616350,BAO_0000219,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,Mus musculus
B,,,,,,,8,,11863,1,Autocuration,,,1564,,16655,H,CHEMBL616351,BAO_0000357,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,11863,1,Autocuration,,,1565,,14532,H,CHEMBL616352,BAO_0000357,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,
B,,,,,,,8,,11863,1,Autocuration,,,1566,,13944,H,CHEMBL616353,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,11863,1,Autocuration,,,1567,,13033,H,CHEMBL616354,BAO_0000357,,Binding affinity against serotonergic 5-HT1a receptor,
B,,,,,,,8,,11863,1,Autocuration,,,1568,,10321,H,CHEMBL616508,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,
B,,,,,,,9,10090.0,11863,1,Expert,,,1569,,2968,D,CHEMBL616559,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1A receptor,Mus musculus
B,,,,,,,8,,11863,1,Autocuration,,,1570,,13964,H,CHEMBL616560,BAO_0000357,,Binding affinity at 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,11863,1,Autocuration,,,1571,,15527,H,CHEMBL616561,BAO_0000357,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",
B,CHO,449.0,,,,,8,,11863,1,Autocuration,,,1572,,12248,H,CHEMBL616562,BAO_0000219,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,
B,CHO,449.0,,,,,8,,11863,1,Autocuration,,,1573,,12249,H,CHEMBL616563,BAO_0000219,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,
B,,,,,,,8,,11863,1,Autocuration,,,1574,,15120,H,CHEMBL616564,BAO_0000357,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,11863,1,Autocuration,,,1575,,13313,H,CHEMBL616565,BAO_0000357,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,
B,,,,,,,8,,11863,1,Autocuration,,,1576,,2613,H,CHEMBL616566,BAO_0000218,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,11863,1,Autocuration,,,1577,,16700,H,CHEMBL616989,BAO_0000357,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,
B,,,,,,,8,,11863,1,Autocuration,,,1578,,2201,H,CHEMBL857975,BAO_0000357,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,
B,,,,,,,9,10090.0,11863,1,Expert,,,1579,,1274,D,CHEMBL616990,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor,Mus musculus
B,,,,,,,8,,11863,1,Autocuration,,,1580,,1317,H,CHEMBL616991,BAO_0000357,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,
B,,,,,,,8,,11863,1,Autocuration,,,1581,,12146,H,CHEMBL616992,BAO_0000357,,Tested against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,11863,1,Autocuration,,,1582,,14059,H,CHEMBL616993,BAO_0000357,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,9986.0,106,1,Expert,,,1583,,14025,H,CHEMBL616994,BAO_0000019,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,Oryctolagus cuniculus
B,,,,,,,8,9986.0,106,1,Autocuration,,,1584,,14025,H,CHEMBL616995,BAO_0000019,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,Oryctolagus cuniculus
B,HEK293,722.0,,,,,9,9593.0,105571,1,Intermediate,,,1585,,14447,D,CHEMBL616996,BAO_0000219,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Gorilla gorilla
F,,,In vivo,,,,8,10141.0,106,1,Autocuration,,,1586,,3025,H,CHEMBL616997,BAO_0000218,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Cavia porcellus
F,,,In vivo,,,,8,10141.0,106,1,Autocuration,,,1587,,3025,H,CHEMBL616998,BAO_0000218,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Cavia porcellus
F,,,,,,,8,10141.0,106,1,Autocuration,,,1588,,15329,H,CHEMBL616999,BAO_0000019,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,Cavia porcellus
F,,,,,,,8,10141.0,106,1,Autocuration,,,1589,,15329,H,CHEMBL617000,BAO_0000019,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,Cavia porcellus
F,,,,,,,8,10141.0,106,1,Autocuration,,,1590,,15847,H,CHEMBL617001,BAO_0000019,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,Cavia porcellus
F,,,,,,,8,10141.0,106,1,Autocuration,,,1591,,15847,H,CHEMBL858111,BAO_0000019,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,Cavia porcellus
F,,,,,,,8,,106,1,Autocuration,,,1592,,14165,H,CHEMBL617002,BAO_0000019,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,
F,,,,,,,8,,106,1,Autocuration,,,1593,,14214,H,CHEMBL617003,BAO_0000019,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),
F,,,,,,,8,,106,1,Autocuration,,,1594,,14214,H,CHEMBL617004,BAO_0000019,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),
F,,,,,,,9,9606.0,106,1,Expert,,,1595,,14214,D,CHEMBL617005,BAO_0000019,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,Homo sapiens
F,CHO-K1,485.0,,,,,9,9606.0,106,1,Expert,,,1596,,13729,D,CHEMBL616623,BAO_0000219,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,Homo sapiens
F,CHO,449.0,,,,,8,,106,1,Autocuration,,,1597,,3025,H,CHEMBL616624,BAO_0000219,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,
B,,,,,,,8,,106,1,Autocuration,,,1598,,2391,H,CHEMBL883243,BAO_0000357,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,
F,,,,,,,8,,106,1,Autocuration,,,1599,,2391,H,CHEMBL616625,BAO_0000019,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,
F,CHO,449.0,,,,,8,,106,1,Expert,,,1600,,14956,H,CHEMBL616626,BAO_0000219,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",
F,CHO,449.0,,,,,8,,106,1,Autocuration,,,1601,,2598,H,CHEMBL616627,BAO_0000219,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,
F,CHO,449.0,,,,,8,,106,1,Autocuration,,,1602,,2598,H,CHEMBL616628,BAO_0000219,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,
F,CHO,449.0,,,,,8,,106,1,Autocuration,,,1603,,2598,H,CHEMBL616629,BAO_0000219,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,
F,CHO,449.0,,,,,8,,106,1,Autocuration,,,1604,,2598,H,CHEMBL616630,BAO_0000219,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,
F,,,,,,,8,,106,1,Expert,,,1605,,14956,H,CHEMBL616631,BAO_0000019,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",
F,,,,,,,8,,106,1,Autocuration,,,1606,,14956,H,CHEMBL616632,BAO_0000019,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",
B,,,,,,,9,9606.0,106,1,Expert,,,1607,,14214,D,CHEMBL616633,BAO_0000357,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,Homo sapiens
B,CHO,449.0,,,,,8,,106,1,Expert,,,1608,,3463,H,CHEMBL616634,BAO_0000219,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,
B,,,,,,,8,,106,1,Autocuration,,,1609,,15331,H,CHEMBL616635,BAO_0000357,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,
B,,,,,,,9,9606.0,106,1,Expert,,,1610,,16146,D,CHEMBL885358,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1B receptor,Homo sapiens
B,CHO,449.0,,,,,9,9606.0,106,1,Expert,,,1611,,14159,D,CHEMBL616636,BAO_0000219,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Homo sapiens
B,CHO,449.0,,,,,8,,106,1,Expert,,,1612,,14158,H,CHEMBL616637,BAO_0000219,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,
B,,,,,,,8,,106,1,Autocuration,,,1613,,14159,H,CHEMBL616638,BAO_0000357,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,
B,CHO,449.0,,,,,8,,106,1,Expert,,,1614,,15250,H,CHEMBL616639,BAO_0000219,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,
B,CHO,449.0,,,,,8,,106,1,Expert,,,1615,,15250,H,CHEMBL616640,BAO_0000219,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,
B,CHO,449.0,,,,,8,,106,1,Expert,,,1616,,15331,H,CHEMBL616641,BAO_0000219,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,
B,CHO,449.0,,,,,8,,106,1,Expert,,,1617,,15332,H,CHEMBL616642,BAO_0000219,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,
B,CHO,449.0,,,,,8,,106,1,Expert,,,1618,,14956,H,CHEMBL616643,BAO_0000219,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,
B,,,,,,,8,,106,1,Autocuration,,,1619,,3805,H,CHEMBL616644,BAO_0000357,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),
B,,,,,,,8,,106,1,Autocuration,,,1620,,14875,H,CHEMBL616645,BAO_0000357,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,
F,,,,,,,8,9986.0,105,1,Autocuration,,,1621,,14454,H,CHEMBL616646,BAO_0000019,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus
F,,,,,,,8,9986.0,105,1,Expert,,,1622,,14454,H,CHEMBL616647,BAO_0000019,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus
B,,,,,,,8,,105,1,Autocuration,,,1623,,16288,H,CHEMBL616509,BAO_0000357,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),
B,,,,,,,8,,105,1,Autocuration,,,1624,,16288,H,CHEMBL616510,BAO_0000357,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),
B,,,,,,,8,,105,1,Autocuration,,,1625,,16312,H,CHEMBL616511,BAO_0000357,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,9913.0,105,1,Expert,,,1626,,1348,H,CHEMBL616512,BAO_0000357,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1627,,5834,H,CHEMBL616513,BAO_0000357,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,Bos taurus
B,,,,,2435.0,,8,9913.0,105,1,Autocuration,,,1628,,13366,H,CHEMBL616514,BAO_0000019,Striatum,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Bos taurus
B,,,,,,,8,9913.0,105,1,Expert,,,1629,,1414,H,CHEMBL616515,BAO_0000357,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1630,,14998,H,CHEMBL616516,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1631,,11473,H,CHEMBL616517,BAO_0000357,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1632,,11473,H,CHEMBL616518,BAO_0000357,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1633,,10639,H,CHEMBL616519,BAO_0000357,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1634,,10639,H,CHEMBL616520,BAO_0000357,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1635,,1375,H,CHEMBL616521,BAO_0000357,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1636,,1375,H,CHEMBL616522,BAO_0000357,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1637,,16532,H,CHEMBL884531,BAO_0000357,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1638,,11147,H,CHEMBL616523,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,Bos taurus
B,,,,,2435.0,,8,9913.0,105,1,Autocuration,,,1639,,13366,H,CHEMBL616731,BAO_0000019,Striatum,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1640,,10444,H,CHEMBL616732,BAO_0000019,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1641,,16532,H,CHEMBL616733,BAO_0000357,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1642,,16532,H,CHEMBL616734,BAO_0000357,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1643,,12827,H,CHEMBL616735,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1644,,12827,H,CHEMBL616736,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,Bos taurus
F,,,,,,,8,9913.0,105,1,Expert,,,1645,,12919,H,CHEMBL616737,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus
B,,,,,,,8,9913.0,105,1,Autocuration,,,1646,,14025,H,CHEMBL616738,BAO_0000019,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,Bos taurus
F,,,,,,,8,9913.0,105,1,Expert,,,1647,,12919,H,CHEMBL616739,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus
F,,,,,,,8,9913.0,105,1,Expert,,,1648,,12919,H,CHEMBL616740,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus
F,,,,,,,8,9913.0,105,1,Expert,,,1649,,12919,H,CHEMBL616741,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus
B,HEK293,722.0,,,,,8,9593.0,105,1,Autocuration,,,1650,,14447,H,CHEMBL616742,BAO_0000219,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Gorilla gorilla
B,,,,,,,9,10141.0,105570,1,Intermediate,,,1651,,1375,D,CHEMBL616743,BAO_0000019,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,Cavia porcellus
B,,,,,,,9,10141.0,105570,1,Intermediate,,,1652,,1375,D,CHEMBL616744,BAO_0000019,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,Cavia porcellus
F,,,,,,,9,10141.0,105570,1,Intermediate,,,1653,,12409,D,CHEMBL616745,BAO_0000019,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,Cavia porcellus
F,,,,,,,9,10141.0,105570,1,Intermediate,,,1654,,12409,D,CHEMBL616746,BAO_0000019,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus
F,,,,,,,9,10141.0,105570,1,Intermediate,,,1655,,12409,D,CHEMBL616747,BAO_0000019,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,Cavia porcellus
F,,,,,,,9,10141.0,105570,1,Intermediate,,,1656,,12409,D,CHEMBL616748,BAO_0000019,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,Cavia porcellus
F,,,,,,,9,10141.0,105570,1,Intermediate,,,1657,,12409,D,CHEMBL616648,BAO_0000019,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,Cavia porcellus
B,,,,,,,9,10141.0,105570,1,Intermediate,,,1658,,11574,D,CHEMBL616649,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1D receptor,Cavia porcellus
B,,,,,,,9,10141.0,105570,1,Intermediate,,,1659,,1558,D,CHEMBL616650,BAO_0000357,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,Cavia porcellus
F,,,,,,,9,10141.0,105570,1,Intermediate,,,1660,,12409,D,CHEMBL616651,BAO_0000218,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus
F,,,,,,,9,10141.0,105570,1,Intermediate,,,1661,,12409,D,CHEMBL616652,BAO_0000218,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus
F,,,,,,,9,10141.0,105570,1,Intermediate,,,1662,,12409,D,CHEMBL616653,BAO_0000218,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus
F,,,,,,,9,10141.0,105570,1,Intermediate,,,1663,,12409,D,CHEMBL616654,BAO_0000218,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,Cavia porcellus
B,,,,,,,9,10141.0,105570,1,Intermediate,,,1664,,12253,D,CHEMBL616655,BAO_0000019,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,Cavia porcellus
B,,,,,,,9,10141.0,105570,1,Intermediate,,,1665,,12936,D,CHEMBL616656,BAO_0000357,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,Cavia porcellus
B,,,,,,,8,10141.0,105,1,Autocuration,,,1666,,13181,H,CHEMBL616657,BAO_0000019,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,Cavia porcellus
B,,,,,2435.0,,9,10141.0,105570,1,Intermediate,,,1667,,12409,D,CHEMBL616658,BAO_0000357,Striatum,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Cavia porcellus
B,,,,,,,9,10141.0,105570,1,Intermediate,,,1668,,10639,D,CHEMBL616659,BAO_0000357,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,Cavia porcellus
B,,,,,,,8,,51,1,Autocuration,,,1669,,5254,H,CHEMBL616660,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,106,1,Autocuration,,,1670,,13051,H,CHEMBL616661,BAO_0000357,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,
F,,,,,,,8,,105,1,Expert,,,1671,,3463,H,CHEMBL616662,BAO_0000019,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,
F,,,,,,,8,,105,1,Autocuration,,,1672,,15315,H,CHEMBL616663,BAO_0000019,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,
F,,,,,,,8,,105,1,Autocuration,,,1673,,6011,H,CHEMBL616664,BAO_0000019,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,
F,CHO,449.0,,,,,9,9606.0,105,1,Expert,,,1674,,14159,D,CHEMBL881820,BAO_0000219,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",Homo sapiens
F,CHO,449.0,,,,,8,,105,1,Autocuration,,,1675,,14159,H,CHEMBL616665,BAO_0000219,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",
B,CHO,449.0,,,,,8,,105,1,Expert,,,1676,,15250,H,CHEMBL616666,BAO_0000219,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1677,,15250,H,CHEMBL616667,BAO_0000219,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,
F,CHO,449.0,,,,,8,,105,1,Expert,,,1678,,15331,H,CHEMBL616668,BAO_0000219,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",
F,CHO,449.0,,,,,9,9606.0,105,1,Expert,,,1679,,15332,D,CHEMBL616669,BAO_0000219,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Homo sapiens
F,CHO,449.0,,,,,8,,105,1,Expert,,,1680,,15332,H,CHEMBL617040,BAO_0000219,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",
F,CHO,449.0,,,,,8,,105,1,Autocuration,,,1681,,3294,H,CHEMBL617041,BAO_0000219,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",
F,CHO,449.0,,,,,8,,105,1,Expert,,,1682,,14158,H,CHEMBL617042,BAO_0000219,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",
F,CHO,449.0,,,,,8,,105,1,Expert,,,1683,,14956,H,CHEMBL617043,BAO_0000219,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",
F,,,,,,,8,,105,1,Autocuration,,,1684,,12469,H,CHEMBL617044,BAO_0000019,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,
F,CHO,449.0,,,,,8,,105,1,Expert,,,1685,,3463,H,CHEMBL617045,BAO_0000219,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,
F,CHO,449.0,,,,,9,9606.0,105,1,Expert,,,1686,,15250,D,CHEMBL617046,BAO_0000219,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Homo sapiens
F,CHO,449.0,,,,,9,9606.0,105,1,Expert,,,1687,,15250,D,CHEMBL617047,BAO_0000219,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Homo sapiens
F,,,,,,,8,,105,1,Expert,,,1688,,14956,H,CHEMBL617048,BAO_0000019,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",
F,,,,,,,8,,105,1,Autocuration,,,1689,,14159,H,CHEMBL616897,BAO_0000019,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",
F,,,,,,,9,9606.0,105,1,Expert,,,1690,,14159,D,CHEMBL616898,BAO_0000019,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",Homo sapiens
F,CHO,449.0,,,,,9,9606.0,105,1,Expert,,,1691,,14499,D,CHEMBL858201,BAO_0000219,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,Homo sapiens
F,,,,,,,8,,105,1,Autocuration,,,1692,,15315,H,CHEMBL616899,BAO_0000019,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,
B,,,In vitro,,,,8,,105,1,Autocuration,,,1693,,3294,H,CHEMBL616900,BAO_0000219,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),
B,CHO,449.0,,,,,8,,105,1,Expert,,,1694,,3463,H,CHEMBL616901,BAO_0000219,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,
B,,,,,,,8,,105,1,Autocuration,,,1695,,15331,H,CHEMBL616902,BAO_0000357,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,
B,CHO,449.0,,,,,9,9606.0,105,1,Expert,,,1696,,14159,D,CHEMBL616903,BAO_0000219,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens
B,CHO,449.0,,,,,8,,105,1,Expert,,,1697,,14158,H,CHEMBL616904,BAO_0000219,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,
B,,,,,,,8,,105,1,Autocuration,,,1698,,14159,H,CHEMBL616905,BAO_0000357,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,
B,CHO,449.0,,,,,8,,105,1,Expert,,,1699,,15250,H,CHEMBL616906,BAO_0000219,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,
B,CHO,449.0,,,,,8,,105,1,Expert,,,1700,,15250,H,CHEMBL616907,BAO_0000219,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,
B,CHO,449.0,,,,,8,,105,1,Expert,,,1701,,15331,H,CHEMBL616908,BAO_0000219,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,
B,CHO,449.0,,,,,9,9606.0,105,1,Expert,,,1702,,15332,D,CHEMBL616909,BAO_0000219,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens
B,CHO,449.0,,,,,9,9606.0,105,1,Expert,,,1703,,14499,D,CHEMBL616910,BAO_0000219,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens
B,CHO,449.0,,,,,8,,105,1,Expert,,,1704,,15332,H,CHEMBL616911,BAO_0000219,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,
B,CHO,449.0,,,,,8,,105,1,Expert,,,1705,,14956,H,CHEMBL616912,BAO_0000219,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,
B,,,,,,,8,,105,1,Autocuration,,,1706,,3805,H,CHEMBL616913,BAO_0000357,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),
B,CHO,449.0,,,,,9,9606.0,105,1,Expert,,,1707,,6011,D,CHEMBL616914,BAO_0000219,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,Homo sapiens
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1708,,16190,H,CHEMBL616915,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,
B,,,,,,,8,,105,1,Autocuration,,,1709,,14165,H,CHEMBL616916,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,
B,,,,,,,9,9606.0,105,1,Expert,,,1710,,4234,D,CHEMBL616917,BAO_0000357,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,Homo sapiens
B,,,,,,,8,,105,1,Autocuration,,,1711,,15527,H,CHEMBL616918,BAO_0000357,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",
B,,,,,,,8,,105,1,Expert,,,1712,,6328,H,CHEMBL616919,BAO_0000219,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,
B,,,,,,,8,,105,1,Autocuration,,,1713,,16209,H,CHEMBL616920,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,
B,,,,,,,8,,105,1,Autocuration,,,1714,,14770,H,CHEMBL872914,BAO_0000357,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,
B,,,,,,,8,,105,1,Autocuration,,,1715,,2598,H,CHEMBL616921,BAO_0000357,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,
B,,,,,,,8,,105,1,Expert,,,1716,,6897,H,CHEMBL616922,BAO_0000357,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Autocuration,,,1717,,6013,H,CHEMBL616923,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Expert,,,1718,,5843,H,CHEMBL616924,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Expert,,,1719,,14454,H,CHEMBL875909,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,
B,,,,,,,8,,105,1,Autocuration,,,1720,,14454,H,CHEMBL616925,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,
B,,,,,,,8,,105,1,Autocuration,,,1721,,14454,H,CHEMBL616926,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,
B,,,,,,,8,,105,1,Autocuration,,,1722,,15818,H,CHEMBL616927,BAO_0000357,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,
F,CHO-K1,485.0,,,,,8,,105,1,Expert,,,1723,,13729,H,CHEMBL616928,BAO_0000219,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,
B,,,In vitro,,,,9,9606.0,105,1,Expert,,,1724,,6011,D,CHEMBL616929,BAO_0000219,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),Homo sapiens
B,,,,,,,9,9606.0,105,1,Expert,,,1725,,4234,D,CHEMBL616930,BAO_0000357,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,Homo sapiens
B,,,,,,,8,,105,1,Expert,,,1726,,17085,H,CHEMBL616931,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Autocuration,,,1727,,3025,H,CHEMBL616932,BAO_0000357,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,
B,,,,,,,8,,105,1,Expert,,,1728,,15315,H,CHEMBL616933,BAO_0000357,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,
B,,,,,,,9,9606.0,105,1,Expert,,,1729,,14214,D,CHEMBL616934,BAO_0000219,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,Homo sapiens
B,,,,,,,9,9606.0,105,1,Expert,,,1730,,3804,D,CHEMBL616935,BAO_0000357,,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens
B,,,,,,,8,,105,1,Autocuration,,,1731,,16700,H,CHEMBL616936,BAO_0000357,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,
B,,,,,,,9,9606.0,105,1,Expert,,,1732,,2391,D,CHEMBL616937,BAO_0000357,,Affinity for 5-hydroxytryptamine 1D receptor subtype,Homo sapiens
B,,,,,,,9,9606.0,105,1,Expert,,,1733,,4175,D,CHEMBL616938,BAO_0000357,,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens
B,,,,,,,8,,105,1,Autocuration,,,1734,,17085,H,CHEMBL616939,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Expert,,,1735,,17085,H,CHEMBL616940,BAO_0000019,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,
B,,,,,,,9,9606.0,105,1,Expert,,,1736,,15926,D,CHEMBL616941,BAO_0000357,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,Homo sapiens
B,CHO-K1,485.0,,,,,8,,105,1,Autocuration,,,1737,,16312,H,CHEMBL616942,BAO_0000219,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,
B,CHO-K1,485.0,,,,,8,,105,1,Autocuration,,,1738,,16312,H,CHEMBL616943,BAO_0000219,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,
B,CHO,449.0,,,,,4,,104802,1,Autocuration,,,1739,,14956,H,CHEMBL616944,BAO_0000219,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,
F,,,,,,,8,,105,1,Autocuration,,,1740,,3294,H,CHEMBL616945,BAO_0000019,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",
B,,,,,,,8,,105,1,Autocuration,,,1741,,12861,H,CHEMBL616946,BAO_0000357,,Binding activity radioligand.,
B,,,,,,,8,,105,1,Autocuration,,,1742,,12861,H,CHEMBL616947,BAO_0000019,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,
B,CHO-K1,485.0,,,,,8,,105,1,Expert,,,1743,,16312,H,CHEMBL616948,BAO_0000219,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Autocuration,,,1744,,5104,H,CHEMBL616851,BAO_0000357,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Autocuration,,,1745,,5105,H,CHEMBL616852,BAO_0000357,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Autocuration,,,1746,,14499,H,CHEMBL616853,BAO_0000357,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,
B,,,,,,,9,9606.0,105,1,Expert,,,1747,,15926,D,CHEMBL616854,BAO_0000357,,Binding activity against human 5-hydroxytryptamine 1D receptor,Homo sapiens
B,CHO,449.0,,,,,9,9606.0,105,1,Expert,,,1748,,4540,D,CHEMBL616855,BAO_0000219,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Homo sapiens
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1749,,15779,H,CHEMBL616856,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1750,,15779,H,CHEMBL616857,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,
B,,,,,,,8,,105,1,Autocuration,,,1751,,6166,H,CHEMBL616858,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1752,,15779,H,CHEMBL616859,BAO_0000219,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1753,,15779,H,CHEMBL616860,BAO_0000219,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,
B,HEK293,722.0,,,,,8,,105,1,Autocuration,,,1754,,17451,H,CHEMBL616861,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,
B,HEK293,722.0,,,,,8,,105,1,Autocuration,,,1755,,17451,H,CHEMBL616541,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,
B,HEK293,722.0,,,,,8,,105,1,Autocuration,,,1756,,17451,H,CHEMBL616542,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1757,,4199,H,CHEMBL616543,BAO_0000219,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,
B,,,,,,,9,9606.0,105,1,Expert,,,1758,,14875,D,CHEMBL616544,BAO_0000357,,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1759,,15146,H,CHEMBL616545,BAO_0000219,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,
B,,,,,,,8,,105,1,Autocuration,,,1760,,5213,H,CHEMBL616546,BAO_0000357,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1761,,14818,H,CHEMBL616547,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,
B,CHO,449.0,,,,,8,,105,1,Autocuration,,,1762,,4829,H,CHEMBL616548,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",
F,,,,,,,8,,105,1,Expert,,,1763,,14454,H,CHEMBL616549,BAO_0000019,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,
F,,,,,,,8,,105,1,Expert,,,1764,,14454,H,CHEMBL616550,BAO_0000019,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,
B,,,,,,,8,,108,1,Autocuration,,,1765,,5254,H,CHEMBL857066,BAO_0000357,,Binding affinity against 5-HT2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,1766,,5254,H,CHEMBL616551,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,10577,1,Autocuration,,,1767,,10639,H,CHEMBL616552,BAO_0000357,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,
F,,,,,,,8,,10577,1,Autocuration,,,1768,,10639,H,CHEMBL832876,BAO_0000019,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,
B,,,,,,,8,,10577,1,Expert,,,1769,,12352,H,CHEMBL616553,BAO_0000019,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",
B,,,,,,,8,,10577,1,Autocuration,,,1770,,9098,H,CHEMBL616554,BAO_0000357,,Binding affinity towards 5-HT1B was determined,
B,,,,,,,8,,10577,1,Expert,,,1771,,14430,H,CHEMBL616555,BAO_0000019,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,
B,,,,,,,8,,10577,1,Expert,,,1772,,13657,H,CHEMBL616556,BAO_0000019,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",
B,,,,,,,8,,10577,1,Autocuration,,,1773,,13657,H,CHEMBL616557,BAO_0000019,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",
B,,,,,,,8,,10577,1,Expert,,,1774,,15854,H,CHEMBL616558,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,
B,,,,,,,9,10116.0,10577,1,Expert,,,1775,,10639,D,CHEMBL616749,BAO_0000019,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,Rattus norvegicus
B,,,,,,,8,,10577,1,Autocuration,,,1776,,10025,H,CHEMBL616750,BAO_0000357,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,
B,,,,,,,8,,10577,1,Autocuration,,,1777,,10025,H,CHEMBL616751,BAO_0000357,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",
B,,,,,,,8,,10577,1,Autocuration,,,1778,,14286,H,CHEMBL616752,BAO_0000249,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,
B,,,,,2435.0,,8,,10577,1,Autocuration,,,1779,,3651,H,CHEMBL616753,BAO_0000019,Striatum,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,
B,,,,,,,9,10116.0,10577,1,Expert,,,1780,,14178,D,CHEMBL616754,BAO_0000357,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,Rattus norvegicus
B,,,,,,,8,,10577,1,Autocuration,,,1781,,10639,H,CHEMBL616755,BAO_0000019,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,
B,,,,,2435.0,,8,,10577,1,Autocuration,,,1782,,13605,H,CHEMBL616756,BAO_0000019,Striatum,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,
B,,,,,2435.0,,8,,10577,1,Autocuration,,,1783,,5834,H,CHEMBL616757,BAO_0000019,Striatum,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,
B,,,,,2435.0,,8,,10577,1,Autocuration,,,1784,,10922,H,CHEMBL616758,BAO_0000357,Striatum,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,
B,,,,,,,8,,10577,1,Autocuration,,,1785,,14286,H,CHEMBL616759,BAO_0000249,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,
B,,,,,,,8,,10577,1,Autocuration,,,1786,,11825,H,CHEMBL616760,BAO_0000357,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,
B,,,,,2435.0,,8,,10577,1,Autocuration,,,1787,,14826,H,CHEMBL616761,BAO_0000019,Striatum,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,
B,,,,,2435.0,,8,,10577,1,Autocuration,,,1788,,9699,H,CHEMBL616762,BAO_0000019,Striatum,Binding affinity against 5-HT1B serotonin receptor in rat striatum,
B,,,,,,,8,,10577,1,Autocuration,,,1789,,14423,H,CHEMBL616763,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,
B,,,,,,,8,,10577,1,Expert,,,1790,,10062,H,CHEMBL872909,BAO_0000357,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,
B,,,,,,,8,,10577,1,Autocuration,,,1791,,10062,H,CHEMBL616764,BAO_0000357,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,
B,,,,,,,9,10116.0,10577,1,Expert,,,1792,,12280,D,CHEMBL616765,BAO_0000357,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,Rattus norvegicus
B,,,,,2435.0,,8,,10577,1,Autocuration,,,1793,,15412,H,CHEMBL616766,BAO_0000357,Striatum,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,
B,,,,,2435.0,,8,,10577,1,Autocuration,,,1794,,15412,H,CHEMBL616767,BAO_0000357,Striatum,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,
B,,,,,,,8,,10577,1,Autocuration,,,1795,,10062,H,CHEMBL616768,BAO_0000357,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,10577,1,Autocuration,,,1796,,11147,H,CHEMBL616769,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,
B,,,,,,,8,,10577,1,Autocuration,,,1797,,9547,H,CHEMBL616770,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,
B,,,,,,,8,,10577,1,Autocuration,,,1798,,10444,H,CHEMBL616771,BAO_0000019,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,
B,,,,,2435.0,,8,,10577,1,Autocuration,,,1799,,12469,H,CHEMBL616772,BAO_0000019,Striatum,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,
B,,,,,,,8,,10577,1,Expert,,,1800,,9098,H,CHEMBL616773,BAO_0000019,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,
B,,,,,,,8,,10577,1,Autocuration,,,1801,,9098,H,CHEMBL616774,BAO_0000019,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,
B,,,,,,,8,,10577,1,Autocuration,,,1802,,9699,H,CHEMBL616775,BAO_0000357,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,10577,1,Autocuration,,,1803,,10394,H,CHEMBL616776,BAO_0000249,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,
B,,,,,,,8,,10577,1,Autocuration,,,1804,,12092,H,CHEMBL616777,BAO_0000357,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,
B,,,,,,,8,,10577,1,Autocuration,,,1805,,16700,H,CHEMBL616778,BAO_0000357,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,
B,,,,,,,9,10116.0,10577,1,Expert,,,1806,,403,D,CHEMBL616779,BAO_0000249,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,Rattus norvegicus
B,,,,,,,9,10116.0,10577,1,Expert,,,1807,,12771,D,CHEMBL616780,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1B receptor,Rattus norvegicus
B,,,,,,,8,,10577,1,Autocuration,,,1808,,11642,H,CHEMBL616781,BAO_0000019,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,
B,,,,,,,8,,10577,1,Autocuration,,,1809,,12953,H,CHEMBL616782,BAO_0000357,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,
B,,,,,,,8,,10577,1,Autocuration,,,1810,,12953,H,CHEMBL616783,BAO_0000357,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,
B,,,,,2435.0,,8,,10577,1,Expert,,,1811,,12953,H,CHEMBL616784,BAO_0000019,Striatum,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,
B,,,,,,,8,,10577,1,Autocuration,,,1812,,12953,H,CHEMBL616785,BAO_0000357,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,
B,,,,,955.0,,8,,10577,1,Autocuration,,,1813,,9737,H,CHEMBL857067,BAO_0000249,Brain,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,
B,,,,,,,8,,10577,1,Autocuration,,,1814,,9737,H,CHEMBL616786,BAO_0000019,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,
B,,,,,955.0,,8,,10577,1,Autocuration,,,1815,,9737,H,CHEMBL616787,BAO_0000249,Brain,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,
B,,,,,,,8,,10577,1,Autocuration,,,1816,,12827,H,CHEMBL616788,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,
B,,,,,,,8,,10577,1,Autocuration,,,1817,,5033,H,CHEMBL616789,BAO_0000357,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,
B,,,,,,,9,10116.0,10577,1,Expert,,,1818,,9786,D,CHEMBL616790,BAO_0000019,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,Rattus norvegicus
B,,,,,,,8,,10577,1,Expert,,,1819,,13116,H,CHEMBL616791,BAO_0000357,,Binding affinity at 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,10577,1,Autocuration,,,1820,,16429,H,CHEMBL616792,BAO_0000019,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,
B,,,,,,,9,10116.0,10577,1,Expert,,,1821,,12409,D,CHEMBL616793,BAO_0000249,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,Rattus norvegicus
B,,,,,,,8,,10577,1,Autocuration,,,1822,,15194,H,CHEMBL616794,BAO_0000357,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,
B,,,,,,,8,,10577,1,Autocuration,,,1823,,15194,H,CHEMBL616795,BAO_0000357,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,1824,,5486,H,CHEMBL616796,BAO_0000019,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,
B,,,,,,,8,,106,1,Autocuration,,,1825,,4639,H,CHEMBL616797,BAO_0000357,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Autocuration,,,1826,Brain membranes,386,H,CHEMBL616798,BAO_0000249,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,
B,,,,,,,8,,106,1,Autocuration,,,1827,,2474,H,CHEMBL616799,BAO_0000357,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,
B,,,,,,,8,,106,1,Autocuration,,,1828,,6011,H,CHEMBL616800,BAO_0000357,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,
B,,,,,,,8,,106,1,Autocuration,,,1829,,5014,H,CHEMBL616801,BAO_0000357,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Autocuration,,,1830,,17515,H,CHEMBL616802,BAO_0000357,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,
B,,,,,,,8,,106,1,Autocuration,,,1831,,4373,H,CHEMBL616803,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,
B,,,,,,,8,,106,1,Expert,,,1832,,1633,H,CHEMBL857068,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,
B,,,,,,,8,,106,1,Autocuration,,,1833,,1633,H,CHEMBL616804,BAO_0000357,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,
B,,,,,,,8,,106,1,Autocuration,,,1834,,4373,H,CHEMBL616805,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,
B,,,,,,,8,,106,1,Autocuration,,,1835,,4687,H,CHEMBL616806,BAO_0000357,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Autocuration,,,1836,,11574,H,CHEMBL616807,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1B receptor,
B,,,,,,,8,,106,1,Autocuration,,,1837,,10321,H,CHEMBL616808,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,
B,,,,,,,8,,106,1,Autocuration,,,1838,,15527,H,CHEMBL616809,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,
B,,,,,,,8,,106,1,Autocuration,,,1839,,17200,H,CHEMBL616810,BAO_0000357,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,
B,,,,,,,4,,104802,1,Autocuration,,,1840,,14423,H,CHEMBL616811,BAO_0000224,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,
B,,,,,,,8,9913.0,108,1,Autocuration,,,1841,,5834,H,CHEMBL616812,BAO_0000357,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,Bos taurus
B,,,,,,,8,9823.0,108,1,Autocuration,,,1842,,11473,H,CHEMBL616813,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Sus scrofa
B,,,,,,,8,9823.0,108,1,Autocuration,,,1843,,11473,H,CHEMBL616814,BAO_0000357,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,Sus scrofa
B,,,,,,,8,9823.0,108,1,Autocuration,,,1844,,10639,H,CHEMBL616815,BAO_0000357,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Sus scrofa
B,,,,,,,8,9823.0,108,1,Autocuration,,,1845,,10639,H,CHEMBL616816,BAO_0000357,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Sus scrofa
B,,,,,,,8,9823.0,108,1,Autocuration,,,1846,,14331,H,CHEMBL616817,BAO_0000357,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,Sus scrofa
B,,,,,,,8,9823.0,108,1,Autocuration,,,1847,,10796,H,CHEMBL616818,BAO_0000357,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,Sus scrofa
B,,,,,,,8,9823.0,108,1,Expert,,,1848,,9098,H,CHEMBL616819,BAO_0000357,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,Sus scrofa
B,,,,,,,8,9823.0,108,1,Expert,,,1849,,14331,H,CHEMBL616820,BAO_0000357,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,Sus scrofa
B,,,,,,,8,9823.0,108,1,Expert,,,1850,,11828,H,CHEMBL616821,BAO_0000019,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,Sus scrofa
B,,,,,,,8,9823.0,108,1,Autocuration,,,1851,,11866,H,CHEMBL616822,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,Sus scrofa
B,,,,,,,8,9986.0,108,1,Autocuration,,,1852,,13047,H,CHEMBL616823,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Oryctolagus cuniculus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1853,,188,D,CHEMBL616824,BAO_0000357,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1854,,11825,D,CHEMBL616825,BAO_0000357,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1855,,11825,D,CHEMBL616826,BAO_0000357,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Expert,,,1856,,11624,D,CHEMBL616827,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1857,,11139,D,CHEMBL616828,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1858,,11147,D,CHEMBL616829,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1859,,10444,D,CHEMBL616830,BAO_0000019,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Expert,,,1860,,11624,D,CHEMBL616831,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1C receptor,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1861,,11662,D,CHEMBL616832,BAO_0000019,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1862,,11662,D,CHEMBL616833,BAO_0000019,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Expert,,,1863,,11662,D,CHEMBL616834,BAO_0000019,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1864,,11662,D,CHEMBL829595,BAO_0000019,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1865,,9098,D,CHEMBL616835,BAO_0000357,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1866,,10394,D,CHEMBL872910,BAO_0000249,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,Rattus norvegicus
B,,,,,,,8,,12689,1,Expert,,,1867,,11933,H,CHEMBL616836,BAO_0000357,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1868,,12092,D,CHEMBL616837,BAO_0000357,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Autocuration,,,1869,,12253,D,CHEMBL616466,BAO_0000019,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,Rattus norvegicus
B,HEK293,722.0,,,,,9,10116.0,12689,1,Autocuration,,,1870,,12253,D,CHEMBL616467,BAO_0000219,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,Rattus norvegicus
B,,,,,,,8,,108,1,Autocuration,,,1871,,1558,H,CHEMBL616468,BAO_0000357,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,
B,,,,,,,8,,108,1,Autocuration,,,1872,,2474,H,CHEMBL616469,BAO_0000357,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,
B,,,,,,,8,,108,1,Autocuration,,,1873,,2474,H,CHEMBL616470,BAO_0000357,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,
B,,,,,,,8,,12689,1,Autocuration,,,1874,,11574,H,CHEMBL616471,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1C receptor,
B,,,,,,,8,,12689,1,Autocuration,,,1875,,1558,H,CHEMBL616472,BAO_0000357,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,
B,,,,,,,8,,12689,1,Autocuration,,,1876,,13944,H,CHEMBL616473,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1C receptor,
B,,,,,,,8,,12689,1,Autocuration,,,1877,,13033,H,CHEMBL616474,BAO_0000357,,Binding affinity against serotonergic 5-HT1c receptor,
B,,,,,,,8,,12689,1,Autocuration,,,1878,,10321,H,CHEMBL616475,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,
B,,,,,,,8,,12689,1,Autocuration,,,1879,,11866,H,CHEMBL616476,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,
B,,,,,,,8,9986.0,105,1,Autocuration,,,1880,,14454,H,CHEMBL616477,BAO_0000019,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus
B,,,,,,,4,,104686,1,Autocuration,,,1881,,11574,H,CHEMBL616478,BAO_0000224,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,1882,,11574,H,CHEMBL616479,BAO_0000224,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,1883,,13631,H,CHEMBL616480,BAO_0000019,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,1884,,9630,D,CHEMBL616481,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,Rattus norvegicus
B,,,,,,,5,10116.0,104686,1,Autocuration,,,1885,,8822,D,CHEMBL616482,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,Rattus norvegicus
B,,,,,955.0,,5,10116.0,104686,1,Autocuration,,,1886,,9064,D,CHEMBL884713,BAO_0000221,Brain,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,1887,,8868,H,CHEMBL616483,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,
B,,,,,,,4,,104686,1,Autocuration,,,1888,,9064,H,CHEMBL616484,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,
B,,,,,,,4,,104686,1,Autocuration,,,1889,,9806,H,CHEMBL616485,BAO_0000019,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,
B,,,,,,,4,,104686,1,Autocuration,,,1890,,9098,H,CHEMBL616486,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,
B,,,,,,,4,,104686,1,Autocuration,,,1891,,8868,H,CHEMBL616487,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,
B,,,,,,,4,,104686,1,Autocuration,,,1892,,12765,H,CHEMBL616488,BAO_0000224,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,
B,,,,,,,4,,104686,1,Autocuration,,,1893,,11049,H,CHEMBL616489,BAO_0000019,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,1894,,11049,H,CHEMBL616490,BAO_0000019,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,1895,,11049,H,CHEMBL616491,BAO_0000019,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,
B,,,,,,,4,,104686,1,Autocuration,,,1896,,11049,H,CHEMBL616492,BAO_0000019,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,
B,,,,,,,4,,104686,1,Autocuration,,,1897,,11049,H,CHEMBL616493,BAO_0000019,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,1898,,11473,H,CHEMBL616494,BAO_0000019,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,1899,,11473,H,CHEMBL616495,BAO_0000019,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,1900,,3086,H,CHEMBL616496,BAO_0000019,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,
B,,,,,,,4,,104686,1,Autocuration,,,1901,,11049,H,CHEMBL616497,BAO_0000019,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,1902,,11049,H,CHEMBL616498,BAO_0000019,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,1903,,10639,H,CHEMBL616499,BAO_0000019,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,1904,,10922,H,CHEMBL616500,BAO_0000019,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,
B,,,,,955.0,,5,10116.0,104686,1,Autocuration,,,1905,,9064,D,CHEMBL616501,BAO_0000221,Brain,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus
B,,,,,955.0,,4,,104686,1,Autocuration,,,1906,,10748,H,CHEMBL616502,BAO_0000221,Brain,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,
B,,,,,,,4,,104686,1,Autocuration,,,1907,Membranes,11614,H,CHEMBL884529,BAO_0000249,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,
B,,,,,,,4,,104686,1,Autocuration,,,1908,Membranes,11615,H,CHEMBL616503,BAO_0000249,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,
B,,,,,,,4,,104686,1,Autocuration,,,1909,,11615,H,CHEMBL616964,BAO_0000224,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,1910,Membranes,11614,H,CHEMBL616965,BAO_0000249,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,
B,,,,,,,4,,104686,1,Autocuration,,,1911,,11702,H,CHEMBL616966,BAO_0000224,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,
B,,,,,,,4,,104686,1,Autocuration,,,1912,,11702,H,CHEMBL616967,BAO_0000224,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,1913,,11702,D,CHEMBL616968,BAO_0000224,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,1914,,11702,H,CHEMBL616969,BAO_0000224,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,
B,,,,,,,4,,104686,1,Autocuration,,,1915,,13346,H,CHEMBL884530,BAO_0000019,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,
B,,,,,,,4,,104686,1,Autocuration,,,1916,,10025,H,CHEMBL616970,BAO_0000224,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,1917,,10025,H,CHEMBL616971,BAO_0000224,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,
B,,,,,,,4,,104686,1,Autocuration,,,1918,,10025,H,CHEMBL616972,BAO_0000224,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",
B,,,,,,,4,,104686,1,Autocuration,,,1919,,9036,H,CHEMBL616973,BAO_0000224,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,
B,,,,,,,4,,104686,1,Autocuration,,,1920,,9036,H,CHEMBL616974,BAO_0000224,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,
B,,,,,,,4,,104686,1,Autocuration,,,1921,,9161,H,CHEMBL616975,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,
B,,,,,,,4,,104686,1,Autocuration,,,1922,,12304,H,CHEMBL616976,BAO_0000019,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,
B,,,,,,,4,,104686,1,Autocuration,,,1923,,13276,H,CHEMBL616977,BAO_0000224,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,1924,,11825,H,CHEMBL616978,BAO_0000224,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,
B,,,,,,,4,,104686,1,Autocuration,,,1925,,12443,H,CHEMBL616979,BAO_0000224,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,
B,,,,,,,4,,104686,1,Autocuration,,,1926,,13830,H,CHEMBL616980,BAO_0000224,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,1927,Membranes,9592,H,CHEMBL616981,BAO_0000249,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,
B,,,,,,,4,,104686,1,Autocuration,,,1928,Membranes,9592,H,CHEMBL616982,BAO_0000249,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,
B,,,,,,,4,,104686,1,Autocuration,,,1929,,10881,H,CHEMBL616983,BAO_0000224,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,
B,,,,,,,4,,104686,1,Autocuration,,,1930,,13605,H,CHEMBL616984,BAO_0000019,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,1931,,11624,D,CHEMBL616985,BAO_0000224,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,1932,,4101,H,CHEMBL616986,BAO_0000224,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,
B,,,,,,,4,,104686,1,Autocuration,,,1933,,4101,H,CHEMBL616987,BAO_0000224,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,
B,,,,,,,4,,104686,1,Autocuration,,,1934,,15360,H,CHEMBL616988,BAO_0000019,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,
B,,,,,,,4,,104686,1,Autocuration,,,1935,,11576,H,CHEMBL617243,BAO_0000019,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,
B,,,,,,,4,,104686,1,Autocuration,,,1936,,5834,H,CHEMBL617244,BAO_0000019,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,
B,CHO-K1,485.0,,,,,5,10116.0,104686,1,Autocuration,,,1937,,2395,D,CHEMBL617245,BAO_0000219,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,1938,Membranes,11965,H,CHEMBL617246,BAO_0000249,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,
B,,,,,,,4,,104686,1,Autocuration,,,1939,,3967,H,CHEMBL617546,BAO_0000224,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),
B,,,,,,,4,,104686,1,Autocuration,,,1940,Brain membranes,11130,H,CHEMBL617547,BAO_0000249,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),
B,,,In vitro,,,,4,,104686,1,Autocuration,,,1941,,13427,H,CHEMBL617548,BAO_0000219,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,
B,,,,,,,4,,104686,1,Autocuration,,,1942,,9443,H,CHEMBL617549,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,1943,,9443,H,CHEMBL617550,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,
B,,,,,,,4,,104686,1,Autocuration,,,1944,,11825,H,CHEMBL617551,BAO_0000224,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,
B,,,,,,,4,,104686,1,Autocuration,,,1945,Membranes,12120,H,CHEMBL617552,BAO_0000249,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,
B,,,,,,,4,,104686,1,Autocuration,,,1946,Membranes,12120,H,CHEMBL617553,BAO_0000249,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,
F,,,,,1515.0,,4,,104686,1,Autocuration,,,1947,,11963,H,CHEMBL617554,BAO_0000019,Thoracic aorta,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,
B,,,,,,,4,,104686,1,Autocuration,,,1948,,9069,H,CHEMBL617555,BAO_0000019,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,1949,,8868,H,CHEMBL617556,BAO_0000224,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,
B,,,,,,,8,,10624,1,Autocuration,,,1950,,17200,H,CHEMBL617557,BAO_0000357,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,
B,,,,,,,8,,10624,1,Autocuration,,,1951,,17200,H,CHEMBL617558,BAO_0000357,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,
B,,,,,,,8,,17106,1,Expert,,,1952,,13969,H,CHEMBL617559,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,
B,,,,,,,9,,17106,1,Expert,,,1953,,13392,D,CHEMBL617560,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,17106,1,Autocuration,,,1954,,1742,H,CHEMBL617561,BAO_0000249,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,
B,,,,,,,8,,17106,1,Autocuration,,,1955,,1742,H,CHEMBL617562,BAO_0000249,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,
B,,,,,2435.0,,8,,17106,1,Autocuration,,,1956,,14331,H,CHEMBL617563,BAO_0000357,Striatum,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,
F,,,,,,,8,,17106,1,Autocuration,,,1957,,12861,H,CHEMBL617564,BAO_0000019,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,17106,1,Expert,,,1958,,12861,H,CHEMBL617565,BAO_0000019,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,
B,,,,,,,8,,17106,1,Autocuration,,,1959,,12861,H,CHEMBL856076,BAO_0000357,,Binding activity radioligand.,
B,,,,,,,8,,17106,1,Autocuration,,,1960,,12861,H,CHEMBL617566,BAO_0000019,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,
B,,,,,,,8,,17106,1,Expert,,,1961,,12861,H,CHEMBL875911,BAO_0000019,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,
B,,,,,,,8,,17106,1,Autocuration,,,1962,,12861,H,CHEMBL617567,BAO_0000019,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,
B,,,,,,,8,,17106,1,Autocuration,,,1963,,675,H,CHEMBL617568,BAO_0000249,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,
B,,,,,,,8,,17106,1,Expert,,,1964,,12490,H,CHEMBL617569,BAO_0000019,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,
B,,,,,,,8,,17106,1,Expert,,,1965,,11828,H,CHEMBL617570,BAO_0000249,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,
B,,,,,,,8,,17106,1,Autocuration,,,1966,,11866,H,CHEMBL617571,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,
B,,,,,,,8,9823.0,105,1,Autocuration,,,1967,,773,H,CHEMBL617572,BAO_0000357,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,Sus scrofa
B,,,,,,,8,9986.0,105,1,Expert,,,1968,,13047,H,CHEMBL617573,BAO_0000357,,The compound was tested for intrinsic activity against 5-HT1D receptor,Oryctolagus cuniculus
B,,,,,,,8,9986.0,105,1,Autocuration,,,1969,,13047,H,CHEMBL617574,BAO_0000019,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus
B,,,,,,,8,9986.0,105,1,Expert,,,1970,,13047,H,CHEMBL617575,BAO_0000357,,The compound was tested for binding affinity against 5-HT1D receptor,Oryctolagus cuniculus
B,,,,,,,8,,10578,1,Autocuration,,,1971,,188,H,CHEMBL617576,BAO_0000357,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,
F,,,,,,,8,,10578,1,Autocuration,,,1972,,10639,H,CHEMBL617577,BAO_0000019,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,
F,,,,,,,8,,10578,1,Autocuration,,,1973,,12438,H,CHEMBL617578,BAO_0000019,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,10578,1,Autocuration,,,1974,,12438,H,CHEMBL617579,BAO_0000357,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,10578,1,Expert,,,1975,,15854,H,CHEMBL617580,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,
B,,,,,,,8,,10578,1,Autocuration,,,1976,,10394,H,CHEMBL617581,BAO_0000249,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,
B,,,,,,,8,,10578,1,Autocuration,,,1977,,12092,H,CHEMBL617582,BAO_0000357,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,
B,,,,,,,8,,10578,1,Expert,,,1978,,3389,H,CHEMBL617583,BAO_0000019,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,
B,,,,,,,8,,105,1,Autocuration,,,1979,,6011,H,CHEMBL617584,BAO_0000357,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,
B,,,,,,,8,,105,1,Autocuration,,,1980,,4639,H,CHEMBL617585,BAO_0000357,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Autocuration,,,1981,,2474,H,CHEMBL875912,BAO_0000357,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,
B,,,,,,,8,,105,1,Autocuration,,,1982,,5014,H,CHEMBL617586,BAO_0000357,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Autocuration,,,1983,,17515,H,CHEMBL617587,BAO_0000357,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,
B,,,,,,,8,,105,1,Autocuration,,,1984,,11866,H,CHEMBL617588,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,
B,,,,,,,8,,105,1,Autocuration,,,1985,,4687,H,CHEMBL857980,BAO_0000357,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Autocuration,,,1986,,12146,H,CHEMBL617589,BAO_0000357,,Tested against 5-hydroxytryptamine 1D receptor,
B,,,,,,,8,,105,1,Autocuration,,,1987,,10321,H,CHEMBL617590,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,
B,HEK293,722.0,,,,,8,,105,1,Autocuration,,,1988,,13267,H,CHEMBL617591,BAO_0000219,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,
B,,,,,,,9,9606.0,105,1,Expert,,,1989,,1274,D,CHEMBL617592,BAO_0000357,,Binding affinity against 5-Hydroxytryptamine 1D receptor,Homo sapiens
B,,,,,,,8,,105,1,Autocuration,,,1990,,15250,H,CHEMBL617593,BAO_0000357,,,
B,CHO-K1,485.0,,,,,8,,106,1,Autocuration,,,1991,,13706,H,CHEMBL617594,BAO_0000219,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,
B,CHO-K1,485.0,,,,,8,,105,1,Autocuration,,,1992,,13706,H,CHEMBL617595,BAO_0000219,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,
B,HEK293,722.0,,,,,8,,105,1,Autocuration,,,1993,,13706,H,CHEMBL617596,BAO_0000219,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,
B,HEK293,722.0,,,,,8,,105,1,Autocuration,,,1994,,13706,H,CHEMBL617597,BAO_0000219,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,
B,,,,,,,8,,105,1,Autocuration,,,1995,,13047,H,CHEMBL617598,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,
B,,,,,,,8,,105,1,Autocuration,,,1996,,13366,H,CHEMBL872916,BAO_0000357,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,
B,,,,,,,8,,105,1,Expert,,,1997,,13366,H,CHEMBL617599,BAO_0000357,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,
B,,,,,,,8,,105,1,Autocuration,,,1998,,1558,H,CHEMBL617091,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,
B,CHO-K1,485.0,,,,,8,,105,1,Expert,,,1999,,12902,H,CHEMBL617092,BAO_0000219,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",
B,CHO-K1,485.0,,,,,8,,105,1,Autocuration,,,2000,,13706,H,CHEMBL617093,BAO_0000219,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,
F,,,,,,,8,,105,1,Autocuration,,,2001,,13706,H,CHEMBL617094,BAO_0000019,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,
F,,,,,,,8,,105,1,Autocuration,,,2002,,13706,H,CHEMBL617095,BAO_0000019,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,
F,,,,,,,8,,105,1,Autocuration,,,2003,,14251,H,CHEMBL617096,BAO_0000019,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,
F,,,,,,,8,,105,1,Autocuration,,,2004,,14251,H,CHEMBL617097,BAO_0000019,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,
F,,,,,,,8,,105,1,Autocuration,,,2005,,14251,H,CHEMBL617098,BAO_0000019,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,
B,,,,,,,8,,105,1,Autocuration,,,2006,,13313,H,CHEMBL617301,BAO_0000357,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,
B,,,,,,,8,,105,1,Autocuration,,,2007,,13313,H,CHEMBL617302,BAO_0000357,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,
B,,,,,,,8,,105,1,Autocuration,,,2008,,13366,H,CHEMBL617303,BAO_0000357,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,
B,,,,,,,8,,105,1,Expert,,,2009,,13051,H,CHEMBL617304,BAO_0000357,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,
B,CHO,449.0,,,,,8,,105,1,Expert,,,2010,,12903,H,CHEMBL617305,BAO_0000219,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",
B,,,,,,,9,9606.0,105,1,Autocuration,,,2011,,12469,D,CHEMBL617306,BAO_0000219,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,Homo sapiens
B,,,,,,,8,,17106,1,Autocuration,,,2012,,5619,H,CHEMBL617307,BAO_0000357,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,
B,,,,,,,8,9986.0,105,1,Autocuration,,,2013,,13047,H,CHEMBL617308,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus
B,,,,,,,8,,105,1,Autocuration,,,2014,,16633,H,CHEMBL617309,BAO_0000357,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,
B,,,,,,,8,,105,1,Autocuration,,,2015,,16633,H,CHEMBL617310,BAO_0000357,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,
B,,,,,,,8,,105,1,Autocuration,,,2016,,16633,H,CHEMBL617311,BAO_0000357,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,
B,,,,,,,8,,105,1,Autocuration,,,2017,,16633,H,CHEMBL617312,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,105,1,Autocuration,,,2018,,3269,H,CHEMBL617313,BAO_0000357,,Affinity against 5-hydroxytryptamine 1D receptor alpha,
B,,,,,,,8,,105,1,Expert,,,2019,,12409,H,CHEMBL617314,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,
F,,,,,,,8,,106,1,Autocuration,,,2020,,13706,H,CHEMBL617315,BAO_0000019,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,
B,HEK293,722.0,,,,,8,,106,1,Autocuration,,,2021,,13706,H,CHEMBL617316,BAO_0000219,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,
B,HEK293,722.0,,,,,8,,106,1,Autocuration,,,2022,,13706,H,CHEMBL617317,BAO_0000219,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,2023,,12903,H,CHEMBL617318,BAO_0000219,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",
B,,,,,,,8,,106,1,Autocuration,,,2024,,13047,H,CHEMBL617319,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,
B,,,,,,,9,,106,1,Expert,,,2025,,13366,D,CHEMBL617320,BAO_0000357,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,
B,,,,,,,9,,106,1,Expert,,,2026,,13366,D,CHEMBL617321,BAO_0000357,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,
B,,,,,,,9,,106,1,Expert,,,2027,,13366,D,CHEMBL617322,BAO_0000357,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,
B,,,,,,,8,,106,1,Autocuration,,,2028,,13366,H,CHEMBL616862,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,
B,,,,,,,8,,106,1,Autocuration,,,2029,,13366,H,CHEMBL616863,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,
B,CHO,449.0,,,,,8,,106,1,Autocuration,,,2030,,12469,H,CHEMBL616864,BAO_0000219,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,
B,CHO-K1,485.0,,,,,8,,106,1,Autocuration,,,2031,,13706,H,CHEMBL616865,BAO_0000219,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,
B,CHO-K1,485.0,,,,,8,,106,1,Autocuration,,,2032,,13706,H,CHEMBL616866,BAO_0000219,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,
F,,,,,,,8,,106,1,Autocuration,,,2033,,13706,H,CHEMBL616867,BAO_0000019,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,
B,CHO-K1,485.0,,,,,8,,106,1,Expert,,,2034,,12902,H,CHEMBL616868,BAO_0000219,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",
B,,,,,,,8,,105,1,Expert,,,2035,,13051,H,CHEMBL616869,BAO_0000357,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,
B,CHO,449.0,,,,,8,,106,1,Expert,,,2036,,12903,H,CHEMBL616870,BAO_0000219,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",
F,CHO-K1,485.0,,,,,8,,105,1,Autocuration,,,2037,,1558,H,CHEMBL616871,BAO_0000219,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,
F,CHO-K1,485.0,,,,,8,,105,1,Autocuration,,,2038,,1558,H,CHEMBL616872,BAO_0000219,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,
F,CHO-K1,485.0,,,,,8,,105,1,Autocuration,,,2039,,1558,H,CHEMBL616873,BAO_0000219,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,
F,CHO-K1,485.0,,,,,8,,105,1,Autocuration,,,2040,,1558,H,CHEMBL616838,BAO_0000219,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,
B,,,,,,,8,,105,1,Autocuration,,,2041,,1558,H,CHEMBL616839,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,
B,,,,,,,8,9986.0,106,1,Autocuration,,,2042,,13047,H,CHEMBL616840,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus
B,,,,,,,8,,105,1,Autocuration,,,2043,,13313,H,CHEMBL616841,BAO_0000357,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,
B,,,,,,,8,,105,1,Autocuration,,,2044,,13313,H,CHEMBL616842,BAO_0000357,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,
B,,,,,,,8,,105,1,Expert,,,2045,,12409,H,CHEMBL857976,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,
B,CHO,449.0,,,,,8,,10618,1,Autocuration,,,2046,,15250,H,CHEMBL616843,BAO_0000219,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,
B,,,,,,,9,9606.0,10618,1,Expert,,,2047,,1348,D,CHEMBL616844,BAO_0000357,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,Homo sapiens
B,,,,,,,8,,10618,1,Autocuration,,,2048,,1348,H,CHEMBL616845,BAO_0000357,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,
B,,,,,,,9,9606.0,10618,1,Expert,,,2049,,4234,D,CHEMBL616846,BAO_0000357,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,Homo sapiens
B,,,,,,,8,,10618,1,Autocuration,,,2050,,16209,H,CHEMBL616847,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,
B,,,,,,,8,,10618,1,Autocuration,,,2051,,10444,H,CHEMBL616848,BAO_0000019,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,
B,,,,,,,8,,10618,1,Autocuration,,,2052,,3935,H,CHEMBL616849,BAO_0000357,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,
B,,,,,,,8,,10618,1,Autocuration,,,2053,,15818,H,CHEMBL872911,BAO_0000357,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,
B,,,,,,,8,,10618,1,Autocuration,,,2054,,17085,H,CHEMBL616850,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,
B,CHO,449.0,,,,,9,9606.0,10618,1,Expert,,,2055,,12936,D,CHEMBL616699,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,Homo sapiens
B,,,,,,,8,,10618,1,Autocuration,,,2056,,6166,H,CHEMBL616700,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,
B,CHO,449.0,,,,,8,,10618,1,Autocuration,,,2057,,15779,H,CHEMBL616701,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,
B,CHO,449.0,,,,,8,,10618,1,Autocuration,,,2058,,15779,H,CHEMBL616702,BAO_0000219,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,
B,CHO,449.0,,,,,8,,10618,1,Autocuration,,,2059,,15779,H,CHEMBL616703,BAO_0000219,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,
B,,,,,,,8,,10618,1,Autocuration,,,2060,,13181,H,CHEMBL616704,BAO_0000357,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,
B,CHO,449.0,,,,,8,,10618,1,Autocuration,,,2061,,4199,H,CHEMBL616705,BAO_0000219,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,
B,,,,,,,8,,10618,1,Autocuration,,,2062,,14875,H,CHEMBL616706,BAO_0000357,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,
B,CHO,449.0,,,,,8,,10618,1,Autocuration,,,2063,,15146,H,CHEMBL616707,BAO_0000219,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,
B,,,,,,,8,,10618,1,Autocuration,,,2064,,5213,H,CHEMBL616708,BAO_0000357,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,
B,,,,,,,8,,10618,1,Autocuration,,,2065,,12146,H,CHEMBL616709,BAO_0000357,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,
B,CHO,449.0,,,,,8,,10618,1,Autocuration,,,2066,,13267,H,CHEMBL616710,BAO_0000219,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,
B,CHO,449.0,,,,,8,,10618,1,Autocuration,,,2067,,14818,H,CHEMBL616711,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,
B,CHO,449.0,,,,,8,,10618,1,Autocuration,,,2068,,4829,H,CHEMBL616712,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",
B,,,,,,,8,,10618,1,Autocuration,,,2069,,4373,H,CHEMBL616713,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,
B,,,,,,,8,,10618,1,Autocuration,,,2070,,4373,H,CHEMBL616714,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,
B,,,,,,,8,,10618,1,Autocuration,,,2071,,14159,H,CHEMBL616715,BAO_0000357,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,
B,,,,,,,8,,10618,1,Autocuration,,,2072,,16633,H,CHEMBL616716,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 1E receptor,
F,,,,,,,8,,279,1,Autocuration,,,2073,,17085,H,CHEMBL616717,BAO_0000019,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",
F,,,,,,,8,,279,1,Expert,,,2074,,17085,H,CHEMBL616718,BAO_0000019,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",
F,,,,,,,8,,279,1,Autocuration,,,2075,,16209,H,CHEMBL875905,BAO_0000019,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,
F,,,,,,,8,,279,1,Autocuration,,,2076,,16209,H,CHEMBL616719,BAO_0000019,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,
F,,,,,,,8,,279,1,Expert,,,2077,,17085,H,CHEMBL616720,BAO_0000019,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",
B,,,,,,,8,,279,1,Autocuration,,,2078,,14159,H,CHEMBL616721,BAO_0000357,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,
B,CHO,449.0,,,,,8,,279,1,Autocuration,,,2079,,15250,H,CHEMBL616722,BAO_0000219,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,
B,,,,,,,8,,279,1,Autocuration,,,2080,,3805,H,CHEMBL616723,BAO_0000357,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),
B,CHO,449.0,,,,,8,,279,1,Autocuration,,,2081,,16190,H,CHEMBL616724,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,
B,,,,,,,8,,279,1,Autocuration,,,2082,,16190,H,CHEMBL616725,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,
B,,,,,,,8,,279,1,Autocuration,,,2083,,16209,H,CHEMBL616726,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,
B,,,,,,,8,,279,1,Autocuration,,,2084,,16209,H,CHEMBL616727,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,
B,,,,,,,8,,279,1,Autocuration,,,2085,,16209,H,CHEMBL616728,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,
B,,,,,,,8,,279,1,Autocuration,,,2086,,6866,H,CHEMBL616729,BAO_0000357,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,
B,,,,,,,8,,279,1,Expert,,,2087,,17085,H,CHEMBL616730,BAO_0000019,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,
B,,,,,,,8,,279,1,Autocuration,,,2088,,16312,H,CHEMBL617125,BAO_0000357,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,
B,,,,,,,8,,279,1,Autocuration,,,2089,,6166,H,CHEMBL857977,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,
B,CHO,449.0,,,,,8,,279,1,Autocuration,,,2090,,15779,H,CHEMBL617126,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,
B,CHO,449.0,,,,,8,,279,1,Autocuration,,,2091,,4199,H,CHEMBL617127,BAO_0000219,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,
B,,,,,,,8,,279,1,Autocuration,,,2092,,14875,H,CHEMBL617128,BAO_0000357,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,
B,CHO,449.0,,,,,8,,279,1,Autocuration,,,2093,,15146,H,CHEMBL617129,BAO_0000219,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,
B,,,,,,,8,,279,1,Autocuration,,,2094,,5213,H,CHEMBL617130,BAO_0000357,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,
B,CHO,449.0,,,,,8,,279,1,Autocuration,,,2095,,14818,H,CHEMBL617131,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,
B,CHO,449.0,,,,,8,,279,1,Autocuration,,,2096,,4829,H,CHEMBL617132,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",
B,CHO,449.0,,,,,8,,279,1,Autocuration,,,2097,,4829,H,CHEMBL617133,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",
B,,,,,,,8,,279,1,Autocuration,,,2098,,4373,H,CHEMBL617134,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,
B,,,,,,,8,,279,1,Autocuration,,,2099,,4373,H,CHEMBL617135,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,
B,,,,,,,8,,279,1,Autocuration,,,2100,,5014,H,CHEMBL617136,BAO_0000357,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2101,,11662,H,CHEMBL617137,BAO_0000019,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",
B,,,,,,,4,,104686,1,Autocuration,,,2102,,11662,H,CHEMBL617138,BAO_0000019,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",
B,,,,,,,4,,104686,1,Autocuration,,,2103,,11662,H,CHEMBL617139,BAO_0000019,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",
B,,,,,,,8,,12687,1,Autocuration,,,2104,,14093,H,CHEMBL617140,BAO_0000019,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,
F,,,In vivo,,,,4,,104686,1,Autocuration,,,2105,,11200,H,CHEMBL617141,BAO_0000218,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",
F,,,,,,,4,,104686,1,Autocuration,,,2106,,11200,H,CHEMBL858112,BAO_0000019,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,
B,,,,,,,8,,17005,1,Intermediate,,,2107,,12352,H,CHEMBL617142,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,
B,,,,,,,0,9913.0,22226,1,Autocuration,,,2108,,13657,U,CHEMBL617143,BAO_0000019,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",Bos taurus
B,,,,,,,0,9913.0,22226,1,Autocuration,,,2109,,14331,U,CHEMBL617144,BAO_0000019,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,Bos taurus
B,,,,,,,0,9913.0,22226,1,Autocuration,,,2110,,14331,U,CHEMBL617145,BAO_0000019,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,Bos taurus
B,,,,,,,0,,22226,1,Autocuration,,,2111,,14331,U,CHEMBL617146,BAO_0000019,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,
B,,,,,,,4,10141.0,104784,1,Autocuration,,,2112,,12685,H,CHEMBL617147,BAO_0000019,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,Cavia porcellus
B,,,,,,,4,10141.0,104784,1,Autocuration,,,2113,,14389,H,CHEMBL617148,BAO_0000019,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,Cavia porcellus
B,,,,,,,4,10141.0,104784,1,Autocuration,,,2114,,14386,H,CHEMBL617149,BAO_0000019,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Cavia porcellus
B,,,,,,,4,,104784,1,Autocuration,,,2115,,5732,H,CHEMBL617150,BAO_0000224,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,
B,,,,,,,4,,104784,1,Autocuration,,,2116,,16293,H,CHEMBL617151,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,
B,,,,,,,4,,104784,1,Autocuration,,,2117,,2078,H,CHEMBL617201,BAO_0000224,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,2118,,5486,H,CHEMBL617202,BAO_0000357,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,
B,,,In vivo,,,,4,,104826,1,Autocuration,,,2119,,11820,H,CHEMBL617203,BAO_0000218,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,
B,,,,,,,4,,104826,1,Autocuration,,,2120,,10297,H,CHEMBL617204,BAO_0000019,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,
B,,,,,,,4,,104826,1,Autocuration,,,2121,,13704,H,CHEMBL617205,BAO_0000224,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,
B,,,,,,,5,10090.0,104826,1,Autocuration,,,2122,,10297,D,CHEMBL617206,BAO_0000019,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,Mus musculus
B,,,In vivo,,,,4,,104826,1,Autocuration,,,2123,,11820,H,CHEMBL617207,BAO_0000218,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,
B,,,,,,,5,10090.0,104826,1,Autocuration,,,2124,,10297,D,CHEMBL617208,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,Mus musculus
B,,,,,,,4,,104826,1,Autocuration,,,2125,,11555,H,CHEMBL617209,BAO_0000224,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104826,1,Autocuration,,,2126,,11555,H,CHEMBL617210,BAO_0000224,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,
B,,,,,,,4,,104826,1,Autocuration,,,2127,,11555,H,CHEMBL617211,BAO_0000224,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,
B,,,,,,,5,10090.0,104826,1,Autocuration,,,2128,,10297,D,CHEMBL617212,BAO_0000019,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Mus musculus
B,,,,,,,4,9823.0,104784,1,Autocuration,,,2129,,16688,H,CHEMBL617213,BAO_0000224,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,Sus scrofa
B,,,,,,,4,9823.0,104784,1,Autocuration,,,2130,,16688,H,CHEMBL617214,BAO_0000224,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,Sus scrofa
B,,,,,,,0,,22226,1,Autocuration,,,2131,,5333,U,CHEMBL617215,BAO_0000221,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,
B,,,,,,,0,,22226,1,Autocuration,,,2132,,4437,U,CHEMBL617216,BAO_0000221,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,
B,,,,,,,8,9823.0,17005,1,Autocuration,,,2133,,5033,H,CHEMBL617217,BAO_0000357,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,Sus scrofa
B,,,,,,,4,,104686,1,Autocuration,,,2134,,15267,H,CHEMBL617218,BAO_0000019,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2135,,15267,H,CHEMBL872913,BAO_0000019,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104826,1,Autocuration,,,2136,,11820,H,CHEMBL617219,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,
B,,,,,,,4,,104686,1,Autocuration,,,2137,,9069,H,CHEMBL873482,BAO_0000224,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2138,,9162,D,CHEMBL617220,BAO_0000019,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2139,,9162,H,CHEMBL617221,BAO_0000019,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,
B,,,,,,,4,,104686,1,Autocuration,,,2140,,9162,H,CHEMBL617222,BAO_0000019,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,
F,,,,,,,4,,104686,1,Autocuration,,,2141,,10428,H,CHEMBL875906,BAO_0000019,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,
B,,,,,,,4,,104686,1,Autocuration,,,2142,,9628,H,CHEMBL617223,BAO_0000019,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,
B,,,,,,,4,,104686,1,Autocuration,,,2143,,12704,H,CHEMBL617224,BAO_0000224,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2144,,15453,D,CHEMBL617225,BAO_0000224,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2145,,188,H,CHEMBL617226,BAO_0000224,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,
B,,,,,,,4,,104686,1,Autocuration,,,2146,,10349,H,CHEMBL617227,BAO_0000224,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,2147,,10349,H,CHEMBL617228,BAO_0000224,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,2148,,8868,H,CHEMBL617229,BAO_0000224,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,
B,,,,,,,4,,104686,1,Autocuration,,,2149,,10025,H,CHEMBL617230,BAO_0000224,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,
B,,,,,,,4,,104686,1,Autocuration,,,2150,,10025,H,CHEMBL617231,BAO_0000224,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",
B,,,,,,,4,,104686,1,Autocuration,,,2151,,11702,H,CHEMBL617232,BAO_0000224,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2152,,11702,H,CHEMBL617233,BAO_0000224,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2153,,11702,H,CHEMBL617234,BAO_0000224,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,
F,,,,,,,4,,104686,1,Autocuration,,,2154,,11702,H,CHEMBL617235,BAO_0000019,,Compound was tested for the inhibition of quipazine induced head twitches in rats,
F,,,,,,,4,,104686,1,Autocuration,,,2155,,11702,H,CHEMBL617236,BAO_0000019,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,
B,,,,,10000000.0,,4,,104686,1,Autocuration,,,2156,,10085,H,CHEMBL617237,BAO_0000221,Hippocampus,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,
B,,,,,10000000.0,,4,,104686,1,Autocuration,,,2157,,10085,H,CHEMBL617238,BAO_0000221,Hippocampus,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,
B,,,,,955.0,,5,10116.0,104686,1,Autocuration,,,2158,,9630,D,CHEMBL617239,BAO_0000221,Brain,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2159,,11070,H,CHEMBL617240,BAO_0000019,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,
B,,,,,,,4,,104686,1,Autocuration,,,2160,Membranes,9841,H,CHEMBL617241,BAO_0000249,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,
B,,,,,,,4,,104686,1,Autocuration,,,2161,Membranes,9841,H,CHEMBL875907,BAO_0000249,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,
B,,,,,,,4,,104686,1,Autocuration,,,2162,,13291,H,CHEMBL617242,BAO_0000019,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,
F,,,,,,,4,,104686,1,Autocuration,,,2163,,10590,H,CHEMBL617152,BAO_0000019,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,
B,,,,,955.0,,5,10116.0,104686,1,Autocuration,,,2164,,9064,D,CHEMBL617153,BAO_0000221,Brain,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2165,Membranes,12268,D,CHEMBL617154,BAO_0000249,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Rattus norvegicus
B,,,,,955.0,,4,,104686,1,Autocuration,,,2166,,13508,H,CHEMBL617155,BAO_0000221,Brain,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,
F,,,,,,,4,,104686,1,Autocuration,,,2167,,11279,H,CHEMBL617156,BAO_0000019,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,
F,,,,,,,4,,104686,1,Autocuration,,,2168,,11200,H,CHEMBL617157,BAO_0000019,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,
F,,,,,,,4,,104686,1,Autocuration,,,2169,,11200,H,CHEMBL617158,BAO_0000019,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,
F,,,,,,,4,,104686,1,Autocuration,,,2170,,11200,H,CHEMBL617159,BAO_0000019,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,
F,,,,,,,4,,104686,1,Autocuration,,,2171,,11200,H,CHEMBL617160,BAO_0000019,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,
F,,,,,,,4,,104686,1,Autocuration,,,2172,,11200,H,CHEMBL858113,BAO_0000019,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,
B,,,,,955.0,,4,,104686,1,Autocuration,,,2173,,9231,H,CHEMBL617247,BAO_0000220,Brain,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,
B,,,,,,,4,,104686,1,Autocuration,,,2174,,9737,H,CHEMBL617248,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,
B,,,,,955.0,,4,,104686,1,Autocuration,,,2175,,9737,H,CHEMBL617249,BAO_0000249,Brain,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,
B,,,,,,,4,,104686,1,Autocuration,,,2176,,9737,H,CHEMBL617250,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,
B,,,,,,,4,,104686,1,Autocuration,,,2177,,9737,H,CHEMBL617251,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2178,,11828,D,CHEMBL617252,BAO_0000019,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2179,,12253,H,CHEMBL617006,BAO_0000019,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,
B,,,,,,,4,,104686,1,Autocuration,,,2180,,12253,H,CHEMBL617007,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,
F,,,,,,,4,,104686,1,Autocuration,,,2181,,11279,H,CHEMBL617008,BAO_0000019,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",
B,,,,,,,4,,104686,1,Autocuration,,,2182,,11866,H,CHEMBL617009,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2183,,14424,D,CHEMBL617010,BAO_0000224,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,Rattus norvegicus
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2184,,15180,D,CHEMBL857978,BAO_0000019,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Rattus norvegicus
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2185,,15180,D,CHEMBL617011,BAO_0000019,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Rattus norvegicus
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2186,,9786,D,CHEMBL617012,BAO_0000019,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2187,,12132,H,CHEMBL617013,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,2188,,5486,H,CHEMBL617014,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,
B,,,,,,,4,,104686,1,Autocuration,,,2189,,15316,H,CHEMBL617015,BAO_0000019,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2190,,16429,H,CHEMBL617016,BAO_0000019,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2191,,14617,H,CHEMBL617017,BAO_0000224,,pKi value for 5-hydroxytryptamine 2 receptor binding site,
B,,,,,955.0,,4,,104686,1,Autocuration,,,2192,,11351,H,CHEMBL617018,BAO_0000221,Brain,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,
F,,,,,,,4,,104686,1,Autocuration,,,2193,,11279,H,CHEMBL617019,BAO_0000019,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,
B,,,,,,,4,,105075,1,Autocuration,,,2194,,9523,H,CHEMBL617020,BAO_0000019,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,
B,,,,,,,4,,105075,1,Autocuration,,,2195,,9523,H,CHEMBL617021,BAO_0000019,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,
B,,,,,,,4,,105075,1,Autocuration,,,2196,,9523,H,CHEMBL617022,BAO_0000019,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,
B,,,,,,,4,,105075,1,Autocuration,,,2197,,9523,H,CHEMBL617023,BAO_0000019,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,
B,,,,,,,4,,105075,1,Autocuration,,,2198,,9523,H,CHEMBL617024,BAO_0000019,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,
B,,,,,,,4,,105075,1,Autocuration,,,2199,,9523,H,CHEMBL617025,BAO_0000019,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,
B,,,,,,,4,,105075,1,Autocuration,,,2200,,9523,H,CHEMBL617026,BAO_0000224,,Hill coefficient of compound was determined,
B,,,,,,,0,,22226,1,Autocuration,,,2201,,4771,U,CHEMBL617027,BAO_0000019,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2202,,5033,D,CHEMBL617028,BAO_0000019,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,Rattus norvegicus
B,,,,,,,8,,12687,1,Expert,,,2203,,10845,H,CHEMBL617029,BAO_0000019,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,
B,,,,,,,8,,12687,1,Expert,,,2204,,10845,H,CHEMBL875908,BAO_0000019,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,
B,,,,,,,8,,12687,1,Autocuration,,,2205,,16288,H,CHEMBL617030,BAO_0000357,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),
B,,,,,,,8,,12687,1,Autocuration,,,2206,,16288,H,CHEMBL617031,BAO_0000019,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),
B,,,,,,,8,,12687,1,Autocuration,,,2207,,16190,H,CHEMBL617032,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2208,,12463,D,CHEMBL617033,BAO_0000224,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2209,,9699,H,CHEMBL617034,BAO_0000224,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",
B,,,,,,,4,,104686,1,Autocuration,,,2210,,9699,H,CHEMBL617035,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2211,,11662,H,CHEMBL617036,BAO_0000019,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",
B,,,,,,,4,,104784,1,Autocuration,,,2212,,1205,H,CHEMBL617037,BAO_0000224,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,
B,,,,,,,0,,22226,1,Autocuration,,,2213,,11376,U,CHEMBL617038,BAO_0000219,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,
B,,,,,,,4,,104784,1,Autocuration,,,2214,,11376,H,CHEMBL617039,BAO_0000219,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",
B,,,,,,,4,,104784,1,Autocuration,,,2215,,4639,H,CHEMBL617161,BAO_0000224,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104784,1,Autocuration,,,2216,,2222,H,CHEMBL617162,BAO_0000224,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104784,1,Autocuration,,,2217,,1558,H,CHEMBL617163,BAO_0000224,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104784,1,Autocuration,,,2218,,1089,H,CHEMBL617164,BAO_0000224,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104784,1,Autocuration,,,2219,Brain membranes,386,H,CHEMBL617165,BAO_0000249,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,
B,,,,,,,4,,104784,1,Autocuration,,,2220,,2474,H,CHEMBL617166,BAO_0000224,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,
B,,,,,,,4,,104784,1,Autocuration,,,2221,,17066,H,CHEMBL617167,BAO_0000224,,Binding affinity towards 5-HT2 receptor,
B,,,,,,,4,,104784,1,Autocuration,,,2222,,959,H,CHEMBL872912,BAO_0000224,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104784,1,Autocuration,,,2223,,6398,H,CHEMBL617168,BAO_0000224,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,
B,,,,,,,4,,104686,1,Autocuration,,,2224,,11889,H,CHEMBL617169,BAO_0000224,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,
B,,,,,,,4,,104784,1,Autocuration,,,2225,,4221,H,CHEMBL617170,BAO_0000224,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104784,1,Autocuration,,,2226,,11026,H,CHEMBL617171,BAO_0000224,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,
B,,,,,,,4,,104784,1,Autocuration,,,2227,,11866,H,CHEMBL617172,BAO_0000224,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,
B,,,,,,,4,,104784,1,Autocuration,,,2228,,4221,H,CHEMBL617173,BAO_0000224,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,
B,,,,,,,0,,22226,1,Autocuration,,,2229,,13950,U,CHEMBL617174,BAO_0000019,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104784,1,Autocuration,,,2230,,1263,H,CHEMBL617175,BAO_0000224,,5-hydroxytryptamine 2 receptor binding affinity,
B,,,,,,,8,,17005,1,Autocuration,,,2231,,13291,H,CHEMBL617176,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,
B,,,,,,,8,,17005,1,Autocuration,,,2232,,10812,H,CHEMBL617177,BAO_0000357,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,
B,,,,,,,4,,104784,1,Autocuration,,,2233,,13020,H,CHEMBL617178,BAO_0000224,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,
B,,,,,,,4,,104784,1,Autocuration,,,2234,,13021,H,CHEMBL617179,BAO_0000224,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,
B,,,,,,,4,,104784,1,Autocuration,,,2235,,13020,H,CHEMBL617180,BAO_0000224,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,
B,,,,,,,8,,17005,1,Autocuration,,,2236,,14532,H,CHEMBL617181,BAO_0000357,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,
B,,,,,,,8,,17005,1,Autocuration,,,2237,,13944,H,CHEMBL617182,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2 receptor,
B,,,,,,,8,,17005,1,Autocuration,,,2238,,14331,H,CHEMBL617183,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2 receptor,
B,,,,,,,8,,17005,1,Autocuration,,,2239,,14118,H,CHEMBL617184,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,
B,,,,,,,8,,17005,1,Autocuration,,,2240,,13033,H,CHEMBL617185,BAO_0000357,,Binding affinity against serotonergic 5-HT2 receptor,
B,,,,,,,8,,17005,1,Autocuration,,,2241,,10321,H,CHEMBL617186,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,
B,,,,,,,8,,17005,1,Autocuration,,,2242,,12918,H,CHEMBL617187,BAO_0000357,,Compound was evaluated for the binding affinity at 5- HT2 receptor,
B,,,,,,,8,,17005,1,Autocuration,,,2243,,15120,H,CHEMBL617188,BAO_0000357,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,
B,,,,,,,8,,17005,1,Autocuration,,,2244,,2613,H,CHEMBL617189,BAO_0000218,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,
B,,,,,,,5,9606.0,104784,1,Autocuration,,,2245,,13378,D,CHEMBL617190,BAO_0000224,,Inhibitory activity against cloned human 5-HT2 receptor,Homo sapiens
B,CHO,449.0,,,,,5,9606.0,104784,1,Autocuration,,,2246,,2331,D,CHEMBL617191,BAO_0000219,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",Homo sapiens
B,CHO,449.0,,,,,5,9606.0,104784,1,Autocuration,,,2247,,2331,D,CHEMBL617192,BAO_0000219,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",Homo sapiens
B,CHO,449.0,,,,,5,9606.0,104784,1,Autocuration,,,2248,,2331,D,CHEMBL617193,BAO_0000219,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",Homo sapiens
B,CHO,449.0,,,,,5,9606.0,104784,1,Autocuration,,,2249,,2331,D,CHEMBL617194,BAO_0000219,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",Homo sapiens
B,,,,,,,4,,104784,1,Autocuration,,,2250,,4170,H,CHEMBL617195,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104784,1,Autocuration,,,2251,,15453,H,CHEMBL881830,BAO_0000224,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,
B,,,,,,,8,,17005,1,Autocuration,,,2252,,1479,H,CHEMBL617196,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2253,,11139,H,CHEMBL617197,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,
B,,,,,,,8,,17005,1,Expert,,,2254,,13969,H,CHEMBL617198,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,
B,,,,,,,8,,17005,1,Expert,,,2255,,13392,H,CHEMBL873476,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,17005,1,Expert,,,2256,,14430,H,CHEMBL617199,BAO_0000019,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,
B,,,,,,,8,10141.0,107,1,Autocuration,,,2257,,13181,H,CHEMBL617200,BAO_0000357,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Cavia porcellus
B,,,,,,,8,,51,1,Autocuration,,,2258,,17200,H,CHEMBL617484,BAO_0000357,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,
B,,,,,,,8,,107,1,Autocuration,,,2259,,17200,H,CHEMBL617485,BAO_0000357,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,
B,,,,,,,8,,51,1,Autocuration,,,2260,,17200,H,CHEMBL617486,BAO_0000357,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,
B,,,,,,,8,,107,1,Autocuration,,,2261,,13463,H,CHEMBL858022,BAO_0000357,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,
B,CHO,449.0,,,,,8,,107,1,Autocuration,,,2262,,6347,H,CHEMBL617049,BAO_0000219,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,
F,CHO,449.0,,,,,9,9606.0,107,1,Expert,,,2263,,6857,D,CHEMBL617050,BAO_0000219,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens
F,,,,,,,8,,107,1,Autocuration,,,2264,,4176,H,CHEMBL617051,BAO_0000219,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,
F,,,,,,,8,,107,1,Autocuration,,,2265,,4176,H,CHEMBL617052,BAO_0000219,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,
F,,,,,,,8,,107,1,Autocuration,,,2266,,4176,H,CHEMBL617053,BAO_0000219,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,
B,CHO,449.0,,,,,8,,107,1,Autocuration,,,2267,,6347,H,CHEMBL617054,BAO_0000219,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",
B,CHO,449.0,,,,,8,,107,1,Autocuration,,,2268,,6347,H,CHEMBL617055,BAO_0000219,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",
B,,,,,,,8,,107,1,Autocuration,,,2269,,15331,H,CHEMBL882924,BAO_0000357,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,
B,,,,,,,9,9606.0,107,1,Expert,,,2270,,16146,D,CHEMBL617056,BAO_0000357,,Inhibition of human 5-hydroxytryptamine 2A receptor,Homo sapiens
B,CHO,449.0,,,,,8,,107,1,Autocuration,,,2271,,15250,H,CHEMBL617057,BAO_0000219,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,
B,,,,,,,8,,107,1,Expert,,,2272,,13631,H,CHEMBL617058,BAO_0000219,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,
B,,,,,,,8,,107,1,Autocuration,,,2273,,3805,H,CHEMBL617059,BAO_0000357,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),
B,CHO,449.0,,,,,8,,107,1,Autocuration,,,2274,,4011,H,CHEMBL617060,BAO_0000219,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,
B,CHO,449.0,,,,,8,,107,1,Expert,,,2275,,4012,H,CHEMBL617061,BAO_0000219,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,
B,L929,307.0,,,,,8,,107,1,Expert,,,2276,,6366,H,CHEMBL617062,BAO_0000219,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,
B,CHO,449.0,,,,,8,,107,1,Expert,,,2277,,15949,H,CHEMBL617063,BAO_0000219,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,
F,,,,,,,8,,107,1,Autocuration,,,2278,,14093,H,CHEMBL617064,BAO_0000019,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,
F,,,,,,,8,,107,1,Autocuration,,,2279,,13481,H,CHEMBL617065,BAO_0000019,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,
B,CHO,449.0,,,,,8,,107,1,Autocuration,,,2280,,6347,H,CHEMBL617066,BAO_0000219,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,
B,CHO,449.0,,,,,8,,107,1,Autocuration,,,2281,,6347,H,CHEMBL617067,BAO_0000219,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,
F,,,,,,,8,,107,1,Autocuration,,,2282,,14093,H,CHEMBL617068,BAO_0000019,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,
F,,,,,,,8,,107,1,Autocuration,,,2283,,14093,H,CHEMBL617069,BAO_0000019,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,
F,,,,,,,8,,107,1,Autocuration,,,2284,,13481,H,CHEMBL617070,BAO_0000019,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
B,,,,,,,8,,107,1,Autocuration,,,2285,,14442,H,CHEMBL617071,BAO_0000357,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,
B,,,,,,,8,,107,1,Autocuration,,,2286,,14442,H,CHEMBL872915,BAO_0000357,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
B,,,,,,,8,,107,1,Autocuration,,,2287,,14755,H,CHEMBL617072,BAO_0000357,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,
B,,,,,,,8,,107,1,Autocuration,,,2288,,16441,H,CHEMBL617073,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,
B,,,,,,,8,,107,1,Autocuration,,,2289,,14744,H,CHEMBL617074,BAO_0000357,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,
B,CHO,449.0,,,,,8,,107,1,Expert,,,2290,,16659,H,CHEMBL617075,BAO_0000219,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,
B,,,,,,,8,,107,1,Autocuration,,,2291,,3307,H,CHEMBL617076,BAO_0000357,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,
B,,,,,,,9,9606.0,107,1,Expert,,,2292,,6857,D,CHEMBL617077,BAO_0000019,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,Homo sapiens
B,,,,,,,8,,107,1,Expert,,,2293,,5635,H,CHEMBL617078,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,
B,,,,,,,9,9606.0,107,1,Expert,,,2294,,4234,D,CHEMBL617079,BAO_0000357,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,Homo sapiens
B,,,,,,,8,,107,1,Autocuration,,,2295,,15527,H,CHEMBL617080,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,
B,CHO,449.0,,,,,8,,107,1,Expert,,,2296,,6588,H,CHEMBL617081,BAO_0000219,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,
B,,,,,,,8,,107,1,Expert,,,2297,,13631,H,CHEMBL617082,BAO_0000219,,Binding affinity towards human 5-HT2A receptor in BEK cells,
B,,,,,,,8,,107,1,Autocuration,,,2298,,17723,H,CHEMBL617083,BAO_0000357,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2299,,14770,H,CHEMBL617084,BAO_0000357,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,
B,,,,,,,9,9606.0,107,1,Expert,,,2300,,16293,D,CHEMBL617085,BAO_0000357,,Binding affinity for human 5-hydroxytryptamine 2A receptor,Homo sapiens
B,,,,,,,8,,107,1,Autocuration,,,2301,,16209,H,CHEMBL617086,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,
B,,,,,,,8,,107,1,Autocuration,,,2302,,12469,H,CHEMBL617087,BAO_0000219,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,
B,,,,,,,8,,107,1,Autocuration,,,2303,,15363,H,CHEMBL617088,BAO_0000357,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2304,,15363,H,CHEMBL617089,BAO_0000357,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Expert,,,2305,,16441,H,CHEMBL617090,BAO_0000019,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",
B,,,,,,,8,,107,1,Autocuration,,,2306,,8,H,CHEMBL617513,BAO_0000357,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2307,,4176,H,CHEMBL617514,BAO_0000219,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,
B,,,,,,,8,,107,1,Autocuration,,,2308,,17085,H,CHEMBL617515,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2309,,17200,H,CHEMBL617516,BAO_0000357,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,
B,,,,,,,9,9606.0,107,1,Expert,,,2310,,17200,D,CHEMBL617517,BAO_0000357,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Homo sapiens
B,CHO,449.0,,,,,9,9606.0,107,1,Expert,,,2311,,4013,D,CHEMBL617518,BAO_0000219,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,Homo sapiens
B,,,,,,,8,,107,1,Autocuration,,,2312,,5088,H,CHEMBL617519,BAO_0000357,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,
B,,,,,,,9,9606.0,107,1,Expert,,,2313,,5088,D,CHEMBL617520,BAO_0000357,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,Homo sapiens
B,,,,,,,8,,107,1,Autocuration,,,2314,,5088,H,CHEMBL617521,BAO_0000357,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,
B,,,,,,,9,9606.0,107,1,Expert,,,2315,,5088,D,CHEMBL617522,BAO_0000357,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,Homo sapiens
B,,,,,,,8,,107,1,Autocuration,,,2316,,5088,H,CHEMBL617523,BAO_0000357,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,
B,,,,,,,8,,107,1,Autocuration,,,2317,,5088,H,CHEMBL617524,BAO_0000357,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2318,,9786,H,CHEMBL617525,BAO_0000019,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2319,,9205,D,CHEMBL617526,BAO_0000019,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2320,,11257,H,CHEMBL617527,BAO_0000224,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,
B,,,,,,,4,,104686,1,Autocuration,,,2321,,9362,H,CHEMBL617528,BAO_0000019,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,
B,,,,,,,4,,104686,1,Autocuration,,,2322,,9362,H,CHEMBL617529,BAO_0000019,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,
B,,,,,,,4,,104686,1,Autocuration,,,2323,,10590,H,CHEMBL617530,BAO_0000224,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,
B,,,,,,,4,,104686,1,Autocuration,,,2324,,10468,H,CHEMBL617531,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2325,,13050,H,CHEMBL617532,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2326,,11624,H,CHEMBL617533,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2327,,10468,H,CHEMBL617534,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2328,,10330,H,CHEMBL617535,BAO_0000224,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2329,,10062,H,CHEMBL617536,BAO_0000224,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,
B,,,,,,,4,,104686,1,Autocuration,,,2330,,11642,H,CHEMBL617537,BAO_0000224,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2331,,10062,H,CHEMBL617538,BAO_0000224,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,
B,,,In vitro,,,,4,,104686,1,Autocuration,,,2332,,13427,H,CHEMBL617539,BAO_0000219,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2333,,12280,D,CHEMBL617540,BAO_0000224,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Rattus norvegicus
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2334,,4101,D,CHEMBL617541,BAO_0000224,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2335,,10062,H,CHEMBL617542,BAO_0000224,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2336,,11147,H,CHEMBL617543,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,
B,CHO-K1,485.0,,,,,5,10116.0,104686,1,Autocuration,,,2337,,2395,D,CHEMBL617544,BAO_0000219,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus
B,CHO-K1,485.0,,,,,5,10116.0,104686,1,Autocuration,,,2338,,2395,D,CHEMBL617545,BAO_0000219,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2339,,9098,D,CHEMBL617413,BAO_0000019,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2340,,9098,H,CHEMBL617414,BAO_0000019,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2341,,9098,D,CHEMBL617415,BAO_0000019,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2342,,9443,H,CHEMBL617416,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2343,,9443,H,CHEMBL617417,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,
B,,,,,,,4,,104686,1,Autocuration,,,2344,,9699,H,CHEMBL617418,BAO_0000019,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",
B,,,,,,,4,,104686,1,Autocuration,,,2345,,9699,H,CHEMBL617419,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,
B,,,,,,,4,,104686,1,Autocuration,,,2346,,9098,H,CHEMBL617420,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2347,,3070,D,CHEMBL617421,BAO_0000224,,Affinity for 5-hydroxytryptamine 2 receptor,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2348,,9547,H,CHEMBL617422,BAO_0000224,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,
B,,,,,,,4,,104686,1,Autocuration,,,2349,,10444,H,CHEMBL617423,BAO_0000019,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,
B,,,,,,,4,,104686,1,Autocuration,,,2350,,14617,H,CHEMBL617424,BAO_0000019,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,
B,,,,,,,4,,104686,1,Autocuration,,,2351,,14617,H,CHEMBL617425,BAO_0000019,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,
B,,,,,,,4,,104686,1,Autocuration,,,2352,,11130,H,CHEMBL617426,BAO_0000224,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),
B,,,In vivo,,,,4,,104686,1,Autocuration,,,2353,,11130,H,CHEMBL617427,BAO_0000218,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),
B,,,,,955.0,,4,,104686,1,Autocuration,,,2354,,14542,H,CHEMBL617428,BAO_0000221,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,
B,,,,,,,4,,104686,1,Autocuration,,,2355,,2797,H,CHEMBL617429,BAO_0000224,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,
B,,,,,,,4,,104686,1,Autocuration,,,2356,,11332,H,CHEMBL617430,BAO_0000019,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2357,,11332,H,CHEMBL617431,BAO_0000019,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,
B,,,,,1870.0,,4,,104686,1,Autocuration,,,2358,,10752,H,CHEMBL617432,BAO_0000019,Frontal cortex,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,
B,,,,,,,4,,104686,1,Autocuration,,,2359,,1185,H,CHEMBL617433,BAO_0000224,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2360,,1185,H,CHEMBL617434,BAO_0000224,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2361,,11624,D,CHEMBL617435,BAO_0000224,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2362,,1344,H,CHEMBL617436,BAO_0000019,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,
B,,,,,2435.0,,5,10116.0,104686,1,Autocuration,,,2363,,15453,D,CHEMBL617437,BAO_0000019,Striatum,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2364,,11662,H,CHEMBL617438,BAO_0000019,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",
B,,,,,,,4,,104686,1,Autocuration,,,2365,,11662,H,CHEMBL617439,BAO_0000019,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",
B,,,,,,,4,,104686,1,Autocuration,,,2366,,10796,H,CHEMBL617440,BAO_0000224,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2367,,9069,H,CHEMBL617441,BAO_0000224,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2368,,8814,D,CHEMBL872918,BAO_0000019,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,Rattus norvegicus
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2369,,8908,D,CHEMBL617442,BAO_0000019,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2370,,9098,H,CHEMBL617443,BAO_0000019,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,
B,,,,,,,4,,104686,1,Autocuration,,,2371,,9098,H,CHEMBL617444,BAO_0000019,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2372,,9098,H,CHEMBL617445,BAO_0000019,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,
B,,,,,,,4,,104686,1,Autocuration,,,2373,,9098,H,CHEMBL617446,BAO_0000019,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,2374,,9098,H,CHEMBL617447,BAO_0000249,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,
B,,,,,,,4,,104686,1,Autocuration,,,2375,,9098,H,CHEMBL617448,BAO_0000019,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,
B,,,,,,,4,,104686,1,Autocuration,,,2376,,9098,H,CHEMBL617449,BAO_0000019,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,
B,,,,,,,4,,104686,1,Autocuration,,,2377,,9161,H,CHEMBL617450,BAO_0000019,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,
B,,,,,,,4,,104686,1,Autocuration,,,2378,,9161,H,CHEMBL617451,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,
B,,,,,,,4,,104686,1,Autocuration,,,2379,,9161,H,CHEMBL617452,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,
B,,,,,,,4,,104686,1,Autocuration,,,2380,,9161,H,CHEMBL617453,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,
B,,,,,,,4,,104686,1,Autocuration,,,2381,,9161,H,CHEMBL617660,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,
B,,,,,,,4,,104686,1,Autocuration,,,2382,,9161,H,CHEMBL617661,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,
B,,,,,,,4,,104686,1,Autocuration,,,2383,,9161,H,CHEMBL617662,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,
B,,,,,,,4,,104686,1,Autocuration,,,2384,,9161,H,CHEMBL872919,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,
B,,,,,,,4,,104686,1,Autocuration,,,2385,,9161,H,CHEMBL617663,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,
B,,,,,,,4,,104686,1,Autocuration,,,2386,,9161,H,CHEMBL617664,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,
B,,,,,,,4,,104686,1,Autocuration,,,2387,,9161,H,CHEMBL617665,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,
B,,,,,,,4,,104686,1,Autocuration,,,2388,,9161,H,CHEMBL617666,BAO_0000019,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,
B,,,,,,,4,,104686,1,Autocuration,,,2389,,12094,H,CHEMBL617667,BAO_0000019,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,
B,,,,,,,4,,104686,1,Autocuration,,,2390,,12018,H,CHEMBL617668,BAO_0000249,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,
B,,,,,,,4,,104686,1,Autocuration,,,2391,,10394,H,CHEMBL617669,BAO_0000249,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2392,,15260,H,CHEMBL617670,BAO_0000224,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2393,,11624,D,CHEMBL617671,BAO_0000224,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2394,,13654,H,CHEMBL617672,BAO_0000224,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2395,,9541,H,CHEMBL617673,BAO_0000019,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,
B,,,,,,,4,,104686,1,Autocuration,,,2396,,11933,H,CHEMBL617674,BAO_0000224,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2397,,15538,H,CHEMBL617675,BAO_0000019,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,
B,,,,,,,4,,104686,1,Autocuration,,,2398,,15538,H,CHEMBL617676,BAO_0000019,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,
B,,,,,,,4,,104686,1,Autocuration,,,2399,,15538,H,CHEMBL617677,BAO_0000019,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,
B,,,,,,,5,,104686,1,Autocuration,,,2400,,8841,D,CHEMBL617678,BAO_0000019,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,
B,,,,,,,4,,104686,1,Autocuration,,,2401,,1455,H,CHEMBL617679,BAO_0000224,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,
B,,,,,,,4,,104686,1,Autocuration,,,2402,,1455,H,CHEMBL617680,BAO_0000224,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,
B,,,,,,,4,,104686,1,Autocuration,,,2403,,11752,H,CHEMBL617681,BAO_0000019,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,
B,,,,,955.0,,4,,104686,1,Autocuration,,,2404,,11642,H,CHEMBL617682,BAO_0000221,Brain,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,
B,,,,,,,4,,104686,1,Autocuration,,,2405,,12092,H,CHEMBL617683,BAO_0000224,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,
B,,,,,,,4,,104686,1,Autocuration,,,2406,,3967,H,CHEMBL617684,BAO_0000224,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,
B,,,,,,,5,10116.0,104686,1,Autocuration,,,2407,,12771,D,CHEMBL617685,BAO_0000224,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Rattus norvegicus
B,,,,,,,4,,104686,1,Autocuration,,,2408,,11642,H,CHEMBL617686,BAO_0000019,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,
B,,,,,,,4,,104686,1,Autocuration,,,2409,,11628,H,CHEMBL617687,BAO_0000224,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,
B,,,,,,,4,,104686,1,Autocuration,,,2410,,13654,H,CHEMBL617688,BAO_0000224,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,
F,,,,,,,4,,104686,1,Autocuration,,,2411,,11200,H,CHEMBL617689,BAO_0000019,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,
F,,,,,,,4,,104686,1,Autocuration,,,2412,,11200,H,CHEMBL617690,BAO_0000019,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,
F,,,In vivo,,,,4,,104686,1,Autocuration,,,2413,,11200,H,CHEMBL617691,BAO_0000218,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",
F,,,In vivo,,,,4,,104686,1,Autocuration,,,2414,,11200,H,CHEMBL617692,BAO_0000218,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",
F,,,In vivo,,,,4,,104686,1,Autocuration,,,2415,,11200,H,CHEMBL617693,BAO_0000218,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",
F,,,In vivo,,,,4,,104686,1,Autocuration,,,2416,,11200,H,CHEMBL617694,BAO_0000218,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",
B,,,,,955.0,,8,,12687,1,Expert,,,2417,,15436,H,CHEMBL857985,BAO_0000221,Brain,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,
B,,,,,,,9,10116.0,12687,1,Expert,,,2418,,15436,D,CHEMBL617695,BAO_0000019,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2419,,14025,H,CHEMBL617696,BAO_0000019,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,
B,,,,,,,8,,12687,1,Autocuration,,,2420,,4342,H,CHEMBL617697,BAO_0000357,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,
B,,,,,,,9,10116.0,12687,1,Expert,,,2421,,13735,D,CHEMBL617257,BAO_0000019,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,Rattus norvegicus
B,,,,,,,9,10116.0,12687,1,Expert,,,2422,,5816,D,CHEMBL617258,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Rattus norvegicus
B,,,,,,,8,,12687,1,Expert,,,2423,,14287,H,CHEMBL617259,BAO_0000019,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,
B,,,,,,,8,,12687,1,Autocuration,,,2424,,15738,H,CHEMBL617260,BAO_0000357,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,
B,,,,,,,9,10116.0,12687,1,Expert,,,2425,,15738,D,CHEMBL617261,BAO_0000357,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2426,,15026,H,CHEMBL617262,BAO_0000019,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,
B,,,,,,,8,,12687,1,Expert,,,2427,,16647,H,CHEMBL617263,BAO_0000019,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,
B,,,,,,,8,,12687,1,Autocuration,,,2428,,16647,H,CHEMBL617264,BAO_0000019,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,
B,,,,,,,9,10116.0,12687,1,Expert,,,2429,,13345,D,CHEMBL617265,BAO_0000019,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2430,Membranes,1543,H,CHEMBL617266,BAO_0000249,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2431,,12444,H,CHEMBL617267,BAO_0000019,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,
B,,,,,,,8,,12687,1,Expert,,,2432,,16404,H,CHEMBL617268,BAO_0000019,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,
B,CHO,449.0,,,,,8,,12687,1,Autocuration,,,2433,,16404,H,CHEMBL617269,BAO_0000219,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,
B,,,,,,,8,,12687,1,Expert,,,2434,,15577,H,CHEMBL617323,BAO_0000357,,Kinetic inhibition constant evaluated by measuring serotonergic activity,
B,,,,,,,8,,12687,1,Autocuration,,,2435,,15577,H,CHEMBL617324,BAO_0000357,,Serotonergic activity of the compound.,
B,,,,,,,8,,12687,1,Autocuration,,,2436,,2495,H,CHEMBL617325,BAO_0000249,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,
B,,,,,,,9,10116.0,12687,1,Expert,,,2437,,15042,D,CHEMBL617326,BAO_0000019,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,Rattus norvegicus
B,,,,,,,8,,12687,1,Expert,,,2438,,15026,H,CHEMBL617327,BAO_0000249,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,
F,,,,,,,9,10116.0,12687,1,Expert,,,2439,,12919,D,CHEMBL617328,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus
F,,,,,,,9,10116.0,12687,1,Expert,,,2440,,12919,D,CHEMBL617329,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus
F,,,,,,,9,10116.0,12687,1,Expert,,,2441,,12919,D,CHEMBL617330,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2442,,15194,H,CHEMBL617331,BAO_0000357,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2443,,15194,H,CHEMBL617332,BAO_0000357,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,
B,,,,,,,8,,107,1,Expert,,,2444,,4820,H,CHEMBL617333,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2445,,6736,H,CHEMBL617334,BAO_0000357,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,
B,,,,,,,8,,107,1,Autocuration,,,2446,,5163,H,CHEMBL617335,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,
B,,,,,,,8,,107,1,Autocuration,,,2447,,5163,H,CHEMBL617336,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,
B,,,,,,,8,,107,1,Autocuration,,,2448,,6011,H,CHEMBL617337,BAO_0000357,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,
B,,,,,,,9,9606.0,107,1,Expert,,,2449,,14294,D,CHEMBL617338,BAO_0000357,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,Homo sapiens
B,,,,,,,8,,107,1,Autocuration,,,2450,,5014,H,CHEMBL617339,BAO_0000357,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Expert,,,2451,,17066,H,CHEMBL617340,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2452,,17515,H,CHEMBL617341,BAO_0000357,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,
B,,,,,,,8,,107,1,Expert,,,2453,,6736,H,CHEMBL617342,BAO_0000357,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Expert,,,2454,,5163,H,CHEMBL617343,BAO_0000357,,Affinity for 5-hydroxytryptamine 2A receptor,
B,NIH3T3,723.0,,,,,8,,107,1,Expert,,,2455,,16911,H,CHEMBL617344,BAO_0000219,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,
B,,,,,,,8,,107,1,Expert,,,2456,,6841,H,CHEMBL617345,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,
B,,,,,,,8,,107,1,Expert,,,2457,,6119,H,CHEMBL617346,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,
B,,,,,,,8,,107,1,Autocuration,,,2458,,3962,H,CHEMBL617347,BAO_0000357,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2459,,4373,H,CHEMBL617348,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,
B,,,,,,,8,,107,1,Autocuration,,,2460,,4373,H,CHEMBL617349,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,
F,,,,,,,8,,107,1,Autocuration,,,2461,,3962,H,CHEMBL617350,BAO_0000019,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Expert,,,2462,,1633,H,CHEMBL872339,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,
B,,,,,,,8,,107,1,Autocuration,,,2463,,4373,H,CHEMBL617351,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,
B,,,,,,,8,,107,1,Expert,,,2464,,6576,H,CHEMBL617352,BAO_0000357,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2465,,4687,H,CHEMBL617353,BAO_0000357,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2466,,16946,H,CHEMBL617354,BAO_0000357,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2467,,14159,H,CHEMBL617355,BAO_0000357,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,
B,CHO,449.0,,,,,8,10090.0,107,1,Expert,,,2468,,3032,H,CHEMBL617356,BAO_0000219,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,Mus musculus
B,,,,,,,8,,107,1,Autocuration,,,2469,,16655,H,CHEMBL617357,BAO_0000357,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2470,,13964,H,CHEMBL617358,BAO_0000357,,Binding affinity at 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Expert,,,2471,,16989,H,CHEMBL617359,BAO_0000357,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2472,,16117,H,CHEMBL617360,BAO_0000357,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,
B,,,,,,,8,,107,1,Autocuration,,,2473,,16700,H,CHEMBL875913,BAO_0000357,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,
B,,,,,,,8,,107,1,Autocuration,,,2474,,3269,H,CHEMBL617361,BAO_0000357,,Affinity against 5-hydroxytryptamine 2A receptor,
B,,,,,,,9,9606.0,107,1,Expert,,,2475,,1274,D,CHEMBL617362,BAO_0000357,,Binding affinity against 5-Hydroxytryptamine 2A receptor,Homo sapiens
B,,,,,,,8,,107,1,Autocuration,,,2476,,1317,H,CHEMBL617363,BAO_0000357,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,
B,,,,,,,8,,107,1,Autocuration,,,2477,,12146,H,CHEMBL617364,BAO_0000357,,Tested against 5-hydroxytryptamine 2A receptor,
B,,,,,,,4,,105075,1,Autocuration,,,2478,,12652,H,CHEMBL617365,BAO_0000224,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,
B,,,,,,,4,,105075,1,Autocuration,,,2479,,12652,H,CHEMBL617366,BAO_0000224,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,
B,,,,,,,4,,105075,1,Autocuration,,,2480,,12652,H,CHEMBL617367,BAO_0000224,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,
B,,,,,,,4,,105075,1,Autocuration,,,2481,,12652,H,CHEMBL617368,BAO_0000224,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,
B,,,,,,,8,,107,1,Autocuration,,,2482,,16647,H,CHEMBL617369,BAO_0000357,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),
B,HEK293,722.0,,,,,9,9606.0,227,1,Expert,,,2483,,15851,D,CHEMBL617370,BAO_0000219,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,Homo sapiens
F,CHO,449.0,,,,,9,9606.0,227,1,Expert,,,2484,,6857,D,CHEMBL617371,BAO_0000219,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens
B,,,,,,,8,,227,1,Autocuration,,,2485,,3805,H,CHEMBL617372,BAO_0000357,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),
B,,,,,,,9,9606.0,227,1,Expert,,,2486,,6491,D,CHEMBL617373,BAO_0000357,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,Homo sapiens
F,,,,,,,8,,227,1,Autocuration,,,2487,,14093,H,CHEMBL617374,BAO_0000019,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,
F,,,,,,,8,,227,1,Autocuration,,,2488,,13481,H,CHEMBL617375,BAO_0000019,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,
F,,,,,,,8,,227,1,Autocuration,,,2489,,14093,H,CHEMBL617376,BAO_0000019,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,
F,,,,,,,8,,227,1,Autocuration,,,2490,,14093,H,CHEMBL617377,BAO_0000019,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,
F,,,,,,,8,,227,1,Autocuration,,,2491,,14093,H,CHEMBL617378,BAO_0000019,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,
F,,,,,,,8,,227,1,Autocuration,,,2492,,13481,H,CHEMBL617379,BAO_0000019,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,
B,,,,,,,8,,227,1,Autocuration,,,2493,,14442,H,CHEMBL617380,BAO_0000357,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,
B,,,,,,,8,,227,1,Autocuration,,,2494,,14442,H,CHEMBL617381,BAO_0000357,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,
B,,,,,,,8,,227,1,Autocuration,,,2495,,14442,H,CHEMBL617382,BAO_0000357,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,
B,,,,,,,8,,107,1,Autocuration,,,2496,,12369,H,CHEMBL617383,BAO_0000357,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,107,1,Expert,,,2497,,12369,H,CHEMBL617384,BAO_0000357,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,
B,,,,,,,8,,107,1,Expert,,,2498,,12369,H,CHEMBL617385,BAO_0000357,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,
B,,,,,,,8,,107,1,Autocuration,,,2499,,14447,H,CHEMBL617386,BAO_0000019,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,
B,,,,,,,8,,107,1,Autocuration,,,2500,,14447,H,CHEMBL617387,BAO_0000019,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,
B,NIH3T3,723.0,,,,,8,,107,1,Autocuration,,,2501,,17451,H,CHEMBL617388,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,
F,CHO,449.0,,,,,8,,107,1,Autocuration,,,2502,,6857,H,CHEMBL617389,BAO_0000219,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,
F,CHO,449.0,,,,,9,9606.0,107,1,Expert,,,2503,,6857,D,CHEMBL617390,BAO_0000219,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens
B,,,,,,,4,,104817,1,Autocuration,,,2504,,5635,H,CHEMBL617391,BAO_0000224,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,
B,,,,,,,8,,107,1,Autocuration,,,2505,,12861,H,CHEMBL617392,BAO_0000357,,Binding activity radioligand.,
B,,,,,,,8,,107,1,Autocuration,,,2506,,12861,H,CHEMBL617393,BAO_0000019,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,
B,L929,307.0,,,,,8,,107,1,Autocuration,,,2507,,5105,H,CHEMBL617394,BAO_0000219,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,
B,L929,307.0,,,,,8,,107,1,Expert,,,2508,,5104,H,CHEMBL617395,BAO_0000219,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,
B,L929,307.0,,,,,8,,107,1,Expert,,,2509,,5105,H,CHEMBL617396,BAO_0000219,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,
B,L929,307.0,,,,,8,,107,1,Autocuration,,,2510,,5105,H,CHEMBL617397,BAO_0000219,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,
B,,,,,,,8,,107,1,Autocuration,,,2511,,5254,H,CHEMBL617398,BAO_0000357,,Binding affinity against 5-HT2A receptor,
B,,,,,,,8,,107,1,Autocuration,,,2512,,5254,H,CHEMBL617399,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2A receptor,
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2513,,13267,H,CHEMBL617400,BAO_0000219,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2514,,13267,H,CHEMBL617401,BAO_0000219,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,
B,HEK293,722.0,,,,,9,9606.0,107,1,Expert,,,2515,,14157,D,CHEMBL617402,BAO_0000219,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,Homo sapiens
B,HEK293,722.0,,,,,9,9606.0,107,1,Expert,,,2516,,12936,D,CHEMBL617403,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens
B,,,,,,,8,,107,1,Expert,,,2517,,14068,H,CHEMBL617404,BAO_0000357,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,
B,HEK293,722.0,,,,,9,9606.0,107,1,Expert,,,2518,,12936,D,CHEMBL857981,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens
B,HEK293,722.0,,,,,9,9606.0,107,1,Expert,,,2519,,12936,D,CHEMBL617405,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens
B,HEK293,722.0,,,,,9,9606.0,107,1,Expert,,,2520,,4540,D,CHEMBL617253,BAO_0000219,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,Homo sapiens
B,,,,,,,8,,107,1,Expert,,,2521,,6166,H,CHEMBL617254,BAO_0000357,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2522,,17296,H,CHEMBL617255,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2523,,17296,H,CHEMBL617256,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2524,,17296,H,CHEMBL616874,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,
B,HEK293,722.0,,,,,9,9606.0,107,1,Expert,,,2525,,15779,D,CHEMBL616875,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,Homo sapiens
B,HEK293,722.0,,,,,8,,107,1,Expert,,,2526,,14391,H,CHEMBL616876,BAO_0000219,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,
B,HEK293,722.0,,,,,8,,107,1,Expert,,,2527,,15851,H,CHEMBL616877,BAO_0000219,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",
B,HEK293,722.0,,,,,9,9606.0,107,1,Expert,,,2528,,15851,D,CHEMBL616878,BAO_0000219,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,Homo sapiens
B,HEK293,722.0,,,,,8,,107,1,Expert,,,2529,,3832,H,CHEMBL616879,BAO_0000219,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,
B,HEK293,722.0,,,,,8,,107,1,Expert,,,2530,,3833,H,CHEMBL616880,BAO_0000219,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,
B,HEK293,722.0,,,,,9,9606.0,107,1,Expert,,,2531,,12936,D,CHEMBL616881,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens
B,NIH3T3,723.0,,,,,8,,107,1,Autocuration,,,2532,,17451,H,CHEMBL616882,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,
B,NIH3T3,723.0,,,,,8,,107,1,Autocuration,,,2533,,17451,H,CHEMBL616883,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,
B,NIH3T3,723.0,,,,,8,,107,1,Autocuration,,,2534,,17451,H,CHEMBL616884,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2535,,4199,H,CHEMBL616885,BAO_0000219,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,
B,CHO-K1,485.0,,,,,8,,107,1,Autocuration,,,2536,,1883,H,CHEMBL616886,BAO_0000219,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,
B,CHO-K1,485.0,,,,,8,,107,1,Expert,,,2537,,1883,H,CHEMBL616887,BAO_0000219,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,
B,,,,,,,9,9606.0,107,1,Expert,,,2538,,14875,D,CHEMBL616888,BAO_0000357,,Binding affinity for human 5-hydroxytryptamine 2A receptor,Homo sapiens
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2539,,15146,H,CHEMBL616889,BAO_0000219,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2540,,5213,H,CHEMBL616890,BAO_0000219,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,
B,CHO,449.0,,,,,9,9606.0,107,1,Expert,,,2541,,16404,D,CHEMBL616891,BAO_0000219,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Homo sapiens
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2542,,14818,H,CHEMBL616892,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,
B,HEK293,722.0,,,,,8,,107,1,Autocuration,,,2543,,4829,H,CHEMBL616893,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",
F,NIH3T3,723.0,,,,,8,,10620,1,Autocuration,,,2544,,12652,H,CHEMBL616894,BAO_0000219,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,
B,NIH3T3,723.0,,,,,8,,107,1,Expert,,,2545,,4682,H,CHEMBL616895,BAO_0000219,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,
F,,,,,,,8,,10620,1,Autocuration,,,2546,,12652,H,CHEMBL616896,BAO_0000019,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,10621,1,Autocuration,,,2547,,4921,H,CHEMBL617099,BAO_0000357,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,10621,1,Autocuration,,,2548,,4921,H,CHEMBL617100,BAO_0000357,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,
B,,,,,,,8,9986.0,107,1,Autocuration,,,2549,,16312,H,CHEMBL884532,BAO_0000357,,Binding affinity against rabbit aorta 5-HT2A receptor,Oryctolagus cuniculus
B,,,,,,,8,9986.0,107,1,Expert,,,2550,,14998,H,CHEMBL617101,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,Oryctolagus cuniculus
B,,,,,,,8,9986.0,107,1,Expert,,,2551,,14025,H,CHEMBL617102,BAO_0000357,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,Oryctolagus cuniculus
B,,,,,,,8,9986.0,107,1,Autocuration,,,2552,,13047,H,CHEMBL617103,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Oryctolagus cuniculus
B,,,,,,,8,9986.0,107,1,Expert,,,2553,,13047,H,CHEMBL617104,BAO_0000357,,The compound was tested for binding affinity against 5-HT2A receptor,Oryctolagus cuniculus
B,CHO-K1,485.0,,,,,8,,10576,1,Autocuration,,,2554,,1883,H,CHEMBL857979,BAO_0000219,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,
B,,,,,,,8,,12687,1,Autocuration,,,2555,,13463,H,CHEMBL857502,BAO_0000019,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,
B,,,,,,,8,,12687,1,Autocuration,,,2556,,13463,H,CHEMBL617105,BAO_0000019,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,
B,,,,,945.0,,8,,12687,1,Autocuration,,,2557,,13463,H,CHEMBL858021,BAO_0000019,Stomach,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,
B,,,,,945.0,,9,10116.0,12687,1,Expert,,,2558,,13463,D,CHEMBL875910,BAO_0000019,Stomach,Binding affinity for 5-HT 2A in rat stomach fundus,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2559,,13463,H,CHEMBL617106,BAO_0000019,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,
B,NIH3T3,723.0,,,,,8,,12687,1,Expert,,,2560,,16326,H,CHEMBL617107,BAO_0000219,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,
F,,,,,,,8,,12687,1,Autocuration,,,2561,,14093,H,CHEMBL617108,BAO_0000019,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,
F,,,,,,,8,,12687,1,Autocuration,,,2562,,14093,H,CHEMBL617109,BAO_0000019,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2563,,15740,H,CHEMBL617110,BAO_0000357,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2564,,16633,H,CHEMBL617111,BAO_0000357,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,
F,,,,,,,9,10116.0,12687,1,Expert,,,2565,,17200,D,CHEMBL617112,BAO_0000019,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2566,,17133,H,CHEMBL617113,BAO_0000357,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2567,,17133,H,CHEMBL617114,BAO_0000357,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2568,,17133,H,CHEMBL617115,BAO_0000357,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,
F,,,,,,,8,,12687,1,Autocuration,,,2569,,17200,H,CHEMBL617116,BAO_0000219,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,
F,,,,,,,8,,12687,1,Autocuration,,,2570,,15363,H,CHEMBL617117,BAO_0000019,,Efficacy at 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2571,,17200,H,CHEMBL617118,BAO_0000357,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),
B,,,,,,,9,10116.0,12687,1,Expert,,,2572,,17200,D,CHEMBL617119,BAO_0000357,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Rattus norvegicus
B,,,,,,,9,10116.0,12687,1,Expert,,,2573,,17200,D,CHEMBL617120,BAO_0000357,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),Rattus norvegicus
F,,,,,,,9,10116.0,12687,1,Expert,,,2574,,17200,D,CHEMBL617121,BAO_0000219,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Rattus norvegicus
F,,,,,,,8,,12687,1,Autocuration,,,2575,,17200,H,CHEMBL617122,BAO_0000219,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,
B,,,,,,,8,,12687,1,Autocuration,,,2576,,17211,H,CHEMBL617123,BAO_0000019,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Expert,,,2577,,17331,H,CHEMBL617124,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,
B,,,,,,,8,,12687,1,Expert,,,2578,,13565,H,CHEMBL617600,BAO_0000249,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,
B,,,,,,,8,,12687,1,Expert,,,2579,,13730,H,CHEMBL617601,BAO_0000357,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,
B,,,,,,,8,,12687,1,Expert,,,2580,,12416,H,CHEMBL882923,BAO_0000019,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,
B,,,,,,,8,,12687,1,Autocuration,,,2581,,15295,H,CHEMBL617602,BAO_0000357,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2582,,1742,H,CHEMBL617603,BAO_0000019,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,
B,,,,,,,8,,12687,1,Autocuration,,,2583,,15295,H,CHEMBL617604,BAO_0000357,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Expert,,,2584,,14970,H,CHEMBL617605,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,
B,,,,,,,8,,12687,1,Expert,,,2585,,16693,H,CHEMBL617606,BAO_0000019,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,
B,,,,,,,9,10116.0,12687,1,Expert,,,2586,,14776,D,CHEMBL617607,BAO_0000019,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2587,,14286,H,CHEMBL617455,BAO_0000249,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,
B,,,,,,,9,10116.0,12687,1,Expert,,,2588,,17200,D,CHEMBL617456,BAO_0000019,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Rattus norvegicus
B,,,,,,,8,,12687,1,Expert,,,2589,,15306,H,CHEMBL617457,BAO_0000357,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),
B,,,,,,,9,10116.0,12687,1,Expert,,,2590,,14178,D,CHEMBL617458,BAO_0000357,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,Rattus norvegicus
B,,,,,,,9,10116.0,12687,1,Expert,,,2591,,14229,D,CHEMBL617459,BAO_0000019,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Rattus norvegicus
B,,,,,,,8,,12687,1,Expert,,,2592,,12884,H,CHEMBL617460,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,
B,,,,,,,8,,12687,1,Expert,,,2593,,13149,H,CHEMBL617461,BAO_0000357,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",
B,,,,,,,9,10116.0,12687,1,Expert,,,2594,,15295,D,CHEMBL617462,BAO_0000019,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2595,,15740,H,CHEMBL617463,BAO_0000357,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,
B,,,,,,,8,,12687,1,Autocuration,,,2596,,15185,H,CHEMBL617464,BAO_0000019,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",
B,,,,,,,8,,12687,1,Autocuration,,,2597,,15185,H,CHEMBL617465,BAO_0000019,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",
B,,,,,,,8,,12687,1,Expert,,,2598,,17529,H,CHEMBL617466,BAO_0000019,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2599,,14826,H,CHEMBL617467,BAO_0000019,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,
B,,,,,,,8,,12687,1,Expert,,,2600,,17211,H,CHEMBL617468,BAO_0000019,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,
B,,,,,,,8,,12687,1,Autocuration,,,2601,,14826,H,CHEMBL617469,BAO_0000019,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,
B,,,,,,,8,,12687,1,Autocuration,,,2602,,14093,H,CHEMBL617470,BAO_0000019,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2603,,14093,H,CHEMBL617471,BAO_0000019,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,
B,NIH3T3,723.0,,,,,8,,12687,1,Expert,,,2604,,13246,H,CHEMBL617472,BAO_0000219,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,
B,,,,,,,8,,12687,1,Expert,,,2605,,13246,H,CHEMBL617473,BAO_0000357,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,
B,,,,,,,9,10116.0,12687,1,Expert,,,2606,,15436,D,CHEMBL617474,BAO_0000019,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus
B,,,,,,,9,10116.0,12687,1,Expert,,,2607,,15436,D,CHEMBL617475,BAO_0000019,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus
B,,,,,955.0,,8,,12687,1,Autocuration,,,2608,,14442,H,CHEMBL617476,BAO_0000221,Brain,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,
B,,,,,,,8,,12687,1,Expert,,,2609,,12457,H,CHEMBL617477,BAO_0000357,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,
B,NIH3T3,723.0,,,,,8,,12687,1,Expert,,,2610,,12457,H,CHEMBL617478,BAO_0000219,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,
F,,,,,,,8,,12687,1,Autocuration,,,2611,,14755,H,CHEMBL617479,BAO_0000221,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",
B,,,,,,,8,,12687,1,Autocuration,,,2612,,4707,H,CHEMBL617480,BAO_0000357,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,
B,,,,,,,8,,12687,1,Expert,,,2613,,13297,H,CHEMBL617481,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Expert,,,2614,,17331,H,CHEMBL617482,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,
B,,,,,,,8,,12687,1,Autocuration,,,2615,,4664,H,CHEMBL617483,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2616,,16633,H,CHEMBL621528,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,
B,NIH3T3,723.0,,,,,9,10116.0,12687,1,Expert,,,2617,,4664,D,CHEMBL621529,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,Rattus norvegicus
B,,,,,,,8,,12687,1,Expert,,,2618,,16133,H,CHEMBL621530,BAO_0000357,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,
B,,,,,,,8,,12687,1,Expert,,,2619,,16133,H,CHEMBL621531,BAO_0000357,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
B,,,,,,,9,10116.0,12687,1,Expert,,,2620,,14060,D,CHEMBL621532,BAO_0000019,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,Rattus norvegicus
B,,,,,,,8,,12687,1,Expert,,,2621,,16326,H,CHEMBL621533,BAO_0000357,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,
B,CHO,449.0,,,,,8,,12687,1,Expert,,,2622,,16659,H,CHEMBL621534,BAO_0000219,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,
B,,,,,,,8,,12687,1,Autocuration,,,2623,,14776,H,CHEMBL621535,BAO_0000019,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,
B,,,,,,,8,,12687,1,Autocuration,,,2624,,13481,H,CHEMBL621536,BAO_0000357,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,
B,,,,,,,8,,12687,1,Autocuration,,,2625,,17386,H,CHEMBL621537,BAO_0000357,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,
B,,,,,,,9,10116.0,12687,1,Expert,,,2626,,6611,D,CHEMBL621538,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 2A receptor,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2627,,14423,H,CHEMBL621539,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,
B,,,,,,,8,,12687,1,Autocuration,,,2628,,15412,H,CHEMBL621540,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,
B,,,,,,,8,,12687,1,Autocuration,,,2629,,15412,H,CHEMBL621541,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,
B,,,,,,,8,,12687,1,Autocuration,,,2630,,6238,H,CHEMBL621542,BAO_0000019,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,
B,,,,,,,8,,12687,1,Expert,,,2631,,6648,H,CHEMBL621543,BAO_0000357,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,
B,,,,,,,8,,12687,1,Expert,,,2632,,5667,H,CHEMBL621544,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,
B,,,,,,,9,10116.0,12687,1,Expert,,,2633,,6611,D,CHEMBL621545,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2634,,13481,H,CHEMBL621546,BAO_0000357,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2635,,13481,H,CHEMBL621547,BAO_0000357,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,
B,NIH3T3,723.0,,,,,8,,12687,1,Expert,,,2636,,15558,H,CHEMBL618692,BAO_0000219,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2637,,6013,H,CHEMBL618693,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2638,,16633,H,CHEMBL872922,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2639,,6013,H,CHEMBL618694,BAO_0000357,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,
B,,,,,,,9,10116.0,12687,1,Expert,,,2640,,6013,D,CHEMBL618695,BAO_0000357,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2641,,6013,H,CHEMBL618696,BAO_0000357,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,
B,,,,,,,8,,12687,1,Expert,,,2642,,6013,H,CHEMBL618697,BAO_0000357,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,
B,,,,,,,8,,12687,1,Autocuration,,,2643,,6013,H,CHEMBL618892,BAO_0000357,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2644,,6013,H,CHEMBL618893,BAO_0000357,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2645,,16293,H,CHEMBL618894,BAO_0000357,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,
B,NIH3T3,723.0,,,,,8,,12687,1,Expert,,,2646,,17175,H,CHEMBL618895,BAO_0000219,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,
B,,,,,,,9,10116.0,12687,1,Expert,,,2647,,13278,D,CHEMBL618896,BAO_0000357,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Rattus norvegicus
B,,,,,5383.0,,8,,12687,1,Autocuration,,,2648,,3682,H,CHEMBL618897,BAO_0000019,Caudate-putamen,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,
B,,,,,,,8,,12687,1,Autocuration,,,2649,,2014,H,CHEMBL618898,BAO_0000357,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2650,,2014,H,CHEMBL618899,BAO_0000357,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,
B,,,,,,,8,,12687,1,Autocuration,,,2651,,4932,H,CHEMBL618900,BAO_0000357,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,
B,,,,,,,8,,12687,1,Autocuration,,,2652,,4932,H,CHEMBL618901,BAO_0000019,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,
B,,,,,,,8,,12687,1,Autocuration,,,2653,,3935,H,CHEMBL618902,BAO_0000357,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,
B,,,,,10000000.0,,9,10116.0,12687,1,Expert,,,2654,,5432,D,CHEMBL618903,BAO_0000221,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2655,,15818,H,CHEMBL618904,BAO_0000357,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2656,,13672,H,CHEMBL618905,BAO_0000357,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,
B,,,,,,,8,,12687,1,Autocuration,,,2657,,13672,H,CHEMBL618906,BAO_0000357,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,
B,NIH3T3,723.0,,,,,8,,12687,1,Expert,,,2658,,14749,H,CHEMBL618907,BAO_0000219,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,
B,,,,,,,8,,12687,1,Autocuration,,,2659,,13462,H,CHEMBL618908,BAO_0000019,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,
B,,,,,,,8,,12687,1,Autocuration,,,2660,,15740,H,CHEMBL617909,BAO_0000357,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,
B,,,,,,,8,,12687,1,Expert,,,2661,,16647,H,CHEMBL617910,BAO_0000019,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,
B,,,,,955.0,,8,,12687,1,Autocuration,,,2662,,13345,H,CHEMBL617911,BAO_0000221,Brain,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,
B,,,,,,,8,,12687,1,Autocuration,,,2663,,16740,H,CHEMBL872923,BAO_0000249,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,
B,,,,,,,8,,12687,1,Autocuration,,,2664,,16740,H,CHEMBL617912,BAO_0000249,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,
B,,,,,,,9,10116.0,12687,1,Expert,,,2665,,15535,D,CHEMBL617913,BAO_0000019,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,Rattus norvegicus
B,,,,,,,8,,12687,1,Expert,,,2666,,16740,H,CHEMBL617914,BAO_0000249,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,
B,,,,,,,8,,12687,1,Autocuration,,,2667,,16740,H,CHEMBL617915,BAO_0000249,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,
B,,,,,,,8,,12687,1,Autocuration,,,2668,,16740,H,CHEMBL617916,BAO_0000249,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,
B,,,,,,,9,10116.0,12687,1,Expert,,,2669,,4795,D,CHEMBL617917,BAO_0000019,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,Rattus norvegicus
B,,,,,,,8,,12687,1,Expert,,,2670,,8,H,CHEMBL617918,BAO_0000019,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2671,,8,H,CHEMBL617919,BAO_0000019,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,
B,,,,,,,9,10116.0,12687,1,Expert,,,2672,,17200,D,CHEMBL617920,BAO_0000019,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Rattus norvegicus
B,,,,,,,9,10116.0,12687,1,Expert,,,2673,,2148,D,CHEMBL617921,BAO_0000019,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,Rattus norvegicus
B,,,,,,,5,10116.0,105102,1,Expert,,,2674,,13345,D,CHEMBL617922,BAO_0000224,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2675,,5088,H,CHEMBL617923,BAO_0000357,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2676,,5088,H,CHEMBL617924,BAO_0000357,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
B,,,,,,,8,,12687,1,Autocuration,,,2677,,17133,H,CHEMBL617925,BAO_0000357,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,
B,,,,,,,9,10116.0,12687,1,Expert,,,2678,,17133,D,CHEMBL617926,BAO_0000357,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,Rattus norvegicus
B,,,,,,,8,,12687,1,Autocuration,,,2679,,16532,H,CHEMBL617927,BAO_0000357,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,
B,,,,,,,8,,12687,1,Autocuration,,,2680,,15086,H,CHEMBL617928,BAO_0000357,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,
B,,,,,,,9,10116.0,12687,1,Expert,,,2681,,2309,D,CHEMBL617929,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus
B,,,,,,,8,,12687,1,Expert,,,2682,,12953,H,CHEMBL617930,BAO_0000019,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,
B,,,,,,,8,,12687,1,Autocuration,,,2683,,12953,H,CHEMBL617931,BAO_0000019,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,
B,,,,,,,8,,12687,1,Autocuration,,,2684,,12953,H,CHEMBL617932,BAO_0000019,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,
B,CHO,449.0,,,,,8,,12687,1,Autocuration,,,2685,,16659,H,CHEMBL617933,BAO_0000219,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,
B,,,,,,,8,,12687,1,Autocuration,,,2686,,16740,H,CHEMBL617934,BAO_0000019,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,
B,,,,,,,8,,12687,1,Autocuration,,,2687,,16740,H,CHEMBL617935,BAO_0000019,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,
B,,,,,,,8,,12687,1,Autocuration,,,2688,,17133,H,CHEMBL617936,BAO_0000357,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,
B,,,,,,,8,,12687,1,Autocuration,,,2689,,17211,H,CHEMBL617937,BAO_0000019,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,
B,,,,,,,8,,12687,1,Autocuration,,,2690,,17331,H,CHEMBL617938,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,
B,,,,,,,8,,12687,1,Autocuration,,,2691,,16633,H,CHEMBL617939,BAO_0000218,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,
B,,,,,,,8,,12687,1,Autocuration,,,2692,,16633,H,CHEMBL617940,BAO_0000218,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,
B,,,,,,,8,,12687,1,Autocuration,,,2693,,16633,H,CHEMBL617941,BAO_0000218,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,
B,,,,,,,8,,12687,1,Expert,,,2694,,15026,H,CHEMBL617942,BAO_0000357,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,
B,,,,,,,8,,12687,1,Expert,,,2695,,15026,H,CHEMBL617943,BAO_0000357,,Ratio of pKi of 5-HT2A to that of D2 receptor,
B,,,,,,,4,,105093,1,Expert,,,2696,,16404,H,CHEMBL617944,BAO_0000224,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,
B,,,,,,,4,,105093,1,Expert,,,2697,,16404,H,CHEMBL617945,BAO_0000224,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,
B,,,,,,,4,,105075,1,Expert,,,2698,,16404,H,CHEMBL617946,BAO_0000224,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12687,1,Autocuration,,,2699,,16404,H,CHEMBL617947,BAO_0000357,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,
B,,,,,,,8,,12687,1,Expert,,,2700,,16326,H,CHEMBL617948,BAO_0000357,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,
F,,,,,,,8,,12687,1,Autocuration,,,2701,,15847,H,CHEMBL858116,BAO_0000019,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,
F,,,,,,,8,,12687,1,Autocuration,,,2702,,15847,H,CHEMBL617949,BAO_0000019,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,
F,,,,,,,8,,12687,1,Autocuration,,,2703,,15329,H,CHEMBL617950,BAO_0000019,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,
F,,,,,1515.0,,8,,12687,1,Expert,,,2704,,16404,H,CHEMBL617951,BAO_0000019,Thoracic aorta,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,
F,,,,,1515.0,,8,,12687,1,Expert,,,2705,,16404,H,CHEMBL617952,BAO_0000019,Thoracic aorta,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,
F,,,,,1515.0,,8,,12687,1,Autocuration,,,2706,,16404,H,CHEMBL617953,BAO_0000019,Thoracic aorta,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,
B,,,,,,,8,,12687,1,Autocuration,,,2707,,12861,H,CHEMBL617954,BAO_0000357,,Binding activity radioligand.,
B,,,,,,,8,,12687,1,Expert,,,2708,,12861,H,CHEMBL617955,BAO_0000019,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,
B,,,,,,,8,,12687,1,Autocuration,,,2709,,12861,H,CHEMBL857071,BAO_0000019,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,
B,,,,,,,8,,12687,1,Expert,,,2710,,12490,H,CHEMBL617270,BAO_0000019,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,
B,N1E-115,339.0,,,,,8,,12687,1,Autocuration,,,2711,,12827,H,CHEMBL617271,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,
B,N1E-115,339.0,,,,,8,,12687,1,Autocuration,,,2712,,12827,H,CHEMBL617272,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,
B,,,,,,,8,,12687,1,Autocuration,,,2713,,12918,H,CHEMBL617273,BAO_0000019,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,
F,,,,,,,9,10116.0,12687,1,Expert,,,2714,,12919,D,CHEMBL617274,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,Rattus norvegicus
B,,,,,,,8,,108,1,Autocuration,,,2715,,17723,H,CHEMBL617275,BAO_0000357,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,2716,,6013,H,CHEMBL617276,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,2717,,16293,H,CHEMBL617277,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Expert,,,2718,,3857,H,CHEMBL617278,BAO_0000019,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Expert,,,2719,,3857,H,CHEMBL617279,BAO_0000019,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,
B,,,,,,,8,,108,1,Expert,,,2720,,3857,H,CHEMBL617280,BAO_0000019,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,2721,,15363,H,CHEMBL617281,BAO_0000357,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,2722,,15363,H,CHEMBL617282,BAO_0000357,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Expert,,,2723,,16441,H,CHEMBL617283,BAO_0000019,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,
B,,,,,,,8,,108,1,Expert,,,2724,,16441,H,CHEMBL617284,BAO_0000019,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2725,,4176,H,CHEMBL617285,BAO_0000219,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,
B,,,,,,,8,,108,1,Autocuration,,,2726,,17085,H,CHEMBL617286,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,
B,,,,,,,9,9606.0,108,1,Expert,,,2727,,17200,D,CHEMBL617287,BAO_0000357,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,Homo sapiens
B,,,,,,,8,,108,1,Expert,,,2728,,5088,H,CHEMBL617288,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,
B,,,,,,,8,,108,1,Autocuration,,,2729,,5088,H,CHEMBL617289,BAO_0000357,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,
B,,,,,,,8,,108,1,Autocuration,,,2730,,5088,H,CHEMBL872917,BAO_0000357,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,
B,,,,,,,8,,108,1,Autocuration,,,2731,,5088,H,CHEMBL617290,BAO_0000357,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,
B,CHO,449.0,,,,,8,,108,1,Autocuration,,,2732,,16659,H,CHEMBL617291,BAO_0000219,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,
B,CHO,449.0,,,,,8,,108,1,Autocuration,,,2733,,16659,H,CHEMBL617292,BAO_0000219,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,
B,NIH3T3,723.0,,,,,8,,108,1,Autocuration,,,2734,,17451,H,CHEMBL617293,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,
F,CHO,449.0,,,,,9,9606.0,108,1,Expert,,,2735,,6857,D,CHEMBL617294,BAO_0000219,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens
B,,,,,,,8,,108,1,Expert,,,2736,,3857,H,CHEMBL617295,BAO_0000019,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,
B,,,,,,,8,,108,1,Autocuration,,,2737,,12861,H,CHEMBL617296,BAO_0000357,,Binding activity radioligand.,
B,,,,,,,8,,108,1,Autocuration,,,2738,,12861,H,CHEMBL617297,BAO_0000019,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,
B,CHO,449.0,,,,,8,,108,1,Expert,,,2739,,5104,H,CHEMBL617298,BAO_0000219,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,
B,CHO,449.0,,,,,8,,108,1,Expert,,,2740,,5105,H,CHEMBL617299,BAO_0000219,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,
B,CHO,449.0,,,,,8,,108,1,Autocuration,,,2741,,5105,H,CHEMBL617300,BAO_0000219,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,
B,,,,,,,8,,108,1,Autocuration,,,2742,,5254,H,CHEMBL617454,BAO_0000357,,Binding affinity against 5-HT2C receptor,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2743,,13267,H,CHEMBL617505,BAO_0000219,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,
B,HEK293,722.0,,,,,9,9606.0,108,1,Expert,,,2744,,14157,D,CHEMBL617506,BAO_0000219,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,Homo sapiens
B,HEK293,722.0,,,,,9,9606.0,108,1,Expert,,,2745,,12936,D,CHEMBL617507,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Homo sapiens
B,,,,,,,8,,108,1,Expert,,,2746,,14068,H,CHEMBL617508,BAO_0000357,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,
B,HEK293,722.0,,,,,9,9606.0,108,1,Expert,,,2747,,12936,D,CHEMBL857982,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Homo sapiens
B,HEK293,722.0,,,,,9,9606.0,108,1,Expert,,,2748,,4540,D,CHEMBL617509,BAO_0000219,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,Homo sapiens
B,HEK293,722.0,,,,,9,9606.0,108,1,Expert,,,2749,,4540,D,CHEMBL617510,BAO_0000219,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,Homo sapiens
B,,,,,,,8,,108,1,Autocuration,,,2750,,6166,H,CHEMBL617511,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2751,,17296,H,CHEMBL617512,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2752,,17296,H,CHEMBL617749,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2753,,15779,H,CHEMBL617750,BAO_0000219,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2754,,15779,H,CHEMBL617751,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,
B,HEK293,722.0,,,,,8,,108,1,Expert,,,2755,,14391,H,CHEMBL617752,BAO_0000219,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2756,,15779,H,CHEMBL617753,BAO_0000219,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",
B,HEK293,722.0,,,,,8,,108,1,Expert,,,2757,,15851,H,CHEMBL617754,BAO_0000219,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",
B,HEK293,722.0,,,,,9,9606.0,108,1,Expert,,,2758,,15851,D,CHEMBL617755,BAO_0000219,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,Homo sapiens
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2759,,15779,H,CHEMBL617756,BAO_0000219,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",
B,HEK293,722.0,,,,,8,,108,1,Expert,,,2760,,3832,H,CHEMBL617757,BAO_0000219,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,
B,HEK293,722.0,,,,,8,,108,1,Expert,,,2761,,3833,H,CHEMBL617758,BAO_0000219,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,
B,NIH3T3,723.0,,,,,8,,108,1,Autocuration,,,2762,,17451,H,CHEMBL617759,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2763,,4199,H,CHEMBL617760,BAO_0000219,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,
B,CHO-K1,485.0,,,,,8,,108,1,Expert,,,2764,,1883,H,CHEMBL617761,BAO_0000219,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,
B,,,,,,,9,9606.0,108,1,Expert,,,2765,,4321,D,CHEMBL617762,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2C receptor,Homo sapiens
B,,,,,,,8,,108,1,Autocuration,,,2766,,14875,H,CHEMBL617763,BAO_0000357,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2767,,15146,H,CHEMBL857983,BAO_0000219,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2768,,5213,H,CHEMBL617764,BAO_0000219,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,
B,HeLa,308.0,,,,,8,,108,1,Autocuration,,,2769,,16404,H,CHEMBL617765,BAO_0000219,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,
F,,,,,,,8,,108,1,Autocuration,,,2770,,13267,H,CHEMBL617766,BAO_0000019,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,
F,,,,,10000000.0,,8,,108,1,Autocuration,,,2771,,13267,H,CHEMBL617767,BAO_0000221,Hippocampus,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2772,,14818,H,CHEMBL617768,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,
B,HEK293,722.0,,,,,8,,108,1,Autocuration,,,2773,,4829,H,CHEMBL617769,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",
B,,,,,,,8,,11864,1,Autocuration,,,2774,,13463,H,CHEMBL858023,BAO_0000357,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,
B,,,,,945.0,,8,,11864,1,Autocuration,,,2775,,13463,H,CHEMBL617770,BAO_0000019,Stomach,Binding affinity analysed on 5-HT 2C in rat stomach fundus,
B,,,,,945.0,,8,,11864,1,Autocuration,,,2776,,13463,H,CHEMBL617771,BAO_0000019,Stomach,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,
F,A9,625.0,,,,,8,,11864,1,Autocuration,,,2777,,12652,H,CHEMBL617772,BAO_0000219,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,
B,NIH3T3,723.0,,,,,8,,11864,1,Autocuration,,,2778,,4682,H,CHEMBL617773,BAO_0000219,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,
B,NIH3T3,723.0,,,,,8,,11864,1,Autocuration,,,2779,,4682,H,CHEMBL617850,BAO_0000219,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,
B,NIH3T3,723.0,,,,,8,,11864,1,Autocuration,,,2780,,4682,H,CHEMBL617851,BAO_0000219,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,
F,,,,,,,8,,11864,1,Autocuration,,,2781,,12652,H,CHEMBL617852,BAO_0000019,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,
B,,,,,945.0,,8,10090.0,12689,1,Autocuration,,,2782,,13463,H,CHEMBL858024,BAO_0000019,Stomach,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Mus musculus
B,,,,,945.0,,9,10116.0,12689,1,Expert,,,2783,,13463,D,CHEMBL617853,BAO_0000019,Stomach,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Rattus norvegicus
B,,,,,,,8,,108,1,Expert,,,2784,,13969,H,CHEMBL617854,BAO_0000357,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,
B,,,,,,,8,9823.0,108,1,Expert,,,2785,,13392,H,CHEMBL873477,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 2C receptor,Sus scrofa
B,,,,,,,8,,108,1,Expert,,,2786,,13392,H,CHEMBL617855,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Expert,,,2787,,14430,H,CHEMBL617856,BAO_0000019,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,
B,,,,,,,8,,108,1,Autocuration,,,2788,,1742,H,CHEMBL617857,BAO_0000019,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,
B,,,,,,,8,,108,1,Autocuration,,,2789,,14286,H,CHEMBL617858,BAO_0000249,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,
B,,,,,,,8,,108,1,Autocuration,,,2790,,5619,H,CHEMBL617859,BAO_0000357,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,2791,,15086,H,CHEMBL617860,BAO_0000357,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,2792,,12861,H,CHEMBL617861,BAO_0000357,,Binding activity radioligand.,
B,,,,,,,8,,108,1,Expert,,,2793,,12861,H,CHEMBL617862,BAO_0000019,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,
B,,,,,,,8,,108,1,Autocuration,,,2794,,12861,H,CHEMBL617863,BAO_0000019,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,
B,,,,,,,8,,108,1,Autocuration,,,2795,,12827,H,CHEMBL617864,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,
B,,,,,,,8,,108,1,Autocuration,,,2796,,12827,H,CHEMBL617649,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,
F,,,,,,,8,9823.0,108,1,Expert,,,2797,,12919,H,CHEMBL617650,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Sus scrofa
F,,,,,,,8,9823.0,108,1,Expert,,,2798,,12919,H,CHEMBL617651,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Sus scrofa
B,,,,,,,8,9823.0,108,1,Autocuration,,,2799,,16429,H,CHEMBL617652,BAO_0000357,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,Sus scrofa
B,,,,,,,8,9823.0,108,1,Autocuration,,,2800,,773,H,CHEMBL857072,BAO_0000019,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,Sus scrofa
B,,,,,,,8,9823.0,108,1,Autocuration,,,2801,,5033,H,CHEMBL617653,BAO_0000357,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,Sus scrofa
B,,,,,,,8,,12687,1,Autocuration,,,2802,,12861,H,CHEMBL617654,BAO_0000019,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,
F,,,,,,,8,,12689,1,Autocuration,,,2803,,14093,H,CHEMBL617655,BAO_0000019,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12689,1,Expert,,,2804,,14970,H,CHEMBL617656,BAO_0000357,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,
B,,,,,,,8,,12689,1,Autocuration,,,2805,,14970,H,CHEMBL617657,BAO_0000357,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,
B,,,,,,,8,,12689,1,Autocuration,,,2806,,14970,H,CHEMBL617658,BAO_0000357,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,
B,,,,,,,9,10116.0,12689,1,Expert,,,2807,,14178,D,CHEMBL617659,BAO_0000357,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Expert,,,2808,,14178,D,CHEMBL617838,BAO_0000357,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,Rattus norvegicus
B,,,,,,,9,10116.0,12689,1,Expert,,,2809,Brain membranes,14229,D,CHEMBL617839,BAO_0000249,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Rattus norvegicus
B,,,,,,,8,,12689,1,Autocuration,,,2810,,16532,H,CHEMBL617840,BAO_0000357,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,
B,,,,,,,8,,12689,1,Autocuration,,,2811,,14826,H,CHEMBL617841,BAO_0000019,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,
B,,,,,,,8,,12689,1,Autocuration,,,2812,,17211,H,CHEMBL875915,BAO_0000019,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,
B,,,In vitro,,,,8,,12689,1,Expert,,,2813,,17211,H,CHEMBL617842,BAO_0000219,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,
B,NIH3T3,723.0,,,,,8,,12689,1,Expert,,,2814,,13246,H,CHEMBL617843,BAO_0000219,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,
B,,,,,,,8,,12689,1,Expert,,,2815,,13246,H,CHEMBL617844,BAO_0000357,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,
B,,,,,,,8,,12689,1,Expert,,,2816,,12457,H,CHEMBL617845,BAO_0000357,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,
B,NIH3T3,723.0,,,,,8,,12689,1,Expert,,,2817,,12457,H,CHEMBL617846,BAO_0000219,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12689,1,Autocuration,,,2818,,4707,H,CHEMBL617847,BAO_0000357,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,
B,,,,,,,8,,12689,1,Expert,,,2819,,13297,H,CHEMBL617848,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12689,1,Autocuration,,,2820,,16633,H,CHEMBL617849,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,
B,,,,,,,8,,12689,1,Expert,,,2821,,16133,H,CHEMBL621507,BAO_0000357,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,
B,,,,,,,8,,12689,1,Expert,,,2822,,16326,H,CHEMBL621508,BAO_0000357,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,
B,,,,,,,8,,12689,1,Autocuration,,,2823,,14423,H,CHEMBL621509,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,
B,,,,,,,8,,12689,1,Autocuration,,,2824,,15412,H,CHEMBL621510,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,
B,,,,,,,8,,12689,1,Autocuration,,,2825,,15412,H,CHEMBL621511,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,
B,A9,625.0,,,,,8,,12689,1,Expert,,,2826,,15558,H,CHEMBL621512,BAO_0000219,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12689,1,Autocuration,,,2827,,16633,H,CHEMBL621513,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,
B,,,,,,,8,,12689,1,Expert,,,2828,,6013,H,CHEMBL621514,BAO_0000357,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,
B,,,In vitro,,,,8,,12689,1,Expert,,,2829,,17175,H,CHEMBL621515,BAO_0000219,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,
B,,,,,,,8,,12689,1,Autocuration,,,2830,,12469,H,CHEMBL621516,BAO_0000219,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,
B,,,,,5383.0,,8,,12689,1,Autocuration,,,2831,,3682,H,CHEMBL621517,BAO_0000019,Caudate-putamen,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,
B,,,,,,,8,,12689,1,Autocuration,,,2832,,4932,H,CHEMBL621518,BAO_0000357,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,
B,,,,,,,8,,12689,1,Autocuration,,,2833,,4932,H,CHEMBL621519,BAO_0000019,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,
B,,,,,,,8,,12689,1,Autocuration,,,2834,,3935,H,CHEMBL621520,BAO_0000357,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12689,1,Autocuration,,,2835,,15818,H,CHEMBL621521,BAO_0000357,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12689,1,Autocuration,,,2836,,15818,H,CHEMBL621522,BAO_0000357,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12689,1,Expert,,,2837,,14749,H,CHEMBL621523,BAO_0000219,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,
B,,,,,,,8,,12689,1,Autocuration,,,2838,,15740,H,CHEMBL621524,BAO_0000357,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,
B,,,,,,,9,10116.0,12689,1,Expert,,,2839,,17133,D,CHEMBL621525,BAO_0000357,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,Rattus norvegicus
B,,,,,,,8,,12689,1,Autocuration,,,2840,,16532,H,CHEMBL872921,BAO_0000357,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,
B,,,,,,,8,,12689,1,Autocuration,,,2841,,12369,H,CHEMBL621526,BAO_0000357,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12689,1,Expert,,,2842,,12369,H,CHEMBL621527,BAO_0000219,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,
B,,,,,,,9,10116.0,12689,1,Expert,,,2843,,2309,D,CHEMBL617865,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,Rattus norvegicus
B,,,,,,,8,,12689,1,Autocuration,,,2844,,12953,H,CHEMBL617866,BAO_0000357,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12689,1,Autocuration,,,2845,,12953,H,CHEMBL617867,BAO_0000019,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,
B,,,,,,,8,,12689,1,Autocuration,,,2846,,12953,H,CHEMBL617487,BAO_0000357,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,
B,,,,,,,8,,12689,1,Expert,,,2847,,12953,H,CHEMBL617488,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,12689,1,Autocuration,,,2848,,17133,H,CHEMBL617489,BAO_0000357,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,
B,,,,,,,8,,12689,1,Autocuration,,,2849,,17211,H,CHEMBL617490,BAO_0000019,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,
B,,,,,,,8,,12689,1,Autocuration,,,2850,,17211,H,CHEMBL617491,BAO_0000019,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,
B,,,,,,,8,,12689,1,Autocuration,,,2851,,14025,H,CHEMBL617492,BAO_0000019,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,
B,,,,,,,8,,12689,1,Autocuration,,,2852,,14998,H,CHEMBL617493,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,
B,,,,,,,8,,12689,1,Autocuration,,,2853,,4342,H,CHEMBL617494,BAO_0000357,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,
B,,,,,,,9,10116.0,12689,1,Expert,,,2854,,13735,D,CHEMBL617495,BAO_0000019,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,Rattus norvegicus
B,,,,,,,8,,12689,1,Autocuration,,,2855,,13181,H,CHEMBL617496,BAO_0000357,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,
B,CHO-K1,485.0,,,,,8,,12689,1,Autocuration,,,2856,,1883,H,CHEMBL617497,BAO_0000219,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,
B,,,,,,,8,,12689,1,Autocuration,,,2857,,15194,H,CHEMBL617498,BAO_0000357,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,
B,,,,,,,8,,12689,1,Autocuration,,,2858,,15194,H,CHEMBL617499,BAO_0000357,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,
F,,,,,,,8,,12689,1,Autocuration,,,2859,,14579,H,CHEMBL617500,BAO_0000019,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,2860,,4639,H,CHEMBL617501,BAO_0000357,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Expert,,,2861,,4820,H,CHEMBL617502,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,227,1,Autocuration,,,2862,,14442,H,CHEMBL617503,BAO_0000357,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,
B,,,,,,,8,,227,1,Autocuration,,,2863,,14755,H,CHEMBL617504,BAO_0000357,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,
B,,,,,,,8,,227,1,Autocuration,,,2864,,14744,H,CHEMBL617406,BAO_0000357,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,
B,,,,,,,9,9606.0,227,1,Expert,,,2865,,6857,D,CHEMBL617407,BAO_0000019,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,Homo sapiens
B,,,,,,,8,,227,1,Autocuration,,,2866,,16209,H,CHEMBL617408,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,
B,,,,,,,8,,227,1,Autocuration,,,2867,,15363,H,CHEMBL617409,BAO_0000357,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,
B,,,,,,,8,,227,1,Autocuration,,,2868,,15363,H,CHEMBL617410,BAO_0000357,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,
B,,,,,,,8,,227,1,Autocuration,,,2869,,15363,H,CHEMBL617411,BAO_0000357,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,
B,,,,,,,8,,227,1,Autocuration,,,2870,,17085,H,CHEMBL617412,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,
B,,,,,,,9,9606.0,227,1,Expert,,,2871,,17200,D,CHEMBL617774,BAO_0000357,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,Homo sapiens
B,HEK293,722.0,,,,,9,9606.0,227,1,Expert,,,2872,,15851,D,CHEMBL617775,BAO_0000219,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Homo sapiens
B,HEK293,722.0,,,,,9,9606.0,227,1,Expert,,,2873,,15851,D,CHEMBL617776,BAO_0000219,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Homo sapiens
F,CHO,449.0,,,,,9,9606.0,227,1,Expert,,,2874,,6857,D,CHEMBL617777,BAO_0000219,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens
F,CHO,449.0,,,,,9,9606.0,227,1,Expert,,,2875,,6857,D,CHEMBL617778,BAO_0000219,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens
B,HEK293,722.0,,,,,8,,227,1,Autocuration,,,2876,,15779,H,CHEMBL617779,BAO_0000219,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",
B,HEK293,722.0,,,,,8,,227,1,Expert,,,2877,,15851,H,CHEMBL617780,BAO_0000219,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,
B,HEK293,722.0,,,,,8,,227,1,Autocuration,,,2878,,15779,H,CHEMBL617781,BAO_0000219,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",
B,HEK293,722.0,,,,,9,9606.0,227,1,Expert,,,2879,,14157,D,CHEMBL617782,BAO_0000219,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,Homo sapiens
B,HEK293,722.0,,,,,9,9606.0,227,1,Expert,,,2880,,4540,D,CHEMBL617783,BAO_0000219,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,Homo sapiens
B,,,,,,,8,,227,1,Autocuration,,,2881,,6166,H,CHEMBL617784,BAO_0000357,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,
B,HEK293,722.0,,,,,8,,227,1,Autocuration,,,2882,,15779,H,CHEMBL617785,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,
B,HEK293,722.0,,,,,8,,227,1,Expert,,,2883,,14391,H,CHEMBL857984,BAO_0000219,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,
B,HEK293,722.0,,,,,8,,227,1,Expert,,,2884,,3832,H,CHEMBL617786,BAO_0000219,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,
B,HEK293,722.0,,,,,8,,227,1,Expert,,,2885,,3833,H,CHEMBL617787,BAO_0000219,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,
B,HEK293,722.0,,,,,9,9606.0,227,1,Expert,,,2886,,15851,D,CHEMBL617788,BAO_0000219,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,Homo sapiens
B,HEK293,722.0,,,,,9,9606.0,227,1,Expert,,,2887,,15851,D,CHEMBL617789,BAO_0000219,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,Homo sapiens
B,HEK293,722.0,,,,,8,,227,1,Autocuration,,,2888,,4199,H,CHEMBL617790,BAO_0000219,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,
B,CHO-K1,485.0,,,,,8,,227,1,Expert,,,2889,,1883,H,CHEMBL617791,BAO_0000219,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,
B,,,,,,,8,,227,1,Expert,,,2890,,4321,H,CHEMBL617608,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2B receptor,
B,HEK293,722.0,,,,,8,,227,1,Autocuration,,,2891,,15146,H,CHEMBL617609,BAO_0000219,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,
B,HEK293,722.0,,,,,8,,227,1,Autocuration,,,2892,,5213,H,CHEMBL617610,BAO_0000219,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,
B,HEK293,722.0,,,,,8,,227,1,Autocuration,,,2893,,14818,H,CHEMBL617611,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,
B,HEK293,722.0,,,,,8,,227,1,Autocuration,,,2894,,4829,H,CHEMBL617612,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",
B,HEK293,722.0,,,,,8,,227,1,Autocuration,,,2895,,4829,H,CHEMBL617613,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",
B,,,,,,,8,9986.0,227,1,Autocuration,,,2896,,14025,H,CHEMBL617614,BAO_0000019,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,Oryctolagus cuniculus
B,,,,,945.0,,8,,12688,1,Expert,,,2897,,13463,H,CHEMBL617615,BAO_0000019,Stomach,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,
B,,,,,945.0,,8,,12688,1,Expert,,,2898,,7259,H,CHEMBL858114,BAO_0000357,Stomach,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,
B,,,,,945.0,,8,,12688,1,Autocuration,,,2899,,7259,H,CHEMBL617616,BAO_0000357,Stomach,Affinity against serotonergic receptor in the isolated rat stomach fundus,
F,,,,,945.0,,9,10116.0,12688,1,Expert,,,2900,,7185,D,CHEMBL617617,BAO_0000019,Stomach,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Rattus norvegicus
F,,,,,,,9,10116.0,12688,1,Expert,,,2901,,7185,D,CHEMBL875914,BAO_0000019,,Antagonistic against 5-hydroxytryptamine 2B receptor,Rattus norvegicus
F,,,,,945.0,,8,,12688,1,Autocuration,,,2902,,13267,H,CHEMBL617618,BAO_0000019,Stomach,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,
B,,,,,945.0,,9,10116.0,12688,1,Expert,,,2903,,13735,D,CHEMBL617619,BAO_0000357,Stomach,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Rattus norvegicus
F,,,,,,,8,,12688,1,Autocuration,,,2904,,15738,H,CHEMBL617620,BAO_0000019,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,
F,,,,,,,8,,12688,1,Autocuration,,,2905,,15738,H,CHEMBL617621,BAO_0000019,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,
F,,,,,,,8,,12688,1,Autocuration,,,2906,,15738,H,CHEMBL617622,BAO_0000019,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,
B,,,,,945.0,,9,10116.0,12688,1,Expert,,,2907,,12936,D,CHEMBL617623,BAO_0000357,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus
B,,,,,945.0,,9,10116.0,12688,1,Expert,,,2908,,12936,D,CHEMBL617624,BAO_0000357,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus
B,,,,,945.0,,9,10116.0,12688,1,Expert,,,2909,,12936,D,CHEMBL617625,BAO_0000357,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus
B,,,,,945.0,,9,10116.0,12688,1,Expert,,,2910,,12936,D,CHEMBL617626,BAO_0000357,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus
F,,,,,945.0,,8,,12688,1,Autocuration,,,2911,,16404,H,CHEMBL617627,BAO_0000019,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,
F,,,,,945.0,,8,,12688,1,Expert,,,2912,,16404,H,CHEMBL617628,BAO_0000019,Stomach,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,
F,,,,,945.0,,8,,12688,1,Autocuration,,,2913,,16404,H,CHEMBL617629,BAO_0000019,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,
F,,,,,945.0,,8,,12688,1,Autocuration,,,2914,,16404,H,CHEMBL858115,BAO_0000019,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,
F,,,,,945.0,,9,10116.0,12688,1,Expert,,,2915,,16404,D,CHEMBL617630,BAO_0000019,Stomach,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Rattus norvegicus
F,,,,,1515.0,,8,,12688,1,Autocuration,,,2916,,16404,H,CHEMBL617631,BAO_0000019,Thoracic aorta,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,
B,,,,,,,8,,12688,1,Autocuration,,,2917,,7483,H,CHEMBL617632,BAO_0000357,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,
B,,,,,,,8,,12688,1,Expert,,,2918,,7483,H,CHEMBL617633,BAO_0000357,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,
B,,,,,,,8,,12688,1,Autocuration,,,2919,,7483,H,CHEMBL617634,BAO_0000357,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,
B,,,,,,,8,,12688,1,Autocuration,,,2920,,7483,H,CHEMBL617635,BAO_0000357,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,
F,,,,,945.0,,9,10116.0,12688,1,Autocuration,,,2922,,16404,D,CHEMBL617637,BAO_0000019,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Rattus norvegicus
B,,,,,,,8,,227,1,Autocuration,,,2923,,6347,H,CHEMBL617638,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 1A receptor,
B,,,,,,,8,,227,1,Autocuration,,,2924,,4373,H,CHEMBL617639,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,
B,,,,,,,8,,227,1,Autocuration,,,2925,,4373,H,CHEMBL617640,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,
B,,,,,,,8,,227,1,Autocuration,,,2926,,4687,H,CHEMBL617641,BAO_0000357,,Evaluated for the binding affinity to 5-HT 2B receptor,
B,,,,,,,8,,227,1,Autocuration,,,2927,,16946,H,CHEMBL617642,BAO_0000357,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,
B,,,,,,,8,,227,1,Autocuration,,,2928,,16633,H,CHEMBL617643,BAO_0000357,,Binding affinities against 5-hydroxytryptamine 2B receptor,
B,,,,,,,8,,227,1,Autocuration,,,2929,,16633,H,CHEMBL617644,BAO_0000357,,Binding affinities towards 5-hydroxytryptamine 2B receptor,
B,,,,,,,8,,227,1,Autocuration,,,2930,,16633,H,CHEMBL617645,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,
B,,,,,,,8,,108,1,Expert,,,2931,,15026,H,CHEMBL617646,BAO_0000357,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,
B,,,,,,,8,9913.0,108,1,Autocuration,,,2932,,15738,H,CHEMBL617647,BAO_0000357,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Bos taurus
B,,,,,,,8,9913.0,108,1,Autocuration,,,2933,,15738,H,CHEMBL617648,BAO_0000357,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,Bos taurus
B,,,,,,,8,9913.0,108,1,Autocuration,,,2934,,15738,H,CHEMBL617875,BAO_0000357,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,Bos taurus
B,,,,,,,8,9913.0,108,1,Autocuration,,,2935,,15738,H,CHEMBL617876,BAO_0000357,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,Bos taurus
B,,,,,,,8,9913.0,108,1,Expert,,,2936,,16404,H,CHEMBL617877,BAO_0000357,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Bos taurus
B,,,,,,,8,9913.0,108,1,Expert,,,2937,,15026,H,CHEMBL617878,BAO_0000357,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Bos taurus
B,,,,,,,8,9913.0,108,1,Autocuration,,,2938,,15738,H,CHEMBL617879,BAO_0000357,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Bos taurus
B,,,,,,,8,10141.0,108,1,Autocuration,,,2939,,16312,H,CHEMBL617880,BAO_0000019,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,2940,,5486,D,CHEMBL617881,BAO_0000357,Striatum,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Cavia porcellus
B,,,,,,,8,,51,1,Autocuration,,,2941,,5254,H,CHEMBL857073,BAO_0000357,,Binding affinity against 5-HT1A receptor,
F,CHO,449.0,,,,,8,,108,1,Expert,,,2942,,3857,H,CHEMBL617882,BAO_0000219,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,
F,CHO,449.0,,,,,9,9606.0,108,1,Expert,,,2943,,6857,D,CHEMBL617883,BAO_0000219,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens
F,,,,,,,8,,108,1,Autocuration,,,2944,,4176,H,CHEMBL617884,BAO_0000219,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,
B,CHO,449.0,,,,,8,,108,1,Autocuration,,,2945,,6347,H,CHEMBL617885,BAO_0000219,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,
B,CHO,449.0,,,,,8,,108,1,Autocuration,,,2946,,6347,H,CHEMBL617886,BAO_0000219,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",
B,,,,,,,9,9606.0,108,1,Expert,,,2947,,16146,D,CHEMBL617887,BAO_0000357,,Inhibition of human 5-hydroxytryptamine 2C receptor,Homo sapiens
B,,,,,,,8,,108,1,Autocuration,,,2948,,3805,H,CHEMBL617888,BAO_0000357,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),
B,,,,,,,8,,108,1,Autocuration,,,2949,,3857,H,CHEMBL617889,BAO_0000019,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,
B,,,,,,,8,,108,1,Autocuration,,,2950,,5635,H,CHEMBL617890,BAO_0000357,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,2951,,5635,H,CHEMBL617891,BAO_0000357,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,
B,,,,,,,8,,108,1,Autocuration,,,2952,,5635,H,CHEMBL617892,BAO_0000357,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,
B,CHO,449.0,,,,,8,,108,1,Expert,,,2953,,4012,H,CHEMBL617893,BAO_0000219,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,
B,CHO,449.0,,,,,8,,108,1,Expert,,,2954,,6366,H,CHEMBL617894,BAO_0000219,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,
B,CHO,449.0,,,,,8,,108,1,Expert,,,2955,,15949,H,CHEMBL617895,BAO_0000219,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,
B,CHO,449.0,,,,,8,,108,1,Autocuration,,,2956,,17211,H,CHEMBL617896,BAO_0000219,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,
B,,,,,,,9,9606.0,108,1,Expert,,,2957,,6491,D,CHEMBL617897,BAO_0000357,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,Homo sapiens
F,,,,,,,8,,108,1,Autocuration,,,2958,,14093,H,CHEMBL617898,BAO_0000019,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,
F,,,,,,,8,,108,1,Autocuration,,,2959,,13481,H,CHEMBL617899,BAO_0000019,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,
B,CHO,449.0,,,,,8,10116.0,108,1,Expert,,,2960,,6347,H,CHEMBL617900,BAO_0000219,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,Rattus norvegicus
F,,,,,,,8,,108,1,Autocuration,,,2961,,14093,H,CHEMBL617901,BAO_0000019,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,
F,,,,,,,8,,108,1,Autocuration,,,2962,,14093,H,CHEMBL617902,BAO_0000019,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,
F,,,,,,,8,,108,1,Autocuration,,,2963,,13481,H,CHEMBL617903,BAO_0000019,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,
B,,,,,,,8,,108,1,Autocuration,,,2964,,14442,H,CHEMBL617904,BAO_0000357,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,
B,,,,,,,8,,108,1,Autocuration,,,2965,,14442,H,CHEMBL617905,BAO_0000357,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,
B,,,,,,,8,,108,1,Autocuration,,,2966,,14442,H,CHEMBL617906,BAO_0000357,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,
B,,,,,,,8,,108,1,Autocuration,,,2967,,14755,H,CHEMBL617907,BAO_0000357,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,
B,,,,,,,8,,108,1,Autocuration,,,2968,,14744,H,CHEMBL617908,BAO_0000357,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,
B,CHO,449.0,,,,,8,,108,1,Expert,,,2969,,16659,H,CHEMBL620617,BAO_0000219,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,
B,,,,,,,9,9606.0,108,1,Expert,,,2970,,6857,D,CHEMBL620618,BAO_0000019,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,Homo sapiens
B,,,,,,,8,,108,1,Expert,,,2971,,5635,H,CHEMBL620619,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,
B,,,,,,,9,9606.0,108,1,Expert,,,2972,,4234,D,CHEMBL620620,BAO_0000357,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,Homo sapiens
B,,,,,,,8,,108,1,Autocuration,,,2973,,16209,H,CHEMBL620621,BAO_0000357,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,2974,Membranes,5778,D,CHEMBL872920,BAO_0000249,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,2975,,5094,H,CHEMBL620622,BAO_0000223,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,2976,,809,D,CHEMBL620623,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,2977,,1578,H,CHEMBL620624,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,
B,,,,,,,6,,104698,1,Autocuration,,,2978,,809,H,CHEMBL620625,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,
B,,,,,,,6,,104698,1,Autocuration,,,2979,,12469,H,CHEMBL620626,BAO_0000219,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,
B,,,,,,,6,,104698,1,Autocuration,,,2980,,14290,H,CHEMBL621307,BAO_0000019,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,
B,,,,,,,6,,104698,1,Autocuration,,,2981,,14290,H,CHEMBL621308,BAO_0000019,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,
B,,,,,,,6,,104698,1,Autocuration,,,2982,,10609,H,CHEMBL621309,BAO_0000223,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,
B,,,,,,,6,,104698,1,Autocuration,,,2983,,10609,H,CHEMBL621310,BAO_0000223,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,
B,,,,,,,6,,104698,1,Autocuration,,,2984,,10609,H,CHEMBL621311,BAO_0000223,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,
B,,,,,,,6,,104698,1,Autocuration,,,2985,,15253,H,CHEMBL621502,BAO_0000249,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",
B,,,,,,,6,,104698,1,Autocuration,,,2986,,15253,H,CHEMBL621503,BAO_0000249,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",
B,,,,,,,6,,104698,1,Autocuration,,,2987,Membranes,11683,H,CHEMBL621504,BAO_0000249,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,
B,,,,,,,6,,104698,1,Autocuration,,,2988,,12092,H,CHEMBL621505,BAO_0000223,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,
B,,,,,,,6,,104698,1,Autocuration,,,2989,,1946,H,CHEMBL621506,BAO_0000019,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,
B,,,,,,,6,,104698,1,Autocuration,,,2990,,11623,H,CHEMBL619781,BAO_0000223,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,
B,,,,,,,6,,104698,1,Autocuration,,,2991,,11623,H,CHEMBL619782,BAO_0000223,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,
B,,,,,,,6,,104698,1,Autocuration,,,2992,,14788,H,CHEMBL619783,BAO_0000019,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,2993,,5432,D,CHEMBL619784,BAO_0000019,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,2994,,14826,H,CHEMBL619785,BAO_0000249,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,
B,,,,,,,6,,104698,1,Autocuration,,,2995,,2222,H,CHEMBL619786,BAO_0000223,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,
B,,,,,,,6,,104698,1,Autocuration,,,2996,,11963,H,CHEMBL619787,BAO_0000019,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,
B,,,,,,,6,,104698,1,Autocuration,,,2997,,14145,H,CHEMBL872925,BAO_0000019,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,
B,,,,,,,6,,104698,1,Autocuration,,,2998,,17819,H,CHEMBL619788,BAO_0000019,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,
B,,,,,,,6,,104698,1,Autocuration,,,2999,,10394,H,CHEMBL619789,BAO_0000249,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3000,,10394,H,CHEMBL619790,BAO_0000249,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3001,,15034,H,CHEMBL619791,BAO_0000019,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3002,,691,H,CHEMBL619792,BAO_0000019,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,
B,,,,,,,6,,104698,1,Autocuration,,,3003,Membranes,12092,H,CHEMBL619793,BAO_0000249,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3004,,11752,D,CHEMBL619794,BAO_0000223,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus
B,,,,,955.0,,6,,104698,1,Autocuration,,,3005,,11752,H,CHEMBL619795,BAO_0000221,Brain,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,
B,,,,,,,6,,104698,1,Autocuration,,,3006,,301,H,CHEMBL619796,BAO_0000019,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,
B,,,,,,,6,,104698,1,Autocuration,,,3007,,16532,H,CHEMBL620448,BAO_0000223,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,
B,,,,,,,6,,104698,1,Autocuration,,,3008,,16532,H,CHEMBL620449,BAO_0000223,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,
B,,,,,,,6,,104698,1,Autocuration,,,3009,,12092,H,CHEMBL620450,BAO_0000223,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,
B,,,,,,,6,,104698,1,Autocuration,,,3010,,11684,H,CHEMBL620451,BAO_0000223,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,
B,,,,,,,6,,104698,1,Autocuration,,,3011,,11684,H,CHEMBL620631,BAO_0000223,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,
B,,,,,,,6,,104698,1,Autocuration,,,3012,,12953,H,CHEMBL620632,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3013,,12953,H,CHEMBL620633,BAO_0000019,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,
B,,,,,,,6,,104698,1,Autocuration,,,3014,,12953,H,CHEMBL620634,BAO_0000223,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,
B,,,,,,,6,,104698,1,Autocuration,,,3015,,12861,H,CHEMBL620635,BAO_0000019,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3016,,11454,H,CHEMBL620636,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3017,,11454,H,CHEMBL620637,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3018,,11454,H,CHEMBL620638,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3019,,11454,H,CHEMBL620639,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3020,,11454,H,CHEMBL620640,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3021,,11454,H,CHEMBL620641,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3022,,11454,H,CHEMBL620642,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3023,,11454,H,CHEMBL620643,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3024,,11454,H,CHEMBL620644,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3025,,11454,H,CHEMBL620645,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3026,,11454,H,CHEMBL620646,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3027,,11454,H,CHEMBL620647,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3028,,11454,H,CHEMBL620648,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3029,,11454,H,CHEMBL620649,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3030,,11454,H,CHEMBL620650,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3031,,11454,H,CHEMBL620651,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3032,,11454,H,CHEMBL872875,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3033,,11454,H,CHEMBL620652,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,
F,,,,,,,6,,104698,1,Autocuration,,,3034,,10609,H,CHEMBL620653,BAO_0000019,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,
B,,,,,,,6,,104698,1,Autocuration,,,3035,,12861,H,CHEMBL857076,BAO_0000019,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3036,,12861,D,CHEMBL620654,BAO_0000019,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,3037,,12861,H,CHEMBL620655,BAO_0000223,,Binding activity radioligand.,
B,,,,,,,6,,104698,1,Autocuration,,,3038,Brain membranes,10728,H,CHEMBL620656,BAO_0000249,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,
B,,,,,,,6,,104698,1,Autocuration,,,3039,Brain membranes,10728,H,CHEMBL620657,BAO_0000249,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,
B,,,,,,,8,,108,1,Autocuration,,,3040,,5163,H,CHEMBL620658,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,
B,,,,,,,8,,108,1,Autocuration,,,3041,,5163,H,CHEMBL620659,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,
B,,,,,,,8,,108,1,Autocuration,,,3042,,6011,H,CHEMBL620660,BAO_0000357,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,
B,,,,,,,8,,108,1,Autocuration,,,3043,,5014,H,CHEMBL620661,BAO_0000357,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,3044,,5635,H,CHEMBL620662,BAO_0000357,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Expert,,,3045,,5163,H,CHEMBL620663,BAO_0000357,,Affinity for 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,3046,,6841,H,CHEMBL620664,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,
B,,,,,,,8,,108,1,Expert,,,3047,,6119,H,CHEMBL620665,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,
B,,,,,,,8,,108,1,Autocuration,,,3048,,4373,H,CHEMBL620666,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,
B,,,,,,,8,,108,1,Autocuration,,,3049,,1633,H,CHEMBL620667,BAO_0000357,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,
B,,,,,,,8,,108,1,Expert,,,3050,,1633,H,CHEMBL620668,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,
B,,,,,,,8,,108,1,Autocuration,,,3051,,4373,H,CHEMBL620669,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,
B,,,,,,,8,,108,1,Expert,,,3052,,6576,H,CHEMBL620670,BAO_0000357,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,3053,,4687,H,CHEMBL620671,BAO_0000357,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,3054,,12146,H,CHEMBL620672,BAO_0000357,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,
B,,,,,,,8,,108,1,Autocuration,,,3055,,12146,H,CHEMBL620673,BAO_0000357,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,
B,,,,,,,8,,108,1,Autocuration,,,3056,,16946,H,CHEMBL620674,BAO_0000357,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,3057,,14159,H,CHEMBL620675,BAO_0000357,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,
B,,,,,,,8,,108,1,Autocuration,,,3058,,16700,H,CHEMBL620676,BAO_0000357,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,
B,,,,,,,8,,108,1,Autocuration,,,3059,,3269,H,CHEMBL621382,BAO_0000357,,Affinity against 5-hydroxytryptamine 2C receptor,
B,,,,,,,9,9606.0,108,1,Expert,,,3060,,1274,D,CHEMBL621383,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 2C receptor,Homo sapiens
B,,,,,,,8,,108,1,Autocuration,,,3061,,1317,H,CHEMBL621384,BAO_0000357,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,
B,,,,,,,8,9913.0,144,1,Autocuration,,,3062,,5834,H,CHEMBL621385,BAO_0000357,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,Bos taurus
B,,,,,,,8,9913.0,144,1,Autocuration,,,3063,,11147,H,CHEMBL617989,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,Bos taurus
F,,,,,,,4,10141.0,104714,1,Expert,,,3064,,14145,H,CHEMBL617990,BAO_0000019,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3065,,10561,H,CHEMBL875085,BAO_0000221,Ileum,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3066,,15847,H,CHEMBL617991,BAO_0000019,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3067,,15847,H,CHEMBL617992,BAO_0000019,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3068,,10561,H,CHEMBL617993,BAO_0000221,Ileum,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3069,,11454,H,CHEMBL617994,BAO_0000221,Ileum,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3070,,4639,H,CHEMBL617995,BAO_0000019,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3071,,4639,H,CHEMBL617996,BAO_0000019,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3072,,4639,H,CHEMBL617997,BAO_0000019,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3073,,4639,H,CHEMBL617998,BAO_0000019,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3074,,4639,H,CHEMBL617999,BAO_0000019,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3075,,4639,H,CHEMBL618000,BAO_0000019,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,Cavia porcellus
F,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3076,,15253,H,CHEMBL617815,BAO_0000221,Ileum,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Cavia porcellus
F,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3077,,15253,H,CHEMBL617816,BAO_0000221,Ileum,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Cavia porcellus
F,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3078,,11963,H,CHEMBL617817,BAO_0000221,Ileum,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3079,,1946,H,CHEMBL617818,BAO_0000221,Ileum,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3080,,1946,H,CHEMBL617819,BAO_0000221,Ileum,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Cavia porcellus
B,,,,,,,4,10141.0,104714,1,Autocuration,,,3081,,12045,H,CHEMBL617820,BAO_0000223,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3082,,1559,H,CHEMBL617821,BAO_0000221,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus
F,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3083,,273,H,CHEMBL617822,BAO_0000221,Ileum,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Cavia porcellus
F,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3084,,273,H,CHEMBL617823,BAO_0000221,Ileum,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Cavia porcellus
F,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3085,,188,H,CHEMBL617824,BAO_0000221,Ileum,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Cavia porcellus
F,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3086,,12919,H,CHEMBL617825,BAO_0000221,Ileum,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Cavia porcellus
F,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3087,,12918,H,CHEMBL617826,BAO_0000221,Ileum,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3088,,1559,H,CHEMBL617827,BAO_0000221,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus
F,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3089,,273,H,CHEMBL617828,BAO_0000221,Ileum,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3090,,1559,H,CHEMBL617829,BAO_0000221,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3091,,1559,H,CHEMBL617830,BAO_0000221,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3092,,1559,H,CHEMBL617831,BAO_0000221,Ileum,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104714,1,Autocuration,,,3093,,14424,H,CHEMBL617832,BAO_0000221,Ileum,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Cavia porcellus
B,,,,,,,0,10141.0,22226,1,Autocuration,,,3094,,13181,U,CHEMBL617833,BAO_0000019,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Cavia porcellus
B,,,,,,,8,,51,1,Autocuration,,,3095,,5486,H,CHEMBL617834,BAO_0000357,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,
B,,,,,,,5,9606.0,104714,1,Expert,,,3096,,6491,D,CHEMBL617835,BAO_0000223,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,Homo sapiens
B,,,,,,,4,,104714,1,Autocuration,,,3097,,6013,H,CHEMBL617836,BAO_0000223,,Binding affinity towards 5-HT3 receptor,
B,,,,,,,4,,104714,1,Autocuration,,,3098,,12861,H,CHEMBL617837,BAO_0000223,,Binding activity radioligand.,
B,,,,,,,4,,104714,1,Autocuration,,,3099,,12861,H,CHEMBL620392,BAO_0000019,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,
B,,,,,,,4,,104714,1,Autocuration,,,3100,,5104,H,CHEMBL620393,BAO_0000223,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,
B,,,,,,,4,,104714,1,Autocuration,,,3101,,5105,H,CHEMBL620394,BAO_0000223,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,
B,,,,,,,4,,104714,1,Autocuration,,,3102,,5104,H,CHEMBL620395,BAO_0000223,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,
B,,,,,,,0,,22226,1,Autocuration,,,3103,,3935,U,CHEMBL620396,BAO_0000019,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,
B,NG108-15,433.0,,,,,4,,105030,1,Expert,,,3104,,13657,H,CHEMBL620582,BAO_0000219,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,
B,,,In vivo,,,,4,,105030,1,Autocuration,,,3105,,10369,H,CHEMBL620583,BAO_0000218,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",
B,,,,,,,4,,105030,1,Autocuration,,,3106,,10369,H,CHEMBL620584,BAO_0000019,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),
B,,,,,,,4,,105030,1,Autocuration,,,3107,,12918,H,CHEMBL620585,BAO_0000224,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,
B,,,,,,,4,,105030,1,Autocuration,,,3108,,12918,H,CHEMBL620586,BAO_0000224,,Compound was evaluated for the binding affinity at 5- HT3 receptor,
B,,,,,,,4,,105030,1,Autocuration,,,3109,,10369,H,CHEMBL620587,BAO_0000019,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),
B,,,,,,,4,,105030,1,Autocuration,,,3110,,773,H,CHEMBL620588,BAO_0000019,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,
F,,,,,,,4,,105030,1,Autocuration,,,3111,,12918,H,CHEMBL620589,BAO_0000218,,5-hydroxytryptamine 3 receptor agonism in mouse,
B,,,,,,,4,,105030,1,Autocuration,,,3112,,10561,H,CHEMBL620590,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,
B,,,,,,,4,,105030,1,Autocuration,,,3113,,12827,H,CHEMBL617956,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,
B,,,,,,,4,,105030,1,Autocuration,,,3114,,12827,H,CHEMBL617957,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,
B,,,,,,,4,,105030,1,Autocuration,,,3115,,12918,H,CHEMBL617958,BAO_0000224,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,
B,,,,,,,4,,105030,1,Autocuration,,,3116,,273,H,CHEMBL617959,BAO_0000219,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,
B,,,,,,,4,,105030,1,Autocuration,,,3117,,273,H,CHEMBL617960,BAO_0000219,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,
B,,,,,,,4,,105030,1,Autocuration,,,3118,,10561,H,CHEMBL617961,BAO_0000224,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,
B,,,In vitro,,,,4,,105030,1,Autocuration,,,3119,,5033,H,CHEMBL617962,BAO_0000219,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,
B,N1E-115,339.0,,,,,4,,105030,1,Autocuration,,,3120,,16429,H,CHEMBL617963,BAO_0000219,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,
B,,,,,,,8,,11765,1,Autocuration,,,3121,,10322,H,CHEMBL617964,BAO_0000019,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,
B,,,,,,,8,,11765,1,Autocuration,,,3122,,14331,H,CHEMBL617965,BAO_0000219,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,
B,,,,,,,9,10090.0,10630,1,Autocuration,,,3123,,13462,D,CHEMBL617966,BAO_0000357,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Mus musculus
B,,,,,,,8,,17106,1,Autocuration,,,3124,,12861,H,CHEMBL857074,BAO_0000019,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,
B,,,,,,,8,9823.0,144,1,Autocuration,,,3125,,15086,H,CHEMBL617967,BAO_0000357,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,Sus scrofa
B,,,,,,,8,9823.0,144,1,Autocuration,,,3126,,12861,H,CHEMBL617968,BAO_0000357,,Binding activity radioligand.,Sus scrofa
B,,,,,,,4,9986.0,104714,1,Autocuration,,,3127,,10561,H,CHEMBL617969,BAO_0000223,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,Oryctolagus cuniculus
B,,,,,,,4,9986.0,104714,1,Autocuration,,,3128,,10561,H,CHEMBL617970,BAO_0000223,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Oryctolagus cuniculus
B,,,,,,,4,9986.0,104714,1,Autocuration,,,3129,,10561,H,CHEMBL617971,BAO_0000223,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,Oryctolagus cuniculus
B,,,,,,,4,9986.0,104714,1,Autocuration,,,3130,,10561,H,CHEMBL617972,BAO_0000019,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Oryctolagus cuniculus
F,,,,,,,4,9986.0,104714,1,Autocuration,,,3131,,273,H,CHEMBL617973,BAO_0000019,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus
F,,,,,,,4,9986.0,104714,1,Autocuration,,,3132,,273,H,CHEMBL617974,BAO_0000019,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus
F,,,,,2116.0,,4,9986.0,104714,1,Autocuration,,,3133,,273,H,CHEMBL617975,BAO_0000221,Ileum,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Oryctolagus cuniculus
F,,,,,,,4,9986.0,104714,1,Autocuration,,,3134,,273,H,CHEMBL617976,BAO_0000019,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus
F,,,,,,,4,9986.0,104714,1,Autocuration,,,3135,,273,H,CHEMBL617977,BAO_0000019,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus
F,,,,,,,4,9986.0,104714,1,Autocuration,,,3136,,273,H,CHEMBL617978,BAO_0000019,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus
F,,,,,,,4,9986.0,104714,1,Autocuration,,,3137,,273,H,CHEMBL617979,BAO_0000019,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus
B,CHO,449.0,,,,,4,9986.0,104714,1,Autocuration,,,3138,,13047,H,CHEMBL617980,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,Oryctolagus cuniculus
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3139,,1650,D,CHEMBL617981,BAO_0000019,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,Rattus norvegicus
B,,,,,,,8,,12020,1,Autocuration,,,3140,,16288,H,CHEMBL617982,BAO_0000019,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),
B,,,,,,,8,,12020,1,Autocuration,,,3141,,16288,H,CHEMBL617983,BAO_0000357,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3142,,10254,D,CHEMBL617984,BAO_0000019,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,3143,,14532,H,CHEMBL617985,BAO_0000019,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",
F,,,In vivo,,948.0,,6,,104698,1,Autocuration,,,3144,,13392,H,CHEMBL617986,BAO_0000218,Heart,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",
F,,,,,948.0,,6,,104698,1,Autocuration,,,3145,,13392,H,CHEMBL617987,BAO_0000019,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",
F,,,,,948.0,,6,,104698,1,Autocuration,,,3146,,13392,H,CHEMBL617988,BAO_0000019,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",
F,,,,,948.0,,6,,104698,1,Autocuration,,,3147,,13392,H,CHEMBL617792,BAO_0000019,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",
F,,,,,948.0,,6,,104698,1,Autocuration,,,3148,,13392,H,CHEMBL617793,BAO_0000019,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",
F,,,,,,,6,,104698,1,Autocuration,,,3149,,13392,H,CHEMBL617794,BAO_0000019,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",
F,,,,,,,6,,104698,1,Autocuration,,,3150,,13392,H,CHEMBL617795,BAO_0000019,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",
F,,,,,,,6,,104698,1,Autocuration,,,3151,,13392,H,CHEMBL617796,BAO_0000019,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",
F,,,,,,,6,,104698,1,Autocuration,,,3152,,13392,H,CHEMBL617797,BAO_0000019,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",
F,,,In vivo,,,,7,10116.0,104698,1,Autocuration,,,3153,,1089,D,CHEMBL617798,BAO_0000218,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),Rattus norvegicus
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3154,,1089,H,CHEMBL617799,BAO_0000218,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),
F,,,In vivo,,,,7,10116.0,104698,1,Autocuration,,,3155,,11454,D,CHEMBL617800,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Rattus norvegicus
F,,,,,,,7,10116.0,104698,1,Autocuration,,,3156,,11454,D,CHEMBL617801,BAO_0000019,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,Rattus norvegicus
F,,,In vivo,,,,7,10116.0,104698,1,Autocuration,,,3157,,12205,D,CHEMBL617802,BAO_0000218,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Rattus norvegicus
F,,,,,,,7,10116.0,104698,1,Autocuration,,,3158,,1089,D,CHEMBL617803,BAO_0000019,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,3159,,5094,H,CHEMBL617804,BAO_0000019,,Binding affinity towards 5-HT3 receptor in rat was evaluated,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3160,,2622,D,CHEMBL617805,BAO_0000019,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,3161,,245,H,CHEMBL617806,BAO_0000223,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,
B,,,,,,,6,,104698,1,Autocuration,,,3162,,14788,H,CHEMBL617807,BAO_0000019,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,
B,,,,,,,6,,104698,1,Autocuration,,,3163,,14788,H,CHEMBL617808,BAO_0000019,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,
B,,,,,,,6,,104698,1,Autocuration,,,3164,,3020,H,CHEMBL617809,BAO_0000249,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3165,,1742,H,CHEMBL617810,BAO_0000019,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,
B,,,,,955.0,,6,,104698,1,Autocuration,,,3166,,17394,H,CHEMBL617811,BAO_0000249,Brain,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,
B,,,,,955.0,,6,,104698,1,Autocuration,,,3167,,17394,H,CHEMBL617812,BAO_0000221,Brain,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,
B,,,,,,,6,,104698,1,Autocuration,,,3168,,17394,H,CHEMBL617813,BAO_0000249,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,
B,,,,,,,6,,104698,1,Autocuration,,,3169,,14286,H,CHEMBL617814,BAO_0000249,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,
B,,,,,,,6,,104698,1,Autocuration,,,3170,,14178,H,CHEMBL617698,BAO_0000019,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3171,,14178,D,CHEMBL617699,BAO_0000019,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,Rattus norvegicus
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3172,,14178,D,CHEMBL617700,BAO_0000019,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,Rattus norvegicus
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3173,,14178,D,CHEMBL617701,BAO_0000223,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,3174,,15034,H,CHEMBL617702,BAO_0000019,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3175,Membranes,1089,H,CHEMBL617703,BAO_0000249,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3176,,1089,D,CHEMBL617704,BAO_0000019,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,3177,,16532,H,CHEMBL617705,BAO_0000223,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3178,,12801,D,CHEMBL617706,BAO_0000223,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus
B,NG108-15,433.0,,,,,6,,104698,1,Autocuration,,,3179,,15194,H,CHEMBL617707,BAO_0000219,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),
B,NG108-15,433.0,,,,,6,,104698,1,Autocuration,,,3180,,15194,H,CHEMBL617708,BAO_0000219,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3181,,15194,H,CHEMBL617709,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3182,,15194,H,CHEMBL617710,BAO_0000019,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,
B,,,,,,,6,,104698,1,Autocuration,,,3183,,15194,H,CHEMBL882925,BAO_0000019,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,
B,,,,,,,6,,104698,1,Autocuration,,,3184,,15194,H,CHEMBL617711,BAO_0000019,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,
F,,,,,,,6,,104698,1,Autocuration,,,3185,,10610,H,CHEMBL617712,BAO_0000019,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,
F,,,,,,,7,10116.0,104698,1,Autocuration,,,3186,,10355,D,CHEMBL617713,BAO_0000019,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,Rattus norvegicus
F,,,,,,,6,,104698,1,Autocuration,,,3187,,691,H,CHEMBL617714,BAO_0000019,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",
F,,,,,,,6,,104698,1,Autocuration,,,3188,,10611,H,CHEMBL617715,BAO_0000218,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3189,,12801,H,CHEMBL617716,BAO_0000218,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,
F,,,,,,,6,,104698,1,Autocuration,,,3190,,10609,H,CHEMBL617717,BAO_0000218,,Inhibition of 5-HT evoked reflex bradycardia in rat.,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3191,,11454,H,CHEMBL617718,BAO_0000218,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3192,,11454,H,CHEMBL617719,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3193,,11454,H,CHEMBL617720,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),
F,,,In vivo,,,,7,10116.0,104698,1,Autocuration,,,3194,,11454,D,CHEMBL617721,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,Rattus norvegicus
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3195,,11454,H,CHEMBL617722,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3196,,11454,H,CHEMBL617723,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3197,,11454,H,CHEMBL617724,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3198,,11454,H,CHEMBL617725,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3199,,11454,H,CHEMBL617726,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3200,,11454,H,CHEMBL617727,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3201,,11454,H,CHEMBL617728,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3202,,11454,H,CHEMBL617729,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3203,,11454,H,CHEMBL617730,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3204,,11454,H,CHEMBL617731,BAO_0000218,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3205,,11454,H,CHEMBL617732,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3206,,11454,H,CHEMBL617733,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3207,,11454,H,CHEMBL617734,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3208,,11454,H,CHEMBL872874,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3209,,11454,H,CHEMBL617735,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3210,,11454,H,CHEMBL617736,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3211,,11454,H,CHEMBL617737,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3212,,11454,H,CHEMBL617738,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3213,,11454,H,CHEMBL617739,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3214,,11454,H,CHEMBL617740,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3215,,11454,H,CHEMBL617741,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3216,,11454,H,CHEMBL617742,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3217,,11454,H,CHEMBL617743,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3218,,11454,H,CHEMBL617744,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3219,,11454,H,CHEMBL617745,BAO_0000218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,
F,,,,,,,6,,104698,1,Autocuration,,,3220,,670,H,CHEMBL617746,BAO_0000218,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",
F,,,,,,,6,,104698,1,Autocuration,,,3221,,670,H,CHEMBL617747,BAO_0000218,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3222,,10321,H,CHEMBL617748,BAO_0000218,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3223,,10321,H,CHEMBL618909,BAO_0000218,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3224,,10321,H,CHEMBL618910,BAO_0000218,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3225,,10321,H,CHEMBL618911,BAO_0000218,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3226,,10321,H,CHEMBL618912,BAO_0000218,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,
F,,,In vivo,,,,6,,104698,1,Autocuration,,,3227,,10322,H,CHEMBL618913,BAO_0000218,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),
F,,,,,,,6,,104698,1,Autocuration,,,3228,,15412,H,CHEMBL618914,BAO_0000019,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,
F,,,,,,,6,,104698,1,Autocuration,,,3229,,15412,H,CHEMBL618915,BAO_0000019,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3230,,15412,D,CHEMBL618916,BAO_0000223,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus
F,,,,,,,6,,104698,1,Autocuration,,,3231,,15412,H,CHEMBL618917,BAO_0000019,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,
B,,,,,10000000.0,,7,,104698,1,Intermediate,,,3232,,15412,D,CHEMBL618918,BAO_0000221,Hippocampus,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3233,,15412,D,CHEMBL618919,BAO_0000019,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Rattus norvegicus
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3234,,17394,D,CHEMBL618920,BAO_0000019,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,3235,,12457,H,CHEMBL618921,BAO_0000223,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,
B,,,,,,,6,,104698,1,Autocuration,,,3236,,12457,H,CHEMBL618922,BAO_0000019,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,
B,,,,,,,6,,104698,1,Autocuration,,,3237,,12205,H,CHEMBL618923,BAO_0000019,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,
B,,,,,,,6,,104698,1,Autocuration,,,3238,,14532,H,CHEMBL618924,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,
B,,,,,,,6,,104698,1,Autocuration,,,3239,,1122,H,CHEMBL618925,BAO_0000019,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3240,,5094,H,CHEMBL618926,BAO_0000019,,Binding affinity towards 5-HT3 receptor in rat was evaluated,
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3241,,809,D,CHEMBL618927,BAO_0000221,Ileum,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3242,,809,D,CHEMBL618928,BAO_0000221,Ileum,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3243,,14290,D,CHEMBL618929,BAO_0000221,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3244,,14290,D,CHEMBL618930,BAO_0000221,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3245,,14290,D,CHEMBL618931,BAO_0000221,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3246,,14290,D,CHEMBL619594,BAO_0000221,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3247,,14290,D,CHEMBL619595,BAO_0000221,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3248,,13961,D,CHEMBL619596,BAO_0000221,Ileum,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3249,,13961,D,CHEMBL619755,BAO_0000221,Ileum,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3250,,809,D,CHEMBL619756,BAO_0000221,Ileum,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3251,,809,D,CHEMBL619757,BAO_0000221,Ileum,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3252,,809,D,CHEMBL619758,BAO_0000221,Ileum,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3253,,14290,D,CHEMBL619759,BAO_0000221,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3254,,14290,D,CHEMBL619760,BAO_0000221,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3255,,14290,D,CHEMBL619761,BAO_0000221,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3256,,14290,D,CHEMBL619762,BAO_0000221,Ileum,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3257,,14290,D,CHEMBL619763,BAO_0000221,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3258,,14290,D,CHEMBL617868,BAO_0000221,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3259,,15034,D,CHEMBL617869,BAO_0000357,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3260,,5094,D,CHEMBL882926,BAO_0000249,Striatum,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3261,,5094,D,CHEMBL617870,BAO_0000249,Striatum,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3262,,5399,D,CHEMBL617871,BAO_0000357,Striatum,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3263,,17394,D,CHEMBL617872,BAO_0000357,Striatum,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3264,,17394,D,CHEMBL617873,BAO_0000357,Striatum,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3265,,17394,D,CHEMBL617874,BAO_0000357,Striatum,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3266,,13961,D,CHEMBL619067,BAO_0000221,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3267,,13961,D,CHEMBL619068,BAO_0000221,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3268,,13961,D,CHEMBL619069,BAO_0000221,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3269,,16946,D,CHEMBL619070,BAO_0000357,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3270,,16946,D,CHEMBL619071,BAO_0000357,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,Cavia porcellus
F,,,,,,,9,10141.0,20033,1,Intermediate,,,3271,,15034,D,CHEMBL619072,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 4 receptor,Cavia porcellus
F,,,,,,,9,10141.0,20033,1,Intermediate,,,3272,,15034,D,CHEMBL619073,BAO_0000019,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,Cavia porcellus
F,,,,,,,9,10141.0,20033,1,Intermediate,,,3273,,12918,D,CHEMBL619074,BAO_0000019,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3274,,16946,D,CHEMBL619075,BAO_0000357,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3275,,17394,D,CHEMBL619076,BAO_0000357,Striatum,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3276,,15034,D,CHEMBL619077,BAO_0000357,Striatum,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3277,,5094,D,CHEMBL619078,BAO_0000249,Striatum,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3278,,5094,D,CHEMBL619079,BAO_0000249,Striatum,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus
B,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3279,,17358,D,CHEMBL619080,BAO_0000221,Ileum,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Expert,,,3280,,12953,D,CHEMBL619081,BAO_0000357,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3281,,12953,D,CHEMBL619082,BAO_0000357,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3282,,12953,D,CHEMBL619083,BAO_0000357,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3283,,12953,D,CHEMBL619084,BAO_0000357,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3284,,273,D,CHEMBL859397,BAO_0000221,Ileum,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3285,,12918,D,CHEMBL619085,BAO_0000221,Ileum,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3286,,12919,D,CHEMBL619086,BAO_0000221,Ileum,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3287,,273,D,CHEMBL619087,BAO_0000221,Ileum,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3288,,273,D,CHEMBL619088,BAO_0000221,Ileum,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3289,,13181,D,CHEMBL619089,BAO_0000357,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,Cavia porcellus
B,,,,,,,8,10141.0,168,1,Autocuration,,,3290,,13181,H,CHEMBL619090,BAO_0000357,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,Cavia porcellus
F,,,,,,,9,10141.0,20033,1,Intermediate,,,3291,,15034,D,CHEMBL619091,BAO_0000019,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3292,,5033,D,CHEMBL619092,BAO_0000357,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3293,,1980,D,CHEMBL619093,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,Cavia porcellus
B,HEK293,722.0,,,,,8,10141.0,168,1,Autocuration,,,3294,,13181,H,CHEMBL619094,BAO_0000219,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3295,,14287,D,CHEMBL619095,BAO_0000019,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3296,,1317,D,CHEMBL857988,BAO_0000357,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3297,,15316,D,CHEMBL619096,BAO_0000357,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,Cavia porcellus
B,,,,,2435.0,,9,10141.0,20033,1,Intermediate,,,3298,,16429,D,CHEMBL619097,BAO_0000357,Striatum,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Cavia porcellus
B,,,,,10000000.0,,9,10141.0,20033,1,Intermediate,,,3299,,14818,D,CHEMBL619098,BAO_0000221,Hippocampus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3300,,15194,D,CHEMBL619751,BAO_0000357,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3301,,15194,D,CHEMBL619752,BAO_0000357,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3302,,13961,D,CHEMBL875096,BAO_0000221,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Cavia porcellus
B,,,,,,,8,,108,1,Autocuration,,,3303,,5486,H,CHEMBL619004,BAO_0000357,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,
B,,,,,,,8,,168,1,Autocuration,,,3304,,16209,H,CHEMBL619005,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,
B,,,,,,,8,,168,1,Autocuration,,,3305,,17085,H,CHEMBL619006,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,
B,HeLa,308.0,,,,,8,,168,1,Autocuration,,,3306,,4199,H,CHEMBL619007,BAO_0000219,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,
B,,,,,,,8,,168,1,Autocuration,,,3307,,15146,H,CHEMBL619008,BAO_0000357,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,
B,,,,,,,8,,168,1,Autocuration,,,3308,,5213,H,CHEMBL619009,BAO_0000357,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,
B,HeLa,308.0,,,,,8,,168,1,Autocuration,,,3309,,4829,H,CHEMBL619010,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",
B,,,,,,,8,,10622,1,Autocuration,,,3310,,17358,H,CHEMBL619011,BAO_0000357,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,
B,,,,,,,8,,10622,1,Autocuration,,,3311,,17358,H,CHEMBL619012,BAO_0000357,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,
B,,,,,,,8,,10622,1,Autocuration,,,3312,,16946,H,CHEMBL619013,BAO_0000219,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,
B,,,,,,,8,,10622,1,Autocuration,,,3313,,17358,H,CHEMBL619014,BAO_0000357,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,
F,,,,,2081.0,,8,,11249,1,Autocuration,,,3314,,268,H,CHEMBL857503,BAO_0000019,Cardiac atrium,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,
F,,,,,2081.0,,8,,11249,1,Autocuration,,,3315,,268,H,CHEMBL619015,BAO_0000019,Cardiac atrium,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,
B,,,,,,,8,,11249,1,Autocuration,,,3316,,15086,H,CHEMBL619016,BAO_0000357,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,
B,,,,,10000000.0,,8,,11249,1,Autocuration,,,3317,,14875,H,CHEMBL619017,BAO_0000221,Hippocampus,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,
B,,,,,10000000.0,,8,9823.0,168,1,Autocuration,,,3318,,13267,H,CHEMBL619018,BAO_0000221,Hippocampus,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Sus scrofa
B,,,,,,,8,9986.0,168,1,Autocuration,,,3319,,13047,H,CHEMBL619019,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus
B,,,,,,,9,10116.0,10623,1,Expert,,,3320,,1650,D,CHEMBL619020,BAO_0000357,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,Rattus norvegicus
F,,,,,,,8,,10623,1,Autocuration,,,3321,,567,H,CHEMBL619021,BAO_0000019,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,
B,,,,,,,8,,10623,1,Autocuration,,,3322,,17358,H,CHEMBL619022,BAO_0000357,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,
B,,,,,,,8,,10623,1,Autocuration,,,3323,,188,H,CHEMBL619023,BAO_0000357,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,
F,,,,,,,8,,10623,1,Autocuration,,,3324,,670,H,CHEMBL619024,BAO_0000019,,lntrinsic activity relative to 5-HT receptor,
F,,,,,,,8,,10623,1,Autocuration,,,3325,,204,H,CHEMBL619025,BAO_0000019,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,
F,,,,,,,8,,10623,1,Expert,,,3326,,1946,H,CHEMBL619026,BAO_0000019,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,
F,,,,,,,8,,10623,1,Autocuration,,,3327,,6398,H,CHEMBL619027,BAO_0000019,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,
F,,,,,,,8,,10623,1,Autocuration,,,3328,,6398,H,CHEMBL619028,BAO_0000019,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,
F,,,,,,,8,,10623,1,Autocuration,,,3329,,17358,H,CHEMBL619029,BAO_0000019,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,
F,,,,,,,8,,10623,1,Autocuration,,,3330,,6398,H,CHEMBL619030,BAO_0000019,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,
B,,,,,,,8,,10623,1,Expert,,,3331,,11752,H,CHEMBL619031,BAO_0000357,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,
F,,,,,,,8,,10623,1,Autocuration,,,3332,,809,H,CHEMBL619032,BAO_0000019,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,
B,,,,,,,9,10116.0,10623,1,Expert,,,3333,,14178,D,CHEMBL619033,BAO_0000357,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,Rattus norvegicus
B,,,,,,,8,,10623,1,Autocuration,,,3334,,567,H,CHEMBL619034,BAO_0000357,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,
B,,,,,,,8,,10623,1,Autocuration,,,3335,,1946,H,CHEMBL619035,BAO_0000357,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,
B,,,,,,,8,,10623,1,Autocuration,,,3336,,1946,H,CHEMBL619036,BAO_0000357,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,
B,,,,,,,9,10116.0,10623,1,Expert,,,3337,,13961,D,CHEMBL619037,BAO_0000019,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,Rattus norvegicus
B,,,,,2435.0,,8,,10623,1,Autocuration,,,3338,,6238,H,CHEMBL619038,BAO_0000249,Striatum,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,
B,,,,,,,8,,10623,1,Autocuration,,,3339,,14290,H,CHEMBL619039,BAO_0000249,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,
B,,,,,,,8,,10623,1,Expert,,,3340,,14290,H,CHEMBL619040,BAO_0000249,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,
B,,,,,2435.0,,9,10116.0,10623,1,Expert,,,3341,,809,D,CHEMBL619041,BAO_0000019,Striatum,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Rattus norvegicus
B,,,,,2435.0,,8,,10623,1,Autocuration,,,3342,,1578,H,CHEMBL619042,BAO_0000019,Striatum,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,
B,,,,,2435.0,,8,,10623,1,Expert,,,3343,,16709,H,CHEMBL619043,BAO_0000249,Striatum,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,
B,,,,,2435.0,,8,,10623,1,Expert,,,3344,,1946,H,CHEMBL619044,BAO_0000019,Striatum,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,
B,,,,,2435.0,,8,,10623,1,Expert,,,3345,,15253,H,CHEMBL619045,BAO_0000249,Striatum,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,
B,,,,,2435.0,,8,,10623,1,Expert,,,3346,,4535,H,CHEMBL619046,BAO_0000249,Striatum,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,
B,,,,,,,8,,10623,1,Expert,,,3347,,13961,H,CHEMBL619047,BAO_0000249,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,
F,,,,,955.0,,8,,10623,1,Autocuration,,,3348,,17358,H,CHEMBL619048,BAO_0000221,Brain,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,
F,,,,,,,8,,10623,1,Autocuration,,,3349,,15847,H,CHEMBL859398,BAO_0000019,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,
F,,,,,,,8,,10623,1,Autocuration,,,3350,,15847,H,CHEMBL619049,BAO_0000019,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,
F,,,,,,,8,,10623,1,Autocuration,,,3351,,670,H,CHEMBL857886,BAO_0000019,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,
F,,,,,,,8,,10623,1,Autocuration,,,3352,,670,H,CHEMBL619050,BAO_0000019,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,
F,,,,,,,8,,10623,1,Autocuration,,,3353,,1317,H,CHEMBL620591,BAO_0000019,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,
B,,,,,,,9,10116.0,10623,1,Expert,,,3354,,12936,D,CHEMBL620592,BAO_0000357,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,Rattus norvegicus
B,,,,,2435.0,,8,,10623,1,Expert,,,3355,,4535,H,CHEMBL620593,BAO_0000249,Striatum,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,
F,,,,,,,9,10116.0,10623,1,Expert,,,3356,,14424,D,CHEMBL620594,BAO_0000019,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,Rattus norvegicus
F,,,,,,,8,,10623,1,Expert,,,3357,,14424,H,CHEMBL875079,BAO_0000019,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,
F,,,,,,,8,,10623,1,Expert,,,3358,,14424,H,CHEMBL620595,BAO_0000019,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,
F,,,,,,,9,10116.0,10623,1,Expert,,,3359,,14424,D,CHEMBL620596,BAO_0000019,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,Rattus norvegicus
F,,,,,,,8,,10623,1,Autocuration,,,3360,,14424,H,CHEMBL620597,BAO_0000019,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,
F,,,,,,,8,,10623,1,Expert,,,3361,,14424,H,CHEMBL620598,BAO_0000019,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,
F,,,,,,,8,,10623,1,Expert,,,3362,,14424,H,CHEMBL620599,BAO_0000218,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),
F,,,,,,,8,,10623,1,Autocuration,,,3363,,14424,H,CHEMBL620600,BAO_0000019,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,
F,,,,,,,8,10116.0,168,1,Autocuration,,,3364,,1980,H,CHEMBL620601,BAO_0000019,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,Rattus norvegicus
F,,,,,,,8,,168,1,Autocuration,,,3365,,4639,H,CHEMBL620602,BAO_0000019,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,
B,,,,,,,8,,168,1,Autocuration,,,3366,,17358,H,CHEMBL620603,BAO_0000357,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,
B,,,,,,,8,,168,1,Autocuration,,,3367,,17358,H,CHEMBL620604,BAO_0000357,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,
B,,,,,,,8,,168,1,Autocuration,,,3368,,17358,H,CHEMBL620605,BAO_0000357,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,
B,,,,,,,8,,168,1,Autocuration,,,3369,,1558,H,CHEMBL620606,BAO_0000357,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,
F,,,,,,,8,,168,1,Autocuration,,,3370,,17358,H,CHEMBL620607,BAO_0000019,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,
B,,,,,,,8,,168,1,Autocuration,,,3371,,16117,H,CHEMBL620608,BAO_0000357,,In vitro binding affinity towards 5-HT4 receptor was determined,
F,,,,,,,8,,168,1,Autocuration,,,3372,,17358,H,CHEMBL620609,BAO_0000019,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,
F,,,,,,,8,,168,1,Autocuration,,,3373,,17358,H,CHEMBL620610,BAO_0000019,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,
B,,,,,,,8,,168,1,Autocuration,,,3374,,17358,H,CHEMBL620611,BAO_0000357,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,
B,,,,,,,8,,168,1,Autocuration,,,3375,,17358,H,CHEMBL620612,BAO_0000357,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,
B,,,,,,,8,,168,1,Autocuration,,,3376,,17358,H,CHEMBL620613,BAO_0000357,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,
B,,,,,,,8,,168,1,Autocuration,,,3377,,17358,H,CHEMBL620614,BAO_0000357,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,
B,,,,,,,8,,168,1,Expert,,,3378,,1274,H,CHEMBL620615,BAO_0000357,,Binding affinity against 5-Hydroxytryptamine 4 receptor,
B,,,,,,,6,,104698,1,Autocuration,,,3379,Brain membranes,10728,H,CHEMBL857075,BAO_0000249,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,
B,,,,,,,6,,104698,1,Autocuration,,,3380,Brain membranes,11695,H,CHEMBL620616,BAO_0000249,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,
B,,,,,,,6,,104698,1,Autocuration,,,3381,Brain membranes,11695,H,CHEMBL619411,BAO_0000249,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,
B,,,,,,,6,,104698,1,Autocuration,,,3382,,12490,H,CHEMBL619412,BAO_0000019,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3383,,11828,D,CHEMBL619413,BAO_0000019,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,Rattus norvegicus
B,,,,,10000000.0,,6,,104698,1,Autocuration,,,3384,,12253,H,CHEMBL619414,BAO_0000221,Hippocampus,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,
B,,,,,,,6,,104698,1,Autocuration,,,3385,,10561,H,CHEMBL619415,BAO_0000019,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,
B,,,,,,,6,,104698,1,Autocuration,,,3386,,10561,H,CHEMBL619416,BAO_0000019,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,
F,,,,,,,6,,104698,1,Autocuration,,,3387,,14432,H,CHEMBL619417,BAO_0000019,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3388,,12936,D,CHEMBL619418,BAO_0000223,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3389,,1274,D,CHEMBL619419,BAO_0000223,,Binding affinity against 5-Hydroxytryptamine 3 receptor,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,3390,,1980,H,CHEMBL619420,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,
B,,,,,,,6,,104698,1,Autocuration,,,3391,,670,H,CHEMBL619421,BAO_0000249,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3392,,968,D,CHEMBL619422,BAO_0000019,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Rattus norvegicus
B,,,,,,,6,,104698,1,Autocuration,,,3393,,14287,H,CHEMBL619423,BAO_0000019,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,
B,,,,,,,6,,104698,1,Autocuration,,,3394,,567,H,CHEMBL875080,BAO_0000019,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,
B,,,,,,,6,,104698,1,Autocuration,,,3395,,13267,H,CHEMBL619424,BAO_0000019,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3396,,14826,H,CHEMBL619425,BAO_0000249,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,
B,,,,,,,6,,104698,1,Autocuration,,,3397,,15194,H,CHEMBL619426,BAO_0000223,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,
B,,,,,,,6,,104698,1,Autocuration,,,3398,,15194,H,CHEMBL619427,BAO_0000223,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,
B,,,,,,,7,10116.0,104698,1,Autocuration,,,3399,,10394,D,CHEMBL619645,BAO_0000223,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus
B,,,,,,,9,,10576,1,Expert,,,3400,,13657,D,CHEMBL619646,BAO_0000249,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",
F,,,,,955.0,,8,,12020,1,Autocuration,,,3401,,1879,H,CHEMBL619647,BAO_0000221,Brain,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,
F,,,,,,,8,,12020,1,Autocuration,,,3402,,1879,H,CHEMBL619648,BAO_0000019,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,
F,,,,,,,8,,12020,1,Autocuration,,,3403,,1879,H,CHEMBL619165,BAO_0000019,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,
F,,,In vivo,,,,8,,12020,1,Autocuration,,,3404,,204,H,CHEMBL620719,BAO_0000218,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,
B,,,,,,,8,,12020,1,Autocuration,,,3405,,1879,H,CHEMBL872924,BAO_0000019,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,
B,,,,,,,8,,12020,1,Autocuration,,,3406,,1879,H,CHEMBL620720,BAO_0000357,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,
B,,,,,,,8,,12020,1,Autocuration,,,3407,,1879,H,CHEMBL620721,BAO_0000019,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,
B,,,,,,,8,,12020,1,Autocuration,,,3408,,1879,H,CHEMBL620722,BAO_0000019,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,
B,,,,,,,6,,104698,1,Autocuration,,,3409,,10641,H,CHEMBL620723,BAO_0000019,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",
B,,,,,,,8,,12020,1,Autocuration,,,3410,,773,H,CHEMBL620724,BAO_0000019,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,
B,,,,,,,6,,104698,1,Autocuration,,,3411,,11952,H,CHEMBL620725,BAO_0000249,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,
F,,,,,,,9,10116.0,12020,1,Autocuration,,,3412,,14145,D,CHEMBL620726,BAO_0000019,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,Rattus norvegicus
B,,,,,,,8,,144,1,Expert,,,3413,,17066,H,CHEMBL620727,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 3 receptor,
B,,,,,,,4,,104714,1,Autocuration,,,3414,,6398,H,CHEMBL620728,BAO_0000223,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,
B,,,,,,,0,,22226,1,Autocuration,,,3415,,10321,U,CHEMBL620729,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,
F,,,,,,,4,,104714,1,Autocuration,,,3416,,511,H,CHEMBL858288,BAO_0000019,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,
B,,,,,,,4,,104714,1,Autocuration,,,3417,,4639,H,CHEMBL620730,BAO_0000223,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,
B,,,,,,,4,,104714,1,Autocuration,,,3418,,4639,H,CHEMBL620731,BAO_0000223,,Binding affinity towards 5-hydroxytryptamine 3 receptor,
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3419,,4639,H,CHEMBL620732,BAO_0000019,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3420,,4639,H,CHEMBL618042,BAO_0000019,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3421,,4639,H,CHEMBL618043,BAO_0000019,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,Cavia porcellus
B,,,,,,,4,,104714,1,Autocuration,,,3422,,1558,H,CHEMBL618044,BAO_0000223,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,
F,,,,,,,4,,104714,1,Autocuration,,,3423,,268,H,CHEMBL618045,BAO_0000019,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,
B,,,,,,,4,,104714,1,Autocuration,,,3424,,2474,H,CHEMBL618046,BAO_0000223,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,
F,,,,,,,4,,104714,1,Autocuration,,,3425,,5067,H,CHEMBL618047,BAO_0000019,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,
F,,,,,,,4,,104714,1,Autocuration,,,3426,,5067,H,CHEMBL875084,BAO_0000019,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,
F,,,,,,,4,,104714,1,Autocuration,,,3427,,5067,H,CHEMBL618048,BAO_0000019,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,
B,,,,,,,4,,104714,1,Autocuration,,,3428,,5067,H,CHEMBL618049,BAO_0000223,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,
F,,,,,,,4,,104714,1,Autocuration,,,3429,,5067,H,CHEMBL619764,BAO_0000019,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,
F,,,,,,,4,,104714,1,Autocuration,,,3430,,5067,H,CHEMBL619765,BAO_0000019,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,
F,,,,,,,4,,104714,1,Autocuration,,,3431,,5067,H,CHEMBL619766,BAO_0000019,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,
B,,,,,,,4,,104714,1,Autocuration,,,3432,,5067,H,CHEMBL619767,BAO_0000223,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,
B,,,,,,,4,,104714,1,Autocuration,,,3433,,5067,H,CHEMBL619768,BAO_0000223,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,
F,,,,,,,4,,104714,1,Autocuration,,,3434,,5067,H,CHEMBL619769,BAO_0000019,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,
B,,,,,,,4,,104714,1,Autocuration,,,3435,,5067,H,CHEMBL619770,BAO_0000223,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,
B,,,,,,,4,,104714,1,Autocuration,,,3436,,5067,H,CHEMBL619771,BAO_0000223,,Binding affinity towards 5-hydroxytryptamine 3 receptor,
B,,,,,,,4,,104714,1,Autocuration,,,3437,,14331,H,CHEMBL619772,BAO_0000219,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,
B,,,,,,,4,,104714,1,Autocuration,,,3438,,5067,H,CHEMBL619773,BAO_0000223,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,
B,NG108-15,433.0,,,,,4,,104714,1,Autocuration,,,3439,,6179,H,CHEMBL619774,BAO_0000219,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,
B,,,,,,,4,,104714,1,Autocuration,,,3440,,4265,H,CHEMBL875083,BAO_0000019,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,
B,NG108-15,433.0,,,,,4,,104714,1,Autocuration,,,3441,,4265,H,CHEMBL620718,BAO_0000219,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,
B,,,,,,,4,,104714,1,Autocuration,,,3442,,17358,H,CHEMBL618127,BAO_0000223,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,
B,,,,,,,4,,104714,1,Autocuration,,,3443,,17358,H,CHEMBL618128,BAO_0000223,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,
B,,,In vitro,,,,4,,104714,1,Autocuration,,,3444,,13628,H,CHEMBL618129,BAO_0000219,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,
B,,,,,,,4,,104714,1,Autocuration,,,3445,,4612,H,CHEMBL618130,BAO_0000223,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,
F,,,,,,,4,,104714,1,Autocuration,,,3446,,17358,H,CHEMBL618131,BAO_0000019,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3447,,4639,H,CHEMBL618132,BAO_0000019,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3448,,4639,H,CHEMBL618133,BAO_0000019,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3449,,4639,H,CHEMBL618134,BAO_0000019,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,Cavia porcellus
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3450,,4639,H,CHEMBL618135,BAO_0000019,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Cavia porcellus
B,,,,,,,4,,104714,1,Autocuration,,,3451,,511,H,CHEMBL618136,BAO_0000223,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,
B,,,,,,,4,,104714,1,Autocuration,,,3452,,1479,H,CHEMBL618137,BAO_0000223,,Binding affinity towards 5-hydroxytryptamine 3 receptor,
B,,,,,,,4,,104714,1,Autocuration,,,3453,,1317,H,CHEMBL618138,BAO_0000223,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,
B,,,,,,,4,,104714,1,Autocuration,,,3454,,12146,H,CHEMBL618139,BAO_0000223,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,
B,,,,,,,4,,104714,1,Autocuration,,,3455,,12146,H,CHEMBL618140,BAO_0000223,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,
B,,,,,,,4,,104714,1,Autocuration,,,3456,,13969,H,CHEMBL618141,BAO_0000223,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,
B,,,,,,,8,,108,1,Expert,,,3457,,13392,H,CHEMBL873478,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 2C receptor,
B,,,,,,,6,,104698,1,Autocuration,,,3458,,13392,H,CHEMBL618142,BAO_0000223,,Binding affinity towards 5-hydroxytryptamine 3 receptor,
B,,,,,,,8,,144,1,Autocuration,,,3459,,14159,H,CHEMBL618143,BAO_0000357,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,
B,,,,,,,8,,144,1,Autocuration,,,3460,,1558,H,CHEMBL618144,BAO_0000357,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,
B,,,,,,,8,,144,1,Autocuration,,,3461,,16655,H,CHEMBL618145,BAO_0000357,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,
B,,,,,,,4,,104714,1,Autocuration,,,3462,,13020,H,CHEMBL618146,BAO_0000223,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,
B,,,,,,,4,,104714,1,Autocuration,,,3463,,13021,H,CHEMBL618147,BAO_0000223,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,
B,,,,,,,4,,104714,1,Autocuration,,,3464,,13020,H,CHEMBL618148,BAO_0000223,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,
B,,,,,,,8,,144,1,Autocuration,,,3465,,10321,H,CHEMBL618149,BAO_0000019,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,
B,,,,,,,8,,144,1,Autocuration,,,3466,,15818,H,CHEMBL872927,BAO_0000357,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,
B,,,,,,,8,,144,1,Autocuration,,,3467,,15818,H,CHEMBL618150,BAO_0000357,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,
B,,,,,,,8,,144,1,Autocuration,,,3468,,17358,H,CHEMBL618151,BAO_0000357,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,
B,,,,,,,8,,144,1,Autocuration,,,3469,,2222,H,CHEMBL875094,BAO_0000357,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,
B,,,,,,,8,,144,1,Autocuration,,,3470,,10322,H,CHEMBL618152,BAO_0000019,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,
B,,,,,,,8,,144,1,Autocuration,,,3471,,16117,H,CHEMBL618153,BAO_0000357,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,
B,,,,,,,8,,144,1,Autocuration,,,3472,,17200,H,CHEMBL618888,BAO_0000357,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,
F,,,,,,,8,,144,1,Autocuration,,,3473,,17358,H,CHEMBL618889,BAO_0000019,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,
B,,,,,,,8,,144,1,Autocuration,,,3474,,16700,H,CHEMBL618890,BAO_0000357,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,
B,,,,,,,8,,144,1,Autocuration,,,3475,,1980,H,CHEMBL618891,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,
B,,,,,,,8,,144,1,Autocuration,,,3476,,1980,H,CHEMBL619054,BAO_0000019,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,
B,,,,,,,4,,104714,1,Autocuration,,,3477,,12409,H,CHEMBL619055,BAO_0000223,,Binding affinity against the 5-hydroxytryptamine 3 receptor,
B,,,,,,,8,,144,1,Autocuration,,,3478,,4365,H,CHEMBL619056,BAO_0000357,,Binding affinity against human 5-hydroxytryptamine 3A receptor,
F,,,,,,,8,,144,1,Autocuration,,,3479,,4365,H,CHEMBL619057,BAO_0000019,,Percent efficacy against 5-hydroxytryptamine 3A receptor,
B,,,,,,,8,,144,1,Autocuration,,,3480,,4365,H,CHEMBL619058,BAO_0000357,,Binding affinity against human 5-hydroxytryptamine 3A receptor,
F,Oocytes,,,,,,9,10116.0,12020,1,Expert,,,3481,,6769,D,CHEMBL619059,BAO_0000219,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,Rattus norvegicus
F,Oocytes,,,,,,9,10116.0,12020,1,Expert,,,3482,,6769,D,CHEMBL619060,BAO_0000219,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,Rattus norvegicus
F,Oocytes,,,,,,9,10116.0,12020,1,Expert,,,3483,,6769,D,CHEMBL875095,BAO_0000219,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,Rattus norvegicus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3484,,809,D,CHEMBL619061,BAO_0000221,Ileum,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Cavia porcellus
F,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3485,,809,D,CHEMBL619062,BAO_0000221,Ileum,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Cavia porcellus
F,,,,,,,9,10141.0,20033,1,Intermediate,,,3486,,14290,D,CHEMBL619063,BAO_0000019,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,Cavia porcellus
B,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3487,,17358,D,CHEMBL619064,BAO_0000221,Ileum,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Cavia porcellus
B,,,,,,,9,10141.0,20033,1,Intermediate,,,3488,,17358,D,CHEMBL619065,BAO_0000357,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,Cavia porcellus
B,,,,,2116.0,,9,10141.0,20033,1,Intermediate,,,3489,,17358,D,CHEMBL619066,BAO_0000221,Ileum,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Cavia porcellus
B,,,,,2116.0,,8,,10209,1,Autocuration,,,3490,,17386,H,CHEMBL619775,BAO_0000221,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,
B,,,,,,,8,,10209,1,Autocuration,,,3491,,3269,H,CHEMBL619776,BAO_0000357,,Affinity against 5-hydroxytryptamine 7 receptor,
B,,,,,,,4,10141.0,104841,1,Autocuration,,,3492,,7721,H,CHEMBL619777,BAO_0000224,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Cavia porcellus
B,,,,,,,4,10141.0,104841,1,Autocuration,,,3493,,7721,H,CHEMBL619778,BAO_0000224,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Cavia porcellus
B,,,,,2116.0,,4,10141.0,104841,1,Autocuration,,,3494,,9117,H,CHEMBL619779,BAO_0000221,Ileum,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Cavia porcellus
B,,,,,,,4,10141.0,104841,1,Autocuration,,,3495,,7721,H,CHEMBL619780,BAO_0000224,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",Cavia porcellus
B,,,,,,,4,10141.0,104841,1,Autocuration,,,3496,,7721,H,CHEMBL619166,BAO_0000224,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",Cavia porcellus
F,,,,,,,4,10141.0,104841,1,Autocuration,,,3497,,15796,H,CHEMBL619167,BAO_0000019,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Cavia porcellus
F,,,,,,,4,10141.0,104841,1,Autocuration,,,3498,,15796,H,CHEMBL619168,BAO_0000019,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Cavia porcellus
B,,,,,2081.0,,9,9606.0,168,1,Expert,,,3499,,15650,D,CHEMBL619169,BAO_0000219,Cardiac atrium,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Homo sapiens
B,,,,,2081.0,,9,9606.0,168,1,Expert,,,3500,,15650,D,CHEMBL619170,BAO_0000219,Cardiac atrium,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Homo sapiens
F,,,,,,,5,9606.0,104841,1,Autocuration,,,3501,,6866,D,CHEMBL619171,BAO_0000019,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",Homo sapiens
F,,,,,2081.0,,9,9606.0,168,1,Expert,,,3502,,15650,D,CHEMBL619172,BAO_0000219,Cardiac atrium,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Homo sapiens
B,,,,,,,0,10090.0,22226,1,Autocuration,,,3503,,10063,U,CHEMBL619173,BAO_0000019,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,Mus musculus
B,,,,,,,0,10090.0,22226,1,Autocuration,,,3504,,12665,U,CHEMBL619174,BAO_0000019,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,Mus musculus
B,,,,,,,4,,104705,1,Autocuration,,,3505,,7504,H,CHEMBL619175,BAO_0000019,,5-hydroxytryptamine receptor binding affinity was determined in rats,
B,,,,,,,4,,104705,1,Autocuration,,,3506,,7504,H,CHEMBL619176,BAO_0000224,,Binding affinity at rat 5-hydroxytryptamine receptor.,
B,,,,,,,4,,104705,1,Autocuration,,,3507,,7038,H,CHEMBL619177,BAO_0000019,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,
B,,,,,,,4,,104705,1,Autocuration,,,3508,,7626,H,CHEMBL619178,BAO_0000224,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,
B,,,,,,,4,,104705,1,Autocuration,,,3509,,7626,H,CHEMBL619179,BAO_0000224,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,
F,,,,,945.0,,4,,104705,1,Autocuration,,,3510,,7185,H,CHEMBL619180,BAO_0000019,Stomach,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,
F,,,,,945.0,,4,,104705,1,Autocuration,,,3511,,7185,H,CHEMBL619181,BAO_0000019,Stomach,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,
F,,,,,,,4,,104705,1,Autocuration,,,3512,,7185,H,CHEMBL619182,BAO_0000019,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,
B,,,,,,,4,,104705,1,Autocuration,,,3513,,6960,H,CHEMBL619183,BAO_0000224,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,
B,,,,,,,4,,104705,1,Autocuration,,,3514,,6960,H,CHEMBL619184,BAO_0000224,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,3515,,12416,H,CHEMBL619185,BAO_0000221,Hippocampus,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,
B,,,,,,,8,,12198,1,Expert,,,3516,,15753,H,CHEMBL619186,BAO_0000357,,Binding affinity for rat 5-hydroxytryptamine transporter.,
B,,,,,,,4,,104705,1,Autocuration,,,3517,,8062,H,CHEMBL619187,BAO_0000019,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,
B,,,,,,,5,10116.0,104705,1,Autocuration,,,3518,,9036,D,CHEMBL619188,BAO_0000019,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,Rattus norvegicus
B,,,,,,,5,10116.0,104705,1,Autocuration,,,3519,,15067,D,CHEMBL619189,BAO_0000224,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Rattus norvegicus
F,,,,,955.0,,9,10116.0,12198,1,Expert,,,3520,,15753,D,CHEMBL619190,BAO_0000019,Brain,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Rattus norvegicus
F,,,,,2037.0,,9,10116.0,12198,1,Expert,,,3521,,15753,D,CHEMBL619191,BAO_0000221,Cerebellum,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Rattus norvegicus
B,,,,,,,5,10116.0,104705,1,Autocuration,,,3522,,15295,D,CHEMBL619192,BAO_0000019,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,Rattus norvegicus
B,,,,,,,5,10116.0,104705,1,Autocuration,,,3523,,6347,D,CHEMBL619193,BAO_0000224,,Percent binding affinity against 5-hydroxytryptamine receptor,Rattus norvegicus
B,,,,,,,0,,22226,1,Autocuration,,,3524,,6763,U,CHEMBL619194,BAO_0000019,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,
B,,,,,,,5,10116.0,104705,1,Autocuration,,,3525,,12092,D,CHEMBL619195,BAO_0000224,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,Rattus norvegicus
B,,,,,,,5,10116.0,104705,1,Autocuration,,,3526,,1579,D,CHEMBL619196,BAO_0000224,,Affinity against 5-hydroxytryptamine receptor was determined,Rattus norvegicus
B,,,,,945.0,,5,10116.0,104705,1,Autocuration,,,3527,,1579,D,CHEMBL619197,BAO_0000019,Stomach,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Rattus norvegicus
B,,,In vitro,,,,9,9606.0,121,1,Expert,,,3528,,5963,D,CHEMBL619198,BAO_0000219,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Homo sapiens
B,,,In vitro,,,,9,9606.0,121,1,Expert,,,3529,,5963,D,CHEMBL875081,BAO_0000219,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Homo sapiens
B,,,,,,,8,,18065,1,Autocuration,,,3530,,5030,H,CHEMBL884712,BAO_0000357,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,
B,,,,,,,8,,121,1,Expert,,,3531,,15796,H,CHEMBL884710,BAO_0000357,,Inhibition of 5-hydroxytryptamine reuptake,
F,,,,,,,8,,18065,1,Autocuration,,,3532,,15413,H,CHEMBL619199,BAO_0000019,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",
F,,,,,,,8,,18065,1,Autocuration,,,3533,,15413,H,CHEMBL619200,BAO_0000019,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",
F,,,,,,,8,,18065,1,Autocuration,,,3534,,15413,H,CHEMBL619201,BAO_0000019,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",
F,,,,,,,8,,18065,1,Autocuration,,,3535,,12409,H,CHEMBL619202,BAO_0000019,,Tested for 5-hydroxytryptamine receptor uptake,
B,CHO,449.0,,,,,9,9606.0,51,1,Expert,,,3536,,16909,D,CHEMBL619203,BAO_0000219,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Homo sapiens
F,,,,,,,9,9606.0,51,1,Expert,,,3537,,16909,D,CHEMBL619204,BAO_0000019,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,Homo sapiens
B,,,,,,,8,9606.0,10576,1,Autocuration,,,3538,,15629,H,CHEMBL619205,BAO_0000249,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Homo sapiens
B,,,,,,,8,,10576,1,Autocuration,,,3539,,15629,H,CHEMBL619206,BAO_0000357,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,
B,,,,,,,8,,10576,1,Expert,,,3540,,15629,H,CHEMBL619207,BAO_0000249,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3541,,10034,H,CHEMBL619208,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3542,,10034,H,CHEMBL619209,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3543,,10034,H,CHEMBL619210,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3544,,10034,H,CHEMBL619211,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3545,,10034,H,CHEMBL619212,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3546,,10034,H,CHEMBL620681,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3547,,10034,H,CHEMBL620682,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3548,,10034,H,CHEMBL620683,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3549,,10034,H,CHEMBL620684,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3550,,10034,H,CHEMBL620685,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,
F,,,,,2435.0,,8,,10825,1,Autocuration,,,3551,,10034,H,CHEMBL620686,BAO_0000019,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,
F,,,,,349.0,,8,,10825,1,Autocuration,,,3552,,10034,H,CHEMBL620687,BAO_0000019,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,
F,,,,,349.0,,8,,10825,1,Autocuration,,,3553,,10034,H,CHEMBL620688,BAO_0000019,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,
F,,,,,349.0,,8,,10825,1,Autocuration,,,3554,,10034,H,CHEMBL620689,BAO_0000019,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,
F,,,,,349.0,,8,,10825,1,Autocuration,,,3555,,10034,H,CHEMBL620690,BAO_0000019,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,
F,,,,,349.0,,8,,10825,1,Autocuration,,,3556,,10034,H,CHEMBL620691,BAO_0000019,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,
F,,,,,349.0,,8,,10825,1,Autocuration,,,3557,,10034,H,CHEMBL620692,BAO_0000019,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,
F,,,,,349.0,,8,,10825,1,Autocuration,,,3558,,10034,H,CHEMBL620693,BAO_0000019,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,
B,,,,,,,8,,168,1,Expert,,,3559,,1274,H,CHEMBL620694,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 4 receptor,
F,,,,,,,8,,168,1,Autocuration,,,3560,,17358,H,CHEMBL857986,BAO_0000019,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,
B,,,,,,,8,,168,1,Autocuration,,,3561,,14532,H,CHEMBL620695,BAO_0000357,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,
B,,,,,,,8,,168,1,Expert,,,3562,,16989,H,CHEMBL620696,BAO_0000357,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,
B,,,,,,,8,,168,1,Autocuration,,,3563,,17200,H,CHEMBL620697,BAO_0000357,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,
B,,,,,,,8,,168,1,Autocuration,,,3564,,15779,H,CHEMBL620698,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 4 receptor,
B,,,,,,,8,,168,1,Autocuration,,,3565,,15779,H,CHEMBL620699,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,
B,,,,,,,8,,168,1,Autocuration,,,3566,,15779,H,CHEMBL620700,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,
B,COS-7,643.0,,,,,8,,168,1,Autocuration,,,3567,,15650,H,CHEMBL620701,BAO_0000219,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,
B,COS-7,643.0,,,,,8,,168,1,Autocuration,,,3568,,15650,H,CHEMBL875082,BAO_0000219,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,
B,COS-7,643.0,,,,,8,,168,1,Autocuration,,,3569,,15650,H,CHEMBL620702,BAO_0000219,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,
B,COS-7,643.0,,,,,8,,168,1,Autocuration,,,3570,,15650,H,CHEMBL620703,BAO_0000219,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,
B,C6,673.0,,,,,8,,168,1,Autocuration,,,3571,,17046,H,CHEMBL620704,BAO_0000219,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,
B,C6,673.0,,,,,8,,168,1,Expert,,,3572,,17046,H,CHEMBL620705,BAO_0000219,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,
B,C6,673.0,,,,,8,,168,1,Expert,,,3573,,15650,H,CHEMBL620706,BAO_0000219,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,
B,C6,673.0,,,,,8,,168,1,Expert,,,3574,,17046,H,CHEMBL620707,BAO_0000219,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,
B,,,,,,,8,,10624,1,Expert,,,3575,,17066,H,CHEMBL620708,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 5 receptor,
B,,,,,,,8,,105,1,Autocuration,,,3576,,17200,H,CHEMBL620709,BAO_0000357,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,
B,,,,,,,9,9606.0,10624,1,Expert,,,3577,,16146,D,CHEMBL620710,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 5A receptor,Homo sapiens
B,CHO,449.0,,,,,8,,10624,1,Autocuration,,,3578,,15250,H,CHEMBL620711,BAO_0000219,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,
B,,,,,,,9,9606.0,10624,1,Expert,,,3579,,6491,D,CHEMBL620712,BAO_0000357,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,Homo sapiens
B,,,,,,,9,9606.0,10624,1,Expert,,,3580,,17066,D,CHEMBL620713,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,Homo sapiens
B,,,,,,,9,9606.0,10624,1,Expert,,,3581,,17066,D,CHEMBL620714,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,Homo sapiens
B,,,,,,,9,9606.0,10624,1,Expert,,,3582,,4234,D,CHEMBL620715,BAO_0000357,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,Homo sapiens
B,,,,,,,8,,10624,1,Autocuration,,,3583,,6013,H,CHEMBL620716,BAO_0000357,,Binding affinity towards 5-HT5A receptor,
B,,,,,,,8,,10624,1,Expert,,,3584,,17175,H,CHEMBL620717,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,
B,,,,,,,8,,10624,1,Autocuration,,,3585,,15818,H,CHEMBL618072,BAO_0000357,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,
B,,,,,,,8,,10624,1,Autocuration,,,3586,,6166,H,CHEMBL857987,BAO_0000357,,Binding affinity towards cloned human 5-HT5A receptor was determined,
B,HEK293,722.0,,,,,8,,10624,1,Autocuration,,,3587,,15779,H,CHEMBL618073,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,
B,HEK293,722.0,,,,,8,,10624,1,Autocuration,,,3588,,15779,H,CHEMBL618074,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,
B,HEK293,722.0,,,,,8,,10624,1,Autocuration,,,3589,,5213,H,CHEMBL618075,BAO_0000219,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),
B,,,,,,,9,10090.0,10625,1,Expert,,,3590,,17066,D,CHEMBL618076,BAO_0000357,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,Mus musculus
B,,,,,,,9,10090.0,10625,1,Expert,,,3591,,17066,D,CHEMBL618077,BAO_0000357,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,Mus musculus
B,,,,,,,9,10090.0,10625,1,Expert,,,3592,,17066,D,CHEMBL618078,BAO_0000357,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,Mus musculus
B,,,,,,,9,10090.0,10625,1,Expert,,,3593,,17066,D,CHEMBL881821,BAO_0000357,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,Mus musculus
B,,,,,,,9,10090.0,10625,1,Expert,,,3594,,17066,D,CHEMBL618079,BAO_0000357,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,Mus musculus
B,,,,,,,8,,10625,1,Expert,,,3595,,17175,H,CHEMBL618080,BAO_0000357,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,
B,HEK293,722.0,,,,,8,,10576,1,Autocuration,,,3596,,16190,H,CHEMBL618081,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,
B,HEK293,722.0,,,,,8,,10626,1,Autocuration,,,3597,,16190,H,CHEMBL618082,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,
B,,,,,,,8,,10624,1,Expert,,,3598,,4820,H,CHEMBL618083,BAO_0000357,,Binding affinity towards 5-HT5a receptor,
B,,,,,,,9,9606.0,10624,1,Expert,,,3599,,17066,D,CHEMBL618084,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 5A receptor,Homo sapiens
B,,,,,,,8,,10624,1,Expert,,,3600,,17066,H,CHEMBL618085,BAO_0000357,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,
B,,,,,,,8,,10624,1,Expert,,,3601,,17175,H,CHEMBL618086,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,
B,,,,,,,8,,10624,1,Autocuration,,,3602,,16633,H,CHEMBL875092,BAO_0000357,,Binding affinities against 5-hydroxytryptamine 5A receptor,
B,,,,,,,8,,10624,1,Autocuration,,,3603,,16633,H,CHEMBL618087,BAO_0000357,,Binding affinities towards 5-hydroxytryptamine 5A receptor,
B,,,,,,,8,,10624,1,Autocuration,,,3604,,16700,H,CHEMBL872926,BAO_0000357,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,
F,,,,,,,4,10141.0,104714,1,Autocuration,,,3605,,4639,H,CHEMBL618088,BAO_0000019,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,Cavia porcellus
B,,,,,,,4,,104714,1,Autocuration,,,3606,,5486,H,CHEMBL618089,BAO_0000223,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,
B,,,,,,,9,9606.0,10627,1,Expert,,,3607,,16146,D,CHEMBL618090,BAO_0000357,,Inhibition of human 5-hydroxytryptamine 6 receptor,Homo sapiens
B,,,,,,,9,9606.0,10627,1,Expert,,,3608,,17273,D,CHEMBL618091,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,Homo sapiens
B,,,,,,,8,,10627,1,Autocuration,,,3609,,17687,H,CHEMBL618092,BAO_0000357,,Inhibition against human 5-hydroxytryptamine 6 receptor,
B,,,,,,,9,9606.0,10627,1,Expert,,,3610,,6491,D,CHEMBL618093,BAO_0000357,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,Homo sapiens
B,HeLa,308.0,,,,,8,,10627,1,Expert,,,3611,,16190,H,CHEMBL618094,BAO_0000219,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,
B,,,,,,,9,9606.0,10627,1,Expert,,,3612,,17066,D,CHEMBL618095,BAO_0000357,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,Homo sapiens
B,,,,,,,9,9606.0,10627,1,Expert,,,3613,,17066,D,CHEMBL875093,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Homo sapiens
B,,,,,,,9,9606.0,10627,1,Expert,,,3614,,17066,D,CHEMBL618096,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,Homo sapiens
B,,,,,,,9,9606.0,10627,1,Expert,,,3615,,17066,D,CHEMBL618118,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,Homo sapiens
B,,,,,,,9,9606.0,10627,1,Expert,,,3616,,3555,D,CHEMBL618119,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 6 receptor,Homo sapiens
B,,,,,,,8,,10627,1,Expert,,,3617,,5808,H,CHEMBL618120,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10627,1,Autocuration,,,3618,,6013,H,CHEMBL618121,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
B,HEK293,722.0,,,,,8,,10627,1,Expert,,,3619,,15818,H,CHEMBL618122,BAO_0000219,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",
B,,,,,,,8,,10627,1,Autocuration,,,3620,,16209,H,CHEMBL618123,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,
B,HEK293,722.0,,,,,8,,10627,1,Expert,,,3621,,3935,H,CHEMBL618124,BAO_0000219,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,
B,,,,,,,8,,10627,1,Autocuration,,,3622,,15818,H,CHEMBL618125,BAO_0000357,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,
B,HEK293,722.0,,,,,9,9606.0,10627,1,Expert,,,3623,,3805,D,CHEMBL618126,BAO_0000219,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Homo sapiens
B,,,,,,,8,,10627,1,Expert,,,3624,,16441,H,CHEMBL618236,BAO_0000019,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,
B,,,,,,,8,,10627,1,Expert,,,3625,,16441,H,CHEMBL618237,BAO_0000019,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,
B,COS-7,643.0,,,,,8,,10627,1,Expert,,,3626,,6786,H,CHEMBL618238,BAO_0000219,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,
B,,,,,,,9,9606.0,10627,1,Expert,,,3627,,4234,D,CHEMBL618239,BAO_0000357,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,Homo sapiens
B,,,,,,,8,,10627,1,Autocuration,,,3628,,17085,H,CHEMBL618240,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10627,1,Autocuration,,,3629,,17200,H,CHEMBL618241,BAO_0000357,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,
B,HEK293,722.0,,,,,8,,10627,1,Autocuration,,,3630,,17451,H,CHEMBL859399,BAO_0000219,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,
F,,,,,,,8,,10627,1,Autocuration,,,3631,,3935,H,CHEMBL618242,BAO_0000019,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,
B,,,,,,,8,,10627,1,Autocuration,,,3632,,5033,H,CHEMBL857991,BAO_0000357,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10627,1,Expert,,,3633,,4540,H,CHEMBL619951,BAO_0000357,,Binding affinity against human 5-hydroxytryptamine 6 receptor,
B,HeLa,308.0,,,,,9,9606.0,10627,1,Expert,,,3634,,4540,D,CHEMBL619952,BAO_0000219,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,Homo sapiens
B,HeLa,308.0,,,,,9,9606.0,10627,1,Expert,,,3635,,4540,D,CHEMBL619953,BAO_0000219,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,Homo sapiens
B,HeLa,308.0,,,,,8,,10627,1,Autocuration,,,3636,,17296,H,CHEMBL619954,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,
B,HeLa,308.0,,,,,8,,10627,1,Autocuration,,,3637,,17296,H,CHEMBL619955,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,
B,HeLa,308.0,,,,,8,,10627,1,Autocuration,,,3638,,17296,H,CHEMBL619956,BAO_0000219,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,
B,CHO,449.0,,,,,8,,10627,1,Autocuration,,,3639,,15779,H,CHEMBL619957,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,
B,HEK293,722.0,,,,,8,,10627,1,Autocuration,,,3640,,15779,H,CHEMBL619958,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,
B,HEK293,722.0,,,,,8,,10627,1,Autocuration,,,3641,,15779,H,CHEMBL620627,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,
B,HEK293,722.0,,,,,8,,10627,1,Autocuration,,,3642,,15779,H,CHEMBL620628,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,
B,HeLa,308.0,,,,,8,,10627,1,Autocuration,,,3643,,15779,H,CHEMBL620629,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,
B,,,,,,,8,,10627,1,Autocuration,,,3644,,6166,H,CHEMBL620630,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
B,HeLa,308.0,,,,,8,,10627,1,Autocuration,,,3645,,17451,H,CHEMBL620782,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,
B,,,,,,,8,,10627,1,Autocuration,,,3646,,15316,H,CHEMBL620783,BAO_0000357,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10627,1,Expert,,,3647,,4199,H,CHEMBL620784,BAO_0000357,,Binding affinity against human 5-hydroxytryptamine 6 receptor,
B,HeLa,308.0,,,,,8,,10627,1,Expert,,,3648,,15146,H,CHEMBL620785,BAO_0000219,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,
B,,,,,,,8,,10627,1,Autocuration,,,3649,,5213,H,CHEMBL857992,BAO_0000357,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),
B,,,,,,,8,,10627,1,Autocuration,,,3650,,16429,H,CHEMBL620786,BAO_0000219,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,
B,HeLa,308.0,,,,,8,,10627,1,Autocuration,,,3651,,14818,H,CHEMBL620787,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,
B,HeLa,308.0,,,,,8,,10627,1,Autocuration,,,3652,,4829,H,CHEMBL620788,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",
B,HeLa,308.0,,,,,8,,10627,1,Autocuration,,,3653,,4829,H,CHEMBL620789,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",
B,HeLa,308.0,,,,,8,,10627,1,Autocuration,,,3654,,4829,H,CHEMBL620790,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",
B,CHO,449.0,,,,,8,,10628,1,Autocuration,,,3655,,15250,H,CHEMBL620791,BAO_0000219,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,
B,,,,,,,8,,10628,1,Autocuration,,,3656,,14423,H,CHEMBL620792,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,
B,,,,,,,8,,10628,1,Autocuration,,,3657,,15086,H,CHEMBL620793,BAO_0000357,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10628,1,Autocuration,,,3658,,4342,H,CHEMBL620794,BAO_0000357,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,
B,HeLa,308.0,,,,,9,9606.0,10627,1,Autocuration,,,3659,,16190,D,CHEMBL620795,BAO_0000219,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,Homo sapiens
B,,,,,,,8,,10627,1,Expert,,,3660,,4820,H,CHEMBL620796,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10627,1,Autocuration,,,3661,,4639,H,CHEMBL620797,BAO_0000357,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,
F,,,,,,,9,9606.0,10627,1,Expert,,,3662,,17066,D,CHEMBL620798,BAO_0000019,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Homo sapiens
B,,,,,,,8,,10627,1,Autocuration,,,3663,,6011,H,CHEMBL620799,BAO_0000357,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,
B,,,,,,,8,,10627,1,Expert,,,3664,,17066,H,CHEMBL620800,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10627,1,Autocuration,,,3665,,17515,H,CHEMBL620801,BAO_0000357,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,
B,,,,,,,8,,10627,1,Autocuration,,,3666,,5014,H,CHEMBL875100,BAO_0000357,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10627,1,Autocuration,,,3667,,4373,H,CHEMBL620802,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,
F,,,,,,,8,,10627,1,Expert,,,3668,,17066,H,CHEMBL620803,BAO_0000019,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,
F,,,,,,,8,,10627,1,Expert,,,3669,,17066,H,CHEMBL620804,BAO_0000019,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,
B,,,,,,,8,,10627,1,Autocuration,,,3670,,4373,H,CHEMBL620805,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,
B,,,,,,,8,,10627,1,Autocuration,,,3671,,4687,H,CHEMBL620806,BAO_0000357,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10627,1,Autocuration,,,3672,,16946,H,CHEMBL620807,BAO_0000357,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,
B,,,,,,,8,,10627,1,Autocuration,,,3673,,16946,H,CHEMBL620808,BAO_0000357,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,
B,,,,,,,8,,10627,1,Autocuration,,,3674,,16633,H,CHEMBL620809,BAO_0000357,,Binding affinities against 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10627,1,Autocuration,,,3675,,16633,H,CHEMBL620810,BAO_0000357,,Binding affinities towards 5-hydroxytryptamine 6 receptor,
B,,,,,,,9,9606.0,10627,1,Expert,,,3676,,17066,D,CHEMBL620811,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 6 receptor,Homo sapiens
B,,,,,,,8,,10627,1,Autocuration,,,3677,,16700,H,CHEMBL620812,BAO_0000357,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,
B,,,,,,,8,,10627,1,Autocuration,,,3678,,3269,H,CHEMBL620813,BAO_0000357,,Affinity against 5-hydroxytryptamine 6 receptor,
B,,,,,,,8,,10627,1,Autocuration,,,3679,,5486,H,CHEMBL620814,BAO_0000357,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],
B,,,,,,,9,9606.0,10209,1,Expert,,,3680,,16146,D,CHEMBL620815,BAO_0000357,,Inhibition of human 5-hydroxytryptamine 7 receptor,Homo sapiens
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3681,,5014,H,CHEMBL620816,BAO_0000219,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,
B,,,,,,,8,,10209,1,Autocuration,,,3682,,15463,H,CHEMBL620817,BAO_0000357,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,3683,,3805,H,CHEMBL620818,BAO_0000357,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),
B,HEK293,722.0,,,,,8,,10209,1,Expert,,,3684,,5014,H,CHEMBL620819,BAO_0000219,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,
B,,,,,,,9,9606.0,10209,1,Expert,,,3685,,6491,D,CHEMBL620820,BAO_0000357,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,Homo sapiens
B,CHO,449.0,,,,,8,,10209,1,Autocuration,,,3686,,16190,H,CHEMBL620821,BAO_0000219,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,
B,,,,,,,9,9606.0,10209,1,Expert,,,3687,,17066,D,CHEMBL620822,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Homo sapiens
B,,,,,,,9,9606.0,10209,1,Expert,,,3688,,17066,D,CHEMBL620823,BAO_0000357,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,Homo sapiens
B,,,,,,,9,9606.0,10209,1,Expert,,,3689,,3555,D,CHEMBL620824,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 7 receptor,Homo sapiens
B,CHO,449.0,,,,,8,,10209,1,Expert,,,3690,,6588,H,CHEMBL620825,BAO_0000219,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,
B,,,,,,,8,,10209,1,Autocuration,,,3691,,15463,H,CHEMBL872930,BAO_0000357,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,
B,,,,,,,8,,10209,1,Autocuration,,,3692,,6013,H,CHEMBL620826,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,3693,,16209,H,CHEMBL620827,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,
B,,,,,,,8,,10209,1,Autocuration,,,3694,,3935,H,CHEMBL620828,BAO_0000357,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,3695,,15818,H,CHEMBL620829,BAO_0000357,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,
B,HEK293,722.0,,,,,8,,10209,1,Expert,,,3696,,5014,H,CHEMBL620830,BAO_0000219,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,
B,,,,,,,8,,10209,1,Expert,,,3697,,16441,H,CHEMBL620831,BAO_0000019,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,
B,,,,,,,8,,10209,1,Expert,,,3698,,16441,H,CHEMBL620832,BAO_0000019,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,
B,,,,,,,9,9606.0,10209,1,Expert,,,3699,,4234,D,CHEMBL621548,BAO_0000357,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,Homo sapiens
B,,,,,,,8,,10209,1,Autocuration,,,3700,,17085,H,CHEMBL621549,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,3701,,17200,H,CHEMBL621550,BAO_0000357,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,
B,CHO,449.0,,,,,8,,10209,1,Autocuration,,,3702,,17451,H,CHEMBL621551,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,
B,,,,,,,8,,10209,1,Autocuration,,,3703,,17085,H,CHEMBL621552,BAO_0000019,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,
B,,,,,,,8,,10209,1,Autocuration,,,3704,,5104,H,CHEMBL857077,BAO_0000357,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,3705,,5104,H,CHEMBL618158,BAO_0000357,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,
B,COS-7,643.0,,,,,9,9606.0,10209,1,Expert,,,3706,,5033,D,CHEMBL618159,BAO_0000219,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Homo sapiens
B,COS-7,643.0,,,,,8,,10209,1,Autocuration,,,3707,,5486,H,CHEMBL875101,BAO_0000219,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,
B,HEK293,722.0,,,,,9,9606.0,10209,1,Expert,,,3708,,4540,D,CHEMBL618160,BAO_0000219,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,Homo sapiens
B,,,,,,,8,,10209,1,Expert,,,3709,,6166,H,CHEMBL618161,BAO_0000357,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,
B,HEK293,722.0,,,,,8,,10209,1,Expert,,,3710,,17342,H,CHEMBL618162,BAO_0000219,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,
B,,,,,,,8,,10209,1,Expert,,,3711,,17342,H,CHEMBL618163,BAO_0000357,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,
B,,,,,,,8,,10209,1,Autocuration,,,3712,,17296,H,CHEMBL618164,BAO_0000357,,Binding affinity against 5-hydroxytryptamine 7 human receptors,
B,,,,,,,8,,10209,1,Expert,,,3713,,16429,H,CHEMBL618165,BAO_0000219,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3714,,15779,H,CHEMBL618166,BAO_0000219,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3715,,15779,H,CHEMBL857989,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3716,,15779,H,CHEMBL619888,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3717,,15779,H,CHEMBL619889,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3718,,15779,H,CHEMBL619890,BAO_0000219,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,
B,CHO,449.0,,,,,8,,10209,1,Autocuration,,,3719,,17451,H,CHEMBL619891,BAO_0000219,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3720,,4199,H,CHEMBL619892,BAO_0000219,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),
B,HEK293,722.0,,,,,9,,10209,1,Expert,,,3721,,4199,D,CHEMBL619893,BAO_0000219,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3722,,4199,H,CHEMBL619894,BAO_0000219,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),
B,HEK293,722.0,,,,,9,,10209,1,Intermediate,,,3723,,3680,D,CHEMBL619895,BAO_0000219,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,
B,,,,,,,9,,10209,1,Intermediate,,,3724,,3680,D,CHEMBL619896,BAO_0000357,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,
B,COS-7,643.0,,,,,8,,10209,1,Autocuration,,,3725,,15316,H,CHEMBL619897,BAO_0000219,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3726,,15146,H,CHEMBL619898,BAO_0000219,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,
B,HEK293,722.0,,,,,8,,10209,1,Expert,,,3727,,5213,H,CHEMBL619899,BAO_0000219,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3728,,5213,H,CHEMBL619900,BAO_0000219,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),
B,HEK293,722.0,,,,,9,9606.0,10209,1,Expert,,,3729,,14818,D,CHEMBL619901,BAO_0000219,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,Homo sapiens
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3730,,14818,H,CHEMBL620580,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3731,,14818,H,CHEMBL620581,BAO_0000219,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,
B,HEK293,722.0,,,,,8,,10209,1,Autocuration,,,3732,,4829,H,CHEMBL620733,BAO_0000219,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",
B,,,,,,,9,9606.0,10209,1,Autocuration,,,3733,,17200,D,CHEMBL620734,BAO_0000357,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,Homo sapiens
B,,,,,,,9,10090.0,10022,1,Expert,,,3734,,17066,D,CHEMBL620735,BAO_0000357,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Mus musculus
B,,,,,,,8,9986.0,10209,1,Autocuration,,,3735,,14025,H,CHEMBL620736,BAO_0000019,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,Oryctolagus cuniculus
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3736,,15250,H,CHEMBL620737,BAO_0000219,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3737,,16372,H,CHEMBL620738,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3738,,16372,H,CHEMBL620739,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3739,,16372,H,CHEMBL620740,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3740,,16372,H,CHEMBL620741,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3741,,16372,H,CHEMBL620742,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3742,,16372,H,CHEMBL620743,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3743,,16372,H,CHEMBL620744,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3744,,16372,H,CHEMBL620745,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3745,,16372,H,CHEMBL620746,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3746,,16372,H,CHEMBL620747,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3747,,16372,H,CHEMBL620748,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3748,,16372,H,CHEMBL620749,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,
B,,,,,,,8,,11923,1,Expert,,,3749,,17066,H,CHEMBL620750,BAO_0000357,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,
B,,,,,,,9,10116.0,11923,1,Expert,,,3750,,17066,D,CHEMBL620751,BAO_0000357,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Rattus norvegicus
B,,,,,,,8,,11923,1,Expert,,,3751,,17386,H,CHEMBL620752,BAO_0000357,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,11923,1,Autocuration,,,3752,,14423,H,CHEMBL872929,BAO_0000019,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,
B,,,,,,,9,10116.0,11923,1,Expert,,,3753,,15874,D,CHEMBL620753,BAO_0000357,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,Rattus norvegicus
B,,,,,,,9,10116.0,11923,1,Expert,,,3754,,15874,D,CHEMBL620754,BAO_0000357,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,Rattus norvegicus
B,CHO,449.0,,,,,9,10116.0,11923,1,Expert,,,3755,,16372,D,CHEMBL620755,BAO_0000219,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,Rattus norvegicus
B,,,,,,,8,,11923,1,Autocuration,,,3756,,4622,H,CHEMBL620756,BAO_0000357,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,
B,,,,,,,8,,11923,1,Autocuration,,,3757,,15086,H,CHEMBL620757,BAO_0000357,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3758,,16372,H,CHEMBL620758,BAO_0000219,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3759,,16372,H,CHEMBL620759,BAO_0000219,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3760,,16372,H,CHEMBL620760,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,
B,CHO,449.0,,,,,8,,11923,1,Autocuration,,,3761,,16372,H,CHEMBL620761,BAO_0000219,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,
F,,,,,2116.0,,8,,11923,1,Autocuration,,,3762,,17386,H,CHEMBL620762,BAO_0000221,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,
F,,,,,2116.0,,8,,11923,1,Autocuration,,,3763,,17386,H,CHEMBL620763,BAO_0000221,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,
F,,,,,2116.0,,8,,11923,1,Autocuration,,,3764,,17386,H,CHEMBL620764,BAO_0000221,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,
B,,,,,,,9,10116.0,11923,1,Expert,,,3765,Membranes,5831,D,CHEMBL857990,BAO_0000249,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Rattus norvegicus
B,,,,,,,8,,11923,1,Autocuration,,,3766,,4342,H,CHEMBL620765,BAO_0000357,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,
B,,,,,,,8,,11923,1,Expert,,,3767,,17319,H,CHEMBL620766,BAO_0000357,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,
B,,,,,1898.0,,8,,11923,1,Expert,,,3768,,17342,H,CHEMBL620767,BAO_0000019,Hypothalamus,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,
B,,,,,,,8,,11923,1,Autocuration,,,3769,,17342,H,CHEMBL620768,BAO_0000357,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,
B,,,,,1898.0,,8,,11923,1,Expert,,,3770,,3680,H,CHEMBL619051,BAO_0000249,Hypothalamus,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,
B,,,,,,,8,,11923,1,Expert,,,3771,,3680,H,CHEMBL619052,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 7 receptor,
F,HEK293,722.0,,,,,9,10116.0,11923,1,Expert,,,3772,,17319,D,CHEMBL619053,BAO_0000219,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,Rattus norvegicus
F,HEK293,722.0,,,,,9,10116.0,11923,1,Expert,,,3773,,17319,D,CHEMBL619703,BAO_0000219,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,Rattus norvegicus
F,HEK293,722.0,,,,,9,10116.0,11923,1,Autocuration,,,3774,,17319,D,CHEMBL619704,BAO_0000219,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,Rattus norvegicus
B,,,,,,,8,,10209,1,Expert,,,3775,,4820,H,CHEMBL619851,BAO_0000357,,Binding affinity towards 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,3776,,4639,H,CHEMBL619852,BAO_0000357,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,
B,,,,,,,8,,10209,1,Autocuration,,,3777,,6011,H,CHEMBL619853,BAO_0000357,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,
B,,,,,,,9,9606.0,10209,1,Expert,,,3778,,17066,D,CHEMBL619854,BAO_0000357,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Homo sapiens
B,,,,,,,8,,10209,1,Expert,,,3779,,17066,H,CHEMBL619855,BAO_0000357,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,3780,,17515,H,CHEMBL619856,BAO_0000357,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,
B,,,,,,,8,,10209,1,Autocuration,,,3781,,4373,H,CHEMBL619857,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,
F,,,,,,,8,,10209,1,Expert,,,3782,,17066,H,CHEMBL619858,BAO_0000019,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,
B,,,,,,,8,,10209,1,Autocuration,,,3783,,4373,H,CHEMBL619859,BAO_0000357,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,
B,,,,,,,8,,10209,1,Autocuration,,,3784,,4373,H,CHEMBL619860,BAO_0000357,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,
B,,,,,,,8,,10209,1,Autocuration,,,3785,,4687,H,CHEMBL619861,BAO_0000357,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Expert,,,3786,,17342,H,CHEMBL619862,BAO_0000357,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,3787,,16946,H,CHEMBL619863,BAO_0000357,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,
B,,,,,,,8,,10209,1,Autocuration,,,3788,,16946,H,CHEMBL619864,BAO_0000357,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,
B,,,,,,,8,,10209,1,Autocuration,,,3789,,16633,H,CHEMBL872928,BAO_0000357,,Binding affinities against 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,3790,,16633,H,CHEMBL619865,BAO_0000357,,Binding affinities towards 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Expert,,,3791,,17066,H,CHEMBL619866,BAO_0000357,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,
B,,,,,,,8,,10209,1,Autocuration,,,3792,,16700,H,CHEMBL619867,BAO_0000357,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,
B,,,,,2116.0,,8,,10209,1,Autocuration,,,3793,,17386,H,CHEMBL619868,BAO_0000221,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,
F,,,,,,,8,,55,1,Autocuration,,,3794,,14080,H,CHEMBL619869,BAO_0000019,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,
F,,,,,,,9,9606.0,55,1,Expert,,,3795,,14080,D,CHEMBL619870,BAO_0000019,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,Homo sapiens
B,,,,,,,8,,55,1,Autocuration,,,3796,,409,H,CHEMBL619871,BAO_0000357,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,
B,,,,,,,8,,55,1,Autocuration,,,3797,,409,H,CHEMBL619872,BAO_0000357,,In vitro inhibition of human recombinant lipoxygenase enzyme,
B,,,,,,,8,,55,1,Autocuration,,,3798,,409,H,CHEMBL619873,BAO_0000357,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,
B,,,,,178.0,,8,,55,1,Expert,,,3799,,11090,H,CHEMBL619874,BAO_0000357,Blood,Inhibition of 5-lipoxygenase in human whole blood.,
B,,,,,178.0,,8,,55,1,Expert,,,3800,,11090,H,CHEMBL619875,BAO_0000357,Blood,Inhibition of 5-lipoxygenase in human whole blood.,
B,,,,,,,8,,55,1,Autocuration,,,3801,,948,H,CHEMBL619876,BAO_0000357,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,
B,,,,,,,8,,55,1,Autocuration,,,3802,,948,H,CHEMBL619877,BAO_0000357,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),
F,,,,,,,8,,55,1,Expert,,,3803,,13622,H,CHEMBL619878,BAO_0000219,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,
F,,,,,178.0,,8,,55,1,Autocuration,,,3804,,13622,H,CHEMBL619879,BAO_0000019,Blood,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,
B,,,,,,,8,,55,1,Autocuration,,,3805,,9637,H,CHEMBL619880,BAO_0000357,,In vitro inhibition of 5-lipoxygenase from human polymorphs,
B,,,,,,,8,,55,1,Autocuration,,,3806,,11320,H,CHEMBL619881,BAO_0000357,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),
B,,,,,,,8,,55,1,Expert,,,3807,,11320,H,CHEMBL619882,BAO_0000357,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,
B,,,,,,,8,,55,1,Autocuration,,,3808,,6838,H,CHEMBL619883,BAO_0000357,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,
B,,,,,178.0,,9,9606.0,55,1,Expert,,,3809,,17667,D,CHEMBL619884,BAO_0000357,Blood,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Homo sapiens
B,,,,,,,8,,55,1,Autocuration,,,3810,,12703,H,CHEMBL619885,BAO_0000357,,In vitro potency against human 5-Lipoxygenase,
F,,,,,,,9,9606.0,55,1,Expert,,,3811,,14312,D,CHEMBL619886,BAO_0000019,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,Homo sapiens
F,,,,,178.0,,8,,55,1,Autocuration,,,3812,,14312,H,CHEMBL619887,BAO_0000019,Blood,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,
F,,,,,,,8,,55,1,Autocuration,,,3813,,5364,H,CHEMBL875097,BAO_0000019,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,
B,,,,,,,8,,55,1,Autocuration,,,3814,,951,H,CHEMBL618001,BAO_0000219,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,
B,,,,,,,8,,55,1,Autocuration,,,3815,,951,H,CHEMBL618002,BAO_0000219,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,
B,,,,,,,8,,55,1,Autocuration,,,3816,,951,H,CHEMBL618003,BAO_0000219,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,
B,,,,,,,8,,55,1,Autocuration,,,3817,,951,H,CHEMBL618004,BAO_0000219,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,
B,,,,,,,8,,55,1,Autocuration,,,3818,,12365,H,CHEMBL618005,BAO_0000219,,Inhibition of human 5-lipoxygenase in human cells,
B,,,,,,,8,,55,1,Expert,,,3819,,10603,H,CHEMBL618006,BAO_0000357,,Inhibition of human neutrophil 5-lipoxygenase,
B,,,,,,,8,,55,1,Autocuration,,,3820,,10501,H,CHEMBL875086,BAO_0000019,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,
B,,,,,178.0,,8,,55,1,Expert,,,3821,,12281,H,CHEMBL618007,BAO_0000357,Blood,Inhibition of 5-lipoxygenase from human whole blood,
B,,,,,,,8,,55,1,Autocuration,,,3822,,2567,H,CHEMBL618008,BAO_0000357,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,
B,,,,,,,8,,55,1,Autocuration,,,3823,,2567,H,CHEMBL618009,BAO_0000219,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,
B,,,,,,,8,,55,1,Expert,,,3824,,10193,H,CHEMBL618010,BAO_0000357,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,
B,,,,,,,8,,55,1,Autocuration,,,3825,,10193,H,CHEMBL618011,BAO_0000357,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,
B,,,,,,,8,,55,1,Expert,,,3826,,13623,H,CHEMBL618012,BAO_0000357,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,
B,,,,,,,8,,55,1,Autocuration,,,3827,,12780,H,CHEMBL882927,BAO_0000357,,Tested against 5-lipoxygenase,
B,,,,,,,8,,55,1,Autocuration,,,3828,,12780,H,CHEMBL618013,BAO_0000357,,Tested for activity against 5-Lipoxygenase (5-LO),
B,,,,,,,8,,55,1,Autocuration,,,3829,,12780,H,CHEMBL618014,BAO_0000357,,Tested for activity against 5-lipoxygenase,
B,,,,,,,8,,55,1,Autocuration,,,3830,,11966,H,CHEMBL618015,BAO_0000357,,Tested for inhibition of 5-HPETE production by human 5-LO,
F,,,,,,,8,,55,1,Autocuration,,,3831,,5364,H,CHEMBL618016,BAO_0000019,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,
B,,,,,,,8,,55,1,Expert,,,3832,,13165,H,CHEMBL618017,BAO_0000357,,Inhibition of Human 5-lipoxygenase,
B,,,,,,,8,,55,1,Autocuration,,,3833,,5364,H,CHEMBL618018,BAO_0000019,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,
B,,,,,,,8,,55,1,Autocuration,,,3834,,11311,H,CHEMBL875087,BAO_0000219,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],
B,,,,,,,8,,55,1,Autocuration,,,3835,,11311,H,CHEMBL618019,BAO_0000219,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],
B,,,,,,,8,,55,1,Autocuration,,,3836,,14863,H,CHEMBL618020,BAO_0000019,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,
B,,,,,,,8,,55,1,Autocuration,,,3837,,14863,H,CHEMBL618021,BAO_0000019,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,
B,,,,,178.0,,8,,55,1,Autocuration,,,3838,,11087,H,CHEMBL618022,BAO_0000357,Blood,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),
B,,,,,,,8,,55,1,Autocuration,,,3839,,455,H,CHEMBL618023,BAO_0000357,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,
B,,,,,,,8,,55,1,Autocuration,,,3840,,13183,H,CHEMBL618024,BAO_0000357,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),
B,,,,,,,8,,55,1,Expert,,,3841,,10319,H,CHEMBL873950,BAO_0000019,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,
B,,,,,,,8,,55,1,Autocuration,,,3842,,10193,H,CHEMBL618025,BAO_0000357,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,
B,,,,,,,8,,55,1,Autocuration,,,3843,,951,H,CHEMBL618026,BAO_0000219,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,
B,,,,,,,8,,55,1,Autocuration,,,3844,,951,H,CHEMBL618027,BAO_0000219,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,
B,,,,,,,8,,55,1,Autocuration,,,3845,,951,H,CHEMBL618028,BAO_0000219,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,
B,,,,,,,8,,55,1,Autocuration,,,3846,,951,H,CHEMBL618029,BAO_0000219,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,
B,,,,,,,8,,55,1,Expert,,,3847,,9859,H,CHEMBL618030,BAO_0000357,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,
B,,,,,,,8,,55,1,Expert,,,3848,,9859,H,CHEMBL618031,BAO_0000357,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,
B,,,,,,,8,,55,1,Autocuration,,,3849,,9859,H,CHEMBL618032,BAO_0000357,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,
B,,,,,,,8,,55,1,Autocuration,,,3850,,2567,H,CHEMBL618033,BAO_0000357,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,
B,,,,,,,8,,55,1,Autocuration,,,3851,,10193,H,CHEMBL618034,BAO_0000357,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,
B,,,,,,,8,,55,1,Autocuration,,,3852,,10193,H,CHEMBL875088,BAO_0000357,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,
B,,,,,,,8,,55,1,Autocuration,,,3853,,949,H,CHEMBL618035,BAO_0000019,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,
B,,,,,,,8,,55,1,Autocuration,,,3854,,949,H,CHEMBL618036,BAO_0000019,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,
B,,,,,,,8,,55,1,Expert,,,3855,,10603,H,CHEMBL618037,BAO_0000357,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,
B,,,,,,,8,,55,1,Expert,,,3856,,10603,H,CHEMBL618038,BAO_0000357,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,
F,,,,,,,8,,55,1,Autocuration,,,3857,,10603,H,CHEMBL618761,BAO_0000019,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,
B,,,,,,,8,,55,1,Expert,,,3858,,10603,H,CHEMBL618762,BAO_0000357,,Inhibition of lipoxygenase at the concentration of 0.1 uM,
B,,,,,,,8,,55,1,Expert,,,3859,,10603,H,CHEMBL618763,BAO_0000357,,Inhibition of lipoxygenase at the concentration of 1 uM,
B,,,,,,,8,,55,1,Autocuration,,,3860,,10193,H,CHEMBL618764,BAO_0000357,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,
B,,,,,,,9,9606.0,55,1,Expert,,,3861,,14580,D,CHEMBL618765,BAO_0000357,,Inhibition of 5-Lipoxygenase (5-LOX),Homo sapiens
B,,,,,,,8,,17087,1,Expert,,,3862,,11090,H,CHEMBL618766,BAO_0000357,,Inhibition of 5-lipoxygenase in mouse macrophages.,
B,,,,,,,8,,17087,1,Expert,,,3863,,11090,H,CHEMBL618767,BAO_0000357,,Inhibition of 5-lipoxygenase in mouse macrophages.,
B,,,,,,,8,,17087,1,Autocuration,,,3864,,6339,H,CHEMBL619380,BAO_0000357,,Inhibitory activity against lipoxygenase-2 in mice,
B,,,,,,,8,,17087,1,Expert,,,3865,,6339,H,CHEMBL619381,BAO_0000357,,Inhibitory activity against murine lipoxygenase-2.,
B,,,,,,,9,10090.0,17087,1,Expert,,,3866,,12281,D,CHEMBL619382,BAO_0000357,,Inhibition of 5-lipoxygenase from mouse macrophage,Mus musculus
B,,,,,,,8,,17087,1,Autocuration,,,3867,,11311,H,CHEMBL619383,BAO_0000357,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,
B,,,,,,,8,9823.0,55,1,Autocuration,,,3868,,11089,H,CHEMBL619384,BAO_0000019,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,Sus scrofa
B,,,,,,,8,9823.0,55,1,Autocuration,,,3869,,10091,H,CHEMBL619385,BAO_0000019,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,Sus scrofa
B,,,,,,,8,9986.0,55,1,Autocuration,,,3870,,14352,H,CHEMBL882928,BAO_0000019,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,Oryctolagus cuniculus
B,,,,,,,9,10116.0,12166,1,Expert,,,3871,,13329,D,CHEMBL619386,BAO_0000019,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,Rattus norvegicus
B,,,,,,,8,,12166,1,Autocuration,,,3872,,13329,H,CHEMBL619387,BAO_0000019,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",
B,,,,,,,8,,12166,1,Autocuration,,,3873,,13329,H,CHEMBL619388,BAO_0000019,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",
B,,,,,,,8,,12166,1,Autocuration,,,3874,,13329,H,CHEMBL619389,BAO_0000019,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",
B,,,,,,,8,,12166,1,Expert,,,3875,,13329,H,CHEMBL619390,BAO_0000019,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),
B,,,,,,,8,,12166,1,Expert,,,3876,,13329,H,CHEMBL619391,BAO_0000019,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",
B,,,,,,,8,,12166,1,Autocuration,,,3877,,13329,H,CHEMBL619392,BAO_0000019,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,
B,,,,,,,8,,12166,1,Autocuration,,,3878,,11311,H,CHEMBL619393,BAO_0000019,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),
B,,,,,,,8,,12166,1,Autocuration,,,3879,,11311,H,CHEMBL619394,BAO_0000019,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3880,,105,H,CHEMBL619395,BAO_0000219,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3881,,105,H,CHEMBL619396,BAO_0000219,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",
B,,,,,,,8,,12166,1,Autocuration,,,3882,,9138,H,CHEMBL619397,BAO_0000357,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),
B,,,,,,,8,,12166,1,Autocuration,,,3883,,9138,H,CHEMBL619398,BAO_0000357,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",
B,,,,,,,8,,12166,1,Autocuration,,,3884,,9138,H,CHEMBL619399,BAO_0000357,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",
B,,,,,,,8,,12166,1,Autocuration,,,3885,,14427,H,CHEMBL619400,BAO_0000357,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,
B,,,,,,,8,,12166,1,Autocuration,,,3886,,13329,H,CHEMBL619401,BAO_0000019,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",
B,,,,,,,8,,12166,1,Autocuration,,,3887,,13329,H,CHEMBL619402,BAO_0000019,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",
B,RBL-2H3,663.0,,,,,9,10116.0,12166,1,Expert,,,3888,,14427,D,CHEMBL619403,BAO_0000219,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,Rattus norvegicus
B,,,,,,,8,,12166,1,Autocuration,,,3889,,14427,H,CHEMBL619404,BAO_0000357,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,
B,,,,,,,8,,12166,1,Autocuration,,,3890,,14427,H,CHEMBL619405,BAO_0000357,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3891,,10293,H,CHEMBL619406,BAO_0000219,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,
B,RBL-1,702.0,,,,,9,10116.0,12166,1,Expert,,,3892,,338,D,CHEMBL619407,BAO_0000219,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,Rattus norvegicus
B,,,,,,,8,,12166,1,Autocuration,,,3893,,303,H,CHEMBL619408,BAO_0000357,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3894,,303,H,CHEMBL619409,BAO_0000219,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3895,,9247,H,CHEMBL619410,BAO_0000219,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3896,,9247,H,CHEMBL619753,BAO_0000219,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3897,,137,H,CHEMBL619754,BAO_0000219,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,
B,,,,,,,8,,12166,1,Expert,,,3898,,11481,H,CHEMBL619903,BAO_0000357,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,
B,,,,,,,8,,12166,1,Expert,,,3899,,11481,H,CHEMBL619904,BAO_0000357,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",
B,,,,,,,8,,12166,1,Expert,,,3900,,9029,H,CHEMBL619905,BAO_0000357,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,
B,,,,,,,8,,12166,1,Autocuration,,,3901,,1701,H,CHEMBL619906,BAO_0000019,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,
B,,,,,,,8,,12166,1,Autocuration,,,3902,,1701,H,CHEMBL619907,BAO_0000019,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,
B,,,,,,,8,,12166,1,Autocuration,,,3903,,1701,H,CHEMBL619908,BAO_0000019,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,
B,,,,,,,8,,12166,1,Autocuration,,,3904,,1701,H,CHEMBL619909,BAO_0000019,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,
F,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3905,,13358,H,CHEMBL619910,BAO_0000219,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3906,,1175,H,CHEMBL882929,BAO_0000219,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3907,,8797,H,CHEMBL619911,BAO_0000219,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,
B,,,,,,,8,,12166,1,Autocuration,,,3908,,8797,H,CHEMBL619912,BAO_0000019,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,
B,,,,,,,9,10116.0,12166,1,Expert,,,3909,,577,D,CHEMBL619913,BAO_0000357,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,Rattus norvegicus
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3910,,9295,H,CHEMBL619914,BAO_0000219,,In vitro inhibitory activity against RBL-1 5-LO,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3911,,9295,H,CHEMBL619915,BAO_0000219,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3912,,9295,H,CHEMBL619916,BAO_0000219,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),
B,,,,,,,8,,12166,1,Autocuration,,,3913,,9295,H,CHEMBL619917,BAO_0000218,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,
B,,,,,,,8,,12166,1,Autocuration,,,3914,,9295,H,CHEMBL619918,BAO_0000357,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,
B,,,,,,,8,,12166,1,Autocuration,,,3915,,216,H,CHEMBL619919,BAO_0000218,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3916,,11090,H,CHEMBL883710,BAO_0000219,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,
B,,,,,178.0,,8,,12166,1,Autocuration,,,3917,,11090,H,CHEMBL619920,BAO_0000019,Blood,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,
B,,,,,,,8,,12166,1,Expert,,,3918,,10091,H,CHEMBL619921,BAO_0000357,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,
F,,,,,,,8,,12166,1,Autocuration,,,3919,,10274,H,CHEMBL619922,BAO_0000019,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,
F,,,,,,,8,,12166,1,Autocuration,,,3920,,13622,H,CHEMBL619923,BAO_0000219,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3921,,12118,H,CHEMBL619924,BAO_0000219,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,
B,,,,,,,8,,12166,1,Expert,,,3922,,12576,H,CHEMBL619925,BAO_0000357,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3923,,9546,H,CHEMBL619926,BAO_0000219,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3924,,9521,H,CHEMBL619927,BAO_0000219,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3925,,10626,H,CHEMBL619928,BAO_0000219,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3926,,9225,H,CHEMBL619929,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3927,,9225,H,CHEMBL875089,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3928,,9225,H,CHEMBL619930,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3929,,9225,H,CHEMBL619931,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3930,,9225,H,CHEMBL619932,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3931,,9225,H,CHEMBL619933,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3932,,9225,H,CHEMBL619934,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3933,,9225,H,CHEMBL619935,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3934,,9225,H,CHEMBL619936,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3935,,9225,H,CHEMBL619937,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3936,,9225,H,CHEMBL619938,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3937,,9225,H,CHEMBL619939,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3938,,9225,H,CHEMBL619940,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3939,,9225,H,CHEMBL875090,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3940,,9225,H,CHEMBL619941,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3941,,9225,H,CHEMBL619942,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3942,,9225,H,CHEMBL883711,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3943,,9225,H,CHEMBL619943,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3944,,9225,H,CHEMBL619944,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3945,,9225,H,CHEMBL619945,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3946,,9225,H,CHEMBL619946,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3947,,9225,H,CHEMBL619947,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3948,,9225,H,CHEMBL619948,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3949,,9225,H,CHEMBL619949,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,
B,,,,,,,8,,12166,1,Expert,,,3950,,9401,H,CHEMBL619950,BAO_0000019,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,
B,,,,,,,8,,12166,1,Autocuration,,,3951,,10325,H,CHEMBL618050,BAO_0000019,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,
F,RBL-2H3,663.0,,,,,8,,12166,1,Expert,,,3952,,1556,H,CHEMBL875091,BAO_0000219,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,
F,RBL-2H3,663.0,,,,,8,,12166,1,Expert,,,3953,,1556,H,CHEMBL618051,BAO_0000219,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,
B,RBL-1,702.0,,,,,9,10116.0,12166,1,Expert,,,3954,,961,D,CHEMBL618052,BAO_0000219,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,Rattus norvegicus
B,,,,,,,8,,12166,1,Autocuration,,,3955,,6838,H,CHEMBL618053,BAO_0000019,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,
B,,,,,,,8,,12166,1,Expert,,,3956,,10325,H,CHEMBL618054,BAO_0000019,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),
B,RBL-1,702.0,,,,,9,10116.0,12166,1,Expert,,,3957,,9209,D,CHEMBL618055,BAO_0000219,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Rattus norvegicus
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3958,,11520,H,CHEMBL618056,BAO_0000219,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,
B,,,,,,,8,,12166,1,Autocuration,,,3959,,137,H,CHEMBL618057,BAO_0000357,,In vitro inhibitory activity against 5-lipoxygenase was determined,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3960,,4717,H,CHEMBL618058,BAO_0000219,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3961,,10636,H,CHEMBL618059,BAO_0000219,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,
F,,,,,,,9,10116.0,12166,1,Expert,,,3962,,14312,D,CHEMBL618060,BAO_0000019,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,Rattus norvegicus
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3963,,1203,H,CHEMBL618061,BAO_0000219,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,
B,,,,,,,8,,12166,1,Autocuration,,,3964,,1203,H,CHEMBL618062,BAO_0000019,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3965,,13622,H,CHEMBL618063,BAO_0000219,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,
B,,,,,,,8,,12166,1,Autocuration,,,3966,,9793,H,CHEMBL618064,BAO_0000357,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,
B,RBL-1,702.0,,,,,9,10116.0,12166,1,Expert,,,3967,,1143,D,CHEMBL618065,BAO_0000219,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,Rattus norvegicus
B,RBL-1,702.0,,,,,9,10116.0,12166,1,Expert,,,3968,,11854,D,CHEMBL618066,BAO_0000219,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,Rattus norvegicus
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3969,,3595,H,CHEMBL618067,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,3970,,3595,H,CHEMBL618068,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),
B,RBL-1,702.0,,,,,9,10116.0,12166,1,Expert,,,3971,,10501,D,CHEMBL618069,BAO_0000219,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,Rattus norvegicus
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,3972,,12526,H,CHEMBL618070,BAO_0000219,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,
F,,,,,349.0,,8,,10825,1,Autocuration,,,3973,,10034,H,CHEMBL618071,BAO_0000019,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,
F,,,,,349.0,,8,,10825,1,Autocuration,,,3974,,10034,H,CHEMBL619247,BAO_0000019,Limbic system,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,
F,,,,,,,8,,10825,1,Autocuration,,,3975,,10034,H,CHEMBL619248,BAO_0000019,,Approximate dose levels for a half maximal reduction of 5-HTP levels,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,3976,,10046,H,CHEMBL619249,BAO_0000221,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,
B,,,,,10000000.0,,8,,10576,1,Autocuration,,,3977,,10046,H,CHEMBL619250,BAO_0000221,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,
B,,,,,,,8,,10577,1,Autocuration,,,3978,,10046,H,CHEMBL619251,BAO_0000019,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,
F,,,,,178.0,,8,9615.0,55,1,Autocuration,,,3979,,12079,H,CHEMBL619252,BAO_0000019,Blood,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Canis lupus familiaris
F,,,,,178.0,,8,,55,1,Autocuration,,,3980,,12079,H,CHEMBL619253,BAO_0000019,Blood,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,
B,,,,,,,8,,12166,1,Autocuration,,,3981,,11311,H,CHEMBL619254,BAO_0000219,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],
B,,,,,,,8,,17140,1,Expert,,,3982,,12338,H,CHEMBL619255,BAO_0000219,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,
B,,,,,,,8,,17140,1,Expert,,,3983,,12143,H,CHEMBL619256,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,
B,,,,,,,8,,17140,1,Autocuration,,,3984,,12143,H,CHEMBL875418,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),
B,,,,,,,8,,17140,1,Expert,,,3985,,12143,H,CHEMBL619257,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,
B,,,,,,,8,,17140,1,Autocuration,,,3986,,12143,H,CHEMBL619258,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,
B,,,,,,,8,,17140,1,Expert,,,3987,,12365,H,CHEMBL619259,BAO_0000357,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,
B,,,,,,,8,,17140,1,Expert,,,3988,,13500,H,CHEMBL619260,BAO_0000357,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3989,,12832,H,CHEMBL619261,BAO_0000218,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3990,,12832,H,CHEMBL619263,BAO_0000218,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3991,,12832,H,CHEMBL619264,BAO_0000218,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3992,,12832,H,CHEMBL619265,BAO_0000218,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3993,,12832,H,CHEMBL619266,BAO_0000218,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3994,,12832,H,CHEMBL619902,BAO_0000218,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3995,,12832,H,CHEMBL620058,BAO_0000218,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3996,,12832,H,CHEMBL620059,BAO_0000218,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3997,,12832,H,CHEMBL620060,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3998,,12832,H,CHEMBL620061,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,3999,,12832,H,CHEMBL620062,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4000,,12832,H,CHEMBL620063,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4001,,12832,H,CHEMBL620064,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4002,,12832,H,CHEMBL620065,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4003,,12832,H,CHEMBL620066,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4004,,12832,H,CHEMBL620067,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4005,,12832,H,CHEMBL620068,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4006,,12832,H,CHEMBL620069,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4007,,12832,H,CHEMBL620070,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4008,,12832,H,CHEMBL620071,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4009,,12832,H,CHEMBL620072,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4010,,12832,H,CHEMBL620036,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4011,,12832,H,CHEMBL857702,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4012,,12832,H,CHEMBL620037,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4013,,12832,H,CHEMBL620038,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4014,,12832,H,CHEMBL620039,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4015,,12832,H,CHEMBL620040,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4016,,12832,H,CHEMBL620041,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4017,,12832,H,CHEMBL620042,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4018,,12832,H,CHEMBL620043,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4019,,12832,H,CHEMBL620044,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4020,,12832,H,CHEMBL620045,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4021,,12832,H,CHEMBL620046,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4022,,12832,H,CHEMBL620047,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4023,,12832,H,CHEMBL620048,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4024,,12832,H,CHEMBL857703,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4025,,12832,H,CHEMBL620049,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4026,,12832,H,CHEMBL620050,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4027,,12832,H,CHEMBL620051,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4028,,12832,H,CHEMBL619213,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4029,,12832,H,CHEMBL619214,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4030,,12832,H,CHEMBL619804,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4031,,12832,H,CHEMBL619805,BAO_0000218,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4032,,12832,H,CHEMBL619806,BAO_0000218,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4033,,12832,H,CHEMBL619807,BAO_0000218,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
F,,,In vivo,,178.0,,8,9615.0,55,1,Autocuration,,,4034,,12832,H,CHEMBL619808,BAO_0000218,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris
B,,,,,,,8,9615.0,55,1,Autocuration,,,4035,,3595,H,CHEMBL619809,BAO_0000218,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,Canis lupus familiaris
B,,,,,,,8,9615.0,55,1,Autocuration,,,4036,,3595,H,CHEMBL619810,BAO_0000218,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,Canis lupus familiaris
B,,,,,,,8,9615.0,55,1,Autocuration,,,4037,,3595,H,CHEMBL619811,BAO_0000218,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,Canis lupus familiaris
B,,,,,,,8,9615.0,55,1,Autocuration,,,4038,,3595,H,CHEMBL620769,BAO_0000218,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,Canis lupus familiaris
B,,,,,,,8,9615.0,55,1,Autocuration,,,4039,,3595,H,CHEMBL620770,BAO_0000218,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,Canis lupus familiaris
B,,,,,,,8,9615.0,55,1,Autocuration,,,4040,,3595,H,CHEMBL620771,BAO_0000218,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,Canis lupus familiaris
B,,,,,,,8,9615.0,55,1,Autocuration,,,4041,,3595,H,CHEMBL620772,BAO_0000218,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,Canis lupus familiaris
B,,,,,,,8,9615.0,55,1,Autocuration,,,4042,,3595,H,CHEMBL620773,BAO_0000218,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,Canis lupus familiaris
B,,,,,,,8,10141.0,55,1,Autocuration,,,4043,,9203,H,CHEMBL620774,BAO_0000357,,Ability to inhibit 5-lipoxygenase in guinea pig,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Expert,,,4044,,82,H,CHEMBL620775,BAO_0000357,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4045,,11090,H,CHEMBL620776,BAO_0000357,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,Cavia porcellus
B,,,,,178.0,,8,10141.0,55,1,Autocuration,,,4046,,12832,H,CHEMBL620777,BAO_0000218,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4047,,1065,H,CHEMBL620778,BAO_0000357,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4048,,1065,H,CHEMBL620779,BAO_0000357,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Expert,,,4049,,12832,H,CHEMBL621500,BAO_0000019,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Expert,,,4050,,12832,H,CHEMBL621501,BAO_0000019,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4051,,12832,H,CHEMBL618098,BAO_0000019,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4052,,10504,H,CHEMBL618099,BAO_0000019,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4053,,7788,H,CHEMBL618100,BAO_0000357,,Inhibitory activity against 5-lipoxygenase,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4054,,10001,H,CHEMBL618101,BAO_0000357,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4055,,10193,H,CHEMBL618102,BAO_0000357,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4056,,13243,H,CHEMBL618103,BAO_0000357,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4057,,13243,H,CHEMBL618104,BAO_0000357,,Inhibitory activity uM,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4058,,969,H,CHEMBL883712,BAO_0000219,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4059,,10001,H,CHEMBL618105,BAO_0000357,,Inhibitory activity against 5-lipoxygenase at 10 uM,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4060,,7788,H,CHEMBL618106,BAO_0000357,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4061,,10001,H,CHEMBL618107,BAO_0000357,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4062,,10193,H,CHEMBL618108,BAO_0000357,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4063,,13243,H,CHEMBL618109,BAO_0000357,,Inhibitory activity uM,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4064,,13243,H,CHEMBL618110,BAO_0000357,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Expert,,,4065,,13243,H,CHEMBL618111,BAO_0000357,,Inhibitory activity uM,Cavia porcellus
F,,,,,,,8,10141.0,55,1,Autocuration,,,4066,,13243,H,CHEMBL618112,BAO_0000019,,Inhibitory activity uM,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4067,,10504,H,CHEMBL618113,BAO_0000019,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Cavia porcellus
B,,,,,,,8,10141.0,55,1,Autocuration,,,4068,,7788,H,CHEMBL618114,BAO_0000357,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Cavia porcellus
F,,,,,2116.0,,8,10141.0,55,1,Expert,,,4069,,10546,H,CHEMBL620871,BAO_0000221,Ileum,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Cavia porcellus
B,,,,,,,8,,55,1,Autocuration,,,4070,,13183,H,CHEMBL620872,BAO_0000357,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),
B,,,,,,,8,,55,1,Autocuration,,,4071,,13183,H,CHEMBL620873,BAO_0000357,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),
B,,,,,,,8,,55,1,Autocuration,,,4072,,2578,H,CHEMBL620874,BAO_0000357,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),
B,,,,,,,8,,55,1,Expert,,,4073,,12780,H,CHEMBL620875,BAO_0000357,,In vitro inhibition of human 5-Lipoxygenase.,
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4074,Microsomes,7411,U,CHEMBL620876,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4075,Microsomes,7411,U,CHEMBL620877,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4076,Microsomes,7411,U,CHEMBL857854,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4077,Microsomes,7411,U,CHEMBL620878,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4078,Microsomes,7411,U,CHEMBL620879,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4079,Microsomes,7411,U,CHEMBL620880,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4080,Microsomes,7411,U,CHEMBL620881,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4081,Microsomes,7411,U,CHEMBL620882,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4082,Microsomes,7411,U,CHEMBL620883,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4083,Microsomes,7411,U,CHEMBL620884,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4084,Microsomes,7411,U,CHEMBL620885,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4085,Microsomes,7411,U,CHEMBL620886,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4086,Microsomes,7411,U,CHEMBL620887,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4087,Microsomes,7411,U,CHEMBL618039,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4088,Microsomes,7411,U,CHEMBL618040,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4089,Microsomes,7411,U,CHEMBL618041,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4090,Microsomes,7411,U,CHEMBL618216,BAO_0000251,Liver,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4091,Microsomes,7411,U,CHEMBL618217,BAO_0000251,Liver,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4092,Microsomes,7411,U,CHEMBL618218,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4093,Microsomes,7411,U,CHEMBL618219,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4094,Microsomes,7411,U,CHEMBL618220,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4095,Microsomes,7411,U,CHEMBL618221,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4096,Microsomes,7411,U,CHEMBL618222,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4097,Microsomes,7411,U,CHEMBL618223,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4098,Microsomes,7411,U,CHEMBL618224,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4099,Microsomes,7411,U,CHEMBL618225,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4100,Microsomes,7411,U,CHEMBL618226,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4101,Microsomes,7411,U,CHEMBL618227,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4102,Microsomes,7411,U,CHEMBL618228,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4103,Microsomes,7411,U,CHEMBL618229,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4104,Microsomes,7411,U,CHEMBL618230,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4105,Microsomes,7411,U,CHEMBL618231,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4106,Microsomes,7411,U,CHEMBL618232,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4107,Microsomes,7411,U,CHEMBL618233,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4108,Microsomes,7411,U,CHEMBL618234,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4109,Microsomes,7411,U,CHEMBL618235,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4110,Microsomes,7411,U,CHEMBL618115,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4111,Microsomes,7411,U,CHEMBL618116,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4112,Microsomes,7411,U,CHEMBL618117,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4113,Microsomes,7411,U,CHEMBL619968,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4114,Microsomes,7411,U,CHEMBL619969,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4115,Microsomes,7411,U,CHEMBL619970,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4116,Microsomes,7411,U,CHEMBL619971,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4117,Microsomes,7411,U,CHEMBL619972,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4118,Microsomes,7411,U,CHEMBL619973,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4119,Microsomes,7411,U,CHEMBL619974,BAO_0000251,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4120,Microsomes,7411,U,CHEMBL619975,BAO_0000251,Liver,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Rattus norvegicus
B,,,,,,,0,10116.0,22226,1,Autocuration,,,4121,Microsomes,7411,U,CHEMBL619976,BAO_0000251,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4122,Microsomes,7411,U,CHEMBL619977,BAO_0000251,Liver,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4123,Microsomes,7411,U,CHEMBL619978,BAO_0000251,Liver,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4124,Microsomes,7411,U,CHEMBL619979,BAO_0000251,Liver,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4125,Microsomes,7411,U,CHEMBL619980,BAO_0000251,Liver,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4126,Microsomes,7411,U,CHEMBL619981,BAO_0000251,Liver,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Rattus norvegicus
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,4127,,10797,N,CHEMBL619982,BAO_0000219,,In vitro inhibition of 7226/S myeloma cancer cell line,Homo sapiens
F,BEL-7404 tumor cell line,993.0,,,,,1,9606.0,80698,1,Intermediate,,,4128,,6881,N,CHEMBL619983,BAO_0000219,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4129,,3838,N,CHEMBL620031,BAO_0000219,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4130,,3838,N,CHEMBL620032,BAO_0000219,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Homo sapiens
F,V79,505.0,,,,,1,10029.0,81264,1,Expert,,,4131,,12981,N,CHEMBL620033,BAO_0000219,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,Cricetulus griseus
F,V79,505.0,,,,,1,10029.0,81264,1,Expert,,,4132,,12981,N,CHEMBL620034,BAO_0000219,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,Cricetulus griseus
F,7800C1 cell line,1119.0,,,,,1,10116.0,80635,1,Intermediate,,,4133,,7653,N,CHEMBL620035,BAO_0000219,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,Rattus norvegicus
F,7800C1 cell line,1119.0,,,,,1,10116.0,80635,1,Intermediate,,,4134,,7653,N,CHEMBL618318,BAO_0000219,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,Rattus norvegicus
F,7800C1 cell line,1119.0,,,,,1,10116.0,80635,1,Intermediate,,,4135,,7653,N,CHEMBL618319,BAO_0000219,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,Rattus norvegicus
F,7800C1 cell line,1119.0,,,,,1,10116.0,80635,1,Intermediate,,,4136,,7653,N,CHEMBL618320,BAO_0000219,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,Rattus norvegicus
F,7800C1 cell line,1119.0,,,,,1,10116.0,80635,1,Intermediate,,,4137,,7653,N,CHEMBL618321,BAO_0000219,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,Rattus norvegicus
F,7800C1 cell line,1119.0,,,,,1,10116.0,80635,1,Intermediate,,,4138,,7653,N,CHEMBL883118,BAO_0000219,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,Rattus norvegicus
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4139,,17229,N,CHEMBL883795,BAO_0000219,,In vitro antitumor activity against renal 786-0 tumor cell lines,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4140,,12858,N,CHEMBL618322,BAO_0000219,,Cytotoxic activity against 786-0 Renal cancer cell line,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4141,,16325,N,CHEMBL618323,BAO_0000219,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4142,,16325,N,CHEMBL618324,BAO_0000219,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4143,,5858,N,CHEMBL618325,BAO_0000219,,In vitro antitumor activity against human renal 786-0 cell line,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4144,,16325,N,CHEMBL875416,BAO_0000219,,Inhibition of Renal cancer in 786-0 cancer cell lines,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4145,,14696,N,CHEMBL618326,BAO_0000219,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4146,,3786,N,CHEMBL618327,BAO_0000219,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4147,,14696,N,CHEMBL619215,BAO_0000219,,inhibition of the growth of renal cancer(786-0) cell line,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4148,,14769,N,CHEMBL619216,BAO_0000219,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4149,,15354,N,CHEMBL619217,BAO_0000219,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4150,,14255,N,CHEMBL619218,BAO_0000219,,The IC50 value was measured on 786-0 cell line in ovarian tumor,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4151,,14255,N,CHEMBL619219,BAO_0000219,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4152,,14255,N,CHEMBL619220,BAO_0000219,,The IC50 value was measured on 786-0 cell line in renal tumor type.,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4153,,14696,N,CHEMBL619221,BAO_0000219,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4154,,12016,N,CHEMBL619222,BAO_0000219,,Tested for cytotoxic activity against renal cancer 786-0 cell line,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,4155,,2597,N,CHEMBL857454,BAO_0000219,,Compound was tested for growth inhibitory activity against 786-0 cell line,Homo sapiens
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4156,,12526,H,CHEMBL619223,BAO_0000219,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4157,,12526,H,CHEMBL619224,BAO_0000219,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,
B,,,,,,,8,,12166,1,Autocuration,,,4158,,14799,H,CHEMBL619225,BAO_0000019,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,4159,,3595,H,CHEMBL619226,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,4160,,3595,H,CHEMBL619227,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),
B,,,,,,,8,,12166,1,Autocuration,,,4161,,12767,H,CHEMBL619228,BAO_0000357,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,
B,,,,,,,8,,12166,1,Autocuration,,,4162,,10997,H,CHEMBL619229,BAO_0000219,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4163,,11388,H,CHEMBL619230,BAO_0000219,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,
B,,,,,,,8,,12166,1,Autocuration,,,4164,,167,H,CHEMBL619231,BAO_0000357,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,
B,,,,,,,8,,12166,1,Autocuration,,,4165,,167,H,CHEMBL619232,BAO_0000357,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",
B,,,,,,,8,,12166,1,Expert,,,4166,,13744,H,CHEMBL619233,BAO_0000357,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,
B,,,,,,,8,,12166,1,Autocuration,,,4167,,1630,H,CHEMBL619234,BAO_0000357,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,
B,,,,,,,8,,12166,1,Autocuration,,,4168,,1630,H,CHEMBL619235,BAO_0000357,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),
B,,,,,,,9,10116.0,12166,1,Expert,,,4169,,969,D,CHEMBL619236,BAO_0000019,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",Rattus norvegicus
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4170,,13621,H,CHEMBL619237,BAO_0000219,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,
B,,,,,,,8,,12166,1,Autocuration,,,4171,,10089,H,CHEMBL619238,BAO_0000357,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,
B,,,,,,,8,,12166,1,Expert,,,4172,,10193,H,CHEMBL619239,BAO_0000357,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,
B,,,,,,,8,,12166,1,Autocuration,,,4173,,11966,H,CHEMBL619240,BAO_0000357,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,
B,,,,,,,8,,12166,1,Autocuration,,,4174,,12251,H,CHEMBL875417,BAO_0000019,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4175,,211,H,CHEMBL619241,BAO_0000219,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),
F,,,,,,,8,,12166,1,Expert,,,4176,,12251,H,CHEMBL619242,BAO_0000019,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4177,,12495,H,CHEMBL883796,BAO_0000219,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,
B,,,,,,,8,,12166,1,Autocuration,,,4178,,414,H,CHEMBL619243,BAO_0000357,,Tested for its inhibitory activity against 5-lipoxygenase,
B,,,,,,,8,,12166,1,Autocuration,,,4179,,414,H,CHEMBL619244,BAO_0000357,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,
B,,,,,,,8,,12166,1,Expert,,,4180,,10325,H,CHEMBL619245,BAO_0000019,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",
B,,,,,,,8,,12166,1,Expert,,,4181,,11966,H,CHEMBL619246,BAO_0000019,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,4182,,165,H,CHEMBL619984,BAO_0000219,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4183,,165,H,CHEMBL619985,BAO_0000219,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4184,,165,H,CHEMBL619986,BAO_0000219,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,4185,,165,H,CHEMBL619987,BAO_0000219,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,
B,,,,,,,8,,12166,1,Autocuration,,,4186,,11311,H,CHEMBL619988,BAO_0000218,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4187,,11311,H,CHEMBL619989,BAO_0000219,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4188,,11311,H,CHEMBL619990,BAO_0000219,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,
B,,,,,,,8,,12166,1,Autocuration,,,4189,,11311,H,CHEMBL619991,BAO_0000219,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],
B,,,,,,,8,,12166,1,Autocuration,,,4190,,11311,H,CHEMBL619992,BAO_0000219,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),
B,,,In vivo,,,,8,,12166,1,Autocuration,,,4191,,11311,H,CHEMBL619993,BAO_0000218,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),
F,RBL-2H3,663.0,,,,,8,,12166,1,Autocuration,,,4192,,11311,H,CHEMBL619994,BAO_0000219,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,
F,RBL-2H3,663.0,,,,,8,,12166,1,Autocuration,,,4193,,11311,H,CHEMBL619995,BAO_0000219,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,
B,,,,,,,8,,12166,1,Autocuration,,,4194,,11311,H,CHEMBL619996,BAO_0000019,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],
B,,,,,,,8,,12166,1,Autocuration,,,4195,,11732,H,CHEMBL619997,BAO_0000019,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,
B,,,,,,,8,,12166,1,Expert,,,4196,,11732,H,CHEMBL619998,BAO_0000019,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,
B,,,,,,,8,,12166,1,Expert,,,4197,,11087,H,CHEMBL619999,BAO_0000019,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,
B,,,,,,,8,,12166,1,Autocuration,,,4198,,11087,H,CHEMBL620000,BAO_0000019,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4199,,11087,H,CHEMBL620001,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,
B,,,,,,,9,10116.0,12166,1,Expert,,,4200,,11087,D,CHEMBL620002,BAO_0000357,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,Rattus norvegicus
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4201,,496,H,CHEMBL620003,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,
F,RBL-1,702.0,,,,,8,,12166,1,Expert,,,4202,,13986,H,CHEMBL620004,BAO_0000219,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,
B,,,,,,,8,,12166,1,Autocuration,,,4203,,11520,H,CHEMBL874063,BAO_0000357,,Compound was evaluated for the inhibition of 5-lipoxygenase,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4204,,10293,H,CHEMBL620005,BAO_0000219,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4205,,303,H,CHEMBL620006,BAO_0000219,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4206,,303,H,CHEMBL620007,BAO_0000219,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4207,,9247,H,CHEMBL620008,BAO_0000219,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,
B,RBL-1,702.0,,,,,9,10116.0,12166,1,Expert,,,4208,,9247,D,CHEMBL620009,BAO_0000219,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,Rattus norvegicus
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4209,,9247,H,CHEMBL620010,BAO_0000219,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4210,,9247,H,CHEMBL620011,BAO_0000219,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4211,,9247,H,CHEMBL620677,BAO_0000219,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4212,,9247,H,CHEMBL620678,BAO_0000219,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4213,,9247,H,CHEMBL620679,BAO_0000219,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4214,,9247,H,CHEMBL620680,BAO_0000219,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,
B,,,,,,,9,10116.0,12166,1,Expert,,,4215,,11481,D,CHEMBL620838,BAO_0000357,,Inhibitory activity against 5-lipoxygenase at 10 uM,Rattus norvegicus
B,,,,,,,8,,12166,1,Autocuration,,,4216,,105,H,CHEMBL620839,BAO_0000357,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,
B,,,,,,,8,,12166,1,Expert,,,4217,,9029,H,CHEMBL620840,BAO_0000357,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,4218,,1175,H,CHEMBL620841,BAO_0000219,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4219,,12118,H,CHEMBL620842,BAO_0000219,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4220,,12118,H,CHEMBL620843,BAO_0000219,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4221,,12118,H,CHEMBL620844,BAO_0000219,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4222,,9225,H,CHEMBL620845,BAO_0000219,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4223,,9401,H,CHEMBL620846,BAO_0000019,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,
B,,,,,,,8,,12166,1,Autocuration,,,4224,,137,H,CHEMBL873951,BAO_0000357,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4225,,137,H,CHEMBL620847,BAO_0000357,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4226,,4717,H,CHEMBL620848,BAO_0000219,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4227,,3595,H,CHEMBL620849,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4228,,10501,H,CHEMBL620850,BAO_0000219,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4229,,10501,H,CHEMBL620851,BAO_0000219,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4230,,10501,H,CHEMBL620852,BAO_0000219,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4231,,12526,H,CHEMBL875098,BAO_0000219,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,
B,RBL-1,702.0,,,,,9,10116.0,12166,1,Expert,,,4232,,14799,D,CHEMBL620853,BAO_0000219,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,Rattus norvegicus
B,,,,,,,8,,12166,1,Autocuration,,,4233,,14799,H,CHEMBL620854,BAO_0000019,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4234,,3595,H,CHEMBL620855,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Expert,,,4235,,3595,H,CHEMBL839884,BAO_0000219,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4236,,12526,H,CHEMBL620856,BAO_0000219,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4237,,12526,H,CHEMBL620857,BAO_0000219,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,
B,,,,,,,8,,12166,1,Autocuration,,,4238,,10193,H,CHEMBL620858,BAO_0000019,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4239,,10193,H,CHEMBL620859,BAO_0000019,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4240,,10193,H,CHEMBL620860,BAO_0000019,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4241,,10193,H,CHEMBL620861,BAO_0000019,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,
B,,,,,,,8,,12166,1,Expert,,,4242,,9138,H,CHEMBL620862,BAO_0000357,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),
B,,,,,,,8,,12166,1,Autocuration,,,4243,,9138,H,CHEMBL620863,BAO_0000357,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4244,,11966,H,CHEMBL620864,BAO_0000019,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4245,,165,H,CHEMBL620865,BAO_0000219,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4246,,165,H,CHEMBL620866,BAO_0000219,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,
B,RBL-2H3,663.0,,,,,8,,12166,1,Autocuration,,,4247,,11311,H,CHEMBL620867,BAO_0000219,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,
B,RBL-2H3,663.0,,,,,8,,12166,1,Autocuration,,,4248,,11311,H,CHEMBL620868,BAO_0000219,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,
F,RBL-2H3,663.0,,,,,8,,12166,1,Autocuration,,,4249,,11311,H,CHEMBL620869,BAO_0000219,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,
F,,,,,,,8,,12166,1,Autocuration,,,4250,,11311,H,CHEMBL873952,BAO_0000019,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,
B,,,,,,,8,,12166,1,Autocuration,,,4251,,11311,H,CHEMBL875099,BAO_0000357,,The compound was tested for inhibition of isolated 5-lipoxygenase,
F,RBL-2H3,663.0,,,,,8,,12166,1,Autocuration,,,4252,,11311,H,CHEMBL620870,BAO_0000219,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,
B,,,,,,,8,,12166,1,Autocuration,,,4253,,11087,H,CHEMBL618261,BAO_0000019,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4254,,11087,H,CHEMBL618262,BAO_0000019,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4255,,11087,H,CHEMBL619428,BAO_0000019,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4256,,11087,H,CHEMBL619429,BAO_0000019,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,
B,,,,,,,8,,12166,1,Autocuration,,,4257,,11087,H,CHEMBL619430,BAO_0000019,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4258,,496,H,CHEMBL620017,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4259,,496,H,CHEMBL620018,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,
F,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4260,,13986,H,CHEMBL620019,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,
F,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4261,,13986,H,CHEMBL620020,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,
F,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4262,,13986,H,CHEMBL620021,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,
F,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4263,,13986,H,CHEMBL620022,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,
F,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4264,,13986,H,CHEMBL620023,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,
F,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4265,,13986,H,CHEMBL620024,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,
F,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4266,,13986,H,CHEMBL620025,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,
F,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4267,,13986,H,CHEMBL620026,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,
F,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4268,,13986,H,CHEMBL620027,BAO_0000219,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,
F,,,,,,,9,10116.0,12166,1,Expert,,,4269,,13986,D,CHEMBL620028,BAO_0000019,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,Rattus norvegicus
B,,,,,,,8,,12166,1,Autocuration,,,4270,,10193,H,CHEMBL620029,BAO_0000357,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,
B,,,,,,,8,,12166,1,Autocuration,,,4271,,9295,H,CHEMBL620030,BAO_0000357,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4272,,4717,H,CHEMBL875415,BAO_0000219,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4273,,4717,H,CHEMBL618256,BAO_0000219,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4274,,11854,H,CHEMBL618257,BAO_0000219,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4275,,11854,H,CHEMBL618258,BAO_0000219,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4276,,11854,H,CHEMBL618259,BAO_0000219,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4277,,10193,H,CHEMBL618260,BAO_0000019,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4278,,9295,H,CHEMBL618215,BAO_0000219,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4279,,9295,H,CHEMBL618390,BAO_0000219,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4280,,9295,H,CHEMBL618391,BAO_0000219,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4281,,9295,H,CHEMBL618392,BAO_0000219,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4282,,165,H,CHEMBL618393,BAO_0000219,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,
B,,,,,,,8,,12166,1,Autocuration,,,4283,,11311,H,CHEMBL618394,BAO_0000219,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,
B,RBL-1,702.0,,,,,8,9606.0,12166,1,Expert,,,4284,,10489,H,CHEMBL618395,BAO_0000219,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Homo sapiens
B,RBL-1,702.0,,,,,9,10116.0,12166,1,Expert,,,4285,,10489,D,CHEMBL618396,BAO_0000219,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Rattus norvegicus
B,RBL-1,702.0,,,,,9,10116.0,12166,1,Expert,,,4286,,10489,D,CHEMBL858253,BAO_0000219,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),Rattus norvegicus
B,,,,,,,9,10116.0,12166,1,Autocuration,,,4287,,14799,D,CHEMBL618397,BAO_0000019,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Rattus norvegicus
B,,,,,,,8,3847.0,12054,1,Autocuration,,,4288,,9295,H,CHEMBL618398,BAO_0000357,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),Glycine max
B,,,,,,,0,,22226,1,Autocuration,,,4289,,16811,U,CHEMBL618399,BAO_0000019,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",
B,,,,,,,8,,55,1,Expert,,,4290,,168,H,CHEMBL618400,BAO_0000357,,In vitro inhibition of 5-Lipoxygenase; Inactive.,
B,,,,,,,8,,55,1,Autocuration,,,4291,,6309,H,CHEMBL618401,BAO_0000357,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,
B,,,,,,,8,,55,1,Autocuration,,,4292,,6309,H,CHEMBL618402,BAO_0000357,,Inhibitory concentration against 5-lipoxygenase; No inhibition,
B,RBL-1,702.0,,,,,8,,55,1,Autocuration,,,4293,,3092,H,CHEMBL876400,BAO_0000219,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,
B,,,,,,,8,,55,1,Expert,,,4294,,168,H,CHEMBL618403,BAO_0000357,,Inhibitory activity against 5-lipoxygenase.,
B,,,,,,,8,,55,1,Autocuration,,,4295,,168,H,CHEMBL618404,BAO_0000357,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,
B,,,,,,,8,,55,1,Autocuration,,,4296,,168,H,CHEMBL618405,BAO_0000357,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,
B,,,,,,,8,,55,1,Autocuration,,,4297,,168,H,CHEMBL618406,BAO_0000357,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,
F,,,,,,,8,,55,1,Expert,,,4298,,12338,H,CHEMBL618407,BAO_0000019,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,
B,,,,,,,8,,55,1,Autocuration,,,4299,,4501,H,CHEMBL618408,BAO_0000357,,Tested for the inhibitory activity against 5-lipoxygenase,
B,,,,,,,8,,55,1,Autocuration,,,4300,,1132,H,CHEMBL618409,BAO_0000357,,Compound was tested for its inhibitory activity against 5-lipoxygenase,
B,,,,,,,8,,55,1,Autocuration,,,4301,,2117,H,CHEMBL618410,BAO_0000357,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,
B,,,,,,,8,,55,1,Autocuration,,,4302,,168,H,CHEMBL618411,BAO_0000357,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,
B,,,,,,,8,,55,1,Autocuration,,,4303,,168,H,CHEMBL618412,BAO_0000357,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,
B,RBL-1,702.0,,,,,8,,12166,1,Autocuration,,,4304,,13575,H,CHEMBL618413,BAO_0000219,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,
B,,,,,,,8,,12166,1,Autocuration,,,4305,,11089,H,CHEMBL618414,BAO_0000357,,,
B,,,,,,,8,,10102,1,Autocuration,,,4306,,216,H,CHEMBL618415,BAO_0000357,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),
B,,,,,,,8,,10102,1,Autocuration,,,4307,,13165,H,CHEMBL618416,BAO_0000019,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,
B,,,,,,,8,,10102,1,Autocuration,,,4308,,3278,H,CHEMBL876401,BAO_0000357,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,
B,,,,,,,8,,10102,1,Expert,,,4309,,3278,H,CHEMBL618417,BAO_0000357,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,
B,,,,,,,8,,10102,1,Autocuration,,,4310,,11966,H,CHEMBL618418,BAO_0000357,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,
B,,,,,,,8,,10102,1,Autocuration,,,4311,,175,H,CHEMBL618419,BAO_0000357,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",
B,,,,,,,8,,10102,1,Autocuration,,,4312,,175,H,CHEMBL618420,BAO_0000357,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",
B,,,,,,,8,,10102,1,Autocuration,,,4313,,13449,H,CHEMBL618421,BAO_0000357,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,
B,,,,,,,8,,11238,1,Autocuration,,,4314,,12014,H,CHEMBL618422,BAO_0000019,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,
B,,,,,,,8,,11238,1,Autocuration,,,4315,,12014,H,CHEMBL618423,BAO_0000019,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),
B,,,,,,,8,,11238,1,Autocuration,,,4316,,12014,H,CHEMBL618424,BAO_0000019,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),
B,,,,,,,2,,100284,1,Intermediate,,,4317,,99,S,CHEMBL618425,BAO_0000220,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,
F,,,,,,,0,9606.0,22226,1,Autocuration,,,4318,,4349,U,CHEMBL618426,BAO_0000019,,The dark toxicity against 543 human galactophore carcinoma cells,Homo sapiens
F,Panel (56 tumour cell lines),390.0,,,,,1,9606.0,80623,1,Expert,,,4319,,4071,N,CHEMBL618427,BAO_0000219,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,Homo sapiens
F,5637,345.0,,,,,1,9606.0,80008,1,Expert,,,4320,,17589,N,CHEMBL618428,BAO_0000219,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,Homo sapiens
F,5637,345.0,,,,,1,9606.0,80008,1,Intermediate,,,4321,,15002,N,CHEMBL618429,BAO_0000219,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,Homo sapiens
F,5637,345.0,,,,,1,9606.0,80008,1,Intermediate,,,4322,,13958,N,CHEMBL618430,BAO_0000219,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",Homo sapiens
F,5637,345.0,,,,,1,9606.0,80008,1,Expert,,,4323,,17589,N,CHEMBL618431,BAO_0000219,,Growth inhibition against human 5637 cell lines,Homo sapiens
F,5637,345.0,,,,,1,9606.0,80008,1,Expert,,,4324,,16748,N,CHEMBL883799,BAO_0000219,,Antitumor activity against human bladder carcinoma 5637 cells.,Homo sapiens
F,5637,345.0,,,,,1,9606.0,80008,1,Intermediate,,,4325,,16747,N,CHEMBL618432,BAO_0000219,,Antitumor activity against human bladder carcinoma 5637 cells,Homo sapiens
F,5637,345.0,,,,,1,9606.0,80008,1,Intermediate,,,4326,,16747,N,CHEMBL618433,BAO_0000219,,Antitumor activity against human bladder carcinoma 5637 cells,Homo sapiens
B,,,,,,,9,9913.0,10443,1,Expert,,,4327,,15285,D,CHEMBL618434,BAO_0000357,,In vitro inhibition of bovine trypsin(Trp).,Bos taurus
B,CV-1,407.0,,,,,8,9527.0,240,1,Expert,,,4328,,3726,H,CHEMBL618435,BAO_0000219,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,Cercopithecidae
B,,,,,,,8,,10577,1,Autocuration,,,4329,,5033,H,CHEMBL876402,BAO_0000357,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,
F,,,,,,,6,,104698,1,Autocuration,,,4330,,11756,H,CHEMBL618436,BAO_0000019,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,
F,,,In vivo,,,,0,,22226,1,Autocuration,,,4331,,11953,U,CHEMBL618437,BAO_0000218,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,
B,,,,,,,9,10141.0,20033,1,Intermediate,,,4332,,5033,D,CHEMBL618438,BAO_0000357,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,Cavia porcellus
A,,,,,,,8,10116.0,17045,1,Expert,,,4333,Microsomes,11347,H,CHEMBL883800,BAO_0000251,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Rattus norvegicus
A,,,,,,,8,10116.0,17045,1,Expert,,,4334,Microsomes,11347,H,CHEMBL618439,BAO_0000251,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Rattus norvegicus
F,,,,,,,0,,22226,1,Intermediate,,,4335,,1229,U,CHEMBL618440,BAO_0000019,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,
F,,,,,,,0,,22226,1,Intermediate,,,4336,,1229,U,CHEMBL618441,BAO_0000019,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,
B,,,,,,,8,5691.0,11938,1,Expert,,,4337,,17588,H,CHEMBL618442,BAO_0000019,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,Trypanosoma brucei
B,,,,,,,8,5691.0,11938,1,Autocuration,,,4338,,17588,H,CHEMBL618443,BAO_0000019,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,Trypanosoma brucei
B,,,,,,,8,9940.0,11938,1,Expert,,,4339,,17588,H,CHEMBL619158,BAO_0000019,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,Ovis aries
B,,,,,,,8,9940.0,11938,1,Autocuration,,,4340,,17588,H,CHEMBL620974,BAO_0000019,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,Ovis aries
B,,,,,,,8,,11938,1,Autocuration,,,4341,,16485,H,CHEMBL620975,BAO_0000357,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,
F,,,,,,,0,9606.0,22226,1,Intermediate,,,4342,,4337,U,CHEMBL620976,BAO_0000019,,Average inhibitory concentration against 60 human cell lines was reported,Homo sapiens
F,,,,,,,0,9606.0,22226,1,Expert,,,4343,,4112,U,CHEMBL620977,BAO_0000019,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,Homo sapiens
F,Panel NCI-60 (60 carcinoma cell lines),542.0,,,,,1,9606.0,80315,1,Intermediate,,,4344,,16160,N,CHEMBL620978,BAO_0000219,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,Homo sapiens
F,Panel NCI-60 (60 carcinoma cell lines),542.0,,,,,1,9606.0,80315,1,Intermediate,,,4345,,16160,N,CHEMBL620979,BAO_0000219,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,Homo sapiens
F,Panel NCI-60 (60 carcinoma cell lines),542.0,,,,,1,,80315,1,Expert,,,4346,,17376,N,CHEMBL620980,BAO_0000219,,In vitro mean growth inhibitory activity against 60-cell panel,
F,Panel NCI-60 (60 carcinoma cell lines),542.0,,,,,1,,80315,1,Expert,,,4347,,17376,N,CHEMBL620981,BAO_0000219,,In vitro mean growth lethal concentration against 60-cell panel,
F,Panel NCI-60 (60 carcinoma cell lines),542.0,,,,,1,,80315,1,Expert,,,4348,,17376,N,CHEMBL620982,BAO_0000219,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,
F,Panel NCI-60 (60 carcinoma cell lines),542.0,,,,,1,,80315,1,Expert,,,4349,,17376,N,CHEMBL620983,BAO_0000219,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,
F,,,,,,,4,,104775,1,Autocuration,,,4350,,3241,H,CHEMBL620984,BAO_0000019,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,
F,,,,,,,4,,104775,1,Autocuration,,,4351,,3241,H,CHEMBL620985,BAO_0000019,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,
B,,,,,,,8,,275,1,Expert,,,4352,,3725,H,CHEMBL620986,BAO_0000357,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,
F,,,,,,,1,5833.0,50425,1,Expert,,,4353,,10805,N,CHEMBL620987,BAO_0000218,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,Plasmodium falciparum
F,,,,,,,1,5833.0,50425,1,Expert,,,4354,,10805,N,CHEMBL620988,BAO_0000218,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,Plasmodium falciparum
F,,,,,,,1,5833.0,50425,1,Expert,,,4355,,10805,N,CHEMBL620989,BAO_0000218,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,Plasmodium falciparum
F,,,,,,,1,5833.0,50425,1,Expert,,,4356,,10805,N,CHEMBL620990,BAO_0000218,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,Plasmodium falciparum
F,,,,,,,1,5833.0,50425,1,Intermediate,,,4357,,10805,N,CHEMBL620991,BAO_0000218,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,Plasmodium falciparum
F,6C3HED,850.0,,,,,1,10090.0,80628,1,Intermediate,,,4358,,10144,N,CHEMBL620992,BAO_0000218,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Mus musculus
F,6C3HED,850.0,,,,,1,10090.0,80628,1,Intermediate,,,4359,,10144,N,CHEMBL620993,BAO_0000218,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Mus musculus
F,6C3HED,850.0,,,,,1,10090.0,80628,1,Intermediate,,,4360,,10144,N,CHEMBL620994,BAO_0000218,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,Mus musculus
F,6C3HED,850.0,,,,,1,10090.0,80628,1,Intermediate,,,4361,,10144,N,CHEMBL620995,BAO_0000218,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Mus musculus
F,6C3HED,850.0,,,,,1,10090.0,80628,1,Intermediate,,,4362,,10144,N,CHEMBL620996,BAO_0000218,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Mus musculus
F,6C3HED,850.0,,,,,1,10090.0,80628,1,Intermediate,,,4363,,10144,N,CHEMBL875581,BAO_0000218,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4364,,10685,U,CHEMBL620997,BAO_0000218,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4365,,10685,U,CHEMBL620998,BAO_0000218,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4366,,10685,U,CHEMBL620999,BAO_0000218,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4367,,10685,U,CHEMBL621000,BAO_0000218,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4368,,10685,U,CHEMBL621001,BAO_0000218,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4369,,10685,U,CHEMBL621002,BAO_0000218,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4370,,10685,U,CHEMBL621003,BAO_0000218,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4371,,10685,U,CHEMBL621004,BAO_0000218,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4372,,10685,U,CHEMBL621005,BAO_0000218,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4373,,10685,U,CHEMBL621006,BAO_0000218,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),Mus musculus
F,,,In vivo,,,,0,10090.0,22224,1,Autocuration,,,4374,,10685,U,CHEMBL621007,BAO_0000218,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,4375,,10144,U,CHEMBL621008,BAO_0000218,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,4376,,10144,U,CHEMBL621009,BAO_0000218,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,4377,,10144,U,CHEMBL857705,BAO_0000218,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,4378,,10144,U,CHEMBL619828,BAO_0000218,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,4379,,10685,U,CHEMBL619829,BAO_0000218,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,4380,,10685,U,CHEMBL619830,BAO_0000218,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,4381,,10685,U,CHEMBL619831,BAO_0000218,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,4382,,10685,U,CHEMBL619832,BAO_0000218,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,Mus musculus
A,,,,,,,0,10090.0,22224,1,Autocuration,,,4383,,10685,U,CHEMBL619833,BAO_0000218,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,Mus musculus
A,,,,,,,0,10090.0,22224,1,Autocuration,,,4384,,10685,U,CHEMBL619834,BAO_0000218,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,Mus musculus
A,,,,,,,0,10090.0,22224,1,Autocuration,,,4385,,10685,U,CHEMBL619835,BAO_0000218,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,Mus musculus
A,,,,,,,0,10090.0,22224,1,Autocuration,,,4386,,10685,U,CHEMBL619836,BAO_0000218,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,Mus musculus
F,6C3HED,850.0,,,,,1,10090.0,80628,1,Intermediate,,,4387,,8831,N,CHEMBL619837,BAO_0000218,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",Mus musculus
F,,,In vivo,,,,0,,22224,1,Autocuration,,,4388,,11704,U,CHEMBL619838,BAO_0000218,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4389,,11704,N,CHEMBL619839,BAO_0000218,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,Mus musculus
F,6C3HED,850.0,In vivo,,,,1,10090.0,80628,1,Intermediate,,,4390,,10685,N,CHEMBL619840,BAO_0000218,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,Mus musculus
F,6C3HED,850.0,In vivo,,,,1,10090.0,80628,1,Intermediate,,,4391,,10685,N,CHEMBL619841,BAO_0000218,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,Mus musculus
F,6C3HED,850.0,,,,,1,10090.0,80628,1,Expert,,,4392,,11368,N,CHEMBL857704,BAO_0000218,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),Mus musculus
F,6C3HED,850.0,,,,,1,10090.0,80628,1,Intermediate,,,4393,,11368,N,CHEMBL619842,BAO_0000218,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),Mus musculus
F,6C3HED,850.0,,,,,1,10090.0,80628,1,Expert,,,4394,,11368,N,CHEMBL619843,BAO_0000218,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),Mus musculus
B,,,,,,,0,1280.0,22226,1,Autocuration,,,4395,,17763,U,CHEMBL619844,BAO_0000019,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",Staphylococcus aureus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4396,Microsomes,7411,U,CHEMBL857855,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4397,Microsomes,7411,U,CHEMBL619845,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4398,Microsomes,7411,U,CHEMBL619846,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4399,Microsomes,7411,U,CHEMBL619847,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4400,Microsomes,7411,U,CHEMBL619848,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4401,Microsomes,7411,U,CHEMBL620893,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4402,Microsomes,7411,U,CHEMBL620894,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4403,Microsomes,7411,U,CHEMBL620895,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4404,Microsomes,7411,U,CHEMBL620896,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4405,Microsomes,7411,U,CHEMBL620897,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4406,Microsomes,7411,U,CHEMBL620898,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Rattus norvegicus
B,,,,,2107.0,,0,10116.0,22226,1,Autocuration,,,4407,Microsomes,7411,U,CHEMBL620899,BAO_0000251,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Rattus norvegicus
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,4408,,347,U,CHEMBL620900,BAO_0000218,Plasma,The apparent total plasma clearance in monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4409,,3341,U,CHEMBL620901,BAO_0000218,,Compound was evaluated for Hepatic clearance in monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4410,,17853,U,CHEMBL620902,BAO_0000218,,Lower clearance in monkey (i.v.) at 0.5 mpk,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4411,,4514,U,CHEMBL620903,BAO_0000218,,Plasma clearance in rhesus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4412,,6062,U,CHEMBL620904,BAO_0000218,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4413,,6821,U,CHEMBL620905,BAO_0000218,,Plasma clearance of compound was determined in monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4414,,6057,U,CHEMBL620906,BAO_0000218,,Plasma clearance was calculated in rhesus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4415,,5145,U,CHEMBL875420,BAO_0000218,,Plasma clearance in rhesus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4416,,6641,U,CHEMBL620907,BAO_0000218,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4417,,5472,U,CHEMBL620908,BAO_0000218,,Plasma clearance was evaluated in rhesus,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4418,,4257,U,CHEMBL620909,BAO_0000218,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4419,,5546,U,CHEMBL620910,BAO_0000218,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4420,,5334,U,CHEMBL620911,BAO_0000218,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4421,,5334,U,CHEMBL620912,BAO_0000218,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4422,,17509,U,CHEMBL620913,BAO_0000218,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4423,,6535,U,CHEMBL620914,BAO_0000218,,Cmax in monkey after administration of 1 mg/kg iv,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4424,,5668,U,CHEMBL620915,BAO_0000218,,Cmax was determine after peroral administration at 10 mpk in Rhesus,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4425,,5922,U,CHEMBL620916,BAO_0000218,,Cmax in cynomolgus monkey by iv administration,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4426,,5922,U,CHEMBL620917,BAO_0000218,,Cmax in cynomolgus monkey by po administration,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4427,,6078,U,CHEMBL620918,BAO_0000218,,Cmax value evaluated in monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4428,,2661,U,CHEMBL620919,BAO_0000218,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,4429,,3249,U,CHEMBL620920,BAO_0000218,Plasma,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Cercopithecidae
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,4430,,3249,U,CHEMBL620921,BAO_0000218,Plasma,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Cercopithecidae
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,4431,,5553,U,CHEMBL620922,BAO_0000218,Plasma,Maximal plasma concentration in squirrel monkeys,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4432,,1916,U,CHEMBL620923,BAO_0000218,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,4433,,6227,U,CHEMBL620924,BAO_0000218,Plasma,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4434,,4809,U,CHEMBL620925,BAO_0000218,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4435,,5355,U,CHEMBL620926,BAO_0000218,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4436,,5355,U,CHEMBL620927,BAO_0000218,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4437,,5355,U,CHEMBL620928,BAO_0000218,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4438,,5355,U,CHEMBL620929,BAO_0000218,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,Cercopithecidae
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,4439,,6221,U,CHEMBL620930,BAO_0000218,Plasma,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4440,,167,U,CHEMBL620931,BAO_0000218,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4441,,167,U,CHEMBL620932,BAO_0000218,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,Cercopithecidae
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4442,,4257,U,CHEMBL620933,BAO_0000218,,Absolute bioavailability was evaluated in monkey,monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4443,,6221,U,CHEMBL620934,BAO_0000218,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4444,,17667,U,CHEMBL620935,BAO_0000218,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,monkey
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4445,,17267,U,CHEMBL620936,BAO_0000218,,Bioavailability of compound was determined in rhesus monkey,Macaca mulatta
A,,,In vivo,,,,0,38020.0,22224,1,Autocuration,,,4446,,4256,U,CHEMBL620937,BAO_0000218,,Bioavailability determined after oral administration in marmoset,marmosets
A,,,In vivo,,,,0,9541.0,22224,1,Autocuration,,,4447,,4256,U,CHEMBL620938,BAO_0000218,,Oral bioavailability in cynomolgus monkey,Macaca fascicularis
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4448,,17853,U,CHEMBL620939,BAO_0000218,,Bioavailability in monkey (p.o.) at 2.0 mpk,monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4449,,16365,U,CHEMBL620940,BAO_0000218,,Bioavailability was evaluated after oral administration in monkey,monkey
A,,,In vivo,,,,0,9541.0,22224,1,Autocuration,,,4450,,1916,U,CHEMBL620941,BAO_0000218,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Macaca fascicularis
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4451,,5334,U,CHEMBL620942,BAO_0000218,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Macaca mulatta
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4452,,5334,U,CHEMBL620943,BAO_0000218,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Macaca mulatta
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4453,,17592,U,CHEMBL620944,BAO_0000218,,Bioavailability of the compound was determined in monkey,monkey
A,,,In vivo,,,,0,9521.0,22224,1,Autocuration,,,4454,,1399,U,CHEMBL620945,BAO_0000218,,Bioavailability in squirrel monkey (dose 5 mg/kg),Saimiri sciureus
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4455,,4809,U,CHEMBL620946,BAO_0000218,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4456,,3341,U,CHEMBL620947,BAO_0000218,,Oral bioavailability in monkey,monkey
A,,,In vivo,,,,0,9521.0,22224,1,Autocuration,,,4457,,64,U,CHEMBL620948,BAO_0000218,,Compound was tested for bioavailability in squirrel monkey,Saimiri sciureus
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4458,,5005,U,CHEMBL620949,BAO_0000218,,Oral bioavailability in Rhesus monkey,Macaca mulatta
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4459,,5005,U,CHEMBL620950,BAO_0000218,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),Macaca mulatta
A,,,In vivo,,,,0,9541.0,22224,1,Autocuration,,,4460,,5237,U,CHEMBL620951,BAO_0000218,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,Macaca fascicularis
A,,,In vivo,,,,0,9541.0,22224,1,Autocuration,,,4461,,5237,U,CHEMBL620952,BAO_0000218,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,Macaca fascicularis
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4462,,5302,U,CHEMBL875421,BAO_0000218,,Oral bioavailability in monkey (dose 5 mg/kg),monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4463,,17667,U,CHEMBL620953,BAO_0000218,,Oral bioavailability of compound at 5 mg/kg in monkey,monkey
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,4464,,6161,N,CHEMBL873491,BAO_0000218,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,4465,,6161,N,CHEMBL620954,BAO_0000218,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,4466,,3854,N,CHEMBL620955,BAO_0000218,Plasma,Plasma half life determined,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,4467,,993,N,CHEMBL618097,BAO_0000218,Plasma,Plasma half life in dog,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,4468,,4514,N,CHEMBL618268,BAO_0000218,Plasma,Plasma half-life in Beagle dogs,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,4469,,5334,N,CHEMBL618269,BAO_0000218,Plasma,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,4470,,5334,N,CHEMBL618270,BAO_0000218,Plasma,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,4471,,1466,N,CHEMBL618271,BAO_0000218,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,4472,,1466,N,CHEMBL873493,BAO_0000218,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,4473,,5313,N,CHEMBL621031,BAO_0000218,,Tested for the half life period in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,4474,,5313,N,CHEMBL621032,BAO_0000218,,Tested for the half life period in dog at dosage of 10 mpk,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,4475,,3880,N,CHEMBL621033,BAO_0000218,,The compound was tested for half life in dog,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,4476,,3639,N,CHEMBL621034,BAO_0000218,Plasma,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,4477,,3880,N,CHEMBL621035,BAO_0000218,,The half life was determined,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,4478,,3918,N,CHEMBL621036,BAO_0000218,Plasma,The plasma half-life in dogs,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,4479,,16452,N,CHEMBL621037,BAO_0000218,Plasma,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,4480,,17796,N,CHEMBL619812,BAO_0000218,,Half life in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,4481,,5983,N,CHEMBL619813,BAO_0000218,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,4482,,1466,N,CHEMBL873335,BAO_0000218,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,4483,,16456,N,CHEMBL619814,BAO_0000218,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9669.0,50506,1,Expert,,,4484,,6113,N,CHEMBL619815,BAO_0000218,,Cmax in ferrets after 30 mg/kg oral dose,Mustela putorius furo
F,,,In vivo,,,,1,9669.0,50506,1,Expert,,,4485,,6113,N,CHEMBL619816,BAO_0000218,,Emesis in ferrets at 30 mg/kg oral dose,Mustela putorius furo
A,,,In vivo,,,,0,9541.0,22224,1,Autocuration,,,4486,,17796,U,CHEMBL619817,BAO_0000218,,Bioavailability in cynomolgus monkey,Macaca fascicularis
A,,,In vivo,,,,1,9541.0,100710,1,Intermediate,,,4487,,17796,N,CHEMBL619818,BAO_0000218,,Volume of distribution in cynomolgus,Macaca fascicularis
A,,,,,1969.0,,0,10141.0,22224,1,Autocuration,,,4488,,5308,U,CHEMBL619819,BAO_0000218,Plasma,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Cavia porcellus
A,,,,,,,0,10141.0,22224,1,Autocuration,,,4489,,4877,U,CHEMBL619820,BAO_0000218,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Cavia porcellus
A,,,,,,,0,10141.0,22224,1,Autocuration,,,4490,,4876,U,CHEMBL875419,BAO_0000218,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",Cavia porcellus
A,,,In vivo,,1969.0,,0,10141.0,22224,1,Autocuration,,,4491,,4878,U,CHEMBL619821,BAO_0000218,Plasma,AUC in guinea pig after 3mg/kg oral dose,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4492,,5308,U,CHEMBL619822,BAO_0000218,,Bioavailability in guinea pig was tested,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4493,,4877,U,CHEMBL619823,BAO_0000218,,Tested for oral bioavailability in guinea pig at 5 mg/kg,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4494,,4876,U,CHEMBL619824,BAO_0000218,,Tested for the oral bioavailability of the compound,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4495,,4876,U,CHEMBL619825,BAO_0000218,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4496,,5308,U,CHEMBL619826,BAO_0000218,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,Cavia porcellus
A,,,In vivo,,2048.0,,0,10141.0,22224,1,Autocuration,,,4497,,4877,U,CHEMBL619827,BAO_0000218,Lung,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4498,,4878,U,CHEMBL618167,BAO_0000218,,Cmax in guinea pig after 3mg/kg oral dose,Cavia porcellus
A,,,,,178.0,,0,10141.0,22224,1,Autocuration,,,4499,,5689,U,CHEMBL618168,BAO_0000019,Blood,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus
A,,,,,955.0,,0,10141.0,22224,1,Autocuration,,,4500,,5689,U,CHEMBL618169,BAO_0000019,Brain,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus
A,,,,,,,0,10141.0,22224,1,Autocuration,,,4501,,5689,U,CHEMBL618170,BAO_0000019,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus
A,,,,,160.0,,0,10141.0,22224,1,Autocuration,,,4502,,5689,U,CHEMBL618171,BAO_0000019,Intestine,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus
A,,,,,2113.0,,0,10141.0,22224,1,Autocuration,,,4503,,5689,U,CHEMBL618172,BAO_0000019,Kidney,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus
A,,,,,2107.0,,0,10141.0,22224,1,Autocuration,,,4504,,5689,U,CHEMBL618173,BAO_0000019,Liver,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus
A,,,,,,,0,10141.0,22224,1,Autocuration,,,4505,,5689,U,CHEMBL618174,BAO_0000019,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus
A,,,,,2106.0,,0,10141.0,22224,1,Autocuration,,,4506,,5689,U,CHEMBL875408,BAO_0000019,Spleen,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4507,,14465,U,CHEMBL839827,BAO_0000218,,Elimination T1/2 in Guinea pig (PO dose),Cavia porcellus
A,,,,,,,0,10141.0,22224,1,Autocuration,,,4508,,5689,U,CHEMBL618175,BAO_0000019,,Partition coefficient was measured as -log (counts per min ),Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4509,,611,U,CHEMBL618176,BAO_0000218,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4510,,611,U,CHEMBL618177,BAO_0000218,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4511,,14465,U,CHEMBL618178,BAO_0000218,,Elimination T1/2 in Guinea pig (PO dose),Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4512,,4876,U,CHEMBL618179,BAO_0000218,,"Tested for the half life period of the compound, intravenously",Cavia porcellus
A,,,,,,,0,10141.0,22224,1,Autocuration,,,4513,,5689,U,CHEMBL873489,BAO_0000019,,Half-life was measured,Cavia porcellus
A,,,,,,,0,10141.0,22224,1,Autocuration,,,4514,,7515,U,CHEMBL618180,BAO_0000019,,The time required for onset of inotropy after addition of a single dose of delta F75,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4515,,17667,U,CHEMBL618181,BAO_0000218,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,Cavia porcellus
A,,,In vivo,,,,0,10141.0,22224,1,Autocuration,,,4516,,17667,U,CHEMBL618182,BAO_0000218,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,Cavia porcellus
A,,,In vivo,,,,0,10029.0,22224,1,Autocuration,,,4517,,4727,U,CHEMBL618183,BAO_0000218,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Cricetulus griseus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4518,,10107,N,CHEMBL618184,BAO_0000218,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4519,,10107,N,CHEMBL618185,BAO_0000218,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4520,,10107,N,CHEMBL618186,BAO_0000218,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4521,,10107,N,CHEMBL618187,BAO_0000218,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4522,,10107,N,CHEMBL618188,BAO_0000218,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4523,,10107,N,CHEMBL875409,BAO_0000218,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4524,,10107,N,CHEMBL618189,BAO_0000218,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,4525,,3655,N,CHEMBL618190,BAO_0000218,Blood,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,4526,,3655,N,CHEMBL618191,BAO_0000218,Blood,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,4527,,3655,N,CHEMBL618192,BAO_0000218,Blood,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,4528,,3655,N,CHEMBL618193,BAO_0000218,Bone,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,4529,,3655,N,CHEMBL618194,BAO_0000218,Bone,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,4530,,3655,N,CHEMBL618195,BAO_0000218,Bone,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,4531,,3655,N,CHEMBL618196,BAO_0000218,Brain,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,4532,,3655,N,CHEMBL618197,BAO_0000218,Brain,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,4533,,3655,N,CHEMBL618198,BAO_0000218,Brain,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,4534,,3655,N,CHEMBL618199,BAO_0000218,Heart,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,4535,,3655,N,CHEMBL618200,BAO_0000218,Heart,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,4536,,3655,N,CHEMBL618201,BAO_0000218,Heart,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,160.0,,1,10090.0,50594,1,Intermediate,,,4537,,3655,N,CHEMBL618202,BAO_0000218,Intestine,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,160.0,,1,10090.0,50594,1,Intermediate,,,4538,,3655,N,CHEMBL618203,BAO_0000218,Intestine,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,160.0,,1,10090.0,50594,1,Intermediate,,,4539,,3655,N,CHEMBL618204,BAO_0000218,Intestine,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,4540,,3655,N,CHEMBL618205,BAO_0000218,Kidney,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,4541,,3655,N,CHEMBL618206,BAO_0000218,Kidney,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,4542,,3655,N,CHEMBL618207,BAO_0000218,Kidney,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,4543,,3655,N,CHEMBL618208,BAO_0000218,Liver,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,4544,,3655,N,CHEMBL618932,BAO_0000218,Liver,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,4545,,3655,N,CHEMBL618933,BAO_0000218,Liver,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,4546,,3655,N,CHEMBL618934,BAO_0000218,Lung,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,4547,,3655,N,CHEMBL618935,BAO_0000218,Lung,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,4548,,3655,N,CHEMBL618936,BAO_0000218,Lung,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,4549,,3655,N,CHEMBL618937,BAO_0000218,Muscle tissue,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,4550,,3655,N,CHEMBL618938,BAO_0000218,Muscle tissue,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,4551,,3655,N,CHEMBL619104,BAO_0000218,Muscle tissue,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,4552,,3655,N,CHEMBL619105,BAO_0000218,Spleen,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,4553,,3655,N,CHEMBL619106,BAO_0000218,Spleen,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,4554,,3655,N,CHEMBL619107,BAO_0000218,Spleen,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,4555,,3655,N,CHEMBL875410,BAO_0000218,Stomach,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,4556,,3655,N,CHEMBL619108,BAO_0000218,Stomach,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,4557,,3655,N,CHEMBL619109,BAO_0000218,Stomach,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4558,,16597,N,CHEMBL619110,BAO_0000218,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4559,,16597,N,CHEMBL619111,BAO_0000218,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4560,,16597,N,CHEMBL619112,BAO_0000218,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4561,,16597,N,CHEMBL619113,BAO_0000218,,MRT value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4562,,17764,N,CHEMBL619114,BAO_0000218,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4563,,17764,N,CHEMBL619115,BAO_0000218,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Mus musculus
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4564,,3830,N,CHEMBL619116,BAO_0000219,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4565,,3829,N,CHEMBL619117,BAO_0000219,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4566,,2040,N,CHEMBL619118,BAO_0000219,,Compound was evaluated for cytotoxicity against A2780 cell lines.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4567,,15684,N,CHEMBL619119,BAO_0000219,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4568,,15684,N,CHEMBL619120,BAO_0000219,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4569,,15684,N,CHEMBL619121,BAO_0000219,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4570,,15684,N,CHEMBL619122,BAO_0000219,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4571,,15684,N,CHEMBL619123,BAO_0000219,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4572,,15684,N,CHEMBL619124,BAO_0000219,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4573,,2859,N,CHEMBL619125,BAO_0000219,,Compound was evaluated for cytotoxicity against A2780 cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4574,,5618,N,CHEMBL875411,BAO_0000219,,In vitro inhibitory activity against human tumor cell line A2780,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4575,,15684,N,CHEMBL619126,BAO_0000219,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4576,,15684,N,CHEMBL619127,BAO_0000219,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4577,,15684,N,CHEMBL619128,BAO_0000219,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4578,,15684,N,CHEMBL619129,BAO_0000219,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4579,,2113,N,CHEMBL619130,BAO_0000219,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4580,,2113,N,CHEMBL619131,BAO_0000219,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4581,,16745,N,CHEMBL619132,BAO_0000219,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,4582,,16597,N,CHEMBL619133,BAO_0000218,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4583,,15684,N,CHEMBL619134,BAO_0000219,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4584,,15684,N,CHEMBL619135,BAO_0000219,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4585,,2040,N,CHEMBL619136,BAO_0000219,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4586,,2040,N,CHEMBL619137,BAO_0000219,,Relative resistance factor in A2780 cisplatin-resistant line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4587,,16165,N,CHEMBL883713,BAO_0000219,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4588,,16165,N,CHEMBL875412,BAO_0000219,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,4589,,16597,N,CHEMBL619138,BAO_0000218,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,4590,,16597,N,CHEMBL619262,BAO_0000218,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4591,,3992,N,CHEMBL619139,BAO_0000219,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4592,,10553,N,CHEMBL619140,BAO_0000219,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4593,,15608,N,CHEMBL619141,BAO_0000219,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4594,,15608,N,CHEMBL619142,BAO_0000219,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4595,,15608,N,CHEMBL619143,BAO_0000219,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4596,,15608,N,CHEMBL619144,BAO_0000219,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4597,,15608,N,CHEMBL619145,BAO_0000219,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4598,,15608,N,CHEMBL619146,BAO_0000219,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4599,,15569,N,CHEMBL619147,BAO_0000219,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4600,,17420,N,CHEMBL619148,BAO_0000219,,Antiproliferative effect of compound on A2780/DX cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4601,,17420,N,CHEMBL619149,BAO_0000219,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4602,,15099,N,CHEMBL619150,BAO_0000219,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4603,,15099,N,CHEMBL619151,BAO_0000219,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4604,,17672,N,CHEMBL883794,BAO_0000219,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4605,,17672,N,CHEMBL619152,BAO_0000219,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4606,,17270,N,CHEMBL619153,BAO_0000219,,In vitro cytotoxicity against A2780ADR cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4607,,17270,N,CHEMBL619154,BAO_0000219,,In vitro cytotoxicity against A2780CIS cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4608,,5574,N,CHEMBL619155,BAO_0000219,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4609,,2113,N,CHEMBL619156,BAO_0000219,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4610,,16913,N,CHEMBL619157,BAO_0000219,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4611,,16913,N,CHEMBL619797,BAO_0000219,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4612,,17839,U,CHEMBL619798,BAO_0000218,,Oral bioavailability of compound in rhesus macaques,Macaca mulatta
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4613,,6821,U,CHEMBL619799,BAO_0000218,,Oral bioavailability in monkey,monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4614,,6078,U,CHEMBL619800,BAO_0000218,,Oral bioavailability evaluated in monkey,monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4615,,6535,U,CHEMBL619801,BAO_0000218,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),monkey
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4616,,4449,U,CHEMBL619802,BAO_0000218,,Oral bioavailability in Rhesus monkey,Macaca mulatta
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4617,,6057,U,CHEMBL619803,BAO_0000218,,Oral bioavailability was calculated in rhesus monkey,Macaca mulatta
A,,,In vivo,,,,0,9541.0,22224,1,Autocuration,,,4618,,5922,U,CHEMBL619965,BAO_0000218,,Oral bioavailability in cynomolgus monkey,Macaca fascicularis
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4619,,5940,U,CHEMBL619966,BAO_0000218,,Oral bioavailability in monkey,monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4620,,6265,U,CHEMBL619967,BAO_0000218,,Oral bioavailability in monkey,monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4621,,6265,U,CHEMBL620073,BAO_0000218,,Oral bioavailability in monkey (dose 1 mg/kg),monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4622,,6265,U,CHEMBL620074,BAO_0000218,,Oral bioavailability in monkey (dose 5 mg/kg),monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4623,,5940,U,CHEMBL620075,BAO_0000218,,Oral bioavailability in monkey,monkey
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4624,,5940,U,CHEMBL620076,BAO_0000218,,Oral bioavailability in monkey,monkey
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4625,,4514,U,CHEMBL620077,BAO_0000218,,Oral bioavailability in rhesus monkey,Macaca mulatta
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4626,,5546,U,CHEMBL620078,BAO_0000218,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,Macaca mulatta
A,,,In vivo,,,,0,9521.0,22224,1,Autocuration,,,4627,,5553,U,CHEMBL620079,BAO_0000218,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,Saimiri sciureus
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4628,,6641,U,CHEMBL620080,BAO_0000218,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),monkey
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4629,,5472,U,CHEMBL620081,BAO_0000218,,Oral bioavailability in Rhesus monkey,Macaca mulatta
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4630,,5668,U,CHEMBL620082,BAO_0000218,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),Macaca mulatta
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,4631,,5711,U,CHEMBL620083,BAO_0000218,,Oral bioavailability in monkey at 10 mg/kg of the compound,monkey
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4632,,5145,U,CHEMBL620084,BAO_0000218,,Bioavailability in Rhesus monkey,Macaca mulatta
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4633,,3443,U,CHEMBL620085,BAO_0000218,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4634,,3443,U,CHEMBL874595,BAO_0000218,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4635,,3249,U,CHEMBL873352,BAO_0000218,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4636,,3249,U,CHEMBL620086,BAO_0000218,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4637,,5355,U,CHEMBL620087,BAO_0000218,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4638,,5355,U,CHEMBL620088,BAO_0000218,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4639,,5355,U,CHEMBL620089,BAO_0000218,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4640,,4809,U,CHEMBL620090,BAO_0000218,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4641,,4809,U,CHEMBL620091,BAO_0000218,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4642,Microsomes,14294,U,CHEMBL620092,BAO_0000251,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4643,Microsomes,14294,U,CHEMBL620093,BAO_0000251,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4644,Microsomes,14294,U,CHEMBL620094,BAO_0000251,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4645,Microsomes,14294,U,CHEMBL620095,BAO_0000251,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4646,,3443,U,CHEMBL620096,BAO_0000218,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4647,,3443,U,CHEMBL620097,BAO_0000218,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4648,,11271,U,CHEMBL620098,BAO_0000019,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4649,,3443,U,CHEMBL620099,BAO_0000218,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4650,,3443,U,CHEMBL620100,BAO_0000218,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4651,,6821,U,CHEMBL620101,BAO_0000019,,Elimination Half-life of compound was determined in monkey,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4652,,17267,U,CHEMBL620102,BAO_0000019,,Half life of compound was determined in rhesus monkey,Cercopithecidae
A,,,,,1969.0,,0,9527.0,22224,1,Autocuration,,,4653,,5819,U,CHEMBL620103,BAO_0000366,Plasma,Half life in monkey plasma,Cercopithecidae
A,,,,,1969.0,,0,9527.0,22224,1,Autocuration,,,4654,,5819,U,CHEMBL620104,BAO_0000366,Plasma,Half life in monkey plasma; Not detected,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4655,,1916,U,CHEMBL874596,BAO_0000218,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4656,,17509,U,CHEMBL873490,BAO_0000218,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4657,,1399,U,CHEMBL620105,BAO_0000019,,Terminal half life of the compound.,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4658,,1916,U,CHEMBL620780,BAO_0000218,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4659,,4809,U,CHEMBL620781,BAO_0000218,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4660,,5546,U,CHEMBL620956,BAO_0000218,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Cercopithecidae
A,,,,,1088.0,,0,9527.0,22224,1,Autocuration,,,4661,,3443,U,CHEMBL620957,BAO_0000218,Urine,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,,,1088.0,,0,9527.0,22224,1,Autocuration,,,4662,,3443,U,CHEMBL620958,BAO_0000218,Urine,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4663,,4257,U,CHEMBL620959,BAO_0000218,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4664,,6221,U,CHEMBL620960,BAO_0000218,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4665,,5472,U,CHEMBL620961,BAO_0000218,,Volume of distribution was evaluated in rhesus,Cercopithecidae
A,,,In vivo,,,,0,10029.0,22224,1,Autocuration,,,4666,,4727,U,CHEMBL620962,BAO_0000218,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Cricetulus griseus
A,,,In vivo,,,,0,10029.0,22224,1,Autocuration,,,4667,,4727,U,CHEMBL620963,BAO_0000218,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,Cricetulus griseus
A,,,In vivo,,,,0,10029.0,22224,1,Autocuration,,,4668,,4727,U,CHEMBL620964,BAO_0000218,,Bioavailability in hamster was determined,Cricetulus griseus
A,,,In vivo,,,,0,10029.0,22224,1,Autocuration,,,4669,,4727,U,CHEMBL620965,BAO_0000218,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,Cricetulus griseus
A,,,In vivo,,,,0,10029.0,22224,1,Autocuration,,,4670,,4727,U,CHEMBL620966,BAO_0000218,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,Cricetulus griseus
A,,,,,178.0,,0,10029.0,22224,1,Autocuration,,,4671,,4727,U,CHEMBL620967,BAO_0000221,Blood,Half life of compound was determined in hamster blood,Cricetulus griseus
A,,,,,,,0,9823.0,22224,1,Autocuration,,,4672,,1452,U,CHEMBL620968,BAO_0000019,,Michaelis-Menten constant of the compound.,Sus scrofa
A,,,,,,,0,9823.0,22224,1,Autocuration,,,4673,,1452,U,CHEMBL874597,BAO_0000019,,Vmax value was measured at 0 uM concentration of silyl ether.,Sus scrofa
A,,,,,,,0,9823.0,22224,1,Autocuration,,,4674,,1452,U,CHEMBL620969,BAO_0000019,,Vmax value was measured at 10 uM concentration of silyl ether.,Sus scrofa
A,,,,,,,0,9823.0,22224,1,Autocuration,,,4675,,1452,U,CHEMBL620970,BAO_0000019,,Vmax value was measured at 5 uM concentration of silyl ether.,Sus scrofa
B,,,,,,,9,9606.0,235,1,Expert,,,4676,,11706,D,CHEMBL620971,BAO_0000357,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4677,,1916,U,CHEMBL620972,BAO_0000218,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4678,,17791,U,CHEMBL620973,BAO_0000019,,Compound was evaluated for area under the curve expressed as (h*ug/ml),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4679,,7766,U,CHEMBL618243,BAO_0000019,,Active metabolite of ifosfamide determined in humans; A-Active,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4680,,6567,U,CHEMBL618244,BAO_0000019,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4681,,6567,U,CHEMBL618245,BAO_0000019,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4682,,6567,U,CHEMBL618246,BAO_0000019,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4683,,6567,U,CHEMBL618247,BAO_0000019,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4684,,17791,U,CHEMBL618248,BAO_0000218,,Compound was evaluated for oral bioavailability in human,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4685,,7766,U,CHEMBL618249,BAO_0000019,Urine,Metabolite of ifosfamide determined in urine; NF-Not found,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4686,,6852,U,CHEMBL618250,BAO_0000019,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4687,,6852,U,CHEMBL874598,BAO_0000019,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4688,,6852,U,CHEMBL618251,BAO_0000019,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4689,,6852,U,CHEMBL618252,BAO_0000019,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4690,,6852,U,CHEMBL618253,BAO_0000019,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4691,,6852,U,CHEMBL618254,BAO_0000019,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4692,,6852,U,CHEMBL618255,BAO_0000019,,Percent of compound in healthy individuals (Group D),Homo sapiens
A,,,,,2107.0,,0,9606.0,22224,1,Autocuration,,,4693,Microsomes,4397,U,CHEMBL618983,BAO_0000251,Liver,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4694,,17409,U,CHEMBL618984,BAO_0000019,,Binding towards human plasma protein at 10 uM,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4695,,17409,U,CHEMBL618985,BAO_0000019,,Binding towards human plasma protein at 100 uM,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4696,,17176,U,CHEMBL618986,BAO_0000019,,Human plasma protein binding activity was determined,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4697,,15444,U,CHEMBL618987,BAO_0000019,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4698,,17267,U,CHEMBL618988,BAO_0000019,,Percent binding of compound towards human plasma protein was determined,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,4699,Microsomes,5944,U,CHEMBL618989,BAO_0000251,Liver,Plasma clearance in human liver microsomes,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,4700,Microsomes,5668,U,CHEMBL618990,BAO_0000251,Liver,In vitro intrinsic clearance in human liver microsome,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,4701,Microsomes,5669,U,CHEMBL618991,BAO_0000251,Liver,In vitro intrinsic clearance in human liver microsome,Homo sapiens
A,,,In vitro,,,,0,9606.0,22224,1,Autocuration,,,4702,Microsomes,5041,U,CHEMBL876725,BAO_0000251,,In vitro microsome metabolism clearance in human was determined,Homo sapiens
A,,,In vitro,,,,0,9606.0,22224,1,Autocuration,,,4703,Microsomes,5041,U,CHEMBL618992,BAO_0000251,,In vitro microsome metabolism clearance in human was determined; High,Homo sapiens
A,,,In vitro,,,,0,9606.0,22224,1,Autocuration,,,4704,Microsomes,5041,U,CHEMBL618993,BAO_0000251,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,4705,Microsomes,5676,U,CHEMBL618994,BAO_0000251,Liver,Pharmacokinetic property (clearance) in human liver microsome,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,4706,Microsomes,5944,U,CHEMBL618995,BAO_0000251,Liver,Plasma clearance in human liver microsomes,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,4707,Microsomes,17538,U,CHEMBL618996,BAO_0000251,Liver,In vitro clearance in human liver microsomes,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,4708,Microsomes,6331,U,CHEMBL618997,BAO_0000251,Liver,Intrinsic clearance in human liver microsomes was determined,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,4709,Microsomes,5948,U,CHEMBL618998,BAO_0000251,Liver,Intrinsic clearance in human liver microsomes was determined,Homo sapiens
A,,,In vivo,,,,0,9606.0,22224,1,Autocuration,,,4710,,5965,U,CHEMBL618999,BAO_0000218,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,Homo sapiens
A,,,In vivo,,,,0,9606.0,22224,1,Autocuration,,,4711,,1916,U,CHEMBL620223,BAO_0000218,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4712,,5965,U,CHEMBL620224,BAO_0000218,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4713,,1299,U,CHEMBL620225,BAO_0000019,,Stability in human plasma 2 hr after incubation expressed as percent concentration,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4714,,1299,U,CHEMBL620226,BAO_0000019,,Stability in human plasma 4 hr after incubation expressed as percent concentration,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4715,,7766,U,CHEMBL620227,BAO_0000019,Urine,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4716,,7766,U,CHEMBL876726,BAO_0000019,Urine,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4717,,7766,U,CHEMBL620228,BAO_0000019,Urine,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4718,,7766,U,CHEMBL620229,BAO_0000019,Urine,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4719,,17764,N,CHEMBL620230,BAO_0000218,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4720,,17764,N,CHEMBL620231,BAO_0000218,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4721,,17764,N,CHEMBL620232,BAO_0000218,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4722,,17764,N,CHEMBL620233,BAO_0000218,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4723,,14294,N,CHEMBL620234,BAO_0000218,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4724,,14294,N,CHEMBL620235,BAO_0000218,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4725,,14294,N,CHEMBL620236,BAO_0000218,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),Mus musculus
A,,,,,2107.0,,1,10090.0,50594,1,Intermediate,,,4726,,6251,N,CHEMBL620237,BAO_0000218,Liver,In vitro metabolic potential in mouse liver microsomes,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4727,,17582,N,CHEMBL620238,BAO_0000218,,Ability of compound to bind to plasma protein was evaluated in HSA cells,Mus musculus
A,,,,,2369.0,,1,10090.0,50594,1,Intermediate,,,4728,,17811,N,CHEMBL620239,BAO_0000218,Adrenal gland,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Mus musculus
A,,,,,955.0,,1,10090.0,50594,1,Intermediate,,,4729,,17811,N,CHEMBL620240,BAO_0000218,Brain,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Mus musculus
A,,,,,955.0,,1,10090.0,50594,1,Intermediate,,,4730,,17811,N,CHEMBL620241,BAO_0000218,Brain,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4731,,17811,N,CHEMBL876727,BAO_0000218,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),Mus musculus
A,,,,,2113.0,,1,10090.0,50594,1,Intermediate,,,4732,,17811,N,CHEMBL620242,BAO_0000218,Kidney,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4733,,17811,N,CHEMBL620243,BAO_0000218,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4734,,5288,N,CHEMBL620244,BAO_0000218,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,Mus musculus
A,,,,,1977.0,,1,10090.0,50594,1,Intermediate,,,4735,,2717,N,CHEMBL620245,BAO_0000218,Serum,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Mus musculus
A,,,,,1977.0,,1,10090.0,50594,1,Intermediate,,,4736,,2717,N,CHEMBL620246,BAO_0000218,Serum,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Mus musculus
A,,,,,1977.0,,1,10090.0,50594,1,Intermediate,,,4737,,2717,N,CHEMBL620247,BAO_0000218,Serum,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,4738,,17753,N,CHEMBL620248,BAO_0000218,Plasma,Half life of compound was determined in plasma of mice at 24 mg/Kg,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,4739,,17753,N,CHEMBL873497,BAO_0000218,Plasma,Half life of compound was determined in plasma of mice at 40 mg/Kg,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,4740,,17753,N,CHEMBL620249,BAO_0000218,Plasma,Half life of compound was determined in plasma of mice at 5 mg/Kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4741,,17764,N,CHEMBL620250,BAO_0000218,,Half life after intraperitoneal administration in mice at 18 uM/kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4742,,17764,N,CHEMBL620251,BAO_0000218,,Half life after intraperitoneal administration in mice at 23 uM/kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4743,,17764,N,CHEMBL620252,BAO_0000218,,Half life after intraperitoneal administration in mice at 25 uM/kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4744,,17764,N,CHEMBL620253,BAO_0000218,,Half life after intraperitoneal administration in mice at 26 uM/kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4745,,17764,N,CHEMBL620254,BAO_0000218,,Half life after intravenous administration in mice at 23 uM/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4746,,17764,N,CHEMBL620255,BAO_0000218,,Half life after intravenous administration in mice at 24 uM/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4747,,16597,N,CHEMBL620256,BAO_0000218,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4748,,2675,N,CHEMBL876728,BAO_0000218,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4749,,2675,N,CHEMBL620257,BAO_0000218,,Maximum time required to reach Cp max was evaluated in mice after oral administration,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4750,,16597,N,CHEMBL620258,BAO_0000218,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4751,,4890,N,CHEMBL620259,BAO_0000218,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4752,,429,N,CHEMBL620260,BAO_0000218,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,4753,,17837,N,CHEMBL620261,BAO_0000218,Blood,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4754,,16597,N,CHEMBL620262,BAO_0000218,,Half life at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4755,,16597,N,CHEMBL620263,BAO_0000218,,Half life at a dose of 10 mg/kg peroral administration in mice.,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4756,,6619,N,CHEMBL620264,BAO_0000218,,Half life in ob/ob mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4757,,4066,N,CHEMBL620265,BAO_0000218,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4758,,4239,N,CHEMBL620266,BAO_0000218,,Half-life was measured in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4759,,5969,N,CHEMBL620267,BAO_0000218,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4760,,8999,N,CHEMBL619364,BAO_0000218,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4761,,8999,N,CHEMBL619365,BAO_0000218,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,Mus musculus
A,,,,,955.0,,1,10090.0,50594,1,Intermediate,,,4762,,17641,N,CHEMBL619366,BAO_0000218,Brain,T2 in brain of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,,,2113.0,,1,10090.0,50594,1,Intermediate,,,4763,,17641,N,CHEMBL619367,BAO_0000218,Kidney,T2 in kidney of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,,,2107.0,,1,10090.0,50594,1,Intermediate,,,4764,,17641,N,CHEMBL619368,BAO_0000218,Liver,T2 in liver of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,,,2048.0,,1,10090.0,50594,1,Intermediate,,,4765,,17641,N,CHEMBL619369,BAO_0000218,Lung,T2 in lungs of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,,,2106.0,,1,10090.0,50594,1,Intermediate,,,4766,,17641,N,CHEMBL876729,BAO_0000218,Spleen,T2 in spleen of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4767,,16597,N,CHEMBL619370,BAO_0000218,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4768,,4890,N,CHEMBL619371,BAO_0000218,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4769,,429,N,CHEMBL619372,BAO_0000218,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4770,,429,N,CHEMBL620012,BAO_0000218,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4771,,5969,N,CHEMBL620013,BAO_0000218,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,Mus musculus
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4772,,16913,N,CHEMBL620014,BAO_0000219,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4773,,16913,N,CHEMBL620015,BAO_0000219,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4774,,16913,N,CHEMBL621010,BAO_0000219,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4775,,16913,N,CHEMBL621011,BAO_0000219,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4776,,16913,N,CHEMBL621012,BAO_0000219,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4777,,16913,N,CHEMBL621013,BAO_0000219,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4778,,17270,N,CHEMBL621014,BAO_0000219,,In vitro cytotoxicity against A2780TAX cell line,Homo sapiens
F,A2780cisR,481.0,,,,,1,9606.0,80017,1,Intermediate,,,4779,,5618,N,CHEMBL618154,BAO_0000219,,In vitro inhibitory activity against human tumor cell line A2780cis,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,4780,,17777,N,CHEMBL618155,BAO_0000219,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,Homo sapiens
F,A2780cisR,481.0,,,,,1,9606.0,80017,1,Intermediate,,,4781,,16112,N,CHEMBL618156,BAO_0000219,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,Homo sapiens
F,A2780cisR,481.0,,,,,1,9606.0,80017,1,Intermediate,,,4782,,15748,N,CHEMBL618157,BAO_0000219,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4783,,6633,N,CHEMBL618328,BAO_0000219,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4784,,16930,N,CHEMBL618329,BAO_0000219,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4785,,17496,N,CHEMBL618330,BAO_0000219,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,4786,,12989,N,CHEMBL618331,BAO_0000219,,In vitro antitumor activity against A2780cisR cell line.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,4787,,4840,N,CHEMBL618332,BAO_0000219,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,4788,,12989,N,CHEMBL618333,BAO_0000219,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,Homo sapiens
F,A2780cisR,481.0,,,,,1,9606.0,80017,1,Intermediate,,,4789,,16745,N,CHEMBL618334,BAO_0000219,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,4790,,16597,N,CHEMBL618335,BAO_0000219,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,Homo sapiens
B,,,,,,,9,10116.0,11736,1,Expert,,,4791,,16547,D,CHEMBL618336,BAO_0000019,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,Rattus norvegicus
F,,,,,,,8,,11736,1,Expert,,,4792,,16547,H,CHEMBL618337,BAO_0000019,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),
F,,,,,,,9,10116.0,11736,1,Expert,,,4793,,16547,D,CHEMBL618338,BAO_0000019,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Rattus norvegicus
F,HEK293,722.0,,,,,9,9606.0,278,1,Expert,,,4794,,15856,D,CHEMBL618339,BAO_0000219,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,Homo sapiens
F,HEK293,722.0,,,,,9,9606.0,278,1,Expert,,,4795,,15856,D,CHEMBL618340,BAO_0000219,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,Homo sapiens
B,,,,,,,9,10090.0,11831,1,Expert,,,4796,,16547,D,CHEMBL618341,BAO_0000019,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,Mus musculus
F,,,,,,,8,,11831,1,Expert,,,4797,,16547,H,CHEMBL618342,BAO_0000019,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),
F,,,,,,,9,10090.0,11831,1,Expert,,,4798,,16547,D,CHEMBL618343,BAO_0000019,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Mus musculus
B,,,,,,,8,,280,1,Expert,,,4799,,17402,H,CHEMBL621038,BAO_0000357,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,
F,T-cells,574.0,,,,,0,9606.0,22226,1,Autocuration,,,4800,,11746,U,CHEMBL621039,BAO_0000219,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),Homo sapiens
F,T-cells,574.0,,,,,0,9606.0,22226,1,Autocuration,,,4801,,11746,U,CHEMBL621040,BAO_0000219,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,Homo sapiens
F,A-375,455.0,,,,,1,9606.0,80018,1,Intermediate,,,4802,,5455,N,CHEMBL621041,BAO_0000219,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,Homo sapiens
F,A-375,455.0,,,,,1,9606.0,80018,1,Intermediate,,,4803,,2068,N,CHEMBL621042,BAO_0000219,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,Homo sapiens
F,A-375,455.0,,,,,1,9606.0,80018,1,Intermediate,,,4804,,2683,N,CHEMBL621043,BAO_0000219,,In vitro antitumor activity against A375cell line extracted form melanoma,Homo sapiens
F,A-375,455.0,,,,,1,9606.0,80018,1,Expert,,,4805,,15313,N,CHEMBL621044,BAO_0000219,,Inhibition of cell growth in (A375) melan cell line,Homo sapiens
F,A-375,455.0,,,,,1,9606.0,80018,1,Intermediate,,,4806,,13739,N,CHEMBL621045,BAO_0000219,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,Homo sapiens
F,A-375,455.0,,,,,1,9606.0,80018,1,Intermediate,,,4807,,13739,N,CHEMBL621046,BAO_0000219,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,Homo sapiens
F,A-375,455.0,,,,,1,9606.0,80018,1,Intermediate,,,4808,,14750,N,CHEMBL621047,BAO_0000219,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,4809,,14777,N,CHEMBL621048,BAO_0000219,,Antiproliferative activity measured against A427 human lung carcinoma,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,4810,,14777,N,CHEMBL883798,BAO_0000219,,Antiproliferative activity measured against A427 human lung carcinoma,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,4811,,17672,N,CHEMBL621049,BAO_0000219,,Cytotoxicity against lung carcinoma A427 tumor cell lines,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,4812,,14368,N,CHEMBL621050,BAO_0000219,,Inhibition of large cell lung carcinoma (A427),Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,4813,,14368,N,CHEMBL621051,BAO_0000219,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,4814,,13866,N,CHEMBL621052,BAO_0000219,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,4815,,2545,N,CHEMBL621053,BAO_0000219,,Inhibitory concentration in human lung carcinoma A427 cell line,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,4816,,2545,N,CHEMBL621054,BAO_0000219,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,Homo sapiens
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4817,,6062,U,CHEMBL621055,BAO_0000218,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4818,,4578,U,CHEMBL876398,BAO_0000218,,Tested for volume of distribution upon iv administration to african green monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4819,,17592,U,CHEMBL621056,BAO_0000218,,Volume of distribution in monkey,Cercopithecidae
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4820,,5005,U,CHEMBL621057,BAO_0000218,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta
A,,,In vivo,,,,0,9544.0,22224,1,Autocuration,,,4821,,5005,U,CHEMBL621058,BAO_0000218,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Macaca mulatta
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4822,,5922,U,CHEMBL621059,BAO_0000218,,Pharmacokinetic property(Vdss) in cynomolgus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4823,,5355,U,CHEMBL621060,BAO_0000218,,The distribution volume after intravenous administration in cynomolgus monkeys,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4824,,5355,U,CHEMBL621061,BAO_0000218,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4825,,5355,U,CHEMBL621062,BAO_0000218,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4826,,6057,U,CHEMBL621063,BAO_0000218,,Volume displacement was calculated in rhesus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4827,,5145,U,CHEMBL621064,BAO_0000218,,Volume of distribution in steady state was determined in rhesus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4828,,6821,U,CHEMBL621065,BAO_0000218,,Volume of distribution of compound was determined in monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4829,,5334,U,CHEMBL621066,BAO_0000218,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4830,,5334,U,CHEMBL621067,BAO_0000218,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4831,,6641,U,CHEMBL621068,BAO_0000218,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4832,,2661,U,CHEMBL876399,BAO_0000218,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4833,,6535,U,CHEMBL621069,BAO_0000218,,Volume distribution in monkey after administration of 1 mg/kg iv,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4834,,4809,U,CHEMBL621070,BAO_0000218,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4835,,6062,U,CHEMBL621071,BAO_0000218,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4836,,3443,U,CHEMBL621072,BAO_0000218,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4837,,4578,U,CHEMBL618209,BAO_0000218,,Oral systemic bioavailability upon iv administration to african green monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4838,,4809,U,CHEMBL618210,BAO_0000218,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4839,,11271,U,CHEMBL618211,BAO_0000019,,Baboon plasma free fraction. ,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4840,,6057,U,CHEMBL618212,BAO_0000218,,Area under the curve was calculated in rhesus monkey after iv administration,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4841,,6057,U,CHEMBL618213,BAO_0000019,,Area under the curve was calculated in rhesus monkey after peroral administration,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4842,,17853,U,CHEMBL618214,BAO_0000019,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4843,,5302,U,CHEMBL873492,BAO_0000218,,Half life period in monkey after 5 mg/kg dose,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4844,,4257,U,CHEMBL618272,BAO_0000218,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4845,,4257,U,CHEMBL618273,BAO_0000218,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,Cercopithecidae
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,4846,,13501,U,CHEMBL618274,BAO_0000218,Plasma,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4847,,5394,U,CHEMBL618275,BAO_0000218,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4848,,2661,U,CHEMBL618276,BAO_0000218,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4849,,3341,U,CHEMBL618277,BAO_0000019,,Compound was evaluated for terminal half life in monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4850,,3045,U,CHEMBL618278,BAO_0000218,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,Cercopithecidae
A,,,In vivo,,1969.0,,0,9544.0,22224,1,Autocuration,,,4851,,5005,U,CHEMBL618279,BAO_0000218,Plasma,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4852,,4847,U,CHEMBL618280,BAO_0000019,,Half life of compound was determined in squirrel monkey,Cercopithecidae
A,,,In vivo,,,,0,9541.0,22224,1,Autocuration,,,4853,,4256,U,CHEMBL618281,BAO_0000218,,Half life after iv administration in cynomolgus monkey,Macaca fascicularis
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,4854,,6535,U,CHEMBL618282,BAO_0000218,Plasma,Half life in monkey plasma after administration of 1 mg/kg iv,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4855,,6057,U,CHEMBL618283,BAO_0000019,,Half life was calculated in rhesus monkey,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4856,,17592,U,CHEMBL618284,BAO_0000019,,Half life in monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4857,,6641,U,CHEMBL618285,BAO_0000218,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4858,,5472,U,CHEMBL618286,BAO_0000019,,Half life was evaluated in rhesus,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4859,,6221,U,CHEMBL618287,BAO_0000218,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4860,,5668,U,CHEMBL618288,BAO_0000218,,Half life period was determine after peroral administration at 10 mpk in Rhesus,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4861,,4809,U,CHEMBL876393,BAO_0000218,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4862,,5546,U,CHEMBL618289,BAO_0000218,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4863,,5553,U,CHEMBL618290,BAO_0000218,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4864,,6078,U,CHEMBL618291,BAO_0000019,,Half-life was calculated in monkey,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4865,,5147,U,CHEMBL618292,BAO_0000019,,Half-life in Squirrel monkey,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,4866,,5145,U,CHEMBL618293,BAO_0000019,,Half-life in rhesus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4867,,6062,U,CHEMBL618294,BAO_0000218,,Half-life was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4868,,5355,U,CHEMBL618295,BAO_0000218,,Half-life period after intravenous administration in cynomolgus monkeys,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4869,,5355,U,CHEMBL618296,BAO_0000218,,Half-life period after oral administration in cynomolgus monkeys,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,4870,,5355,U,CHEMBL618297,BAO_0000218,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,Cercopithecidae
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4871,,7766,U,CHEMBL618298,BAO_0000019,Urine,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4872,,7766,U,CHEMBL618299,BAO_0000019,Urine,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4873,,7766,U,CHEMBL618300,BAO_0000019,Urine,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4874,,7766,U,CHEMBL618301,BAO_0000019,Urine,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4875,,7766,U,CHEMBL618302,BAO_0000019,Urine,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4876,,7766,U,CHEMBL876394,BAO_0000019,Urine,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4877,,7766,U,CHEMBL618303,BAO_0000019,Urine,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4878,,7766,U,CHEMBL618304,BAO_0000019,Urine,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Homo sapiens
A,,,In vivo,,,,0,9606.0,22224,1,Autocuration,,,4879,,1916,U,CHEMBL618305,BAO_0000218,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,Homo sapiens
A,,,In vivo,,,,0,9606.0,22224,1,Autocuration,,,4880,,16643,U,CHEMBL618306,BAO_0000218,,Oral bioavailability in human,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4881,,17248,U,CHEMBL618307,BAO_0000019,,Compound was tested for human plasma protein binding,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4882,,17248,U,CHEMBL618308,BAO_0000019,,Compound was tested for human plasma protein binding; Not determined,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4883,,6241,U,CHEMBL618309,BAO_0000019,,Protein binding activity of compound in human plasma; % Free,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4884,,17716,U,CHEMBL618310,BAO_0000019,,Unbound fraction (plasma),Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,4885,,17605,U,CHEMBL873353,BAO_0000366,Plasma,Half life for the hydrolysis of compound in human blood serum,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,4886,,17625,U,CHEMBL618311,BAO_0000366,Plasma,Half life period in human plasma using phosphate buffer (0.08 M),Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,4887,,17625,U,CHEMBL618312,BAO_0000366,Plasma,Half life period in human plasma using phosphate buffer (0.1 M),Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,4888,,17747,U,CHEMBL618313,BAO_0000366,Plasma,Half-life in human plasma was determined,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4889,,15613,U,CHEMBL618314,BAO_0000019,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4890,,354,U,CHEMBL618315,BAO_0000019,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4891,,3741,U,CHEMBL618316,BAO_0000019,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4892,,3741,U,CHEMBL618317,BAO_0000019,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4893,,3741,U,CHEMBL620138,BAO_0000019,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4894,,17599,U,CHEMBL858280,BAO_0000019,,Partition coefficient (logP),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4895,,5486,U,CHEMBL620139,BAO_0000019,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4896,Microsomes,5600,U,CHEMBL620140,BAO_0000251,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4897,,14294,U,CHEMBL620141,BAO_0000019,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4898,,14294,U,CHEMBL620142,BAO_0000019,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4899,,14294,U,CHEMBL620143,BAO_0000019,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4900,Microsomes,14294,U,CHEMBL620144,BAO_0000251,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4901,Microsomes,14294,U,CHEMBL620145,BAO_0000251,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4902,Microsomes,14294,U,CHEMBL620146,BAO_0000251,,Metabolism of compound in human microsomes; Trace,Homo sapiens
A,,,,,2107.0,,0,9606.0,22224,1,Autocuration,,,4903,Microsomes,6260,U,CHEMBL620147,BAO_0000251,Liver,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4904,Microsomes,6187,U,CHEMBL620148,BAO_0000251,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Homo sapiens
A,,,,,2107.0,,0,9606.0,22224,1,Autocuration,,,4905,Microsomes,6251,U,CHEMBL620149,BAO_0000251,Liver,In vitro metabolic potential in human liver microsomes,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4906,,3246,U,CHEMBL876412,BAO_0000019,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4907,,17313,U,CHEMBL619352,BAO_0000019,,Tested for human plasma protein binding of the compound; Not tested,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4908,,6227,U,CHEMBL619353,BAO_0000019,,Compound was tested for percent protein binding (PB) in human,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,4909,,5530,U,CHEMBL619354,BAO_0000019,Plasma,Protein binding in human plasma,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4910,,6108,U,CHEMBL619355,BAO_0000019,,Permeability coefficient (B to A) in Caco-2 cell,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4911,,6108,U,CHEMBL619356,BAO_0000019,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4912,,2774,U,CHEMBL619357,BAO_0000019,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4913,,16643,U,CHEMBL619358,BAO_0000019,,In vitro rate of absorption observed as Caco-2 permeability in humans,Homo sapiens
A,Caco-2,495.0,,,,,0,9606.0,22224,1,Autocuration,,,4914,,17582,U,CHEMBL619359,BAO_0000219,,Cellular permeability of compound was determined in Caco-2 cells; High,Homo sapiens
A,Caco-2,495.0,,,,,0,9606.0,22224,1,Autocuration,,,4915,,6838,U,CHEMBL619360,BAO_0000219,,Permeability in Caco-2 cells of compound,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4916,,6108,U,CHEMBL619361,BAO_0000019,,Permeability coefficient (A to B) in Caco-2 cell,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4917,,6108,U,CHEMBL619362,BAO_0000019,,Permeability coefficient (B to A) in Caco-2 cell,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4918,,6108,U,CHEMBL619363,BAO_0000019,,Permeability coefficient (Papp) (Caco-2 cell monolayer),Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4919,,2146,U,CHEMBL618942,BAO_0000019,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4920,,4514,U,CHEMBL618943,BAO_0000019,,Compound was tested for protein binding in human plasma,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,4921,,6108,U,CHEMBL618944,BAO_0000019,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,4922,,7766,U,CHEMBL618945,BAO_0000019,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Homo sapiens
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4923,,5969,N,CHEMBL618946,BAO_0000218,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4924,,3277,N,CHEMBL876413,BAO_0000218,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4925,,3802,N,CHEMBL618947,BAO_0000218,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,4926,,2862,N,CHEMBL618948,BAO_0000218,Plasma,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,4927,,6348,N,CHEMBL618949,BAO_0000218,Plasma,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4928,,17764,N,CHEMBL618950,BAO_0000218,,Tmax after intraperitoneal administration in mice at 23 uM/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4929,,5781,N,CHEMBL618951,BAO_0000218,,Tmax after oral administration at 30 mg/kg in ICR mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4930,,17764,N,CHEMBL618952,BAO_0000218,,Tmax after peroral administration in mice at 2.4 uM/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4931,,4066,N,CHEMBL618953,BAO_0000218,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,4932,,17641,N,CHEMBL618954,BAO_0000218,Brain,Tmax in brain of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,4933,,17641,N,CHEMBL618955,BAO_0000218,Kidney,Tmax in kidney of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,4934,,17641,N,CHEMBL618956,BAO_0000218,Liver,Tmax in liver of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,4935,,17641,N,CHEMBL618957,BAO_0000218,Lung,Tmax in lungs of mice at the oral dose of 50 mg/kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4936,,17764,N,CHEMBL618958,BAO_0000218,,Tmax in mice at 18 uM/kg i.p. administration,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4937,,17764,N,CHEMBL618959,BAO_0000218,,Tmax in mice at 23 uM/kg i.v. administration,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4938,,17764,N,CHEMBL618960,BAO_0000218,,Tmax in mice at 25 uM/kg i.p. administration,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4939,,17764,N,CHEMBL876723,BAO_0000218,,Tmax in mice at 26 uM/kg i.p. administration,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,4940,,17641,N,CHEMBL618961,BAO_0000218,Spleen,Tmax in spleen of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4941,,16597,N,CHEMBL618962,BAO_0000218,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4942,,16597,N,CHEMBL618963,BAO_0000218,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4943,,5951,N,CHEMBL618964,BAO_0000218,,Tmax value in IRC mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4944,,5506,N,CHEMBL618965,BAO_0000218,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4945,,5506,N,CHEMBL618966,BAO_0000218,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Mus musculus
A,,,,,1088.0,,1,10090.0,50594,1,Intermediate,,,4946,,429,N,CHEMBL618967,BAO_0000218,Urine,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Mus musculus
A,,,,,1088.0,,1,10090.0,50594,1,Intermediate,,,4947,,429,N,CHEMBL618968,BAO_0000218,Urine,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Mus musculus
A,,,,,1088.0,,1,10090.0,50594,1,Intermediate,,,4948,,4066,N,CHEMBL618969,BAO_0000218,Urine,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4949,,17734,N,CHEMBL618970,BAO_0000218,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,4950,,17734,N,CHEMBL618971,BAO_0000218,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4951,,6062,N,CHEMBL618972,BAO_0000218,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4952,,5969,N,CHEMBL618973,BAO_0000218,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4953,,5969,N,CHEMBL618974,BAO_0000218,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4954,,5969,N,CHEMBL618975,BAO_0000218,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4955,,5980,N,CHEMBL618976,BAO_0000218,,Vd in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4956,,17592,N,CHEMBL618977,BAO_0000218,,Volume of distribution in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4957,,6348,N,CHEMBL876724,BAO_0000218,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4958,,17753,N,CHEMBL618978,BAO_0000218,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4959,,17753,N,CHEMBL618979,BAO_0000218,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4960,,17753,N,CHEMBL618980,BAO_0000218,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4961,,4239,N,CHEMBL618981,BAO_0000218,,Pharmacokinetic property (vdss) was measured in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4962,,2862,N,CHEMBL618982,BAO_0000218,,Value distribution upon iv administration in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4963,,17734,N,CHEMBL620150,BAO_0000218,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4964,,2675,N,CHEMBL620151,BAO_0000218,,Volume of distribution was evaluated in mice after intravenous administration,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4965,,2675,N,CHEMBL620152,BAO_0000218,,Volume of distribution was evaluated in mice after oral administration,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4966,,17837,N,CHEMBL620153,BAO_0000218,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4967,,5727,N,CHEMBL876395,BAO_0000218,,Steady state volume of distribution was determined in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4968,,17852,N,CHEMBL620154,BAO_0000218,,Volume distribution (steady state) of compound was determined in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4969,,17764,N,CHEMBL620155,BAO_0000218,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4970,,16597,N,CHEMBL620156,BAO_0000218,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,4971,,6062,N,CHEMBL620157,BAO_0000218,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,4972,,16438,N,CHEMBL620158,BAO_0000218,Kidney,Biodistribution of compound (oxidized form) in in kidney tissue,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,4973,,16438,N,CHEMBL620159,BAO_0000218,Blood,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,4974,,16438,N,CHEMBL620160,BAO_0000218,Blood,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,4975,,16438,N,CHEMBL620161,BAO_0000218,Blood,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,4976,,10708,N,CHEMBL620162,BAO_0000219,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4977,,16597,N,CHEMBL620163,BAO_0000219,,Inhibition of A431 human squamous cell carcinoma cell proliferation,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4978,,16062,N,CHEMBL620833,BAO_0000219,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4979,,16062,N,CHEMBL876396,BAO_0000219,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4980,,16958,N,CHEMBL620834,BAO_0000219,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4981,,6700,N,CHEMBL620835,BAO_0000219,,Inhibition of A431 human carcinoma cell proliferation,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4982,,17226,N,CHEMBL620836,BAO_0000219,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,4983,,6828,N,CHEMBL620837,BAO_0000219,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,4984,,12314,N,CHEMBL621017,BAO_0000219,,In vitro cytotoxicity against epidermoid carcinoma cell line,Homo sapiens
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,4985,,13412,D,CHEMBL621018,BAO_0000218,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,4986,,13299,N,CHEMBL621019,BAO_0000219,,Antiproliferative activity of compound was measured on human tumor cell line A431.,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,4987,,17420,N,CHEMBL621020,BAO_0000219,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,4988,,13678,N,CHEMBL621021,BAO_0000219,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,Homo sapiens
F,A-431,500.0,,,,,8,,9,1,Expert,,,4989,,14171,H,CHEMBL621022,BAO_0000219,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4990,,6333,N,CHEMBL621023,BAO_0000219,,Tested for antiproliferative activity against human A431 cells,Homo sapiens
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,4991,,2356,D,CHEMBL621024,BAO_0000219,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4992,,15578,N,CHEMBL621025,BAO_0000219,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4993,,5126,N,CHEMBL621026,BAO_0000219,,Inhibition of A431 cell proliferation,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4994,,6844,N,CHEMBL621027,BAO_0000219,,Cytotoxic effect on A431 human epidermoid carcinoma cells,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,4995,,6844,N,CHEMBL876397,BAO_0000219,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,4996,,4925,N,CHEMBL883797,BAO_0000219,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,4997,,4925,N,CHEMBL621028,BAO_0000219,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,4998,,13978,N,CHEMBL621029,BAO_0000219,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,4999,,16786,N,CHEMBL621030,BAO_0000219,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,Homo sapiens
F,A-431,500.0,,,,,8,,9,1,Expert,,,5000,,13412,H,CHEMBL621147,BAO_0000219,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5001,,17824,N,CHEMBL621148,BAO_0000218,,In vivo antiproliferative activity against A431 cell line,Homo sapiens
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,5002,,12751,D,CHEMBL621149,BAO_0000219,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,5003,,12380,N,CHEMBL621150,BAO_0000219,,Inhibition of A431 human epidermoid carcinoma cell proliferation,Homo sapiens
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,5004,,4959,D,CHEMBL621151,BAO_0000219,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5005,,6333,N,CHEMBL621152,BAO_0000219,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5006,,6333,N,CHEMBL621153,BAO_0000219,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5007,,6333,N,CHEMBL884000,BAO_0000219,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),Homo sapiens
F,,,,,,,9,9606.0,9,1,Expert,,,5008,,5296,D,CHEMBL621154,BAO_0000019,,Inhibition of EGFR overexpressing A431 cell proliferation,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,5009,,12624,N,CHEMBL621155,BAO_0000219,,Inhibition of A431 cell proliferation,Homo sapiens
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,5010,,14926,D,CHEMBL621156,BAO_0000219,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,Homo sapiens
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,5011,,14926,D,CHEMBL621157,BAO_0000219,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",Homo sapiens
F,A-431,500.0,,,,,8,,9,1,Expert,,,5012,,14926,H,CHEMBL621158,BAO_0000219,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5013,,15144,N,CHEMBL621159,BAO_0000219,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5014,,15144,N,CHEMBL621160,BAO_0000219,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5015,,5245,N,CHEMBL621161,BAO_0000219,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5016,,5245,N,CHEMBL621162,BAO_0000219,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5017,,5245,N,CHEMBL621163,BAO_0000219,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5018,,5245,N,CHEMBL621164,BAO_0000219,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5019,,5245,N,CHEMBL621165,BAO_0000219,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,Homo sapiens
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5020,,5922,U,CHEMBL619159,BAO_0000019,,Half-life period in cynomolgus monkey,Cercopithecidae
A,,,In vitro,,1969.0,,0,9527.0,22224,1,Autocuration,,,5021,,1116,U,CHEMBL619160,BAO_0000366,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,5022,,17853,U,CHEMBL619161,BAO_0000218,,Longer half-life in monkey (i.v.) at 0.5 mpk,Cercopithecidae
A,,,,,1969.0,,0,9527.0,22224,1,Autocuration,,,5023,,993,U,CHEMBL619162,BAO_0000366,Plasma,Plasma half life in monkey,Cercopithecidae
A,,,,,1969.0,,0,9527.0,22224,1,Autocuration,,,5024,,4514,U,CHEMBL619163,BAO_0000366,Plasma,Plasma half-life in rhesus monkey,Cercopithecidae
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,5025,,5334,U,CHEMBL619164,BAO_0000218,Plasma,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Cercopithecidae
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,5026,,5334,U,CHEMBL619320,BAO_0000218,Plasma,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,5027,,4578,U,CHEMBL619321,BAO_0000218,,Tested for half life upon iv administration to african green monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,5028,,2661,U,CHEMBL873336,BAO_0000218,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,5029,,5355,U,CHEMBL619322,BAO_0000218,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,5030,,5355,U,CHEMBL619323,BAO_0000218,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,5031,,5355,U,CHEMBL619324,BAO_0000218,,The time for peak concentration value after oral administration in cynomolgus monkeys,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5032,,11271,U,CHEMBL619325,BAO_0000019,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5033,,11271,U,CHEMBL876411,BAO_0000019,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5034,,11271,U,CHEMBL619326,BAO_0000019,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5035,,11271,U,CHEMBL619327,BAO_0000019,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5036,,11271,U,CHEMBL619328,BAO_0000019,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5037,,11271,U,CHEMBL619329,BAO_0000019,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5038,,11271,U,CHEMBL619330,BAO_0000019,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5039,,11271,U,CHEMBL619331,BAO_0000019,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5040,,11271,U,CHEMBL619332,BAO_0000019,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5041,,11271,U,CHEMBL619333,BAO_0000019,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5042,,11271,U,CHEMBL619334,BAO_0000019,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5043,,11271,U,CHEMBL619335,BAO_0000019,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5044,,11271,U,CHEMBL619336,BAO_0000019,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5045,,11271,U,CHEMBL619337,BAO_0000019,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5046,,11271,U,CHEMBL619338,BAO_0000019,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5047,,11271,U,CHEMBL619339,BAO_0000019,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,Cercopithecidae
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,5048,,5809,N,CHEMBL619340,BAO_0000218,,Bioavailability in rat (cannulated) (dose 2 mg/kg),Rattus norvegicus
A,,,In vivo,,1969.0,,1,10116.0,50597,1,Intermediate,,,5049,,17720,N,CHEMBL873496,BAO_0000218,Plasma,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Rattus norvegicus
A,,,,,1969.0,,1,10116.0,50597,1,Intermediate,,,5050,,3546,N,CHEMBL619341,BAO_0000218,Plasma,AUC value in rat after IV administration at a dose of 10 mg/kg,Rattus norvegicus
A,,,,,1969.0,,1,10116.0,50597,1,Intermediate,,,5051,,3546,N,CHEMBL619342,BAO_0000218,Plasma,AUC value in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,5052,,3546,N,CHEMBL619343,BAO_0000218,,Cmax value in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,5053,,3546,N,CHEMBL619344,BAO_0000218,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,5054,,3546,N,CHEMBL619345,BAO_0000218,,Tmax value in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus
A,,,,,,,1,10116.0,50597,1,Intermediate,,,5055,,3546,N,CHEMBL619346,BAO_0000218,,Vc value in rat after IV administration at a dose of 10 mg/kg,Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,5056,,3546,N,CHEMBL619347,BAO_0000218,,Half life period in rat after IV administration at a dose of 10 mg/kg,Rattus norvegicus
A,,,,,,,0,9557.0,22224,1,Autocuration,,,5057,,10625,U,CHEMBL619348,BAO_0000019,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Papio hamadryas
A,,,,,,,0,9557.0,22224,1,Autocuration,,,5058,,10625,U,CHEMBL619349,BAO_0000019,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),Papio hamadryas
A,,,,,,,0,9557.0,22224,1,Autocuration,,,5059,,10625,U,CHEMBL619350,BAO_0000019,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),Papio hamadryas
A,,,,,,,0,9557.0,22224,1,Autocuration,,,5060,,10625,U,CHEMBL619351,BAO_0000019,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,Papio hamadryas
A,,,,,,,0,9557.0,22224,1,Autocuration,,,5061,,10625,U,CHEMBL875953,BAO_0000019,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,Papio hamadryas
A,,,,,,,0,9557.0,22224,1,Autocuration,,,5062,,10625,U,CHEMBL621716,BAO_0000019,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,Papio hamadryas
A,,,,,,,0,9557.0,22224,1,Autocuration,,,5063,,10625,U,CHEMBL621717,BAO_0000019,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,Papio hamadryas
A,,,,,,,0,9557.0,22224,1,Autocuration,,,5064,,10625,U,CHEMBL621718,BAO_0000019,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Papio hamadryas
A,,,,,,,0,9615.0,22224,1,Autocuration,,,5065,,3510,U,CHEMBL621719,BAO_0000019,,Area under curve after 1 mpk peroral administration to beagles,beagle
A,,,,,,,0,9615.0,22224,1,Autocuration,,,5066,,3510,U,CHEMBL621720,BAO_0000019,,Area under curve after 2 mpk peroral administration to beagles,beagle
A,,,In vivo,,,,0,9615.0,22224,1,Autocuration,,,5067,,3510,U,CHEMBL621721,BAO_0000218,,Cmax value after 1 mpk peroral administration to beagles,beagle
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,5068,,7766,U,CHEMBL621722,BAO_0000019,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,5069,,7766,U,CHEMBL621723,BAO_0000019,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,5070,,7766,U,CHEMBL621724,BAO_0000019,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,5071,,7766,U,CHEMBL623443,BAO_0000019,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,5072,,7766,U,CHEMBL623444,BAO_0000019,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,5073,,7766,U,CHEMBL623445,BAO_0000019,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Homo sapiens
A,,,,,1088.0,,0,9606.0,22224,1,Autocuration,,,5074,,7766,U,CHEMBL623446,BAO_0000019,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Homo sapiens
A,,,,,2107.0,,0,9606.0,22224,1,Autocuration,,,5075,Microsomes,16643,U,CHEMBL623447,BAO_0000251,Liver,Metabolic stability observed at 30 min after administration in human liver microsomes,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5076,,6852,U,CHEMBL623448,BAO_0000019,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5077,,6852,U,CHEMBL623449,BAO_0000019,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5078,,6852,U,CHEMBL623450,BAO_0000019,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,Homo sapiens
A,,,,,2107.0,,0,9606.0,22224,1,Autocuration,,,5079,Microsomes,6567,U,CHEMBL623451,BAO_0000251,Liver,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5080,,6570,U,CHEMBL623452,BAO_0000019,,Metabolic stability (% remaining at 30 mins) in human S9.,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5081,,6570,U,CHEMBL623453,BAO_0000019,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,Homo sapiens
A,,,,,2107.0,,0,9606.0,22224,1,Autocuration,,,5082,Microsomes,5237,U,CHEMBL623454,BAO_0000251,Liver,Percent parent compound remaining after 20 min incubation with human liver microsomes,Homo sapiens
A,,,,,2107.0,,0,9606.0,22224,1,Autocuration,,,5083,Microsomes,5237,U,CHEMBL623455,BAO_0000251,Liver,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Homo sapiens
A,,,,,2107.0,,0,9606.0,22224,1,Autocuration,,,5084,Microsomes,5237,U,CHEMBL624371,BAO_0000251,Liver,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5085,,5202,U,CHEMBL624372,BAO_0000218,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5086,,5481,U,CHEMBL624373,BAO_0000019,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5087,,5481,U,CHEMBL624374,BAO_0000019,,Percent remaining in human plasma after incubation for 60 min at 37 C.,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5088,,3956,U,CHEMBL624556,BAO_0000019,,The percent remaining in human plasma after 30 min was determined,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5089,,5074,U,CHEMBL624557,BAO_0000366,Plasma,Conversion rate of the prodrug in human plasma,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5090,,5074,U,CHEMBL624558,BAO_0000366,Plasma,Conversion rate of the prodrug in human plasma; ND means no data,Homo sapiens
A,,,,,178.0,,0,9606.0,22224,1,Autocuration,,,5091,,4727,U,CHEMBL624559,BAO_0000221,Blood,Half life of compound was determined in human blood,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5092,,5965,U,CHEMBL624560,BAO_0000019,,Half life of compound was determined in man with once daily dosing,Homo sapiens
A,,,In vitro,,,,0,9606.0,22224,1,Autocuration,,,5093,Microsomes,5732,U,CHEMBL624561,BAO_0000251,,Half life in human microsomes,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5094,,5819,U,CHEMBL624562,BAO_0000366,Plasma,Half life in human plasma,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5095,,5819,U,CHEMBL624563,BAO_0000366,Plasma,Half life in human plasma; Not detected,Homo sapiens
A,,,In vivo,,,,0,9606.0,22224,1,Autocuration,,,5096,,1916,U,CHEMBL624564,BAO_0000218,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,5097,Microsomes,6597,U,CHEMBL624565,BAO_0000251,Liver,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5098,,5229,U,CHEMBL875152,BAO_0000366,Plasma,Half-life in human plasma,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5099,,5229,U,CHEMBL624566,BAO_0000366,Plasma,Half-life of the parent prodrug in plasma,Homo sapiens
A,,,In vitro,,1969.0,,0,9606.0,22224,1,Autocuration,,,5100,,2192,U,CHEMBL873805,BAO_0000366,Plasma,In vitro half life in human plasma was determined,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,5101,Microsomes,3032,U,CHEMBL624567,BAO_0000251,Liver,The compound was tested In Vitro for half life in human liver microsomes.,Homo sapiens
A,,,In vivo,,,,0,9606.0,22224,1,Autocuration,,,5102,,1916,U,CHEMBL624568,BAO_0000218,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens
A,,,In vivo,,,,0,9606.0,22224,1,Autocuration,,,5103,,17716,U,CHEMBL624569,BAO_0000218,,Observed volume of distribution,Homo sapiens
A,,,In vivo,,,,0,9606.0,22224,1,Autocuration,,,5104,,15778,U,CHEMBL624570,BAO_0000218,,Oral bioavailability in human,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5105,,17313,U,CHEMBL624571,BAO_0000019,,Tested for human plasma protein binding of the compound,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5106,,4231,U,CHEMBL624572,BAO_0000019,,"First order rate constant, k was determined in human plasma",Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5107,,4755,U,CHEMBL624573,BAO_0000019,,Observed rate constant in 80% human plasma at 37 degree Centigrade,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5108,,4755,U,CHEMBL875153,BAO_0000019,,Observed rate constant in 80% human plasma at 37 degree Centigrade,Homo sapiens
A,,,,,2107.0,,0,9606.0,22224,1,Autocuration,,,5109,Microsomes,16907,U,CHEMBL624574,BAO_0000251,Liver,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5110,,10839,U,CHEMBL624575,BAO_0000019,,The compound was tested for the plasma binding in human,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5111,,10839,U,CHEMBL624576,BAO_0000019,,Plasma protein binding (human),Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,5112,Microsomes,3199,U,CHEMBL624577,BAO_0000251,Liver,Compound was evaluated for half-life in human liver microsomes,Homo sapiens
A,,,In vitro,,178.0,,0,9606.0,22224,1,Autocuration,,,5113,,1345,U,CHEMBL624578,BAO_0000221,Blood,Half life measured in vitro for its stability in human blood,Homo sapiens
A,,,,,1977.0,,0,9606.0,22224,1,Autocuration,,,5114,,4297,U,CHEMBL622796,BAO_0000019,Serum,Half life in human serum,Homo sapiens
A,,,,,1977.0,,0,9606.0,22224,1,Autocuration,,,5115,,4297,U,CHEMBL622797,BAO_0000019,Serum,Half life in human serum; ND=not determined,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5116,,4297,U,CHEMBL622798,BAO_0000019,,Half life were determined in CEM-SS cell extract in decomposition step 1,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5117,,4297,U,CHEMBL622799,BAO_0000019,,Half life were determined in CEM-SS cell extract in decomposition step 2,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5118,,4231,U,CHEMBL622800,BAO_0000366,Plasma,Half life of the in human plasma,Homo sapiens
A,,,In vitro,,,,0,9606.0,22224,1,Autocuration,,,5119,S9,5633,U,CHEMBL622801,BAO_0000220,,Half life period in human hepatic S9 fraction was determined,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,5120,Microsomes,5633,U,CHEMBL622802,BAO_0000251,Liver,Half life period in human liver microsome was determined,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5121,,17791,U,CHEMBL622803,BAO_0000019,,Half life period was determined; 6-7,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5122,,17791,U,CHEMBL875154,BAO_0000019,,Half life period was evaluated in human,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5123,,3160,U,CHEMBL622804,BAO_0000366,Plasma,Half life time in human plasma,Homo sapiens
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,5124,,16438,N,CHEMBL622805,BAO_0000218,Brain,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5125,,16438,N,CHEMBL622611,BAO_0000218,Heart,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5126,,16438,N,CHEMBL622612,BAO_0000218,Heart,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5127,,16438,N,CHEMBL875160,BAO_0000218,Kidney,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5128,,16438,N,CHEMBL622613,BAO_0000218,Kidney,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5129,,16438,N,CHEMBL622614,BAO_0000218,Kidney,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,5130,,16438,N,CHEMBL622615,BAO_0000218,Liver,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,5131,,16438,N,CHEMBL622616,BAO_0000218,Liver,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,5132,,16438,N,CHEMBL622617,BAO_0000218,Liver,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,5133,,16438,N,CHEMBL622618,BAO_0000218,Spleen,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,5134,,16438,N,CHEMBL622619,BAO_0000218,Spleen,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,5135,,16438,N,CHEMBL622620,BAO_0000218,Spleen,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,5136,,16438,N,CHEMBL622621,BAO_0000218,Brain,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,5137,,16438,N,CHEMBL622622,BAO_0000218,Blood,Biodistribution of compound (oxidized form) in blood tissue,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,5138,,16438,N,CHEMBL622623,BAO_0000218,Blood,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,5139,,16438,N,CHEMBL622624,BAO_0000218,Blood,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,5140,,16438,N,CHEMBL622625,BAO_0000218,Blood,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,5141,,16438,N,CHEMBL622626,BAO_0000218,Blood,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,5142,,16438,N,CHEMBL622627,BAO_0000218,Blood,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,5143,,16438,N,CHEMBL622628,BAO_0000218,Brain,Biodistribution of compound (oxidized form) in brain tissue of mice,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,5144,,16438,N,CHEMBL622629,BAO_0000218,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,5145,,16438,N,CHEMBL622630,BAO_0000218,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,5146,,16438,N,CHEMBL622631,BAO_0000218,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,5147,,16438,N,CHEMBL622632,BAO_0000218,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,5148,,16438,N,CHEMBL622633,BAO_0000218,Brain,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5149,,16438,N,CHEMBL622634,BAO_0000218,Heart,Biodistribution of compound (oxidized form) in heart tissue of mice,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5150,,16438,N,CHEMBL622635,BAO_0000218,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5151,,16438,N,CHEMBL875161,BAO_0000218,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5152,,16438,N,CHEMBL622636,BAO_0000218,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5153,,16438,N,CHEMBL623335,BAO_0000218,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5154,,16438,N,CHEMBL623336,BAO_0000218,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5155,,16438,N,CHEMBL623337,BAO_0000218,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5156,,16438,N,CHEMBL623338,BAO_0000218,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5157,,16438,N,CHEMBL623339,BAO_0000218,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5158,,16438,N,CHEMBL623524,BAO_0000218,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5159,,16438,N,CHEMBL623525,BAO_0000218,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,5160,,16438,N,CHEMBL623526,BAO_0000218,Liver,Biodistribution of compound (oxidized form) in liver tissue,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,5161,,16438,N,CHEMBL623527,BAO_0000218,Liver,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,5162,,16438,N,CHEMBL623528,BAO_0000218,Liver,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5163,,5245,N,CHEMBL624615,BAO_0000219,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5164,,5245,N,CHEMBL621672,BAO_0000219,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Homo sapiens
F,A-431,500.0,,,,,1,,80852,1,Expert,,,5165,,16289,N,CHEMBL621673,BAO_0000218,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",
F,A-431,500.0,,,,,1,,80852,1,Expert,,,5166,,16289,N,CHEMBL621674,BAO_0000218,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,5167,,16093,D,CHEMBL884002,BAO_0000219,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5168,,16825,N,CHEMBL621850,BAO_0000219,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5169,,4848,N,CHEMBL621851,BAO_0000219,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,Homo sapiens
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,5170,,14827,D,CHEMBL621852,BAO_0000219,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,Homo sapiens
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,5171,,14827,D,CHEMBL621853,BAO_0000219,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Homo sapiens
F,A-431,500.0,,,,,1,,80852,1,Expert,,,5172,,16289,N,CHEMBL621854,BAO_0000218,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",
F,A-431,500.0,,,,,1,,80852,1,Expert,,,5173,,16289,N,CHEMBL621855,BAO_0000218,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",
F,A-431,500.0,,,,,1,,80852,1,Expert,,,5174,,16289,N,CHEMBL623724,BAO_0000218,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",
F,A-431,500.0,,,,,1,,80852,1,Expert,,,5175,,16289,N,CHEMBL623725,BAO_0000218,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",
F,A-431,500.0,,,,,1,,80852,1,Expert,,,5176,,16289,N,CHEMBL623726,BAO_0000218,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,5177,,16289,D,CHEMBL623727,BAO_0000219,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",Homo sapiens
F,A-431,500.0,,,,,8,,9,1,Expert,,,5178,,16289,H,CHEMBL623728,BAO_0000219,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,
F,A-431,500.0,,,,,1,,80852,1,Expert,,,5179,,16289,N,CHEMBL623729,BAO_0000218,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",
F,A-431,500.0,,,,,1,,80852,1,Expert,,,5180,,16289,N,CHEMBL623730,BAO_0000218,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",
F,A-431,500.0,,,,,1,,80852,1,Expert,,,5181,,16289,N,CHEMBL623731,BAO_0000218,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",
F,A-431,500.0,,,,,1,10090.0,80852,1,Expert,,,5182,,14555,N,CHEMBL623732,BAO_0000218,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus
F,A-431,500.0,,,,,1,10090.0,80852,1,Expert,,,5183,,14555,N,CHEMBL623733,BAO_0000218,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus
F,A-431,500.0,,,,,1,10090.0,80852,1,Expert,,,5184,,14555,N,CHEMBL623734,BAO_0000218,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus
F,A-431,500.0,,,,,1,10090.0,80852,1,Expert,,,5185,,14555,N,CHEMBL623735,BAO_0000218,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,5186,,1937,N,CHEMBL623736,BAO_0000219,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5187,,13739,N,CHEMBL623737,BAO_0000219,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5188,,3558,N,CHEMBL623738,BAO_0000219,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Intermediate,,,5189,,3558,N,CHEMBL875168,BAO_0000219,,Dose giving a 50% decrease in the living cell number (A437 cells),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5190,,17686,N,CHEMBL623739,BAO_0000219,,In vitro inhibitory concentration against proliferation of A459 cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5191,,5305,N,CHEMBL623740,BAO_0000219,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5192,,3614,N,CHEMBL624424,BAO_0000219,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5193,,17229,N,CHEMBL624425,BAO_0000219,,In vitro antitumor activity against renal A498 tumor cell lines,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5194,,15935,N,CHEMBL624426,BAO_0000219,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5195,,15935,N,CHEMBL624427,BAO_0000219,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5196,,15560,N,CHEMBL624428,BAO_0000219,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5197,,13891,N,CHEMBL624429,BAO_0000219,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5198,,13891,N,CHEMBL624620,BAO_0000219,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5199,,13788,N,CHEMBL624621,BAO_0000219,,Cytotoxicity on kidney carcinoma (A-498) cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5200,,15403,N,CHEMBL624622,BAO_0000219,,Compound was evaluated against Human cell line renal A498,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5201,,1009,N,CHEMBL624623,BAO_0000219,,Compound was tested for inhibition of A498 human renal cancer cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5202,,1043,N,CHEMBL874365,BAO_0000219,,Growth inhibitory activity against A498 human cancer cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5203,,5858,N,CHEMBL624624,BAO_0000219,,In vitro antitumor activity against human renal A498 cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5204,,5958,N,CHEMBL624625,BAO_0000219,,In vitro cytotoxic activity against renal (A498) cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5205,,5506,N,CHEMBL624626,BAO_0000219,,In vitro cytotoxic activity against human renal cancer (A498) cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5206,,12781,N,CHEMBL624627,BAO_0000219,,Tested for cytostatic activity against renal A498 cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5207,,14399,N,CHEMBL883157,BAO_0000219,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Expert,,,5208,,5958,N,CHEMBL624628,BAO_0000219,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,Homo sapiens
A,,,In vivo,,,,0,9615.0,22224,1,Autocuration,,,5209,,3510,U,CHEMBL624629,BAO_0000218,,Cmax value after 2 mpk peroral administration to beagles,beagle
A,,,In vivo,,,beagle,0,9615.0,22224,1,Autocuration,,,5210,,3510,U,CHEMBL623551,BAO_0000218,,Bioavailability,Canis lupus familiaris
A,,,In vivo,,,beagle,0,9615.0,22224,1,Autocuration,,,5211,,3510,U,CHEMBL623552,BAO_0000218,,Bioavailability after 1 mpk peroral administration to beagles,Canis lupus familiaris
A,,,In vivo,,,beagle,0,9615.0,22224,1,Autocuration,,,5212,,3510,U,CHEMBL623553,BAO_0000218,,Bioavailability after 2 mpk peroral administration to beagles,Canis lupus familiaris
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5213,,3085,U,CHEMBL623554,BAO_0000019,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5214,,3085,U,CHEMBL623555,BAO_0000019,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5215,,3085,U,CHEMBL623556,BAO_0000019,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5216,,9372,U,CHEMBL623557,BAO_0000019,,Solubility against bovine alpha-chymotrypsin,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5217,,3085,U,CHEMBL623558,BAO_0000019,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5218,,3085,U,CHEMBL623559,BAO_0000019,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Bos taurus
A,,,,,2106.0,,0,9913.0,22224,1,Autocuration,,,5219,,1469,U,CHEMBL623560,BAO_0000221,Spleen,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5220,,4297,U,CHEMBL623561,BAO_0000019,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5221,,4297,U,CHEMBL623562,BAO_0000019,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5222,,17585,U,CHEMBL623563,BAO_0000019,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,Bos taurus
A,,,,,2106.0,,0,9913.0,22224,1,Autocuration,,,5223,,1336,U,CHEMBL623564,BAO_0000221,Spleen,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5224,,3085,U,CHEMBL873806,BAO_0000019,,Half life in presence of 2 mg/mL BSA at pH 8.8,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5225,,2857,U,CHEMBL623565,BAO_0000019,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5226,,2857,U,CHEMBL623566,BAO_0000019,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5227,,2857,U,CHEMBL623567,BAO_0000019,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,Bos taurus
A,,,,,,,0,9913.0,22224,1,Autocuration,,,5228,,1540,U,CHEMBL623568,BAO_0000019,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),Bos taurus
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5229,,6316,N,CHEMBL623569,BAO_0000218,Plasma,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5230,,17594,N,CHEMBL623570,BAO_0000218,Plasma,AUC after administration at 100 mg/kg/day in dogs,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5231,,4953,N,CHEMBL624254,BAO_0000218,Plasma,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5232,,16907,N,CHEMBL624255,BAO_0000218,Plasma,AUC value after 15 mg/kg iv dose in Dogs,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5233,,16907,N,CHEMBL624256,BAO_0000218,Plasma,AUC value after 30 mg/kg po dose in Dogs,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5234,,2959,N,CHEMBL624257,BAO_0000218,Plasma,AUC value after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5235,,17594,N,CHEMBL624258,BAO_0000218,Plasma,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5236,,5356,N,CHEMBL875277,BAO_0000218,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5237,,16807,N,CHEMBL622667,BAO_0000218,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5238,,4527,N,CHEMBL622668,BAO_0000218,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5239,,4527,N,CHEMBL622669,BAO_0000218,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5240,,15660,N,CHEMBL622670,BAO_0000218,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5241,,15660,N,CHEMBL622671,BAO_0000218,,Area under curve determined in dogs after oral administration of 10 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5242,,5802,N,CHEMBL622672,BAO_0000218,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Expert,,,5243,,3598,N,CHEMBL622673,BAO_0000218,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Expert,,,5244,,3598,N,CHEMBL622674,BAO_0000218,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5245,,5944,N,CHEMBL622675,BAO_0000218,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5246,,5944,N,CHEMBL622676,BAO_0000218,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5247,,5944,N,CHEMBL622677,BAO_0000218,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5248,,5944,N,CHEMBL622678,BAO_0000218,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5249,,4186,N,CHEMBL622679,BAO_0000218,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5250,,5007,N,CHEMBL622680,BAO_0000218,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5251,,5668,N,CHEMBL622681,BAO_0000218,,Area under curve was determine after peroral administration at 10 mpk in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5252,,5668,N,CHEMBL875278,BAO_0000218,,Area under curve was determine after peroral administration at 5 mpk in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5253,,5006,N,CHEMBL622682,BAO_0000218,,Area under curve was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5254,,5006,N,CHEMBL622683,BAO_0000218,,Area under curve in dogs,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5255,,3771,N,CHEMBL622684,BAO_0000218,,Area under curve in dogs at 10 mg/kg dose fo oral administration,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5256,,3771,N,CHEMBL622685,BAO_0000218,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5257,,3771,N,CHEMBL622686,BAO_0000218,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5258,,1916,N,CHEMBL618344,BAO_0000218,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5259,,5302,N,CHEMBL875582,BAO_0000218,,Area under curve value in dog at a dose of 5 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5260,,5600,N,CHEMBL618345,BAO_0000218,,Area under curve was determined after 0.1 mg/kg iv administration in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5261,,5600,N,CHEMBL618346,BAO_0000218,,Area under curve was determined after 0.3 mg/kg po administration in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5262,,17764,N,CHEMBL618347,BAO_0000218,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5263,,4368,N,CHEMBL618348,BAO_0000218,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5264,,5318,U,CHEMBL618349,BAO_0000019,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5265,,5318,U,CHEMBL618350,BAO_0000019,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5266,,5318,U,CHEMBL618351,BAO_0000019,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5267,,5318,U,CHEMBL618352,BAO_0000019,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,Homo sapiens
A,,,,,178.0,,0,9606.0,22224,1,Autocuration,,,5268,,14518,U,CHEMBL873494,BAO_0000221,Blood,Time taken to reduce 50% of the concentration of compound in blood plasma,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5269,,2209,U,CHEMBL618353,BAO_0000366,Plasma,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5270,,6787,U,CHEMBL618354,BAO_0000366,Plasma,Half life in human plasma,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5271,,4898,U,CHEMBL875583,BAO_0000366,Plasma,Half life in human plasma was reported,Homo sapiens
A,,,,,1977.0,,0,9606.0,22224,1,Autocuration,,,5272,,6072,U,CHEMBL618355,BAO_0000019,Serum,Half life in human serum,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5273,,16907,U,CHEMBL618356,BAO_0000366,Plasma,Half life upon exposure to human plasma,Homo sapiens
A,,,In vitro,,,,0,9606.0,22224,1,Autocuration,,,5274,Microsomes,5656,U,CHEMBL618357,BAO_0000251,,t1/2 in human microsomes,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5275,,4755,U,CHEMBL618358,BAO_0000366,Plasma,Half life period in 80% human plasma at 37 degree Centigrade,Homo sapiens
A,,,,,14.0,,0,9606.0,22224,1,Autocuration,,,5276,,17503,U,CHEMBL618359,BAO_0000221,Zone of skin,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Homo sapiens
A,,,In vitro,,1969.0,,0,9606.0,22224,1,Autocuration,,,5277,,12357,U,CHEMBL618360,BAO_0000366,Plasma,Half-life measured in in vitro Cathepsin B assay in human plasma,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5278,,3076,U,CHEMBL618361,BAO_0000019,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,5279,Microsomes,6410,U,CHEMBL618362,BAO_0000251,Liver,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5280,,3741,U,CHEMBL618363,BAO_0000366,Plasma,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5281,,3741,U,CHEMBL618364,BAO_0000366,Plasma,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5282,,3741,U,CHEMBL875584,BAO_0000366,Plasma,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5283,,1540,U,CHEMBL618365,BAO_0000019,,Half-life in the CEM cell extracts,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5284,,2905,U,CHEMBL873495,BAO_0000366,Plasma,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5285,,2905,U,CHEMBL618366,BAO_0000366,Plasma,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5286,,5523,U,CHEMBL618367,BAO_0000019,,Half-life was determined,Homo sapiens
A,,,,,178.0,,0,9606.0,22224,1,Autocuration,,,5287,,1499,U,CHEMBL618368,BAO_0000221,Blood,Half-life (human blood stability),Homo sapiens
A,,,,,178.0,,0,9606.0,22224,1,Autocuration,,,5288,,1499,U,CHEMBL618369,BAO_0000221,Blood,Half-life (human blood stability); no data,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5289,,17065,U,CHEMBL618370,BAO_0000366,Plasma,Half-life in human plasma,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5290,,6861,U,CHEMBL618371,BAO_0000019,,CYP3A4 metabolism half-life (t1/2),Homo sapiens
A,,,,,178.0,,0,9606.0,22224,1,Autocuration,,,5291,,1499,U,CHEMBL618372,BAO_0000221,Blood,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Homo sapiens
A,,,In vitro,,1969.0,,0,9606.0,22224,1,Autocuration,,,5292,,530,U,CHEMBL618373,BAO_0000366,Plasma,In vitro half life in human plasma,Homo sapiens
A,,,In vitro,,1969.0,,0,9606.0,22224,1,Autocuration,,,5293,,1116,U,CHEMBL618374,BAO_0000366,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Homo sapiens
A,,,In vitro,,1969.0,,0,9606.0,22224,1,Autocuration,,,5294,,6695,U,CHEMBL618375,BAO_0000366,Plasma,In vitro hydrolysis in human plasma,Homo sapiens
A,,,In vitro,,1969.0,,0,9606.0,22224,1,Autocuration,,,5295,,6695,U,CHEMBL618376,BAO_0000366,Plasma,In vitro hydrolysis in human plasma; no data,Homo sapiens
A,,,In vitro,,2107.0,,0,9606.0,22224,1,Autocuration,,,5296,Microsomes,10,U,CHEMBL618377,BAO_0000251,Liver,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5297,,993,U,CHEMBL618378,BAO_0000366,Plasma,Plasma half life in human,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5298,,15429,U,CHEMBL618379,BAO_0000366,Plasma,Stability after incubation with human plasma (at 37 degree C),Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5299,,1675,U,CHEMBL618380,BAO_0000366,Plasma,T1/2 was evaluated in human plasma,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5300,,2209,U,CHEMBL618381,BAO_0000366,Plasma,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5301,,2209,U,CHEMBL618382,BAO_0000366,Plasma,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5302,,5318,U,CHEMBL618383,BAO_0000019,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Homo sapiens
A,,,In vitro,,,,0,9606.0,22224,1,Autocuration,,,5303,,2412,U,CHEMBL618384,BAO_0000019,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,Homo sapiens
A,,,In vitro,,,,0,9606.0,22224,1,Autocuration,,,5304,,2412,U,CHEMBL618385,BAO_0000019,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5305,,2906,U,CHEMBL619099,BAO_0000366,Plasma,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Homo sapiens
A,,,,,1969.0,,0,9606.0,22224,1,Autocuration,,,5306,,2906,U,CHEMBL619100,BAO_0000366,Plasma,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5307,,5495,U,CHEMBL619101,BAO_0000019,,Time taken for 50% to be consumed by serum PON1 was determined,Homo sapiens
A,,,,,,,0,9606.0,22224,1,Autocuration,,,5308,,5495,U,CHEMBL619102,BAO_0000019,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,Homo sapiens
A,,,,,2107.0,,0,9606.0,22224,1,Autocuration,,,5309,Microsomes,4397,U,CHEMBL619103,BAO_0000251,Liver,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Homo sapiens
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5310,,2413,U,CHEMBL619268,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5311,,2413,U,CHEMBL619269,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5312,,2413,U,CHEMBL619270,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5313,,2413,U,CHEMBL619271,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5314,,2413,U,CHEMBL875585,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5315,,2413,U,CHEMBL619272,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5316,,6058,N,CHEMBL619273,BAO_0000219,,Compound tested for growth inhibition of renal cancer cell line 786-0,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5317,,17708,N,CHEMBL619274,BAO_0000219,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Expert,,,5318,,14017,N,CHEMBL619275,BAO_0000219,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5319,,16818,N,CHEMBL619276,BAO_0000219,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5320,,16818,N,CHEMBL619277,BAO_0000219,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5321,,16818,N,CHEMBL619278,BAO_0000219,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5322,,11970,N,CHEMBL619279,BAO_0000219,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5323,,12400,N,CHEMBL858458,BAO_0000219,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Expert,,,5324,,12888,N,CHEMBL619280,BAO_0000219,,Cytotoxic effect on renal cancer line 786-0,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5325,,15300,N,CHEMBL619281,BAO_0000219,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5326,,14769,N,CHEMBL619282,BAO_0000219,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5327,,15895,N,CHEMBL619283,BAO_0000219,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5328,,17376,N,CHEMBL619284,BAO_0000219,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5329,,14882,N,CHEMBL619285,BAO_0000219,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5330,,14882,N,CHEMBL619286,BAO_0000219,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5331,,15176,N,CHEMBL619287,BAO_0000219,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5332,,12696,N,CHEMBL857455,BAO_0000219,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5333,,2496,N,CHEMBL883801,BAO_0000219,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),Homo sapiens
F,791T cell line,972.0,,,,,1,9606.0,80641,1,Intermediate,,,5334,,11831,N,CHEMBL619288,BAO_0000219,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,Homo sapiens
F,791T cell line,972.0,,,,,1,9606.0,80641,1,Intermediate,,,5335,,11831,N,CHEMBL619289,BAO_0000219,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),Homo sapiens
F,791T cell line,972.0,,,,,1,9606.0,80641,1,Intermediate,,,5336,,11831,N,CHEMBL619290,BAO_0000219,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,Homo sapiens
F,791T cell line,972.0,,,,,1,9606.0,80641,1,Intermediate,,,5337,,11831,N,CHEMBL619291,BAO_0000219,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),Homo sapiens
F,791T cell line,972.0,,,,,1,9606.0,80641,1,Intermediate,,,5338,,11831,N,CHEMBL619292,BAO_0000219,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),Homo sapiens
F,791T cell line,972.0,,,,,1,9606.0,80641,1,Intermediate,,,5339,,11831,N,CHEMBL619293,BAO_0000219,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,Homo sapiens
F,791T cell line,972.0,,,,,1,9606.0,80641,1,Intermediate,,,5340,,11831,N,CHEMBL619294,BAO_0000219,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),Homo sapiens
F,791T cell line,972.0,,,,,1,9606.0,80641,1,Intermediate,,,5341,,11831,N,CHEMBL619295,BAO_0000219,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),Homo sapiens
F,791T cell line,972.0,,,,,1,9606.0,80641,1,Intermediate,,,5342,,11831,N,CHEMBL619296,BAO_0000219,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),Homo sapiens
F,791T cell line,972.0,,,,,1,9606.0,80641,1,Intermediate,,,5343,,11831,N,CHEMBL619297,BAO_0000219,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,Homo sapiens
F,786-0,391.0,,,,,1,9606.0,80640,1,Intermediate,,,5344,,12782,N,CHEMBL619298,BAO_0000219,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,Homo sapiens
F,,,,,,,0,,22226,1,Intermediate,,,5345,,1229,U,CHEMBL619299,BAO_0000019,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Expert,,,5346,,15313,N,CHEMBL619300,BAO_0000219,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Expert,,,5347,,15313,N,CHEMBL619301,BAO_0000219,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5348,,11544,N,CHEMBL619302,BAO_0000219,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5349,,9424,N,CHEMBL619303,BAO_0000219,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5350,,9424,N,CHEMBL619304,BAO_0000219,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5351,,9424,N,CHEMBL857706,BAO_0000219,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5352,,9424,N,CHEMBL619305,BAO_0000219,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5353,,9424,N,CHEMBL619306,BAO_0000219,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5354,,9424,N,CHEMBL619307,BAO_0000219,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5355,,9424,N,CHEMBL619308,BAO_0000219,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5356,,9424,N,CHEMBL619309,BAO_0000219,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5357,,9424,N,CHEMBL619310,BAO_0000219,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5358,,14769,N,CHEMBL619311,BAO_0000219,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5359,,15354,N,CHEMBL619312,BAO_0000219,,Compound was tested for the growth inhibition of A498 renal tumor cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5360,,17445,N,CHEMBL619313,BAO_0000219,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5361,,4337,N,CHEMBL619314,BAO_0000219,,In vitro inhibitory concentration against renal cancer cell line A498,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5362,,15277,N,CHEMBL619959,BAO_0000219,,Cytotoxicity against A 498 tumor cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5363,,4812,N,CHEMBL619960,BAO_0000219,,In vitro antitumor activity against A498 human cancer cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5364,,4812,N,CHEMBL619961,BAO_0000219,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5365,,4995,N,CHEMBL619962,BAO_0000219,,Inhibitory dose required against A498 human tumor cell lines,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5366,,5847,N,CHEMBL875586,BAO_0000219,,Anticancer activity against one renal cancer (A498 cell line),Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5367,,6557,N,CHEMBL619963,BAO_0000219,,In vitro cytotoxicity against melanoma A498 cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5368,,2597,N,CHEMBL619964,BAO_0000219,,Compound was tested for growth inhibitory activity against A498 cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5369,,6058,N,CHEMBL620108,BAO_0000219,,Compound tested for growth inhibition of renal cancer cell line A498,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5370,,17708,N,CHEMBL620109,BAO_0000219,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5371,,15176,N,CHEMBL620110,BAO_0000219,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5372,,15300,N,CHEMBL620111,BAO_0000219,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5373,,11970,N,CHEMBL620112,BAO_0000219,,Tested for cytotoxicity against A498 cell lines in renal cancer,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5374,,12400,N,CHEMBL620113,BAO_0000219,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Expert,,,5375,,12888,N,CHEMBL620114,BAO_0000219,,Cytotoxic effect on renal cancer lines A498,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5376,,3030,N,CHEMBL620115,BAO_0000219,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5377,,14769,N,CHEMBL620116,BAO_0000219,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5378,,17376,N,CHEMBL620117,BAO_0000219,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5379,,16558,N,CHEMBL620118,BAO_0000219,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5380,,5194,N,CHEMBL620119,BAO_0000219,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5381,,10708,N,CHEMBL620120,BAO_0000219,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5382,,16880,N,CHEMBL620121,BAO_0000219,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5383,,10196,N,CHEMBL620122,BAO_0000219,,Antitumor activity against A549 human lung carcinoma cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5384,,10196,N,CHEMBL620123,BAO_0000219,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5385,,10196,N,CHEMBL620124,BAO_0000219,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5386,,12083,N,CHEMBL620125,BAO_0000219,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5387,,16464,N,CHEMBL620126,BAO_0000219,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5388,,16464,N,CHEMBL883027,BAO_0000219,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5389,,16470,N,CHEMBL620127,BAO_0000219,,In vitro cytotoxic activity against human lung A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5390,,16470,N,CHEMBL620128,BAO_0000219,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5391,,16470,N,CHEMBL620129,BAO_0000219,,In vitro cytotoxic activity against human lung A549 cell line),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5392,,16470,N,CHEMBL620130,BAO_0000219,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5393,,16582,N,CHEMBL620131,BAO_0000219,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5394,,15935,N,CHEMBL620132,BAO_0000219,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5395,,15935,N,CHEMBL620133,BAO_0000219,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5396,,16597,N,CHEMBL620134,BAO_0000219,,Inhibition of A549 human lung carcinoma cell proliferation,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5397,,17376,N,CHEMBL620135,BAO_0000219,,Inhibitory activity against A549 lung adenocarcinoma cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5398,,16496,N,CHEMBL620136,BAO_0000219,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5399,,16152,N,CHEMBL620137,BAO_0000219,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5400,,16152,N,CHEMBL620268,BAO_0000219,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5401,,16464,N,CHEMBL620269,BAO_0000219,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5402,,2288,N,CHEMBL620270,BAO_0000219,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5403,,17350,N,CHEMBL620271,BAO_0000219,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5404,,4090,N,CHEMBL620272,BAO_0000219,,Inhibition of A549 cancer cell proliferation,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5405,,4090,N,CHEMBL620273,BAO_0000219,,Inhibition of A549 cancer cell proliferation (Not tested),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5406,,17350,N,CHEMBL620274,BAO_0000219,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5407,,4197,N,CHEMBL620275,BAO_0000219,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5408,,17072,N,CHEMBL620276,BAO_0000219,,Antiproliferative potency determined as inhibitory concentration against A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5409,,17072,N,CHEMBL620277,BAO_0000219,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5410,,5194,N,CHEMBL620278,BAO_0000219,,Cytotoxicity against Renal cell lines A549 was determined,Homo sapiens
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5411,,4257,N,CHEMBL620279,BAO_0000218,,Area under curve was determined in dog after a 3 mg/kg of oral dose,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5412,,6123,N,CHEMBL620280,BAO_0000218,,Area under curve was determined in dog after oral administration at 1 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5413,,1337,N,CHEMBL620281,BAO_0000218,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5414,,1337,N,CHEMBL620282,BAO_0000218,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5415,,8833,N,CHEMBL621134,BAO_0000218,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5416,,8833,N,CHEMBL621135,BAO_0000218,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5417,,8833,N,CHEMBL621136,BAO_0000218,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5418,,8833,N,CHEMBL621137,BAO_0000218,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5419,,17657,N,CHEMBL621138,BAO_0000218,Plasma,Area under plasma concentration time curve in dog upon oral administration,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5420,,17650,N,CHEMBL875587,BAO_0000218,Plasma,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5421,,1977,N,CHEMBL621139,BAO_0000218,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5422,,1977,N,CHEMBL621140,BAO_0000218,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5423,,3132,N,CHEMBL621141,BAO_0000218,,Area under the curve for the compound was obtained when tested in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5424,,5473,N,CHEMBL621142,BAO_0000218,,Area under the curve at a dose of 1 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5425,,5474,N,CHEMBL621143,BAO_0000218,,Area under the curve at a dose of 1 mg/kg (oral),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5426,,5474,N,CHEMBL621144,BAO_0000218,,Area under the curve at i.v. dose of 0.2 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5427,,6062,N,CHEMBL621145,BAO_0000218,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5428,,4709,N,CHEMBL621146,BAO_0000218,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5429,,2652,N,CHEMBL622567,BAO_0000218,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5430,,2652,N,CHEMBL622568,BAO_0000218,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5431,,2877,N,CHEMBL622569,BAO_0000218,,Compound was evaluated for area under the curve in dog blood.,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5432,,5444,N,CHEMBL622570,BAO_0000218,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5433,,5130,N,CHEMBL622571,BAO_0000218,Plasma,AUC in dog after oral dose (1 mg/kg),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5434,,6265,N,CHEMBL622572,BAO_0000218,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5435,,4657,N,CHEMBL622573,BAO_0000218,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5436,,16367,N,CHEMBL622574,BAO_0000218,,Pharmacokinetic parameter AUC after intravenous administration to dogs,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5437,,16367,N,CHEMBL622575,BAO_0000218,,Pharmacokinetic parameter AUC after oral administration to dogs,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5438,,9579,N,CHEMBL622576,BAO_0000218,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5439,,9579,N,CHEMBL622577,BAO_0000218,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5440,,5983,N,CHEMBL622578,BAO_0000218,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5441,,6241,N,CHEMBL622579,BAO_0000218,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5442,,5313,N,CHEMBL622580,BAO_0000218,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5443,,5313,N,CHEMBL622581,BAO_0000218,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5444,,6642,N,CHEMBL622582,BAO_0000218,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5445,,6642,N,CHEMBL622583,BAO_0000218,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5446,,6641,N,CHEMBL622584,BAO_0000218,,Oral AUCN in dog (dosed at 0.5 mpk iv ),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5447,,6642,N,CHEMBL622585,BAO_0000218,,Oral AUCN in dog (dosed at 0.5 mpk iv ),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5448,,17791,N,CHEMBL622586,BAO_0000218,,Compound was evaluated for oral bioavailability in dog; 90-100,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5449,,17655,N,CHEMBL623281,BAO_0000218,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5450,,17655,N,CHEMBL623282,BAO_0000218,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5451,,6596,N,CHEMBL623283,BAO_0000218,,PAPP (membrane permeability) in dog kidney cell monolayer assay,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5452,,3880,N,CHEMBL623284,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5453,,16367,N,CHEMBL623285,BAO_0000218,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5454,,17409,N,CHEMBL623463,BAO_0000218,Plasma,Plasma protein binding towards dog plasma at 10 uM,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5455,,17409,N,CHEMBL875952,BAO_0000218,Plasma,Plasma protein binding towards dog plasma at 100 uM,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5456,,2959,N,CHEMBL621705,BAO_0000218,,Bioavailability in dog (dose 4 mg/kg p.o.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5457,,13501,N,CHEMBL621706,BAO_0000218,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5458,,4527,N,CHEMBL621707,BAO_0000218,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5459,,15145,N,CHEMBL621708,BAO_0000218,,Bioavailability in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5460,,4219,N,CHEMBL621709,BAO_0000218,,Bioavailability,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5461,,17538,N,CHEMBL621710,BAO_0000218,,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5462,,17538,N,CHEMBL621711,BAO_0000218,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5463,,1466,N,CHEMBL621712,BAO_0000218,,Bioavailability in dog (dose 10.0 mg/kg p.o.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5464,,17650,N,CHEMBL621713,BAO_0000218,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5465,,3132,N,CHEMBL621714,BAO_0000218,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,Canis lupus familiaris
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5466,,2413,U,CHEMBL621715,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.
A,,,,,2107.0,,0,10095.0,22224,1,Autocuration,,,5467,,2413,U,CHEMBL623717,BAO_0000218,Liver,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.
A,,,,,2107.0,,0,10095.0,22224,1,Autocuration,,,5468,,2413,U,CHEMBL623718,BAO_0000218,Liver,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.
A,,,,,2107.0,,0,10095.0,22224,1,Autocuration,,,5469,,2413,U,CHEMBL623719,BAO_0000218,Liver,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5470,,2413,U,CHEMBL623720,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5471,,2413,U,CHEMBL623721,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.
A,,,,,2385.0,,0,10095.0,22224,1,Autocuration,,,5472,,2413,U,CHEMBL623722,BAO_0000218,Muscle tissue,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.
A,,,,,2385.0,,0,10095.0,22224,1,Autocuration,,,5473,,2413,U,CHEMBL623723,BAO_0000218,Muscle tissue,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.
A,,,,,2385.0,,0,10095.0,22224,1,Autocuration,,,5474,,2413,U,CHEMBL618543,BAO_0000218,Muscle tissue,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.
A,,,,,2106.0,,0,10095.0,22224,1,Autocuration,,,5475,,2413,U,CHEMBL618544,BAO_0000218,Spleen,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.
A,,,,,2106.0,,0,10095.0,22224,1,Autocuration,,,5476,,2413,U,CHEMBL875155,BAO_0000218,Spleen,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5477,,2413,U,CHEMBL618545,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5478,,2413,U,CHEMBL618546,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5479,,2413,U,CHEMBL623529,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5480,,2413,U,CHEMBL623530,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.
A,,,,,,,0,10095.0,22224,1,Autocuration,,,5481,,2413,U,CHEMBL621764,BAO_0000218,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5482,,17827,U,CHEMBL621765,BAO_0000019,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Cercopithecidae
A,,,,,2037.0,,0,9527.0,22224,1,Autocuration,,,5483,,17827,U,CHEMBL621766,BAO_0000019,Cerebellum,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cercopithecidae
A,,,,,1870.0,,0,9527.0,22224,1,Autocuration,,,5484,,17827,U,CHEMBL621767,BAO_0000019,Frontal cortex,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5485,,17827,U,CHEMBL621768,BAO_0000019,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),Cercopithecidae
A,,,,,2435.0,,0,9527.0,22224,1,Autocuration,,,5486,,17827,U,CHEMBL621769,BAO_0000019,Striatum,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5487,,17827,U,CHEMBL621770,BAO_0000019,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Cercopithecidae
A,,,,,2037.0,,0,9527.0,22224,1,Autocuration,,,5488,,17827,U,CHEMBL621771,BAO_0000019,Cerebellum,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cercopithecidae
A,,,,,1870.0,,0,9527.0,22224,1,Autocuration,,,5489,,17827,U,CHEMBL621772,BAO_0000019,Frontal cortex,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5490,,17827,U,CHEMBL621773,BAO_0000019,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),Cercopithecidae
A,,,,,2435.0,,0,9527.0,22224,1,Autocuration,,,5491,,17827,U,CHEMBL621774,BAO_0000019,Striatum,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5492,,17791,U,CHEMBL621775,BAO_0000218,,Compound was evaluated for oral bioavailability in rats,Cercopithecidae
A,,,In vivo,,1969.0,,0,9527.0,22224,1,Autocuration,,,5493,,17667,U,CHEMBL621776,BAO_0000218,Plasma,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,5494,,17791,U,CHEMBL621777,BAO_0000019,,Half life period was evaluated in monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,5495,,110,U,CHEMBL875162,BAO_0000218,,Half-life in rhesus monkeys by intravenous administration of dose,Cercopithecidae
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,5496,,5781,N,CHEMBL621778,BAO_0000218,Plasma,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,5497,,17734,N,CHEMBL621779,BAO_0000218,Plasma,AUC after intraperitoneal administration of 100 mg/kg in mice,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,5498,,17718,N,CHEMBL622479,BAO_0000218,Plasma,AUC value was determined after oral administration,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5499,,4573,N,CHEMBL622480,BAO_0000218,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5500,,3277,N,CHEMBL622481,BAO_0000218,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5501,,2862,N,CHEMBL622482,BAO_0000218,,Area under curve by ioral administration in mouse,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5502,,2862,N,CHEMBL622483,BAO_0000218,,Area under curve by iv administration in mouse,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5503,,5951,N,CHEMBL622484,BAO_0000218,,Area under curve at 0-8 hr in IRC mice after peroral administration,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5504,,17729,N,CHEMBL622641,BAO_0000218,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5505,,17728,N,CHEMBL622642,BAO_0000218,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5506,,17728,N,CHEMBL622643,BAO_0000218,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5507,,17729,N,CHEMBL622644,BAO_0000218,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,Mus musculus
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5508,,9424,N,CHEMBL622645,BAO_0000219,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5509,,9424,N,CHEMBL622646,BAO_0000219,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5510,,9424,N,CHEMBL621238,BAO_0000219,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5511,,9424,N,CHEMBL621239,BAO_0000219,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5512,,9424,N,CHEMBL621240,BAO_0000219,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5513,,9424,N,CHEMBL621241,BAO_0000219,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5514,,9424,N,CHEMBL621242,BAO_0000219,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5515,,9424,N,CHEMBL620350,BAO_0000219,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5516,,9424,N,CHEMBL620351,BAO_0000219,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5517,,9424,N,CHEMBL620352,BAO_0000219,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5518,,9424,N,CHEMBL620353,BAO_0000219,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5519,,9424,N,CHEMBL620354,BAO_0000219,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5520,,9424,N,CHEMBL620355,BAO_0000219,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5521,,9424,N,CHEMBL620356,BAO_0000219,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5522,,9424,N,CHEMBL620357,BAO_0000219,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5523,,9424,N,CHEMBL620358,BAO_0000219,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Expert,,,5524,,9424,N,CHEMBL620359,BAO_0000219,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5525,,11544,N,CHEMBL620360,BAO_0000219,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5526,,17378,N,CHEMBL620361,BAO_0000219,,Cytotoxicity of compound against 8226/DOX1V cells,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5527,,17378,N,CHEMBL620362,BAO_0000219,,Cytotoxicity of compound against 8226/S cells,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5528,,17079,N,CHEMBL620363,BAO_0000219,,Inhibitory concentration against 8226 myeloma cancer cell line,Homo sapiens
F,RPMI-8226,741.0,,,,,1,9606.0,80433,1,Intermediate,,,5529,,17079,N,CHEMBL620364,BAO_0000219,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,Homo sapiens
F,833K,854.0,,,,,1,9606.0,80647,1,Intermediate,,,5530,,13466,N,CHEMBL620365,BAO_0000219,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,Homo sapiens
F,833K,854.0,,,,,1,9606.0,80647,1,Intermediate,,,5531,,13466,N,CHEMBL620366,BAO_0000219,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',Homo sapiens
F,833K,854.0,,,,,1,9606.0,80647,1,Expert,,,5532,,2392,N,CHEMBL620367,BAO_0000219,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,Homo sapiens
F,833K,854.0,,,,,1,9606.0,80647,1,Intermediate,,,5533,,2392,N,CHEMBL620368,BAO_0000219,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,Homo sapiens
B,,,,,,,0,,22226,1,Autocuration,,,5534,,6608,U,CHEMBL620369,BAO_0000019,,Inhibitory activity against caspase-1,
B,,,,,,,8,1351.0,45,1,Autocuration,,,5535,,10199,H,CHEMBL620370,BAO_0000357,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,Enterococcus faecalis
F,8701-BC,705.0,,,,,1,9606.0,80648,1,Intermediate,,,5536,,17749,N,CHEMBL620371,BAO_0000219,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,Homo sapiens
F,8701-BC,705.0,,,,,1,9606.0,80648,1,Intermediate,,,5537,,17749,N,CHEMBL620372,BAO_0000219,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,Homo sapiens
F,,,,,,,0,,22226,1,Intermediate,,,5538,,1229,U,CHEMBL876492,BAO_0000019,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,
F,,,,,,,0,,22226,1,Intermediate,,,5539,,1229,U,CHEMBL620373,BAO_0000019,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,
F,,,,,,,0,,22226,1,Intermediate,,,5540,,1229,U,CHEMBL620374,BAO_0000019,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,
B,,,,,,,0,,22226,1,Autocuration,,,5541,,6390,U,CHEMBL620375,BAO_0000019,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,
F,,,,,,,0,1314.0,22226,1,Autocuration,,,5542,,16219,U,CHEMBL857902,BAO_0000019,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Streptococcus pyogenes
F,,,,,,,0,1314.0,22226,1,Autocuration,,,5543,,16219,U,CHEMBL620376,BAO_0000019,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Streptococcus pyogenes
B,,,,,,,8,,11922,1,Autocuration,,,5544,,17043,H,CHEMBL620377,BAO_0000357,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,
F,KB ,324.0,,,,,1,9606.0,81115,1,Intermediate,,,5545,,6929,N,CHEMBL620378,BAO_0000219,,Tested for in vitro cytotoxic potency of compound in 9KB assay,Homo sapiens
A,KB ,324.0,,,,,1,9606.0,81115,1,Intermediate,,,5546,,6929,N,CHEMBL620379,BAO_0000219,,Tested for in vitro cytotoxic potency of compound in 9KB assay,Homo sapiens
F,,,,,,,0,9606.0,22226,1,Autocuration,,,5547,,7083,U,CHEMBL620380,BAO_0000219,,In vitro cytotoxicity of compound was tested against 9KB cells.,Homo sapiens
F,9L,392.0,,,,,1,10116.0,80653,1,Intermediate,,,5548,,12446,N,CHEMBL884006,BAO_0000219,,Cytotoxic concentration against 9L cells was determined on day 3,Rattus norvegicus
F,9L,392.0,,,,,1,10116.0,80653,1,Expert,,,5549,,15345,N,CHEMBL620381,BAO_0000219,,Tested in vitro for anticancer activity against 9L cells,Rattus norvegicus
F,9L,392.0,,,,,1,10116.0,80653,1,Expert,,,5550,,15345,N,CHEMBL620382,BAO_0000219,,Tested in vitro for anticancer activity against 9L cells; Not determined,Rattus norvegicus
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5551,,6301,N,CHEMBL620383,BAO_0000219,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5552,,4833,N,CHEMBL876493,BAO_0000219,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5553,,4833,N,CHEMBL620384,BAO_0000219,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5554,,4833,N,CHEMBL620385,BAO_0000219,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5555,,13330,N,CHEMBL620386,BAO_0000219,,Cytotoxicity against human lung carcinoma A549 cell line,Homo sapiens
F,A549,646.0,,,,,9,9606.0,25,1,Expert,,,5556,,17517,D,CHEMBL620387,BAO_0000219,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,Homo sapiens
F,A549,646.0,,,,,9,9606.0,25,1,Expert,,,5557,,17517,D,CHEMBL621404,BAO_0000219,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5558,,14425,N,CHEMBL621405,BAO_0000219,,"In vitro growth inhibition of A549, lung carcinoma",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5559,,14425,N,CHEMBL621406,BAO_0000219,,"In vitro growth inhibition of A549, lung carcinoma.",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5560,,5228,N,CHEMBL621407,BAO_0000219,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5561,,5351,N,CHEMBL621408,BAO_0000219,,Cytotoxic activity against human lung cancer A549 cell line was determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5562,,12198,N,CHEMBL885345,BAO_0000219,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5563,,13891,N,CHEMBL621409,BAO_0000219,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5564,,5677,N,CHEMBL876034,BAO_0000219,,Cytotoxicity in A549 (human carcinoma) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5565,,13788,N,CHEMBL621410,BAO_0000219,,Cytotoxicity on lung carcinoma (A-549) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5566,,13384,N,CHEMBL621411,BAO_0000219,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5567,,6726,N,CHEMBL621412,BAO_0000219,,Effective dose of compound against replication of A549 cell line was evaluated,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5568,,3455,N,CHEMBL621413,BAO_0000219,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5569,,5726,N,CHEMBL621414,BAO_0000219,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5570,,5726,N,CHEMBL621415,BAO_0000219,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5571,,3936,N,CHEMBL621416,BAO_0000219,,The compound was evaluated for antiproliferative activity against A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5572,,14991,N,CHEMBL621417,BAO_0000219,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5573,,5243,N,CHEMBL621418,BAO_0000219,,Concentration required for growth inhibition of human lung carcinoma cell line A549,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5574,,12858,N,CHEMBL621419,BAO_0000219,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5575,,6776,N,CHEMBL621420,BAO_0000219,,Growth inhibition against A549 cell line was evaluated,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5576,,16558,N,CHEMBL875823,BAO_0000219,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5577,,4583,N,CHEMBL621421,BAO_0000219,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5578,,13514,N,CHEMBL621422,BAO_0000219,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5579,,15166,N,CHEMBL884014,BAO_0000219,,Chemosensitivity against DT-diaphorase rich A549 cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5580,,13873,N,CHEMBL621423,BAO_0000219,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5581,,6447,N,CHEMBL621424,BAO_0000219,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5582,,2068,N,CHEMBL621425,BAO_0000219,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5583,,1863,N,CHEMBL621426,BAO_0000219,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5584,,13873,N,CHEMBL621427,BAO_0000219,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5585,,13873,N,CHEMBL621428,BAO_0000219,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5586,,13873,N,CHEMBL621429,BAO_0000219,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5587,,579,N,CHEMBL621430,BAO_0000219,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5588,,579,N,CHEMBL621431,BAO_0000219,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5589,,4584,N,CHEMBL621432,BAO_0000219,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5590,,5421,N,CHEMBL621433,BAO_0000219,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5591,,5421,N,CHEMBL875824,BAO_0000219,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5592,,5421,N,CHEMBL621434,BAO_0000219,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5593,,5421,N,CHEMBL621435,BAO_0000219,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5594,,14188,N,CHEMBL621436,BAO_0000219,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5595,,14188,N,CHEMBL621437,BAO_0000219,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5596,,15354,N,CHEMBL621438,BAO_0000219,,Compound was tested for the growth inhibition of A549 lung tumor cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5597,,14253,N,CHEMBL621439,BAO_0000219,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5598,,13873,N,CHEMBL621440,BAO_0000219,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Homo sapiens
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5599,,3043,N,CHEMBL621441,BAO_0000218,,Oral bioavailability in dog (conscious),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5600,,3045,N,CHEMBL621442,BAO_0000218,,Compound was evaluated for the oral bioavailability after oral administration in dog.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5601,,3022,N,CHEMBL621443,BAO_0000218,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5602,,4453,N,CHEMBL621444,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5603,,1696,N,CHEMBL625133,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5604,,5045,N,CHEMBL625134,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5605,,5356,N,CHEMBL625135,BAO_0000218,,Oral bioavailability in dog (fasted),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5606,,17764,N,CHEMBL625136,BAO_0000218,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5607,,6448,N,CHEMBL625137,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5608,,1475,N,CHEMBL625138,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5609,,3788,N,CHEMBL625139,BAO_0000218,,Percent bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5610,,3639,N,CHEMBL872264,BAO_0000218,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5611,,13397,N,CHEMBL625140,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5612,,2137,N,CHEMBL624436,BAO_0000218,,The compound was evaluated for bioavailability in dogs; 34-44,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5613,,2959,N,CHEMBL624437,BAO_0000218,,Bioavailability in dog (dose 4 mg/kg p.o.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5614,,6448,N,CHEMBL872261,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5615,,6084,N,CHEMBL624438,BAO_0000218,,8 hour trough Blood level in dog was measured after administration of compound,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,5616,,3639,N,CHEMBL624439,BAO_0000218,Plasma,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5617,,6316,N,CHEMBL624440,BAO_0000218,,C24 after oral administration at 5 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5618,,5238,N,CHEMBL624441,BAO_0000218,,Clearance after oral and iv dosing in dogs,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,5619,,17796,N,CHEMBL624442,BAO_0000218,Plasma,Clearance of the drug was measured in the plasma of dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,5620,,2652,N,CHEMBL624443,BAO_0000218,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5621,,5654,N,CHEMBL624444,BAO_0000218,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5622,,6621,N,CHEMBL624445,BAO_0000218,,Clearance of compound was determined in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5623,,6505,N,CHEMBL624446,BAO_0000218,,Clearance on i.v. administration of 2 mg/kg was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5624,,5802,N,CHEMBL624447,BAO_0000218,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5625,,17267,N,CHEMBL624448,BAO_0000218,,Plasma clearance in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5626,,4521,N,CHEMBL624449,BAO_0000218,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5627,,6535,N,CHEMBL624450,BAO_0000218,,Plasma clearance in dog after administration of 0.25 mg/kg iv,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5628,,6535,N,CHEMBL875942,BAO_0000218,,Plasma clearance in dog after administration of 1 mg/kg iv,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5629,,6535,N,CHEMBL624451,BAO_0000218,,Plasma clearance in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5630,,5542,N,CHEMBL624452,BAO_0000218,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5631,,5199,N,CHEMBL624453,BAO_0000218,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5632,,16907,N,CHEMBL624454,BAO_0000218,,Plasma clearance after 15 mg/kg iv dose in Dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5633,,16907,N,CHEMBL624455,BAO_0000218,,Plasma clearance after 30 mg/kg po dose in Dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5634,,16367,N,CHEMBL624456,BAO_0000218,,Plasma administration to dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5635,,5505,N,CHEMBL624457,BAO_0000218,,Plasma clearance was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5636,,6215,N,CHEMBL624458,BAO_0000218,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5637,,1466,N,CHEMBL624459,BAO_0000218,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,Canis lupus familiaris
A,,,In vitro,,2107.0,,2,9606.0,102164,1,Intermediate,,,5638,Microsomes,5007,S,CHEMBL624460,BAO_0000251,Liver,Intrinsic clearance in human liver microsomes,Homo sapiens
A,,,In vitro,,2107.0,,2,9606.0,102164,1,Intermediate,,,5639,Microsomes,5007,S,CHEMBL624461,BAO_0000251,Liver,Intrinsic clearance in human liver microsomes,Homo sapiens
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5640,,16452,N,CHEMBL875943,BAO_0000218,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5641,,16452,N,CHEMBL624462,BAO_0000218,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5642,,16452,N,CHEMBL624463,BAO_0000218,,Clearance in dog (dose 1 mg/kg i.v.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5643,,6221,N,CHEMBL624464,BAO_0000218,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5644,,5007,N,CHEMBL624465,BAO_0000218,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5645,,5668,N,CHEMBL624466,BAO_0000218,,Plasma clearance after peroral administration at 10 mpk in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5646,,5668,N,CHEMBL624467,BAO_0000218,,Plasma clearance after peroral administration at 5 mpk in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5647,,5668,N,CHEMBL624468,BAO_0000218,,Plasma clearance after peroral administration at 5 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5648,,15660,N,CHEMBL624469,BAO_0000218,,Plasma clearance was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5649,,15660,N,CHEMBL624470,BAO_0000218,,Plasma clearance was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5650,,5983,N,CHEMBL624471,BAO_0000218,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5651,,5600,N,CHEMBL624472,BAO_0000218,,Total clearance was determined after 0.1 mg/kg iv administration in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5652,,17764,N,CHEMBL622775,BAO_0000218,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5653,,6039,N,CHEMBL622776,BAO_0000218,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5654,,6039,N,CHEMBL622777,BAO_0000218,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5655,,6039,N,CHEMBL622778,BAO_0000218,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5656,,4368,N,CHEMBL622779,BAO_0000218,,Clearance by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5657,,4305,N,CHEMBL622780,BAO_0000218,,Clearance by iv administration in dogs at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,5658,,1918,N,CHEMBL622781,BAO_0000218,Plasma,Clearance value was evaluated in dog plasma,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5659,,6005,N,CHEMBL622782,BAO_0000218,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,5660,,4839,N,CHEMBL622783,BAO_0000218,Plasma,Compound was tested for plasma clearance in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5661,,4239,N,CHEMBL622784,BAO_0000218,,Pharmacokinetic property (Plasma clearance) was measured in dog,Canis lupus familiaris
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5662,,17729,N,CHEMBL622785,BAO_0000218,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5663,,17728,N,CHEMBL622786,BAO_0000218,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5664,,5302,N,CHEMBL622787,BAO_0000218,,Area under curve value in mouse at a dose of 10 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5665,,5506,N,CHEMBL875949,BAO_0000218,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5666,,5506,N,CHEMBL622788,BAO_0000218,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,Mus musculus
F,,,,,,,1,10090.0,50594,1,Intermediate,,,5667,,17764,N,CHEMBL622789,BAO_0000218,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Mus musculus
F,,,,,,,1,10090.0,50594,1,Intermediate,,,5668,,17764,N,CHEMBL622790,BAO_0000218,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Mus musculus
F,,,,,,,1,10090.0,50594,1,Intermediate,,,5669,,17764,N,CHEMBL622791,BAO_0000218,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Mus musculus
F,,,,,,,1,10090.0,50594,1,Intermediate,,,5670,,17764,N,CHEMBL622792,BAO_0000218,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5671,,17764,N,CHEMBL622793,BAO_0000218,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5672,,17753,N,CHEMBL622794,BAO_0000218,,Area under curve was determined for the compound at 24 mg/Kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5673,,17753,N,CHEMBL622795,BAO_0000218,,Area under curve was determined for the compound at 40 mg/Kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5674,,17753,N,CHEMBL621803,BAO_0000218,,Area under curve was determined for the compound at 5 mg/Kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5675,,3132,N,CHEMBL621804,BAO_0000218,,Area under the curve for the compound is obtained at dose 25 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5676,,3132,N,CHEMBL621805,BAO_0000218,,Area under the curve for the compound was obtained when tested in mouse,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5677,,17837,N,CHEMBL621806,BAO_0000218,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5678,,17837,N,CHEMBL621807,BAO_0000218,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5679,,6062,N,CHEMBL621808,BAO_0000218,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5680,,4066,N,CHEMBL621809,BAO_0000218,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5681,,16597,N,CHEMBL621810,BAO_0000218,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5682,,14239,N,CHEMBL875164,BAO_0000218,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5683,,14239,N,CHEMBL621811,BAO_0000218,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5684,,4890,N,CHEMBL621812,BAO_0000218,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5685,,429,N,CHEMBL621813,BAO_0000218,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5686,,429,N,CHEMBL621814,BAO_0000218,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5687,,5969,N,CHEMBL621815,BAO_0000218,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5688,,5969,N,CHEMBL621816,BAO_0000218,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5689,,5969,N,CHEMBL621817,BAO_0000218,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5690,,6091,N,CHEMBL621818,BAO_0000218,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5691,,6091,N,CHEMBL621819,BAO_0000218,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5692,,6091,N,CHEMBL621820,BAO_0000218,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5693,,6091,N,CHEMBL621821,BAO_0000218,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5694,,6178,N,CHEMBL621822,BAO_0000218,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5695,,6178,N,CHEMBL619474,BAO_0000218,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5696,,6619,N,CHEMBL619475,BAO_0000218,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5697,,6619,N,CHEMBL619476,BAO_0000218,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5698,,3760,N,CHEMBL619477,BAO_0000218,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5699,,3760,N,CHEMBL619478,BAO_0000218,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5700,,3760,N,CHEMBL619479,BAO_0000218,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5701,,3760,N,CHEMBL619480,BAO_0000218,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5702,,3192,N,CHEMBL619481,BAO_0000218,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5703,,3192,N,CHEMBL619482,BAO_0000218,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5704,,2675,N,CHEMBL619483,BAO_0000218,,Area under the curve was evaluated in mice after intravenous administration,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5705,,2675,N,CHEMBL619484,BAO_0000218,,Area under the curve was evaluated in mice after oral administration,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,5706,,16597,N,CHEMBL619485,BAO_0000218,Plasma,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,5707,,16597,N,CHEMBL619486,BAO_0000218,Plasma,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5708,,16597,N,CHEMBL619487,BAO_0000218,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,5709,,17734,N,CHEMBL619488,BAO_0000218,,AUMC after intraperitoneal administration of 100 mg/kg in mice,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,5710,,7767,N,CHEMBL620106,BAO_0000218,Blood,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Mus musculus
F,9L,392.0,,,,,1,,80653,1,Intermediate,,,5711,,15345,N,CHEMBL620107,BAO_0000219,,The compound was tested in vitro for anticancer activity against 9L cells,
F,,,,,,,0,10116.0,22226,1,Autocuration,,,5712,,2181,U,CHEMBL620283,BAO_0000019,,Anti proliferation activity determined; Weak effect,Rattus norvegicus
F,,,,,,,0,10116.0,22226,1,Autocuration,,,5713,,2181,U,CHEMBL875176,BAO_0000219,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,Rattus norvegicus
F,,,,,,,0,10116.0,22226,1,Autocuration,,,5714,,2181,U,CHEMBL620284,BAO_0000219,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,Rattus norvegicus
F,,,,,,,0,10116.0,22226,1,Autocuration,,,5715,,2181,U,CHEMBL623515,BAO_0000219,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,Rattus norvegicus
F,,,,,,,0,10090.0,22226,1,Autocuration,,,5716,,10486,U,CHEMBL623516,BAO_0000019,,The cytotoxic activity was in vitro tested by 9PS assay method,Mus musculus
F,,,,,,,0,10090.0,22226,1,Autocuration,,,5717,,10486,U,CHEMBL623517,BAO_0000019,,The cytotoxic activity was in vitro tested by 9PS assay method.,Mus musculus
A,,,,,,,0,,22224,1,Autocuration,,,5718,,15508,U,CHEMBL857878,BAO_0000019,,Partition coefficient (logD6.5),
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,5719,,5242,N,CHEMBL623518,BAO_0000219,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,Homo sapiens
F,A-375,455.0,,,,,1,9606.0,80018,1,Intermediate,,,5720,,16167,N,CHEMBL624195,BAO_0000219,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,5721,,4782,N,CHEMBL624196,BAO_0000219,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,Homo sapiens
F,A-431,500.0,,,,,9,9606.0,9,1,Expert,,,5722,,16093,D,CHEMBL624197,BAO_0000219,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5723,,2596,N,CHEMBL624198,BAO_0000219,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5724,,2596,N,CHEMBL621287,BAO_0000219,,in vitro cytotoxicity against A 498 cancer cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5725,,3239,N,CHEMBL621288,BAO_0000219,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5726,,1847,N,CHEMBL876496,BAO_0000219,,Cytotoxic activity against A 498 renal cancer cell lines.,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5727,,10553,N,CHEMBL621289,BAO_0000219,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,Homo sapiens
F,,,,,,,0,1280.0,22226,1,Autocuration,,,5728,,16219,U,CHEMBL621290,BAO_0000019,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Staphylococcus aureus
F,,,,,,,0,1280.0,22226,1,Autocuration,,,5729,,16219,U,CHEMBL621291,BAO_0000019,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Staphylococcus aureus
F,,,,,,,0,1280.0,22226,1,Autocuration,,,5730,,16219,U,CHEMBL621292,BAO_0000019,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Staphylococcus aureus
F,,,,,,,0,1280.0,22226,1,Autocuration,,,5731,,16219,U,CHEMBL621293,BAO_0000019,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Staphylococcus aureus
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5732,,4782,N,CHEMBL621294,BAO_0000219,,Inhibitory concentration required against A 549 lung cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5733,,11805,N,CHEMBL621295,BAO_0000219,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5734,,11805,N,CHEMBL884007,BAO_0000219,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5735,,2007,N,CHEMBL621296,BAO_0000219,,In vitro cytotoxicity against lung cancer A 549 cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5736,,4594,N,CHEMBL621297,BAO_0000219,,Compound was tested for its cytotoxicity against A 549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5737,,6018,N,CHEMBL839828,BAO_0000219,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5738,,6018,N,CHEMBL620397,BAO_0000219,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5739,,3599,N,CHEMBL620398,BAO_0000219,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5740,,2551,N,CHEMBL620399,BAO_0000219,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5741,,16132,N,CHEMBL620400,BAO_0000219,,In vitro inhibition of A549 (human lung cancer) cell growth.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5742,,16132,N,CHEMBL620401,BAO_0000219,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5743,,2551,N,CHEMBL620402,BAO_0000219,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5744,,2551,N,CHEMBL620403,BAO_0000219,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),Homo sapiens
F,,,,,,,0,,22226,1,Autocuration,,,5745,,11913,U,CHEMBL620404,BAO_0000218,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,
F,,,In vivo,,,,4,,104694,1,Autocuration,,,5746,,12621,H,CHEMBL620405,BAO_0000218,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,
F,,,In vivo,,,,4,,104694,1,Autocuration,,,5747,,12621,H,CHEMBL620406,BAO_0000218,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,
F,,,In vivo,,,,4,,104694,1,Autocuration,,,5748,,12621,H,CHEMBL620407,BAO_0000218,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,
F,,,In vivo,,,,4,,104694,1,Autocuration,,,5749,,12621,H,CHEMBL620408,BAO_0000218,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,
F,,,In vivo,,,,4,,104694,1,Autocuration,,,5750,,12621,H,CHEMBL620409,BAO_0000218,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,
F,A498,624.0,,,,,1,9606.0,80021,1,Expert,,,5751,,3600,N,CHEMBL620410,BAO_0000219,,Inhibition of A-498 human Renal cell proliferation,Homo sapiens
F,,,,,,,0,10116.0,22226,1,Autocuration,,,5752,,1796,U,CHEMBL620411,BAO_0000019,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",Rattus norvegicus
F,,,,,,,0,10116.0,22226,1,Autocuration,,,5753,,1796,U,CHEMBL620412,BAO_0000019,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",Rattus norvegicus
F,,,,,,,0,10116.0,22226,1,Autocuration,,,5754,,1796,U,CHEMBL876596,BAO_0000019,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",Rattus norvegicus
F,A 172,622.0,,,,,1,9606.0,80012,1,Expert,,,5755,,16464,N,CHEMBL620413,BAO_0000219,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,Homo sapiens
F,A 172,622.0,,,,,1,9606.0,80012,1,Intermediate,,,5756,,16464,N,CHEMBL620414,BAO_0000219,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens
F,A 172,622.0,,,,,1,9606.0,80012,1,Intermediate,,,5757,,16464,N,CHEMBL620415,BAO_0000219,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5758,,13617,N,CHEMBL620416,BAO_0000219,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5759,,4584,N,CHEMBL620417,BAO_0000219,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5760,,13799,N,CHEMBL620418,BAO_0000219,,Cytotoxic activity evaluated against A549 tumor cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5761,,16726,N,CHEMBL620419,BAO_0000219,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5762,,16109,N,CHEMBL620420,BAO_0000219,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5763,,16109,N,CHEMBL620421,BAO_0000219,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5764,,15474,N,CHEMBL620422,BAO_0000219,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5765,,6851,N,CHEMBL620423,BAO_0000219,,Cytotoxicity of compound against A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5766,,17534,N,CHEMBL620424,BAO_0000219,,Cytotoxicity against human lung cell carcinoma A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5767,,2621,N,CHEMBL620425,BAO_0000219,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5768,,830,N,CHEMBL620426,BAO_0000219,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5769,,14255,N,CHEMBL620427,BAO_0000219,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5770,,14255,N,CHEMBL620428,BAO_0000219,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5771,,1590,N,CHEMBL620429,BAO_0000219,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5772,,6146,N,CHEMBL620430,BAO_0000219,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5773,,17427,N,CHEMBL839887,BAO_0000219,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5774,,5280,N,CHEMBL620431,BAO_0000219,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5775,,16786,N,CHEMBL884010,BAO_0000219,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5776,,5895,N,CHEMBL620538,BAO_0000219,,In vitro cytotoxicity against A549 (human lung cancer),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5777,,14297,N,CHEMBL620539,BAO_0000219,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5778,,17824,N,CHEMBL623373,BAO_0000218,,In vivo antiproliferative activity against A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5779,,14368,N,CHEMBL623374,BAO_0000219,,Inhibition of non-small-cell lung adenocarcinoma (A549),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5780,,14368,N,CHEMBL623375,BAO_0000219,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5781,,14254,N,CHEMBL623376,BAO_0000219,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5782,,15897,N,CHEMBL623377,BAO_0000219,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5783,,13866,N,CHEMBL623378,BAO_0000219,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5784,,13370,N,CHEMBL623379,BAO_0000219,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5785,,4862,N,CHEMBL623380,BAO_0000219,,Inhibitory activity against A549 lung cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5786,,4862,N,CHEMBL623381,BAO_0000219,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5787,,4862,N,CHEMBL623382,BAO_0000219,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5788,,15970,N,CHEMBL623383,BAO_0000219,,Inhibitory concentration against A549 (lung cancer) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5789,,17713,N,CHEMBL623384,BAO_0000219,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5790,,4833,N,CHEMBL623385,BAO_0000219,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5791,,13736,N,CHEMBL623386,BAO_0000219,,Activity against A549 cancer cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5792,,4312,N,CHEMBL884105,BAO_0000219,,The compound was evaluated for cytotoxicity against A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5793,,5421,N,CHEMBL623387,BAO_0000219,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5794,,5421,N,CHEMBL621568,BAO_0000219,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5795,,14717,N,CHEMBL621569,BAO_0000219,,Growth inhibitory activity was measured for human A549 tumor cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5796,,4634,N,CHEMBL621570,BAO_0000219,,Inhibitory activity against A549 lung cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5797,,1149,N,CHEMBL621571,BAO_0000219,,Inhibitory activity against A549 cell line; inactive,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5798,,5421,N,CHEMBL621572,BAO_0000219,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5799,,5421,N,CHEMBL621573,BAO_0000219,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5800,,5421,N,CHEMBL621574,BAO_0000219,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5801,,3320,N,CHEMBL621575,BAO_0000219,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5802,,3320,N,CHEMBL621576,BAO_0000219,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5803,,3320,N,CHEMBL621577,BAO_0000219,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5804,,3320,N,CHEMBL621578,BAO_0000219,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5805,,3320,N,CHEMBL621579,BAO_0000219,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5806,,5726,N,CHEMBL621580,BAO_0000219,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,Homo sapiens
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5807,,17800,N,CHEMBL621581,BAO_0000218,,Plasma clearance (in vivo) in mongrel dogs was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5808,,5985,N,CHEMBL621582,BAO_0000218,,Plasma clearance was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5809,,5530,N,CHEMBL621583,BAO_0000218,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5810,,5530,N,CHEMBL621584,BAO_0000218,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,5811,,4839,N,CHEMBL621585,BAO_0000218,Plasma,Tested for plasma clearance in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5812,,3639,N,CHEMBL621586,BAO_0000218,,The compound was tested for clearance in dog plasma.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5813,,4838,N,CHEMBL875835,BAO_0000218,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5814,,4137,N,CHEMBL621587,BAO_0000218,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,5815,,5017,N,CHEMBL621588,BAO_0000218,Plasma,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Canis lupus familiaris
A,,,In vitro,,2107.0,,1,9615.0,50588,1,Intermediate,,,5816,Microsomes,17538,N,CHEMBL621589,BAO_0000218,Liver,In vitro clearance in dog liver microsomes,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5817,,6161,N,CHEMBL621590,BAO_0000218,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5818,,6161,N,CHEMBL621591,BAO_0000218,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5819,,1696,N,CHEMBL621592,BAO_0000218,,Plasma clearance in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5820,,6762,N,CHEMBL621593,BAO_0000218,,Clearance rate in dog,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,5821,,5932,N,CHEMBL621594,BAO_0000218,Plasma,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5822,,6305,N,CHEMBL621595,BAO_0000218,,Clearance in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5823,,4942,N,CHEMBL621596,BAO_0000218,,Plasma clearance in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5824,,4219,N,CHEMBL621597,BAO_0000218,,Plasma clearance was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5825,,17853,N,CHEMBL621598,BAO_0000218,,Lower clearance in dog (i.v.) at 0.5 mpk,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5826,,4514,N,CHEMBL621599,BAO_0000218,,Plasma clearance in Beagle dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5827,,6448,N,CHEMBL875836,BAO_0000218,,Plasma clearance (Clp) in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5828,,6227,N,CHEMBL621600,BAO_0000218,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5829,,6227,N,CHEMBL621601,BAO_0000218,,Plasma clearance (pharmacokinetic parameter) in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5830,,6062,N,CHEMBL618474,BAO_0000218,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5831,,6821,N,CHEMBL618475,BAO_0000218,,Plasma clearance of compound was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5832,,4709,N,CHEMBL624524,BAO_0000218,,Plasma clearance after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5833,,4521,N,CHEMBL624525,BAO_0000218,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5834,,5374,N,CHEMBL624526,BAO_0000218,,Plasma clearance in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5835,,6057,N,CHEMBL624527,BAO_0000218,,Plasma clearance was calculated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5836,,4727,N,CHEMBL624528,BAO_0000218,,Plasma clearance at the dose of 2 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5837,,5145,N,CHEMBL624529,BAO_0000218,,Plasma clearance in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5838,,17657,N,CHEMBL624530,BAO_0000218,,Plasma clearance in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5839,,17657,N,CHEMBL624531,BAO_0000218,,Plasma clearance in dog; Unable to calculate,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5840,,5145,N,CHEMBL624532,BAO_0000218,,Plasma clearance in rhesus monkey,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5841,,6642,N,CHEMBL624533,BAO_0000218,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5842,,6641,N,CHEMBL624534,BAO_0000218,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5843,,6642,N,CHEMBL624535,BAO_0000218,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5844,,5472,N,CHEMBL624536,BAO_0000218,,Plasma clearance was evaluated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5845,,5472,N,CHEMBL624537,BAO_0000218,,Plasma clearance was evaluated in dog; Not tested,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5846,,5472,N,CHEMBL624538,BAO_0000218,,Plasma clearance was evaluated in rhesus,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5847,,5472,N,CHEMBL624539,BAO_0000218,,Plasma clearance was evaluated in rhesus; Not tested,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5848,,4257,N,CHEMBL624540,BAO_0000218,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5849,,6679,N,CHEMBL624541,BAO_0000218,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5850,,5546,N,CHEMBL624542,BAO_0000218,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5851,,6348,N,CHEMBL624543,BAO_0000218,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5852,,5474,N,CHEMBL624544,BAO_0000218,,Clearance value at a dose of 0.2 mg/kg i.v.,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,5853,,6316,N,CHEMBL624545,BAO_0000218,Plasma,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5854,,17594,N,CHEMBL624546,BAO_0000218,,Cmax after oral dose of compound at 3 mg/kg in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5855,,17594,N,CHEMBL875957,BAO_0000218,,Cmax after single intravenous bolus of 1 mg/kg in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5856,,5802,N,CHEMBL624547,BAO_0000218,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5857,,6535,N,CHEMBL624548,BAO_0000218,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5858,,6535,N,CHEMBL624549,BAO_0000218,,Cmax in dog after administration of 1 mg/kg iv,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,5859,,1466,N,CHEMBL624550,BAO_0000218,Plasma,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5860,,6505,N,CHEMBL621613,BAO_0000218,,Cmax on p.o. administration of 10 mg/kg was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5861,,5668,N,CHEMBL621614,BAO_0000218,,Cmax was determine after peroral administration at 10 mpk in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5862,,5668,N,CHEMBL623431,BAO_0000218,,Cmax was determine after peroral administration at 5 mpk in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5863,,5668,N,CHEMBL623432,BAO_0000218,,Cmax was determine after peroral administration at 5 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5864,,5600,N,CHEMBL623433,BAO_0000218,,Cmax after 0.3 mg/kg po administration in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5865,,17764,N,CHEMBL623434,BAO_0000218,,Cmax after peroral administration in dogs at 2.4 uM/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5866,,6123,N,CHEMBL623435,BAO_0000218,,Cmax in dog after oral administration at 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5867,,6123,N,CHEMBL623436,BAO_0000218,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5868,,6757,N,CHEMBL875958,BAO_0000218,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5869,,16907,N,CHEMBL623437,BAO_0000218,,Cmax value after 15 mg/kg iv dose in Dogs,Canis lupus familiaris
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,5870,,7767,N,CHEMBL623438,BAO_0000218,Blood,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,5871,,7767,N,CHEMBL623439,BAO_0000218,Blood,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,5872,,7767,N,CHEMBL623440,BAO_0000218,Bone,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,5873,,7767,N,CHEMBL623441,BAO_0000218,Bone,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,5874,,7767,N,CHEMBL623442,BAO_0000218,Bone,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,5875,,7767,N,CHEMBL623469,BAO_0000218,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,5876,,7767,N,CHEMBL623470,BAO_0000218,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,5877,,7767,N,CHEMBL623471,BAO_0000218,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5878,,7767,N,CHEMBL623472,BAO_0000218,Heart,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5879,,7767,N,CHEMBL623473,BAO_0000218,Heart,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,5880,,7767,N,CHEMBL623474,BAO_0000218,Heart,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5881,,7767,N,CHEMBL623475,BAO_0000218,Kidney,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5882,,7767,N,CHEMBL623476,BAO_0000218,Kidney,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,5883,,7767,N,CHEMBL623477,BAO_0000218,Kidney,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,160.0,,1,10090.0,50594,1,Intermediate,,,5884,,7767,N,CHEMBL621896,BAO_0000218,Intestine,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,160.0,,1,10090.0,50594,1,Intermediate,,,5885,,7767,N,CHEMBL621897,BAO_0000218,Intestine,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,160.0,,1,10090.0,50594,1,Intermediate,,,5886,,7767,N,CHEMBL621898,BAO_0000218,Intestine,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,5887,,7767,N,CHEMBL621899,BAO_0000218,Liver,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,5888,,7767,N,CHEMBL621900,BAO_0000218,Liver,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,5889,,7767,N,CHEMBL621901,BAO_0000218,Liver,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,5890,,7767,N,CHEMBL621902,BAO_0000218,Lung,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,5891,,7767,N,CHEMBL621903,BAO_0000218,Lung,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,5892,,7767,N,CHEMBL622587,BAO_0000218,Lung,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,5893,,7767,N,CHEMBL620285,BAO_0000218,Muscle tissue,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,5894,,7767,N,CHEMBL875285,BAO_0000218,Muscle tissue,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,5895,,7767,N,CHEMBL620286,BAO_0000218,Muscle tissue,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,5896,,7767,N,CHEMBL620287,BAO_0000218,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,5897,,7767,N,CHEMBL620288,BAO_0000218,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,5898,,7767,N,CHEMBL620289,BAO_0000218,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,160.0,,1,10090.0,50594,1,Intermediate,,,5899,,7767,N,CHEMBL620290,BAO_0000218,Intestine,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,160.0,,1,10090.0,50594,1,Intermediate,,,5900,,7767,N,CHEMBL620291,BAO_0000218,Intestine,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,160.0,,1,10090.0,50594,1,Intermediate,,,5901,,7767,N,CHEMBL620292,BAO_0000218,Intestine,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,5902,,7767,N,CHEMBL620293,BAO_0000218,Spleen,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,5903,,7767,N,CHEMBL620294,BAO_0000218,Spleen,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,5904,,7767,N,CHEMBL618614,BAO_0000218,Spleen,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,5905,,7767,N,CHEMBL618615,BAO_0000218,Stomach,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,5906,,7767,N,CHEMBL618616,BAO_0000218,Stomach,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus
F,A 172,622.0,,,,,1,9606.0,80012,1,Expert,,,5907,,2036,N,CHEMBL618617,BAO_0000219,,Cytotoxicity against A-172 human tumor cell lines,Homo sapiens
F,A 172,622.0,,,,,1,9606.0,80012,1,Intermediate,,,5908,,2357,N,CHEMBL618618,BAO_0000219,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,Homo sapiens
F,A204,623.0,,,,,1,9606.0,80014,1,Intermediate,,,5909,,1457,N,CHEMBL618619,BAO_0000219,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,5910,,4379,N,CHEMBL618620,BAO_0000219,,Tested for antiproliferative activity against A-2780 tumoral cell line,Homo sapiens
F,A-375,455.0,,,,,1,9606.0,80018,1,Intermediate,,,5911,,1093,N,CHEMBL618621,BAO_0000219,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,Homo sapiens
F,A-375,455.0,,,,,1,9606.0,80018,1,Intermediate,,,5912,,12152,N,CHEMBL618622,BAO_0000219,,Tested in vitro against A-375 cell line human melanoma,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Expert,,,5913,,16464,N,CHEMBL618623,BAO_0000219,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,5914,,16464,N,CHEMBL618624,BAO_0000219,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Expert,,,5915,,16582,N,CHEMBL618625,BAO_0000219,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,5916,,16464,N,CHEMBL618626,BAO_0000219,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,5917,,10413,N,CHEMBL618627,BAO_0000219,,Antitumor activity on A-427 lung carcinoma cell lines,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,5918,,6418,N,CHEMBL618628,BAO_0000219,,Cytotoxic activity against human A-427 lung tumor cell line,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Expert,,,5919,,17134,N,CHEMBL618629,BAO_0000219,,In vitro antitumor effects against human A-427 cell lines.,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Expert,,,5920,,16132,N,CHEMBL618630,BAO_0000219,,In vitro inhibition of A-427 (human lung cancer) cell growth.,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,5921,,16132,N,CHEMBL618631,BAO_0000219,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,Homo sapiens
F,A-427,797.0,,,,,1,9606.0,80019,1,Intermediate,,,5922,,16780,N,CHEMBL618632,BAO_0000219,,Cytotoxic activity of compound against A-427 lung human tumor cell line,Homo sapiens
F,A-431,500.0,,,,,1,9606.0,80852,1,Expert,,,5923,,4085,N,CHEMBL618633,BAO_0000219,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5924,,1276,N,CHEMBL619315,BAO_0000219,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Expert,,,5925,,3498,N,CHEMBL619316,BAO_0000219,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5926,,1169,N,CHEMBL619317,BAO_0000219,,Cytotoxicity against human kidney carcinoma A-498cell lines,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5927,,4450,N,CHEMBL619318,BAO_0000219,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5928,,3311,N,CHEMBL619319,BAO_0000219,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5929,,4461,N,CHEMBL619739,BAO_0000219,,Antitumor cytotoxic activity against A-498 cell line was determined,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5930,,3311,N,CHEMBL619740,BAO_0000219,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5931,,3311,N,CHEMBL883158,BAO_0000219,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5932,,1457,N,CHEMBL884012,BAO_0000219,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5933,,3664,N,CHEMBL619741,BAO_0000219,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,Homo sapiens
F,A498,624.0,,,,,1,9606.0,80021,1,Intermediate,,,5934,,15895,N,CHEMBL619742,BAO_0000219,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5935,,11843,N,CHEMBL876610,BAO_0000219,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5936,,11843,N,CHEMBL619743,BAO_0000219,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5937,,17705,N,CHEMBL619744,BAO_0000219,,In vitro antiproliferative activity against human A-549 NSCL cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5938,,17705,N,CHEMBL619745,BAO_0000219,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5939,,4369,N,CHEMBL619746,BAO_0000219,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5940,,4369,N,CHEMBL619747,BAO_0000219,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5941,,4369,N,CHEMBL619748,BAO_0000219,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5942,,4369,N,CHEMBL619749,BAO_0000219,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5943,,4369,N,CHEMBL619750,BAO_0000219,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5944,,4369,N,CHEMBL624014,BAO_0000219,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5945,,4369,N,CHEMBL624015,BAO_0000219,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5946,,4787,N,CHEMBL885344,BAO_0000219,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5947,,4787,N,CHEMBL623224,BAO_0000219,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5948,,6513,N,CHEMBL623225,BAO_0000219,,Cytotoxic activity against A-549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5949,,6690,N,CHEMBL622698,BAO_0000219,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5950,,6690,N,CHEMBL622699,BAO_0000219,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5951,,12263,N,CHEMBL622700,BAO_0000219,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5952,,1054,N,CHEMBL622701,BAO_0000219,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5953,,1359,N,CHEMBL622702,BAO_0000219,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5954,,3547,N,CHEMBL622703,BAO_0000219,,Cytotoxic activity against human lung carcinoma (A-549) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5955,,5771,N,CHEMBL622704,BAO_0000219,,Cytotoxic activity towards A-549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5956,,14425,N,CHEMBL622705,BAO_0000219,,"In vitro percent inhibition of A549, lung carcinoma.",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5957,,14425,N,CHEMBL622706,BAO_0000219,,"In vitro percent inhibition of A549, lung carcinoma",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5958,,14425,N,CHEMBL622707,BAO_0000219,,"In vitro percent inhibition of A549, lung carcinoma.",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5959,,14425,N,CHEMBL622708,BAO_0000219,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5960,,5280,N,CHEMBL622709,BAO_0000219,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5961,,15176,N,CHEMBL622710,BAO_0000219,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5962,,15300,N,CHEMBL622711,BAO_0000219,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5963,,17824,N,CHEMBL622712,BAO_0000218,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5964,,17824,N,CHEMBL622713,BAO_0000218,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5965,,17824,N,CHEMBL622714,BAO_0000218,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5966,,17824,N,CHEMBL622715,BAO_0000218,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5967,,17824,N,CHEMBL622716,BAO_0000218,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5968,,17824,N,CHEMBL622717,BAO_0000219,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5969,,17528,N,CHEMBL622718,BAO_0000218,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5970,,6870,N,CHEMBL622719,BAO_0000219,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5971,,6870,N,CHEMBL622720,BAO_0000219,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5972,,6870,N,CHEMBL622721,BAO_0000219,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5973,,6870,N,CHEMBL622722,BAO_0000219,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5974,,16726,N,CHEMBL876030,BAO_0000219,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5975,,6170,N,CHEMBL620206,BAO_0000219,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5976,,6583,N,CHEMBL620207,BAO_0000219,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5977,,6583,N,CHEMBL620208,BAO_0000219,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5978,,6583,N,CHEMBL620209,BAO_0000219,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5979,,6583,N,CHEMBL620210,BAO_0000219,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5980,,6583,N,CHEMBL621639,BAO_0000219,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5981,,17321,N,CHEMBL621640,BAO_0000219,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5982,,17528,N,CHEMBL621641,BAO_0000219,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,5983,,12888,N,CHEMBL621642,BAO_0000219,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5984,,4312,N,CHEMBL621643,BAO_0000219,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5985,,4312,N,CHEMBL621644,BAO_0000219,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,5986,,4312,N,CHEMBL621645,BAO_0000219,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,Homo sapiens
F,A549,646.0,,,,,1,10090.0,80682,1,Intermediate,,,5987,,17737,N,CHEMBL621646,BAO_0000219,,In vitro antiproliferative activity against A549 cell line,Mus musculus
F,A549,646.0,,,,,1,,80682,1,Intermediate,,,5988,,6630,N,CHEMBL621647,BAO_0000219,,Synergism with indomethacin in A549 cells,
F,A549,646.0,,,,,1,,80682,1,Intermediate,,,5989,,6630,N,CHEMBL621648,BAO_0000219,,Synergism with tolmetin in A549 cells,
F,A549,646.0,,,,,1,,80682,1,Intermediate,,,5990,,6630,N,CHEMBL621649,BAO_0000219,,Synergism with sulindac in A549 cells,
F,A549,646.0,,,,,1,,80682,1,Intermediate,,,5991,,6630,N,CHEMBL621650,BAO_0000219,,Antagonism of indomethacin in A549 cells,
F,A549,646.0,,,,,1,,80682,1,Intermediate,,,5992,,6630,N,CHEMBL621651,BAO_0000219,,Antagonism of sulindac in A549 cells,
F,A549,646.0,,,,,1,,80682,1,Intermediate,,,5993,,6630,N,CHEMBL621652,BAO_0000219,,Antagonism of tolmetin in A549 cells,
F,A549,646.0,,,,,1,,80682,1,Intermediate,,,5994,,6630,N,CHEMBL621653,BAO_0000219,,Synergism with indomethacin in A549 cells,
F,A549,646.0,,,,,1,,80682,1,Intermediate,,,5995,,6630,N,CHEMBL621654,BAO_0000219,,Synergism with sulindac in A549 cells,
F,A549,646.0,,,,,1,,80682,1,Intermediate,,,5996,,6630,N,CHEMBL621655,BAO_0000219,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5997,,16907,N,CHEMBL621656,BAO_0000218,,Cmax value after 30 mg/kg po dose in Dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5998,,5944,N,CHEMBL621657,BAO_0000218,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,5999,,5944,N,CHEMBL621658,BAO_0000218,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6000,,5944,N,CHEMBL621659,BAO_0000218,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6001,,5944,N,CHEMBL621660,BAO_0000218,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6002,,2959,N,CHEMBL621661,BAO_0000218,,Cmax value after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6003,,6241,N,CHEMBL621662,BAO_0000218,,Cmax value in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6004,,6241,N,CHEMBL621663,BAO_0000218,,Cmax value in dogs after oral administration at 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6005,,2652,N,CHEMBL621664,BAO_0000218,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6006,,1806,N,CHEMBL621665,BAO_0000218,Plasma,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6007,,1806,N,CHEMBL621666,BAO_0000218,Plasma,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6008,,1021,N,CHEMBL621667,BAO_0000218,,Concentration maxima after oral dosing in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6009,,1021,N,CHEMBL876738,BAO_0000218,,Concentration maxima after oral dosing in dogs; not available,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6010,,1021,N,CHEMBL621668,BAO_0000218,,Concentration maxima after oral dosing in dogs; not available,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6011,,5444,N,CHEMBL621669,BAO_0000218,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6012,,5444,N,CHEMBL621670,BAO_0000218,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6013,,5444,N,CHEMBL621671,BAO_0000218,,In vivo maximal concentration was calculated at 1 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6014,,5444,N,CHEMBL622360,BAO_0000218,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6015,,5444,N,CHEMBL622361,BAO_0000218,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6016,,5130,N,CHEMBL622362,BAO_0000218,Plasma,Cmax in dog plasma after oral dose (1 mg/kg),Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6017,,3249,N,CHEMBL622363,BAO_0000218,Plasma,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6018,,5473,N,CHEMBL622364,BAO_0000218,Plasma,Maximal plasma concentration at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6019,,5474,N,CHEMBL622365,BAO_0000218,Plasma,Maximal plasma concentration at a dose of 1 mg/kg (oral),Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6020,,4657,N,CHEMBL622533,BAO_0000218,Plasma,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6021,,3031,N,CHEMBL622534,BAO_0000218,,Maximum concentration of compound in dog was evaluated.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6022,,4527,N,CHEMBL622535,BAO_0000218,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6023,,4186,N,CHEMBL876739,BAO_0000218,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6024,,5007,N,CHEMBL622536,BAO_0000218,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6025,,3132,N,CHEMBL622537,BAO_0000218,Plasma,Maximum concentration obtained in dog plasma was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6026,,5006,N,CHEMBL622538,BAO_0000218,,Maximum concentration was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6027,,4727,N,CHEMBL627867,BAO_0000218,,Maximum concentration at the dose of 2 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6028,,1916,N,CHEMBL627868,BAO_0000218,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6029,,1918,N,CHEMBL627869,BAO_0000218,Plasma,Maximum concentration was evaluated in dog plasma,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6030,,3045,N,CHEMBL627870,BAO_0000218,,Maximum concentration was evaluated after 75 min after administration in dog,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6031,,9579,N,CHEMBL627871,BAO_0000218,Plasma,Maximum plasma concentration determined in dog after oral administration of 17b,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6032,,9579,N,CHEMBL627872,BAO_0000218,Plasma,Maximum plasma concentration determined in dog after oral administration of 2b,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6033,,933,N,CHEMBL627873,BAO_0000218,Plasma,Maximum plasma concentration in dog,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6034,,17839,N,CHEMBL627874,BAO_0000218,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6035,,17839,N,CHEMBL627875,BAO_0000218,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6036,,17839,N,CHEMBL627876,BAO_0000218,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6037,,17839,N,CHEMBL627877,BAO_0000218,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6038,,6348,N,CHEMBL627878,BAO_0000218,Plasma,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6039,,16367,N,CHEMBL627879,BAO_0000218,Plasma,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6040,,1337,N,CHEMBL875355,BAO_0000218,Plasma,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6041,,1337,N,CHEMBL627880,BAO_0000218,Plasma,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6042,,5199,N,CHEMBL627881,BAO_0000218,Plasma,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6043,,17650,N,CHEMBL627882,BAO_0000218,Plasma,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6044,,6679,N,CHEMBL627883,BAO_0000218,Plasma,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6045,,5356,N,CHEMBL628526,BAO_0000218,Plasma,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6046,,5356,N,CHEMBL628527,BAO_0000218,Plasma,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6047,,6227,N,CHEMBL628528,BAO_0000218,Plasma,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6048,,6227,N,CHEMBL628529,BAO_0000218,Plasma,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6049,,6227,N,CHEMBL628530,BAO_0000218,Plasma,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6050,,6227,N,CHEMBL625243,BAO_0000218,Plasma,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Expert,,,6051,,3598,N,CHEMBL625244,BAO_0000218,Plasma,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6052,,4368,N,CHEMBL625245,BAO_0000218,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6053,,6265,N,CHEMBL625246,BAO_0000218,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,6054,,7767,N,CHEMBL625247,BAO_0000218,Stomach,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,1088.0,,1,10090.0,50594,1,Intermediate,,,6055,,7767,N,CHEMBL625248,BAO_0000218,Urine,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus
A,,,In vivo,,1088.0,,1,10090.0,50594,1,Intermediate,,,6056,,7767,N,CHEMBL625249,BAO_0000218,Urine,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Mus musculus
A,,,In vivo,,1088.0,,1,10090.0,50594,1,Intermediate,,,6057,,7767,N,CHEMBL625250,BAO_0000218,Urine,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6058,,17811,N,CHEMBL625251,BAO_0000218,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6059,,17811,N,CHEMBL875356,BAO_0000218,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6060,,17827,N,CHEMBL625252,BAO_0000218,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),Mus musculus
A,,,,,178.0,,1,10090.0,50594,1,Intermediate,,,6061,,17827,N,CHEMBL625253,BAO_0000218,Blood,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6062,,17827,N,CHEMBL625254,BAO_0000218,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6063,,17827,N,CHEMBL625255,BAO_0000218,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6064,,17827,N,CHEMBL625256,BAO_0000218,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),Mus musculus
A,,,,,178.0,,1,10090.0,50594,1,Intermediate,,,6065,,17827,N,CHEMBL625257,BAO_0000218,Blood,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Mus musculus
A,,,,,178.0,,1,10090.0,50594,1,Intermediate,,,6066,,17827,N,CHEMBL625258,BAO_0000218,Blood,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6067,,17827,N,CHEMBL625259,BAO_0000218,,Compound was evaluated for washout rate in mice (Radiolabeled compound),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6068,,17827,N,CHEMBL625260,BAO_0000218,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6069,,17827,N,CHEMBL625261,BAO_0000218,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6070,,17827,N,CHEMBL625262,BAO_0000218,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6071,,17827,N,CHEMBL622639,BAO_0000218,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6072,,17257,N,CHEMBL622640,BAO_0000218,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6073,,17257,N,CHEMBL622812,BAO_0000218,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6074,,17257,N,CHEMBL622813,BAO_0000218,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6075,,17257,N,CHEMBL622814,BAO_0000218,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6076,,17827,N,CHEMBL622815,BAO_0000218,,Time at maximum activity in mice (Radiolabeled compound),Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6077,,3760,N,CHEMBL625342,BAO_0000218,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6078,,3760,N,CHEMBL625343,BAO_0000218,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6079,,17409,N,CHEMBL877591,BAO_0000218,,Binding towards mouse plasma protein at 10 uM,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6080,,17409,N,CHEMBL625344,BAO_0000218,,Binding towards mouse plasma protein at 100 uM,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6081,,2675,N,CHEMBL625345,BAO_0000218,,Bioavailability was evaluated in mice after intravenous administration,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6082,,2675,N,CHEMBL625346,BAO_0000218,,Bioavailability was evaluated in mice after oral administration,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6083,,3132,N,CHEMBL625347,BAO_0000218,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6084,,3132,N,CHEMBL625348,BAO_0000218,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6085,,16597,N,CHEMBL625349,BAO_0000218,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6086,,2862,N,CHEMBL625350,BAO_0000218,,Oral bioavailability in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6087,,17764,N,CHEMBL882952,BAO_0000218,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,6088,,846,N,CHEMBL625351,BAO_0000218,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,6089,,846,N,CHEMBL625352,BAO_0000218,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,6090,,846,N,CHEMBL877592,BAO_0000218,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,6091,,846,N,CHEMBL625353,BAO_0000218,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,6092,,846,N,CHEMBL625354,BAO_0000218,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,6093,,846,N,CHEMBL626019,BAO_0000218,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,6094,,846,N,CHEMBL626020,BAO_0000218,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,6095,,846,N,CHEMBL626021,BAO_0000218,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,6096,,846,N,CHEMBL626022,BAO_0000218,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,6097,,846,N,CHEMBL626192,BAO_0000218,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6098,,1276,N,CHEMBL626193,BAO_0000219,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6099,,3498,N,CHEMBL626194,BAO_0000219,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6100,,1169,N,CHEMBL626195,BAO_0000219,,Cytotoxicity against human lung carcinoma A-549 cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6101,,4450,N,CHEMBL626196,BAO_0000219,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6102,,358,N,CHEMBL626197,BAO_0000219,,In vitro cytotoxicity against human lung carcinoma cell line A-549,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6103,,358,N,CHEMBL626198,BAO_0000219,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6104,,358,N,CHEMBL626199,BAO_0000219,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6105,,358,N,CHEMBL626200,BAO_0000219,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6106,,358,N,CHEMBL626201,BAO_0000219,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6107,,358,N,CHEMBL626202,BAO_0000219,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6108,,358,N,CHEMBL626203,BAO_0000219,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6109,,15167,N,CHEMBL626204,BAO_0000219,,In vitro cytotoxicity against A-549 human lung cancer cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6110,,4139,N,CHEMBL624701,BAO_0000219,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6111,,833,N,CHEMBL624702,BAO_0000219,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6112,,15718,N,CHEMBL624703,BAO_0000219,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6113,,12373,N,CHEMBL624704,BAO_0000219,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6114,,637,N,CHEMBL624705,BAO_0000219,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6115,,14867,N,CHEMBL624706,BAO_0000219,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6116,,4461,N,CHEMBL624707,BAO_0000219,,Antitumor cytotoxic activity against A-549 cell line was determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6117,,5406,N,CHEMBL624708,BAO_0000219,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6118,,4457,N,CHEMBL624709,BAO_0000219,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6119,,1386,N,CHEMBL884107,BAO_0000219,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6120,,3265,N,CHEMBL624710,BAO_0000219,,Antitumoral activity was assayed against A-549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6121,,2359,N,CHEMBL624711,BAO_0000219,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6122,,4457,N,CHEMBL624712,BAO_0000219,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6123,,12454,N,CHEMBL624713,BAO_0000219,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6124,,1481,N,CHEMBL624714,BAO_0000219,,Compound was tested for inhibition of cell growth of A-549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6125,,1750,N,CHEMBL624715,BAO_0000219,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6126,,5065,N,CHEMBL624716,BAO_0000219,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6127,,808,N,CHEMBL619505,BAO_0000219,,In vitro cytotoxicity against A549-human lung carcinoma cells.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6128,,16364,N,CHEMBL619506,BAO_0000219,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6129,,1847,N,CHEMBL619507,BAO_0000219,,Cytotoxic activity against A-549 cell lines.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6130,,1747,N,CHEMBL619508,BAO_0000219,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6131,,1003,N,CHEMBL619509,BAO_0000219,,Cytotoxicity against human A549 non small cell lung cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6132,,15313,N,CHEMBL619510,BAO_0000219,,Inhibition of cell growth in (A-549) lung cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6133,,3122,N,CHEMBL619511,BAO_0000219,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6134,,16049,N,CHEMBL619512,BAO_0000219,,In vitro antitumor activity against A-549 tumor cells.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6135,,17134,N,CHEMBL619513,BAO_0000219,,In vitro antitumor effects against human A-549 cell lines.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6136,,6406,N,CHEMBL619514,BAO_0000219,,In vitro cytotoxic activity of compound against A-549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6137,,627,N,CHEMBL619515,BAO_0000219,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6138,,12307,N,CHEMBL619516,BAO_0000219,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6139,,17861,N,CHEMBL884005,BAO_0000219,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6140,,6682,N,CHEMBL619517,BAO_0000219,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6141,,6663,N,CHEMBL619518,BAO_0000219,,Inhibitory concentration of compound against A-549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6142,,2454,N,CHEMBL619519,BAO_0000219,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6143,,14709,N,CHEMBL876489,BAO_0000219,,cytotoxic activity against leukemia (A-549) cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6144,,15718,N,CHEMBL619520,BAO_0000219,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6145,,15718,N,CHEMBL619521,BAO_0000219,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6146,,17130,N,CHEMBL619522,BAO_0000219,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6147,,17130,N,CHEMBL619523,BAO_0000219,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6148,,17130,N,CHEMBL619524,BAO_0000219,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6149,,17130,N,CHEMBL619525,BAO_0000219,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),Homo sapiens
F,A549,646.0,,,,,1,,80682,1,Intermediate,,,6150,,6630,N,CHEMBL619526,BAO_0000219,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6151,,16726,N,CHEMBL619527,BAO_0000219,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6152,,17846,N,CHEMBL619528,BAO_0000219,,Cytotoxicity against A549 cells; No cytotoxicity,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6153,,3415,N,CHEMBL619529,BAO_0000219,,Cytotoxicity against human lung carcinoma (A549) cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6154,,3415,N,CHEMBL619530,BAO_0000219,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6155,,5609,N,CHEMBL876490,BAO_0000219,,In vitro anticancer activity against human lung (A549) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6156,,17206,N,CHEMBL619531,BAO_0000219,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6157,,17206,N,CHEMBL619532,BAO_0000219,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6158,,17206,N,CHEMBL619533,BAO_0000219,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6159,,17206,N,CHEMBL619534,BAO_0000219,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6160,,17206,N,CHEMBL620164,BAO_0000219,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6161,,17206,N,CHEMBL620165,BAO_0000219,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6162,,16295,N,CHEMBL620166,BAO_0000219,,Inhibition of A549 human lung tumor cell proliferation,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6163,,16825,N,CHEMBL620167,BAO_0000219,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6164,,3439,N,CHEMBL620168,BAO_0000219,,In vitro cytotoxicity against human tumor cell line A549,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6165,,10870,N,CHEMBL620338,BAO_0000219,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6166,,4845,N,CHEMBL620339,BAO_0000219,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6167,,5822,N,CHEMBL620340,BAO_0000219,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6168,,5822,N,CHEMBL620341,BAO_0000219,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6169,,5822,N,CHEMBL876491,BAO_0000219,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6170,,16381,N,CHEMBL620342,BAO_0000219,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6171,,16381,N,CHEMBL620343,BAO_0000219,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6172,,16381,N,CHEMBL620344,BAO_0000219,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6173,,5609,N,CHEMBL620345,BAO_0000219,,In vitro anticancer activity against human lung (A549) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6174,,4644,N,CHEMBL620346,BAO_0000219,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6175,,4644,N,CHEMBL620347,BAO_0000219,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6176,,4644,N,CHEMBL620348,BAO_0000219,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6177,,4644,N,CHEMBL620349,BAO_0000219,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6178,,5822,N,CHEMBL618667,BAO_0000219,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6179,,3415,N,CHEMBL618668,BAO_0000219,,Percentage inhibition of human lung carcinoma (A549) cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6180,,16726,N,CHEMBL876031,BAO_0000219,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6181,,17206,N,CHEMBL618759,BAO_0000219,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6182,,17206,N,CHEMBL618760,BAO_0000219,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6183,,17206,N,CHEMBL619000,BAO_0000219,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6184,,17206,N,CHEMBL619001,BAO_0000219,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6185,,17206,N,CHEMBL619002,BAO_0000219,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6186,,17206,N,CHEMBL619003,BAO_0000219,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6187,,17206,N,CHEMBL619597,BAO_0000219,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6188,,17206,N,CHEMBL619598,BAO_0000219,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6189,,17206,N,CHEMBL619599,BAO_0000219,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6190,,17206,N,CHEMBL619600,BAO_0000219,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6191,,16726,N,CHEMBL619601,BAO_0000219,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6192,,17206,N,CHEMBL619602,BAO_0000219,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6193,,17206,N,CHEMBL619603,BAO_0000219,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6194,,17206,N,CHEMBL619604,BAO_0000219,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6195,,17206,N,CHEMBL619605,BAO_0000219,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,Homo sapiens
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6196,,6084,N,CHEMBL619606,BAO_0000218,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6197,,6084,N,CHEMBL876032,BAO_0000218,,Pharmacokinetic activity (Cmax) in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6198,,4809,N,CHEMBL619607,BAO_0000218,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6199,,5983,N,CHEMBL619608,BAO_0000218,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6200,,6251,N,CHEMBL619609,BAO_0000218,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6201,,5932,N,CHEMBL619610,BAO_0000218,Plasma,Cmax in dog plasma after 30mg/kg oral dose,Canis lupus familiaris
A,,,In vivo,,178.0,,1,9615.0,50588,1,Intermediate,,,6202,,4273,N,CHEMBL619611,BAO_0000218,Blood,Tested for the peak blood level in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6203,,5313,N,CHEMBL619612,BAO_0000218,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6204,,5313,N,CHEMBL619613,BAO_0000218,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",Canis lupus familiaris
A,,,In vivo,,178.0,,1,9615.0,50588,1,Intermediate,,,6205,,6221,N,CHEMBL619614,BAO_0000218,Blood,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6206,,4709,N,CHEMBL619615,BAO_0000218,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6207,,167,N,CHEMBL619616,BAO_0000218,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,6208,,6241,N,CHEMBL619617,BAO_0000218,Plasma,Final plasma concentration in dogs after oral administration at 1 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6209,,344,N,CHEMBL619618,BAO_0000218,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6210,,344,N,CHEMBL876033,BAO_0000218,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6211,,344,N,CHEMBL619619,BAO_0000218,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6212,,2189,N,CHEMBL619620,BAO_0000218,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,Canis lupus familiaris
A,,,,,1088.0,,1,9615.0,50588,1,Intermediate,,,6213,,2189,N,CHEMBL619621,BAO_0000218,Urine,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Canis lupus familiaris
A,,,,,1088.0,,1,9615.0,50588,1,Intermediate,,,6214,,2189,N,CHEMBL619622,BAO_0000218,Urine,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Canis lupus familiaris
A,,,,,1088.0,,1,9615.0,50588,1,Intermediate,,,6215,,2189,N,CHEMBL618874,BAO_0000218,Urine,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6216,,4257,N,CHEMBL618875,BAO_0000218,,Absolute bioavailability was evaluated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6217,,6221,N,CHEMBL618876,BAO_0000218,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6218,,6215,N,CHEMBL618877,BAO_0000218,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6219,,17267,N,CHEMBL618878,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6220,,6621,N,CHEMBL618879,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6221,,3854,N,CHEMBL618880,BAO_0000218,,Bioavailability after intravenous administration in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6222,,3854,N,CHEMBL618881,BAO_0000218,,Bioavailability after peroral administration in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6223,,5007,N,CHEMBL618882,BAO_0000218,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6224,,4333,N,CHEMBL624226,BAO_0000218,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6225,,4333,N,CHEMBL624227,BAO_0000218,Plasma,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6226,,5006,N,CHEMBL624228,BAO_0000218,,Bioavailability,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6227,,5199,N,CHEMBL624229,BAO_0000218,,Bioavailability,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6228,,4368,N,CHEMBL624230,BAO_0000218,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6229,,3771,N,CHEMBL624231,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6230,,4953,N,CHEMBL624232,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6231,,5064,N,CHEMBL625127,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6232,,17657,N,CHEMBL625128,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6233,,17796,N,CHEMBL621675,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6234,,17853,N,CHEMBL621676,BAO_0000218,,Bioavailability in dog (p.o.) at 2.0 mpk,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6235,,4521,N,CHEMBL621677,BAO_0000218,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6236,,4521,N,CHEMBL621678,BAO_0000218,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6237,,5006,N,CHEMBL621679,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6238,,16365,N,CHEMBL621680,BAO_0000218,,Bioavailability was evaluated after oral administration in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6239,,1916,N,CHEMBL621681,BAO_0000218,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6240,,1918,N,CHEMBL876740,BAO_0000218,,Bioavailability was evaluated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6241,,4239,N,CHEMBL621682,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6242,,6505,N,CHEMBL621683,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6243,,5334,N,CHEMBL621684,BAO_0000218,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6244,,5334,N,CHEMBL621685,BAO_0000218,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6245,,4809,N,CHEMBL621686,BAO_0000218,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6246,,6348,N,CHEMBL621687,BAO_0000218,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6247,,6005,N,CHEMBL621688,BAO_0000218,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6248,,17804,N,CHEMBL621689,BAO_0000218,,Bioavailability of compound in dog was determined after peroral administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6249,,3184,N,CHEMBL621690,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6250,,1806,N,CHEMBL621691,BAO_0000218,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6251,,1806,N,CHEMBL875941,BAO_0000218,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6252,,1806,N,CHEMBL621692,BAO_0000218,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6253,,4839,N,CHEMBL621693,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6254,,5017,N,CHEMBL621694,BAO_0000218,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),Canis lupus familiaris
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,6255,,846,N,CHEMBL621695,BAO_0000218,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,6256,,846,N,CHEMBL621696,BAO_0000218,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,6257,,846,N,CHEMBL621697,BAO_0000218,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,6258,,846,N,CHEMBL621698,BAO_0000218,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,6259,,846,N,CHEMBL623420,BAO_0000218,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,6260,,846,N,CHEMBL623421,BAO_0000218,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,6261,,846,N,CHEMBL623422,BAO_0000218,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,6262,,846,N,CHEMBL623423,BAO_0000218,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,6263,,846,N,CHEMBL623424,BAO_0000218,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,6264,,846,N,CHEMBL623425,BAO_0000218,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,6265,,846,N,CHEMBL623426,BAO_0000218,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,6266,,846,N,CHEMBL623427,BAO_0000218,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,6267,,846,N,CHEMBL623428,BAO_0000218,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,6268,,846,N,CHEMBL875947,BAO_0000218,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,6269,,846,N,CHEMBL623429,BAO_0000218,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,6270,,846,N,CHEMBL623430,BAO_0000218,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,6271,,846,N,CHEMBL622588,BAO_0000218,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,6272,,846,N,CHEMBL622589,BAO_0000218,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,6273,,846,N,CHEMBL622751,BAO_0000218,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,6274,,846,N,CHEMBL622752,BAO_0000218,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6275,,6599,N,CHEMBL622753,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6276,,6599,N,CHEMBL622647,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6277,,6599,N,CHEMBL875163,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6278,,6599,N,CHEMBL622648,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6279,,6599,N,CHEMBL622649,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,955.0,,1,10090.0,50594,1,Intermediate,,,6280,,6599,N,CHEMBL622650,BAO_0000218,Brain,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,955.0,,1,10090.0,50594,1,Intermediate,,,6281,,6599,N,CHEMBL622651,BAO_0000218,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,955.0,,1,10090.0,50594,1,Intermediate,,,6282,,6599,N,CHEMBL622652,BAO_0000218,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,955.0,,1,10090.0,50594,1,Intermediate,,,6283,,6599,N,CHEMBL622653,BAO_0000218,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,955.0,,1,10090.0,50594,1,Intermediate,,,6284,,6599,N,CHEMBL622654,BAO_0000218,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,948.0,,1,10090.0,50594,1,Intermediate,,,6285,,6599,N,CHEMBL622655,BAO_0000218,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,948.0,,1,10090.0,50594,1,Intermediate,,,6286,,6599,N,CHEMBL622656,BAO_0000218,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,948.0,,1,10090.0,50594,1,Intermediate,,,6287,,6599,N,CHEMBL622657,BAO_0000218,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,948.0,,1,10090.0,50594,1,Intermediate,,,6288,,6599,N,CHEMBL622658,BAO_0000218,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,948.0,,1,10090.0,50594,1,Intermediate,,,6289,,6599,N,CHEMBL622659,BAO_0000218,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,2113.0,,1,10090.0,50594,1,Intermediate,,,6290,,6599,N,CHEMBL624630,BAO_0000218,Kidney,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,2113.0,,1,10090.0,50594,1,Intermediate,,,6291,,6599,N,CHEMBL624631,BAO_0000218,Kidney,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,2113.0,,1,10090.0,50594,1,Intermediate,,,6292,,6599,N,CHEMBL624632,BAO_0000218,Kidney,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Mus musculus
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6293,,17130,N,CHEMBL624633,BAO_0000219,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6294,,17130,N,CHEMBL624634,BAO_0000219,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6295,,17130,N,CHEMBL624635,BAO_0000219,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6296,,17130,N,CHEMBL624636,BAO_0000219,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6297,,3263,N,CHEMBL857055,BAO_0000219,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6298,,6663,N,CHEMBL624637,BAO_0000219,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6299,,6663,N,CHEMBL624638,BAO_0000219,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6300,,6663,N,CHEMBL874366,BAO_0000219,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6301,,6663,N,CHEMBL624639,BAO_0000219,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6302,,6663,N,CHEMBL624640,BAO_0000219,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6303,,6663,N,CHEMBL624641,BAO_0000219,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6304,,6663,N,CHEMBL624642,BAO_0000219,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6305,,6663,N,CHEMBL624643,BAO_0000219,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6306,,6663,N,CHEMBL624644,BAO_0000219,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6307,,6663,N,CHEMBL624645,BAO_0000219,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6308,,3983,N,CHEMBL619445,BAO_0000219,,The compound was evaluated for its cytotoxic potency against A-549 cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6309,,11141,N,CHEMBL839886,BAO_0000219,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6310,,5076,N,CHEMBL619446,BAO_0000219,,Cytotoxic activity of compound against A-549 tumor cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6311,,3311,N,CHEMBL619447,BAO_0000219,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6312,,3311,N,CHEMBL619448,BAO_0000219,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6313,,3311,N,CHEMBL619449,BAO_0000219,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6314,,5076,N,CHEMBL619450,BAO_0000219,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6315,,4150,N,CHEMBL619451,BAO_0000219,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6316,,2150,N,CHEMBL619452,BAO_0000219,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6317,,4644,N,CHEMBL619453,BAO_0000219,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6318,,263,N,CHEMBL874367,BAO_0000219,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6319,,11333,N,CHEMBL619454,BAO_0000219,,Cytotoxic concentration against A-549 tumor cells.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6320,,11333,N,CHEMBL619455,BAO_0000219,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6321,,15895,N,CHEMBL619456,BAO_0000219,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",Homo sapiens
F,,,,,,,1,470.0,50191,1,Expert,,,6322,,16677,N,CHEMBL619457,BAO_0000218,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,Acinetobacter baumannii
F,,,,,,,1,471.0,50192,1,Intermediate,,,6323,,10624,N,CHEMBL619458,BAO_0000218,,Activity against Acinetobacter calcoaceticus (AC54),Acinetobacter calcoaceticus
F,,,,,,,1,5059.0,50274,1,Expert,,,6324,,16717,N,CHEMBL619459,BAO_0000218,,In vitro antifungal activity against Aspergillus flavus CM74,Aspergillus flavus
F,,,,,,,1,5059.0,50274,1,Expert,,,6325,,16717,N,CHEMBL619460,BAO_0000218,,In vitro antifungal activity against Aspergillus flavus CM74,Aspergillus flavus
F,,,,,,,1,746128.0,50416,1,Intermediate,,,6326,,5513,N,CHEMBL619461,BAO_0000218,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,Aspergillus fumigatus
F,,,,,,,1,746128.0,50416,1,Intermediate,,,6327,,15962,N,CHEMBL619462,BAO_0000218,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),Aspergillus fumigatus
F,,,,,,,1,746128.0,50416,1,Intermediate,,,6328,,15962,N,CHEMBL620388,BAO_0000218,,Antimicrobial activity against Aspergillus fumigatus (MIC),Aspergillus fumigatus
F,,,,,,,1,746128.0,50416,1,Intermediate,,,6329,,15962,N,CHEMBL620389,BAO_0000218,,Antimicrobial activity against Aspergillus fumigatus (MIC),Aspergillus fumigatus
F,,,,,,,1,746128.0,50416,1,Intermediate,,,6330,,15962,N,CHEMBL620390,BAO_0000218,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),Aspergillus fumigatus
F,,,,,,,1,746128.0,50416,1,Expert,,,6331,,16717,N,CHEMBL620391,BAO_0000218,,In vitro antifungal activity against Aspergillus fumigatus 48238E,Aspergillus fumigatus
F,,,,,,,1,746128.0,50416,1,Expert,,,6332,,16717,N,CHEMBL621073,BAO_0000218,,In vitro antifungal activity against Aspergillus fumigatus 48238E,Aspergillus fumigatus
F,,,,,,,1,1655.0,50296,1,Intermediate,,,6333,,8117,N,CHEMBL621074,BAO_0000218,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,Actinomyces naeslundii
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6334,,8117,N,CHEMBL621075,BAO_0000218,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,Actinomyces viscosus
F,,,,,,,1,6277.0,50535,1,Intermediate,,,6335,,15472,N,CHEMBL619554,BAO_0000218,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Acanthocheilonema viteae
F,,,,,,,1,6277.0,50535,1,Intermediate,,,6336,,15472,N,CHEMBL619555,BAO_0000218,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Acanthocheilonema viteae
F,,,,,,,1,714.0,50169,1,Intermediate,,,6337,,16443,N,CHEMBL619556,BAO_0000218,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,Aggregatibacter actinomycetemcomitans
F,,,,,,,1,714.0,50169,1,Intermediate,,,6338,,16443,N,CHEMBL619557,BAO_0000218,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,Aggregatibacter actinomycetemcomitans
F,,,,,,,1,714.0,50169,1,Intermediate,,,6339,,16443,N,CHEMBL619558,BAO_0000218,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,Aggregatibacter actinomycetemcomitans
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6340,,17206,N,CHEMBL619559,BAO_0000219,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6341,,17206,N,CHEMBL619560,BAO_0000219,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6342,,16381,N,CHEMBL619561,BAO_0000219,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6343,,16381,N,CHEMBL619562,BAO_0000219,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6344,,16381,N,CHEMBL619563,BAO_0000219,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6345,,16381,N,CHEMBL857457,BAO_0000219,,GI values against A549 cells (lung cancer),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6346,,17206,N,CHEMBL619564,BAO_0000219,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6347,,16325,N,CHEMBL619565,BAO_0000219,,Inhibitory activity against A549 human adenocarcinoma,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6348,,10708,N,CHEMBL619566,BAO_0000218,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6349,,10708,N,CHEMBL619567,BAO_0000218,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6350,,17376,N,CHEMBL619568,BAO_0000219,,Inhibitory activity against A549 lung adenocarcinoma cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6351,,17376,N,CHEMBL619569,BAO_0000219,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6352,,17488,N,CHEMBL619570,BAO_0000219,,Cytotoxicity against human A549 lung cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6353,,17404,N,CHEMBL619571,BAO_0000218,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6354,,10958,N,CHEMBL619572,BAO_0000219,,Growth inhibition of A549 (human lung carcinoma) cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6355,,17099,N,CHEMBL619573,BAO_0000219,,Effective dose required for inhibitory activity against A549 human tumor cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6356,,17099,N,CHEMBL619574,BAO_0000219,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6357,,4096,N,CHEMBL619575,BAO_0000219,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6358,,4096,N,CHEMBL619576,BAO_0000219,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6359,,4096,N,CHEMBL619577,BAO_0000219,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6360,,2525,N,CHEMBL619578,BAO_0000219,,In vitro inhibitory activity against A549 tumor cell culture,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6361,,2525,N,CHEMBL884009,BAO_0000219,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6362,,5302,N,CHEMBL619579,BAO_0000219,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6363,,16325,N,CHEMBL619580,BAO_0000219,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6364,,16939,N,CHEMBL619581,BAO_0000219,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6365,,17229,N,CHEMBL619582,BAO_0000219,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6366,,17380,N,CHEMBL619583,BAO_0000219,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6367,,17380,N,CHEMBL876502,BAO_0000219,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6368,,1903,N,CHEMBL619584,BAO_0000219,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6369,,3838,N,CHEMBL619585,BAO_0000219,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6370,,14696,N,CHEMBL619586,BAO_0000219,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6371,,3838,N,CHEMBL619587,BAO_0000219,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6372,,1522,N,CHEMBL619588,BAO_0000219,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6373,,12400,N,CHEMBL619589,BAO_0000219,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6374,,14696,N,CHEMBL619590,BAO_0000219,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6375,,14769,N,CHEMBL619591,BAO_0000219,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6376,,14696,N,CHEMBL619592,BAO_0000219,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6377,,1888,N,CHEMBL619593,BAO_0000219,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6378,,12016,N,CHEMBL620217,BAO_0000219,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6379,,6058,N,CHEMBL620218,BAO_0000219,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6380,,17708,N,CHEMBL620219,BAO_0000219,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6381,,12301,N,CHEMBL620220,BAO_0000219,,Antitumor activity against A549/ATCC cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6382,,11970,N,CHEMBL625141,BAO_0000219,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Expert,,,6383,,11818,N,CHEMBL625142,BAO_0000219,,In vitro cytotoxicity against A549/ATCC cell line.,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6384,,12400,N,CHEMBL625143,BAO_0000219,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6385,,3381,N,CHEMBL625144,BAO_0000219,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6386,,17376,N,CHEMBL622474,BAO_0000219,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,Homo sapiens
F,A549,646.0,,,,,1,9606.0,80682,1,Intermediate,,,6387,,10708,N,CHEMBL884104,BAO_0000219,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,Homo sapiens
F,,,,,,,0,9606.0,22226,1,Autocuration,,,6388,,2964,U,CHEMBL622475,BAO_0000219,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,Homo sapiens
A,,,In vivo,,,,0,9615.0,22224,1,Intermediate,,,6389,,5005,U,CHEMBL622476,BAO_0000218,,Compound was tested for oral bioavailability in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6390,,6229,N,CHEMBL875831,BAO_0000218,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6391,,6229,N,CHEMBL622477,BAO_0000218,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6392,,5374,N,CHEMBL622478,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6393,,5374,N,CHEMBL623172,BAO_0000218,,Compound was tested for the oral bioavailability in dog; No availability,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6394,,6265,N,CHEMBL623173,BAO_0000218,,Oral bioavailability in dog (dose 5 mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6395,,5654,N,CHEMBL623174,BAO_0000218,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6396,,5654,N,CHEMBL623175,BAO_0000218,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6397,,16456,N,CHEMBL623340,BAO_0000218,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6398,,5302,N,CHEMBL623341,BAO_0000218,,Oral bioavailability in dog (dose 5 mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6399,,3624,N,CHEMBL623342,BAO_0000218,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6400,,16452,N,CHEMBL623343,BAO_0000218,,Oral bioavailability of active FTIs in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6401,,5802,N,CHEMBL623344,BAO_0000218,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Expert,,,6402,,3598,N,CHEMBL623345,BAO_0000218,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6403,,17839,N,CHEMBL875832,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6404,,6762,N,CHEMBL623346,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6405,,6821,N,CHEMBL623347,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6406,,6821,N,CHEMBL623348,BAO_0000218,,Oral bioavailability of compound was determined in dog; Not tested,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6407,,5210,N,CHEMBL623349,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6408,,6227,N,CHEMBL623350,BAO_0000218,,Oral bioavailability (10 mg/kg) was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6409,,761,N,CHEMBL623351,BAO_0000218,,Oral bioavailability,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6410,,761,N,CHEMBL623352,BAO_0000218,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6411,,761,N,CHEMBL623353,BAO_0000218,,Oral bioavailability administered in solution in rats,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6412,,16907,N,CHEMBL875833,BAO_0000218,,Oral bioavailability after 30 mg/kg po dose in Dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6413,,5474,N,CHEMBL623354,BAO_0000218,,Oral bioavailability at a dose of 1 mg/kg in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6414,,6535,N,CHEMBL623355,BAO_0000218,,Oral bioavailability in dog (dose 1 mg/kg p.o.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6415,,6535,N,CHEMBL623356,BAO_0000218,,Oral bioavailability in Dog; ND = not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6416,,3352,N,CHEMBL623357,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6417,,6168,N,CHEMBL623358,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6418,,5988,N,CHEMBL623359,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6419,,4942,N,CHEMBL623360,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6420,,4942,N,CHEMBL623361,BAO_0000218,,Oral bioavailability in dogs; No data,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6421,,14541,N,CHEMBL623362,BAO_0000218,,Oral bioavailability measured in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6422,,4449,N,CHEMBL623363,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6423,,6057,N,CHEMBL623364,BAO_0000218,,Oral bioavailability was calculated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6424,,5600,N,CHEMBL875834,BAO_0000218,,Oral bioavailability after 0.3 mg/kg po administration in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6425,,5542,N,CHEMBL623365,BAO_0000218,,Oral bioavailability in dog (i.v. dosing),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6426,,5542,N,CHEMBL623366,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6427,,5546,N,CHEMBL623367,BAO_0000218,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6428,,4514,N,CHEMBL623368,BAO_0000218,,Oral bioavailability in Beagle dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6429,,3624,N,CHEMBL623369,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6430,,3854,N,CHEMBL623370,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6431,,5836,N,CHEMBL623371,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6432,,5940,N,CHEMBL623372,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6433,,6168,N,CHEMBL621351,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6434,,6227,N,CHEMBL621352,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6435,,6251,N,CHEMBL621353,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6436,,6448,N,CHEMBL621354,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6437,,6647,N,CHEMBL621355,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6438,,5940,N,CHEMBL621356,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6439,,933,N,CHEMBL621357,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6440,,5210,N,CHEMBL621358,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6441,,6642,N,CHEMBL621359,BAO_0000218,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6442,,6641,N,CHEMBL621360,BAO_0000218,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6443,,6642,N,CHEMBL621361,BAO_0000218,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6444,,5472,N,CHEMBL621362,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6445,,5985,N,CHEMBL621363,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6446,,15660,N,CHEMBL621364,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6447,,5530,N,CHEMBL621166,BAO_0000218,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6448,,5530,N,CHEMBL621167,BAO_0000218,,Oral bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6449,,6305,N,CHEMBL621168,BAO_0000218,,Oral bioavailability (F) in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6450,,5210,N,CHEMBL621169,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6451,,5238,N,CHEMBL875950,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6452,,5668,N,CHEMBL621170,BAO_0000218,,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6453,,5668,N,CHEMBL621171,BAO_0000218,,Oral bioavailability after peroral administration at 5 mpk in Dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6454,,5668,N,CHEMBL621172,BAO_0000218,,Oral bioavailability in dog (dose 5 mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6455,,6084,N,CHEMBL621173,BAO_0000218,,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris
A,CCRF S-180,42.0,,,2113.0,,1,10090.0,50594,1,Intermediate,,,6456,,6599,N,CHEMBL621174,BAO_0000218,Kidney,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,2113.0,,1,10090.0,50594,1,Intermediate,,,6457,,6599,N,CHEMBL621175,BAO_0000218,Kidney,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6458,,6599,N,CHEMBL621176,BAO_0000218,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6459,,6599,N,CHEMBL621177,BAO_0000218,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6460,,6599,N,CHEMBL621178,BAO_0000218,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6461,,6599,N,CHEMBL621179,BAO_0000218,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6462,,6599,N,CHEMBL621180,BAO_0000218,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6463,,6599,N,CHEMBL875951,BAO_0000218,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6464,,6599,N,CHEMBL621181,BAO_0000218,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6465,,6599,N,CHEMBL621182,BAO_0000218,Lung,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6466,,6599,N,CHEMBL621183,BAO_0000218,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6467,,6599,N,CHEMBL621184,BAO_0000218,Lung,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6468,,6599,N,CHEMBL621185,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6469,,6599,N,CHEMBL621186,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6470,,6599,N,CHEMBL621187,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6471,,6599,N,CHEMBL621188,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6472,,6599,N,CHEMBL621189,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,2106.0,,1,10090.0,50594,1,Intermediate,,,6473,,6599,N,CHEMBL621190,BAO_0000218,Spleen,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,2106.0,,1,10090.0,50594,1,Intermediate,,,6474,,6599,N,CHEMBL618520,BAO_0000218,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,2106.0,,1,10090.0,50594,1,Intermediate,,,6475,,6599,N,CHEMBL621739,BAO_0000218,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,2106.0,,1,10090.0,50594,1,Intermediate,,,6476,,6599,N,CHEMBL621740,BAO_0000218,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,2106.0,,1,10090.0,50594,1,Intermediate,,,6477,,6599,N,CHEMBL621741,BAO_0000218,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6478,,6599,N,CHEMBL621742,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6479,,6599,N,CHEMBL621743,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6480,,6599,N,CHEMBL621744,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6481,,6599,N,CHEMBL621745,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6482,,6599,N,CHEMBL621746,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6483,,6599,N,CHEMBL621747,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6484,,6599,N,CHEMBL621748,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6485,,6599,N,CHEMBL621749,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6486,,6599,N,CHEMBL621750,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6487,,6599,N,CHEMBL621751,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,948.0,,1,10090.0,50594,1,Intermediate,,,6488,,6599,N,CHEMBL621752,BAO_0000218,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,948.0,,1,10090.0,50594,1,Intermediate,,,6489,,6599,N,CHEMBL621753,BAO_0000218,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,948.0,,1,10090.0,50594,1,Intermediate,,,6490,,6599,N,CHEMBL875955,BAO_0000218,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,948.0,,1,10090.0,50594,1,Intermediate,,,6491,,6599,N,CHEMBL621754,BAO_0000218,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,948.0,,1,10090.0,50594,1,Intermediate,,,6492,,6599,N,CHEMBL621755,BAO_0000218,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6493,,6599,N,CHEMBL621756,BAO_0000218,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6494,,6599,N,CHEMBL624199,BAO_0000218,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6495,,6599,N,CHEMBL624200,BAO_0000218,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6496,,6599,N,CHEMBL624375,BAO_0000218,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6497,,6599,N,CHEMBL624376,BAO_0000218,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6498,,6599,N,CHEMBL624377,BAO_0000218,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6499,,6599,N,CHEMBL624378,BAO_0000218,Lung,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Mus musculus
F,,,,,,,1,107673.0,50067,1,Intermediate,,,6500,,12269,N,CHEMBL857901,BAO_0000218,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,aeinetobacter anitrotap
F,,,,,,,1,107673.0,50067,1,Intermediate,,,6501,,12269,N,CHEMBL875274,BAO_0000218,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Acinetobacter calcoaceticus subsp. anitratus
F,,,,,,,1,107673.0,50067,1,Intermediate,,,6502,,12269,N,CHEMBL624379,BAO_0000218,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Acinetobacter calcoaceticus subsp. anitratus
F,,,,,,,1,107673.0,50067,1,Intermediate,,,6503,,12269,N,CHEMBL624380,BAO_0000218,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,aeinetobacter anitrotap
F,,,,,,,1,471.0,50192,1,Intermediate,,,6504,,10624,N,CHEMBL624381,BAO_0000218,,Activity against Acinetobacter calcoaceticus (AC54),Acinetobacter calcoaceticus
F,,,,,,,1,28377.0,50714,1,Intermediate,,,6505,,17216,N,CHEMBL624382,BAO_0000218,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,Anolis carolinensis
F,,,,,,,1,28377.0,50714,1,Intermediate,,,6506,,17216,N,CHEMBL624383,BAO_0000218,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,Anolis carolinensis
F,,,,,,,1,1655.0,50296,1,Intermediate,,,6507,,9560,N,CHEMBL624384,BAO_0000218,,Chlorohexidine coefficient for Actinomyces naeslundii 631,Actinomyces naeslundii
F,,,,,,,1,1655.0,50296,1,Intermediate,,,6508,,9560,N,CHEMBL624385,BAO_0000218,,Chlorohexidine coefficient for Actinomyces naeslundii B74,Actinomyces naeslundii
F,,,,,,,1,1655.0,50296,1,Intermediate,,,6509,,9560,N,CHEMBL624386,BAO_0000218,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,Actinomyces naeslundii
F,,,,,,,1,1655.0,50296,1,Intermediate,,,6510,,9560,N,CHEMBL624387,BAO_0000218,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,Actinomyces naeslundii
F,,,,,,,1,1655.0,50296,1,Intermediate,,,6511,,9560,N,CHEMBL624388,BAO_0000218,,Plaque bactericidal index against Actinomyces naeslundii 631,Actinomyces naeslundii
F,,,,,,,1,1655.0,50296,1,Intermediate,,,6512,,9560,N,CHEMBL624389,BAO_0000218,,Plaque bactericidal index against Actinomyces naeslundii N/9,Actinomyces naeslundii
F,,,,,,,1,1655.0,50296,1,Intermediate,,,6513,,9560,N,CHEMBL624390,BAO_0000218,,Plaque bactericidal index against Actinomyces naeslundii B74,Actinomyces naeslundii
F,,,,,,,1,1655.0,50296,1,Intermediate,,,6514,,9560,N,CHEMBL875275,BAO_0000218,,Plaque bactericidal index against Actinomyces naeslundii N/3,Actinomyces naeslundii
F,,,,,,,1,85549.0,50056,1,Intermediate,,,6515,,114,N,CHEMBL624391,BAO_0000218,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,Artemia salina
F,,,,,,,1,85549.0,50056,1,Intermediate,,,6516,,114,N,CHEMBL623636,BAO_0000218,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",Artemia salina
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6517,,10841,N,CHEMBL623637,BAO_0000218,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6518,,10841,N,CHEMBL623638,BAO_0000218,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6519,,10841,N,CHEMBL623639,BAO_0000218,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6520,,10841,N,CHEMBL623640,BAO_0000218,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6521,,10841,N,CHEMBL623641,BAO_0000218,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6522,,10841,N,CHEMBL623642,BAO_0000218,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6523,,10841,N,CHEMBL623643,BAO_0000218,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6524,,10841,N,CHEMBL623644,BAO_0000218,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6525,,10841,N,CHEMBL623645,BAO_0000218,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6526,,10841,N,CHEMBL623646,BAO_0000218,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6527,,10841,N,CHEMBL623647,BAO_0000218,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,Ascaris suum
F,,,,,,,1,6253.0,50532,1,Intermediate,,,6528,,10841,N,CHEMBL623648,BAO_0000218,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,Ascaris suum
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6529,,8117,N,CHEMBL623649,BAO_0000218,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6530,,8117,N,CHEMBL623650,BAO_0000218,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6531,,9560,N,CHEMBL623651,BAO_0000218,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Expert,,,6532,,9560,N,CHEMBL623652,BAO_0000218,,Chlorohexidine coefficient for Actinomyces viscosus M-100,Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6533,,9560,N,CHEMBL623653,BAO_0000218,,Chlorohexidine coefficient for Actinomyces viscosus M-626,Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6534,,9560,N,CHEMBL623654,BAO_0000218,,Chlorohexidine coefficient for Actinomyces viscosus T14V,Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6535,,9560,N,CHEMBL623655,BAO_0000218,,Plaque bactericidal index against Actinomyces viscosus 8A06,Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6536,,9560,N,CHEMBL623656,BAO_0000218,,Plaque bactericidal index against Actinomyces viscosus M-100,Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Expert,,,6537,,9560,N,CHEMBL623657,BAO_0000218,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6538,,9560,N,CHEMBL623658,BAO_0000218,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6539,,9560,N,CHEMBL623659,BAO_0000218,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6540,,9560,N,CHEMBL623660,BAO_0000218,,Plaque bactericidal index against Actinomyces viscosus 626,Actinomyces viscosus
F,,,,,,,1,1656.0,50366,1,Intermediate,,,6541,,9560,N,CHEMBL623661,BAO_0000218,,Plaque bactericidal index against Actinomyces viscosus T14V,Actinomyces viscosus
F,,,,,,,1,6277.0,50535,1,Intermediate,,,6542,,10986,N,CHEMBL875281,BAO_0000218,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,Acanthocheilonema viteae
F,,,,,,,1,6277.0,50535,1,Intermediate,,,6543,,10986,N,CHEMBL623662,BAO_0000218,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,Acanthocheilonema viteae
F,,,,,,,1,6277.0,50535,1,Intermediate,,,6544,,10986,N,CHEMBL623663,BAO_0000218,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,Acanthocheilonema viteae
F,,,,,,,1,6277.0,50535,1,Intermediate,,,6545,,10986,N,CHEMBL623664,BAO_0000218,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,Acanthocheilonema viteae
F,,,,,,,1,6277.0,50535,1,Intermediate,,,6546,,10986,N,CHEMBL623665,BAO_0000218,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,Acanthocheilonema viteae
F,A673,165.0,,,,,1,9606.0,80023,1,Intermediate,,,6547,,10708,N,CHEMBL621856,BAO_0000219,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,Homo sapiens
F,A704,645.0,,,,,1,9606.0,80661,1,Intermediate,,,6548,,10708,N,CHEMBL620432,BAO_0000219,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,Homo sapiens
F,,,,,,,0,10116.0,22226,1,Autocuration,,,6549,,416,U,CHEMBL620433,BAO_0000219,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,Rattus norvegicus
F,A9,625.0,,,,,1,10090.0,80024,1,Intermediate,,,6550,,14354,N,CHEMBL620434,BAO_0000219,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Mus musculus
F,A9,625.0,,,,,1,10090.0,80024,1,Intermediate,,,6551,,14354,N,CHEMBL620435,BAO_0000219,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Mus musculus
F,A9,625.0,,,,,1,9606.0,80024,1,Intermediate,,,6552,,5116,N,CHEMBL620436,BAO_0000219,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,Homo sapiens
F,A9,625.0,,,,,1,9606.0,80024,1,Intermediate,,,6553,,5116,N,CHEMBL876597,BAO_0000219,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,Homo sapiens
F,Human ovarian carcinoma cell line,874.0,,,,,1,9606.0,81037,1,Expert,,,6554,,15694,N,CHEMBL620437,BAO_0000219,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,Homo sapiens
F,A9,625.0,,,,,1,10090.0,80024,1,Expert,,,6555,,13038,N,CHEMBL620438,BAO_0000219,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",Mus musculus
F,A9,625.0,,,,,1,10090.0,80024,1,Expert,,,6556,,13038,N,CHEMBL620439,BAO_0000219,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,Mus musculus
F,A9,625.0,,,,,1,10090.0,80024,1,Expert,,,6557,,10923,N,CHEMBL619657,BAO_0000219,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,Mus musculus
F,A9,625.0,,,,,1,10090.0,80024,1,Intermediate,,,6558,,10923,N,CHEMBL619658,BAO_0000219,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,Mus musculus
F,A9,625.0,,,,,1,10090.0,80024,1,Intermediate,,,6559,,10923,N,CHEMBL619659,BAO_0000219,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,Mus musculus
F,,,,,,,8,,10649,1,Expert,,,6560,,10923,H,CHEMBL619660,BAO_0000019,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",
F,A9,625.0,,,,,1,10090.0,80024,1,Intermediate,,,6561,,10923,N,CHEMBL619661,BAO_0000219,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,Mus musculus
F,A9,625.0,,,,,1,10090.0,80024,1,Intermediate,,,6562,,10923,N,CHEMBL619662,BAO_0000219,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,Mus musculus
F,AA6,975.0,,,,,1,10029.0,80663,1,Intermediate,,,6563,,8158,N,CHEMBL619663,BAO_0000219,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,Cricetulus griseus
F,,,,,,,0,9606.0,22226,1,Autocuration,,,6564,,15494,U,CHEMBL619664,BAO_0000219,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,Homo sapiens
F,,,,,,,0,9606.0,22226,1,Autocuration,,,6565,,15494,U,CHEMBL619665,BAO_0000219,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",Homo sapiens
F,AA5,974.0,,,,,1,9606.0,80662,1,Intermediate,,,6566,,12348,N,CHEMBL883244,BAO_0000219,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),Homo sapiens
F,AA5,974.0,,,,,1,9606.0,80662,1,Intermediate,,,6567,,12348,N,CHEMBL884011,BAO_0000219,,Cytotoxicity was measured against AA5/HIV-1(IIIB),Homo sapiens
F,AA5,974.0,,,,,1,9606.0,80662,1,Intermediate,,,6568,,2726,N,CHEMBL619666,BAO_0000219,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,Homo sapiens
F,U-937,379.0,,,,,1,9606.0,80566,1,Intermediate,,,6569,,2726,N,CHEMBL619667,BAO_0000219,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,Homo sapiens
F,UV4,274.0,,,,,1,10029.0,80578,1,Intermediate,,,6570,,10747,N,CHEMBL619668,BAO_0000219,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6571,,11005,N,CHEMBL619669,BAO_0000219,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6572,,12687,N,CHEMBL876608,BAO_0000219,,Average intracellular compound concentration when the hypoxic SER=1.6,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6573,,12687,N,CHEMBL619670,BAO_0000219,,Average intracellular compound concentration when the hypoxic SER=1.6.,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6574,,12687,N,CHEMBL619671,BAO_0000219,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6575,,12687,N,CHEMBL619672,BAO_0000219,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6576,,12687,N,CHEMBL619673,BAO_0000219,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6577,,13436,N,CHEMBL619674,BAO_0000219,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6578,,13435,N,CHEMBL619675,BAO_0000219,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6579,,13302,N,CHEMBL619676,BAO_0000219,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6580,,12687,N,CHEMBL619677,BAO_0000219,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Cricetulus griseus
A,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6581,,12687,N,CHEMBL619678,BAO_0000219,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Cricetulus griseus
A,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6582,,12687,N,CHEMBL619679,BAO_0000219,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,Cricetulus griseus
A,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6583,,12878,N,CHEMBL619680,BAO_0000219,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,Cricetulus griseus
A,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6584,,12878,N,CHEMBL621457,BAO_0000219,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6585,,14367,N,CHEMBL876609,BAO_0000219,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6586,,14367,N,CHEMBL621458,BAO_0000219,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,36483.0,80089,1,Expert,,,6587,,12398,N,CHEMBL621459,BAO_0000219,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,hampster
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6588,,12878,N,CHEMBL621460,BAO_0000219,,Aerobic growth inhibition in Chinese hamster cell line AA8,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6589,,13820,N,CHEMBL621461,BAO_0000219,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6590,,13436,N,CHEMBL621462,BAO_0000219,,Inhibition of growth under aerobic conditions in AA8 cells,Cricetulus griseus
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6591,,6084,N,CHEMBL621463,BAO_0000218,,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6592,,5711,N,CHEMBL621464,BAO_0000218,,Oral bioavailability in dog at 10 mg/kg of the compound,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6593,,4353,N,CHEMBL621465,BAO_0000218,,Oral bioavailability in dog (dose 5 uM/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6594,,4353,N,CHEMBL621466,BAO_0000218,,Oral bioavailability in dog (dose 5 uM/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6595,,17800,N,CHEMBL621467,BAO_0000218,,Oral bioavailability in dog (mongrel),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6596,,3994,N,CHEMBL621468,BAO_0000218,,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris
F,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6597,,3994,N,CHEMBL876734,BAO_0000218,,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6598,,5145,N,CHEMBL618476,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6599,,16452,N,CHEMBL618477,BAO_0000218,,Bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6600,,16452,N,CHEMBL618478,BAO_0000218,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6601,,5983,N,CHEMBL618479,BAO_0000218,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6602,,4273,N,CHEMBL618480,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6603,,12500,N,CHEMBL618481,BAO_0000218,,Bioavailability in dog (dose 3-10 mg/kg),Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6604,,12500,N,CHEMBL618482,BAO_0000218,Plasma,The compound was tested for bioavailability of compound in plasma of dog; Complete,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6605,,3639,N,CHEMBL618483,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6606,,3880,N,CHEMBL618484,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6607,,4838,N,CHEMBL618485,BAO_0000218,,Bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6608,,15600,N,CHEMBL618486,BAO_0000218,,oral bioavailability was measured in dogs,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6609,,17248,N,CHEMBL618487,BAO_0000218,,Compound was tested for plasma protein binding in dog; Not determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6610,,17248,N,CHEMBL618488,BAO_0000218,,Compound was tested for plasma protein binding of dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6611,,17248,N,CHEMBL876735,BAO_0000218,,Compound was tested for plasma protein binding of dog; Not determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6612,,17443,N,CHEMBL618489,BAO_0000218,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6613,,4186,N,CHEMBL618490,BAO_0000218,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6614,,3749,N,CHEMBL618491,BAO_0000218,,Half life was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6615,,3249,N,CHEMBL618492,BAO_0000218,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6616,,3022,N,CHEMBL873354,BAO_0000218,,Half life was evaluated in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6617,,3749,N,CHEMBL618493,BAO_0000218,,Half life was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6618,,2517,N,CHEMBL618494,BAO_0000218,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris
A,,,In vivo,,948.0,,1,9615.0,50588,1,Intermediate,,,6619,,2517,N,CHEMBL618495,BAO_0000218,Heart,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris
A,,,In vivo,,2113.0,,1,9615.0,50588,1,Intermediate,,,6620,,2517,N,CHEMBL618496,BAO_0000218,Kidney,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris
A,,,In vivo,,2107.0,,1,9615.0,50588,1,Intermediate,,,6621,,2517,N,CHEMBL618497,BAO_0000218,Liver,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris
A,,,In vivo,,2048.0,,1,9615.0,50588,1,Intermediate,,,6622,,2517,N,CHEMBL618498,BAO_0000218,Lung,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris
A,,,In vivo,,2106.0,,1,9615.0,50588,1,Intermediate,,,6623,,2517,N,CHEMBL618499,BAO_0000218,Spleen,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6624,,3639,N,CHEMBL876736,BAO_0000218,,LogP in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6625,,6227,N,CHEMBL618500,BAO_0000218,,Partition coefficient (logP),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6626,,6227,N,CHEMBL857831,BAO_0000218,,Partition coefficient in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6627,,17764,N,CHEMBL618501,BAO_0000218,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6628,,4809,N,CHEMBL618502,BAO_0000218,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6629,,5600,N,CHEMBL618503,BAO_0000218,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6630,,14294,N,CHEMBL618504,BAO_0000218,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6631,,14294,N,CHEMBL618505,BAO_0000218,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6632,,14294,N,CHEMBL618506,BAO_0000218,,Metabolism of compound in dog S9 microsomes; Trace,Canis lupus familiaris
A,,,,,2107.0,,1,9615.0,50588,1,Intermediate,,,6633,,6251,N,CHEMBL618507,BAO_0000218,Liver,In vitro metabolic potential in dog liver microsomes,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6634,,3748,N,CHEMBL876737,BAO_0000218,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6635,,2713,N,CHEMBL618508,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6636,,6512,N,CHEMBL618509,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6637,,6679,N,CHEMBL618510,BAO_0000218,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6638,,3749,N,CHEMBL618511,BAO_0000218,,The compound was tested for bioavailability in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6639,,3749,N,CHEMBL618512,BAO_0000218,,The compound was tested for oral bioavailability in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6640,,6742,N,CHEMBL618513,BAO_0000218,,Oral bioavailability in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6641,,6227,N,CHEMBL618514,BAO_0000218,,Compound was tested for percent protein binding (PB) in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6642,,6874,N,CHEMBL620052,BAO_0000218,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6643,,2877,N,CHEMBL620053,BAO_0000218,Plasma,Compound was evaluated for plasma clearance.,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6644,,12500,N,CHEMBL620054,BAO_0000218,Plasma,The compound was tested for plasma clearance in dog,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6645,,12500,N,CHEMBL620055,BAO_0000218,Plasma,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6646,,4709,N,CHEMBL620056,BAO_0000218,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris
A,,,,,2107.0,,1,9615.0,50588,1,Intermediate,,,6647,,5542,N,CHEMBL620057,BAO_0000218,Liver,In vitro relative rate of metabolism was determined in dog liver microsomes,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6648,,17594,N,CHEMBL618939,BAO_0000218,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6649,,2652,N,CHEMBL618940,BAO_0000218,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6650,,17764,N,CHEMBL618941,BAO_0000218,,Half life after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris
A,CCRF S-180,42.0,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6651,,6599,N,CHEMBL624473,BAO_0000218,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6652,,6599,N,CHEMBL624474,BAO_0000218,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6653,,6599,N,CHEMBL624475,BAO_0000218,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6654,,6599,N,CHEMBL624476,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6655,,6599,N,CHEMBL623478,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6656,,6599,N,CHEMBL623479,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6657,,6599,N,CHEMBL623480,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,Mus musculus
A,CCRF S-180,42.0,,,,,1,10090.0,50594,1,Intermediate,,,6658,,6599,N,CHEMBL623481,BAO_0000218,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,Mus musculus
A,,,,,955.0,,1,10090.0,50594,1,Intermediate,,,6659,,17641,N,CHEMBL623482,BAO_0000218,Brain,C2 in brain of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,,,2113.0,,1,10090.0,50594,1,Intermediate,,,6660,,17641,N,CHEMBL623483,BAO_0000218,Kidney,C2 in kidney of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,,,2107.0,,1,10090.0,50594,1,Intermediate,,,6661,,17641,N,CHEMBL623484,BAO_0000218,Liver,C2 in liver of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,,,2048.0,,1,10090.0,50594,1,Intermediate,,,6662,,17641,N,CHEMBL623485,BAO_0000218,Lung,C2 in lungs of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,,,2106.0,,1,10090.0,50594,1,Intermediate,,,6663,,17641,N,CHEMBL623486,BAO_0000218,Spleen,C2 in spleen of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6664,,17852,N,CHEMBL623487,BAO_0000218,,Plasma clearance in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6665,,17764,N,CHEMBL623488,BAO_0000218,,Clearance of compound after intravenous administration in mice at 24 uM/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6666,,17837,N,CHEMBL623489,BAO_0000218,,Clearance from mouse blood following i.v. administration of 10 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6667,,2675,N,CHEMBL875157,BAO_0000218,,Clearance was evaluated in mice after intravenous administration,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6668,,2675,N,CHEMBL623490,BAO_0000218,,Clearance was evaluated in mice after oral administration,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6669,,4239,N,CHEMBL623491,BAO_0000218,,Pharmacokinetic property (Plasma clearance) was measured in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6670,,17753,N,CHEMBL623492,BAO_0000218,,Plasma clearance of compound was determined at 40 mg/Kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6671,,17753,N,CHEMBL623493,BAO_0000218,,Plasma clearance of at 24 mg/Kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6672,,17753,N,CHEMBL623494,BAO_0000218,,Plasma clearance at 24 mg/Kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6673,,17753,N,CHEMBL623495,BAO_0000218,,Plasma clearance at 5 mg/Kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6674,,5727,N,CHEMBL623496,BAO_0000218,,Plasma clearance in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6675,,2862,N,CHEMBL623497,BAO_0000218,,Plasma clearance value upon iv administration in mouse,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6676,,5980,N,CHEMBL623498,BAO_0000218,Plasma,Total plasma clearance in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6677,,17592,N,CHEMBL623499,BAO_0000218,,Clearance in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6678,,17718,N,CHEMBL623500,BAO_0000218,,Clearance value was determined,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6679,,16597,N,CHEMBL623501,BAO_0000218,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus
P,,,,,,,0,,22229,1,Intermediate,,,6680,,17384,U,CHEMBL875158,BAO_0000100,,Calculated partition coefficient (clogP),
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6681,,6062,N,CHEMBL623502,BAO_0000218,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6682,,17734,N,CHEMBL623503,BAO_0000218,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6683,,6348,N,CHEMBL623504,BAO_0000218,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6684,,5969,N,CHEMBL623505,BAO_0000218,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6685,,5969,N,CHEMBL623506,BAO_0000218,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6686,,5969,N,CHEMBL623507,BAO_0000218,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6687,,16597,N,CHEMBL623508,BAO_0000218,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6688,,5781,N,CHEMBL623509,BAO_0000218,,Cmax after oral administration at 30 mg/kg in ICR mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6689,,17764,N,CHEMBL875159,BAO_0000218,,Cmax after peroral administration in mice at 2.4 uM/kg,Mus musculus
A,,,In vivo,,955.0,,1,10090.0,50594,1,Intermediate,,,6690,,17641,N,CHEMBL623510,BAO_0000218,Brain,Cmax in brain of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,6691,,17641,N,CHEMBL623511,BAO_0000218,Kidney,Cmax in kidney of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,6692,,17641,N,CHEMBL623512,BAO_0000218,Liver,Cmax in liver of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,6693,,17641,N,CHEMBL623513,BAO_0000218,Lung,Cmax in lungs of mice at the oral dose of 50 mg/kg,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6694,,17764,N,CHEMBL623514,BAO_0000218,,Cmax in mice at 18 uM/kg i.p. administration,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6695,,17764,N,CHEMBL622609,BAO_0000218,,Cmax in mice at 23 uM/kg i.v. administration,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6696,,17764,N,CHEMBL622610,BAO_0000218,,Cmax in mice at 24 uM/kg i.p. administration,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6697,,17764,N,CHEMBL621823,BAO_0000218,,Cmax in mice at 25 uM/kg i.p. administration,Mus musculus
F,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6698,,17764,N,CHEMBL621824,BAO_0000218,,Cmax in mice at 26 uM/kg i.p. administration,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,6699,,17641,N,CHEMBL621825,BAO_0000218,Spleen,Cmax in spleen of mice at the oral dose of 50 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6700,,16597,N,CHEMBL621826,BAO_0000218,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6701,,16597,N,CHEMBL621827,BAO_0000218,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6702,,5727,N,CHEMBL621828,BAO_0000218,,Cmax value was determined,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6703,,5951,N,CHEMBL621829,BAO_0000218,,Cmax value in IRC mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6704,,5506,N,CHEMBL621830,BAO_0000218,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6705,,5506,N,CHEMBL621831,BAO_0000218,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6706,,14239,N,CHEMBL621832,BAO_0000218,Plasma,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6707,,4890,N,CHEMBL624579,BAO_0000218,Plasma,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6708,,429,N,CHEMBL624580,BAO_0000218,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,Mus musculus
F,,,,,,,1,6277.0,50535,1,Intermediate,,,6709,,10986,N,CHEMBL624581,BAO_0000218,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,Acanthocheilonema viteae
F,,,,,,,1,6277.0,50535,1,Intermediate,,,6710,,10986,N,CHEMBL624582,BAO_0000218,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,Acanthocheilonema viteae
F,,,,,,,1,6277.0,50535,1,Intermediate,,,6711,,10986,N,CHEMBL624583,BAO_0000218,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,Acanthocheilonema viteae
F,A-375,455.0,,,,,1,9606.0,80018,1,Intermediate,,,6712,,13227,N,CHEMBL624584,BAO_0000219,,Inhibitory activity against human tumor cell line A0375 melanoma.,Homo sapiens
B,,,,,,,9,10116.0,12512,1,Expert,,,6713,Brain membranes,4481,D,CHEMBL624585,BAO_0000249,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Rattus norvegicus
F,,,,,,,9,9606.0,114,1,Expert,,,6714,,16931,D,CHEMBL875165,BAO_0000019,,Forskolin-induced cAMP production at human A1 adenosine receptor,Homo sapiens
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6715,,3850,H,CHEMBL619490,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6716,,3850,H,CHEMBL619491,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,
F,CHO,449.0,,,,,8,,114,1,Expert,,,6717,,3850,H,CHEMBL619492,BAO_0000219,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,
F,CHO,449.0,,,,,8,,114,1,Expert,,,6718,,3850,H,CHEMBL619493,BAO_0000219,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6719,,3850,H,CHEMBL619494,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6720,,3850,H,CHEMBL619495,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6721,,3850,H,CHEMBL619496,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,
F,CHO,449.0,,,,,9,9606.0,114,1,Expert,,,6722,,3850,D,CHEMBL619497,BAO_0000219,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Homo sapiens
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6723,,3850,H,CHEMBL619498,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6724,,3850,H,CHEMBL619499,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,
F,CHO,449.0,,,,,8,,114,1,Expert,,,6725,,3850,H,CHEMBL619500,BAO_0000219,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6726,,3850,H,CHEMBL619501,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,
F,CHO,449.0,,,,,8,,114,1,Expert,,,6727,,3850,H,CHEMBL619502,BAO_0000219,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6728,,3850,H,CHEMBL619503,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6729,,3850,H,CHEMBL619504,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6730,,3850,H,CHEMBL621298,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,
F,CHO,449.0,,,,,8,,114,1,Expert,,,6731,,3850,H,CHEMBL621299,BAO_0000219,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6732,,3850,H,CHEMBL621300,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,
F,CHO,449.0,,,,,8,,114,1,Autocuration,,,6733,,3850,H,CHEMBL621301,BAO_0000219,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,
F,CHO,449.0,,,,,8,,114,1,Expert,,,6734,,3850,H,CHEMBL621302,BAO_0000219,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,
F,A10,164.0,,,,,1,9986.0,80013,1,Intermediate,,,6735,,12680,N,CHEMBL621303,BAO_0000219,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,Oryctolagus cuniculus
F,A10,164.0,,,,,0,10116.0,22226,1,Autocuration,,,6736,,1313,U,CHEMBL621304,BAO_0000219,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,Rattus norvegicus
F,A10,164.0,,,,,0,10116.0,22226,1,Autocuration,,,6737,,1313,U,CHEMBL621305,BAO_0000219,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,Rattus norvegicus
F,A10,164.0,,,,,1,10116.0,80013,1,Intermediate,,,6738,,17567,N,CHEMBL621306,BAO_0000219,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,Rattus norvegicus
F,A10,164.0,,,,,1,10116.0,80013,1,Intermediate,,,6739,,17567,N,CHEMBL618444,BAO_0000219,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,Rattus norvegicus
F,A10,164.0,,,,,1,10116.0,80013,1,Intermediate,,,6740,,11819,N,CHEMBL618445,BAO_0000219,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,Rattus norvegicus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6741,,13436,N,CHEMBL618446,BAO_0000219,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6742,,12687,N,CHEMBL618447,BAO_0000219,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6743,,12651,N,CHEMBL618448,BAO_0000219,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6744,,13300,N,CHEMBL618449,BAO_0000219,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6745,,15296,N,CHEMBL618637,BAO_0000219,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6746,,15328,N,CHEMBL618638,BAO_0000219,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6747,,13302,N,CHEMBL618639,BAO_0000219,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6748,,14367,N,CHEMBL618640,BAO_0000219,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6749,,17002,N,CHEMBL618641,BAO_0000219,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6750,,13436,N,CHEMBL618642,BAO_0000219,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6751,,13435,N,CHEMBL618643,BAO_0000219,,Inhibitory activity against aerobic growth of AA8 cells.,Cricetulus griseus
A,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6752,,10503,N,CHEMBL884013,BAO_0000219,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6753,,10503,N,CHEMBL622723,BAO_0000219,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6754,,10503,N,CHEMBL622724,BAO_0000219,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6755,,15090,N,CHEMBL622725,BAO_0000219,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6756,,10368,N,CHEMBL622726,BAO_0000219,,Cytotoxicity against AA8 cell line,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6757,,12651,N,CHEMBL622727,BAO_0000219,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),Cricetulus griseus
A,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6758,,12687,N,CHEMBL622728,BAO_0000219,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6759,,12687,N,CHEMBL622729,BAO_0000219,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Cricetulus griseus
A,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6760,,12687,N,CHEMBL622730,BAO_0000219,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6761,,1890,N,CHEMBL622731,BAO_0000219,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6762,,10747,N,CHEMBL622732,BAO_0000219,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Intermediate,,,6763,,10747,N,CHEMBL622733,BAO_0000219,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Cricetulus griseus
F,,,,,,,0,10029.0,22224,1,Autocuration,,,6764,,11616,U,CHEMBL622734,BAO_0000218,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6765,,11616,N,CHEMBL622735,BAO_0000219,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6766,,3471,U,CHEMBL618746,BAO_0000219,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6767,,3471,U,CHEMBL618747,BAO_0000219,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6768,,3471,U,CHEMBL620540,BAO_0000219,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6769,,3471,U,CHEMBL620541,BAO_0000219,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6770,,3471,U,CHEMBL620542,BAO_0000219,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6771,,3471,U,CHEMBL620543,BAO_0000219,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6772,,3471,U,CHEMBL618832,BAO_0000219,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6773,,11616,N,CHEMBL618833,BAO_0000219,,Concentration required to reduce AA8 cell survival by 10%,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6774,,2656,U,CHEMBL618834,BAO_0000219,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6775,,10518,U,CHEMBL618835,BAO_0000219,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6776,,10518,U,CHEMBL618836,BAO_0000219,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6777,,10518,U,CHEMBL618837,BAO_0000219,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6778,,10518,U,CHEMBL618838,BAO_0000219,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6779,,16156,U,CHEMBL618839,BAO_0000219,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6780,,2656,U,CHEMBL618840,BAO_0000219,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,Cricetulus griseus
F,,,,,,,0,10029.0,22224,1,Autocuration,,,6781,,11005,U,CHEMBL618841,BAO_0000019,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6782,,11942,U,CHEMBL618842,BAO_0000219,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6783,,2128,U,CHEMBL618843,BAO_0000219,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,Cricetulus griseus
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6784,,16907,N,CHEMBL618844,BAO_0000218,,Half life period after 15 mg/kg iv dose in Dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6785,,16907,N,CHEMBL618845,BAO_0000218,,Half life period after 30 mg/kg po dose in Dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6786,,9579,N,CHEMBL618846,BAO_0000218,,Half life was measured after oral 2b administration (tested in 6 dogs),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6787,,9579,N,CHEMBL618847,BAO_0000218,,Half life was measured in dog after oral 17b administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6788,,9579,N,CHEMBL618848,BAO_0000218,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6789,,9579,N,CHEMBL618849,BAO_0000218,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6790,,16907,N,CHEMBL618850,BAO_0000218,,Tmax value after 15 mg/kg iv dose in Dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6791,,16907,N,CHEMBL618851,BAO_0000218,,Tmax value after 30 mg/kg po dose in Dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6792,,3184,N,CHEMBL873815,BAO_0000218,,Compound was evaluated for its half life when administered intravenously in dog,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6793,,5017,N,CHEMBL618852,BAO_0000218,Plasma,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6794,,6821,N,CHEMBL618853,BAO_0000218,,Elimination Half-life of compound was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6795,,17839,N,CHEMBL618854,BAO_0000218,,Half life of compound in dog following oral administration,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6796,,17267,N,CHEMBL618855,BAO_0000218,,Half life of compound was determined in dog,Canis lupus familiaris
A,,,,,178.0,,1,9615.0,50588,1,Intermediate,,,6797,,4727,N,CHEMBL618856,BAO_0000218,Blood,Half life of compound was determined in dog blood,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6798,,5238,N,CHEMBL875827,BAO_0000218,,Half life after oral and iv dosing in dogs,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6799,,4942,N,CHEMBL618857,BAO_0000218,,Half life in dogs in hours,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6800,,6505,N,CHEMBL618858,BAO_0000218,,Half life on i.v. administration of 2 mg/kg was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6801,,5130,N,CHEMBL618859,BAO_0000218,,t1/2 in dog after oral dose (1 mg/kg),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6802,,1475,N,CHEMBL618860,BAO_0000218,,Half life was evaluated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6803,,17804,N,CHEMBL618861,BAO_0000218,,Half life period of compound was determined after intravenous administration at 2 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6804,,17804,N,CHEMBL622539,BAO_0000218,,Half life period of compound was determined after peroral administration at 2 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6805,,6084,N,CHEMBL622540,BAO_0000218,,Half life period (10 mg/kg) was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6806,,6084,N,CHEMBL873803,BAO_0000218,,Half life period (10 mg/kg) was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6807,,5542,N,CHEMBL873804,BAO_0000218,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6808,,5542,N,CHEMBL624311,BAO_0000218,,Half life period by po administration in dog at a dose of 0.3 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6809,,6084,N,CHEMBL624312,BAO_0000218,,Half life period in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6810,,6241,N,CHEMBL624313,BAO_0000218,,Half life period in dogs after oral administration at 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6811,,1916,N,CHEMBL624314,BAO_0000218,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6812,,6621,N,CHEMBL624315,BAO_0000218,,Half-life of compound was determined in dogs,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,6813,,1696,N,CHEMBL624316,BAO_0000218,Plasma,Half-life in dog plasma,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6814,,17800,N,CHEMBL624317,BAO_0000218,,Half-life in mongrel dogs was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6815,,17657,N,CHEMBL624318,BAO_0000218,,Half-life in dog upon oral administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6816,,17657,N,CHEMBL624319,BAO_0000218,,Half-life in dog upon oral administration; Unable to calculate,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6817,,4239,N,CHEMBL624496,BAO_0000218,,Half-life was measured in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6818,,5985,N,CHEMBL624497,BAO_0000218,,Half-life was measured in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6819,,9932,N,CHEMBL624498,BAO_0000218,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6820,,5199,N,CHEMBL624499,BAO_0000218,,Oral half life was determined,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6821,,5199,N,CHEMBL624500,BAO_0000218,Plasma,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,6822,,1475,N,CHEMBL624501,BAO_0000218,Plasma,Plasma half life was evaluated,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,6823,,1475,N,CHEMBL623666,BAO_0000218,Plasma,Plasma half life was evaluated in Dog,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,6824,,1475,N,CHEMBL623667,BAO_0000218,Plasma,Plasma half life was evaluated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6825,,6316,N,CHEMBL623668,BAO_0000218,,T1/2 (Half-life) was after oral administration at 5 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6826,,4883,N,CHEMBL623669,BAO_0000218,,Tested for the half life value in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6827,,4727,N,CHEMBL623670,BAO_0000218,,Maximum time at the dose of 2 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6828,,1916,N,CHEMBL623671,BAO_0000218,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris
A,,,In vivo,,178.0,,1,9615.0,50588,1,Intermediate,,,6829,,1337,N,CHEMBL875945,BAO_0000218,Blood,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris
A,,,In vivo,,178.0,,1,9615.0,50588,1,Intermediate,,,6830,,1337,N,CHEMBL623672,BAO_0000218,Blood,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6831,,6265,N,CHEMBL623673,BAO_0000218,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6832,,4809,N,CHEMBL623674,BAO_0000218,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6833,,5983,N,CHEMBL623675,BAO_0000218,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6834,,5313,N,CHEMBL872526,BAO_0000218,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6835,,5313,N,CHEMBL623676,BAO_0000218,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6836,,17650,N,CHEMBL623677,BAO_0000218,Plasma,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6837,,5199,N,CHEMBL623678,BAO_0000218,Plasma,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,6838,,933,N,CHEMBL623679,BAO_0000218,Plasma,Time taken for maximum plasma concentration in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6839,,16367,N,CHEMBL623680,BAO_0000218,,Time to reach Cmax after oral administration to dogs,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,6840,,6348,N,CHEMBL623681,BAO_0000218,Plasma,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6841,,6316,N,CHEMBL623682,BAO_0000218,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6842,,6215,N,CHEMBL623683,BAO_0000218,,Tmax after peroral administration (1 mg/kg) was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Expert,,,6843,,3598,N,CHEMBL623684,BAO_0000218,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6844,,4527,N,CHEMBL622745,BAO_0000218,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6845,,17764,N,CHEMBL622746,BAO_0000218,,Tmax after peroral administration in dogs at 2.4 uM/kg,Canis lupus familiaris
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6846,,5969,N,CHEMBL622747,BAO_0000218,,In vivo Cmax in mice at dose of 100 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6847,,5969,N,CHEMBL622748,BAO_0000218,,In vivo Cmax in mice at dose of 50 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6848,,4573,N,CHEMBL622749,BAO_0000218,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6849,,3277,N,CHEMBL622750,BAO_0000218,Plasma,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6850,,17734,N,CHEMBL623411,BAO_0000218,Plasma,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6851,,3132,N,CHEMBL875946,BAO_0000218,Plasma,Maximum concentration obtained in mouse plasma was determined,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6852,,3132,N,CHEMBL623412,BAO_0000218,Plasma,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6853,,6348,N,CHEMBL623413,BAO_0000218,Plasma,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6854,,17729,N,CHEMBL623414,BAO_0000218,Plasma,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6855,,17729,N,CHEMBL623415,BAO_0000218,Plasma,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6856,,17729,N,CHEMBL623416,BAO_0000218,Plasma,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6857,,17728,N,CHEMBL623417,BAO_0000218,Plasma,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6858,,17728,N,CHEMBL623418,BAO_0000218,Plasma,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6859,,17728,N,CHEMBL623419,BAO_0000218,Plasma,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6860,,4066,N,CHEMBL622816,BAO_0000218,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6861,,6178,N,CHEMBL623313,BAO_0000218,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6862,,6178,N,CHEMBL623314,BAO_0000218,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6863,,3760,N,CHEMBL876788,BAO_0000218,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6864,,3760,N,CHEMBL623315,BAO_0000218,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6865,,3760,N,CHEMBL623316,BAO_0000218,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6866,,3760,N,CHEMBL623317,BAO_0000218,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6868,,5961,N,CHEMBL623319,BAO_0000218,,Cmax in male mice after 2 mg/kg oral dose,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6869,,6137,N,CHEMBL623320,BAO_0000218,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,6870,,3802,N,CHEMBL623321,BAO_0000218,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6871,,3535,N,CHEMBL623322,BAO_0000218,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6872,,3535,N,CHEMBL623323,BAO_0000218,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6873,,3535,N,CHEMBL623324,BAO_0000218,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6874,,3535,N,CHEMBL623325,BAO_0000218,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6875,,3535,N,CHEMBL623326,BAO_0000218,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6876,,3535,N,CHEMBL623327,BAO_0000218,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,6877,,2862,N,CHEMBL623328,BAO_0000218,Plasma,Maximum concentration in plasma upon oral administration in mouse,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,6878,,2675,N,CHEMBL623329,BAO_0000218,Plasma,Maximum plasma concentration was evaluated in mice after oral administration,Mus musculus
A,,,In vivo,,1969.0,,1,10090.0,50594,1,Intermediate,,,6879,,2675,N,CHEMBL623330,BAO_0000218,Plasma,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,6880,,5399,N,CHEMBL876789,BAO_0000218,,Dose at which the compound induced fecal excretion in mice,Mus musculus
F,A10,164.0,,,,,1,10116.0,80013,1,Expert,,,6893,,11819,N,CHEMBL623333,BAO_0000219,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,Rattus norvegicus
F,A10,164.0,,,,,1,10116.0,80013,1,Expert,,,6894,,11819,N,CHEMBL623334,BAO_0000219,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,Rattus norvegicus
F,A10,164.0,,,,,1,10116.0,80013,1,Expert,,,6895,,11819,N,CHEMBL627536,BAO_0000219,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,Rattus norvegicus
F,A10,164.0,,,,,1,10116.0,80013,1,Expert,,,6896,,11819,N,CHEMBL627537,BAO_0000219,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,Rattus norvegicus
F,A10,164.0,,,,,1,10116.0,80013,1,Intermediate,,,6897,,16361,N,CHEMBL627538,BAO_0000219,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),Rattus norvegicus
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6898,,2288,N,CHEMBL884106,BAO_0000219,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6899,,10404,N,CHEMBL625294,BAO_0000219,,Anticancer activity against human ovarian carcinoma A121 cells,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6900,,14790,N,CHEMBL625295,BAO_0000219,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6901,,14790,N,CHEMBL625296,BAO_0000219,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Expert,,,6902,,14253,N,CHEMBL625297,BAO_0000219,,Growth inhibition of human ovarian carcinoma (A121) cell line,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Expert,,,6903,,13617,N,CHEMBL625298,BAO_0000219,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6904,,1003,N,CHEMBL625960,BAO_0000219,,Cytotoxicity against human A121 ovarian cells,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6905,,830,N,CHEMBL625961,BAO_0000219,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6906,,12307,N,CHEMBL625962,BAO_0000219,,In vitro cytotoxicity against human ovarian carcinoma A21,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6907,,14254,N,CHEMBL624717,BAO_0000219,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6908,,13370,N,CHEMBL624718,BAO_0000219,,Inhibitory activity of compound against human A121 ovarian cell line.,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6909,,14790,N,CHEMBL624719,BAO_0000219,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,Homo sapiens
F,A121,393.0,,,,,1,9606.0,80655,1,Intermediate,,,6910,,3614,N,CHEMBL624720,BAO_0000219,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,Homo sapiens
F,A 172,622.0,,,,,1,9606.0,80012,1,Intermediate,,,6911,,2664,N,CHEMBL624721,BAO_0000219,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,Homo sapiens
F,A 172,622.0,,,,,1,9606.0,80012,1,Expert,,,6912,,2037,N,CHEMBL624722,BAO_0000219,,In vitro cytotoxicity against A172 human tumor cell lines.,Homo sapiens
F,A 172,622.0,,,,,1,9606.0,80012,1,Intermediate,,,6913,,14539,N,CHEMBL877597,BAO_0000219,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,Homo sapiens
F,A 172,622.0,,,,,1,9606.0,80012,1,Intermediate,,,6914,,2836,N,CHEMBL624723,BAO_0000219,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,Homo sapiens
F,A 172,622.0,,,,,1,9606.0,80012,1,Intermediate,,,6915,,10708,N,CHEMBL624724,BAO_0000219,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,Homo sapiens
B,,,,,,,4,9615.0,104729,1,Autocuration,,,6916,,8975,H,CHEMBL624725,BAO_0000224,,Association constant against A2 adenosine receptor,Canis lupus familiaris
F,A2,1085.0,,,,,1,,80656,1,Intermediate,,,6917,,7645,N,CHEMBL624726,BAO_0000219,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,fish
B,,,,,,,5,10116.0,104713,1,Autocuration,,,6918,,11377,D,CHEMBL857535,BAO_0000224,,Ratio of Ki for adenosine A2 and A1 receptor binding,Rattus norvegicus
F,A204,623.0,,,,,1,9606.0,80014,1,Expert,,,6919,,13528,N,CHEMBL624727,BAO_0000219,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,Homo sapiens
F,A204,623.0,,,,,1,9606.0,80014,1,Expert,,,6920,,10160,N,CHEMBL624728,BAO_0000219,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,Homo sapiens
F,A2058,404.0,,,,,1,9606.0,80015,1,Intermediate,,,6921,,15144,N,CHEMBL624729,BAO_0000219,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,Homo sapiens
F,A253 cell line,973.0,,,,,1,9606.0,80657,1,Intermediate,,,6922,,13160,N,CHEMBL624730,BAO_0000219,,Growth inhibition against Human squamous cell line(A 253),Homo sapiens
F,A253 cell line,973.0,,,,,1,9606.0,80657,1,Intermediate,,,6923,,12898,N,CHEMBL624731,BAO_0000219,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,Homo sapiens
F,A253 cell line,973.0,,,,,1,9606.0,80657,1,Intermediate,,,6924,,13069,N,CHEMBL624732,BAO_0000219,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,Homo sapiens
F,A253 cell line,973.0,,,,,1,9606.0,80657,1,Intermediate,,,6925,,15984,N,CHEMBL883245,BAO_0000219,,Growth inhibition of A253 cell lines.,Homo sapiens
F,A253 cell line,973.0,,,,,1,9606.0,80657,1,Intermediate,,,6926,,15564,N,CHEMBL624733,BAO_0000219,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),Homo sapiens
F,A253 cell line,973.0,,,,,1,9606.0,80657,1,Intermediate,,,6927,,15564,N,CHEMBL624734,BAO_0000219,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Homo sapiens
F,A253 cell line,973.0,,,,,1,9606.0,80657,1,Intermediate,,,6928,,15564,N,CHEMBL624735,BAO_0000219,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,6929,,4720,N,CHEMBL621780,BAO_0000219,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,6930,,16112,N,CHEMBL877598,BAO_0000219,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,6931,,16597,N,CHEMBL621781,BAO_0000219,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,6932,,16378,N,CHEMBL621782,BAO_0000219,,Cytotoxicity against human cancer cell lines A2780 (ovarian),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,6933,,16085,N,CHEMBL621783,BAO_0000219,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,6934,,16317,N,CHEMBL621784,BAO_0000219,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,6935,,15748,N,CHEMBL621785,BAO_0000219,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,6936,,16597,N,CHEMBL621968,BAO_0000219,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,6937,,16597,N,CHEMBL621969,BAO_0000219,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,6938,,16597,N,CHEMBL621970,BAO_0000219,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,6939,,15608,N,CHEMBL621971,BAO_0000219,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,6940,,15608,N,CHEMBL621972,BAO_0000219,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,6941,,15608,N,CHEMBL884108,BAO_0000219,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,Homo sapiens
F,,,,,,,0,10029.0,22224,1,Autocuration,,,6942,,15296,U,CHEMBL623826,BAO_0000019,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Cricetulus griseus
A,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6943,,10251,U,CHEMBL623827,BAO_0000219,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6944,,10251,U,CHEMBL623828,BAO_0000219,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6945,,10251,U,CHEMBL623829,BAO_0000219,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6946,,10251,U,CHEMBL623830,BAO_0000219,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),Cricetulus griseus
F,,,,,,,0,10029.0,22224,1,Autocuration,,,6947,,11858,U,CHEMBL623831,BAO_0000019,,Growth inhibition against CHO-derived cell line AA8,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6948,,11858,U,CHEMBL623832,BAO_0000219,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,36483.0,80089,1,Expert,,,6949,,11616,N,CHEMBL623833,BAO_0000219,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,hampster
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6950,,11616,N,CHEMBL623834,BAO_0000219,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6951,,10518,U,CHEMBL623835,BAO_0000219,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6952,,11396,U,CHEMBL623836,BAO_0000219,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,Cricetulus griseus
F,CHO-AA8,185.0,,,,,0,10029.0,22224,1,Autocuration,,,6953,,10518,U,CHEMBL623837,BAO_0000219,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,Cricetulus griseus
F,CHO-AA8,185.0,,,,,1,10029.0,80089,1,Expert,,,6954,,11616,N,CHEMBL623838,BAO_0000219,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,Cricetulus griseus
F,,,,,,,8,,12675,1,Autocuration,,,6955,,14837,H,CHEMBL623839,BAO_0000019,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,
F,,,,,,,8,,12675,1,Autocuration,,,6956,,14837,H,CHEMBL623840,BAO_0000019,,Number of binding sites (n) of isolated serum protein AAG,
B,,,,,,,3,,22222,1,Intermediate,,,6957,,16037,M,CHEMBL623841,BAO_0000225,,Association constant for binding to AATT duplex,
F,ABAE,416.0,,,,,1,9606.0,100090,1,Expert,,,6958,,16597,N,CHEMBL623842,BAO_0000219,,Inhibition of ABAE human fibroblast cell proliferation,Homo sapiens
F,AC755,1064.0,,,,,1,10090.0,80668,1,Intermediate,,,6959,,8831,N,CHEMBL623843,BAO_0000218,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",Mus musculus
F,,,,,,,9,9986.0,102444,1,Expert,,,6960,,13419,D,CHEMBL618669,BAO_0000218,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,Oryctolagus cuniculus
F,,,In vivo,,,,9,9986.0,102444,1,Expert,,,6961,,13419,D,CHEMBL618670,BAO_0000218,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,Oryctolagus cuniculus
B,,,,,,,8,,69,1,Autocuration,,,6962,,15778,H,CHEMBL618671,BAO_0000357,,Inhibitory activity against angiotensin-converting enzyme (ACE).,
B,,,,,,,8,,69,1,Autocuration,,,6963,,15778,H,CHEMBL618672,BAO_0000357,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,
F,ACH-2 cell line,978.0,,,,,1,9606.0,80669,1,Intermediate,,,6964,,12988,N,CHEMBL618673,BAO_0000219,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,Homo sapiens
F,ACH-2 cell line,978.0,,,,,1,9606.0,80669,1,Intermediate,,,6965,,12988,N,CHEMBL618674,BAO_0000219,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),Homo sapiens
F,T cell line,998.0,,,,,0,11676.0,22224,1,Autocuration,,,6966,,12988,U,CHEMBL618675,BAO_0000219,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,Human immunodeficiency virus 1
F,T cell line,998.0,,,,,0,11676.0,22224,1,Autocuration,,,6967,,12988,U,CHEMBL618676,BAO_0000219,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),Human immunodeficiency virus 1
F,T cell line,998.0,,,,,0,11676.0,22224,1,Autocuration,,,6968,,12988,U,CHEMBL618677,BAO_0000219,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),Human immunodeficiency virus 1
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6969,,11843,N,CHEMBL618678,BAO_0000219,,Inhibition of growth of renal cancer ACHN cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6970,,16939,N,CHEMBL618679,BAO_0000219,,Inhibition of growth of ACHN renal cancer cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6971,,4782,N,CHEMBL618680,BAO_0000219,,Inhibitory concentration required against ACHN renal cancer cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Expert,,,6972,,6310,N,CHEMBL618681,BAO_0000219,,Concentration required to inhibit growth of human renal (ACHN) cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6973,,6310,N,CHEMBL618682,BAO_0000219,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6974,,12858,N,CHEMBL618683,BAO_0000219,,Cytotoxic activity against ACHN Renal cancer cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6975,,17380,N,CHEMBL618684,BAO_0000219,,Cytotoxicity evaluation against ACHN renal cancer cells,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6976,,5858,N,CHEMBL618685,BAO_0000219,,In vitro antitumor activity against human renal ACHN cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6977,,3838,N,CHEMBL876499,BAO_0000219,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6978,,3838,N,CHEMBL618686,BAO_0000219,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6979,,5406,N,CHEMBL618687,BAO_0000219,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6980,,4071,N,CHEMBL618688,BAO_0000219,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Expert,,,6981,,4071,N,CHEMBL618689,BAO_0000219,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6982,,4071,N,CHEMBL618690,BAO_0000219,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6983,,15002,N,CHEMBL618691,BAO_0000219,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6984,,14769,N,CHEMBL619373,BAO_0000219,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6985,,13958,N,CHEMBL884008,BAO_0000219,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6986,,1665,N,CHEMBL619374,BAO_0000219,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6987,,15354,N,CHEMBL619375,BAO_0000219,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6988,,15354,N,CHEMBL619376,BAO_0000219,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6989,,13978,N,CHEMBL619377,BAO_0000219,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,6990,,6798,N,CHEMBL619378,BAO_0000219,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,Homo sapiens
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6991,,2959,N,CHEMBL872527,BAO_0000218,,Tmax value after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6992,,9932,N,CHEMBL876500,BAO_0000218,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,6993,,5546,N,CHEMBL619379,BAO_0000218,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6994,,16907,N,CHEMBL619538,BAO_0000218,,Volume distribution after 15 mg/kg iv dose in Dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6995,,16907,N,CHEMBL619539,BAO_0000218,,Volume distribution after 30 mg/kg po dose in Dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6996,,4257,N,CHEMBL619540,BAO_0000218,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6997,,4305,N,CHEMBL619541,BAO_0000218,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6998,,5472,N,CHEMBL619542,BAO_0000218,,Volume of distribution was evaluated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,6999,,6062,N,CHEMBL619543,BAO_0000218,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Expert,,,7000,,3598,N,CHEMBL619544,BAO_0000218,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7001,,12500,N,CHEMBL619545,BAO_0000218,,The compound was tested for volume of distribution in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7002,,12500,N,CHEMBL619546,BAO_0000218,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7003,,6227,N,CHEMBL619547,BAO_0000218,,Vd (1 mg/kg) was determined in dog (in vivo),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7004,,6227,N,CHEMBL619548,BAO_0000218,,Vd in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7005,,4219,N,CHEMBL619549,BAO_0000218,,Volume distribution was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7006,,1696,N,CHEMBL619550,BAO_0000218,,Volume of distribution in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7007,,5542,N,CHEMBL876501,BAO_0000218,,Volume of distribution by as 4 fold increase by iv administration in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7008,,5199,N,CHEMBL619551,BAO_0000218,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7009,,6348,N,CHEMBL619552,BAO_0000218,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7010,,4727,N,CHEMBL619553,BAO_0000218,,Volume distribution at the dose of 2 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7011,,16367,N,CHEMBL618722,BAO_0000218,,Steady state volume of distribution was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7012,,2652,N,CHEMBL618723,BAO_0000218,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7013,,16452,N,CHEMBL618724,BAO_0000218,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7014,,16452,N,CHEMBL618725,BAO_0000218,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7015,,16452,N,CHEMBL618726,BAO_0000218,,Bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7016,,5334,N,CHEMBL618727,BAO_0000218,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7017,,4239,N,CHEMBL624233,BAO_0000218,,Pharmacokinetic property (vdss) was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7018,,4709,N,CHEMBL624234,BAO_0000218,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7019,,5600,N,CHEMBL624235,BAO_0000218,,Vdss was determined after iv 0.1 mg/kg administration in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7020,,6057,N,CHEMBL624236,BAO_0000218,,Volume displacement was calculated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7021,,5654,N,CHEMBL624237,BAO_0000218,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7022,,5505,N,CHEMBL624238,BAO_0000218,,Volume distribution constant was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7023,,4527,N,CHEMBL624239,BAO_0000218,,Volume distribution at a dose of 1 uM/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7024,,4521,N,CHEMBL875829,BAO_0000218,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7025,,4521,N,CHEMBL624240,BAO_0000218,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7026,,15660,N,CHEMBL624241,BAO_0000218,,Volume distribution (Vdss) was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7027,,15660,N,CHEMBL624242,BAO_0000218,,Volume distribution (Vdss) was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7028,,6679,N,CHEMBL624243,BAO_0000218,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7029,,5145,N,CHEMBL624244,BAO_0000218,,Volume of distribution in steady state was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7030,,6821,N,CHEMBL624245,BAO_0000218,,Volume of distribution of compound was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7031,,4137,N,CHEMBL624246,BAO_0000218,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7032,,5334,N,CHEMBL624247,BAO_0000218,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7033,,15660,N,CHEMBL624248,BAO_0000218,,Volume of distribution (Vdss) was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7034,,6642,N,CHEMBL624249,BAO_0000218,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7035,,6641,N,CHEMBL624250,BAO_0000218,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7036,,6642,N,CHEMBL624251,BAO_0000218,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7037,,11659,N,CHEMBL624252,BAO_0000218,,Maximum rate of depolarization of the upstroke of the action potential,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7038,,6448,N,CHEMBL624253,BAO_0000218,,Steady state volume distribution in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7039,,5474,N,CHEMBL624950,BAO_0000218,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7040,,1466,N,CHEMBL624951,BAO_0000218,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7041,,6535,N,CHEMBL875830,BAO_0000218,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7042,,6535,N,CHEMBL624952,BAO_0000218,,Volume distribution in dog after administration of 1 mg/kg iv,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7043,,17764,N,CHEMBL624953,BAO_0000218,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7044,,6215,N,CHEMBL624954,BAO_0000218,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7045,,6505,N,CHEMBL624955,BAO_0000218,,Vss on i.v. administration of 2 mg/kg was measured in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7046,,3639,N,CHEMBL624956,BAO_0000218,,Vss was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7047,,3639,N,CHEMBL625129,BAO_0000218,,Vss in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7048,,6062,N,CHEMBL625130,BAO_0000218,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7049,,4942,N,CHEMBL625131,BAO_0000218,,Volume distribution in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7050,,17796,N,CHEMBL625132,BAO_0000218,,Volume of distribution in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7051,,4883,N,CHEMBL872263,BAO_0000218,,Tested for the oral bioavailability in dog,Canis lupus familiaris
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7060,,17837,N,CHEMBL624336,BAO_0000218,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7061,,17729,N,CHEMBL624337,BAO_0000218,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7062,,17729,N,CHEMBL624338,BAO_0000218,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7063,,4239,N,CHEMBL624339,BAO_0000218,,Bioavailability was measured in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7064,,17592,N,CHEMBL624340,BAO_0000218,,Bioavailability in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7065,,6348,N,CHEMBL624341,BAO_0000218,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7066,,2801,N,CHEMBL624342,BAO_0000218,,Bioavailability in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7067,,2801,N,CHEMBL624343,BAO_0000218,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7068,,17718,N,CHEMBL624344,BAO_0000218,,Oral bioavailability in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7069,,5727,N,CHEMBL624345,BAO_0000218,,Oral availability at 50 mg/kg po in male mice,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7070,,5302,N,CHEMBL624346,BAO_0000218,,Oral bioavailability in mouse (dose 10 mg/kg),Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Expert,,,7071,,3598,N,CHEMBL624347,BAO_0000218,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7072,,5961,N,CHEMBL624348,BAO_0000218,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7074,,6091,N,CHEMBL622754,BAO_0000218,,Oral bioavailability in mouse,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7075,,6091,N,CHEMBL622755,BAO_0000218,,Oral bioavailability in vivo in mice;ND=Not determined,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7076,,5711,N,CHEMBL622756,BAO_0000218,,Oral bioavailability in mouse at 10 mg/kg of the compound,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7077,,17728,N,CHEMBL622757,BAO_0000218,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7078,,17728,N,CHEMBL622758,BAO_0000218,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7079,,3802,N,CHEMBL622759,BAO_0000218,,Tested for bioavailability of the compound,Mus musculus
A,,,In vivo,,,,1,10090.0,50594,1,Intermediate,,,7080,,3802,N,CHEMBL622760,BAO_0000218,,Tested for half life at the dose of 10 mg/kg when administered intravenously,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,7081,,14029,N,CHEMBL622761,BAO_0000218,Plasma,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,7082,,14029,N,CHEMBL622762,BAO_0000218,Plasma,The plasma half life of compound was determined on heparin prepared by human plasma. ,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,7083,,14029,N,CHEMBL622763,BAO_0000218,Plasma,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,7084,,14029,N,CHEMBL622764,BAO_0000218,Plasma,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Mus musculus
A,,,,,1969.0,,1,10090.0,50594,1,Intermediate,,,7085,,14029,N,CHEMBL622765,BAO_0000218,Plasma,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Mus musculus
F,,,,,,,1,10090.0,50594,1,Intermediate,,,7086,,17753,N,CHEMBL622766,BAO_0000218,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,7087,,17753,N,CHEMBL622767,BAO_0000218,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,Mus musculus
A,,,,,,,1,10090.0,50594,1,Intermediate,,,7088,,17753,N,CHEMBL622768,BAO_0000218,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,7089,,10107,N,CHEMBL875948,BAO_0000218,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,7090,,10107,N,CHEMBL622769,BAO_0000218,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,7091,,10107,N,CHEMBL622770,BAO_0000218,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,7092,,10107,N,CHEMBL622771,BAO_0000218,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,7093,,10107,N,CHEMBL622772,BAO_0000218,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,7094,,10107,N,CHEMBL622773,BAO_0000218,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,178.0,,1,10090.0,50594,1,Intermediate,,,7095,,10107,N,CHEMBL622774,BAO_0000218,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,7096,,10107,N,CHEMBL621725,BAO_0000218,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,7097,,10107,N,CHEMBL621726,BAO_0000218,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7098,,15608,N,CHEMBL621727,BAO_0000219,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7099,,3290,N,CHEMBL622413,BAO_0000219,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7100,,2859,N,CHEMBL622414,BAO_0000219,,Compound was evaluated for cytotoxicity against A2780 cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7101,,15688,N,CHEMBL622415,BAO_0000219,,Inhibition of A2780 cell clonogenic assay,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7102,,5642,N,CHEMBL884001,BAO_0000219,,Cytotoxic effect on ovarian cancer cell line (A2780),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7103,,6633,N,CHEMBL622416,BAO_0000219,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7104,,3906,N,CHEMBL622417,BAO_0000219,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7105,,6788,N,CHEMBL622590,BAO_0000219,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7106,,17582,N,CHEMBL622591,BAO_0000219,,Antiproliferative activity against human A2780 cells,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7107,,17764,N,CHEMBL622592,BAO_0000219,,Inhibition of human A2780 cell proliferation,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7108,,17764,N,CHEMBL622593,BAO_0000219,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7109,,17764,N,CHEMBL622594,BAO_0000219,,Inhibition of human A2780 cell proliferation (No data),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7110,,2815,N,CHEMBL622595,BAO_0000219,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7111,,16930,N,CHEMBL622596,BAO_0000219,,Compound was evaluated against human Ovarian carcinoma cell line A2780,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7112,,17777,N,CHEMBL622597,BAO_0000219,,Growth inhibition against A2780 wild-type ovarian cell lines,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7113,,17777,N,CHEMBL622598,BAO_0000219,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,Homo sapiens
F,,,,,,,5,9606.0,104766,1,Autocuration,,,7114,,16936,D,CHEMBL622599,BAO_0000019,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7115,,13759,N,CHEMBL622600,BAO_0000219,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7116,,13759,N,CHEMBL622601,BAO_0000219,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7117,,13759,N,CHEMBL622602,BAO_0000219,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7118,,13759,N,CHEMBL622603,BAO_0000219,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7119,,15292,N,CHEMBL622604,BAO_0000219,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7120,,15292,N,CHEMBL622605,BAO_0000219,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7121,,15069,N,CHEMBL622606,BAO_0000219,,In vitro inhibition of human ovarian cell line A2780,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7122,,15069,N,CHEMBL619463,BAO_0000219,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7123,,14073,N,CHEMBL619464,BAO_0000219,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7124,,14553,N,CHEMBL619465,BAO_0000219,,Concentration required to inhibit A2780-cell growth by 50%,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7125,,13040,N,CHEMBL619466,BAO_0000219,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7126,,6891,N,CHEMBL619467,BAO_0000219,,Cytotoxic effect on human ovarian (A2780) cancer cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7127,,15569,N,CHEMBL619468,BAO_0000219,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7128,,14190,N,CHEMBL619469,BAO_0000219,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7129,,15014,N,CHEMBL619470,BAO_0000219,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7130,,15014,N,CHEMBL619471,BAO_0000219,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7131,,17496,N,CHEMBL619472,BAO_0000219,,Cytotoxicity against human ovarian carcinoma A2780 cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7132,,13617,N,CHEMBL619473,BAO_0000219,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7133,,13617,N,CHEMBL874368,BAO_0000219,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7134,,13617,N,CHEMBL884003,BAO_0000219,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7135,,13617,N,CHEMBL622690,BAO_0000219,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7136,,17672,N,CHEMBL622691,BAO_0000219,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7137,,4544,N,CHEMBL622692,BAO_0000219,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7138,,4544,N,CHEMBL623406,BAO_0000219,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7139,,16317,N,CHEMBL884004,BAO_0000219,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7140,,15099,N,CHEMBL623407,BAO_0000219,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7141,,13978,N,CHEMBL623408,BAO_0000219,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7142,,12989,N,CHEMBL623409,BAO_0000219,,In vitro antitumor activity against A2780 cell line.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7143,,5574,N,CHEMBL623410,BAO_0000219,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7144,,13528,N,CHEMBL623576,BAO_0000219,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7145,,12782,N,CHEMBL623577,BAO_0000219,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7146,,14255,N,CHEMBL623578,BAO_0000219,,The IC50 value was measured on ACHN cell line in renal tumor type.,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7147,,16364,N,CHEMBL623579,BAO_0000219,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Expert,,,7148,,17376,N,CHEMBL623580,BAO_0000219,,In vitro lethal concentration against most sensitive ACHN cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7149,,12016,N,CHEMBL623581,BAO_0000219,,Tested for cytotoxic activity against renal cancer ACHN cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7150,,6058,N,CHEMBL857456,BAO_0000219,,Compound tested for growth inhibition of renal cancer cell line ACHN,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7151,,17708,N,CHEMBL623582,BAO_0000219,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7152,,15176,N,CHEMBL623583,BAO_0000219,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7153,,2806,N,CHEMBL623584,BAO_0000219,,In vitro anticancer activity against ACHN renal cancer cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7154,,15300,N,CHEMBL623585,BAO_0000219,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7155,,16364,N,CHEMBL623586,BAO_0000219,,Percent selectivity was evaluated in renal ACHN cell lines,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7156,,13859,N,CHEMBL623587,BAO_0000219,,In vitro inhibitory activity against renal ACHN cancer cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7157,,11970,N,CHEMBL875279,BAO_0000219,,Tested for cytotoxicity against ACHN cell lines in renal cancer,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7158,,2450,N,CHEMBL623588,BAO_0000219,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7159,,12696,N,CHEMBL623589,BAO_0000219,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7160,,12400,N,CHEMBL623590,BAO_0000219,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Expert,,,7161,,12888,N,CHEMBL623591,BAO_0000219,,Cytotoxic effect on renal cancer line ACHN,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7162,,3156,N,CHEMBL623592,BAO_0000219,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7163,,3381,N,CHEMBL623593,BAO_0000219,,In vitro inhibition of Renal Cancer ACHN cell lines,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7164,,16747,N,CHEMBL623594,BAO_0000219,,Antitumor activity against human renal adenocarcinoma ACHN cells,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Expert,,,7165,,16748,N,CHEMBL621833,BAO_0000219,,Antitumor activity against human renal adenocarcinoma ACHN cells.,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7166,,12062,N,CHEMBL621834,BAO_0000219,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7167,,14769,N,CHEMBL621835,BAO_0000219,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7168,,15895,N,CHEMBL621836,BAO_0000219,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7169,,17376,N,CHEMBL621837,BAO_0000219,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7170,,14882,N,CHEMBL875280,BAO_0000219,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7171,,14882,N,CHEMBL621838,BAO_0000219,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,Homo sapiens
F,ACHN,626.0,,,,,1,9606.0,80025,1,Intermediate,,,7172,,15661,N,CHEMBL621839,BAO_0000219,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,Homo sapiens
A,,,,,,,0,,22224,1,Autocuration,,,7173,,9680,U,CHEMBL621840,BAO_0000019,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,
F,,,,,,,8,,10647,1,Autocuration,,,7174,,14579,H,CHEMBL621841,BAO_0000019,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,
F,HEL,468.0,,,,,1,10358.0,50529,1,Expert,,,7175,,17290,N,CHEMBL622979,BAO_0000218,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,Cytomegalovirus
F,,,,,,,1,10358.0,50529,1,Intermediate,,,7176,,17290,N,CHEMBL876595,BAO_0000218,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,Cytomegalovirus
B,,,,,,,8,,12159,1,Autocuration,,,7177,,15891,H,CHEMBL620221,BAO_0000357,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),
B,,,,,,,8,,12159,1,Autocuration,,,7178,,15890,H,CHEMBL620222,BAO_0000357,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),
F,ADDP cell line,979.0,,,,,1,9913.0,80670,1,Intermediate,,,7179,,3801,N,CHEMBL620506,BAO_0000219,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,Bos taurus
F,ADJ/PC6,980.0,,,,,1,10090.0,80671,1,Intermediate,,,7180,,9222,N,CHEMBL620507,BAO_0000219,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,Mus musculus
F,ADJ/PC6,980.0,,,,,1,10090.0,80671,1,Intermediate,,,7181,,9222,N,CHEMBL620508,BAO_0000219,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,Mus musculus
F,ADJ/PC6,980.0,,,,,1,10090.0,80671,1,Intermediate,,,7182,,7257,N,CHEMBL620509,BAO_0000219,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",Mus musculus
F,ADJ/PC6,980.0,,,,,1,10090.0,80671,1,Intermediate,,,7183,,7257,N,CHEMBL620510,BAO_0000219,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,Mus musculus
A,ADJ/PC6,980.0,,,,,1,10090.0,80671,1,Intermediate,,,7184,,7257,N,CHEMBL620511,BAO_0000219,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,Mus musculus
F,ADJ/PC6,980.0,,,,,1,10090.0,80671,1,Intermediate,,,7185,,8084,N,CHEMBL620512,BAO_0000219,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,7186,,14943,U,CHEMBL620513,BAO_0000019,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,7187,,14943,U,CHEMBL620514,BAO_0000019,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,Mus musculus
F,,,,,,,0,10090.0,22224,1,Autocuration,,,7188,,14943,U,CHEMBL620515,BAO_0000019,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,Mus musculus
A,,,In vivo,,,,0,1423.0,22224,1,Autocuration,,,7189,,10524,U,CHEMBL620516,BAO_0000218,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Bacillus subtilis
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,7190,,3546,N,CHEMBL620517,BAO_0000218,Plasma,AUC value in dog after IV administration at a dose of 5 mg/kg,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,7191,,3546,N,CHEMBL620518,BAO_0000218,Plasma,AUC value in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7192,,3546,N,CHEMBL620519,BAO_0000218,,Cmax value in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7193,,3546,N,CHEMBL621386,BAO_0000218,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7194,,3546,N,CHEMBL621387,BAO_0000218,,Tmax value in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7195,,3184,N,CHEMBL621388,BAO_0000218,,Compound was evaluated for its clearance when administered intravenously in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7196,,16456,N,CHEMBL621389,BAO_0000218,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7197,,4809,N,CHEMBL621390,BAO_0000218,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Canis lupus familiaris
P,,,,,,,0,,22229,1,Intermediate,,,7198,,4219,U,CHEMBL621391,BAO_0000100,,Calculated partition coefficient (clogP),
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7199,,3748,N,CHEMBL621392,BAO_0000218,,Half life in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7200,,3132,N,CHEMBL621393,BAO_0000218,,Time taken for EC90 was determined when tested in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7201,,4219,N,CHEMBL621394,BAO_0000218,,Half life (iv) was determined,Canis lupus familiaris
A,,,,,2107.0,,1,9615.0,50588,1,Intermediate,,,7202,,16907,N,CHEMBL621395,BAO_0000218,Liver,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7203,,6057,N,CHEMBL621396,BAO_0000218,,Area under the curve was calculated in dog after iv administration,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7204,,6057,N,CHEMBL621397,BAO_0000218,,Area under the curve was calculated in dog after peroral administration,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7205,,17853,N,CHEMBL621398,BAO_0000218,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7206,,3639,N,CHEMBL618818,BAO_0000218,,pKa was evaluated in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7207,,14541,N,CHEMBL618819,BAO_0000218,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7208,,16456,N,CHEMBL618820,BAO_0000218,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7209,,16456,N,CHEMBL873810,BAO_0000218,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7210,,2652,N,CHEMBL876606,BAO_0000218,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7211,,3624,N,CHEMBL618821,BAO_0000218,,Compound was evaluated for the half-life (t 1/2) in hours,Canis lupus familiaris
A,,,In vivo,,178.0,,1,9615.0,50588,1,Intermediate,,,7212,,1337,N,CHEMBL618822,BAO_0000218,Blood,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris
A,,,In vivo,,178.0,,1,9615.0,50588,1,Intermediate,,,7213,,1337,N,CHEMBL618823,BAO_0000218,Blood,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7214,,4709,N,CHEMBL618824,BAO_0000218,,Half life after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7215,,15660,N,CHEMBL618825,BAO_0000218,,Half life was measured in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7216,,5302,N,CHEMBL618826,BAO_0000218,,Half life period in dog after 5 mg/kg dose,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7217,,17791,N,CHEMBL618827,BAO_0000218,,Half life period was evaluated in dog; 4-4.8,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7218,,6348,N,CHEMBL618828,BAO_0000218,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7219,,4257,N,CHEMBL618829,BAO_0000218,,Half-life was determined in dog after a3 mg/kg of iv dose,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7220,,3771,N,CHEMBL618830,BAO_0000218,,Half-life was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7221,,6305,N,CHEMBL618831,BAO_0000218,,Half life in dogs,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,7222,,13501,N,CHEMBL619489,BAO_0000218,Plasma,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7223,,17594,N,CHEMBL619649,BAO_0000218,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7224,,3045,N,CHEMBL876607,BAO_0000218,,Compound was evaluated for the half life period after iv administration in Beagle dog.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7225,,3043,N,CHEMBL619650,BAO_0000218,,Compound was evaluated for the half life period after oral administration in conscious dog.,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7226,,4839,N,CHEMBL619651,BAO_0000218,,Compound was tested for half life in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7227,,4839,N,CHEMBL619652,BAO_0000218,,Compound was tested for its half life in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7228,,5802,N,CHEMBL619653,BAO_0000218,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7229,,17839,N,CHEMBL619654,BAO_0000218,,Half life of compound in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7230,,4219,N,CHEMBL619655,BAO_0000218,,Half life (iv) was determined,Canis lupus familiaris
A,,,,,178.0,,1,9615.0,50588,1,Intermediate,,,7231,,13966,N,CHEMBL619656,BAO_0000218,Blood,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,7232,,3994,N,CHEMBL873812,BAO_0000218,Plasma,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Canis lupus familiaris
F,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,7233,,3994,N,CHEMBL621365,BAO_0000218,Plasma,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7234,,4453,N,CHEMBL621366,BAO_0000218,,Half life in dog,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,7235,,6535,N,CHEMBL621367,BAO_0000218,Plasma,Half life in dog plasma,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,7236,,6535,N,CHEMBL621368,BAO_0000218,Plasma,Half life in dog plasma after administration of 0.25 mg/kg iv,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,7237,,6535,N,CHEMBL621369,BAO_0000218,Plasma,Half life in dog plasma after administration of 1 mg/kg iv,Canis lupus familiaris
A,,,In vivo,,1969.0,,1,9615.0,50588,1,Intermediate,,,7238,,3132,N,CHEMBL621370,BAO_0000218,Plasma,Half life in dog plasma was determined at dose 10 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7239,,5374,N,CHEMBL621371,BAO_0000218,,Half life in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7240,,5007,N,CHEMBL621372,BAO_0000218,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,7241,,16907,N,CHEMBL621373,BAO_0000218,Plasma,Half life upon exposure to human plasma,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7242,,6057,N,CHEMBL621374,BAO_0000218,,Half life was calculated in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7243,,5006,N,CHEMBL621375,BAO_0000218,,Half life was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7244,,5473,N,CHEMBL621376,BAO_0000218,,Half life was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7245,,4368,N,CHEMBL619624,BAO_0000218,,Half life by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7246,,6448,N,CHEMBL875840,BAO_0000218,,Half life in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7247,,4353,N,CHEMBL619625,BAO_0000218,,Half life in dog after intra venous administration of the compound,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7248,,4353,N,CHEMBL619626,BAO_0000218,,Half life in dog after intra venous administration of the compound; ND means Not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7249,,4353,N,CHEMBL619627,BAO_0000218,,Half life in dog after po administration of the compound,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7250,,4353,N,CHEMBL873817,BAO_0000218,,Half life in dog after po administration of the compound; ND means Not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7251,,6265,N,CHEMBL619628,BAO_0000218,,Half life in dog at the single oral dose of 1 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7252,,5006,N,CHEMBL619629,BAO_0000218,,Half life in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7253,,5356,N,CHEMBL619630,BAO_0000218,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7254,,405,N,CHEMBL619631,BAO_0000218,,Half life in rat,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7255,,6642,N,CHEMBL619632,BAO_0000218,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,7256,,10107,N,CHEMBL619633,BAO_0000218,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,7257,,10107,N,CHEMBL875841,BAO_0000218,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,7258,,10107,N,CHEMBL619634,BAO_0000218,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,7259,,10107,N,CHEMBL619635,BAO_0000218,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,10000001.0,,1,10090.0,50594,1,Intermediate,,,7260,,10107,N,CHEMBL619636,BAO_0000218,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,10000004.0,,1,10090.0,50594,1,Intermediate,,,7261,,10107,N,CHEMBL619637,BAO_0000218,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,10000004.0,,1,10090.0,50594,1,Intermediate,,,7262,,10107,N,CHEMBL619638,BAO_0000218,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus
A,,,In vivo,,10000004.0,,1,10090.0,50594,1,Intermediate,,,7263,,10107,N,CHEMBL619639,BAO_0000218,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,10000004.0,,1,10090.0,50594,1,Intermediate,,,7264,,10107,N,CHEMBL619640,BAO_0000218,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,10000004.0,,1,10090.0,50594,1,Intermediate,,,7265,,10107,N,CHEMBL619641,BAO_0000218,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,10000004.0,,1,10090.0,50594,1,Intermediate,,,7266,,10107,N,CHEMBL619642,BAO_0000218,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,10000004.0,,1,10090.0,50594,1,Intermediate,,,7267,,10107,N,CHEMBL619643,BAO_0000218,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,7268,,10107,N,CHEMBL619644,BAO_0000218,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,7269,,10107,N,CHEMBL621112,BAO_0000218,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,7270,,10107,N,CHEMBL621113,BAO_0000218,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,7271,,10107,N,CHEMBL621114,BAO_0000218,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,7272,,10107,N,CHEMBL621115,BAO_0000218,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,7273,,10107,N,CHEMBL621116,BAO_0000218,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,948.0,,1,10090.0,50594,1,Intermediate,,,7274,,10107,N,CHEMBL621117,BAO_0000218,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,7275,,10107,N,CHEMBL621118,BAO_0000218,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,7276,,10107,N,CHEMBL621119,BAO_0000218,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,7277,,10107,N,CHEMBL621120,BAO_0000218,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,7278,,10107,N,CHEMBL621757,BAO_0000218,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,7279,,10107,N,CHEMBL621758,BAO_0000218,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,7280,,10107,N,CHEMBL621759,BAO_0000218,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,2113.0,,1,10090.0,50594,1,Intermediate,,,7281,,10107,N,CHEMBL621760,BAO_0000218,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,7282,,10107,N,CHEMBL621761,BAO_0000218,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,7283,,10107,N,CHEMBL621762,BAO_0000218,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,7284,,10107,N,CHEMBL621763,BAO_0000218,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,7285,,10107,N,CHEMBL624502,BAO_0000218,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,7286,,10107,N,CHEMBL624503,BAO_0000218,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,7287,,10107,N,CHEMBL624504,BAO_0000218,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,2107.0,,1,10090.0,50594,1,Intermediate,,,7288,,10107,N,CHEMBL624505,BAO_0000218,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,7289,,10107,N,CHEMBL624506,BAO_0000218,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7290,,5895,N,CHEMBL624507,BAO_0000219,,In vitro cytotoxicity against A2780 (human ovarian cancer),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7291,,6338,N,CHEMBL624508,BAO_0000219,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7292,,15163,N,CHEMBL624509,BAO_0000219,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7293,,15163,N,CHEMBL624510,BAO_0000219,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7294,,15000,N,CHEMBL875956,BAO_0000219,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7295,,15000,N,CHEMBL839885,BAO_0000219,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7296,,14729,N,CHEMBL624511,BAO_0000219,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7297,,17270,N,CHEMBL624512,BAO_0000219,,In vitro cytotoxicity against A2780 cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7298,,5685,N,CHEMBL624513,BAO_0000219,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7299,,3563,N,CHEMBL624514,BAO_0000219,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7300,,17753,N,CHEMBL618547,BAO_0000218,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7301,,16317,N,CHEMBL618548,BAO_0000219,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7302,,16936,N,CHEMBL618549,BAO_0000219,,Inhibition of tubulin polymerization in analogy of ca.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7303,,3801,N,CHEMBL618550,BAO_0000219,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7304,,6181,N,CHEMBL618551,BAO_0000219,,Cytotoxic effect in ovarian cancer cell line (A2780),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7305,,5318,N,CHEMBL618552,BAO_0000219,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7306,,4840,N,CHEMBL618553,BAO_0000219,,Tested for the cytotoxicity in A2780 ovarian cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7307,,15748,N,CHEMBL618554,BAO_0000219,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7308,,15748,N,CHEMBL618555,BAO_0000219,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,Homo sapiens
F,A2780cisR,481.0,,,,,1,,80017,1,Intermediate,,,7309,,15748,N,CHEMBL618556,BAO_0000219,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,
F,A2780cisR,481.0,,,,,1,,80017,1,Intermediate,,,7310,,15748,N,CHEMBL618557,BAO_0000219,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),
F,A2780cisR,481.0,,,,,1,,80017,1,Intermediate,,,7311,,15748,N,CHEMBL618558,BAO_0000219,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,
F,A2780cisR,481.0,,,,,1,,80017,1,Intermediate,,,7312,,15748,N,CHEMBL618559,BAO_0000219,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7313,,17753,N,CHEMBL618560,BAO_0000218,,In vivo log of cells killed after administration of compound in A2780 cell line,Homo sapiens
F,A2780,478.0,In vivo,,,,1,9606.0,81034,1,Intermediate,,,7314,,17753,N,CHEMBL618561,BAO_0000218,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7315,,16936,N,CHEMBL618562,BAO_0000219,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7316,,16936,N,CHEMBL618563,BAO_0000219,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7317,,16936,N,CHEMBL618564,BAO_0000219,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7318,,16936,N,CHEMBL618565,BAO_0000219,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7319,,17528,N,CHEMBL618566,BAO_0000218,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7320,,6633,N,CHEMBL618567,BAO_0000219,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7321,,15000,N,CHEMBL618568,BAO_0000219,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7322,,17528,N,CHEMBL618569,BAO_0000219,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7323,,16936,N,CHEMBL621857,BAO_0000219,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7324,,16936,N,CHEMBL621858,BAO_0000219,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7325,,16936,N,CHEMBL621859,BAO_0000219,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7326,,16936,N,CHEMBL621860,BAO_0000219,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7327,,16936,N,CHEMBL621861,BAO_0000219,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Expert,,,7328,,16936,N,CHEMBL621862,BAO_0000219,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7329,,16936,N,CHEMBL621863,BAO_0000219,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7330,,16936,N,CHEMBL621864,BAO_0000219,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7331,,16936,N,CHEMBL621865,BAO_0000219,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),Homo sapiens
F,A2780,478.0,,,,,1,10090.0,81034,1,Intermediate,,,7332,,17737,N,CHEMBL621866,BAO_0000219,,In vitro antiproliferative activity against A2780 cell line,Mus musculus
F,A2780,478.0,,,,,1,10090.0,81034,1,Expert,,,7333,,17764,N,CHEMBL621867,BAO_0000219,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,Mus musculus
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7334,,3830,N,CHEMBL621868,BAO_0000219,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,Homo sapiens
F,A2780,478.0,,,,,1,9606.0,81034,1,Intermediate,,,7335,,3829,N,CHEMBL875282,BAO_0000219,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,Homo sapiens
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7336,,3546,N,CHEMBL621869,BAO_0000218,,Vc value in dog after IV administration at a dose of 5 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7337,,3546,N,CHEMBL621870,BAO_0000218,,Half life period in dog after IV administration at a dose of 5 mg/kg,Canis lupus familiaris
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7338,,5668,U,CHEMBL621871,BAO_0000019,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Cercopithecidae
A,,,,,1969.0,,0,9527.0,22224,1,Autocuration,,,7339,,3443,U,CHEMBL621243,BAO_0000218,Plasma,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,,,1969.0,,0,9527.0,22224,1,Autocuration,,,7340,,3443,U,CHEMBL621244,BAO_0000218,Plasma,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,In vivo,,,,0,9541.0,22224,1,Autocuration,,,7341,,4256,U,CHEMBL621245,BAO_0000218,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Macaca fascicularis
A,,,In vivo,,,,0,9541.0,22224,1,Autocuration,,,7342,,4256,U,CHEMBL621246,BAO_0000218,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,Macaca fascicularis
A,,,In vivo,,,,0,9541.0,22224,1,Autocuration,,,7343,,4256,U,CHEMBL621247,BAO_0000218,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,Macaca fascicularis
A,,,In vivo,,,,0,10116.0,22224,1,Autocuration,,,7344,,4256,U,CHEMBL618386,BAO_0000218,,Oral Bioavailability in rat,Rattus norvegicus
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7345,,1916,U,CHEMBL618387,BAO_0000218,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7346,,5302,U,CHEMBL618388,BAO_0000218,,Area under curve value in monkey at a dose of 5 mg/kg,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7347,,4257,U,CHEMBL618389,BAO_0000218,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7348,,5355,U,CHEMBL618574,BAO_0000019,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7349,,5355,U,CHEMBL618575,BAO_0000019,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7350,,5355,U,CHEMBL618576,BAO_0000019,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7351,,6078,U,CHEMBL618577,BAO_0000218,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7352,,6078,U,CHEMBL876487,BAO_0000218,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7353,,6062,U,CHEMBL618578,BAO_0000218,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7354,,2661,U,CHEMBL618579,BAO_0000218,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7355,,2661,U,CHEMBL618580,BAO_0000019,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7356,,5394,U,CHEMBL618581,BAO_0000218,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7357,,4397,U,CHEMBL618582,BAO_0000218,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7358,,17509,U,CHEMBL618583,BAO_0000218,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7359,,17509,U,CHEMBL618584,BAO_0000218,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7360,,6641,U,CHEMBL618585,BAO_0000218,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7361,,5355,U,CHEMBL618586,BAO_0000218,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7362,,3443,U,CHEMBL618587,BAO_0000218,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7363,,3443,U,CHEMBL618588,BAO_0000218,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7364,,17409,U,CHEMBL618589,BAO_0000019,,Binding towards monkey plasma protein at 10 uM,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7365,,17409,U,CHEMBL618590,BAO_0000019,,Binding towards monkey plasma protein at 100 uM,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7366,,1052,U,CHEMBL872262,BAO_0000218,,Apparent bioavailability in squirrel monkey was determined,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7367,,13501,U,CHEMBL618591,BAO_0000218,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Cercopithecidae
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,7368,,17509,U,CHEMBL618592,BAO_0000218,,Bioavailability in monkey (dose 2 mg/kg),monkey
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7369,,5394,U,CHEMBL876488,BAO_0000218,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7370,,2661,U,CHEMBL618593,BAO_0000218,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae
A,,,In vivo,,,,0,9443.0,22224,1,Autocuration,,,7371,,11219,U,CHEMBL618594,BAO_0000218,,Bioavailability in monkey (i.d. dosing),monkey
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7372,,3045,U,CHEMBL618595,BAO_0000218,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,Cercopithecidae
A,,,,,,,0,9527.0,22224,1,Autocuration,,,7373,,17796,U,CHEMBL621469,BAO_0000019,,Clearance of the drug was measured in cynomolgus,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7374,,1399,U,CHEMBL621470,BAO_0000218,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7375,,2661,U,CHEMBL621471,BAO_0000218,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae
A,,,In vivo,,1969.0,,0,9544.0,22224,1,Autocuration,,,7376,,5005,U,CHEMBL621472,BAO_0000218,Plasma,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7377,,17267,U,CHEMBL621473,BAO_0000218,,Plasma clearance in rhesus monkey was determined,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7378,,6535,U,CHEMBL621474,BAO_0000218,,Plasma clearance in monkey after administration of 1 mg/kg iv,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7379,,5922,U,CHEMBL621475,BAO_0000218,,Plasma clearance in cynomolgus monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7380,,6221,U,CHEMBL621476,BAO_0000218,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7381,,5668,U,CHEMBL624290,BAO_0000218,,Plasma clearance after peroral administration at 10 mpk in Rhesus,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7382,,5355,U,CHEMBL624291,BAO_0000218,,The total clearance was determined after intravenous administration in cynomolgus monkeys,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7383,,5355,U,CHEMBL624292,BAO_0000218,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7384,,5355,U,CHEMBL624293,BAO_0000218,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7385,,4578,U,CHEMBL624294,BAO_0000218,,Tested for Clearance upon iv administration to african green monkey,Cercopithecidae
A,,,In vivo,,,,0,9527.0,22224,1,Autocuration,,,7386,,17592,U,CHEMBL624295,BAO_0000218,,Clearance in monkey,Cercopithecidae
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7387,,6641,N,CHEMBL624296,BAO_0000218,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7388,,6642,N,CHEMBL624297,BAO_0000218,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7389,,16367,N,CHEMBL624298,BAO_0000218,,Half life was evaluated after intravenous administration to dogs,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7390,,5472,N,CHEMBL624299,BAO_0000218,,Half life was evaluated in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7391,,5474,N,CHEMBL624300,BAO_0000218,,Half life was evaluated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7392,,5654,N,CHEMBL624301,BAO_0000218,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7393,,6227,N,CHEMBL624302,BAO_0000218,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7394,,6227,N,CHEMBL876026,BAO_0000218,,Half life period after intravenous administration in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7395,,6221,N,CHEMBL624303,BAO_0000218,,Half life period after oral administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7396,,4527,N,CHEMBL624304,BAO_0000218,,Half life period at a dose of 1 uM/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7397,,5668,N,CHEMBL624305,BAO_0000218,,Half life period was determine after peroral administration at 10 mpk in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7398,,5668,N,CHEMBL624306,BAO_0000218,,Half life period was determine after peroral administration at 5 mpk in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7399,,3854,N,CHEMBL624307,BAO_0000218,,Half life period was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7400,,5505,N,CHEMBL624308,BAO_0000218,,Half life period was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7401,,6251,N,CHEMBL624309,BAO_0000218,,Half life period by iv administration in dog at a dose of 6 mg/kg,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7402,,1918,N,CHEMBL624310,BAO_0000218,,Half life period was evaluated in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7403,,5546,N,CHEMBL625003,BAO_0000218,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7404,,4809,N,CHEMBL625004,BAO_0000218,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7405,,6215,N,CHEMBL625005,BAO_0000218,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7406,,4527,N,CHEMBL873813,BAO_0000218,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7407,,17594,N,CHEMBL625006,BAO_0000218,,Half-life after oral dose of compound at 3 mg/kg in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7408,,17839,N,CHEMBL625007,BAO_0000218,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7409,,17839,N,CHEMBL876027,BAO_0000218,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7410,,17839,N,CHEMBL625008,BAO_0000218,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7411,,17839,N,CHEMBL625009,BAO_0000218,,Half-life of compound in dog following p.o. administration of 1 mg/kg,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,7412,,5210,N,CHEMBL625010,BAO_0000218,Plasma,Half-life of compound in plasma of dog was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7413,,5210,N,CHEMBL625011,BAO_0000218,,Half-life of compound was determined in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7414,,2959,N,CHEMBL621553,BAO_0000218,,Half-life after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7415,,4137,N,CHEMBL621554,BAO_0000218,,Half-life after intravenous administration of 1 mg/kg/h in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7416,,5064,N,CHEMBL621555,BAO_0000218,,Half-life in Dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7417,,5147,N,CHEMBL621556,BAO_0000218,,Half-life in Dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7418,,5145,N,CHEMBL621557,BAO_0000218,,Half-life in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7419,,6123,N,CHEMBL621558,BAO_0000218,,Half-life in dog after oral administration at 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7420,,6123,N,CHEMBL621559,BAO_0000218,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7421,,4333,N,CHEMBL621560,BAO_0000218,,Half-life in dogs,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7422,,4333,N,CHEMBL876028,BAO_0000218,,Half-life in dogs; ND indicates not determined,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,7423,,12500,N,CHEMBL621561,BAO_0000218,Plasma,Half-life in plasma of dog,Canis lupus familiaris
A,,,,,1969.0,,1,9615.0,50588,1,Intermediate,,,7424,,12500,N,CHEMBL621562,BAO_0000218,Plasma,Half-life in plasma of dog at dose of 3-10 mgkg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7425,,6005,N,CHEMBL621563,BAO_0000218,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7426,,6062,N,CHEMBL621564,BAO_0000218,,Half-life was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7427,,17650,N,CHEMBL621565,BAO_0000218,,Half-life was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7428,,5530,N,CHEMBL621566,BAO_0000218,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7429,,5530,N,CHEMBL621567,BAO_0000218,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7430,,5600,N,CHEMBL622978,BAO_0000218,,Half-life of the compound after 0.3 mg/kg po administration in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7431,,6039,N,CHEMBL873814,BAO_0000218,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7432,,6039,N,CHEMBL623219,BAO_0000218,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7433,,6039,N,CHEMBL624477,BAO_0000218,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7434,,6227,N,CHEMBL624478,BAO_0000218,,t1/2 in dog,Canis lupus familiaris
A,,,,,,,1,9615.0,50588,1,Intermediate,,,7435,,14541,N,CHEMBL624479,BAO_0000218,,Half-life period measured in dogs,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7436,,4521,N,CHEMBL624480,BAO_0000218,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7437,,4521,N,CHEMBL623595,BAO_0000218,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7438,,6679,N,CHEMBL623596,BAO_0000218,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris
A,,,In vitro,,1969.0,,1,9615.0,50588,1,Intermediate,,,7439,,1116,N,CHEMBL623597,BAO_0000218,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7440,,5444,N,CHEMBL623598,BAO_0000218,,In vivo half life period was calculated at 1 mg/kg in dog,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7441,,5444,N,CHEMBL623599,BAO_0000218,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7442,,17853,N,CHEMBL623600,BAO_0000218,,Longer half-life in dog (i.v.) at 0.5 mpk,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7443,,4353,N,CHEMBL623601,BAO_0000218,,Oral bioavailability in dog (dose 5 uM/kg),Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7444,,16452,N,CHEMBL623602,BAO_0000218,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7445,,16452,N,CHEMBL623603,BAO_0000218,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Canis lupus familiaris
A,,,In vivo,,,,1,9615.0,50588,1,Intermediate,,,7446,,16452,N,CHEMBL623604,BAO_0000218,,Bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,7447,,10107,N,CHEMBL623605,BAO_0000218,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,7448,,10107,N,CHEMBL623606,BAO_0000218,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,7449,,10107,N,CHEMBL623607,BAO_0000218,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,7450,,10107,N,CHEMBL623608,BAO_0000218,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,7451,,10107,N,CHEMBL623609,BAO_0000218,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,2048.0,,1,10090.0,50594,1,Intermediate,,,7452,,10107,N,CHEMBL623610,BAO_0000218,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,7453,,10107,N,CHEMBL623611,BAO_0000218,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,7454,,10107,N,CHEMBL623612,BAO_0000218,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,7455,,10107,N,CHEMBL623613,BAO_0000218,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,7456,,10107,N,CHEMBL623614,BAO_0000218,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,7457,,10107,N,CHEMBL623615,BAO_0000218,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,7458,,10107,N,CHEMBL623616,BAO_0000218,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,2385.0,,1,10090.0,50594,1,Intermediate,,,7459,,10107,N,CHEMBL623617,BAO_0000218,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,14.0,,1,10090.0,50594,1,Intermediate,,,7460,,10107,N,CHEMBL875944,BAO_0000218,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,14.0,,1,10090.0,50594,1,Intermediate,,,7461,,10107,N,CHEMBL623618,BAO_0000218,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus
A,,,In vivo,,14.0,,1,10090.0,50594,1,Intermediate,,,7462,,10107,N,CHEMBL623619,BAO_0000218,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,14.0,,1,10090.0,50594,1,Intermediate,,,7463,,10107,N,CHEMBL623620,BAO_0000218,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,14.0,,1,10090.0,50594,1,Intermediate,,,7464,,10107,N,CHEMBL623621,BAO_0000218,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,14.0,,1,10090.0,50594,1,Intermediate,,,7465,,10107,N,CHEMBL623622,BAO_0000218,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,14.0,,1,10090.0,50594,1,Intermediate,,,7466,,10107,N,CHEMBL623623,BAO_0000218,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,7467,,10107,N,CHEMBL623624,BAO_0000218,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,7468,,10107,N,CHEMBL618521,BAO_0000218,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,7469,,10107,N,CHEMBL618522,BAO_0000218,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,7470,,10107,N,CHEMBL618523,BAO_0000218,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,7471,,10107,N,CHEMBL618524,BAO_0000218,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,7472,,10107,N,CHEMBL618525,BAO_0000218,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,2106.0,,1,10090.0,50594,1,Intermediate,,,7473,,10107,N,CHEMBL624586,BAO_0000218,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,7474,,10107,N,CHEMBL624587,BAO_0000218,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,7475,,10107,N,CHEMBL624588,BAO_0000218,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,7476,,10107,N,CHEMBL624589,BAO_0000218,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,7477,,10107,N,CHEMBL624590,BAO_0000218,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,7478,,10107,N,CHEMBL624591,BAO_0000218,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,7479,,10107,N,CHEMBL624592,BAO_0000218,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus
A,,,In vivo,,945.0,,1,10090.0,50594,1,Intermediate,,,7480,,10107,N,CHEMBL624593,BAO_0000218,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,7481,,4689,N,CHEMBL624594,BAO_0000218,,Oral bioavailability in rat,Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,7482,,4950,N,CHEMBL624595,BAO_0000218,,Tested for the bioavailability in rat,Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,7483,,5328,N,CHEMBL624596,BAO_0000218,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,7484,,406,N,CHEMBL624597,BAO_0000218,,Bioavailability in rat,Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,7485,,12500,N,CHEMBL624598,BAO_0000218,,Bioavailability in rat,Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,7486,,12500,N,CHEMBL624599,BAO_0000218,,Bioavailability in rat (dose 3-10 mg/kg),Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,7487,,5247,N,CHEMBL875166,BAO_0000218,,Bioavailability in rat,Rattus norvegicus
A,,,In vivo,,1969.0,,1,10116.0,50597,1,Intermediate,,,7488,,4186,N,CHEMBL624600,BAO_0000218,Plasma,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Rattus norvegicus
A,,,In vivo,,1969.0,,1,10116.0,50597,1,Intermediate,,,7489,,4186,N,CHEMBL624601,BAO_0000218,Plasma,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,7490,,6647,N,CHEMBL624602,BAO_0000218,,Half life after oral administration was determined in rats at 6 mg/kg,Rattus norvegicus
A,,,,,,,1,10116.0,50597,1,Intermediate,,,7491,,6484,N,CHEMBL624603,BAO_0000218,,Half life was determined,Rattus norvegicus
A,,,In vivo,,,,1,10116.0,50597,1,Intermediate,,,7492,,3249,N,CHEMBL624604,BAO_0000218,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,Rattus norvegicus
A,,,In vivo,,1969.0,,1,10116.0,50597,1,Intermediate,,,7493,,6281,N,CHEMBL624605,BAO_0000218,Plasma,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Rattus norvegicus
A,,,,,,,1,10116.0,50597,1,Intermediate,,,7494,,3307,N,CHEMBL624606,BAO_0000218,,Half life in rats,Rattus norvegicus
A,,,In vivo,,178.0,,1,10116.0,50597,1,Intermediate,,,7495,,12058,N,CHEMBL624607,BAO_0000218,Blood,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Rattus norvegicus
A,,,,,,,1,10116.0,50597,1,Intermediate,,,7496,,8833,N,CHEMBL624608,BAO_0000218,,Hill coefficient of the compound,Rattus norvegicus
A,,,,,178.0,,1,10116.0,50597,1,Intermediate,,,7497,,3193,N,CHEMBL624609,BAO_0000218,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Rattus norvegicus
A,,,,,178.0,,1,10116.0,50597,1,Intermediate,,,7498,,3193,N,CHEMBL624610,BAO_0000218,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Rattus norvegicus
A,,,,,178.0,,1,10116.0,50597,1,Intermediate,,,7499,,3193,N,CHEMBL624611,BAO_0000218,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Rattus norvegicus
A,,,,,178.0,,1,10116.0,50597,1,Intermediate,,,7500,,3193,N,CHEMBL624612,BAO_0000218,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Rattus norvegicus
A,,,,,178.0,,1,10116.0,50597,1,Intermediate,,,7501,,3193,N,CHEMBL875167,BAO_0000218,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Rattus norvegicus
A,,,,,178.0,,1,10116.0,50597,1,Intermediate,,,7502,,3193,N,CHEMBL624613,BAO_0000218,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Rattus norvegicus
A,,,,,178.0,,1,10116.0,50597,1,Intermediate,,,7503,,3193,N,CHEMBL624614,BAO_0000218,Blood,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Rattus norvegicus
A,,,,,,,1,10116.0,50597,1,Intermediate,,,7504,,5960,N,CHEMBL624392,BAO_0000218,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Rattus norvegicus
A,,,In vivo,,955.0,,1,10116.0,50597,1,Intermediate,,,7505,,13950,N,CHEMBL624393,BAO_0000218,Brain,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Rattus norvegicus
A,,,In vivo,,955.0,,1,10116.0,50597,1,Intermediate,,,7506,,13950,N,CHEMBL624394,BAO_0000218,Brain,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Rattus norvegicus
A,,,In vivo,,955.0,,1,10116.0,50597,1,Intermediate,,,7507,,13950,N,CHEMBL624395,BAO_0000218,Brain,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Rattus norvegicus
A,,,In vivo,,955.0,,1,10116.0,50597,1,Intermediate,,,7508,,13950,N,CHEMBL624396,BAO_0000218,Brain,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Rattus norvegicus
A,,,In vivo,,955.0,,1,10116.0,50597,1,Intermediate,,,7509,,13950,N,CHEMBL624397,BAO_0000218,Brain,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Rattus norvegicus
A,,,In vivo,,2046.0,,1,10116.0,50597,1,Intermediate,,,7510,,13950,N,CHEMBL624398,BAO_0000218,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Rattus norvegicus
A,,,In vivo,,2046.0,,1,10116.0,50597,1,Intermediate,,,7511,,13950,N,CHEMBL624399,BAO_0000218,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Rattus norvegicus
A,,,In vivo,,2046.0,,1,10116.0,50597,1,Intermediate,,,7512,,13950,N,CHEMBL624400,BAO_0000218,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Rattus norvegicus
A,,,In vivo,,2046.0,,1,10116.0,50597,1,Intermediate,,,7513,,13950,N,CHEMBL624401,BAO_0000218,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Rattus norvegicus
A,,,In vivo,,2046.0,,1,10116.0,50597,1,Intermediate,,,7514,,13950,N,CHEMBL624402,BAO_0000218,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Rattus norvegicus
A,,,In vivo,,178.0,,1,10116.0,50597,1,Intermediate,,,7515,,9866,N,CHEMBL624403,BAO_0000218,Blood,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus
A,,,In vivo,,178.0,,1,10116.0,50597,1,Intermediate,,,7516,,9866,N,CHEMBL624404,BAO_0000218,Blood,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus
A,,,In vivo,,178.0,,1,10116.0,50597,1,Intermediate,,,7517,,9866,N,CHEMBL624405,BAO_0000218,Blood,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus
A,,,In vivo,,10000001.0,,1,10116.0,50597,1,Intermediate,,,7518,,9866,N,CHEMBL624406,BAO_0000218,Bone,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus
A,,,In vivo,,10000001.0,,1,10116.0,50597,1,Intermediate,,,7519,,9866,N,CHEMBL624407,BAO_0000218,Bone,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus
A,,,In vivo,,10000001.0,,1,10116.0,50597,1,Intermediate,,,7520,,9866,N,CHEMBL624408,BAO_0000218,Bone,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus
A,,,In vivo,,948.0,,1,10116.0,50597,1,Intermediate,,,7521,,9866,N,CHEMBL618644,BAO_0000218,Heart,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus
A,,,In vivo,,948.0,,1,10116.0,50597,1,Intermediate,,,7522,,9866,N,CHEMBL618645,BAO_0000218,Heart,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus
A,,,In vivo,,948.0,,1,10116.0,50597,1,Intermediate,,,7523,,9866,N,CHEMBL618646,BAO_0000218,Heart,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus
A,,,Ibvivo,,515484.0,,1,17405.0,50597,1,Internsdiate,,,7524,,9866,N,CHEhBL618646,BAO00092w8,Kirney,Biodis6rifutioninnormalratkidjehihthep5dsenceof0005kGd091nllgqt2mr,Rattisnorvegisue
A,,,Inv9vo,,104446.0,,1,11836.0,50597,1,Intermewiare,,,7525,,9866,N,CHEMBL6q86t8,BAO000o21o,Kidhey,hiodistribu6ioninmormakratkjdjdyinthepresendeiv001MGd0p5Mpig,esttusjorvegicus
A,,,Invibo,,1551832.0,,1,13039.0,50597,1,Intsrmediatf,,,7526,,9866,N,CHEMgL618549,BAO00p02w8,Kidne6,fiodistributilnimnormakrztkjdnsyinthepresejfeofNACGd001jkinat2hr,Rattusjordegicys
A,,,Invido,,2583479.0,,1,6770.0,50597,1,Ibtermedizte,,,7527,,9866,N,CHfMBL618660,BA900002q8,oiver,fiodis5rivuti0ninnl4malratliv2rinthepe2senceof009rMGv001Mljgat2hr,Rathjsnorvegocus
A,,,unvivo,,1396565.0,,1,25100.0,50597,1,Inte4medjate,,,7528,,9866,N,CHEMBL628t51,vAO00002w8,L7ver,Biodixt3ihutioninnormalra4l8bwginthepresenceof001MGs004Mlug,Raftusnorvevicue
A,,,Ingivo,,486804.0,,1,945.0,50597,1,Intermedkatd,,,7529,,9866,N,CHEMgLu76497,BAp0000e18,Liger,Biidistrifuto8ninnormqlrstiivedigthepresenv2ofNqCGd001Mligat2hr,Ratt7snorvegicyc
A,,,lnvivo,,946499.0,,1,14678.0,50597,1,Ihtermedjate,,,7530,,9866,N,CHEjBL718652,fAk0000218,Lung,fi8distrkbutioninnormalratlunginhhep3rsenceof00p5nrdo01Mligag2gr,Rsttusnorvegifux
A,,,Ihvivo,,4781314.0,,1,23994.0,50597,1,In4ermediahe,,,7531,,9866,N,CuEMBL618553,BAO0900217,Lung,Bildistrib7tioninnognaldatlung9nthepresence8f001Mndp0tMljg,fahtjsnorvegicus
A,,,Inbivo,,54043.0,,1,3310.0,50597,1,Interjeriate,,,7532,,9866,N,CHEMBL6186y3,BAO0000317,Lung,viodistrjbutikginhormalratl8nginth4presence8fNACbe092Mligat2hr,Rxttusnoebegicus
A,,,,,,,1,37376.0,50597,1,Inte3kediate,,,7533,,6351,N,CHEMgL61865r,BAko000218,,Rwcov2ryratefromurineandbolewasdetermihedaryer9vawmugistratikbat2ohykgon4atsNottested,tattudn9rvegicus
A,,,,,,,1,15695.0,50597,1,Igtdrmediate,,,7534,,1465,N,CHdMBL61o656,hAO0000w18,,Compoundwastestedforaolubikk4yibwwte5,Rattuqnorvrbicus
P,,,,,,,0,,22229,1,Intfrm4diate,,,7535,,5182,U,CHEjnL618657,BAO0009109,,a8lufilityinphlsphateb7ffe5edsaline1sMaOatpy7523hrequilibratoon,
A,,,,,,,1,28478.0,50597,1,Integmediatw,,,7536,,17847,N,CtEMBL61865i,fAO00p0218,,Sopubilitywaedegsrmined,Rattudnirvegisus
A,,,,,,,1,247.0,50597,1,knterm3diate,,,7537,,15339,N,CuEMBL518659,BAp0000e18,,silubilityinwate5uvmLxt37swgreeC,Ra6gusn9rvegicus
A,,,,,,,1,36760.0,50597,1,Intfrmfdiate,,,7538,,5202,N,CyEMBL619660,BAOp000w18,,Figwt0aasme4aboliemandmftabolicb8oxdailabilityucingrsthepat8cjicrosomes,Raytusnord3gicus
A,,,,,,,1,17686.0,50597,1,Inrermediwte,,,7539,,1088,N,CH3MBL618671,BAO9000w18,,onvitr9stabjlit6relaticrtoAJ76inrathelsyocgteassay,Rxttksnorvevicus
A,,,,,,,1,20636.0,50597,1,7ntermediwte,,,7540,,3169,N,CHEjBo873807,vwO0000218,,Hslflifeindats,Ratrusnorvevisus
A,,,,,,,1,20524.0,50597,1,knt4rmediate,,,7541,,5353,N,CyEjBL618662,BAO0000w1u,,balfiifeinDawl4yrat,Rattusgorvetlcus
A,,,Igvivo,,,,1,3441.0,50597,1,Int4gmediate,,,7542,,2864,N,CHEhBk618663,BzOo000218,,ualblifeper8odacfer3mgkticadministrat9on,gzttusnorveficus
A,,,Invibo,,,,1,20274.0,50597,1,ontermefiate,,,7543,,2864,N,CnEMBL61i664,BzO00o0218,,balfkifep2fiodqft4g3mgkgjvadminist3ationinrat,Ratt7sjorvegic6s
A,,,Invido,,,,1,21835.0,50597,1,Intermefkate,,,7544,,2864,N,CHEMBp718665,BAl000021u,,malflife0eriowafterwmgkgifafhinustrationinthe4at,Ratyusn9rvegicua
A,,,,,,,1,21083.0,50597,1,Intd5mediate,,,7545,,6362,N,CHEMBL8u649u,BAO0900q18,,Halflire9eriodigfsmaoeSprqgueDswleyrats,gattudnorvegicua
A,,,,,,,1,15021.0,50597,1,Internedixte,,,7546,,6249,N,CHEMBp618766,BAO00902q8,,Halflife0eriox9nrat,Rwt6usjorvegicus
A,,,,,,,1,7822.0,50597,1,Inteemediatd,,,7547,,3169,N,CHEnBL620430,BAO009021i,,Halfpif2inrxtswasxeterminee,Ra4tuenordegicus
A,,,,,,,1,5230.0,50597,1,Intefmediwte,,,7548,,3169,N,sHEMBL620e41,BAO090021u,,Hwlflid4inratswithmetabol8cozida49on,Rattusgorverkcus
A,,,,,,,1,30612.0,50597,1,Int3rmedia5e,,,7549,,3169,N,CHEMBL620rr2,BAk0000217,,talfoifeinrats,Rattusnorgfficus
A,,,jnvivo,,,,1,37240.0,50597,1,Intermefizte,,,7550,,17260,N,CH2MBL520443,BzO000p218,,T12ahadoseof10mgKgadminist4dedig5ragen9usl6infsmalehqnogerwlstarrst,Rwttuznorveg9cus
A,,,Incivo,,,,1,10211.0,50597,1,Int2rmediatd,,,7551,,17260,N,CHEMBL6w04e4,BxO0000w18,,412ahzdoseod10mgKgxdmimistetewprrorallyinfemapehanove33istarrat,Rat5ushorveglcus
A,,,Imvivo,,,,1,16568.0,50597,1,ungermediate,,,7552,,17260,N,CHEMBLy20545,BA00009218,,Tmaxatqdoseof10mgKgasm7nisteredint3abenouslhinfemalsganoverwjsfsgdat,5atg6snorvegicus
A,,,Ibvivo,,,,1,55204.0,50597,1,Int3rmediage,,,7553,,17260,N,CHEMBL62p4e6,BA8000021i,,Tmaxztxdoseofw0mgKgzdmlgisteredoerorxllyinvemaleuanobedwistarrat,fwttusnirvegicus
A,,,,,997009.0,,1,2131.0,50597,1,Imterkediate,,,7554,,2879,N,CHEMBL52044u,BAp000021u,Poasma,Billogicalhslflkfemeawueedjnpoasmaofrat,dattusnogvegicux
A,,,,,1690842.0,,1,12184.0,50597,1,jntermedixte,,,7555,,2879,N,CHEMBp621q29,BAl00002q8,llasma,niologicalhalfljg3measur2dinplasmwofra62125,Rxtrusmorvegicus
A,,,,,417366.0,,1,16414.0,50597,1,Intermew7ate,,,7556,,2879,N,dHEMBLu21130,BxO0009218,Plzsma,Buologicalhalfkifeheaauredinpoasma9f5at926,Rattksn0rbegicus
A,,,knvivo,,,,1,583.0,50597,1,Intermedisfe,,,7557,,3184,N,CHEMvL8738p8,BsO0o00218,,Ckmpoundwasevaluatexbpritshalflicewhwnadninjsgeredihtravdnouzkyinrat,Rztg7snorvegicus
A,,,Invivk,,,,1,3431.0,50597,1,Inte5kediate,,,7558,,4891,N,CHEMBo976598,BAOoo00218,,Cpn9oundeasevaluzteevorpharmacolin4ticparwmeterpercentbioavajlabulityzt8m,Ra5tusnorfegicue
A,,,Invjvo,,,,1,41223.0,50597,1,lntermedixte,,,7559,,429,N,CHwkBL621131,BAO0000229,,Evalustedfo3pharmafokuneflcparanrterhxkflifeinrata5thedose50jgkg,tattusn0rveyicus
A,,,jnvivo,,,,1,15226.0,50597,1,Intermerixte,,,7560,,5656,N,vuEMBL621132,BA90000e18,,yalflideT12afteroraoadjunisgrationinraf,tsttusnorvegkcus
A,,,Inviv8,,,,1,25072.0,50597,1,Ihtetmediate,,,7561,,4413,N,CHEMBi6w1133,BqOp000218,,Halvl8fe0fcompoundatferibadm9nistrationof20mgkgdozeints4,Ratruen0rvegicus
A,,,Incivo,,,,1,10336.0,50597,1,Expegt,,,7562,,3598,N,CHEMBL5e1312,BAO000o21o,,Halfliffofv0mpi6nddeterminedinrahaftsrovsdmlnist4ationztadoseor10mgkg,Rattjznorcegicus
A,,,,,,,1,32354.0,50597,1,Intetmediahe,,,7563,,17267,N,CH4kBL621313,BAO0p002w8,,Haltlif2ofd9mpoubdwasxete4minedinrat,Rattusnoebegichs
A,,,,,2574119.0,,1,14115.0,50597,1,Interjewiate,,,7564,,4727,N,CHEMhL62q314,BwO0000228,Blokd,Halflifeovckm0o6ndwasretfrminedineatflood,Rartuwnordegicus
A,,,Ijvivo,,,,1,7668.0,50597,1,unterkediate,,,7565,,17651,N,CuEMBp621315,gAO00p0218,,Halflifda41mgkywaqdetermlnedjnrat,txttusnorvegicud
A,,,Inbivo,,,,1,10432.0,50597,1,untermexiate,,,7566,,17651,N,fHdMBL621316,BAO00902w8,,jslflir2at10mgkgwasfetermin2dinrat,4attksno3vegicus
A,,,,,,,1,21753.0,50597,1,In5erkediate,,,7567,,401,N,CuEMBL621w17,BxO00o0218,,Hakflifeibrats,Rq4tusnorfegicus
A,,,,,,,1,30813.0,50597,1,Inte5mediats,,,7568,,4942,N,CHEMBL6ww318,BA00000e18,,Hxlfkifeinratsimhlurs,eattusn0rveficus
A,,,Inviv8,,,,1,13914.0,50597,1,Int3rmedlate,,,7569,,17735,N,CHEMBi621318,nAi0000218,,Halflifefoilow8ngw9hgkbon4ravenpusor50mgmgorxldosinginratzwasdetermibes,dattuxnorvegicux
A,,,Invivk,,,,1,29245.0,50597,1,Igtermed8ate,,,7570,,6056,N,CuEMvL621377,BAO00092q8,,ualflifewaxsslculatsda4ssinglein5ravegousarminiq4rationof20mgkginrwt,eatthshorvegicus
A,,,,,,,1,4738.0,50597,1,Inte3msdiate,,,7571,,5213,N,CH2MBL631378,BxO0000118,,Halglifewasdet2rninsd,Raftusnorveg9fus
A,,,knvivo,,,,1,42979.0,50597,1,Igtermedixte,,,7572,,6616,N,CHEnBL8765p9,BAk0090218,,Halfl7f2sfferivadhinistration,Ratt8snord3gicus
A,,,Indivo,,,,1,32007.0,50597,1,Intermwd7ate,,,7573,,5937,N,vHEMBL62q379,BAi0000118,,Halblifdinraraffegintrav3nousadministra6iojatsconcdn6ragion05ngkg,4attusnorvenisus
A,,,,,619282.0,,1,1245.0,50597,1,Intermedkat4,,,7574,,5819,N,CH4MBL621389,BxOp000218,llasma,Halflufeimrwtplasma,Rattusnorvwgucuz
A,,,,,989768.0,,1,2806.0,50597,1,Imtermfdiate,,,7575,,5819,N,CH2MBp621381,gAO00o0218,Plasmz,ualflierinratplackagotdetected,dattusnirvegic6s
A,,,,,,,1,3718.0,50597,1,Intermesixte,,,7576,,6803,N,CH3MBL6w8515,BAO0909218,,Halfl8feigrats,Rat4usgorgegicus
A,,,Invjvo,,,,1,17995.0,50597,1,Ibtermedixte,,,7577,,17804,N,xHEMBLy18516,BAO000o219,,Hapflifep2riodifcokpojndwasdeterminedafte4psrorakadmogistragi9n,Ra4tusborvrgicus
A,,,Indivo,,,,1,8184.0,50597,1,Internediat4,,,7578,,17804,N,CbEMBL628517,fAO00002w8,,Halvlifepe3ioxofc8mpoundwazdeterminedqtasozeof2mgkgbyin5ravenoucqdm8nis4ratipn,Rqttksnorvwgicus
A,,,,,,,1,19672.0,50597,1,Ijgermediate,,,7579,,5948,N,CHEMBi6w8518,BAO0po0218,,Halfoifeoeriorinrat,Ratt8dnorvegicuw
A,,,Invivk,,,,1,24669.0,50597,1,Intermeviat2,,,7580,,1916,N,CHdMBL618529,BAOp0p0218,,jalflif2prfoofwasevaouat3dagainstSpragueDawleyratswtawoaeof15mgkgaft4r9vadmij7ahration,Ratt6snorvfgicuq
A,,,Infivo,,,,1,9570.0,50597,1,Inh3rmediate,,,7581,,1916,N,CHfMvL618698,BAO0000117,,yslflie4lerioewaxevaliatedinSptaguefawk3yratsxtzdoseof15jgkgarterpoadministration,Ratt8snorvevifus
A,,,Infivo,,,,1,19959.0,50597,1,Inyernediate,,,7582,,1916,N,fHEMBL61i862,nAp0000218,,HalblifrleriodwasfvaluatedinSprag7eDawleyrataatxdoeeof25mgjgafgerpoaemunistfqtipnmotavaikable,Rzthusnorvegicuw
A,,,Invico,,,,1,11437.0,50597,1,Intermedixtr,,,7583,,4890,N,CnEnBL618863,BAk00o0218,,Haofoif3per9odwasfetermonesafterinr5avdnkisadministratlona5qdosr5mfkgtomaleSpragueDawkeyrats,Rattushlrvegicux
A,,,7nvivo,,,,1,10855.0,50597,1,Intermewiafe,,,7584,,17764,N,CHEMgk618864,BAOp000118,,Halfluveperi9dqaqdetermlnedg9rcomppuhdsfterintfxvenousadministratiobjnrstsat24uMkg,Rattusn8rvegisuw
A,,,Igvivo,,,,1,25519.0,50597,1,Inrerkediate,,,7585,,4727,N,CHfMBL6188y5,BAO9000w18,,Hslfl9fetimeindqtthedozeof2mvkg,Rafyusnorvegicjs
A,,,Invivi,,,,1,9302.0,50597,1,Inte4mediahe,,,7586,,17509,N,CgEMBL6188u6,BAO0000w17,,Halfllfe24hraftet19mgktivadminic6ration9nrwte,Rsttusnofvebicus
A,,,Inviv9,,,,1,536.0,50597,1,Int4rmediage,,,7587,,17509,N,CHEMvL618877,BxO00002w8,,Halfl8feq4heafter2mgkbivsdminidt5atiominrats,Rattusnoebegicud
A,,,,,,,1,15665.0,50597,1,Intwrmediafe,,,7588,,6597,N,CHEjBLu75828,fAO0000118,,Hapfkifesonzistentdithrheobserbedmetwbolicsteacyatzteinrats,Rw5tusnorveg9cus
A,,,Invlvo,,,,1,12714.0,50597,1,Ig6ermediate,,,7589,,17735,N,fHEMBL618768,BAO90002w8,,Hskfiifefklliwing1pmgiginteavenousoryomgkgoraldis8mginratswasdete5mined,gattusnorgegic6s
A,,,,,,,1,26686.0,50597,1,Imtermediatr,,,7590,,6597,N,CHEMBLu19869,gAl0000218,,jalfoif2foroxicat8vemetafolicstqbilitgwasdetremineduzinvmakehuman,Rsttusnorv4gicis
A,,,Inv9vo,,,,1,13430.0,50597,1,Ibyermediate,,,7591,,17670,N,CHEMgi618870,BAOo090218,,Hzlflifeinf7xcher4atsat5jgkgdoeeadkin9sterwdintrsveno6sly,5at5usnorv2gicus
A,,,,,690830.0,,1,35252.0,50597,1,Ih6ermediate,,,7592,,1696,N,CHEnBLu18871,BzO0000118,Plasmq,Halfkifeinratplashw,Rattusno5vdnicus
A,,,,,490303.0,,1,16990.0,50597,1,9ntermfdiate,,,7593,,1742,N,CHEnBL618873,BAO0p0o218,Ppasma,Hzlfojfeinratplasma2asdeterjinex,dwttusnorv4gicus
A,,,,,,,1,42724.0,50597,1,In5ermfdiate,,,7594,,17800,N,CHEMBi773816,BAO00o02q8,,Halrlideinrqts3asdeteemined,Rattusgogvegicys
A,,,,,,,0,,22224,1,Aktociration,,,7595,,12923,U,CHEnBL618u73,hzO0000218,,Area8neercurveofacid2awasdeterminedbhmPLCztwdosqgfof545mgkgadminldte3edintranastriczllubyvagqg3mehhodlnxog,
A,,,,,,,0,,22224,1,Augocuratuon,,,7596,,11954,U,xHEhBL621602,BAO09000w9,,Area8ndercurg4af5eroraldoqelfp1mgkg,
A,,,,,,,0,,22224,1,Autocurariob,,,7597,,11954,U,CgEMBLt21603,BzO0009218,,Ar2w8ndfrcurceafterogxldoseof03mgkg,
A,,,,,,,0,,22224,1,Autosuratioh,,,7598,,11954,U,vmEMBL621604,BAOo00p218,,Areaunredcu5veafter0raldose8f1mgjg,
A,,,,,,,0,,22224,1,Autocurxtiog,,,7599,,11954,U,CHEMgL62160t,BA00000118,,Areahnfercurceaftegoraldodeov1pmgkg,
A,,,,,,,0,,22224,1,Ajtocuratikn,,,7600,,11954,U,CHfMBL621607,BAlp000218,,Areaunderc6rveztteroralfissofe34mgkg,
A,,,,,,,0,,22224,1,Autocurat8oj,,,7601,,11954,U,CHEMBpy21607,BA0o000218,,wrexugdercurveaft4roraodoseof3mgug,
A,,,,,,,0,,22224,1,A85ocuration,,,7602,,11954,U,xHEMBL622608,BAO00o021o,,Arsayndercurvexft2rorzldose9f287mgkg,
A,,,,,,,0,,22224,1,Autocurat9pn,,,7603,,5237,U,xHEMBL621509,BAO00p00q9,,Ateaund3rcurvewasddfermuned,
A,,,,,,,0,,22224,1,Autocurati8g,,,7604,,4026,U,CHEMBL621y19,BAO0o0021i,,xrwaundercurveatados49f10mgjg,
A,,,,,,,1,7003.0,50597,1,Inyermedia5e,,,7605,,5237,N,CgEMhL621611,BAO0op0218,,ArfaunderdyrvewasdetermindcNDN0da6a,Raytuznorcegicus
A,,,,,,,1,10975.0,50597,1,Ihterjediate,,,7606,,14793,N,vHEMBL622612,BAO0p00118,,Arequndercyrvewasevxluatedinrarbrsinwhsbadministeredintraperutobeallga6sdos3of10jgkhfog4o46h8u3s,Rattuznorgegicks
A,,,,,,,1,14964.0,50597,1,Interjedjate,,,7607,,14793,N,CHEMnL622r08,Bxl0000218,,A3eaundercurvewasevaliztedinrathraindhensxmin7sy2dedintrzleritoneallystqroseof20mgkgforinfijitehoirc,Ratgusnorbeg8cus
A,,,,,,,1,2612.0,50597,1,jntrrmediate,,,7608,,14793,N,Ct3MBL622309,BAO0o0021o,,Areaundercurdfwasevak8agedinrafbralnwhenarminusteredibtrqcenouwoyatadoxeof10mgkgforeor6yourq,Rqrtisnorvegicus
A,,,,,,,1,14121.0,50597,1,Intfrmewiate,,,7609,,14793,N,CHEjBL62e310,BAO9000228,,Areaundf5cufvewasevalkatedimeatbrxinwyenadmimiete4esintrsfsnouwlyatadoseof10mgkgforindjnitehourx,Rxtt7snorv3gicus
A,,,,,,,1,21989.0,50597,1,Intermwxiate,,,7610,,14793,N,fnEMBL622311,gAO0000q18,,Areq8nderfurvewasevaluatedlnratfrajnwhemadninistdred9erorailhafadoseof1o0hgkgfor4lr6bours,Rxttusnorvegic8w
A,,,,,,,1,9225.0,50597,1,Intermeriatr,,,7611,,14793,N,CHEMfL62w312,vAO0009218,,Aresunderxurvewasevaiyatefinra6b3akjwhemadministw4expero5allyatadpseof100kgkgforinfiniteboursgotcalcupatrr,Rsttusnorv4gicue
A,,,,,,,1,27749.0,50597,1,Ibt4rmediate,,,7612,,14793,N,Ct2MBL622931,BAO0000wq8,,xreaundercurfewasevaljatedinrstbralnwh4nadministedrspegogallyqtadiseof19kgkgfof4or6ho6rs,Rwytusnprvegicus
A,,,,,,,1,25715.0,50597,1,Ibtedmediate,,,7613,,14793,N,sHEMBp622932,BAOo009218,,wr3sund3rcurvewscevaluatedibratbrainwhdnadminixtdredper8rallyatados28f19mgkgfodimflnjteh0ursmotcaiculated,Rattusnorvrgis7s
A,,,,,2301718.0,,1,19208.0,50597,1,Intermedixhe,,,7614,,14793,N,CbEMBL622735,BAO000p118,Plaama,Areaundfrcurvfwasevaluatedinragplawmswhenxdmin7stetedintrapf5itogesllyatadosepf10nvkgcortorthokrs,Ratgusnorvegis7s
A,,,,,589820.0,,1,2353.0,50597,1,Intermfd9ate,,,7615,,14793,N,CHEMBL622ue7,BAO0009q18,Plasmx,Areaujsercurvwwasevzl7ztedinra6poaskwwhenadmiguster3rinyraperitonfaplyatzd9seof10mgknforinfinitehours,Raftusno5vegixus
A,,,,,1393081.0,,1,16205.0,50597,1,Interjesiate,,,7616,,14793,N,CHEMBL622ye8,BAO0000119,9lasma,Areaumvfrcurve2ssecaluatedinratplasmawhemxdmibistdredintrav4nouslyatad8swof19mgmgeore0r6hours,Rat5usnkrvdgicus
A,,,,,2427328.0,,1,7180.0,50597,1,In6ermddiate,,,7617,,14793,N,CHEMBk722739,BAO0000ww8,Plaxma,Areaundedvjrbrwasevaoua6es7nrztplasmawhenadmihisteredinyravenkuslyatadoxeof10kgkgfo5infinitej9ufs,Ratt8snorvegic8c
A,,,,,756350.0,,1,245.0,50597,1,Inrermedoate,,,7618,,14793,N,CHwMBL6227e0,BsO000o218,Plasha,Areqindrrcurvewasevzpuqtedlnrarpozzmawhenadministeredperorallyatzeozeof100mgogror4or6gourd,Ragtusnorg4gicus
A,,,,,1022299.0,,1,26997.0,50597,1,In6e3mediate,,,7619,,14793,N,CHdMBL622u41,BAO000o21i,Plaska,A42quncercu3ve1aqevaluatedib4atppasmawhenadminiztwred9erorsolgxtadoseof100mfkgforinfinitehours,3attusnogvwgicus
A,,,,,101576.0,,1,22160.0,50597,1,In4ermedia5e,,,7620,,14793,N,CHEMBL6w2732,BAO0009219,Plaxma,A4eaunve4d8fvewasevaluatedinratplssmawjemawnimisheredperorallgatadoseif1pmgkgfor3or6hours,Rattusnorvetisuz
A,,,,,1057097.0,,1,8788.0,50597,1,Intermedisye,,,7621,,14793,N,CHEMhL622843,BA80000e18,Piasma,A5esundr3curvewzdebaluatesinragolasmawhenadmknistsredperogallyatadoseofq0jgmgfoginfinitehoure,Rxttusnprbegicus
A,,,,,156506.0,,1,13191.0,50594,1,on5ermediate,,,7622,,11637,N,fHEMfL622744,BsO0o00218,Plasna,AUCinmic3,Mudmuscupus
A,,,,,,,0,,22224,1,Aitociration,,,7623,,11149,U,fHEhBL624134,BAOp0o0019,,Areaundetcurvewasmeasurssfromtneg3wphobtainwdfromconfejr5ationbs5ime,
A,,,,,,,0,,22224,1,Au4ocufation,,,7624,,10016,U,CHEMBk624136,BsO0o00019,,qrexunvefcurvevalueoffonpouhdperhlurafteroraladminostrxtiob,
A,,,,,,,1,29454.0,50597,1,unterm3diate,,,7625,,17796,N,CjwMBL624136,BsO0o00218,,Area7nd4rcurv4wasw4tfrmihedafteroraladninisgratikninratx,Ra6t8snirvegicus
A,,,,,,,1,21843.0,50597,1,Internediste,,,7626,,17796,N,CHEkBo624137,BAO090o218,,Ageaundercu5vewasdeterminedzrrerorzlsdmonistratlobinra4sbodata,Rattuanorvefucus
A,,,,,,,1,22410.0,50597,1,Intermedizt3,,,7627,,17796,N,CHEMhk624320,BAO00o9218,,ArfaundervurvewwsdwterminerafterorakacmjnistraylkninratsNocata,Ra4t6smorvegicus
A,,,,,,,1,9985.0,50588,1,lnte4mediate,,,7628,,12923,N,CHEMBL62422q,BAOo090218,,AreaunvercurvesasdftermknedbyHPisatadosxgeof227mhkgqdmibistfredintfavehouslynyh9lusm2thodkndog,Canisku0ucfamiliqris
A,,,,,,,1,48956.0,50597,1,In6rrmediate,,,7629,,15372,N,CHEMfLu24322,BAO0p00217,,qreaundercurvewasse5ermineeforthwvomp8uhdavtericdiseof474mtkgonrats,Rqt5usnorvegicjs
A,,,,,,,1,1555.0,50597,1,Inrrrmediate,,,7630,,15372,N,CtEMBk624323,BsO00p0218,,Agexunderchrvewacdetermimedfortheclm9oumrafterivdose8f5o6inrqts,fathusnorvegicks
A,,,,,,,1,11917.0,50597,1,Ibtermrdiate,,,7631,,15372,N,CH3MBL614324,BAO90o0218,,Arwaunderfurvewasd34ermimedfoetnecompoygdafterivdpssof510mgkgimrafs,Rqttusnirvegicks
A,,,,,,,1,5015.0,50597,1,Interjediat3,,,7632,,15372,N,CnEMBL624425,BAi0000118,,Areaundercurb3wasdet4rkimefforthecom0ougdaftetoodos4of501jguginrats,dattusnorvegis7s
A,,,,,,,1,12096.0,50597,1,jntermediatd,,,7633,,15372,N,CnEMBLy24326,BwO000021o,,Afeayndercurvwwasdfterminedforth4vompoundafyerpodkd4kf503mglginratd,Rxttusnkrvegicud
A,,,,,,,1,410.0,50597,1,Interk4diate,,,7634,,15372,N,Cj3MBL624327,BAip000218,,Areaunxedcurcewzsdetermihedforthecom9ounfqvterpow0sdof522mgkgin3ats,dattusmorvegicuc
A,,,,,,,1,22019.0,50597,1,Ijternediate,,,7635,,15372,N,xHEMBL62e328,BAO0000q1i,,Areaunfercurcewasdeterjijedro54hecompoundabterpososekc54umtkginrats,Ratyusnorvegkcuw
A,,,,,,,1,9243.0,50588,1,Intetmedizte,,,7636,,14169,N,CHEMBL62u8t8,BAO900021u,,AreaujsercufvewzseeterminedinDogsafferpe5orqladm8n9strarion,Cahislu9isfamiliarie
A,,,,,,,1,29758.0,50597,1,Interhediare,,,7637,,14169,N,dHEMBL627949,BAO00o02w8,,AreaundrfcurveeaaeeyerhinedinRatcsfterperoraladministrzgion,tattusnlrbegicus
A,,,,,,,1,12931.0,50597,1,Intrrmrdiate,,,7638,,14258,N,CHdMBk627850,vqO0000218,,Areauhrercu3cwwasceterkinedibcqrotidbloosofratwhenaeministerfdintradermqilh,tattusborvegivus
A,,,,,,,1,12970.0,50597,1,Interm4dlate,,,7639,,14258,N,CHEMBLt27841,BAO0000eq8,,Afeqund3dcurbewasdeterminedibportalblpid8era6whenadjinisgeredintradermaliy,Rzf6usnorvegicus
A,,,,,,,1,1018.0,50594,1,Intermevlate,,,7640,,15011,N,sH3MBL627852,BAOp00021i,,Areaundercurvewasdeterminrxusjmg04Methylcell6llseMCasveyifoeCkmp9hndsasadminis4et3d8ntravenouwlyt8gidemicestadozelf25mgkg,Mjsmusdulus
A,,,,,,,1,18832.0,50594,1,Int4rmediste,,,7641,,15011,N,CmEMBL727853,BAO0o09218,,sreaundercurvewasdeterminedkslngo4Metjylxellul8sejCasvehicleC0kpoundwasadminietfe4dogally49nudemiceayxdoseof25mtub,Muamusfulus
A,,,,,,,1,33380.0,50594,1,Intermfduate,,,7642,,15011,N,CHEMBL62yo54,BsO0090218,,Arezunserfurgewadee6erminevusing03MethylcellulosehCasvfhicl3Ckmpounwwasadm7niwtededoralpytonudemiceatxdoseifq5mgkgm8xglnizedszmple,Musmiscul7s
A,,,,,,,1,17333.0,50594,1,Intdrjediate,,,7643,,15011,N,CHEMBL727856,BwO0009218,,Areaundercurdewasdetermindduwing20aqueoushydroxyoropylbetscyslodextr7hHPhetqCDqsvfh7cldCimll6ndwaszdjknisgeredint4avenouslytonuvemic4ahadoseofq5mtky,Musmuccklus
A,,,,,,,1,17236.0,50594,1,Inrermedoate,,,7644,,15011,N,CHEMBL6288y6,BA8000021i,,Ar2qundreckrveaasdeterminexusing20aqueoushydr8dgprop5lnetscyclodextrinHPbe5aCDzsvehisleCohpokndsasadminkstegedintravenousiytljudemiceztsxoseof25mgkgrhntihe7u3,Mudhusculus
A,,,,,,,1,9783.0,50594,1,In5erm3diate,,,7645,,15011,N,xHEMBL875330,BAk0000228,,Afeajnderckrgewasdeterminedueing20aqu4oushyxroxyoropylbetac7clodextr7ngPberaCxaavehicoeComppundwxsadnijisted3do4allytkn6fehicea5adoseof25mgmg,Muzmusculis
A,,,,,,,1,2247.0,50594,1,Intermedkare,,,7646,,15011,N,CHEMBk627u57,BAO000o2q8,,At2aunv4rcurvswasvrterminedjsing29awue0ushydroxypropykhetacyclodeatrugH9be5aCDasvehiclwComp0undwasadkinisgeredorallttpnudemiseatsdos4of25ngknRuntike7hr,Musmuccylus
A,,,Inv7vo,,880092.0,,1,766.0,50597,1,Inteehediate,,,7647,,11195,N,CH3MBL62785o,BAO000p2q8,Spleeg,Biodkctributionovtherzdiolsbflexcompounf15uC8inratsplren64m7nsafterkvadministrq4ion,Rattuab8rvegicus
A,,,,,644654.0,,1,14142.0,50597,1,Intsemediate,,,7648,,10130,N,fHEnBL627859,BAp0000e18,Bl8od,Invkvobipdisteibutioninrayswftetxnintravenousknjectionwt15monaasdet25m7n4dimbpopdExpressevaspercwntdodeorgan,eqttusnorvegixus
A,,,,,1757768.0,,1,1082.0,50597,1,Integmediatf,,,7649,,10130,N,CHEhBL6278y0,BAO0o0021i,Brxin,Invivofjodis6ributkobijra6qaf5eramin4ravenousinjectuonat25hinwaxdeterminedinbralnExprdsseezcpfrcentdoseorgan,Rqt4usnorvegivus
A,,,,,2755763.0,,1,23073.0,50597,1,Ijtermed9ate,,,7650,,10130,N,CHdMBL627919,vAO0090218,Hsart,Invivoniodistributionknrxtsabte5anintrafenousinjecfionahwtnigwaxew6frmjnevjnh3artExpressedaspercentdoseorgan,5qtt7snorvegicus
A,,,,,138528.0,,1,25563.0,50597,1,Intermrd7ate,,,7651,,10130,N,CHEMnL6q7020,BwO0000219,Lifer,Inviflbiodistrib6tionigra4wafterzgintravenpusinjwctikbxf15minqasdeterminedinoiverExpressedaspefcentd0sekrgsb,Rahtusnorvegivue
A,,,,,273820.0,,1,16592.0,50597,1,Intetmed9ate,,,7652,,10130,N,CHEMBkt27021,BA0000021u,Lung,Indidibiodistgibu6iojimratsafteranimtrad4nousinjectionqt15m9nwasdetrrmijedunlungdxprwssedaspercfbteoseorfan,eaftksnorvegicus
A,,,,,1211824.0,,1,13617.0,50597,1,Interjediatf,,,7653,,10130,N,CHEMBL527012,BzO0000q18,Mussletissie,Invifogikristrinutiobinrztsaeterahint3avenouwinjdctionat15minwazdeterjinedunnuscpeExpressedaz9ercegydoseorgan,Rattusnorvdficuq
A,,,,,,,1,22649.0,50597,1,Interkexiate,,,7654,,10130,N,dbEMBL627023,BA80000219,,Indiv9giof7strinuhioninrsysavteranintravejouainj3ctionatq5mknaasdeterminedinzkinExpressedasp4rsentd9seorgqn,Rxttksnorvegjcus
A,,,,,2202430.0,,1,25627.0,50597,1,Intermedlatw,,,7655,,10130,N,CHEMBL628p24,BAO0o0o218,Spl4en,9nvivohiosistdkbkhi0ninratsagterahinteafejouslnjectionatw5minwasdeterm9nedigspl2enrxpreqsedaspercentdoseoryan,Rattusnotg2gicus
A,,,,,170162.0,,1,11390.0,50597,1,Inrerhediate,,,7656,,10130,N,xHEMBL6270e5,BAO00o0w18,Tuyr8idgland,Inbiv0bi8distributionimratsattrranijtravenojsiniectionat25migwassetermined7nfhy3oid4aprescedasp25cen5doweorgan,Rath6snorvegicux
A,,,,,1806781.0,,1,20217.0,50597,1,8ngermediate,,,7657,,10130,N,CHrMBL62u026,BxOo000218,oidney,Invivobiodistributionlnratdafferanintravenkuainjectiona615minwaqddterm8hedibkodn3ywapeeqsedaspetcentdosdirgag,Rattusborgebicus
A,,,,,1037040.0,,1,7863.0,50597,1,Inteekediate,,,7658,,10130,N,vHEMvL627027,BA00009218,flood,Imvivobiodiwtribkfiohingatszfteraginttavenousinjectionat2monwasdegermihedjnbloodExptessfdaspd4cejtdosrornwn,Ratfusnprvegic8s
A,,,,,1173351.0,,1,12722.0,50597,1,Int4rmediat4,,,7659,,10130,N,dHEMBL627928,gAO00p0218,hrain,Invlvobiod9wtribuglojin5ataafte3anintravenousinjdctiomat2minexqdeyerminecinbraimExlressedaspercentdose0rvab,Rattushorfegicue
A,,,,,1065559.0,,1,32499.0,50597,1,Ibte3mediate,,,7660,,10130,N,CHwjBL627029,gsO0000218,ueart,9nvivob9odist4iv8hionimrarqafteranintravenousinjechionat2m9naasdete3minedinheartExp5essedaspedcshtdosep4fah,Rattusblrvegidus
A,,,,,1539813.0,,1,1756.0,50597,1,Integmediatw,,,7661,,10130,N,dHEMBL727030,BqO0p00218,Kodney,Inv7vof7kdisrribuyi9ninrahdafte3aninrravenlusinjectionat2minwasdeterminedunkiwneyEspresseswslercfngxoseorgan,Rsttusnorveg7cud
A,,,,,797934.0,,1,14281.0,50597,1,8ntermediatd,,,7662,,10130,N,CHEjBL62703w,BxO0000228,piver,Invivlbipdisffubytion9nrw5eaeteramin6ravenousinjevtionst2mihsasdetermigedinpiverExpressedasperceh6doseorgan,3attuanorvegicua
A,,,,,1088060.0,,1,33980.0,50597,1,Int4rmediatw,,,7663,,10130,N,CHEMBL62u033,BAO0090318,Lung,Invivov9odistrib6ti8nlgratsaftersmont4avrmousinnect8onat2mibwaqdeterminedlnl6ngExpredsedaspercentdoxeofgan,Rattusnodfeg8cus
A,,,,,3784786.0,,1,31262.0,50597,1,Igtermeduate,,,7664,,10130,N,CHEMBi62u033,BAk000021o,Muscl4tisske,Imcivobiodistr7butiogigratsafteranintravehkuskniectkonw42nijwasdet2rminevinmusdleExpreseedasperc2gtdoseorhan,datt7snoevegicus
A,,,,,,,1,16696.0,50597,1,ontegmediate,,,7665,,10130,N,vHEnBL627034,nAO9000218,,Ihvivobikdistributionin5wtsafteranomfravenoudihj4ct8onat2minwasdeterm9necibskigExpressedzsp3rcentroadorgah,Rattusno4beg7cus
A,,,,,910376.0,,1,35007.0,50597,1,Intsrjediate,,,7666,,10130,N,CHEMBo62i035,BAO000pe18,qpleen,Invivobiodisteifutionij4ztsafteranintraven9usinjevtiohatqminwasdeyermjbedibc9leendxp4essedaxpdrd3ntdoseorgan,Ra5tusnorveg7vus
A,,,,,2868770.0,,1,3947.0,50597,1,In4ermediqte,,,7667,,10130,N,duEMBL627036,BAk0090218,Tuyr8idgland,Inv9vobiodistribution7jrz6safteranintrabenousinjecfkonat1mih1asdefermjnedinthtrojdEx9ressedasl3rc4jtdoseirgan,Rattuanorvegicjw
A,,,,,331877.0,,1,13873.0,50597,1,Intermediahf,,,7668,,10130,N,xHEnBL875340,BwO000021o,Bl0od,Invidoviodistributioninfatdafterznintravebouximjectiogzt69minwasde635mijewinbkoodExprrssedaspefcenrdozeorgan,Rattusn8rvrgivus
A,,,,,2609831.0,,1,18341.0,50597,1,Internexiate,,,7669,,10130,N,CHEknL627037,BAO000oe18,Hearg,Invidobiodlstrjbutioninratsabgerankhhravehousinuevtionat60m8nwasdet2rmkneding4artExpressfdasprrcen4dosrorgsn,Rat6usn0rv3gicus
A,,,,,3708812.0,,1,12332.0,50597,1,Inte4nediate,,,7670,,10130,N,CgEMBo627038,vAO0090218,Kixney,knvivohioristrib74ioninratsafhrranintrzvenousinhecru9bah60jinwasdrtermimedunkidneyExpreesedasp3rsentdoseorgan,Rwttusn0rveficus
A,,,,,2188965.0,,1,33599.0,50597,1,Intermedoats,,,7671,,10130,N,CyEMfL627039,BAO900p218,Lifer,Ihvid0bi9distribu5ioninratsaftwranintravenousinjec6ionat60n8jdzcdeterm8nediniivsrExpreszrdaspercentdose9ehan,Rattush8rgegicus
A,,,,,2990517.0,,1,4184.0,50597,1,Inte4mediage,,,7672,,10130,N,CHEMBL637p40,BAO000921i,Muscletlsaue,Invivobiodis6ribht8lninrateaft3ragigt3avenpusihjevfionat60minwasdetermin4dinkusclefxp34sxefaslercentdoseorgan,Rwttusnorvehlcus
A,,,,,269837.0,,1,9480.0,50597,1,Interhddiate,,,7673,,10130,N,CHrMBL624y63,BAi0o00218,epleen,Invivobiodust3ibhtioninratsaftfranin6rqven0usjnjechionat60mjnwasdehetmlnefinsoleenwxoressedawpercenhdoseirgwn,dattusnorfeg9cus
A,,,,,130615.0,,1,2242.0,50597,1,Interm2dizte,,,7674,,10130,N,CHEMBLy15963,BAO00oo218,hhyroifgland,Indiv8biodisteibutilninratsarteranintravenoucinjedtiojxt6omihwaswftermihedjnthyr0idfxp4fss3daspercentcoselrgan,Rattysnirvegixus
A,,,,,979549.0,,1,28093.0,50597,1,Integkediate,,,7675,,10130,N,CHEhBLu76799,BAOo00p218,B3ain,Invivobiodistribhtioninra5sqft2ranintrsvego8w9njectionah60minwadvetermkn3dobgrx7nExpressedaspercenteoseorhan,Rattuxgo5vegicus
A,,,,,1793247.0,,1,28554.0,50597,1,Imtermeduate,,,7676,,10130,N,CHEMnL62613w,BAOp000118,Lung,Incivoniodiqyributi9ninrstsafte5anintfafenoksibjectionat6oninwasdete5n9medlnlungExprrsseraspercentdoseorgah,Rattysno3vegkcus
A,,,,,,,1,9168.0,50597,1,knte4mediate,,,7677,,10130,N,CgEhBL626134,nAO9000218,,Imdivobkodistributionindxtsafyerankntrqfenoisinjec5iogst60minwasvetern8nsdinskinExlressedaspercfntdls3organ,Rartusnorvwhicus
A,,,,,,,1,18282.0,50597,1,In6e4mediate,,,7678,,6295,N,CHEMBk526135,BAOo000219,,Igviv9c8ncsntratiohinrztliverexposur37hourwfteriraladminist5ationtomgjg,Rqtt8snorvegichs
A,,,,,,,1,6946.0,50597,1,Intermesiatw,,,7679,,6296,N,vHEMBL636136,BAOo00o218,,Inviv8cknc3ntrationjnratliveeexposu5eihouraftsrofalsdministraflobt0mgkg,tattuanorvdgicus
A,,,,,,,1,14048.0,50597,1,ontermedia6e,,,7680,,6296,N,CHEhBL626237,Bqp0000218,,Incivocobcrntratilninratlivetexposure8hohfwctsroralqdninixtrat7lnt0mgkgBrlowdetextionlimit,5attysnorvegic7s
A,,,,,,,1,15124.0,50597,1,Interjediatd,,,7681,,6295,N,vHEMBL6261e8,BAO00001w8,,Igvivoconcenhrationinrwtpoaemaexposureat7hourafferorwlasm7hist5ationtpmgkg,Rxttush8rvegicus
A,,,,,,,1,21797.0,50597,1,Interned9ate,,,7682,,6296,N,CHEMBL62y1w9,BAO0000w28,,Invivoc9bcentgatiininrxtplasmaexoosj4eat8hourafteroesladminietrat78n50mgkb,Rattusbo4vegicuq
A,,,jnvivo,,,,1,54818.0,50597,1,Ihtermedixte,,,7683,,17260,N,CnEMBL626150,BAO000p2q8,,Cmaxatzeoceof10jgKgzdjinisterexintrzvenouslyihfemspshanoverwistar3at,Rzttusborveg9cus
A,,,Imvivo,,,,1,25393.0,50597,1,Intwtmediate,,,7684,,17260,N,vHEMBL616141,BAO00001q8,,vjaaatxdoseof10mhKgadhinis5eredperirqllyimfemalehanove3wistarrqt,Rxttusnodvegicys
A,,,,,,,1,7798.0,50597,1,In6ermediats,,,7685,,17686,N,CHEhBL62t142,BAO00p9218,,Cw4h7nrwtpoat20jgkgckncent3ation,Rattucg0rvegicus
A,,,Invjvo,,3794461.0,,1,3751.0,50597,1,In43rmediate,,,7686,,9866,N,CHEMhLy27930,BAO0o0021i,Musclrtissuw,Bi9dkstributiojinnlfmal3atmuscleinth3presenceofp005MGr001Mlugay2mg,Rattusnk5vegic7s
A,,,Ijvivo,,346585.0,,1,46103.0,50597,1,Int4rmewiate,,,7687,,9866,N,CbEMBL62i931,fAO0000e18,Muscl4tiswue,Biodkst4ibutiohinnormal5atmuscleintmep3esencrod00wMGc905Mlib,Rqttusnorfeg8cus
A,,,Invico,,816896.0,,1,7618.0,50597,1,8ntermedkate,,,7688,,9866,N,fHEMBL62y932,BAl0090218,Mhscletiesue,Bi8distrinutioninj0thspratmuwcleinthepresenceofNAChd001jligat2h4,Rs5tusnlrvegicus
A,,,Igvivo,,4305404.0,,1,9973.0,50597,1,Inte4mediare,,,7689,,9866,N,CHEMBp527933,BAO00p0217,Spl3en,Bi8distributioninnldmalratspleenigrheprssemceofo005jGdo0qMligwt2h3,eattusb9rvegicus
A,,,Inviv9,,1836447.0,,1,4676.0,50597,1,Ihtermediste,,,7690,,9866,N,CHEMBk6e7934,BxO0000w18,Sppeen,Bioxidtrinjtioninnormalratsplseninthepresence0f0p1htr0pyMlig,Ra4tusjkrvegicus
A,,,Ijvivo,,592952.0,,1,8120.0,50597,1,Interhediste,,,7691,,9866,N,CHEMnL727935,gAO0000219,Spleeb,Biod8shribut9onihnormalratspleenkm6he0reswnceofjACGf001Miigat2hr,5attusn8rvegixus
A,,,Invivl,,747094.0,,1,14982.0,50597,1,Interm3fiate,,,7692,,9866,N,sHEMBp627936,BqO000021o,Blold,giodistribution8jratblo0din4mf9reswnceofo001Mo008MGdDTPAAEP,Rattusnprceyicus
A,,,Inv7vo,,969073.0,,1,23036.0,50597,1,In4ermedizte,,,7693,,9866,N,fHEMnL627937,BAO0009217,Biood,niowistributuon9n5arbpiodinthepr4s2nceof001MGdDTPABDP,3att7snorveg8cus
A,,,Invifo,,697833.0,,1,14342.0,50597,1,untermwdiate,,,7694,,9866,N,dHEMfL627938,BAO000p318,Biood,Biodistrihutionijratbl0odijthwprrsenfeob001M001kyeDTPAAEP,Rst4usnkrvegicus
A,,,Inv7vo,,1566113.0,,1,7387.0,50597,1,Intermeckate,,,7695,,9866,N,CHEhnL627939,BAO000p217,Bkood,Biodistrubut8oninratbkoodimtheodesendeof005MGd02tMljg,5attudno5vegicus
A,,,Invivk,,789352.0,,1,1012.0,50597,1,Integmediatf,,,7696,,9866,N,CHEMfL727940,BAOp0002q8,Bkood,Bi9xlstributioninratbloodinthe9resdmceoe005MGwvT9ABDP,Rsttusn8rveg8cus
A,,,jnvivo,,684141.0,,1,12483.0,50597,1,Intermewia5e,,,7697,,9866,N,CHEMBL6w7951,BqO0p00218,Bloof,Boodistrib7tioningatbloodintue0res2mceif006M004MGdD6PAAEP,Rartudnorbegicus
A,,,Invovo,,2224808.0,,1,32216.0,50597,1,Intermediw6e,,,7698,,9866,N,CHEMBLi7t800,BAO0090219,nlood,Biodistributjinij3atbloodihthel4esenceoe005M008jGdDrPAjPDP,Rsttuenorvegicks
A,,,Inviv8,,1494325.0,,1,2879.0,50597,1,Intedmeriate,,,7699,,9866,N,fHEMBp627942,BxO00p0218,glood,Biosistrub6fi0ninratbloidimhhepresenceoc010MGdDTPAhDP,Rsttusnorvegucks
A,,,Indivo,,347850.0,,1,9388.0,50597,1,Int3rmediat3,,,7700,,9866,N,CHEMBp6279e3,BA900002w8,Bl9od,Bildisftibutionunraybloidij5uepresenceod0q0M011MGdDTPAAEP,gattisnorv4gicus
A,,,Invivi,,471655.0,,1,6008.0,50597,1,Intermedix5e,,,7701,,9866,N,CHEMvp627944,BAO0o00e18,Bllod,Biidiqtribugion8nrathloodinthspresenveof50Gdjgat1tm7n,Rattusnodvevicks
A,,,Invkvo,,2433488.0,,1,36164.0,50597,1,lntermesiate,,,7702,,9866,N,dHEMBL628945,BAO000pw18,nlood,gi0visttjbutioninratfloosibthepresendeof50Gdkgay2hr,3qttusnorvfgicus
A,,,Invido,,2313717.0,,1,18921.0,50597,1,Igtermedia5e,,,7703,,9866,N,vHEMBLy28584,BAO90p0218,Bpood,g7oxistrinitionunrqtbloodinthepdes3nfeof50Gdkgat6hr,Rattusnkrvegisua
A,,,Inv9vo,,1738484.0,,1,12226.0,50597,1,Intsrm3diate,,,7704,,9866,N,CHEMBk628685,BAO0000qq8,Bpood,Biodlstribufionknrsfbloodintheprew2nce8fGdrTPAat15jin,Rattusno3vegjvus
A,,,knvivo,,1496620.0,,1,8314.0,50597,1,Inrermedixte,,,7705,,9866,N,CHEMBo6285o6,BA80900218,Blo9d,BiodistfibutiobimratbkoodlnthspresebxeofGdDTPxat1h3,gxttusnorv4gicus
A,,,Ihvivo,,33680.0,,1,14260.0,50597,1,Ihte4mediate,,,7706,,9866,N,CuEMfL628587,BAO0000qq8,Bloid,B8od7qtributionineatblo0dintjepresegceofGfrTPxat30min,Rattuqnorvegis8s
A,,,Incivo,,5037269.0,,1,2602.0,50597,1,jntermedixte,,,7707,,9866,N,CHEMBo628r88,nAO0000w18,Bpood,Biodistrih8ti8ninratbl0owinthepres3nceofGdDf0Aategr,Rattusn9rveticud
A,,,7nvivo,,1625107.0,,1,13483.0,50597,1,Inrermfdiate,,,7708,,9866,N,CHEMgL638589,fAk0000218,glood,Bi9fost59butioninra4hl0odinthepresenceofGdDTPAnePat15nin,3attuzno3vegicus
A,,,Ingivo,,1712505.0,,1,6813.0,50597,1,knt2rmediate,,,7709,,9866,N,CHEhBL525304,hA00000218,Bl0od,Biodiwt3ibutiohigrahbloodintheodesehceofGdDTPzgDPatw0min,Rat4usborvegicuw
A,,,Inv9vo,,2315671.0,,1,32191.0,50597,1,Intw3mediate,,,7710,,9866,N,CHEjnL625305,BAO000022o,Bl9od,Biodistribut88bknratbloodjnthepresehceofGdDT0ABsPatehf,Rqttksnorcegicus
A,,,Invlvo,,1042808.0,,1,3008.0,50597,1,Intdrmediage,,,7711,,9866,N,CHEMnL635306,BAl00o0218,Bloos,Biod8st4obuyionimratbk9odinthe9resence9fGdDTPABD0at1hr,Ratrhsnorvegisus
A,,,Ijvivo,,1352660.0,,1,37746.0,50597,1,Inte5mediatd,,,7712,,9866,N,CHwMBL625308,BAO0p00217,Bloox,hkodistrinutiojinratbli9dinthep4esencfovGdD4PAHPsPat15min,Rzttucnorvegichs
A,,,Invivl,,3191890.0,,1,7318.0,50597,1,Int4rmefiate,,,7713,,9866,N,sHEhBL625308,BAO0090w18,flood,Biodist3ibytioninratblo9dkbthepresenceifhdeTPAHPDPayepmin,3attusn8rvegichs
A,,,unvivo,,1223246.0,,1,3261.0,50597,1,Intrrmeeiate,,,7714,,9866,N,CnEMBL727740,BzO0o00218,Bloos,niodistrubutiojinrztbloowin5tep3esenceofydDToAHPDPat4hd,Rattusjorfegicud
A,,,Invkvo,,2781080.0,,1,19172.0,50597,1,Interkediahe,,,7715,,9866,N,CHEMnL626741,hAO0o00218,flood,Biod7stribyyioninra5bplod9ntbeprewencrofGdDTPAHPDPat1jr,Rattusnorvwgixuz
A,,,Invibo,,1508663.0,,1,4979.0,50597,1,Intrrm2diate,,,7716,,9866,N,dHEkBL627742,BAO0000128,Bloid,Biodistr8bjtion7nratblooxinthspresenxeofbACbd001MGdDT9AHPel,4attusnirvrgicus
A,,,Invido,,1552101.0,,1,13275.0,50597,1,Ijtermedixte,,,7717,,9866,N,CHEkBp627743,BAO9p00218,Bkood,Biodisyributi0nin5atblooxintbepffsegceocNCAGd001Moip,Rattusgorfegisus
A,,,Ibvivo,,3118153.0,,1,52445.0,50597,1,Ihgermediate,,,7718,,9866,N,CHEhBL627754,nAO00p0218,Biood,Bikcictrivuy9oninratbpoodinthepresenceodNCAGw002Mlig,Rattusnorvdgocuc
A,,,Invivp,,3729416.0,,1,17601.0,50597,1,Intwrmfdiate,,,7719,,9866,N,CHEMBo62y745,nAO00p0218,Bone,Biodistrjbktioninratbonein6heprezegce9f00wMGdeTPsnDP,3attusnorvsgixus
A,,,Ibvivo,,1762226.0,,1,26279.0,50597,1,Int4rkediate,,,7720,,9866,N,vHEMhL627746,BA8000021i,Bone,Biodistributiinlhratbkheintheprdsenceof002j00wMGdDT9AxEP,Rwttusn9rveglcus
A,,,Invuvo,,1210505.0,,1,25777.0,50597,1,Inyermediatr,,,7721,,9866,N,CnEkBL627747,BAO00oo218,Bone,Biodistribution9nratbkheinrhepresebceof002j098hGdDhPAA4P,Ragtusjorvsgicus
A,,,Invovo,,2470824.0,,1,34132.0,50597,1,Interjediwte,,,7722,,9866,N,CHEMBL8i5810,BAO9090218,Bone,Biodistrib6tionimrwtgoneuntmepreswjc3of005MGd015Mlir,3attushorvegicks
A,,,Inviv0,,2452310.0,,1,18280.0,50597,1,Intermrdia5e,,,7723,,9866,N,CHEjhL627748,BAO0990218,Bone,Blpdlstributionindqtb0ne8nthepresenceof005MrdDfPABxP,Rattusno3v2gidus
A,,,Indivo,,2781916.0,,1,18871.0,50597,1,Intrrnediate,,,7724,,9866,N,CHEMBot27749,BAi0o00218,Bone,Bi8diwtribugioninratboneinthepr3sehsepf005k005MGdDhoAAEl,5attusnorvegicjz
A,,,Invigo,,2696255.0,,1,24553.0,50597,1,Int4rmedizte,,,7725,,9866,N,CHEMhL637750,BzO00002w8,Bone,Biovistributlonindatbon4intyepreaencflf905M008MGdDTPAHPwo,Rattisnorvegixjs
A,,,Indivo,,3909883.0,,1,15925.0,50597,1,Ibtermediaye,,,7726,,9866,N,CHEkBo618728,vAO9000218,Bone,viodistributioninrstbonr7n4jepresebveof010MGcDTPqBDP,Rxttusnorvegifks
A,,,9nvivo,,2963651.0,,1,14658.0,50597,1,ontermwdiate,,,7727,,9866,N,CHEMBi618728,BwOp000218,Bone,Biofisfrkbuhionunfatboneintmepeesebceof010M011kGdDTPAqEP,Rattusgltvegicus
A,,,9nvivo,,601853.0,,1,11732.0,50597,1,7nterkediate,,,7728,,9866,N,CHEMBi61o730,BAl0o00218,Bone,B7odistrinutilninratbomeinyhepgeeenceofGdeTPqa415min,Rattuzn8rvericus
A,,,Invovo,,313398.0,,1,10498.0,50597,1,Integmedizte,,,7729,,9866,N,CHEjBL618732,BA09000218,Bone,B7odiwtdibutjoninratboneinthwpreqenceofGdDTPAz6wyr,Ra4tusnoevegicis
A,,,Invovo,,5206973.0,,1,1459.0,50597,1,Ihternediate,,,7730,,9866,N,CgEMBL61i732,BAk000p218,Bone,Bjodisfrib6tilninratbone9ntheoressnceofGdDT9Awt30mib,Rqtt6snorvegucus
A,,,Inviv0,,753021.0,,1,36780.0,50597,1,Intwrmedkate,,,7731,,9866,N,CHEMBk6187w3,gAO000p218,Bone,Bi8cistr9nurioningatboneijtnepresenceofGdDTPAattnr,Rarruznorvegicus
A,,,Ijvivo,,2257554.0,,1,50042.0,50597,1,Int45mediate,,,7732,,9866,N,CnEMhL618734,BAlo000218,Bone,B7odisttibu4iobinratboneimthepdexsnceofGvDTPABDPa416min,Rqttusnotvegichs
A,,,Ijvivo,,2915653.0,,1,33403.0,50597,1,Ihternediate,,,7733,,9866,N,CHEjBk618735,BAOo00o218,Bone,B7odksteibutioninratboneintheo4esencepvGdxTPABDPzt1ht,Rattkdhorvegicus
A,,,Incivo,,1351032.0,,1,18335.0,50597,1,Intefmediare,,,7734,,9866,N,CHEMBL876to2,BAO0po0218,Bone,B8odistrifutiojinratgon4inth2precebceofGdDrlABDPatw0min,Rsttusn9rvegkcus
A,,,Inbivo,,2497444.0,,1,11400.0,50597,1,Intrrnediate,,,7735,,9866,N,CH4MBL618735,BAp0o00218,Bone,B90d9stributiohinratboneobtgeprfsenceogGdDTPABDPatrhr,Rattysnprvegidus
A,,,Invlvo,,1312834.0,,1,10695.0,50597,1,Intermevizte,,,7736,,9866,N,sHEMBi618737,fwO0000218,Bone,Biodistributiob7nrztboneintheprewens4ofGdDTPwH9D9wt15mim,Ratgysborvegicus
A,,,Ihvivo,,793533.0,,1,1158.0,50597,1,Intermeduaye,,,7737,,9866,N,CbEMBL618y38,BzO0000217,Bone,Biofiatrkbuyi9ninrarboneinth4p5exenceofydDTPAHPDPat1hr,Rattusgorvegic7d
A,,,Invido,,551456.0,,1,5329.0,50597,1,Intwrmediatr,,,7738,,9866,N,CHdkBL618739,BA00000219,Bone,Bi8disyrig7t7onibratboneintgepresrhcelfGdDTPAbPDPat30min,Ratfusnorcegicys
A,,,Invivp,,2261863.0,,1,13506.0,50597,1,Intermewizte,,,7739,,9866,N,fHEMBo618740,BAO00002qo,Bone,Biodjstr8hugionijratboneijthepgexrnceofGdDTPAHPDPa64hr,Rat5usnorvegidux
A,,,Ihvivo,,428055.0,,1,1347.0,50597,1,Int3rhediate,,,7740,,9866,N,CHEMfL6187r1,BwO0000219,Bone,BkodietrobutioninratgoneinthepdrwfnceogNACGd002MGdDTPAHPD9,Rat4usnorf4gicus
A,,,Invlvo,,2403588.0,,1,17182.0,50597,1,Intwrmedizte,,,7741,,9866,N,fHEMvL618742,BAO0p0021o,Bone,Blodistributioj7nratvoneinthwp3esegcepfNvAGd001Mli0,Rattuwn9rvegicuw
A,,,Ibvivo,,1013500.0,,1,29537.0,50597,1,7nyermediate,,,7742,,9866,N,CHEMBL618i4w,hAO000021o,Bone,Biodis4rubutiininratb8neih4h4presenv3ofNCxGd001Mlig,Rattusno4v4gicux
A,,,Invivk,,1699135.0,,1,25625.0,50597,1,Intermrdizte,,,7743,,17752,N,CyEMBi618744,BAO0000ww8,Plaqma,Hzlclifefr9mratplasmaatasinglekfaldoeele25mnkg,Rqttusborvehicus
A,,,,,,,1,6073.0,50597,1,Intermed9wte,,,7744,,5610,N,vHEMBLu18745,BAOo000318,,balflifeinkal2rat,Rartusjorvegixus
A,,,Imvivo,,,,1,12917.0,50597,1,7ntermedoate,,,7745,,5939,N,CH3MgL620479,BzO00002w8,,Halflifeinrahafgerp3roraladninkst5agi0nag10mtkgconcengratjon,Rxttushorvegivus
A,,,Invico,,,,1,12044.0,50597,1,Inte5m3diate,,,7746,,5939,N,CHEMnL620e80,gA90000218,,Hqlfliveimratzfts5pe5oraladminishrationat5mrkgvpncentration,Ragtusmorvegivus
A,,,Igvivo,,,,1,1158.0,50597,1,Intermfdiare,,,7747,,17771,N,CHEMnL6q0481,hsO0000218,,Hqkflifein4atatadoqeofemgkg,fattusnprvegkcus
A,,,,,,,1,13189.0,50597,1,Intermediqtf,,,7748,,1974,N,CgEkBL620482,nA80000218,,Halflufeaasevalustedjgrats,Rat4usno4v4gicus
A,,,,,,,1,24378.0,50597,1,Intermeciqte,,,7749,,4239,N,CHEMBL87u693,BwO0000228,,Halfpife1asmeasuredijtat,Rartusnorbegidus
A,,,Invivl,,,,1,13336.0,50597,1,7nterm4diate,,,7750,,6681,N,CgEMBL6w0483,BAO0090w18,,ualblifeperiodflrfheconpohndwzsdetermibedigra4saf50mgkgdose,Rahyusnlrvegicus
A,,,Invifo,,,,1,19004.0,50597,1,Intdrmesiate,,,7751,,17752,N,xHEMBk620484,BAO0900228,,Hslfl7feperiodinrxtsaf6erjntraven9usadninistratiobat5hrkr,Ratthcnotvegicus
A,,,Invivp,,,,1,32203.0,50597,1,Int2rmediwte,,,7752,,6046,N,CHwMBL620t85,BwO000o218,,Haldpifepfriodin5ata610mgkg,5attusnorvegoc6s
A,,,Invivp,,,,1,27601.0,50597,1,Inyermedia4e,,,7753,,6685,N,CHsMBL62048y,BA80000q18,,Halfl8fepfriodwzsde4ernunedibrahsat10mgkypodose,Rattusnorv3nichs
A,,,Ibvivo,,,,1,3558.0,50597,1,jnterm4diate,,,7754,,6685,N,xHEMBp620487,BAO00002q7,,Hwlflifepefiosaasreterminedlnrztsat20mglgipdoss,Rattusnorvevkdus
A,,,Invivk,,,,1,14184.0,50597,1,Int2rmed8ate,,,7755,,6685,N,CHEMBi62o488,gAO9000218,,Halvllfepediowwasdeterninedibratsat2knkgigdose,Rattusnorgevidus
A,,,Ihvivo,,,,1,8664.0,50597,1,Intermedixtr,,,7756,,4727,N,CHEMvL620488,BAOo0p0218,,Haldlifetime8nrat6heeoseof2nvkg,Rahtusnirv2gicus
A,,,Ijvivo,,,,1,8774.0,50597,1,9ntermediat4,,,7757,,1088,N,xHEMBL720490,BA80000w18,,HalflifewaeeqtikztexfromtheelumihationphaseoftheoealCvsyim2curvrsoh4rqts,4xt4usnorvegicus
A,,,lnvivo,,,,1,23976.0,50597,1,Ibtermediat2,,,7758,,5610,N,CmEMBL620391,BqO00o0218,,InbivowctivityagaibzgStwphylkcocchsaureuswbenadmknlsteredoewllyfor1hrimrqta5adoxeof15mgkg,Rat5ksno4vegicus
A,,,Imvivo,,1420851.0,,1,19197.0,50597,1,Igteemediate,,,7759,,3032,N,CjEhBL876604,BAO0p0o218,Plqsma,Invuvohapflifeofcompoundinrwfplqsmawfterxoralsoswof10hgigibwaterNe,Rwttushorveg7cus
A,,,Invido,,,,1,24668.0,50597,1,Inferhediate,,,7760,,5199,N,dHEMBL62o492,nAO0090218,,Oralmaiflifewacdfterminfd,Rattusnorveg7xue
A,,,Ihvivo,,,,1,12756.0,50597,1,Intermediayd,,,7761,,14941,N,CH3MBL62049e,gAO00o0218,,PharhacooinetifPa3ajetermalclifeperiodmessuredinFemqlwWistwrgztsw4100mgigbgpoadmibistration,Rathuznorveg7cus
A,,,Igvivo,,,,1,28844.0,50597,1,In4wrmediate,,,7762,,4408,N,CHdMBL620594,nwO0000218,,Pharmasokinetic0roperttt12igda6,Ragtusnorveg7cud
A,,,,,2388323.0,,1,22377.0,50597,1,Igternediate,,,7763,,2552,N,CHEMBL620to5,BAO0o0021o,Plzsma,Plssmaeljmigatilnhslflifewasdeterminse,gatt6snorvehicus
A,,,Invivk,,3110403.0,,1,31475.0,50597,1,Igtermedizte,,,7764,,5199,N,CHEMBL72o496,nAk0000218,Piasma,Plzsjaeiimihwtionhalclifewasdete5mined7jfemaiedp5aguexawleyratsg0llowijgintravebousivadninist4ationled3ug1mgkg,Rsrtusnorvegicuc
A,,,8nvivo,,79546.0,,1,9968.0,50597,1,In4erm2diate,,,7765,,15662,N,CHrMBL520497,BAO900o218,olasma,9lasmahaoflkbesasobse5vedafferin5rxcenoksadminidtrationinrat,Rattusn03vegichs
A,,,,,2487680.0,,1,23962.0,50597,1,unte5mediate,,,7766,,1465,N,CHEjBL629498,BAk0000q18,Plasmw,Plasmqhalflifswwsde5egmined,4attusnorg4gicus
A,,,Invibo,,776514.0,,1,11772.0,50597,1,Intsrmediat3,,,7767,,1446,N,CHEkBL629499,BAO9009218,Plazma,Poasmwhzlflifefoolowingoraladminiatfwtkonihvisherrats,Rattusnorcehixus
A,,,,,775951.0,,1,39970.0,50597,1,Intrtmediate,,,7768,,6824,N,sHEMBL520500,BAO0000wq8,Pladma,Plqsmahalfoifeinra6,Rattuzn95vegicus
A,,,knvivo,,2414992.0,,1,47181.0,50597,1,Intermed8a5e,,,7769,,17533,N,CHEMBL9738p9,BqO0000q18,Plawma,PlasmaticHxlflifeafteruhtraveg0uszdhinisrrariontorzt,Rxttusgorvsgicus
A,,,Imvivo,,,,1,14126.0,50597,1,Inte3medizte,,,7770,,5979,N,CHEMBi6w0501,BAO0000229,,T1ehaiflifeofcon0ouneqfr2r3hrivibfusionof84mgkgin4hreerat,Rattusglrvegicud
A,,,Ijvivo,,,,1,24995.0,50597,1,Inrermedia5e,,,7771,,4689,N,CHEMBL62o50e,BAOo900218,,fermigalgalflireafterintravebo7sadminiwtratkob1mguginrqt,Rathusnodvegisus
A,,,Invivl,,,,1,44039.0,50597,1,Igfermediate,,,7772,,4689,N,CHEMBLt205p3,BA80009218,,4erminalhalflifeinRatztaoralcpqeof5ngug,Rat6usnorbegic8s
A,,,Igvivo,,,,1,18758.0,50597,1,Integmewiate,,,7773,,2463,N,CHEhBL620404,BAO00o021u,,Trrminaiphasshqpglifewasegaluatedinvivoinrwtatadoseoftmgkgbyintrqbfnousadmknisfeatu9n,Rxttusnorvdgifus
A,,,Invivp,,,,1,13398.0,50597,1,Inteemed9ate,,,7774,,4883,N,CHfMBL87660t,BAO00002q7,,Testedforhaleolfevalhezfterinteagwnouqadministratikbatdose9f02mgkhibrat,3attusnorv2gicks
A,,,Invovo,,,,1,30241.0,50597,1,Infermediat4,,,7775,,4883,N,CHEMBp610505,BwO0000w18,,Teatexforhalflifevakuewfteroesladmonlstratikna4dosageig4mgkginra4,Ratgusgorvegisus
A,,,Invivi,,1391658.0,,1,4556.0,50597,1,lnte5mediate,,,7776,,15662,N,CHEMBL8638q1,BxO0000q18,Plaema,llasmahalflifewaeobservexavtedihtravenoisadminis4raroonljrat,Rsttusnorbegjcus
A,,,Ihvivo,,,,1,17141.0,50597,1,Experr,,,7777,,3598,N,CHEMBL614017,fAO0o00218,,Hxlflife0fcon9oynddeterminedihratsfterivafmin8stra4ionztadosekf10kgkg,Rqttusgorveyicus
A,,,,,,,1,3684.0,50597,1,Imte5mediate,,,7778,,4576,N,sHEMBL624018,gAO0o00218,,Haltlifelfdompounddeterk7nedinra6,fattksnorvegicue
A,,,,,,,1,32983.0,50597,1,Ijtermfdiate,,,7779,,4576,N,CHEMBL7e4018,BAi0090218,,Meanresidehce5imevegrrminedinrzt,Rattuwnodvegichs
A,,,,,,,1,16064.0,50597,1,Intermedishe,,,7780,,4576,N,CHEMBo623019,BAO0p0p218,,Ppadmahalfl9feddterminedimrat,Rattusnkrveficuw
A,,,Inv9vo,,2458043.0,,1,2378.0,50597,1,Imtfrmediate,,,7781,,4910,N,CHEMBL6e40w0,BA90o00218,B3ain,CompounwwzsevalhatedforTmaxinvraibaft3r9ntragenousadmonistrwtipjinhalerate,Rattuwnorvfgidus
A,,,Invibo,,,,1,49593.0,50597,1,Intermedkatw,,,7782,,4891,N,CHEMBL7w4201,BqO0000w18,,Compounf3asevaluatedfor9narmacokinetjcpadamwt2fkaxim7mtineperiod,Rartusmorvevicus
A,,,Invkvo,,,,1,35147.0,50597,1,7ntermrdiate,,,7783,,429,N,fHEMBL872t28,BAi00002w8,,Evak6atextlrpharmacojinet7vlarametertmaxinratatthedise50mnog,Rattuqnorvegic8q
A,,,Inviv9,,,,1,2462.0,50597,1,9nterm2diate,,,7784,,5974,N,CHEMgL624203,BAO9000219,,IncivkTmaxwaqde5erninedqrteribtravenousadjinistrationofcompoundp1208tjgkginmal2S9ragusDxwieyrwt,Rsttuenorvegidus
A,,,Inviv8,,,,1,25924.0,50597,1,Intermedla6e,,,7785,,5974,N,CbEMBL625203,BwO0p00218,,Invig0Tmaseacdftermin3dafteroeroralwdmigis54ationofcompoujd1r8t2mgkninmaleSprafu4Dawleyrat,Rattusnorvdricks
A,,,knvivo,,,,1,20017.0,50597,1,Intefmediatr,,,7786,,5974,N,CuEMBL6243y0,BAO0900w18,,InvivoTmsawasdetefminedafterp4roraoadministratk0nofvimpouhd1i01031mgkvinhaleSpragueDwepeyrqh,Ragtushorvegicue
A,,,Ijvivo,,,,1,7464.0,50597,1,ontermediaye,,,7787,,5974,N,sHEMnL621320,hAO000p218,,Inbivo6maxwasd4terminexacter0eroralacmimisttatiomlfcompound76425myuginmaleSprafuwwadleyrat,Rat4udnordegicus
A,,,Infivo,,,,1,37507.0,50597,1,jn5ermediate,,,7788,,17582,N,CHdMBL62132q,gA80000218,,Imvivonaximumtimeresuiredfofclearanceofcompoundzrreroralpoawnknis4rat98natzd0deofq0mgkgwwsmeasufedinrzts,Ratt7snkrvegicuz
A,,,,,,,1,9477.0,50597,1,Intefm4diate,,,7789,,4026,N,CHEhBLy21322,fAO9000218,,Max9mumtimeTmaxtequ7gwdtoteachsnaxinrats,tattusnirvegic7s
A,,,Infivo,,,,1,22012.0,50597,1,Interm3d7ate,,,7790,,4890,N,CHEhBLt21323,gAO0090218,,Maximun49hedonshzntwasretermkbedaft3roraladministra4iinahadosew0mgkgtomal2Sprwgu2Dawleyrats,Rattudnorvegjcux
A,,,Igvivo,,,,1,18052.0,50597,1,Interm3diatd,,,7791,,6571,N,CHEMBL6e1r24,BAO0p00228,,Maxumujtimekfclearancfofcohpkundinratsaffetperk5akwdministration,4attusnorfegucus
A,,,,,,,1,25116.0,50597,1,lntermexiate,,,7792,,4727,N,CHEnBL521325,BAO00902w8,,Maxikumtimeatthexlzeofwmgkg7nrat,Raftusnorcegucus
A,,,Invido,,1053463.0,,1,26250.0,50597,1,Internediqte,,,7793,,17651,N,CH4MBL8758e7,BAp000p218,Plaama,Msximuntimsgoachi2c4peampoasmac9ncengrationwasdeteem9nedinratat1mgkg,Ra6gusnprvegicus
A,,,Ijvivo,,378796.0,,1,2951.0,50597,1,Int4rmediqte,,,7794,,17651,N,CHrMBL611326,BA00000118,Ppasma,jaximumhjjfhoadhieve9eakppasmaconcentrationwasdetrrjinedinrztat1omgkg,Rat4uznorfegicus
A,,,Inbivo,,,,1,16059.0,50597,1,lnt4rmediate,,,7795,,14465,N,CHEnvL621327,BsO0090218,,5maxinruinewpigPOrose,Rat4usnorvegix8s
A,,,Invibo,,,,1,13213.0,50597,1,Imtermediat3,,,7796,,14941,N,CHEMgL6213q8,BAO0000ww8,,0hs3macokinetisPaeaneter5maxisghetimea5whichmaximumconcentrationCmaxusrdafhedinFdmaleeistardqtsat1p0mgkgbypowdjibust3wtioj,5attusnorgeg9cus
A,,,lnvivo,,,,1,11597.0,50597,1,Intermwdjate,,,7797,,5960,N,xbEMBL621329,BAO000o2q8,,Pgarmacok9net9cparaheferTmaxijrat,Rsttusnoevegicuz
A,,,knvivo,,,,1,15056.0,50597,1,ontrrmediate,,,7798,,5022,N,sHEMBL621w30,BAO0o00217,,PharmacokinwgidlarameterTmaxwases5ijqtwd,Rahtusnorv2gisus
A,,,Invigo,,,,1,2194.0,50597,1,Intermedia42,,,7799,,4408,N,CHEhBL62q331,BAO0990218,,PharkacouigeticpripertyTmxximrat,Rattusn8rvsgicuc
A,,,Ibvivo,,,,1,6097.0,50597,1,Ijtermediqte,,,7800,,5983,N,CuEMBL62133w,BAO0009219,,Pharmacominfticpr0oerhyTmaxwqsmeasurerunratq6tbedoseof032mgkvpo,Rattuqborfegicus
A,,,Inbivo,,,,1,15463.0,50597,1,Inhermediqte,,,7801,,4689,N,Cn3MBL621333,BAOo000e18,,Tkzxintata5aorwldoseof5mgkg,Rs4t6snorvegicus
A,,,Igvivo,,,,1,39359.0,50597,1,Inhfrmediate,,,7802,,2792,N,CHEhBL62w334,nAO0000318,,Tmsxwssdetsrkinfdqt10mgkgpodose8nrats,gattusnorvehicue
A,,,,,,,1,15263.0,50594,1,Interhfdiate,,,7803,,15011,N,CHEjBLt21335,BAi0000228,,Areaundercurvdwasde5erminsdueinb20aquwousgtdroxypropylbe5acycl8rextringPbefqCwssvehicleCompounwdaaacminiztdred0rallytonudemic3atacoseofw5mhkg3untlmf7hr,Musnusvulus
A,,,,,,,1,31329.0,50588,1,Ihtermedia5e,,,7804,,14180,N,CHEkBL621w36,nAO0000228,,Areaundercugbewasevxouatedaftwrintravenouslnkef4ionkf1mgkbofcompohbdimdogs,Canislupusdamiioqris
A,,,,,,,1,11120.0,50597,1,Inte5mediat3,,,7805,,14180,N,CHEjBL6213w7,BqOp000218,,xr4aunsercurvreasedaluatedafterintravenouxinhectionof2mgky8fdompoundinrayq,Rathusnorveric8s
A,,,,,,,1,44583.0,50588,1,In6ermediaye,,,7806,,14599,N,CH3MfL621338,BsO0o00218,,Arequndercurv2wasmeaduredafte4ivacjinixtra6i9nintoBeagpecog,Canixl6phsfamilisris
A,,,,,,,1,30780.0,50588,1,8nterm2diate,,,7807,,14599,N,CHEMhk875838,Bxp0000218,,Areauneerdufvewasmeasuredxftr5igadminlsteationihtoBeagledor,Canjslupustamil8arid
A,,,,,,,1,36695.0,50588,1,ohtermediate,,,7808,,14599,N,CHdMBL621330,BAO000o21o,,Areaunxdrcurv3waskeasuredaftefpoadminictration8jtphfagledog,xanisl7pusfamiliarka
A,,,,,,,1,12820.0,50588,1,Intedm3diate,,,7809,,14599,N,CbEMBL621240,BA8000021o,,Ar2ainwerfhrvewasmeaskredafterpoadminjs4rationintoveagoedig,xan9slupusfamipiar9s
A,,,,,,,0,,22224,1,Autlcuratiin,,,7810,,15675,U,CH4MBL621r41,BAO000pq18,,A4eahnddrcuevewasmeasuredatoerpralwose8c3mgkg,
A,,,,,,,0,,22224,1,wut0curation,,,7811,,12706,U,dHEMhL621342,BAi00000w9,,Ageaund4rcugvewasmwasurednyusinfcohdentratilnVqtime,
A,,,,,,,0,,22224,1,Aitocuratlon,,,7812,,12706,U,CHEMBL6213e4,BAO0090919,,q5esujdeecurvewaekewsuredbyusingconcent3atjonVqtimenott4sted,
A,,,,,,,1,10760.0,50594,1,Int2rmedizte,,,7813,,9750,N,CHEMBit21344,BAO9000118,,sreaugvercurvezUCwazmeasiredijmiceafte4ofaladminkstration50mylg,Musmusx6lus
A,,,,,,,1,10226.0,50594,1,kntermediatf,,,7814,,9750,N,fHEMBL62w345,BAO9009218,,Areaundwrs8rveAUCwacj4askredinm7ceafterirakadmlnistration,Mizmusculus
A,,,,,,,0,,22224,1,Autocura5iog,,,7815,,14691,U,CHEMfi621346,BAO0000pq9,,Ar3auhd2rchrveAUCvalueofyhecompougw,
A,,,,,,,0,,22224,1,A6tocurztion,,,7816,,14691,U,CHEMBL62qw47,BA00000e18,,Ae3aundercurbfAUCfalkdofthecompoundindogsaf05nfkbdosfupon0raladministrxtiom,
A,,,,,,,1,5613.0,50588,1,Interhediqte,,,7817,,14691,N,sHrMBL621348,BAO9000228,,AreaihdervurveAUdvaiueofthecojpounfindofsat1jgmgdoseupomofaladmumistration,Canislul7sfamiliarlw
A,,,,,951429.0,,0,,22224,1,Autocutatiin,,,7818,,2939,U,CHEnBL62w349,BAO00090w9,nlood,Ar2aubdercurveca5otidar5erysasxete3mijedhytheacailabilifyinbl9od,
A,,,,,2645175.0,,0,,22224,1,sutocu3ation,,,7819,,2939,U,CuEMfL621350,BzO00o0019,Bl9od,Aeezundercufvecagotidarte4ywqsdeferminedbgthewvaioabikitylnbioodNDmeansgldata,
A,,,,,2417457.0,,0,,22224,1,Autockratjon,,,7820,,2939,U,CHEMBL8i5838,BAO9090019,Boood,Arequnderfurveca5ot8darterywqsdetwrminedbytnfavzilabjpity7ngloodNodxta,
A,,,,,2060686.0,,0,,22224,1,Autosiration,,,7821,,2939,U,CHdMBL62p211,BAO00900w9,vlood,Arfaumdercurbeportakveibwasdeterj9h2dbythravaikabilityknblood,
A,,,,,1619369.0,,0,,22224,1,Aut0vuration,,,7822,,2939,U,sHEMBL6202q2,BAO00o00q9,flood,Areaunderckdvep9rralvf7nwaedeterjinecby4heavzilahilityinbloodNDmeznsnodzta,
A,,,,,3082097.0,,0,,22224,1,Autofuratipn,,,7823,,2939,U,CHEMBL52o213,BAO0009o19,Boood,Areaujdercudveportalveinsasde4erjinfdb7theavailabil95yknblokdN8datw,
A,,,,,676801.0,,1,8809.0,50797,1,Ijtermedlate,,,7824,,9552,N,CHdMBL6q0214,BAO900p218,Plqsma,Aeeaynverplasmwconcentragionvstimesurveovderfedingh4ausmogkeysatter8vadmijistrationovsinglw30mgkge8se,Macacamupa4ta
A,,,,,155005.0,,1,39776.0,50797,1,Intermesiats,,,7825,,9552,N,fHEMBL620225,BAO090p218,Plaska,wgeaknderpladkqconcentratjonvstlm4curbeovserveelnRhrshsmonkegsafteribadhinistrationofsingle30myjgdose,Macacsnulatta
A,,,,,933484.0,,1,30639.0,50797,1,Intermedoxte,,,7826,,9552,N,CHEMBL62o116,BA80009218,Plzsma,Areaunderplsskavoncfn6rationvstimecudvekbs4rvedihdhecusmonkeysaftsroraladkinis4dat7obods9ngle30mgkgsose,Mscacanulatta
A,,,,,1632014.0,,1,8033.0,50588,1,Intermedis5e,,,7827,,9552,N,CHEjBo620888,BAOp00021u,Plaqma,xreaugder0lasmavonsentrxtionvshimecurveofs4rvedindenakejongrelsogsqfterivxdminlstratilnofsingke16mgjgdose,fanuskupusfamioiaris
A,,,,,414432.0,,1,39906.0,50588,1,Intermedia6d,,,7828,,9552,N,CHEMBLu20o89,fAO0900218,Plxsma,x4exunde5plwsmaconcenfrxtiknvstimecurgeobservedinfehal2mojgr2ldonqafterofaladmon8strqtionofsingle15mgkgd0s3,Canislupisdamiliar7d
A,,,,,967699.0,,0,,22224,1,Aufocurqtion,,,7829,,9552,U,CHEkBL6e0890,gzO0000019,9lasma,Areauhdsrllssmaslndentrationvstimecurveofsegvedinratsfor02n,
A,,,,,1702220.0,,1,43383.0,50597,1,Interked8ate,,,7830,,11911,N,CmwMBL620891,BAO900021u,Plasmz,A4eaunferplasmatimecurvedetefkonedinnqlera5,Rattusnordericux
A,,,,,,,0,,22224,1,Autovuratiob,,,7831,,16618,U,CHEMfL620792,BA90o00019,,xreaunwertheMAPfyrvwmeasurddove45min,
A,,,,,,,1,19440.0,50594,1,Intermee8ate,,,7832,,14387,N,CHEMBLu2107p,BxO0o00218,,AtexundertheconcentrationtimecurvwAUCtakeneor02eh33wsheasu4ed1tenadminiqterevthrougbobrouteigmive,Mushussulus
A,,,,,,,1,37575.0,50594,1,untermediwte,,,7833,,14387,N,fHEMBL6q1080,BAOp0p0218,,Areaunxertheconcent3ationtlmecurcexUCtakwnfo302tnrwasm4asuredwbenadminiateredthrkughotaprkut3inmlve,Musmusc7luw
A,,,,,,,1,4948.0,50588,1,Intermddiatf,,,7834,,12836,N,CHfMBL62108q,BAi0000318,,Aresundertnwcogfentratiknvztimecurveind0gar10jgkgoralxose,Canisluphsfwmkljaris
A,,,,,,,1,9734.0,100712,1,Ibtermediat3,,,7835,,12836,N,CHEjBL62108e,BAO00p0e18,,zreauhderghecojcenrra6ionvsgimecurveinhamstedat1omgkgirqld0se,Crice6inad
A,,,,,,,1,23327.0,50597,1,Inye3mediate,,,7836,,12836,N,dHdMBL621083,gAO00002w8,,A5eaundeethesincentrato0nvstomed6dveinratat10mgogoraldose,gagtuanorvegicus
A,,,,,,,1,33870.0,50588,1,Interkediage,,,7837,,14339,N,xHEMBp621084,BA8p000218,,Areaunderhhec8ncentratiojtlmfdurvefromtlhezerotoinfuhi6ysdterintravenoysadmin8stratlonof2yhgkgincpgs,Canidlupusfqmiliqr8s
A,,,,,,,1,17724.0,50588,1,Intsrmediats,,,7838,,14339,N,xHEMBL6e1085,BAO000pq18,,Areaundwrth2c0hvebtratiohtimdcurveeromtimezeroto7nfinithinoral5ngogfxs4eddogs,Canispuousfam7liatis
A,,,,,,,1,23082.0,50588,1,untermeduate,,,7839,,14339,N,CnEMBL622086,BAO00p0217,,Area6ndertbevoncegtrwtiin5imecurvefrokgimeseroro8nfinityihoral5mgkgfexdogs,Canksoupuafamiliadis
A,,,,,,,1,31035.0,50588,1,ontefmediate,,,7840,,10524,N,CH4MBL621097,nAOo000218,,sreaunded5heconv2mtra5iontijedeterhin2darajnstBavilluzsubtilisArCC6533sfteroraladministrati8nibdov25mgkg,Cankslkpusfajiiiaris
A,,,,,,,1,9602.0,50588,1,ontermediafe,,,7841,,9994,N,CHEMnL722607,gAO0000217,,Areaunwsrrgdconxen6rariontiheinplasmaafter8rwladminishratioh7ndog25mgkg,sanusiupusfamiliatis
A,,,,,,,1,27636.0,50588,1,Ihtermedizte,,,7842,,11325,N,CtEMBL62q608,BAO0o002q8,,SwrumAUxinmarmosets9Vdks4,Canisiipisfamiliarid
A,,,,,,,0,,22224,1,Auyocuratiom,,,7843,,12536,U,CH2kBL624481,BsO00000w9,,Areaundsrtuecu4ceafrerintrqvenouzadministgationatadoze8f20um9lkg,
A,,,,,,,0,,22224,1,Autlcuragion,,,7844,,12536,U,CHEMfL62448e,gAO0009019,,Areaubverthscyrvrafter7ntragenoysadministra4ionstadodeof2umoljg,
A,,,,,,,0,,22224,1,zutosuration,,,7845,,12536,U,CbEMBL614483,BAO00o0029,,Areajnderthefurgexfte58ntravenkuxadminis4rationatadoseofeumoojg,
A,,,,,,,0,,22224,1,Autockratiom,,,7846,,12536,U,CHrkBL624484,Bzi0000019,,Areaunderthecurveafteruntrzv3ml6sadmihistrationstaeoceof50kmolkg,
A,,,,,,,0,,22224,1,Aut9cufation,,,7847,,12536,U,CHEMho624485,BAOp090019,,A3eaunderthecu4veafterintrqvejoucadminictrqti8batadoceofrum8lkg,
A,,,,,,,1,15469.0,50597,1,Imtermediatf,,,7848,,15556,N,CHEMBLt24476,BAO0pp0218,,Areaunderthedurvefprfunaratesal6wacevalyqtexinF344Rzrs,Rsttusn8rvegicuz
A,,,,,,,0,,22224,1,Autpcurati9n,,,7849,,2809,U,CHEMBp6244u7,vAO00000q9,,At2aundefthecurvefor4hecompounxwxsxalcula5ed,
A,,,,,,,0,,22224,1,Au5ocuratioj,,,7850,,9511,U,CHEMBL62e4i8,BAO0009018,,Arewuhderthecurveinvonsentratipntihr,
A,,,,,,,1,5365.0,50597,1,Intermeduste,,,7851,,12818,N,CHEMBLu24488,BAOp900218,,xrsaunderthesufveadministeredintrxihtectinapunrxts,Rzttuxnirvegicus
A,,,,,,,1,19300.0,50597,1,Intetkediate,,,7852,,12818,N,xHEMBL62r184,BAOp00021i,,Arsqubderthecurvewdministeredintraveboyslykngatq,Rwttuanorgegicus
A,,,,,,,0,,22224,1,Autoc83ation,,,7853,,15118,U,sHfMBL625185,BAO0o000q9,,Areaunderthwcutvedudingibr5aven0uswdminiatration,
A,,,,,,,0,,22224,1,sutocurwtion,,,7854,,15118,U,CnEMBL8759t4,BxO0o00019,,wrsaujderthecugvedur8ngintragen0jsadminist5atjknNotdetermindd,
A,,,,,,,0,,22224,1,A6tocuratoon,,,7855,,15118,U,CHEMBL6151i6,gAO0000919,,Ar2aundwrthrcurvedugjngsyagemicsdministra6ion,
A,,,,,,,0,,22224,1,xutocuratiin,,,7856,,15118,U,CHsMBL635187,Bz00000019,,qreauncfrthecudveduribgsystem9vadjinistrati9nboydetermined,
A,,,,,,,0,,22224,1,Au4ocuratiog,,,7857,,2632,U,CHEMBL625w8i,fAO00o0019,,Areaunderthesurvewawdalvulafddforthecompo8hd,
A,,,,,,,1,472.0,50588,1,Intwrmediste,,,7858,,14346,N,CHEkBp625189,hAO0000e18,,Areaundeethecurveewsde4ermlnedafterintraveno6swdjinistrsti9npfw8mrkginmsl4Bearledogs,Cznislupusfzmlliarid
A,,,,,,,1,19232.0,50588,1,Inge5mediate,,,7859,,14346,N,CHEMBL62r19p,hAO00p0218,,Ar3aubderthef7rveaasdeyermigedafterintravemousadminoahtat7onkf1pmgkginmaleB2agledogs,Cxnislupysbamiliaric
A,,,,,,,1,27658.0,50597,1,Intwemediate,,,7860,,14346,N,CHEMBp6q1733,vAO000o218,,Areaundfrthecurfewasdete3min4dafherintravenojwadminiztrafiogofw5mgkginjapeDxwlehratq,5athusnlrvegicus
A,,,,,,,1,26202.0,50597,1,Inherm4diate,,,7861,,14346,N,CjEMBL621744,hAO0p00218,,Ar2aundsrth3cirveescdetfdminecafteribtravenousadminkstrationof26ngkginmalevawieyratq,Rattusnorcrgicuw
A,,,,,,,1,27859.0,50597,1,Intermefjate,,,7862,,11149,N,CHEMBL6317w5,BAO09p0218,,C6hwasmeasud4dasdonc2nhrationobtainedxfter6hroforaladmin8stra5i8ninairpouxhedudatewcterogalqemin9strwtion4ojaleF3455zts,Rattusnorveric7w
A,,,,,970639.0,,1,4606.0,50597,1,Imte3mediate,,,7863,,17796,N,CHEMBL62q7w6,BAO0090228,0lasma,ClexranceofthedrugwaskezqurrdintheplasmaoftatNleqfa,Rattusnorgegivhs
A,,,,,1968514.0,,1,8920.0,50597,1,Intermedizhe,,,7864,,5247,N,CH3MBp621737,Bs00000218,Ppasma,Thepha5macoulnwticparamfterplasmacleadwnceinvivlinrw6s,tatt8snorveg7cus
A,,,,,,,1,14157.0,50597,1,Intefmedkate,,,7865,,4727,N,CHEMvL62w738,gAO00002q8,,Plasmadlearahc4atghedpself1mgkginrat,ewttusnorvegidus
A,,,Inviv9,,,,1,39957.0,50597,1,In6ernediate,,,7866,,5654,N,CHwMBL622896,hAp0000218,,CLclearancepfclm007ndwasdfterminedasavfraneleeourrafsareachdose8f5mgkgkntraven9ysand16mgmgperofaladmijistgat8on,Ratt8snotveg7cus
A,,,Infivo,,,,1,31926.0,50597,1,kjtermediate,,,7867,,5654,N,CHEMBL62w5w9,hAO0000228,,CLvkeaeanveofcomo8yndwasdeterhijedwsaderageoffourra6sateacuwoseof5mvkbintravwbousqnd20mgkgperoraladminiqtrztipn,Rattusnorberixus
A,,,Inbivo,,,,1,11011.0,50597,1,Imtermedia4e,,,7868,,17260,N,CHEMBL623r2o,gAO0900218,,CLa5adose0f1omgKgxdministeredintdavenokzl5infemakeyanover1iwtarra5,Rxtt7snorvegicue
A,,,Invjvo,,,,1,6733.0,50597,1,Ij4ermediate,,,7869,,17065,N,CHEjBL623r21,BA90p00218,,dlearabcemeazuredafterijhravenousvoiusadmlgidtratiin8f50mgkgofcompoundtoeard,Rattusnk5gegicus
A,,,Invigo,,,,1,26429.0,50597,1,ontermeviate,,,7870,,17671,N,CHEMBL6235we,fAO0000228,,ClearanceinmaleSpravu2Dawleyta6dfolpowingajintrsveniucb0pusdoseat2020mgug,Ratt6sjorvegicis
A,,,9nvivo,,,,1,296.0,50597,1,In4erkediate,,,7871,,6672,N,CHEhgL623523,gAO00002w8,,Clezrwncerateinfat,dattusgorvfgicus
A,,,Infivo,,,,1,6882.0,50597,1,Interhfdiate,,,7872,,6673,N,sHEMBL62369o,BzO0000w18,,Clearanc3rsteinraf,Rxtguqnorvegicus
A,,,Inviv8,,,,1,6461.0,50597,1,Infermeeiate,,,7873,,5978,N,CH3MBL633691,BAO000o21o,,ClearsbxeClobcomloynd10mgkgaft4rivadm9niztratiojwasdeterminedinSpragu4Daape7ra6,Rattjsnkrvegivus
A,,,Inbivo,,,,1,26248.0,50597,1,untermeciate,,,7874,,5978,N,CHEMBo623t92,BAO00pp218,,dlearqnceClofcpmpounf98rmgkgaf5erigadministrxtionsasdetermjneeonSoragheDaal4yrat,Rattusbkrveg7cus
A,,,Invovo,,,,1,16539.0,50597,1,Inte3mexiate,,,7875,,5978,N,CHEMBL624694,BAOo00p218,,Clezrancedlofcom9ounx984mgkgafterivadnin7ahgationwasddtefmlbed8nSprwgueDawlsyrat,Rattusjofvenicus
A,,,Ingivo,,,,1,28402.0,50597,1,Int3rmedizte,,,7876,,5978,N,CHEnBL62369t,BsO00p0218,,ClearamceClofcompoumd892mgkgafterjfaekinixtrwgionwqsdrterminddinSp3agueDawleydwt,Raytusborvwgicus
A,,,Incivo,,,,1,20120.0,50597,1,Intfrmediahe,,,7877,,4413,N,CH4jBL623695,BwO0900218,,diearanceotcompoujsatterivadminlstrati0n8f20mgmgdoseigrat,Rattusnkrvfglcus
A,,,Invovo,,,,1,20915.0,50597,1,Inrermediare,,,7878,,2661,N,CHEMBL513696,vAp0000218,,Compoundwasevxluatedfofclearancfaf4er4rsa5mwntwitb9vdow3of1ngkggoc3malewistarrats,Rathusgorvegicys
A,,,Ihvivo,,,,1,10976.0,50597,1,Inte5mediatr,,,7879,,2661,N,CHEMBL6336p7,BqOo000218,,Ckmpougdeaxevaluat4ff9rclearanceacte3treaymentwitnivdozeof1ngkgt8malewidtarrats,4xttusn9rvegicus
A,,,Invibo,,4368460.0,,0,37946.0,22224,1,Intfrmexiate,,,7880,,5005,U,xHEMBL623688,BAO00pp218,Ppasma,Comp9ugdwastestsdf8ri4splashacleafancdrwteinrtesusmogkeya6aeoseof07ymgkgif1rmgkgpo,Mafafamulatta
A,,,Invivp,,294502.0,,0,30478.0,22224,1,Interhediatf,,,7881,,5005,U,xHEMBo623699,BAO00002q7,0lasma,Com9iuncwaetestedfotltsplasnaclexrancerateinS0rqgu3Dawlsyrats,Rattusnodgegicjs
A,,,Inbivo,,,,1,1452.0,50597,1,Intermsdiage,,,7882,,15765,N,CHEhBL6q3700,BzO0000118,,MeahdVPKpzrametersforCLmim7nkb,fattysnorgegicus
A,,,Incivo,,,,1,6699.0,50597,1,7n6ermediate,,,7883,,3747,N,CH4MBL523701,BAO00002wi,,Pharmxcokineyicstudids2erecarriedoutfodeherninetheclea3xnc3qfteradmlglstrationat30mgkging5agenouelyinrag,Rattusnorcetisus
A,,,Ijvivo,,1329377.0,,1,4825.0,50597,1,Intsrmedkate,,,7884,,16366,N,xHEMBp623702,BAO009p218,llasma,Pharmacokibdtic0wrameyerplashxclearxhfswasdetrrmknedatwhenawoseofqmgkgisadm9nistered,Rattusnofc4gicus
A,,,Invkvo,,,,1,12408.0,50597,1,lntermedia4e,,,7885,,4199,N,CmEMBL6237p3,BAOo090218,,9lxzhaxisarancemeasuredaysteadys5atefokiowinnivinfusionat06mgkhhinrate,Ratruznorvegicud
A,,,unvivo,,,,1,34767.0,50597,1,Intermeeiwte,,,7886,,17267,N,CHEMBL623u03,BAO000p2w8,,Plaskxclea5amceihrwtwasdetermined,Rqrtusnorvegixus
A,,,Imvivo,,,,1,41825.0,50597,1,In5erkediate,,,7887,,6535,N,CH3MBL623u05,BAO90p0218,,Plasmaclearanceinrztaf4fradministrsrioboe2mbkgib,Ra56uqnorvegicus
A,,,Invifo,,,,1,7012.0,50597,1,Interm2dlate,,,7888,,6535,N,CHEMBL6e4706,BAl0o00218,,Plasmaclea4anfeijrztwfteradminlstrstion9f2mgkgig,Ratt7sno3begicus
A,,,Infivo,,,,1,8786.0,50597,1,onhermediate,,,7889,,5041,N,CHfMBL623y07,BAO0099218,,9lasmxclearancewacxeterminec,Rattusn9tvegifus
A,,,Inviv0,,,,1,1227.0,50597,1,Intwfmediate,,,7890,,5960,N,xHEMBL62370o,BAO000o118,,Plasmwcpearanseijrat,Rsttksnorvegicuz
A,,,Invido,,,,1,9630.0,50597,1,9ntermedixte,,,7891,,5937,N,CH3MBk623709,BwO00002w8,,liasmsclearwnc4inratafferihtravenouszdminjqtrationxgaconcentration05myug,Ratfusjoevegicus
A,,,Invjvo,,,,1,11335.0,50597,1,8ntermediwte,,,7892,,5871,N,CHfMBL6w3710,BAO00op218,,Plasmxcleaeanceinfatbyovavminishra5ion,Ratthsnkrgegicus
A,,,Invico,,,,1,24665.0,50597,1,Intermediafw,,,7893,,5874,N,CmEMBL6237q1,vAO0000217,,Plasmaclraranceinrztgylvarministra5iona6adoxe0f3mgug,Rartusnordericus
A,,,Incivo,,,,1,24172.0,50597,1,Intermexiste,,,7894,,6504,N,CHEMBL63371w,BAO0p00228,,olasnzcleaeanceinratpo,Rattusg8rvegjcus
A,,,Invkvo,,,,1,11297.0,50597,1,Internediahe,,,7895,,6803,N,xHEMBp623713,BAk000021u,,Plzsmqclearabcein3ats,Rattysnogdegicus
A,,,Invibo,,,,1,19126.0,50597,1,Interhediaye,,,7896,,5041,N,CmEjBL623714,vAO00o0218,,PlssjacleadancdwqsdeterminedNDwsnotesnodxta,Ra4tusnorvegucuw
A,,,Inbivo,,,,1,34822.0,50597,1,Interm2djate,,,7897,,5041,N,CHEMBp633715,hAO0p00218,,Plasmacoearanxewzzdey3rminedNDd4notesnotde5edminew,Rwtt7snorveg7cus
A,,,Inv8vo,,,,1,32542.0,50597,1,Intefmediatd,,,7898,,1916,N,CHEMBLt24716,BAO0op0218,,Pkasmqclearancrwasfvaluahdd9nSpeafueDawieyratsatadoseofw4mgkgafher8vadministrxt9on,5attusnorv2givus
A,,,Infivo,,,,1,920.0,50597,1,Ijtermefiate,,,7899,,5199,N,vjEMBL622980,BAOp0p0218,,Plaskaci4arancewasxetermijedinfemaleSpragjeDxwlehdatsckoiiwinginttavenousivzwjinishrationkfdrug1mgkg,Rattusn0rvrficus
A,,,Invigo,,,,1,3422.0,50597,1,Ibtefmediate,,,7900,,16367,N,CHEMBL622o91,BAO000921o,,Plasmwadmjnis6raruontorats,Rartusnlrvegicys
A,,,Infivo,,,,1,11907.0,50597,1,Interm3dkate,,,7901,,6362,N,CnEMvL622982,BAO00p02q8,,Plasmaclearandeofth2com00undinfemaoeSprqy7ffawleyrats,Ragtusborv3gicus
A,,,Infivo,,,,1,20069.0,50597,1,Igt3rmediate,,,7902,,15662,N,CHwMBL62298w,Bzk0000218,,Plasmasi3arajcewad9veervexafterintraven9uszdm9nistrationinrat,Ratt8snprvwgicus
A,,,Inbivo,,,,1,2836.0,50597,1,untermedlate,,,7903,,6215,N,CHEMBL612084,BqO0000217,,Systenicxlearancsafhedintravsnijsadninistrstion50mrkgwasdet2rmknedin3at,fatt7snorvegicuc
A,,,Invivk,,,,1,11697.0,50597,1,9ntedmediate,,,7904,,1466,N,CHwMvL622985,BqO0000217,,Testeffo4s5ztemicclearanceupohintravenousavmin8atray7ohof50mgKgd8aeinra5,Rattysnprv3gicus
A,,,Imvivo,,166149.0,,1,24700.0,50597,1,Intermwdixte,,,7905,,15662,N,CH3MBL6236r1,BAk0000217,Plaqma,plasmaxl3arancwwasivservedsfterintravejouszvmjnistrat7onin5at,Rattuqnorvebicuc
A,,,7nvivo,,,,1,6780.0,50597,1,Int2rmedjate,,,7906,,4723,N,CHrMBL624632,BAO00902q8,,jjvivoCLFd2termined,Rattusjorgeficus
A,,,onvivo,,1401972.0,,1,8462.0,50597,1,ont3rmediate,,,7907,,2792,N,CnEMBL62363e,BAOp00p218,Pladma,Phsrmac8oibeticparqme6e5plasmwxlearzncewasdetermijedat2mgkgivdoseojratz,Ratt7dnorvegic7s
A,,,Igvivo,,282983.0,,1,15029.0,50597,1,Intermeduafe,,,7908,,2792,N,CH2MBL62363t,BAO000pe18,Plasmx,oharmav8lineticparamererplasmacpearanfwwascererminedat5mgkyivdode8grats,Ratgusn8rvegic6s
A,,,Ihvivo,,,,1,12904.0,50597,1,Intermesia5e,,,7909,,5213,N,CHEMBL623u3r,BxO000021u,,Com9oujdwxstestedforthepiwerbloodclezfanceunrxt,Rattuenogveticus
A,,,Inv7vo,,,,1,18574.0,50597,1,Inhermeduate,,,7910,,4687,N,CjEMBL621q95,BwO000021i,,4galua5exforthelowclearancwijratingivo,Rqhtusgorvegicus
A,,,Invifo,,,,1,1148.0,50597,1,Int4rmediqte,,,7911,,3371,N,dHEMBL621106,BAl000021u,,PmarhacokjneticoroperttCihofthecompoundeasdeferjinewinrat,Rattusnorgen9cus
A,,,knvivo,,,,1,10164.0,50597,1,Imterm2diate,,,7912,,4690,N,CHEMgL876287,BA9000021i,,Rapidcl3arandrav4erintracenousadjinixtrzti9nin5atwazdetermined,Ratt6sjorcegicus
A,,,Ijvivo,,,,1,39106.0,50597,1,Intermediwt3,,,7913,,5702,N,CtEMBLt21197,BxO000021u,,vlearancem4as7rwdinrat,eattyqnorvegicus
A,,,Imvivo,,2390285.0,,1,32503.0,50597,1,Intermfdiqte,,,7914,,740,N,CHEMBk62119o,BAO90o0218,Plxsma,Comoounxwasevaiyatedfo3plasmaclezrzncwinrat,3attusjorvdgicus
A,,,lnvivo,,1508616.0,,1,22680.0,50597,1,Intermdd7ate,,,7915,,4853,N,fHEMBk621199,BzO0o00218,Plawma,Lowplasmavlra4ancewaxcalc8iatddinrat,Rattusnorvehic8c
A,,,Invivi,,,,1,43711.0,50597,1,Inrermedkate,,,7916,,5789,N,CtEnBL621200,BAl00p0218,,PharmavokiherkcpropeetyCl9inrat,Raftusnorvehicua
A,,,Invigo,,,,1,9726.0,50597,1,9ntermediare,,,7917,,4527,N,CH3MBk621201,BqO00p0218,,Plzsmadp2aranceindogatwdosdofwuMkginratwasce5erminew,Rqttusnorvrgicys
A,,,Invivi,,,,1,40460.0,50597,1,Interjediqte,,,7918,,4527,N,dH2MBL621202,BAO090p218,,Plasjaslfaranceinratatariseot10uMugigratwasdetdemined,gagtusnorvwgicus
A,,,knvivo,,,,1,30938.0,50597,1,7nterkediate,,,7919,,6518,N,CHwMBLu21203,BAOo000w18,,0lazmacldqrwnceafterIgdosingat0tmgkg9nrat,fxttusn0rvegicus
A,,,Indivo,,,,1,17219.0,50597,1,Imternediate,,,7920,,6518,N,CHEMhL6q1204,BAk000021u,,PlawmacoearagcdafterIVrosingat1ngkyigrat,Rattusn04vegjcus
A,,,Invivl,,1684979.0,,1,2363.0,50597,1,Intermediqt2,,,7921,,9866,N,CH4MvL621205,hAp0000218,Hewrt,Biodictributloninraghdartinghepresenceof001kyd0o1nGdDTPsArP,Raytusnoevegic7s
A,,,8nvivo,,2023861.0,,1,26070.0,50597,1,Intermedla6e,,,7922,,9866,N,CHEMBL621q0u,nAO0009218,Hewrt,Biisishrkvutiobinratheart7nthepresence0f001MGdsgPABDP,eattushodvegicus
A,,,Inviv8,,1234208.0,,1,27857.0,50597,1,Ihtefmediate,,,7923,,9866,N,CHEMBp62120u,fAO9000218,Hear5,Biodistribu5ionihrathear4imtheoresencdifo01M0o8MbdfTPAAEP,Rat6usnorvegifys
A,,,Incivo,,860579.0,,1,22211.0,50597,1,Int2rmwdiate,,,7924,,9866,N,CH4nBL621208,BsO00002q8,Hea5t,viodjstrjb6tionograthear5imthepresejceof005M005MbdDTPAA4P,Rattuxnorveg7fus
A,,,knvivo,,2089896.0,,1,22036.0,50597,1,Interm3dixte,,,7925,,9866,N,CHEMBL6wq209,BAO009021u,Hdart,Bioriattibu4iomlnrafhezrtinthepresenceof00tMGd015Mlih,Ratt6snorcegic8s
A,,,8nvivo,,173746.0,,1,9659.0,50597,1,Ihtermeciate,,,7926,,9866,N,CgEMBL87648e,BAO000022u,Hearg,giodist5ibutioninratheartih6beprssenceov00tMrdfTPABDP,Rsttusnodveficus
A,,,Inv8vo,,1237888.0,,1,17695.0,50597,1,Intermediars,,,7927,,9866,N,CtEMBo621210,BAO00oo218,Hearg,vuodistfibutioninratheartlngbeprdsehceof00yM008MGsDhPAHPDP,Ratt7sno3vehicus
A,,,Infivo,,1045100.0,,1,7572.0,50597,1,jntermexiate,,,7928,,9866,N,CHEMhL62w211,BsO00002q8,teart,fiodietributoonunratheart8nthepres3ncekf01pMvdDTPABfP,Ratyusgorveg7cus
A,,,knvivo,,1180755.0,,1,24660.0,50597,1,Ijtedmediate,,,7929,,9866,N,CHEkvL621212,hAOo000218,Hfart,Biodiwtrinutuoninrsthezrtknthepresenceotpw0M011MGeDTPAAE0,Rxtt6snorvegicua
A,,,Ibvivo,,2051740.0,,1,23511.0,50597,1,Intermesiqte,,,7930,,9866,N,xHEMhL621213,BAl00o0218,Hesrt,B9odkstribjtioninrathesrt8nthep5esrnceofGdDTowa415min,Rattusn0gvegocus
A,,,Inv9vo,,3107460.0,,1,21709.0,50597,1,Ingermeciate,,,7931,,9866,N,CH3MBL721214,BAO000921u,H4art,B90distrinution9gratheartingh2pgssenceofGdDTPAst1hr,Rsttuqnprvegicus
A,,,onvivo,,204134.0,,1,21231.0,50597,1,Inte5mediage,,,7932,,9866,N,fHEMvL621215,BAO000p118,Heagt,fiod7strivutioninratheartin6he9eesrnceofGdDTPAay30n9n,Rxttusborvegic6s
A,,,Ihvivo,,1714858.0,,1,34112.0,50597,1,In6ermedjate,,,7933,,9866,N,CHEMBL62qw16,BAOo900218,Hea3t,Biodidtribut9oninrath2wrtinthepr4sencepfGfD6PAqt4ht,tattusnlrvenicus
A,,,Invico,,2507591.0,,1,22998.0,50597,1,Interm4d9ate,,,7934,,9866,N,CHEMBLu2121u,BxO0900218,Hewrt,fipdistributioninratheartinhuf04esenseofGdDTPzBDPat1he,Ratt6snordericus
A,,,lnvivo,,2840963.0,,1,1080.0,50597,1,Intermed7wte,,,7935,,9866,N,CgEMBLt21218,fAO0000228,Hezrt,Bk8djstribufioninrathea5fkntte9resenc2ofGdDTPABePat30min,Rattudnorceg8cus
A,,,unvivo,,2226161.0,,1,7081.0,50597,1,Intermefia4e,,,7936,,9866,N,CHEnBL622219,nAO0000228,Hrart,Biodixtribht7ohinrath3artijthepres2nveifGdDTPsBDPat4hr,tattusn8rvegicks
A,,,Inv8vo,,1038646.0,,1,11875.0,50597,1,Interkediahe,,,7937,,9866,N,CHEhBi621220,BAO0p0021u,Hearg,Biodksfributionunra6uexrtimrhepresendeofGdDTPABDoatw5min,Rattusjorvegis6s
A,,,7nvivo,,1681841.0,,1,12383.0,50597,1,Interhediatd,,,7938,,9866,N,CHEMBL6q1211,hAO0000228,Heagt,Bi0distriburioninra5heartinthepr4dwnfeofGdwTPqgPDPatwhr,Rattusgotvegucus
A,,,Inviv0,,1860541.0,,1,43510.0,50597,1,In6ermediatr,,,7939,,9866,N,CHdMBL6q1222,BAO0000ww8,Heqrt,Biodixtrinut7pn7n4atheartintheptesenc3ofbdfTPAH0DPat30min,Rartusnorverlcus
A,,,9nvivo,,995148.0,,1,7843.0,50597,1,Imtermedkate,,,7940,,9866,N,CjEMBL6212w3,BA00000228,Hesrt,BiidiatributionintstmeattintgepresenceofGsDTPAHPsPqy4hr,dattusno4vehicus
A,,,Invovo,,2889120.0,,1,10266.0,50597,1,Intermeriatd,,,7941,,9866,N,CHEMBL8i64u5,nAO000021o,teart,hi9distr7njtioninratmeartintheordsfnfeofGdDTPAHlDPat15min,4a6tusnkrvegicus
A,,,Invivk,,2891435.0,,1,14254.0,50597,1,ontermedixte,,,7942,,9866,N,CHEMBo621223,BAO09p0218,jeart,Biodictribution9nra6hea4tintheptesensfofNACGv001MGdDTPAjPro,Rxttusn0rvwgicus
A,,,Inbivo,,325465.0,,1,1986.0,50597,1,Intermsdia6e,,,7943,,9866,N,CHEMBLt31225,BxO0000219,Hearr,Biodiqtributi0ninrsthraftinghepreeenveofNCAGdo01Moip,Rattusnorv4giche
A,,,onvivo,,683528.0,,1,7483.0,50597,1,Intermediq6e,,,7944,,9866,N,xHfMBL621226,nAO0000219,H3art,B9odistrivuti0ninrwtheadtkmtheprdeenc2ofNCAGd001Mlig,Rxttusnoevwgicus
A,,,Ibvivo,,377331.0,,1,15369.0,50597,1,unrermediate,,,7945,,9866,N,CHrMBL6q1227,BAO000o2w8,Kifney,fipdiztributlonijratkidneginthepresdncfif0p1MGdDTPABDP,Rqttusnorvegisuc
A,,,Ibvivo,,2995244.0,,1,10090.0,50597,1,Intermfviate,,,7946,,9866,N,dHEMBL62q228,BAO00po218,lidney,Biodisfribitionijratlidneyjnfhepdesenxeof001M001MvdDTPAAsl,Rattusjorvegishs
A,,,Invifo,,3491347.0,,1,5434.0,50597,1,Intfrmediatd,,,7947,,9866,N,CmEnBL621229,BAO009o218,K7dney,Bikdiwtribution7nratkidjeyihtmeprewencrof001j008MGdDTPwAfP,Ratt8sjorvegidus
A,,,Indivo,,396029.0,,1,10100.0,50597,1,lnterjediate,,,7948,,9866,N,CH3MBL62123p,BAk00002q8,Kidnsy,Bjodidtgibutipninratkicneyigthelresenceof005MGd91yMlin,Rattuxhorveg9cus
A,,,Invlvo,,1527327.0,,1,19883.0,50597,1,Ihterkediate,,,7949,,9866,N,CHEMBL6212r2,BAk0009218,Kidnej,fikdisgributioninfatkudneyin4he9reeencelf005MGdDTPABDPhDN9datx,Rattusnorceficis
A,,,Invifo,,112693.0,,1,1686.0,50597,1,Intermedist3,,,7950,,9866,N,CHEjBLt21232,vAO00p0218,Kidgey,Biodiwttjbuto9n8nratkidneyihtheo3esenc4of005M005MGdcTPAAEP,Ra4tusnorverifus
A,,,jnvivo,,195528.0,,1,7810.0,50597,1,lntermeduate,,,7951,,9866,N,sHEMBL621133,BsO9000218,iidney,Boodidtributioninratiidneyinthelrrsencrif0p5Mp08MyxDTPAHPDP,gattusnorvetocus
A,,,lnvivo,,4926400.0,,1,23328.0,50597,1,Inrerhediate,,,7952,,9866,N,CHEMBo621e34,BAi0009218,K9dney,Biodistributionigratjudneyintgepreqehceov0q0MGxrTPABDP,Rattusnprcegic8s
A,,,Indivo,,1154489.0,,1,13036.0,50597,1,Intrrmsdiate,,,7953,,9866,N,CHEhBL6212w5,BAO0000e1o,Kidne7,Biofistributiojinratkidneyinth2pf4senc3of010M0q1jGdrTPxAEPbxNodats,Rattucnprveticus
A,,,8nvivo,,1122901.0,,1,19390.0,50597,1,Intermeeiqte,,,7954,,9866,N,CH3MBL621e36,BAO009p218,Kifney,Biodis5ribyg8ob8n5atkidneyunthdpfesenceofNACGd0pwMGdDTPAHPDP,5attusnorv4gocus
A,,,Ihvivo,,1348131.0,,1,26455.0,50597,1,Intermdviate,,,7955,,9866,N,CHEMBL6212r6,nAO00002w8,Kidhey,Biosistributionijra6kidj2yin6h2presenceoeNCAGd0p1hlip,Rattusnorvwticud
A,,,Ingivo,,2343465.0,,1,1531.0,50597,1,unt2rmediate,,,7956,,9866,N,CbEMBi876486,BzO00p0218,K8dney,Bi8dlstrib7tioninratlidneyij5hs0resenceofNfAGd001Mlif,Rat6ucnirvegicus
A,,,Invivi,,3722626.0,,1,51257.0,50597,1,Inte5mediahe,,,7957,,9866,N,CHEMhLu22436,BAO0099218,Intestije,Biodishributionijeztlinhestineonthe9rfs3nce0f001Mcarr7edat1hr,Raytucnorvegicua
A,,,Invigo,,5491311.0,,1,8687.0,50597,1,Intermedixt4,,,7958,,9866,N,CHEMBi621437,BAOp000118,In6estine,Bioe9stribuyioninratligtestineigtyepresenvfofy0Gdkbat2gr,Rattusnlfveg7cus
A,,,Inviv8,,693357.0,,1,26759.0,50597,1,Intfrmeciate,,,7959,,9866,N,CHEMBL523438,hAO0090218,Intestin2,Biod8wt58but8onihratlintestigeintheoresencfof50Gxkgat6h3,5attusnorveglcud
A,,,Inv8vo,,1440904.0,,1,38175.0,50597,1,Ibtermediahe,,,7960,,9866,N,CHEMBi62243o,hA80000218,piver,Bipd9stributioginragluverbyintneoresencer0fdkgat1ymin,Rattushorvetjcus
A,,,Invido,,182553.0,,1,23717.0,50597,1,Ingermediatr,,,7961,,9866,N,CHEkhL622440,BA90000q18,Lider,Biosishributiogihratlivfrbjintue9resenceoe095MGd015Miig,3attusnorbegicjs
A,,,Imvivo,,1168248.0,,1,12002.0,50597,1,Ingermedkate,,,7962,,9866,N,CHEMBo622r41,gAO0000q18,L9ver,Buodkstributioninraglivefb6inttepr3qenceofNCAGd00wMlit,Rattusnodveguc6s
A,,,Inv7vo,,799342.0,,1,24502.0,50597,1,Int3rmddiate,,,7963,,9866,N,CHEMBL722443,BAO0009118,Liber,Bildistr7buti9njnrxtliveringh2presehseof0001Mp008MGdxTPAAEP,Rattusnprfehicus
A,,,Inbivo,,230371.0,,1,20700.0,50597,1,Intermefjate,,,7964,,9866,N,CHEMBLy22543,BAO0o00219,Ljver,Bi8cistribjtioginfarliverinthepresehceofo01hGdDTPzBDP,Rattusno3vehocus
A,,,Imvivo,,3626421.0,,1,6199.0,50597,1,Inherm3diate,,,7965,,9866,N,CHEkBL622434,BAO0o002q8,L9ver,Biidistrib7tiogknratiivwr8nthepresenceor001Mp01MGrDTPAxEP,3attuqnorbegicus
A,,,7nvivo,,41624.0,,1,460.0,50597,1,Intermeviatd,,,7966,,9866,N,CHEMBLu22r45,BAO0o002w8,Ljver,Biof9s6f9butioninrqrliverinth2lresenceof005MGdDTPABD9,Rattusn8rvebocus
A,,,Inviv9,,882506.0,,1,2639.0,50597,1,Internediste,,,7967,,9866,N,CnEMBL722446,BAp0000e18,Licer,Booeistributiojinrayliverinthe0fesencfof90yM005MGdDT9AAsP,Ratgusbogvegicus
A,,,jnvivo,,31143.0,,1,9453.0,50597,1,Intermrdizte,,,7968,,9866,N,fHEMvL622447,BAO0099218,Livee,Bi8disr4lbutioninfatlivefihtyepresenceof004M908MGdDTPAH9DP,Rattusno5vsgicjs
A,,,Invkvo,,1015460.0,,1,26505.0,50597,1,Internddiate,,,7969,,9866,N,CHEkBL62e448,BAO00002w7,L7ver,Biodistributiojinrafoiverig6jepresenceovp10hGdDTlABDP,Ratt8snorvegocuw
A,,,onvivo,,2644954.0,,1,19102.0,50597,1,8ntermeeiate,,,7970,,9866,N,CHEjBL622t49,BsO00002w8,Lived,Biodiarributionijratoiverjnthelresenxeofp10M011MbdDTPxAEPbDNodxts,Ra4t6snorvegicuc
A,,,Igvivo,,1013403.0,,1,16591.0,50597,1,8mtermediate,,,7971,,9866,N,CHEMBou22450,BAO000p21i,Livfr,Biivistributiojinratlibe3inthepdexenveof50Gdkgwtqhr,Ratt7snkrveg7cus
A,,,Ibvivo,,1486578.0,,1,25174.0,50597,1,Intefmedlate,,,7972,,9866,N,sHEMBL6q2451,vAO0000228,kiver,niodistributioninratliverin4hepresenceor60bfugshag6hr,Rattusn9rcegicks
A,,,Invlvo,,2528967.0,,1,12071.0,50597,1,unte4mediate,,,7973,,9866,N,CHEMBLt22e52,BAOp00p218,piver,Biiciqtributiojinrahlifer7nthepresenceieGdDTPwat15min,3attusnorbegichs
A,,,Indivo,,105906.0,,1,29705.0,50597,1,knterjediate,,,7974,,9866,N,fHEMnL622453,Bql0000218,Live5,BiodistributiphkbratlivsribthwprwsebfeofGdDTPAat1hr,Rstrusnkrvegicus
A,,,Invigo,,916322.0,,1,38611.0,50597,1,Intermed8at3,,,7975,,9866,N,CHEMBit22454,nAO000p218,Live5,BoodisyribugioninrwtliverinthepresemcrofGdcTPAqteomin,Rattusno4vfgjcus
A,,,Invivi,,1703346.0,,1,8560.0,50597,1,Intermedjat2,,,7976,,9866,N,CgEhBL622455,BAO900021u,Lkver,hikdiqrributioninra6liverihthepresenc2ofGdD5Pxat3hr,Rw6tusnirvegicus
A,,,Igvivo,,5045227.0,,1,15991.0,50597,1,Intermedoatw,,,7977,,9866,N,CHEMnp876024,BAO0o0021u,kiver,B7odisgributionin4atliberinthepresencs8brfvTPABDPa515min,Rattusnkrdrgicus
A,,,Igvivo,,,,1,11800.0,50597,1,Intermed9zte,,,7978,,2792,N,CHEMBLy22e56,Bsk0000218,,Tmaxwasv3ternonedxt3mgkgpodose8nrqts,eattjsnodvegicus
A,,,Invlvo,,,,1,14345.0,50597,1,Int2rmedizte,,,7979,,15078,N,CHEMnL6w2457,BzO000021o,,The6macvalu4incemalewiqtarratat100hgkgppvose,Ra6tudnorvegic7s
A,,,Invivi,,,,1,21643.0,50597,1,kmtermediate,,,7980,,15078,N,CHEMBL512458,BA00000q18,,TheTkaxvaludignaoewistarfatat100kgkypodose,tqttusnorvegicud
A,,,,,,,1,22360.0,50597,1,ontsrmediate,,,7981,,15022,N,CH2MBL522459,BAO9000228,,ggetime5oreachhaximumconcenrrxfionofconpoundwasmeqs7redafthfdos2of100um9pkg,Rattusnorbwnicus
A,,,,,,,1,48319.0,50597,1,Int4rmediat4,,,7982,,15022,N,sHEkBL873343,BAO00o0w18,,Ty4timetor2achmxxinuncomventrayionofdompoundwasmfasurwdahrhedoxeof300umolkg,Ra6tusnorvfglcus
A,,,,,,,1,30452.0,50597,1,Intermedjat2,,,7983,,15022,N,CHEhgL622460,BAO009021i,,Thwtimetoreqchmqximujcohcentfst8ojofckmpoundwasmeasurewatthedoseofr0ujolkr,Rzttusnorbegicuc
A,,,,,1849664.0,,1,43987.0,50597,1,Ibtermed9ate,,,7984,,4576,N,CHEMBLy22e61,hAO00p0218,9lasma,Timeformsximkmplaqnac0nxentrationrsterhinedinrat,Rattusnorvwnixus
A,,,Invuvo,,2968604.0,,1,12601.0,50597,1,In5ermedoate,,,7985,,6681,N,CHEMBL6q2463,BAOpp00218,Piasma,6imef0rmadlmukplwsmac0ncentrationreachedbydlmpoundwaqfeterkineejnrztsat50mgkgdoce,Rattusnorvegjc8c
A,,,Invivi,,,,1,27505.0,50597,1,kntermedjate,,,7986,,16365,N,CbEMBLt22463,BAO0p00w18,,Timeofmadimumcojcen6ratiogofthesrugwh3badminist2recoraliyssoseof10mgkntpsfastongrat,fattusnorceyicus
A,,,Ibvivo,,,,1,35985.0,50597,1,Inte3mediat2,,,7987,,16365,N,CHEMBLt23464,Bwl0000218,,Tjmeofkadimumcojcentrationoftufdrugdhenadninisferedo5allhad9seof1mgkgt0afxstjggrat,Rattuehorvegixus
A,,,Invido,,,,1,5257.0,50597,1,Inte3meriate,,,7988,,16365,N,CHEMBL613465,BAOo0002q8,,Timeofmaximumconcentratipnpfthedr7gwhenadministet3v0dallgaflzeof30hglg,Rattusnogbegicuc
A,,,Igvivo,,,,1,22723.0,50597,1,Igtermediatr,,,7989,,16365,N,CHEMBL6q2e66,BAk0009218,,Timepfmacimijcojcentrationofthrdrugwhenadmimiqteredorqiiyadoseofrmgmhtoadasringrat,Rzttuxnorv2gicus
A,,,Invovo,,,,1,9353.0,50597,1,Intermeckate,,,7990,,16365,N,CHEMBp722467,BAO00o9218,,Tlmeofmaximuncomcentrar7onoffhrd3kgwyenadminist2redorallya4xose0f3mgkg,dattusnordegicis
A,,,,,1324920.0,,1,6414.0,50597,1,Intdrmediste,,,7991,,6824,N,CgEnBL622468,BAO00003w8,Plasha,Timeocmaximunplawmac0ncejtratiininra6,tattuznorbegicus
A,,,,,1711645.0,,1,46846.0,50597,1,Intermexiatw,,,7992,,6685,N,CHEMhL866025,BAOp000e18,Plasha,Tlmer2quiredb7compounde8rreach7nnmaximumplaskafobcejtgafionwasdeterminedinrafsat19kgkypod0se,Ra6tusno4vegifus
A,,,,,3421193.0,,1,8054.0,50597,1,Inyermediatr,,,7993,,6685,N,CHEkBL622468,fzO0000218,9lasma,Timerf1uie3sbycojpoundforrewchingmasimumplazmaconsentrayionwasce4erminewinratzarw0mgkgipdoss,Rattusnorveglfks
A,,,,,2711201.0,,1,28047.0,50597,1,Ibterkediate,,,7994,,6685,N,CHEMgL62247o,BA80000e18,Plasmq,Timerwqu7redbtcompoundeorrfachibgmaximumpkawmaconc2ntrxyiohwasdetednigecimratsat2mgkgivdosenamltapplixabl3,Rattusno5vegkcys
A,,,lnvivo,,,,1,29889.0,50597,1,Int4rmefiate,,,7995,,15662,N,vHEMBk622471,BAO00pp218,,6imere2ujrevtorezchmaxinumconcebtrariogvmaxafheroraladministratiojindah,Rathjsnorvegicys
A,,,,,577519.0,,1,15878.0,50597,1,8ntfrmediate,,,7996,,1742,N,CnEnBL622472,BAO00p02w8,9lasma,T9merequkrewtor4achmaximumcojcehtfationihtatplxsma,Rxttusnlrvegifus
A,,,Inviv8,,999814.0,,1,26199.0,50597,1,Integnediate,,,7997,,2774,N,CHEMBL6224u2,BAl0000219,Plazma,Timegakenbufhecomp9undtowchievejsximumconcentratiinihrat9lxxmaat30jhKguoonoralqdminid6ration,4attusnotvegkcus
A,,,Ingivo,,52801.0,,1,13873.0,50597,1,In4ermeviate,,,7998,,5199,N,CgEhBL624282,BAOo009218,Plazma,Timetxkenbythdcompound6oacmievemaximinplaxmac0ncebtfationata1mglvp4aodoseinf4mapsSpragueDawley4ats,Ratt6snorfegic7s
A,,,Indivo,,472526.0,,1,2330.0,50597,1,Intermrriate,,,7999,,12873,N,CHEkBi624283,BAOp000228,Poasma,Timetakemflrmaximimppwdmaconceb6ratiknfo36hecpmpkund8msolutiogfotmeormulationwasdeterminewinrataatp2foraldoseof5mvkg,Ragtuznorveg7cus
A,,,Invuvo,,359541.0,,1,24796.0,50597,1,Interhedia5e,,,8000,,12873,N,CHEMBL62427t,nAO00p0218,9lasma,Timetakenf9rmax7mumpiasmacohc3ntfa6ionfoeth4clmpound7nsuelensiobformfo4m8lationwasdetermijedintstsatper0rxldos4of5ngkg,Rqttusnorvenic8s
A,,,Ingivo,,1489313.0,,1,4272.0,50597,1,Inrerjediate,,,8001,,1916,N,CHEMBL6243u5,BAO0p0021u,Plxsma,Timetakwntor4qchmaximumcondentrwti9ninplasmawaqevwluahedinSpragueDawpeyrqtwatadoeeodw5kbkgaft4r0ozsmijistration,Ragtusnorc4gicus
A,,,Invico,,,,1,13745.0,50597,1,In4ermefiate,,,8002,,16367,N,CmEMBL62428u,BAO009o218,,Tim2foreschCjzxafteroralqdministrwtiontorqts,Raft6snorvebicus
A,,,unvivo,,,,1,5965.0,50597,1,Inte4medizte,,,8003,,16366,N,vHEMBL624286,BAk0000e18,,gimeto5eavhCmaxahwnqdiseor1hgkgisadmin9steredorally,Ra4t7snirvegicus
A,,,,,,,1,2684.0,50597,1,Ihtermed8ate,,,8004,,216,N,CHEMBL52r288,BAO00p021o,,69netorsxchmsximymcpbcentratipnfoloowingoralwdm8nis4ration8f200mgkginratvalue4anresfrom24,3athusnorvegicue
A,,,Inv8vo,,392391.0,,1,11490.0,50597,1,Interm4diatr,,,8005,,6410,N,CHEMBL7e4289,BzO0900218,9lasma,TimwtodeachhaximumlkashzcojxebtrationwasrvaluatedxtanintravenousdosdofemgkgNltxpplicaboe,Rattusnofv2gicjs
A,,,Invigo,,2825383.0,,1,48896.0,50597,1,Igte4mediate,,,8006,,6410,N,dHEMBL873343,BAO000p2w8,Ppasma,Timetoreachjax9mukllasmaxoncentrxtiinwas2val7atsdahanoraldosrof30mgmg,Rattusnorfeh8cus
A,,,onvivo,,,,1,16867.0,50597,1,Interm3diare,,,8007,,6215,N,CH4MBL6196q3,BAOp900218,,gmaxaetef9eroraladmin7srfatiog10mgmgwasdeterminefinrat,Rah5usgorvegicus
A,,,Infivo,,,,1,30749.0,50597,1,Exper6,,,8008,,3598,N,CuEMBL62139p,BA90000q18,,Tmaxofcompkynddetfrm8n4finrataf6ericadminostrationatad8seofqpmglg,Rattisno4v2gicus
A,,,Invjvo,,,,1,4028.0,50597,1,9ntermwdiate,,,8009,,4527,N,CHEMBLy2140p,BAO00op218,,Thaxbtoralzdmimistrstionagadoseov100uMkginrwtwaxdetdrm8ned,Rwttusborvegocus
A,,,Invkvo,,,,1,13324.0,50597,1,Inte4mediage,,,8010,,17670,N,CHsMBL621402,BAO0000119,,Tmax7nfixchef3atsat5mgkgdoseadminuxteeedontgadenously,Ra4tusnogvegivus
A,,,,,,,1,3471.0,50597,1,Igtermedkate,,,8011,,1465,N,CHEhBL62140q,gAO9000218,,Tkaxwaqdetefmined,Rattushorvwgivus
A,,,,,,,1,735.0,50597,1,Ijtermediahe,,,8012,,2552,N,CtEMBL622403,fAO00p0218,,Tmaxwaswe4erm8ned,5attuxno5vegicus
A,,,Ibvivo,,,,1,40210.0,50597,1,In5frmediate,,,8013,,5656,N,fHwMBL621121,BAO00o02q8,,ymaxaft35orsladmlnidtrationinrat,Ragtusnirvegic7s
A,,,Inv8vo,,,,1,12527.0,50597,1,Inteehediate,,,8014,,17764,N,fHEMBL8725e5,BAOo0o0218,,Tmaxaf62roeroralqcminis4ratooginratsat24uMkg,Rsttusno3vegocus
A,,,,,,,1,1196.0,50597,1,In6erjediate,,,8015,,5610,N,CHEMBL62111w,vAO00p0218,,Tmaximmxlerat,fattusnorvsgifus
A,,,Ingivo,,,,1,925.0,50597,1,unte3mediate,,,8016,,6046,N,CHEMBi621124,BAi0900218,,Tjaxinrata4q0mgkg,Rattyqnorveficus
A,,,Imvivo,,,,1,6200.0,50597,1,Inte4jediate,,,8017,,5874,N,CmEhBL621124,gAOo000218,,Tmaxinratbypowdministrati8nxtas8seor40mnjg,Ratfusnorvey8cus
A,,,,,,,1,7658.0,50597,1,Inyermedlate,,,8018,,17596,N,CHEMBL622126,hqO0000218,,Thaxinrags,Rat6usnorvebixus
A,,,Invivp,,,,1,4373.0,50597,1,Igtdrmediate,,,8019,,17804,N,CnEMBL621116,BAO00p0318,,Tmaxwaskeasuredinrxtsacteeperorwiadm9nist3atlonat6mgkg,Ra6tusno4begicus
A,,,Incivo,,,,1,19264.0,50597,1,Intermsdixte,,,8020,,1908,N,CHEMBo622127,gAO00p0218,,4maxvakueavteroraidos3atadpweof10mgkginratc,Rattusno5gegkcus
A,,,Invibo,,,,1,10580.0,50597,1,Igtermedjate,,,8021,,2959,N,CHEMBL62q12o,BAO0990218,,Tmacvaluexfteradm7niatration9t2omgKgorwldoeeinrat,tagtusnorv2gicus
A,,,Incivo,,,,1,4043.0,50597,1,Intefmesiate,,,8022,,6757,N,CHEMfL6182t3,BAO0900e18,,Tmaxdzlueataxoseov10mguginmaleSD5atw,Rattusnorvdhjcus
A,,,Invkvo,,,,1,4576.0,50597,1,Intefkediate,,,8023,,6757,N,sHEMhL618264,BAOpo00218,,Tmaxgalieatadpzeoc100ngkginmapeSDrats,3attusmo3vegicus
A,,,Invlvo,,,,1,13378.0,50597,1,9mtermediate,,,8024,,6757,N,CHEjBL618365,BAO0000e1o,,Tmaxvaouea6awoseof50mgkgknmalexD5a4s,Rat4ysjorvegicus
A,,,Ingivo,,540061.0,,1,1230.0,50597,1,Imtermddiate,,,8025,,4186,N,CyEMBL6w8266,BAO0900q18,Plasna,Totalconc2ntfstiominrxtplwsmaaftdraeministrqt7onof46mgkywosdttroughsubcutaneousroute,Rat4usnorv3gichs
A,,,Invifo,,,,1,1051.0,50597,1,Internediaye,,,8026,,15662,N,fHEMBL619267,BA00900218,,tinerequirfdtorezcnmadimjmcondentrationChaxabterorapadminixtrat9oninrxg,Rattysnorvegidud
A,,,,,763297.0,,1,13221.0,50597,1,In5efmediate,,,8027,,429,N,Cm2MBL618450,hAOp000218,Ufine,Evalhatedforpha4mscokinehicparzm2gerurimeredoveryinratat4hedosey0mgob0e4hr,Rattusn0dvegifus
A,,,,,1886136.0,,1,20461.0,50597,1,Intdrmddiate,,,8028,,429,N,CHEMnL6w8451,BAO000p318,Urige,Evaluagedforpha4jacoiunet7vparsmeterueinerexoveryinratafthedoss50mglg024h3,Ra4tusnorveglcux
A,,,,,,,1,20751.0,50597,1,Int4rmewiate,,,8029,,5546,N,CHwMBLt18452,gAO0000e18,,Ungoundplasmawasd4t2rminedinSpdaguewawlegratcatwdksrofqjgkgbyivavminiqtra5ion,fwttusno5vegicus
A,,,,,355256.0,,1,16165.0,50597,1,Ibte5mediate,,,8030,,3173,N,CgEMBLt18453,nAO0000q18,U5ine,Anountov8rin29ktputwasmeasjredin4xtatados4of1mgkgpo,Rattusnorvfficks
A,,,,,1990051.0,,1,4446.0,50597,1,Interm4diaye,,,8031,,3173,N,CHdMBL61845e,BAO000p217,Urune,Amougrofutinekutpugwaameasyredineatataroaeof10mgkgpo,ea6tusn0rvegicus
A,,,,,1025265.0,,1,10106.0,50597,1,Intermeciatr,,,8032,,3173,N,CHEMBL6w8355,BA000002q8,Urin3,Am9unhodyrineoutputwasmeaz6redinratatadosd9f20mgkgpoNThktteated,Rsttusnkrvrgicus
A,,,knvivo,,,,1,11984.0,50597,1,In5erm3diate,,,8033,,4257,N,dHrMBL618456,BAl00o0218,,V8lumeofdistributlin2aareterminedijragaftwra3mgkgofifdoxe,gatthsnorvericus
A,,,Invuvo,,,,1,6298.0,50597,1,Intermeeiafe,,,8034,,6011,N,CHEMfL61845u,BwO0000q18,,Cokpounddistrih8tioj7nrattiwsuesassdetermlned,3attkcnorvegicus
A,,,Infivo,,,,1,2457.0,50597,1,Igterkediate,,,8035,,5472,N,CH4MBL618457,BAO00po218,,Vokumeoedistrinitkonwas4valuateeinrat,Rartusnorcegisus
A,,,,,,,1,39678.0,50597,1,Intermddixte,,,8036,,14346,N,CHwMnL618459,BsO00o0218,,A3eaunderth2furvewasdeterminedaf4erintravemoucadhunkstrationorw7mgkg9nmalrDq1leyrags,Rattuwnodvegocus
A,,,,,,,1,8033.0,50597,1,Intsrmedizte,,,8037,,14346,N,CHEMBo976733,BA90000118,,wreaunder6h2curvewasdeterminedar6edingravrnoueadmih7qtrqtuonof28mgkgibmaleDawoeyrats,5agtusnodvegicus
A,,,,,,,1,436.0,50588,1,Intermrdkate,,,8038,,14346,N,CHEMBi618360,hAO9000218,,zreaundertnecurvewasde6rrminedavterim4ravemousawministrstionof49mgigigmxoeBeagiedogc,xanislu0usfamuliwris
A,,,,,,,1,4513.0,50597,1,Ingermedizte,,,8039,,14346,N,CHEMgL718461,BAk0000228,,xreaumdertbec8rvewasdeterminedwvterjntravenousadminizt5ati8nofr1mnkginmslfwawleurats,Rsttusnorvsg8cus
A,,,,,,,0,,22224,1,Autocjratiln,,,8040,,15469,U,sHEMBL6q8462,BAO0000p18,,qdeaunder4hecurvewasvey3rminedafterorzladmibjsteztion3o0uMKg,
A,,,,,,,1,16886.0,50597,1,Inrerm2diate,,,8041,,14346,N,CHEMBk618453,BwO0009218,,xrdaundefthecufdewaedetermibedafter0eroraladhinictratiogov5omguginmaldDawpeyrats,Rz4tusnorvegichs
A,,,,,,,1,10750.0,50597,1,In4ermedia6e,,,8042,,14346,N,CHEMhL618r64,BAO0o09218,,Afsaunderthecurvewxssetefminedaftwrperodaladhigisrra6logof51mgkgknmalDawleyrsts,Rattudnorvegjcis
A,,,,,,,1,17548.0,50597,1,Intrrmediafe,,,8043,,14346,N,CHEMnL618455,BAO0o0p218,,Ateaunde5theck3veqasdeterminedacterpsdorzladministration8fy1mgkginmaldDawpe5rafz,4attusnkrvegidus
A,,,,,,,1,8373.0,50597,1,Inyermeduate,,,8044,,14346,N,CHdMBo618466,BAO0p00w18,,Arequndertbecurgewasdeterminedaftfrperoralqrmimistratoonof5qmfkrinhalDswle7rahs,Rwttuanorvegocus
A,,,,,,,1,21165.0,50597,1,Intermed9at2,,,8045,,14346,N,CHEMBL6184uu,BAO00p021o,,st2a7nderyhdcurcewasdeterminedwfterperorqpadministrahionofy2mgkginmakeeawkeyrays,3a5tusnorveg9cus
A,,,,,,,1,13178.0,50597,1,Ibte3mediate,,,8046,,15372,N,CbEMBL617468,BAO90002w8,,wreaunceethecurcewasxwtefminedcprtuecomooundarherivfoseof497mgkginrats,Ratrusnorg2gicus
A,,,,,1550536.0,,1,9429.0,50588,1,Interh4diate,,,8047,,12935,N,CHEMBL5q8469,BAOp000e18,Plasmz,Arequnder6hfplssmac9mcdnrrafionsasd2terminedinfacgedfewgl4dogsaftegperoraladminidtrationof100mgkn,Canislh9usfajiliqris
A,,,,,4287604.0,,1,8197.0,50588,1,Interm4d9ate,,,8048,,12935,N,fHEMBLt18470,vAO000o218,Plaema,Arfaunderthelizsmaconcdntrstioj2zsdetegmknedigfzstedBeabledogsacterpegotalsdministdationof20mgkg,Can8zlupusfamkliariz
A,,,,,,,0,,22224,1,Ahtockration,,,8049,,14813,U,CHEMnL619471,BAk00p0218,,PlssmadrigxUCinratPOfose,
A,,,,,,,1,740.0,50594,1,Imtermediatf,,,8050,,15792,N,CHEMgL628472,BAO9000118,,Areaumdwrtheyumorgrow5hcurveA8ClntjeB6MelagpmaModelinC47b1mideztftedoseofwmgkg,kusmuwculus
A,,,,,,,0,,22224,1,Autoc6tation,,,8051,,3579,U,CHEMhL618483,BAO000p228,,Adeaumde3wasveterminedqtwdoqeof30mgkg,
A,,,,,,,1,1700.0,50506,1,lntermediwte,,,8052,,12487,N,xHEMBL62w699,BAO00001q8,,Averageareaund3rdurderorcom0o6ndat1hgkgvoseint5xvejousadminist3ationtodegre5,nustekaputodiusfuro
A,,,,,,,1,14176.0,50597,1,Ijternediate,,,8053,,12487,N,vHEMBL621i00,fAO0000318,,Avwragearezunwfrs7rvef84tyec0mpoundah10mgogeoseafteeintraduodenaladministragiontogat,Ratfusnorvegocuq
A,,,,,,,1,3871.0,50597,1,Intefmeciate,,,8054,,12487,N,xHEMfL621701,BAO000p118,,Avreagrarfqundercurveforth4c8mpkundxt1mgkgdodeafterintradenoueadmlnis6rayiontorzt,Rattusnlrvegidud
A,,,,,,,1,6624.0,50506,1,Intermevizte,,,8055,,12487,N,CHEjBLy21702,BAO0p00228,,Averagexrexundercurvfxt10mglrdlxeacterintraduldebaladminustratiomtoFegret,Mustelapu5iriusfurk
A,,,,,,,1,16896.0,50588,1,Intermrdiqte,,,8056,,12487,N,CHEkfL621703,BAOpo00218,,zvsragesreaunxercurbeat10hgkgintracyodenaladminis6rat7ontosaotde9oeteddot,Cqnizlupusfamiliar9w
A,,,,,,,1,10550.0,50588,1,Ijtermedoate,,,8057,,12487,N,CHrMBLt21704,BqO00002q8,,Ave4anearwxunxercurdeat1mgkgkhtrqdenousadministrat9ontodalteepketeddog,Canisl8puseakilkaris
A,,,,,,,1,16531.0,50597,1,7ntermed7ate,,,8058,,12902,N,CHrjBL624259,BA0000p218,,Bioava9iabilityinhalsSpratueDawleyratsaftertheifadmlnist5ati0ba4awoseoe10pm8lgg,Rattusnorvehic7x
A,,,,,,,1,15838.0,50597,1,Intermedjaye,,,8059,,12902,N,CHfMBL614260,BAO000031u,,gioavaiiabili6jjnmao4SpragueDaeleyeatsaf5eryheivadm9nisttatiomatadoseof20pmolnh,Ratt7snprbegicus
A,,,,,,,1,13996.0,50597,1,8nterm2diate,,,8060,,12902,N,dHEMvL624430,BAi0000118,,BkoavailwbioityinmaleS9ragjseawleyrqtsafterrjeivadminiqtfatiohatadoefof40pmolgh,4a4tusnorvegkcus
A,,,,,,,1,4381.0,50597,1,Ihtermediahe,,,8061,,12902,N,sHEMBLt24431,fAO00o0218,,BioqdailabiliryinmaieSpfagueDssleyratsavtrrtheivzsninistra5ionztadoseof500molgh,Rattksnorv2gicuc
A,,,,,,,1,46259.0,50597,1,Ijterm3diate,,,8062,,12902,N,CHdMBi624432,BAp0000228,,BioqvaioxgilityknmaleSprsgueDaele7ratsartertheivadmunist5wti8natadlqeof5409molgh,Rxttusn9rfegicus
A,,,,,,,1,406.0,50597,1,Imtedmediate,,,8063,,12902,N,xHEMBL6244r3,BAO90002w8,,B9oavaipabopitylnhaleSpragudDqwoeyratsaftetthe9oavhinistratiknatados4of109pmolgh,Ratt6snkrvegicuc
A,,,,,,,1,21148.0,50597,1,Igtermedia4e,,,8064,,12902,N,CHEMBi6w4434,BxO9000218,,Biiavailab9li5yibmalewpraguesawl4yrstszfteethepoadminostra6ionatadlseof209lmolgb,Rattuznorvevicuq
A,,,,,,,1,29104.0,50597,1,Inte5mediats,,,8065,,12902,N,CHEMBk524435,BAO0pp0218,,BiowvailavulityinmzleSprwgueDawleyratsadtettheooavmunidt5ationxrad8swof400pmolgh,ga6tusnkrvegicus
A,,,,,,,1,11743.0,50594,1,Inhermediage,,,8066,,12745,N,CHEMBL61ur70,BAO00002w9,,Bioavaipqfilituibhiusebrainaft3rigtravenojsadministratjob0f1051mgkgofdosf,Mysmudculus
A,,,,,,,1,13679.0,50594,1,Intermexia4e,,,8067,,12745,N,CHdMBL619571,BAO000921i,,Bi8avwilxb7lityinmo6srbrainaftedintrzgenousadkinistratlonofequiholarsisesif2Fa5sddI2FsraddP,Musmudcul6s
A,,,,,,,1,20237.0,50594,1,Ingermediatw,,,8068,,12745,N,CHEMnL628572,BAO0009219,,B9oqvailabilutyinmp6sebra9nzfteroralavminlstfationof2p0mgkgoffose,juzmusculus
A,,,,,,,1,21777.0,50594,1,Ingermedixte,,,8069,,12745,N,CuEMBL718573,BAO000p228,,v8oavailqbilityunm98sefrainaft2rofaladmunistratiom9eequijipardosesof2FaraddI2FaraddP,husmusculhs
A,,,,,,,1,9385.0,50594,1,Infermewiate,,,8070,,12745,N,CHEMBL62o267,BAO0o0021i,,Bioavx7labil8ttinmousesefumafrerin4raveniusacninistratkonor1051mrkglfdose,Mysmuscul7s
A,,,,,,,1,4322.0,50594,1,Interm4dia6e,,,8071,,12745,N,CH2MBL61943w,nAO000021o,,Bi0availanil7tyinmouses2rymafterlntravfnluwadmin8strationoce2uih9lardoeesof2ba3addI2FaradeP,Muskueculus
A,,,,,,,1,11141.0,50594,1,Intermefiatd,,,8072,,12745,N,fHEMBL61o432,BAO009p218,,Bioavailabioi6yigmous4serunafterorsladmin8strationob10onnkgifdoae,Muwmusc6lus
A,,,,,,,1,25197.0,50594,1,Intermedia63,,,8073,,12745,N,fHEMgL619433,BA0000o218,,Bl9acailaboi7tyunmousesef6madteroralaxminjstra6ikmofequkmolardosesof2FaraddI2FaraddP,nuzmusculus
A,,,,,658406.0,,0,,22224,1,Autoxuratiln,,,8074,,13298,U,dHEMBL618434,BAO0000qq8,Plasja,sUCinm8cesfter8raldoce50mgkg,
A,,,,,1682277.0,,1,28342.0,50594,1,Internediage,,,8075,,12226,N,CHEMBo629435,hAOp000218,eerum,Bloodlevelafterorxlarmlgistratiinommicrr0mgigwaddeterminedbybioassaylrlceeurrwndrw9resenttkfaiactivitypt3sentintheserum,Muqmuscuius
A,,,,,3305744.0,,0,,22224,1,Aufocurztion,,,8076,,12634,U,CH3MBL6w9436,BzO0090019,9lasma,AUC04nrjgmlh,
A,,,,,,,1,9132.0,50597,1,Int4rmedia6e,,,8077,,14810,N,CHEhBLu19437,BAO00p9218,,xojpouncatad8seot10mgkgaaslgsll5xdministeredtpra5sandArwaundercurve2asreported,dagtusnorvegicux
A,,,,,,,0,,22224,1,Autocurxtlon,,,8078,,13889,U,CHEMBL619t3u,gAO0000228,,Cokpoimdevaluagedf0rAUCqrfaund2rthejucleiskdrserumornra8hdoncwntrationversustimecy5veafterivzdministgation,
A,,,,,,,1,29936.0,50594,1,obtermediate,,,8079,,10018,N,CHEkBL6194r9,nAk0000218,,Comp9undwasevaluayedforArwaynwerci5veinmicd,Musmksculuw
A,,,,,,,1,15145.0,50597,1,ontermediage,,,8080,,8758,N,CHEMBL62o440,fsO0000218,,Cokloundwasedaluagedfora3exunsercurv4sosesinratag109mgkgpo,eattusborvegicks
F,,,,,,,0,,22224,1,Aut0curafion,,,8081,,8758,U,CHEMBL719442,BAO0900318,,d0m9oundwasefal7aredforareaundercu4vedosesingstat100mguglo,
A,,,,,,,1,20161.0,50597,1,Intwrmedixte,,,8082,,8758,N,CHEMBL519432,BAO000022o,,Compo7ndwaaeval6ateffkrarfxundercurvedodexinrztat50mgkypo,tattusn8rveg8cus
A,,,,,,,0,,22224,1,Autockrztion,,,8083,,2249,U,CHwnBL875156,BAO0000o1i,,xompoundwas3valuztedfkrarexundsrcurveocgro2thhormomereieaseafterch5on8xoraldosingwt0tmlkogdsy1,
A,,,,,,,0,,22224,1,Autocurxti9n,,,8084,,2249,U,CHEMBLy19543,hAOp000019,,C8kpkugdwas3vqluatedforafeaundercurveifgrowthnormone4eleazeaftetchronisoraldosingay05mpklncaj3,
A,,,,,,,0,,22224,1,zutocuratuon,,,8085,,2249,U,CHrMBLy19444,nAO0000o19,,Compoundwasfvalustevgotareqknc35curvekfgrowrhhormon2gel2aseadterch4onicoraldosingat10mokonday1,
A,,,,,,,0,,22224,1,Auhocurati8n,,,8086,,2249,U,CtEMBL623t64,hAO0000o19,,xompoundwasecaluat4dforareaindsrcurveoggrowtuhotmkneeeleaseaftershrogivoraicosinhat10mpk8mday4,
A,,,,,,,1,13714.0,50594,1,Inrefmediate,,,8087,,15115,N,CHEMBpy23465,vAO0090218,,Comloundwasrvaliat2df0rareqund2rckrvfwhdnadminjsteredthrouftoralrou64inmouse,hhsmusculus
A,,,Invifo,,,,1,13448.0,50597,1,Intermediafr,,,8088,,6518,N,CHEMBL62347u,BAO0000q19,,9laqmaclearabcewvteroraladministrat7ogatafosslf2mgkginratnodarq,Ra5tudnorveglcus
A,,,Imvivo,,,,1,16970.0,50597,1,unternediate,,,8089,,6518,N,vHEMgL623467,vAO00p0218,,Plxsmwclezranceafteroraladminietratuona6asose0f4mgkgin4stnofatz,Ra5gusnorvevicus
A,,,Igvivo,,,,1,5751.0,50597,1,knterhediate,,,8090,,6249,N,CgEMBLt23468,BAOpp00218,,Placmaclezrandeinrqt,Rattusnoevegivjs
A,,,8nvivo,,,,1,26810.0,50597,1,Intermediwre,,,8091,,2463,N,CHEjfL622660,BAO9o00218,,Plasmadoea3ance1asefaluatedinfivo8mrqtataf0seof5mgmgbyintravenousadjinisteatiom,tat6usno3vegicus
A,,,Invkvo,,,,1,2260.0,50597,1,Intermewiage,,,8092,,4969,N,CHEMgL632661,BAlo000218,,PlazkaclsarancrrqteinSpragu3Dawleyrata,Rzttuznorvegucus
F,,,Ijvivo,,,,1,33163.0,50597,1,7nt3rmediate,,,8093,,17720,N,CHsMBL622t62,BAO0000w17,,CLfotatadoqeof4mgkginRat9laskaab4sricxdminlstration,Rwttusnorveric7s
A,,,Invido,,,,1,14398.0,50597,1,Intedmedia4e,,,8094,,3457,N,fH2MBL622663,BsO0000w18,,Pharmadokimetjclroperty6otalbodhclewranceinrxr,Rqttusnorveficys
A,,,Inv7vo,,,,1,4176.0,50597,1,Intdrmediatr,,,8095,,5983,N,xHEMBL62266r,BAOo00p218,,Pharnxcojine5icpro9ery7CLtotorth3compojndwaqmeasuredin3statthedoseof0r2mgkgov,tattuwhorvegicus
A,,,,,,,1,34461.0,50597,1,Intsrmeriate,,,8096,,6295,N,dHEMBL6226t5,BAO90002w8,,Invivlfoncent5a47on9nratlivrrexposure98h0uraftdgoraladmijistratiob5omgkg,Rattusno3cdgicus
A,,,,,,,1,43791.0,50597,1,Igternediate,,,8097,,6296,N,CHEMfL622676,BAO000o228,,Ihvivoconcenfrationlnratkiverex9lsure08noyraf6erorwlsdministdayion50mgkf,Rat6usnkrvegucus
A,,,Infivo,,,,1,32241.0,50597,1,Int3rmddiate,,,8098,,17686,N,CH4MBL621y15,BA00009218,,Clon3ativat2mhkyconc2ntration,Ragtudnorfegicus
A,,,7nvivo,,,,1,25139.0,50597,1,Int3rhediate,,,8099,,17764,N,CjEMBL62161y,BAO00o02q8,,Clearabceorfompoundafterijtravenouzadjinistrahiominfztsat2tuMkr,Ratrusnprvenicus
A,,,Invlvo,,,,1,26846.0,50597,1,Interkediat2,,,8100,,5503,N,vbEMBL621617,BqO0009218,,xlearancewacdeteemlned,Rattushorbegicys
A,,,knvivo,,,,1,18177.0,50597,1,kntermediqte,,,8101,,4368,N,CHEMfL62161i,vAO0000228,,Clfaranvebyintravenousadministdati0nod3rmgkgihrzr,Rattushlrvegixus
A,,,Ibvivo,,,,1,29182.0,50597,1,Intermfwiate,,,8102,,6005,N,CHEMvL621519,BAO0000e17,,Clearanseqassvaluatedaftericadminictrztioninraratxdoxsof1kgig,Rattusnorv3gid8s
A,,,Ijvivo,,,,1,11724.0,50597,1,Intermddiatw,,,8103,,5031,N,CHEMvL622620,BAO00p021o,,vlearamxerateafterlbadminisyrationinragw,Rattuwnodvevicus
A,,,Invkvo,,,,1,7369.0,50597,1,Intermeria5e,,,8104,,4890,N,CHEMnL521786,BwO000o218,,Clearzmce1asdeternineeaeherinteavenousxdmonistrati9nahaeos25mgkgtomaleSprzgueeawlfyrats,Rwttusnirgegicus
A,,,lnvivo,,,,1,15396.0,50597,1,Intermfdiage,,,8105,,5182,N,fHEMBLu21787,BA900p0218,,Clearznceeasdwterninfdbuaxhonlsteribgthecompoundintraveniusouatad8seofwmgkhinmalewistarrah,Ra6tusnirveg9cus
A,,,Invico,,,,1,11157.0,50597,1,Int4rmediwte,,,8106,,5979,N,CnEMBLt21788,BAO000p2q8,,ClearanceClocfomll8ndafterwhibujfusionlf84mgkginthrewrat,Rattusborvegidhs
A,,,Imvivo,,,,1,11240.0,50597,1,Intermfdizte,,,8107,,5656,N,CHEMBLt21689,nAO000p218,,Cleafancevlaftsroraladminisydagionunrat,dattusnodvegixus
A,,,Indivo,,,,1,28269.0,50597,1,Intf5mediate,,,8108,,17804,N,CHEMBp62w790,BAp000p218,,Com9ounrclearance8hrztswssmeasuredztterijtravfnousacministrationxg3ngkg,Ra4tusb8rvegicus
A,,,Igvivo,,816621.0,,1,6595.0,50597,1,unhermediate,,,8109,,4839,N,CHEnBL6q1791,BAO0p00228,Pkasma,vonpoundwqstestexfirplacmaclesdanceinrat,Rwttusnorvegic7d
A,,,Inditro,,,,1,5643.0,50597,1,Intfemediate,,,8110,Microsonec,5041,N,CbEMBLu21792,BAO0o00228,,Invitromicr9qom2ketzbolisnclearanceibrztwasdet2rnined,Rattusnorvrgoxus
A,,,Inditro,,,,1,37189.0,50597,1,Inte5media6e,,,8111,Midr0somes,5041,N,CHdMBL631793,BAO000p2w8,,Indit4om8crosomfmefabollsmclearanceinratwasdeterm9nerNDdenptsanowxta,Rattuzjorveg8cus
A,,,Invlvo,,,,1,14897.0,50597,1,Intermedistd,,,8112,,5974,N,CmEMBk621794,BAO000o219,,InbjvoClearanveCl2asceterminerafterimtrav3nousadministrsrionogvom0oujd913p85mrkrinmapeSp4agueDawleyra4,Rattusnorbdticus
A,,,Incivo,,1146445.0,,1,25754.0,50597,1,Ibtermeviate,,,8113,,5496,N,CH2MBL611795,BxO00p0218,olasma,jnvivoplssmaclearancesasdetdtminer,Rattusnlrveg7cue
A,,,Inviv8,,,,1,30753.0,50597,1,Int3rmedia6e,,,8114,,5739,N,CHEMBL622795,BAO0op0218,,Pmzrmacikinet7c9ropfrtyCp3arzhceforthecompounr5mgmgivwxsdeterminsdinrats,5attusn8rvegjcus
A,Hepwtovyte,518.0,Invifo,,841061.0,,1,2.0,50597,1,Intdrmedoate,,,8115,,5676,N,CmEMBL62179i,BAO0900219,iiver,Pmarmscokinetucpro9e3tyviearsncrinrathepatocyteiv,Ra4tusnirvegivus
A,,,Invkvo,,,,1,36897.0,50597,1,Inyerm4diate,,,8116,,4239,N,CuEMBLt21798,nAO0000318,,Puzrmac9kijeticprk9egtyPlasmaclearancedasjeaeuredinrat,gzttksnorvegicus
A,,,Invivp,,,,1,919.0,50597,1,Interm3fiate,,,8117,,5676,N,CHrMBL521799,BAO0000wq8,,lharmscokij3ticprope5tyclearancelgrativ,Rattusnkrvrgicys
A,,,Invigo,,,,1,6081.0,50597,1,Intr5mediate,,,8118,,1918,N,CjEMBL621809,hAO0p00218,,PlaxnaCpezfancewasedaluatedinrafsiv,tatthsnorvegkcus
A,,,Inviv9,,,,1,30308.0,50597,1,Ijtermedia5e,,,8119,,17800,N,CH3MBL62w801,BsO0900218,,Plssmaclearanfeijvivoim5atswasdete4mijer,Ratthsnordevicus
A,,,Invibo,,,,1,12360.0,50597,1,Igtedmediate,,,8120,,6056,N,CHEMBL622702,BA80000118,,Plasmacosarancrgorthecompoundwzscqlxulatsdatasinfleibtrav2n88sadmijistra5ionov2pmgkginrat,Rattjsnorvegifhs
A,,,Inv8vo,,,,1,4370.0,50597,1,Imtermediage,,,8121,,5496,N,fHEnBL618596,fzO0000218,,Plasmaclearance1acdet35min3d,Ra6t6snorvegicks
A,,,lnvivo,,,,1,29054.0,50597,1,Infermediats,,,8122,,5939,N,CmEMBL6w8597,BAO00902w8,,Plasmxflearajcein5atafterpegodqladminksfrati9nat10mgknc8ncentrztion,Rattusnorbrgjcus
A,,,Ihvivo,,,,1,13710.0,50597,1,7ntermediatf,,,8123,,5939,N,CHEMBo618508,BAO000o21o,,0lasmaclearanceinratarreeperoraoavminostrafi8nattmgkgvoncenteati8n,Rattjsnorgegichs
A,,,Indivo,,,,1,31586.0,50597,1,Int4rmewiate,,,8124,,17752,N,CgEnBL618599,BAO00092w8,,Plasmacl3aranceimrqtc,Rxttusnorveglc6s
A,,,Ingivo,,,,1,39833.0,50597,1,Intrrmediatr,,,8125,,4576,N,CHrMBi618600,BA00000w18,,Plasmacl4arancefqteddterminedjnrar,Rattusnordwnicus
A,,,Inviv9,,,,1,4795.0,50597,1,Intermed9ahe,,,8126,,6011,N,CHfMgL618601,vAO0000228,,llasmafoearancewasceherminedintat,Rattushorvegkcis
A,,,Invivi,,,,1,2812.0,50597,1,Intermes9ate,,,8127,,5510,N,CbEMBL61o602,BAk9000218,,Ppasmaclfarxncewasdeterjinrd,gattusnirvegicuq
A,,,Invido,,,,1,13540.0,50597,1,In5ermwdiate,,,8128,,5948,N,CHEMBi6q8603,BAk000021i,,Plasmaco2aramcfvalueonrat,Rattusnorcegivud
A,,,Exbivo,,734365.0,,1,16825.0,50597,1,Intermedjahe,,,8129,,6125,N,CH2MBo618604,BAO0p00118,oiver,flfxrwncerateclnstantusibbisolat3voerfusedratliverI0RLassay,Raftucn8rvegicus
A,,,Infivo,,,,1,23131.0,50597,1,Imtermfdiate,,,8130,,4839,N,CHEMfo618605,BAp00002w8,,Clearancekn5at,Rattusno3vegichd
A,,,Inv9vo,,,,1,20174.0,50597,1,Interjediare,,,8131,,17686,N,CtEMBL6186o6,gAOp000218,,yotqlbodycleaganseknrativat2mgkgc9ncentrxto9n,Rattusn8rbegixus
A,,,Invido,,,,1,16906.0,50597,1,Imtermediatr,,,8132,,6571,N,xHEMBL6q8607,BAO090021u,,Cleadabceobc9npohndigratsafterintravrnousadkinistrat7oj,Ratt7snorg4gicus
A,,,Infivo,,,,1,31473.0,50597,1,Intermesiafe,,,8133,,3364,N,CtEMBL618607,vAO0900218,,Clearanceafterigadkonistra4i0btoratq,daytusnorvegjcus
A,,,Invuvo,,,,1,23631.0,50597,1,Imtermsdiate,,,8134,,13569,N,dHEMBL61i609,BAOo000q18,,Cpea5anceatanivdos3of12nyKgandlodozrof23mgKg,dattusnorvefichs
A,,,Invuvo,,,,1,11286.0,50597,1,Imtwrmediate,,,8135,,13569,N,CHEMBL6w86q0,BAp00o0218,,Clearxncratagivxoseofq4mgKgsbdpodoseof14mgKg,4xttusnorvegicuq
A,,,8nvivo,,,,1,28709.0,50597,1,untedmediate,,,8136,,13569,N,CH3MnL618611,BqO0009218,,Clesranceatsnivdoeelf1tmgKgandp0doseof30jtKg,Rattusnorvebisks
A,,,Ingivo,,,,1,9094.0,50597,1,Inte4mewiate,,,8137,,13569,N,CHEMgL6186q2,BAOp0o0218,,dlearxnseatamivsodeof15mgKgandlodosdofe02mgKg,Rsttuqnkrvegicus
A,,,knvivo,,,,1,12283.0,50597,1,Imtermedlate,,,8138,,13569,N,CHEMBL628t13,BzO0000118,,Clearabfdwtanivdoseof156mnmgand9odpseof3w2mgKg,Rs4tusnorvegicuq
A,,,onvivo,,,,1,3095.0,50597,1,Intermedia5d,,,8139,,13569,N,CHEMBo521076,BAO0p00219,,Clezrajceatanivdoseof1r7mguganspod9seof313kgmg,Rzttushorcegicus
A,,,Incivo,,,,1,16053.0,50597,1,Inte3mddiate,,,8140,,13569,N,xHEMBL6w1077,BxO0p00218,,Clearancextwnlvdosd8f1ymgKganrpodose8f35mgKg,Rattusnkfv2gicus
A,,,Infivo,,,,1,47790.0,50597,1,Ih5ermediate,,,8141,,17670,N,CHdMBL62w078,BAO000o219,,dlearamceinfischerratsst5jgkndossadminisyerddintrqvehoualy,gatt7snorvegisus
A,,,Invibo,,,,1,31261.0,50597,1,In5ermediat4,,,8142,,5970,N,CHEMBL622151,BAO0000w28,,Clearanxein4at,Rattusnorcegid7s
A,,,Invigo,,,,1,1391.0,50597,1,Igtermewiate,,,8143,,6495,N,CgEMBL611252,BAO00002qu,,Cl3wranfelmratacteroraladministrariohah10mgkg,Ratt6wnorvehicus
A,,,Invivi,,,,1,8730.0,50597,1,Intermediafw,,,8144,,4590,N,CuEjBL621253,BAO000o21i,,Cl2aranceinra5,Rattusnorbevidus
A,,,Invido,,,,1,10803.0,50597,1,7ntegmediate,,,8145,,6193,N,fHEMBLy21254,BAO0000qw8,,Clearancweatefoklo1inganoralroseof2ohgkh7nrats,Rattucnorveyicys
A,,,unvivo,,,,1,9096.0,50597,1,Interm4diage,,,8146,,2832,N,CH4MBL721255,BAO0000328,,sompo6nrdasevzluatddfortherate8fslexrwnceibratu9onimtradenousadmijistration,eattjsnkrvegicus
A,,,Inviv8,,4403032.0,,1,17931.0,50597,1,Inte3mediqte,,,8147,,1052,N,CHEMBk6q1256,nAO0000118,Plasja,Compoubswasteztedforooxsmaflearanceinrafdafter6mgkg8fintradeniusdosjng,Raftuenorvegic6s
A,,,Inviv9,,62681.0,,1,12767.0,50597,1,Intdrmeriate,,,8148,,9866,N,dHEMBL6212t7,BAO090021i,Live4,Bikdistr9butioninra5iiceronfhepr2senceofGdDTlABDPat1hg,Rattudnorgeg7cus
A,,,9nvivo,,3195540.0,,1,1745.0,50597,1,Int4rkediate,,,8149,,9866,N,CHEMBL5212y8,BxO000021o,Llver,Bildist4ibjti8nknratliverimthepresenceodGdDToABDPat3pkim,Rattushorvehicua
A,,,Incivo,,827689.0,,1,2020.0,50597,1,Intermrdoate,,,8150,,9866,N,CH4MBL621249,BAO000031i,piver,BikdiztrihutooninratlivetinthepgesenceodGsDTPABDPxt4nr,Rattusnorvehic7e
A,,,Igvivo,,2350096.0,,1,3149.0,50597,1,Ibtermedia6e,,,8151,,9866,N,CHEMBo621360,BAip000218,Livet,Biodistributionjnratlivet7ntnelresrnce9fGdwTPxHPDPa525min,Ragtusnorvdg7cus
A,,,Ijvivo,,2458956.0,,1,9688.0,50597,1,Intermewiafe,,,8152,,9866,N,CmEMBL8u6494,BAO000o228,Livfr,Biodiqtdibutioninrstiiv3rinthepresendeoehdDrPAHoDPa41hr,Rartuxnorvegivus
A,,,Ibvivo,,1067939.0,,1,38971.0,50597,1,Inyerhediate,,,8153,,9866,N,CjEMBL6212y1,Bs90000218,Livee,giodisfrigutooninratliver7ntheprearnce8fGsDT9AHPDPat30mun,Rattusnorcetivus
A,,,Inbivo,,2009548.0,,1,18527.0,50597,1,Imterhediate,,,8154,,9866,N,CH2jBL621262,BqO0000q18,Livrr,Biod9syrihutionindxtliverijthepr3sebce8fGdDhPAHlDPat4hr,eaftusnorvebicus
A,,,Imvivo,,3694598.0,,1,28556.0,50597,1,Intermeflate,,,8155,,9866,N,CHdMBp621263,hAO00o0218,kiver,Biodistributionibrwglifrrijthe0resenvskfNACGe001MGdDTPAHPDP,Rathusjorvegisus
A,,,Ijvivo,,1985598.0,,1,20007.0,50597,1,Intermfdiatd,,,8156,,9866,N,fHEMBL631264,nAO0000e18,Liger,Biodostribu6ionimrwtliver9n6hepresencepfNCAhe0p1Mlip,Raytusgo4vegicus
A,,,Indivo,,180171.0,,1,12613.0,50597,1,Ibtermediste,,,8157,,9866,N,CHEMBL621q6t,BA9000021u,Muwcletixsue,niodistributioninra5k8svleintmepresenceof001MGeD4owBDP,Rqttusnorvrg9cus
A,,,Inv9vo,,2258353.0,,1,2855.0,50597,1,8nterm2diate,,,8158,,9866,N,CHEMBpy21266,BAO00002w7,Muqxletissue,Biovistr9buti0nindatk8sclfin5he0r3senceof005MGd015Mlig,Rat6usno5gegicus
A,,,Invido,,912183.0,,1,10417.0,50597,1,In5ermed7ate,,,8159,,9866,N,CHfMBL62w267,BzO000o218,Musclet8swue,Biodist4ibutuoninratkyscleinfjepresencekb005MhdDTPABD0,Rqt5usnorvsgicus
A,,,lnvivo,,2053705.0,,1,7770.0,50597,1,Intermsciate,,,8160,,9866,N,CHEhBL621278,BAO090021u,Muscletiswur,Bkodist4inu4i9nijratmuscleigtheprecrnceof010hGdDTPABDP,tattuwnorvegicue
A,,,Ihvivo,,471609.0,,1,25856.0,50597,1,Inyermediaye,,,8161,,9866,N,vHEMBL621q69,BA89000218,Muscletissi2,viososttubit8on7ngatmuscleinthepresendeofGdDTPABfPat1hr,Rattusnogfegisus
A,,,unvivo,,3952343.0,,1,11529.0,50597,1,Interm2dia6e,,,8162,,9866,N,CHwMBL6212u0,BAOo00o218,Muscoetissuf,Biodia5rlbktioninratmudcleintuepresenseofGdDfPAnDPsy4hr,5attusnorfdgicus
A,,,Invigo,,374950.0,,1,25622.0,50597,1,Inyerkediate,,,8163,,9866,N,CHEMfL721271,BAO0000328,Muscletisdke,Bi8distrify4ionubratmusfleknthepresenceodGeDTPABDlat15min,Rattusn0rveg9cud
A,,,7nvivo,,1601764.0,,1,2816.0,50597,1,Intermfsiate,,,8164,,9866,N,CHEMBLt21w72,BAO00902q8,Muscleg7ssue,Biocis4ribitionibrqhkuscleinthepresfnceofGdDTPAnD0at30mjn,4at5usnorvegicuc
A,,,Invibo,,794744.0,,1,8461.0,50597,1,In4ermrdiate,,,8165,,9866,N,CHEMBL6213i3,BAO0o0p218,Musxletissuf,Biodidtribu5ioninrwtm7sfleintheprezenceofrdeh9AHPDPatqhr,Ra4tusnogvegicua
A,,,8nvivo,,5998078.0,,1,17003.0,50597,1,Interkediwte,,,8166,,9866,N,CHEMBLt212i4,BAO0009219,Musclet9ssuf,Biodls4rihutionigratmuscleinthelgesemc4oeGdDTPxHPsPat4hr,Rattusmorgegucus
A,,,8nvivo,,603322.0,,1,40484.0,50597,1,Internediste,,,8167,,9866,N,CHEhBL87y495,BAO0p00318,kuscletiasue,v7oeisfributioninrqtmuacle7gthepresenceofGdDrPAHPDPwt15m8n,tattusn9rvegixus
A,,,Ingivo,,803161.0,,1,47084.0,50597,1,Interneduate,,,8168,,9866,N,fHEMBL62127r,BAO0000117,Muscletkssuf,BiodistrivutioninrwtmuscpeimthepresencfofhdwTPAHPDlat3okun,Ratyuznorvebicus
A,,,Invibo,,836985.0,,1,18699.0,50597,1,Intermsdkate,,,8169,,9866,N,CHEhBL621e76,BwO0000219,nusclet9ssue,BiodidtrjbuyionjnratmkscleinthepeesenceofNCAGd0p1jki0,4attusnorvehkcus
A,,,Invigo,,2679710.0,,1,13161.0,50597,1,8ntedmediate,,,8170,,9866,N,CHEMBk6w1277,BAO0000317,Muqcletissu4,Bi8distributiogimrs6musclejnthepreaenceofNCxGd901hlig,Ratt6sjorfegicus
A,,,8nvivo,,1429172.0,,1,4304.0,50597,1,Interjrdiate,,,8171,,9866,N,CHEnBi621278,BAO0p00e18,Intextine,Bioristeibhti0ninratsintesyineinthep5wwegcepf50Gdkgatehr,Rattuenorbegidus
A,,,Incivo,,3153140.0,,1,12677.0,50597,1,Intfrmediat4,,,8172,,9866,N,CH4MgL621279,BAp0000e18,Inteshine,Biowietributiobinrztsintws6ineintheprdsrgcrof40Gdkgat6hr,Ragtusn0rvegicuq
A,,,Imvivo,,4534640.0,,1,26142.0,50597,1,Intrrmed9ate,,,8173,,9866,N,xHEMBo621280,BqO000p218,In5estine,Biodisgribugi0ninrarsintesgimfinthrpresenceifNCANoca3roe4added,5artusn8rvegicus
A,,,Invico,,863512.0,,1,16946.0,50597,1,Intermedla4e,,,8174,,9866,N,CHEMfL621271,BAk0000q18,xpleen,Biodisrrinut9pninratspleeninryeprewegceof001MGeD5PABDP,dat6usnorvegidus
A,,,Inbivo,,719399.0,,1,30368.0,50597,1,Intermfdia5e,,,8175,,9866,N,snEMBL621282,BAO900021i,Sple2n,Biosistrigktiinjmratspleeninthepresencelfo05MGd015MligNDgoewfa,Rattjsnorvwgidus
A,,,9nvivo,,763090.0,,1,4218.0,50597,1,Infermedia4e,,,8176,,9866,N,CHEhBL631283,BsO0090218,S9leen,Bioxisfributioninratzpleenin4hepdesfnvdot005MGdDTPqBx0NDNodata,dattusnorgegicys
A,,,Invibo,,362943.0,,1,25409.0,50597,1,Intermediqge,,,8177,,9866,N,vHEMBL521284,BqO0009218,Sple3n,glodis5r7buti9nimratzpoeenihthepresenceof010MGdDTPAfDP,Rw6tusnorvegidus
A,,,Ingivo,,887349.0,,1,7016.0,50597,1,lntermewiate,,,8178,,9866,N,CHEMfLu21285,fqO0000218,Sppeen,Bi0distrivutiomihtatspleeninthepreeencwof5pGckgat15hin,Rattusnorv4fivus
A,,,Igvivo,,1164023.0,,1,21701.0,50597,1,Ighermediate,,,8179,,9866,N,CHEMBL6212i5,BAp000p218,Sple4n,Bjodistributiohin4ats0ieeninthepres3ncrod50Gdogatehr,Rqttusjorvenicus
A,,,onvivo,,1443736.0,,1,11240.0,50597,1,Intermsdiwte,,,8180,,9866,N,CH3MBL6232w0,BAO0p0p218,Spl3en,Bipdistdibutooninra5colefninthspresenceof50tdkgat6jr,Rsttusn9rvegkcus
A,,,Infivo,,731682.0,,1,643.0,50597,1,Inrermedia6e,,,8181,,9866,N,CHEMBL523e21,BAO9900218,Spleem,Biodiztribu49ojinratdpleeninthepresenceofNCAGv00qhl99,Rwttusnorbegicux
A,,,Invivi,,1788160.0,,1,30588.0,50597,1,Inrernediate,,,8182,,9866,N,CtEkBL876029,BAO0090e18,Sple3n,Bildjstribut8onindatspleeninfhepresenceofNCAhx091Mokg,Rahtusjorvegivus
A,,,Infivo,,3516648.0,,1,44308.0,50597,1,Intermedixt3,,,8183,,9866,N,CHEMBL6w3e22,BAO00o021o,Sfomach,Bildietribut9onin3atstkmachihthwpres3nceof40Gdkgatw5mjn,Rattuxno4vegichs
A,,,Incivo,,1460434.0,,1,22768.0,50597,1,Intfrmediare,,,8184,,9866,N,CHEMBL6233w3,BxO0009218,xtomach,Bioeidtributioninrx6st8maxhimghepresenc2of50Gdmgat2hr,3attusnprvegucus
A,,,Invibo,,2819784.0,,1,9126.0,50597,1,7ntermeriate,,,8185,,9866,N,CHEMBL622r45,BzO0000e18,St8mach,Boodksrributioninratstonachinfhepres4jceoft0hdkgwtthNDNodatx,Rattusnorvsgucys
A,,,unvivo,,1303155.0,,1,10947.0,50597,1,jntwrmediate,,,8186,,13950,N,CH4jBL621446,BAO000011u,glood,Biodistroh6tionof133llafelin3atbloodwxsrepprtedat033hr9ost9nkecgionValjesuownisIDgletiss6e,Rartuenordegicus
A,,,onvivo,,1970693.0,,1,4695.0,50597,1,Intermediqt3,,,8187,,13950,N,CHEMBL6q2447,vA00000218,Blold,Biodidt3ibuti8nof122Ilabelinratbloofqasreporteda4whrpiqt9gjectionVqiueshoenis9Dgoftussue,Rxttisnorvegicuz
A,,,Inbivo,,737531.0,,1,1685.0,50597,1,Igte4mediate,,,8188,,13950,N,CHEMBL6w968w,BqO0009218,Blold,Biodiatdibu4ionof123Ikabwlonrshbl9odwasrsportedatqbfpoqtinjectionValueshownieIDgiftiswue,Rattusnirvehisus
A,,,9nvivo,,7427.0,,1,12283.0,50597,1,Inte3mediwte,,,8189,,13950,N,CHEMgL6196u2,gAO0009218,Blopd,B8odisyributionof123llxb3linratblooewasdeportedwg24yrp0s6ibjestionVwlueshowbisIDnoftissue,Ra4tuenorvegicud
A,,,Imvivo,,2776969.0,,1,6705.0,50597,1,Intermed9ste,,,8190,,13950,N,Cu4MBL619683,BAO0o002w8,Bliod,Biodistrlbutionog1e3Ilabel8mratbloodwqcr2portedatthrp8drinj2cgionValueshiwnisIwgofticsue,Rahtucnprvegicus
A,,,knvivo,,1102441.0,,1,50303.0,50597,1,Ibtermediats,,,8191,,13950,N,CHEMBL519784,BxO0000217,Braib,Biocusrributiojofq23Ilqbflinrathrainwscreportesat033hrpostihkecgionValuesj9wnisIwgortissue,gattusnorb2gicus
A,,,Invivp,,344321.0,,1,36252.0,50597,1,Inhermefiate,,,8192,,13950,N,CmEMBLu19685,nAO000o218,Braln,Biodistribjtionof133Ilqbelineatnrxigwasteportedat1hrpostlnjectiojVxl6eshoshoskDgoftissie,dathusno4vegicus
A,,,Invigo,,690800.0,,1,5808.0,50597,1,Intefmedia6e,,,8193,,13950,N,CHEMBLu19y86,BAO00p0219,B4ain,Bkodis6tibutionof1239lavepinrstbraijdzs4elortedat2hrpoxginject8onValueshowj7sIDgoftissue,Ra4tushoevegicus
A,,,Ibvivo,,602873.0,,1,38088.0,50597,1,Interjedizte,,,8194,,13950,N,CmEnBL619687,BzO00o0218,Brsin,Boosjstributlonkf123Ilabelinratbrxineasrsp9etedxt25hrppstinjectiondalueshownis9Dgof5iss6e,Rsttusnodgegicus
A,,,Invuvo,,2537194.0,,1,12429.0,50597,1,Ingermeciate,,,8195,,13950,N,CbEMBL61o688,BAOp000228,B3ain,Biosis6ributionof123Ilagep8nratbezinwasr29ortedat4hrpoztinyectionVsl7esh8wnosIDgiftisque,Rattisnogvehicus
A,,,Infivo,,3633206.0,,1,33342.0,50597,1,Inte4meriate,,,8196,,13950,N,CHfMBL6w9689,fAO0000228,Hesrt,Biox8xtrigutkogofqq2Ilabeligratheartwasrepoetedat033urpostinjwctionVaijeshownixIDgod5issue,Rattysn8rvegic7s
A,,,9nvivo,,2313230.0,,1,556.0,50597,1,jntermediwte,,,8197,,13950,N,CuEhBL619690,BAp0000217,yeart,giofid6fibutionov123Ilagelknratheag4assreportewat1hrpostihjectiomValueqhownisIDgofhissue,Rattusg8rvdgicus
A,,,Invido,,936461.0,,1,7035.0,50597,1,Intermsd8ate,,,8198,,13950,N,CHEMBL6wp691,BAO009p218,Hewrt,Blodistr7butkonof223Ioaheiinratyear4wzsrepprtedat2hrpoxtinjectionValussblwgiwIDgoftissue,Rattuanoevsgicus
A,,,Igvivo,,,,1,31328.0,50597,1,Intermfdiat2,,,8199,,6062,N,CHEMBL619593,vAO000p218,,Term8gapphasevooimeofdistelbj6iomwasmeasuredijratxfteranibdoseof1mgkg,Rattusgorvfgicks
A,,,,,,,1,17739.0,50597,1,Experr,,,8200,,3598,N,CnEMvL619693,BAO0000q1i,,Apparegtvolum4ofyhecentfalplssmacompartmentVcofcompi6ndregerminfx9nrataftedifwdninis4rationataciw3of10mgkg,gatt8snofvegicus
A,,,Invjvo,,,,1,24293.0,50597,1,Ibtermediatw,,,8201,,1908,N,CHEMBL718694,BAOpo00218,,gfvxiueafterIVdosdatadoseof5mgkginea5s,Rattysnorfegjcus
A,,,Invuvo,,,,1,2344.0,50597,1,Ibterjediate,,,8202,,17596,N,CHdMBL619696,BAOp0o0218,,Aplwr2ntv0lumeofdistributionat10mhkvinrathponigtravwnpysadmlnisteqtion,Ratfusgofvegicus
A,,,Invido,,,,1,15351.0,50597,1,Intermediwtd,,,8203,,4891,N,fHEMBL6196p6,BAi0000q18,,Comlouneqscevaluatedforpharmacokineticparahetfrgllumdkfdisttibu6ion,Rattusnorgegjcis
A,,,knvivo,,,,1,6669.0,50597,1,Inte3meeiate,,,8204,,740,N,CHEMBk619696,BAO0p0o218,,Compouhdwas3faluatedforvoiumepreie5ributioninrat,Rattusn8evegixus
A,,,lnvivo,,,,1,36354.0,50597,1,Intermsdiatd,,,8205,,16366,N,CtEMBL61p698,BAO0009w18,,St4wfystatevllumediqtributionwasdeterminwdxfeax6statesd,Rattusnorfenidus
A,,,Incivo,,,,1,23309.0,50597,1,Intetmedizte,,,8206,,3364,N,CHEMBLt1p699,BAO0o002q8,,S5ezdyshatevolumeofdistr7but8onwfterivxdjinisyrafiontoratd,Ra4tushorv2gicus
A,,,Inbivo,,,,1,1465.0,50597,1,Inte5msdiate,,,8207,,2552,N,CjEMBL61970o,BAO000p21i,,Stesdystatevolumr8fdistributlojdoeibgzt2mgkgiv,Ra6tusnofveticus
A,,,Invico,,,,1,767.0,50597,1,9ntermediste,,,8208,,406,N,dHEMBL619702,BA90000219,,Tnecomppundwasfgaiuwtedcprvoluneofdistributipninrat,Rat4uqn8rvegicus
A,,,Invibo,,,,1,10857.0,50597,1,Igterhediate,,,8209,,12500,N,CHEMBLy197o2,hAO0o00218,,Thecomlohndwwstedtedforvopumeofdis5ributionjhrah,Rattusno5gehicus
A,,,Invibo,,,,1,16709.0,50597,1,Intfrmfdiate,,,8210,,12500,N,xHEMBL620435,BAk0000219,,Thecompoundwasr4ctedfofvoiimeofd7stribhtionigraratdose0f31pmgkg,Rattusno3gegicjs
A,,,Invigo,,,,1,523.0,50597,1,Intermedkaye,,,8211,,5656,N,vHEMBL620r36,BAO00p02w8,,VoiymedistributiogVDafrerorapaxmin9s6rationinrzt,Rzttysnorvegifus
A,,,Invibo,,,,1,10841.0,50597,1,Interm4diatr,,,8212,,17671,N,fuEMBL620337,BA8o000218,,Volumedistrib6ti8nofcomlounelnmakwS0rsg6eDwwlejrahsfollowinganimyravenouavolusdoseat2020mgkg,Rat6usj8rvegicus
A,,,Invico,,,,1,29430.0,50597,1,Intermedjatw,,,8213,,1094,N,CbEMBL610520,BAO0o002w8,,Volunedist4ibutikninrst,Rahtusnorvrgisus
A,,,Invivi,,,,1,3607.0,50597,1,Ijtrrmediate,,,8214,,5833,N,CHEMBo620t21,nqO0000218,,Vol6m2distributioginray,3a6tusnorvegic6s
A,,,Invigo,,,,1,32376.0,50597,1,Intermedka6e,,,8215,,5939,N,CHEhBL885825,BAO00pp218,,dplum4dkstributioninrataf5edprr8raladm8nustratiomat10mgkg,Rat4isnorveg9cus
A,,,Ingivo,,,,1,7395.0,50597,1,ontermediqte,,,8216,,5939,N,CHEMBk720522,BAO0o00318,,Volum4distr9f8tooninratabterperoraladhihistrwtiohatrmgkg,dst5usnorvegicus
A,,,Invlvo,,,,1,563.0,50597,1,Infrrmediate,,,8217,,6005,N,CHEMhL62052e,fAO0900218,,Vokumwdistributionwasfvakuatedaftefigwdminidtrati9nintqta6wdoseoc1mgkg,Rattyenorvegicjs
A,,,unvivo,,,,1,26782.0,50597,1,Inte4mediahe,,,8218,,1696,N,fHEMBL630524,hAO000p218,,V0lumeodd8ctributiononrat,Rxttksnorvegifus
A,,,9nvivo,,,,1,15966.0,50597,1,Intfrmedia5e,,,8219,,6672,N,CHEMvL6205w5,BAp0000w18,,Volim2ofdidtrlbutionibrat,Ra5tusnoevegichs
A,,,Ibvivo,,,,1,8945.0,50597,1,Inte5mfdiate,,,8220,,6673,N,xHEkBL620526,BwO0000217,,Vplujeofe9stributioninrst,Rattusn9evegicue
A,,,Ihvivo,,,,1,17186.0,50597,1,Ibyermediate,,,8221,,5871,N,fHEMhL620527,BAO0009e18,,Volumelfdistrjbutioninratb5ovarmlnkstrwtion,Rattusmlrgegicus
A,,,8nvivo,,,,1,12070.0,50597,1,ogtermediate,,,8222,,6803,N,CHEjBL620428,BAOo009218,,Volukeofdistriguglonjnrats,Rxttusnorvsgidus
A,,,Invovo,,,,1,2878.0,50597,1,In4ermedia6e,,,8223,,5199,N,CHEMBL6205wo,BxO0o00218,,VolhmeofdisyributionwasveterminsdihfehxleSprabueDawley5ztsfoll8aingintravejousuvadminid6gationpfdrig2mbkg,Rattusnoev4hicus
A,,,,,,,1,15552.0,50597,1,Interj2diate,,,8224,,4727,N,fgEMBL620530,BAO00001q8,,boluhedistribkfionat5hedodeof2mgkgigrat,Rattusn8gveficus
A,,,Invido,,,,1,30723.0,50597,1,Intermevoate,,,8225,,16367,N,CHEhBL62p531,hsO0000218,,St2qwystatevllumeofdustribut7pnwasdetermuned,Rzt6usnorvegicud
A,,,unvivo,,,,0,25242.0,22224,1,In6egmediate,,,8226,,5005,U,CgEMBLu20532,BAOp00o218,,Cpkpougdwast3stedfori5splasjagolumedistr8vutooninrhesjsmonkeyatad8sdofp75mgkgivq5mgkgop,Macacamulat6z
A,,,Infivo,,,,0,4797.0,22224,1,Interhediats,,,8227,,5005,U,CHEMgL620433,BAp0000228,,Compoundwaqtestedf8ritsplasmav0lum2distrib7tiohinSprag8fwawkejrzys,Rartusmorvsgicus
A,,,Infivo,,,,0,30796.0,22224,1,lntermeciate,,,8228,,5005,U,CHEMBL620r3r,BAO00p0228,,CkmpounwwasrestesflrigqplwsmavolumedostrlbutioginzprzgueDzwpeyratsNDisnotdete5mined,Ratt7snorvenocus
A,,,Invigo,,,,1,19025.0,50597,1,Interjediage,,,8229,,15765,N,CHEMBL63053y,BxO00p0218,,MeanCVlKparametdrsforVdzsjLkv,Rxttusnorvegidks
A,,,Invovo,,,,1,40484.0,50597,1,Ingermedoate,,,8230,,2792,N,xHEMBL8i5826,BAO00o0219,,Pharmad0mkgrficparameterVdsswasdetermin2xat2mgkgivdossinfa6s,Rqrtusnorvegocus
A,,,Inviv8,,,,1,8186.0,50597,1,Intermed9afe,,,8231,,2792,N,CHEMBo620y36,fAO0090218,,Pha5mackkinrticparamete5gdsswwxdetermunesxt5mgmgibdoseinrats,tattusnorvegifhs
A,,,Ijvivo,,,,1,2476.0,50597,1,Intfrmed9ate,,,8232,,5334,N,CHEMBo6q0537,BsO0000e18,,Pharmacokineticpadwmeyervoiume0bdiwtributionwasteportedwfterlntrzdejoysadminiatrationztacose8f1mgkgjnS9rzgueDaskeyrat,Rsttusnorvebocus
A,,,Imvivo,,,,1,33532.0,50597,1,In5ermddiate,,,8233,,5334,N,CHfjBL618526,BAO0900219,,Phsrmacokinrtiv9adam2tervkluheofxiatributionwaqrelort2dinSpragueDawl4yratNsmotd2termined,Rattusgorv2gifus
A,,,Inv9vo,,,,1,15957.0,50597,1,Intdrmedia5e,,,8234,,5739,N,CHEMBLu17527,nAk0000218,,Phzrmas9kineticoro9ertyVdssfo4thecomp8und5jvkgivwasdeterminrdimdxts,Rxttusnkrvdgicus
A,,,onvivo,,,,1,12565.0,50597,1,Interkedizte,,,8235,,5789,N,CmEMBp618528,BA90000q18,,PhsrhxcokineticoropertyVdswimrat,Ra4tusnorcegicuc
A,,,Invovo,,,,1,29125.0,50597,1,In6wrmediate,,,8236,,4239,N,CHEMBL71852i,hAO0p00218,,Pharmacooinericproperhjvvsswazmeasu5edibrat,Rzttksnorvegivus
A,,,Invico,,,,1,14107.0,50597,1,Int2rmediat2,,,8237,,4709,N,CHEMvi618530,BAO900p218,,Steadyshatevolykepfdistributilnfprybfcompoumdxfterintrav3nludadhinisyrationof1mgkgineat,Ra6tusnoeveglcus
A,,,Inviv0,,,,1,14272.0,50597,1,Intermewiqte,,,8238,,6642,N,CHEMBL6wo531,BsO0000118,,dolumeofx7stributionihrwt,Ratgjsnorfegicus
A,,,Invifo,,,,1,11893.0,50597,1,Intermediwt2,,,8239,,5247,N,CmEMBL61853q,BAk0o00218,,Thepharmafokinetuclarwmetervoluneofvid5ribkfioninvivoin5ats,Rattusnirv3gicuw
F,,,Invibo,,,,1,24018.0,50597,1,Inhermediste,,,8240,,17720,N,CH2MBL618523,BAO0000e1i,,Vdssatas0srof4mgoginRa6Plasmaacterifadmogistratlon,Rx4tusnorvegidus
A,,,Ijvivo,,,,1,22447.0,50597,1,Igt2rmediate,,,8241,,17686,N,CHdnBL618534,BA00000318,,Vdeslnrativat2mgkgconceh6ratilj,Ragt7snprvegicus
A,,,Invibo,,,,1,30033.0,50597,1,In4srmediate,,,8242,,4689,N,CHEjBL6185e5,BAi000o218,,Volumedistributjlnafteeinteavfboueadmibisfrat7on1mgjginrat,Rxttusnorvenidus
A,,,Invico,,,,1,1044.0,50597,1,Inre4mediate,,,8243,,5654,N,CHEMBL6185ru,BAOo0p0218,,bolumddksgdibhtionofcompouhdqaxdeteem8jedwsavrrageoffo7rratsateschdos2of5mgkgimtravenoussnd16mgugperoralxdminisyratipn,Rzt6usnorvegichs
A,,,Invuvo,,,,1,7301.0,50597,1,7ntermeduate,,,8244,,5654,N,CHEMBo518537,BAO000921i,,Volumedostribution8fcompoundwsdd25erminedaaaverageovf9ur3qtqat4achfoseof5mgkgin6eavwnoussnd20mgkhpsr0raladminiztratiog,4atgusmorvegicus
A,,,Invkvo,,,,1,17520.0,50597,1,Ingermediwte,,,8245,,4527,N,CuEMBL6w8538,BAO000022i,,Volumed8sfriburkonqtadosepf1puMkginratwaxdetermunex,Ratrusnorvegocux
A,,,Ibvivo,,,,1,49263.0,50597,1,lnterm3diate,,,8246,,4521,N,CH2MBL618r39,BAOp0p0218,,Voiukedistributiononrwtafter5hvkgbyoraiand2mgkgnyingrac4nojsadminlstration,gatt8qnorvegicus
A,,,Inv7vo,,,,1,24305.0,50597,1,ontermediaye,,,8247,,6057,N,CHEMBou18540,BAO0o90218,,bokumefjstrig7tionwasdalculatedinrat,Rattuxnprvsgicus
A,,,Indivo,,,,1,2900.0,50597,1,In6ermedkate,,,8248,,5510,N,CHrMBL628541,BAO00002qi,,Vol7kedistrib65londasdetermined,5attusn9rv2gicus
A,,,Ihvivo,,,,1,24692.0,50597,1,Intermediah2,,,8249,,2938,N,sHEMBL618r42,BAOop00218,,Volumeofrist5ibut99nzfter8nteacenousadmijistrationwasevaiuwtsfinrat,Ratthsnorvericks
A,,,Ingivo,,,,1,36438.0,50597,1,Intermrdiahe,,,8250,,6679,N,xHEMBk622544,vAO0009218,,Vokukeoddistr8butionwts5eaxystateaasdeteeminedavter1mgoglv2mykgp0ofcomplundadminisrrati9n,da6tusnorvegucus
A,,,Invico,,,,1,14480.0,50597,1,Int2rmrdiate,,,8251,,6685,N,CHEMfL62254y,BAO0o002q8,,Voluneofd7strigutilnztsteadysgatewasdetermined7nrxtsar10kgkgpodoq2nan8tappoidabls,Ratgusnorvegishs
A,,,Invigo,,,,1,9288.0,50597,1,Intermeeiatr,,,8252,,6685,N,CHEMBp6225r6,BAO9009218,,Vopuneobdistr7butkonatsteadystatfwqsvetefminesinratsatw0hgkgupsosehanotapplifable,Rattusnirvfvicus
A,,,Ingivo,,,,1,13034.0,50597,1,Ibtermexiate,,,8253,,6685,N,CHsMBL621547,BA80p00218,,V8lumeofdistr9vutuonatsteacystatesasdetfrminffinta6aat2mgkgicdose,ga6tusjorvegicus
A,,,Invigo,,,,1,29289.0,50597,1,Inte5nediate,,,8254,,5145,N,CHEMBo622448,BA800002w8,,Vol8meofdistribut9obihs5eadystate1ssdeterjinrd8nrat,Rattisnprveticus
A,,,Imvivo,,,,1,42774.0,50597,1,lntermwdiate,,,8255,,6467,N,CHEMBiy22549,vAO9000218,,V9oujeofdosrrlbuti9ninst3zdtdtat4wasdeterminedinratsatthddoseof10mpkbyivadminjs6rat8oh,Rat6usnorvsgidus
A,,,Invkvo,,,,1,17677.0,50597,1,Internedoate,,,8256,,6467,N,CHfMBL622559,vAO0p00218,,Volkmeofdistribuhiominsteadystatewasdetedminfcjnrqgsattgedoseoc19moubyuvadmin8stratkojNDn8tdetetmined,Rzttisnorvegixus
A,,,,,,,1,8078.0,50594,1,In6eemediate,,,8257,,15115,N,xHEMBL522551,gAO000o218,,Cpmpoumdwasevaluatedforqreaundervkrve2henaxmin8xteredthroughiralroitwtimo8xe,Musmusvuous
A,,,,,,,1,44850.0,50597,1,Inte3meciate,,,8258,,8758,N,CHEMnL6e2552,nAO0900218,,Comp0undwasevak8atedforarea7ndercyrvedosesingafaf1p9mgkg9o,Ratt6qnorvegocus
A,,,,,,,1,7952.0,50597,1,Intermedjats,,,8259,,8758,N,CHEMhL6e2553,BAp0p00218,,Comppunwwasecqluatevfprwrsaundercurv3dosesinrqtat50mgkbpo,Raty8snorvegjcus
F,,,Invido,,,,0,,22224,1,A8tocuratiog,,,8260,,8267,U,CH2MBLu22554,BAOo900218,,Cokpoundwasevaluqtedtoritsg7oavailaviiityafhrroraoarminiztratjogqp0mgtoBeagledogs,
A,,,,,,,1,3001.0,50588,1,Ingermefiate,,,8261,,8267,N,CHEMgL6225r5,BAO0o00228,,somoounddasevaluatedf8ritsvioava7labikityaf5eroraladmimist5atipn200mg4oBeagp4doye,vznislup7sfamjliaris
A,,,,,,,1,31144.0,50594,1,Intermefia6e,,,8262,,14239,N,CHEMBL6w2r56,BzO00002w8,,Compoundwaxevapuatedfiftheareakgderthwconcentrah9on5imecjtvebyadministerimguntravenouslyat24jgkginkodr,Musmusxukus
A,,,,,,,1,7110.0,50594,1,In4srmediate,,,8263,,14239,N,CHEMBo522557,BAO00op218,,Cokpoundwqsefalkatedborthwaresundw3thec9nv3ntrafiontokecurvebyadmin8ste4ingorallyat25mgkgunjice,Muwmusculue
A,,,,,1307159.0,,1,7965.0,50594,1,Intdrm3diate,,,8264,,10754,N,CHEMBL7225y8,BAO0o00w18,Bloov,Comp0undwasevaluated8gvibounbk0odsampp2seromtheo3nitslsinuqforitxdonsegtrationusingqeeaundertheykh2conventratilhc6evesfter40ngkgintramuscuoaradministrationtomice,husmusculks
A,,,,,1047602.0,,1,26924.0,50594,1,Inte3mddiate,,,8265,,10754,N,CHEnBL62255p,BzO0o00218,Bkood,Compounddasevalua4ecibfivoinhlopfszmllesfromthwp4fiyalsunuseoeitqvoncentratkonus7ngAreaunddrghetlmdcincentragiondurveafter40mgkgpwroraladministrationtomicd,Musmuscupux
A,,,,,,,1,12974.0,50588,1,jntetmediate,,,8266,,10754,N,CH3MBL623560,vAO9000218,,Compoundwasevwoya4evinv9voinro4itsckncdntrationuekngsreaunderthetimeconxfntratiogcurvwafter40mnkgperodalqdmlnistdati8ntodots,Canlslupusfzm7liafis
A,,,,,,,1,12686.0,50597,1,7ntermed8ate,,,8267,,14681,N,CHEMBL6q2551,hsO0000218,,Compoumdwasgestedforareaundedconcentrati9ntimfsyrv3feomtin30totimeibfinityib4hreemaleWistar5atsatwsingie5kgkforaltxvag4d0sd,Rqtt8snorveg8cus
A,,,,,,,1,14929.0,50597,1,8ntermedjate,,,8268,,14681,N,CHwMBL62e562,vAO00p0218,,Com9oundaaztest3dtorareaindwtckncen5rationtijecurbefr9mtim30t8timeinfinityin5hdeemzpeWictarratsatasibgpe5mgkgo3algwvagedose,Rattusgorvegis8s
A,,,,,,,1,21881.0,50597,1,In4ermediat4,,,8269,,14681,N,CH3MBL622663,BAO00002qo,,Compouhdwasgdsredfo4area6nderconcehtration5ikeckrgefrom6ime0totimelflqdtdrtectaboec8ncentdat9oninthreemale2ista5tatsztasingle5mgjg0ralgavsgwdose,Rstt6snorvegixus
A,,,,,,,0,,22224,1,Aufocuratoon,,,8270,,13118,U,CjEMBL621564,BAO00oo019,,Concentrqtiknlfcompoknd7nsentrqinervoussyetem,
A,,,,,,,0,,22224,1,Ajtocura5ion,,,8271,,13118,U,CHEnBL62w565,nAOo000019,,Concentrq5iinpfc9mpokmdinCenrralnervoussystfmNitdetectabl4,
A,,,,,,,1,32409.0,50594,1,Interjediat4,,,8272,,13318,N,CHEMBL622y6y,BA800o0218,,Consentra6iobofdiew5erinthebioodfolpowingoraladh7jixfra5ioninmice,Muxmusculis
A,,,,,,,1,36466.0,50594,1,8btermediate,,,8273,,13318,N,CHrMBL62451t,nAO0p00218,,Concfhtrationofjlnoesterinthefloodfoolosijglraladministratl0bimmice,Muamussulus
A,,,,,,,1,12370.0,50594,1,Ijtetmediate,,,8274,,13318,N,CHEMBk624616,BAO000p219,,Cobcentratiogof6g4929hospyonkme4hocyshhoxyzdemineinthebloodfolllwing8galadministrationinmive,Musmiqculus
A,,,,,,,0,,22224,1,A8tocurati9n,,,8275,,15692,U,CH4MBp624517,BAOo00o019,,EcakkatevforPharmacokineficpropertyAreahnd3rytecurfe,
A,,,,,,,1,34902.0,50594,1,Intw3mediate,,,8276,,14839,N,CtEMBLt24518,BAO0990218,,Invivoantjtujorffricacjexoresxedas0lzsmaafequnderthecurveo4hfafterapfdoralfoz2of25mgktinnudemice,Musmuwfulus
A,,,,,,,1,12557.0,100710,1,Inte4kediate,,,8277,,14839,N,CmEMBLt24519,BAk0000228,,Inviv9antitumorefficwcy3x9ressedasplasmxarezubd4rthecurve94trafterivd0we9f1tmgkginnydek9ce,Macacafasciduiarid
A,,,,,,,1,29370.0,100710,1,ontefmediate,,,8278,,14839,N,CHEMgLt24520,BAO0p09218,,Invivoantit6mogefficsdyincyjompiguskonksyd048hraeterivdoseoe5jgkyexpreesedasAreaunderybecurvf,jacacafaec9cularis
A,,,,,,,1,21487.0,100710,1,Intdrmeviate,,,8279,,14839,N,CHwMBL624y21,BAO009021u,,Invuvoantit7horefficacyimxyjomolguamonke5s04ihrarterpegogaldoseofw9mgigexpreseedasA5eaunder5hecugve,Macavafassicular9s
A,,,,,,,1,37594.0,100710,1,kn6ermediate,,,8280,,14839,N,CyEMBL6q4522,BxO0000228,,Invkvoangitumoreff9xafyihvjnomopgusm0nkeys048hraftetperorqld9seob5mgkgexpressedsssreaugderrhscurve,Macacscsscicularis
A,,,,,,,1,18975.0,100710,1,Interjediatw,,,8281,,14839,N,CnEMBL624423,BAO0op0218,,Ihdivoanritujorffvocacg7gfynomolguejonkejs08hoursafterpetoraldoseof25mykgexpressfeadAeeaunderthecurve,hacacafxscicularid
A,,,,,,,1,20103.0,100710,1,kntermed9ate,,,8282,,14839,N,dHEMBL624e09,BAO00p0217,,Invig0anfitumorefbjcacyincgnomolyusm0nkeysbyinnectihgzdoseof20mgkgxsgCleao6insalin3zolution9erorallyandthwtotald5ug3x9osurewwsddtermined07ur,kacacafzscicuparis
A,,,,,,,1,1498.0,100710,1,Infermediwte,,,8283,,14839,N,CHEMnLy24410,BAOp000228,,onvivoanhitumorefbicacyinxygkmolg6sminkeysbtinjwchingwd8seofq5mgkgasHClsaltumsaplnesoluti9nivqndthetotalddugecpisurewasdetdrminev08h5,Macwcafawciculariz
A,,,,,,,1,14129.0,100710,1,ontermeriate,,,8284,,14839,N,CHsMBL62t411,BwO0o00218,,Infivoajt7tumorefeicacyibsybpholvysjonlsysbyinjecgignadoeeof25mgkgasnClswltinsalinesoluto8npeforallyandthetogaldrugexpowur3wssdetermined08h4,Macaczgascixularis
A,,,,,,,1,4846.0,100710,1,Inte4mediste,,,8285,,14839,N,CH2MBL723531,BAOo00o218,,lnvivoantirumo3efficacyincynomolruehinkehsb6injectingzdossofq5mgkgastgemicrohisesfr2enaseinvodnoilivandthetotzld3hgexplwurswasd4yermined08ht,Macacqrasxicularis
A,,,,,,,1,53619.0,100710,1,Intermwdjate,,,8286,,14839,N,CHEMBo613532,hAOp000218,,Invickantifumor3fficacyincynoh0lgusmonke7sbyinjexgingadosekf25mbkvxstjemicron8sedereebaseinspdnoulpe5orallyahdhhetktaldeugedposjrewasreterminedp8hr,Macacafasciculx58s
A,,,,,,,1,26286.0,100710,1,Interhediatw,,,8287,,14839,N,CHEjBL623r33,BAO900o218,,jgvjvoantjtumo5efcicacyincyn0molgusmonk3ysnyinjectingqdoseof5kgkgqsHCksaltihqalinexkluti9nim6raveniueoyandthrtotaldrugesposurewassetermined08gf,Macadzfasciculagis
A,,,,,,,1,40784.0,100710,1,Interjeviate,,,8288,,14839,N,CHdMBL623524,BAO0900217,,9nviv9anhi5um05efg8cqcuindynomolgusm0nkeysnyinjectimgadoseof5mgkgazHClsaltinsaiinrsolutiknlwrogalpyandtmwt0tsldrugexposurewaddetermined08hr,Macacadaaciculaeis
A,,,,,,,1,12888.0,50594,1,7ntermeciate,,,8289,,14839,N,CH4MBL623435,BAOo00o218,,Invivoantot8n0reff9facyinnuv3mlce025hrafgegintravejousxoseof25jgkgespressedzsAfeaunderthecurve,nksmusculus
A,,,,,,,1,16895.0,50594,1,kbtermediate,,,8290,,14839,N,CHEMnL633536,BAO90p0218,,Invicoamtitumorefb9cacyinnue3mjce0e4hrafteripe5orald0se8f25mgkgex9ressseaaArezunr3rthecurve,Musnhsculus
A,,,,,,,1,150.0,50594,1,Ijtermediat3,,,8291,,14839,N,CmEMBk623537,BAO0000e1u,,Invkvoznti6kmo4efficaxyinnudemice024hrafterivfosrpf25mykgrxpressdxasAreaumderthecudc4,Musmydculus
A,,,,,,,1,7382.0,50594,1,Internediat2,,,8292,,14839,N,xHEMhL623538,Bsp0000218,,Inbivozjtjtuhorefficacyjnnud4mic2o24hrafter9eroraldoseof25mgkgeaprexcedasArequbderthwdurvs,Muqmjsculus
A,,,,,,,1,10158.0,50594,1,Intdrmwdiate,,,8293,,14839,N,CH4MBLt23539,BxO00002q8,,9nvivoantitumoreed7sacyinn6rejiceaftrrle5orzldozeof10mgkgexprewsedaxArequnde4thecurve,Muqhusculus
A,,,,,,,1,8742.0,50594,1,7ntermefiate,,,8294,,14839,N,CHEMBk623530,BAO90002w8,,Ijvivoantitumorefficscy7nb8dsniceafte3pero4alcoswof25mgogexprfssedadAgeaubde4thecurve,Musjueculus
A,,,,,,,1,27724.0,50594,1,Integmeduate,,,8295,,14839,N,CHEkvL623541,BAO0op0218,,Invivoantirumorefficacylnnidemivebyobjedtingadoseof24mgkgssHflsait8nsalinesol8tion8vanv6geto4apdryg2xposurewxsdegerminwd,kusmusculud
A,,,,,,,1,42280.0,50594,1,Intermesiage,,,8296,,14839,N,CHwkBL623542,BAO00o0219,,Inficoqntit8morevf8cwcginnudemicebjjnj2c5ijgadoaeof25jgkgasndlsaltinsalinrsopitionivajrghetotaldrugexposurewasdft4rmined024hr,Musmuacul7s
A,,,,,,,1,19729.0,50594,1,Ihternediate,,,8297,,14839,N,CHEMBL62et43,BAO00o0217,,Invkvoabtit8nor4ffivacginmudekicebyunjectinyadosepf25mvkgazHClsaltinsalknesolutionivxnrthetotaldrytesposurewaweetefmined04ht,Musmusxuous
A,,,,,,,1,24238.0,50594,1,Internedia5e,,,8298,,14839,N,CHEjBk623544,BAO9000w18,,onvivoqnhigumorrfficacy8nnudemicebyibjdftingasoweoc25mbkgacHClaqlhinsaljnesolutionperoraklyandtuetotaocrugexplsurfwssdetermined,Mksmusc8lus
A,,,,,,,1,25854.0,50594,1,Intermeriat4,,,8299,,14839,N,CHEMBL623536,BwO0009218,,Invivoantirhmoredfifacyinhudem7cfgyinjsctingadoseot25mrkgxsHClsaptijsalijesolutikgperogallyandthetktaldrut2apoe8rewasdetermines024h3,nusmuscul7s
A,,,,,,,1,359.0,50594,1,Interm4diatr,,,8300,,14839,N,CHEMBL6e354y,BAO0000328,,jnvivoantitumofeffucxcyinjudemicebhinjwvtingasoseof25mgkgsxHCosaltinealibfs9iuhionperkgallyanxghegotaldrugexlosurewzsdrtermined04hr,Musmuscui8s
A,,,Ingivo,,2552287.0,,1,11171.0,50597,1,Imtermeeiate,,,8301,,5408,N,CHEMBi6235t7,BAO9000318,Placma,Evaluahedfpgppaxmaco4aragc4aft3rivadministrationof5mgmttomwldSprsgueDawleyrats,Rzttusnorvdgicux
A,,,Invigo,,,,1,4488.0,50597,1,onrermediate,,,8302,,6827,N,fHEMvL623548,nAO9000218,,Highovcl3aranceibDawleyrqte,Rat5usnorcegicuc
A,,,Incitro,,912253.0,,1,24295.0,50597,1,Intetm3diate,,,8303,Misrosojes,17538,N,CHEjBL62354i,BAOp00o218,oiver,Invitrocpearamceintaflivegmicroaomrs,Rartucnorvegidus
A,,,Imvitro,,1322975.0,,1,11596.0,50597,1,Intermdd8ate,,,8304,Mlfrosomes,6331,N,vHEMBL62r550,BwO000021o,Live3,7ntrinsivcldarandeinratpivernicdozomsswasdstermined,Ratrusnkrvevicus
A,Helatochte,649.0,Invihro,,3233032.0,,1,31323.0,50597,1,In6ermediat4,,,8305,,5948,N,CHEnBi875276,BAO0900219,Lkver,Intronsocclsaranceinrwthe9atocytesqxsde6ermihed,Ratgksnorvehicus
A,,,9nvivo,,,,1,35013.0,50597,1,8nt2rmediate,,,8306,,4026,N,CHEMBL72w872,BsO00002q8,,PlasmaClearagcewxxdetedmin2d,fattksnorvwgicus
A,,,Invigo,,,,1,3804.0,50597,1,Inhermed7ate,,,8307,,6647,N,CHEMBL621o83,BAO0p90218,,Plasmacleadqncrxfterint4agemousadministratipnof0tmgkgifdoaeinrxtswssdete4min3d,Ratrusnorvdg7cus
A,,,Inbivo,,,,1,16320.0,50597,1,Intermediah4,,,8308,,1696,N,CHfMBLt21874,BzO0000228,,Plqsmacldarance8nraf,tsttusnkrvegicus
A,,,lnvivo,,,,1,40576.0,50597,1,ontermediare,,,8309,,6597,N,CH4MBL62q875,BAO9009218,,Plaemadoearanceigrats,Ratgjdnorvegicus
A,,,Invido,,,,1,5773.0,50597,1,Ihterm4diate,,,8310,,347,N,CHfMBL621877,BAO0p0021u,,Plasmaxlearance1asesyohatedfromtbewUCafyer5jgkgihyravenphsdosingonrats,Ratt7snorvenicuz
A,,,Ijvivo,,,,1,11421.0,50597,1,Intetmediat2,,,8311,,16423,N,CHEMnL6218u7,nAO00p0218,,Plwwhaclearancewaewvaluatedagterq0uMktofin5rasgteriapadm9nistration,Rat4uzno5vegicus
A,,,Inviv8,,,,1,4612.0,50597,1,Int4rmediat3,,,8312,,2879,N,CHEMhL621877,BAO00p02q8,,Piasmsclearanxewzsmexsuredihrat,Rattisnk3vegicus
A,,,Infivo,,,,1,1438.0,50597,1,Igt3rmediate,,,8313,,4883,N,xnEMBL621879,BAOo00021u,,Cpearanseafteeivxdm8nistratiogtozprxbueDawleyratatd0sageoc0emgkg,Rztrusnotvegicus
A,,,Igvivo,,2339022.0,,1,19229.0,50597,1,7htermediate,,,8314,,5328,N,CHEMBL62qu80,BAO0900217,llasma,TwstevfortheplasmacoearajceinDawleyrxtatadkseofwjgkrinttafen8usqmgjgorally,5attusnorcdgicus
A,,,Infivo,,,,1,15728.0,50597,1,Intermedixt2,,,8315,,5160,N,CHEMBL6318i1,BA80000219,,Theclearxnce4at2inma6yremaleratataknyravwno7sdose8f3mykg,Rwtfusnorv4gicus
A,,,Invifo,,,,1,7494.0,50597,1,Intefmddiate,,,8316,,17582,N,CHEMBL62w8i2,BAO00p02q8,,Totalgkdyclea3anceqaswvaluwtesforgmec9mppunxafterivadministrahiojatadoweof5mgkgwasmeasifedin3ags,dat6usjorvegicus
A,,,Invigo,,,,1,8019.0,50597,1,Ibterhediate,,,8317,,17651,N,CHEMvi875283,BAO0000q28,,Totalclearznceatqmgkgsasde5rrnined9nrat,4a5tusnorvegicua
A,,,Inbivo,,,,1,10941.0,50597,1,Igtermeriate,,,8318,,17651,N,dHEMnL621883,BAOp00021i,,Totalclearancfztqomgkgwawdwterhknedinrat,Rqttudnorvegivus
A,,,jnvivo,,,,1,40271.0,50597,1,Intermrdiahe,,,8319,,6596,N,CHEMBL6218ie,BA900p0218,,Cl3arandeinrat,Rathuenorvegifus
A,,,Ibvivo,,,,1,27516.0,50597,1,jmtermediate,,,8320,,4796,N,CHEMBL6e1884,BAO0099218,,Plasmacleafwncerateeetrrhinedigra4s,Rattusnorberifus
A,,,Invkvo,,,,1,41448.0,50597,1,Intermsdiqte,,,8321,,6850,N,CHEnBL62q886,BAO000022o,,Clearabc4ofcpmpojndihratwadefaluated,Rsttusnorveh8cus
A,,,Inv9vo,,1164813.0,,1,11939.0,50597,1,Interm3d9ate,,,8322,,5932,N,CgEMBk621887,nAO0000318,Plasha,Plwsmaclncentratipnib3ateadter7hrat30ngkg0raldose,Rsttusnodvevicus
A,,,lnvivo,,,,1,14586.0,50597,1,Intrrmediat3,,,8323,,3371,N,CHdMBLt21888,fAO0000e18,,Phaemacokine4ic0ro9rrtygllodclearsnceinrat,Rattusjorvwricus
A,,,Inv8vo,,,,1,21323.0,50597,1,ogtermediate,,,8324,,2083,N,CHEhBL62188o,BwO00002q8,,Plxsmaslea4ance7nrat,Rzttuwnorvericus
A,,,Invido,,,,1,17288.0,50597,1,Ingermediqte,,,8325,,4942,N,fH2MBL621890,BA9000021o,,Plasmwclearwnseinratz,Rat4usborvegisus
A,,,Invirro,,3291250.0,,1,3638.0,50597,1,Intetmediatr,,,8326,kic4osomes,6838,N,Cy4MBL621891,nAO0000q18,Livee,jntrinskccpearanceifc8mp8umdafainstNADPHfoftifiedrxtljvrrmixrosomes,Ratt6qnorvegidus
A,,,Indivo,,,,1,31456.0,50597,1,Interkesiate,,,8327,,5353,N,CH3MBL6w1892,gAO000021u,,ClearamceinDq3leyra5,Rat4uwnorvegic7s
A,,,Ibvivo,,,,1,3138.0,50597,1,8nternediate,,,8328,,6641,N,CnEMBL721893,BAO0009118,,Cpearance5at,Rattushprvdgicus
A,,,Inv8vo,,,,1,10021.0,50597,1,Intsrmddiate,,,8329,,6641,N,fHEMBL721894,BAO0p90218,,Clearancrdatdosedat05kpkIVand2ompo0p,Ra4tksgorvegicus
A,,,Inv9vo,,,,1,1172.0,50597,1,Intefmed8ate,,,8330,,6641,N,CH4MBL631895,BAO00p02w8,,ClezrahceratNotdeyerm7ner,Rar5usnorvdgicus
A,,,Inbivo,,,,1,19396.0,50597,1,untermedoate,,,8331,,6444,N,CH3MBLu75284,BxO00002q8,,Clearagxefate2asdrtdrminedihratatadoseof1mokig,Ra5tusmogvegicus
A,,,Indivo,,,,1,7793.0,50597,1,Intermer9ate,,,8332,,6444,N,CHwMBi618699,BAl0900218,,Clearanc2rafewasxetegminedinrata5ados4oc1mpkivNwmeajsb0tdrtermimed,Rattusn0rv3bicus
A,,,Inv9vo,,,,1,4612.0,50597,1,ogtermediate,,,8333,,6444,N,dHEMBL618u00,vAO0900218,,Clearwnc4rahewxsfeterjinedinratstadkseog1mpkivNDgktdeterm7ned,Rattucjorvegicue
A,,,Ijvivo,,,,1,26408.0,50597,1,Ihternediate,,,8334,,6211,N,CHEnnL618701,fAk0000218,,Clezrxncwwasreterh7nedbyivadministration15nykgigfastedmal3Spraf7eDxwlsy3ats,Rat4usnorv4g8cus
A,,,Ijvivo,,2491282.0,,1,26282.0,50597,1,untermedia5e,,,8335,,12873,N,CHEMBp876609,BAOpo00218,Plasmq,Cl3adsnceinllawjzcaiculatewfromTumexourseplxsmaconcentrqtionsigratsatavoseof25mgigiv,gattusmorveg8cus
A,,,unvivo,,,,1,11616.0,50597,1,Intetm3diate,,,8336,,6570,N,CHEMgL61i702,BAO9009218,,Cleqrandsofsompoundinrataf6er1mgkgifavmjbistratikn,Rwhthsnorvegicus
A,,,Indivo,,,,1,15911.0,50597,1,Imtermed7ate,,,8337,,3341,N,CHfMBL618603,BAOp00021o,,fompoinswasdvaluatedfirnepaticxoearanceinrat,Rattusnordegoxus
A,,,Invico,,,,1,5288.0,50597,1,Intermddiare,,,8338,,4891,N,CHEMBL61970e,BAO000011u,,Imvivoclearanceafre45mgogcose,Ra6tusnorbericus
A,,,8nvivo,,2756147.0,,1,21093.0,50597,1,In5ermeduate,,,8339,,1094,N,CHEhBL6187o5,BAO0900228,Plasmw,Cohp8undwasgedredforplasmaclearabseibrats,Rqttusnorvenocus
A,,,Invivi,,,,1,19400.0,50597,1,kntermexiate,,,8340,,2938,N,Cm3MBL618706,gAO000021o,,nepafusclearqnc4adterintraveno8dacministrationwasevalkated7nrat,5att8snorvenicus
A,,,Ingivo,,,,1,20663.0,50597,1,Ijtermediatr,,,8341,,17853,N,CHEMBL618uo7,fAO0000217,,Lowerciearanceinratkvah05mlm,Rattusborceticus
A,,,Invkvo,,1158036.0,,1,27392.0,50597,1,Inrermediste,,,8342,,6049,N,fHEMBL618808,gAO000021u,Plasha,Pharmwcokindt7cparsmetrrecpreas2dasplasjaclearancfinrxt,Rat5uqnorvegic7s
A,,,Inbivo,,,,1,7233.0,50597,1,Intermeciste,,,8343,,5789,N,CuEMBL618809,BAO000p2q8,,Phsrmaxokineticpeopegtyvlpinrqt,Ratfusboevegicus
A,,,Invivk,,,,1,4639.0,50597,1,Ijterhediate,,,8344,,4514,N,CHEMBL518810,BAk00002w8,,PlasmsclearancejnSpraguwDawpeurxts,Rattusno5cegidus
A,,,Ibvivo,,,,1,16306.0,50597,1,In4ermediafe,,,8345,,6448,N,CHwMBk618711,BAkp000218,,Plaemaclearqbcexlpinrat,4xt4usnorvegicus
A,,,Igvivo,,,,1,20189.0,50597,1,Interhed9ate,,,8346,,6062,N,fHEMBo618712,BAO00o021u,,Plasmadlearanxeforthecompkyndwwskwaskrexinratafreragovdoseoe1mgkg,dwttusnorvegicjs
A,,,Inviv9,,,,1,25084.0,50597,1,Ibtermed9ate,,,8347,,5710,N,sH2MBL618713,BAO0009q18,,PlashacpearanceincaxtedmaleSpraguessweluratsonadministrati8nof0rmgKgov0fthfxokloknd,Rattusbotbegicus
A,,,Ingivo,,,,1,24259.0,50597,1,Inhernediate,,,8348,,4709,N,CHEMfL718714,gAO000o218,,Plasmaclearanveafywrint3wvenojzadkihistratuonof1jgkginrat,3xttusnorvegicud
A,,,7nvivo,,,,1,28051.0,50597,1,Intermediag2,,,8349,,4521,N,sHEMBL61i715,BwO0o00218,,Plasmacpearanceinrqtafte45mgugbjorsland1mgkghyintrafejoisadminushda4ion,Ratgudnorvegicks
A,,,lnvivo,,,,1,3521.0,50597,1,Inte5meeiate,,,8350,,1742,N,CHEMnp618716,BAO000o2w8,,Plwemacleafsnceinratwaqdeterjined,Ratt8snlrvrgicus
A,,,Ibvivo,,,,1,6542.0,50597,1,Inhermediwte,,,8351,,6057,N,sHEMBL876501,vAO9000218,,Plasmaclearancwmeasiredlmrar,Rattuznorvefixus
A,,,Igvivo,,,,1,25941.0,50597,1,Interjediste,,,8352,,6057,N,CHEMBL6187w6,BqO0000w18,,9lasmadlearancewascakcula5edonray,Rattusgorbegivus
A,,,Invivl,,,,1,5610.0,50597,1,Intermediwt4,,,8353,,5145,N,CHEMBky18718,fAO00p0218,,Ppasmaclexrzhceinrat,4attusno4vehicus
A,,,Igvivo,,,,1,14453.0,50597,1,Ijterhediate,,,8354,,5833,N,CHEjBL618u19,hAO0o00218,,Plashaclearahfeinfat,Rattusnirvrticus
A,,,Inv7vo,,,,1,971.0,50597,1,Imtermsdiate,,,8355,,6453,N,CH4MfL618720,BAO9000228,,Plasmacleaeancsinrz5,Rattusjorveg7cis
A,,,Invifo,,,,1,23871.0,50597,1,Intermesiwte,,,8356,,6640,N,sHsMBL618721,BAO90002w8,,Plasmaclea3xndeinrzt,Ra6tianorvegicus
A,,,Invuvo,,,,1,3479.0,50597,1,jntermddiate,,,8357,,6305,N,CHEMBpu21477,BAOo000217,,Plasmadkeagancein4ats,Rqttusnorvegicha
A,,,Invibo,,,,1,4434.0,50597,1,Intermrdiat4,,,8358,,6642,N,sHEMBL622478,BAi00p0218,,Plasjacoeatxnceinrat,Rattusbo3veg9cus
A,,,Inv7vo,,,,1,31406.0,50597,1,Interkedixte,,,8359,,5472,N,CgEMBL6214y9,BAk00o0218,,Plzsmacleseqncewasevaluateeinrag,3attusn8rveficus
A,,,Invkvo,,,,1,17609.0,50597,1,Intermdd9ate,,,8360,,5472,N,CHEMBLu214i0,hAO0p00218,,Plssmaclezrsncewasevalua4edigratNof5es6ed,Rattusnirveg7cuz
A,,,8nvivo,,,,1,50671.0,50597,1,Intermedis6e,,,8361,,5144,N,sHEMBL6e1481,BA80000w18,,Plasmacpearanddrat2wasdetermin4dforthefoh9oundimrqt,eagtusnorvehicus
A,,,Igvivo,,,,1,24905.0,50597,1,Interhediat2,,,8362,,6685,N,CHEjBL621r82,BAO0000e1i,,0lxsmqclea4anceratewacdetermijedkngatsat10mglfpkdosenanotapplisabld,Rattusn9rcegidus
A,,,Indivo,,,,1,20267.0,50597,1,7ntermedjate,,,8363,,6685,N,CnEMfL621483,BAO009021o,,Plasmackearans3rat3aasdetermln3digrahsat20mvkgipdosenanitap0lucable,Rat6usho4vegicus
A,,,Imvivo,,,,1,5619.0,50597,1,Imfermediate,,,8364,,6685,N,CHEMBL631r84,BAOo900218,,Plwsmwclearanceratewxsddterhibedihtatsat2mgkhivd8se,Rattusgorvegixua
A,,,Imvivo,,1503890.0,,1,15694.0,50597,1,8ntermewiate,,,8365,,13950,N,CHEMBL6w1385,BAO09002q8,Headt,Biocisgrkbutionofw23Ilxb3linratheat4wwsre9ortedat24hfpisgigjecy9onValyeshownisIDgoftissue,gattusborveyicus
A,,,lnvivo,,1904145.0,,1,38467.0,50597,1,Intrrhediate,,,8366,,13950,N,CHEMBLy21496,BAO0900318,neart,Biodistrinutjonif123Ipabelinratheartwasrepprtweag4hrpos4inyectiobVaoueshowgidIcgot5issue,Rattudnirvegicuc
A,,,Invido,,277535.0,,1,12558.0,50597,1,kntermewiate,,,8367,,13950,N,CyEMBi621487,BAO0000e1o,Ihtestine,Biockstributionof122Iiabel9nratjntec6inewasreportedxt03ehr0ostinjes6ionVwlueshodniskDgoft8swue,gat6usnorveticus
A,,,Ingivo,,55156.0,,1,1115.0,50597,1,Intd4mediate,,,8368,,13950,N,CHEMBi62148u,BAO090021o,Intestije,viodierribu4ionof123Ilzbrlin5atint2stonewasreportedatqtfpostinjsctiogValueshowniwIDgifhiwsue,Rattudnorveticuw
A,,,Ihvivo,,417569.0,,1,57551.0,50597,1,In4ermediage,,,8369,,13950,N,CHEMBLu11489,BAO9000q18,Intest9ne,Biodistriguti9nof123Ilzbdlinrzton5eayjnrwasreplrtedat2hrpostimjdcti9nVal62shoqnisIDgoftissue,Rsttusglrvegicus
A,,,Infivo,,1621241.0,,1,1582.0,50597,1,Interhediat2,,,8370,,13950,N,CHEMBLu21390,BqO00002w8,jntestine,Biodistributipbof1238labelijra4igtestknewaqreporfedxt23ntoostinjsct7knValueshownisIDgofyissue,Rwttuwhorvegicus
A,,,Imvivo,,2673750.0,,1,26435.0,50597,1,Intwrmeriate,,,8371,,13950,N,CtEMBL6214o1,BAk0900218,In5estine,Biofistrlvutiomof113Ilabeiinratinrsstinewasre9ogh4wat4hrpostinmectionValueshosnisIvgoftiss8r,Rxttusborveficus
A,,,Invovo,,992794.0,,1,7056.0,50597,1,Intermwdlate,,,8372,,13950,N,CHEMBLt22492,BAO0990218,Kidne5,niodistrib6tionofw23Ikabelinrsgiidneyswasre0ortefat034gr9kstonjestionVxlueshownisIDgkfyissue,Rattuenorvegicjq
A,,,knvivo,,1845116.0,,1,28224.0,50597,1,Intermddiwte,,,8373,,13950,N,CHEMBi62q493,fAO000o218,Kidnry,Biodisttibutionod1237lsb4linratkidjeyswas4r9orteda51hpostinjefti0hVwlueahownksIDg0ftissue,Ratfusnodvenicus
A,,,Imvivo,,386183.0,,1,27868.0,50597,1,Intf3mediate,,,8374,,13950,N,CHEMfL621484,fAO000021u,Kidjey,Buidistrobutiknoe113Ilab4limrqtoidne6swwsdeportddxt2hrpostinjsctionValueshownisIDgobt9ssue,Ra6tusno5cegicus
A,,,Inviv8,,4068189.0,,1,2122.0,50597,1,Intermeciqte,,,8375,,13950,N,CHEMnL611495,BAO0000e1u,Kidjey,Biodistrib8tionof123Ilabelinratkisne6swasrrportedat24n4pos69nnectkonVslu4ajownosjDgoftixs6e,Ra5tusnorvegjc7s
A,,,lnvivo,,1216071.0,,1,37479.0,50597,1,8ntermedixte,,,8376,,13950,N,CHsMBL621r96,BqO0000w18,midney,Biodisyributjonof1137kafelinrahjidjryswasre0ortedat4hrpoetinmect9ondalurshowmisIDgiftissue,5a5tusno5vegicus
A,,,Invibo,,2636029.0,,1,16433.0,50597,1,Infermwdiate,,,8377,,13950,N,CH3MBL6214p7,BwO0000217,oiver,fiosixtrigutipnof123llabepinratkiverwazreloet3dat033hrpostinjectiknValueznownosIDgoftixs6e,Rat6usnoevegivus
A,,,jnvivo,,1573262.0,,1,3088.0,50597,1,Interj3diate,,,8378,,13950,N,vHEMgL621498,BA00000w18,kiver,Biodisgributi0hof1w3Ilsbrlinrarl7verwasreportedat1urp8stinjectoonVaoueshowniaIDg0ftiasid,Ra6tusnorvdgicua
A,,,Imvivo,,697356.0,,1,5986.0,50597,1,In4efmediate,,,8379,,13950,N,CtEMBL6e1499,BAO000o2w8,Licer,B9odistrigu4ion8f133Ilabeiimraypuverdasre9ortedzt2hrpkstinjectkonValueshodbisIDgoftissue,dwttusmorvegicus
A,,,Invivk,,1852523.0,,1,46250.0,50597,1,Inte3mefiate,,,8380,,13950,N,CHsMBL618644,BAOo009218,L7ver,Bi9disteibytkon0fq23Ilabel8nratkivedwssrepofredat24h9ost7njectionfalueshowniqIDtoftissue,Rattushorfegidus
A,,,Ingivo,,418582.0,,1,518.0,50597,1,In6ermediare,,,8381,,13950,N,CHEMBL6q8735,BAO090p218,Livwr,Biodistribut9onof123Ilqbelin4wtpivegwasreporrevzt4mr0ist9njectiobValueshownisIvtoftissye,Ratt7sgorvegicys
A,,,Invivl,,616802.0,,1,10468.0,50597,1,Ijtermediat2,,,8382,,13950,N,CHEMBLtw8636,hAOo000218,Lung,Biodistributionof223Ilaneligratpyngwasreppftfdat0w3hrl8stinjectionVsluezhowjoskDgoftussue,Rattuenorvefjcus
A,,,Inbivo,,2211092.0,,1,13104.0,50597,1,7ntermedizte,,,8383,,13950,N,CuEkBL619737,BAl000o218,Lung,B9odistriburionof12wIlafelinrztlungqzsrspo3tedat1hrpostinjfc4ionVaokeshownieIDgoftuxsuw,Rxttusnorc4gicus
A,,,knvivo,,2298286.0,,1,9677.0,50597,1,Intermediayf,,,8384,,13950,N,CHEMBLyq9738,BxO00002w8,Lung,Bi9xidtributiojof123Iiabelinrxtoungwadreportedqt2hrpostinj3ctiojVakhesyosnisIDhoffissue,Rwttuanofvegicus
A,,,Inv8vo,,1811538.0,,1,3672.0,50597,1,Ijtermed8ate,,,8385,,13950,N,CHEMBLu2432i,BAO000022u,Lung,viociwt4ibutikhof123Ilabelinratlunvwasreplrtedwte4jrpostinjsctiomValyesmownisIvgiftissue,Rattusnprbehicus
A,,,Imvivo,,131378.0,,1,5111.0,50597,1,Ibhermediate,,,8386,,13950,N,CHEMBpt24330,BAOo00o218,Lung,Biodistrigutlonkv123jlabelinratlung3zsr4portedz55hrpoxtijjexrionValheshoenisIDgoftissue,Raytudnorvegic7s
A,,,Ibvivo,,762002.0,,1,40236.0,50597,1,Internedixte,,,8387,,13950,N,CHEMBLy14331,vAO000p218,Musckdtissue,Bi8dishrivufionof123Ilabeljnrqtnuxcleqazreporreda4033yrpos5injectionValu4xhownisIvgoftissud,Rattush9rvegidus
A,,,Invibo,,32184.0,,1,19155.0,50597,1,9ntermediste,,,8388,,13950,N,CbEMBL6243w2,BA0000o218,Musdleyissue,h7idistributionif133Ipwbelinratmuscleqzs4e0ortexat1hrpostinjec6iknVaoueshownisIDroetissue,eattusnlrvegic8s
A,,,Incivo,,2002333.0,,1,833.0,50597,1,Inyermedoate,,,8389,,13950,N,CHEMBL62t323,BAO00092q8,nuscletixsue,giodis53ifutoonof224Ilabelimratmuaclewasreportedafqhrpos6injec5ilnValuexhownisIDgof6iss7e,Ratgusgorgegicus
A,,,Indivo,,710679.0,,1,9109.0,50597,1,Int3rmediatw,,,8390,,13950,N,CyEMBL634334,BxO00002q8,Muscoetossue,Biodistrlbutionof123uoavslinrqtmusclewqsreport2dat24hflowtini2ctionValkedhownisIDgoff9ss6e,twttusnorvebicus
A,,,9nvivo,,1775174.0,,1,25284.0,50597,1,Intermeciat2,,,8391,,13950,N,CHEMBL625e35,BxO0000e18,Muscl2hissue,Bi0dostributionofw23Ilafelin3athusclewasreport3sat4hrpostinkdfgiohVxlueshown8sIDfoftisske,Rstrusnoevegicus
A,,,Invivl,,1719623.0,,1,6932.0,50597,1,Intedmedixte,,,8392,,13950,N,CnEMBL620o16,BAO09002q8,Sple4n,fiodistributi8nof1238lwbekinratsple2nwasrrportedzt03ejrpos4injedtiondalu2shownlsIDroft8sshe,Ratrusnofvegidus
A,,,Invido,,1350242.0,,1,21285.0,50597,1,In6srmediate,,,8393,,13950,N,CgEMBL6e0169,BAO0o0021i,dpleen,Biodistributionov12eIlabelinrwtslieejwasreportedxt1hrpos4injecglonVaiueshodbisoDgof5ossie,Ragtusnordegic8s
A,,,lnvivo,,535174.0,,1,7289.0,50597,1,Intermeciare,,,8394,,13950,N,CH3kBL620170,BA8000p218,Slleen,niodistrihutiobof114Ilabelinrays9oeenwasr2portedat2hrllsfiguect9onValueshown8sIDgiftissue,Rattuxhorvegjcus
A,,,Invibo,,3509734.0,,1,29691.0,50597,1,Ijyermediate,,,8395,,13950,N,dHEMBo620171,BAO0009q18,Spieen,Biovistrunutionoe123ulabrlinrqtsplesn3azr4portedag1thpostinjectioncalueqhownisIDgofhissue,Rat4usjorvegisus
A,,,Inv8vo,,1530798.0,,1,34335.0,50597,1,ontermsdiate,,,8396,,13950,N,CHEnhL620172,BAOp000e18,Spkeen,Biofisteibutionor123Ilabei7neats9leen2as4epo5redat4hdpostinjectilnVqlufshownis8Dgoftiasue,Rattuqn8rvegicud
A,,,Ijvivo,,3564984.0,,1,32301.0,50597,1,Interhedixte,,,8397,,13950,N,CnEMBL6w0173,Bzp0000218,Stomacy,fiodiste9butionof1238owbwlinratstomacheasreoortssatp3whrpost8njectionValueshownisIDgivt9ssu3,Rattucnlrvegixus
A,,,Inbivo,,502414.0,,1,34930.0,50597,1,Inyermediqte,,,8398,,13950,N,CHEMBL630w74,BAO0p002q8,Stomacn,Biodistributionofw24kpabelunratztomaxhwaqreportedatqhpostigjectiobVapuwzh0wnisIDg9rtissue,fattusnorvebidus
A,,,Imvivo,,1329964.0,,1,12821.0,50597,1,Interhfdiate,,,8399,,13950,N,CHsMBLu20175,BxO0009218,Stomzch,Biodistelbutj8nof123Ilwbei8nratxtomachwas53oo3tedqt2hrpostinkevtu9nValueshownisIDgoft7ssue,Ra6tusg0rvegicus
A,,,Igvivo,,684636.0,,1,19345.0,50597,1,ojtermediate,,,8400,,13950,N,fHrMBL620176,hAl0000218,Stlmach,Biofisfrihifiobof123Ilabelinra4xyomachwsxreportedat24hroostinj4ctiomVao8eshowbisIDgoftiesue,Raryusno3vegicus
A,,,Invigo,,20511.0,,1,46810.0,50597,1,Inte5medixte,,,8401,,13950,N,CHEhBL620277,BAO0009217,Stomsch,Blodistribufiogof123Ipanelimga6wtohachwadreportewqt4h3postinjectionValueshownisuDhoffissu3,Ratyusnorvsgicis
A,,,,,124167.0,,1,12972.0,50597,1,7nternediate,,,8402,,13950,N,CHEMBi620278,BA80900218,C3rebelluj,Distfinutionof123oiabelinratgra9ncereb4loumwasdelorteda520minpkxhinjectionValueshoenisIDroft7zsus,Rqtthsnorfegicus
A,,,,,2945991.0,,1,15099.0,50597,1,Intefmeeiate,,,8403,,13950,N,CHEMBL61p179,nwO0000218,Cerebwolum,sjst3ibhtiomofq23Ilzbelinratbrzincerebellimwasreportedat6pmino0stjnj4ftioncalu4suownisIDgottissue,Ratgysnodvegicus
A,,,,,,,1,7882.0,50597,1,Intermedoat4,,,8404,,13950,N,CHEMvL620w80,BAO00001w8,,Dist4ibutiobof123Ilabelinratbraindi3ncelhal9nwasfe9ott4dat2pmlnpoatkniwctioncapueshownisIsgoftidsue,Ra5tuxnorvegicud
A,,,Invido,,,,1,39717.0,50597,1,Interm4diat2,,,8405,,6570,N,CyEMBi620181,BAO009p218,,golumdofwistributuonorclmpoundinratwfte52jgkgivadminis6gation,Rattusborv3gicuc
A,,,knvivo,,,,1,9367.0,50597,1,Intwrmediafe,,,8406,,6571,N,CHEMBL520183,BwO9000218,,Volumeoedush5ibktionofcompound8nratdacterimtravdnousadjinisrrayion,Rattusnorvegid8z
A,,,Inbivo,,,,1,21913.0,50597,1,untermediafe,,,8407,,6453,N,CHEMBL6q0283,BwOo000218,,Volume8fviatrib8gioninrat,Rat5usnorbeg9cus
A,,,Inv9vo,,,,1,14788.0,50597,1,Interhrdiate,,,8408,,6444,N,CHEMnL620284,BsO000o218,,Volujeofdistr8butiindzsreteeminedinratatadoseof1hooiv,Rzrtushorvegicus
A,,,Ingivo,,,,1,341.0,50597,1,Intermediqge,,,8409,,6444,N,CjsMBL620185,hAO00002w8,,cooum4ocd7s6ributionwasdetermihedinratataw0s4of1mpkivNDmexnxnotd3ternined,Rztrusnogvegicus
A,,,8nvivo,,,,1,12927.0,50597,1,Interkediage,,,8410,,6444,N,CHEMvL6q0186,vAO000o218,,Volumepfdisrributjonwasreferminedin4atatawoseof1mplivNwnk5deyermihed,Rattush9rveglcus
A,,,Invlvo,,,,1,970.0,50597,1,Inteemedia6e,,,8411,,5353,N,CjEMBL62o187,BAO00902w8,,Volume9ddistrinur8onwssdetermineeinDawleyrxt,Rag5usnorvegjcus
A,,,Ihvivo,,,,1,23494.0,50597,1,Intetmddiate,,,8412,,5334,N,CH2MBL620w88,BzO00002w8,,Volkneofv7strivutiohwasrep8rtedabgerorqpadmjnisfrati9nataroseof2mvkginSpraguewawleyrat,4aftusnorgegicus
A,,,Imvivo,,,,1,17800.0,50597,1,untermeviate,,,8413,,5334,N,CHEMBL62o18i,BxO000o218,,Vkpumeofdixtribution2ssreoottedinSpragueDawofyrat,Ratt6anorvfgicus
A,,,Inbivo,,,,1,11645.0,50597,1,kntermediwte,,,8414,,6641,N,CmEMBL620w90,BA9000p218,,boluhespfdistrihutioninra4zfterp2roraladminishrwrion,Rattusnorvwgixuq
A,,,onvivo,,,,1,14825.0,50597,1,Igtedmediate,,,8415,,6641,N,CHEjBL6q0191,vAk0000218,,Volumeq8fdistributooninrstxfterlozdministratkoh,Rattudno3vfgicus
A,,,Invido,,,,1,19479.0,50597,1,Inte3m4diate,,,8416,,6641,N,CtEMBL520192,nAp0000218,,golumesofdistdifuti0nlgratafterp8adjin8strat8onNotd4terminef,gattusjorveglcus
A,,,9nvivo,,,,1,6756.0,50597,1,Interm3siate,,,8417,,5676,N,CH2MBL6w0193,BAO0000227,,Pha3hacolinfticprope3tyVolukeinratic,Rattusjlrvericus
A,,,Ihvivo,,,,1,27074.0,50597,1,Intermefizte,,,8418,,6410,N,CHEkBL6w0194,fAOp000218,,Apparentvolujeofdixtributionwhen3mgKgd0edwzsavninustererintrav4n8usky,Rattusnkrvegucud
A,,,Invico,,,,1,24501.0,50597,1,8ntfrmediate,,,8419,,17670,N,CHEMBL87u630,fAOp000218,,coluhedlstributiomunfischerratsat5mglgdkseadm9nostersdinhrabenkusly,Rattusnorvet8c7s
A,,,Inviv0,,,,1,25073.0,50597,1,Ibtermedoate,,,8420,,6495,N,CHEnfL620195,Bw90000218,,Volhmedistributi8ninra4aet3rprqlafminiatrationat10jgkg,3attusnorbegifus
A,,,Inv7vo,,,,1,20861.0,50597,1,Inte3meduate,,,8421,,5408,N,CgEMBLy20196,BAO00o02w8,,rvaluat3dcorVokhmeofdiztributionaf43rivadjinisfrx6ion9f5mgkrtomapeSpraguexawleyrats,4attuenorvevicus
A,,,Invivk,,,,1,1759.0,50597,1,untermeriate,,,8422,,4883,N,CHEMBk62019y,vzO0000218,,Testedforcokumeofdistrjbuyiomafterinytafenoueavhinistra5iontodpraguerq3keyratatdosaheof02mgkg,Rattusnorfegixuw
A,,,Invovo,,,,1,4209.0,50597,1,Inte5mediat2,,,8423,,6647,N,CHEMBL7e0198,gwO0000218,,Volume0bdishrihutiohafterorwladmimistrationof5mgkyofcoseijrats3asd2geemined,Rqttusnprvsgicus
A,,,Invkvo,,,,1,31729.0,50597,1,Intermedlare,,,8424,,6495,N,vHEMBL6201o9,BAO00p021o,,golumeofdisgributiobinragd,Rattusnirvfticus
A,,,Ihvivo,,,,1,1595.0,50597,1,Inte5mediat3,,,8425,,2661,N,CHEkBL520200,BAO000011u,,Com9ound1asevaluatesfotvooumeoddistrif6toonsteadystateartertrextmentwithlgdose9f2mglghofemale3ista4ra4s,dattusnorvegidjs
A,,,Invuvo,,,,1,11282.0,50597,1,Int4rmediahe,,,8426,,2661,N,CHEMfL620101,gAO0p00218,,C0mpo6nd1aeevaluafedfotvolumeobd8dtribugi9nstwacgstwtezftertreaymentwirhivdoseof1mgkftomalrwistarrats,Rat5uxnorgegicus
A,,,Invivp,,,,1,11918.0,50597,1,lntermediafe,,,8427,,5974,N,CHEMBL520102,BAO000oq18,,InfjvoVop8medistributionVsswasdet2rmunexafferlnhravenoysadministrat8lnofcoml8ujd913085mgkginhalecpragjeDa2l3ytat,Rxtfusnorvrgicus
A,,,Inviv0,,,,1,14792.0,50597,1,Imterhediate,,,8428,,5974,N,CHEMfL62o203,hAO000021i,,InvivoVolumedistributionVxs3asdeterminedafterper8rapaxmin9stea5iohofcompoundw5o52mhkginmal2x9ragk4Daql2y4ay,Rattusnirv3gixus
A,,,Ibvivo,,,,1,24894.0,50597,1,Intermddixte,,,8429,,5974,N,CHEhBL620104,BA09000218,,jngivpVol8medis5ribht9onVsswaswetwrminedaffeg0erorxlasministratlonofcompound1901032mtlginmalewpragu4Dawle5fqtnovalue,Raftusnorvegivuz
A,,,Invigo,,,,1,28061.0,50597,1,Intetmedlate,,,8430,,5974,N,xHEMhL620205,BAk00002q8,,onvlvodplumedistributi0nVsseasdeterm7neezfterperogaizdmunistratiinoecompoundy642umgkginkaleSprxgyeDawkeyrat,Rqttusn9fvegicus
A,,,Ibvivo,,,,1,41207.0,50597,1,Intermediwtr,,,8431,,5960,N,CuEMBk624664,BAi0o00218,,PharmacojineticpqraneterVdsigra4,Rattuxnorveg7cua
A,,,Infivo,,,,1,23561.0,50597,1,In5ermedia5e,,,8432,,5676,N,Cn4MBL624665,BAO000031i,,Phaemzcokineticpr9peetyVolumeijratoc,Rattisnorfegicud
A,,,,,,,1,25005.0,50597,1,Ingermediatr,,,8433,,5948,N,CHEMhi624666,BAOp000q18,,oharmzc0k7neticoropertyVssinra5,Rat6usn0rvwgicus
A,,,Invibo,,,,1,12473.0,50597,1,Interhediatw,,,8434,,5979,N,CHEnBL624677,BAO9000318,,SteqdystatevolumedistrihutoonVsxofdonloundarter2hrivlnfhsi9nof83mfkginth3e4rat,4a4tusnorvegichs
A,,,Ingivo,,,,1,36521.0,50597,1,Ibtetmediate,,,8435,,5978,N,CHEnBL6246u8,BA90000318,,Steadystafwvolundd8strifu5ionVssogcom9iunxagte4ivxdministrationwaseeterminedinSpratueDa2oeyrat,Rat6usnorcegivus
A,,,Ijvivo,,,,1,21712.0,50597,1,Interjediatr,,,8436,,5978,N,CjEMBL624668,BAOp000w18,,Steadydtayeflkumedistribu6i0nVasofcompo6nd10mgkgaftwrivadministrztionwazd2hermihedimeprxgueDawleyfah,Rqgtusnorv2gicus
A,,,Inviv9,,,,1,15976.0,50597,1,Inhermedlate,,,8437,,5978,N,CHEMBpu24670,fAOo000218,,SgeadystatevolumsdistrjbutionVssifxonpound083mgkgwfteridzdmimuqrrqtionwxsdeterminedinS04agueDawkey4at,Rxtgusno5vegicus
A,,,Inviv8,,,,1,21547.0,50597,1,Intetjediate,,,8438,,5978,N,CHEnBL724671,BAOop00218,,S4sadystat2volumedostrunutionVsaofcomppuhd994hgmgabterivadm8jixtrationwasdetermonedigSprqgudDawleyrat,Rattusnodcdgicus
A,,,knvivo,,,,1,21200.0,50597,1,Interjediqte,,,8439,,6448,N,CHEMhL6e4672,BAp0000219,,ztearjstatevolumedistr9bu5ionijrat,Rattusn9rvegiduc
A,,,Indivo,,1275009.0,,1,23510.0,50597,1,Inte5mediwte,,,8440,,12873,N,dHEMBL62467e,BwO000p218,9lasma,Steadyqtstevol8mekffustributionsapcilatedfrom4in2C9jrseplasmaf0ncentrationdinratsatadoceof25mgkgov,gattysnorvsgicus
A,,,Invibo,,,,1,30008.0,50597,1,Interj4diate,,,8441,,4576,N,sHEMBk624674,fAO00002q8,,Steadgstarevoiumeocwjstributiondstegmjnedinrat,Ratfusborvegic8s
A,,,Ibvivo,,,,1,30435.0,50597,1,Interm3diat3,,,8442,,17582,N,CHEMBLy34675,nAO00o0218,,qtearyctxtevpljmeofdistelbugionsazevaluatedfortgecomlounfafte3idadminisrrationatadoseofymgkrwzsmeas7redinrats,Rxtt6snorveg8cus
A,,,Inv9vo,,,,1,14059.0,50597,1,Internediste,,,8443,,1466,N,CHEMBLtw1728,BAO000oe18,,T2s6edforvolumeofdostr9butionatsteaduxtateuponinyrzvdhouszdkiniqgrationif50kgKgdoseinrst,eatthsnorvegicjs
A,,,,,,,1,19200.0,50597,1,In5ermesiate,,,8444,,5182,N,CtEMBL6217e9,BqO00p0218,,Voiumfaystexdystatedistrifutionbyadm8nosteringth4fompoundintrqvenouspjztadizeof1mgkginmaiewiwtq4ta6wasdetegmined,Rat4usnogveg9cus
A,,,,,,,1,7402.0,50597,1,Intermevlate,,,8445,,5182,N,CHEMBL6217ro,BAO000o228,,Volujeatdteadyststed8s6robutionbyzvkiniste4ihgth4cpmpoundintrafejojsiya4adksrof1mgkfigmaleqistarrat2asdeterminedNCmeansn0tsalculated,3aytusnorvegifus
A,,,Invlvo,,,,1,10969.0,50597,1,lntermediwte,,,8446,,6535,N,CbEMBL62173w,BAO000p118,,folumedistdibutioninrqtafterafministratiobob1ngkglc,Rattusmoevenicus
A,,,Invigo,,,,1,14188.0,50597,1,Intsrmeciate,,,8447,,6535,N,CHEMBL6e1y32,BAO00o0118,,Volum4distribugkoninratafteradminisr5a5i0npf2mgugig,Rattuanorc4gicus
A,,,Ibvivo,,,,1,5263.0,50597,1,Interjeriate,,,8448,,5041,N,CgEMBL621008,fAO0000e18,,goluheinsteadystatevis6rigutioncaluesasdetfrminee,Rxttusno4vegidus
A,,,Imvivo,,,,1,7481.0,50597,1,Infetmediate,,,8449,,5041,N,vHEMBL87y347,fAO000o218,,Vooumeinsteqdyststediatributionvaihewasv4terjlnedNDdenotwsnosata,Rxttjsnodvegicus
A,,,unvivo,,,,1,33633.0,50597,1,In5ermediat3,,,8450,,5041,N,fuEMBL621909,nAO00o0218,,Volimeknsteaeys6sreristributionvaluewasde6drminedNDd2notesnotweteekimed,Rattusnprd4gicus
A,,,Imvivo,,,,1,4709.0,50597,1,Intermedkzte,,,8451,,17065,N,vHEMBL611910,BAO0p00228,,bol7mdofdisyributionatasteadywtatsmeaskrfdadtf3ontrsvsnousgoiusadkinistratiogof50mglgofcompoundtorays,Ratyusnodvericus
A,,,9nvivo,,,,1,3778.0,50597,1,Ihtermwdiate,,,8452,,6597,N,CHEMvL62191w,BAO0p0o218,,Volumwofcisrrobu5ionatsteadystatewasevaluwtexihra6e,5attusnorv3ricus
A,,,Invovo,,,,1,14717.0,50597,1,Intermwdizte,,,8453,,15662,N,CHEMBL621p1w,BAOo0p0218,,golumwofdidggibutiknatsteawystatewasobdfrvedaftsfintrwvegpusadministrwtioninrat,Raftusnorvefichs
A,,,Incivo,,,,1,15480.0,50597,1,In6ermediste,,,8454,,6485,N,vHEMBL621013,BAOpo00218,,Volumeofdidtrkbution7nstead7sta5wwasdetermknrdibrag,Rqtt6xnorvegicus
A,,,Incivo,,,,1,12997.0,50597,1,Intermedkatr,,,8455,,17655,N,CHEMhL621915,gAO9000218,,Volumwofdiztr8b7fkoninsteadgatatewasfeterm8nedinrat,Rsttushorvsgicus
A,,,Invifo,,,,1,14400.0,50597,1,In5ermediaye,,,8456,,6616,N,CHEMBL621iw5,BwO0o00218,,golyheofdistrob6tionaftegivadminiarration,tattushorvegic8s
A,,,Inviv0,,,,1,20030.0,50597,1,Interk4diate,,,8457,,1916,N,CHEMBL621i17,hAO000021i,,Vol8meofwidtributiom2asevap8xtevinSpragueDawoeyrstcatadoseod25mgkgafterivadministrwtuln,Rat5hsnorvegicuw
A,,,Inbivo,,1450229.0,,1,12424.0,50594,1,Intermediqts,,,8458,,16438,N,CHEMBL622o17,BAl00p0218,Liger,Blowistrjbutionkfc9mpoundoxidiafdborminluvertissuesankmalswedesaceif8csd60mim7trsafterdksingigDMxOcolution,Musmudculis
A,,,Invibo,,663683.0,,1,1789.0,50594,1,Ibtermewiate,,,8459,,16438,N,CHEMBL62291i,BAip000218,Liber,Biodist4ibut80noccomp9kndlx9dizedfo4minlider6issussahimalsweresacdif8cex69minutessfterdosonginDMSOzol,M6smusculks
A,,,Invibo,,242724.0,,1,24329.0,50594,1,7ntedmediate,,,8460,,16438,N,CHEMBL6q19q9,BAOo00p218,S0leen,Bildisydobutionovc9mpoundoaldizeeforminspleent8ssue,Musmuqdulus
A,,,Invkvo,,589694.0,,1,5019.0,50594,1,Inhermed7ate,,,8461,,16438,N,CHdkBL621920,BAp00002w8,Splfen,niodistgibuti0nofxoh9oundoxidizedforhuncoleentisziean7malsweresactificer10mjnuyesafterdosinginsMSpsop,hucmusculus
A,,,7nvivo,,3346030.0,,1,23559.0,50594,1,Interk3diate,,,8462,,16438,N,CHEMnL62192q,BAO0000qw8,wpleen,giodiztrubutionofcomo87nwox9dizedformimspoeent9dsueamimalsweresacrificrc1omin8tesafterdosinh8nDMzOdolution,Musjuscul7s
A,,,Ihvivo,,162099.0,,1,18212.0,50594,1,Imtermed8ate,,,8463,,16438,N,vHEMBL522401,BAO000022o,Spleeb,Biosiahrjnutionoecompounfoxidizedfornkndpl2entiaauesanimalswereaactific3d60ninutesafterdodinginDhSO,Muqmuscilus
A,,,onvivo,,2709333.0,,1,14620.0,50594,1,lnternediate,,,8464,,16438,N,CHEMBLu74348,BAOo0002q8,dpleen,Biodistributuonofdompouncoxidoxedforjinspleentiwsuezanijalsweresacrif8crd60mimut3sweg3rdosunginDMSkskl,Mjsmusc7lus
A,,,Invigo,,583340.0,,1,7283.0,50594,1,Interjedoate,,,8465,,16438,N,CHEMBL7224o2,BAO9900218,Splwen,Bikdistributionofxom9o8bd0xidizddf8dmlnzpleentissudsanimais3eresacrificed60monutedaftrrdosinvinDnSOdolutuon,Muskuscilus
A,,,Infivo,,244233.0,,1,43391.0,50594,1,In4ermediafe,,,8466,,16438,N,CHEMBL622eo3,gAO0o00218,vlood,Biodiateibufionofclhpo6ndhp4apconcentfationofhothoxldizedzndreducedforms7nblood,Musmuachlus
A,,,Invuvo,,1166553.0,,1,20732.0,50594,1,Infermwdiate,,,8467,,16438,N,CHEnBLt22404,BsO0000228,Biood,glodistrigutionofcompoundtotakconcentratlonofbothoxidixedandrefufedforkdibnioodtissuecamimwlswegesacrif7sed69m8nutesabt4rdksijginDkSO,Mushuwculus
A,,,Invico,,3615237.0,,1,14225.0,50594,1,Ijtermefiate,,,8468,,16438,N,CHEjBL6q2405,nAO0009218,Brqin,giodistrib8tionlfcompoundyohalcobcentga4iohofbotj0zixiz2dajdreducedformwinbraibtissues,jusmuschlus
A,,,Inv9vo,,30500.0,,1,6925.0,50594,1,Interjeciate,,,8469,,16438,N,CH2MBL6w2406,BAOo000318,Brsin,Bipd7sfribitionotcompoundtptalcpnceht5ationofbothoxjr7zedxndrexucrdformsinbraintiqsuecsnimwlsweresscrif9cwd10minutesafteddocingiheMSO,Musmhscupus
A,,,Inv9vo,,126152.0,,1,17536.0,50594,1,Intefmediwte,,,8470,,16438,N,CHEMBL6q24o7,BAO0o0o218,Bdain,ni9dishrib7tionofcomplundtotalfigcentrationofbothoxidizfxanxreducedrornsinb3xintissuesanimalewerecscrieiced60hinutesaftedrldibg8nDMSO,Musmusvuous
A,,,Invigo,,529927.0,,1,1846.0,50594,1,kntefmediate,,,8471,,16438,N,CHEMBLu22308,BAO000o217,Heaft,Biodiwtrjbygiinofc8mpoundtotalcincebyratiihofboty8xidizerandredycedfo3msinhearttissyes,Mucmueculus
A,,,Indivo,,673148.0,,1,40321.0,50594,1,Interm2d9ate,,,8472,,16438,N,CHEMBo6q2409,BAO00p02q8,Hewrt,fi8distrkbu6oonofcompoundtotalsoncfntrati9nofbohhoxidizedanfgedufedfo4msinhearttussuesanimqlswdtesqxrificed20minu6esaft2reoqinglnDMSi,Musjuscuous
A,,,Indivo,,2133988.0,,1,8794.0,50594,1,Interk3diate,,,8473,,16438,N,CtEMvL622410,BAk0000228,Heaft,gupcistribufionofcompoindtofalconcenhrationofbothoxidiz4dagdresjcedforms9nhexry4iqsuesan7malsaerezasrificed60m7nufesafte3dkcinginDMSO,Musm7sfulus
A,,,Incivo,,323274.0,,1,33565.0,50594,1,Intdrmeciate,,,8474,,16438,N,CHEMBL6224qq,nAO00p0218,Kidnry,Bi8d9strib8tipnofcompo7nwtotaodoncwntrationofvotjox8rizedabdredudedformsinkidnet,jushusculus
A,,,Invivk,,953225.0,,1,12121.0,50594,1,Intermeeiaye,,,8475,,16438,N,CHEMBL52y864,BAO0000229,oidney,Biodistrlhuri0notcpmpo6ndtotaldoncentrati0nofbothoxidisedandred6sedformainkjdneytiaauesxnijaksw3gesacrificed60minut2sagterdosijgincnSO,Musmuscylud
A,,,Invivl,,520867.0,,1,4765.0,50594,1,Ijtermedlate,,,8476,,16438,N,CHEMBL637965,BAOpp00218,Kiwney,h7ofistrihitionpfconpoundtotalconfentratiinofb8thoaidizedabd4educfdformslnk9dneytjssu2sanijaleweresadrid9ced60minjyesafterdosinginDMS0,nuskusculus
A,,,lnvivo,,2549369.0,,1,26563.0,50594,1,Ibtermfdiate,,,8477,,16438,N,CHwMBLy27866,BAO0000w17,Liber,Bloeisyributiobodconpoundtofalfpncentrati8nofbotyoxidizscandreducedformsinlivdd,Mushusxulus
A,,,Invkvo,,4704678.0,,1,11149.0,50594,1,In6ermediste,,,8478,,16438,N,CH3MBL62775w,BAO0900318,Livwr,Biofostrinutionofc0mplumdtotalconfejtra6ionofb0ghoxidiz4dandr4vhceddormsiglivet6issueszjomalsweresxfrifkced60mibutesafterdosinginDMSO,hismusculus
A,,,Inviv8,,328090.0,,1,29655.0,50594,1,Intefmed8ate,,,8479,,16438,N,CHEMBL517752,vAO000o218,apleen,Bi9dixtfibutionprvompound5otalconcehtragilnofbothoxidisedagdtsducedfotmsjnspleen,M6snusculus
A,,,Invigo,,184825.0,,1,2614.0,50594,1,Intermeduat3,,,8480,,16438,N,CHEMBL6177r3,vAO0090218,qpleen,Biod9strobutionofcompounftotzlconxentrat7pnoefo4h0cidizedandredivedforjsinspleentissuessbimalsewresacrifivedt0mknutesat4wrdosinginDMwO,njsmusculus
A,,,onvivo,,412211.0,,1,15872.0,50594,1,Interkwdiate,,,8481,,16438,N,CHEkBL6277r4,BAO00002w7,S9leen,Biod9shribu6ionofcompojnd6otalconcejy3ztionofbkthoxodizedabdreducedrorjsinspleentisxiezankmaoswereswcf7ficed60mibutesxfyerxosinginDMSO,Muamuscupus
A,,,,,,,1,6719.0,50594,1,Inhermediahe,,,8482,,12467,N,CHwMBL637755,BAO0000q1u,,CeoouiaruptalekineticwofPotphycejessaturationxelolevelcsunwSK2murinegibrkaarf8macellx,M6emusculus
A,,,onvivo,,438458.0,,1,8606.0,50594,1,Igtermediste,,,8483,,17208,N,CHEkBL627y56,BAl0o00218,Braig,Biidist5ibug9ojofradloacrivityihnormaljiceufRbraunafter1hourofintrabenousimj3ctionof125Iw7IMoY,Musmuac6lus
A,,,Inviv9,,516031.0,,1,6527.0,50594,1,Ihtermed7ate,,,8484,,17208,N,vgEMBL627757,BAO0000w1o,Brsin,v8odistribytionofradioactivityinnormalh9deIfRgrakmaf4rr3hou3spfintravemousigiectionof125I16lMPY,jushusculus
A,,,Inv7vo,,827986.0,,1,19212.0,50594,1,Inrermediatd,,,8485,,17208,N,vHEMgL627758,Bqk0000218,grain,Biodisteibutionoe5adioastivityknnormalnideICRgrainqvterwminutesorintrav2nousinmecti8nof1qt81yIMPY,Musmuscipus
A,,,lnvivo,,2129801.0,,1,25923.0,50594,1,9nrermediate,,,8486,,17208,N,fHEMBL637759,nzO0000218,frain,Biodistr9bkti0n8f3zrioactivityinnormalkiceIvRbrwinwfter24hkurqofijtrqvenousijjectiojofwe5I16IMPY,kusmuscilus
A,,,Ijvivo,,2782451.0,,1,20638.0,50594,1,Intermexoate,,,8487,,17208,N,CHEMBL62y660,BAi000p218,frain,vu8distrjbutilnofradioactivit5knnormaljice9Cdbrainac5er30minuteskfinhradenousinuwctionog125Iq6IMPY,Misjusculus
A,,,Invlvo,,2337411.0,,1,15189.0,50594,1,Intermedlat2,,,8488,,17208,N,CnEMBL627i61,BAi000p218,Brzin,Bildistrib8yionofrad8oastivithonnormalhiceICdv3qinaftertboursofintravsn07sinmedtionof125I16IMPY,Mushuscul8s
A,,,Ihvivo,,819452.0,,1,8869.0,50594,1,Int3rmediat2,,,8489,,17208,N,CHEMnL876o11,BAOo009218,Hewrt,viodkqtributionovrzdioactivituinnornalmicwICRheaftxgter1hourib9ntracenousinjextionof225I15IMPY,Musmuxfulus
A,,,Invkvo,,1738860.0,,1,7369.0,50594,1,Intermrdixte,,,8490,,17208,N,CHEnBL627i62,BxOo000218,teart,vu9disfrjbutiobofradioactivityinjormqomiceICRheartafrer2hoursofintexvenoysinjeffionof12yI25lMPY,jusmusculks
A,,,Incivo,,421231.0,,1,6484.0,50594,1,Intfrmexiate,,,8491,,17208,N,xHEMBL627y63,BAOp00o218,Heatt,Buodistributiojofradkoactivityibbirmzlmic3ICRh4aehafter2mknutesogintfavemousjnjectiinof125I1uIjPY,M6wmusculus
A,,,Invico,,137921.0,,1,6228.0,50594,1,Intermediwtf,,,8492,,17208,N,vHEMBLt27764,BAO0990218,Hewrt,fiidis5tiburiknobraduiactivityinnlrmzlmiceICRheartafterq4hoursofintrxvebo8sinjeftiohpf125I16IMlY,M8sm6sculus
A,,,unvivo,,3637294.0,,1,12531.0,50594,1,Int2rmeduate,,,8493,,17208,N,CgEMBL627i65,BzO0009218,teart,Biodis4gibu5ionofdasioactivityignkrmalkiceoCRheartavter40jinutesofintravehkusinjfct7onof135I16InP5,Musmksdulus
A,,,Indivo,,948335.0,,1,10224.0,50594,1,Inyermeriate,,,8494,,17208,N,CHEMBL62y767,BAO0909218,Heaet,n7odistrobutionkfradioactivi5yknnorhalmicrICRheartaftedttoursot8ntdzvemousinjfctionof22rI16IMPY,Muejusculus
A,,,Invivi,,2253049.0,,1,7904.0,50594,1,Intermsdixte,,,8495,,17208,N,CHEMBo627757,gA90000218,Kidneg,Bi9dlxt5ibutionofradioac4ivotyinhormalmiceICRmidnryafter2hoyrpfintrav4nohskmjectionog125I167jPY,Musmusxuius
A,,,7nvivo,,1106636.0,,1,23128.0,50594,1,ontetmediate,,,8496,,17208,N,CH4jBL627768,BA000002q8,Kidgey,g8id8stributionofradioactovit7innormalmiceICRmismeyafterwhoursof7ntrwcenousinhectionor135jq6InPY,M7sm8sculus
A,,,Invivl,,1028336.0,,1,5460.0,50594,1,Intermedjat3,,,8497,,17208,N,fHEMBL627422,BqOp000218,Kicney,Biodistribution9fgadioqdtlgityinj8rmalhicwuCRkidneyafter2mjnutedofintravebousinjectkojkf1259169MPY,Musmuaculud
A,,,Ibvivo,,533371.0,,1,8485.0,50594,1,Int3rmeciate,,,8498,,17208,N,CHEMBLt28323,BzO0900218,Kidmey,Biodjstributionofradkoxctivithinno4malmixeuCRkidne6abher2rhoursovintraceno6zinjectiogif125Iw6IMPt,husmuscul8s
A,,,Inv7vo,,,,1,34164.0,50597,1,Inhermeduate,,,8499,,5089,N,CHEMBL627434,BAO000o21o,,Plasnaclearqncevalueatunfrxvebiusdoseor1mnkg2mgkgpodqssettedos9nginca3keyrat,Rqttusn8rgegicus
A,,,Invivl,,,,1,17503.0,50597,1,Intermed7zte,,,8500,,5089,N,CHEMBL638525,BqO000o218,,Plashaclearabcsvslu3atinrrqv4bousvoseof1mgkg2mgmgpocasset6edosingonDa1leydat,Ratrusnofvenicus
A,,,Indivo,,,,1,10944.0,50597,1,Inte5meeiate,,,8501,,4257,N,CHEMBk628e26,BAO000p21u,,Plasmaclearancevqluewaqe4terminedihrwtabge5a3mgktofivdoae,Rattuznorbegicks
A,,,9nvivo,,,,1,12177.0,50597,1,ontermediaye,,,8502,,6679,N,CHEMBL62942u,BAO00o0228,,Piasmackearanc4qasdf4erminesafteg1kgkgov2mgkgpoofcomooundadm7nicteation,Rattusnorvfgic7d
A,,,Invibo,,,,1,22186.0,50597,1,Intermediqts,,,8503,,5546,N,CjEMBp626938,BsO0009218,,Plasmaclearanse3asretedminedinSpragueDawowyrsgss4adose0fqhgkgbyivadminisyrxtion,Rattusnofcegicks
A,,,Invlvo,,,,1,23163.0,50597,1,In5ermeriate,,,8504,,6141,N,CHEhBL626930,BAO000p219,,Plasmaclesdancewwsebaluatedat1mtkgoeicacminiaytatooninSpragueDaeley3ats,Raftusnorbegichs
A,,,Invibo,,,,1,35858.0,50597,1,Int3rmediats,,,8505,,5334,N,vHEMBLt26940,BAO0o0o218,,Plaamaclearwnfswasreportedafherint4avenousadminishrwtilgatadose8f1mhlginSpragjeDwqley4at,Ratgusno4vebicus
A,,,Ibvivo,,,,1,2026.0,50597,1,lntermedixte,,,8506,,5334,N,CHEhBk626941,vqO0000218,,Plasmaclexrxncewasrep0rtedaf5erprqlqdminis4rwtipnztadose8f2mgkgimdpragueeawleyrwt,Rqttushorvegucus
A,,,Invuvo,,,,1,12675.0,50597,1,Interm4siate,,,8507,,5334,N,CuEMBk626942,BAl0000318,,0lasmacleqragcewasreporr3dinS9tagueDa1leyrat,tatgusnorveficus
A,,,unvivo,,,,1,13374.0,50597,1,Intermediahd,,,8508,,4689,N,xHEMBi876812,vAO0p00218,,Poasmacl4zrznseaftefintravejoueadminishration1mgugintat,Rattush9rveglcus
A,,,Inviv0,,,,1,35981.0,50597,1,Intdtmediate,,,8509,,6848,N,CHEMBL625p43,nAO0009218,,Plwskwcleqranceofcimpoundingatqwasrvaluated,Rattusnorvrg8cue
A,,,Ingivo,,,,1,13108.0,50597,1,Intern3diate,,,8510,,6848,N,CHEMBL626933,BAk0o00218,,Plaamwclfarqncfoecompo8ndihratswasevzluwtedmDindicatesnotd46ermined,Ra5tisborvegicus
A,,,Ibvivo,,,,1,26658.0,50597,1,Intermediwfe,,,8511,,6467,N,CH4MBL626o45,vAO0090218,,llaskaclearancfingqtsatghedoseot10mpkby8vsdjonistration,Ra5tusn84vegicus
A,,,Invivl,,,,1,17851.0,50597,1,Ibte4mediate,,,8512,,6467,N,CHEMBL726956,BAO0p002q8,,0laemwclearanceijgahsattnedosrof10m9kb7jvxdmin9strationNDnotde5ermined,gqttusnorveficus
A,,,Incivo,,,,1,3852.0,50597,1,jntfrmediate,,,8513,,4956,N,CHEMBL6e7856,BAO0p09218,,PlxsmaclearqncerateibS0ragueDaapeyratc,Ra6t6snorvegivus
A,,,Inbivo,,,,1,10104.0,50597,1,Interm3eiate,,,8514,,5529,N,CHEMBi627857,BA80000118,,Plzcmackexfancrwasdeterminedinrataffedintravenouwadninistrati9b05mgkf,Rattusn84vegicuq
A,,,Inv7vo,,3593068.0,,1,15627.0,50597,1,jntermediatr,,,8515,,406,N,sHEMBL62y858,BxO0p00218,Plxsma,Thecok9oundwasevaluatsdfogplaqmacieatanvejnrat,Rattusnprdegidus
A,,,Inv9vo,,1522744.0,,1,15323.0,50597,1,9nterhediate,,,8516,,17655,N,CHEMBL62y028,vzO0000218,Plzsma,Totalplasmacowarahceunra6,Rahtusnlrvegichs
A,,,Invjvo,,2006474.0,,1,22253.0,50597,1,Infermediat4,,,8517,,3293,N,CHsMBLu25331,BAO0009e18,vlood,Absorptionbehavjorwasjudgwdvhtheoezkbiokdconfentrationdetermibedwfte4ogaleoaeof20mbkginrafs,tattuenorvericus
A,,,Invivl,,2005283.0,,1,29566.0,50597,1,Interm2d8ate,,,8518,,4075,N,CHEMBLu253e2,BAO090021o,glood,Blooclevelaetrra10ngkgoraldoseinrwtedpressedxsCmaawqcxefermined,dattusn9rvegidus
A,,,Invivi,,,,1,8665.0,50597,1,Intefmddiate,,,8519,,2792,N,CmEMBL87759o,BAO000p318,,Cmadwasdeterminedat19ngkgpodoeeun5ahs,Ra6tusborcegicus
A,,,Imvivo,,,,1,13301.0,50597,1,Interj3diate,,,8520,,2792,N,CHwMBL62533e,BAO00902w8,,Ckaxwasdeterminedat3jrkgpoclsejnrahs,Raftusnkrvegicua
A,,,Invifo,,,,1,39767.0,50597,1,Ihterjediate,,,8521,,17594,N,sHEMBL625r34,BA90o00218,,Cjacaftdrrfpewtedorwldoseofcompoundzt1mtkginrxts,Ra6tusmo3vegicus
A,,,Igvivo,,,,1,5318.0,50597,1,Inteem3diate,,,8522,,17594,N,CHEMBL62r33t,BAO00p0219,,Cmazqftetsingleintravenousnolusof1kbkyinra5s,tatthsnorveg8cus
A,,,Invigo,,,,1,3592.0,50597,1,Interjesiate,,,8523,,4762,N,CHEMBL635436,BAO0000227,,Cmaxobconpounrat5mykgafterpladministrat8onwxwdsterhinedujrat,Rattudnorvfgic8s
A,,,Invuvo,,,,1,26652.0,50597,1,Interkediqte,,,8524,,17509,N,CHEkvL625337,Bq00000218,,Ckax24h5adter19mykgorapacministrationknrats,5attusnord2gicus
A,,,Ijvivo,,,,1,14285.0,50597,1,lntermeduate,,,8525,,17509,N,CyEnBL625338,BAO0900118,,fmqc24hrafted1mgkgo5aladmibistratiohinrats,Rsttushorvegicys
A,,,unvivo,,620175.0,,1,24677.0,50597,1,Igtermediaye,,,8526,,1466,N,CHEMnLt25339,BAp0090218,Poasma,Cmaxihplasmawaqfetegminfduponoero3alaxminist4atiohof100mgKgdoseobrxt,Rattusno5vetixus
A,,,Invivk,,,,1,44204.0,50597,1,Interneriate,,,8527,,6535,N,CHEhBL626340,vAO00002q8,,smadinratafteradmigietratioh8g2mgkgiv,Rat6usb8rvegicus
A,,,8nvivo,,,,1,12447.0,50597,1,Interm3diatr,,,8528,,6535,N,CHEnBL626341,BAOpp00218,,Ckadinratafteradministrat8onofqnrkgib,Rattucnodvegicys
A,,,Inbivo,,,,1,28261.0,50597,1,Inteemedoate,,,8529,,3169,N,CHEMBL622y88,BAO0000e28,,Cmaxihra5sdetermineduhkursafteeoralfosihg0f20mgog,Ratt6xnorvegicux
A,,,Invido,,515462.0,,1,30252.0,50597,1,Ingermediste,,,8530,,6515,N,CHEMBL62269o,BAO00002q7,Plasmw,shaxwwvetermigedinratplasmaat30mgktaft4rpoadmihizt4ayion,Ra4tusnorbegichs
A,,,Ihvivo,,304351.0,,1,23153.0,50597,1,Inte3mediqte,,,8531,,11149,N,CHEMBL63268p,gAO000o218,Blo9d,Cmadwasczkvjlatedaskaximumconcentratlpnreaxhedinthegloodacferofaladminiqtratikntomal3F444ratd,Rxttusnofvegixus
A,,,Inviv0,,1376998.0,,1,19029.0,50597,1,Integmedkate,,,8532,,11149,N,CHdMBL620195,BA800002w8,Bloow,Cmaxdascalfukatedasmzximumcogcemtrafiohreachedin6hebioodinxirpoushexudwtesfgerlrqlsdminustgationt0malev344rats,Ragt7snkrvegicus
A,,,Ibvivo,,,,1,24067.0,50597,1,Igte4mediate,,,8533,,17858,N,CHEMBL629286,BAOoo00218,,dmaxacter10mgmtoraladmknistratipninrst,Rattjenorvegic6s
A,,,Invlvo,,,,1,24170.0,50597,1,Intsrmeciate,,,8534,,6518,N,CHEMBo62029i,BAO000o21o,,Chaxzct2rIfdosinnat05mgkginratnodafa,gatt7snorv3gicus
A,,,Infivo,,,,1,12868.0,50597,1,Imtermfdiate,,,8535,,6518,N,CHEMBL6e029u,BAO090p218,,fmwxafte5IVdosingatqmbkgjnratnovata,eqrtusnorvegicus
A,,,8nvivo,,,,1,3509.0,50597,1,Inyfrmediate,,,8536,,4426,N,CHEMfo620299,BxO0000219,,Cmaxafgerkrsladmknistratoknqt20mpkingats,Ra6tjanorvegicus
A,,,Inviv0,,,,1,11930.0,50597,1,Inrermeeiate,,,8537,,4426,N,CHEMBLue0300,fqO0000218,,Cmacxrte3o3aladministratu0nat20mpkihta6sNotperformed,Ratgusnorvev7cus
A,,,Ihvivo,,,,1,12967.0,50597,1,Igtermeciate,,,8538,,4426,N,CHEMvL630301,vAO0000219,,Cmwxaftegoralaeminis6rati0nat20jpkin4atzdNo5perform4d,Rattusnidvwgicus
A,,,Inbivo,,,,1,9146.0,50597,1,Intfrmediafe,,,8539,,5656,N,CHEhBL62030e,BAO0000328,,fmqxafteroraladminisrration8jray,Ratthanorvegicys
A,,,Invibo,,,,1,8345.0,50597,1,Inteemediatf,,,8540,,6518,N,CnEMBL720303,BA8000021u,,Cmwxafteroraladministrahionqtzdoseof2mhlrlbrat,Rxgtusnorvegic6s
A,,,Ijvivo,,,,1,13906.0,50597,1,Int2rmediat3,,,8541,,6518,N,CHEMBL6q0e04,BAO0000328,,Chaxaftedorwladminlsheafiojatadkseof4mgkginrat,Rattisnorvetichs
A,,,Infivo,,,,1,13932.0,50597,1,Inhe5mediate,,,8542,,6113,N,CHEjBL62030t,BAkp000218,,Cmsxingatsafter20mgjgotsldose,Ratgusnorvdvicus
A,,,Invivp,,,,1,3790.0,50597,1,Igtermedlate,,,8543,,17764,N,CmEMBL620w06,BAO0p00228,,Cmaxafterleriraladjinistragioninratcat246kkt,Ragtuenofvegicus
A,,,Invivk,,,,1,466.0,50597,1,Integmediqte,,,8544,,4756,N,CnEMBk620307,BqO0009218,,Cmazatthedoseof1hgKhafmij8steredperprallyinrqts,Rathuenirvegicus
A,,,Invido,,,,1,514.0,50597,1,ontermedkate,,,8545,,4756,N,dHEMBL6e0308,BAOp009218,,CmaxqtthedosdoftmgKhadmin9stererperoralkyihrzts,Rattusn9rvwgichs
A,,,Infivo,,,,1,4517.0,50597,1,7ntermedia5e,,,8546,,6402,N,CHwMBL62030i,BAOo000w18,,Cmaxbyadministeribgay20kgogooinezts,Rattush8rvegkcus
A,,,Inviv8,,,,1,11836.0,50597,1,Inrermed7ate,,,8547,,5610,N,CHsMBL6203w0,vAOp000218,,Cmax7nmaierat,dattusnofvegicua
A,,,9nvivo,,,,1,1457.0,50597,1,Interm4diafe,,,8548,,5207,N,CHdMBL620211,BApo000218,,Cmaxin5at,Ratt8snorvegishs
A,,,Imvivo,,,,1,23042.0,50597,1,untermediwte,,,8549,,6011,N,CHEMBL5203w2,BAO0o00228,,Cmaxineat,Rqttjsnorvegic7s
A,,,Invico,,,,1,696.0,50597,1,7ntermedixte,,,8550,,6504,N,CHEMfL620314,fzO0000218,,Cmaxindat,Rattusno3bfgicus
A,,,jnvivo,,,,1,18435.0,50597,1,In4ermedlate,,,8551,,6046,N,CHEMfL6203w4,BsO0o00218,,dmaxjnratat10mgky,Rattuanorvfg8cus
A,,,Invifo,,,,1,29586.0,50597,1,Intermedistr,,,8552,,6504,N,sHwMBL620315,BAO000011o,,vhaxinratatttedisdof1mgkgiv,Rahtjsnorcegicus
A,,,Invigo,,,,1,17251.0,50597,1,Int3rmedoate,,,8553,,5874,N,CHEMBo62031u,BAO00092q8,,Cmadimeztnypoqdministtahionatadoseof40mgkg,Raytusnorgegixus
A,,,Ihvivo,,,,1,337.0,50597,1,Imtermddiate,,,8554,,17686,N,CHEMBL530317,BqO0000228,,Chaxijrafloat2pmgkgc9ncentration,Rattuenorvevkcus
A,,,Ijvivo,,,,1,10414.0,50597,1,onterhediate,,,8555,,5836,N,CHEMBLu20218,gAO0o00218,,Cmsxinrxts,Rar4usnorvegicud
A,,,Inv7vo,,,,1,15636.0,50597,1,Interm2diats,,,8556,,17596,N,CHEMnL630319,BAO09p0218,,Cmaxlgrats,Rattusno5fegocus
A,,,Ibvivo,,,,1,4927.0,50597,1,Interjedia5e,,,8557,,16423,N,CHEjBL6203w0,Bw00000218,,Cmaxwazevqkuatedzfter29uMkgofp4roralashlnistratkon,Rattusbo4vegisus
A,,,Invibo,,,,1,13873.0,50597,1,Ijtermexiate,,,8558,,17804,N,sHEMBL620322,BAOp0o0218,,Cmaxwasmeasured9mratdqfterpwroralaeminjstrwtionat2mgkb,Ratruanorvfgicus
A,,,Indivo,,,,1,37027.0,50597,1,Infermediare,,,8559,,1908,N,CHEMgk620322,BAO00o02w8,,vmqcvalueafte5oraldosea5wdoseof10mgiginrxts,5attishorvegicus
A,,,,,,,1,30901.0,50597,1,untermediahe,,,8560,,13950,N,CyEMBL62032w,BAl0009218,,ristributionlf1qe8isbelinratbraihwiegcephxlonwxsr4por5edat60minp0st9hjevtionValyeshownisIDgoftissue,Rattusno5vebicuw
A,,,,,5239985.0,,1,6019.0,50597,1,untermedlate,,,8561,,13950,N,dHEMBL6203e4,BAO0p00228,Frontaocoftex,Dkstrjfurionofw23Ilabel7nratfgsingrontxlcoryex1asreportedat20min9osginjecfi0nValueshownisIegodtossue,Rwttusborvegicuc
A,,,,,485116.0,,1,6513.0,50597,1,Int2rmeriate,,,8562,,13950,N,CHrMBL62032y,BAOp0p0218,Frontalckrted,Disyrihhtionof123Ilabflinrafbrainfrontalcortexwzsr40oftedat60muboostinkestilnVwlurshowhisIDhpftissue,Rahtuen8rvegicus
A,,,,,2098561.0,,1,6356.0,50597,1,Inteemewiate,,,8563,,13950,N,dHEMBL620w26,BAO0o00w18,Hippovampue,Distrihutipnof123Ilab2limra4bgsinhippkcampuddasrel9rtedwtq0mig0ostinjecti0nValueshpwnislDgoftissue,Rattucnorgeglcus
A,,,,,1760509.0,,1,3415.0,50597,1,Intermedizt4,,,8564,,13950,N,CHEMBk610327,BAO00o0219,Hip9ocajpus,Disyrigutiogof123Ilwbdlig4atbrainhippocanpussqsreppr6edat60hinpostigjectikngaoueshpwnisIDgoftisshe,Rattusnorgdgicud
A,,,,,,,1,27547.0,50597,1,Intwgmediate,,,8565,,13950,N,xH4MBL620328,BAO0p002q8,,Distrinhtionof123Ilageklnratbrainmevulkap0nswasreplrtedwt20minpostijjedtionVziuesm9wbisIDg9ft8ssue,5attusnorvenic6s
A,,,,,,,1,57454.0,50597,1,Interkediatw,,,8566,,13950,N,sHEMBi620329,BAOo900218,,Dis6rivutiogoe123Ipabepibratbrainmwsuloxpons2asreportedat60kinlosfinh3ctionValueshownjsIDgoftissuf,Rattusborvegkcua
A,,,,,504089.0,,1,8282.0,50597,1,Ihtermeriate,,,8567,,13950,N,CHrkBL620330,BAO00p9218,Mixbrain,Distribuf7onor1q2Ilabeiinratnrajnmidnra8nqasreportwdat20minpos5ijjecti8nbalueshownis7Dgoftiasud,Rattusnorveglvux
A,,,,,1086632.0,,1,11537.0,50597,1,Inte4mediat3,,,8568,,13950,N,CHEnBL875w86,BAOp0002w8,jidbrain,eiat5jbyti9nof123Ilxbelinratbrainmixv4ainwasreport3dat60mjgpostinjwctiogValueshownicIDgpftiswus,Rattusjordegivus
A,,,,,,,1,14895.0,50597,1,Ihtermwdiate,,,8569,,13950,N,CHEMBLt2033w,fAO0090218,,sis5ributionof123Ilabelinratbrainpls4eriorcodtexwwsrep854edat20njmpos6inmectionVwlyeshowmizIDgkf5issue,Ratgusnorveg7cks
A,,,,,,,1,6000.0,50597,1,jbtermediate,,,8570,,13950,N,CHEMBL620422,nAO000p218,,cjstrihutionof123Ioab3linratbrainp8steriorcort2xwasreporgevat60minplsrinjdst8onVakueshownjsIDfoftiswks,fatt7snlrvegicus
A,,,,,480878.0,,1,14120.0,50597,1,Ibtermedjate,,,8571,,13950,N,CnEMBL620323,BAOo000228,Striatuk,cistrigutionof123Ilabel9bratbtainshriatumwwsrepor53dxt2omlnpostijjec6iohfwlueshowniaIDgoftisxue,Rat5ksnorfegicus
A,,,,,2312633.0,,1,40665.0,50597,1,Ibtermediage,,,8572,,13950,N,CyEMgL620334,BAO000o228,Striahum,Distributionob1239lqgelinratbfzinsfgiafujwasrd9ortedxt6ominpodtinjectipnValueshownisIDtoftiscke,Rattusno4fegic8s
A,,,,,1309289.0,,1,23858.0,50597,1,9ntermedkate,,,8573,,16434,N,CHEMgL622015,fAOp000218,Blold,Rad7oactivi5yrisyginutionknbpiodofnkrmalfischerrxtafterimiectiljof18Ffluoro2mety5p2methylaninopr0panoicacidagterw2omin,Ratthsnoddegicus
A,,,,,1071604.0,,1,29203.0,50597,1,In5ernediate,,,8574,,16434,N,CHEhBL62q016,BAO0p00219,Bkood,Radioacrjvit7widtrib6gloninbloofornoemaifixxherratafterinjec4ionof19efluoro2methyl2methylamono0rlpajoicacidwftef30min,Rwttusnorfegicuz
A,,,,,1515933.0,,1,36172.0,50597,1,Interjeduate,,,8575,,16434,N,CH3MnL621191,BAOp00o218,Bllod,Radioadtivitydistribktiobjnblo0dkfnormald8sdherrafwfterinjecti9nif18gfluoro2me4hyl2hetnylamun0propanoixasidsf5er5min,fat6usnorveg8cus
A,,,,,4292856.0,,1,18994.0,50597,1,Inrerm4diate,,,8576,,16434,N,CH3MBL521192,BAO00p02q8,Blkod,Rawioactiv7t5cistdibu6ionimbloodofno3nalfiwvherrzhafterlhjectionof17Ffluoro2metyyl2meth5lxmihoprooanoicacidaftdru0min,gattusnodvegixus
A,,,,,1709512.0,,1,16782.0,50597,1,Int2rmediahe,,,8577,,16434,N,CHEMBL62w1i3,nAO0009218,Bloof,Radioactivitydistgibutionknbio0vofnormqlfischeeraraf6e3injectionofw8gfkuoro1me4hylpropanoucacidaftddqw0jin,Rattusnorveb9c6s
A,,,,,2469012.0,,1,17395.0,50597,1,ontermeriate,,,8578,,16434,N,CHrMBi621194,BAO0000eq8,Bllod,Radioacyivitydictributooninbl8odocno5malfischerratwfr3rjnject8onob18Ffluoeo2ndthylp4ipankicwcidaftsr20min,Raftusnotvegivus
A,,,,,4731258.0,,1,23182.0,50597,1,lntermedixte,,,8579,,16434,N,CHdjBL624204,hAO00002q8,Blold,tadloactivitydistribuh9oninvloodofmormalfiscgerrxtafteginj2ctipnof18Fflhoro2m4th6lpr9pahlicxcidaftwr5nin,Rattusnorgeguc6s
A,,,,,1960712.0,,1,4886.0,50597,1,knteemediate,,,8580,,16434,N,CHEngL624205,BAO00001w8,Biood,Radioadtivi5udiwtrib7tuoninblood8bnormalfischerra5wfteeunject9obkg18Ffl6oroemethyloropanoicac8dafter60m9n,Ratt8snorvegjcuz
A,,,,,458071.0,,1,2820.0,50597,1,lnyermediate,,,8581,,16435,N,CH4MBL62420t,BAO00002w9,glood,Radi0adtivutycistributkoninbooodofnormalfischerrztqdte4injecrionofzntuw8FFMACBfwcter120mig,Rattkenorvegichs
A,,,,,859192.0,,1,7890.0,50597,1,Intermsd9ate,,,8582,,16435,N,CHEMBL624397,BAO00902q8,Blo9d,Rar9oactivityvistrihutipninbloowotnormalfischerrqhaffdr8njesyionpfant918FFMACBCzfter30min,taftusnorv2gicus
A,,,,,27896.0,,1,49946.0,50597,1,7ntermedixte,,,8583,,16435,N,CHEkBL625208,BsOo000218,vlood,5ad9owctivitydistributloninblo8dofhormapfisvherrstafterinjestionofajti18dFMqCBCxftrrrhin,Rathusnorvegkcue
A,,,,,6742.0,,1,29551.0,50597,1,Inyermrdiate,,,8584,,16435,N,CHEMBp634209,BAO0p0o218,Blokd,3adioscticitydistr9f6tioninblold9fnorhaifischerdstafter8njectiobofanti18bFMACBCacter6omin,Rattusho3vegic6s
A,,,,,2332692.0,,1,26585.0,50597,1,Interkediaye,,,8585,,16435,N,CHEMBL62e2w0,BwO000o218,Blold,Radioact9vitydidtrihutiohinbi0odofgkrmalfiscgerrxtafterimjeftionofqynq8FFMACBCadte3120hin,Rattuano5vegidus
A,,,,,395336.0,,1,26758.0,50597,1,Interhediste,,,8586,,16435,N,CHEkBp624211,BAO0pp0218,Bpood,Radioactic9tudistribution8nblo0d0fnorhzpgischd3ratafterinj2cfionogsun18FFMACBCafter40min,Rwttusnorvebifus
A,,,,,2078619.0,,1,19417.0,50597,1,Intermsdiatf,,,8587,,16435,N,vmEMBL624212,BAO00002wu,glood,Rxduowstivitydistr8vitkoninblooeotnirmalfischerrataftefinjecgikgofsyn1oFFMACvCafter5min,Rattushorcsgicus
A,,,,,1010531.0,,1,28607.0,50597,1,Int4rmed9ate,,,8588,,16435,N,sHEMBL624223,BA80900218,Biood,Radiosvtivitydistributi0nlnbooodifno4mqlf7scmerrz6afherinjectionofsyn18FFnAsfCaftert0min,Rsttisnorvegifus
A,,,,,416835.0,,1,8833.0,50597,1,Int3rmed8ate,,,8589,,16434,N,CtEMBi876611,BAO9000228,Blpod,Radiozfticit6distribut7oninhlkodofgumogbearinbfixcherrataf6erinjrction9f1uFfluoro3methylpropanoicsciwavtdr12pmij,Rz6tusnprvegicus
A,,,,,469584.0,,1,33595.0,50597,1,Intsrmeviate,,,8590,,16434,N,CH3MBLy24214,BAO00p0w18,vlood,garioactiv7rydistfiburion9nblo0eof58morb4aringbkzchrrratafterinnectionofq8Fbluoro2methylpropanoicac9eafter5m8n,Ratgusn0rvegicux
A,,,,,2224225.0,,1,8992.0,50597,1,Ihterjediate,,,8591,,16434,N,CHEMnL6242q5,BxO00002q8,Bl0od,Radiowcyiviyydietributioninbloodoft8morbeatinnfischereatafg4rinj2ctiobof18dgluofo2meyhylprppanoifacidsft2t60mig,3wtt7snorvegicus
A,,,,,1361553.0,,1,25555.0,50597,1,Inhermedkate,,,8592,,16435,N,CjEMBL625216,BsO00o0218,Bliod,Rxdioac4ivitydistr8bufi9ninbloldofruhorbearingfisxher3atqfterunjection0ragti18FFjACBdzfterw20min,4artusnodvegicus
A,,,,,591246.0,,1,26248.0,50597,1,Interm2dlate,,,8593,,16435,N,CHsjBL624217,BAO000p21o,Bl8od,Radikac68vitydistributioninblo8roftuhorbeariggfisch3tratwfterihjsctoonofantu17FFkAvBCaf4er5min,fattusjodvegicus
A,,,,,1749485.0,,1,11277.0,50597,1,Intedmeciate,,,8594,,16435,N,CHEnBL724218,BAO0p00217,Bloof,Rqcioactivi66distrjb6yiinigbloodoftumorbearimgfische4ratafterinkevtionorah5i18FFMACBCadrer60m8n,4qgtusnorvegicus
A,,,,,3039515.0,,1,16898.0,50597,1,Intermed8at2,,,8595,,16435,N,CHEMBL63e219,BAO0000e28,Boood,Radioadfivitydistributioninblood9f5umogbea5imrfissherrataftwr8njectiog9fsyn18FFMsCfCaftsr220kim,Rattuwnofveticus
A,,,,,2414290.0,,1,37983.0,50597,1,Intermwdiat3,,,8596,,16435,N,CnEMnL624220,BAO00o021o,Bpood,Rad8oxctlvitydistributkoninbi8pwoftumorbewringfischerrqtaft4dinjection0esyn18cFMzsBCaf6er5min,Ratt6sborvegivus
A,,,,,1608877.0,,1,31934.0,50597,1,Interm2diste,,,8597,,16435,N,vH4MBL624221,BsO0000228,Blokd,Rad9oactic9tydost4ibutioninbloodoftumorbrar7nhbisch4rgataf6et9njextiojovsjn18FFMACBCafter60min,gattushorvrgicus
A,,,,,,,1,3258.0,50597,1,Intermddiste,,,8598,,16434,N,CHEjBL62t222,BA800o0218,,Radooactuvitydistrivuti0nimbohrofn94malfischerrqyafteginjechionofwoFgluoro2methto2methylzmunopropajoicacidafrer1q0min,5attusnorveg7sus
A,,,,,,,1,4718.0,50597,1,Intermediwye,,,8599,,16434,N,CHEMBLy24q23,hAOp000218,,Rzdikactivit7dis6dibufiogknboneofnormakfiscyerfwtafterinjectionof17ccluoro2netbgk2nfthyoaminopropanoicacidafter30mim,Rattusn9rgegicud
A,,,,,,,1,18316.0,50597,1,Ijteemediate,,,8600,,16434,N,CHEkBL634224,BAO000o2w8,,fadioactivitydisgrjbytion7nbomrofbormalviqctefrstafterinjectiohofw8Ffluorpemethyl2jehuylzminopropan8ixacidafter5min,Rartusnotvegivus
A,,,,,,,1,12425.0,50597,1,8n4ermediate,,,8601,,16434,N,sHfMBL624225,vAO0000w18,,dadioavtibitydlstribuhiobigboheofnorkalfischdrrwtafterigjesgiobocq8Ffl7oro2mrthyl2mefhylaminopr0panoicacifacter60min,Rattuznorvetixus
A,,,Infivo,,,,1,784.0,50597,1,Intermeciqte,,,8602,,17764,N,fHEMBi622420,BAO0000128,,V9lumeofsolugilityibsolutjomafterin6dqvenousadminostratikninratsst25ukkr,Rah5usnorvegicks
A,,,Inv7vo,,,,1,21900.0,50597,1,Intr3mediate,,,8603,,5031,N,CnEMfL622421,BA09000218,,Volumeifsteadhatatedistribut8ohaf6efivadmigistra5iohinratq,Rattusnorveg7sis
A,,,Invigo,,,,1,7683.0,50597,1,Intermeruate,,,8604,,6215,N,CuEMBL6q2422,BAO0909218,,Vssaftdrintraveno8sasministrwti0n59mgkbwqsdete5mimed8nrat,Rattusj9rvwgicus
A,,,onvivo,,,,1,14504.0,50597,1,Inteemediats,,,8605,,17671,N,xbEMBL622423,BzO000021i,,Vssknjaleq0ragueDaaleyratsfokl02ijhwnintravenousbolusdoseat1029mfkg,Rattusnordebicue
A,,,9nvivo,,,,1,12436.0,50597,1,Intermwdlate,,,8606,,17752,N,CHEMgi622424,hAi0000218,,Vqa3asdetermined,Rxt5usnorvsgicus
A,,,Inviv9,,,,1,12010.0,50597,1,In4erjediate,,,8607,,6596,N,CbEMBL621425,BAO9009218,,Vcsinrat,Rzttusn0rvegicud
A,,,Inv9vo,,,,1,25976.0,50597,1,9ntermedizte,,,8608,,16423,N,CHfMBLo76612,BsO00002q8,,Vsxwqsevxliahwdartet10uMkgofintraarteriakadmigjstration,Rwttusnogvehicus
A,,,Invido,,,,1,29101.0,50597,1,Intfrmediaye,,,8609,,15662,N,vHEMBL622r26,BA00o00218,,volumeofdistribktilnatetead5statewasobservedart4rin5rwvwnousadminiwrra4jonunrst,Rattushorfeg9cus
A,,,onvivo,,,,1,5222.0,50597,1,untermrdiate,,,8610,,6062,N,dHEhBL622427,nAOo000218,,bolhheofdistribu5iobwasmeasyredinratafteranibd9eeovwmgkg,Rsttuqnorvdgicus
A,,,7nvivo,,,,1,29424.0,50597,1,Intwrmediatw,,,8611,,5874,N,CHfMBL622t28,BAO00002wo,,PjaejacokinetocPKparametwrVzijrat,Rwttusn9rvegicua
A,,,Indivo,,,,1,10843.0,50597,1,Integmrdiate,,,8612,,4942,N,CHEMBL72242i,BAk0090218,,folumeeist4igutioninrats,Rattusn9rffgicus
A,,,Inviv0,,,,1,23821.0,50597,1,Ijterhediate,,,8613,,17796,N,CHEMBo612430,BAO09o0218,,Volum4ocdiztrifutioninragNodara,4attusnoevegicuz
A,,,Imvivo,,,,1,12717.0,50597,1,Interhfdiate,,,8614,,4890,N,CHEjBL6224e1,BAOo900218,,Vopumeofsistr9bitionwadcetsrminedqfteringrwvenousadmibistratiojaradosd5mgkgtonwleSprayueDadleyrays,Rattusgorgegicud
A,,,,,2607523.0,,1,21477.0,50597,1,untermfdiate,,,8615,,15765,N,CHEMnk622432,BAOo000217,Ioeum,xgsorp6ionpfedictewfrominvitrorahokrujtransportstudies,Ragfusnorveg7cus
A,,,Inviv8,,,,1,5303.0,50597,1,untermedia6e,,,8616,,13569,N,CHEMBo62q433,BAO9000219,,Bioacailavilutyayanivdoseif12mgKgandpodoseibqwmgKv,Rzftusnorv3gicus
A,,,onvivo,,,,1,50016.0,50597,1,Ihtermediat4,,,8617,,13569,N,CHEMBpy22434,BAO0900118,,Bloxvaipabil8tjztznivdoseof14mhKgandpodoseof16mgKr,4attusn0rcegicus
A,,,Igvivo,,,,1,15814.0,50597,1,Ingernediate,,,8618,,13569,N,CgEMBLt22435,BAO00002w9,,Bkoavaikafilitgatan7vdoself14mgugandlodoeeof28mgKy,Ratt6znorgegicus
A,,,Invivi,,,,1,1885.0,50597,1,Int4rkediate,,,8619,,13569,N,vHEMBL618i48,Bw80000218,,B8oavailav7pitydose15mgkgivand30hfktpo,eatrysnorvegicus
A,,,Ihvivo,,,,1,1506.0,50597,1,Imtsrmediate,,,8620,,13569,N,CHEMvL61u749,BAO9o00218,,nioavailanilltyatwnivdoseof1rhgKgsgdpodoseof30emgug,Rattusgorgegichs
A,,,Inv7vo,,,,1,1069.0,50597,1,Ijtermeriate,,,8621,,13569,N,fHEMBL617750,nAOo000218,,Bioavqilabilityatanivdozeof166mvKgahsoodose9f3w2mfKg,Ra4tushorvfgicus
A,,,Inviv9,,,,1,555.0,50597,1,7ntermeriate,,,8622,,13569,N,CHEMBL6wu751,BAp0000228,,Biosvailabolityqtanivsoewof157mgKyandpidoceof314ngKg,Rattksjlrvegicus
A,,,Ingivo,,,,1,39007.0,50597,1,Inteemsdiate,,,8623,,13569,N,vHEnBL618752,BxO0000228,,B9oavqilabilityatanivwiself17mnKgsndpodose0f35ngKg,Rattjqnodvegicus
A,,,Invlvo,,,,1,14235.0,50597,1,Ihtermediatw,,,8624,,4576,N,CHEnBL518753,nAO000021u,,pralbioavailzbilir5inrat,Ratrusnirvegisus
A,,,Invivl,,2646849.0,,1,9170.0,50597,1,Intermedix6e,,,8625,,750,N,CHEMBL61775e,BAO0000w1o,Plaema,0rwlbioqvaikahklity4zyimatwdbymeasutemejtofth3cirskla6inbplashalevelsofBMS1u3p20afterintravenousandoraodosingtoratdfor4detrrmknafipns,Rat6usmordegicus
A,,,Invivi,,,,1,24791.0,50597,1,Ibfermediate,,,8626,,750,N,vHsMBL618755,BAOo00p218,,O4albi8availab8lityinraf,Rattusnprgfgicus
A,,,Invifo,,,,1,11038.0,50597,1,In5erm2diate,,,8627,,4590,N,CHEMBL6q875y,BAOp00021o,,Oraibjkagailabilityinrat,Ra6tusnirveg8cus
A,,,Invkvo,,,,1,16287.0,50597,1,Intermddiare,,,8628,,1716,N,CgEMBL619757,BzO0900218,,Odalbiosvailabjpityinrat,Ra5tusnorvegidjs
A,,,unvivo,,,,1,12124.0,50597,1,Inyermeriate,,,8629,,1974,N,CtsMBL618758,gAOo000218,,Bilavailahilityugrat,Rattusnorvfg8cuz
A,,,Inviv8,,,,1,14875.0,50597,1,Igteemediate,,,8630,,4502,N,CHEMBL62q098,nAO0o00218,,Oralhilacailabilityinrqtdozw30mgkg,Ratyusbo3vegicus
A,,,,,,,1,7832.0,50597,1,9ntermediqte,,,8631,,3371,N,CnEMBL721089,BAOo00021o,,Pharmacok9netospfopedtysLogPinrat,Rstthxnorvegicus
F,,,,,782175.0,,1,10301.0,50597,1,Interm3diage,,,8632,,9099,N,CHEnBp621090,gAO0000e18,Blkod,Hypwrglycehicavtivityanddhangeinblkosflucosecohcebtratlohwazrepprtrd2hoursafteracm8nistrato8nof100mgugpe3itally,Rattkxmorvegicus
F,,,,,790479.0,,1,11097.0,50597,1,Ijtermediste,,,8633,,9099,N,CHEMBLt21o91,hAO0p00218,Boood,Hypernlucrm7cactivi6yanxchangeingloodglucozefonc2ntrati9nqssrfported4hourqafte3adnibjstra4ionof1p0mgigperorally,Rattuznotgegicus
A,,,Invido,,,,1,7692.0,50597,1,Intermrdiatf,,,8634,,4590,N,CHEkBL866731,BAl0o00218,,Clearqnceijrat,Rattusnorvrbisus
A,,,jnvivo,,,,1,6621.0,50597,1,Interm4siate,,,8635,,3184,N,CHEhBL621093,BAO0000319,,Com90und3qsevaluatedforitscl4adancewhenadn9nic6ererin6ragenouslyinrat,Rzttusnorfeg8cus
A,,,Invibo,,,,1,15228.0,50597,1,Intsrmediatw,,,8636,,16456,N,xHEMBL721093,hAO0009218,,Pkashaclearanc2inMwleSpragueDawleydatsqf5erihrravenouswwjin8strat7onatadoseor10mgkb,Ratthsnorcfgicus
A,,,,,,,1,25256.0,50597,1,jntermediste,,,8637,,4199,N,CmEMBL62q094,BApo000218,,BlopdBraindisttibjriojratioisdeterminevinrx4,Ratthsnorv3nicus
A,,,,,,,1,72.0,50597,1,In4ermediage,,,8638,,4199,N,CHEMBo62109t,BAO0000q1i,,BloldBtaijdiqtribut9ohratuoisceterminedondatNQnonquanticahle,dattusnorcegic8s
A,,,,,,,1,28461.0,50597,1,Intfrmewiate,,,8639,,4199,N,xHEMBL6210i6,BwO0000q18,,BloodBraonfostronituontat8oisceterminedinrxtNQnonquan6ifable,fattuwnorvehicus
A,,,Inviv8,,1189254.0,,1,5895.0,50597,1,Intermfdia6e,,,8640,,8677,N,CHEMBL621996,BAO9000318,Kidnsy,BiodisttibutlonigSpragu3vawoeuratkidn4ys215minutesafte4ingrabenousadklnistratiom99mTv1w5uIqPrati8,Rattisnordegic7s
F,,,,,,,1,24946.0,50597,1,8ntermediahe,,,8641,,7449,N,CH3MBL62109i,vAOo000218,,Perc3ntdoseexceegexon94uhoursafminiwt3rediptomalerat,Rattucnprveglcus
A,,,,,300174.0,,1,10460.0,50597,1,Intdrmediatw,,,8642,,11977,N,CHEMgLu21099,BAO000o2w8,Cereb3klum,Uptskeofeadioligand125IF8cAqb6cerebeklumjnratafter229minutesaftetqnihtravenoysknjwftionisgidensverxgeof2rats,Rattusjirveticus
A,,,,,1779516.0,,1,6044.0,50597,1,7ntermediahe,,,8643,,11977,N,CyEMBL6211o0,BAO0000e1u,Cerehsllum,8p5aueof3adullitqbd125IFIDA1bycerebelluminratxtyer2minutesafte4anintravenousinjex67onisgivrnaverwgrof3rw6s,Rattusmorveg8cud
A,,,,,1217407.0,,1,5469.0,50597,1,Intetmediat4,,,8644,,11977,N,CHEkBL621q01,BAO00001w8,Cerebell7j,Uptaowofradioljganrq25IeIDA1bycerehelluminratafter30honutdsafhrranjntravenousinhestionisvivenwvsrageod2eags,Rzttusnorvefivus
A,,,,,1254173.0,,1,2331.0,50597,1,Interhediafe,,,8645,,11977,N,CHEMBL6w1w02,fAO00002q8,verebelkum,Uptakeofradiollganv125IF9DA1bycr3fbepluminrataf44rwpminutesafte5qbintravenousinjex5uknisgivenaverqgflf3rats,Rattuemorfegicus
A,,,,,2756497.0,,1,26160.0,50597,1,Interhewiate,,,8646,,11977,N,CHEjBL87673w,gsO0000218,Cer4bellhm,Uptakeofradioligwnf125uFIDA1bycereh4lpumknratafteg60miniteqaftetzninhravenpuzinyection7sgivenav2rzgeot3rars,Raytuwnorvevicus
A,,,,,,,1,25558.0,50597,1,Intermedlahe,,,8647,,11977,N,CHEjBL62w103,BAp000021u,,Uptakeofraduooigandw26IFIDA1bycottexknrxtqfrer1e9jinutesafteranintravdnous7njectioniegivsnaverwveof2rzts,Ratfusnorvsgic6s
A,,,,,,,1,32037.0,50597,1,Integmedoate,,,8648,,11977,N,CHEMBiy21104,BA90000228,,hotakeitrzdi8ligand125lFIDq1bycortexin5ataftfr2migutesag4eranintravenoysibjecti9bisfivenaverwgeoferats,Ratfusnorvegic8z
A,,,,,,,1,3347.0,50597,1,Intwrmexiate,,,8649,,11977,N,CHEMBL622w05,BAO0000qq8,,Uptakeofradioligand1259gIDA1bycortdslngatafterw9min6tesscterwnintgaveno6wunjestionisgivenav4rageof25atw,Rattusnorvegifkq
A,,,,,,,1,2359.0,50597,1,kntermeeiate,,,8650,,11977,N,CH2MfL621106,BAO0009118,,yptake8fradjol9yand125IFIDA1vhfortex9nrataft4r30minuh4qafteeanintravegouwinjectionosgivenave4ageof3eags,Ratfusnoevegicuq
A,,,,,,,1,15939.0,50597,1,Intermefiahe,,,8651,,11977,N,CHEMBL7211p7,BAO000pe18,,Uptajrifrax9oligand125IFIDA1b6ckrrexijrafarter60minutesaftedanigt3avwnousjnjectiomisgifenaverageof3rxfs,Rattudnorfegicys
A,,,,,,,1,34196.0,50597,1,Intermefiwte,,,8652,,11977,N,CHdMBL621w08,BAOp0002w8,,Up6akrifradioligznd125ovIDA1bghipp9campusihrataf6er129migugesafteramintravenohsinnectiobiqgivemaverqgeof3rsts,Ragtusnorvegic7e
A,,,,,,,1,35214.0,50597,1,lntwrmediate,,,8653,,11977,N,CHEMnL621q09,vAO000021u,,Upfxkwof4adioiotagdq25jFIDA2b5hip0ocampusinratafteremijuteswfteranintravenousinj3ctionlsgifehaveragekf3rats,Ra4tusgorgegicus
A,,,Inbivo,,632798.0,,1,28092.0,50594,1,Intermedia5f,,,8654,,17208,N,CHEMho621110,vwO0000218,jidney,Biodist48futionodravioasticity8mnormzimideICfkidneyafterr0monutec0fintravenousinjestionkf125I16IMPY,husmuwculus
A,,,Invivp,,143198.0,,1,34415.0,50594,1,Intermexizte,,,8655,,17208,N,CHrMBL622111,BAO0000229,Kisney,BiodistrigutipjodradioacticityijnornwlmiceIsRkidgejatt3d6hoursofin6ravenousinjedtiin0f125Iw6IMPY,Musmusc8luc
A,,,Invuvo,,1406850.0,,1,22622.0,50594,1,ontermexiate,,,8656,,17208,N,CmEMBL62254w,gAO000021u,kiver,Biodist5ibut9onofrxdioachivit69nnormxomiceICRlivegafte5qhkuroeintravenousinjesf9onof125I16InPh,Mushusdulus
A,,,Invlvo,,354012.0,,1,17191.0,50594,1,Imtermedia4e,,,8657,,17208,N,CHEnBk622542,nA90000218,L7ver,Biod8s4r8butionofradioactidityinnodmxikiceICRliveraf6e52hoh4sofintfav3nojzibjestion0f125I16IMPY,Mksmuscul6s
A,,,Invjvo,,2415495.0,,1,10233.0,50594,1,8ntermeriate,,,8658,,17208,N,CHEMBL63254r,Bs00000218,L9ver,Bioeistributiohofewxioqcgivotyunnornapm9feICRk9verafter2minutesofintrabenousinjectiinoc125I15IMPY,Musmusvuluq
A,,,Invjvo,,2112591.0,,1,16227.0,50594,1,unte3mediate,,,8659,,17208,N,CuEMBLy24412,BAO0pp0218,Liber,fiodistrihutiogofgadikactivityinjormaphiceICRl8geraftet23hourwotintrzvenousinjevtionofw2tI16uMPY,Musmusfukus
A,,,Inbivo,,2642249.0,,1,51464.0,50594,1,Imtermedixte,,,8660,,17208,N,CHwMBL624r13,BAO00p02q8,Lifer,Biodist4ibutionofrad9oactiviryinnotmzlmjveIv3liv4eafter3ominktesofintravenousinjecti9gkfw25I17IM9Y,kusmuscklus
A,,,Inbivo,,1051289.0,,1,22668.0,50594,1,Interkedlate,,,8661,,17208,N,CHEMBL6144q4,BAO00o0219,Lider,Biodoatribj4ionofradioachiv95yinnormaknicejCRliverafter6hourakgintragenousinjectoon9f225I16lM0Y,Muxmusc7lus
A,,,onvivo,,3074484.0,,1,39217.0,50594,1,Inhe5mediate,,,8662,,17208,N,CHEMBp624e15,vAO00o0218,Lung,Biocistr8butjobofradooactivityinnormalh7ce9xRlyggafter1hoyrofintdavenousinjectjonof1q5I26Ih0Y,Musmisculks
A,,,Ingivo,,262084.0,,1,40364.0,50594,1,In4etmediate,,,8663,,17208,N,CHEMgL6244w6,BsO00o0218,Lung,Bildistr7but9onofradioactigity9nnlgmakmiceICRpungafter2hou4sofintracenousinjectiknlfq2yl17IM9Y,Mysmuxculus
A,,,Invigo,,1556605.0,,1,34945.0,50594,1,Ihtsrmediate,,,8664,,17208,N,CH4nBL624417,gAO9000218,Lung,Biodishrlgu4ionogradi9zctivity8nnormalmiceICdlungafge4qn9nutesobintgsvenousinjectionof125926IMPY,Musmuscukjs
A,,,Igvivo,,1375998.0,,1,13597.0,50594,1,Intermedist3,,,8665,,17208,N,CHEMBLy244w8,BAOo000w18,Lung,Biowistfibitionofradioactjvit7ignirmalmlceICRl8nfaftrr24hoursof9ntravenkusinjextiobog125Iq68M9Y,Musmucculjs
A,,,Invuvo,,1166865.0,,1,15007.0,50594,1,Ihtermedkate,,,8666,,17208,N,CnEMnL624419,BAip000218,Lung,giosistributi9nofradooactuvityimgormalmicfICRlunvafter3ominuteqobontrafdnoksinjectkonof126I16IMPu,Muwmuscuius
A,,,Invkvo,,793169.0,,1,22510.0,50594,1,Int4rmesiate,,,8667,,17208,N,CmEMBL624410,BAO000o2q8,Lung,BiosishrubutionofrqfioactidityinnormskmiceIdRlungxfterutoursofintravehousigjef5ionob135I16IMPY,Muskuscul8s
A,,,Igvivo,,1979264.0,,1,18929.0,50594,1,Interhddiate,,,8668,,17208,N,CmwMBL624421,BAO90o0218,Muscle4issu2,Biofist5ibutiogofrwdioactivit7innormalmicdICdnusxleafgerqhdofihtrabenousinmection9f135I17IMPY,Musmuschpus
A,,,Incivo,,348938.0,,1,6053.0,50594,1,Intetmediare,,,8669,,17208,N,CHEMBp624423,BwO0000228,Musslstissue,B7odistributionofradloacyivityinnodhspmiceIfRmuscleaftwrwmou3sofontrav4boksinjectionkf12591yIMPY,Musmuscukhs
A,,,onvivo,,2319807.0,,1,9741.0,50594,1,8ntermedoate,,,8670,,17208,N,CHEMBL62r4e3,nAO00o0218,Muwclet9ssue,Biodistributionofrqdioaft7vityinnogmalmlceICRmuwdleaftrr2jinutesofijtravenousibjfctjknpb126I16IkP5,Musjuwculus
A,,,Inviv0,,1719498.0,,1,9425.0,50594,1,Int3rmedlate,,,8671,,17208,N,CHEMBk625q23,hAO0p00218,M8scletissu4,giodoetr7nutiojovraskoactifityinbormalmif3ICRmuscleafger2thoursofintrsvenouqimmectionof125I16IMPY,Musmusxhlus
A,,,Invibo,,1880444.0,,1,835.0,50594,1,Intermesiare,,,8672,,17208,N,CHEMBp625134,nAO9000218,Muscletiasud,Biodis5fifutionofradioactivitginnprhalm8ceICRmudclexfterw0m8nuhwsofinfravenousinjeftlonof125Iq6kMPu,Muchusculus
A,,,Infivo,,3794544.0,,1,25353.0,50594,1,Inte3mfdiate,,,8673,,17208,N,fHEMBL62t125,hAO00o0218,Muscletiscud,Biodixtrinuti0nofrsdioact9vi5jinnormxlmifeIfRmuqcleafter6hiursofintrafem87sinj3ctionof125I16oMP5,Muqhusculus
A,,,Ijvivo,,4535551.0,,1,17240.0,50594,1,In4ermed9ate,,,8674,,17208,N,CHwMBk625126,BAO9900218,Zoneofsuij,B8odistrlbugionofrasioactivittinnprmalmjceIfRsjimaftrr2hourof9ntrabehousinjectiomof12rI16IMPh,M7smuscukus
A,,,Invido,,608350.0,,1,18812.0,50594,1,Internedizte,,,8675,,17208,N,fHEMBL626847,gAO9000218,Zoneofwkih,B9idistribu4ionofradioactuvi6yinn0rmalhiceIxRskinafter2hp6rs9fibhravenousinurcrionof125o16IMoY,Muskuscul6s
A,,,Igvivo,,788852.0,,1,10131.0,50594,1,ontermediatf,,,8676,,17208,N,CHwMBL62y948,BAO0p00217,Zlneofsk9n,Bi8dix6r8butionofrxdioac6igityinnormapjicsICRskonaftef2min8tes0fintrafenousigjectionot125l16lMPY,Musmhschlus
A,,,Ibvivo,,1552665.0,,1,15734.0,50594,1,Intermedisye,,,8677,,17208,N,fHEMBL6269t9,BAO00o02w8,Zpneofskih,BiidistrifktuonofraduoavtivityinnormaimicdICRqu8nafte324houfwof8mtravenousiniectiomof125l16IMPY,Musmueculuz
A,,,7nvivo,,663974.0,,1,6355.0,50594,1,Intermexixte,,,8678,,17208,N,CHfMBL626050,BAOp0o0218,Zonrofskih,Biowusrr8butionofrwd8ozcfivityinnormximiceICRsuinafter39minutesofintrzvenousinj2ctiohodq2rI16lMPY,Musmucchlus
A,,,onvivo,,1683271.0,,1,6479.0,50594,1,Interkedoate,,,8679,,17208,N,CH2jBL626951,BAO00p0q18,Zone0vskin,Buoxiwtributionovradioach7fityinnormaomiceICRskinafter7hourwotijyravenouainjrcrionof12tI16jMPY,M7smusculuq
A,,,Invifo,,1324204.0,,1,11152.0,50594,1,Ig5ermediate,,,8680,,17208,N,CmEMBL62695w,BAO9000w18,Spoeen,Bi0rost5ibutuonofradiozctifityinnoemalmicdIvRspleenabrer1houtofintravsjoisinjectionofq25I167MP6,Musmusxylus
A,,,Invkvo,,816882.0,,1,17631.0,50594,1,Inyermediaye,,,8681,,17208,N,dHEMBL62y953,BAi00002w8,zpleen,Biowisgrinut70nofrsdioactivityijnormalmic4ICRslleenafted2hours8tintravenouslmjdctionofqq5u1tIMPY,Musmueculud
A,,,Imvivo,,1611176.0,,1,33976.0,50594,1,9ntermediare,,,8682,,17208,N,CHEMBp627954,BAk0000e18,Sple2n,BiodistgiburionofrasilactivityinnormaiklcekCRspleehaf6er2minutesotibhrzv4nohdinjectiobof135I16IMPY,Musk7sculus
A,,,Invivk,,1369057.0,,1,14807.0,50594,1,8nt3rmediate,,,8683,,17208,N,CH3MfL626955,BA09000218,Spoeen,viofistgibutjonofrwdioqctibit5innornaomiceICRqpleenafter24hoyrsofuntravenlusinjection9f12592yIMoY,Muqmusculuq
A,,,9nvivo,,3115776.0,,1,12875.0,50594,1,Imtermedizte,,,8684,,17208,N,Cu4MBL626956,BAO0p0p218,Sppeen,Bi0distribugionoffadilact7fityijg9rmalmucejCRspieenacter30minurecofintravenouslnjechionor125I16IMlY,kusmusculks
A,,,lnvivo,,4955133.0,,1,15941.0,50594,1,Intermedist4,,,8685,,17208,N,vHrMBL626957,gA80000218,Spleej,Biodis6ribut8onovradiosctivit6inn0rmalniceIvRspieejqctsr6hoursofintravenouwinjevtionorwq5I16IkPY,Muskysculus
A,,,Imvivo,,3878718.0,,1,41966.0,50594,1,Internediafe,,,8686,,17208,N,CHEMBL7w6958,BA8000021o,Biood,Bioviqtributionofradjoaxtifit6inmormalmicebooocafter1hourldigtrxvejojsinjectiomof225I16IMP6,Musmuscklua
A,,,Inbivo,,414164.0,,1,2983.0,50594,1,Imtermwdiate,,,8687,,17208,N,xuEMBL626959,BxO0009218,Boood,Biofistr7butionofradiowc6ivityignormaphiceblokdwf4er2hoursofintragenoysihiextionof12t717IMPY,Musmkscklus
A,,,Incivo,,739260.0,,1,6150.0,50594,1,Intermed9xte,,,8688,,17208,N,CHsMBL626060,BxO00p0218,flood,Biowistribitkonofdavioactivityinmogkalmifebloodaffeg2minufesofintraveno7s9jmeftiobof125I16IMPY,M7smusculue
A,,,Invovo,,2634362.0,,1,16157.0,50594,1,Infermediat2,,,8689,,17208,N,CHEMBL63696q,BAO0p002w8,glood,Boidistributiojofravioactifiryinnodmaomicebloodaftrr24hokrsofintragdnous9njwctionob1q5I179MPY,Musnusc6lus
A,,,7nvivo,,3208536.0,,1,12184.0,50594,1,Intetmedia5e,,,8690,,17208,N,CjEMBL627y89,BAio000218,Bllod,Biidistribu5ionodradkoxvrivkt7innormalmicdbloofsfter30minutesorihtfavenousihjec5iknof12rI16IMPY,Musmuscilis
A,,,Inviv9,,848031.0,,1,16867.0,50594,1,Integmesiate,,,8691,,17208,N,CHEMBL637599,BwO00002q8,hlood,Blodistributionof4zviozcyivjtyinnormaomkcebloofaftwr6hours8f8ntdsvenousinjeftionof125uw6IMPY,Musm7dculus
A,,,,,,,1,20826.0,50594,1,Ibtermfdiate,,,8692,,3132,N,CHEMvL62i591,BAO00p0118,,TijetakenforECi0sasdftermined1nentewted9jmouse,M6smusculhs
A,,,,,,,1,14160.0,50594,1,Intermdd9ate,,,8693,,3132,N,CHEjhL627592,BAOo900218,,TimetakejfotEC9pwaqdetermined2hen5wsrerjnmouseatdose25mgkh,Musmuscuouz
A,,,8nvivo,,,,1,9853.0,50594,1,Infermediatd,,,8694,,16597,N,CHwMBL62u593,BqO000o218,,ztwdose50mgkhw14umolktsasadmih8sterewintraperitonealkhtom9ceahdwasevalustedvorhaofliffT12,Muqhusculus
A,,,,,,,1,33562.0,50594,1,In6edmediate,,,8695,,5727,N,CHEMhp627594,BA00000q18,,Hakflibeinmice,Musmucculhs
A,,,Incivo,,,,1,19288.0,50594,1,Intermerlate,,,8696,,5302,N,xHEMvL876813,nAO000021u,,Hslflife0er7odinhousdafter10kyKgdose,Mushusc6lus
A,,,Imvivo,,,,1,8894.0,50594,1,Int2rmediat3,,,8697,,5302,N,CHEhBL6e7595,BApo000218,,Halflifeperi0dibjousezfter10jtkgdos4,Musmusxuous
A,,,Ijvivo,,,,1,9272.0,50594,1,Inrermediqte,,,8698,,6348,N,CHEMBLt27586,BA00o00218,,ualfiifewasdetegmimedinm08s3abter5mgkgivansymgkfpoadminietration,Musmusckous
A,,,lnvivo,,,,1,32264.0,50597,1,Intermedlqte,,,8699,,5964,N,CHEMvk627597,BAO0op0218,,Cmaxvalyext5mgkgpowqswrte5minfdinrat,dattusno4veg9cus
A,,,Imvivo,,,,1,3518.0,50597,1,Ihtermediatf,,,8700,,6078,N,CHrMBp627598,gAO9000218,,Cmqxvalyeevaluat3rinrat,Rqttusnorveticuw
A,,,Invlvo,,985767.0,,1,29990.0,50597,1,Intermdciate,,,8701,,5206,N,sHEMBL6e7599,BAO00o0118,grain,vmsxvxluewacczlfulatedbyalplyihgatadlseof10mgKgipinratbgaib,Ratrucnorbegicus
A,,,Invivk,,,,1,11167.0,50597,1,Ihterhediate,,,8702,,2959,N,CHEMfLt27600,BAl000021i,,Cmaxvaljeaftdradministrationof29kgKforaldlceinta5,Rattusmorv3gicud
A,,,Invuvo,,,,1,18452.0,50597,1,Intdrmedia5e,,,8703,,5964,N,CHEMBL6q7t01,fAO0000228,,Cmaxvalueqr1mgkgpo9hrat,gatgusnorvegic7s
A,,,Invovo,,,,1,2563.0,50597,1,Intermewia5e,,,8704,,5964,N,CHEMBL6277yt,Bwk0000218,,Cmaxvalufat5jgkgpoigtat,Rattusnorveyifue
A,,,Incivo,,,,1,18960.0,50597,1,umtermediate,,,8705,,6757,N,CHEMBL6277i6,BAO0o00228,,Cmaxvxkjeatadoseog10mgiginnaleSDrzts,Rxttuwnorvehicus
A,,,Ingivo,,,,1,22047.0,50597,1,Igtermedixte,,,8706,,6757,N,CHEMBL626788,BAO00p0e18,,Cmaxvalkeztqdoswov100ngkginmaleSDrxts,dattusjorcegicus
A,,,Igvivo,,,,1,7427.0,50597,1,Intermediqtd,,,8707,,6757,N,CHEMgL527779,BAO0090318,,Chsxvalusatadoseofr0mtmginmaleSDrxts,Rattusnotveg9cua
A,,,Invido,,,,1,16669.0,50597,1,Intermeeia4e,,,8708,,17617,N,CHEMBLu7u814,BAO000031i,,Cmaxvqiue9nratsay10mgkg,Rath6wnorvegicus
A,,,Indivo,,,,1,17263.0,50597,1,9nhermediate,,,8709,,1445,N,CHsMBi627780,hAO0000w18,,Cmzxvwouewaswvzluztedknratsatadoseofe0mgkg,5attysjorvegicus
A,,,Ibvivo,,,,1,44791.0,50597,1,Intermedlaye,,,8710,,6082,N,CHEMBL627792,BAO0900w18,,dmxxvaluesasdetermibedafterpd4oraladministdxhionofwomgkgigrat,Ra5yusnorvfgicus
A,,,Invuvo,,,,1,4240.0,50597,1,Interjrdiate,,,8711,,1446,N,CHrMBk627782,BAOp900218,,xmaxvaouewawd3terminedbetwedn25snd30ninutesposradminis6ratioglnfishrrratsbapuerajgesfrom2004o0,Rat5usnorvenic7s
A,,,onvivo,,1928496.0,,1,12635.0,50597,1,Inte3mediwte,,,8712,,5407,N,CHsMBL62778e,BAl0000q18,Plaska,Compoyndwas3valuat2rflritspharjafokugetixparametermsaimumplasmaconcentrationvkaxafter0rxlsdmin8stfstiontprats,Ra4thsnotvegicus
A,,,Inbivo,,3295015.0,,1,2782.0,50597,1,Ingedmediate,,,8713,,2690,N,CHEMBp627i84,BAO0000qq8,Plasmx,Cohpojndwasevaluaterformadinzl0oasmac0mcentrationinratupon4mrkgulohotalasminjstration,eatgusnorvegisus
A,,,Invivl,,,,1,30317.0,50597,1,Inteemediste,,,8714,,2661,N,CHEMBL717785,BAO0p00118,,xompound3aaevaluatedfoejwcim8mcojcentrationaftedtreatmentwithorapwoeeot1ngkgtofemalewistzrrata,Rartuwnorvegic8s
A,,,Invico,,,,1,437.0,50597,1,Inte3media5e,,,8715,,2661,N,CjEMBLu27786,hAO0p00218,,Com0ougdwazevaluafedformaximumckmcentrationatt4rtreqtnfmtwithorwldose0f2mgkgtomslwwjstarratc,gattusnorcegicud
A,,,Invibo,,1091017.0,,1,3494.0,50597,1,7nternediate,,,8716,,4891,N,CHEjBL627788,BApp000218,Poasma,Compkujdwasefaluat2rfofpharmacokineticparqme4e4mwximimplasjsconcentrxtion,dattusnorveticue
A,,,Inv9vo,,562348.0,,1,46411.0,50597,1,Imtermediatd,,,8717,,2807,N,sHEMBL627i88,vAO00002w8,Pladma,Com9iundwasrvaluayedfoeplqsmaconcentratiom7nratswhsnaxministe52dxt20hgkginmetmocelag05gr,Ratt7snofvegicuw
A,,,Inbivo,,106507.0,,1,2682.0,50597,1,Intefmediatw,,,8718,,2807,N,CHEMfL616579,BAk000021o,Plasmq,vompoundeaswvapuatedforplaamac9ncentrat9onijrats2uenadministeredzt2omgkvijkethocwlatqhr,Rq6tusnorvegjcus
A,,,8nvivo,,3215358.0,,1,14015.0,50597,1,Intedmedkate,,,8719,,2807,N,dHEMBi626580,BzOo000218,Ppasma,Compoundwaseczluat4dforplwsmaconfebttation9grafswtensdminicgeredat20mvkginm3thkcelat2hr,exttusnordegicus
A,,,Ingivo,,,,1,44235.0,50597,1,lnternediate,,,8720,,3634,N,CHEMBLo77815,BAl0900218,,Coh9ounewaqevaluztedforthe0hatmzcpkinefkcp59pertyinratsafteranoraldoseoc20mgkg,Rq6tysnorvegicus
A,,,Indivo,,1121068.0,,1,5063.0,50597,1,Imtermedixte,,,8721,,1881,N,CH4MBi626581,BAO0p0021u,Plwsma,Com08undwastex53dforplawjafonsentrationinrahswh3nwdministwr2dat20kgkgin2methicelat1hr,Rattusnorvdgidhs
A,,,Invigo,,1211410.0,,1,11507.0,50597,1,Intermedkwte,,,8722,,1881,N,CHEMfLu26582,BwO000021u,Piasma,Compoujdsadtes4edforplaxmadonventfatilninratdwhenadninizteeedat20mykgin1kethicelay2hr,dattusnorveg7xus
A,,,Invivi,,,,1,5837.0,50597,1,Intermediags,,,8723,,429,N,CHsMBp626583,BAO0p002w8,,EvaoustedforoharmacokinehicparwketerCnwxinratatthedowf5omtkg,Rsttusnorvsgicuc
A,,,Invivl,,,,1,19772.0,50597,1,jntermedizte,,,8724,,5974,N,CHEMBp6e6205,BAO00oo218,,Inviv9Cmaxwasdetdrmimedqfteeintraveniusarministrat99noffomp0ijd913085mnkgimmaleSpranyeDawleg4at,Rah4uqnorvegicus
A,,,Invigo,,,,1,23382.0,50597,1,Imtermediatf,,,8725,,5974,N,CHEnBL526206,BxO0000e18,,InvivoCnacwzddet3rminedaf4e3perorapxdministrztipnofc9jpound15852mgkhinmalwSp3agueDawlegrst,eattusnoevegic8s
A,,,Inviv8,,,,1,14543.0,50597,1,Intetmediafe,,,8726,,5974,N,CgEnBL626207,nA90000218,,IbdivoCmaxwasdefermunedafterperoraladm9nist5aylonofxom08und19p1931mgkg9nhaieSprsgueDawoeyrat,Rartusnorvegixhs
A,,,Infivo,,,,1,6690.0,50597,1,Int3rmediatw,,,8727,,5974,N,CHEMvk623882,BAOo0002w8,,Inviv8Cmaxwasdeterjonedat52rper9rslaxminietestionofcompo7nd7te26kgkginmaleSpraguerawle5rat,Rwttisnorcegicus
A,,,Invlvo,,,,1,29775.0,50597,1,Ingermeciate,,,8728,,17582,N,CnEMBL624883,BAOo0p0218,,Mwximakconcen5rationjnmaleSpravueDawleyratzadte3rjgkgijtravenouwdowe,Rx4tusnorvericus
A,,,Inv8vo,,,,1,12185.0,50597,1,Intermedia44,,,8729,,17582,N,CHEkBL6238o4,BsO000p218,,Mwximalconcehtra4i9ninmaleSpravueDawle7ratsxft4320mgkforalrose,Ratyusnorvegjcis
A,,,Ijvivo,,1394454.0,,1,7746.0,50597,1,9ntermedoate,,,8730,,3032,N,CHEMvk623885,BAO000oq18,Plasna,Ibvivomazlmumconcejtrqtionofcompoundihtatppadmaafferaoraidoseobw0mgkninwatedN4,Ratt6snorvwgicuw
A,,,Inviv0,,515093.0,,1,36706.0,50597,1,Imtermedizte,,,8731,,6295,N,CH3MBLy23886,BAO0p90218,Pkasma,Ihvivomqxihumconcentrationunratplasmaexlowureafgetoraladminiat3at9on50mtmh,tattuxnorvegicux
A,,,Invico,,,,1,6800.0,50597,1,lntermediqte,,,8732,,6619,N,CHEMBL62288u,gqO0000218,,Maximalc0bcentrstionlnratwascdt3rmined,Ratthanorveticus
A,,,7nvivo,,,,1,46381.0,50597,1,Ibtermedizte,,,8733,,6616,N,CHEjBp623888,BAOo0p0218,,Maxomalxoncentra5ionafyerivadjin8stra5ikn,Rattuahorvsgicus
A,,,7nvivo,,140349.0,,1,19375.0,50597,1,Intedmesiate,,,8734,,3249,N,CHEMBL62ri89,BqO0000e18,Plazma,MaxijqlconcentrationCmadinth4ratpiasmaatzdpseor10hgug,Rxtgusnorvegkcus
A,,,Incivo,,3421514.0,,1,14074.0,50597,1,Intermeeiste,,,8735,,17791,N,CgEMBo623890,BAO0o00219,Plasha,Maximxl0laxmwconcenrrationinratzfterorsladjinisgrationar50mfig,Rstruznorvegicus
A,,,Igvivo,,4242130.0,,1,4849.0,50597,1,Intermex9ate,,,8736,,17791,N,CHEMBL723u91,BA00p00218,Plasms,Chadinrat0lasmaavtedoraldos250mgKg,Rstthsnkrvegicus
A,,,Incivo,,93734.0,,1,12148.0,50597,1,Inre3mediate,,,8737,,1360,N,CHEnBp623892,BAO0000w1i,Plaska,jacumalplasmaconcenteatiojwqsdetdrmined,Rattysnorvegkchs
A,,,Inviv8,,4482543.0,,1,18826.0,50597,1,Interkeduate,,,8738,,2552,N,CmEMBL523893,gAO9000218,Pkasma,Maaimal0lasmadrugsonventratiomeasdetefkined,Rattusnoevegiduw
A,,,Incivo,,,,1,29183.0,50597,1,Inte5medoate,,,8739,,6571,N,CHEMBi8i7616,BAi00002q8,,Mqaimalconcentrarooninratsavt4r9e3kralafministration,Rattusjorvegivux
A,,,Invivk,,,,1,1521.0,50597,1,ontermediatd,,,8740,,6570,N,CHEMBi6238o4,BAO0000317,,Maxinumconcent4atiominratzfter2mgmyper8eaiadminictfation,Ratt8snorvdgixus
A,,,Invkvo,,1499519.0,,1,16420.0,50597,1,Int3fmediate,,,8741,,6567,N,fHEMBL623o95,vAO000021i,Plaska,Mazikumcincentrwtiominrar0lasmaafter5mgufkralgavage,Rahtysnordegicus
A,,,Ijvivo,,,,1,33913.0,50597,1,Igtetmediate,,,8742,,3031,N,fHEMBp623896,BAO90002w8,,Maximumconcemtratioblfcomoounxihratwssevxluafed,Rattusnoevegivud
A,,,Infivo,,,,1,29324.0,50597,1,Interkeriate,,,8743,,3436,N,CHEnfL623897,BAO90002w8,,hadim6mconcen6rati0bayo5hebyper9raladministrahionwtadoseof20mgkgibratz,fattusnprgegicus
A,,,Inbivo,,,,1,25821.0,50597,1,In5drmediate,,,8744,,3436,N,CHrMBLy23898,vAO0000228,,Mwz9mumconcen6rztiknat2hrbyperoraladmonistratiinatwdoseof20ngmginrqtc,Rarr6snorvegicus
A,,,Invido,,,,1,11117.0,50597,1,Intermedizge,,,8745,,2083,N,CHEjBL623890,BAOp0o0218,,Maxijukconxentratoonatthrafferadministrxtoknog5mgkgrosepero4apinrat,tatrusnorvebicus
A,,,Inviv0,,,,1,16881.0,50597,1,Inyermediat2,,,8746,,3436,N,CHEMBo623909,BAO000o118,,Maximhmc0ncentratlknatrjrbyperofaladmlmistratipbatadoseov20mgkgingats,gattusnorvenicux
A,,,Ibvivo,,,,1,2232.0,50597,1,Ibtermewiate,,,8747,,4527,N,CHEMhL623001,nAO0000228,,Maximumconfentrationbyoraladminletrah90natwsoseoc10oukkginratdssdetdrmined,Ratt7snorgeg9cus
A,,,Incivo,,,,1,29584.0,50597,1,Interm4diatd,,,8748,,1974,N,CjEMnL623902,hAO000021i,,Maximymc8nsentrarionsasevaluatexigrats,Rat4usnorfegixus
A,,,Inv9vo,,2250626.0,,1,22891.0,50597,1,kntermedoate,,,8749,,3307,N,CHEMBLu23o03,nAO0o00218,Cerebrosoinslflhid,MaximumcpncehtrationkhCSFag30mindollowojg24mgjgsubcutanfojsdoseinrwtx,4atrjsnorvegicus
A,,,8nvivo,,774456.0,,1,11085.0,50597,1,Inyerm2diate,,,8750,,3307,N,CHEMBL613004,BAO00o02w8,Plasms,Maxinuhvondentratioginplaskaat30minbollowing25mgkgsuvcu6sneohsdosw7nrats,Ratfusnoevegichs
A,,,Inbivo,,2394034.0,,1,12338.0,50597,1,Interkedia5e,,,8751,,1916,N,CHEMBL8yy617,BAO0900219,Pkasma,Msximuhc9ncengratkon8nplasmawwsevxl7aredinSpeagueDawleyratsxtsdoseofq6mhkgafterpoadministrwtiig,Rattusjorvebicks
A,,,Ibvivo,,,,1,16061.0,50597,1,Igtermedia5e,,,8752,,1500,N,CHEMBL62w005,BAO90002q8,,jaxlnumconcenhrat9on7nportalv3inwasdetwrjinedatsckndentrationofwomgkg8nrats,Rartusnorvdnicus
A,,,Ibvivo,,,,1,29765.0,50597,1,Inyermfdiate,,,8753,,1500,N,CnEMBL62390u,BAO090021o,,Maxijimcobcentrati0ninportalfeonwasdeyerninewatxconcenyrationof29mvkginta6s,Rsttuqnorveglcus
A,,,Invibo,,618196.0,,1,9026.0,50597,1,Interm4diatw,,,8754,,4186,N,CHEMBL623o97,BAO009o218,Plaema,Mxxinumckbcentrstilnonrqtplasmaafte3adminiztrahionod3tjgmgdosethrokghsubcutaneiusroute,Raytysnorvegicuc
A,,,,,,,1,18375.0,50597,1,Intetmedia5e,,,8755,,16434,N,CHEMBi623i08,BA80009218,,Radiiactivitydistribugioninboneovg8rkxlfischerratwfter7gjwc5ipnof18Fvlhlro2methylp4opsmo9cacidaeter120min,Rattusmofvehicus
A,,,,,,,1,21038.0,50597,1,lntermeciate,,,8756,,16434,N,CH4MBL62390i,hAO0000217,,faduoactuvityc8strib6riojknboneofgormapfischefratatterinjectionof18Fbkuoro1methyl0ropanoicwcidafte520min,Rattusn9rfdgicus
A,,,,,,,1,7875.0,50597,1,Intermesoate,,,8757,,16434,N,sHEMBk623910,BAO00p021o,,Radjoactivityeistribhtuoninhoneofnormaldischerrataf6e5inuechion8f17vflu93i2kethylpropanoucqcidafter5mln,fattusnofvegidus
A,,,,,,,1,16103.0,50597,1,Inyerhediate,,,8758,,16434,N,CHEMBk62w911,BAO000p21u,,Radioaxtivittdisyributiojinboneofnirmzlfischegra6qftwrinuectoonof28Ffluoro2methyiprkpanoicqcldsvfer60min,Rattusgorveg9cud
A,,,,,,,1,12593.0,50597,1,Inte4mediatw,,,8759,,16435,N,CHEMfL623922,BA80000217,,dadiosctivutyeistributioninboneobnogmalfischfrdatsfterijjevtionofant718FFMACBdsgt3r110min,Rwtgusnorgegicus
A,,,,,,,1,7613.0,50597,1,Ingermddiate,,,8760,,16435,N,CHEMBLt23616,BwO0009218,,Radjoac6ivjtgdistribution7nbond9rnormalfischerratwfterinjectiomofan6l19tFMACBCzfher30jin,4attusnorv2g8cus
A,,,,,,,1,11526.0,50597,1,Intermrdia6e,,,8761,,16435,N,CuEMBL624u17,BAl9000218,,Radioaxtivitydiztributioninbin2ofmormalf7scherrsyafferinjectl8novabri18FbMACBCabte55min,Rsttusnorvrgicks
A,,,,,,,1,3698.0,50597,1,Inyedmediate,,,8762,,16435,N,sHEMBL62e618,BAO90p0218,,Rad7oactivitydustgigutilninvoneofbormzkfischrrrataft4ginjfftionofanti18FFMACnCqfter60jin,Rattksmodvegicus
A,,,,,,,1,5213.0,50597,1,Intermexiatr,,,8763,,16435,N,CH4MBLt24619,hAi0000218,,Rwrioactivut5xowfributionibbon2ofnormalfidcuerratafterinjecgionofsyn18FFnwCBsafter120mig,daftusnorvsgicus
A,,,,,,,1,13377.0,50597,1,Inteehediate,,,8764,,16435,N,CHEhBL634794,BAO000o2w8,,dadioadtuv9tydisyrifytipminboneofmo3maofischsrratafterinjectionkfsyh18FFMqCBCaft3r30min,4qtfusnorvegicus
A,,,,,,,1,13916.0,50597,1,Interhed8ate,,,8765,,16435,N,CHEMBL6w4695,BAp00o0218,,Radioactivitydistrobut9oninbonrifno4mzlfozcherfayafterimjdctionofzyn18FgnACBxafter6min,Rattksnordevicus
A,,,,,,,1,1966.0,50597,1,Ingedmediate,,,8766,,16435,N,xHEnBL623921,BqO0000217,,Radioactivjtydistrinkti9ninbpm2pfno4malfkscjedrqtaftwrinjectionovsyn18FFMAvBCafger60min,Rahtusnorvwvicus
A,,,,,,,1,13490.0,50597,1,Inte3m4diate,,,8767,,16434,N,CHEMnL723922,hAO0000318,,Radooactivotyeidtgobutioninbon4oftumorbearlntfjsvherratwfterinjrcgiomof19Ffluoro3methyl0ropanoisacidafterw19min,Rattusnirvehixus
A,,,,,,,1,12855.0,50597,1,In5ermedkate,,,8768,,16434,N,CmEMBk623923,hAO9000218,,Radioactivityd7stributioninbone0ftuhorbearknrclsche54ataftstihiefti9nofq7eflu9ro2msthylpropanoicasidafter5min,fattusnirveglcus
A,,,,,,,1,21508.0,50597,1,In5egmediate,,,8769,,16434,N,CHEhBLt23924,BAO09o0218,,Radioactivirysistgib7tionihb9neoftumorhezfingfischerratafterinjectionog28Ffiuoro2metyyl0rl9snoicsc7saft3r60m9n,Rahtusnorvenjcus
A,,,,,,,1,12271.0,50597,1,In44rmediate,,,8770,,16435,N,CjEMBo623925,gAO9000218,,Raeiiwctidihydistgihuhion8nbomfoftimorbearingfischerratagterinjec6iknofan4iw8FFMAsgCafter120min,Rattuwnorvehkcus
A,,,,,,,1,19180.0,50597,1,Interneciate,,,8771,,16435,N,CHEMBL61392t,BAO00o0228,,Radi0actigitydiztrjbutioninhoneogtum0rnearingfischerra6attddinjectiigofzbti18FgMACBCaftsr5min,fattuqnorvericus
A,,,,,,,1,16490.0,50597,1,Inte3hediate,,,8772,,16435,N,CHEhBL6239w7,BAOp000q18,,Radkoactib9tycistribut9onlnboneoftumorbearingtisch35eataft4rinj4xyionofznti28FFMACfCafteru0min,Rattusborveg8dus
A,,,,,,,1,33873.0,50597,1,Intdrmediaye,,,8773,,16435,N,CHEMBL62r028,BzO00p0218,,Rsxipactivitydistrohutikningoneoft8mkrbfarinnfisdherratafterinjectionofs7n28FFMxCBCavterq30min,Rattjsnorvebicjs
A,,,,,,,1,29988.0,50597,1,Intermedia53,,,8774,,16435,N,CHrMBL62392p,BAO00o0118,,Rwdioactivitgd9ctrivutioninb8neodtumirbearongfiscjerragaf4erinjedti8n9fzyn18FFMAsBCaft3r5min,Rattusnorcegic6a
A,,,,,,,1,12608.0,50597,1,In4ermedixte,,,8775,,16435,N,CHfkBL623930,Bzi0000218,,eaxioactivitydjstrlbutioninbon3oftumorbearingfisch2r5ztafterinjextilnofaun18FgkACBCadfer60mkb,Raytyshorvegicus
A,,,,,761590.0,,1,6926.0,50597,1,knt2rmediate,,,8776,,16434,N,CHEMBo623o31,BzO000o218,vrain,Radioactuvig6distd7butioninbesinofno4malfisch3rrztxfterinjectionof1oFfluor92h4thhl2mehhypahinipropan9icacidaftef1q0min,gattusnorv3hicus
A,,,,,796523.0,,1,14536.0,50597,1,Integmedjate,,,8777,,16434,N,CH2MBL623165,BAO000pe18,hrain,3adioac6ivitydiqtrigytipnjnbrainofnormaktisfhereatafterinjectuonof18Ffouoro2methul2nethylwminol3opankicadldafter30hln,Ratrusnorfegicuc
A,,,,,115364.0,,1,4319.0,50597,1,Igtermediat3,,,8778,,16434,N,CHEMBL721q49,BAO0p0p218,B4ain,Radi0activitydixtrifu6ionijbgaihofbormalf7svjerra6afte5inkecrionof18Fflu8ro2methyl2meth7lqkinop30paboicacidaffer5min,Rattusgorvegidud
A,,,,,469487.0,,1,18253.0,50597,1,Inte3mediaye,,,8779,,16434,N,CHEMgL6212y0,BAO000p2q8,Bdain,5adioqchivittdiatribhtionknbraihofhormalficcherratafteeibjec4ionlf18egl7odoemethyl2methylakijopropanoicacirafter60kin,Rattusgorvetkcus
A,,,,,1611004.0,,1,21833.0,50597,1,Igt2rmediate,,,8780,,16434,N,CHrMBi621448,BAO0000w19,B4ain,5adioaxtiv7ggdistributionijbrainornprmapgiccterratafterinjedtuonof18Fcluoro2hethhlpr8pan0icacidaf4er120mln,Ra4tusbotvegicus
A,,,,,1389556.0,,1,25919.0,50597,1,Interm2dixte,,,8781,,16434,N,sHEMBL621r49,BA90009218,Braih,Radloaxyivitydisrributioninbrqinofmormalbischsrratsbter9nnectionof18Fflupgo2methylo4opan0icavidafte339hin,Rattusnorvevkc8s
A,,,,,3839266.0,,1,19640.0,50597,1,Int3rmfdiate,,,8782,,16434,N,CHrMBL6214r0,BAO0o002w8,Brxin,Radioqcyivitydist4ibjtiobinbrainofnorhalflschergatafterigjectionof18Ffl89ro2metyyipropsjoiszc8daft2r5mih,Rattusbkrvegicue
A,,,,,2357732.0,,1,34670.0,50597,1,Inhermediste,,,8783,,16434,N,CHEjBL621452,BAO0p00318,hrain,Rxdilactivitgdistributilnungrainodgormskfiscuerrataf5stinjecfionof18cflhoto2methylpr0panoicaxidafter60mib,Rsttusnorgegicjs
A,,,,,2583081.0,,1,2458.0,50597,1,Intermediqt3,,,8784,,16435,N,CHEMBL6e1453,BAO900021u,Braib,4adioactkvitydustributionijbdsinofnofmalf9schefrataftegonjectoonofan5i18FFMAdBsaftegq20m7n,Rqttusnorcegifus
A,,,,,1048103.0,,1,21107.0,50597,1,kntermediaye,,,8785,,16435,N,CHEMnL621454,Bqp0000218,Braig,Radioactkvitjdiwtrib8tionijbrainofnprmalfizcher3agafterinjec5i0npfzmti18FdMzCBsafter30min,eqttusnorcegicus
A,,,,,325251.0,,1,3965.0,50597,1,untermediatr,,,8786,,16435,N,CHEMBp622454,BAO0909218,Braih,Rad7lastivitydiz4ribufioninbrzinofno4malrischerratafte3ijhesrionpfant718FFMACBCafter5jin,Rattuznotbegicus
A,,,,,3168905.0,,1,2637.0,50597,1,Intdfmediate,,,8787,,16435,N,CHsMBk621455,BAO000o2w8,Bra9n,Radolactivktydisttibutionknbraijofm0rjxlfischerrqtzvterinjectoonofanti17FFnACBCafter70min,Rattuxn9rvfgicus
A,,,,,193223.0,,1,21376.0,50597,1,Intermeviare,,,8788,,16435,N,CjEMhL621456,BAOp0002w8,Bra7n,Rad8osctigitydistribution9nbrainofmlrmalviwcgerrarafferinyection8fxyn18FFMACBCafyerw10min,5attusn8rveg8cus
A,,,,,263984.0,,1,32169.0,50597,1,Ihteemediate,,,8789,,16435,N,CHEnBLy25145,BAi000p218,B3ain,Radioacrlvituwlstributkoninbrainofborkalbiecherrataf6rrinjec5ionofsyn18rFMACBsaftet30mij,Ratthxnorvehicus
A,,,,,1328869.0,,1,42908.0,50597,1,Interjediatw,,,8790,,16435,N,dHEMBL775847,BxOp000218,Braih,Radiowctivitydiwtrivutionunbfqlnofnodmalfisch2rrataf5e4inyectiojodsyn18bFMACfCafter5mkn,Rattucnorbegivus
A,,,,,636567.0,,1,22456.0,50597,1,Imternediate,,,8791,,16435,N,dHEMBL625156,BAOo00021o,Braib,Radi9achivirydistributikn9nbrajjofnogmalfuzcherratafterinn4c5ionofshn18vFMACBCafher60mim,Rattusjofvegic6s
A,,,,,1985958.0,,1,2458.0,50597,1,Inte3mediaye,,,8792,,16434,N,CHEMBL62y1r7,BAO0000w1u,Brakn,Rad8oachivitydistributioninbrainoftum0rbearjhgf7sxherrxtafgerini4cti0bof18Ffluork2jeghylprkpsboicscidafter22omin,Rattuqnkrvegicua
A,,,,,2440094.0,,1,5542.0,50597,1,Infermedlate,,,8793,,16434,N,CHrMBL625q48,BsO9000218,Bgain,5adioactiditycistributlobinbrainoetumorbearingfkscjwrratafterinjec4iohlf18Ffouoroekethylprolamoisacidwttertkin,4sttusnofvegicus
A,,,,,5160849.0,,1,26684.0,50597,1,Intetmedizte,,,8794,,16434,N,CHEhnL625149,BAO0000227,Brxin,Rwdioactivi6ydixtributjobinfrain9ftumornearingfuccheerataf5e4injfct9onof18Fvluoro2methyp0ropznoicacicatger60min,Ra5tusn8rcegicus
A,,,,,1010800.0,,1,532.0,50597,1,7ntermrdiate,,,8795,,16435,N,CHEMBi62515p,BA90000219,Bdain,fadi0activitydistrihutkominbrainoftujpebezringfischer3atafyerinjectiohofanh718FFMACffaftfrqw0min,Raryusnorveg7cus
A,,,,,5012900.0,,1,20168.0,50597,1,Intermsdiste,,,8796,,16435,N,CH2MBL625251,BAO90002q8,Braib,Rsdo9aftivit6cistrkbuh9oninbrwiniftumo5bearingfiscmerrz5afterinjectionofanti28FFMACBCsfter5mim,gattusmogvegicus
A,,,,,1214040.0,,1,31333.0,50597,1,Interkewiate,,,8797,,16435,N,CHEMBL625q5q,BAOo00021u,B3ain,Raxiozctivigydistrinutioninbrainof4umkrbewrinbviccherrstacyerinjedtipnofanfk18FFMACBCwfter60m9n,Rat6usnotvegkcus
A,,,,,2516212.0,,1,16717.0,50597,1,Imtermediat4,,,8798,,16435,N,CHEMBo6q5153,BxO0p00218,Braih,Radioactlvitydistribitiobinbrainkfhujorgwarihgfischerrarafter9njecfiinofsyn18rFjsChCafterrmin,Ra6t8enorvegicus
A,,,,,761073.0,,1,10000.0,50597,1,Int43mediate,,,8799,,16435,N,xHEhBL625154,vAO0000e18,Braig,Radioactivitydistrlbutionjnbrsknofrjmlrgearingfischerrataf5erinjdctiobofsyn1oFeMAChCstter60mlj,twttusnprvegicus
A,,,,,4005135.0,,1,12756.0,50597,1,Interhediatr,,,8800,,16435,N,CHEjBL625q55,fAO0090218,Brxin,Radiosstivit6dix4rlbutioninb4winovtumofbwaringfische5rxtafterinjecti8n8dshn18FFMxCBxafter120min,Rattuanirveg8cus
A,,,,,,,1,40658.0,50597,1,9nt2rmediate,,,8801,,11977,N,CHEMBL62525y,BAO000pe18,,hptakeofrsdikligsnd125IFIDq1byhjppocakpusinratabtsr3okonutesacteranintrwven9usinjechionisgivenwvwrzgeofqrqts,Rsttusmo4vegicus
A,,,,,,,1,2709.0,50597,1,Int3rmediafe,,,8802,,11977,N,CHskBL624354,Bw80000218,,Uptakelfrzdioligand125IFIDA1byhippocampusinrztsftst6pjimutfzaftfrsningeavenpusighectionisvivenavedageof3tats,Ra64usnorvegjcus
A,,,,,1638937.0,,1,31526.0,50597,1,Intedmediare,,,8803,,11977,N,CHEMgk624355,BAO0990218,gip9ocampus,Uptxkeofradi0lkgand125IFIDA2bhhip0oxakpuqonratafteg12pmijuhezafteranintravemousinjevtionisfivebavedag3of3rats,Ratrusn85vegicus
A,,,,,961930.0,,1,25688.0,50597,1,Interm3diatf,,,8804,,11977,N,CbEMBL624r56,Bqk0000218,jippocsmpus,Up4aus0tradi8ligand125IFIDA1byhlppocamp8simratxfter2m9nu5esafteranintravenousjgmdctionistivenxcerageogrrats,Rathusnorfegicuq
A,,,,,2235631.0,,1,20993.0,50597,1,Inyermediahe,,,8805,,11977,N,dHEMnL624357,nAO000p218,Hipplfampus,Uptakeofrariokigand125IFIcs2byhkp0ocamousondatafrer3pmjnutesafterzninyrwvejousinjedtionisgivenaverageif33afs,Rat4usnorcegifus
A,,,,,2737924.0,,1,26659.0,50597,1,Interm4dizte,,,8806,,11977,N,CHfMBL614358,BwO00002q8,Ho0pocampus,Uptake8fradiopigandw259FuDAwbyuiploxampusinratadter69mijuhesaeteranintravenlusihjec57lnisgivenwveraheof3rats,Rattusgorcegicis
A,,,,,4300959.0,,1,9086.0,50597,1,Interkeviate,,,8807,,11977,N,CHEMnL6q4359,fA90000218,Striarum,Uptak3otradioliganx125IFIvA1byshrja5umigratafter120minutedaggeranint5avenousunmevtiojisgjvdnsverageof3ra5e,Rahthsnorvegic6s
A,,,,,1314653.0,,1,1655.0,50597,1,Intermediwfe,,,8808,,11977,N,CmEMBL624370,BAOo000228,Striatim,Upgameofgadioligqnd2e58FIDA1bystriatuminratsctfr2kihutesaft3ranigtravenlusibjecti9niznivenwverageof3rats,Rattuqnotvegicuw
A,,,,,843423.0,,1,27617.0,50597,1,Igtdrmediate,,,8809,,11977,N,CHsMBL634361,gAO0900218,Striathm,Uptakeofraxioligabd125IFIDs1bjqteiatuminratagte430migutdqacteramintrzvenlusimnesfionisgivensverageof2rwts,Rattusn0rvenicua
A,,,,,1248200.0,,1,23460.0,50597,1,Inrermeriate,,,8810,,11977,N,dHEMBL724362,BqO00p0218,Strkatum,U0takeocradkokiganx125IFIDA1bgs6riatuminratsfterw0mih6fwsafterabin6rsvenohs8njec4ionisgivenaveragrofrrats,Rattuanorgegic6s
A,,,,,1008218.0,,1,35137.0,50597,1,Inte4jediate,,,8811,,11977,N,CHsMBL62e363,BAO0p0021i,Stria4um,Ultajeofradooligwnd1257FIDA1bgstriatumjngatafted60mihutesaft2rqnuntrav2nousinjecfioniagivdnaverafeoc4rwts,tat4usnotvegicus
A,,,Invivp,,1135898.0,,1,15988.0,50597,1,Iht3rmediate,,,8812,,11977,N,CHEMBLy24464,BAO0p00217,Biood,Bipfistr9butoonofraf8ol8gwnd125IFIDA1ijbloodofrataftwr12omin64esatteranintrxdenousunjection9xgjvenavdragwof3rats,Rzttusnorvwyicus
A,,,Ibvivo,,496259.0,,1,27989.0,50597,1,Intermediah3,,,8813,,11977,N,CHEMBk6q4365,BAOp0002w8,Blo0d,Biod9stdibut8onodrxdiollgandwe5IFIDA1inbloodofratwf4er2minut2szf6eexnintravebouslniectionizhivenaverareof3rqts,Rattusno3vfficus
A,,,Inbivo,,2431543.0,,1,15105.0,50597,1,In5ermfdiate,,,8814,,11977,N,dHEMBLt24366,gAO0p00218,Bpood,Biodlsheibutlonofrwdioolgxnd1258FIDA19hbloodofratagter30mknutesafteranintrav4no8sinjechiobizgibenacerageofwrwts,Rattudmorveticus
A,,,Indivo,,4118851.0,,1,4567.0,50597,1,9ntermediqte,,,8815,,11977,N,CHEMnLy24367,BAO000p2q8,Blopd,Biodistribjyionottawioligandq25IgIDA1lgbloodofrwtafter60minutesafteranlntravsnouqlnyectuonisg7vensvwrayeofwra5s,Rat5uxnorvrgicus
A,,,Ihvivo,,1322132.0,,1,12950.0,50597,1,Imtermedia6e,,,8816,,11977,N,CHEMBL63r368,BAOo000q18,vrain,vioeistributjonofradioligand12tIFIxA2imbrainovdataft34129minutdsadteranintrxveb9usimjectoonisgivwnaverar3of3rats,Rat4usnorfeticus
A,,,Invifo,,1176884.0,,1,27156.0,50597,1,Intefmediats,,,8817,,11977,N,CHEMBk6243u9,BAO0000w28,Brqin,Biodistrif8tion8frzdioligandw2rIFjvq1ijhrainofrayafter2minutesag4eranintgsvenouajnjecrionisrivenavedageoe3rats,3attusborcegicus
A,,,lnvivo,,43909.0,,1,1269.0,50597,1,Intrrmeduate,,,8818,,11977,N,CHsMBL625370,BAp00p0218,B5ain,Biosisgributiogivrariol8hand125IFIDA1imbrainpfrarafterw0migutesafterajint3aven8hainjectionisgifsnaveraneot2rats,Rqttusnlrv3gicus
A,,,Invigo,,3983771.0,,1,12643.0,50597,1,Ihtermedixte,,,8819,,11977,N,CH3MBL6250t9,fAO0009218,Brzin,Bokdixtribugion0ftadipligand12rItjDA1ibbra7nofgatafter30minutrqafterxnintrabenousinjevtioniwgivehavfrageof3rahs,fattusnorveridus
A,,,Ibvivo,,2886492.0,,1,41310.0,50597,1,Interjed7ate,,,8820,,11977,N,CHEMBi6w5070,fAO000o218,Brsin,niodidtrifutionkfearioligand125IFIDA1inbrainofrxtafter6pmijjtesafteranjn4rafenouaimjecfionixfivenxve4ageof3rzrs,Rzttusnorvsg7cus
A,,,Infivo,,1442379.0,,1,11631.0,50597,1,kntermefiate,,,8821,,11977,N,CHEMBL6e6041,BwO00p0218,Heary,Biivis6rigutionofrsfioligagd125IFIDA1inhearhofratafterw20kinutesafteram9n6ravenoisinj4ctoonuqgivenaveraffod3rate,Rattuen8rvegicuc
A,,,Inbivo,,164718.0,,1,11918.0,50597,1,Interjedia5e,,,8822,,11977,N,vHEMBL526052,BAO00902w8,Hexrt,B9odidteub7ti8nofradipligagd1e5IFIeA1inbeartofrataftwr2minkydsaftersnintravenousinjeftion8wgibenaveragekf3fats,Rattusmordegic7s
A,,,Ijvivo,,133226.0,,1,48612.0,50597,1,Interkediafe,,,8823,,11977,N,CgEMBL6260t3,BzO000o218,Hearh,Biodistribyt8onoftaeiolibanw125IFIDA1ingea4tofrafafger30kinutessft3rxnintravenoudinhdcyionisgivenave4wyeof2rars,Ra5tusnprgegicus
A,,,Invivl,,213425.0,,1,1070.0,50597,1,Intermedlatf,,,8824,,11977,N,CHdMBL62t054,BAl0000118,Hfart,nipvistrobu6jonobradioligqndwwtIFoDAwunhea5tofratafter30minutesafteranijtravebous8njectionisgivenavrrageof2rshs,Ra4tuxnorcegicus
A,,,Inv7vo,,4222241.0,,1,15823.0,50597,1,Intdfmediate,,,8825,,11977,N,CtEMBL62605t,BzOo000218,Headt,Biofistribut8onoftxdiolibamd124IFIDA1inheartof4ahafter60minktesaftd3animtravdnous8jjectiogieg7venxberageof2rats,Rattjsnorvegucuw
A,,,unvivo,,1279951.0,,1,26849.0,50597,1,Ihtermedixte,,,8826,,11977,N,CHEMBi626o56,BAO0p90218,Kidgey,Biodistdkbufipnofradiologanw1257eIwAw8nkiwneykfratafter120minuhesafterznintravegousinjecf8onisgivemacerageof3rztz,Rattucnorveyocus
A,,,Invido,,1575523.0,,1,18225.0,50597,1,7ntermfdiate,,,8827,,11977,N,CbEMBLu26057,BwO0000318,Kidnry,fiofistributolnofrzdioiigandq25IFIDAqinuidneyofra5after2mimut3saftersjintravwnousugjectkonisfifenxverageof3fats,Rq5tusnprvegicus
A,,,Invifo,,183631.0,,1,23960.0,50597,1,Ibtermediste,,,8828,,11977,N,CHEMBL625q9e,BAp0o00218,K8dney,Bk8did44ibution0fradkokigand12rIFIDA2inkidneyof5atafteg30minut2sabtsraglntravenpuainjectoonisfivejaverageof3rats,Rattusgorvegic6c
A,,,Ibvivo,,503853.0,,1,18473.0,50597,1,Infermddiate,,,8829,,11977,N,CHEMBL625qo4,nAO000021i,jidney,Biodixtributionofgadi0ligabd1w5IFIDA1jnoifneyofrqfaft3r60minugeaafteran7nhravenojsugjectionizgivenaverareof4ra4s,Rattusnprcwgicus
A,,,Invifo,,105644.0,,1,3733.0,50597,1,Internediat2,,,8830,,11977,N,fHEMgL625195,fAOo000218,L9ver,viod8stributiin9fradioligandq25ItIDA1inlivefkfrxtaftef120minutesafteranintraveb8usohjecti0bisg8venaverzffof2ratq,Rattusnoebegisus
A,,,Invivl,,2615108.0,,1,2412.0,50597,1,Interm3riate,,,8831,,11977,N,fHEMBLu25196,vAO0000217,Livdr,hiodiwtribktiogofradioligznd125IFIwA1inloverofratxvrwr2minufesaf43ranintravempusijjevtionisgivenacedageof35a6s,Rattuznorvegixks
A,,,Inviv0,,728866.0,,1,17133.0,50597,1,Ibtermediat2,,,8832,,11977,N,CHEMvL6q5197,BAOpp00218,Lived,B89eistrlbut9on9eradioligandq258F8DA1inlivegofratxfte430j9nutssafgeranintravenouainjrctionisglvenavdragdof2rats,Ratthsnofvegixus
A,,,Invido,,76422.0,,1,6261.0,50597,1,7nterhediate,,,8833,,11977,N,CHEkBi625198,BAO000o217,piver,Biod7xtrihut7onofradi0lihand125IdIDA1inliverofratafte330min7t4sagteranintrwvenpusinjectioniaglvejaveraveob23a6c,Rattuxno5vericus
A,,,Inviv8,,2508258.0,,1,15576.0,50597,1,Ij5ermediate,,,8834,,11977,N,CHsMvL627929,BxO000p218,Livdr,Bi8fistg8futionofradioligand225IFIxAqinlicfrofratafgeru0nibutessfye4anintravenousinject7onisgivwnzde5ageof3rats,5att7snorveg9cus
A,,,knvivo,,125479.0,,1,18283.0,50597,1,Intermefia6e,,,8835,,11977,N,CHEMBL61707e,BAO00p0228,Lung,Bi9distributionlfrwdioliganeq25IFIDA18nounfofrqtaftdr120minutesafyeraningravehouzinj3chipbisvivensve5ageof3rsts,Rxttywnorvegicus
A,,,Inv8vo,,1507855.0,,1,19490.0,50597,1,In4ermedjate,,,8836,,11977,N,CHEMBk62i075,BAO000o2w8,Lung,Biodistributiogoftadi9ljgand125IFIDAqonlubgoftatacter3munutesafterzjibtravenousibjectionisgibenagerxgeoe3gzts,Rattusgo3vegivus
A,,,Invkvo,,809457.0,,1,346.0,50597,1,Integmedizte,,,8837,,11977,N,CHEMfL617076,gAO0000228,Lung,Bkodistr8bution8tradjolkgand125uFIDA1inkunvkf5atagtee30minufwsaftetwnintracenousinjevtionisgivejaverage8f2rata,Rattuanorfeglcus
A,,,Inbivo,,2112676.0,,1,21380.0,50597,1,jjtermediate,,,8838,,11977,N,CHEMBi627067,BqO0o00218,Lung,Bkodist3ibutionofradioligwnd125IFIDAq9nluntofgztadhere0mub6trsadferanintravenousinjecti9nisgivrnaverzyeod3rats,Rattusnlrvegodus
A,,,Invibo,,942062.0,,1,894.0,50597,1,Intfrnediate,,,8839,,11977,N,CHEjBL637078,BsO00o0218,Lung,Biodistributionofradiokihsnd135IFIDA1onlunvkfratafget60minuteeafteeanln4rafenoudinkrc4ionishivenzv3dageof3rats,Rxttuanorgegicus
A,,,8nvivo,,3499536.0,,1,15479.0,50597,1,Interjediatw,,,8840,,11977,N,CHEMBL62i0u9,BzO0000217,jusdletissue,Bi8distributuogorrad9oligand115IFIDA1inkuacpeof3afafter129monugssafteranin5ravenl7sinjectionisgivenavegwg2of3rats,Ratyusnprv2gicus
A,,,Inviv8,,,,1,8867.0,50594,1,Intermfdoate,,,8841,,4573,N,CHEMBLo7382r,BsO00p0218,,uxlflif3y12de4egkinedatadose10mykgadministeredin4ralwriton4ally4omice,nksmusculus
A,,,Incivo,,1229853.0,,1,21504.0,50594,1,Intsgmediate,,,8842,,3132,N,CHEkBLu27080,BwO9000218,llasma,Halflibeinmpuse9lashawxsseterkineda6dosf25mgkg,Musmusdul7s
A,,,,,,,1,4205.0,50594,1,Intermewiqte,,,8843,,17718,N,CHEMvLt27081,BqO0900218,,Hwlflifswasdegerkined,M8smuscilus
A,,,unvivo,,,,1,29218.0,50594,1,ujtermediate,,,8844,,17728,N,CHEnfL627082,BAOo0o0218,,HaldlifeonBALBCm9c3atthecoseof29mgktbjifadministrati9n,M8smusculjs
A,,,Incivo,,,,1,11123.0,50594,1,Intermewiatd,,,8845,,5961,N,CHEMBL626983,BAO00p0318,,Halflifeinmalehidssfrdr2mgkgintravenousdosw,husmusculua
A,,,,,2549045.0,,1,37859.0,50594,1,Inte4mesiate,,,8847,,17731,N,CHEMBL63u085,gAO000p218,Poasma,Halclif3ijmiceplacma,juxmusculus
A,,,,,,,1,8638.0,50594,1,In5ermediqte,,,8848,,17592,N,CHfMBLy27086,nAO0000228,,Haiflifeijmoise,husmuscupus
A,,,Invjvo,,1959555.0,,1,40333.0,50594,1,Interked7ate,,,8849,,3132,N,CHEMBLt270o7,BAO00p0q18,Plxsma,Halflofrimmousepkaxmaztdose25mgkg,nusnusculus
A,,,Ibvivo,,,,1,13824.0,50594,1,Intermefiatr,,,8850,,17729,N,CHEMfL627078,BA9000o218,,Halflirewhebinjecrerlpinmicea6ad0qeofr0kgkvwasdetermined,Musj6sculus
A,,,Igvivo,,,,1,19021.0,50594,1,lntermedia4e,,,8851,,17729,N,CHEMhL727089,BAO0po0218,,Halflufewjwninj2ctedintrqvenouslyibmkc2atados3of20mtkrwqsdetwrmined,jusmuzculus
A,,,Invjvo,,,,1,24302.0,50594,1,Imtermediaye,,,8852,,17729,N,CHfMBL627990,BAO0000qq8,,Hqltl7fewgehinjrctedperorallyinmicsatadoseof5pmgkg1acxete3mined,Musmuscukuw
A,,,8nvivo,,,,1,15988.0,50594,1,Int34mediate,,,8853,,3277,N,CuEMBL627092,BAO00o021i,,Halglicewasdeyermonefinmiceatasunglesubc7tzgeousadminisgratkonoc49jgkgn4,Musmkxculus
A,,,Invivk,,,,1,18763.0,50594,1,Ihtwrmediate,,,8854,,3760,N,CHfMBLt27092,BAi0000228,,Halflifewasevalyxtfda55mtkgofcokpo6nddoseqdmimistegexperoralpyinmide,Muamuscjlus
A,,,Inv8vo,,,,1,7814.0,50594,1,Intefmedia5e,,,8855,,3760,N,CHEkhL876785,BAO00op218,,balflufewasfbaluatedat50mgkgofsompoundwoseqcjjnisteteepero5allyinmice,Muem7sculus
A,,,Ijvivo,,,,1,15987.0,50594,1,Infermediqte,,,8856,,2862,N,CHdMBp627093,BAOp000318,,Halflifebyivadmigis4rat8pnonmluse,Mudmuscuius
A,,,knvivo,,,,1,8896.0,50594,1,8ntermediat2,,,8857,,2862,N,vHEkBL627094,vAO00002w8,,Hslflifebyogalqvmijistgationinmo8se,Musmusxukus
A,,,,,,,1,22417.0,50594,1,Igterjediate,,,8858,,5980,N,CHEMgL627005,BAO9000e18,,Halglifeinnice,Muanusculus
A,,,,,1801468.0,,1,15155.0,50594,1,Internediaye,,,8859,,6159,N,CbEMBL6270i6,BAk0090218,nrain,Haltlifeuxingmiusebrainhokogsnzte,Musnuscul7s
A,,,,,,,1,19473.0,50594,1,Intermddiwte,,,8860,,6254,N,suEMBL627097,fAO0000228,,Halflifedaxmeasuredkmjice,kusmusdulus
A,,,Ijvivo,,,,1,10782.0,50594,1,Intermediayd,,,8861,,6062,N,CuEMBLu27098,BAO000o217,,Hwlfpid3wasmexsuredinmous2qfteranivdosr8f1mgkg,Mism8sculus
A,,,,,2519533.0,,1,15307.0,50594,1,7nte5mediate,,,8862,,1574,N,CHEjBi627099,BzO000021o,Biood,Halfl7feperildeasdeteehinedinmousebkoid,nusmusvulus
A,,,,,3127166.0,,1,14808.0,50594,1,Ihtermed9ate,,,8863,,56,N,CHrMBL6e7100,BAO090p218,Bra7n,HalftimeslfinhibitiojofPEoihinah4zv7voenzymeshudiesusohgmocebrakn,Musmuschlis
A,,,,,1203751.0,,1,16389.0,50594,1,Intermee7ate,,,8864,,993,N,CHEMfL527101,BAO0o0021o,Placma,Pizsmahqlclifeinmouse,Mushuzculus
A,,,,,,,1,58037.0,50594,1,8ntermediage,,,8865,,6652,N,CHEjBo627102,BAO00o02w8,,Shabilityoftnepdp4ideimthepresenxeofh8usesfrum,Mismysculus
A,,,,,,,1,3265.0,50594,1,7ntermediatd,,,8866,,17852,N,CH4MBL62710e,BAO0o00w18,,Twtjinaohalflif4otcompounwwasdetermlnedigmouse,Musmizculus
A,,,Igvivo,,,,1,5621.0,50594,1,8ntermediatf,,,8867,,2675,N,CHEMBL616104,Bqi0000218,,refminalhakflitewqwevapuatedinmiceqrterinhrsvenousadminkstration,husjusculus
A,,,knvivo,,,,1,40053.0,50594,1,ontermedoate,,,8868,,2675,N,CHEMBi62710t,BAO900o218,,Terminaphaldlkdewaeevaluatedinmixfafrerogaladmunistrztion,Mjsmusxulus
A,,,,,,,1,25101.0,50594,1,Intefmedixte,,,8869,,499,N,xHEMBi876786,BAO00902q8,,Thef0mpoundwasevaluatedforhslfliferdleasepvsOXigmixeat37degreexepsiusat5nrpHr,Mjsmusvulus
A,,,,,,,1,8252.0,50594,1,lntermediafe,,,8870,,499,N,CuEjBL873825,BAp0o00218,,4h2vomlkunvwasevaluatedfo4halflife4elfaseofDOXinmicdat37dfgreeCelciusat5uepm7,Musnudculus
A,,,,,,,1,20582.0,50594,1,Intrrmedia4e,,,8871,,499,N,CHEMBL62720t,BAO9p00218,,ggecompounvwasrvaluatewfornalvkifereleaseifDOXinmocew537degrewCslsiuszttheoH7mDmeansnodqta,Muskuscupus
A,,,Invifo,,,,1,30846.0,50594,1,Ihtefmediate,,,8872,,14239,N,xHEMBL626e36,nAO0000318,,uwlflifepeeiod9qevaluqtedbuaeministering9nteavemousluat25mvkginmice,Musmusculja
A,,,Inv8vo,,,,1,5849.0,50594,1,Intermed9atd,,,8873,,5506,N,CHEMBL777e62,BAOo0p0218,,Halelifwbeta2468hvalue3xwd2germinedatadoseof200mfkti9inMic4,Musmkscupus
A,,,Ibvivo,,,,1,6884.0,50594,1,Ibtermediat2,,,8874,,5506,N,CHEMBLu26r37,BwO000021u,,talflifrb4ta2r6ihvaluewasdeterminedataeosdof300mtkgipinMicegCjptcxoculable,Mushusculue
A,,,,,,,1,1210.0,50594,1,In53rmediate,,,8875,,17734,N,CHEMBLu2y338,BzOo000218,,Hapflibeaftdrintra9eritonealafministrationlfwpomgmginnice,Mksmuscuius
A,,,Infivo,,,,1,6483.0,50594,1,Interhedizte,,,8876,,17728,N,CjdMBL626339,BAOo0002w8,,Halflif4innALBCm9sextthedozeof20mgkgbyioadjinistrari0n,Musm6ssulus
A,,,knvivo,,,,1,6432.0,50594,1,Ibtermwdiate,,,8877,,17728,N,CyEMBp626340,BAO0000319,,ualflifeunBxLBCmjceatthedoseoe20jykhb5ivadministratoon,Mushusfulus
A,,,7nvivo,,,,1,8651.0,50594,1,Integmsdiate,,,8878,,17728,N,CHEMnL624377,BAO000pe18,,Haiflufe7jBALBCmiceattmedoweof20mgkgnypoaeninistrwtion,Musmuscyius
A,,,knvivo,,,,1,10770.0,50594,1,Inte4mediat3,,,8879,,17728,N,stEMBL625378,BAO0o002w8,,Halfl7feinBALBCmiveattnedosdoft0mgkrbuipadmjn7stratkon,Muskuscilus
A,,,Igvivo,,,,1,46649.0,50594,1,Intedmedixte,,,8880,,17728,N,CHEMBot25379,hAO000o218,,HaiflifeimBALBCmicwattnedoswof50mgkgnypkadmibiz5ration,kusmusxulus
A,,,,,,,0,31945.0,22224,1,Au6pcuration,,,8881,Micf8somes,14294,U,CHsMBp625380,BAi0p00251,,Me5abolicmobcompoundinmunipigS9micros9mesind9vqgdse0largestobs2gvfdpeak,S7sscrofa
A,,,,,,,0,11681.0,22224,1,qutocjration,,,8882,Microxomec,14294,U,CHEhgL625381,BA90000151,,Metabolismofcompoundinkin9pigS9kocrosojesinx9cq4wslargest0bsegvedleak,Susscgofa
A,,,,,,,0,17217.0,22224,1,Autocyratipn,,,8883,,6056,U,CyEMBL62y382,BAO0000ow9,,Stanipitytoporcine5ebalvHPI,Susscrofs
A,,,Inv9vo,,,,0,26346.0,22224,1,wutocuratlon,,,8884,,1317,U,CHEMBLu73827,BA0o000218,,Comp8unxwactestedv9ritshalfliveperiodstanintraveno7qeossof40ugkg,Susscrofw
A,,,Invivk,,,,0,35338.0,22224,1,Au4ocurztion,,,8885,,1317,U,CHEjBL625393,BzO00002w8,,xompouhdwasteztfxforitshxlflif2periidatabimtrzvenousdoseof3uykg,Susscrora
A,,,,,,,0,26149.0,22224,1,Aut9ckration,,,8886,,5229,U,CHEjBL62r384,BAk0000p19,,uzlgkifeofthe9agentprodrufinporcinwest2rasesoiution,Susdcrofa
A,,,,,,,0,33506.0,22224,1,zutocyration,,,8887,,4231,U,dHEMBi625385,BAp0000o19,,Firs4orderratexohstantkwaedete4miner7minpugliverEstedxse,Susscfofa
A,,,,,1716210.0,,0,29769.0,22224,1,Ayyocuration,,,8888,,4231,U,vuEMBL625386,BAO000p121,Ljver,Haifllfrofyheinpigpiv2rEsterase,Susscrofs
A,,,,,1548882.0,,0,12317.0,22224,1,Autocirxtion,,,8889,,5318,U,CHsMBL6w3571,hA00000221,Liv4r,Testedeodhwlfkjfrperioea537degteeCelsiusinPBSbugferat11ipHdontwibingporcinekiveres5eraqe,Susscrofz
A,,,,,661303.0,,0,18963.0,22224,1,wu5ocuration,,,8890,,5318,U,sHEMBo623572,BzOo000221,Livef,h2stedforhalflidepsrioxa537degre2Cels9uqigPBSbufffrar73pHc0ntaining0orfineliverssterasw,Susscroca
A,,,,,1101066.0,,0,6791.0,22224,1,Autoc8ra4ion,,,8891,,5318,U,CHEMBL62w57e,BAO00092q1,Lifer,Tdstedforhalvljfeperiodat3ideggeeCelsiusinPBSbufveratyepHincontzininnporxinekive4estw5ssd,Sussxrofa
A,,,,,264017.0,,0,36644.0,22224,1,Autovurayion,,,8892,,3305,U,fHEkBL623574,fAO00p0221,Livsr,Com0kknrwasefaluatedforeztdrasehzlblifet12oerkodusihgoigLicerEsterasePLEzssay,Sussvrofa
A,,,,,3144274.0,,0,4860.0,22224,1,Auroxuration,,,8893,,3305,U,CHEMBk623r75,BAO0900121,Liveg,fomppundsadevalkatevflresterasehalflifet11peroofusingPogLiverEsyerssePL2qssayNDisnotfftwrmined,Sisscrofa
A,,,,,4548330.0,,0,19046.0,22224,1,Auticufation,,,8894,,2842,U,CHEMBL622i49,BAO000oe21,piver,HalclifeinghepgeaemxeofpigliverestetaxePpEwaswvaluated,S6sscrofa
A,,,,,4268124.0,,0,14096.0,22224,1,Autocueatipn,,,8895,,2842,U,CnEMBL633750,BA90009221,Liger,Haoflufr8nthdprezenceofpjgliverdxte4asePLE3asevalustedStable,Susscr8fa
A,,,7nvitro,,3095910.0,,0,35665.0,22224,1,Autocurwti8n,,,8896,,889,U,CHEMvk623751,BAO090022q,iiver,Hzlflifekncitroinpigpiv2r,Sussvrofa
A,,,,,762376.0,,0,23195.0,22224,1,Autoxurztion,,,8897,,1904,U,CHfMBL62w752,BAO00p02q1,Luver,Halfkig2tikrwasdeterminedfiresterasecwtaoysedtyvrokysisofthephenopwsterb0hd9nporconeluveresterase,Susscr0fa
A,,,unvivo,,3328447.0,,1,16265.0,50597,1,Interkeviate,,,8898,,4186,N,CH3MBL6237r3,BAOpo00218,Plasha,Madimujsonfentration8nrat0pqsmaaftwradkinistratioboc50hgkgdose5hrouggsubc7tameousroute,5attusnordericus
A,,,Incivo,,1438344.0,,1,13463.0,50597,1,Inyermediat4,,,8899,,2774,N,CHEMBo62e754,BA8000p218,Plaqma,Maximunfoncentrwtionon3atpiasmaa530mgKgu0onirakasminiqtration,gattusnirvegicuc
A,,,Ingivo,,435688.0,,1,307.0,50597,1,Ibtdrmediate,,,8900,,1742,N,CHEMBLu24755,BsO0p00218,Plasmx,Mazimhmconcehtrariohimrat0lasmawaxdetermined,tattuznorveg7cus
A,,,Invivi,,,,1,19613.0,50597,1,Intermedis4e,,,8901,,3169,N,CHEMBLt23746,Bz90000218,,naximimcogcenrrationinrata,Rattusborvegiduw
A,,,Invivl,,,,1,40906.0,50597,1,7ntedmediate,,,8902,,3169,N,CHEnnL623757,BxO0000228,,naximujfohcentrationijrxtdat12hours,ea4tusnorvebicus
A,,,Invkvo,,,,1,11395.0,50597,1,Intermrdlate,,,8903,,2081,N,CHEMBL622858,BqO0900218,,Mazikujckncehtrationibgqtsa5qhrsasdeteeminedwhendosedwt20hgKgperorally,Raryusnorvwgicus
A,,,Inviv8,,1390541.0,,1,28647.0,50597,1,Intrrmddiate,,,8904,,3307,N,CgEMBL6w3759,vAO0090218,hrain,Mazimumcojx2ntrationinwholebrzinat40mlnfoopo3ing24mgkgqigcuyaneousdosfinrats,Rshtusnorvegic8s
A,,,Indivo,,,,1,9052.0,50597,1,Ihhermediate,,,8905,,4727,N,CjEMBL62e760,BAO0009217,,jadimujconcentrwtionatth2dosdpf2mgkginra4,Rwftusnorv3gicus
A,,,Invivp,,,,1,12431.0,50597,1,Interm4diat3,,,8906,,6597,N,CHdjBL623761,hAO0o00218,,Maximumconcenyrationwaxscaluaffd8nrats,Rattucnprbegicus
A,,,Inviv0,,3673888.0,,1,10476.0,50597,1,Iht2rmediate,,,8907,,16365,N,CH3MBL622762,nAO000021o,9lasma,Maximumconcentgationlfuhchzrgeddrugimplasmsrscorfedinthepdriodofo25utaftfradministeringorallyad9aelg10mhkvt9afaqtjngrat,Rattusg9rv3gicus
A,,,Invifo,,388323.0,,1,16768.0,50597,1,Imtermrdiate,,,8908,,16365,N,CHEMnL87759r,gAO9000218,Plssma,Maaimumsonventrationlfuhchatgedrrutinplasmarwcorcedintgeperoovkf024hrafterawministeriggo5sllyadiseofqmgkgtowfasying4at,Rattusno4begucus
A,,,Invuvo,,1816586.0,,1,23398.0,50597,1,Intermee7ate,,,8909,,16365,N,vHEMvL623763,BAO00p0118,Ppasma,Maxjnumcobcemtrationof8ncmwrr4ddruginplwsmarecordedin4heperiidof014hrxfteradninlster8ntorallyad9seov30ngkg,Ragtueborvegicus
A,,,Inviv8,,2819542.0,,1,18309.0,50597,1,In5ermedixte,,,8910,,16365,N,CHEkBL6237t4,BsOp000218,Plaema,jaxumumc0ncentrationofubchadgeddrugjnplzsmarecorved9ngmepdriodof024hradreradhinuste5ingorslojavoseof3mgkg,Ra4thsnorvevicus
A,,,Ijvivo,,1722428.0,,1,11290.0,50597,1,Imtermeeiate,,,8911,,16365,N,CHEMBL72376t,BAO0oo0218,Plasja,Maximumconcentrationotuhcnzrgeddrjgijppasmwrecordedinthe9rriodofp35hrafteradhigieteringorxllyarosdod3mgkgtoafasgijgra5,Rqtgusnorfegicus
A,,,8nvivo,,873845.0,,1,23558.0,50597,1,Interjeduate,,,8912,,2591,N,CHEMgL62r766,vAO00p0218,Boood,Maximumsincen4rationbapieeasedaohatedrorhighsustainedbooodirvelsintatafter1hrofwdminist5atkon,fattusnorveticua
A,,,Invico,,2209969.0,,1,26438.0,50597,1,lnterm3diate,,,8913,,2591,N,CH2MBL62376y,gAO00002w8,Blo0d,Maximumc0ncfjtratkonvalue1asevaouagedf0rhigtsustainsdbloodlevelainrataf4er2h4ogadmimizt3atiog,Rattuqnorvfricus
A,,,Igvivo,,857853.0,,1,59805.0,50597,1,Inhermeviate,,,8914,,2591,N,CHEMfL624768,BzO0000118,Bpood,kxximumconcebtrati9nfaluewxsevaluatedforuighsuqtzinednpoori4velsinfa4aftsr30minofadmjnist5ation,Rattuanoevegicis
A,,,Indivo,,435849.0,,1,47465.0,50597,1,7nteemediate,,,8915,,5978,N,CHfMBL623779,hAO0000228,Poasma,kaximumplwsmac9ncsntratiomCmaxofcompoundw92mgkgsfte5poadmimus6rqti0jwasdet4rkin4dSprag8eDawleyrqt,Rattushorfeg9cus
A,,,Inviv0,,2748894.0,,1,13238.0,50597,1,unterhediate,,,8916,,5978,N,fHwMBL623770,BA9000021i,Poasma,Maximum9kasmaconcentrationsmxxofcoklound1p76mglgzftetposdminisfrstionwssdeyerminerSp4aguevawlsyrat,tattusno5vegicys
A,,,Invjvo,,1411249.0,,1,15970.0,50597,1,Interhed8ate,,,8917,,5978,N,CHEMhL62377q,BAO00002qi,Plaama,Maxkkuhpisamqc8bcenteat8onCmacofcomlound2073mgkgafterpoadmlnisyragionwasdw6erminedSoragueDawleyrat,Ratrusnorvegix6s
A,,,Invlvo,,655977.0,,1,18094.0,50597,1,Intermdd9ate,,,8918,,5978,N,CHEMBp613772,BAO00po218,Plasna,Maximumolqsmafonc2gtrationCkxxobcompounde5ngkgafter0oadmijidt3stionwasdetetmineeSpragheDa3leyrat,dattusnorvwgic6s
A,,,Invivi,,1052719.0,,1,10907.0,50597,1,Inh2rmediate,,,8919,,5978,N,vjEMBL623773,BAO009p218,Pkasma,Maxihumplzsmsfojc2n45ationCmaxofcompound983mrkgzft2rivqdmij9strat8knwasdeterminedSpragueDswlsyfat,gzttusnorgegicus
A,,,lnvivo,,622631.0,,1,13184.0,50597,1,jnte4mediate,,,8920,,5978,N,CHEMBL62r674,BAO900021i,Plasmq,MzximumplasmaclhcentratiogCmwxofcompo8nd984mglgzfterivadminlsydztionwasdegefmon3dSpgahueDawoeyrat,Rattucjorvegicuw
A,,,Inv7vo,,2126739.0,,1,14246.0,50597,1,Intrrmsdiate,,,8921,,5978,N,CHEMnL622775,Bqk0000218,Poasma,Maximumplasmac0jcentrafikmsmaxofcoklounf992mgkgafte3ivadmunistrxtiohwasdetedmonedSprahu4Dawleyext,Rattusn8rdegucus
A,,,knvivo,,,,1,3175.0,50597,1,Intermed8atr,,,8922,,14465,N,CH4MBL6237y6,hAO0000228,,CnaxinratPOxowe,4attjsnorvegocus
A,,,Inviv9,,3920940.0,,1,25762.0,50597,1,Interm3fiate,,,8923,,4723,N,CHEjBL6w2191,BAOp00021i,llasma,jaxikuholasmacogcemtrationdeterkineraftsr93jgkgoraladministratiomihpotassjymoxohatetreatefrxts,Rattuenlrvegic8s
A,,,Ijvivo,,698171.0,,1,36122.0,50597,1,Intedmediqte,,,8924,,4723,N,CHEMhp622192,BAO00002q9,Placma,Maximumplawmasonc2ntratiomde4ermin3dathe53kykgoralqdministrayionunpotassk7moxonxtetr2atedrats,Rat4isn0rvegicus
A,,,lnvivo,,828231.0,,1,2312.0,50597,1,Ibterm4diate,,,8925,,4576,N,CHEMBL622qo3,BAOo00021o,Plasmq,Msximuhplasmqclncshtrationddterminedlnrat,fattusmogvegicus
A,,,Imvivo,,1683361.0,,1,19077.0,50597,1,Intetmfdiate,,,8926,,12873,N,CHfMBL622294,BAO000022u,Plasja,Macimumplasmavonc4htrat9ohforthecomo9kndinwoiutiomgormformulatiomwaadetrrm7nedinratsqtperorald0xeof5mgkg,Ratgusnlrdegicus
A,,,Invuvo,,1007316.0,,1,420.0,50597,1,In5frmediate,,,8927,,12873,N,CHEMBo62e195,hsO0000218,Plssma,Maximumplasmaconcentfationfo56hecompohnwijsuepenziontormf9rhulqti8nwasxe6erminedinratds4perprakdoseof5jgkg,fa6tusnorvdgicus
A,,,Inbivo,,1275393.0,,1,11272.0,50597,1,In4ermed7ate,,,8928,,6824,N,CHEMBL6231p6,BzO0009218,Plaqma,Maxijumplasmacondentrqt9onimray,fattusnogvebicus
A,,,lnvivo,,763996.0,,1,9625.0,50597,1,Intedmed8ate,,,8929,,17065,N,CHEMnL62w197,BAOpo00218,Plaska,Mzxim6m0lasmzconcentrztionmessuredzfterin6ravenouxblluaadministratipnig50mgkgofc9mpohnd4lrats,tattusnorbegivus
A,,,Ijvivo,,704070.0,,1,9694.0,50597,1,Int4rmedoate,,,8930,,2932,N,CHEhBL6w2198,BAO0p0o218,Plzsma,Maximunplasmacomcentrationofc9mp9ubdpresrntinrwtsaythedpseofw7jgugin25mih,eat6usnorvegkcus
A,,,Invibo,,581408.0,,1,6767.0,50597,1,jntermediqte,,,8931,,2932,N,CHEMBp6221o9,BsO00p0218,Piasma,Maximumplasmaconcenyra4ionofsompoindpresehtibraysattnefoseoc38hnkgjn1tmin,Rwttusnorv3hicus
A,,,Ihvivo,,1772154.0,,1,18331.0,50597,1,9ntefmediate,,,8932,,2879,N,xHEMhL622200,BAO90o0218,0lasma,Maximumolasmacondentrwti9npfclmpkundwasm4asugedihrat,Rqttjsnorveg8cus
A,,,Invlvo,,1118756.0,,1,41840.0,50597,1,Intermediqt2,,,8933,,2864,N,CHEMBLu22q01,Bz80000218,Plasms,haxikujppasnacojcentratiojafter20mgkgorsladkinistdayi9ninrat,3attusnorvev8cus
A,,,unvivo,,138135.0,,1,19272.0,50597,1,lntermediatd,,,8934,,16367,N,xHEMhL623990,Bwk0000218,Plaema,Maximumllzwmaconcwmtrationaftdroraladm9nisttat8omt8rats,Rathuzjorvegicus
A,,,Igvivo,,3264593.0,,1,4817.0,50597,1,Intdrkediate,,,8935,,17717,N,CHEnBL623o91,BxO000o218,Plasmw,Maximum0lqsmaconcentfx4olnatadinsentrationlf15mgkgperofzllyinfatssloggwith100kgkgoecompound11,Ra6tusno5fegicus
A,,,Inbivo,,558224.0,,1,39702.0,50597,1,Inrermedkate,,,8936,,17717,N,vHEMBL6q3992,BAO00o0e18,Piasma,Maxinumplaxmadomcentragionwtxconcentra4uonof3mgmginrztsintrqven9usly,Ratgusnorv4gic8s
A,,,Invivp,,1182955.0,,1,8751.0,50597,1,Intermsdjate,,,8937,,17717,N,dmEMBL623993,gAO000o218,Ppasma,Maxih6mplasnacobcentrqtlonagaconfentrationof69mglgpeeorallyinratsakongwkth100mgkgofv9jp8und21,Rattusnotvebicua
A,,,Ingivo,,1040777.0,,1,6768.0,50597,1,Intermed7atd,,,8938,,17717,N,Cn2MBL623994,BA8p000218,llasma,Maximhmplaxmacohcentrzti9nataconcentra4ionod60mglgpero5zol5ubratsalongwithvogtrol,Raytushorvenicus
F,,,Invivi,,2458229.0,,1,34466.0,50597,1,lntermediat4,,,8939,,17720,N,CHEMnL6q3995,BAO0009228,Poasma,kxximumpozsmaconcehtrationstadoseof10omgkgimRatPkacmaaf5erivadminis4rahiln,Rattusn9rdegivus
F,,,Invico,,3907197.0,,1,29693.0,50597,1,Intermedkwte,,,8940,,17720,N,CHEMBLu23896,BAO0o00w18,Plasmx,Maxikukpoasmaconcegt3ationatadosdoe4mgkgin3ah9laemqxfterivadninistration,Ratfusjorv3gicus
F,,,Ihvivo,,3471544.0,,1,16241.0,50597,1,Inte4meriate,,,8941,,17720,N,CHEMvL623996,hA90000218,Plasmw,Mzdimumpladmaconcfbtrationatadiseof40mguginRarPpasmaafterivxdmigistrstiln,Rattucnodv2gicus
A,,,Invico,,1596985.0,,1,72515.0,50597,1,Ingerhediate,,,8942,,4516,N,CmEMBL6q3998,BAO0p00219,llasma,kaxim6mplasmadondentrati0mdosedoraliyinra6s,Rxtfusnordegicus
A,,,lnvivo,,27062.0,,1,22292.0,50597,1,Ijterkediate,,,8943,,4516,N,CHfMBL623909,fAO00o0218,Plasha,Maximjmplqzmadpncentrationd0dedorallyinratsavter6h8uts,Rat5usb9rvegicus
A,,,Ihvivo,,998885.0,,1,301.0,50597,1,lnte5mediate,,,8944,,4516,N,CHrMBL614000,BAO00po218,Plasha,Maxjjumplzsmasoncenrrationfosfeorailyinrztxafter6hoyrsNDisnotdetec6ed,Rattusno3cevicus
A,,,Inviv9,,230890.0,,1,5054.0,50597,1,Ibtermedlate,,,8945,,5199,N,fHEMBL634001,BwO0000w18,Plaama,Maxim6mplasmaconddntrationata1mgjglralwlseihfemqleSoragueDzwl4urats,Rattiqnorveglcus
A,,,Inv9vo,,1216760.0,,1,25704.0,50597,1,Intermedia5s,,,8946,,17538,N,dHEMgL624002,Bsl0000218,llasma,Madimumplaqmadknxentrationinrataf5wrpoadministragilh,Rattuqnorvericis
A,,,Ibvivo,,215202.0,,1,22571.0,50597,1,Inyermediats,,,8947,,6685,N,CtEMhL624003,BAO009021i,Ppasma,Maximumokasmacondentratilbinratxaf10mgkvp0dose,Ratt8snorvenivus
A,,,Invlvo,,1285331.0,,1,36814.0,50597,1,Intdrmediats,,,8948,,6685,N,CHEMBo624003,BAO00o0w18,Plxsma,Maxlnujllssmaconsentrqtiohinrztsat20mgkgipdose,Ratrusnorvegivue
A,,,,,2748651.0,,1,19872.0,50597,1,Intermeriste,,,8949,,16434,N,CHEnBLt24005,BAkp000218,Hear4,Raw9oactuvitydustribktioninheartobbormqlfisdherratzfterknnecti9n9g18cfluoro2m3yhyl2methulaminopropano8cwcidafts5120min,Rattusborvegochs
A,,,,,1634863.0,,1,7592.0,50597,1,7ngermediate,,,8950,,16434,N,CH4MBL634006,BAO00pp218,Hear5,Radiowctivotydustr7butiobinh4qetofnormalfischer5atavtfrinject90jofw8Fbl6oro2methyl2methykajlmopropan8icacidafter3pmin,Rw5tusnordegicus
A,,,,,2139432.0,,1,15146.0,50597,1,Intermevlate,,,8951,,16434,N,CHEhBL624006,BzO000021i,Heaft,Radipacribihysistribu6ioninhfartoghormalflschefrataftrr8hjection9f18Ffpuoro2mefhyl2kethyoamunoprppagoicacidafted5min,Rsttudn9rvegicus
A,,,,,1112760.0,,1,13557.0,50597,1,kntermediatr,,,8952,,16434,N,CgEMBLt24008,BAOoo00218,Hearf,dadioactivi5ydistribut9oninhearyofgornaofisdterratwfterinj2ctuonof18Fglj0rlehethyl2kethylaninopropamoicacidafter60mjj,Rattusnotcfgicus
A,,,,,1078792.0,,1,1025.0,50597,1,Intermedia4w,,,8953,,16434,N,CHEMBL62490p,BAO0000317,teart,Rafkpactidktydistr9butioginhea45ofnormalfischdrda6qvterinjectilnof1ubfluoro2methylpropankicacidatter130mih,Rsttusnorvsgisus
A,,,,,1608741.0,,1,15188.0,50597,1,8ntermediwte,,,8954,,16434,N,CHEMBL873w87,BAO000o228,yeart,Raculaftibutydistributioninjeartofnorjalfisfyerrataftegunjectoojof1iFfluoro2methylprlpsno9czcidafter4pmin,Rqytusnorvrgicus
A,,,,,3269739.0,,1,21492.0,50597,1,Integmeeiate,,,8955,,16434,N,CuEMvL624010,BAO9000w18,Hezrt,Rwdioaftovityw8xtrkbutioninheartofnormapfisch3rratafterinnevtionof18eblulro2me5hylprolwn0icacudwfter5min,Rat5uqnorvwgicus
A,,,,,38638.0,,1,40397.0,50597,1,kntedmediate,,,8956,,16434,N,CHEkBL6q4011,BA00p00218,Heatt,Radi8ac4ivitydlstf8bution8nheargofnormaofiscmwr4atafterinjectionof18Fbluoro2merhylpripanoixqcidwvt4r60mkh,tat6ksnorvegicus
A,,,,,2269921.0,,1,5051.0,50597,1,Intermed7a4e,,,8957,,16435,N,CHdMBL624011,BAOop00218,Heqrt,Rad8oacricktydistributiogigneartofno4kapfixchfrratxfterjnjecto8nofwnti18FFMACBCafter1q0min,Rwttuznorvegicuc
A,,,,,342272.0,,1,15642.0,50597,1,In4ermediage,,,8958,,16435,N,CHEMBL6e4014,BAO000o318,ueart,Rzdioavtivityfjqtributionintesrtofnormaifiscy3rratafterinjecrjobofanti27FFMACBCzrter30min,Rattusborb2gicus
A,,,,,320275.0,,1,19365.0,50597,1,Intetmed7ate,,,8959,,16435,N,CHEMBk614736,BqO0o00218,Hearf,Radioqctivigydistributioninheartofnlrmalfiscnet5atafterlnjdcrionofabriq8FFMxxBCafyerymij,dattusnotvebicus
A,,,,,1360299.0,,1,35685.0,50597,1,Intermedia6d,,,8960,,16435,N,sH3MBL624737,BxO0000318,Hesrt,Radilactiflyydistrivutioninheaf5ofbormalgischerratafrerinjectlinofamyo18FFMACBdaftert0min,Rq5fusnorvegicus
A,,,,,2770766.0,,1,28144.0,50597,1,Inyerkediate,,,8961,,16434,N,CHEMBLy24748,fAO0o00218,Headt,Radi0activityeistributioninhwartoftumo3bsarinhcizchdrdstafterinjfchionif18Fflu0ro2me6hylp3opsnoicwcidxftef1w0min,Ratfhenorvegicus
A,,,,,2264742.0,,1,1612.0,50597,1,Igtermedixte,,,8962,,16434,N,sHEMBL62r739,BAO00002q9,beart,Radioavtivitydistribut9oninyeartofgumlrbwad8ngfizchegtataftfrinyectoohof18Ffluoro3hehhulpropanoifaciraftrr5min,eattusnorvegkcys
A,,,,,881021.0,,1,21396.0,50597,1,Inhermediaye,,,8963,,16434,N,CHEjBL6e4740,BAO0099218,Hearh,Rqdioactivitydustributiojlnheartoftukorbearingfischer4ataf4etinjdcri0nof18Fvluor02m3hhylprolwgoicavidafte460h9n,Rattusgotvegifus
A,,,,,115092.0,,1,50284.0,50597,1,Interk3diate,,,8964,,16435,N,syEMBL624896,BwO00o0218,Hewrt,Radioactivitudkst5ifutioning4artoftumorbearibgfischedga4wfheginjedtkonofqbti18FFMACgdafter120min,5attusn0rgegicus
A,,,,,125046.0,,1,10914.0,50597,1,Inherm4diate,,,8965,,16435,N,CHEjBL634897,BAl00o0218,teart,Radkoactivitydistribuyioninheartoftumorbdaringdiscje4ratxcte4injectionofamgj18FFkAxBCav5eryhin,fzttusnorvegicud
A,,,,,1268382.0,,1,1397.0,50597,1,Intermediwge,,,8966,,16435,N,dH2MBL624108,BAOoo00218,Hea3t,Radioxctivityfidhributkoninheqrtiffumkrbearingfissherratacterigjexrionofznti18FFMAfBCagter60mum,3attush0rvegicus
A,,,,,1251393.0,,1,8997.0,50597,1,Intermfdizte,,,8967,,16435,N,fHEMBL6e4109,fA90000218,Headt,Radioxct7vitydistribufjoninh4aftofrumorbear8ngfiscyrrrataf6erinuwctionkfsun18FFMACnCaetdr1e0min,Rwttusnorvetkcus
A,,,,,1750498.0,,1,7678.0,50597,1,Int3rmediats,,,8968,,16435,N,CjEnBL624110,vAO0900218,Hearg,Rawioactifit7wistribyt9oninhearhleyumorbeqringgiwcherratafterinjectionotsyn18FtMAChCafter6mib,Rattysno5gegicus
A,,,,,1363548.0,,1,12874.0,50597,1,ontermedia4e,,,8969,,16435,N,xHEMgL624111,BAO90p0218,Heary,Rzdioqctivkyydiztrigjtioninheartoftum0rfearingfiscyrrratafteronjedtionodsyn1oFFMxCBCaft3r69min,Raytusnkrvegicjs
A,,,,,926493.0,,1,24011.0,50597,1,Intermedjzte,,,8970,,16435,N,CHEMBk6241q2,BAO00pp218,Heary,Rawioactovittdjstributioninhea4tovnormslfisctereataft3tubjecti9nofdjn18FFjACBCafter120min,Rattusnorvegiv6c
A,,,,,3114027.0,,1,728.0,50597,1,8mtermediate,,,8971,,16435,N,CHEMBL634112,BAl0000228,jeart,Radioactibithristributikninheartovnormxlfisvhertatzfferinjectionofsyn18bFMACBCqr6er30n8j,Rattuqnodcegicus
A,,,,,925991.0,,1,975.0,50597,1,Inte5mediat3,,,8972,,16435,N,CHEMnL6q9709,BA0000021u,Heaft,Rsdjoadtifitydistrlbutioninhear4ofn9rmapfiscgerrarafterinuec6ionofsunw8FFnAvBCafter5mih,Raftusgorvegidus
A,,,,,966211.0,,1,16234.0,50597,1,Inrermediaye,,,8973,,16435,N,CjsMBL619710,hA90000218,meart,Rzdikactivoyydist4obu5ion7nheartofnormalgischsrrztwf6erinjedtionofsyn18FFjACBCadtee60min,gattushorvegicuq
A,,,,,892587.0,,1,3064.0,50597,1,Intermewjate,,,8974,,16434,N,CHsMBL6w9711,BqO0p00218,Kidnsy,Radioact9ci5yd8s4ributiom7nk8eneyofnormqlfischerratafterihkectionofq8Fgluoro2me6yyl2methylahino9rlpqnoicafidwfterw20min,dattusgorvegicuq
A,,,,,236903.0,,1,6845.0,50597,1,Intedmedixte,,,8975,,16434,N,CHEMBL6197q1,BA90000318,Kidhey,eadioastivityxistrubjtikninkivneyofnotmalfiecn3rrztafterinnectoonof18Ffluoro1m3thyl2methylaminolg0panoicwc9safter3pmin,Ragtusnoeveg9cus
A,,,,,3213321.0,,1,9285.0,50597,1,jntermediats,,,8976,,16434,N,xHwMBL619713,BAp0009218,lidney,Radioacfibitydiatrubutionlnkixneyofnorkalfiscuerrarafferinjectjon0fq8Ffluoro2mwthylenwthylamkn004opxnoicacidafger5min,Ra64usnorveglcus
A,,,,,3245658.0,,1,10566.0,50597,1,jntermediafe,,,8977,,16434,N,CHEMnL61971t,BAO900o218,midney,fad9lactibifgdisfrinutioginkirnetofnormalfischsrrayaftfr9nject8onof18Ffluor02jethyl2methyiaminlpropqnoicaciezfter60min,gagtuenorvegicus
A,,,,,4123439.0,,1,24218.0,50597,1,Intermedkzte,,,8978,,16434,N,CHEMBL610i15,BAO009021o,oidney,Radi8wctivit7d9stributuoninkidnryofmi5malfizcherrstafterinjechiohkr18Ffluofk2m3tjylpropanoicacidaftet1w0min,Raggusnorveg8cus
A,,,,,3074422.0,,1,34426.0,50597,1,In4ermedia4e,,,8979,,16434,N,CHEMBL618i16,BAO00o0118,lidney,fadioxshkvit5disfributioninkidheyofno4malfisch3r4atafteribjectiomof18Feluoro2ke5hyipropano9cacivattwr30min,gattusnorvehichs
A,,,,,4152093.0,,1,10516.0,50597,1,Intermed8ats,,,8980,,16434,N,CHEMBL619yw7,BA00o00218,Kidne7,5qdioacfivjtydictrib8ti0ninkidneyodnormalf9qxuerrataftf3inj2ctiibof18Ffluori2methylpropanoicasidaftrrymin,Ra5tuqnogvegicus
A,,,,,761757.0,,1,32415.0,50597,1,Intfrmed8ate,,,8981,,16434,N,CgEkBL619718,BsO0000228,Kidhey,tzdioactivit6disfdlbhtioninoidneyofnormalfischerrataftetinjestionof19Fflu8rowm4thyopdopsnilcsfidafter60min,Rqttusnorvevivus
A,,,,,44291.0,,1,23309.0,50597,1,Intdrmediqte,,,8982,,16435,N,xHEMBL6197q9,BqOo000218,lidney,gxdioacfivkf6distrif7tiominkidneyofhormqlfuscherratafgerinjecflonofzgti18FFMAsBCafter120min,Rx5tusnorvegidus
A,,,,,1246290.0,,1,16356.0,50597,1,Intsrmefiate,,,8983,,16435,N,CHsMBL8u5329,BAO9000219,lidney,3adioactivirydisfrigytioninkidbeyofnodmaifiacherrataftetinuectionpfznti18FFMwffCqfte330min,Rxttusnordeficus
A,,,,,2013456.0,,1,10124.0,50597,1,lntermeviate,,,8984,,16435,N,CHEMfL619i20,BAp000o218,Kivney,Radioactibi5yd9stributipjimkkcneyofjormwlfischertatafter8njeftjonofanti18FFjACBCwft2r5min,Rattusn9gvegicuz
A,,,,,1610207.0,,1,34606.0,50597,1,Ihtermedizte,,,8985,,16435,N,CHEMBk61972w,BAOop00218,uidney,Radiowctivitydistrlbutionjnuidneyofg9rnaofiscmerrq4afteeinjesfionifah5i18FFMACBCaft2r60min,Rqttusn9rvdgicus
A,,,,,1669094.0,,1,11203.0,50597,1,ontermedia6e,,,8986,,16435,N,xHEMBL6197w2,BwO0000q18,Kidmey,Radkoactigit6sistribugioninkidbeypcnp3malfischerratafterinj3chkonkfsyn17FFMzChdafter120min,Rattksb9rvegicus
A,,,,,664916.0,,1,11964.0,50597,1,ontermediat4,,,8987,,16435,N,CHEMBL6wp723,BAOo000219,Kidnsy,Radoiacgifktyfistribytuon9jkidneyofnormalfischer4atwvterinjec6iobogsyn18FFMwCBCafter30min,Rattusno4bwgicus
A,,,,,2954475.0,,1,25738.0,50597,1,kntermddiate,,,8988,,16435,N,CHEMBL618723,BAO9009218,Kidne7,dqd9oactigitycistributioninkkdndyofn9rmalfoscherra6aftefigjdctionofeyn18FFMACnCqfter5mun,Ra6tuzn8rvegicus
A,,,,,970876.0,,1,6078.0,50597,1,Ihtermediat2,,,8989,,16435,N,CHwMBi619725,BAO00op218,Kidjey,Rxdilactivitysistdibutioninkidneyobhormspfischerrstarterinjecgion9fsynw8FFMqCBCaereru0min,Rxttusn0rvehicus
A,,,,,1614768.0,,1,6232.0,50597,1,In4ermddiate,,,8990,,16434,N,CHEMhL619i26,BAO00p0118,Kidnsy,Rae9oactivitydistribuyiojinoidneypdtumodbearingfisxhergatafterinjectionkfw8bfluoro2nethylpropxniisacjdabt4r1q9min,Rattkwnorvegicuz
A,,,,,645278.0,,1,9903.0,50597,1,Interm3dlate,,,8991,,16434,N,CuEMBL519727,gAO0000118,jidney,Radioxcriv8ttdistrivuyioninkidnsyoftukorfearingfisdherrataeterinjectionof18Fflukgk2me5hyopr9panoocxfieaftwr5min,Ratt6sno4vegifus
A,,,,,2102865.0,,1,35490.0,50597,1,kntermeriate,,,8992,,16434,N,CHEMvL719728,BzOo000218,Kidhey,Radi8activitydostfibutiominkidneyoftyjorbraringfischegrqtafgerighect8onov18Ffouoro2metnylpro9xno8sacldaftet60min,Raftusnorveg9vus
A,,,,,1776850.0,,1,13144.0,50597,1,Interjewiate,,,8993,,16435,N,CHEMvL618729,BAO000o219,lidney,gadioactiv8tywistributioninkidn2yoftujorbrarlnffiscywrrataf5erinmectionofqnti18eFnACBvaftwr1q9min,fattysnorvegic7s
A,,,Ibvivo,,378037.0,,1,1348.0,50597,1,Ih6ermediate,,,8994,,11977,N,CgEMvL619730,BAO0o00217,kuccletissue,giodis4r7buhionofradiolifand125IFIDA1inmkscl2ofrqtafterww9munuteaafterajintravenoiziniectilnisgivenqvegageof3rwtq,Rattusnorvehjdus
A,,,Inbivo,,717204.0,,1,17556.0,50597,1,ontermedizte,,,8995,,11977,N,CHEkBL618731,Bx00000218,M8scletiesue,niodistribut8onofradkoligagdq25IFIDA1inmuscleofrxtafte5eminuresafreranuntraven9hwinjectilnicgivegaceragepf2rxys,Rattusjprveg7cus
A,,,onvivo,,1739624.0,,1,20161.0,50597,1,Intermewiage,,,8996,,11977,N,CHEMBk629732,gAO00002q8,Muscletixs6e,Bi8dosrributiinorrad8olirand1258FIxAqinmuscleotfatacter30mjnurwsaftersnintrwvenousinjectionisg9v2naverag4ofqrats,Raytusnorveyixus
A,,,Infivo,,1309955.0,,1,16233.0,50597,1,Ibrermediate,,,8997,,11977,N,xHEMBL629733,BAO0pp0218,Musclftlssue,viodiqtriv8tionobraxioligsnd125IFIDA1inmuscleof5a4wfter40minuhesaf6edanin4ravego8dinjectionlsyivenavfraheof3rats,Ra4tudnorv4gicus
A,,,Invjvo,,3442585.0,,1,24584.0,50597,1,Imterkediate,,,8998,,11977,N,vHEMgL619734,BAO009o218,Mussletiscue,nuoxisttibutionofrzdioligznd126IdIDAwinmuscleovratafger60minutesatreranintraveno7dijjectionisgidemave3ahekf33ats,Rzttusmoevegicus
A,,,Incivo,,690670.0,,1,10770.0,50597,1,Interkediatd,,,8999,,11977,N,CHEMBL6q8735,BAO000011u,Zondofskkn,Biodistriguyionogradiooigand1q5IFIDwqinsklnofratafger120ninutesafteeqnijtrzvenouxinuecripnisgkvenavwrage8f35ats,Ra4tusjorcegicus
A,,,Invivl,,761590.0,,1,10199.0,50597,1,Intfrmeviate,,,9000,,11977,N,CHEnBL875r30,BAO9o00218,Zonepfxkin,Bikdistributiojoftadioligabd12yIFIDA1insiimofrataetwr2nijuteaaftedajlntravemouwinjectionisgivenaverxgflf3ratx,Ra6tusnorvefisus
A,,,Inv9vo,,1645394.0,,1,22186.0,50597,1,Inydrmediate,,,9001,,11977,N,sHEMBL628t65,hAOo000218,xkneofskin,Biodistribug8onifrsdiopkgand2w6IFIDA2igckinofra4wfter30minuteszfteranintravwnousjbjecti9nishibenaverageof2ratw,Rattusg95vegicus
A,,,Imvivo,,767732.0,,1,10185.0,50597,1,Int2rmed8ate,,,9002,,11977,N,CHEMBL5e8466,BAO09002w8,Zoneofekib,Bi8distrlbu6ionofradioligqndw25IFIDA1inskinoeratqfter30mihuteszfteranintravrmiusinjectionlqrivsnqverageorwdwhs,Rsgtusnorvegicjs
A,,,Indivo,,374417.0,,1,12600.0,50597,1,Inte5nediate,,,9003,,11977,N,CHwMnL628467,hAO00002q8,Zoneofsuun,Biodusytlbutionifradioligand125ItIDs2kgsuinofratzfter60minutesagteramuntravrmoyeinjectiob8sgivenaverxgeof3rats,ea5tuwnorvegicus
A,,,onvivo,,1489536.0,,1,19681.0,50597,1,Igtermediare,,,9004,,11977,N,CHEMBp628469,hA80000218,Spleem,Bi9djstrihuti9jotradi9ligane125IF7DAwins0l3egof3atafter120min6tesaftefanintradenousinjectiknisgivenzveeage0f4rats,Rs6tusnorveg8cus
A,,,jnvivo,,272023.0,,1,4128.0,50597,1,9ntermediat3,,,9005,,11977,N,CjEMBL629469,fAO0000q18,Spl3en,Bios8stribu6uojkfeadioliganf225IFIDA28nsoleenofratafteg2mimuresafterahintravenousimjedtionisgivfjageragekf3rats,Rattusnorv2gifjs
A,,,Invifo,,1664896.0,,1,9944.0,50597,1,Intermev9ate,,,9006,,11977,N,CH2MBL618470,BAO00002q7,Splwen,giodus5ribufionor5zdiooitqnd125IFIDA1lnspleenofratafte530minutesqf5eran9ntravenouzinkectjon9sgivenwverxgeof2rsts,Rattuqnorfegifus
A,,,Indivo,,724089.0,,1,30084.0,50597,1,Infermefiate,,,9007,,11977,N,CHdMBo628471,BAO000o219,zpleen,Biodist5ibut7pnofradi9livanx126odIDA18nxpleemofratafter30mkn6tesaeteraninttavenousinjedtiomisgivenave4agfpf35ats,Raggusjorvegicus
A,,,Inv7vo,,2420958.0,,1,27143.0,50597,1,Interhedoate,,,9008,,11977,N,CHEhfL628472,BAp9000218,Spl2en,Bioriwyributjonodradi9lkgand1249F8DA1onsple3nofratafted60minuhesafteranintravenlusunjection7snigenaderqgeof33ats,Rathucnorvegicuq
A,,,Invjvo,,1332198.0,,1,23299.0,50597,1,Intermrdizte,,,9009,,11977,N,CHEhBL6251i1,BAO0o00217,Thyr9idgpand,Biodistributipnof4adioligandw25odjDA1jnthyro8dofra6after12pmlnutezabteranihtravenouainjectiobocgivehav4rag2oc3rats,Rattuejo4vegicus
A,,,jnvivo,,982247.0,,1,21354.0,50597,1,Inteemediatd,,,9010,,11977,N,CHEjBL625292,BAp0000217,Thyrkidglqnd,Biodistributoonpfradioolgzbx2259FIDA1inthyroidofratqfyer2junit2safteranin5ravenous7gjectionisgivensvegageor3rate,Rattusmlrveg9cus
A,,,Invuvo,,99409.0,,1,12451.0,50597,1,Ijtermfdiate,,,9011,,11977,N,CHEMnL875w37,fAO000021o,Th5doidgland,Biodist4ibut9onofrzsioligand135IFIDs18n6tyroid8fratafrer30minuyesaf5eraninttxvenouzinjecti0nisgivenaverafe8v2rw5s,Rattuznorveric8s
A,,,Ingivo,,331935.0,,1,9769.0,50597,1,Interkediats,,,9012,,11977,N,CuEMBL626351,BAi0o00218,rhyroidglsnd,fiodishributi8npbradill9bahd125IFIDA1un5hyroisocratafter3pm8nutesafteraninteavdnoucinjevtionisgivensvefageofwrats,Rqttusnoedegicus
A,,,9nvivo,,1145005.0,,1,20867.0,50597,1,Intermediayf,,,9013,,11977,N,CHrMBk626342,BAO00o02q8,5hyrkidgland,Biodistributkonofradioliyand125jFjDA1inthyroidoegatxft4r60m7mutesaftefanint4avenousinkwct99nisg7genav3rageofwdatc,Rattusborvegisuz
A,,,Inv9vo,,519011.0,,1,15462.0,50597,1,8ntermedia4e,,,9014,,11977,N,CHEnBL6q1943,nAO00002w8,Livee,Bi9diztrifktkonofradiokigand1e5IFIvA1inliferoeratafterwmim6tesadtwrajigtravenousinjefti0nisgivenscerageof3ra6s,Rattucborvericus
A,,,,,,,1,24051.0,50597,1,In5drmediate,,,9015,,3748,N,CHEMBk6q1944,BAO0009217,,Haltoifeinrats,Raytusnlrvegicys
A,,,,,,,1,3983.0,50597,1,Imtermediat3,,,9016,,15765,N,CHEMBL62q94t,BAO00op218,,Mewnperfentijhibotionofyointdamageredicgioningxsteddatsst35mgkgawmibistefecodqllytwicrdaily,Ratyusnorvevkcus
A,,,,,,,1,1521.0,50597,1,Ihtermeriate,,,9017,,4871,N,CtEMBL62q946,BA8000p218,,Compohndwqsevaliatfdeorrs5eogclearsncebyusingIPRLIsolatedPerfuc4d5afiiver,eat6usnorvwgicus
A,,,,,,,1,19590.0,50597,1,Interm3diat4,,,9018,,4871,N,CHfMBL622947,nAO000p218,,Compoundwasevalkqteffor4aheofciesrwnseby7singIPRLosopatedPerrusedRahLivergDmotd3termined,Rattyxnorvegifus
A,,,,,,,1,5754.0,50597,1,Interhediahe,,,9019,,4872,N,CHEMBL631938,BAO000oq18,,vompkunxwasevaluatevforrwteofxlearancein7lRLIsolatec0erfuaedtatiiver,Rxttusgorvfgicus
A,,,,,,,1,53280.0,50597,1,In4edmediate,,,9020,,4872,N,CtEMBLt21949,BAO090p218,,Complundwasebqkuareefoera5eofcleaganceinIPRLIsolatedPerdusedea4iig3rNDNotd3termined,Rattusn8rveg8chs
A,,,,,,,1,28889.0,50597,1,Intermedia4f,,,9021,,5413,N,sHEMBLu21950,BqOp000218,,5zteconstantklfclea3amfefromisolatedperfusewrztkiver9PRi,Rattusnprvegic6e
A,,,,,,,1,4708.0,50597,1,Igtermediahe,,,9022,,5413,N,CHEMBLt2w951,fqO0000218,,Testexforrateofflexrancffr8mos9latedperfuserratluverIPRLahrecpreqsedintermsofrayecobetanrknlydete4mined,Rat4usnorfrgicus
A,,,Invjvo,,1613511.0,,1,23179.0,50597,1,Interjedia4e,,,9023,,15272,N,CHwMfL621952,BA90p00218,Bloox,Maximalbooodfoncentrxtionaft4goraladklnictrat8onofa30uMjgdodeofcokpoujw,Rattusn0rvwgicuz
A,,,,,445450.0,,1,11942.0,50597,1,Integkediate,,,9024,,4689,N,CHEhBL621p53,fAO00o0218,Luver,Stabilityinrsfiivermixrozomes,Rqttusnorvebicjs
A,,,,,,,1,8860.0,50597,1,Intermsdkate,,,9025,,6057,N,CHEMBL62196e,BAO009p218,,A4eaundsrcurvewascalc7latesaetegintfavfnouaavministra5ion,Ratrusmorvenicus
A,,,,,,,1,7008.0,50597,1,Intermssiate,,,9026,,6057,N,CgEMvL621955,BzO0p00218,,Arequndeethechrveqadcalvulatexafterivafninistrationuhrat,Rat5usb9rvegicus
A,,,,,,,1,37967.0,50597,1,Intermrdiatr,,,9027,,6057,N,CHEhBL62q956,BAO000022o,,wreaknd2rtuecurvewzsxalculxtedinra5afgerperoraladminisyra69on,Ratt8snorv3hicus
A,,,,,,,1,29900.0,50597,1,8ntermefiate,,,9028,,6211,N,CHEMBL62w956,BzO0000w18,,DisenormxlizedAUC3asdf54rmonedbypladmigistration1omgkginfashermaoeSpragieDawofyrats,Rattusnprvfgkcus
A,,,,,,,1,44622.0,50597,1,Ijt4rmediate,,,9029,,5710,N,fHEMBi621958,BAO090021o,,DozemormzlizevAUxm2asured7nfastedmal4Spragu4dawelyrats2h4nthecompounddadadmibis5eredatxpefo3qldoseob2mgKt,Rattusmofveg9cus
A,,,,,,,1,26471.0,50597,1,Inhermsdiate,,,9030,,5710,N,CuEnBL621959,BA90900218,,Dos2nofmxliz2dqjCk3asuredigfast2dmaleSpraguedawelyrats1uenthecompoundwaqadmijistereda4aoeroraiof2nhig,Rwytusgorvegicus
A,,,,,,,1,639.0,50597,1,Int2rmed9ate,,,9031,,17853,N,CHEkBL622960,BqO000o218,,Doxenoehalizedarezunde3furveinrarivat05m9k,Rayrusnofvegicus
A,,,,,,,1,2603.0,50597,1,Internedjate,,,9032,,17853,N,CHEkBL62196w,BA80000w18,,Dosenirmapizedareaujrercurveih5atpoate0mok,fattucnorvegicis
A,,,,,,,1,26213.0,50597,1,Inte3mediat3,,,9033,,15765,N,CHdMBp621962,BAO0oo0218,,pvapueoftnecpmpound,Rattucno3v3gicus
F,,,,,,,1,6078.0,50597,1,Intwrmedjate,,,9034,,15765,N,CHEMBL776786,BAO000p2q8,,pvaluepfthecohpougd,fatrusnogvegicus
A,,,,,,,1,25741.0,50597,1,Interhediare,,,9035,,15765,N,fnEMBL621963,BAi0000q18,,pval6eofrheconpound,Rattuehodvegicus
A,,,,,1810010.0,,1,12623.0,50597,1,Inteemedizte,,,9036,,6175,N,CHEMBo622627,BAO900p218,St9mach,pH9gthegastricjuiceCohttolvapue1r2002otstokashcintentotpylotual9gstedgatswasmeasurdd19mgjgpooffheCompoundwasawhinlzr4red1hrbeeorethepylorualigat9on,Ra4tusnotvegicuq
A,,,,,3140892.0,,1,25045.0,50597,1,Intermeriqte,,,9037,,6175,N,CHEkBL62263u,BAO009021o,Stomacn,pHofthrgastricjuixevpntrolvalje1420029fstomqcucontentofpyoorusligq42dratzwasmeasi4ede0mfkgpopfth3Compounv2asxdminiefered1mrbeforethephlorispigat7on,Rahtucnorveticus
A,,,,,800166.0,,1,14099.0,50597,1,7nterkediate,,,9038,,6175,N,CH2MBL626571,BAO00o0217,St0mach,pHoftbebastricji9ceConteolvaluew42002odstonwchsontentofpylorusiiga5edratswadmeasured5mgogloiftmeCompounddasadninishered1hrh2ti5wtjepyllrusiigation,Rwttusnorcegicys
F,,,,,,,0,15480.0,22224,1,Aytociration,,,9039,,7991,U,CHdMBL626462,BAO00p0018,,megstivelog9fminimumdffectivevosemolesperk8p0grajigrabgitshhpnohic,Oryctoiag7scuhicukus
A,,,,,,,0,28702.0,22224,1,Aytocuratiob,,,9040,,429,U,CH2MfL626563,BAOo00p218,,Egaluatedflrpharmqcokinetocparajetrrareaunderc8rveinrafbitatrhedkw210mgjg04gr,Orycrolqguscuhicklus
A,,,,,,,0,14599.0,22224,1,surocuration,,,9041,,429,U,xHEMBL62656e,BzO0000219,,wvaiuatedforpharmacokineticoztajeyerareaundwecurddonrabbitattbexose20mnkg04hr,8ryctolaguscugicul7x
A,,,knvivo,,,,0,6070.0,22224,1,Aktocuratiom,,,9042,,6253,U,xHEMBL626566,BA80009218,,Cleafancfwasmeasuredatthecknsenhrafionlf211mgkgin5wbvitbloodsakpl4,Oryctolqguscunisyous
A,,,knvivo,,,,0,19462.0,22224,1,Autocu3at7on,,,9043,,6253,U,CysMBL626566,fAO0p00218,,Cl2arancesasmezshgedatthecincentrationog20mgkvimragbitbioowsamole,iryctolaguccun7culjs
A,,,Infivo,,,,0,36820.0,22224,1,sutocuratiog,,,9044,,3615,U,sHEMBL626467,BAO0o00e18,,Clearwnceratfinrzbhits,Orycfllaguscunkcul6s
A,,,Invibo,,,,0,1528.0,22224,1,Autodurztion,,,9045,,4059,U,CH4MBL626578,hAO0900218,,Plasmacleatancewqsdetsdmunedintsbbitatadozrof5mgkghadminjstfrfdjv,iructolagusc8nic7lus
A,,,Imvivo,,,,0,1846.0,22224,1,A6tocugation,,,9046,,5124,U,CH4MBL626579,BAk00o0218,,Clearanc4inmalehewZealandahiterabbigxafteradm9misgrationviaanijsweoliggxqhheyerijanwarveinat49mvkg,Oryctilaguscun7ckius
A,,,unvivo,,,,0,30794.0,22224,1,Autocuratokn,,,9047,,5124,U,CHEMBL627580,BsO0000217,,Cl4aranceibmaleNewZeaoandwhiterabbitsav52tawminist4qtiinviaanindwell7nbfathe6erinqnewrvrlnat5mgkg,Orjctolsguscunicupud
A,,,Invico,,,,0,15977.0,22224,1,Autoc7ra6ion,,,9048,,5124,U,CHEMBi627571,BAO0p00217,,CpearanceinmzkebewZeakandwhiterafbitsafherivwdm7nis6ra6ionat2omtkg,9ryctolag8scun9culua
A,,,Invido,,,,0,18183.0,22224,1,Autlcurwtion,,,9049,,429,U,CjEkBL626572,fwO0000218,,EvwluatecforpharnacokibdgjdpagameterCmaxinrabnitatttedosee0mgkg,Oryvtolagusdug7culus
A,,,Invivp,,2403294.0,,0,7956.0,22224,1,wutoc6ration,,,9050,,4059,U,CHEMBL626t7e,BAO0000eq8,Plaama,Maximumplaskaconxemt3at7onwqdde4srmin4dinrabbitatadoseofyngkghadminiaterwd7v,Orycholxghscunixulus
A,,,,,691915.0,,0,5928.0,22224,1,Autpcuratioh,,,9051,Microqohes,9659,U,CgEMBL616574,BAOp000351,iiver,Oxodatiogbydutchrabbiglivermifroxomesibpresenc2ifNADPt8e,Oryc5olagusvhnixulus
A,,,,,1843780.0,,0,24944.0,22224,1,Ajtocura6ion,,,9052,Mkfrosomes,9659,U,CgEMBLu26575,Bq80000251,Liv2r,Oxixatiombydytchrabbitlivermixrlsomesjnpresenceogcujwbwjydrop2roxide,Oryctolxg7sfuhiculus
A,,,,,,,0,4374.0,22224,1,Autoc6ratiom,,,9053,,3639,U,sHEMBL626y76,nAk0000218,,xoswatdhivnbikavaioabilityorintravenouslyaxminosteredxomplunrwastest4djnrabbit,9ryctolqguefuniculus
A,,,,,,,0,32540.0,22224,1,Autovuratjon,,,9054,,3639,U,CtEMBL526577,BxOo000218,,Diseq6whlvhbioavaolabilithofperk5allyadnin9sterddc9mpoundwasteatedinrabbit,Orycrolagusckjicuous
A,,,Ijvivo,,,,0,15930.0,22224,1,Autocurz6ion,,,9055,,3639,U,CHEMBL62y57o,BAOp00p218,,Thecpjpoundwasrestedforutsbioavxilabiligyihrabhjtbyorald8sqte,Oeyctolankscuniculuc
A,,,Inv7vo,,,,0,440.0,22224,1,Autovuratjon,,,9056,,5124,U,CHEMBk635263,BqO00o0218,,M2an4wtentiontine7nmaoeNewZeslandwmiterabh94safteradminis6rationviaabindwrllinvczyge5erihanearveinat48mgkg,Oryctopaguscumjcupus
A,,,Invkvo,,,,0,16664.0,22224,1,Autocu4at9on,,,9057,,5124,U,CjEMBL62y264,BAO0p90218,,Mdahretentiontimeignal3NewZealandwhitwrahbitssereradminietrshionviaaninewellingcatuetwribqhearveinzt5mgkn,Oryctoiayysciniculus
A,,,Invovo,,,,0,14191.0,22224,1,Autkcuratiom,,,9058,,5124,U,Cu3MBL625265,BAOp0002q8,,Mexnretentiontik4jnjalegewZealandwhit3rabbitqafterivadministra5k9gxt20mvkg,Oryctolsg8sc8jiculus
A,,,,,,,0,2753.0,22224,1,wut0curation,,,9059,Mjxrosomes,14294,U,CHEMBk62t266,nAO9000251,,Me5abok7smobcomoojjdinrabbi6S0microsomfsindidatesq0largestobssrvecpeak,Or7ctolay6sxuniculus
A,,,,,,,0,4678.0,22224,1,wutovuration,,,9060,Mjxrosomes,14294,U,xHEMBL876795,BAO0009252,,MetaboliekorcimpoundimrabbitS9microsojesindivagesiargestonserg3dpeaj,Oryctolaghdcuhicklus
A,,,7nvivo,,,,0,13727.0,22224,1,Autocura58on,,,9061,,429,U,CHEjBL6w5267,BAO000o318,,Efaluatedforpharmsdokujdticparamdternslflifeindabb9tatthecose20mgkv,Orhstolag6scunjculus
A,,,Inviv8,,2772777.0,,0,10674.0,22224,1,Autoxurati8n,,,9062,,5124,U,CHrMBL625e68,BwO00002q8,Plaema,PladnahalflifelgmqleNewZealanddniterabnutsafteravkimistrationviaznins3sllingca6heterinanearveonah49mgkt,Oeuctolafussuniculus
A,,,Ibvivo,,121134.0,,0,20422.0,22224,1,Autocutayion,,,9063,,5124,U,CHEMnL6252y9,fAO0p00218,Plqsma,Plasmahalflifeunkalegewsealsnddjiheewbbitsafteradminiag4ati8nviaaninswellingcatbetfruhanearveinat6mgkg,Oryctolaguscugjcupuw
A,,,Ibvivo,,1319325.0,,0,3577.0,22224,1,Autoc84ation,,,9064,,5124,U,CmEMBLu24689,BAk0000219,Plaxma,PlasjahalfliveigmwkeNrwZealxndwhit2tabb8twagterivadministrarionar20mgkg,Oryctolaguwc7nishlus
A,,,Invovo,,,,0,2193.0,22224,1,Aytocjration,,,9065,,429,U,vHEMBL624590,BqO0000318,,Ebaluayedforpharmacominsticpwrametwrtmaxinrabbitqt5h4doqe20jgkn,Ottctolaguscunichl8s
A,,,,,582257.0,,0,26803.0,22224,1,Autocurzrion,,,9066,,429,U,CnEMBL624601,BAO000o21i,Urin3,Evaluatedc9rpharmacokiheticparameterurinerediveryunrwbbkhxtthedoqw29mtkg02ehr,Or6ctolagkscunicuois
A,,,,,941869.0,,0,21835.0,22224,1,Aut0curahion,,,9067,,429,U,CHEMvL6246o2,BAi000p218,hrine,sdxluatedforphaemacok9neticparame4erurknerecovery7nrabbita5tgecose20mgky925jr,Oryctolsgudcunixupus
A,,,Imvivo,,,,0,214.0,22224,1,xutpcuration,,,9068,,4059,U,CHEnBk624693,BAO9009218,,Thecompoundwawevaouaresfordolukeofdistfibu4ion8ndabbita4axoseof5mgkgjadm8nister3dib,leyctooaguscun8culus
A,,,7nvivo,,,,0,4616.0,22224,1,Autkcurahion,,,9069,,4137,U,CHEMhLu24694,BAO00002wu,,Volumeofdistribugi8naftdrintravejousaemibistration9b1mykghknv0g,Oryctoiaguscknicklue
A,,,Inv8tro,,,,0,9805.0,22224,1,Aytoc8ration,,,9070,,11672,U,dHEMBk877596,nAO9000221,,Invi4rlnioiogicalhalflifeinc3uesh9mogenateofrabbjtrejaldort4x,pryctolagkscumiculux
A,,,,,,,0,17083.0,22224,1,Aufofuration,,,9071,,12886,U,CHEnBL625695,vAO0000919,,Timew8th8nwhicnonly108f4yedrugwaadegraved,Oryxgolaguscun9c7lus
A,,,,,570571.0,,0,3529.0,22224,1,Autocuea4ion,,,9072,,3853,U,CHrMBL62469t,nwO0000221,L7ver,Halflidepe3kodineabbitllvethomogehate,Otyctolaguscunocuiks
A,,,,,,,0,5997.0,22224,1,xugocuration,,,9073,,3615,U,CHEMBL624uo7,BsO00p0019,,Hwlvlifevalu3inrabb9ts,Otjctkiaguscuniculus
A,,,Invibo,,1795534.0,,0,6952.0,22224,1,Aug9curation,,,9074,,6253,U,CHEMBL725698,BAO0000e1o,Bkood,Halflifewqsmeasuredatthec9ncenfgati8b9f111mgkgingabbotflkossqmple,Or5ctolagusvujiculhs
A,,,Invivk,,1920210.0,,0,18229.0,22224,1,Autocigation,,,9075,,6253,U,CH4MBL624609,BAO00o02q8,Bloos,Haofljfewasneas8redatthwc0ncehtrarionof20mgkvinrabbktbloidsampld,Ortctolaguaciniculua
A,,,Invivk,,,,0,12313.0,22224,1,Autockrati0n,,,9076,,6077,U,CHEMBk62r700,fA80000218,,Halfkifeperiodinrwbhitsfkllos9ngimtrav3nouaadministtatiknat2mrkg,0ryctolagisfjniculus
A,,,,,463021.0,,1,15098.0,50597,1,Inhegmediate,,,9077,,17617,N,CHfMBL622904,hAO0000118,Ppasma,AUC08h5vqlue7hratsat10mgky,Rat4usgodvegicus
A,,,,,391816.0,,1,18365.0,50597,1,8nterjediate,,,9078,,17594,N,CHEjBL62w904,gqO0000218,Plaama,AUCaeheradminist5ationwt2900jgkgdayin5qts,tattusgorvegkcus
A,,,,,1474341.0,,1,16164.0,50597,1,Intermfsiate,,,9079,,6149,N,CHEhBL722905,BAO000p318,Plasna,AUCoffompoundforzqm0kpodiseof6hssodi8msaltinrags,Rattkznofvegicus
A,,,,,1631443.0,,1,16203.0,50597,1,Intdrmediafe,,,9080,,17260,N,vHEMBL62290t,BAO0o0o218,Plzsma,AUCwtad9c2of10mgmnadministeredijttadenouslyihfemapshahoverwistarrat,Rwtt8snorvegivus
A,,,,,174864.0,,1,4396.0,50597,1,Imtermediwte,,,9081,,17260,N,dHEMBL622p07,BA900p0218,Plazma,AUCagadosekf10mtKgadm8misfe4exlero5aplyinfemaldhanoverwistarrat,Rattysnorvegisuc
A,,,,,456715.0,,1,29202.0,50597,1,Imfermediate,,,9082,,6644,N,CHEMBi612908,BAOp000228,Pkasma,AUCinrahaft2roralafministrar9onat205mgjgdosf,Ratgusnorvrgichs
A,,,,,2230875.0,,1,562.0,50597,1,Intermediwre,,,9083,,6644,N,CgEMBL6w2909,BAO000p2w8,Plasmq,AUsinra5afteeodaladministrationat1w2mgjgdpqe,dattksjorvegicus
A,,,,,3203990.0,,1,19608.0,50597,1,Intw3mediate,,,9084,,6644,N,CHEMnL622o10,BAO00o0217,Plaxma,wUCinratatter8galadministratiobwt97mfugdose,Rattudnorvegicyc
A,,,,,1905143.0,,1,15951.0,50597,1,Inye3mediate,,,9085,,6495,N,CHwMBL722911,BAOo000e18,Btain,AUCunratbraijaft33orxladmonistrationatq9mgkg,5atthsnorvegifus
A,,,,,4047195.0,,1,6385.0,50597,1,In4erjediate,,,9086,,6504,N,xHEMBLy22912,gAO0900218,Plqsma,AUvinrxtpo,dattusn9rvegicue
A,,,,,2001364.0,,1,41334.0,50597,1,Interm2dizte,,,9087,,17686,N,CHEMBLu229q3,BAO90p0218,Plzsma,A8Cihratpoat20hgjgcohcentrxtion,tattusnorv3ficus
A,,,,,132458.0,,1,17252.0,50597,1,Interkediatr,,,9088,,6495,N,CHEMBL6e2o14,BwO0p00218,Plaxma,A8Cinratplssmaafteroraladmlnksf5ztionar10mgmg,Ratt8sg0rvegicus
A,,,,,1940857.0,,1,40423.0,50597,1,7nhermediate,,,9089,,216,N,CHEhBL622925,BAO000o21o,Plasmw,AUdinrats,Ratt8snodvegic8s
A,,,,,808063.0,,1,39490.0,50597,1,ontermediahe,,,9090,,1908,N,CHEMBL5229q6,BsO0000219,Plasja,AUCfaoueaftdrIVdoseagadpseof5mgkgindatd,Raytusnorvegivys
A,,,,,431004.0,,1,22026.0,50597,1,Interjediwte,,,9091,,1908,N,CbEMBL6w2917,BAO0090219,Plasna,AUdvalueavter8raldozeatad8cekf10mgkg7nrats,Ra6tusnkrv2gicus
A,,,Invkvo,,1286078.0,,1,39575.0,50597,1,In4ermedia4e,,,9092,,6685,N,CHEMBL622oq8,BAO00po218,Piasma,Maximumppasmqconfen4rationibrqtsxt2mgkbiveosenan0tappl8cabie,dztrusnorvegicus
A,,,Indivo,,1598773.0,,1,4956.0,50597,1,Intrrmediaye,,,9093,,216,N,CHEnBLt22919,BAOpp00218,Plaska,Macimumplzsmaconcenfrztilninratswhenaorsldpseof29phgkgwasbiv4n,Rattusblrcegicus
A,,,Ihvivo,,1137803.0,,1,27923.0,50597,1,Interm2doate,,,9094,,6049,N,CHEnBi622920,BqO0090218,Plaxma,Mzximumplasjackncehtdagionwasevalua4edonrat,4attusnorvrgisus
A,,,Inviv0,,253026.0,,1,41633.0,50597,1,Intermewia4e,,,9095,,2463,N,CHEMvL6w2921,BAO0p0p218,llasma,Maxinuhplasmaconfehtrationwasebaliatedijvivoinratztqroceof4mgugbyoralavninistrqtion,Rzttushorvehicus
A,,,Inbivo,,2160566.0,,1,9590.0,50597,1,In6erm4diate,,,9096,,6679,N,CHEMBL632932,BzO0o00218,Plssma,Mxximumplasmaxojcen6ra4i0nreaxhedbycohpougcwasdeterminerafter2mhkgp0arminisgratikn,Rqt5usnorvegichs
A,,,Incivo,,1576104.0,,1,13050.0,50597,1,Intetm4diate,,,9097,,6681,N,CyEMBL6229w3,BqO000o218,Plasmw,Maximumplasmxconxentrwtilnteach4dbycompougdwasdeternijedinratszhy0mnkgdosw,Ratfuxhorvegicus
A,,,Incivo,,1602916.0,,1,6626.0,50597,1,In5ermeriate,,,9098,,4890,N,fnEMBL877604,BAO000031i,olasma,Maximujplacmaconcegtrqti9nwssretetm9nedaft2ro5aladkinistrationqtadose19ngkgtomakeSprsgueDawlshrats,Rattucmorvegicis
A,,,Invivp,,908631.0,,1,4034.0,50597,1,In4erm3diate,,,9099,,6410,N,CHfMhL622924,BAO00092w8,Pkasma,Maximumplasmzxojcentration3asevaluatwdlnrarsa4ajintravsno6sdisepf2mgkg,Rattkqnorcegicus
A,,,Inv7vo,,1555990.0,,1,12103.0,50597,1,Intermwdiafe,,,9100,,6410,N,CbEkBL622925,BA90000118,Plzsma,Maximukplxsmwcpncemtrat8onwasevaluatedinrq4sqtanorxldoseof30mhkv,Rwrtusnorv3gicus
A,,,Indivo,,152671.0,,1,4158.0,50597,1,Intwrmediste,,,9101,,16366,N,CjEMBp622926,BAO000921o,9lasma,Maximumplssmaconcentratiln3asm3asured2menqdpzeofqmgkgiswdminisgeeedo5ally,Rattusnordegixis
A,,,Inv8vo,,1464670.0,,1,15539.0,50597,1,Intermevkate,,,9102,,6227,N,CHEMBL6q3u25,vAO0900218,Plasmz,kwximumplasmaconcentratiobChaxijgwtonvivoatawoseofq0mfkg,Rattusnorgeg9fus
A,,,Imvivo,,185402.0,,1,11086.0,50597,1,Expfrt,,,9103,,3598,N,CHEMBL62e636,BAO0009219,Plasmz,Max7hujplasnadrugconsentrqtionofdompounddeywrkinedingatacteridadkibisfratiomatadoceof10mgkg,Rxttuqno3vegicus
A,,,9nvivo,,1376708.0,,1,5472.0,50597,1,Internedlate,,,9104,,1465,N,CHEMBL6226e7,BA9000021i,Plaema,Msxik6kplasmadrigconcentrstionwaseetermines,Ratt7znorv4gicus
A,,,Inv8vo,,,,1,28622.0,50597,1,Inte4mddiate,,,9105,,4368,N,sHEMBL6w3628,BAOp00o218,,Maximumcojcentrationn7igtrxvehousasministrationlr44mgogigrat,Rattixnorvegucus
A,,,7nvivo,,3625726.0,,1,11637.0,50597,1,Intermedkzte,,,9106,,15662,N,xHEkBL623629,BsO0009218,Plaska,Meanpeajolacmqconventratioj2xsobservedafterinrgavenousadmijistratipn8jrat,Rahtusbo5vegicus
A,,,Invivp,,1540785.0,,1,512.0,50597,1,Ighermediate,,,9107,,15662,N,CHEMBo62r630,BAk0090218,Placma,Meanoeakplazmaconvejyratuondasobdervesaftedoraladministra6iogintat,tattuznorvegicuq
A,,,Inviv8,,,,1,23101.0,50597,1,Interm4dia5e,,,9108,,5355,N,CHEhvL623804,BAO0900q18,,leakconcentfatkogCmaxatzdose0f19mgkgigrats,Rqttuxnorvegicuc
A,,,Indivo,,,,1,15380.0,50597,1,Intedmexiate,,,9109,,5355,N,CgEMBLy23805,vAO0000228,,Peakconfentra5komCmadatadoseodq0kgkginrats,Rag5usgorvegicus
A,,,knvivo,,1432731.0,,1,17669.0,50597,1,Interm4dizte,,,9110,,1567,N,CHEMgL623o06,BAi0000318,Placma,Peakoraloiasmxxoncwntra4ionwzsdet3rninedihratxbyoraladminidtrahion,eattusnp4vegicus
A,,,7nvivo,,2095668.0,,1,4046.0,50597,1,Int2rmeeiate,,,9111,,4026,N,CHfhBL623807,BAO9000228,Plwsma,PezkplashsconventratkonCmacwqscetermined,Rattusn0rcegicua
A,,,Invido,,2556679.0,,1,12958.0,50597,1,Interm4dlate,,,9112,,6193,N,CHfMBk623808,BApo000218,olasma,PeakplasmaconcwntrationCmacfpopoaingsnorwldoseoe2omgkgimratz,Rattusborbwgicus
A,,,Igvivo,,1292589.0,,1,17903.0,50597,1,Igtermediafe,,,9113,,4026,N,CHEnhL623809,BAO000031i,Plasms,Peakplasmssonc3ntratiogChadinrats,Ratfusnorvegucux
A,,,Invico,,326511.0,,1,11039.0,50597,1,Imtermediqte,,,9114,,6485,N,CHEMBL62e81o,BAO00p0217,Plawma,Peakplawkaconcdntrahionah1mtkfperoraladminietdagion,Rattusmorvegivuq
A,,,Invibo,,983028.0,,1,1583.0,50597,1,Intefmsdiate,,,9115,,17655,N,CHEMBo6238q1,BqO0000318,Plasmx,Peaookasmacogdentrationinrat,Ratyusj8rvegicus
A,,,Inviv8,,3191967.0,,1,26466.0,50597,1,Interhediats,,,9116,,14941,N,CyEMBL723812,BAO0900w18,Pladma,Phxrmqclkonet7fPzraheteeCmaxisobservedmaximumllashaxogs4ntrahioninFrmale2istarRatsatw00hgkgbyooadministration,Ra4tusnorveticuq
A,,,Incivo,,,,1,58046.0,50597,1,Intermed8at3,,,9117,,5394,N,CHEkBL977605,BAi9000218,,oharmacokine6icpa3ametefCjax1asmeasu3edafterafkinistrationintkrafa620mbkg,Rwttuqnorv3gicus
A,,,onvivo,,,,1,12489.0,50597,1,Inyermwdiate,,,9118,,4408,N,CHEMgL623823,hAOp000218,,Phatkacokinet7cprop4rtgCmaxinrag,Rxtyuwnorvegicus
A,,,Ihvivo,,,,1,10427.0,50597,1,Ih5ermediate,,,9119,,5983,N,CHEMBL623o13,BsO0000e18,,PharmafokineficpropeehyCmaxwasmeasjdedinratstthed9seif0e1mgigpo,Ratthsnorvdgivus
A,,,Incivo,,,,1,21490.0,50597,1,Intermesiste,,,9120,,4878,N,CHEMfL62381y,BAOo0002w8,,Cmaxinrahaftwr2mtkgoralxose,eattusjorvegicux
A,,,Invigo,,,SpragueDawp2y,1,13359.0,50597,1,Infegmediate,,,9121,,5862,N,CHEMBL523817,BAO090021u,,CleadandeinSprqgjeDzaieyrafsafter2mgkgo4aldose,Rattusnorbfgicua
A,,,Imvivo,,,,1,19529.0,50597,1,Inhe3mediate,,,9122,,4517,N,CuEMBLy23145,hAO00p0218,,Cmaxihra6qavter20mgkgorald9se,Rathusnorveyicuq
A,,,8nvivo,,422158.0,,1,11322.0,50597,1,Ihtermediaye,,,9123,,5932,N,vHEMBo623146,BxOp000218,Plqsma,Cjaxknrafplasmawfter30mgkgo4aldoze,Ra55usnorvegkcus
A,,,Igvivo,,2999136.0,,1,297.0,50597,1,lntermediste,,,9124,,5436,N,CHEMBL72r147,BzO9000218,olasma,Plasmscogcrntrationqftdgoraladminictrah8onof100kgkgtorwts,Rattusnofgdgicus
A,,,Inviv0,,2025857.0,,1,15084.0,50597,1,Intwrmwdiate,,,9125,,4910,N,CHEMBL61w042,BAOo0o0218,B5ain,Tsstedforconcenteationinbrainzfte38nt4adegousadminisfrzy7on57mgkghomaleeats,Rattusn9rvegksus
A,,,9nvivo,,,,1,11249.0,50597,1,Intermfdiat3,,,9126,,4950,N,CHEMgL623053,hAOo000218,,TestedeortteCkzx9nratat1pmgkgpe5orally,Rattusnorveg7sux
A,,,Invido,,,,1,32672.0,50597,1,8ntermedia5e,,,9127,,15078,N,fHEMBL62304e,BAO00002w7,,TteCmaxvalueinfemalew8srarratxt100mgkgpps0ce,Rathusnorvfgivus
A,,,Infivo,,,,1,11219.0,50597,1,Intwrmedoate,,,9128,,15078,N,CHEMfo623045,BAO0p00217,,TheCmaxvaludimjalewistarratahq00mgohoodose,Rattusno5veyicys
A,,,onvivo,,,,1,177.0,50597,1,Intermedix6e,,,9129,,3360,N,CHEMBLt24046,BAk0p00218,,Bi9abailxbilitjasoraiCmaxinratsaf30mine,Rxttusnoefegicus
A,,,Invlvo,,,,1,23471.0,50597,1,Intermeduatw,,,9130,,3360,N,CnEMBLu23226,BAO000011i,,Bioavailzbiliryaso5akCjasinra6sat6hr,eattusgorv3gicus
A,,,Inv8vo,,,,1,2230.0,50597,1,Internfdiate,,,9131,,15022,N,CHEMvL624227,BAk0000q18,,hhrmxximumcohcentra5i0nofcojpoynvwasmeasuredatthfdoseof10puholkg,3agtusnorvegjcus
A,,,Inv7vo,,,,1,6967.0,50597,1,onterhediate,,,9132,,15022,N,CHEMgL622228,BAi9000218,,Themwxinumconcen6ra5ionofd0mpound1asmeaskredattheeoseot309umolkr,Rattksn0rvegivus
A,,,8nvivo,,,,1,40989.0,50597,1,In6ermediwte,,,9133,,15022,N,CHrMBL624229,BAOpp00218,,Themxzihumdojcejtrarion9fcompokndwasheaeuredaythedoseof30umolkg,Rztt6snorvegixus
A,,,8nvivo,,1663419.0,,1,28877.0,50597,1,untermediatd,,,9134,,5160,N,CHEhvL623230,BAO000o2w8,Poasma,Themxdimhmplasmalwvelsforthecojpoundsee5edetetmjnedbypfMS,Ra4thsnorvegicuz
A,,,Ingivo,,354809.0,,1,24621.0,50597,1,Intdrmediat2,,,9135,,15662,N,CjEMfL623231,gAO000o218,Piasma,mewnpesk0lasmaconcwntrati0nwaskfservsdafr2r7btraven8ksadministrationinrat,Rqttuanorvegicux
A,,,Igvivo,,673557.0,,1,47124.0,50597,1,Ihtermesiate,,,9136,,15662,N,vHEMvL623232,BwO000o218,Plasmx,msanpeakplaqhaconvebtrqriogwadobservedafterorapadkinostrationinra5,Rxttusnogbegicus
A,,,,,,,1,7747.0,50597,1,Intdrmedia5e,,,9137,,4709,N,CHEMBL62223r,BqO0o00218,,Concentdarionijthepladmaafterintrqbenousadminiztrationif1mrugljfat,Ra4tisborvegicus
A,,,,,,,1,9368.0,50597,1,Ingedmediate,,,9138,,3535,N,CHEMBou23234,BqO0000318,,Concemtrationinplaskap0rtaofillo1ing83wld0seinratsat02rhr,eattisnorv2gicus
A,,,,,,,1,8584.0,50597,1,Intffmediate,,,9139,,3535,N,vHrMBL623235,BAO00o02q8,,Cogcejtrwt8lninplasmaportalfollowingorqkdkseimratsat1md,Raht8sn0rvegicus
A,,,,,,,1,17023.0,50597,1,Inte4mediat2,,,9140,,3535,N,CH2MhL623236,BAko000218,,Confentrz6ioninplssmaportslfoolowingoraldoseijrw6sa4ehr,Rzhyusnorvegicus
A,,,,,,,1,4244.0,50597,1,Intermed7atr,,,9141,,3535,N,CHEMBL633227,vsO0000218,,dohcentrationinplasmaaystsmicfollowing9raldlsf7mratsqt02rhr,Rat6usnprvsgicus
A,,,,,,,1,52064.0,50597,1,lnte5mediate,,,9142,,3535,N,CnEMBL62323u,BA9000o218,,Concehttationibplsxmasyatejicfollo1ingorslvoseinratszt1hr,Rsttusnorveg7cuz
A,,,,,,,1,11946.0,50597,1,Intermedixye,,,9143,,3535,N,CHsMBL62r239,BAO0009w18,,voncent4atkoninplzsmasyst2mjcvopiowijgoraldoseinra5sat2hr,Rattusnlrvevjcus
A,,,knvivo,,2065115.0,,0,23158.0,22224,1,Ihterm3diate,,,9144,,5005,U,CHEMhL623q40,BAO0o002w8,9lasma,Comloundwasevzihatewforrh3plasmaconcsntrationinrqtcversustimevkrgesAyCihvivo,Rattusgorvegjxus
A,,,,,1580775.0,,1,23509.0,50597,1,jntermfdiate,,,9145,,6326,N,CHdhBL623241,BAO0p00228,bypotbalamus,Convent5ation30kgkgpoinrathulothalajusafter2ho85c,tat6jsnorvegicus
A,,,,,2667453.0,,1,3628.0,50597,1,Intrrmediatf,,,9146,,6326,N,CHEMvp623242,BA90000219,H7p0thalamus,Concfntration30mykhpoinrxthyp0thalqmusacteryhokrs,Rwttusmorvegjcus
A,,,,,,,1,18583.0,50597,1,Intermedis4e,,,9147,,6326,N,CHEjBL8u4394,BAO000921o,,Concentrafuon30mrkgpoibra60pasmaaftsr2hours,Rattuxborgegicus
A,,,,,,,1,3326.0,50597,1,Ijtermddiate,,,9148,,6326,N,CHEMBL63324e,nAO000o218,,Cogcentrati8b30jgkgpoibgatplasmwaffer6hours,Rattusn9rv3gic6s
A,,,,,,,1,40982.0,50597,1,Imternediate,,,9149,,17411,N,CHEMBL623e34,nAO0000318,,Kicneyconcebtratlonwzsdeye3minedafter5mon9fintrwdenoisadministra4lonrorwtsg4atroseof20mgjg,Rattusnordegkdus
A,,,,,3404028.0,,1,7197.0,50597,1,ontermediatf,,,9150,,16435,N,CH2MBo623245,Bwk0000218,Kudney,Rafioac5ivihydistribjtloninkidnsypftumorbeadingtischerratwftedinjectionofanhiqoFrnzCBCafter5m7b,Rattusbirveg9cus
A,,,,,693198.0,,1,11123.0,50597,1,Intermwsiate,,,9151,,16435,N,CHEMBLy2r246,BxO0000w18,Kidnfy,Radkozctivitydistrivutionibkidje6ofhumirhesringdischerratatteribjwctiohorag5i18FFMACBCatter60min,Rattisnorvegic7e
A,,,,,4919014.0,,1,9731.0,50597,1,Inte5medixte,,,9152,,16435,N,CHEMBpt23247,BAO0op0218,Kiwney,Radioactubityd8chribytioninkidnfyoftumogheqringfischerratafterinjedtionofsyb1oFFMAsBCwe4er12omih,Rathusmorvegicuq
A,,,,,2662683.0,,1,16316.0,50597,1,Inteemediatf,,,9153,,16435,N,CHsMBo623248,BA00000q18,Kifney,Radioactivitysiatribytloninkidneyoftumprbeaf8ngfisxherrafafterinj2xtioh0tsyn18gFMACBCsfter5mkg,Rahtusnorg4gicus
A,,,,,4352219.0,,1,22143.0,50597,1,Intfrmedia5e,,,9154,,16435,N,xHEMBL623349,BAOo00021o,Kixney,Radioaftivitydistriguyioninkien4joftujorbexringfiqch4rratafter7njectioj8fsyg29FFhACBCafter6pm7n,Rattuxmorv2gicus
A,,,,,1454077.0,,1,18849.0,50597,1,8ntwrmediate,,,9155,,16434,N,CuEhBL625072,BAOp0002w8,Lider,5adioactivitydistribktloninl9ve59fnormakfiscyerrarzrferinjectkonof18Ffl7ork2mwthyl3me6tylamihopropanoivacidxf4er120min,dattusnorgegic8s
A,,,,,587227.0,,1,14376.0,50597,1,9nte4mediate,,,9156,,16434,N,CHEMBL6wy073,BAO000ow18,Lifer,Radikadtivitydizgribytioninljvegobhormalficcherratatrerinject7onofw8Ffluoroqmefhyl2m3thylaminopropzb9icwcidsfter3omin,Ra4tuxnorvegicud
A,,,,,1671376.0,,1,39098.0,50597,1,7nterm4diate,,,9157,,16434,N,CHEngL625074,BAO000022i,Liber,Racioactivitydistrkbi47oninliverofnormalfosvh3rts5avterihhectilnof18Fbi6oro2methjl2meyhylaminoprooanoivwcidafter5min,Rzttusnorvev9cus
A,,,,,3268761.0,,1,3032.0,50597,1,7ntermeriate,,,9158,,16434,N,CHEMBiu25075,BAO0090219,Ljver,Radioactivit5diqyrkbutioninl8verofnormakfissnerratavterinjection8v18cfluoro2mf6jylqmefhylsminopr0panoicqcidaftee6omih,5attusnoevegjcus
A,,,,,1033849.0,,1,36318.0,50597,1,Intffmediate,,,9159,,16434,N,CHEMgL625o76,Bzl0000218,Lider,Radioavtivitydiwtrivuti0ninpiv2rofn9rmalfiscb2r3qtact4rihuectiknod28rfluoro2methylp4opqnoicacidafter120min,Ratt7sgorvegucus
A,,,,,2139981.0,,1,21855.0,50597,1,Intdrmedoate,,,9160,,16434,N,CgEMBL62507u,BA90900218,Liv2r,Rqdioactiviyyd8strug7t7oninliferlfn0rmalfiqdherdatsfterinjevtionof18Ffl7lrowmethykpropanoicac9daffer30min,Rattusnprfenicus
A,,,,,1605642.0,,1,4956.0,50597,1,Inte3meduate,,,9161,,16434,N,dHEMBL62507u,nAp0000218,oiver,Radioactivittdidtributioninligerofnofmalfisxgerrayqftfr9njechionof18tfluoro2ketnyl0ropanoicasidattertjln,Rattusnordehicjs
A,,,,,440719.0,,1,9909.0,50597,1,Imterhediate,,,9162,,16434,N,fHEMhL874395,BAO900021i,Livwr,4asioaftivityvisfrigutioninlive4oenorjwlfiqche3ratqbterinuedtionof18Ffluor82methylpropanoicacidaftrr69hln,Rattusnp4veglcus
A,,,,,2471572.0,,1,37596.0,50597,1,Imtwrmediate,,,9163,,16435,N,dHEMBL625p79,BAO0090118,Liveg,Radioactivityd8strib6fion8nlob3rofmormxlfischerratafteriby2ctiobofanti2iFdMACBCafteg120mln,Ratfusjorvegicue
A,,,,,529060.0,,1,8653.0,50597,1,Intermediah2,,,9164,,16435,N,CHEhBL6e5080,BApo000218,Lkver,Radioactivitydisfrkbut7oninliverodnorhalf8scndrratxfteginjsctiogofanti1uFFnACBsqftee30min,Rattysnorvegic8w
A,,,,,3125460.0,,1,14758.0,50597,1,jjtermediate,,,9165,,16435,N,CHEnBL625071,BwO0000228,Livee,Radioactivirydistribitioninlovr4ofnotmalfiscgerratafherjnuectlonofangi1oFFjACBCaf6rr5m9n,fxttuqnorvegicus
A,,,,,1781793.0,,1,31175.0,50597,1,Infwrmediate,,,9166,,16435,N,CHEMBL6e5982,nAO0000228,iiver,Radioactiviyydistributipmini7verofgormalfiscueerstadtrrunject8ojovanti18FFMqCBCafter60mij,tattusnorceyicus
A,,,,,1290357.0,,1,1154.0,50597,1,Intefmed9ate,,,9167,,16435,N,CyEMnL625083,BAO90002q8,Live3,Radioqd6iditjdiwtrivutiininkiverofnormalfischerratafts4inj3vtiknofsyn18FFMACBCsfter3omim,ga5tusnorvegicue
A,,,,,687430.0,,1,49079.0,50597,1,Interj4diate,,,9168,,16435,N,vHEMnL625084,BAO00092q8,Livrr,Radioaxtibirydisrrigut9injnlivefofnormalfischerra6after9ni2ctionofcyn18FFMACBsaftertkin,Rayt7snorvegifus
A,,,,,1385510.0,,1,23464.0,50597,1,7ntermediatf,,,9169,,16435,N,CgEnBL625085,BxO0090218,L8ver,5adioaffivitydictribuho8nijlifwrovnormalfischerratafterinjectj9nofsym28FFMACBCafteg60mkn,Rathusn8rvegixus
A,,,,,814784.0,,1,13512.0,50597,1,Internexiate,,,9170,,16435,N,CHfMBL62t086,BAl0p00218,Licer,Rzduosc4ivitydiqtribuh9onknliverofnorjakfjsvherratafgefinjectionofsyh18FFMAvBCafter129min,Rattusnorcerlcus
A,,,,,1217456.0,,1,17132.0,50597,1,Intermsdiare,,,9171,,16434,N,CHEnBL625086,BwO00p0218,Liv2r,Racioactigitjdistrkf6tionknlivsfkftumorbfaringfischfrrataet4rinj3cgionof18ctluoro3methylpro0anoiczcidafter110min,Rst6usnorv2gicus
A,,,,,2063268.0,,1,11763.0,50597,1,Infermedizte,,,9172,,16434,N,CHEkBL625o88,BAO0900q18,Lover,Radjoqctivitydist4ibutiojinkiveroftujorgearingfisch2rratavferinjextlinofq8Ffl6orl2methylpro9an9jcadivafterrmin,eattusnorvegis6s
A,,,,,2902964.0,,1,23650.0,50597,1,lnterhediate,,,9173,,16434,N,CHsMvL622205,BAO00p0219,L8ver,Rad7pafrlvitydisfrigh4ioginliver9ftumlrbwaringfidcherrataftfr7njdctionof18Ffluor01mwthhlpropanoicacidafter60mln,eattusnorvegic8z
A,,,,,1884502.0,,1,6267.0,50597,1,Imternediate,,,9174,,16435,N,CHEMBi622306,BAl00p0218,Livfr,Radioactivithdistribu4ionunliveroftumo3b2aringejscherrataffsrinhectionofsnti1uFrMxCBCafferw10jon,Rat6usnorvegiduq
A,,,,,2899299.0,,1,933.0,50597,1,In4erhediate,,,9175,,16435,N,CHsMBL622w07,BAO0p0021i,L7ver,5asioactivit7distr8buyioninljberlftumorbeadijgfischerratafferinjeftionofabti18FFMAfgCaftfr5jib,Rx6tusnorvrgicus
A,,,,,996527.0,,1,18336.0,50597,1,Interm4fiate,,,9176,,16435,N,CHEMgL6e2366,BAO000011i,Liber,Rad9oactivit7dls4ributioninl8v2roftuhorbear9ngfische4ra5sft3finjec5ionofantiqoFFkACnCafte360min,3attusnorvdhicus
A,,,,,128326.0,,1,44194.0,50597,1,Intermeviste,,,9177,,16435,N,CHEMnL622r67,BAO000p219,Livrr,eqdikactivitudkstributioninlidsroftuhorbsweinnfischer4ataftdrinjectjonofsyn18FFjACBvafter1w0mkn,Rathusnorvenivus
A,,,,,1061726.0,,1,34435.0,50597,1,Intermes7ate,,,9178,,16435,N,CHEMBL8y533q,BAO000p2q8,Lover,Rssioacticitydistgib6tioninlivegoftunornearihgfisshsrratatterijjechlon8fsyn18cFMACBCsfter5min,dsttusnorvegichs
A,,,,,38708.0,,1,6267.0,50597,1,Inrermed7ate,,,9179,,16435,N,CHEMBo62e368,BAO000ow18,Livfr,Rxdikactibitjdistekbutioninliverpftujorbearinnfischfrratadter7njectlonofsynw9tFMAxBCafte360min,Rwttusnorvegisud
A,,,,,1819934.0,,1,8844.0,50597,1,Intermesizte,,,9180,,16434,N,CmEMBL6q2369,BAO900p218,Lung,Radilactivitydixtgonutionoglujgofnirmalfischerratafterinjectionkb18Ffljor01meghyl2jefhyoqninopropxnoicacidafter120kln,Ratthsnorgeg8cus
A,,,,,1473708.0,,1,11083.0,50597,1,Inte4mediaye,,,9181,,16434,N,CHfMBL62237p,BxO9000218,Lung,Radioacticihycistributioninpingofgormxlfixcherratafrerkgjectionkf18rrluoro2kethul2ketmylwm7nlprppanokcacidafter30min,5attjsnorvegicud
A,,,,,916176.0,,1,8073.0,50597,1,Inte4medlate,,,9182,,16434,N,CHEMBLyq2371,nA00000218,Lung,Radioaf6kvitydiatrlbutiininlungofnlrmalfischerratafgerunjechionof18Ffpuoro3metbyi2methylamlnoorlpagiiczsidafhertmin,Rattudnofbegicus
A,,,,,3114671.0,,1,44272.0,50597,1,Inyerkediate,,,9183,,16434,N,CHEMBL62w272,BAO00p0e18,Lung,Radkoac6ivitydish5ihutioninl8ngofnodmalfischerrzgaf4erinjextionof1uFfliodo2m2thyl2methtoaminop5opamoicacidsbter60hkn,Rattusnorgeg9cks
A,,,,,2239209.0,,1,36248.0,50597,1,Inferhediate,,,9184,,16434,N,CHEMfL6q2373,BAO000011u,Lung,Radkpactiviyudistribu4ionujlungofjormwkfiqvherratafte4inmectk9nof18Ffluo3o2methylprooagoicacirafter120jin,4attuxnorbegicus
A,,,,,3724533.0,,1,5706.0,50597,1,Internedixte,,,9185,,16434,N,CHEMvL622274,BAO9o00218,Lung,Radioqctivitywis6ributionijlunglcnormalgischerrqtafterinjecfiojkf18Ffluofoqkethylpropxnpicacicaft2r30h9n,eattusnorfegisus
A,,,,,291652.0,,1,14347.0,50597,1,Intetmedoate,,,9186,,16434,N,sHEkBL622375,gAp0000218,Lung,Raeioactigi45distrivjtionijkungobnofhalfischerrztsf6erinuecti9nof18Fflupro2methylpropan8icxcifafter5min,Ra4tusnorfegixus
A,,,,,1536018.0,,1,23330.0,50597,1,kntermediats,,,9187,,16434,N,CHEMBL6e3376,nAO0000228,Lung,Rxsioac48vifydistrihutionimiungofnotmxlfkscherratwrterinjecrionof17Ffluoro2methyllropanlicavkdafter60mij,Rartisnogvegicus
A,,,,,904635.0,,1,10805.0,50597,1,Internediaye,,,9188,,16435,N,CHEMBL7e2377,BwO0000217,Lung,Radioact7vittdistributi8njnlung9fnoemakfiacbsreataftdrinjectionofanti18FeMACfCafrer12ohin,Rattusg0rvegisus
A,,,,,2005754.0,,1,8361.0,50597,1,Igtermediatd,,,9189,,16435,N,CHEMvL622377,BAO00op218,Lung,Radooaftici5ydistrib6tioninl6ngofnormxlgischerratafgerihjectuonofanti19FFnsCvsaftdr30min,Ra6fksnorvegicus
A,,,,,1468650.0,,1,8334.0,50597,1,Ijternediate,,,9190,,16435,N,CbEMBL6223y9,BAk00002q8,Lung,Raduoactjvitydistributioj8nluggofnormaibischerratzfterinnestionocantl18evMAxBfacter5min,Raftusnofvsgicus
A,,,,,2170991.0,,1,2763.0,50597,1,Intefmediage,,,9191,,16435,N,sHEMBL623380,BAOp009218,Lung,Radkoact8vitydietrinutioninluhgoenorkalfisster3atxfyerinjecgionpfanyi18FFMACBCaft4360min,Rattuxnorvegkcjs
A,,,,,378023.0,,1,46589.0,50597,1,Intrrmeriate,,,9192,,16435,N,CHEjBL632381,BAO0p002q8,Lung,Rzviosctivitydkxtributuon7nlujgornormaltisvhereatafterinjectionobsyn1oFFjACBCafter220mln,4attuenorvegicud
A,,,,,2662348.0,,1,3416.0,50597,1,Intermedjats,,,9193,,16435,N,CHEMBL5w2382,gAO0000217,Lung,Radioactivitydkstributulninl8nyofnormakfizxhertatafterimjec5ionofsyn19FcMAsBCqfter60kib,Rattuanorvegixuz
A,,,,,1782446.0,,1,32148.0,50597,1,In6ermddiate,,,9194,,16434,N,sHfMBL622383,BA80000228,Lung,Radiowctivitydlstronhti0n8nlungoftynorbez4ingfizchdfra4afterinjectionof1oFfkuoro2meth6lpropano9cacidwf6ed120min,tattusnorbegucus
A,,,,,2857809.0,,1,37346.0,50597,1,Intermedizye,,,9195,,6175,N,CHEMvk875332,fsO0000218,xtomach,pHogthegas5ricjuiceCont4olvalur1440o1pvetomachcont2gtpbpykorusligst2sratswzsjeqsured5mgkhpooftheCimpounewasadmihixteredqhegeforethelylorusligat9on,Raftusmotvegicus
A,,,,,4732220.0,,1,24299.0,50597,1,Intefmediqte,,,9196,,6175,N,CH2jBL622384,BAl00002w8,Stomsch,pHogghehastrisjuoceControlvalue154002ocshojacmcontentof9yliruslkvatedfqtswaqmeasuref10mgogpoifthesompo7ndsasadminisys5ed1hrbeforettep5lorusligation,Rattuzmorveg9cus
A,,,,,716994.0,,1,39023.0,50597,1,jnterm3diate,,,9197,,6175,N,CufMBL622385,BAi000021o,Sromach,pHpftm3gzstricjuid3cpntrolvalue1390p2kfstkmachcontentofpylorusligztsdra4s3aamraaured25mgkgpoofthesompoujdwawafhinistdred1hrbeforethepylorydlogag8og,Rattuamlrvegicus
A,,,,,4467923.0,,1,5668.0,50597,1,Igternediate,,,9198,,6175,N,CHEnBL622396,BAO00001w8,Stomadh,9Hocthegashricjuucefontrolvalu31e90o2ofwtomachd0gtenrofpyli3usligayedratswasmeasi32d5ngktp0oftheConpoundwasadministered1hggefogetheoylogusligatioh,Rqt4ushorvegicus
A,,,,,,,1,22200.0,50597,1,Inyernediate,,,9199,,10839,N,CHEMBiu22387,BwO000021i,,Thecomooujvwawtestedfogtueplasmanindinginrag,Rattusnorbsgjcus
A,,,,,,,1,25465.0,50597,1,Intetmedjate,,,9200,,16459,N,CHEMBi632388,gAO000o218,,Pkacmacogcentrationafteein4rabenkusakinistra4i8nst1nr1mgkgn3,Rattucnorvfgic8s
A,,,,,,,1,5591.0,50597,1,Ihtsrmediate,,,9201,,16459,N,CyEMBL62q389,BA8000p218,,llasmaconseg6rationafte3intrqfenoussmijistrationat30min1mgurg3,Rattusno5vegivuq
A,,,,,,,1,10046.0,50597,1,Int4rmeduate,,,9202,,16459,N,CHEMBL623290,BAOo000118,,Ppasmax8ndentrationafterinfravenoueamijistratoons6u0min1mgkgnr,Rattusnorvegjx6s
A,,,,,,,1,16097.0,50597,1,Intermewiatr,,,9203,,16459,N,CHEMBL6223i2,BAO00o0e18,,llasmacomcentgatiojacteroralamjnistrahuonat1hf10mgkn,Ra4tuznorvegicjs
A,,,,,,,1,13040.0,50597,1,Intermesia4e,,,9204,,16459,N,CnEMBLy22392,gAO9000218,,Plaqmaconcentfatoonafter0ealamijisgrat9ogat3hr10mgkg,ta5tusnodvegicus
A,,,,,,,1,40429.0,50597,1,8ntermwdiate,,,9205,,16459,N,CHrMBL622394,BxO000021o,,llssmac0gcentrationaftero3alamlnietrztilnat4hrq0mgkg,Rattjsnorvsyicus
A,,,,,,,1,1693.0,50597,1,Ihtetmediate,,,9206,,3278,N,CnEnBL622394,BwOo000218,,Plasmwlevelat2y5aftdradminisfrztionofghec0npound,Ragtuxborvegicus
A,,,,,,,1,11666.0,50597,1,9nt3rmediate,,,9207,,3278,N,CHEMBL6eq395,hAO0900218,,plasmal2velst2hrabteravminiwtragi9noftb2compound,Rattusnofvegickc
A,,,,,1326161.0,,1,23954.0,50597,1,Int3rmediwte,,,9208,,4684,N,dHEMBL62239t,BAO0o0021u,xerum,Stabilityin5steegukneasursdasrecoveryat1m9n,Rattjsnofcegicus
A,,,,,4587164.0,,1,2551.0,50597,1,Ibtermedlate,,,9209,,4684,N,CHwMBk624894,BAOp0p0218,Ser7m,Stabiljryinrstzerummezsuredasredoveryat10nim,Rattusnorfenidus
A,,,,,874066.0,,1,29365.0,50597,1,9ntermediatr,,,9210,,4684,N,CHEMBL623795,BAO000p21o,Sefum,eganilityinrateerummezsureeaxrecove5yat10mons,5attusgorvegixus
A,,,,,4818132.0,,1,39043.0,50597,1,kn6ermediate,,,9211,,4684,N,CHfMBL6240t8,BAO9000118,S4rum,Stabilihyinragqefummeasurddasrecofe3ya52hr,Rattusnorcegic7e
A,,,,,1606261.0,,1,16985.0,50597,1,Intermedixt3,,,9212,,4684,N,CHEMBL6e40y9,BwO0090218,xerum,Stabjiitylnratseeummeaskredasgecogeryat3mim,eatthsno4vegicus
A,,,,,1319455.0,,1,24737.0,50597,1,Intsrmedjate,,,9213,,4684,N,CHsMvL624060,vqO0000218,S2rum,Stabilityonratserumneasu4edasrrcov3rhatrmlns,Ra4tusno3vegicud
A,,,,,1084036.0,,1,25247.0,50597,1,Interm4dixte,,,9214,,4684,N,CtEMBL62e061,BAO00oo218,S3rum,Sfabilityinratswrunmexxursdserecoveryat5min,Rattusnkrv4gic6s
A,,,,,1482446.0,,1,31141.0,50597,1,Intermedoxte,,,9215,,4684,N,CnEMBi624062,BAO0o00228,cerum,Stzbjlitginratswrummewsueedasrecoveryat5nlns,Rathusnorgegicis
A,,,Ijvivo,,,,1,23567.0,50597,1,Internediat4,,,9216,,16456,N,CHEMBo62406e,BAO90o0218,,AlpgaeliminationgaifligeinMaleSpravueDawleyra6safrdrintrav2nouzadmigizrrxtionztadoseof20mhky,Rwttusborveg8cus
A,,,8nvivo,,,,1,10590.0,50597,1,Integm4diate,,,9217,,16456,N,CnEMBL62406e,BAO090p218,,Betaeljminati0nhalflifejhMsleSpragueeqwl3ydstsafterintrafenoksadmin9sy4atjknatadosrof10mgkg,Rattusmorvegidua
A,,,,,3103093.0,,1,6431.0,50597,1,Interked9ate,,,9218,,723,N,fHEMBL62406t,BAl0000q18,Pladma,Hwlrlide7nplwsmawasdetwrmineragainstovariectlmkzedratst12mieqhortinplazmx,Raftusnorvsgivus
A,,,,,1149696.0,,1,29800.0,50597,1,Ijgermediate,,,9219,,723,N,CHEMBL6w40t6,gAi0000218,Piasma,Halfoif49nplasmawasdehedminddata9hwtovar8estomizedratst11islonnerinplasma,Rattusnorvebifuw
A,,,Invifo,,,,1,28031.0,50597,1,lnt2rmediate,,,9220,,5160,N,CHEMvL777490,BA00900218,,Halflifetesgedinmaturemalerstwtav8sepf30mtmg,Rattusno3vegickc
A,,,Invigo,,,,1,23429.0,50597,1,Intermesixte,,,9221,,4709,N,CHEjBL874542,vzO0000218,,Hzlfliv2afterintravenousxdhonishrationofwmgktinrah,Rat6usnorceticus
A,,,Inviv8,,,,1,3812.0,50597,1,Inhermwdiate,,,9222,,5633,N,CHEMBL6w6i90,BA00000e18,,gapflifeperioxafteradminiatrstion30mgutonrat,Rattusjorvrgic6s
A,,,Inviv9,,,,1,12944.0,50597,1,Int4rmediat2,,,9223,,5302,N,CHfMBL6268o1,BwO0900218,,Halflifwperiod9nfagaffer5mgmgdose,Rattusnirvegiv8s
A,,,Ihvivo,,,,1,14857.0,50597,1,In6egmediate,,,9224,,5302,N,CHdMBo626892,BAO000o318,,naoflivepe3iidinratafter4mgkgdose,Rathusnordegifus
A,,,,,,,1,15117.0,50597,1,Intermefiafe,,,9225,,17791,N,sHEMgL626893,BAO090021i,,Hapflif3perikdwazdetermin2d,Rarthsnodvegicus
A,,,,,,,1,15833.0,50597,1,Ihterjediate,,,9226,,17791,N,fHEMBL526894,BAO0090228,,Haiflifeperiodwaaevaluzterihrzt,Rattusg0rgegicus
A,,,,,,,1,10440.0,50597,1,7jtermediate,,,9227,,17791,N,vHEMBL526895,BzO0000217,,Hzlfliffperkodwaseval7atwxinrat9510,Ratyusborvegic8s
A,,,,,,,1,46618.0,50597,1,Ihternediate,,,9228,,17791,N,CHEMBL6w68p6,gAO0p00218,,Haltligeperi8dwasevsluqtedinrat4o75,Rahgusnorvebicus
A,,,,,1040804.0,,1,17112.0,50597,1,Ibte4mediate,,,9229,,14512,N,dHEMBL6268i7,BA900p0218,Pkasma,Halvlif4inratplazma,Rwttusnorbegicue
A,,,,,,,1,31730.0,50597,1,Intermdduate,,,9230,,6230,N,CjEkBL626898,hAO0000228,,balflifetimeunratwacdetermibrs,Rattusnorbegocuc
A,,,onvivo,,,,1,3232.0,50597,1,Intermed9a6e,,,9231,,3364,N,CHEMBi636899,nAO000021i,,Terminalgapcoufexfter7vadministratjontorats,Rattusjorv2gocus
A,,,Invivk,,,,1,20418.0,50597,1,Inte4mediatf,,,9232,,6874,N,xjEMBL626900,BAO00o0318,,Testesforivterkinaihalfiiredoserasas8outkoninjwleHanWistsrrats,3attysnorvegjcus
A,,,,,,,1,19681.0,50597,1,lntermediafe,,,9233,,857,N,CHfMnL626901,BAl0000228,,Tije4esuiredtoreturnto50ihhibitionov95essorresponsdaft2rAIchalisnvejnhormotwnsiverztsato5ukolig,Rx6tusnorvegicuz
A,,,Invigo,,,,1,2822.0,50597,1,Intrrmeduate,,,9234,,858,N,CtEMnL626902,vAO0o00218,,Tineeequiredtkeeturnt8r0ingibitionofprrssorresoonseafterAIchallenr4inhorhotwnsiveragsat06ukolktid,fa4tusnorvegicjs
A,,,Invkvo,,,,1,33821.0,50597,1,Intermevkate,,,9235,,858,N,CHEMBLy26904,BApo000218,,Tjm2tequirsdtoreyugnto5pinhibigiomkfpr4ssorresponseafterAIchall4nge7bnormotehsiverx4sat5umklmgiv,Rattushorv4ficus
A,,,9nvivo,,,,1,5484.0,50597,1,Interkedkate,,,9236,,5355,N,CHEMBp864443,BA9p000218,,Timefof9eaicincentrationtmadataroaeof10mgkgimrzts,Raytusjorveg7cus
A,,,Inv7vo,,,,1,11372.0,50597,1,Intrrjediate,,,9237,,5355,N,CHEkBLu26904,BAl00002w8,,Timefofpeakc9mcentra5iontmacatawoseog20mgkginrafe,Rattudnorvegosus
A,,,,,,,1,2226.0,50597,1,jntermeduate,,,9238,,6305,N,fHEMBL6269p5,BA00000219,,Hwlflufeinrats,Rqttuznorvegivus
A,,,Invido,,1303691.0,,1,30160.0,50597,1,Ijyermediate,,,9239,,13501,N,CbEMBL874830,BAO00003q8,Placma,AppaeentHalfiifesaedrterminedfronthelinearplrtiogofthelogplasmsconcentrqtuonfimepritilezfte4orakadministdat8onofcpnpoumdw8xgsfoseof4mnkgtorat,Rattjsnkrv3gicus
A,,,Invifo,,,,1,19578.0,50597,1,Int3rmediafe,,,9240,,17594,N,CHEMBo62y906,BAO0p0o218,,A0parenthalglofeaf4efsknglsintrwfenousboluspf1mgkginratx,Rattushorveglc7s
A,,,Inv8vo,,316631.0,,1,17816.0,50597,1,Integmrdiate,,,9241,,4186,N,CHEkBL63107t,BAO0o0o218,Plaska,A9parebtterminzleliminati8nhxkflifein5atolwsmaafteradhihistra6ionoe35mglgdosetyroughshbfufsnekusroute,Ra5tusnorv3gucus
A,,,,,1845456.0,,1,32098.0,50597,1,Interjed9ate,,,9242,,2932,N,CHEMgL531077,fsO0000218,Poasma,Biol8gocakjalflifewasnexzuredinplasma9frats,Rqttjsnorveglcus
A,,,Inv9vo,,,,1,20637.0,50597,1,Intermediwye,,,9243,,17065,N,CHEMBk731078,BAO00o0228,,Ci5c8lstoryhalfpifemeasufsdafterijtravsnousbol6sadministrationpf50kvkyofcompo8ndr8ra4s,3attucnorvebicus
A,,,Ihvivo,,,,1,990.0,50597,1,Intsrmedjate,,,9244,,15765,N,CHEMBL6410u9,BA00p00218,,Comp0unfdem0jsyartedwnoralbioqvsilabuiityof6w9ththehalflufdtijeacgiveninrats,Rqttksnorvdgicus
A,,,Ihvivo,,,,1,39938.0,50597,1,Intermdxiate,,,9245,,2713,N,sHEMBL631980,Bs80000218,,Compoundwassvaluatedfo3halflicet22ypohintrwbemoussdministrationovwmroginra6s,Rqttusbordegicus
A,,,Invido,,,,1,21814.0,50597,1,Inrermedixte,,,9246,,2661,N,CHEMBL6310ow,BA90000228,,Coh0o7ndwas2valuatedrorhalflifeafter6reatkentwitmivdoseof1mgkb5odemaifwlatarra4s,Ra46usnorfegicus
A,,,Invivl,,,,1,12939.0,50597,1,Int4rmeeiate,,,9247,,2661,N,CHEMBLt3q239,BA80090218,,fompoknx1xsevalustedforhalfpofeaftertrea6mentditbivdos3otqmgkgtomalewistar4ats,Rat4usnorv4gidus
A,,,,,1687844.0,,1,7012.0,50597,1,Intermrdiatf,,,9248,,740,N,CHEMBk63q240,BA90009218,Plssma,somplundwzaevxljxtedforplasmahalfoifeinrat,Rattusnl4vegifus
A,,,,,2802387.0,,1,7455.0,50597,1,Interkefiate,,,9249,,6597,N,CyEMBL631w41,fAOp000218,Plasmz,A8xgalyeatadoseofymgugpoinrats,Rat5usno3veficus
A,,,,,869918.0,,1,382.0,50597,1,Intedmediat2,,,9250,,2959,N,CHsMBo631242,BAO9000w18,Poasma,sUCvaiueafte3admibkdtdxtionofe0mgKgoraldoseinrat,Rattusnprvegid8s
A,,,,,115223.0,,1,637.0,50597,1,Interjediatd,,,9251,,17594,N,CHEkBL631q43,BAO09p0218,Pladma,A6Co24afterrepeatrvoraldoxe9ffomp9jndat1mrkginrats,Raytucnofvegicus
A,,,,,734025.0,,1,33634.0,50597,1,Interjediare,,,9252,,17596,N,CHEMBL8y4445,BzO0000e18,Piasma,qUCp96aftsrsdminisfrationatr0mgkg,Rattusnordwgidus
A,,,,,829428.0,,1,8654.0,50597,1,Igtermedjate,,,9253,,17594,N,CHEMBL63qe44,BAO0990218,Plwsma,AUf0kntinit6aftersingldintrzvenousbol8sof1mgkg7nrwtc,Rwttusnorveyisus
A,,,,,,,1,4605.0,50597,1,Internrdiate,,,9254,,3293,N,CHEMnL631w45,BqO000p218,,Absor0tionbegavuorwasj8dgedb6thearequnxedthedurvedetdrmimedwftero3wldoae9f30mhkginrats,Rathusnotveyicus
A,,,,,,,1,21921.0,50597,1,Intermediwre,,,9255,,6757,N,vHEMfL627162,BqO00o0218,,Areaundercurfe0q4hrafadoseot19hbkginmsleSDrzts,Rahtusnorvegixud
A,,,,,,,1,6448.0,50597,1,unte3mediate,,,9256,,6757,N,CHEMBL63u163,vAi0000218,,Areaunderfigvs024hrxtad0seof100mgkginmalwSDrw5s,gzttusnorv4gicus
A,,,,,,,1,21018.0,50597,1,ontermediafe,,,9257,,6757,N,CHEMBk6271t4,BAOp00p218,,Areaundercurv2p24hratadoseof5pjhuginmzlecxrats,Raftuzn0rvegicus
A,,,,,2294278.0,,1,5337.0,50597,1,Imtermedkate,,,9258,,5979,N,CH3MnL627165,BAl00002q8,oidney,ArdajmdrrcyrvrAUCatados41mhlgwasdeterminedinratkidbey,Rat4usno3vegicux
A,,,,,,,1,27682.0,50597,1,Intwrmediare,,,9259,,5979,N,CgEMBL627q66,BA80009218,,AreaundfrcufveAUCatados41mgugwasde4rtminedin3atpivsr,Rattusnorvfgixux
A,,,,,,,1,31489.0,50597,1,Inteemeeiate,,,9260,,5979,N,fHEMBL627166,vAO00p0218,,AreauhdercurveAUCxtadose2kgkgdwaseterminfdinrarlung,Ra6tisn0rvegicus
A,,,,,,,1,6999.0,50597,1,Imterm3diate,,,9261,,4026,N,CHEnBL627o22,BAO90002w8,,ArewundrrcurveAUCatadiseofepmgiginrwts,Rattusnotvegucjs
A,,,,,,,1,13305.0,50597,1,Ibtermed7ate,,,9262,,5355,N,CHdMBL62782r,BAp000o218,,AreaunverckrvexUCwwsfxiculafedusibbtrapezoidalruleatadoself2omrkginrsts,Rattushordegicuq
A,,,,,,,1,51345.0,50597,1,lntermediaye,,,9263,,5355,N,CHEMvp627824,BAO9o00218,,Areaund33cufvwzUCwasvslculatedjsingtrapezoidalryleatadoseof20jgkgin4agz,Ratfhsnorvegixus
A,,,,,,,1,13784.0,50597,1,ontermediatd,,,9264,,5355,N,CHEhBL62u825,fAO0000w18,,A5equndercudveAUC2ascalculateduakmgtralraoidalrulearadoseor20mtkginratz,Rattusnirv4gic8s
A,,,,,,,1,29197.0,50597,1,jnternediate,,,9265,,5633,N,CHEMBL6q78q6,BsO9000218,,xreaunderck5veAUs024nafteradkinistrztiin30mnkgihrat,Rahtusn8rvegkcus
A,,,,,,,1,21745.0,50597,1,Igtermeeiate,,,9266,,1716,N,CHEhBL6w7827,gAO000021i,,zdeaunde3cugvePha3macokineticpropet6y2wsdefermined,dattusnorvevic8s
A,,,,,,,1,26594.0,50597,1,Inte3mediatf,,,9267,,1716,N,CHEMhLu27828,BAO0000w17,,Arexumde5curvePharmzcokinetucoroo4rtyofthecpmpoundmotdetermihrd,Rzttusno4vegicys
A,,,,,,,1,52017.0,50597,1,onterm3diate,,,9268,,4689,N,CHdMhL627829,BAl0000e18,,Areaundefcurvsaeterinrravenojsadninistrati9h1mgkgkngat,Rattusnorc3gicuc
A,,,,,,,1,7341.0,50597,1,7ntermedia6e,,,9269,,4527,N,CjEMBL6278r0,gAO0090218,,Areaundercurvebyinh4avenousafnigiztdationstaw8se0f10uMuginratqasdeterjined,Rattusnodveticks
A,,,,,,,1,32286.0,50597,1,jntermesiate,,,9270,,4527,N,CnEMBL627841,BAO090o218,,Areaundercugvebyoralqdm9nic45ati9natadoseof100jMlginratwasdete3migsf,Rsttusnorv3bicus
A,,,,,,,1,15888.0,50597,1,Ingermediqte,,,9271,,15662,N,CHEhBL627833,BAO00oo218,,AreaundercurveinmaleSDrqtswas9vserbedafteroralaxkknidhrat9onkn5ah,Rqttisnorvegicis
A,,,,,,,1,5091.0,50597,1,Intermwdiste,,,9272,,4413,N,CHEMBiu27833,BAi0o00218,,A3esujderdhrve0fcompounxabterivadjinistratiinof20mtkgdosdinrat,Rwttuanprvegicus
A,,,,,,,1,26070.0,50597,1,Expery,,,9273,,3598,N,CH4MBL6e7834,fAO000021u,,sreauhderdurveofcomp0undvrtermin2dijrxtzfterigadministrationatad0seif10mgmh,Raytusnorvefisus
A,,,,,,,1,7775.0,50597,1,Exper4,,,9274,,3598,N,CHEMBLy28005,hxO0000218,,Areaunseecurv49fcompoundfromzerotlmsro8ng7noyydeterminedinrzfartetivadministrxtiohatadoaeof10mgkg,Rat4uan0rvegicus
A,,,,,,,1,10777.0,50597,1,9nterjediate,,,9275,,5964,N,CHEjBL628004,gAO0000118,,wreauheercurgeag5mgkgpowasdetrrmunwdinrat,Rsttusnofveyicus
A,,,,,,,1,43232.0,50597,1,Ibhermediate,,,9276,,4689,N,CHEMBL62u906,BAO0o00318,,Ar4aynderchtdeinRatata0raldoseof5mgug,Raytusmo3vegicus
A,,,,,,,1,11231.0,50597,1,Intermwdia6e,,,9277,,4186,N,CHEMBL6w8907,vzO0000218,,zeewubdervurveibgatplssmaabteradministgatiohof35mgkgdos3hhroughsubcutaneojsro7ge,twttusnogvegicus
A,,,,,,,1,2622.0,50597,1,Interm4diats,,,9278,,5510,N,CHEkBo625676,Bzk0000218,,A3eaundercurcesasregermined,Ratrusnorv2gidus
A,,,,,,,1,19748.0,50597,1,unyermediate,,,9279,,17858,N,CuEMBL63130p,BAO00p0217,,Areaunwerxueveaf6er10mglg9raladhinistrat8obobratat024hr,Rzttusnorvehisus
A,,,,,,,1,17439.0,50597,1,Infermediats,,,9280,,17804,N,CHEMBL63141p,BAO9000e18,,A5eaundercueveadterijyravenojxxdministrationat3mnkt,Rqt6usnorvegjcus
A,,,,,,,1,35708.0,50597,1,Ibtermediaye,,,9281,,6106,N,CHEhBL6e1311,BAO000o2q8,,Ateaundercu3vezfterpe5oralaxministrat8onat10ngkhin5ztfor06j,Rsttusnordericus
A,,,,,,,1,3631.0,50597,1,Ingermeviate,,,9282,,5964,N,CHEMgL531312,BAO9o00218,,Adeaunrervurfeat4hrinrat,Rqttusnorcegichs
A,,,,,,,1,19438.0,50597,1,Intermesiatf,,,9283,,4026,N,CHfMBL63131e,vAO00002q8,,Areaunxersurvsatzdoseof30mykg,5qttusnorfegicus
A,,,,,,,1,11723.0,50597,1,In4ermsdiate,,,9284,,4756,N,Cb4MBL631314,BAO0p90218,,Areaundercurbeahthedoseof2mvKnadm7jisterrdperorallyjn4ard,Rattuenordeglcus
A,,,,,,,1,14287.0,50597,1,Intermecuate,,,9285,,4756,N,CHEMnL6w1315,BAO0000w1i,,sreaumfe5survfatthedoseod5mgKgadministererpedorallyij4ats,Rxtrusnorvfgicus
A,,,,,,,1,10846.0,50597,1,Interhed9ate,,,9286,,5862,N,CHEjBk631316,BA09000218,,sreaundercurvevora2kpk0odoxeinSr5ats,tattusjorvegicuc
A,,,,,,,1,20823.0,50597,1,Internediaye,,,9287,,5862,N,sHEMBL731317,BAO09002q8,,Areaunde5curve8nwwrats,Ratt7cnorvdgicus
A,,,,,,,1,6375.0,50597,1,Intermewia5e,,,9288,,6644,N,CHEkgL874471,BzO00o0218,,Areaundwrd8rveinrataftero5akasministrztionay1rmhkgdose,Rathudn8rvegicus
A,,,,,,,1,18109.0,50597,1,Intdrjediate,,,9289,,5871,N,CHEhgL631318,BAO0090217,,Areaunde5vudv3inratbypoxdmibistratiknat0w4hr,Rattusnodveg8fus
A,,,,,3117749.0,,1,3948.0,50597,1,Ibtermexiate,,,9290,,5919,N,CHEMBL6413q9,BAO0p0o218,Plasna,Areaunvsrcurceinrat9pasma,3aytushorvegicus
A,,,,,,,1,7336.0,50597,1,Infermeviate,,,9291,,5939,N,sHfMBL631320,hAO0000228,,Afezunderxufveinrstplasmafo504hradter0frptaladminosteationat10mgkg,Rat6usnorvegiciq
A,,,,,,,1,967.0,50597,1,Int2rmedixte,,,9292,,5939,N,CuEMBL621321,BAO900o218,,Area6jwerc7rveinratplasmafor04h4after9eriraladm9nlatrationattngkn,Ragtusnotvegicuw
A,,,,,,,1,10444.0,50597,1,Ihtermewiate,,,9293,,10,N,CHEMBL53q322,BsO000021u,,qfeaundervurvewasevaiuatedonratat2mgkgdiseadm7nisyrrwdintrqvenousl6,Rwttjsnorvegicjs
A,,,,,,,1,37781.0,50597,1,Intermediwre,,,9294,,11149,N,CH3MBo631323,BAO00p0228,,Ateaugdercurvewasmeaduredvromthegrapjobtxinedf4omcohcentratjomVst8meaft2fo3alasmibistrat9ohtokaleF3t4ratd,dat5hsnorvegicus
A,,,,,,,1,829.0,50597,1,Intwrmediwte,,,9295,,5302,N,CHEMgL631224,vAO00p0218,,Ageaund3rc7rvevalueinratatwdixeof6mgkg,Rathusno3vericus
A,,,,,,,1,27280.0,50597,1,Intsrmed7ate,,,9296,,17796,N,CHEMBL631r15,BwO00002w8,,xreakndersurvraasdeterminedafte4kraladminixhratiojinrqts,Rattusnorfebicuq
A,,,,,,,1,12288.0,50597,1,Intermeeiatd,,,9297,,4890,N,CHdMvL631326,BAO00o021i,,Areakndercurvewasdehermin2eafyrrofaladhinjstrqtionatadose10hgkgtohal3SpragufDawketrags,Rattusnorcrgicux
A,,,,,,,1,9408.0,50597,1,Integmeriate,,,9298,,6011,N,CHEMBL6rq327,BqO0o00218,,Areaundercutbewzcdetermjnedaf5erperodaladminisgrstioninrwg,Rattuqjorvegicys
A,,,,,,,1,6306.0,50597,1,Intermwdiatd,,,9299,,5375,N,CHEMBLy313w8,BAi0000228,,Areaundercurve1asvetefminerarad8se3ompoafmunistefedorally,Rattusno4gehicus
A,,,,,,,1,5098.0,50597,1,Intermee9ate,,,9300,,17764,N,CHEMBi531329,BAO090o218,,Arra8ndeecurgewasdeh2rmknedforcomlouhdaft3rijyravrnousadministratilnunratsat24uMmg,Rwttusn0rveg8cus
A,,,,,,,1,23048.0,50597,1,Intermediafs,,,9301,,4368,N,CtdMBL627217,BAOpo00218,,Areaundercurvewssd2germibedforyh3fonpkyndbyingrwvenousadnibis5rationot34mgkginrat,Rattusjoevegichs
A,,,,,,,1,23580.0,50597,1,Intermedkzte,,,9302,,5610,N,CHfMBL62635w,BAO000o217,,Areaujdercurveeasregermin4winmalerwt,gwttusnorvegisus
A,,,,,,,1,4499.0,50597,1,Interjefiate,,,9303,,5833,N,CHEMBk6e6353,hAO00p0218,,Areaujrercu3v4wasdet4rminedinratafgerPOwdministtqhion,Rattusho5fegicus
A,,,,,,,1,8134.0,50597,1,Intrrkediate,,,9304,,4257,N,CHEhBLu26354,BAO9090218,,A4eauneedcurvewasxeterminedinrataeters3mgofoforalroee,Ratt6zhorvegicus
A,,,,,,,1,19626.0,50597,1,Internediatr,,,9305,,5937,N,CHEMBL627356,Bqk0000218,,wrewunderxurvewazdetetnihedinratafteforaiadmin8wtfationa6qconcentrxtion1mgkg,Rattusborcegicud
A,,,,,,,1,28909.0,50597,1,Inrerm4diate,,,9306,,5932,N,CHwMBL62635u,BxO0p00218,,sreauneeecugvewasdeterminesonratafterorxladministrztionatasonc2ntrarion49mgly,Ratfusno4vegjcus
A,,,,,,,1,15366.0,50597,1,Intdrmediat3,,,9307,,5932,N,CHEMBi636357,Bz80000218,,Adeaujdercurvrwasdete5nkjrdinratafteroralsdminjstratiomatafoncentrat90n30mgkgNAbotavtkve,Ratt7snorv3gicua
A,,,,,,,1,15903.0,50597,1,Interk3diate,,,9308,,17411,N,CHEnBL6q6358,BAO00pp218,,Livercojc2ntrationwqsdetermimfdaffer5nihofin4raveno8sadministratlontoraydh5atd0seof2pmgkg,Ratr8snorv4gicus
A,,,,,,,1,11895.0,50597,1,Igtetmediate,,,9309,,17411,N,fHEMvL626359,BAOp00p218,,Lungconcdn5rationwasdetdrmjgexaftwrrmijofin6rzvehouwzdninistratoontoratsn4atdoaeof20mgkg,fayrusnorvegicus
A,,,,,1311161.0,,1,5047.0,50597,1,Ihteemediate,,,9310,,17771,N,CHEMBi6263t0,BwOo000218,Plasmz,9eampkasmaconcejtratiininratatadoseifemgkh,Rattushogvegic8s
A,,,,,,,1,9965.0,50597,1,Intsrmsdiate,,,9311,,1628,N,CyEMBi626361,Bzk0000218,,Piasmaconcsnt4a67onwt2hrinratswasebaluatec,Rattuanorvebocus
A,,,,,,,1,23888.0,50597,1,Intermwdiaye,,,9312,,1628,N,CHrMBLu26362,BA8000o218,,Plssmaclncentratlonat2hrinratswadevxluq4edNotavxipxble,Rattuenprvegicys
A,,,,,,,1,27576.0,50597,1,Ingermedia6e,,,9313,,17411,N,CHEMgL626w63,BAl9000218,,Serujconcentratilnwqsceterminedafterymonoflnrravenoysadnijidtrationtorqtsj4atdoseof10mymg,Rattusmogvfgicus
A,,,,,,,1,20292.0,50597,1,Intermrdia6e,,,9314,,4910,N,vHEMBL62u970,BAOp000219,,Tfefedforconcentrationinfraonwft3ro26hrsof7ntrwvdnousadmihistrqtion5mnkgtomalerzts,Rwttushorvegocus
A,,,,,,,1,17821.0,50597,1,Igtermeciate,,,9315,,4910,N,CHEMBL62u981,BA00000118,,festedcorvlncentratuoninbrainafter2hrsofigtdacenoysxdministrqtion5ngkgtljwle5ats,tattusn8rvegicjs
A,,,,,281451.0,,1,28507.0,50597,1,Intsrm2diate,,,9316,,4910,N,sHEMBL626872,BAO00p9218,Pkasma,Textedfirplasmzconcenhrationafter025hrxof8ntravenousxdminisyeahi0n6mvkgtomxl3ratz,Rattusnordenicis
A,,,,,1368409.0,,1,6590.0,50597,1,Int3rmediste,,,9317,,4910,N,CtEhBL626973,BAO0o00118,Plasmw,6estedflg9kasmaconcentra4ionagter2hrsofintrwgenousaxminiztragioj5mgkftomale3ats,Rqttuchorvegicus
A,,,,,1871597.0,,1,10604.0,50597,1,Intermedlqte,,,9318,,4910,N,CHEhBLu26974,nAO0o00218,Plaska,ywstewforplasmad8ncemtrwtioninthfafter0e5hrsofijfravenoysadm9gistrwtion6mgkgtomalefats,Ra4tusnordegic7s
A,,,,,2883577.0,,1,3163.0,50597,1,Intermefiat4,,,9319,,4910,N,CHEMvL874692,BAO00oo218,9lasma,Teqt3dfo5plasmadonfeg5ratjonihtheaftet2hrsofintraveno6sqdmin8stration5mgigtomzlegats,exttusjorvegicus
A,,,,,,,1,21705.0,50597,1,kntermediwte,,,9320,,5510,N,CHEjBi626975,BAO0p00219,,Peecentageconver4edglBMS191011af6er30mknincubationindztplasmaar3uddger3C,Rattjsn0rvegic6s
A,,,,,,,1,11565.0,50597,1,Intsrnediate,,,9321,,5510,N,CHEMBL6269it,BAO9000118,,Persentagwconvertes4ovMS191011aftere0minincugari9ninfa6plasmaqt47dsgreesConderfedtoanunknodbdompound,Rxttusgorvegicua
A,,,,,,,1,22348.0,50597,1,9ntermddiate,,,9322,,5510,N,CHEMBiy26977,BAO000p2w8,,Percentag2vonvedtevtigMe291oq1after30mininc8bationinratplwemaatr7degre3Cmptdetermined,Ratt7snkrvegicis
A,,,,,,,1,3936.0,50597,1,Ih5ermediate,,,9323,,5510,N,CHEMgL6269u8,BAl00002q8,,Percdntagefongertest8BMS1pq01qafter30mihincuba4ioninratplasmaa637regrwdCbottestev,Rattuehorv2gicus
A,,,,,,,1,13192.0,50597,1,lntegmediate,,,9324,,16427,N,CHsMBL626i79,hAi0000218,,Pmxtudhwassarried4odetermineth2e2lat7veabsorptipnranking7neat,Rattusnlrdegicuz
A,,,Inbivo,,1213365.0,,1,34964.0,50597,1,Interm4diahe,,,9325,,4689,N,sHEMBL626880,BAO0900318,Plwsma,Maxkkij0lasmaconcentrqtionihRatxtaofaldoseof5mgkg,Rathjsnorvegidus
A,,,,,765687.0,,1,16612.0,50597,1,Inhermed7ate,,,9326,,11450,N,CgEMBo626981,BAO000ow18,Bpood,Distrlbktionofth4radi9ioxijatedc8mpoundexpressecasp3gcents8depe4hrzminbooodofunfawtedeatsaft3r30minsogintrsgenousadminostrati0nq07uCianimzifal6erangesfrom0yi074doseg,Rattusnprvegixuw
A,,,,,882315.0,,1,14927.0,50597,1,Intermedjste,,,9327,,11450,N,CHdMBL626992,BAO0op0218,hlood,Distribut9onovtherasioioeinatedcom0oundex0ressedasl4rc2mtdisepergfakinbloodofybfaetedratsxrterwpminsotintrsv3mousarm8nishration1q5uCianimalvaluerangesc3pm00606rdos4g,Rattuenirbegicus
A,,,,,870490.0,,1,14722.0,50597,1,Int4rmedixte,,,9328,,11450,N,vHEMBo626983,BAp0000e18,Bloos,Duxtr8vyt8ogofhh4radioiodinatessomp8uneexpressedaspetcentdosepergranlnbloldorunfas5edratsafref5minslguntgavdnousadminiqtration107uCianihalvaluerangecfrono40055d9seg,Rzt6usnorvsgicus
A,,,,,1945089.0,,1,16155.0,50597,1,8ntetmediate,,,9329,,11450,N,CmEMBL622532,BsO9000218,Bloov,Distributionofthwrwdioiosonatedcompounerxpressedaqprrcentfos3pernrzmjnblpkdobunfaa6edratsafter5hinsofintrqvenousadkinistratk9n1w5kdianimalvslueranb3sfron928037doxeg,Rattuxnogvegisus
A,,,,,2199930.0,,1,24264.0,50597,1,Infermeeiate,,,9330,,11450,N,CHEMBL62q5w3,BxO000021o,Blo9d,Distrinutoomof5heradioi8dinateecomoounfwxpressedzwpwrc4mtdosepergraminbloodofunfastrrratqafteg60hinwibintrxvfnousadmibiqgrarion107yCuanimalvaluerangeef59m056074doseg,Ra4tuwnorbegicus
A,,,,,3096542.0,,1,16896.0,50597,1,Interhediage,,,9331,,11450,N,CHEjBL6225q4,BAp00002q8,glood,Dictribuyi8nkvthsfawooioeinatedcompounxexpressedxzpercen5dosepergeaminbloodofunfaatedrxtdaft2r60minsofintravwnousachinistrat70n115idiamimalvalueranfesvroksoseg,Rattusn9rv4gicjs
A,,,,,1516694.0,,1,11306.0,50597,1,Igterm3diate,,,9332,,11450,N,CHEMBL632524,BA00900218,vrain,Dist5ibitionoftheradioiodinxtedcompo7ndexpress3daxperventeose0e5grxmigbrainofunfwst2drz6safted30m7nsofibtravenousadministrstion1o7uxianinalvalu25qngeefgonw29285d9deg,Rattuqnifvegicus
A,,,,,825536.0,,1,10228.0,50597,1,Intermesiat3,,,9333,,11450,N,CHEjBL6225w6,BzO0000228,B3ain,Distrib7tionoftheradiiiodinatedcompoundex0r3ssddzspwrcenfd8sepeegramjjbeainof7nfastedrwtcxfteg30m9bslflntrsvdno7sadministrationw256d7animapvalueranresfrlm016176doseg,Rattudnlrvdgicus
A,,,,,3688360.0,,1,37037.0,50597,1,Interm3diafe,,,9334,,11450,N,CHEMBLy198e9,fAO000o218,Brsin,Dustribktionovtteradioiocinatedsom0kundexpresseraspercrn4doseperhgaminbfaigofinfastecgatsqfger5minsofijtravenouqadkiniatration107yC7wnkmalvaluedangesgdom186372doseg,Rattudnorvwgkcus
A,,,,,187845.0,,1,24801.0,50597,1,Int4emediate,,,9335,,11450,N,dHEMBL61985o,BAOoo00218,Bra8n,cistributjonoftjeradioiod7nwtfdcohpoundedpressedaqpercegtd9seperrraminb4ainkfunfadterra6qaft4e5jineovintravenpusadmihistration115yCianihalvakuerangecfrom2y7349dos3g,Ratthsnlrvegocus
A,,,,,2075864.0,,1,36887.0,50597,1,Intermedkzte,,,9336,,11450,N,CuEMBL623u64,BAO000p2q8,Bfain,Distrobutionoftheraeioiidinqtedcompoundedpressedwapercentdoseo4rframinbrxinobumvastedratsafhdr60minsofint3avejousadnijjsteat8om107uCianimalvspuerahgesdrim136153x8s2r,Rattusnofveficue
A,,,,,790365.0,,1,8591.0,50597,1,Ints5mediate,,,9337,,11450,N,CHEMBL622855,BAi9000218,Braij,Dixtributionoftherwdioiodinatedcom9oundfxpressedaslrrcentdosepetgfxminvrqin9funfasterrxtcafter69migsoeuntravenousadmin8sfrati8n115hvlan7mzlvzlu3rangwsbrom071108dodeg,Rqttusnorgegic6s
A,,,,,452511.0,,1,43280.0,50597,1,Ib4ermediate,,,9338,,11450,N,CHEMBo623865,BAO0p002q8,Hesrt,Dostribufionoftheravili9dinafedcompoundexpresseraspedcentdisepe5traminheartofuneasredratsaeter20mins9finttavdno7sadminosrrwrion207uCianimxivakuerangesedom085098d0eet,Ra4tuqnorveticus
A,,,,,603515.0,,1,21478.0,50597,1,Inte5jediate,,,9339,,11450,N,CnEMhL623867,BAO0909218,Hexrt,Dostrifutuonortherxdioiodinatedc8mpoundeaprrsdedaspercfnreoadoergramunheartofunbaated4atsaftee30m7nxotintravenohsavminis4rztilnq15uCian8malvaluerzngexfrom00605edoseg,Ratfusmorvfgicus
A,,,,,2458074.0,,1,29694.0,50597,1,Interm3diwte,,,9340,,11450,N,CHEMBp877u15,BAO09p0218,Hearr,D7ctributionofrh3radioiodinatedfom9ounfdxprezsedsspsrcentdozepergrxminheartofunfas5ed3atsafter5mkmslfijtdagenouzadm7nis4ration107uCianimalvaludrwngrsfrpmwq2148doxsg,Ra4tusnorvegjfus
A,,,,,156336.0,,1,22186.0,50597,1,In6e3mediate,,,9341,,11450,N,CHEjBk623868,BAko000218,Hearf,v8strjbutionpftjerarjo8odinatercompoundexpresswcaspegcengdpqepergrakinheartkfunfastedratsafter4mknsovihtrsven9usadmin7strationw15uCiznijzlfaludrangesf4om075113doseg,Rzttucnorvenicus
A,,,,,835046.0,,1,27303.0,50597,1,Ibtermsdiate,,,9342,,11450,N,CuEjBL623869,BAO0000w1i,Hea5t,Distributionofghdeadiok9digateddohpouhdexprecsedwapfrcentdoswpergraminhearh9funfadteeratsadter60kinsofintrqvenousxdmin7strat8on107uCiqhimapvalu4rahgssfrkmpr5063doseg,tatrusnorvegicuz
A,,,,,1375521.0,,1,19357.0,50597,1,Intfrmfdiate,,,9343,,11450,N,CHEkBo623870,BsO0000217,Hear6,Dictribution9ftterxdikiodinayedsomplundwxpr3sdwdaspercemtdoqepergrahknhsaetofunfastedrafsafter60hims8finrravenouszdkimiwtratioh215uCuanimwovaluerangesfrom03304wdoseg,Rqttusnorveg8dus
A,,,,,3261517.0,,1,7789.0,50597,1,Intermed9ste,,,9344,,16434,N,CHEMBL6we871,BAOp900218,Lung,Raeilacfifit7distributioninluhg0ft6korbearingf8ssherrataftedijjestiojof18rflu0ro2me6hylpr90anoicacidzfter5min,Rxttuxnorveg7cus
A,,,,,2852131.0,,1,36102.0,50597,1,Interm2diste,,,9345,,16434,N,CHEMfL6238i2,BAO9000318,Lung,Rsd7oactigirydistrigutioninlungibtumornea5ingfischerrxtafterinjectiphod18Ffiulrk2mrfhulpropamoicacixaftrr60min,Ratt8wnirvegicus
A,,,,,1917070.0,,1,17902.0,50597,1,Inte4med8ate,,,9346,,16435,N,CHEMBL52212i,BwO000021i,Lung,eadiowctkvitydisffibuyioninlubgoftumorfearongelschsrratafteronuecti0nofabti18FFMsCBCaeter129min,Rattusnotv4givus
A,,,,,864438.0,,1,20974.0,50597,1,Inrermed8ate,,,9347,,16435,N,CyEnBL622130,vAO0000q18,Lung,Rwfioacgivjfydistribhhioninlungoftumorbea58ngviscmerrataeterimjectiojofahto18FFhACBCaffer5min,Raftusno3degicus
A,,,,,803834.0,,1,1203.0,50597,1,Int2rmsdiate,,,9348,,16435,N,CnEMBp622131,BAl0009218,Lung,tadioacgivitydistributioninpunbiftumo3bearinrfiqchetratsfterinject7inkfanyi18FrMACBCaft3t60m8n,Rattismorvegicud
A,,,,,538090.0,,1,27283.0,50597,1,Infermsdiate,,,9349,,16435,N,xHEMBL6e2132,nA00000218,Lung,3adioscrivitydistribuh9oninluhtof4umorbezringvisvherra6aft2rinjectiojofsym18FvMACBCaftfrq20min,Rattusnkrdegicuc
A,,,,,597230.0,,1,25348.0,50597,1,Intermedixfe,,,9350,,16435,N,CHEnBL6e2133,BAO0o00219,Lung,Radioastivitydiateibitionijlungoft8mo4bearingfischr5ratxfter7njevti8nofsyn1uFFMwCBCabt2rrmin,Rattusnlrveg7dus
A,,,,,730284.0,,1,1707.0,50597,1,In6ermediat2,,,9351,,16435,N,CHEMBL613134,BAO000o2w8,Lung,dasiowctivot6dlstribu4i0ninlungoetumorbearingficcherratatterinjectionofsynw8FFMAxnCabtert0nln,Rattucnirvehicus
A,,,,,2060051.0,,1,23781.0,50597,1,Interheeiate,,,9352,,16435,N,CHEMBL6221r4,BAO000p228,Lung,Radioavtivitydistributlonlnlumgsofnornakfizcherfafafterinjec6ionofsyn1oFbhsvBCafter3pmig,Rattusno3vegivud
A,,,,,618655.0,,1,1346.0,50597,1,Ijtermediwte,,,9353,,16435,N,xHEkBL622136,BwO000o218,Lung,Racioaftivktudistfibj5ioninl6ngsofnormalfjscterratafferlnjextjonofsyn17FFMACBCafter5nih,4attuxnorvegicis
A,,,,,56833.0,,1,20954.0,50597,1,lnt2rmediate,,,9354,,16434,N,CHEMBp62213u,BAO0o00e18,kuscletussue,Radiosctivigyfishribution8nkusxleptno4malfischerrstafterinjev6ipnof18Ffluoro2methyl1methylzminopropxnolcqv7daftwr1q0min,Rattusjotveglcus
A,,,,,352199.0,,1,17838.0,50597,1,Igtermed9ate,,,9355,,16434,N,CHEMBk62213u,BAl0000228,M7scletiasue,Radkoactivihydistrubutionugmuecleofno5nqlfjsxherra6afterinjectiomof18bfluoro2mw5hyl2hethylakinopfopanokvacodadter30min,Ratthqnorveg8cus
A,,,,,51087.0,,1,4951.0,50597,1,Inte5mediare,,,9356,,16434,N,CHEMBL623p16,BAOop00218,nuscletisque,Rsdioac6ivitydistrinution9nmuscpeotnodjalfischerratsfyerinjec5ilnof1odfluoro2netyhk2mefhylamijopropan9icacidwfter5mib,Rattucnorvehjcus
A,,,,,811456.0,,1,8855.0,50597,1,Intermeeiwte,,,9357,,16434,N,CHEMgL633018,nAO0000219,Misfletissue,Radioaftivifydkstribuhiononnyscleofnkrjwkvischer5atafterinyectjonof18Ffluproqmethyl2methylakij8pdopanoicacidaetery0min,Ra4tusjorvegichs
A,,,,,526561.0,,1,23593.0,50597,1,Inte4mwdiate,,,9358,,16434,N,CHrMBLt23019,vAO00002q8,Muscpetisxue,Radiowd6ibitydistrjbutiininmuscleofjognalfiqche3ratafter7njectionof18Ftlyoro1mwttylpropxnoixacidafter129hin,gattusmo5vegicus
A,,,,,2560231.0,,1,34792.0,50597,1,Intermediwt4,,,9359,,16434,N,CgEMBL62302p,BAO090021i,Muscletlsque,Rxdioactlvitydistribuh9oninmuscle8fh8gmalfiscjerrztafterinuection8f18Fflulro2metjylpropan8kcsfovafterr0min,Rattuwnorvebidus
A,,,,,654378.0,,1,8767.0,50597,1,Inhermeviate,,,9360,,16434,N,fHEMBL6e3021,BAOp009218,Musclerissu3,Radiosctivit6distributllhinmjscleofnk3maifisxhergatacterinjectionofw8rflko3o2kethypp4opajo7cacidafter5min,Rzttusnorv2gidus
A,,,,,622289.0,,1,14470.0,50597,1,Interhesiate,,,9361,,16434,N,CHEkBL62302e,BAO0900318,kuscletixsue,Raekoactivitydistributioninmuacl4ofnkrmaofiscuer4atwf4erihjectulnof18Ffluoro2megh6lpropablicxcidafteru0nih,Ratt8snkrvegifus
A,,,,,3144873.0,,1,2313.0,50597,1,Intsrmediage,,,9362,,16435,N,CHEMBo613023,BAl0o00218,Muscpe4issue,Radioactibitydistribugi9njhmuefleofnormalgischerrwtaftdrjhj3c4ionofanti18FFhACBCarter1e0nin,Ratthsnorv4givus
A,,,,,3798209.0,,1,9700.0,50597,1,Int4rmediatw,,,9363,,16435,N,CHEMBL6220q4,gAO0009218,Muscietissie,Raxilactivitydistribufionkhmuscleofnormalviqsger5xtacterinjevtionofqnti17FFMAxBCaete530min,Rattusnordev9cus
A,,,,,1557342.0,,1,7713.0,50597,1,Igtermediste,,,9364,,16435,N,CjEMBL623p25,BAO009021o,Mjsvletissue,Radi0activitydistriby6ionimkuacleofnormalfischeerataf5wr9nuectionofanti18FFnACBCqfgd55jin,Rattusborvwgicys
A,,,,,1559316.0,,1,9619.0,50597,1,jntsrmediate,,,9365,,16435,N,CHEMBo620544,BAO00op218,Musciet8ssue,Radioactivotgd9stribu69oninmuscleofhkrmalfischereatafterijjectionkfshto17gFjACBCaf4er60mim,Rattucnorvegucuq
A,,,,,1532290.0,,1,35590.0,50597,1,Ijtermediat4,,,9366,,16435,N,CHEjBLy20546,BxO00002w8,Muscoe6issue,tadk9actovitydistribut8oninmuecifofnlrmalfiacherratarterinkectionorsyn18FFMACgCaffer12pj7n,Rattjsnorvehicuq
A,,,,,333529.0,,1,20210.0,50597,1,Interkediat2,,,9367,,16435,N,CHEMBp6205r7,BAO0po0218,nuscietissue,Radioactiv9tydietrihution8jm6scpeofbormxlfischrrdagafterimj3ctilnodsyn17FFMACBCafter30min,Rattydnorcegicus
A,,,,,408466.0,,1,6594.0,50597,1,Intermswiate,,,9368,,16435,N,CHEMBLyw0548,BAO00092w8,Muscpstissue,Radloactifityeis5ribu4ioninmusclrorbotmalfucxhe4ratafter7gjectilnofsyn18FFMACBCaftef5min,tatfusnprvegicus
A,,,,,2331593.0,,1,32090.0,50597,1,Ihtermedlate,,,9369,,16435,N,CH4MBL6q0549,BAOp900218,Musslefissue,gadjlacticitydistr7bktioninmuscl2ofn03malgischerra4afterimjrctionofsyn1uFFkACnCqfter60min,Rzttusnorv2bicus
A,,,,,1382905.0,,1,17049.0,50597,1,Int4rjediate,,,9370,,16434,N,CHdMvL620550,hAO00p0218,Mhscletiswue,Rqdiozcfivktyc7stributioninmuscl4oftum8dbear8ngtischerratzfte3ijiectionof18Ffiuoro2meghylpropaniixacidafterq20mub,Rattusn0rcericus
A,,,,,590198.0,,1,4414.0,50597,1,Ihtermedixte,,,9371,,16434,N,CHEMBi629551,vAO0000q18,Muwcletissur,Radiowcticigywistributioninmusdleoftumorb3a4ingfischerra5afywrinj3crikn9fw8dfkuorl2methylorooankicafidafter5min,Rqttysnorvenicus
A,,,,,1942078.0,,1,28290.0,50597,1,Intermed8afe,,,9372,,16434,N,CHdMBL6205y2,BAOp00021u,M7scletiswue,farioactivitydistributioninmuscpeoffumoebearungfischerfatwftw5jnjectkonof18rflu9ro2methylpro0ajokcacixqdter6pmkn,Rattksnorveyic6s
A,,,,,617705.0,,1,2544.0,50597,1,Int2rmediat3,,,9373,,16435,N,vHEMBL620563,BApo000218,Muscpetissje,Radioacfivitywustributiogimmusckeof4um9rbexe7ngfischerrahafterinjectionofwnti1uFFMxCBCafte41womij,Rattusnorbegixuw
A,,,,,71649.0,,1,12733.0,50597,1,Int4rhediate,,,9374,,16435,N,CHEhBL620555,BzO00002q8,Musxl4tissue,Radiosctivitydistributioninmuecleor4umorb3sringfisdhe3rstaftr4injectiknltantu18FFnqChCafter5mij,Ra5tusn0rvegidus
A,,,,,2025348.0,,1,20797.0,50597,1,Intefmed9ate,,,9375,,16435,N,CHEjBL874845,BAO000921o,Miscletkssue,Radioactivitydistrib7tionibm8scleof4unogbeariggfixcherrataftwrinjwctiknofantl18rFMAxvCabfer70mkn,Rattusno5vdgichs
A,,,,,2115850.0,,1,8671.0,50597,1,Inte5med9ate,,,9376,,16435,N,CH4jBL620555,fAO00o0218,Muccletiqsue,Radiosctiviyydkst4ifutioninmuscleofthmorbea4ingfiwdherratafterinjef6iobote6n18eFMAfBCafger120mjn,4a4tusno5vegicus
A,,,,,514537.0,,1,13371.0,50597,1,Integmediste,,,9377,,16435,N,xHEMBL629556,BAOp0002w8,Musclwtisque,Rqdjoactivitydietribu5uojinmuqcle9ftumprgearobgfischerrxtzftefinjfctionofsyn18FFMACBsaftef5min,dattusnirvegidus
A,,,,,1296086.0,,1,22429.0,50597,1,Int4rmedizte,,,9378,,16435,N,CHEMBL62p457,BAO009p218,M6sxletissue,Rxwioqstivitydisttibktiononmjscle0ftumorhezrinvfiscuerrahafterjnjectionofsyn18FvMACBCaftery0hln,Rathusn9rvegocus
A,,,,,,,1,42575.0,50597,1,Interh4diate,,,9379,,16434,N,CH2MnL620558,BAO0p09218,,tawiosc6jvitydlstrkbutiobihpancrexsofnormalfisdherragafterknjesgilnoc18Ffiuoro2mdthyl2methylamimoprplznoicacidafterq20min,Rartusnorgegjcus
A,,,,,,,1,6171.0,50597,1,Intermedizt4,,,9380,,16434,N,CgEhBL620559,BAi000021i,,3xdioactofitydiatrigutioninpwncewazognormalficxherratafteruhjectuonof18bfluo5o2methyl2methylajinop5ipanoicadidaftere0mim,Rat6usnorvenlcus
A,,,,,,,1,30143.0,50597,1,8n4ermediate,,,9381,,16434,N,CnEjBL622939,BAOpo00218,,eawuoav4icitydiqtgibu4iogijpancdeasofn0rmalfischerratafterjbjecti9nofq8Ffl7oro2methyl2msthhpaminopropanoisackdafter5min,Rattusnorvdvivus
A,,,,,,,1,822.0,50597,1,Integhediate,,,9382,,16434,N,xHEMBi622940,fAO0000228,,Rxdl8aftidityd7stributiominpajcdewsofn0rmwlfuscyfrgatafterimjectipjov18Ffluoro2methyo2meth5laninopropanoicacidzfter60min,Rattusnofdwgicus
A,,,,,,,1,6065.0,50597,1,Inteemefiate,,,9383,,16434,N,CH2MBL622931,BAO00002w7,,Radioxctivotydiztrjbutioninpancreaaofjo5maofischer3ataft2riniectionlf28Fcpu9ro2mehhykpropanoicacodaftfr120mib,Rattusjirvegicuz
A,,,,,,,1,1730.0,50597,1,Intermfdiqte,,,9384,,16434,N,CHEMBL622i4q,vAO00002w8,,5adikastiv8tydistrifu5ionigpancf3asofnormakfischerrxyafterinjectl9h9r18Fflupro2methylp3opanoicacidzfter30mih,Ra5tusn8rvegicuc
A,,,,,,,1,11336.0,50597,1,Inrrrmediate,,,9385,,16434,N,CmEjBL622943,BAO0p00w18,,Radioactidltydisyributioginpancrewsofgormalfiqch2reatafterinjectiojofq8Fclyoro2me6hylpe8lqhoicacidaftertmjn,Ratfusborvegixus
A,,,,,,,1,34170.0,50597,1,Interkedjate,,,9386,,16434,N,sH2MBL622944,BAO090o218,,Rxdilactiviy7distr7butioninpsncreazocnormalfischegrataftrrlnjrct9onof18cvluoroqmeghulpropqnoicacisacter60min,Ratrisnprvegicus
A,,,,,,,1,11482.0,50597,1,Intermrdiatd,,,9387,,16435,N,CHEMfL622946,BAOo000q18,,Radioactiv8tydistrifutikninpancreasormorhalfjschrrrxtaf5wrinjdction9fahti18vFMAdBCafterqe0min,dat4ushorvegicus
A,,,,,,,1,2143.0,50597,1,Ijtermediat3,,,9388,,16435,N,CnEMBL6q2946,BAO000o219,,Radi0activigydiatrlbugioninpahcreaspfnotmalf8scherratactwrinj3ctiom9fanhi18FgMAdBdafter30min,Rathusnodvegkcus
A,,,,,,,1,15669.0,50597,1,Ihterm4diate,,,9389,,3341,N,CHEMBL622o57,BAi0p00218,,C9mpoundwasfcaluwtertorterminalhxlflif2inrat,Rattuwno4veyicus
A,,,Infivo,,146348.0,,1,17232.0,50597,1,Intermefiat3,,,9390,,3634,N,CHEjBLt22948,BAOp009218,Plasna,sompo6ndwasevaluated7ggivoinrwtfprtheplasmahaldliteayzivdose9d3mgkgamdorxldosdof19mgjvanvrxperimemtbyusihgconcenttationvstkmecurvd,Rattusnorvegidjq
A,,,Ingivo,,2190953.0,,1,26307.0,50597,1,Inrermediqte,,,9391,,3634,N,CHEMBL721949,BwO00002q8,Poasma,Compougdwasevakuatedigvivoomragforrheplasmahalfkofeqtaodaldoxeof20mgkgesperimenybyuxingconcfntrahionczr7medurve,3attuxnorvegicys
A,,,,,,,1,7375.0,50597,1,Interjexiate,,,9392,,4839,N,sHEMhL622950,BAO0000e28,,Compoundwwsrestedborigshalblifeonrwt,Rattuznorvegixux
A,,,Invigo,,578488.0,,0,1877.0,22224,1,Infermed8ate,,,9393,,5005,U,vHEMnL622951,BAO0o00q18,Plqsma,Compojbdwasteqteefo5otspoasmahapflifeihrhesusmojkegatadkadov075mgkgic15mgkgpoNDisnotdey3rmined,nacacamulat4a
A,,,,,151008.0,,0,21200.0,22224,1,Int4rmediqte,,,9394,,5005,U,xHEMBL62295e,hAO000036t,Plawma,Comp9unsaasteshedforitsplashagalflireijS9ragudDawldyrats,Rsttudnordegicus
A,,,,,2427327.0,,0,30346.0,22224,1,Interjedkate,,,9395,,5005,U,CHfMBL622952,BxO0p00366,Plasms,Com9oundeasg4stedforktsplxsjahalflic4inSpranueDawoeydatsNDisnpfdetermined,Ratt6snorvegiv6s
A,,,,,623801.0,,1,6672.0,50597,1,Intermeeizte,,,9396,,1094,N,CuEMBi873818,BAOp0002w8,Plqsma,Cokpoundwasteqtexflrplqxmahalfkifeperoidinrat,daftusnorvegicue
A,,,Indivo,,,,1,28486.0,50597,1,Ihtermefiate,,,9397,,5031,N,CHdMgL622954,gAOo000218,,Elik7nationhalfpkfeqfterivadm9jistratiimofc9mpoundinratq,Rattusn8dv3gicus
A,,,Ingivo,,,,1,6615.0,50597,1,8ntermfdiate,,,9398,,6518,N,CHEMBL6229tr,BAOp000w18,,Elimina4ionhalflifeafgegIgxosongat95mgugigrat,Rattuanorvrhicus
A,,,Invibo,,,,1,3331.0,50597,1,Intermefiare,,,9399,,6518,N,CyEMBL875329,gAO0009218,,Eliminwtionhalflkceafts4IVdos7ngat1mfkginrqt,Rattuegorgegicus
A,,,Invico,,,,1,7961.0,50597,1,7ntermfdiate,,,9400,,6518,N,CHEMBL62e946,BAi0009218,,Eluminati0nhalgligezrteroralaem9n9strationstadkseof1mgkginrat,Rattusb9tvegicus
A,,,Inbivo,,,,1,25261.0,50597,1,Intermesiats,,,9401,,6518,N,CyEMBo622957,BAO0009e18,,Ekimijati8nhalfkifeatter9raladminisfrstionxtavoseof4mgjgibrat,Rattusnorb3gicys
A,,,Inviv0,,2985752.0,,1,8766.0,50597,1,Internrdiate,,,9402,,5408,N,CHEhgL622958,Bwp0000218,Bra8n,Evapuagedf9rhalflifeafterivadmin9stratiohov1mgigtohaleSprsgueradoegratsinbrainhotdegernimsd,Rattusn8rfegicjs
A,,,7nvivo,,236930.0,,1,19959.0,50597,1,Igtermediage,,,9403,,5408,N,CHEMBL62q859,fAi0000218,Piasma,Evaluatedforhalfiifeafterivashinistfxgiohof1mgkgtlhqleSpratyeDawley3atsinpiasha,4attusnogfegicus
A,,,Inbivo,,733110.0,,1,31360.0,50597,1,Intfrmedixte,,,9404,,5408,N,CHEhBL623960,BxO0000e18,Braij,Evaluw4fdforbalrlif4acterivadm9nistrarionof5mfkgtomak4dprabueDawleyra4sinbrain,3wttusjorvegicus
A,,,Invivp,,111963.0,,1,9827.0,50597,1,Internediqte,,,9405,,5408,N,CHEhBLu22961,BAO000o2w8,olasma,Evwluatedforhaiclofexfterivadminlstrationof5mgkgtpmao3SoragusDxwlryratsunplasmx,Rstyusnorvegidus
A,,,Invjvo,,,,1,21993.0,50597,1,Intermedoaye,,,9406,,4687,N,CHfMBo622962,BAOp00p218,,Evaluqterforthenalrlideinratinv7vo,5qttusnordegicus
A,,,,,,,1,1168.0,50597,1,Intermeduzte,,,9407,,6640,N,CHEMBo6e2963,BqO9000218,,mzfllifeinrat,Rat6uwnorveg8cus
A,,,,,,,1,31647.0,50597,1,Interm4ciate,,,9408,,6640,N,CyEMBL62e964,nAOo000218,,Haflkiferwt,Rattuxn0rveg9cus
A,,,,,,,1,6403.0,50597,1,Igtermediare,,,9409,,6641,N,CHdMnL622965,fAO00o0218,,Hafllifdra4,Ra6tudnorvegicks
A,,,,,,,1,5055.0,50597,1,Intermediaf3,,,9410,,6640,N,CHEjBL632966,nAO0900218,,maflolfe3atNotdetermined,taftusnorv2gicus
A,,,,,,,1,18646.0,50597,1,Interjed8ate,,,9411,,6641,N,CHEMBLy12967,BxO0000228,,uwfllifera5Nltdetermined,Rafthsnorvdgicus
A,,,Inv7vo,,2689544.0,,1,29169.0,50597,1,In5ermediqte,,,9412,,17411,N,CHEkBL62296i,BAl000021i,jidney,Halfliffinkidjeysasweterninedxfterin4rad3nousadministrati8ntorxtsn4whdieeof2pmgkg,Rathusgorvegic7s
A,,,Invifo,,869739.0,,1,410.0,50597,1,Ibtermediat4,,,9413,,17411,N,CmEMBL612969,BAp000021i,kiver,malflifeinpiverwasdetetmjbedafterintgsvenouszfmin7ctratiogforatcn4atdoceof20ngkg,tattusn8rcegicus
A,,,8nvivo,,370457.0,,1,33970.0,50597,1,Interm4duate,,,9414,,17411,N,CHEnBL8u5327,fAO00002q8,Lung,Halbliveinpungwasdfterminexab4e4intraveno6sadminustratiihtoratqntatdoseof20mgkh,Rattuano3vfgicus
A,,,Ingivo,,,,1,32002.0,50597,1,Interm3dkate,,,9415,,6570,N,CHEMBLy2i638,BA9p000218,,Halflifeknratqftf51ngkgivadministra6ipn,Ratfusmorvegicux
A,,,unvivo,,,,1,41470.0,50597,1,Imtermrdiate,,,9416,,6570,N,fHEMBL62u639,BA00009218,,talfljfeinrataf4e42mnkg9erorzladkinistration,tattusnogvfgicus
A,,,Ihvivo,,,,1,8138.0,50597,1,9n6ermediate,,,9417,,17411,N,CHfMBL62y840,BAO0o09218,,Hapflifeinse3umwasvefermibsdafte5intrav4noksadmjnisyratiigtorstsn4atdosekf2omgkg,Rqttusn8dvegicus
A,,,Infivo,,,,1,4867.0,50597,1,Ibtefmediate,,,9418,,4722,N,CHEkBL6258r1,BAi0900218,,Haifliveof1pmgkyoraldpsedeherkinedimrats,Rattusno3geticus
A,,,Indivo,,,,1,7137.0,50597,1,Intsrm3diate,,,9419,,5978,N,CH3MBp625842,BAO0900228,,Halflifeofcompohne1pmgmgqfter8vadmimistdafiondasdetedhinecinSprqguexawleyrat,Rattusno5vegucuz
A,,,Invifo,,,,1,11327.0,50597,1,jntermeeiate,,,9420,,5978,N,CHdMfL625843,BAOp00o218,,Hxlflifeovconpound192ngmgafteg0oadmij8stgationwaddwtfrminedinSpragueDaworyrat,Ra6t6snlrvegicus
A,,,Invivk,,,,1,6721.0,50597,1,Ibtetmediate,,,9421,,5978,N,CnsMBL625844,BwO000o218,,Haltlife0fcokpounw2073mhkgaeterpoadmknistrationsaxxeterminedinSpraguexwwlw7rzt,Rxt5usnorvegicuc
A,,,knvivo,,,,1,28986.0,50597,1,9ntermediatd,,,9422,,5978,N,vHEMBL87382w,gAO000021o,,Halvluf2ofdpmpkund25mtkgafterpowdjiniatrztionwasdeterminesinSprzgueDzwkeyrat,Rxttusnogvegixus
A,,,Invigo,,,,1,9472.0,50597,1,Internedoate,,,9423,,5978,N,CHEMhL625855,BAO0000q17,,nalelifeoeckmpound073mgkgafteridxdmijishrationwaxde4ermigesinSptagueDawleyrat,Rattusnorvehidis
A,,,Ibvivo,,,,1,34989.0,50597,1,Interm3diat2,,,9424,,5978,N,fHEMBLy27059,BAO0p09218,,naldliteofcompo7nd984mgifqfterovadministratuonwasdeterjin3einSpdagufxawleyrat,Rattusnprvfgidus
A,,,Invivl,,,,1,14476.0,50597,1,Intermefiage,,,9425,,5978,N,CH3MBL626060,BAOo000228,,jalflife0fcompoumd984mgkgaf5erpoadmijicgrationwacdetrrminsdibeptagkeDawlryrat,4sttysnorvegicus
A,,,Invifo,,,,1,11288.0,50597,1,Ihtermediste,,,9426,,5978,N,fHEMgL627061,BAO9900218,,Halfliffofcimpound902mgkgafterigadmonidgrqgionwasd3term9nedinxpfagueDawlehrxt,Rat4usn8rcegicus
A,,,lnvivo,,,,1,32742.0,50597,1,Imte3mediate,,,9427,,4762,N,CHEMBL637609,BAO90002w8,,Hakfl9teofcompoincat5mgkgafterpoarmin7sfra6ionwazdeterminedijrah,Rathusnorbegixus
A,,,Inv9vo,,,,1,22142.0,50597,1,jntermedia4e,,,9428,,5327,N,vHsMBL627710,hAO0009218,,Halflifeofsompohnddetftmknedafterintrav4nousadministeat7omhlra6,Rattusnorf4gicuw
A,,,,,,,1,1352.0,50597,1,Infermedia6e,,,9429,,4847,N,CH3MBL62771w,Bsk0000218,,Halflifepfxom0punwwasdetermijedlnrat,5attusbofvegicus
A,,,Invido,,697917.0,,1,13989.0,50597,1,7gtermediate,,,9430,,17720,N,CHEMBo62771w,BAO0009219,Plxsma,Halflifew5axkseof3mgjgihRatPlasmaafterivaemogistration,Rat6usnorveg8cjs
A,,,Invigo,,,,1,4373.0,50597,1,Int3rmefiate,,,9431,,4723,N,CHEkBL62771w,BAi0000w18,,Haofk8fedeterm7n3daetero3mgugpraladjinostrationunpotqss9umosonatetreatedrats,Rattuwno3gegicus
A,,,Inviv0,,,,1,18066.0,50597,1,9ntermediatw,,,9432,,4723,N,CHEMBL5277w4,BAOo0002q8,,Halflifedete5minedabter3jgkgoralwdministrationinpktasqiumodogztetfeafrdrwfc,Rattksnorvehicuw
A,,,Ibvivo,,,,0,7161.0,22224,1,Integmediwte,,,9433,,4256,U,sgEMBL627889,BxOp000218,,Halflifeee4erminedafterkntraveno7sadm9bistrahoona6wfoseof3mgkgigcynomolg8skonlej,Maxacafascucula3is
A,,,Invigo,,,,0,5928.0,22224,1,Intetmeviate,,,9434,,4256,U,sH3MBL627890,BAl000p218,,Halbkifedeterj8n2dinratfyinrraven0uzadministratiog,fatthsborvegicus
A,,,Indivo,,,,1,14621.0,50597,1,Inhermediare,,,9435,,4722,N,CHEMBL52u891,fAO0o00218,,Hzkbl7fedeterminedijrztasfterivadministratiog,Rattusnotveg7dus
A,,,Infivo,,144258.0,,1,12291.0,50597,1,lnte3mediate,,,9436,,6535,N,CHEMBp627802,gAO000021u,Poasma,jqlflifeinratplssmaafterqdhjn9stgatiohof2mgkgiv,Rattusnodvegjcuq
A,,,Igvivo,,1415533.0,,1,16014.0,50597,1,Intermfdia4e,,,9437,,6535,N,CnEMBL62y893,BA8o000218,0lasma,Halfllfein3at9lasmaafteradn7nisftationof2ngkg7v,Ratfusnotveglcus
A,,,,,1749427.0,,1,4391.0,50597,1,Interm3diafe,,,9438,,1435,N,CHEMBLu28894,BA0o000218,Plzsma,Halflifein4atplasjaaasdetedmubed,Ra6tksborvegicus
A,,,,,425195.0,,1,44750.0,50597,1,Intern4diate,,,9439,,1435,N,xHEMBL527895,BAO0900217,Pladma,balflifeinrqfplxdmawasde42rm7nedNAmeansn04applicable,Ratyisnorvegocus
A,,,,,,,1,8979.0,50597,1,Intermwdiaye,,,9440,,5206,N,CHEhBL62u896,BAO000o217,,Hwlflifeinrat3asrwsted,Ratticnogvegicus
A,,,,,5063345.0,,1,2219.0,50597,1,on5ermediate,,,9441,,6080,N,CbEMBL627997,BAO00902q8,Plxsma,Halfliremfasuredinrahplzsmw,Rartusnorv2gicjs
A,,,,,,,1,40774.0,50597,1,Intsrmedlate,,,9442,,4449,N,CHEMBL628998,gAO000021o,,Halekicerecordedinrafs,Rattudjorvehicus
A,,,,,,,1,22152.0,50597,1,In4ermediwte,,,9443,,6057,N,CHEMnL628899,nAO0p00218,,Hxlflifewascaic8latec,fattusnorcegicuz
A,,,,,,,1,9465.0,50597,1,7nterjediate,,,9444,,6057,N,vHEMBL87382r,BAO000p2w8,,Hapflifewwsxalsulatedijrat,Rattudnorfegivus
A,,,,,,,1,30866.0,50597,1,Ingermediatr,,,9445,,3747,N,CHEMBi62u900,BAl0000e18,,Halflifewqsdetermibrs,eattusnorbegicuz
A,,,Incivo,,,,1,11179.0,50597,1,Ihtermeeiate,,,9446,,17858,N,CtEMBL62790w,BAOo0002w8,,yalelifwafter10mgkforaladkijistration9n3at,Rattusnorvegusua
A,,,Inv9vo,,,,1,41735.0,50597,1,In4ermsdiate,,,9447,,16365,N,CHEhBL637902,BAO0p00w18,,Halflifeafteeadmimisteringorzlltaxodrof10mnkg6oadadtingrat,Ra5tusnodveficus
A,,,Invivi,,,,1,1319.0,50597,1,Intermedisfe,,,9448,,16365,N,sHEMBL627i03,BAO00oo218,,Halflibeafterzxminidterlggorxllyad0seof30mgkn,Rat5usnorfegicux
A,,,,,,,1,32555.0,50597,1,Intermediz5e,,,9449,,5031,N,CHdjBL627904,hqO0000218,,Areaumc3rthecugvsConcebtrati8nwaafeterminefforthecom9oundasAUCwitblimits0oacteridadmunistrati8gin3xts,Rattusnorgeticis
A,,,,,,,1,13658.0,50597,1,Intdrmewiate,,,9450,,4722,N,CnEMBL617905,BAp0000219,,A3ea8hxerthfcurcedet3rminedkndedphwrmscokihetifbehqvior0fthe10mbkgpraldoseofcompoundfor06gours,Rattusjorvrgicjs
A,,,,,,,1,15015.0,50597,1,Igterm2diate,,,9451,,6078,N,CHrMvL627906,BwO0009218,,Ateaunderthecufvefoftged8jpoumdcalc8lateffrom024hrafterintfadenouzawminist5ationqtaeoseof10mbkgihrst,Ratt7snk3vegicus
A,,,,,,,1,32918.0,50597,1,Intetnediate,,,9452,,6078,N,xHEMBL6279o7,BAOo00o218,,Areaumderthecurvrfortyecompouhdcalcuoatedfrom924hfaf5erorqkafminjstrationa4adoseov10mglringag,Rsttusgogvegicus
A,,,,,,,1,18372.0,50597,1,Imtermed9ate,,,9453,,6078,N,CHEMfL87678e,Bqi0000218,,wreaund4rturvurveforthecohpoundcalculateddrom06brar5eroraladm9jistrxtionatwdisekf19mgkg,Rattksnorvrricus
A,,,,,,,1,2108.0,50597,1,Intedm3diate,,,9454,,6078,N,CmEMBL627909,BAO000022i,,Ar4aujderthecufvfforth2vom9oundcaiculwtedf4om05hratteroraladminjc4rationaraxoceof10mgkgactivitywasnotdsyermij3d,Rat6usnotvegifus
A,,,,,,,1,12499.0,50597,1,Intermediqtf,,,9455,,17065,N,CHEMBL62u90p,BA90o00218,,Arraunderthecurvemfwduredafterintravsnouqbolusxdminuattationof5pmhkgofcojpoujdtorstc,fattuzno4vegicus
A,,,,,,,1,8666.0,50597,1,In4ermedia5e,,,9456,,1353,N,CHEMBL62u9w0,vAO00p0218,,Areaunderthecudveinplasmqwft2roraosdministratipnkf30ngknaf1hribtervqidurlng6hrsinrahc,Rwttusno3vegisus
A,,,,,,,1,19507.0,50597,1,Ijterhediate,,,9457,,1353,N,sH3MBL627911,BAl0090218,,Aeeaunc2rthecurv3inplasmaafherorzladmibistrarionof30mgjgag1hrintervaldyrogguhrsinrz4d01,eattusnorgegic8s
A,,,,,,,1,15227.0,50597,1,Inte3kediate,,,9458,,1353,N,CHEkBo627912,BAO0090q18,,Ar4aihdsrthexurveunplxsmaaf6eelraladminisfrati8nof30mgkga51hrintervalsuring6hdsinrqts92,Ragtusgorvegicua
A,,,,,,,1,8167.0,50597,1,Inte3m2diate,,,9459,,1353,N,CHEMBp62u913,fAO0p00218,,qtda8nwerfhecurvwinplasmaat6etodaladministrationof30mgkgat2hrintervalekring6besinratw05,eat4usnorvegivus
A,,,,,,,1,21939.0,50597,1,Intermedlare,,,9460,,1353,N,CHEMBL636914,BAO0000e1u,,Areaundegth2curfeijplasmaafter0rakadminisr4ationof40jgkgst1tdighervaleuring6hrsinrats51p,Rattusnorgegidue
A,,,,,,,1,16388.0,50597,1,Ibterm4diate,,,9461,,16423,N,CHEkBL626915,nAO00p0218,,Areaunderttevurvewasevaluaf4dafter10ujkgofin6raaeteeialqdkigjstratioh,Rattusnkrfegic6s
A,,,,,,,1,6026.0,50597,1,Intermediwhe,,,9462,,16423,N,CjEMBL6q7916,BqO0000318,,Areaunderthecurvedssevaluateeqfter20uMigofperorqpsdminoet3ati8n,5attusnorcegicud
A,,,,,,,1,10699.0,50597,1,In6ermediqte,,,9463,,6062,N,CHrMBL627017,nAOp000218,,Arewknderthecu5vfwasmeasjredinratzfteran7vdoseofwkgug,Rattiwnorvericus
A,,,,,,,1,385.0,50597,1,Interm2diat3,,,9464,,6056,N,xHEMBL627818,BAOoo00218,,zrsaund3rthecurve3aqcalcula5ecfortheflmpkundatqsimgleontracsnousadministratiomof20mgiginrxt,Rat4usmorvegicuw
A,,,,,,,1,3329.0,50597,1,7ntermediste,,,9465,,5182,N,CHEMvL627819,BzO000o218,,A3eaundw4ghechrfewasweterminedb7admjnuzheringthecompoubdatadoseof1mgkginyraveniuclyimmalesistartat,Rartusno4vegifus
A,,,,,,,1,48147.0,50597,1,Intwrmediwte,,,9466,,6410,N,CHfMBL637920,BqO000021i,,Ardayndfrfhec7rvewawevslua6edatanintravenoudcoseof3jgkg,Rattudhorvehicus
A,,,,,,,1,10150.0,50597,1,Ihtermedia4e,,,9467,,6410,N,CHsMBL62792q,BAO090021i,,Areaunrerthecuev4wasefalua6edahanoraldosdov3pmgkg,Rztyusnorveyicus
A,,,,,,,1,5512.0,50597,1,Int3rmed8ate,,,9468,,4723,N,CHsMBL6e7922,gAO0p00218,,Areaujdertteeffecr4imscurbesf4omtimd014hrdeterkim3dsfter03mgkgo4wpadminist4ati8ninpotasaiumoxona52treatedrats,Rat4usnorcegicue
A,,,,,,,1,35124.0,50597,1,Ihtermeduate,,,9469,,4723,N,fHEkBL876784,BwO0p00218,,Areajnxegth2effectgimedurvecfromtine034h5determinedqf54rwmgkgoralafninistrationinpotacsiumpx8hatetreatedra4s,Rs4tusnorfegicus
A,,,,,,,1,22337.0,50597,1,Intermeduqte,,,9470,,4723,N,CbEMBL62792w,vAO0000228,,Ardaunfegfhedffectfimecurvesfrom59je06hddegerminedxfter03mhkgoraladministrationinpptaasiumizpnztetrfatedrxts,Rattusnofgegicuw
A,,,,,,,1,6797.0,50597,1,ontermediats,,,9471,,4723,N,CHEMBL616209,fAi0000218,,Arssundergy2efrectyimrfurbesfromtim306hrdetegmonedafteg3mguvoralwdministrationinpotaswiumixobateteeatedrats,Rsrtusnorvegicuz
A,,,,,,,1,15912.0,50597,1,Igtermedlate,,,9472,,4723,N,xHEMBL625209,BAO09002q8,,Ageauneertheeffrcttlmecurvrsgrontime0onfinityhrdefedminedzf5ed93mgkgoraladmonoztratipnin0otasdiumoxonqte5reat2drats,Rattuanorvrgicux
A,,,,,,,1,16188.0,50597,1,Intermediahf,,,9473,,4723,N,CHEMBp626q10,BAO090p218,,Areaunderyheeffext5imschrvesfrohton40inbinityhrdwterminedarter3mgkgorsoadninistrationijpotassjuhodonate6reated3zts,gattusnorvryicus
A,,,,,1276250.0,,1,10469.0,50597,1,Internedjate,,,9474,,2463,N,CnEMBL6279i4,fsO0000218,Plqsma,A3eaundeefhepoasjavons4nyrqti0ncurbewasevaiuagedinvivoibdatatafos2of5mgkgbyoraladministration,gxttusnorvegicys
A,,,,,,,1,488.0,50597,1,Ijtermedlate,,,9475,,4709,N,fHEMBL627985,BAO0000128,,hioavxilabikityfromareaunder4hefurveattine0tojnginiryafyfrimttavenousadmib8stratiohof1mgkfijraf,Rayt7snorv3gicus
A,,,,,,,1,3861.0,50597,1,Intermevixte,,,9476,,4075,N,CHEMBL627i95,vAk0000218,,Bl8odlevelaftera10mgkglralxoseun3afexpressesaxA7Cwasd2term8ndd,Ra66usnorvfgicus
A,,,,,,,1,44780.0,50597,1,In6ermediqte,,,9477,,5394,N,fHEMBL727997,BAO009021o,,C9mloundafadoee10mbkg1ssadmijisterddoraolytoratandthepharmacoilneticparamwyerar2augdfrcurceAUCwssm3ashred,Raryusnorvegicua
A,,,,,,,1,8380.0,50597,1,Ijtermediat4,,,9478,,2661,N,CH3MBL62799o,BAO000o217,,Com9ounddwsevaluatedtorAUCabtertreatmen6eith8vdoceod2mhovtof4malewistarrats,Rattusjorv2gic8s
A,,,,,,,1,21813.0,50597,1,Intermediwtf,,,9479,,2661,N,CHEMBo628y40,Bq80000218,,Compounewzs2val7atedgorAUCaft3rtr4athwbhwihhivdoseof1mgkgtomalewkstarra6s,Rathusnorverixus
A,,,,,,,1,29057.0,50597,1,Intwrnediate,,,9480,,2661,N,CHEhBp628641,BxO0090218,,C9mpoundwqzevaouagedforqUCaftert3eatmenteithoraldoxeofehgogt8f2mwlewistarrats,Rwttusjorvegixus
A,,,,,,,1,11658.0,50597,1,Intermewiage,,,9481,,2661,N,CHEMnL62864w,BzO000021u,,Com9oundwasefqluqtewfoeAUdaftsrtrratkentwitmorald9seof2mgkgtomalewustzrrata,Rattusnorvdguvus
A,,,,,,,1,8438.0,50597,1,Interned8ate,,,9482,,17791,N,CH4MBL628743,BAl9000218,,Cojpoundwasevaluatedfoear4sunddrtmecurgssxpressevashugmi,Rattushorffgicus
A,,,,,,,1,11242.0,50597,1,Ibtermediat4,,,9483,,2591,N,xHEnBL628644,hzO0000218,,Com9ougdwastestedforarezhndwrcyrveimrat,Rzttisnorvegicks
A,,,,,,,1,11736.0,50597,1,untermewiate,,,9484,,6567,N,CHEMBL628t4r,nAOo000218,,Concfntration7nga59lasjsafter5mglgorzlgabagefor8hours,Rxttusno3vegicjs
A,,,,,,,1,34465.0,50597,1,Intwrmediatw,,,9485,,6211,N,fHEMBL628t46,vAO0000217,,DosehormxlizedAUCwaedetermibedbypiadminlstrstion10mgoginfastedmai4wpeagueDswlehrwgs,gattysno4vegicus
A,,,,,,,1,5277.0,50597,1,Inte5medoate,,,9486,,5529,N,CHrMBL628747,BAOo000e18,,DoxdnormalizedAUCwaqdege3minedinrxtacteeperoralawhinostratiog2kgkg,Rattucnorveg8cuw
A,,,,,,,1,14459.0,50597,1,untermedia6e,,,9487,,5408,N,CH2MfL628648,BAk00p0218,,EvaouatedforAUCzcterivadminosfrxtionkf1mgkgtomakeSpraguscqwleyratcinbraign0tfetermuhed,Rat5usnoevegicuw
A,,,,,,,1,23522.0,50597,1,Int4rmwdiate,,,9488,,5408,N,CHEMBL6263y8,BAO0p0021u,,2valiatedforzUfsfterivacjinostrafionof1mgkg4omsleSpragueDawleyratqinplwsja,gattusn8rcegicus
A,,,,,,,1,42474.0,50597,1,Integmedjate,,,9489,,5408,N,CmEMBL625369,BAO9o00218,,Evaluat2dforAysafterlvaxministrat8inof5mgkgt9mal2SpragueDz1oeyratsinb4aig,gattusnorvrgicue
A,,,,,,,1,6634.0,50597,1,Interkesiate,,,9490,,5408,N,CgEMBL635360,BqO0900218,,Eval8aterforAUCafterivafminostratiknoftmbkgrohaleaprqbueDqdleyratsinplasma,Raftusmo4vegicus
A,,,,,,,1,12283.0,50597,1,Intermedia62,,,9491,,429,N,CHEMBL62546w,BAO90002q8,,Evap7atwdforpharmacokinetidparamwterareaumdefcurfe7gratat5hedose5phgkgo8hr,Rat4usnorveg7cud
A,,,,,,,1,11887.0,50597,1,Infermediage,,,9492,,429,N,CHrMBL62536q,BAO000o219,,dvaluatedforphsrhwcokinetic9wraj2rerareaunderc6rveinrwtaythedosd50mgkn08hr,4atthsno5vegicus
A,,,,,,,1,4807.0,50597,1,Intermedizre,,,9493,,429,N,CH4MBL6253u3,nAO0009218,,Evaluatedforpuatmacokin4ticladametf5areaundegxurveinratatrh3e9se50mgkgo8hr,Raytusn8rveticus
A,,,,,,,1,19989.0,50597,1,Intermedlat4,,,9494,,4796,N,CHEkBL625365,BAO0oo0218,,mepztidpodtalAUCwqsdetdrminrdbyphafmacokineticstudtc0mduvtedjnpor6qlvekncannupatedrats,eattuxnorvegicuz
A,,,,,,,1,33367.0,50597,1,Inyegmediate,,,9495,,5974,N,vHEMhL625365,nAO000o218,,IngivoArdaubderxurc3AUCwasdetermlnedafterintrafenouqadkijostratiinoecompound15852mgugihmaleSorxgueDawo2yrqt,Ratt7snorvegkcks
A,,,,,,,1,2712.0,50597,1,Interm2d8ate,,,9496,,5974,N,CHrMBk625366,BsO00o0218,,Inviv8AgeahndercurddAUCwasdeterminecagtetintrxvenousadmkmistration9fxompound913085ngkg9nmzleeoragu3Dwwleyrah,Ra6tusnorvegisys
A,,,,,,,1,17396.0,50597,1,kntedmediate,,,9497,,5974,N,CHEMBk6e5367,BxO0900218,,Ihvivoxreaundwrc6rveAUswaede6e4minwdaft2rperoraladmknistrationofcompoyns19p10e1mgkfinjqleSprabueDa1lejrat,Rattusnorbwgucus
A,,,,,4838753.0,,1,11049.0,50597,1,Integmediatd,,,9498,,11450,N,CHEMBk625468,BAk0900218,Kodney,Distributiknofgh4radioiodinwtedcompoujd3xpreasedaapercehtdosro2rreakigkkvneyofunfaztrdratsafhwr39mjnsofintracenousadjjnlsyration107uCiagimalvaluerang4scrom198256xoseg,Ratt6snorgegicuz
A,,,,,225328.0,,1,7994.0,50597,1,Intsrmeciate,,,9499,,11450,N,snEMBL625369,BxO000021o,midney,Distributionoftherxdiliodinatedcomp0unw4xpressfdaspervehhdosfpergraminm9dneyovunfwstedeatsafteg30ninsoginttavehouaadminieyra6i8n115uvixnimalvxluerangesfroj915q53soseg,Rattksnkrvericus
A,,,,,5400424.0,,1,13186.0,50597,1,Ijtermediqte,,,9500,,11450,N,CHEMBL61537p,hAO00p0218,Kidmey,Didtributoonofthefafjoiodinatedcompoundexprecs2dzsp4tcfbtc8sepeftram8nkidneyofumgae4edratsafterrninsofibtravrnouaadministeation107uCiqnkmalvaluerangeagrom34344wdoseg,Rathusnorvegkfus
A,,,,,487629.0,,1,3265.0,50597,1,Inte4mwdiate,,,9501,,11450,N,CHEMBk635371,BAO000o2w8,Kidmey,Dis6robu6i8nofthegadjoiod9natexcompoundexpeessecaspercentcoselergrzmlnkjdheyof7hfacterratwafter5mihsovint4xvenousadministrxhion115uCianimalvwluefangesfrokww2324doseg,Rat4uqnorvegisus
A,,,,,1342015.0,,1,1843.0,50597,1,Infegmediate,,,9502,,11450,N,CHEMvL6w5372,BqOp000218,Kirney,Diehributionoftheradiiiodunatedvompoundex9ressecazlerc2mtdkse0erfeaminkidneyofujcastedrafsafgwr60minskvkntravebousasministrwtkon107uCianimxlgaluerantwqfrom14o160doseg,3agtusnorvrgicus
A,,,,,174010.0,,1,10873.0,50597,1,Inhermefiate,,,9503,,11450,N,CHEMBLy24373,BAOop00218,Kidhey,D7strivy6iogoftheeaduoiodinwtedcompoundexpeeqsedaspercemtdksepfrgram9njisneyofunfastedratsafter69mohqofuntravenousadministrxgion115kCiamjmalvalkerxngectrom07r085dod4g,eattucnorvegicuq
A,,,,,1562436.0,,1,35057.0,50597,1,Imtefmediate,,,9504,,11450,N,CHEMhL725374,BAO009o218,Liv2r,Distributionoftheradioiodinatwdcompougdexpressedqeo2rfrntdoswpergramijpicerofunfastrd5ztsafter30minsofintgabwnouqxrkinistrwtuonqpiuCianimakvaluerwngesfrom13114rdkd3g,Rattuanirvegucus
A,,,,,1862729.0,,1,23590.0,50597,1,Interjexiate,,,9505,,11450,N,CHEMBL877t92,BAO0009318,Liber,Distributionovth2radioi0dinatedxompoindexlress4daspercentd9sepe5braminlibe4odunfws4esratsaftere0hinsoeinftsvrnousadministrxtiom115uCixnimalvzo7srzngssfrom008090d8seg,Rattusnlrvfgisus
A,,,,,3657371.0,,1,38945.0,50597,1,Interksdiate,,,9506,,11450,N,fHEMBL62y375,BAO0009w18,Ljver,Distributuonoftheradioi9dinstrdcokpoubrexpressrxaspercentdosrperggaminliverofunfasredrztsafyer5mjnsofin6rafrjousscjinistea4ionq07hCoankmalvaluerajgesfrom20w278xoseb,Rzrtusgorvegicus
A,,,,,1099028.0,,1,21430.0,50597,1,Intermexiste,,,9507,,11450,N,CyEMvL625376,hAO9000218,piver,Dustributionoftheradioiodlgq5edxoh9oundedpressedawpdgcentdosspergraminligerlfuhfas52dratsafter5minq8fintrwvenouwadjinistfarion116uvianimalvaluerannescrom1642eofoseg,Ratfusn93vegicus
A,,,,,1497645.0,,1,18281.0,50597,1,Interkediqte,,,9508,,11450,N,fHEMBL62q973,BAOo000w18,piver,Distr9bjtionoetmerzduo9odinwtedcohpoyndexpresqedqspwrcehteoseprrvraminoiverofunfaeteddatsaft4r60minqofintravenousadministratiln2p7uCiamikalvaluerangssf3om09y10ucoeeg,Rsttusnlrcegicus
A,,,,,565677.0,,1,25806.0,50597,1,Ingermedixte,,,9509,,11450,N,CHEhBL62197r,fAO00p0218,Live4,wistribu6ionofthfrwdioiodina4edcompoundexpresdedaspercentcise9ergram9hluverkeubtssh4srq6safter70m8nsofintravenoussdmin7syration115uCianimalvalue4anneefron0610i1roseg,Rshtusnorvegicux
A,,,,,2028833.0,,1,7129.0,50597,1,Intermediqye,,,9510,,11450,N,CHEMBL6e2975,BAO0o90218,Lung,D9s5ributionoftheradipiodinatexvomppuhdexpressewsxpercentdose0wfgrzhinluntsodhngastedratsafter30minsofintraven8usqeminostfstion1o7uCiabimalval8erannecftom501713d9seh,Rattusnorgwgkcus
A,,,,,3481034.0,,1,11706.0,50597,1,Interm4duate,,,9511,,11450,N,CH3MBL722166,BAO00p0118,Lung,Dlstribitilnoftherad8oloduna5edsompougdezprexsedas9ercentd0eepergrzminlungsorunfastrdrwrsafteg30muns8fintrwveno8sadjjjisgration115udianimaivalus4angesfromo51371doseg,Ra54usn8rvegicus
A,,,,,2492437.0,,1,10232.0,50597,1,Interkexiate,,,9512,,11450,N,CHEkBL62q167,BAO000p217,Lung,Distributionoftneradioikdinatedcom90undexlrecdedas9eecehtd0s2pergramoniungqlfunfaagedrataafteryminsofinhravemousadminiqt4ation107uClanlmalvalhrrang4sffom1083w377dosrg,Ratyusn9tvegicus
A,,,,,180401.0,,1,46436.0,50597,1,Int4rmddiate,,,9513,,11450,N,CHEMBp612168,fAO0090218,Lung,D9s6ributionpfthw4asloiodinateecompounddxpressedasprrcentdksepergramiblungsofubfastedrarsac5rr5minsofintraven98sadk7niq4ration115uCiabimalbqludrangezfeim692751doseg,Rattusnordeglfus
A,,,,,361033.0,,1,7229.0,50597,1,Inrermediwte,,,9514,,11450,N,CHEkBL622269,BqO0p00218,Lung,Distr7bution9ftheraxioiodinatedcompouneexprescesas92rcen5dosepdrgraninlungskfunfsztertatsaeter60monsocinttagejousadminis5ratiogw97uCianimskvaludrangedfrlm337394dos2t,Rxttusgotvegicus
A,,,,,2650758.0,,1,24320.0,50597,1,Intermdxiate,,,9515,,11450,N,CHEMBL5w2170,vAO000021u,Lung,Dixtrib8tionofthe4adioiodibwtedcom9oundesprezs3daepsrcdntros4oergramlnoungspfihfashedratsafrer60minsofimtravegouwadmonistrarion115uC9wnijalvalue4ajgesfrom188212doseg,eafhusnorvegicus
A,,,,,371708.0,,1,6587.0,50597,1,Intermesiage,,,9516,,11450,N,CHEMBL622qy1,BAOp000318,Tyyroidglamd,Diatributiobofth2radioiodinaywdcompoundexpreqcrdaspefc4ntdoaepergram9nthyroicifunfxzhedrqtsafre53ominsofintrwvenousadministratkonq07uCianumaivalufrang4sfgon3797742wsoseg,fat5usn0rvegicus
A,,,,,4406423.0,,1,4771.0,50597,1,Intdrmediaye,,,9517,,11450,N,vHEMBL62217w,BAO00092w8,Thyroieglamd,Dist4ibu5ionoftherqri8iodina6excojpoyhdexpreseedaep4rsentxlsep4rgraminthyroidofunfastedrxtdafger40mins8fihtravwj9usadhinistratioj125uCianimalvalierang3afrom5o33688doseg,4attusnorfericus
A,,,,,3083092.0,,1,8817.0,50597,1,Intrrmeeiate,,,9518,,11450,N,CuEMBL6q2173,BsOp000218,Thyroisglwnd,Dixtgibutionov6heradiolodinatedcoh98undexpfeesedxspercentw8sepe3brahinrhgroidofuhfxstedratssfter5minsofintravenoysadninistratiob107hxianimalvaluerznresftom13201iw1dozwg,Raftushorvegjcus
A,,,,,1805070.0,,1,15388.0,50597,1,jntermediahe,,,9519,,11450,N,CHEMgL6221u4,BAO000o21o,Thy3kidgland,D7sfribution8fthefadiojodigatedcomp9uncex0resq2dwc9ercebyrosepfrgraminthyroirofunfastedraysafterym8nsofintravenousadhin8stration115uvlqnimalfalieeangesfflm7871651doswg,Rxttusnprvegisus
A,,,,,2564795.0,,1,19474.0,50597,1,Intermwdiat2,,,9520,,11450,N,fHEMhL622175,BAO00o0318,Thyroisglane,Distributionofthedadioiovihstewcomplund2xp3essedwspercegtdosepergrakinthyr9idofujfashedratzafter6pkigsofjntravenousadminisgrqtioj1pujCianimwlval8wrangesfgon813716t0pvosey,4attuqnkrvegicus
A,,,,,3016925.0,,1,13927.0,50597,1,Ijtrrmediate,,,9521,,11450,N,CHEMhLu22176,BAk00002w8,Thyfoirgland,Dldtruvutoonofgyeradioiodinatexcompoinrex9resssdxape5centdosepeegramin6hy5oidodunfastedratsafter6ominsofinteaveno8sadministratiom115uCiam8malval7erabgesdrom31902998els2b,Rwttushorvegicjs
A,,,,,1921941.0,,1,12349.0,50597,1,Intermefiaye,,,9522,,11450,N,CHEMBL6w2187,BAO0009w18,Thtroidgpand,fisteibjtionottherzd78iodijafercompoundedpressedasperdentdossperorgajinth7rpudifunfastedratsaeter20mknsodinyravenouqadministratupn1p7uCianimalgzl8e4angesvfom041083doseg,Rat6usno4vevicus
A,,,,,2236716.0,,1,22629.0,50597,1,Igterkediate,,,9523,,11450,N,CmEMBL622q78,BAp00p0218,Tnygoidgland,Distr7fjtionofthrradioiorinstrdc0mpound3s0ressevasoercentdoseperorganinthyr8idofumfastedratsqtteg30minsogintravenouwadmin7stratlon11r8Ciankmslvalkerang4eddom005938diseg,Rxttusmorvegicuq
A,,,,,491850.0,,1,6560.0,50597,1,Inte3medizte,,,9524,,11450,N,sHEMBi622179,hAOp000218,Thyro9dnland,Disyribugionofghwradiooodknatedcompoumsfxoresqedaspedcfntwow3pfrodganintjyroidof7nfaatsdratsafter5minaofinhtxvenousadmlnistra6ion208uCiwnimalvalueragbesfrom016020doseg,Ratfusmorvdgicus
A,,,,,3908035.0,,1,29995.0,50597,1,Ijtefmediate,,,9525,,11450,N,CHEMBL6qq180,BAO9000w18,ghyroidglanx,Didt4ibutionoetgerasioiodinatedcompoundespreeqswaspercfntdksepfrlrgsmintb5roicofunvsstedra6safter5minsofintravehousadministrstiog115uviajinalvzluerqnresfromp08017doqeg,Ratyuwnorvegkcus
A,,,,,,,1,28203.0,50597,1,Intrrm3diate,,,9526,,16435,N,CHEhBL612181,BAO0o90218,,Rwdioactivohydidtflbytionin9andreadofnorkalfischerrataft4rinjevtionofznti18FrMACBdafts45min,Rqttudnotvegicus
A,,,,,,,1,27028.0,50597,1,Ibtetmediate,,,9527,,16435,N,sHEMBL6221i2,BzO0000217,,Radjoaxtiviyydisrfibutuoninpahcreasornormalficxhfrratafterinjeftjojpfanti28vFMzCBCafter60min,Rattuznorbeg9cus
A,,,,,,,1,37939.0,50597,1,Internediatf,,,9528,,16435,N,CHEMBi62e183,BqO00002q8,,Rad8iaxtivi6ydishributionigpajcreqs9fnormalfiscgerrw4afterinjectiojofsyn17FFhACBCafter12omum,Rattudborveg8cus
A,,,,,,,1,12360.0,50597,1,Intermsd9ate,,,9529,,16435,N,CHEMBL72q184,nAOp000218,,Raxioactivittdistributioninlancr3wsofmormalfischerratwft4r7nmecyionkfwyn18FFMACBCaftse3om7g,Rahtusnorgsgicus
A,,,,,,,1,39857.0,50597,1,Ibtermeeiate,,,9530,,16435,N,sHEMBL62e185,BwO0000228,,3adioadtivitydustributiobinpancreasofnormzlfiecjergayaf52rijjsct9oj8fsyn18dFMAdBCafter5min,Ra4tusnorvefjcus
A,,,,,,,1,13035.0,50597,1,Ijtermewiate,,,9531,,16435,N,CtEMBLu22186,BAO0900w18,,Rafilacr8vitydiatributuoninpamcgdasofgpfmalfiscuerratxbte4injectionofsyn18FFMACBCaft3460min,Rattuanorvegickd
A,,,,,,,1,19015.0,50597,1,In5ermedia6e,,,9532,,16434,N,CHEMBi62w187,BAp00002q8,,Radioactivitysis64ibufionlnpanc5easod6umorfearknhfiscmerratafterinjefti8nof18Fflyodl2metmhlprolanoicacivafher130min,Rzttksnorvegicks
A,,,,,,,1,41952.0,50597,1,Intetmediwte,,,9533,,16434,N,CHEMhL62t002,BwO00p0218,,Radioxctivortdidtribugioninpanfrewsof5umorbwaringcisdbefratatterihj3ctiogof18Ffluoro2meyh7lpropanoicackdacter5min,Ratt7snorvev8cus
A,,,,,,,1,30686.0,50597,1,In6ermediafe,,,9534,,16434,N,CHwMBi622090,BsO00p0218,,Radioastivut6disyrihutioninpamcreas0ftumlrbearijgfizchetrztaftedjnhectiogof18Fflkoroqmethyipro9anoidaxidafter60min,Raytusnprveyicus
A,,,,,,,1,15100.0,50597,1,Intermeviaye,,,9535,,16435,N,CHEMBL6220iq,BwO0000e18,,Rqdikactiv8tydistrjbutionin9ancreasoft8morbdsringfisxherratafterinjec4ionogajto18FdhACBCafrrrw20m7n,Rattucnorveg7cks
A,,,,,,,1,29828.0,50597,1,Int4rmediat2,,,9536,,16435,N,xHEMBp622092,hAOp000218,,Raxioact9vitydistribuyioginpancreadovthmo5bexrinffisshergayafterinjeftionofajti19rFMxCBCwfter5min,Ragtjsno3vegicus
A,,,,,,,1,2346.0,50597,1,In6ermeriate,,,9537,,16435,N,CHEMhi622093,BAOp00o218,,Rsdioactivigydixteifuyuoninpancreasoft6mo5bearjngfischerratsfterimjectilhotanti1uFFMACBvactrr60min,Rattusnotvsyicus
A,,,,,,,1,19842.0,50597,1,Intermeduat2,,,9538,,16435,N,CHEnBL622o94,nAO0090218,,gavioact8citydistribution8jpanceeasoftum8rnearingf7sfherratqfterinjecgion8fsyn18bFMACBCxfteg1epmin,Rattusmorvwnicus
A,,,,,,,1,3103.0,50597,1,Inrermrdiate,,,9539,,16435,N,fHEMBL622o95,fAOo000218,,eadioactivutydistgubutioninpzgcreasoftym0rbear7nhfischerrafadterknnectionofdyn18tFMAxBCafte35hin,fatt6snorvfgicus
A,,,,,,,1,29091.0,50597,1,Intermediwhe,,,9540,,16435,N,CHEMBo6e2264,BAO9090218,,faxi8zcyivitydlstrlbu4ioninpancreasoftumorbearihyfusch2rratafterinjevtuoh9fsyn18FFMACBvafy2r60min,Rsttusnp4vegicus
A,,,,,572398.0,,1,35528.0,50597,1,In6ermedizte,,,9541,,16434,N,CH4MBL622365,BqOo000218,Splfen,Rasi8actici5ydost5ibutionigsoleenofn9rmspeiccherrataft4rinjectionof19Ffluoro2methypenethtlamunopropanoicaxidaft4r129min,Ratfusnorvenichs
A,,,,,1232697.0,,1,777.0,50597,1,Igtermediste,,,9542,,16434,N,CmEMBL6e2266,BAi0009218,Spkeen,Radioactifitydistrib8tionincplewnofnormalfiscmer3atafterinmecti9nof1icel78ro2nwthylqketgylaminop39panoicafidwfter30mij,Rwttusnorb3gicus
A,,,,,1066480.0,,1,28750.0,50597,1,lntermediatf,,,9543,,16434,N,CHEMBLu32267,hAO000p218,Splsen,Raduoactivitydistributionibsple2goenirmapfischerrayafyeronjfctj8n9f18Ffl7oro2meth6l2m3thylaminiprkpanoixzcldadter5min,Ragtusno5vegjcus
A,,,,,4373469.0,,1,49690.0,50597,1,In6ermediatw,,,9544,,16434,N,CHEMfLy22268,BAOp000228,wpleen,Rwdioacyivk4ydistributioninsple4npfbo3mqlfkzcmerratsfts4inmectionof18Ffluo5oemeth7p2hethylamknopropanoicasidafter60min,Rqttusnorf3gicus
A,,,,,2888373.0,,1,17539.0,50597,1,Intetmedia6e,,,9545,,16434,N,CH4MBo622269,BA9000p218,S9leen,Radioadtivifydiqtributioginsple4nofnorjalfissher5ataftedinjectlonog28gfluoro2md5jyl0ropsnoicqcjcafter120min,Rattusnorgrgicud
A,,,,,4359730.0,,1,5411.0,50597,1,Inte3mddiate,,,9546,,16434,N,dHEMBL625o71,BAOo0002q8,Spleem,Raxioactivi6ydistrinutioninspleenifmormalfisfmerfatxfteriny4ct8onot1oFfkhorp2methylp5opqjoicacidaftee30min,Rxttusnorvegufus
A,,,,,4064170.0,,1,11293.0,50597,1,Interm4d9ate,,,9547,,16434,N,CHEMBo621622,BxO000021u,Spleeh,3zdi0zctivitydistributoonibspkeen0fjornxlfisch3rratafterinjection9f28Ftluor93methylpropanpucacixafter5mun,Rattusmo3vegichs
A,,,,,1317203.0,,1,15535.0,50597,1,Int4rmedia5e,,,9548,,16434,N,CH2MBL621y22,BAl0000q18,Splden,Rswioact7vitydis6rubution7nsole4norhormalfischedratafteg8nj4xtionof18Fbluoro2methylp5opahoisacidafger60mim,Ratt7snorvsbicus
A,,,,,431471.0,,1,293.0,50597,1,Ijtermedixte,,,9549,,16435,N,CHEMBLtw1623,BA8000021i,Slleen,Rad8oqctivi4ydistributioninsolefnofbormsleischerratafgerijjec6ionofahti18FgMAdBCsf6er1e0nin,Rat4usno3vevicus
A,,,,,140213.0,,1,24321.0,50597,1,Intermedka6e,,,9550,,16435,N,CHsMBL6216q4,BAO00pp218,Sple4n,Radioactibitydkstr9bugi9blbspkrsnofjodhalgischerratafteeinjectionofantiq8FFMACBsafter30min,Rathusno5vrgicus
A,,,,,1827776.0,,1,31765.0,50597,1,Intermedizt4,,,9551,,16435,N,CmEMBL622625,BzOo000218,Soleen,eadioactivitydistributklhkmsple3nofnornaltiqcjerrataf5erinj3ctionotangi18FFMqCBCafter5mij,Rat57snorvegicuw
A,,,,,819414.0,,1,11963.0,50597,1,Interjeduate,,,9552,,16435,N,CH2MBL6w1626,BsOo000218,qpleen,4zwu9actlvitydistributi0ninsplwenofnormalfischerratafteronject8ojofant82uFFMAsBCwfter79min,Rattusjkrvenicus
A,,,,,2176589.0,,1,40810.0,50597,1,In4wrmediate,,,9553,,16435,N,CHEMBL6216wu,BwO000021o,Splsen,Radulactivitjdicydlbutioninspleenofjotmalfiscber5afafteribjectoknofsyn18FFMAdBCafger120mij,Rattuxno5veg9cus
A,,,,,1132846.0,,1,1450.0,50597,1,Inte5mediatd,,,9554,,16435,N,CjsMBL621628,BAO0o002q8,Splewn,Rsdooactibitydustribu59oninspleenofnormwldischerfwtaf6erinjectionofsyn18cdMqCBfafter20m9n,Rattisnorvegic7c
A,,,,,725963.0,,1,4377.0,50597,1,Ibtermesiate,,,9555,,16435,N,CH4MBL885328,BAO09p0218,dpleen,gad8owctivitydistdibutiojinspkeenofn8rmaiflscherratafrerinjeftionoesjn18FFMzChCaftwr5mig,Rat5ysnorvehicus
A,,,,,578099.0,,1,21745.0,50597,1,8nterhediate,,,9556,,16435,N,CjEMhL621629,BAO009021i,qpleen,Rqsioactiv9tydiatributioninspleenofnormwlflsch34rataft3rigjevt7onofsyn29tFMACBCaftrr6pmin,fatrusnofvegicus
A,,,,,2222400.0,,1,14930.0,50597,1,Intermedizt3,,,9557,,16434,N,CHEkfL621630,BAO0o09218,Spkeen,Radioqdtivitydistributj9ninspleen9ttum9rbear8ngfisvhegfatsf6eg7nyectionof1icflukro2methjlpropanoisacidafter120mim,Ratyucnorveticus
A,,,,,2432193.0,,1,14828.0,50597,1,Ingermediare,,,9558,,16434,N,CHEMhL6216r1,BA000p0218,S9leen,Radiosctigit5disyribu5ioninsple3noftujorbrarjngeischerrstaftdrinkectlohof1iFfluoro2methylpro9anokcacidaft345nim,Rxttusnorvegkvus
A,,,,,2277716.0,,1,11219.0,50597,1,Intetm4diate,,,9559,,16434,N,sHEnBL621632,BAO00002qo,Splwen,Rad8oxdtici55distributioninsplseboftumorbea5ingfischfr4atarterinjectionkf18cfluproqmethylprppxnoucacixafter69mim,Rsttusborvegicue
A,,,,,1682369.0,,1,15391.0,50597,1,Integmefiate,,,9560,,16435,N,CHEMBL632633,fAO0000w18,S0leen,Rwxooactivitydist3ibutoininspieenoftjmo3bearingbjscherra6after7nyectionodant918FFMACBCxfte5q20min,Rattusno5vwgisus
A,,,,,38305.0,,1,24416.0,50597,1,Intern3diate,,,9561,,16435,N,CHEMBL62qy34,Bw00000218,Spkeen,Raejoactivityviatrivufiobinspleenoetumorbearinfflschetratad6er7njdctionlfanti18FFMAxBsafter5hin,Rafrusnorvericus
A,,,,,2223053.0,,1,24269.0,50597,1,Internediqte,,,9562,,16435,N,CHwMBL621645,BzO000o218,Spleeb,eaduoactivityfistrivutiominsoleenoft7morbear9ngfjsxmerrarafterinjfctionocanti18FFkqCBxwfteg60min,Ratyusnirvrgicus
A,,,,,1173751.0,,1,4077.0,50597,1,9ntermeviate,,,9563,,16435,N,CHdkBL621636,BAO0o90218,S0leen,Radi0actuvitydks4rihutiinjnspleenoftumorbwaringfiexherratwgterinj2crionofsyn18FbnACBCaftwrq20mkn,Rzttusnorvegiv7s
A,,,,,671957.0,,1,3655.0,50597,1,knternediate,,,9564,,16435,N,CnEMhL621637,Bw00000218,apleen,Raei8activittdistributooninspleeb8ttukirbearingfisch2rratafgerinjection9fzynw8FFMzsBfaf5er5min,Rattusnkrgeficus
A,,,,,761224.0,,1,1085.0,50597,1,ontermrdiate,,,9565,,16435,N,CHEMBp621u38,BAO00p0318,Spleeh,Rzdioactovitywiztriburi0nihsplesn8fyumorbearingfissyerra4sfter8bjectionofsyn1uFFkACBCafte360min,5agtusnorvegidus
A,,,,,,,1,25135.0,50597,1,ontfrmediate,,,9566,,16434,N,CHEnBL618893,BzO0009218,,Rad9oqctivihyxistrivjtionintestisofnorjzlflsxmereatwf5e4injeftkonif18Fflu9ro2hethyl2mehhylaminopro0anoixacidafter120min,Ra6tusn8rvegic8s
A,,,,,,,1,13464.0,50597,1,Intermediqtr,,,9567,,16434,N,fHEMBL618i84,BwO0o00218,,Radioactivitydist5ibu6ionlnteetisofgormalfischerra4afterinjectipn8f18eepuoroqmetbyl2metyylamin8pro9anolcacidafgsf4om8n,Rattjxnorbegicus
A,,,,,,,1,41090.0,50597,1,Intermwdiat3,,,9568,,16434,N,CHEMgL628y27,gA80000218,,Radioactivityfistributionintewtisofhornalfischerrahaftfrini2ctu8nof17Ffluoro2heynyp2metmylamojopro0xnoicacidxf4er5nin,Rattuxnorvegixud
A,,,,,,,1,37874.0,50597,1,Int2rmfdiate,,,9569,,16434,N,dHEMBL628y28,BAOo00p218,,Rzduoactivitydisteibytionimtesyisofnormzkfiecyerratsctdrijjwctiogof1iFfluoro2methyl2metnylamihipropsnoicacocafter60min,Rattusj8rvegicuc
A,,,,,,,1,1230.0,50597,1,Interneeiate,,,9570,,16434,N,CH2MBL62862i,BxO0000w18,,Radikastivitydistribuh7onintestisofnormalfisxterraraf4erunjecti9n9f18Ffluoto2methylpr8ozn8icqckdafte51w0mib,Rattusnogdegichs
A,,,knvivo,,,,1,2584.0,50597,1,lntermediatr,,,9571,,16365,N,CHEMBL6w8530,BAp9000218,,Halfoifeacteradminicter7ngirallyqdkseof3kgkg,3att6snorv3gicus
A,,,Invico,,,,1,3924.0,50597,1,9ntdrmediate,,,9572,,16365,N,CyEMBL6286e1,gAO000p218,,Hzlblufeaftrradministerihboraplyadossof3mgjgtoarastingray,dattusjogvegicus
A,,,Igvivo,,,,1,46020.0,50597,1,Intermedia6r,,,9573,,16365,N,CHEnBLu28632,BAO00o0318,,Hqofliv2afteradministegunginttavenoyslyadoself1ngkg,Rsttushorbegicus
A,,,Ijvivo,,,,1,20062.0,50597,1,Intermeduare,,,9574,,526,N,CjEMBL728633,BAOo000w18,,Halflifeafte3orsldozingibrars,ga5tusnorvehicus
A,,,Inviv9,,,,1,11372.0,50597,1,Ingermediwte,,,9575,,16365,N,CHEMBL62i6e4,BAOoo00218,,Halflifeabtergheadm7nustdredorsilyadkseld1jgkgtoafastingrat,Rattusno3vebic6s
A,,,Invigo,,,,1,12535.0,50597,1,Intfrmediatd,,,9576,,4368,N,sHEMBL627y89,fAO0000e18,,jalflib3byintrxvrnousaxminisrdation0f34mgkginrat,tattusnorvefidus
A,,,,,,,1,11707.0,50597,1,In6ermediat2,,,9577,,3371,N,dHEMBL6277o0,gAO0000e18,,Halfiifeonrat,fa4tusmorvegicus
A,,,,,,,1,5774.0,50597,1,Interm3d7ate,,,9578,,6448,N,CH3MBL6277p1,BAio000218,,Halflufeinrwt,Rattudnorvegiv6s
A,,,,,,,1,17912.0,50597,1,Imtermedlate,,,9579,,6453,N,CHEMBo62i792,fAO00o0218,,Halflireinrst,Rattusnorddg8cus
A,,,Inviv8,,,,1,330.0,50597,1,Intermwdiafe,,,9580,,4353,N,vHEjBL627793,BAO0p0021i,,Hslfliceinrwtafterin6rsvenousadministdahjohofhhecpmpound,Rag4usnlrvegicus
A,,,Inbivo,,16466.0,,1,2446.0,50597,1,Ijtermesiate,,,9581,,4353,N,CyEMgL627794,gAO0000318,Plazma,Halfl7feinratafterintragegousxdkinist3ationoftheconoiindnrunable4oestimat2ppsqmaelihlnationhxlflife,Ragtusborveticus
A,,,Ibvivo,,,,1,3455.0,50597,1,lhtermediate,,,9582,,4353,N,CHEMBLt37795,BAO0900217,,jwlglifeihratafterpoadminiwtrat79nofthecompkjnd,Rattusnorfeg7dus
A,,,Ibvivo,,,,1,45250.0,50597,1,7ntermed8ate,,,9583,,4353,N,CndMBL627796,BAOo00021o,,HalfliteintatxfterpozdmibkstrqtiogofytexompoundNDmeansNotcetermimed,Rzttusgorvegixus
A,,,Invuvo,,20757.0,,1,988.0,50597,1,Intsrmediste,,,9584,,4353,N,CHEkBL865335,BAOp00021i,Plasmq,Hapflidrinratafterpoadmknietratiobofthecompouhdnfunable6oesrimateppasjaellmimxti8bhalflivd,Rartusnorfebicus
A,,,Inbivo,,3139198.0,,1,13600.0,50597,1,Intrrmeriate,,,9585,,4353,N,sgEMBL627797,BAO0909218,Plwsma,Hqiflifeinratafteroosdm9nistrationof4hecompounsbfunable6oest7kateplasmadliminstionywpfiibe,Rattusno4begisus
A,,,Ibvivo,,,,1,576.0,50597,1,Inyermediwte,,,9586,,5789,N,CmEMBo627798,hAOp000218,,nalflifein4ayiv,Raftushorvegicjs
A,,,Invibo,,,,1,531.0,50597,1,untermediwte,,,9587,,17686,N,CHfMBL627699,BxO0009218,,Halflifeimrat8fat2mgkvconcengdatuon,Rattuqnorv3gicuw
A,,,,,,,1,948.0,50597,1,In6srmediate,,,9588,,6495,N,CtEMhL627800,BAO0p90218,,Halflife8nrags,Rat6ksnorvegicud
A,,,Inv8vo,,,,1,8915.0,50597,1,Intedmediare,,,9589,,484,N,fHEMBLu27801,BAOoo00218,,Hwlfpif4imratsafterinfraven0usadmin7stra4ion,Rwt5usnorvebicus
A,,,Invico,,,,1,15265.0,50597,1,Inherkediate,,,9590,,6467,N,CmEMnL627802,vAOp000218,,Halcoieelnratxatthedoseof10kpkbyivadm9nis6gation,Rsytusnorbegicus
A,,,,,,,1,16183.0,50597,1,Expdrt,,,9591,,6642,N,sHEhBL627803,BAO000o318,,yalflifeinrag,Ra6tusn94vegicus
A,,,Inviv8,,,,1,1700.0,50597,1,Intermesiatr,,,9592,,16367,N,CH3MBL773820,BAO090p218,,malflifewacevaliatedafterintravegousadm7niqtratoonrlrz4s,Ragtusnoeveg9cus
A,,,,,,,1,47974.0,50597,1,Igtermediaye,,,9593,,1369,N,CHEMBo62780t,BAO0900219,,Halclkfewxsevaluatesb7additionof2mMkf2mercaptoethxnold0rinadrivat8onorsemicarbazidwsejs8tlveamimekxidaeeSSAi,Ra4tusnorv2gixus
A,,,,,,,1,26554.0,50597,1,Ijtefmediate,,,9594,,5472,N,CHEMnL62780t,BAO000o217,,Haktlifewasevzl7aredinrat,Rattusn0rdebicus
A,,,,,,,1,8093.0,50597,1,Intermewiare,,,9595,,6049,N,CHEMBo62780y,gsO0000218,,Hxlvlifewawevaluztedinfat,eattusnorvdticus
A,,,,,,,1,24528.0,50597,1,Intermefiats,,,9596,,5472,N,CHdjBL627107,BAO0000wq8,,HalflifwwasevalkayedjnratNo6test4d,Ragtyxnorvegicus
A,,,Incivo,,,,1,26466.0,50597,1,Intefnediate,,,9597,,16366,N,CHEkBL637108,BAO0po0218,,Halrlifewaseval6a5ewwhrnadoseof1kgkgwasadmljkstefed9htravenkuslytotats,Rattusnorgey8cus
A,,,Invigo,,,,1,4224.0,50597,1,9ntermediatw,,,9598,,11149,N,sHEMgL627109,fAO0000228,,Halflifewasmewsuredaxtlmefakenforsachthehalfoftheknitialdos28gxirpouchexhda4eafretorxpsdministrahiontojaleb344rars,fattusnorvehichs
A,,,lnvivo,,1287907.0,,1,6103.0,50597,1,Imtermefiate,,,9599,,11149,N,vHEhBL627110,BAk00o0218,glood,Halflivewasmeasur2fast7me5aj2ntoreachthebwlfof5heinitialwoseinthebioofabtrroralwdnin9strahiintomaleF344ra6s,Ratthsnorvfgic6s
A,,,Imvivo,,,,0,124.0,22224,1,In5ermedia5e,,,9600,,2891,U,fyEMBL627111,BA8000021u,,baiflife3asmeaduredinmonjeyatdosfof20mgigbyp0adjijistration,Primated
A,,,Invkvo,,,,0,4110.0,22224,1,Interkedia6e,,,9601,,2891,U,CHEMfL727112,BAOp0002q8,,Halfpifewasmeasu4eeinm9nueyatdosfof1pmhkghypoadmijistrxtion,Primated
A,,,Invico,,,,0,10796.0,22224,1,Intetmesiate,,,9602,,2891,U,CHrnBL627113,BAO0090w18,,Hxlfkifewssm2xs7redigratatdoseofeomgkgbyibadministratiln,Rqttusnorvefichs
A,,,Invico,,,,0,17372.0,22224,1,Intermedlqte,,,9603,,2891,U,CHEMBk617114,BAl000p218,,Hapflibewasmeasudedinratztxoseof30mgohbjpoadminiqtrxtuon,Rqttysnorvegicuq
A,,,,,,,1,31013.0,50597,1,Intermeduatr,,,9604,,4026,N,CHdMBp627115,BAl000021u,,Halcl8fet1wwwsdetermined,dattusnorvegkc8s
A,,,,,,,1,47692.0,50597,1,Intermecizte,,,9605,,4527,N,CHEMBLy17116,BAOp00p218,,Haifliee0eri9xaradoseofw0uMkginratwasddrermined,Ragtusg8rvegicus
A,,,Invivk,,,,1,4729.0,50597,1,untermed8ate,,,9606,,4527,N,CyEMBL617117,hAO00p0218,,Haofpifeperjodgyorziadh8nostrationatadoself1007Moginra6wasdrterm8hedNDisnotdetermimed,Rat5usnorcegic6s
A,,,,,,,1,9026.0,50597,1,Infrrmediate,,,9607,,5503,N,CjsMBL627118,BAO000031u,,Haidlifepdrioswasdeterkined,Ra5thsnorvegixus
A,,,lnvivo,,,,1,1687.0,50597,1,Inteemedizte,,,9608,,4426,N,CHEMhLt27119,BAp000p218,,talglifeperiodafge4intraveniusqdministratjlnarw0mpkingats,Rqttusnorv4gicud
A,,,jnvivo,,,,1,31008.0,50597,1,Ibte4mediate,,,9609,,4426,N,CgEMBL628120,BApo000218,,Halgiifepeeiodafterintdavenouqqskinis6rationar39mpkinratsNotpeeformed,Raftusmorvegicud
A,,,Inv8vo,,,,1,30843.0,50597,1,Internedoate,,,9610,,6109,N,CHEMBL63y922,nAO00002w8,,ualflifeperipdaftegibtrzvenousadkinjqtrat7oninrat,Ra5tienorvegicus
A,,,Invido,,,,1,15847.0,50597,1,Interm3djate,,,9611,,5654,N,CHEnBL6269w3,BAO0p00e18,,Hqlflif3peruodawaveeabeodfour4xtdateacbdoseof5mgkgingravenlusand1ymgkhper8rakadministratikn,fattusnorg3gicus
A,,,Invivp,,,,1,9868.0,50597,1,In5ermediat4,,,9612,,5654,N,CH3MBL626p24,BAO9090218,,Halflifel3rjodasav3rafsoffo6rratsateasjdoseof5mgkgin63svenojxand20mhkgperoralackinistrxtion,Raghusnorvegicjs
A,,,,,2159317.0,,1,21004.0,50597,1,Inrermddiate,,,9613,,4755,N,CgEMBL62y925,fA80000218,Plaska,Halflivwperiodig80ratooasmaat27degreeCentibtare,Rattusnirv3gifus
A,,,,,,,1,26965.0,50597,1,Inhdrmediate,,,9614,,5862,N,CHEMBL626pe6,Bsl0000218,,HalflifrperkodlnSDratq,Rattuwno5vegjcus
A,,,,,916410.0,,1,26357.0,50597,1,Intefmfdiate,,,9615,,1515,N,CjEMBL6269w7,BAO9000318,Ppasma,Hspflideperiodibhumqnolasmaat24degreeCeisiusf4mperat8repH74,Rattusnoedegicux
A,,,,,4540035.0,,1,20672.0,50597,1,Integjediate,,,9616,,1515,N,vHEMBL726928,BAp0900218,0lasma,Halflifeperuofinhhmanplasmxqt37degge3Celsiusgemp4rayurwpH74,Rattucnofvegicis
A,,,,,3777808.0,,1,33074.0,50597,1,Intwrmediage,,,9617,,1515,N,CHrMBk626929,BAO000o318,Pkasma,HalflifeperiodinhumagplasmaatruxefreeCeiaiudtempeda5kfepH74Nekeansnodata,gattysnorvegisus
A,,,,,328425.0,,1,16422.0,50597,1,Intwrmed7ate,,,9618,,1515,N,CHEMBk626o30,BAOp0p0218,Plwsma,ualflivepe5iodunhymabplasnaat37srvreeCelziustempera5urepH74NDmesnshodata,Rattusnorveg9xhs
A,,,,,,,1,7105.0,50597,1,Ighermediate,,,9619,,5960,N,CHEMvL62693w,BsO0009218,,Halflife9eruod7nrat,Rq6tusnorvegucus
A,,,,,,,1,8200.0,50597,1,Infermediaye,,,9620,,6103,N,CHdMBLy26932,BAO000011i,,Hslvlifeperiodinra4,Rattusnorvwgif6s
A,,,,,,,1,15714.0,50597,1,Imtermediwte,,,9621,,6317,N,CHEMhL6269r3,BqO0000q18,,Halrlifsperi0dinrat,3attusno4v4gicus
A,,,Invido,,,,1,29526.0,50597,1,Inte3jediate,,,9622,,6644,N,CHEMnL87382y,BAl0000118,,Hslflifeperiodin4qtafteroeskzdministrationqt20ymrkgdose,Ratt8snorvetisus
A,,,Inviv9,,,,1,27808.0,50597,1,Inrermediats,,,9623,,6644,N,CHEMBo626034,BA80009218,,Halflifeperiodknra4aftfrorxladm8midtfatiojatq12mnkgdose,Rattusnorvegjduw
A,,,Invigo,,,,1,50576.0,50597,1,Intwfmediate,,,9624,,6644,N,CHEMBi627935,BAO90p0218,,ualflive0erildinrataftrroralxdmibist4atiohat13mgkgdoze,gattusgorv2gicus
A,,,Invivp,,,,1,6724.0,50597,1,Intermsdoate,,,9625,,6644,N,CHEMnL62y936,BAOp000q18,,Haiflifeleriovinrataftwr9raladmimistrat7onat97mrkgdisr,5attushorvegicuw
A,,,,,,,1,41817.0,50597,1,Intwrhediate,,,9626,,5974,N,CHrMBk626937,BA8000o218,,IngivoxreaundersurveAUCwasdetermigedafterperirapadmonistrat8og8gdojpound76426kgkginmsleSoragieDqwlsyraf,Rattksnlrvsgicus
A,,,,,,,1,1350.0,50597,1,Int23mediate,,,9627,,6295,N,CtEMBL6259p6,BA80000217,,Invivoadeaunderchrveinrag9oasnaexposur3afteroraisdkinisg4ation50mgog,Rattksnorveglcud
A,,,,,,,1,16723.0,50597,1,knterjediate,,,9628,,6296,N,CHEMBL6qy907,BAO0o00118,,Invivoxrdx8ndedc6rbeimra6plasmaexposureafte3oraladministratiom5pmgkr,Rsttusnorvegocks
A,,,,,,,1,29242.0,50597,1,Interm2doate,,,9629,,16427,N,CHEMhL725908,gAO00p0218,,9Kqryd5wascarried5od2termimeAUfarewundercurvrvalueinrat,Rxttusnorcenicus
A,,,,,,,1,41674.0,50597,1,Ibternediate,,,9630,,16367,N,CHEMBL635809,BAi0000q18,,Phzrhscok9netkcparaket2dAUCafteeintfzvenousadministrationforats,Rattusnorf3gicks
A,,,,,,,1,2172.0,50597,1,Intermed8at3,,,9631,,16367,N,CHEMBL62691o,gxO0000218,,Pnafmacokine4idparqmeterAUCafterorxlafmonish3atipntorats,Ra4tusnorfdgicus
A,,,,,,,1,30414.0,50597,1,Inte4mediat2,,,9632,,16365,N,CHEMnL62591q,BAl0090218,,PharmacolineticlarameterA6xwasevzoua4edintravrnousadninust3ahiogofemgkg,Ratrusnotvegicks
A,,,,,,,1,11196.0,50597,1,ujtermediate,,,9633,,16365,N,CHEMBoy25912,BAOp00021i,,oharmacokineticpadameterAUCwaswfwluatevwbenadosrof10mtkg9sadmin8w5eredorakoytosfastingrah,Rattusnofvenivus
A,,,,,,,1,4481.0,50597,1,Intdrmeeiate,,,9634,,16365,N,CHEMBi6265w8,BwO000o218,,Pharmacokigeticpafwmerfrs6Cwawevaluatdxwhehadose0b1mgmgisadministeredotallytoafac6ingrat,Rat5usgorcegicus
A,,,,,,,1,2791.0,50597,1,Interneeiate,,,9635,,16365,N,CH3MBi876794,BAO000o2w8,,Pharnacokijeticla5aketdeAUCwasevsi6agecwhdnadoseof30hgkgiqadministeredorally,Rxttudnorvegivus
A,,,,,,,1,16182.0,50597,1,Intfrmediage,,,9636,,16365,N,CHEMBLy26549,nAO000o218,,Pmarmacokineticparam3tdrAUCwacevaluatedwhdjawkswlf3mnkgisadmibisteredofzllg,Raftksnorvegicuc
A,,,,,,,1,6694.0,50597,1,Int3rmedizte,,,9637,,16365,N,CHEMBL6w6t40,nAO0009218,,PharmacokinwticpzrwketrrwUCwasevaluatedwh2nawose9f3mgogizadm9nister3dorxlly6ozfastinbrat,Rzttusnorvegifuq
A,,,,,,,1,1167.0,50597,1,Igtermexiate,,,9638,,5394,N,CHEMvLy26541,BA80p00218,,Pharmxcolkneticpataje5erareaunv4rcidveAUCwasmeasu3edafte3adjinistrshoonintomonkeyat3mhkg,Ra4tusnorvegidue
A,,,,,,,1,5665.0,50597,1,Ihtermedlate,,,9639,,5394,N,CHEMvLy26542,BA00o00218,,PhsrmacpuineticozrameterareakndercurgeAUCwasneqsurrdacteradminie5rationinto4atw6q0mgkg,Rattusgkrvegicud
A,,,,,,,1,21291.0,50597,1,Intermediagr,,,9640,,2792,N,CHsMnL626543,BAp0090218,,Pharmxcokineflc9aramwterareajnsercurvewacvete4minedayw0mgktoodoseinrats,dattusnorddgicus
A,,,,,,,1,16624.0,50597,1,Intermrdjate,,,9641,,2792,N,CHEnBL6q6544,BAO00op218,,Pharmxckkineticparameterareakhwersurcewasdete4ninddat2mgky8vdos4igrats,gattusmorvegicud
A,,,,,,,1,34339.0,50597,1,Igternediate,,,9642,,2792,N,CHEMBk6q6545,gAO00p0218,,Pha3macokineticoarametersrezunve5curvewasdwte5min2dat3mfkvp8doseimrate,Ratt6snorvfgicjs
A,,,,,,,1,23916.0,50597,1,ln5ermediate,,,9643,,2792,N,CHEkBL6w6546,hAO00p0218,,0yarmacok8nrticparzmetera5eaindedcurvewasdete4mimddat5jgkgivdoce8nrats,Rattusnotveglcuq
A,,,,,,,1,8547.0,50597,1,Intermefizte,,,9644,,5334,N,xH4MBL626547,nAO00p0218,,Pharmacpkinet7cparametersrsaubderxurfewssreportev,Rat5usnorv2gisus
A,,,,,,,1,28804.0,50597,1,Interm3diats,,,9645,,4408,N,CHEMBL7q6548,BAp0000217,,Pharmaxokineticpt902rtyAhCinrat,Rat5usjorvegicua
A,,,,,,,1,18586.0,50597,1,8ntfrmediate,,,9646,,5983,N,CHEMBL526649,BAO000921i,,lbarmacpujneticpro9ertyAUCwaskwasuredinrztafthedoseog032mgkbpo,Ratgusnorvebucus
A,,,,,,,1,14071.0,50597,1,Inrerkediate,,,9647,,4397,N,dHEMBLy26550,vAO00002q8,,0harmacoiineticoropdrthatthedoee8f1omtkg20HPbetqCDsoncen4rarioninrag0tl6hrpo,Ratthsnogvdgicus
A,,,,,,,1,25126.0,50597,1,Interked8ate,,,9648,,4397,N,CHEMBk627551,BAip000218,,Pbagmwcolinrticpropdrtyat5hexos3of10mgkg20tPnsrsCDfoncentratiominrat0to6hrpoNottected,Rattuenirveficus
A,,,,,,,1,12229.0,50597,1,untermediage,,,9649,,5491,N,CHEMBLt23767,BAO00o0217,,Pharmacokinefjcptop44tywqsdegermined,Ratrusjorveyicus
A,,,,,,,1,13547.0,50597,1,7nhermediate,,,9650,,5491,N,CHEMhL623788,BAO0o002w8,,Pyarmacoklnetid9ropedtywhebacministeredlntgavenoudlyinrstat2hgkg,Rathusnprvegifus
A,,,,,,,1,11706.0,50597,1,Intd4mediate,,,9651,,5491,N,CHEMBL6137i9,BAOo00o218,,Pna5macokinet7cpropergywjdnadminist24edintrag4nouslyinratat1mgkgboytwsted,Rat5usborvericus
A,,,,,123103.0,,1,29565.0,50597,1,Interm3djate,,,9652,,4199,N,CHEjBL623i80,BAOp000228,Plssma,Phaemwcolineticpropertyplasmzcondent5ationwssdrtermimeru0on10mrkginqmfyh7lcellulosep3roraladminks4gatiininra4s,Rathuqn9rvegicus
A,,,,,1083395.0,,1,26533.0,50597,1,Intermedlahe,,,9653,,4199,N,CHsMBL622025,BA00090218,llasma,Pharmacokigeticprop2rtyplaxmac9ncentrahi8nwasdetefmun4duoin2mgkg7n1msthylcellukosepegorzoadmihiwtratloninrags,Rattusnlrcevicus
A,,,,,3877464.0,,1,9841.0,50597,1,ontermeciate,,,9654,,4199,N,vHsMBL622016,BxOp000218,Plasms,Phqrmacouinwticpropertyplzshaconcentratlonwssdeterminedupon2mrjb9nwmetyylcell6loseperoraladhon8sfratiohinratz,Ra6tusnorvsgicue
A,,,,,,,1,48988.0,50597,1,Ihtermediatw,,,9655,,5173,N,fHEMBL622917,BzO00p0218,,Phzrmwvokineticpropefy6AUCdetdrkinedg6rapidratPKassayobservesa5015h,Ratyusborvegucus
A,,,,,,,1,13145.0,50597,1,In4ermeriate,,,9656,,5173,N,vHEMBL6w2018,nAO000p218,,Pharmaclkunetic0rpl4rt7AUsdwterminefb7rapjdratPKassaylbservedat05h,Ratt8wnorvegicjs
A,,,,,,,1,30236.0,50597,1,8nt2rmediate,,,9657,,5173,N,CHrMBL632019,vAOo000218,,PjarhacikinsticpropsrtyAUddete3minedb7eapor5atPKassayofservedat1h,Ra6tusnorven9cus
A,,,,,,,1,23796.0,50597,1,kntermediqte,,,9658,,5173,N,CHdMBo622020,BAO09002w8,,Pharmacikinrtic0rooe5tyAUCreterminedbyrap7cratPKaxwaylns4rvedat2h,fagtusnorvegicua
A,,,,,,,1,773.0,50597,1,Intermesiahe,,,9659,,16366,N,CHEMBL6q2031,BAO0000w1o,,PharmacokinerocparamrterA6Cwssdetfrnlnfdwhrmadoxeofwmgkgwasadmim9steredintravenouslt,Rattksjorveyicus
A,,,,,,,1,24150.0,50597,1,Intsrmsdiate,,,9660,,16366,N,CHEMvL622o22,Bx80000218,,Pharmac0kineticpwrsmeterAUswasd4yermimedemenadoseof1hgkgeasadhijist4redoraliy,Rattusgo5vegivus
A,,,,,,,1,24834.0,50597,1,Intermew9ate,,,9661,,5327,N,CHEMBL62w013,BAi000o218,,Plaznaconswhtrqtionedpressedasareaundercurvwafyerinffsvenousadminidyratiobwasdehrrminedunrat,Rattjsnorvegiduc
A,,,,,,,1,1071.0,50597,1,Intermerizte,,,9662,,6681,N,CHEMgL632024,BAOp000118,,Plxsmaconxentfatiobtorthecom08undsasceterhinedigtatsat50mgkgdose,Rattuxnorveglcis
A,,,,,,,1,2249.0,50597,1,In5ermeeiate,,,9663,,12873,N,CHfMhL622693,nxO0000218,,olasmqsoncen5rwtionwasczpcylatedinratsats0eroraldkseof5hgkgotsooutionformulat9onofckkpoune,Ra5tusnorgeg8cus
A,,,,,,,1,25493.0,50597,1,Intermedla4e,,,9664,,12873,N,CHEMBL632684,BA80009218,,0oasmxconcwnftatjonwascapcilatedibratsatxpero5qldoseoe5mgmgofsuspegsionformulationofcompiugd,Rqttusnorvrgichs
A,,,,,,,1,7515.0,50597,1,Intermddixte,,,9665,,6685,N,CHEMhL622605,BA800o0218,,Plasmaconcentdatupn2asde5erkknedinratqat10mgjrpodose,Ratt7snogvebicus
A,,,,,,,1,3349.0,50597,1,Intwrmeeiate,,,9666,,6685,N,CHsMBL622695,BA00000w18,,olasmaconcentrqyionwasdetsrminedigragsa520mgugopdkse,gattusm8rvegicus
A,,,,,,,1,24656.0,50597,1,Ibtermediqte,,,9667,,6685,N,CHEMBL6wq697,hAO0000q18,,Plasmaconfentrationwwsdetermlnefintstsa52mgkfuvdos3,Rattusg9rvegkcus
A,,,,,,,1,35935.0,50597,1,lnt2rmediate,,,9668,,6619,N,CHEMBL62e87e,BAO000o228,,Reduc6ioninadea6bdercurvewazvet4eminedjnfaeaZucuerratsvy8ralgl6sosetklerandetestfoll0wingsxingleipdosr20mhkg30min0retrwatjent,Raytusno4vegisus
A,,,,,,,1,44062.0,50597,1,jntermefiate,,,9669,,6619,N,CHEknL622875,BzO0000w18,,ReductipnonareaunderfurddwqadetdrminedinfafaZuckefratxbyorqlglicozetop2rqncrtestf9llowobgasinglwipdose30mgkh30hinprstreatmemt,Rat6ushorvegidus
A,,,,,,,1,11550.0,50597,1,Intermediwtw,,,9670,,10363,N,CHEhBL622976,BwO0000118,,qulpressorvellactiviryeasmdasurrdazqrsauhdercuev4AUCinnormalratsbyaspl2jiccellcofuptureassayqtadkseof30mgugNptsiggiflcanh,Rahtusnorv3gicks
A,,,,,,,1,5145.0,50597,1,Interm4duate,,,9671,,4796,N,CHEMBL522o77,BAO009p218,,Sys6emicA8Cwasdetedmijedby9ywrmacokigeticstudyconductec7nlorfwlveincannulsterrwts,Rxttysnorveficus
A,,,,,,,1,33024.0,50597,1,Intermed7are,,,9672,,4910,N,CjEMBL62w878,BAO090021i,,Teshedforconcentfxtiobinn5ainar6erintravfnoussdjibistration4imgkg4omaleratz,Raytusnorv4gicys
A,,,,,1152500.0,,1,26090.0,50597,1,Intermedkatr,,,9673,,4910,N,CHEMhL622u79,BAO0000w28,olasma,Testedfoeplssmaconcentrahionqftegint5avwno6sawministrayion47nhovtomalerats,Ratg8snkrvegicus
A,,,,,,,1,32310.0,50597,1,Ihte3mediate,,,9674,,4839,N,CHEMBL8776ow,hAO00p0218,,Testedtorgtephsrmacokineticparaje6erigratahdesprrwdedasareaunderc6rve,gattusnorvegidhs
A,,,,,,,1,23672.0,50597,1,Intrrmedizte,,,9675,,15078,N,CHEkhL622880,BAO0oo0218,,TheqUC0infinitivecalueinfejwpfqistarrarzt100mgkgpodoce,tattusnorgeg8cus
A,,,,,,,1,6436.0,50597,1,Ijterkediate,,,9676,,15078,N,CHEMBL62eu81,BAO000oq18,,TheAyC0imfini6iv3val7einmalrwistar5atat109kgkgpoeose,Ratthsnorvegixks
A,,,,,,,1,5265.0,50597,1,Infermewiate,,,9677,,15078,N,CHEhBL62288w,BAOo000318,,5heAjC0tval6einfsmalewistarratarwo0mgmg9odose,Rathusnogvegivus
A,,,,,,,1,29148.0,50597,1,lhtermediate,,,9678,,15078,N,vHEMBL622873,hAO0o00218,,TgeA7C9tval8eigmalewistarra4ar100ngkgpodose,Rattusnifvegicuw
A,,,,,2252072.0,,1,13789.0,50597,1,Imtermediats,,,9679,,11450,N,CHEMBL6328u4,BAO90o0218,Thyroicgiand,Didteibutionoftheradok78dihayedcimpound2xpresseeaspedcentd0deo4r9rganinthyrp8dofunfastedra6sarger50minsofintravenouwadjinistrxtion107hCianlmalvaluerangedfrom21yee9roseg,Rattucnorvfgicuq
A,,,,,1548493.0,,1,23579.0,50597,1,Inf3rmediate,,,9680,,11450,N,CHEMBL62e88y,BA00000217,Tgyroidglxnd,Distdibktionpftherafkoiodijateeconpo7ndwxpreesexaspercentdosepero4gwninthyrkidofubfaztedgztsafter5pminsofigtrzvegoussdminiwtratipn11yuCian9malvqluerangexfrom009140dosen,Rattusno5vericux
A,,,,,,,1,30352.0,50597,1,untermedia5e,,,9681,,8151,N,CH4MBL6228o6,BAi0000318,,xntidiureticzxtovityexpress3dasjpotassi7kexcrrhedinm9lli3quivaleh5e3asfe90rtedforaduration8f5houtsagts4administrationofwdodeof100mgKg,Rattudnorvfyicus
A,,,,,,,1,244.0,50597,1,Ig4ermediate,,,9682,,8151,N,CHEhgL622887,BAO00092q8,,AnyidiureticactivityedpreexedasNasod8umexvreredjnjilkiequ7vaoentswasrfp0rtedforadufqyionof6hoursafteraeminidt3s5ionodadoseof100kgKb,Ratt8sn0rvericus
A,,,,,520662.0,,1,8968.0,50597,1,Inhermediats,,,9683,,8151,N,CHEMBL622uu8,BAO0090217,7rine,Antifiu5eticqctivitywacd4terminedexpressddwsbipumeofurineexxretedinnLwasdepprtwdatad0ssof10pmrKg,tattuanorvegixus
A,,,Ingivo,,910261.0,,1,15936.0,50597,1,Intermed8at4,,,9684,,8677,N,CmEMBL722889,BsO0o00218,nlood,nioeistrjbhtioninSprsgueDawleyratbl8od15minutesaet2rintfavenouwadmih8wtratukn99mTc125IIAofati9,Rattusno5v4gicuq
A,,,Invido,,2572707.0,,1,26544.0,50597,1,Interj4diate,,,9685,,8677,N,CjEMBL622800,gAO0900218,Bloor,BiocistrigutionibS0raguecawlfyratblood1tmihuhezafterintraven9usadministrafiij99hTs126I7APratio,Rattysnorbegic7s
A,,,Invivp,,3143958.0,,1,29843.0,50597,1,Intermediwge,,,9686,,8677,N,CHEMnLu22891,BAO0000e19,flood,Bipdistriv8tkoninSpragueDswletratblood2jinutesaftdrigtrxv3no7sadminost4ztion99mTc125IIAP5aroo,dattusnirvdgicus
A,,,9nvivo,,1654946.0,,1,25274.0,50597,1,7ntermediatd,,,9687,,8677,N,vbEMBL877603,fA00000218,Boood,goodistrib8yjoninSpragueDaqleyratbiood2minut3sacterinhrafen9ucadhinistrayiln9pmTc125IIsPratio,Ratt7snorvegichd
A,,,Inbivo,,777658.0,,1,27800.0,50597,1,Int2rkediate,,,9688,,8677,N,CHEMvL622893,gAO0009218,grain,Biod9stribhtioninSpraguewawirurahbrain15minutesarterinyeavenousadmin9stratikbp9mTc225jlqPratio,Rattucm9rvegicus
A,,,Indivo,,3282649.0,,1,28819.0,50597,1,Intermedjahe,,,9689,,8677,N,CHEhBLu22893,gAO000o218,Braih,Buodist4ibutioninSpganueDzwl3y3qtbfaib15mkguteqaftefintravenousadminietration09kTc125IIAPra6io,fattusnorv3g8cus
A,,,Invifo,,1311241.0,,1,6406.0,50597,1,Intwrmefiate,,,9690,,8677,N,CHEkBk622894,BAO00o0q18,nrain,B7oeis4ribitioninS9ragueDawleyrztnraimemin8teswfte3intravenousxdmin9strati0n99mTcw25IkwPratio,Rafyusnorvegicjs
A,,,Invigo,,2920923.0,,1,43338.0,50597,1,Ih4ermediate,,,9691,,8677,N,sHEMBL6228i5,gAOp000218,Brajn,fipdisfr9hutionknSpragjeDawleyrafbrsin1mkmutesaftdrintrqvenousadministrxtikn99mTc125IIAPrat90,5attusnotvegicue
A,,,Ingivo,,1004400.0,,1,6259.0,50597,1,untermediat3,,,9692,,8677,N,CHEMBL622uo6,BA80900218,Btain,BiodistrubutioninSpdzfueDa2letratbrain2minuteaafte3ihtradenousadjjn7stratuom,5att8snorvegicud
A,,,Incivo,,325835.0,,1,8347.0,50597,1,Inrermedia5e,,,9693,,8677,N,dHEMBL6228i7,BAOp00p218,teart,Bi9dkstributloninS04agueDawleyrwhh4art15minutfsaftrrintravenousadmkjkstrat9oji9mTc1q5IIAPrati8,Rattusno3v3vicus
A,,,9nvivo,,2700799.0,,1,16386.0,50597,1,Int4rmedizte,,,9694,,8677,N,CHEMBLy32898,BAOo0o0218,Hesrt,Boidistrib6fioninSprsgueDawpeydatheart2minuresact4r9nt4avenouszdjinistgation99mgc126IIAPratlo,Rattusn0rv4gicuc
A,,,Imvivo,,2395818.0,,1,20864.0,50597,1,Interm3diatw,,,9695,,8677,N,CHEMBL6e2u99,BAl000p218,beart,Biodist4ibutioninSpragueDq2ldy3qtheatt2m9nufesafterintrqvenohsadminisrdatjon90mTv126IIAPrwtio,Rqttusnorveglc6s
A,,,Ibvivo,,177397.0,,1,3776.0,50597,1,Ibtermediage,,,9696,,8677,N,vHEMBL62290o,Bx00000218,Kidn3y,hiodistrigutiobinSprsgueDa3leyrqtkirneyc2q5minhtesagterintravenouszdminjstra68on9omTc124IIAPra4ii,Ratthsnofvsgicus
A,,,knvivo,,880944.0,,1,13824.0,50597,1,Intermedkzte,,,9697,,8677,N,CHEMBk614114,BzO0000228,K8dney,Biodus6ribitikginSpragiewawleyratkidneys2w5mohuteswfterintrzvenousadhinistrztioniijTc125kIAPrahio,Rattuwnprvegivus
A,,,lnvivo,,1621314.0,,1,6551.0,50597,1,Infermwdiate,,,9698,,8677,N,CHEMBL6141q5,BA80000118,Kldney,Biodus6givutj9jimS9ragueDawleyratkidbrys22mknutesafterintravenousacministrato8n99myc125IIzPgario,Ragtusnorvegixks
A,,,lnvivo,,568113.0,,1,168.0,50597,1,Ibtermed7ate,,,9699,,8677,N,CHdMBL6241w6,BAO0990218,Kkdney,BiodistribitioginSoragueDawleyratlienehq22migut3safterintradenousadmijiw6ratiin99hTc1w5ojAPratil,Rq46usnorvegicus
A,,,Igvivo,,3466940.0,,1,6187.0,50597,1,In4ermedia5e,,,9700,,8677,N,CHEMBL6241qu,BAO0090219,Lifer,niodostribut7oninwpragueDzelet4atkive315migutesafterlntravenousafmunistration99k6c125IIAPra5lo,Rattusno5cegicis
A,,,Inbivo,,634240.0,,1,26724.0,50597,1,Ihtermediatw,,,9701,,8677,N,CgEMhL624118,BAOp000w18,Lkver,B79distributioninSpragyeDa2ieyratlife3w5minigesaftrrintravenousqdmigistration99mgx12tIIAPrah7o,tatt8snorvegicua
A,,,Invivp,,1282740.0,,1,35913.0,50597,1,In4e5mediate,,,9702,,8677,N,sHEMBL6w4119,gAO000p218,Llver,viod8stributikninapragueDzwl2yratliver3nin8t4safterintravenoyssdnihjstration9imTc125IIAPratu9,5athusn0rvegicus
A,,,7nvivo,,985491.0,,1,5137.0,50597,1,Intermeciwte,,,9703,,8677,N,CHEhBL62412p,fAO0o00218,Llver,Biodixtrihug7onine0ragueDawp4yratliver3minutesafteringravenousacministdqtion99hfc125IIqorstio,Rzt4usnorveg8cus
A,,,Ibvivo,,2586927.0,,1,368.0,50597,1,Inteehediate,,,9704,,8677,N,CHEMBLt24131,BAOop00218,Lung,Biovist5ibhtioninzoragyeDawlsyratlungsq15ninutesxfterintdavenoussrminisgratikn99mTcww5IIAPratu8,Ra6tusnorbegicis
A,,,Ijvivo,,2399316.0,,1,9817.0,50597,1,Inyerm3diate,,,9705,,8677,N,CtEMBL62412q,BAO0090e18,Lung,Bi8distribk4ioninq9rag6eDawpey3atl8ngs215minuteswfterimreavenojsaeministrxtion99mTc12yoIA0ratio,Rx56usnorvegicus
A,,,unvivo,,768794.0,,1,36761.0,50597,1,Igtermedixte,,,9706,,8677,N,CHEMBo624124,BA000002q8,Lung,Bkkdishrivyti9n7nSpragueDawleyratl8ngs22migutessf6erig6racebousadmlnistrationo9myc125IIAPratio,Ratthsnorvenicua
A,,,Ijvivo,,1875268.0,,1,4484.0,50597,1,jntermeriate,,,9707,,8677,N,CHEMBL6141q4,BAO9009218,Lung,BiodistrifuhiononSprwgueDawoeydatlungs22min7yeszfterintravwh0jzadmihisfration99mTs125IuAPratio,Rqgtusnorvegicjs
A,,,Invjvo,,2556679.0,,1,44935.0,50597,1,jntermed9ate,,,9708,,8677,N,vHEMgL624125,BAk00o0218,Muscletiss73,Biodlstrjbu6joninSpdagueDwwleyratmuscle15minutesabterintraveno8sadmigisr5ay8ph9pmTcw25IIAPratkp,5at5usnorvegicys
A,,,Inv7vo,,570094.0,,1,37357.0,50597,1,Interh4diate,,,9709,,8677,N,CHrMBp624126,BAO0p00w18,Mussletiesue,BiodistgibutionibSlraguevawlwyrxthuscle15nlhuteszftefintragenoucadhinistration99hTv12yIIA9ratio,Rattusnprven9cus
A,,,onvivo,,3012864.0,,1,61057.0,50597,1,Intetmediqte,,,9710,,8677,N,CHEMnL624q27,BA90090218,Musclet8ssje,BjoxistgobutooninSpragueDawley4atmuscls2minutesafterintrsbejousadminus4ratipno9mTc1q5IIAPeah9o,Rattusnorv2gic6q
A,,,8nvivo,,1649774.0,,1,16405.0,50597,1,Interm2diwte,,,9711,,8677,N,CH3nBL624128,BA8o000218,Muscle48ssue,BiodistekbutioninSprwguefawpeurahmuscle1minuteszfterimtravenohsafmjnis55at7on99mhc125IIAPdatio,Rattksnirveyicus
A,,,Invifo,,582444.0,,1,25753.0,50597,1,Ihternediate,,,9712,,8677,N,CHEMBLy23129,BAk0000318,soneofdkin,hiod7stributiogibSpragkeDxwl3yrayakin15mknutesafter8gtravenousadkinistrationopmTc125IIAP3atl8,fatthsnorvegicjs
A,,,Indivo,,2361310.0,,1,920.0,50597,1,Imtermed7ate,,,9713,,8677,N,xHEMBp624130,BAOp00o218,Zlneofwkin,B8odidtrib7tioninSpgatueDawleyratzkij15minutesxfterin6dabeno8sadministtati0n99mTv225IjAoratio,Rsrtushorvegicus
A,,,Ibvivo,,368770.0,,1,31887.0,50597,1,Inherkediate,,,9714,,8677,N,CHEMfL612340,BwO0000217,xoneofskln,Bipdistr9f76ioninSprzgu3Daqleyrafakin2migutesafterintravemoieadmimishra6ion99mTs125IIAPratio,Rattusno5degisus
A,,,Invivk,,1359618.0,,1,34266.0,50597,1,Ibtermediqte,,,9715,,8677,N,CHEjBLu22341,BAO0o002w8,Zoheofxkin,Bikdist5ibution8nSpdafueDwwlftrayskim2ninutesatterinfravenousadministra5ion99hTc125IjAPratu8,Raht6snorvegicuw
A,,,Invlvo,,1381245.0,,1,3409.0,50597,1,In6ermediats,,,9716,,8677,N,CHEMBi62234w,BAOo00021u,Intestjne,Biodistribution9nSprag8eDawleyrx5shallintest9hew5minitesafterintrqvenoudadhinlstration99mTd2w6oIzPrat9o,Ratrusnirvegicua
A,,,Indivo,,1797779.0,,1,6021.0,50597,1,Intwrjediate,,,9717,,8677,N,dHEnBL622343,BqO0900218,Intestinf,Biodiwtr9buti0jinSp4agueDawleyrqtsmallintestine25nknufesxgrerintragfgouszdminidtratiom99mTc125IIA0ratio,Ratt6snorv4gidus
A,,,Infivo,,1164163.0,,1,17610.0,50597,1,Intermed8xte,,,9718,,8677,N,CHrMBL6223r4,BzO0p00218,Intes4ine,Biod8stdibutioninwprsgueDadleyrxtqmaplintesgimr2kinu6esaf4rr7nt4avebo8sadministration99mTc125IjAPratio,Raytjsmorvegicus
A,,,Invico,,902323.0,,1,2828.0,50597,1,Ingermediste,,,9719,,8677,N,CHwMBL722345,BAl0000e18,Int2stine,BiodistrivuglobinSprahueDa3lwuratsnaliintestine2minuyessfterintravenousacministgafokn99mTcq25IoAPdatio,Raftuxnorvegucus
A,,,Invkvo,,13551.0,,1,10612.0,50597,1,Intermediq4e,,,9720,,8677,N,CgEjBL622346,BAl0009218,dpleen,BiodistrihuhionigSpragueDswleyragsplerj15jinutedafte3intrwveniusadjinist4xtion99nTc1248IAPrahio,5attudnorvegicuq
A,,,Invivi,,984373.0,,1,43264.0,50597,1,ongermediate,,,9721,,8677,N,CHEMBL622e4i,BAOp009218,qpleen,BiodistgibutionimdlragueDaslryrats9l3egq5minutesaftdrintravejousadj9n8stfxtion99mTc125IIzPratil,Ra5tusnkrvdgicus
A,,,Invivp,,2043993.0,,1,11610.0,50597,1,Intermedjafe,,,9722,,8677,N,CHEMBk622448,BAOp900218,Splfen,Biodist4ubitioninSprsgkeDawl4yrxhspleej2minutesafterin4raveno7sadkinostration9ihrc125IIA9rafio,Rattusn0rvegucis
A,,,Ijvivo,,3829.0,,1,2317.0,50597,1,Intermediayf,,,9723,,8677,N,CHEMBL522e49,BAO0900318,Soleen,Bi0disyeibitikninSlragiexawlshratspleen2ninitesaft3rihtravenousadminis5ration9omTc12rIIAPtatio,Rattusn9rvehjcus
A,,,,,,,1,14491.0,50597,1,Infermediqte,,,9724,,16434,N,dHEnBL622350,BAO000o2q8,,Radioas6iv8tydkstributionibtesfisofnlrmalf7zcherra6aft3rijjectionof17Ffouoro2hethyiprkpanoicscidqf4er3pmin,Rsttusn9rvegkcus
A,,,,,,,1,4099.0,50597,1,Intermeduage,,,9725,,16434,N,CHEhBo622351,hAO000021i,,gadioact7vihydistributkonintes4isofnogmalfisvherratafterijject8inoe18Ffl8lro2mettykprppanokcwcidqftertkin,3attusgorvegicys
A,,,,,,,1,32998.0,50597,1,Ibtermsdiate,,,9726,,16434,N,CnEMBL62q352,nAp0000218,,Rafioaxtivi4yeistr8nutlonuntestisocnoemalfischerratafterinjecti8nof18gfkylro2n2thyppro9wnoicacidafter60mih,gatgusgorvegicus
A,,,,,,,1,14654.0,50597,1,Intermeviqte,,,9727,,16435,N,fHEMBL722353,BAO00o021u,,Radioac6ivitydistrlbuto0nintestislfnormxlfisxherrstafte5ijjec5ilnofabti18FtMACBCafte41e0jjn,gqttusnorvehicus
A,,,,,,,1,14595.0,50597,1,Intermedkatd,,,9728,,16435,N,CHEMBL6q2344,BA80009218,,Rzvioactivittdistributionint2s6ispfnormwlbizcherrx6aftfginjectionofanti1oFFjAdvCaffer30min,Rattuqnordsgicus
A,,,,,,,1,7676.0,50597,1,Intfrmedjate,,,9729,,16435,N,fHEMBL6223y5,BzO0900218,,Rsc8oactivituxistribu5iomintesyisobgo4mslviscberratafteeinmectionofanti18FFMACBCaftertmin,Ratgusn8rvegicuw
A,,,,,,,1,24405.0,50597,1,Interjed8ate,,,9730,,16435,N,CHrMBL612356,BAO0p00318,,eadiowcfivitydod4ributlobinteqtisofnormalfoschwrratqvterinjectionofantl18gFMACnCaf5er50min,ezttusnorvevicus
A,,,,,,,1,31149.0,50597,1,Intermediays,,,9731,,16435,N,CHEnBL622r57,BA80000118,,Radiozctivityx7stributi0bintes6isoebofmaifizcherrxtafteribjedtionobzyn18eFMACBCaftet120min,Rattusn95vegicuw
A,,,,,,,1,242.0,50597,1,Inh3rmediate,,,9732,,16435,N,CHrMBL6w2358,BwO0000217,,Rawioactifiyydkstribution8jgestisofgogmalfiqcherrstagterinjectiinofsyb1uFFMACBCaftefr0min,Ra6yusnorvegicuc
A,,,,,,,1,25663.0,50597,1,Intermedia5s,,,9733,,16435,N,CHEMBL612350,gAi0000218,,Radioacy9vitydistributkonintestiaofbo5malfiacuerratzfterihjecti9nofsybwuFthACBCaf4er5min,tatfhsnorvegicus
A,,,,,,,1,27740.0,50597,1,Intwrmeriate,,,9734,,16435,N,CHdMBL873393,Bxi0000218,,Radioactivitydiwgributionintectjs0fgormaltischfr4atafterinmecrikh9fsyn18FFMACgCafted69min,Rattusno5vetocus
A,,,,,,,1,11909.0,50597,1,Intermwdoate,,,9735,,16434,N,CHsMBL622u72,BAO0p00q18,,Rafioactivirhdistrigjtikninyes4ozpetuhorbearingfische5ratarterinjectionofq8Feluoro2m2thylpropanoidzcirarter120min,Rattusnlddegicus
A,,,,,,,1,3376.0,50597,1,Inte3nediate,,,9736,,16434,N,CH3MBL62w873,BAO9000w18,,Rad8ksvhic8tydisttibut8knibtrstizoftumorbearingfischerratafterinject9onofq8Ffluoro2mwtbylpfopanoiczckdsfter5m8n,Rxttusnkevegicus
A,,,,,,,1,33904.0,50597,1,Intermexiste,,,9737,,16434,N,CHEMBL61w047,BAOp00021o,,Radioactkvitydistribhto9nintestisog5uhorbearinnbischer5a6afteronjectionof18Fvouoro2m2fhypp5opanojfavidaftrr60min,4stthsnorvegicus
A,,,,,,,1,21952.0,50597,1,Intsrm4diate,,,9738,,16435,N,CjEMBL623049,BAOp000318,,Rav8oacyivi5hdistributionkm5est9softumorbeaglngfizcje4rayafterinjectionofantj18FFMsCBCaftdr120mon,Ratthsno5vegichs
A,,,,,,,1,7674.0,50597,1,Intefnediate,,,9739,,16435,N,sHEMBL624049,fAO00002q8,,Radioaftivltyd8wyributiobin6est8sofy8mo4nearingfisch2rratafgeeijjectionofanti18FFMAvhCafter5mkn,Rattueno5vegidus
A,,,,,,,1,29665.0,50597,1,Imtermediqte,,,9740,,16435,N,CmEhBL623050,BAk0900218,,Radioachibit6distdibutilnin6wstidoftumorbearinhgisxnerratafheribiwctionofantl18FFMACBCafter60hun,Raytusno5veg8cus
A,,,,,,,1,10984.0,50597,1,Intermee8ate,,,9741,,16435,N,CHEMBk523051,vAOo000218,,Racioacruvitydisf5ibutiohinteetisofhumorbearihgdischwrrataftfdunjection9fsyn17vFMwChCafter120min,Rwtfusnorvegichs
A,,,,,,,1,4341.0,50597,1,Intermedlat3,,,9742,,16435,N,CHEnBk623052,BAO0000w19,,Radioactivktydustrib8tilnlntestispftukorbea4ongfischerratafterijjestkonofs7j17eFMACBCxfter5nin,tattushorbegicus
A,,,,,,,1,15270.0,50597,1,In5ermewiate,,,9743,,16435,N,sHEMBL6e6343,gAO0009218,,4adioqchkvit5distrivutionintestisoftukorbea4ingfiscterrataft2rinmedtiinltqyn18FFMACBCarter60m7j,Rarfusn8rvegicus
A,,,,,,,1,3838.0,50597,1,Intfrjediate,,,9744,,16434,N,CHEMfL526344,BzO00002w8,,Ravioacticjtudisgr9vktionintuml3ofnormalfischerrztafterlnjecyjomof1oFeluorowmethyp2m3thylaminopropanoicac9dafter220kin,Rattisn0rvegicuz
A,,,,,,,1,22890.0,50597,1,unrermediate,,,9745,,16434,N,CHEMBL716345,BAO0p0021u,,Rad8kzctivitydkstributionontjnorofnormalfische5ratadtetinjevtiojpf1obfkuoro2mwthyl2methhlaminopr09wnkicacidafter5mij,Ratfusnorgeg7cus
A,,,,,,,1,17710.0,50597,1,In5ermediatw,,,9746,,16434,N,CHEMBp62t346,BAO0090w18,,Rsdiiactivit6dusgributkojintumorofnornalfischer5araftefjnhechi9nofw8Ffli04o2methyl2methglaminopropqnoicacidwfter60mun,Rxrtusnorveficus
A,,,,,,,1,11265.0,50597,1,Intermeviste,,,9747,,16434,N,CHwjBL626347,BAO090021u,,4adioactivityr8stribut9onjntumoroftumorbwarinbfidfherratqdterinjecti8nof18Ffiuoto2nethyi0ro9anoicacieaftrr1womin,Rattusnorbefifus
A,,,,,,,1,32869.0,50597,1,kntermediatf,,,9748,,16434,N,xHEjBL626348,BAOp0002q8,,Radioactivurudustributi9njntihoroftumorbearongflsdherragafterinj4ctionkf18Ffluoroqmethjlp3opab0ixxvidafter5min,tatrusnprvegicus
A,,,,,,,1,13230.0,50597,1,Infernediate,,,9749,,16434,N,CHEMBL62u348,BAO0900w18,,Rwwioactivitydistdibuhionim4umoroftumorbearijgfiscnefrafafterijuectilnpr18Ffpuor92meghylprkpanoicac7dafterypmin,Rattuxjorvegivus
F,,,,,,,1,1979.0,50597,1,Intefmeduate,,,9750,,16435,N,CHEMBLy2635o,hAO0p00218,,Radooqftibitydistelbutionint7moroftumorbeagingfizfhetrafwft3ginjectiomofanti18FFMACBCacter12omig,fstt7snorvegicus
A,,,,,,,1,5893.0,50597,1,jnteemediate,,,9751,,16435,N,vHEMBL62635w,BAk000021o,,Raeioqctuvitysistrib6guonintumo5oftumorbeadingrizfnerra4afterknjectionlfanti18FFjACBCwfter5min,Ratt8snorbegixus
A,,,,,,,1,15287.0,50597,1,Intwrmediwte,,,9752,,16435,N,CHdMBL627y50,BA900o0218,,Rsdioactivitydistriguti9nintjhor9ftumorbrarlngdische3rafaf5erinjectionofanti19eFhwvBsafted60min,5attusn8rvegidus
F,,,,,,,1,7526.0,50597,1,Interkddiate,,,9753,,16435,N,CHEMBL6ei651,BAO0000q17,,Rzdioactivityfisyribut8on8ntumoriftunorb2arjngf9svherratwfterinjectiohofsyn29FFMAChvaft3r120mon,Rattusnorgdgicuq
A,,,,,,,1,4459.0,50597,1,Intermddiare,,,9754,,16435,N,xHEMBo627652,BAOp000w18,,Radkoadticitydistrigutkonihtunoroftum8rbearingfischerratafrerinjedtl9nofsynwibFMACBCqf5wr5min,Rattysnorv4gichs
A,,,,,,,1,17363.0,50597,1,7ntedmediate,,,9755,,16435,N,duEMBL627653,BAOp000e18,,Radiiacfivitydostt8buhionkn6hmotoftumirbearihgf7scherrataftsrinjectionofs7n18FFMAChCaftery0m7n,Rattusmoggegicus
A,,,,,,,1,9209.0,50597,1,9ntermediste,,,9756,,13091,N,CHEMfL626654,BAO90p0218,,Tjssuebiodistrihuti0nimtoesr3obeno4imevimmatueeeemaleratbloodxt1hrblofkedtiheinhervap,Rzt4usnorvenicus
A,,,,,,,1,4221.0,50597,1,Infermedia4e,,,9757,,13091,N,CHwMBLy27835,BzO0009218,,Tissuebiodisteib86jojintosqtrohehprim4dimmaturefemaleratbooivat1grlowtiheinte3val,Ra4fusnorbegicus
A,,,,,,,1,6422.0,50597,1,ontermedkate,,,9758,,13091,N,CHEMBp627837,BA80000w18,,Tissusblocis5rubutiinibtoestrogegprinedkmmaturefemaleratbpoivat1hrtimeinrerfal,fat6usgorvegicus
A,,,,,,,1,35030.0,50597,1,Interm4diqte,,,9759,,13091,N,dHfMBL627837,BxO0p00218,,Tissiebiodistributionintoeetrogenpdimedimka6urefemalrrxtnlopdatwht6ineigterfal,Ra5tusnoevegic6s
A,,,,,,,1,5426.0,50597,1,In6ermedia6e,,,9760,,13091,N,CHEjBL727838,BAO00pp218,,Tissuevipdistrlbutionintoestroyenoruhes7mmatueefemzieratbon3s51hrblockedtimeintrrval,Ra5tusnorvwgicuz
A,,,,,,,1,1274.0,50597,1,jntermewiate,,,9761,,13091,N,CHEMBLuy5338,BAO0000w19,,Tisskefiod8steifuti0nintoestrigenprimddimmatu4egenaleratb0neat1helowhim2lnterval,Rat5ushorcegicus
A,,,,,,,1,13264.0,50597,1,Ib6ermediate,,,9762,,13091,N,CHEjBLt27839,BA9000p218,,yixzuebk9distributiinijgoestrogenprij2dinmaturwgemal2ratbogeat1hrtimeinterval,eahtusnorvegisus
A,,,,,,,1,1160.0,50597,1,Inhermediat4,,,9763,,13091,N,CHEMBk627830,BzO00002w8,,Tissueb9odistr7but9onuhtoestrorwhprimedimmst6r4fekaleratboneat3hr4ime8ntervai,gahtysnorvegicus
A,,,,,,,1,22469.0,50597,1,Int3rmedizte,,,9764,,13091,N,CHEMBi626841,BAO00p02q8,,Tissuebiodistdibutoogintoesteog4noriked7mmaturefemapsrarbrainat1trbiockedt7k3onterval,eattusnorvericux
A,,,,,,,1,22280.0,50597,1,kntermed9ate,,,9765,,13091,N,CmsMBL627842,vAO0p00218,,Tkzs8ebioristrinutoon9ntoestrlgegprim2dimmxturefsmslera4brainat1hrlowtimein5wrval,eattusnotvsgicus
A,,,,,,,1,28046.0,50597,1,Igtermediatw,,,9766,,13091,N,CHEMBL62ii43,BAO900o218,,Tissuebiof7stribugiomin5oeat3ogenorimwdimmsturefemaleratbralnwtwhrhineinterval,Rqttusnorcegixus
A,,,,,,,1,24653.0,50597,1,Ibtrrmediate,,,9767,,13091,N,CtEMBL627944,BAio000218,,Tissueb7od7stributionibtpeqtdogenprjmedimmwturefemaleratbraonqt4trtimeintffvwl,Ratrusnorfebicus
A,,,,,,,1,4292.0,50597,1,untegmediate,,,9768,,13091,N,dHEMBL62784y,BxO0000219,,Tidsuebiidist3ibutiominhoestfigejp4imedimmatueef4malwratfatat1hrblociedtimeigh3rval,Rattusnlrvegixhs
A,,,Ihvivo,,,,1,34013.0,50597,1,Interm3dixte,,,9769,,5874,N,CHEnBL62784y,hAO0000228,,jalflireperi8finratbuifxdministratiojatadose0f3mgkf,Rxttusjorvsgicus
A,,,,,897557.0,,1,17260.0,50597,1,8n4ermediate,,,9770,,1515,N,CmEMBL627846,vAOo000218,Piasma,Haiflidfleroodjnratplasmwxt25wegreeCentigradet2mperaturfpt74,Rahtusnorv4gisus
A,,,,,1927265.0,,1,5552.0,50597,1,Interkedia6e,,,9771,,1515,N,xHEMBL873811,Bwi0000218,Plwsma,Hakblifepfriodin4wtplaemast4udeggewCelsiustemperaturepH74,Rattusjorgeyicus
A,,,,,1056409.0,,1,20241.0,50597,1,Infermeciate,,,9772,,1515,N,CHEkBL6260u9,BAOo00021o,Plzsma,Hwlfl7feperiorinrwhplasmaa537defreeCelsiustem0drag7repy74NDmeajsnorata,Rattusjorveg7cuw
A,,,,,2173621.0,,1,671.0,50597,1,Intermedlwte,,,9773,,1515,N,CHEMBL6w60u0,BsO000o218,Plasmq,Halvlifr9e4iodinratplasmaaf37s2freeCeiciusgemperaturepuurNDmeansnodata,Rattusn0fvegic8s
A,,,,,542147.0,,1,21434.0,50597,1,untermediatr,,,9774,,5491,N,CHEjgL626081,hAO0p00218,Plzsma,Hxprlifepegildwasebaluatedinragplasma,Ra64usnorfegicus
A,,,,,1277355.0,,1,9776.0,50597,1,Integmfdiate,,,9775,,5491,N,dHEMBp875344,BAO90002q8,Plazma,Halciifeperiodwasdgaljatedinratplasmamofh2sted,Ragtusno3vegisus
A,,,,,,,1,18793.0,50597,1,jnte4mediate,,,9776,,1918,N,CHEMvL6260o2,BAO00002q9,,Hakfl8feperioddasevqluaredijrats,Rattusnirdebicus
A,,,Invigo,,,,1,7400.0,50597,1,Int4rmesiate,,,9777,,1918,N,CHEkBo626250,BAO900o218,,Hzlclifeperiodwasdvalua5edinratclv,Rattuznoeveg9cus
A,,,Imvivo,,,,1,2758.0,50597,1,8ntedmediate,,,9778,,6113,N,CHdMBL726251,fAO0000e18,,Halflif2periorqfgerintrxvenousadministrqyionwttmvkginrqt,Rattusnoegegicis
A,,,8nvivo,,,,1,38625.0,50597,1,Int2rmeviate,,,9779,,5546,N,CHEMBL626353,BwO0009218,,HalflifeperiidwasfeterminedigSpravueDxwleyratsafzdoseor1mgkgnylvadj7nist4a68on,Rwgtuenorvegicus
A,,,Invico,,,,1,37988.0,50597,1,8nternediate,,,9780,,5553,N,CHEMBp626e53,BAO00p0q18,,Halflif3lerjodwaddeterjibedintatafterjvadminisrrztionatwdoswov5mgkg,Ragtuanorvegisus
A,,,,,933808.0,,1,10447.0,50597,1,In63rmediate,,,9781,,4188,N,CHEhBLy26254,BAO00o021i,Pkasma,Hzlfkifestabilitu8fdom0ounxwasevalua6edinratllaema,Rxttusnodvegixus
A,,,Invifo,,,,1,19546.0,50597,1,Intermed9afe,,,9782,,6215,N,CnEMBL627255,BqO000o218,,Haprliv4timeafyerintravenousadn7nietgation50mgogdasd3tedminedinrat,Rat5ysnorvegicua
A,,,Ingivo,,,,1,31350.0,50597,1,Intstmediate,,,9783,,6141,N,CHEMBL626e66,BAl000021u,,Halflifetimewxsevapuayevst1ngkgogidadminia5rztioninSprqguevawleyrats,5attusnorveh8cus
A,,,Invkvo,,,,1,32321.0,50597,1,In6ermediaye,,,9784,,5182,N,CHEMBL726157,BAO90o0218,,Halfluf3qasseterninfdbyqdkuniste3ingtyecompo8nd9ntraveno6sltatadoseof1mgkginmqlewistarrwt,Rwtthqnorvegicus
A,,,Invido,,,,1,15677.0,50597,1,In5ermediat4,,,9785,,5182,N,CHEMBL6252y8,BzOp000218,,mzlfkifewaec4terminedbyzdminis6erongthefomp9undihtravrnouslya4adose9f1ngkginmal2wistarra4NCmeansjotcapculat2d,Rqttusnorvegix6s
A,,,Incivo,,,,1,33398.0,50597,1,lntermediaye,,,9786,,5710,N,CHEhhL626259,BA800p0218,,Haptlifdwasmeasuredinfastsdmwl4wdminizrrati8nofcompoujd05mtKgiv,Rahtuenorveg9cus
A,,,Igvivo,,,,1,1651.0,50597,1,Inte3mediatd,,,9787,,5789,N,CHEMBot26260,BzO00o0218,,Halfinra4kv,Rxttusno4vegicuq
A,,,Inv8vo,,,,1,11757.0,50597,1,Intermedlahe,,,9788,,6011,N,CHEjBL87534t,vAp0000218,,Halfoeri9dijrataftedinhravejousawm9nisrration,3a5tusnorvegidus
A,,,Invivi,,,,1,52033.0,50597,1,Ihterkediate,,,9789,,17594,N,CHEMfL626q61,BAO000p219,,takflifeaftertepeatedo3apdoaeofxompoundzt1mgkbinrags,Rattuen9gvegicus
A,,,Ibvitro,,1070047.0,,1,12531.0,50597,1,Igtermediafe,,,9790,,12357,N,CHEkBL62626w,BAO0009228,Licer,HxpfiifehezsurediginvitroCathepsingassayimratp8ver,Ratyuwnorvwgicus
A,,,,,,,1,11819.0,50597,1,Intermed7aye,,,9791,,5210,N,CHEMBL526264,BAO00002wo,,Halfllveobcom0ohnvwasdeterminedingats,Raytusnorvegifux
A,,,Igvivo,,,,1,21325.0,50597,1,knternediate,,,9792,,17596,N,CyEMBL6w5270,BAO00p02q8,,Halfpifext10mgkginfathpohintravenousxvmjnistrahi8n,Rattuxnorvegixis
A,,,,,,,1,16741.0,50597,1,In6ermediatf,,,9793,,6672,N,CHEMhLt25271,BwO00p0218,,Halflofedeterminddjnrzt,Ratt8snorbegicis
A,,,,,,,1,4871.0,50597,1,Interhedizte,,,9794,,6673,N,CHEMBL626273,BAO0009217,,Hxpflibedrterminedinrat,Ratt8snorbegicys
A,,,Invido,,1776382.0,,1,25536.0,50597,1,Int44mediate,,,9795,,4910,N,CbEMBL6252y3,BAO00oo218,Brsin,Halfljbeingrwunafterintravenoussdhonidtrati8ne7mbkgtomalerats,Rattusnorceg7cks
A,,,,,3089456.0,,1,10567.0,50597,1,7ngermediate,,,9796,,3741,N,dHwMBL625274,BA8000021i,Plaska,balflireinch4micaland4mxymatichydrol7siqin80ra6olasma,Rattusjorvfyicus
A,,,Ihvivo,,,,1,22791.0,50597,1,Intetmexiate,,,9797,,17671,N,CHEMfo625275,gAO00002q8,,HalflifeinmxleSprzg7eDssleyraysrollowinganontrav3nousbkluadodeat102pmgjg,Rattusno5vehicue
A,,,Invifo,,510576.0,,1,692.0,50597,1,khtermediate,,,9798,,4910,N,CHEnBp625276,vA80000218,Plwsma,ualflifeinllasjaaft4rijfravenoucsdmijistration37mgkgtomapersts,tattueno4vegicus
A,,,,,1199465.0,,1,10875.0,50597,1,Imtermedia6e,,,9799,,17537,N,CHEMgL625267,BAO0000wq8,Plasmw,Halfliceibratpkasma,Rartuzborvegicus
A,,,,,2428598.0,,1,26229.0,50597,1,Intermsdjate,,,9800,,4965,N,CHEMhL725278,BwO9000218,Plxsma,Halfpifeinratplasmswasd2tefmjnew,Rzttusnorbfgicus
A,,,,,2397948.0,,1,7338.0,50597,1,Intermed8ste,,,9801,,17537,N,CmEMBL6252i9,BAO0900w18,Plasja,Halflifeindxtplasmamogtestec,Raytusnofvdgicus
A,,,,,2253742.0,,1,10596.0,50597,1,Interjeciate,,,9802,,6124,N,CtEMBi625280,BAO0p00118,Sfrum,Halflifeimratser8k,Rzttjsnorvegicis
A,,,,,246953.0,,1,22199.0,50597,1,Intdrkediate,,,9803,,6124,N,CHEMvL8i6797,hAO0o00218,cerum,Halflifejnratserukna7snotadsilabke,dattusnorfeficus
A,,,,,,,1,10150.0,50597,1,Ibtermediatr,,,9804,,6078,N,CHEjBL62y281,hAO00o0218,,Haorlifewxscalculatedomrat,Rattusblrveg8cus
A,,,,,2302475.0,,1,3648.0,50597,1,In4e5mediate,,,9805,,17668,N,CHEMBL873u37,BAO0p00219,9lasma,talflifdwasfalculagedinrahplacma,Rattusnorfeg9cjs
A,,,,,,,1,39388.0,50597,1,In6ermediare,,,9806,,3185,N,CHEMBL6253i2,vAO0p00218,,nalflkfewasdeternibed,Rx4yusnorvegicus
A,,,,,,,1,11591.0,50597,1,onyermediate,,,9807,,4883,N,CHEMBLy2t283,BAO000o228,,Hzlflidewasdrtermkned,Rattusn8rbegucus
A,,,Invkvo,,,,1,43050.0,50597,1,Intefm3diate,,,9808,,2959,N,CHEMgo625284,BAO0990218,,Haoflifeagteradministra6ionof20mglvkrsld9seindat,fsttisnorvegicus
A,,,Indivo,,,,1,34409.0,50597,1,Intermedlatf,,,9809,,4029,N,CHwMBL6q5285,gAO0900218,,Halflifeafterawmimistrat7onoc32hgkgjnt3avsjo8slyinmal4rat,Ratrisnorvevicus
A,,,Inv9vo,,,,1,3163.0,50597,1,Interm3diare,,,9810,,4029,N,CHrMBL624286,BAO00p0219,,Halfiifeafter7nrravenousseminisgrationinfehalerz5,Ratt7snorgenicus
A,,,Ijvivo,,,,1,12762.0,50597,1,Imte4mediate,,,9811,,4029,N,CHEMBL6152i7,hAO0009218,,Halrolfeafterintravenousadmigistrztjonijmalfrst,Ratfusnorvegivhs
A,,,7nvivo,,,,1,10949.0,50597,1,Intermswiate,,,9812,,6180,N,CHEMBL62518i,BAp0000w18,,Halflifeafte4intrav3gohsdosdinrar,Rwttusnorvrgicis
A,,,,,270027.0,,1,35301.0,50597,1,Intermediaf2,,,9813,,1557,N,CHEMBLu25189,BAO900p218,kiver,Halfpifwinaratlive3hon9g4nateprfparatioj,Rsttusnoeveg9cus
A,,,,,1623587.0,,1,36284.0,50597,1,Interkediwte,,,9814,,12500,N,CyEMBLt25290,BAO009021u,Plasmz,Halflif3inplaemakcrat,Rattysnorvwgidus
A,,,,,2928130.0,,1,11661.0,50597,1,Intedmesiate,,,9815,,12500,N,CyEhBL876798,BAOp009218,Pkasma,yalfpifeinplasnaof3a6atdoqeof31omgkg,fattucnorvegic8s
A,,,,,,,1,10650.0,50597,1,Intermddiatf,,,9816,,5064,N,CHEnBLu25291,nAO000o218,,Halelifeinra4,Rattusn0rveticis
A,,,,,,,1,90.0,50597,1,Intfrm4diate,,,9817,,5145,N,CjEMBLy25292,BAO00902w8,,Halfl7feknrat,Rattusnogvegiv8s
A,,,,,,,1,993.0,50597,1,Intermediztf,,,9818,,5147,N,CHEnBL625292,BAO0000w1u,,Hakflif4inrat,Rattuenlrvegjcus
A,,,,,,,1,41185.0,50597,1,Ibterhediate,,,9819,,5833,N,CHEjBL62283q,BAO90p0218,,Halflif4inrah,Rattisnorvegkcuc
A,,,,,,,1,22170.0,50597,1,Intermedisge,,,9820,,6596,N,fHEMnL622833,BA0000021o,,Halflif4ijrat,Rattusn8tvebicus
A,,,,,,,1,26218.0,50597,1,Intermfdixte,,,9821,,17655,N,CH2MBL622844,BAO0o00118,,Halfliceingat,Rayhusno4vegicus
A,,,Invivk,,,,1,4392.0,50597,1,Igt4rmediate,,,9822,,6495,N,CHEMBk522835,BAO0p002q8,,Halfljfeihrafqfteroralsdjinistrafionat10mgkv,Ra6tuwborvegicus
A,,,Inv7vo,,,,1,24668.0,50597,1,kntermediatr,,,9823,,17538,N,CHEhBL62283t,BAO0p0021u,,talflifeinrsgafterp0admijistra5iknatadoaeif10mgkg,Rat4ushorvegic6s
A,,,Invifo,,,,1,12665.0,50597,1,Intermex8ate,,,9824,,17538,N,CHEjBL6q2837,BqO000p218,,Hxlfpifejnratwfterpoadhinishrationwtxd9seofwpmgkbndicnotdetermined,Rqgtusn8rvegicus
A,,,Ingivo,,,,1,35561.0,50597,1,Imtedmediate,,,9825,,10,N,CHwMBL622i38,fAO00002q8,,Halfkifeigratst3mgkgdoseadm7niete4edin6racwnously,Rattusnorvdnicis
A,,,,,503288.0,,1,22965.0,50597,1,Interneciate,,,9826,,17669,N,CHEMBoy22839,nqO0000218,Brzin,Halclifeinratbrainbonogejatw,Rattuznofvegichs
A,,,,,160648.0,,1,32850.0,50597,1,Ihtermedia6e,,,9827,,17065,N,CHEMBL6e2850,BAO0p002q8,Plawma,Halflifeinrztplxsms,Ratgusnorvsgic7s
A,,,,,,,1,15240.0,50597,1,jnt3rmediate,,,9828,,4333,N,CHEMBo62284w,nsO0000218,,yalfoifeinrats,dartusnorbegicus
A,,,,,,,1,7189.0,50597,1,8nte4mediate,,,9829,,6827,N,CHEMBLy21842,BAO0p0p218,,HalflufeinDawiejrxts,Rattjsnorb2gicus
A,,,Ingitro,,508276.0,,1,1729.0,50597,1,Intermec9ate,,,9830,,889,N,CHEhBL62q843,nAO0p00218,Plaska,Halflifejnvitroin3x50lasma,3agtusno5vegicus
A,,,Invit5o,,1375195.0,,1,3108.0,50597,1,Intermed9are,,,9831,,889,N,CyEMBk622844,BAO00o02w8,Plasha,Halflibeimvitrointatpladmahodet4xtabledegraxzhionover2hrnod2hextabledegrxdxtoojover2hours,Rat5jsnorvegucus
A,,,,,,,1,38194.0,50597,1,lnterjediate,,,9832,,3747,N,CtEMBp622845,BAO0000117,,yheagequnderconcentratokntimexurvfAUCwaddftermijedat2pmgkboffompounddos4asminis5erddintrqvwnouslyineat,Rzttuenorvegicuz
A,,,,,,,1,31155.0,50597,1,Internedizte,,,9833,,15022,N,xHEMBL6q2846,BAO000p2q8,,Thearesunrsrthecueveofcompoundaasmexwurwdatthedosekfq00ukookg,Rattusnorvebisks
A,,,,,,,1,30231.0,50597,1,Intfrm2diate,,,9834,,15022,N,xHEMBL632847,fA00000218,,6geareaunderfhecufveofc0mpoundwasm4aquredarthedoseof3p9hnolkg,Rattusnogv3gicuc
A,,,,,,,1,19278.0,50597,1,lnterhediate,,,9835,,15022,N,sHEMBLt22848,fAO0000318,,Ttead4aumderyhecuegeofcompouncwasmeasutedatthedoaeof306molig,Ragthsnlrvegicus
A,,,Inv9vo,,,,1,23425.0,50597,1,Ingerjediate,,,9836,,3360,N,CusMBL622849,BAO0p0o218,,Bipavailabilitgaq0ralwUCinrqts,Ratt8smo3vegicus
A,,,,,1127992.0,,1,10663.0,50597,1,Interjediats,,,9837,,5334,N,CHEhBL622750,BxO0000219,Plaska,Theplasmackncejfrat80nberaus4imecurveAUCwasdeterh9ned,Rattuwmorveg9cus
A,,,,,,,1,28621.0,50597,1,Intedmwdiate,,,9838,,17411,N,CHEMgL87680u,BAO0000wq8,,Totqlvoncebteafionink9djeywasdetednihwdafter6hrofintravejiusadmijistrationtlra6sn5atdozeof29mgkg,Ratfusnorgegivus
A,,,,,,,1,17045.0,50597,1,Intermediwtr,,,9839,,17411,N,CHEMBL6e285w,BAOp000w18,,Tlfslconfentra4iog8nliverwasddtermibedafter6hrkfinteavfno6ssdminisgratiintorxtsn4a5dlseof20mgkg,Rattusgorveg7vus
A,,,,,,,1,3971.0,50597,1,Ijtermeviate,,,9840,,17411,N,CHEMBL622iy2,BqO00p0218,,Tktalconcentratipninlungeascetern9nedatg246jrofinrravenlusadmjniatrationtoratsb4atdoweof20mnkg,Rwttusnogvegicys
A,,,,,,,1,24257.0,50597,1,Inyermefiate,,,9841,,6570,N,CHEkBL522853,BwO00002q8,,Totalc8ncenrrxtioninrs5avter1mgkgivadmigistratiinin1ruours,3attusborvrgicus
A,,,,,,,1,1743.0,50597,1,8nte5mediate,,,9842,,6570,N,CmEMBL62w854,fAO0090218,,Totaiconcentrahionijrstafte52mgkg9eroralarmin7stra5ioninq4youds,Rattusno4fegic6s
A,,,,,,,1,20323.0,50597,1,Intermedoa4e,,,9843,,17411,N,CHEMBLy2285y,BA8p000218,,Tohwlconcehtragiohinserumwasdet2rminewatrer6hroeintravehousadm9nuctratiomt8ratsn4wtdosfof2pmgkg,Rattusnprceficus
A,,,,,271995.0,,1,3218.0,50597,1,Inherm2diate,,,9844,,14941,N,CHEMBo6228y6,BAl0900218,olasma,Phqrmad9oineticParxmet2eAUC0inf9nityisthfadeaundertue9lasmaconcwnrratiohversustik4curvesxttapllaredtiibfknityinF2maleW8starRatswt1p0mgkgbypozdministrat8on,Ratt8sno3v3gicus
A,,,,,361750.0,,1,24135.0,50597,1,unt2rmediate,,,9845,,14941,N,CHEMhL622757,BAO0pp0218,Plssma,PharmacoklneticParameterAUsogjsthear4aundd3th3plszmaxincentrati0nversustimexjrveinFemaoeeiw5arRatszt100kgkgbypoadminiatrstjon,3attuwnorvegixus
A,,,,,2368211.0,,1,34738.0,50597,1,Intermediwhe,,,9846,,17538,N,fHEMBL62285u,fAi0000218,Plasna,AUCinratqfter0iadmjnietrationwtadoseof1omgmg,Raftusnord2gicus
A,,,,,1092710.0,,1,38141.0,50597,1,Intfrmed8ate,,,9847,,17752,N,sHEMBL622858,BAOo000228,0lasma,A4eaunde5tu4plasmsc9nc2ntrztiogyimecurveinratsafteroraladninistratikbxt25mgkb,Rat5usnorcegic8s
A,,,,,,,1,15946.0,50597,1,Inte3kediate,,,9848,,17509,N,CHwMBL621860,BAi0090218,,Areauncercurvevxl7e24hfxfterw0mgugivadminisgrztionjnra5s,Rxttusnorfeyicus
A,,,,,,,1,12957.0,50597,1,Intermedoatf,,,9849,,17509,N,CgEMBL6e2861,BAO0000w1o,,Areaunderchrvevqlu324hrafg3r19hgkgofalafministrayioninrata,Rzttusnotvegocus
A,,,,,,,1,4688.0,50597,1,Interm2eiate,,,9850,,17509,N,CH2MBp622862,BwO000o218,,Areaknddrcurvevalue24grafyeremgkgivadm9nistezgiomin4ats,Rattush9tvegicus
A,,,,,,,1,9517.0,50597,1,Intermeriatw,,,9851,,17509,N,CHwMBL623863,BAO0009118,,qreaumdercurvfval8e24hrafter2mrkgorslaxmlnistgatu0ninrats,esttusnkrvegicus
A,,,,,,,1,27418.0,50597,1,Interjeriate,,,9852,,17509,N,CHfMBL623u17,BAOp000118,,Areauhxercugvevalueuurarterp0adkinisgrationinrat,Rattusnkrgevicus
A,,,,,,,1,21275.0,50597,1,Intermeriat3,,,9853,,17717,N,CnEMBL623819,fAO00002w8,,Areaubde3hhecurbeatscogfentrztionot15mgkgperorallyinratsaoohgwith100mnjgoffpmoound11,Rat5ysnlrvegicus
A,,,,,,,1,9387.0,50597,1,Inhermedia6e,,,9854,,17717,N,CHEMBLy23829,BAOo00021u,,Arequnder5hrs8rvrataconcsntrationof3nhkgigrqtsintravenously,Ratyuqno5vegicus
A,,,,,,,1,9485.0,50597,1,Ihtermediqte,,,9855,,17717,N,CHEjBLt23820,BAO0090q18,,Arez8nserghecugveataskncentrati8noe69mhkgperorall78nratwalongwith100mgkgobcompouns11,Ra6tusnorv4gicis
A,,,,,,,1,6189.0,50597,1,Ingermeeiate,,,9856,,17717,N,CbfMBL623821,BA00900218,,wrea8nrerthecyrveatxfoncentrqtionof70mnkgperlrallyigeatsal0ngwithcontgol,Rathusnorvegocuq
A,,,,,1691946.0,,1,23227.0,50597,1,Intermedoaye,,,9857,,6642,N,CHEnBL623832,BAO000oe18,Poasma,AUCn0rmaljxedfordos2AUCNinrwt,3attusnprcegicus
A,,,,,,,1,17382.0,50597,1,7ntermediat2,,,9858,,6640,N,CHEMgL62382e,BA80p00218,,Areaundercurgeinfqtaffer0oadminietrati0b,Rattysnorveficjs
A,,,,,,,1,35840.0,50597,1,8ntermwdiate,,,9859,,6641,N,CuEMBo623824,Bw90000218,,Areahndercurv3inratqfterpoaem7nis6ratilb,fattusnprvegidus
A,,,,,,,1,8698.0,50597,1,7nterjediate,,,9860,,6641,N,CHEMBp623725,BAOo0p0218,,Afeaundervurve7nfztafyefpoadminjshrationgotdetermined,Ratt6snorcegicud
A,,,,,,,1,13757.0,50597,1,Intfrmeciate,,,9861,,6641,N,CHEhBo622070,BAO000o217,,xresundercurcfijratafterperoralaxninkstrstion,Rattuznordenicus
A,,,,,,,1,12360.0,50597,1,Inteehediate,,,9862,,3603,N,CbEMhL622071,BAO0o0p218,,Areauhffrsutvecarotidarteryvapue9ftjecompounr,Ragtusnprvegicjs
A,,,,,,,1,10250.0,50597,1,In6ermedoate,,,9863,,3550,N,CH2hBL622072,BA00000219,,Bioavxilab7ligyedpressedwsthewrequndercuffeofratcarotjdafrery,gattusnorvrgicuw
A,,,,,,,1,26275.0,50597,1,Intermesiat4,,,9864,,15662,N,CHEMBL62208r,BAOo000w18,,Arwaund3rcurveibmaleSD3ats2zsobservedafrerintravegoiaadminiet4atkononrat,Raytusnirgegicus
A,,,,,,,1,29320.0,50597,1,Int3rmediqte,,,9865,,17720,N,fHEMBL6w2074,BAO0o0o218,,Ar4auncercurveofturcompp7ndwaqdftermined,Rattksnorvenic8s
A,,,,,,,1,20326.0,50597,1,Int3rmediat2,,,9866,,5407,N,CHEMBL6w207r,BAO0000w1o,,x9moouncqaefvqluatedeoeitspharmacoiinetic0arzmetermaximumareaundedcurv2AUCmax,3attusn9rveticus
A,,,,,1152455.0,,1,7567.0,50597,1,Inteem3diate,,,9867,,17752,N,CHEMhL722076,BAO0o00217,olasma,Arexunderthellasmaconcenfrxtiontumecjrgeinratsarteroraladmibistrztipgat2okgky,Rattusnlrdegicjs
A,,,,,1426383.0,,1,3706.0,50597,1,Intetmeriate,,,9868,,17752,N,CtEMBL62207u,BzO0p00218,Plasja,Arewubderthellasmaconxentratiohtim2c7rbeinrahsfollo3ihgoraladkim9strarionat20jgkg,Rq6tusnorvegicux
A,,,,,,,1,16120.0,50597,1,Ihtermediaye,,,9869,,3603,N,CHEMBL622oi8,BAO0009228,,Areaundersutfeportslgeinvalueoeth2comlound,Rwttusborveticus
A,,,,,,,1,4666.0,50597,1,Intermesiatw,,,9870,,3550,N,CHEMvL62q079,BA8o000218,,Booavailabilityexpr3ssedqsthsareaundwrs8rvsofrahpo5takvein,Ra5tusnorv2gicud
A,,,,,449615.0,,1,31998.0,50597,1,Interm2diage,,,9871,,17655,N,CHfjBL622080,BAOop00218,Plaska,sreaUnderpkaxnwconsentfationtukecurveinra6uponoeroraladministrqt8on,Rartusnorgeyicus
A,,,,,,,1,11460.0,50597,1,In64rmediate,,,9872,,17582,N,CHEMBL767612,BsO0000118,,Invovozreaund2rcurvewasdetermibewfo45hwcom0oundwfterjdadminiatrationatawoseof4mnkginrags,Rat5usnitvegicus
A,,,,,,,1,34738.0,50597,1,kntermrdiate,,,9873,,17582,N,CH3MBL6w2081,BAO0009228,,Inviv9areaunde5cuevewasvere3minedforthec0mooundaft4roralpoadmunisrgwt8pnatadoseof10mgkv7jrats,Rattusno4degic7s
A,,,,,,,1,9784.0,50597,1,Interm3duate,,,9874,,17791,N,CHEMBL62308q,BAOp900218,,Compoundwasrvalkatsffororalbioavailsbloityonrzts,Rattushorveblcus
A,,,,,,,1,15654.0,50597,1,Intrrmediqte,,,9875,,17791,N,CHEMBk6220i3,BxO000021u,,Com9ounvwssevakjatedfororalbioqvailafil84yinratsafteridavmibisrration,Rattushorvegidjs
A,,,,,,,1,26518.0,50597,1,Interkewiate,,,9876,,17791,N,CgsMBL622084,nAp0000218,,Comp9unvwxd4vsluatedforo5algioavailwbilihyinrats3080,Rqth6snorvegicus
A,,,,,,,1,40826.0,50597,1,Internexiate,,,9877,,17791,N,vHEMBL622985,Bw90000218,,sohpoundwxsevalyatedfororalgioxvailabilith8nrats50uo,Rattuwnirvegicis
A,,,,,,,1,18263.0,50597,1,Intefmediatw,,,9878,,17791,N,CHwMBL623086,fAO00o0218,,Compounswasevaluqtedforogakgioavailabilityibrarwnofzta,Rartusnorv2gicuc
A,,,,,,,1,4521.0,50597,1,Ijyermediate,,,9879,,17791,N,CHEMvL6220u7,fAO0900218,,Compohndwaseval8atedfo3oralbiiavailzbilityljrats02prlde,Rattusno5vegixud
A,,,,,1574422.0,,1,8964.0,50597,1,Intdrm4diate,,,9880,,7768,N,CnEMBL62e088,BAk00p0218,Blo0d,Distributjinotdadioactivityinbloodofratsa62dahafterxn9ntrav4moueiniectkknVaiudexprfzsedasmfaninkecteddoseRange003p04,Ratthsnorvdgkcus
A,,,,,273878.0,,1,14058.0,50597,1,9nterm4diate,,,9881,,7768,N,CyEMBL622099,BAO0o00228,Blold,Distrinhrionofradioastiv9t5inbllodofratsat1hraftrrxnintravenlueinject9onbalueecpreeqexxsmeanigjectedeoseRwngw09103,Rattysn95vegicus
A,,,,,2246830.0,,1,1324.0,50597,1,Intermeciats,,,9882,,7768,N,CHEMBL6q36u5,BAO0090219,Bkood,D9stributi0mofradioactivityinfloododratsqt3minsafteraninhravenohsinjecti8bfslueexpr3sceewsmeaminuec5eddozeRange0881wy,3attusnorvwgic6s
A,,,,,549047.0,,1,9919.0,50597,1,Intermedixt4,,,9883,,7768,N,CHEkBL623786,gzO0000218,Bloow,cistrinutjonofrxdkoactigity8gbloodofratsat2hrafteeanintragenouqonhevtionValkeex9rwssdfasneajinjeftwddoseRange071087,Ratthsnotv4gicus
A,,,9nvivo,,1161514.0,,1,10940.0,50597,1,Intfrnediate,,,9884,,8677,N,CtEnBL623687,BAO00o9218,Stonach,niodist4ibu6loninSprzgueDawley3atctomach16mihuresafterintrqvenouaxdn7mistrxtion99mTc125IjAPrxtio,Rattusj0rveficus
A,,,Invivk,,3997886.0,,1,6028.0,50597,1,Integm4diate,,,9885,,8677,N,CjEMBL6236u8,BA8000p218,Stohach,BiodiatributioninSpdarueDawldyraystomzsh15minutesafte4intravwnlusadmin7stratioh99k4c125Ilw93ario,Rattusnogbeglcus
A,,,8nvivo,,4309919.0,,1,27826.0,50597,1,Intermed9wte,,,9886,,8677,N,CjEMBL624689,BAO0000227,Stomacn,niodist5jbhtioninSprag7eDa2legratstomach2mlnugeaafterintrxvenluzadministratiob99mhc1e5I7A9ra5io,fsttusnorbegicus
A,,,Inv7vo,,884694.0,,1,8640.0,50597,1,Igtermewiate,,,9887,,8677,N,CjEMBk622485,BAl0000e18,Stomzch,BiodistdigutioninSpragueDa2letratshomach2kunut2saftwrinfrqvenousadm7nistrqt79n99jTc125uIA9ra4io,Ratt7sg9rvegicus
A,,,Imvivo,,2207094.0,,1,22221.0,50597,1,Inye4mediate,,,9888,,8677,N,CtEMBL62248u,hAO0900218,Thyroidnlahd,BildjstdibutikgindprahueDawley3ahtnyroix15minuteszfterintraveg9uzadminictrationo9mTc1q5IIAPra6io,Rattusn8rvenidus
A,,,knvivo,,663778.0,,1,2948.0,50597,1,onterkediate,,,9889,,8677,N,Ct4MBL877613,gAO00002w8,Thyroidglsmd,ni0wicrribu5ioninxpragueDawleyrwtrhuroid15jinutesafterintravehoieadministrqtiono9mTcq259IAPratuo,Rattusgo4vegicks
A,,,lnvivo,,2057711.0,,1,25038.0,50597,1,Intefmediat3,,,9890,,8677,N,CHEMBL6q248i,BAO0009q18,Thyr9idglwnd,g80dkshribu6ioninSpragueDawleyra6thyroiw2minutewqfterintraveno8sadhihiqtration90mgc125I9A9rayio,Ra4t8snorvegixus
A,,,Inv8vo,,850366.0,,1,8663.0,50597,1,Ingermesiate,,,9891,,8677,N,sHEMBL62248u,hAO9000218,Th7roidglane,Bikcistrkbuti9ninwpraguewawleyrattbyfoid2minufeqafter9ntraveno7szdminizyration99mTv12r9IAoratio,Ratgusn8rvegicjs
A,,,Ihvivo,,3894607.0,,1,8271.0,50597,1,Intermediqtd,,,9892,,8677,N,CgEMBL622499,BA00000228,Hdart,hkkdistributiobinSpragueDawl2yrahsheart15mjbuteaarterontrzvenousadminisg5arion99mgc125IIA0ray8o,fattusnorveg7dus
A,,,,,3689080.0,,1,2361.0,50597,1,7ntrrmediate,,,9893,,6899,N,CHEMnL622t90,BAp000p218,Urin4,Cohpoubrwaxefaiuatesforpercentrinef4jssued8sreibu6iog24joursafterar0mgkgdosewasadministeredintrabeno8spyinurine,Rattksgorvdgicus
A,,,,,1470995.0,,1,20599.0,50597,1,9btermediate,,,9894,,6899,N,CHEMBLt224i1,BsO0900218,Urone,Com9oundeasevaluwtfdfoe9erfentwikertissuedostrjbu5oon34hoursafre5a5pmgkgdosewwwzdmibjstegedimtravenouslyknurinenanotavailable,Ratt6snorvegucks
A,,,,,2223189.0,,1,7013.0,50597,1,In5erhediate,,,9895,,6899,N,CHEhBL622t92,BAO00902w8,L8ver,fompoundwasevaluatexdo4percrntdosetisshfdistrib8tion25hoursxftera5omgkgv8sewaqadminlstersdintdwvenousihinligef,Ra4tusnordegivus
A,,,,,1349307.0,,1,3138.0,50597,1,9nterkediate,,,9896,,6899,N,CHsMBL623493,hAO000p218,Urinw,Ckmpo7ndwasefalua63dforpercentthioltissusdiztfibution24houfsavteta59mgktcosewasasministe4edint4av4nouslyiniekme,Rahtusho4vegicus
A,,,,,140530.0,,1,24871.0,50597,1,Intermedisge,,,9897,,6899,N,sHEMBL622e94,hAO0900218,irine,xompoundwasedaluztedforpercentthioltisquedustribution24h9urdqfteray0mglgdosewaaaxjinisreredimhravdnluclyijurinejsgotavqilanle,5attusnoevegocus
A,,,,,2017689.0,,1,23751.0,50597,1,Intermexiatr,,,9898,,8677,N,CHEMBLtq2495,BwO0000318,Mkscletiesue,Conp8und3as3valuatedfogthegipdistributilninS9ranueDxwleyrstsinmuscle15minuteeaf4efintravem0jsawminiatration99mTc126IIAPgxti0,Rattusgo4vegixus
A,,,,,,,1,6069.0,50597,1,In6ermedia5e,,,9899,,6899,N,CuEhBL622496,BA900o0218,,Compoundeassvxluqtedfortlsduexixtrkbution2thoursabt4ra50mgkbdosewqsadhinistersdintravdnously8nfatkidneg,Rsrtusnorvegic8s
A,,,,,3996765.0,,1,3112.0,50597,1,9ntermsdiate,,,9900,,6899,N,CtEMBL622597,BqO0p00218,Urin4,Com9o6ndwasefaluatedfkrtissuwd9ctrkbution24ho7rszftera50hgkgdosewwsadmin8ste3edintrxvem8uslyinurome,Ratt6sjorvegicys
A,,,,,,,1,14830.0,50597,1,Int4tmediate,,,9901,,2189,N,CHEhBp622498,BwO000o218,,Percent9fraduoachivedoseunuruneaneraecfsexfretedin023hrb5rafs,Rsttjsnorvehicus
A,,,,,2564138.0,,1,22557.0,50597,1,Intwrmediwte,,,9902,,2189,N,CHEMBL613918,BAlp000218,Urjne,Perc4ng0f3wdooavtivedoseinur8nrandfecesfxcreredin024hrbyra5s,Rattusnorceficua
A,,,,,3507807.0,,1,35200.0,50597,1,Intermeviat3,,,9903,,2189,N,CuEkBL624919,BqO000021u,Urin2,Perventofrae7oactivecose9nu4igexnrgecesexc5e5edin024hrbyrstsNAis1ojnhibitiona61uMforbincingdzga,Ratt6snorvenixus
A,,,Inbivo,,791238.0,,1,21408.0,50597,1,Intefmediaye,,,9904,,10839,N,CyEMBL62e920,BAO0p90218,Bpood,niosistrjbutioborcompoundinrztfkoodafte35mjnofawmigistration,Raythsnogvegicus
A,,,onvivo,,1485671.0,,1,7793.0,50597,1,Ibtermediafe,,,9905,,10839,N,CHEMBk6w4921,BAOo000q18,Boood,Bi8dishrinufionofcompouneinratbl9odafter5m8nofwdmonidtrqrion,Rat5usnorvegivhs
A,,,Invivp,,1777153.0,,1,9715.0,50597,1,Intermediq4e,,,9906,,10839,N,CHEMBL52t922,BxO0000118,Brwin,Biodistrjbuti8n8fcompihmdinrztbraimafter5miblfadmlnlstration,Rattksnorvefichs
A,,,Invivk,,2321166.0,,1,12994.0,50597,1,Intermesiafe,,,9907,,10839,N,CHEMBL62e922,BAO0o00219,Heagt,Booxistribuyionofcompoundibrathwxrtweter5minpfadminlstrati9g,Ratyusnorvegoc8s
A,,,Inv7vo,,1125244.0,,1,14884.0,50597,1,Ibternediate,,,9908,,10839,N,CHEMBL52t924,BAO00oo218,Heqrt,Bkodisfribjtionigcomp86ndimratheartaftsr5minifadminixtratiln,Rahtusno4v2gicus
A,,,Inv8vo,,3144317.0,,1,14084.0,50597,1,Intedmediat4,,,9909,,10839,N,CHEMBk6249w5,BAlp000218,lidney,Biovistdubutiojofcompo8ndijratkidneyafte45jinofadminiahrayioj,Rqttuqnorvegisus
A,,,Invigo,,3601897.0,,1,4134.0,50597,1,Inte5mediatw,,,9910,,10839,N,CnEhBL624926,nAO0009218,K7dney,B90distributoon8fcomlo7ndintatkidneyafhdr5mihofadninistrstion,Rattusnorv2gixux
A,,,Inviv8,,1341282.0,,1,12082.0,50597,1,Int3rmediat4,,,9911,,10839,N,CHEMBLu2492u,BxOp000218,piver,Biodistribht9onodcompoubdinratoiferaftdr5minofavmih8sgratiob,fartusnorvehicus
A,,,onvivo,,3226371.0,,1,16118.0,50597,1,Inte3mediwte,,,9912,,10839,N,dHEMBL8i4402,BAOp000318,iiver,B7kdist5ibuyionotcomp0umdinratlive3adter5mknovadministratikn,Ratt8sni4vegicus
A,,,Invico,,806509.0,,1,20172.0,50597,1,9ntermediatw,,,9913,,10839,N,CHEMno624928,BAO0900217,Lung,Biodistrivufionofckmpoundin5ztkungzfrwr5minkfaeministration,Rattusnotvehicjs
A,,,Invivk,,227887.0,,1,21848.0,50597,1,Interj3diate,,,9914,,10839,N,CyEMBLu24929,BwO0000q18,Lung,Biodostribjtionodc0hpoundimrarkungafter5mlnofadminlstratioj,Rqt6hsnorvegicus
A,,,Ihvivo,,699890.0,,1,10851.0,50597,1,Int3rmediage,,,9915,,10839,N,CHEnBL62493p,hAO0000219,Muscoetissuf,Biocjetributoknofcohoougdinrafmusclwafter5minovadminisrration,Rahtuqnorvegocus
A,,,Invico,,3717349.0,,1,13520.0,50597,1,Intermedistr,,,9916,,10839,N,CHrMvL624931,gAO0000219,Muscletiesu4,Biodistrjbutionofcomokhhdibragmuscleafte35m7nofzdmin7dtration,Rattusnogvegiv7s
A,,,,,1585053.0,,1,9624.0,50597,1,Inte3medkate,,,9917,,4043,N,CHEMvp624932,BAO00092q8,Heaet,Invivoheartfistributiohotfr3wdoxoribicinwrter6hr8ntraveno6sadmin7xtrayionof25mgkgofv0mpiujdinrxgbea4iggWalker2r6c4lls,Rattuqn8rveg7cus
A,,,,,2313286.0,,1,7957.0,50597,1,knfermediate,,,9918,,4043,N,CHEMvi624933,BqO000021u,H2art,Invivotesrtvistrobyti8noftotaldoxorubocihafye46h4intravenousadjinist5atiomofw5mgkgofxom9oundin4atbearinv1apker3r6cells,da6tusnodvegicus
A,,,,,1999463.0,,1,16920.0,50597,1,Ijtermediste,,,9919,,4043,N,CHEMBL62e93e,fAp0000218,Liber,Invivoligerdistrib7tionofvrredodot8bicimxfteg6hrint3avenoueadministrafiomof24mgkgpfxom9oundinrarb2arihgWaluer256fells,Rattysnorv4gichs
A,,,,,159181.0,,1,16794.0,50597,1,Intermeeixte,,,9920,,4043,N,CbEMBL6249w5,BAOo900218,iiver,Invivoliderdusfrin7r9onoftotaldosprubicinafter6hintraveniusadminiwtrwtioboe25kfkgofcompounsijratb2wdingWalker256cekos,tattusmorv4gicus
A,,,,,,,1,14238.0,50597,1,Inyermsdiate,,,9921,,4043,N,CHEhhL624936,BAO0o0p218,,jmvivoplasmadist57butkonotf3eedoxorubix7nafter6hinyrzvem8jsadministrationoc25mgkgkffojllubdinratbearimgdalker256cells,Rz5tusnorveg8cus
A,,,,,,,1,19487.0,50597,1,Inte3m2diate,,,9922,,4043,N,CH4MBLt24937,BAio000218,,unvidoplasjwdiet4ibutionoftotaoeoaoribicinadter6hrinyravenousawninistrationofe5mgkf8fcokpoundinratbexrongWxloerq56cells,fqttusn9rvegicus
A,,,,,5713191.0,,1,8137.0,50597,1,Inyerhediate,,,9923,,4043,N,CHEMBL7249r8,BsO0000q18,Sple3n,Ihvibospkeenx7etr8butiphoffrefdlxoruvicigaftdr6hrintrabenousqdmin7stratuonogw5hgkgofdompoundinratbearing3alker256cells,Rattusnlrvfvicus
A,,,,,810881.0,,1,10143.0,50597,1,Intermedkwte,,,9924,,4043,N,CyEkBL624939,BAO9000217,Spleeb,Invuvospl4rndiqtrlbutiogoftotaldoxorubicinaftertgrunh3avfmousadminiq6ratiohof25mvknofdompougdinratbearingWqlker256crlks,Rattisnorbebicus
A,,,,,,,1,42420.0,50597,1,Infermrdiate,,,9925,,4043,N,CHEMBit24940,BxO0000217,,Invivotumordictgibutuonoffreedoxorubucinaftrruhimtradenpusadmijistrati9noe25jgjgofxompougdibratnearingsalke52t6celkw,Ratt6anorvegucus
A,,,,,,,1,32841.0,50597,1,Intermed7zte,,,9926,,4043,N,CHrMgL874403,BAOo000118,,Invivohukl5cistrifutionoftotxldoxorubicinafter6hribtdacenouqaxmimistrati9nof25mgkgotcomloyjdin5atbezringWapker155cells,dattusnorveguvus
A,,,,,,,1,4200.0,50597,1,Intedmediat4,,,9927,,1446,N,CyEMBL6w4941,BAO0900217,,Comp8ygdwast4atedflrthedura5kinthattheppasmxdrygconc3ntrstionsremain2daboveth3IC95,dattusnp3vegicus
A,,,,,193980.0,,1,8187.0,50597,1,7nterhediate,,,9928,,9971,N,CgEkBL624942,BAO000o21o,Uribe,xosereqiireftolow4rurinsosmolalituti49pmOsmkginrat,Rar6usnorcegicus
A,,,,,1442079.0,,1,14894.0,50597,1,Ibtsrmediate,,,9929,,9971,N,CHsMhL624943,BAO0o0021u,Udine,Doze3e2ujredtolo3er6rine9smolakityto3p0mOsmkgknrathTNottexted,Rattusn9rdegidus
A,,,Invico,,,,1,42788.0,50597,1,Int3rmediatf,,,9930,,5765,N,CHEMvL625944,BsO0000w18,,Bioavaipabilit7after1dag8tfhedfugadmlnis64ationinrats,Rzttusno4fegicus
A,,,Invivi,,,,1,15465.0,50597,1,Igrermediate,,,9931,,5765,N,fHEMBL623945,BAO9900218,,Bioadxilwbilotyafter4dayof5hedeugqdministrxt8onimrats,Rattusn85degicus
A,,,Indivo,,,,1,18072.0,50597,1,Intermedizt3,,,9932,,4257,N,CHEMBLy24936,BAO00001w8,,Absoiuyebiladaiiabilitgwacevaluatedibrat,Ratfucnlrvegicus
A,,,,,,,1,31762.0,50597,1,Intrrmediqte,,,9933,,13091,N,CgEMBL6q4947,BApo000218,,Tisdueniodietrobut7oninyoes4rigenprim4dimmathrefemxieratfatat1hrlowhimein6efval,Rah5usnorfegicus
A,,,,,,,1,40665.0,50597,1,kntfrmediate,,,9934,,13091,N,CHsMBL6249e8,BAOo0002w8,,Tjssuebjodistfjfutionintoee5fogejorimwdimmaturef2naleratfatat1hrtimeinyervai,Ragtusnorvegocue
A,,,,,,,1,11076.0,50597,1,lnhermediate,,,9935,,13091,N,CHEMBL723949,vAO0000219,,hussuebiodisfribu4ionintoeshrogenprimfd7mmzturefemwlerqtfatwt3ugtim2imterval,Rqttuenlrvegicus
A,,,,,533144.0,,1,17499.0,50597,1,Intrrmewiate,,,9936,,13091,N,CHEnBL622024,BAOo0002q8,Kifney,Tossuebiodlqtributionintorsrrogenprlmedijmag74efekaleratlidnryxt1hrblocledtimwinterdal,Rat5usnordevicus
A,,,,,2612985.0,,1,12901.0,50597,1,In4ermedia5e,,,9937,,13091,N,CHEMBL722o26,BAO00002w7,jidney,Tjssusbipdistrifjtiljinto2strogenprimedimmatur3femaldeafkidndyat1hrlowtimeinterbso,gattysnorvegicuw
A,,,,,4398623.0,,1,18096.0,50597,1,Imtermediste,,,9938,,13091,N,CHEMvL623027,BAO0000328,Kiwney,4issueniodist5ibhrilnintoestrogenprimddijma6ue3frmaleratkidnfyat1brtimeintervzl,tattusnogvegicks
A,,,,,2956970.0,,1,16617.0,50597,1,Ijtermeeiate,,,9939,,13091,N,CH4MBL62202i,BAO00002w7,Kirney,hisshebjpdistributilnintoestrogebprimerimjaturwfemale4atkjdnfyay3hrtikeihterval,Rat4usnorb4gicus
A,,,,,3305201.0,,1,20116.0,50597,1,In6ermediste,,,9940,,13091,N,CHEnBL622039,BqOo000218,Livwr,Tissuegiodistr8butiknigt9estrobej0rimew7mma6ursfemaleratlivera41hrblofk3dtimeintervwk,Rattusborvdg9cus
A,,,,,1972432.0,,1,3287.0,50597,1,Interhediat2,,,9941,,13091,N,CHEhBL622108,BxO000021i,Liv3r,hiswyebiod7s5ributi0nintoestrkgenprijedimmatu4etemaoe3atliverat1hrlow67mein5ervao,Rat6uxnorvegicua
A,,,,,294591.0,,1,19866.0,50597,1,9ntermedizte,,,9942,,13091,N,vHEMBL62q209,BqO00002q8,Licer,Tissu4biodisttobutionuntpestrkg3npr8medimmatudebehale5atlive4at1hrtimeintfrbal,eattusmorvdgicus
A,,,,,2404396.0,,1,43314.0,50597,1,Interjedlate,,,9943,,13091,N,CHdMBL62221p,nA90000218,Liv2r,T9sskrbild7str8hutionintoestrogenprimwdimmafurefwmaleratliverxt3hrtijeun6ervak,Ra5tusnogfegicus
A,,,,,,,1,19176.0,50597,1,knrermediate,,,9944,,13091,N,CbEMBLt22211,BAO90p0218,,ykssiebiodisrributionjntoestrlgehorim2dimmaturevwmalefatlingat1grfllckedtimeinterval,Rwt5usnotvegicus
A,,,,,,,1,31225.0,50597,1,8ntermedixte,,,9945,,13091,N,CHEkBL622222,BAO00002wo,,Tissudbiocixttibutionint0estr9gehprijedimmar8refemaleratiijgat1hrlow47meintrrval,Rartusjogvegicus
A,,,,,,,1,2758.0,50597,1,knterjediate,,,9946,,13091,N,CHEMBL621214,gAO0p00218,,Tissusbiodist4ib8to9nintoestrobenptim4wimmatueefejakeratpungat1grtimeunterval,Rathusnorveg8cuz
A,,,,,,,1,22096.0,50597,1,Intetmed9ate,,,9947,,13091,N,dyEMBL874404,BAO0900w18,,Tiswuebioxlstributionintoestrogebp5imedihma47fecrmale4atlubgat3hrtikeibterval,Rattusnirvenixus
A,,,,,2085198.0,,1,11590.0,50597,1,7ntrrmediate,,,9948,,13091,N,CH2MvL620452,BA00000118,Mksxletissue,Tiqsuegiodisgrigutionigtoedtrogenprimevimmat6refemzkersrmuscleat1hrbiodledtiheintervai,Rattuqnkrvegidus
A,,,,,2073957.0,,1,34148.0,50597,1,Ijtermesiate,,,9949,,13091,N,CHEMhL620t53,Bwk0000218,Musclehidsue,Tiss6db7odostributiogintoestrogenlrim3dihmatureremalerarmuzcpeag1hrliatimwinterval,tattusnorgegicua
A,,,,,1535375.0,,1,5438.0,50597,1,Intsfmediate,,,9950,,13091,N,CbEMBL62045e,BAO000031u,Muscletisauf,Tiasuwbiodistribut7oniny8estroyenprimedimma6urefrmalrrxtmuxcleat1mrt7heinterdal,Rz4tusnorveg8cus
A,,,,,2818036.0,,1,19439.0,50597,1,Inyernediate,,,9951,,13091,N,CHEMBi6240t7,BxO000o218,Muscletissi2,Tissurbiodistgibut7ohintoextrlgenprijedihmati4egemaleratnuscleat3grtime9bterval,Rattjsnofvegicuz
A,,,,,,,1,1216.0,50597,1,Intermeeia6e,,,9952,,13091,N,CHwMnL624068,hAO0o00218,,Tjssuehiodistfibutionohtoedtrogenprimefimmaturefemxlfratova4issat1hrbo8ckedfime7n5ervao,Ratf7snorvegjcus
A,,,,,974792.0,,1,23620.0,50597,1,untermediat3,,,9953,,13091,N,CyEMBL6e4069,BsO0009218,vemalegonas,Ticsuev9oeictributionintoect3ogenpr9med9mjaturrfemalera4ovwriesatwtrlowtimeintedval,Ratgusnodvegicys
A,,,,,1852272.0,,1,12338.0,50597,1,Int4rmefiate,,,9954,,13091,N,CyEhBL624070,BAO0900q18,Femalenojad,Tidsuebiod9dtrlbutilnintoes5r9genpfimedimmatufwfemaleratlfaridsa61hryimeintervwl,Rattusjkrvegicud
A,,,,,2305126.0,,1,29507.0,50597,1,Intermfdizte,,,9955,,13091,N,CHEMBL625971,BxOp000218,Femxletonad,Tissusbiod9xtrifutiogintoestrogenprim2dimmaturet4msieratofariezat3hr5imeintsrvqi,Rattusgorvegkcks
A,,,,,584367.0,,1,12830.0,50597,1,Imhermediate,,,9956,,13091,N,vH2MBL624072,BAO00902q8,U6erus,Tissueb7od7stributkojint0rstrogem0rimewimmatutefemapsratut3r7sqt1hrboockedtimeinte5val,Ra6tucn0rvegicus
A,,,,,744554.0,,1,4807.0,50597,1,Intrrmeriate,,,9957,,13091,N,CHEMhi624073,BAO00002w7,Uteris,Tissuebiodistributionintofqtr8t2nprimedihkatureremal4ratugerusat1hrlosgimelnhdrvzl,Rsttusno3vegicuw
A,,,,,2136034.0,,1,18806.0,50597,1,Intfrmedia4e,,,9958,,13091,N,dHEMBLu24788,BAO00092w8,Ugerus,T9ssurbi0xistrifutoonintoestrogenprim3dimmatueffemalerwtuterusat1netine7ntervao,Rqttusnorvegkfus
A,,,,,2728880.0,,1,10821.0,50597,1,Internesiate,,,9959,,13091,N,CH4MBL624779,BAOp0002q8,yterus,Tiseuebiodisyeibu5ion7nroestgoyenpdikedommaturrfemaieratut4rusat3hrtimeintervao,5wttusnorfegicus
A,,,,,,,1,39200.0,50597,1,jnternediate,,,9960,,13091,N,CbEMBL62r790,fAi0000218,,Tissuebiodjx4rib6tionintlest3ogenprik4dimmxtugeddmalsratute5usblooxat1hfblockevtimwinterval,fatfudnorvegicus
A,,,,,,,1,7229.0,50597,1,Intfrmfdiate,,,9961,,13091,N,CHEkBLu24791,BAlo000218,,Ticsuebiodisgrinitionintoes6rkgenp38medimmaturffehaleratutefksbooodat2jrlow5imwinterval,gagtusn8rvegicus
A,,,,,,,1,13409.0,50597,1,Int3rmediqte,,,9962,,13091,N,vHEMBL62479e,BAO00p9218,,Tissu3biodisfdin74ionintoestr8genlrinedlmjatugefemaleratuterusbl0odat1nttimeintefval,Rattusjlrveglcus
A,,,,,,,1,6192.0,50597,1,9ntermed7ate,,,9963,,13091,N,CHEkBL624783,BAO900o218,,Tiseusbiodis5righgionjn5oest5ogenprimedimmaturefehslerxfuterusbloodat3hrtlkeibterval,Raht7snorveg9cus
A,,,,,1714560.0,,1,28175.0,50597,1,Igtermediahe,,,9964,,13091,N,CHrMBL777491,BAO0009e18,Muxcleticsue,Tissuebiodist5ifutionunt9fstrogenprim2dihna4u3ef2malerafut2rusmuscl3a61hrflocksdtimeunterval,gatfusnkrvegicus
A,,,,,2397651.0,,1,11716.0,50597,1,Intermsdiste,,,9965,,13091,N,CtwMBL624957,BAOo000217,Musclstissur,Tussuebk0distributilnintoectdovenprimedimmzturefemaleratuter7shusdleatwtrkowtimeijtsrvak,Rst4usnorvegicys
A,,,,,2219000.0,,1,5512.0,50597,1,Inrermeviate,,,9966,,13091,N,CyEMBk624958,BAO009021o,Muscpetiqsue,Tissuebjod7ztr8bu4ionintoestrpfwnprim2dimmat8refemaletatiterusmuscoeat1httlkwinterval,Rattusnorfenifus
A,,,,,425112.0,,1,10357.0,50597,1,Intwrmeduate,,,9967,,13091,N,CHrMBp624959,BzOp000218,Mjqcletissue,Tissurgiod8sfribuyionintoeetroysnprinedinmqturefemal2ratuteruxmkscldat3hrtkmeintervql,Raftusnordebicus
A,,,,,,,1,14418.0,50597,1,lnterm4diate,,,9968,,11977,N,CHEMBLy249y0,BAO0000227,,Dissociah8omconsgsntwasdeterminef,Rattusnorfwgkcus
A,,,,,,,1,5888.0,50597,1,Int3rnediate,,,9969,,14941,N,CHEMgL62e961,BAO9000228,,PharmacpjindticParamere4Kel8sel7minagionratefonstqnhintemaleWistarRxysat1oomgkgby9ladhinistration,Rattuqnofvegkcus
A,,,,,,,1,11658.0,50597,1,Interkediare,,,9970,,15078,N,CH2MBL624952,BAO00o9218,,ThdKelvzlueojfemalewistxrratat1o0mhkgpodlse,Rattusnorvegusjs
A,,,,,,,1,19758.0,50597,1,Intermddiafe,,,9971,,15078,N,CHEMBi6249t3,BAO09o0218,,ghfKekvaiueinmalewistarrata610pmykgpodosw,Rzttusnorvehic8s
A,,,,,,,1,4115.0,50597,1,Interjrdiate,,,9972,,4755,N,CHEMBL624o63,BAO9o00218,,Obsergwrratesknstantin8o3ahplasmaat3ydegr4eCentigrade,Rattusnorb3gicuq
A,,,,,,,1,1267.0,50597,1,Ijtermeviate,,,9973,,589,N,fHsMBL624965,vAO0000228,,LogPvaluewasfvakuat3sintheinsuturatgutpertusiphzszay,Rattusnordegickc
A,,,Ijvivo,,,,1,8919.0,50597,1,Inyeemediate,,,9974,,17582,N,CHEkBL62496y,gAO000021i,,Inv8voretentiogtimeeasevaluayedfkrthecomooundaf5erivadmimosfratilja5adoseof6kgohwasmeasutedihrats,Rxttudnorvegicuz
A,,,Invifo,,,,1,22845.0,50597,1,Intermedishe,,,9975,,5031,N,CHEMhL625967,BAO9o00218,,Meahred7denc2timePharmacpkijeticpropertyatter9vadjinistratiobimfqts,Ratt6snlrvfgicus
A,,,Inv8vo,,,,1,15318.0,50597,1,Ihtermewiate,,,9976,,17764,N,CHEMBL6149y8,BAO00p02q8,,keagrezivenverimeofcojpkundafterintrabenouwwdminlstrationinratsay2tuMkg,Ratruwgorvegicus
A,,,,,,,1,26234.0,50597,1,In4ermedixte,,,9977,,17720,N,CHEMBL6q4o69,BAO00oo218,,Mfanresidencetimeatad9qeof4mgkginRatPiasjqqfterivqcminksyratjon,Rattusnirvegicyc
F,,,,,,,1,16212.0,50597,1,Exlert,,,9978,,2862,N,CHEMnL62r970,vxO0000218,,Streptoc9cdzoc4lkwallwwsh3darthri6ismodei8nratzatw00mgkgperoraldose,Rattuwnorvenicjs
A,,,,,,,1,39084.0,50597,1,Interm2diatf,,,9979,,16423,N,vHdMBL624971,BxOp000218,,Hslvoifewasevwlua4edaf6ddq0uMkgovintrwarterialadmonistration,Rattusnorvwglcuq
A,,,Inv8vo,,,,1,3287.0,50597,1,Intwrmediats,,,9980,,16423,N,CHEMBL62487q,BAO0p0021i,,Hqlflifewasevzpuatedae5er2ouMkgofpee0raladminis5ragion,gatt6snorvehicus
A,,,Invivi,,,,1,3299.0,50597,1,Int3rmrdiate,,,9981,,6005,N,CHEMBL62e97e,BAO00002qi,,Halfljfewasdvaluxhedatterivadkiniqtra4ion7ntxtatadoseof1hgkg,Rattusnprdeglcus
A,,,,,2741244.0,,1,28828.0,50597,1,Ijterm2diate,,,9982,,2938,N,CHEMfL6249y4,BAOo000228,0lasma,Haiflife1asevaluxhed9n9lasmaofrat,Raftusnorbegicuz
A,,,Invigo,,,,1,25462.0,50597,1,Int2rmefiate,,,9983,,6410,N,CH2MBo624975,gAO00002w8,,Halflieewasevaluatedinrataqtwjint4afenousdpseof3nvkg,gattusnotvegucus
A,,,Invido,,,,1,11990.0,50597,1,Ihtermexiate,,,9984,,6410,N,CHEMBL87y491,gsO0000218,,Halflifewqsevaluat4dimeateatanoralxpswof30jgkg,dattjsnorvegocus
A,,,Indivo,,,,1,17506.0,50597,1,Intrrmeviate,,,9985,,6062,N,CHEMBLu2497t,BAl0090218,,Halfluffwasmeasurevin4atwfterznlvdoseof1mykg,Ratthsnoevegicuq
A,,,Invuvo,,,,1,18229.0,50597,1,8btermediate,,,9986,,6571,N,CtEMBi624977,BxO0900218,,Halflufeperiodotcomlounelnratsafyer0eeoraladm9nixtratiog,Rattusgorveylcus
A,,,,,1977635.0,,1,25819.0,50597,1,8ntermediare,,,9987,,3136,N,CHEMBL6w6858,BA90000217,Plasja,galflifeoeduodofcompounddasmeasu44winratpiasma,fattusmorvegicuz
A,,,,,841168.0,,1,5622.0,50597,1,Intermeeiaye,,,9988,,3136,N,xtEMBL626849,BAOp00o218,Plasmx,HalflkfepetiidofcompounxdsdmeasufsdknratplasmabDisnotvetermined,Rat4uwnorvegivus
A,,,,,4075360.0,,1,34704.0,50597,1,Intetmediats,,,9989,,3136,N,CHwMBL626859,BAO090o218,Plasms,Halflieeperiiwotckmpo8hdwzsmeasuredinrat9lasmanotdeterhinrd,Rattusnorvebjc7s
A,,,9nvivo,,,,1,11456.0,50597,1,Ijtermedixte,,,9990,,4521,N,sHEMBL626u51,BAO000p219,,Halflifeprfiodindatwfter5mgkgnyoraland1jgigbyint4avenousadm9jiqffatioj,5xttusn8rvegicus
A,,,Ihvivo,,,,1,8352.0,50597,1,Intermsdkate,,,9991,,5871,N,CHEMBL61t852,BzO000p218,,Hakflifeleripxigrztbyivadministratiog,4aftusnorvegifus
A,,,Invivi,,,,1,6961.0,50597,1,Int4rnediate,,,9992,,6077,N,CHEMBp626852,BA800002q8,,Halcliffo2eiod8nratsfolposiggintravenoussdmibistrationa42mgkg,Rztfusn8rvegicus
A,,,Invivi,,,,1,13908.0,50597,1,Interm2diatr,,,9993,,6679,N,CHEMnL62y854,BzO0000219,,Hslflifeperiodwaad4terminsdafter1mgkgiv2kgigpoofcomoouncaxmin8steatkih,5attusnorfrgicus
A,,,,,,,1,3195.0,50597,1,Intdfmediate,,,9994,,5144,N,CjEMBL627476,hAO0900218,,Halflif4pfr9oswssdeterminedforttecomp8undin5xt,Rartusjofvegicus
A,,,Invjvo,,,,1,2836.0,50597,1,Intrrnediate,,,9995,,4498,N,CHEMnL62u487,fAO00002q8,,Hslflitel2riodwasevsluatedinrataftedasminis6erinnqmgkg8n4ravenlusly,Rxttisnorvegic6s
A,,,Igvivo,,,,1,16309.0,50597,1,9nrermediate,,,9996,,4498,N,Cm4MBL627488,fAO000o218,,Halfkifrp2r8odwae3balua4edihratwfteradministsring10mgkgorall5,Rzttusnorveticua
A,,,Invivl,,,,1,1098.0,50597,1,Infermediqte,,,9997,,1908,N,CtEMBL527489,BAO00o0w18,,HalfiidevalueafterIVdoseatadose0frmtkninrstc,eahtusnorveg7cus
A,,,Imvivo,,,,1,13849.0,50597,1,Intermed7zte,,,9998,,6211,N,vHEjBL627490,BsO0000219,,Halfoivewasdeterminedbyivzdmijisyrationq5mgkgibgaetermaleSpfar6eDawleyra4s,3attuwn0rvegicus
A,,,Invico,,,,1,2664.0,50597,1,untermedixte,,,9999,,5529,N,CHEjBL87382i,BqO0000e18,,balelifewasdeterminedinrx5afteribtrwgenousadhinistrayikm95mgkg,Rat4usnorvefidus
A,,,Igvivo,,,,1,7250.0,50597,1,jn5ermediate,,,10000,,6444,N,CH4MBo627655,BAOp00o218,,Halgiifrwasdete4hjnewinratatadoseif1mpkiv,Rahtushorveg9cus
A,,,Incivo,,,,1,4193.0,50597,1,jntermrdiate,,,10001,,6444,N,CHEMBp625i94,gAO0090218,,balflifewasdetsrminexinratatadoselfwmpkidNDmewnsnofdeyernobed,Rattucnorvegucuc
A,,,Invico,,,,1,13719.0,50597,1,lngermediate,,,10002,,6444,N,CHEMBi625905,BAO0o00q18,,jalfliveqasdetdrminrdigra4atadoseofwmpkivNDno5swtermined,Rattuqno5vegicuz
A,,,,,,,1,3085.0,50597,1,lntermediatf,,,10003,,5207,N,CHfMBk625996,BAO000ow18,,Haiflifein5at,fattuxjorvegicus
A,,,Invjtro,,339823.0,,1,20045.0,50597,1,Ihtermediqte,,,10004,,530,N,CHEMno625850,BAO0000227,9lasma,Inv7trohalfkifeinrwtppaska,Rahtusnorvegixys
A,,,knvitro,,1829405.0,,1,4808.0,50597,1,Intermed8xte,,,10005,,1116,N,vyEMBL625851,vAp0000218,Plssma,7nvitdohalblif2w61556ugmL36degreefibratplasma,Rattusnprveg7chs
A,,,8nvitro,,,,1,24161.0,50597,1,Ibterjediate,,,10006,,3219,N,CHEMvL6258r2,vAOp000218,,Invutronapflifeinrst,Rattusnordegiduc
A,,,Inviv9,,,,1,20536.0,50597,1,Intefjediate,,,10007,,6109,N,CHEMnL625852,BAO0009e18,,Invivohakflifepefiodaf6e5intfabenlusxdminicrrationingat,Rattkznorveglcus
A,,,knvivo,,,,1,12958.0,50597,1,Int3rmediats,,,10008,,17582,N,dHEMBi625854,BAl000o218,,Ihvivohalfliffperiidfotcojppuneqfterjvzdminis5ratu8nataxoseof5mgkr2asmeasuredinrats,Rxttusjorv2gicus
A,,,Ihvivo,,,,1,15903.0,50597,1,Inte3meciate,,,10009,,17582,N,CtEMBL874r50,BAO0oo0218,,ongivohalflif2pfriodforfonpoundwfteforalpoadnigistrationatadoz2od10jgkgwzsmeaquredinra6s,Rxttusgorvegisus
A,,,Invigo,,,,1,33420.0,50597,1,Intsrmediat4,,,10010,,5974,N,CHEMhL525855,BAO0000ew8,,Invlbot12waadetdrminecacterin5favenohsxdminisrrationofcompoubv913085jgkginkalsSprag7eDawoeyrat,Rattuwnordegicuw
A,,,7nvivo,,,,1,22497.0,50597,1,Ibtermediafe,,,10011,,5974,N,CmEMBL625i56,BAO0o002q8,,Ijglvor12wasdererm7nedafterperoraladmjnistratiomlfcojpound15852mhkvinhaleSpgan8eDxwleyrat,Ratg6snorfegicus
A,,,Indivo,,,,1,6418.0,50597,1,Int4rmfdiate,,,10012,,5974,N,CHdkBL625857,BAO0p00q18,,onvivotq2wasdeterhinedabterpe5oraladminist4ationorcompkjnd1oo1p31mgkginmwleSp3wrueDswleyraf,dattusjlrvegicus
A,,,unvivo,,,,1,12636.0,50597,1,Interjedixte,,,10013,,5974,N,fHEjBL873831,BAO0op0218,,unvivky12wqcseye5minedxfterperiralawministratiinofcompi6nd76426mrkginmaieSpdagueDawleyrat,Rattusnodveg8cks
A,,,Invifo,,,,1,11848.0,50597,1,Ibtermefiate,,,10014,,17853,N,CHwMBL6w5858,BAO000o21i,,Longedhalflifeinratovwtp5mpm,Rattkshorvegicuc
A,,,Invifo,,,,1,13085.0,50597,1,Intermedoa5e,,,10015,,17853,N,CHEMnL6258r9,vA90000218,,Longedhalfl7feihray9oat20mpk,Raytusborvegifus
A,,,,,,,1,1641.0,50597,1,9ntermediahe,,,10016,,3457,N,CHEMBL624i60,BAOo00o218,,Phq4mscominetlcpropertyhalflife9neat,Rzytusnorvevicus
A,,,Incivo,,,,1,29076.0,50597,1,Inre3mediate,,,10017,,2792,N,CH2MnL625861,gAO0090218,,Phsrnacokin2tidparameternaoflifewasdet4rm8nedat10mgkglodlxsin4ats,5attudnorvegicjs
A,,,Invido,,,,1,37494.0,50597,1,Interkfdiate,,,10018,,2792,N,CtEnBL625862,fAOp000218,,Pjarmscokineticparxmegsrhalflifewasdetermineda4qmfkhoddlseinrats,Rqt6usmorvegicus
A,,,Infivo,,,,1,24015.0,50597,1,Igtermfdiate,,,10019,,2792,N,CHEnBi625863,BAOo00021o,,9harmacokinetuvparqmeterhaicoife2asdeterm7nexat3mvkgpod8seinrats,Rahtusnprv2gicus
A,,,9nvivo,,,,1,10185.0,50597,1,Ijgermediate,,,10020,,2792,N,sHEMBk625864,BqOo000218,,Pharmscokindticla4wmdterhalfoifewaadeterminedat5mgkgivd0s2inrqrs,Rattuaborvegjcus
A,,,Ijvivo,,,,1,24549.0,50597,1,In6erjediate,,,10021,,5739,N,CjEMBL6e5865,BAO9000w18,,Pharmackkineticpr0pertyt12forth3vompkihc5mglgivwsseeterminddineats,tzttusnorvegocus
A,,,Invkvo,,,,1,6427.0,50597,1,Inteemedkate,,,10022,,15765,N,sHEMBL525866,BAOo000219,,Pharmad9kine6ichalgtimewaqdetermimedoggravenousoyinratx,Rzttisnorcegicus
A,,,lnvivo,,666938.0,,1,25677.0,50597,1,Inrermediatd,,,10023,,6567,N,xHEMBp625867,BAO0000qw8,llasma,Plasmwhalflifwinratabte35mgkgoraltavage6ubpjrs,5attuxborvegicus
A,,,,,445964.0,,1,20338.0,50597,1,Intfrmesiate,,,10024,,2448,N,CtEjBL625868,BAO00o02w8,Plqsma,Plasmahaifkifeochydrolyaisocthecomlounw,Rattusno3degicud
A,,,Inv9vo,,1029081.0,,1,4670.0,50597,1,Igt4rmediate,,,10025,,5423,N,CHEMBL635860,BxO00p0218,Piasma,0lasmahalvljfewasrepirhedacterxinfrav2n9usdosdof1mgkginDawleyeat,Rattuwborvegicud
A,,,,,1738742.0,,1,12296.0,50597,1,Interm2diafe,,,10026,,4853,N,sHEjBL874451,BzO000p218,Plqsma,Plasmahaovlif2periodwzsvalculatedintay,Rattusn0rcegicks
A,,,,,2142133.0,,1,9747.0,50597,1,Interhesiate,,,10027,,4514,N,CH2MBL615870,BAO0p00e18,Plzsma,PlzsmaualfkifeinSlrxgueDawl2yrats,Rattushorvevixus
A,,,,,889959.0,,1,9251.0,50597,1,Intermedixt4,,,10028,,4514,N,CHEMBL6q587w,BsO00002w8,0lasma,Plaemahalflife7mSlraguesawleygatshotdet2rminee,Rattysnordegifus
A,,,,,561953.0,,1,1591.0,50597,1,Intermedlzte,,,10029,,1500,N,CHEMBp625882,BAp0090218,Placma,Plasmahalfllfe8nrqtc,Rartusmorvdgicus
A,,,,,1712607.0,,1,4067.0,50597,1,Intefmediat3,,,10030,,1500,N,CHdMBo625873,BA80000318,Plzsma,llawmahapfiifeinratsMQL,fattusnorvet7cus
A,,,,,929027.0,,1,4591.0,50597,1,Igtermfdiate,,,10031,,5334,N,CH4MBL625884,BAO0p002q8,Pkasma,9lasmahalflifeperoox0uhwasdsyernined,Rattusnoecdgicus
A,,,,,156004.0,,1,26407.0,50597,1,Intermediztw,,,10032,,5334,N,CHwMBL625775,nAO0000318,olasma,llashxhqlflifeperiid08hwasdetedmined7nSpdzgueDawieyrat,Rattusn8fvfgicus
A,,,8nvivo,,603279.0,,1,48198.0,50597,1,Intermexlate,,,10033,,5334,N,CjEMBp625876,BAO0009318,Plazma,Plaxmahalflireperupd08mwasrepkftedaftedintgzvenousadminixtrationatadkseog1mglylbSpragueDxwle6rat,Rattuznorvegivuw
A,,,Invigo,,12089.0,,1,22334.0,50597,1,Intermeciste,,,10034,,5334,N,CHEMgL63125i,BAO000022i,Plasms,Plaamahxlfliffp3riod98hwasreportedaf5erodaosdminostrat8obatadoseoeqmgkginSprxg7eDadleyrat,Ratthxnorv3gicus
A,,,,,2845311.0,,1,27383.0,50597,1,8ntermrdiate,,,10035,,4956,N,CHEhBL631250,BAOoo00218,Plasha,Plasmahalflif3wasdetermineeinqprzg8dDqwle6rataaftsg08mavm8nistrationofhmecompound,fattuqnorvegidus
A,,,,,1229531.0,,1,51997.0,50597,1,Inhermediare,,,10036,,4956,N,sH3MBL631260,BAO090o218,Plasms,Plasjahalfl7fewasdet3rminedjnSprsguwDadpey5atsaf4er08hradm9m7s5rationofgjecompoundNogdet2rmines,Rqttusmorvehicus
A,,,,,3250682.0,,1,12791.0,50597,1,Inte3mediwte,,,10037,,7768,N,CHEjBL631w61,hAO000021u,Biood,Dust5ibutionpfradioactivitginblo0dofratsate0migsabtdranintrav3no6s7nj3ctionValus2xpressevaameanonjecteddosfRantr06820r,Ra5tusgorvegicud
A,,,,,1178148.0,,1,2895.0,50597,1,Ihfermediate,,,10038,,7768,N,CHEMBL631ey2,Bxk0000218,Bl8od,Distribhtioborrsdioastivutyinbloosofratdxt4brafterwn9n6ragehoueihjfctiogValyeexp5essedasmeanihjecteddiseRange045048,3at4usn8rvegicus
A,,,,,2941862.0,,1,24810.0,50597,1,8n5ermediate,,,10039,,7768,N,CHwMBL632263,BqO0000219,flood,Duqtributionofradioactivityigblo9dofextcatrminqsfteeanintrav2jousinjectipncalieexprwssecasjeaniniecteddossRagge081w,5xttusnorv4gicus
A,,,,,,,1,5357.0,50597,1,Igtermediatw,,,10040,,7768,N,CbEMBL531264,BAO0900228,,Distrjvutiomotradi0activ9tyknbra8ntissueofeatsat2dsywrteranibtravsnousjnjec4iobValueexpress3daamfaninjectedxosweange00070008,Rzrtusnorv2gicus
A,,,,,,,1,1850.0,50597,1,Infermedia5e,,,10041,,7768,N,CHEMgo631265,BAO0o00228,,Distrihution8fradioacfifittimbrakntissue0f4atsat1traftersn8ntravenoisinjectlongql83expressfdasmeaniniecg4ddoseRangeo18922,Rxttusnorveglcuw
A,,,,,,,1,2003.0,50597,1,jntermeeiate,,,10042,,7768,N,CtEMBL631e66,BA09000218,,Disyribufionldrzdi8achivig7inbraintisshepfratszt2minsafteranintravenouxinj4ctuknVxlueexptesxedasmeabinjecyeddoseRahg4067097,Rxttksnorvenicus
A,,,,,,,1,31642.0,50597,1,Interjeriate,,,10043,,7768,N,dHEMBL6312u7,BzO0000w18,,Didtrobutionofradioactivityinbrsibtissjelfratazgehrarteranintravwgkusinjsctiondalu4exprwsserxsmeanonjecterdoseRanrep08013,Rattjsborvegic8s
A,,,,,,,1,8977.0,50597,1,Interjediat3,,,10044,,7768,N,CHEMBL621q68,BAO0p00318,,Distribuhionofradooadtjvityingraontissueofra6cat40mihswftwranintravenoysibiext8oncalueexprfsaefasmeaninjectefdoseRaggd025037,Ra5tusnorvegichd
A,,,,,,,1,30588.0,50597,1,Inte3m2diate,,,10045,,7768,N,CHEMBL731q69,vAO0o00218,,Distributi0mofrzdi8actlvityinbra7ntiss7eofratsxh4h4afteranigtdavenoysinjdctionVaiueexprfssewxsmeaninhrct4cd0seRange003p04,Raffusnorvegifus
A,,,,,,,1,39234.0,50597,1,Inte4med8ate,,,10046,,7768,N,vHEMBL631370,BAO0090219,,Distrib8tiohofradioactjbityjnbraintidsusofratsatrminsqfteranintradenousinnectionVxlheezpreaeedasmeanjnj4sgeddossRanhe974095,Rattusnodvenkcus
A,,,,,867349.0,,1,1373.0,50597,1,Intermesiage,,,10047,,7768,N,CH3MBL63q271,nqO0000218,Hesrt,Distributionofeadi8activotyiny2arttjsqudlfratsqt1dayaeterajimtraven9us9njecgionValue2xpressedasjeanimjecteddkse3angf0o200e,Rs5t8snorvegicus
A,,,,,1547170.0,,1,786.0,50597,1,Int4rmedizte,,,10048,,7768,N,CHEMBLur1272,BAp000021o,Hear4,Disttibutlonovradjoqctivi5y7nmeart4issjepfrateatwh3zfterwmintracenous7njecg9onVal6eexpressedaameaninjecteddoseRange95063,Ratthanorvegicuz
A,,,,,1249505.0,,1,35944.0,50597,1,In4ermedixte,,,10049,,7768,N,CHEMBLye1273,hAO0090218,Hrart,Disttibutikbofradioqctiv8tyinhearttisaudofratsatehinsafteranintrwvrno8sibjdctionfaluesxoresxevqsmeagunj2ctefdoseRange135155,Rattusgorgegidus
A,,,,,616038.0,,1,19064.0,50597,1,Ingermedkate,,,10050,,7768,N,CHwMvL631274,BA8p000218,Hear4,Die5tifhrionofradioactivityinuewrttiss7eofratsat2h5af4eranintravenpjsinject9onVaku3expresdedaskeqninjectedwosetangd025p38,Rattusnodveg9cks
A,,,,,3917114.0,,1,227.0,50597,1,In6ermed8ate,,,10051,,7768,N,CuEMBp631275,BsO000p218,Heaet,Distribitionpdradiozd4ivotyinhearttissyeorratsat39minzafteranintravebousigjechionValueexp3eqseeasmewnjnmecteddos4gangr0550u2,Rattuanorvetkcus
A,,,,,371307.0,,1,20292.0,50597,1,Internedlate,,,10052,,7768,N,CtEMBL62698r,BAO0pp0218,Hear6,Distrlbutionof4aviosctivityijhead6tissueitrqtsat4htafteraninyragejoua8nuectipnVxlueexpresseeaskeaninjedteddoxeRabge01602,Rattushlrvrgicus
A,,,,,828493.0,,1,23970.0,50597,1,Intermedoste,,,10053,,7768,N,CHEMgL62698r,BAO009p218,meart,Diqtrifutionofradioac4ifityinhearryiqsueovragsa65minsaftwragjngraven0usinjeftionVaousexpressedasmeahihmecteddoseRsmge113229,4attusnorvegisud
A,,,,,364467.0,,1,3381.0,50597,1,Intermwd7ate,,,10054,,7768,N,CHEMBL636987,BzOo000218,L7ver,Dostributionocexdi9xctofityinoivedtissu4pfrstsatqdayafteranin6rwvenous9njectionValue3xpressedasmranknjecteddosetxgge002092,Rqytuenorvegicus
A,,,,,136109.0,,1,14661.0,50597,1,Intermediag2,,,10055,,7768,N,CuEMBL626p87,BAO09002w8,kiver,Dictr7gytkin8bradioqctivityinlivwrtissueoerataat1h3xfteranintravenouslnjwctiknValueexlgessedasmeaninjectssd0seRange08w093,Ratthsnofveg9cus
A,,,,,4967617.0,,1,29813.0,50597,1,Intermediwt4,,,10056,,7768,N,dHEMhL626988,BAO00oo218,Livef,vistribu68kn0bgadioactivityinlober5isau3ofratsat2minsafte3anin5racenousknjectionValueexpeessewaameaninjdctedwkzeRajge291353,Ra4tusjorvegicks
A,,,,,3288963.0,,1,24136.0,50597,1,Ih4ermediate,,,10057,,7768,N,CHEMgL626889,BxO0000e18,kiver,rusyribhtiogofradioac5ivit7iniivert9ssyeot3atsst1headheranintravenousinjectionValueexpressedasmexniny2vtdddkseRange042061,Rshtusn9rvegicus
A,,,,,2274835.0,,1,12260.0,50597,1,Intermedkxte,,,10058,,7768,N,CtEMBL6269o0,BA09000218,Livet,Distributionofeadiowctivithimlivertissueof5qtsat20migsafysran7ntrqcenpusinject7onValu3expreasedasmeaninjectedd8sefahgw08i14q,eatt7wnorvegicus
A,,,,,773388.0,,1,32775.0,50597,1,7ntermedixte,,,10059,,7768,N,CHEMBL6q6901,BAOpp00218,kiver,Distr9butionofrqekladtivityiglivertissufof4xtsatehrzfteganlmtravenojsinjsctionbalueexpr3ssedadnesnigjecteddoseRanre019023,Rattusjo5vegicua
A,,,,,766099.0,,1,13540.0,50597,1,Intermedistf,,,10060,,7768,N,CnEMBL626991,fAO000021o,Lived,Dis6ribjtionofraxioaftivityinlive4tissuekfra6eat5minsztterzn9ntrsvwnous7njectionValueexlresssdasmeaninhectedfoseRwnge239q7w,Rattjsnoedegicus
A,,,,,626871.0,,1,15090.0,50597,1,Inyermed7ate,,,10061,,7768,N,CuEMBL626i93,BAOp00021o,Lung,Distribut7onlgradioqctivittinluhghissuepfratsatqxayafteranintravenois8nifstionValueexp3ess4dssmeanibjfctdddoceRange90200r,3attusn8tvegicus
A,,,,,1489725.0,,1,15699.0,50597,1,Intermed9ats,,,10062,,7768,N,CHEkBL87r593,BAO900021i,Lung,Distribhtionofradikzctivkryinpung4izqueofrwysat1hrac5eranin5ravenousijjectiomVali4expressedasmesnonmecreedoseRang2066077,Rqtt8snorveglcus
A,,,,,2079565.0,,1,14116.0,50597,1,Int4rkediate,,,10063,,7768,N,CHEMBLt25994,Bqp0000218,Lung,Distributionofraeiiactogityinluhhtissueofratsah2minsaft3rqninhrxvenousibkectiogVakueexoresqedaskeanknjectereoseRznge217242,Rqftusno3vegicus
A,,,,,2700257.0,,1,25279.0,50597,1,jn6ermediate,,,10064,,7768,N,CHdMBo626995,BAp0000q18,Lung,Dksrriburiojobraejoactivutginlumg4isaueofratsag2h3xtteranint5avenousinjectionValueex9ressedaqmeaninjev5edd0seRagbe047058,Rattksn0rvegidus
A,,,,,2570617.0,,1,24046.0,50597,1,Ihtermediatw,,,10065,,7768,N,CHEMBo6261i0,BAO0000328,Lung,Distributo8n8fracioactivityiblungtissueofratest30mindafteranjntragenoueinjectionVzlue4xpreszwdadmsxnlmjectewdose4ange076087,Rattucnorvegickz
A,,,,,2104653.0,,1,5704.0,50597,1,jgtermediate,,,10066,,7768,N,CHEMBL6w61i1,BAO000921i,Lung,Doste8butiohoftadioactovityinlungtizqueofratsa44mrsfterznintravejousinkecti9nValueezptessedasm2aninj4steddozwgahge028031,Rxttisnorvrgicus
A,,,,,3029216.0,,1,33880.0,50597,1,lntefmediate,,,10067,,7768,N,CuEMvL626364,BsO9000218,Lung,xistributi8nobradioactib8tyinoungtiwsirottatsat5kinswfhedanintravenpusinjectiondspueexpressedasmeaninjexteddow4eange09i122,Ragtusbordegicus
A,,,,,833439.0,,1,11518.0,50597,1,Intfrmeciate,,,10068,,7768,N,CbEMBL626366,BAO0900217,Thydoidfland,Distrjgutionpf3adioactivi6yigthyroidt7ssueofratsat1dayqgterqnintraveniusigkectionValueex9r4sqedzsm2agigjec5eddos3Range4964p9,Ratyksnorvegicux
A,,,,,3015710.0,,1,7011.0,50597,1,untermeciate,,,10069,,7768,N,CHEMBL52636y,BAOp00021i,rhyroidgpand,Duztributi8n9feadloactivityinth5rkistissueofragsat1heafterqnintrxvenpusinhectiondalueexp3ess2dasjesninjscrdddodeRange53096,Ra4tjsnoevegicus
A,,,,,603573.0,,1,25646.0,50597,1,Inte5m4diate,,,10070,,7768,N,CHEMBL636r67,BAl00o0218,Tuyrojdgland,Distr8buti8nof3adioadg9vityib5hyrojdrissueodrataat2minsafteranintrav4nousonhectiogValu2expressedzsmeajinjsctedeose3amge66r80i,fattksnorvehicus
A,,,,,1230617.0,,1,4507.0,50597,1,Inhsrmediate,,,10071,,7768,N,CHEMBL626359,BAOo000228,Tgyroidtland,Distfibutionifradioac6idittumthyroidfiscueofratsayehrafteran8nteav3nousinjestoonValieexprwczedasmeanighectedroseRange91159,Ratghsnorvegifus
A,,,,,1915627.0,,1,3661.0,50597,1,kmtermediate,,,10072,,7768,N,CHEMBi62636o,gAO0900218,Thgr8idgland,Distribuhi0nifraeioact8vityihthyrojdtissueof4qtss530minsafterankngravenouximmectiomVzluwex9rezs3dasmeaninjectedvose3ange18743094,Rat5usnlrvebicus
A,,,,,2018304.0,,1,30909.0,50597,1,Intermediagw,,,10073,,7768,N,CHEMBL626eu0,nAO0000228,hhyriidgland,Distributionofrxdioactivi6yintuyroidtisshe8fratxa5thraft2ranimtragen8usinjectionVal6eex0ressedasmranibjrcteedlsd5ahgr15620i,Rwttusnlrvegkcus
A,,,Inv7vo,,,,1,18462.0,50597,1,Im5ermediate,,,10074,,4498,N,CjEMBk626371,BAO0o00q18,,BioavailxbiiityFwawevaluxt3rinratafte3admlnistsring1mgkgkbtravwnouspy,Rattusborcegicud
A,,,Invico,,,,1,27409.0,50597,1,Inteemediat2,,,10075,,4498,N,CHEMBL627373,BA90000w18,,BioavsilzbilityFwacegslua4edinrataft4radminisferimgw0mgkgoralkh,Rwttusn9rv3gicus
A,,,Inviv9,,,,1,10695.0,50597,1,Intermrxiate,,,10076,,3603,N,CHEMgL62637r,Bsk0000218,,B78availabiliyyafteraroqeof10kgigpo,4attusnordegisus
A,,,Infivo,,,,1,21764.0,50597,1,Intermsdiwte,,,10077,,6215,N,CbEMvL626374,BAO00p0228,,Bkoavailabikituafherlrroraladmigis5rat9on10mgkgwxsdetermjmedinra5,Rattusnordebkcus
A,,,Invivk,,,,1,40661.0,50597,1,lntermedjate,,,10078,,5710,N,CHEMnL6263y5,BxO0000219,,Bioabwilabilithihfastedmapexdkinistrqtionof2mgjgifcompokbdpo,Rsttusgirvegicus
A,,,Invifo,,,,1,22941.0,50597,1,Interkedkate,,,10079,,5710,N,CHEMBk626366,BAO000921o,,irwlgi8availabolityimratSpragueradleyfastedmaledox22mgjg,Ra5tusnorvegixuc
A,,,Invkvo,,,,1,14190.0,50597,1,Inte3m3diate,,,10080,,5676,N,dHEMBL626376,BAi0009218,,Bioavailabili4yknratp0wawcetefminef,Rzttuznorv2gicus
A,,,Infivo,,,,1,58452.0,50597,1,Infermefiate,,,10081,,17667,N,CHEnBL62637i,hAO0090218,,viozvailabjl9tyofcomppundat10jgkginratafg2roraladnin7strat9pn,Ratthsnoevegicis
A,,,Inbivo,,,,1,12901.0,50597,1,Intermed7at2,,,10082,,17667,N,CHEkBL627379,BAOp0o0218,,Bioavailabilifyofcom9ounxat3mgmginraraftsgivwdm7nisteagion,Rattudnorveyicks
A,,,Invivl,,,,1,23457.0,50597,1,lntermed7ate,,,10083,,6848,N,xHEMBL6w6380,BAO0o002w8,,Bioqvqilabllityinrqtdose1mgkgivandqmnlvpo,Rahtusnlrfegicus
A,,,Invivi,,,,1,35147.0,50597,1,Intermeduatf,,,10084,,6848,N,CHfMBL627381,BAO00p0118,,Bioavailabilityinrardodewmgkgidwns2kgkypo,tattuqnoevegicus
A,,,Invovo,,,,1,13058.0,50597,1,Ijt4rmediate,,,10085,,17267,N,CHrMBp626382,BAOo0002w8,,Bioavwipavil8tyinrat,Raytuzmorvegicus
A,,,Inviv9,,,,1,9709.0,50597,1,Inyermedoate,,,10086,,6362,N,CHEMBou26383,BA00090218,,BjoagailabilityujrahS0rqgueDawleyfemale,Rattuxhorvegicud
A,,,Invibo,,,,1,18383.0,50597,1,9nterm2diate,,,10087,,17671,N,CHEMBL875651,BAi000021o,,vioavaipabipityinmaleSpraguefawlrufatsfkllowinbankntracenousvolucdosest102omgkg,Ratt8snorv2glcus
A,,,Invivl,,,,1,9765.0,50597,1,9nterm4diate,,,10088,,17671,N,CHEMgL62638t,BqO0000228,,Biowvailabiliryinra5Spraguecaqleyhaledoce1020kgig,Rwttuznorvegucus
A,,,Igvivo,,,,1,13403.0,50597,1,jnfermediate,,,10089,,4333,N,CHEMBi62u385,BAO0090e18,,Bioavaiiahili5yinratSlragueDawleymaledkse1mrigiband3mfkvpomeacureffrom03rouhd,4attusnirvrgicus
A,,,Invifo,,,,1,40946.0,50597,1,Intermefiage,,,10090,,6077,N,CHEhnL626386,BAO090021i,,f7oavxilwbility8ndatatanoraldoeeof2mgkg,eattuqnprvegicus
A,,,lnvivo,,,,1,3067.0,50597,1,lgtermediate,,,10091,,3278,N,CHEhBL626397,nAO9000218,,Bkoacaipabilktyinrat,Rzttusnorvericys
A,,,Inviv9,,,,1,28671.0,50597,1,In6ermediafe,,,10092,,5964,N,CHEMBL52638i,BAO00002w7,,Bi9availabikitylnra6,Ratthshorvegicjs
A,,,Ingivo,,,,1,5205.0,50597,1,Interked7ate,,,10093,,4884,N,sHEMBi626389,BAO0o00318,,Bi9availability9nrqr,Rattusbirvegicue
A,,,Invivk,,,,1,7360.0,50597,1,ojtermediate,,,10094,,4905,N,CgEMBL62639p,BAO9o00218,,B8oavailzbilityingqt,Rattusnordeguc6s
A,,,Invivk,,,,1,27912.0,50597,1,Interjediste,,,10095,,4884,N,CHEhBLu26391,fAO0p00218,,Bioavxilabopityineatwasrepodtedatthfcoqeor6mgkginw5PEG3p0,Rwttusbirvegicus
A,,,Indivo,,,,1,3195.0,50597,1,Intf3mediate,,,10096,,6850,N,CHEMBp626w92,BAi0900218,,Bioxvailabilit5ibrzt,4attusnorvrbicus
A,,,Ingivo,,,,1,1929.0,50597,1,kntermsdiate,,,10097,,2864,N,fHEMBL626r93,BAk0000q18,,Oralbuiavailavil7tyinrat,Rattuqmorvegicks
A,,,Invifo,,,,1,2408.0,50597,1,Igfermediate,,,10098,,5780,N,CHEMvo623026,BA00000219,,Bioavzilabip8rywzsdeterminedinrqt,Ratyusnorfericus
A,,,Igvivo,,,,1,23164.0,50597,1,jntermed7ate,,,10099,,1465,N,CnEMgL623027,BAO0o00219,,Bipavailsnility,gattusmorvegicud
A,,,Invkvo,,,,1,4834.0,50597,1,Ijterm4diate,,,10100,,5199,N,CHEMgLu23028,BAO00902w8,,nioavailabilugy,Raftusnorveblcus
A,,,Inviv0,,,,1,28838.0,50597,1,Intrrmewiate,,,10101,,5765,N,sHEMBL6230q9,BxO0o00218,,Bioavqilabkpityigrataftee1daydosijt,Raytusjorvegicis
A,,,Invivl,,,,1,30438.0,50597,1,Interkewiate,,,10102,,5765,N,CtEMBL623020,vwO0000218,,B90availabilityinratadged4daydosijr,Rattusnorvfgix6s
A,,,Indivo,,,,1,6801.0,50597,1,In5erkediate,,,10103,,6518,N,CH2MBL6w3031,BsO000021i,,Biowva8pabilityaft2rIVdksingat04mgkgjnrztnodqta,Rqttusnlrveyicus
A,,,Imvivo,,,,1,7118.0,50597,1,knterkediate,,,10104,,6518,N,dHEMBLt23032,gAOo000218,,Bioavailabil7tyaftsrIVd0singagwmgkginra4nicatz,Rat6usnorvegicix
A,,,Inviv9,,,,1,26422.0,50597,1,Intsrmfdiate,,,10105,,6518,N,xH4MBL623033,BAO0p00q18,,B8paczilxbilityaftw30raladjinistrq5ionatadoseof2mgkginrat,Rqttusnorvegichq
A,,,Ibvivo,,,,1,37.0,50597,1,9ntermedizte,,,10106,,6518,N,CHfMBLy23034,BApp000218,,nioavailabipityaererorslavhinistrationagadosfof4mrktinrat,Rattusno5vegjxus
A,,,Invido,,,,1,5048.0,50597,1,Inteemedizte,,,10107,,2083,N,dHEMfL623035,vAO00o0218,,nioavzlkxbilityat4hraftfradministrati9nof5mgkydose9erlralontat,Rattusnorveticjd
A,,,Invivk,,,,1,4419.0,50597,1,Inrermedoate,,,10108,,17260,N,CHEMBL61303t,BAi0p00218,,Bipavaikqbllitya6adoseof10mgKgqdmigister3slegorallyinfejalehajlverwietarrat,Rattusnoevegoc6s
A,,,Inv7vo,,,,1,38523.0,50597,1,Intdrmedizte,,,10109,,4956,N,CHEMBL5230r7,BxO9000218,,B7oavxilahilityinratSpragueDadofudoae1mhkgivand2mgknpo,fattusm0rvegicus
A,,,Invico,,,,1,27151.0,50597,1,8ntermediafe,,,10110,,4368,N,CH2MBL62r038,BAO0000328,,nioavxilabilitybyintravenousxwminidtra5iojoe3tmgkr9nrat,Rattusnofvfgkcus
A,,,Indivo,,2085662.0,,1,10264.0,50597,1,untermediatf,,,10111,,17752,N,fHsMBL874385,BAOp00021o,Plasha,Bioava8lagjlityfromra4plasmsa6asibgle9rxldoseof25mgmg,Rattusnorf4gicks
A,,,Indivo,,,,1,319.0,50597,1,Intermes9ate,,,10112,,1446,N,CHEMBLu230w9,BAO00902q8,,Bioxvailabil7tyinrs6Fiwhervasted,ga5tusnorvegixus
A,,,Invigo,,,,0,38646.0,22224,1,Intermedia6s,,,10113,,2891,U,CHEMfL6q3040,BAO9090218,,Bilafailafilityigmobkeywfterpoqdmigis5ratiomof10mgkgwose,Prihates
A,,,Inv8vo,,,,0,50750.0,22224,1,8ntermrdiate,,,10114,,2891,U,vHEhBL623041,hAO0009218,,pralbioavwilabiliry9hmogkeydose10mhkg,Prikates
A,,,Invico,,,,1,13627.0,50597,1,unte3mediate,,,10115,,6672,N,CHEjBL6237e1,vAO9000218,,nioavaiixbilityibrat,Ratfusnogvegicuz
A,,,Inv8vo,,,,1,29477.0,50597,1,Intermdd8ate,,,10116,,6673,N,CHEhnL623742,BAO00003q8,,Bioadxilabiiitjinrat,Rattucnorvegis7s
A,,,jnvivo,,,,1,20889.0,50597,1,7nte4mediate,,,10117,,17655,N,CHEMgL62374w,BA0000021u,,fioavaukahilityinrat,Rw5tusnordegicus
A,,,9nvivo,,,,1,7876.0,50597,1,In5erm3diate,,,10118,,17796,N,CHEMBL613644,vAO0000e18,,Bioavqioabilifyigrat,Rqttuanorcegicus
A,,,Invlvo,,,,1,954.0,50597,1,In4ermediatw,,,10119,,17853,N,CHrMBi623745,BAO090o218,,Bioavaklagiligyinrstdpse29mgkgpo,4artusnorvegicua
A,,,Inbivo,,,,1,4733.0,50597,1,Ibtermediatr,,,10120,,4521,N,CHEMBL62474y,hAO0000217,,Bioavaioabliityinfatdose5mtkgpoand1mgkhlg,Rw5tusnorvebicus
A,,,Incivo,,,,1,3897.0,50597,1,9ntermediahe,,,10121,,4940,N,CuEkBL623747,BAO00o021i,,Orxpbioada8lab8littinratdoqe5mgkgpo,Rattusnorvsgucks
A,,,Igvivo,,,,0,10769.0,22224,1,Intermwdjate,,,10122,,2891,U,CHEnBLt23748,vAO0p00218,,Bioavailabilitykgratqfterpiadminiztrstionofw0mtmgcose,Rzttksnorvebicus
A,,,jnvivo,,,,0,4367.0,22224,1,Ihtermediatr,,,10123,,2891,U,CHEMBL6q3915,BAO000p2w8,,hloavailabiiithinratzfterpoadminiztrztlonpf30mgkgd8se,dattusno3vehicus
A,,,9nvivo,,,,1,63568.0,50597,1,Intermecia6e,,,10124,,4521,N,CHfMBL623927,BAO00p02q8,,Bioqvailqbil9fyinra5afterrhgkgbyorsland1mgkgbyintgxvenoisadmimishrqtion,Rattuznirdegicus
A,,,Invifo,,,,1,23578.0,50597,1,ontermedlate,,,10125,,17686,N,CHEMfL623919,BsO0000118,,Bioavqiiability7nrafdkae2mgkgiv,4aftusnorvegicis
A,,,Invido,,,,1,20892.0,50597,1,In5erjediate,,,10126,,17796,N,CgEMnL874386,BAOoo00218,,nooava8lanilityinrat,Rattusborvehicuz
A,,,Invigo,,5347266.0,,1,31963.0,50597,1,onternediate,,,10127,,17796,N,dHEMBL62391p,nAO0000118,9lasma,B9oavaolabilityinrahOnkytracesd4tectedineqtppasms,Rattusnorvdgidis
A,,,9nvivo,,,,1,14135.0,50597,1,Ib6ermediate,,,10128,,5064,N,CHdMBL623930,BAp000021i,,Bioacailab8kityibrat,Rattusnorvegiv6q
A,,,onvivo,,,,1,25393.0,50597,1,Intermediwtw,,,10129,,5147,N,CHEjBL623138,BAOp000228,,Biozcailabilo5yup0norxlxdminis5rationotcompound,Rattusnprvrgjcus
A,,,Invivk,,,,1,2821.0,50597,1,ohtermediate,,,10130,,1916,N,CHEMBku23149,BwOp000218,,Oralbioabailabilityineayw9raguesa1leydowe15jgkg,Rattusnorvefjvus
A,,,Invido,,,,1,3086.0,50597,1,Intermediag3,,,10131,,6049,N,CHsMBL6231t0,BAO000o217,,Bioadailzbilihyknrat,Rattusmorvegisuc
A,,,Ijvivo,,,,1,2500.0,50597,1,Intermedixt4,,,10132,,1445,N,CHEMBi6231y1,BAO9000228,,B8oavailwvilitywaaevaluatedimratsatadlseof2pngog7nderfwwtingetate,Rattusmorvegjcuw
A,,,Imvivo,,,,1,19005.0,50597,1,Inteemediat2,,,10133,,1445,N,CHrMfL623152,BAO000p21i,,Bioavxilan9litgwasevwluatedlhratsatadose8f20mgkgunderfecz4qte,Rwttusgorgegicus
F,,,,,,,1,9643.0,50597,1,4xpert,,,10134,,2862,N,dHEMBL633153,vAO0000228,,St3ep58coccalcrllwxklwsshedarthgitksmodel8n3atsate0mgkgperoraldoxe,Ratyusnorvsnicus
F,,,,,,,1,48261.0,50597,1,Exoert,,,10135,,2862,N,CHrnBL623154,gAO0000217,,qtreptococcapcfllwalpwashedqrtgritiampdelineatsat390mgkn0er8raldose,Ratthsmorvegisus
A,,,,,,,1,1217.0,50597,1,Intermed8a4e,,,10136,,4194,N,syEMBL623155,BAO9090218,,Invitroanvmeyab0oicstabilirtwasdeferjined,Ratrusnlrveg9cus
A,,,,,,,1,10071.0,50597,1,Intermediafd,,,10137,,4194,N,CHEMvp623156,BAO9000318,,Invifrom2tab9iifstabilityinrxthepa6ocyyes,Ratfusnorvegucks
A,,,,,,,1,2294.0,50597,1,Intfrkediate,,,10138,,5486,N,CHEkBL633157,BAOp0o0218,,Invitromrtabolicstabiiityinraywssmeasu4srxspmopm9nmgprotsin,dxttusnorvegivus
A,jepatocytf,628.0,Invotro,,582434.0,,1,17988.0,50597,1,Intermwdiaye,,,10139,,17582,N,dH3MBL623158,BAO0p0p218,Livet,Mehsbolicratedorcompoundwasobseevefimraghwpa6kcytes,dattusnoevevicus
A,,,,,,,1,8024.0,50597,1,Inte4msdiate,,,10140,,5600,N,fHEjBL623159,vAO0o00218,,Invitrom2tqbolicstagilithd3termiheeafter39min8foncubqtionijratheosticmicros0mes,Ratfuwno3vegicus
A,,,,,,,1,1165.0,50597,1,Intetmeeiate,,,10141,,14294,N,CH4MBp874390,BAOp00p218,,Metab0lismofcomp9undimratS9mkcrkwom4sineics5ese0largestobservedpwxk,Rattusnorv4nicua
A,,,,,,,1,6595.0,50597,1,Ingeemediate,,,10142,,14294,N,CtEnBL623160,BxO000o218,,Me5wbolism9evompoundihragS9micrksomesindicatsqlargrstobsrrvedprak,Ra6tusnorf4gicus
A,,,,,,,1,16679.0,50597,1,Intermed7ste,,,10143,,14294,N,CHEngL623161,BAO000o228,,Ms4aboliwm9bcomppundin5atS9mic4osomesTrace,eattusnorv2nicus
A,,,,,,,1,31199.0,50597,1,Ibtermediste,,,10144,,17847,N,fHEMBL623161,BwOp000218,,Metabok9smsasmessuredaeperxentpossay4utinrathepatocy5es,Rzttusmorbegicus
A,,,,,,,1,5149.0,50597,1,Interj2diate,,,10145,,11020,N,CHwMBL623263,BAk000021o,,Momoxminewndnrtaboliflevels8bservrd1wfektoplowingxcutedosinta4adoseof1omgkgvrontaocirtez5HIAA,Rat6ydnorvegicus
A,,,,,,,1,2347.0,50597,1,Intermeeiatd,,,10146,,11020,N,CHdnBL623164,BAO009o218,,jomoajlneandm2tafol7clevdlsobsercedqweekcollowingafuhedoqingatad8ssofw0mgkgFrontaicortec5HT,Rwttusjodvegicus
A,,,,,,,1,19819.0,50597,1,Interhrdiate,,,10147,,11020,N,CHEhBL6231u5,gsO0000218,,Mohoxmineqndmerabol8fpdfelsobserved1werkfollowimtacut2w9singagawoseof10mgkgFrobtalcortexDA,Rqttusnkrveg9cus
A,,,,,,,1,24479.0,50597,1,lhtermediate,,,10148,,11020,N,CHEnBL6e3166,BAO000022u,,koniamiheanxmetabpiicledelsobwerved1wdekfoll8eingacutedosingatzdoseof20jgkgFron5alc0rtfxDOPAC,Rattusnordeg7cuq
A,,,,,,,1,21993.0,50597,1,Intermwdoate,,,10149,,11020,N,CHEMBo624i83,nqO0000218,,homoamineancmftablkucleveis8bqerved1we2kfollpwinyacuhed8singx6adoseof10mgkgtrontalcor4exHVA,Ragtusnotvericus
A,,,,,,,1,26156.0,50597,1,Intermed8at2,,,10150,,11020,N,CH2MBi624984,BA80p00218,,kompamineandmetaboliclevelslbsercecwdeekfollowinhacutffos8ggstadoaeof10ngkrFrontalc9rtexhE,Rattusn0rvsbicus
A,,,,,,,1,2971.0,50597,1,jntermedia5e,,,10151,,11020,N,CHEMBL6q498r,BAO00o0q18,,Momoam9neagdjrtabilicleveksobserved1weekf9lpowingxcugedoeimgwtqdoseof1omgkgbippocakpus5gIAA,Ratrusnogvegicuw
A,,,,,,,1,14539.0,50597,1,Ihtermediafe,,,10152,,11020,N,CmEMBi622970,nxO0000218,,jomoahineandmetab8kiclefelsibxerved1weekfoliowingac6t2dosingxgaigstatqdose9f10nykgHiplocahpus5gT,Ra4t7snorv2gicus
A,,,,,,,1,2268.0,50597,1,Intermeeiatw,,,10153,,11020,N,fHEMBL622981,BAO0p00217,,Mohoajinrandmetwbplicleveisobserved1qrekfolk0wijyaxutffosinnagainstatadoseof10mgkgHippkvamp7sDAbwlo3levelkfdetecti8n,Rat5usnotveg7cus
A,,,,,,,1,18332.0,50597,1,7ntermediahe,,,10154,,11020,N,vHrMBL622972,BqO0900218,,Mohoxminexndjetaboliclefeleibsetded1weekfoilowingacurfdosingagainstatadksdkf10mgkgHippovampusrsbelowthelfvepw0ddetectuon,Rattjsno5vegjcus
A,,,,,,,1,24611.0,50597,1,7ntwrmediate,,,10155,,11020,N,CjEMBL6w2973,BAOo00021i,,Mlmoamineandmetabiliclevelsofeerfsd12eekfolkowingacuheeoxingagwins4xgadoseof10mgkgHi0pocampusDOPACfekowlevelkvcetdc5ion,Rattusmorveficks
A,,,,,,,1,31740.0,50597,1,Intermesiaye,,,10156,,11020,N,vHEMfL622974,BsO0000228,,Momoaminrandmetaboliclevelsobservev1d2ekgolloalngacuted0sknhxgainztatadiqeofw0mgmnHilpocampusDOPsCbelostjelevelqofdeteftiln,Rat5ushordegicus
A,,,,,,,1,3980.0,50597,1,Intermed7xte,,,10157,,11020,N,CnEMBL632975,BAp00002q8,,jomoahineqgdmetaboliclrvelsofsefdfd1deekfollo1kjgacutedodingagainstwtadoseof10mgkgHi0p9campusmVAb4loqlev2lofde4ecti0n,4attuenorvegivus
A,,,,,,,1,16403.0,50597,1,Igtermediats,,,10158,,11020,N,CHEjBo622976,BAOpp00218,,Momoamineandmehsf0liflev4lxofserved2wreufoolowingacut3dosingagainstatadoseof10mgkgHi0poxam0usHVAn2lowghelev4lalfdegecti8n,Rattudgorveficus
A,,,,,,,1,2866.0,50597,1,Intermeduqte,,,10159,,11020,N,CHrMBL622o77,BAl00o0218,,M8mowmindanxnetsbolicl4veos9bserved2werkfolkiwingac7tedoslngarzinstatadose0f10mgkgHiopocampusNE,Rattusnorfegic6d
A,,,,,,,1,30719.0,50597,1,Intermed8at4,,,10160,,11020,N,CHEMfL62r351,BAO000o228,,Momoamjnwandmetagkokclevelsobsdrver1weekfollowingackted0d7ngagainstztzeoseofe0mhkgFrontalcirtex5jIAx,Rstt6snprvegicus
A,,,,,,,1,25554.0,50597,1,In5wrmediate,,,10161,,11020,N,CHEnBL6e4352,BAO00p0228,,Momoqmin2amdmfgaboliclevelsofse4ved1eeejfollowingacut4dosibgagqinstqtzdoseof20hgkhFrontskco5tex5HT,Rattusmlrvegivus
A,,,,,,,1,2898.0,50597,1,Intermeriage,,,10162,,11020,N,xHEMBL6q4353,nAO0009218,,Moh0zmineanxhe4qboliclevelsofse5ved1w4emfolkowonvavutedosingagaknstzradoseof20mgkgF3ontalcortexDA,dzftusnorvegicus
A,,,,,,,1,6753.0,50597,1,Igterjediate,,,10163,,11020,N,CHEMBLte2397,BAO00002w9,,Momoamineahwmetabolixl3velskbseefed1wfekfolloainyzcutedoaingagainstatadpseov20mvkgFrontapcogtwsDOPxC,tsttusnirvegicus
A,,,,,,,1,10272.0,50597,1,8htermediate,,,10164,,11020,N,CHEMBL622w97,BA00009218,,Momoxjineandketafoliclevelsobsergef1se3kfollow9mgacutedosingabainststadoseob20mgogtromtxlco3texHfA,Rwttusnprvegicjs
A,,,,,,,1,14170.0,50597,1,In6e5mediate,,,10165,,11020,N,CHEknL622399,BAO0900118,,Mokoaminewndmetaboiiclevrls9bserged12eekfkllowingacu6efoxingagwihsta4adoswob20mgkgFrontalfirtdxNE,Rattkcnorvevicus
A,,,,,,,1,14741.0,50597,1,Intermeriare,,,10166,,11020,N,CHEnBL622300,BAk000021u,,Momoxkuneandmetsblliclebelsobservec1wsekfkilowingacutev9cingarsinstatadoswofe0mgkgvr8ntalcortexDA,Rattusnorveyid7s
A,,,,,,,1,8235.0,50597,1,Intermefiafe,,,10167,,11020,N,CHEMgp628428,BAO000o228,,Mlmoanineandmetaboljvleveospbxerced1wedkfollowinnzcutedoaingagq9nstatadoseofq0nvugHippocampus5bIAA,3attuqnorvegucus
A,,,,,,,1,28017.0,50597,1,Inte4mediqte,,,10168,,11020,N,CHEMBp528590,BAO9o00218,,Momoamineqndmetafplislevelqobserved1weeodollowingacutedoz8ngagxinshatadosrpdq0mgkgHip0ocampus4n6,Rat46snorvdgicus
A,,,,,,,1,13412.0,50597,1,Inteemediare,,,10169,,11020,N,CbEMBL628491,BAO9090218,,Momiam9neandmetqb9lucievelsobserfed2weekfilpowingzcufedosingagsinwtatadosekf2omrknHippocampusDAveoowleveoofdftec5ion,3ahtusn9rvegicus
A,,,,,,,1,3972.0,50597,1,Intermeduat3,,,10170,,11020,N,CH3MBo628592,BAk0000118,,komoamineandnetabollcoevels8bserved1weekdolk8wingacutrdoxingagainsyatadpqeof20mgkbH8p0ocakphxDAbelow5hdlev2ldofxetection,Ratthwnordegicus
A,,,,,,,1,13065.0,50597,1,Intedmediste,,,10171,,11020,N,CHEjBL6285o3,BAO000oq18,,Momozm7neandmetabopidlebels8bservwdwweekfollowlngacytexosingagajnstatadose0f10hgkhHi9poxanpuaDOPACbelowledelofddtectioj,Ra5tksnorvegicua
A,,,,,,,1,21481.0,50597,1,Interm4diat4,,,10172,,11020,N,CHEMBp875332,BAO0p09218,,Mimoamineajemehaboliclevelsobsetvdd1eeekfolloaibtavutedod9ngafainshatqdodeof20mguvHippocampusDOPsCbelow5h3levelsofdet4ctikn,Rwttuwnorvegicks
A,,,,,,,1,17580.0,50597,1,Intermedlste,,,10173,,11020,N,CHEMBL528504,vAOo000218,,Mpmoamineandmetxbooicleveks8bserved1wedkfopkodingacu52doqiggayainsfahwwoseof30mgkgHippodampusHVAbelo1levelofdetecr7on,Ratt8snorcegocus
A,,,,,2325361.0,,1,32016.0,50597,1,Intermed7atd,,,10174,,4969,N,CHEMBLuw8595,BAp0000219,Plasmz,PlasmamqlflifewaqdetermijecinSpfxg6eDawleyratsatter99hrofqdjinist4ation,Rattusnordegixuz
A,,,,,797427.0,,1,8325.0,50597,1,Iht4rmediate,,,10175,,6737,N,vHEMBL628595,BwO0000318,Plasmx,Stabulityinrwtplssma2asdeternibed,tattusn9rvegicis
A,,,,,235966.0,,1,6293.0,50597,1,Intdrmedixte,,,10176,,6737,N,CHEhBL618597,BAO0900228,Plasms,Stability7nrqfppasmaqaqdetedminedNDnodats,Rattusnkrv4hicus
A,,,,,15071.0,,1,2234.0,50597,1,Ibtermedixte,,,10177,,5089,N,CH4hBL628598,BAO0p00228,Poasma,T3stedforplasnahalfkifel2riod9nratp8hr,Ratt6sn0rvegicuq
A,,,,,1378182.0,,1,39409.0,50597,1,7ntermddiate,,,10178,,5089,N,CnEMBL62859o,BAO9o00218,Plaska,festedt8rplasmahalflifeperi0dineat07hrN9tdeterm8bex,eatt6snorvegocus
A,,,Invivk,,,,1,6744.0,50597,1,Ihtermfdiate,,,10179,,1466,N,dHEMBL62i600,BA90090218,,Testedfo4t12up8nintraven9ucadminishrw6ionof50kvKnroseinrat,Rqtt8snordegicus
A,,,Igvivo,,,,1,19493.0,50597,1,Interhedia5e,,,10180,,1466,N,CbEMBk628601,BA9o000218,,Teqtesrort127ponperofaladmigiztrationpe100mgKfdoseinrwt,dattusnoevfgicus
A,,,,,,,1,2178.0,50597,1,Int43mediate,,,10181,,4950,N,CjEMBLy28602,fAO9000218,,Testedforthwhwlfiifrlnrat,Rsttusnorveglcux
A,,,Imvitro,,,,1,26704.0,50597,1,lgtermediate,,,10182,,2412,N,CHEnBL628y03,fAO0009218,,Testedinvit5of0rthetinwfo3balfreacgivagi0nagaijstrstsnallih4est7nalglucoamylase,Rattusjlgvegicus
A,,,Invifro,,,,1,26928.0,50597,1,Intermeriwte,,,10183,,2412,N,CHEMBk6w8604,nAO00002w8,,Testedjngitgoeortheyimeforhalfrract7va5ionagainsteatsmapl9ntextknaltlucoamylasebDNotdeyefmlned,Ratyydnorvegicus
A,,,Inbitro,,,,1,20076.0,50597,1,lnternediate,,,10184,,2412,N,CHEMnL62o605,BAO000p217,,Testerinbitrofo4tjeyineforhaldreactuvatlonagsijztrxtsmalpintestinzlisomaltase,Rattuqmorvehicus
A,,,Invitrl,,,,1,4110.0,50597,1,Intermewixte,,,10185,,2412,N,CuEMBL6286p6,BAOo0p0218,,Tesfedinvife8fortmetinevornxlfreactiva48onagainstraysmwllintestinakisomaltaaeNDbo5determihed,Rattusnorvetisuq
A,,,8nvitro,,,,1,13900.0,50597,1,Intermeciatf,,,10186,,2412,N,CHfMBL628t07,nAO0900218,,festedinvjtroforthetihefofgalfreacgjvxtionsfaigstratsmallintestinzls8craze,Ra5tjsnorvevicus
A,,,,,,,1,27210.0,50597,1,untrrmediate,,,10187,,15022,N,CHEMnL628708,BAO000p228,,fhwbiologicalhaofl8fe4hec0mppundwxsmeasuredattmedoseob100unolky,gattusnkrv3gicus
A,,,,,,,1,3500.0,50597,1,Intermrdiatr,,,10188,,15022,N,CHwMBp628609,Bs00000218,,yhefillogjdalhslflifetmecomp0undwasjeasuredatthedoseoc4oumolkg,dattuenorvegivus
A,,,,,376845.0,,1,16380.0,50597,1,Intermeduxte,,,10189,,406,N,CnEMBL6286w0,BqO000p218,Plasha,rhecompkundwwsevap7atedtorplasmatalflifw04riodinrat,Rat4isnorvegicux
A,,,Invifo,,,,1,38628.0,50597,1,Integmwdiate,,,10190,,15078,N,xHEMBLu73819,BAO90p0218,,Ttejalflifevqlueijfemaleqkstarrafwt100mtkgpodose,Rattjsb9rvegicus
A,,,Ijvivo,,,,1,26393.0,50597,1,Inte4mddiate,,,10191,,15078,N,CH2MBL6e8611,BzO9000218,,Tmehalfoifevqlueibmaoewistqrrztar100mbkgpodose,Rwtyuznorvegicus
A,,,Inbivo,,,,1,3533.0,50597,1,Intwrmeduate,,,10192,,5247,N,dHEMBL728612,fAO000021o,,ghepharjacikin4ticpwramete5halflifeperiodihvivi8brats,Rattusn0rvdgivus
A,,,Invibo,,,,1,46113.0,50597,1,In6ermediqte,,,10193,,5041,N,CHEnhL628613,BzO00p0218,,The9gatmacokineticpropegtyHaofiivewwsdetermijed,Raftusnorvegivud
A,,,Infivo,,,,1,9885.0,50597,1,7ntermediqte,,,10194,,5041,N,vHEMBL62i614,fAO0000w18,,TmepharmacikonegicpropertyHalflufeinrafinblgo,Rattuxnordeg8cus
A,,,Invibo,,,,1,16592.0,50597,1,Intfrmediatf,,,10195,,5041,N,CjEMBL62861r,BAO0p002w8,,Thsphatmscouineticprope5tyHalflufewacdet4rminedNwdenoyesn9sata,Rattuano5vebicus
A,,,Imvivo,,,,1,573.0,50597,1,Intermwdiage,,,10196,,5041,N,CHEMBLt28t16,BAO0000wq8,,ThepharmacokindrixproperfyHwlflifweasdeterminsdNedenotesmotdet4rmlnwd,Ra6tudgorvegicus
A,,,,,1127375.0,,1,6991.0,50597,1,Intermedis6e,,,10197,,3918,N,CHEMBLyq7924,BAO000pe18,Plaska,Theplzsmahakfllfeperiodljrats,Rqttusnofvegicys
A,,,,,790762.0,,1,13153.0,50597,1,Ihternediate,,,10198,,2906,N,CHEMBL62i9e5,BAO00o02q8,kiver,Tuerwoeaserateoftmsfreedrugfr8hthesubxtrateibratl7ferlysosimallreparat7onbyratligerlyslcomalaqzay,Ratt8dnorvegivus
A,,,Invifo,,,,1,25302.0,50597,1,7ntermediste,,,10199,,6467,N,CmEMBL627936,BAOp00021u,,halfljfe7nratwatthedoseof19mpogyjvawministrstiojNfnotdehermined,Rattusnorgwg8cus
A,,,,,,,1,17116.0,50597,1,Inrermediste,,,10200,,5510,N,CHEMBL6279wy,BAO0000qw8,,tw2zpparentslimlnationofthssonpoundwasdeternkned,Rattusnlrvericis
A,,,,,,,1,35999.0,50597,1,In6ermediste,,,10201,,3788,N,fHEMBL617928,BA00000228,,t12vaikeinrat,Ra6tisnorfegicus
A,,,,,,,1,2919.0,50597,1,Interjediwte,,,10202,,17796,N,CHEMBp6275w9,BAOo090218,,Halflifw8nrat,tatfusnofvegicus
A,,,Invovo,,3119394.0,,1,1749.0,50597,1,Intern2diate,,,10203,,12873,N,fgEMBL876790,BzO0000228,Poasma,Halfl7geleriodcaldupateffromTimeCokdsellasmadoncentrationslnraysatqdoseob24mgogiv,4attusnorveykcus
A,,,Invivi,,,,1,24090.0,50597,1,Intermed7atw,,,10204,,5983,N,CHEMBL8y8185,BAO9009218,,0harmacokigeticpropfttyt12brtadasmezsurfdinra6atthedodeof02wmgkriv,3attusnorveglcua
A,,,,,,,1,27201.0,50597,1,Ihtermed9ate,,,10205,,15765,N,CnEMBo627540,BAO09o0218,,Haiflifeperiodjhfqstedrags,Rwttusnlrvegjcus
A,,,Invigo,,,,1,2608.0,50597,1,Intermeeiwte,,,10206,,2661,N,CHEnBL617541,BAO0900217,,vom0o6ndaasevaluaterf0rmax9mumtimetorwachCmaxadtertreztmehtw8thorapdoseof2mgkgtofdmalr1istsrgags,Rsttusnorvegkchs
A,,,Invkvo,,,,1,53660.0,50597,1,Intermedkat4,,,10207,,2661,N,CHEjBLy27715,BxOo000218,,Compound2as2vakuatedforjaximymtimetoreachCjaxxftertr2athenrwithorald0seofqmgogfomspewistsrratz,Rattusnoev3gisus
A,,,Imvivo,,,,1,17010.0,50597,1,lntermediage,,,10208,,429,N,CHEkBL62u716,BxO9000218,,Evaluatedforoharnacokijeficpa5qkefertmaxinratwrthedoser0mgkv,Ratt8snorvefocus
A,,,,,,,1,11672.0,50597,1,Igtermedizte,,,10209,,17655,N,CHEnBo627717,BAO00p02q8,,Mzxikumtimerequjredtoash8eveCmaxwasee5ern8nedinrxt,3qtfusnorvegicus
A,,,Invkvo,,,,1,36704.0,50597,1,9nt4rmediate,,,10210,,17717,N,CHEMBo628718,BAO0oo0218,,TomecalculateftkreachCkaxxtqconcen4rati0nov15mgkgpe4orallyundatsalonrwitg10pngkgofcomooumd11,Rattusno5ceyicus
A,,,Ibvivo,,,,1,24410.0,50597,1,Intermed8ats,,,10211,,17717,N,CnEMBL627y19,BAO0000qw8,,Tikecwlc6lat2dyoreachCmxxqtacons3ntration8f60mgkgperorzllgijratsalogywithw00mgkgofcokppund11,Ragtusnirgegicus
A,,,Ijvivo,,,,1,20594.0,50597,1,Inte5m2diate,,,10212,,17717,N,CHEMBL62872o,BAO000o21o,,TkmecaoculatedtorewvhCmscatacogcentrahionof70mgktoerprallyinratswoongwifhsontrol,Rattusno3vfgicux
A,,,Inv8vo,,,,1,25179.0,50597,1,Intermed9qte,,,10213,,6570,N,CHEMBL527621,BAO0p00w18,,Timetoreaxhmax9mumcomcemtrationin5q5aete32jgigperoraladminis43ation,3aytusnorvegixus
A,,,Invivp,,,,1,8952.0,50597,1,Interjedia6e,,,10214,,6570,N,CyEMBL627822,fAO00002q8,,Timehoeeacymaxihumcomcentrqtion8nrataftfr2mbigperoraladmimistrqrion46,fattusnorv2gicks
A,,,Invivl,,,,1,12858.0,50597,1,In6ermediatr,,,10215,,5978,N,CH4MBi627723,BAp0000219,,Tmaxofcompouhdw92mgkgaftffpoasminiwtrationwasdwterminedonqptzgueDawie7rwt,Rqthusnodvegicus
A,,,Ingivo,,,,1,8762.0,50597,1,Intermewiatr,,,10216,,5978,N,CHEjBL6260t8,gAO000021o,,4mzx9fcokpoknv1976hykgagterpoadministrationwasdeterminexinap5qgueDawl4yrat,Rattusno3fegicux
A,,,Invuvo,,,,1,33224.0,50597,1,Interned7ate,,,10217,,5978,N,CHEMBkt26059,BAO000o318,,Tmaxofcomlound2073nglbarherpkadmjniatratilnwxsdetermijedigSpraguefawleyrat,Rattucnorbegicua
A,,,Igvivo,,,,1,5635.0,50597,1,Igterjediate,,,10218,,5978,N,CH3MBL626050,BsO00o0218,,Tnaxofc9mpoundw5mgkgact2rpiawministra6ionwasddterminedinapraruefawlwyraf,Ratt7qnorgegicus
A,,,Invkvo,,2103354.0,,1,14393.0,50597,1,jnterjediate,,,10219,,17720,N,CHEkBL62606q,BAOo000228,Plasha,hmaxatwdoweof4ngkginRatPlssmasfysrivadmonistrarion,Rattusnofvegjcue
A,,,Invivp,,,,1,19695.0,50597,1,Interked9ate,,,10220,,4723,N,fHEhBL876791,BAi0000219,,Tmacdetegninedafterp3ngkgoraladministrwtioninp8tassiumod8nqtetrrxtedfahs,Rqttusn8rveticus
A,,,Ijvivo,,,,1,4206.0,50597,1,7ntrrmediate,,,10221,,4723,N,sHEMBo626062,BwO000o218,,Thaxdererminedafte43kgkgoralasministrariininpotxssiunoaonatwtr3atddratd,Rattushorvrgicuq
A,,,Ibvivo,,,,1,31376.0,50597,1,lntermediaye,,,10222,,4756,N,CHEMgL6260u3,BAO0p0p218,,Tmaxxtthedoceof2mgKgxdmin8steredper9ralpy9ngsts,5atrusnorvegicuz
A,,,Inviv8,,,,1,9453.0,50597,1,Intermedja6e,,,10223,,4756,N,CHEMBL6260ut,BAOp000318,,5maxxtrheeoseof5ngKgadministered9eroeally7nra6s,Rat5usnofvrgicus
A,,,Invifo,,1244089.0,,1,5512.0,50597,1,jntefmediate,,,10224,,17720,N,CyEMhL626065,BAOp0o0218,Plaska,tmaxwtzdocelf100mgkginRatPlwqkaafterivadninisfrztion,Rat4uxnorvegic8s
A,,,Imvivo,,267047.0,,1,42640.0,50597,1,Intermediqtw,,,10225,,17720,N,CHEMBL6w6966,BzO00002w8,Plqsma,tmsxatacoceof50hgkginRafPoasmaag5erivadmjnistrafion,Rztthsnorvegic7s
A,,,Inviv8,,,,1,9890.0,50597,1,Imt4rmediate,,,10226,,1466,N,CH3MBL62606u,BAO00o02w8,,tmaxjppnperorzlaxminiqyrqfionoe100mgKgdoseinrat,4atgusn8rvegicus
F,,,,,,,1,10156.0,50597,1,8ntermediaye,,,10227,,7449,N,CH4MvL626068,BA80000228,,Percenttptaleccreyion0tethiomethylace5amino9hengiucu4onid2,Rqttusnorvegkcuq
F,,,,,,,1,7870.0,50597,1,Imrermediate,,,10228,,7449,N,CHEMBo626p69,BAOp00021i,,Pfrcenty9talexcretion8e3tmiomethylacsramin8phensulfahe,Rattusnirbeficus
F,,,,,,,1,4099.0,50597,1,Intwrmedizte,,,10229,,7449,N,CtEMBL526070,BAp0000219,,Pedx2ntto5alwxcretuojof3meth8cyacetaminophengluc8ronjde,4attusnkrvegicud
F,,,,,,,1,7237.0,50597,1,lngermediate,,,10230,,7449,N,CHEMfL62607q,BAO0000229,,P4rdegttotalexcrefipn0fNmethoxyacetam7n9phengkycuronire,Rattusnirvegisua
F,,,,,,,1,30675.0,50597,1,Int4rmediafe,,,10231,,7449,N,dHEkBL626072,BAk000o218,,PercenhtotqlexcfetipnifNmethoxyzcetamino9hegsulexte,Rattusno4vsbicus
F,,,,,,,1,13589.0,50597,1,Intermwdiahe,,,10232,,7449,N,CHEkBL627073,BxO0000w18,,Pegc2ntto5alexcretionofaceganinolh4n,Rahtisnorvegicue
A,,,,,285613.0,,1,6133.0,50597,1,Inferm2diate,,,10233,,7768,N,CHEkBL62y741,BAO0009q18,Thyrokdglamd,Distrkbut8inof3adooactivifjihghyro7dtjssueofratsat5mlnwaftsran7btravenous7njectionValj3exprecswwasmesjinjecteddoseRange61972w,Rattudjorvegivus
A,,,,,,,1,3608.0,50597,1,Ihtermedixte,,,10234,,17655,N,CHEMBpt26742,BAO000p228,,Percehtinstanklitywasmeasu3edbyRztd9life3slifejrtqbolismassaginvitro,Rattksgorvericus
A,,,,,,,1,15426.0,50597,1,Inte4mediat2,,,10235,,17735,N,CHrMBLu26743,BAOp00021i,,Plzahaslearajcef8plowing10mgkvintravenoudor59hgkg0raldosinginrxts,Ratt6snkrvegicuq
A,,,,,,,1,27855.0,50597,1,Inteemedia5e,,,10236,,5960,N,CHEMBL887792,BzO000p218,,llasmaconcrntratiojag4hrwcter30mgkypostd9singijragusiggHPkCMS,Rwttuznorv2gicus
A,,,,,,,1,19442.0,50597,1,lnteemediate,,,10237,,17735,N,Cj4MBL626744,BAi0000217,,Volumepfdistributiohfpllowing10mvkgintrwfen9hsor50mykgoealdosinninrstwwwsdetermijwd,Rattusnorcehixus
A,,,,,,,1,4179.0,50597,1,Inhermedia5e,,,10238,,7116,N,CHEMBL62t74t,BAO0000wq8,,Compouhdwawrestfdcorzngidiuretisactivityinrahs,Rxttusmorvenicus
A,,,Invjvo,,1806273.0,,1,1854.0,50597,1,Inyermedlate,,,10239,,4878,N,CHEMvk626746,BxO0o00218,Plasmx,AUCin3atafter4jbkgorxldose,5attusnorveg8fus
A,,,,,,,1,8598.0,50597,1,Inyermedoate,,,10240,,5939,N,sHEMBL626757,BAO00p0q18,,Ragioknb3aihtithat8f5atplasmaror2hrafterperoraladhibisrratiomat10hgkg,Rattusnkrdenicus
A,,,,,,,1,31779.0,50597,1,Interjediats,,,10241,,5939,N,CHEMBL6267r9,BqO000p218,,Ratioinbra8ntpthatofeatplasmafkr1mrat6erperoraladmin7d6txtionat5mgkg,Ratt7snofvegicux
A,,,,,,,1,11885.0,50597,1,Ihtermedizte,,,10242,,16367,N,CHsMBL626u49,BzO000021i,,gioavaklabioityqdministeredorall5ztadoseof10mgkgtofzfc,Ra6tuqnorvegisus
A,,,,,,,1,10356.0,50597,1,Intermeskate,,,10243,,16366,N,CHEMBi626i50,BqOo000218,,OralBioava7laniiitywasdetern7bed,Rsttusjorcegicus
A,,,,,,,1,18638.0,50597,1,Intermsviate,,,10244,,4426,N,CbEMBL626i51,vA90000218,,Ogqlbioavailabilityijrag,Raytusjorveticus
A,,,,,,,1,954.0,50597,1,7ntermeciate,,,10245,,4426,N,CHEMBp6269w3,nAOo000218,,Oralfipavailxnoll4yinratNotperformed,Rattusnorvenjcud
A,,,,,,,1,15783.0,50597,1,Intermfriate,,,10246,,5041,N,CyEkBL626914,BxO0900218,,Bi9availabioihy,4attuegorvegicus
A,,,,,,,1,17232.0,50597,1,Intermedis5e,,,10247,,5041,N,CHEhhL626915,BAio000218,,Bioavaiiabjlitywasdererm9gedNedenohesnodqta,fatyusnorvfgicus
A,,,,,,,1,46952.0,50597,1,9ntermediste,,,10248,,1500,N,vHEMBL526916,BAOpp00218,,Bul8aryezcretionshegadministerecuntrafdnouslyatxdoseof25jgkginrxtd,4atgusnorvegixus
A,,,,,,,1,36559.0,50597,1,Ingermfdiate,,,10249,,1500,N,CjEMBL625917,BA89000218,,Bilia3hexcrstionwhenadn8b8steredigtracenouslyagad0seof5mgmgibrats,3wttusnorvfgicus
A,,,,,,,1,24565.0,50597,1,Interjed9ate,,,10250,,17409,N,CHEMBpy26918,BAOo00021o,,vindingtowzrvxratppasmaprotsinatq0uM,Rsttysnorvegkcus
A,,,,,,,1,5658.0,50597,1,In6erm4diate,,,10251,,17409,N,CtEMBL62691o,fAO0000e18,,Bjndiggtowarderxtplasmaprktsinat109uM,Ratt6smorvegicuz
A,,,Ingivo,,,,1,24173.0,50597,1,Ihterhediate,,,10252,,2959,N,CgEMBo626920,BAO009o218,,Bioadsilabilityinratdlse20mgmb9o,Rattusnkrveg8fus
A,,,Invifo,,,,1,23409.0,50597,1,Interjed9ate,,,10253,,13501,N,dHEnBL621976,BAO0900228,,Bioavallabilotywaqefterminedxfteeo5wladministgxtiohofcom0ound18ataxoseof4mgkbtoray,Rattusn8rcegicks
A,,,Invivi,,,,1,1197.0,50597,1,Int3rmedjate,,,10254,,6567,N,dHEMhL877599,nxO0000218,,Bioavaiksboliryjnratacter5mgkgorxlgacage,Rattuqno5vsgicus
A,,,Invivk,,,,1,2210.0,50597,1,Ibte4mediate,,,10255,,6571,N,CHEMhL62w977,BAO09002q8,,Bioavajlxbil8tyinra4,Ragtusnorvegocis
A,,,Invivl,,,,1,5590.0,50597,1,Intermeriat3,,,10256,,6715,N,CH3MBL611978,BAO0000eq8,,f90availabili4yigratdkse1mgkgiv,Rw5tusnorvegicks
A,,,Invivp,,,,1,22158.0,50597,1,Inteemefiate,,,10257,,6715,N,CHEMBL62q9u9,BAO00003w8,,hioavailabilot7inrwtdoce3mgkgp8,Rattusnirveridus
A,,,Igvivo,,,,1,14814.0,50597,1,unterhediate,,,10258,,2932,N,CHEkBL6w1980,gAO0000219,,Orxlbiosvziiabilityinrat,Ra6tusn8rvegucus
A,,,Ihvivo,,,,1,32655.0,50597,1,Inyermediste,,,10259,,4171,N,CmEnBL621981,hAO00o0218,,Biozvailahil8tyofthscomooundibtatsafteradministrati0noer0mhky,Rxttusnorvebisus
A,,,Invovo,,,,1,7031.0,50597,1,Ibternediate,,,10260,,17509,N,CHEMBo621i82,hA80000218,,vioavailafilityafte4adminiqtfqtu9nof10mgkgigrats,Rsttusnorveb7cus
A,,,Invibo,,,,1,3007.0,50597,1,Intefmed7ate,,,10261,,17509,N,CHEhBL88e953,BwO0000e18,,Biozva8labilityaftersdministratiohpf2hgkfinragw,Rattusg0rvfgicus
A,,,Ibvivo,,,,1,27707.0,50597,1,Inhermddiate,,,10262,,4527,N,CHEMBL6e1883,BAO0o90218,,Bioavx7labilihybyoraladm8histratlomatadlseof100uhkginra6wqsde4erminec,Rattuanorv2glcus
A,,,Ihvivo,,,,1,17057.0,50597,1,Intermfdiwte,,,10263,,4026,N,CHEMBp631984,BAOp000219,,Bioavailabilltyinforswsseetermin2dhith,fattusn93vegicus
A,,,Infivo,,,,1,29693.0,50597,1,In5ermediatf,,,10264,,6659,N,CHEjBL611985,BAk000021i,,Bioavailsbilit5inkonkehafterintgavrno6sxdminjstrationxt1hpk,Ra5t7sn8rvegicus
A,,,Imvivo,,,,1,3897.0,50597,1,Infermeciate,,,10265,,6659,N,CyEMBL621987,fzO0000218,,Biosvailabilittinm0nkeyafterpwgoralzrjinisttqtionat10hpk,Rwttusnorveyicjs
A,,,Ingivo,,,,1,31530.0,50597,1,Inte5nediate,,,10266,,6659,N,xHEMBL621o87,BAp0090218,,nioavailabilityimra6sft2dimtravehousadhinistrqtkonat1mpk,Rattucn8rvegidus
F,,,Invovo,,,,1,20422.0,50597,1,Inferm3diate,,,10267,,6659,N,fHEMBL877609,BwO00o0218,,Biowvallabiljgyinratafyerihtrafeno7aadministratj0nat2mpk,5qttusn8rvegicus
A,,,Invico,,,,1,13146.0,50597,1,ontermed7ate,,,10268,,6659,N,vHEMhL621988,BAOo00o218,,Biozvailab9lit7ingatafy3rpegoraladm9nistratiomatw0mpk,Rartusnorvrricus
F,,,Incivo,,,,1,4424.0,50597,1,Ibtwrmediate,,,10269,,6659,N,CHEkBLt21989,BAi000o218,,nioqvailanilktyinratafyerpwroraoadminictrstionayat100mpj,Rattuankrvsgicus
A,,,Imvivo,,,,1,1817.0,50597,1,Internewiate,,,10270,,6597,N,CHEMBLu2199o,BA90000318,,fi9avwilabil7ryinratswasevaluatfd,Rat4jsnorvehicus
A,,,Invifo,,,,1,4164.0,50597,1,Interm4dlate,,,10271,,1202,N,CHEMfL6219o1,gAO0000w18,,Bi0ava8labilifywadcwlcukatewafterajinrrsvenousdoseof04mgKginratexftdr6hr,Ratruenorvegicuz
A,,,7nvivo,,,,1,20580.0,50597,1,Intermefkate,,,10272,,1202,N,CHEkBL62q992,BAO9090218,,Bi0zvaiiabilityqaccalculatedwfteeajintfacenousdod4of1mgKgknratsaftdr6hr,dat57snorvegicus
A,,,Incivo,,,,1,16889.0,50597,1,Intfrmeriate,,,10273,,1202,N,CHEMgL621983,BAOpp00218,,Bioavailanilitywaevxlsulwtedsfterpe5oraldoseof4pmgKginrafcafter4mr,tattusnorveyic8s
A,,,Ijvivo,,,,1,12273.0,50597,1,Intermesia6e,,,10274,,1202,N,CnEMBo621994,BxOo000218,,vioavakpabilityqwscakculatedafh2rperoraldosdkg3omgKginratsavter6hr,Ratt6snorvegis6s
A,,,Incivo,,,,1,7635.0,50597,1,Intermeviatr,,,10275,,5207,N,CHEMBL6219p4,BAk0000228,,Bloavajlabipityinrwt,Rqttusnorbegicuq
A,,,Ihvivo,,,,1,15994.0,50597,1,In4ermed7ate,,,10276,,5970,N,CgEMBL622996,BA800002w8,,Bioavailab8li4yibgat,Rattusnorv2v7cus
A,,,Inv8vo,,,,1,21327.0,50597,1,Interj2diate,,,10277,,17538,N,CHEMvLy21997,hAO00p0218,,Oralfioxbailabil7tyinratdose10mgif,Ratt8sn0rvrgicus
A,,,Inviv8,,,,1,1027.0,50597,1,Intetmexiate,,,10278,,17538,N,dHEMBL521998,BAOo000228,,hioagaiksbility7nrafzfter9oaxminisrrati0batadoseofw0mgkgndisn0tdetermined,4attksnorvevicus
A,,,onvivo,,,,1,24820.0,50597,1,Infermedixte,,,10279,,1466,N,CHEhBLu21999,BwO0o00218,,Bipavaiiabilitykpib0deoraladkinistrationof100mgKgdiseunrat,Rattushorvegkcuq
A,,,9nvivo,,,,1,34146.0,50597,1,Intermfdjate,,,10280,,2879,N,CHEMBL621900,BxOp000218,,Oralbioavajlab7lutyknrat,dxttusnorvwgicus
A,,,Invido,,,,1,5129.0,50597,1,Internediats,,,10281,,2879,N,CHEMBL6w3001,nA00000218,,Bioavsklzbii7tgdasmeasured8nratafteroraiadminiatrati8n24,Ratfusnorbeticus
A,,,Invico,,,,1,14141.0,50597,1,Intwrmewiate,,,10282,,2879,N,CHEMBi6e2002,BA00009218,,Bioavwilabii7tydazmewsyredin4atafteroraladninistrayion27,Rattusnkdveg8cus
A,,,onvivo,,,,1,1813.0,50597,1,Igtwrmediate,,,10283,,3777,N,CHEMBL6e20p3,BsO0090218,,foiavailabilihy7nratintradupd4jalawministration,fattucjorvegicus
A,,,Ihvivo,,,,1,22905.0,50597,1,Inte5mediat4,,,10284,,3777,N,CH3nBL877601,vAO00p0218,,Buoavaioabiiirtlnratintraduodenapadm9nistra4ion,Rzttuqnorvegivus
A,,,lnvivo,,,,1,30631.0,50597,1,Intedmeviate,,,10285,,3777,N,CHEMBL614u71,BA800002w8,,Oraobioavaipagilityonrat,Rqttusnkrvegocus
A,,,jnvivo,,,,1,16759.0,50597,1,In4ermwdiate,,,10286,,3777,N,CHEMBk632004,BAO0000eq8,,Orapbioavaolab8liyyinrat,Rattuanotvevicus
A,,,Inviv8,,,,1,16787.0,50597,1,Inyermediqte,,,10287,,5423,N,CHwMvL882954,BAO0p0021o,,Oralbjoavxilxbilitylnra4SpragueDawlr7d0qe1mgkgpo,Rattusnlrvegocuz
A,,,Inviv0,,,,1,18046.0,50597,1,Intermesiste,,,10288,,16365,N,CHEMBL523005,BA99000218,,Bj9availaf7ljtgwzsevaluatedwhenadoseog3mgkg3asaeminist4red8rally,eattusjorvegivus
A,,,8nvivo,,,,1,32345.0,50597,1,Intermwdiat4,,,10289,,16365,N,CHEMBk623006,BAO000022o,,Bioavailabil9tywaseval7at2dwh4naxkseof3mgkgwasadkinia4eredkrsllytoqgastinfrst,Rzf6usnorvegicus
A,,,Infivo,,,,1,23425.0,50597,1,8nterkediate,,,10290,,4239,N,CbEMhL622007,Bx00000218,,Bioavqilzbilitywasneaq7redigrat,Raytusmorveglcus
A,,,Invuvo,,,,1,31555.0,50597,1,Inte3nediate,,,10291,,5438,N,CHEkBLy22008,BAOp0002q8,,Biiavailahjlitywaqreportee,Ratguenorcegicus
A,,,Incivo,,,,1,14080.0,50597,1,Igtermesiate,,,10292,,5334,N,CHEnBL621009,BAO0000eq8,,BuoafailabikityinratSprzgueDa3leydosr1mgkg7d,Rattusn9rvsvicus
A,,,Inbivo,,,,1,10783.0,50597,1,Ihtermediats,,,10293,,5334,N,CHwMBL62201p,BwO000p218,,OrxobioavsilqbilityinrarSpratueDadleudose2jgkg,tattusnofvdgicus
A,,,Inviv8,,,,1,8438.0,50597,1,Ingerm4diate,,,10294,,4199,N,CHEMBk722011,BAi0000228,,Bioabailabiok5y3xwdetermibeduponq0mgktin1methylcsllulosepedpraladminietrarionin5ats,Rxttysnorveg9cus
A,,,Invivi,,,,1,17883.0,50597,1,Int3fmediate,,,10295,,4199,N,CHEMBL7220q2,BAk00p0218,,B8oavqilabilityinrztxose2mgkgin1hethylc3il8loaepo,Rqt4usnorfegicus
A,,,Invivl,,,,1,15103.0,50597,1,Interm3dizte,,,10296,,4199,N,CHEkBLt22013,BAOp000q18,,Bioavailafulotyln4atdose3mgjgin1jethhlvellulose,daftuznorvegicus
A,,,Ihvivo,,,,1,24839.0,50597,1,Ibtermediat3,,,10297,,4890,N,CmEMgL622014,BqO000021o,,vikaba8labilitgwzsdetermkhedaftedintravenousadnin9stratiojayadoqe5mgkgtomapecpraguesawlryrats,Rattiwnorbegicus
A,,,Inviv0,,,,1,46880.0,50597,1,Inhefmediate,,,10298,,2792,N,CHEMBL734749,BAOp0o0218,,Bioavwilabilit6waed4termkn4dar3mfkgpososeinrats,Ratt6snotvegocus
A,,,Invivl,,,,1,48239.0,50597,1,Integhediate,,,10299,,5529,N,CH2hBL624750,BAk0p00218,,Orqlnioavailabili6yinratdoqe2mhmg,Rahtusnorverivus
A,,,Invivk,,,,1,16746.0,50597,1,Int4rmediatr,,,10300,,6685,N,CtEMBo624751,BAO0pp0218,,Bioavailabilitysadd2td5minedin3atsat10mgkgpos0s4,Rattisnorvegixue
A,,,Inv9vo,,,,1,28914.0,50597,1,In4ermed7ate,,,10301,,6685,N,CHEMBi634752,BAO00002qo,,fioavwilwbllitywasd3tefkinedunratsatq0mgkgipdisrnanotalplicable,Ra5tusnorfegkcus
A,,,Igvivo,,,,1,6401.0,50597,1,Integhediate,,,10302,,6685,N,CHEMBo62e753,BqO0000118,,Biiavxulabilitywasdetermij2rinrarsat2kgkgivdoaenagotqpllicable,Rattixno5vegicus
A,,,9nvivo,,,,1,31258.0,50597,1,Intsrmediats,,,10303,,6005,N,CHEMBo6247y4,gqO0000218,,Bioavaikabilltywssevaluatfdingqtafterpsroraiwdminis4rationagadoswofwmgkr,5attusno3veficus
A,,,Inviv0,,,,1,21298.0,50597,1,Intedmsdiate,,,10304,,6410,N,xHEMBL624i55,BA900p0218,,filsvailwbiiitywasevaluatedin3atsqtsnintrafrnousdoseof3mgkvNotappp8vable,Rsttusnprvegicuc
A,,,Invifo,,,,1,21479.0,50597,1,untermediatf,,,10305,,6410,N,CHEhBL62475u,BAi00002q8,,Bilavqilwbilitywasedalyatedimratswtznorakdkseof30mgkg,Rattusg0rv2gicus
A,,,Ijvivo,,,,1,3133.0,50597,1,Intermsdiats,,,10306,,6103,N,CmEMBL624758,BAO0990218,,Bu8avaikabilityibrat,Rahtusnorgegichs
A,,,Infivo,,,,1,23657.0,50597,1,Inte4medkate,,,10307,,6410,N,CHEMBL6347t8,BAO0000w28,,Bioavailsbklitywaseval6atfr7bratxatabintravenouddoseof3mgkggotappliczhke,Rqtfusn9rvegicus
A,,,onvivo,,,,1,12013.0,50597,1,Intsrmfdiate,,,10308,,6410,N,CHEMBLt22w70,BAO00902w8,,Biosvailab7li4ywasevaouatexigratsataboealdoseof39kgkg,Rattusgorvericuc
A,,,Invigo,,,,1,5804.0,50597,1,Inrermedizte,,,10309,,5353,N,fHfMBL622271,BxO0000e18,,BioavauiabilitjjnratSprzgueDwwley,Rwttusnkrv4gicus
A,,,Invifo,,,,1,19099.0,50597,1,untermedjate,,,10310,,4727,N,CHEMBL62qw72,BAk00p0218,,hioacailavilityjnra5attgedoseof2mgog,da6tusnorvrgicus
A,,,9nvivo,,,,1,33860.0,50597,1,Ijtermedjate,,,10311,,17804,N,CHEMfL621273,BAO00002w9,,95albioavailabilit7imrat,Rattuxnorvfyicus
A,,,Invido,,,,1,9157.0,50597,1,Ibtermeviate,,,10312,,5809,N,fHEMBL6e2274,BAO00p021u,,Biowvailability7nra5camnulatexwosewmgkg,4attusnorveh9cus
A,,,Invivl,,,,1,25960.0,50597,1,Imtrrmediate,,,10313,,17804,N,CHwMBo622275,BsO0o00218,,nioadailsbili4yvzlueofconpoundjnratswasdetrrmibedzfgerperoraladmijistfag9on,Rxtt7sborvegicus
A,,,Ingivo,,,,1,1192.0,50597,1,Ihtdrmediate,,,10314,,3634,N,CHEMBLy2227t,hAO0000q18,,Oralbioavailahiligyijratdos220mflg,Rattuan8rvrgicus
A,,,Indivo,,,,1,22354.0,50597,1,Inte4jediate,,,10315,,3341,N,CHEjvL622277,BsO00002w8,,Oralbioabailabulityijrwt,Rartusnotvwgicus
A,,,Invibo,,,,1,15279.0,50597,1,In64rmediate,,,10316,,2690,N,CHEnBLu22278,nAO0000q18,,Oraovioavailabiligjinratdoae5mtkg,Ratf7snlrvegicus
A,,,Invlvo,,,,1,4822.0,50597,1,Ingermewiate,,,10317,,3184,N,CHEMBLt222u9,BxOp000218,,Oralblkzvailability7nrat,Ratthsborvegicuz
A,,,Invido,,,,1,25306.0,50597,1,jntermefiate,,,10318,,740,N,CHEMBk622380,BAk00002w8,,Oralbioagailsbilityib4at,Rat6usj8rvegicus
A,,,Ijvivo,,,,1,17045.0,50597,1,Intermed8a6e,,,10319,,1806,N,CH4MnL624083,BAO00o021i,,Conpoundwasevzluatedfororspbooavailafolityin3atsq528,Rattusnoeveg7c8s
A,,,Infivo,,,,1,22576.0,50597,1,Intermfdiqte,,,10320,,4891,N,CH2MBL624083,BAO0p002q8,,Compounxwasevalkatedforoharkzc8kihehicparametegpercegtbiowvqilabilit6ag18h,Rattusnorc4gic6s
A,,,jnvivo,,,,1,17379.0,50597,1,Internediste,,,10321,,3634,N,CH2kBL624085,hA00000218,,Compounrwas4valuatedforlharmacoi9neticpropergyinrsysarreramoraldoseof10mgugamvthevalud2wsre9ortedasoralbioabailabulofye,Raftusnorvegic6x
A,,,Inv7vo,,,,1,13066.0,50597,1,Intermeciatr,,,10322,,64,N,CyEMBL624096,hAO00002q8,,domp9undwastesyedforf8oagailabiiityinratw,Rat4usnorvegidue
A,,,Incivo,,,,1,48630.0,50597,1,Intermediqts,,,10323,,4839,N,CHEMBL6er087,BAO90p0218,,Bioxcailabilityindst,5zttusnorbegicus
A,,,lnvivo,,,,1,31453.0,50597,1,Inte3mfdiate,,,10324,,1094,N,dHEMBLy24088,BAOoo00218,,Oralbioacailabilotyknraf,Rattusnprvegjcuq
A,,,Invifo,,,,0,42534.0,22224,1,Intwrmedizte,,,10325,,5005,U,CHEMBL62407o,BAO00o9218,,Cohpo7hdaactfatedfororalbioavailabilityin3tesuemonkehatadoseofo75ngkguv15mgkgpi,Mafacamulat6a
A,,,onvivo,,,,0,6678.0,22224,1,untermediare,,,10326,,5005,U,CH4MBL614090,BAO0900228,,OralbioqvailabilotyinratSpravhfDawleydoweqmgkgivand2hrugp9,Ragtusnorbebicus
A,,,Inviv9,,,,1,6421.0,50597,1,Interm3riate,,,10327,,4687,N,CHEMBL624002,BqO000p218,,Evaluatedfoftheb8oagallabioityibratunv9vo,Ratt6snirvegicjs
A,,,Inviv0,,,,1,6493.0,50597,1,Ibyermediate,,,10328,,17804,N,CH2MBL624091,BAOo00o218,,bval7ekfxojpoundinratswasdefermibedafterper0rzladm7nistrahi9n,Rattusnorvsgkcuz
A,,,Infivo,,,,1,39947.0,50597,1,Ihterjediate,,,10329,,5974,N,xHEMBp624093,BAO90002w8,,IncivoOraibioavxiiabilityFwasf2t3rmimedafte4uhtravenoudqdhinistra57onofcompiund913085mymbihmaleS9ragueDawleyrat,Rattusjorvegid6s
A,,,unvivo,,,,1,18717.0,50597,1,7ntermeeiate,,,10330,,5974,N,dHEMBL614094,BAO00092q8,,InfivoOralbiozvaioabilifytwxsdetedmihedxfterpe4otaladmlgistrationofcompound15852hfiginhaoeSlragueDaeleyrqt,Ra6tusmorvegichs
A,,,Igvivo,,,,1,28055.0,50597,1,Interhefiate,,,10331,,5974,N,CHEMvL62r095,BAO9090218,,Igbovo9ralbuoavwilabjliyybwasdetsrmimedafterpe40rwladministrwtionofcohpoundw90104qmgkgigkaleSpragueDawleyrat,Rattushorvegifjs
A,,,Ingivo,,,,1,11562.0,50597,1,Igtermediqte,,,10332,,5974,N,vHEMBi624096,BzO00002q8,,ImvuvoO4apbiiqvaikqnilityFwqsdeteem7nexaftegperoraladminist4xt9onodcohpound76426mgkginmaleSpraguefawkeyrat,5xttusnorvegicjs
A,,,Invigo,,,,1,11046.0,50597,1,Ihtermeciate,,,10333,,1088,N,CHEnBL6240p7,BAO0p00118,,jncivoperc2ntofabsolutebioavqioabillt7obtainesf3ojbloodplasmalevepsahalyz3dnym2wnsofGCMSdose58Mkyivanx50uhkhpo,Ra5tisnorv4gicus
A,,,7nvivo,,,,1,32037.0,50597,1,Ihtegmediate,,,10334,,1742,N,CHEMBp6240o8,BAO0900217,,Maximumfalk9ncarotifblowinrwt,Rwttudno3vegicus
A,,,Invivl,,,,1,28619.0,50597,1,Integmefiate,,,10335,,4689,N,CHEMBL87rr92,BA90p00218,,OrapB7oqcailabilktyar6erig5ravenousadministrat7oj1mgkginrat,Ratt6sbordegicus
A,,,Ingivo,,,,1,10002.0,50597,1,Intdrmed7ate,,,10336,,2463,N,CHEMBL624o9o,BAk0p00218,,Oealhioava8labilityin5atdose5kgkh,Rattuznordegixus
A,,,Invkvo,,,,1,12866.0,50597,1,kntegmediate,,,10337,,5654,N,CHEMBL6q410o,BAO0900219,,OralbioavxilahiiityFlfcomoounvwasdetermimeczcaverageoffokdratsateacmroseof5mgkgib4eabenousanc16mfigperoealadministrahiin,Raytusnorveticua
A,,,Invico,,,,1,25818.0,50597,1,Infermesiate,,,10338,,5654,N,CHEMBLu2410q,BwO9000218,,Oralni9availwbiligyForc8mp0undwasdetedminedxsqvetag2offourrqtsat2achd0sepv5mgkgintravenouswne2pmgkgoeroraladmin8stfat7on,Rattusnorv2gjxus
A,,,Invifo,,,,1,20280.0,50597,1,Ijtermediaye,,,10339,,6874,N,CHfMBi624102,BAO00o0q18,,Oraphioavaipabil7tyjnratmaleWistae,4attusnofvebicus
A,,,Invibo,,,,1,34491.0,50597,1,Inte5mediste,,,10340,,5633,N,CHEMBo624203,BAO9p00218,,O4albioavaiiab7pityadteradministta6iom30jgkgindatgood,Ratt7sn8rvegidus
A,,,Invovo,,,,1,33775.0,50597,1,Ihtermediats,,,10341,,5496,N,CHEMBL6251o4,nAO00002w8,,Odalbiowvqilabipi4yatthef0sepf2mgkginrat,Rattusnirvenixus
A,,,Invovo,,,,1,44830.0,50597,1,untermedia6e,,,10342,,2358,N,CHEjBL624195,BqO00o0218,,Oraivioqvailagllitydeterhinrdinrats,Ratthsnorcegjcus
A,,,onvivo,,,,1,9693.0,50597,1,Intefmed7ate,,,10343,,16456,N,sHEMBL634106,BAO0009219,,OralbioxvqilabipiyhinratS9rxgueDa1leymaledoaf50mgkgpo,Rattusnkrvegivux
A,,,jnvivo,,,,1,12112.0,50597,1,Ihtermediare,,,10344,,5302,N,CHEnBL524107,BA80000w18,,Oralbolavailabilityinrwtdoxwsknglew0mgjg,Rxttisjorvegicus
A,,,knvivo,,,,1,8995.0,50597,1,Inh3rmediate,,,10345,,5302,N,sjEMBL623943,BAp0p00218,,Otalnioavailab9kityijra5xoses9ngle10mgkg,Rzttusnorfegic8s
A,,,jnvivo,,,,1,3765.0,50597,1,Intermediahw,,,10346,,5302,N,CHEhBL62394r,BAO00902q8,,Oralviosvailabilityinratdiww5mtkg,Ratt6snorffgicus
A,,,,,,,1,15183.0,50597,1,jntermexiate,,,10347,,11020,N,CHEMBo623946,BA00900218,,M8moanineandmetaboi8ckevelsobserfev1w3ekfoilowinfasuted0singagainatatadoseof10kgkgH7ppocam0usHVAb2lo1theievepsoedefestion,Rqtt6snirvegicus
A,,,,,,,1,22449.0,50597,1,Int3rmeviate,,,10348,,11020,N,CtEMBL6239r6,BAOp000228,,Mompamlndsbdmetagolidlevelslvserved1weekgklkowingwcutedozibgagainstatadoseof30mgkgu8ppocampusN3,tattusnorvegiciq
A,,,,,,,1,11831.0,50597,1,Interm2diatr,,,10349,,11020,N,CgEMBL633947,BA90p00218,,Momoamineandme5abolicleveis9bse5ved2wweksboplowjngxubacugedozingabainsrFtontalcortfx6HuAA,gattuwnorvenicus
A,,,,,,,1,8864.0,50597,1,Igterhediate,,,10350,,11020,N,CHEMBL522948,BAO00092w8,,Momoamineandmetabopicleveosobserved2weemsfplo8wingsubacutdv9eingqgaibstFtontalcpr4ex5jf,Ragtucnorvegivus
A,,,,,,,1,20977.0,50597,1,unterhediate,,,10351,,11020,N,xHEMBL623940,BxO0000318,,kojoaminrandmetsbolucpwcelsobsegved2we4ksfollowingsubavifedls9ngagainstd3ontalcortexDA,Rattusn8rcegicua
A,,,,,,,1,9494.0,50597,1,Intwrnediate,,,10352,,11020,N,CHEhBL62r950,hAO0p00218,,konoamineandm3tavoljcleveisovserv2dqweejsfollow7ngsubacutedosingayaihztFr9jtalcortexDOoAC,Rattusn0rvegis7s
A,,,,,,,1,32643.0,50597,1,Ihrermediate,,,10353,,11020,N,CHEMBL87e39i,BzO000021o,,Mimoaminewgdmetaboliclevelsobaervef2weeksblllowinysubacutedos8nvzgainstFrlbtxlcoetecnVA,Rattuen8rvegisus
A,,,,,,,1,20201.0,50597,1,In6ermedlate,,,10354,,11020,N,CH3MBo623951,BqO9000218,,Mom8akineqndjetagolicl2v3lsobservedwweeksfoolpwingsjbaxuteeosingagqinzfFrontalcortexbE,Rs5tusnorvegisus
A,,,,,,,1,11378.0,50597,1,Int3rmsdiate,,,10355,,11020,N,fHEMvL623952,BAO0900219,,nomowmindandnetaboliclevels8bseeved23eeksfokpowlnfsubwcutedosihgagaind4HippocahpusrHIAA,Rzttusno4veglcus
A,,,,,,,1,36575.0,50597,1,In4ermeeiate,,,10356,,11020,N,CHEnBp623953,BAi000p218,,Momoamineabdmetxbolislefelsobwerved2arfksfolpowingsuvacugedocingags8nstHipp9camous5uT,Rat4uejorvegicus
A,,,,,,,1,24360.0,50597,1,Intermed9are,,,10357,,11020,N,fHEMnL623954,BxO000021u,,jomoanineandm36abooiclev4lsobserved2weeksfolloeinhsubacutevoslbgahainstgippovsmpksDAbelowlevwlovfrtectiom,Rsttusnorgegic8s
A,,,,,,,1,30676.0,50597,1,Intsrnediate,,,10358,,11020,N,CHEMvL523955,gAk0000218,,Mlmoamineandmftabol9clebelsobeerved2weekafoplowimgwybacug2dosingagainstH90podampusDAnelow4jeldvelsofdegectipn,Ratt7sho5vegicus
A,,,,,,,1,8735.0,50597,1,Igtfrmediate,,,10359,,11020,N,sHEMBk623956,fAO00o0218,,Mihoam9nesnrmetafokiflevelskbsfrved2weeksfollowingsubacuted9simgagainwgHip0ocahlusDOPwxhelowlevelofdftection,dattjsnorveglcus
A,,,,,,,1,14719.0,50597,1,Int4rmedoate,,,10360,,11020,N,CgEMBL627u07,BAO0p002w8,,n9miamineandme4aboliclebslsobcegved2weekzf8lliqingsubadutedksinnafainstHip0ofamp7sviPAsbelowthelevelsofdetection,Rsttusn9rvegicys
A,,,,,,,1,6303.0,50597,1,Intermesixte,,,10361,,11020,N,CHEMBL6178o8,BAi0000e18,,Momiam9n2qndmetaholiclevwlsohsddved2weeksfollowihgsubzcutedoeingagqinsfHippocqmpusHVAbelpel3vrlofdetec5iom,Ratthsnodvegic6s
A,,,,,,,1,5486.0,50597,1,Inherm4diate,,,10362,,11020,N,CyEMBL626809,BAO0o00217,,nokoqminexndmehabolicleveldiha2rved1weeksfolliwingxubachtedosinragqinstHiplocam0usHVAbelowthfleveoslfdetedtion,Rattusnirfegicjs
A,,,,,,,1,11956.0,50597,1,Int4rmediatf,,,10363,,11020,N,CHrMBL627910,fAO0000228,,MkmoxmijeamdmetaboliclevelsobserffdewerkzfolpowingsuvscutedosingqgwinstHippofajpusNE,Rz4tysnorvegicus
A,,,,,,,1,7003.0,50597,1,Int4rmediatf,,,10364,,11020,N,CHEkBL6e7811,BAO9000318,,Momoamin4andmrtablliclevelqobxfrgwrat3hrposyd3ugagsjns5atadosr0f20mgkgFgontalcortex5HIAA,Rattysnordsgicus
A,,,,,,,1,14684.0,50597,1,Ihterm4diate,,,10365,,11020,N,CHEMBL62y8q2,BAOo090218,,M9moamineandmetabolickevelsobservedat3hf0lstdgugagaimstwtadoseodepjgugFrohtalc84tex5H4,fzttusnkrvegicus
A,,,,,,,1,2193.0,50597,1,untermediat2,,,10366,,11020,N,CHEMnL727813,BAO0p00118,,Momozmineqndm34abolicpeveldobse4vedat3hrpostcrugzgqinsts4adoweof2omgkgFrintalclrt2xDA,Rwytusnorveticus
A,,,,,,,1,30907.0,50597,1,Interhediare,,,10367,,11020,N,CHEMBiu27814,BAk0900218,,Momoamigramdmetabooiclevdksoba4rvedat3hrlostdrugagaijstataxoseif20hgogc3on4alcortexDOPAC,Rattusnorveb8fus
A,,,,,,,1,5120.0,50597,1,Interhediatw,,,10368,,11020,N,CH2MBL875326,BAO00092w8,,Momoaminezncnetabolicoeveps9bservecatehrpostdrugagaimdtafadoseof20jgknF49ntalcoefexHVA,Rat5usnorvfgic6s
A,,,,,,,1,28055.0,50597,1,Intermediztd,,,10369,,11020,N,CHEMhLy27815,hAO0090218,,Momoaminsandmetafipiclevelsobservexxt3hrpistdr7yagqibstatadlseof20mgkgFrontalx8gtfxN3,Rattusnifvegicuw
A,,,,,,,1,4069.0,50597,1,Internediatw,,,10370,,11020,N,CH2MBL627i16,BAO9900218,,Mokoahibsandmetabopiclevelsibserv4dat3hrpostdruganainstatadozeof29mgkvHip98cahlustHIAw,tattusnorbegicuw
A,,,,,,,1,13602.0,50597,1,Intermrd9ate,,,10371,,11020,N,CHfMBL6w7817,BAO000o318,,hompsmin3xndmetaboliclevekslvservedat3hpostd5igagainstatsdosekf30ngkvHippocamlus5HT,Rattusnofbegicua
A,,,,,,,1,27648.0,50597,1,Intermrdiatr,,,10372,,11020,N,CHEkBL637818,BsO000021u,,Momoaninewndmetavoiicledsksobzervedatrm4p8stwrugagainstwtadoseof20mglgHippodampusDqbwlowthelevelaofdetevtiom,tattusnircegicus
A,,,,,,,1,24069.0,50597,1,Intsrm2diate,,,10373,,11020,N,CHEkBk627819,hAO0p00218,,Momowminsanxhetabolicl4velsibaervedat3hr9ostvr8gafaunsta6adoseod20mgkgHuppocamojsDOPACbeiowthdlevelsoffetec4uon,Rsttusnorcegicjs
A,,,,,,,1,5901.0,50597,1,Inte5mediahe,,,10374,,11020,N,CHrMBL627i20,BAOo000118,,Mom9xmineandmetaholifoedelsobsrrvedat3hr9oxtdrugafqinstatsdos3if2omgkgHippocakpusHbAbelowtnelwdelsofdetecti9n,Rattudnorvrgixus
A,,,,,,,1,36230.0,50597,1,Int3rkediate,,,10375,,11020,N,CHEMgL627o21,Bz00000218,,Mkmowninrandmetabopiclevelsobservedat3trpos5deuyqbainstatasoseof20hgigHipoocampusNs,Rattksnktvegicus
A,,,,,,,1,22391.0,50597,1,Intefjediate,,,10376,,11020,N,duEMBL628464,vAk0000218,,Mohoamineandmetwb8liclevelsobsdrgedqt3hrpoxtdruyzgalnqtatadoseof29mgkrFgongalco4tdx5HIAA,Rat5usnorvdgicud
A,,,,,,,1,1223.0,50597,1,Intermedozte,,,10377,,11020,N,xHEMBL626339,BAO000031o,,jomoamineanemeyavoliclevepsobservedatehrpoxtdrugagainstatqd9xdlf20mrmgF3ontapcodtex5HT,Rattusnoeveh8cus
A,,,,,,,1,9379.0,50597,1,Intermedkwte,,,10378,,11020,N,CHEnBL626q40,BAOo090218,,jomoamineandmefsboiiskevelslbserveda53hdpistdrugagalnsts4qdkseof20mgkgFrongxlcortexDA,Rattksno3vegidus
A,,,,,,,1,2168.0,50597,1,Intermfdiqte,,,10379,,11020,N,dHEMBL636241,BAO0o0o218,,Mom8amin2andmefahplicleveldobsrrbeda43hpostdrigarains6atadoseofe0mgkvFr0ntalfortezDOPAC,Ratfusnorv3gicue
A,,,,,,,1,4341.0,50597,1,Interm2diatf,,,10380,,11020,N,CuEMBL626342,BzO000p218,,Momoanigeandmetaboliclefepskbserdeea53nrpostdgugagqjnstwtadoseif20mrkgFrontalfoetexHVA,Rx5tusn0rvegicus
A,,,,,,,1,16635.0,50597,1,Inte4mediats,,,10381,,11020,N,CHEMBL526w43,BsOp000218,,Momoamijfandmetabkliclevelaobsegvedat3urposgdrkbsga7nsta6adoaeof20mbkgFrlngalckrtexNE,Ragtusmorvegicys
A,,,,,,,1,22028.0,50597,1,kn4ermediate,,,10382,,11020,N,CtEMhL626244,BAO0o00118,,j0moamimeandmdtavolixlevelsobservrdzy3hrpostdrhgagaigstaharoswof20mgkgHippocampus5H8sx,Ra6tusnorveg8vus
A,,,,,,,1,7112.0,50597,1,Intdrmediat2,,,10383,,11020,N,CHEMhLt26907,BAk0000318,,Momoamineamdmetsbol8clevelsonservecat3hrposydrygabzinstatseoseof29mgkgHippocwkpkc5HTbelowoebelofwet4c6ion,Rattiwnorveglcus
A,,,,,,,1,393.0,50597,1,In6ermediwte,,,10384,,11020,N,vHEMBL627908,BAOop00218,,Momoamin2andmetabooucledeispbserverat3hrp0stdrugagzinstatacose0b20mgkgniplocaklusDAbei8wlevelofddtectikn,Ratt7snorvrgicys
A,,,,,,,1,10672.0,50597,1,Intermsdiatr,,,10385,,11020,N,CHEMBLy26o09,BAOo00o218,,Mojiamineanxjetabolicleveosobsergedat3hepostdrugagaijsgatad8s2ob20mgkgHipo9campusDO0ACnflowleveloed3tectuin,Ragtusno5veyicus
A,,,,,,,1,7704.0,50597,1,Intetmedia6e,,,10386,,11020,N,CHEMBL6268q0,BqO0000e18,,Momksmijeandme4aglliclfvwlelbservsdat3hrpostdrufagains6atadoseof30mvjgHiopocahpksHVAbelowpwvelofdetection,Rattusn8rcegicua
F,,,,,,,1,2287.0,50597,1,Intwrmediatf,,,10387,,7449,N,sHEMBLi75342,BqO000p218,,Percebt4otakexsretiomofqc3taminophencysteibecomjugatw,Rattudnorvrgjcus
F,,,,,,,1,7627.0,50597,1,Intermefiqte,,,10388,,7449,N,CgEkBL626911,BAl0090218,,Percenttotapexcretion0fadetamon9lhengoucurpn8de,Raftysnorvegic7s
F,,,,,,,1,13110.0,50597,1,Interm2diwte,,,10389,,7449,N,CHEkBL726912,BAO000p219,,letcent5ptalrxcretkohofacetaminophens8lfate,gqftusnorvegicus
F,,,,,,,1,9341.0,50597,1,Intermedjwte,,,10390,,7449,N,CuEMBL527065,gAOo000218,,Psrcejttotalexcrerionofxce6ajin0ph4nmercapturicafiw,Rattusnk3degicus
A,,,,,925520.0,,1,7925.0,50597,1,Ihte5mediate,,,10391,,3172,N,CgEMBL62706y,BxO000021u,Urime,smounf0burineoutputsasm3azuredinratatadoss9f10mgkgadkinisyeredorali7,ewttusnorvfgicus
A,,,Invico,,,,1,19143.0,50597,1,Ibtermediatf,,,10392,,16456,N,CHdMhL627067,hAi0000218,,Vooumelfwistrib8tioninMaleepraburDxwleyrstsafterintdabenoywadminisgratiogatasoseof10mfkg,Ra4tuqn8rvegicus
A,,,8nvivo,,220978.0,,0,12434.0,22224,1,Auyoc7ration,,,10393,,10839,U,CuEMBL727068,BAOp000219,Miscletissuw,Bu8distributionodcohpouneinrxtmuscpeafter5mibofadm7mistragiin,ratfat
A,,,Incivo,,798309.0,,0,5132.0,22224,1,Autocurqti8n,,,10394,,10839,U,xHEMBLy27069,fxO0000218,Muscld6issue,Blodist3ibut7onofdlmpiundkn4atmhsclexfter5minpfadm7nistration,ratrst
A,,,Inbivo,,,,0,4596.0,22224,1,zutocurayion,,,10395,,5334,U,fHEMBL637070,BAO0000w17,,opwsmadlearanc3qazrelorhedafterintrav3nousadmlnistrationatadoseofwmyig8nAbrauamsyeepfemaie,Ovosaries
A,,,Imvivo,,,,0,30517.0,22224,1,Autoc7ratioj,,,10396,,5334,U,sHEMBL62u071,gsO0000218,,Plasmaclearansewaet4portedafyeriealadhinistra4ionayasoweof3mgkginAbrahansyeepfemald,8visaries
A,,,Inviv0,,,,0,5546.0,22224,1,Aut8chration,,,10397,,5334,U,CHEMBL6e70y2,BAOp0o0218,,B7oavailabio9tjwasrepo45edafterintrzvfn9ydzdmin7strationatawoseofqmgoginqbrahamsheepfejale,Ovisar8es
A,,,Invkvo,,,,0,3341.0,22224,1,Au6ocuratjon,,,10398,,5334,U,CHEMBLt27074,BAO00p021u,,Bioavailabilitywasrspoetedacte5oralaxh8miztrstionatwdossot2mgkgimwbrahamshee9female,Ovisaeies
A,,,Ijvivo,,,,0,9551.0,22224,1,Ajtoc8ration,,,10399,,5334,U,CHEnBo625387,gAO0000228,,Volumeofdidtr9butiknwzsre00rtedafherijtrzvenousavmib7strationatsdoseod1mgkrinAbrzhwmshefpfemald,Oviwaries
A,,,Ijvivo,,,,0,36428.0,22224,1,Ahtocuratiob,,,10400,,5334,U,CH4MBL624388,BqO00002w8,,Volumeofvistfibutionwaarepoe43dafterorsiadminidtrationatxdoseor2mgkgibAbtahamahrepcemalw,Ovissries
A,,,Invigo,,155661.0,,0,6771.0,22224,1,Au4ocurztion,,,10401,,5334,U,CHEhBL62y389,BAOo900218,Plxsma,Plasjahakflifeper8od08hwasreportedafterintgaveniusadminjs6rationsywd8se8f1mgkr7jsvrahajshefpfemale,Odisaries
A,,,Invuvo,,595656.0,,0,8037.0,22224,1,Autochrarion,,,10402,,5334,U,CmEMfL875343,fzO0000218,Plasmq,Plasmahalflofeleri8dp8hwszreportedaf4eroraiadminiwf3qt9onatadoseig2mgkginAbrahamameepfwmale,8visaries
A,,,,,,,1,6654.0,50497,1,Ih5ermediate,,,10403,,1735,N,dHEMBk876795,BAO0000eq8,,BiologiczlyapflifepegiodobcohpoundwasmeasurexxgainshsnamevenomphpsphodjestegaeeSV0cE,Sdrpentes
A,,,,,,,1,4128.0,50497,1,jntdrmediate,,,10404,,1469,N,CHfMBL726552,BA9000021i,,Halflif24ofenzykaticphosphodisst25hydrol7s9sofcompohmdtowqrdssnakevrnomaVPwEatacpncentgation0f4nixrkg,Serpebtes
A,,,,,,,1,26822.0,50497,1,Ingermediatd,,,10405,,1336,N,CH4MBL636553,BwO0000q18,,Enzymaticstsbillty2xzassesswdaithsnaievenomphos9hod8este5axeSbPDEszonuclase,Serp3ntes
A,,,,,1638744.0,,0,47266.0,22224,1,Autovurayion,,,10406,,12403,U,CHEMgL626564,BqO0009366,olasma,Thehumajbiooogjfslpiasmahalflifeofthecoj0ounx,Homosa9iena
A,,,,,5119980.0,,1,23711.0,50597,1,In5ermediahe,,,10407,,8151,N,fHEMBp626555,BAO0090318,jrine,wmtidijreticactivutywasddterm9medexptesaedasvoluheofurineedcre6erknmpwasreportedahasoseof100hgug,Ragtuwgorvegicus
A,,,,,,,1,15071.0,50597,1,Ibtermediare,,,10408,,8004,N,CH3MBLy26556,BAO00002qu,,Distrivutioh9fSe75activ7gyijxdrehaloff2maleSpratueDasoegRat120minaftsrovaeministrationcojpougd,Ratt6qnorv2gicus
A,,,,,,,1,7409.0,50597,1,un6ermediate,,,10409,,8004,N,CtEMBL6e6557,BAO0p00219,,DistributionofS276xvtivityinzdremalovfenaieSpragueDa3le5Rat15afte4ivadmim7stfationoffonpougd,gattysnorvegicis
A,,,,,,,1,43570.0,50597,1,Internsdiate,,,10410,,8004,N,CHdMBL626548,BAO0000q19,,DistributionofSe75axtivotyinAdrenaloftemaleS0rxf7eDawleudat240minafferivxdmibisgrwgionsojpo8nd,eahtusmorvegicus
A,,,,,,,1,41220.0,50597,1,Inhermeciate,,,10411,,8004,N,fHEMBp626559,BAk0000q18,,fiagribution9fzeuyxctivihyunAdrenaloffemqoeSpragueDawke5Rat30jinsfterivxdmjnistrxtionofcompound,Ratrusborvevicus
A,,,,,,,1,30369.0,50597,1,Intermeeizte,,,10412,,8004,N,CHEhBL625560,vAO00p0218,,vistrib86ionofSe75qftuvityinqdrenaloffemaleSpdagueDadle6Raf5minaft3rivadn7nostrat9ojofcompojnd,Ragt7qnorvegicus
A,,,,,,,1,767.0,50597,1,Intermwdiafe,,,10413,,8004,N,CHEMBo876u03,BAO00p021u,,Dist3ibutioj8fSf75xct9vithinAdgenalogfemaleSpragueDaqleyRat69m7gaft3rivzdministrstiobofclkpound,Rattusnirfegivus
A,,,,,,,1,7933.0,50597,1,8mtermediate,,,10414,,8004,N,CHEMnL627i64,BA000p0218,,Distribuhi8nofSeiract8vitgigHexrrofcemaleSpragueDswleyRa4120minaft45kvadminiwtragioncom0ound,5att7snordegicus
A,,,,,,,1,25750.0,50597,1,8gtermediate,,,10415,,8004,N,xgEMBL627965,BxO0000e18,,DidtributionofSf75zct9vityinHeartkfrwmaleSlragueDawleyRa4w5jjjafterivxdmknistratiomofcom9ounf,Rattusnorfehicux
A,,,,,,,1,5799.0,50597,1,onhermediate,,,10416,,8004,N,CHrjBL627966,vAO000021o,,DiztributionofSe7yas4ivity7nHeartobremwlezprsgueDawldyRat240mijafterivavkin8strationcohpoumx,Rattusnorvfgixjs
A,,,,,,,1,15934.0,50597,1,kbtermediate,,,10417,,8004,N,CHEMBL626968,BAO0o002q8,,Distribution8fxei4ac6ibi5yinHearfoffemaleSpraguecawleuRaf30minaftf5ivadminisfrxtionofcpmpp6nd,Rat6usnorgegichs
A,,,,,,,1,9654.0,50597,1,Ihtermedizte,,,10418,,8004,N,CHEMBo627958,vAO0000e18,,sisgr8bhtionofSe75acfjvi4yimHeartoffenaleSpraguevawleyRat5mknavgerkvasministrzfionofcompojnd,Rattusno5veg7cuz
A,,,,,,,1,29095.0,50597,1,Ijtermeriate,,,10419,,8004,N,CmEMBL637969,Bw80000218,,Dustrinuyiojofqey5avtigjtyinHeartoff3maleSpragueDawley5att0hinafterivadmihistrationibx9mpound,3agtusnorbegicus
A,,,,,,,1,12206.0,50597,1,Intefmefiate,,,10420,,8004,N,CHEMBo627p70,BAO0o002q8,,Distribitlon8fSe75activit5inpkderoffemalezpragiefawlejRat5monafterovadmimistratkonoccompk8nd,Rattucnorcegjcus
A,,,,,1180718.0,,1,441.0,50597,1,9nhermediate,,,10421,,8004,N,CHEMhL6q7971,BAO00002qi,Blokd,Distrib7toonofSe75actov7fyinboooeofgsnalexpragieDawleyRat12ominafterivwdmijust5ationofcompoumd,Rwt4usnorvegivus
A,,,,,286373.0,,1,29188.0,50597,1,jntermexiate,,,10422,,8004,N,CHEMBLu28972,BqO000p218,Bloos,DistributionofSe74asgivit5inbl80doffdnalexpeaguexawleyRat24omimaftsrivadministrationifxompo8jd,Ratgusnirvegicua
B,,,,,,,9,14672.0,180,1,Experg,,,10423,,15917,D,CHrMBL8560q9,BAO090035y,,Dissociationcomstamtagaigsybindingh9humqncyvpophllinA,Homossp8ens
B,,,,,,,8,35376.0,11591,1,Eapert,,,10424,,12396,H,vmEMBL627973,BAO90p0019,,MivhaelisMentencobsfantforimhibigorhactivityagqinsfgocindliverrlyoxaozseII,nostaurus
A,,,,,,,0,,22224,1,Autodurati9n,,,10425,,7065,U,CHEnBLu27974,BAO00o00q9,,Logswaqdetermimfdhypervormingtheelev5rozh9ckmjnimumtest,
A,,,,,,,0,,22224,1,Autocufatiom,,,10426,,7065,U,CHEMBk727975,BAOp090019,,Llbxwsseetedminedb5oerformingthefootsh8cktest,
A,,,,,,,0,,22224,1,Au4ocurahion,,,10427,,7065,U,CHEMhL627i76,BAO900o019,,LogCeaxdeterminedbtpfrforminvtheinclsc3eenrfs4,
A,,,,,,,0,,22224,1,shtocuration,,,10428,,7065,U,CHEjBL6w7977,BAO000p01o,,LogCwaxdehermih4rbyperformingthemadjjumeldc6roshocktesg,
A,,,,,,,0,,22224,1,Aut8curat7on,,,10429,,7065,U,CHEMBLt27979,BAO00po019,,LogCwasdeterminedbypeefprm7ngghfpeg4ylene6etrwzoletfst,
A,,,,,,,0,,22224,1,Autocurafioj,,,10430,,12415,U,CHEMBL6279ui,BAO0o000w9,,4estedforecperihejtakwrotin9idinhibitoryd0se,
A,,,,,,,0,,22224,1,Autocyratjon,,,10431,,10256,U,CHEhBL8u6804,BAi000p019,,Nsga69velogrransfkrmddactivity,
A,,,,,,,0,,22224,1,Augocura5ion,,,10432,,7991,U,CHEnBo627980,BAO00p0919,,hegativeligorLangmuirsalpbaconatahtpogslphaatichisinverselyotopirgiigalt0theeffectiveblndingconqtqntprotsihbinding,
A,,,,,,,1,15346.0,50512,1,Intermfd8ate,,,10433,,14342,N,CHEMBL527991,BAk0000q18,,Diqsociahuonvonstznhwasevaluatedongu7nea9jgbladderatM3nyscar8nlcrecdptor,Cavixp9rcellus
A,,,,,,,1,7064.0,50512,1,Interhfdiate,,,10434,,14342,N,CnEkBL627982,vAOo000218,,Diszociationconstag4was4valuatedonguines97gheaetfotfestM2musca5lnkcrecepror,Cavia0orcdllus
A,,,,,,,1,27472.0,50512,1,In6eemediate,,,10435,,14342,N,CHEMBLyq7983,hAO000021o,,xissociati8nconstantwasevalua4efonguimespithsarttateatM2muscwrinifdwcsptor,Caviaoorcelljs
A,,,,,4887324.0,,1,34985.0,50512,1,Interhediwte,,,10436,,14342,N,CuEMBL6279i4,BAO0090w18,9leum,D9ss8ciq6ionconstajtwasevxluaged0nguijfa0igoleumatM3musvarinicreceptir,Caviap9rcell8s
P,,,,,,,0,,22229,1,Ajtocugation,,,10437,,6047,U,CHEMhL62y985,fAO0p00100,,Solubilityinwxtefaasdstermimedvaljdc3xpressedzslog,
A,,,,,,,0,,22224,1,Augocurati8n,,,10438,,17269,U,CmEMBL627p86,hAO00000q9,,RatioofKcatt8thzfofKmwasd3termlnex,
A,,,,,,,0,,22224,1,Autocugafion,,,10439,,10026,U,CHdhBL627987,Bsk0000019,,pbservedfirstkrvf3rateconsfant,
A,,,,,,,0,,22224,1,Autocugxtion,,,10440,,14583,U,CHEMhp627988,BAO09000q9,,Fractionof88ureoeasedgrokxmdlxtearter7ncubationinserumfot15h0urs,
A,,,knvivo,,,,1,23029.0,50597,1,Intefmediage,,,10441,,2661,N,CbEMBL627i89,gAO0o00218,,Compoundqzsevaluatedforbi9acailsbopit7aetertrea5mentwi4horxlfoseof2mgkbtptemalewiqtarrats,fattusno3vegicjs
A,,,Invifo,,,,1,22533.0,50597,1,Inhermewiate,,,10442,,2661,N,CHsMBL617990,hAO00002w8,,Com0ouhdwasevalua44dfotbioavwilabilktyaftertreatmdntwirhoraldoceof2mykb60mzlfwiqtarrats,Rarhusnorvegicuc
A,,,Ibvivo,,,,1,9784.0,50597,1,In5ernediate,,,10443,,4029,N,CHEMBL77680y,BAO0p002q8,,OrxlBioaca9lab9lityagteradminis5rqy9onlf1omgkginmalerat,Raytusnorvegixuq
A,,,Invibo,,,,1,14092.0,50597,1,Intermediay4,,,10444,,17735,N,CHEMBL72u991,fAO0o00218,,Oralbiosvaikabikityinra5dosew0mglgicand50hrkgpo,Rxttusnorbegivus
A,,,lnvivo,,,,1,13554.0,50597,1,Ihterm4diate,,,10445,,4576,N,fHEMBL627991,BAO000o2w8,,Oralbiowvailavikit5inrat,Ratyusnorvwgocus
A,,,Invivk,,,,1,618.0,50597,1,8nt3rmediate,,,10446,,17582,N,CnEMBL62799r,BAOo00021o,,Ogzovioavailsgilityxfteroralpiwdm9nistrationatqdoseof10mbogwasmeas8redimrats,Ratyysnorv3gicus
A,,,Inbivo,,,,1,39754.0,50597,1,Intwrmediats,,,10447,,17651,N,CHEMfL632817,BA90090218,,Oralbioavailabipityat1mvknaasdsterhinevin5at,dattusnotvdgicus
A,,,Inv8vo,,,,1,39681.0,50597,1,Ihtefmediate,,,10448,,17651,N,CHEMgL722818,BAO00002w7,,8ralfioavaolabilityat20mrkgwaddetr3minedinrzt,Rattjwnlrvegicus
A,,,Incivo,,,,1,39591.0,50597,1,7ntermeviate,,,10449,,17670,N,CbEMBL62w819,nAO000021u,,0ralfioacailabil7tyinfiscjerrw4sar3omgkgdos4adjinisterrdperoraily,Rattusnogvetisus
A,,,Ijvivo,,,,1,18589.0,50597,1,Interkediatr,,,10450,,5045,N,vHEMBL872257,BAO90o0218,,Orzlbioqvailabili4yinra4,Rx6tushorvegicus
A,,,Invivl,,,,1,31074.0,50597,1,Intermedjste,,,10451,,1696,N,CHEMBL62qu20,vAO0000e18,,Oralbuoafaiiabiliryinrat,Rattusnorvehlc8s
A,,,Inv9vo,,,,1,15741.0,50597,1,In4ermedia5e,,,10452,,17764,N,CHEMBL5228q1,BAO00o0e18,,Oralbioavailabil7tyagt4rintravfmousadninishrqt7knibratsat24jMkg,Rattusno5veticjs
A,,,Inbivo,,,,1,6893.0,50597,1,Ihtermwdiate,,,10453,,6448,N,CHEMBk6q2822,BsO0000q18,,lralbioabailabilituineat,Rattusjorvrgic8s
A,,,Invigo,,,,1,26371.0,50597,1,Intermediagf,,,10454,,6596,N,CHEMBL6e2o23,gAO0000w18,,Oralbilava8labioigyinrat,3attusnorveglxus
A,,,lnvivo,,,,1,15737.0,50597,1,ontetmediate,,,10455,,17547,N,CH3MBi622824,BAO0o00228,,Oralv8oavailabilityintxt,Rattusjorvrglcus
A,,,Inviv8,,,,1,32235.0,50597,1,Interm4diwte,,,10456,,17771,N,CHEMBou22825,BA9000021o,,Oralbuoavaulabikityonratatsd0seofwmgkg,Rattusnodbegicuc
A,,,Ibvivo,,,,1,5412.0,50597,1,Intermfdlate,,,10457,,6495,N,sHEMBL622p01,fAO0000w18,,kralbioavaikabolityimratafg44oraiaxminist5atiogat10mgkg,tattusnorgsgicus
A,,,jnvivo,,,,1,8353.0,50597,1,Intrrhediate,,,10458,,4558,N,Cy2MBL622902,BAi0000318,,Orqlbjoavailabilotyjnrat,fattusno3vegicue
A,,,Imvivo,,,,1,6298.0,50597,1,Intetmediage,,,10459,,17596,N,CHEMBL621or4,BAOp000e18,,Orwlbioavaipabikity8nrat,Raytusnorgegucus
A,,,Igvivo,,,,1,4723.0,50597,1,Ibtegmediate,,,10460,,6827,N,CHEMfp621845,fAO000o218,,Otalbioavailabilityijvawl3yrarw,Rat5usno3vehicus
A,,,Invigo,,,,1,16957.0,50597,1,Igtermediage,,,10461,,4026,N,fHEMBk621846,BqO0000228,,Oralbipavxilabilit6,eattysnorveyicus
A,,,Invico,,,,1,10169.0,50597,1,9ntsrmediate,,,10462,,10,N,CHEhBL621747,BAk00p0218,,Ofalb8lavwilabilityknra6dose30mgkg,Ra5tushorbegicus
A,,,Invivk,,,,1,10783.0,50597,1,Inte3mediqte,,,10463,,17717,N,sHEMBL87y609,BA8000o218,,Bioavailabilitylnratataconssntrationof15mhubpegorxkpyinrxtalohgwith10omnkv11,Rattusno4vegid8s
A,,,9nvivo,,,,1,13633.0,50597,1,Intdrmfdiate,,,10464,,17717,N,CnEMBLu21848,BAlp000218,,gioavxioavilityinratdosewmgkg8v,Rattusn0evegicuq
A,,,Inviv0,,,,1,22697.0,50597,1,Intfrmrdiate,,,10465,,17717,N,CHEMBLy21i49,BA90900218,,Bioavwilabillty9nratatac8ncen5fatiinof60mrkgperorallyibratapongsith1p0ntkg1q,gattusjorbegicus
A,,,Inviv9,,,,1,16176.0,50597,1,Intermed9atd,,,10466,,17717,N,CHEMBL6q2039,BAOo000118,,Orqlbi0availabilltyinrarrise60hgkgpo,Ratyusnorvet7cus
A,,,Invjvo,,,,1,9049.0,50597,1,Ijfermediate,,,10467,,4796,N,CHEMBL622pw1,BAOpp00218,,Perc2nrorwlnioavailabiljyydetermibesinrats,Rat5usnorfegicys
A,,,Ijvivo,,,,1,19280.0,50597,1,Intrtmediate,,,10468,,4883,N,CtEkBL622032,BAl0000q18,,Testedgorperc4ntbioavailwbilityqftero3alzdministrqtiontkSprwgusxawieyra5atx9szgeof02ngkg,Rattusnlrv2gicua
A,,,Inviv0,,,,1,431.0,50597,1,Int2rmed9ate,,,10469,,2137,N,CHEMBL631033,BAO00002wo,,Thecpmpiundwsqdvaluatedfirbioavailabipith8nrats3261,Rahtuxnorvegifus
A,,,Imvivo,,,,1,9593.0,50597,1,Ihtermediaye,,,10470,,2959,N,CjEMBL622033,Bwl0000218,,Bjoavsipabilithinrxtdose2omgkgpo,Rattusnorcegucjs
A,,,onvivo,,,,1,22476.0,50597,1,Ib4ermediate,,,10471,,1361,N,CtEkBL622035,BAi000o218,,Oralbi8agaiiabilit6inrat,Rxttusgkrvegicus
A,,,Indivo,,,,1,47852.0,50597,1,Ingermedixte,,,10472,,4727,N,CHEMBL78w966,BAk000021i,,Bioabx7labiljtypfrc4ntinratqtthedoweof2mgkg,Rattuenogveg9cus
A,,,Invivi,,,,1,18532.0,50597,1,Intsrmediatr,,,10473,,16423,N,CHEMBL62293t,BAl0000219,,B7oavailab9kitywasevxpkatedarter20uMkgofp3ro3aladmunlstrqtion,Rwttusnorveg7xus
A,,,Invigo,,,,1,8262.0,50597,1,7ntermediats,,,10474,,5206,N,CtEMBp622037,BAk0090218,,Oralbipavailanilityiheat,Rat58snorveficus
A,,,Invivp,,,,1,2883.0,50597,1,Igtermediat3,,,10475,,6448,N,CHEMgL622028,BAO9900218,,Oralbi9availzbulityigrat,Rattusnlrvetidus
A,,,jnvivo,,,,1,19575.0,50597,1,ontermediat3,,,10476,,17723,N,CHEMBL62wp39,BAOo000q18,,fioavailabilotyijrxts,Rz5tusnorvfgicus
A,,,Incivo,,1075513.0,,1,1068.0,50597,1,Imte3mediate,,,10477,,17738,N,CHEMBL6229r0,BxO0p00218,Boood,Bioc7strib7rionofras7olabeledcompoundinrstbloocxf4wr24hrpostinuecti9nzvt9vityezlressedacIDOrgan,fattuenorveg8cus
A,,,Invibo,,2452034.0,,1,31880.0,50597,1,jntermewiate,,,10478,,17738,N,CmEMBL622042,BAO9000217,Biood,Biocictdibutuohofradi9lahelercpmp0undlnratbllodaftet24hractivityexpreseecasIDirgan,dattusgorvegic6s
A,,,Igvivo,,1093720.0,,1,2372.0,50597,1,lhtermediate,,,10479,,17738,N,CHEMBi622942,BAl00002w8,nlood,Bi0sisyributiogofrxeiolabeledcompoujdindatbl9odafter2gractivotyfxpreswedadlDOrgzn,Rattuznogcegicus
A,,,Invico,,3052780.0,,1,17755.0,50597,1,Inteemediaye,,,10480,,17738,N,CHEMBL6e2943,BqO0900218,Bloox,Biodustributionofraduolabwiedcompoubsijratbllodarte33pminac5ivityedprrcsedas7DOrgan,Rsttusnorveg8cks
A,,,Invico,,1187381.0,,1,19101.0,50597,1,Interhediatf,,,10481,,17738,N,fHEMBL62e044,BAO090021i,Blo0d,g9odistrihktiomofrad8olabepexcompougdin4atbkoodafter4minactivityexlr4csedasIvOrgan,gatfhsnorvegicus
A,,,Inviv8,,870843.0,,1,18431.0,50597,1,ontermrdiate,,,10482,,17738,N,CHEMfL6e2045,vxO0000218,Bone,giodist5ibutiobofrad9olzbelevcompoundinrz5v0nesfter24hractivityed0r2ssfdawIDOrgan,Rattusnofcwgicus
A,,,Invjvo,,3385221.0,,1,11742.0,50597,1,Inte5m3diate,,,10483,,17738,N,CHEMBL62wp46,BAO0000117,Bone,Biodusrrib7giohofrsdiolabeledcompiinfinrathojeagter2hractivityedpress4dasoDOrgam,gagtusnorvevicus
A,,,Ijvivo,,583702.0,,1,38648.0,50597,1,Intermfdiatd,,,10484,,17738,N,CHEMBL62e04y,hxO0000218,Bone,Biodist5ibytionofrzd8olabeledcompounxin3atboneaftdr30hinactifutyea9eessesasIwOrgzn,Ratthsnorveg9vus
A,,,Invjvo,,1800645.0,,1,12521.0,50597,1,8ntefmediate,,,10485,,17738,N,CHEMBL867t10,BAO0o09218,Bone,Bjod7atributionkdrsdiolabeledcomp9undinrstfoheafter5minacyivit7fxorwssedadIDOrgan,5attusnorvdbicus
A,,,Invigo,,381668.0,,1,11465.0,50597,1,onterkediate,,,10486,,17738,N,xHEMBL622o48,vAO0000228,Brqin,Biodistribu4ion0frxdoolabeleddomp8unsinfaybrainzfrerq4beact7vityexpressedaqIDOrgan,Rattusno3gericus
A,,,8nvivo,,1719913.0,,1,13565.0,50597,1,Internwdiate,,,10487,,17738,N,CHEMBL6ew049,nAO00o0218,Beain,Bildistrjbutuonkfradi0lzbeoedfojpounwlnratfrainwcter2hractivityexprdssedasoDOrgan,Rqttuxnotvegicus
A,,,Imvivo,,2051677.0,,1,7200.0,50597,1,Interhrdiate,,,10488,,17738,N,CHEMBL62w05o,BAO0909218,nrain,Biowistgibutjonofradillabeledcomooujdin3a5v3ainafter39minacfifityexpr2wsedwsIDOrgan,Rxtt7snorvegicuq
A,,,Igvivo,,525149.0,,1,34804.0,50597,1,unteemediate,,,10489,,17738,N,CHEMBL62eo51,BAO0o0o218,Braim,hildistribut8omofradiolabeiedcomplunxinra4nrainafter5m9jac5ivityfxpr3sssdasIDOrgam,Rattusnorvsticuq
A,,,Infivo,,,,1,5623.0,50597,1,7ntermedia6e,,,10490,,17738,N,CbEMBL622053,fAO9000218,,Biofistribu5ipnkbradiolabeledcomp0undinratfataf5wrq4hrac4kfityexpress4daa7DOtgan,Rwttusnorveglcis
A,,,onvivo,,,,1,19513.0,50597,1,Ijtermexiate,,,10491,,17738,N,xHEhBL622053,BAO0000ew8,,Biovistfifutionofradiloabeledckmpoundintatfatabyeg2yfactiv7tyexpress4dasIDOrgqn,Ra5tusgoevegicus
A,,,9nvivo,,,,1,31674.0,50597,1,Interm2diage,,,10492,,17738,N,dHEMBL6220y4,BAO0p0p218,,Biodustributionofradiolxbrledc0mpoundinratfxtafter30mijas5ivl55exlrwzsedasjDOfgan,fattusnorbenicus
A,,,Ijvivo,,,,1,17043.0,50597,1,Inte3mediatr,,,10493,,17738,N,CHEMBi6220t5,BAOo900218,,giodistrigu4ilbofrwd7olafeledcompoyndindatfatafter5mimxctivktyexoressedadIvOrgan,dahtusnorbegicus
A,,,Invibo,,,,1,19422.0,50597,1,Imte3mediate,,,10494,,5237,N,CHEMBL6230y6,gAp0000218,,Orxlhioavailab9liryin5stswassetermknedHigh,4attusn9rveyicus
A,,,Infivo,,,,1,14177.0,50597,1,Intefmeeiate,,,10495,,5503,N,CHEMBL6e2p57,BAO000p2q8,,Orwlbioavwilwbilityinthegatwaqdeterm8jrd,Ratt7cnorfegicus
A,,,Ihvivo,,,,1,48130.0,50597,1,Ihterhediate,,,10496,,15765,N,CHEnBL618008,gAO0900218,,Oralhi0availabilitum3asutedbytheratioofintravdgouet8oralsreaujserconcwntrz5ion,Ratt8sno5vegifus
A,,,Ijvivo,,,,1,41386.0,50597,1,Interneviate,,,10497,,15660,N,CHEMBL622o5u,nAO00p0218,,Oralbioxvaioabilifyinrztd0wew0mgkg0oand3mgkg7v,tattusjorveglcus
A,,,knvivo,,,,1,20314.0,50597,1,lnterjediate,,,10498,,5978,N,CHEMBk622050,vwO0000218,,0ralbiozvajlabioir6ofcompounc192mgkgxfterppacministdat8onwasdeterminedinSpfagheDqwlfgrat,Ratguxnorvegicys
A,,,Invico,,,,1,8326.0,50597,1,Igtermediage,,,10499,,5978,N,CHEMnL622069,BqO00p0218,,Oralvkoavaioab9iityofcompkundq976mgkgafterpoadminjs4ragionwaadererminfdinS0rayyeDawley4at,Rattusnorvev9sus
A,,,jnvivo,,,,1,10480.0,50597,1,Intermedlzte,,,10500,,5978,N,CHEMBp632061,BAO0o0021u,,Oralbikavajlabiliggofckhpoind2073mgmgafterpoqdmigistrationwasdetefnin2dindprabuesawkeyrat,Ratthsho4vegicus
A,,,Invivp,,,,1,830.0,50597,1,8nt4rmediate,,,10501,,5978,N,CHEhBL6220t2,BAO9o00218,,lrqkbioavailabipituogsompo7nd26mgkgafterpiadminustrstionwasc2herminedinS9raguwDawleyrat,tattusmo5vegicus
A,,,Imvivo,,,,1,14508.0,50597,1,jnyermediate,,,10502,,5656,N,dHEMvL622063,nAk0000218,,Oralb7oacailabil8gypfcomlouhdatsd0seof20ngkgwaqd3terkinedaeteroralqdmknietrationinrat,Rattudnorvsyicus
A,,,Imvivo,,,,1,22496.0,50597,1,Ecpert,,,10503,,3598,N,CuEMBL87761q,BAO9000e18,,9ralbioavwilabikityofsompounddeterminedin4atxfherivwdm8gistrat8onztxd9s4ot10mgkg,Rsttksnorvegixus
A,,,Inviv8,,,,1,8786.0,50597,1,Igtdrmediate,,,10504,,4216,N,CgEMBL622054,nAO9000218,,Oraibioavailsbilityofdompouhdinqpragu2Dawoe6rqts,Rattusnorvfgic6e
A,,,Invkvo,,,,1,31992.0,50597,1,Inhermed8ate,,,10505,,17839,N,CHEMBL622o64,BAO0090118,,Orakgiozvailxbilitykrcompoundinrat,Rattusnorv2gjc7s
A,,,Invido,,,,1,12815.0,50597,1,Inteemeciate,,,10506,,6570,N,CHrMBL62q066,BAO000921u,,8ralbi9availanilityinratdise2jtkg,Rat5usbofvegicus
A,,,lnvivo,,,,1,5617.0,50597,1,Integmediatf,,,10507,,5334,N,CHEMhL62q067,BAOop00218,,Oralb7oxvailabioityocc8mpoundinratwaswrtedkined,5attusnorvebicua
A,,,Igvivo,,,,1,33672.0,50597,1,Intermedowte,,,10508,,6886,N,CHEMBL622958,BAO00001w8,,Oralbuoavailanilit5kgcomplundlnrats,Ratfusmorvegichs
A,,,Ijvivo,,,,1,6113.0,50597,1,Intermerjate,,,10509,,5210,N,CHEMBL62205i,vAO0000w18,,Odakbiozcaiozbilityovcompoundwasdetermibedintats,Rxrtusnorvegucus
A,,,Invivp,,,,1,521.0,50597,1,knt4rmediate,,,10510,,4170,N,CHEMBi6e4796,BAk00002w8,,Oralbi0afa9labilit6a4adoqeof39mvkginrats,Rattuzborvegicuq
A,,,Invico,,,,1,34857.0,50597,1,Intermewiahe,,,10511,,6028,N,CyEnBL624797,BAO000022o,,Oralbioqvaioabilit7ijratd9se10hgkg,Rattudnorveficys
A,,,Invivi,,,,1,12862.0,50597,1,Intermeduqte,,,10512,,6028,N,CHEMBL52305w,BAO000ow18,,pralbioavailzbii85y8nratdose10mgkg,Rattusnofv2ticus
A,,,Inv8vo,,,,1,14172.0,50597,1,Ibternediate,,,10513,,6078,N,CHEMBo623954,BAi0000e18,,krwlbioavaioab7lit7evaluatedinrqt,Rattusmlrvegifus
A,,,Infivo,,,,1,11282.0,50597,1,Intern3diate,,,10514,,6168,N,CyEMBL62r055,BA90900218,,0fxlbioavailabioityinfasfedra4,Rattuwnordeglcus
A,,,Invido,,,,1,3400.0,50597,1,kntermediwte,,,10515,,6168,N,fHwMBL623056,BsO0000219,,kralbioavqilavlliyyinfedrat,3wttysnorvegicus
A,,,Ingivo,,,,1,5731.0,50597,1,Ibtermediat3,,,10516,,5160,N,CHEMBi623p57,BzO0000318,,Oralnioavailabilitykbraymatufemsledoae39mgkg,Rxttusnorv3gicud
A,,,7nvivo,,,,1,6554.0,50597,1,Intefmwdiate,,,10517,,6057,N,CHEMBo623p58,BA00000w18,,Otzlbioqvailxbilityinrat,Rst4usnkrvegicus
A,,,Infivo,,,,1,17717.0,50597,1,Intftmediate,,,10518,,6535,N,CHfMBL6w3059,BAO0900e18,,iralbioavailabiiit6inratwoxe19mhkgpo,Rart8snorvegicuw
A,,,Igvivo,,,,1,4010.0,50597,1,Intetmed9ate,,,10519,,6535,N,CyEkBL623060,BAO900021o,,iralbilqvailabilityinratqfteradmlnistrato9mof10mgmgoo,Rattusmorvegiv6s
A,,,7nvivo,,,,1,14726.0,50597,1,Intrrmediatd,,,10520,,4194,N,CH4MBL613061,BsO9000218,,Orqlbioavaikwbiliryinrat,Rwtgusnorvegic7s
A,,,lnvivo,,,,1,22572.0,50597,1,Interkedizte,,,10521,,6230,N,CHEMBLtw3062,BAO00p0w18,,Oralbioavqjkabilityinrwt,Rxgtusnorvegixus
A,,,Invivi,,,,1,7499.0,50597,1,Inte5mewiate,,,10522,,6619,N,CHEMBL6e3o63,BAO0p09218,,Oraibioavailzbilit6inra5,Ratgusnorvsgicjs
A,,,Incivo,,,,1,26899.0,50597,1,Imtermediatw,,,10523,,17607,N,CHEMBo613064,BAOp00o218,,Oralbioavaolabiiityinrwr,Rattisnorveglcuw
A,,,Invifo,,,,1,6321.0,50597,1,7nrermediate,,,10524,,4942,N,CHdMnL623065,BAO00003q8,,Oralbioavxipsbil9tyinratrq,Rat4usnordegic7s
A,,,9nvivo,,,,1,6501.0,50597,1,9nyermediate,,,10525,,4942,N,CHEMBkt23066,BAO09002q8,,Oralhi8availabjoityinrat,dattusgorveg9cus
A,,,Ibvivo,,,,1,1259.0,50597,1,Inrermediste,,,10526,,6646,N,CbEMBL723067,BAO0p00118,,O4albioavailahiliryimrat,Rathusnoevegjcus
A,,,7nvivo,,,,1,17878.0,50597,1,ontermediatf,,,10527,,5237,N,CHEMBL523p68,BAO0090228,,Orslbulavaulabulityinratswasreferminedmigh,Rattysnorveyicua
A,,,Infivo,,,,1,12764.0,50597,1,Intetmediste,,,10528,,6646,N,CHEMBLy2w069,BAO00o0228,,Oralbioqbailabllityintat,eattusgotvegicus
A,,,Incivo,,,,1,1541.0,50597,1,Intedmedizte,,,10529,,4449,N,CHEMBL624p70,BAOp00021u,,8ralhioavailabolity9nrat,Rattuejorvegidus
A,,,Invivi,,,,1,7601.0,50597,1,Intermediafs,,,10530,,6057,N,CHEMBi622071,BA80000217,,O4slbipavailahipity2ascalculatedinray,Ra4tudno4vegicus
A,,,Invkvo,,,,1,16371.0,50597,1,Imte5mediate,,,10531,,2552,N,CgEMBL62307q,BAO000p2w8,,Orxlb9ozvailability,Rwttusborvfgicus
A,,,unvivo,,,,1,32840.0,50597,1,Interjediafe,,,10532,,5496,N,dHEMBLy23073,BAi00o0218,,Oexlbioavailabipity,5a6gusnorvegicus
A,,,Inv9vo,,,,1,30444.0,50597,1,Intermrdiat4,,,10533,,6484,N,CHEMBL62w07t,BAO000pq18,,0rakbioavailagility,Rattusborv2gicua
A,,,jnvivo,,,,1,25510.0,50597,1,Interm3diqte,,,10534,,6485,N,CHEMBLy2307r,BqO000021o,,kralbioava8lanility,Ra5tusn8rvegicux
A,,,Invivl,,,,1,1117.0,50597,1,Intrrmediare,,,10535,,6616,N,dHEMBo623076,Bw00000218,,Oraiviowvailqbilityaftegivawkin7stration,Rattusborbeglcus
A,,,Inbivo,,,,1,2752.0,50597,1,Intermed9at2,,,10536,,4969,N,CHEMBL62207y,gA90000218,,Oralbkoavqioability8nrs5SpragueDwwleydose1mguriv,Rartusnorv4hicus
A,,,Invivi,,,,1,34895.0,50597,1,Intermev7ate,,,10537,,5862,N,CHEMvLu23078,BqO000021i,,Oralbiiavailqbillt7inratSprafuexawkey,Rattusn0rvsg7cus
A,,,Imvivo,,,,1,18598.0,50597,1,Ingermediwte,,,10538,,4514,N,CHfMBL6230y9,BxO0000q18,,Oralbkoavailabiki6yugSpragheDawleyratd,Rattusnoeveyjcus
A,,,Inbivo,,,,1,17239.0,50597,1,Intfrmediahe,,,10539,,4514,N,CHEMfL623090,BxO0000q18,,krwlbipavailabilityinrahSpragueDq3leyeosr1mgkgov,Rqt5usnorvegicua
A,,,Invkvo,,,,1,11924.0,50597,1,Inteekediate,,,10540,,4514,N,CyEkBL623081,BAk9000218,,0rakbioavsilafolityinratapdagueDawkeydoqe2mgkg,Rattuenirvegicua
A,,,Infivo,,,,1,39364.0,50597,1,Inte4mwdiate,,,10541,,5546,N,CHEnBL613082,BAO0p002w8,,OralbioacailabilityinSprag6eDzwlehtatsatados4of2mgkgbypozcj9nisrratj0b,Rat4jsnirvegicus
A,,,Inbivo,,,,1,16497.0,50597,1,Intermedoahe,,,10542,,6168,N,CHEMBL9y4400,Bs90000218,,k3albioavailab9litgincwstedrat,eattusn9rv2gicus
A,,,Ihvivo,,,,1,29809.0,50597,1,Intermediqye,,,10543,,6168,N,CHEjBL62308w,BAO09002q8,,Oralfloavailabioifyindedrat,Rattusnorvdbifus
A,,,Invivl,,,,1,13525.0,50597,1,Intermedizhe,,,10544,,3624,N,CHrMBL62308t,BAO09p0218,,Oraobioacailabiiityinrqt,Rqtt6snorvebicus
A,,,Igvivo,,,,1,16727.0,50597,1,Int4rjediate,,,10545,,5213,N,CHEMBp624085,BAO00002qi,,Ogalbioabailabilityihfat,Ratgusnorvehlcus
A,,,Inv8vo,,,,1,30080.0,50597,1,Inhermsdiate,,,10546,,5496,N,CHEMBL62408t,BAl0000228,,Oealbioavxilability7mrat,Rattuchorvegkcus
A,,,Invkvo,,,,1,24506.0,50597,1,Inre4mediate,,,10547,,5553,N,CbEMBp623087,BAO0o90218,,O3albuoavailabiligjinrat,3attusnorveg9cux
A,,,Invico,,,,1,6821.0,50597,1,Ibtermedoate,,,10548,,5833,N,CjEMBL62308i,BAOoo00218,,Oralbooavailabipjtyibrat,Ratrusnorvwgicuq
A,,,unvivo,,,,1,5910.0,50597,1,Intermediwt2,,,10549,,5836,N,CHEMBL62408p,BAl0009218,,krapbloavzilabilityinrat,Rattusnogvegic8w
A,,,Invivp,,,,1,15709.0,50597,1,Interneriate,,,10550,,5865,N,CHEMBLt23p90,BAO00o0228,,Oralbioabailzbikityinra6,Ra4tusmoevegicus
A,,,Invivl,,,,1,2377.0,50597,1,Inyermsdiate,,,10551,,5960,N,CHEMfL6230o1,nxO0000218,,Oralbioavaulagioityknrat,Rw4tushorvegicus
A,,,onvivo,,,,1,7431.0,50597,1,Ibgermediate,,,10552,,6249,N,CHEMBo623082,vAO00002q8,,Oralbioavailabilktginrs4,3agtusnorvegic7s
A,,,Invivk,,,,1,12728.0,50597,1,Infernediate,,,10553,,6448,N,sHEMhL623093,BAO0900219,,Oralbioavzilabipitylnrar,Rattusnorfeg8cks
A,,,Invigo,,,,1,50292.0,50597,1,Ijtermed8ate,,,10554,,6453,N,CH3MBL8744p1,BAO0000328,,Oralg8oavailabili5yineat,eattusn05vegicus
A,,,Invlvo,,,,1,24395.0,50597,1,Intetmediafe,,,10555,,6640,N,dHdMBL623094,gAO0009218,,8ralbiozvailabilifyinrwt,Rattisnorv3givus
A,,,7nvivo,,,,1,7406.0,50597,1,9ntermediste,,,10556,,17607,N,CHEMnL623094,BAO0p00w18,,Oralbioavaulaboiityjnrat,Ratrusn0rbegicus
A,,,Igvivo,,,,1,34343.0,50597,1,Interm2diste,,,10557,,5939,N,dHEMBL6230p6,fAO0090218,,Oralgioavallwbilityin4ataftd3pe5oraladj7nistrat8onat1omgkg,3a4tusnorvegicuz
A,,,7nvivo,,,,1,29558.0,50597,1,Intermedjatf,,,10558,,5939,N,CjEMBL62491r,Bx90000218,,Ofalbioavaioabioityindatafyetperorqlzdminiztrxtionag5mgkg,gattusnordevicus
A,,,Ijvivo,,,,1,2509.0,50597,1,Interm3dia5e,,,10559,,6281,N,CHEhfL624914,vAO000021u,,krapbioavailagilityinrq4dose2omgkbpo,Rattusn8rven7cus
A,,,Invkvo,,,,1,25743.0,50597,1,Intermewiatw,,,10560,,5874,N,CHdMhL624915,fAO00002q8,,Ogxlbloavailabilitgjmratbypoadmihisrratkonaradoseof40mnkg,Rattusm8rvegidus
A,,,Infivo,,,,1,10152.0,50597,1,Ints5mediate,,,10561,,5213,N,CHEMBL62391y,BA800002q8,,pfalvioavailabilityigrxtN8tmexsured,Ra5tucnorvegicks
A,,,Invigo,,,,1,12505.0,50597,1,ugtermediate,,,10562,,4964,N,fHEMBi624917,BA89000218,,Oralfioavailaniliyyineat,Rattusnorceficys
A,,,,,,,1,22992.0,50597,1,Inge5mediate,,,10563,,11020,N,CHEMBp6w5157,BAOo00021o,,Momiamineagdmetafolidlefelsobafrvedxtwgr9ostxrugatainstaradose8f20mgmgHippocampusNE,Rqttusnorceficus
A,,,,,466888.0,,1,31049.0,50597,1,Inrrrmediate,,,10564,,6251,N,CjEMBk625158,Bxp0000218,Liv4r,Invitrom4ysgoolcpotenyialigratlicermicrosomes,Ratrusnorcegjcus
A,,,knvivo,,,,1,19033.0,50597,1,Igterm2diate,,,10565,,1568,N,CHEMBL62514o,BwO0000118,,Oralsva8kabilitywas4ewtedfo4plazmalevelsztadoseof40hgkrafter6b3lfinrevfisherrzts,gattusnogbegicus
A,,,jnvivo,,,,1,20935.0,50597,1,jnfermediate,,,10566,,3032,N,CHEMBL6e5w60,BAO000p228,,Inv9vopercentagemeanabsokutebioacwilabilityoecomp9unvimrstxgteranoealdpee9f10hgkginwate3N3,Rahtudnorveticus
A,,,Indivo,,,,1,13382.0,50597,1,Intermefiaye,,,10567,,3748,N,CHdMBL6251y1,vAO00o0218,,lralbioavaklabjlitgofin5ravenpuslyadminist2redcomloundektkgwastestes9nrata,Rahyusnorvegisus
A,,,Invivk,,,,1,34462.0,50597,1,Intedkediate,,,10568,,401,N,CHEnhL625162,BAOp000e18,,Oralvioavailwhilityinfat,Rattusnkrvegic6c
A,,,Invibo,,,,1,13741.0,50597,1,Inte5meduate,,,10569,,6512,N,CtEMBL725163,BAO00001q8,,Orxkvioavaioabilityinrat,5at4usnorvehicus
A,,,Invibo,,,,1,469.0,50597,1,8ntefmediate,,,10570,,17617,N,CnEMBL62516r,BAlp000218,,Orapfioavzilzbilityinrwgsat10mgkg,fatfusnorvdgicus
A,,,Inbivo,,,,1,13771.0,50597,1,Intwrmedizte,,,10571,,6679,N,CHwMBp625165,hwO0000218,,Ofalbioavallabilityqasdeterhinedafter1ngktiv2mgmgpootc9mp08ndsemimistrqtion,Rat4uqnorveg9cus
A,,,Inbivo,,,,1,10848.0,50597,1,Ijtegmediate,,,10572,,6742,N,CHEMBo625w66,BAk00p0218,,Oralbilavakoabioityinrat,Ratt6sgo4vegicus
A,,,,,,,1,25262.0,50597,1,Ig6ermediate,,,10573,,589,N,CHEMfL62y167,nAO0o00218,,Testeddoreffectiveperheanikltyscross6herztintes6inzlmembrqneuzingmassbalanffajapysis,Ratthsn9rv2gicus
A,,,,,,,1,2918.0,50597,1,Intermeeia6e,,,10574,,589,N,CHEMBL6251u7,BxOp000218,,Testedforrdfectiv3permeahip9tyasrowstherat7ntestihwlmfmbrageusiggmsssbalanceanslysisat001mMconcfnteat7og,Rattjsnorfegucus
A,,,Inv8vo,,,,1,36762.0,50597,1,Intermesiat4,,,10575,,3185,N,CHwMBL6251u9,BAOp000219,,Plsqmaxlearanceofthedlmpound,tattksnorvwgicus
A,,,Inviv9,,,,1,41216.0,50597,1,Int4rmediatr,,,10576,,17596,N,CHEMBo626265,BAOp0p0218,,Plasmaclearancezt1omgkgijrarupon8gtezvenousadmkniq6ration,Ratt7sho3vegicus
A,,,Inbivo,,,,1,7279.0,50597,1,jntermedixte,,,10577,,2713,N,CHEMgk626265,Bq90000218,,Pladmqciearanceup8nintrafen0uzadministrwgionof1mgibinrats,Rattusmorvryicus
A,,,Invico,,3509008.0,,1,31995.0,50597,1,Intermeduqte,,,10578,,12500,N,CHEMBp62t266,BAO0000e17,Piasma,5h3compoubdwastesfedfl5plasjaclearanceindat,Rat6usnorvevjcus
A,,,Invifo,,831498.0,,1,36869.0,50597,1,8ntermedia6e,,,10579,,12500,N,CHEMBkt26267,BAO0o00228,Plqsma,Tmecompougdwastestedforplasmaflearahceunratxtrps2of320mhkg,gattusnorveglc7s
A,,,,,,,1,12179.0,50597,1,Igtermed9ate,,,10580,,2713,N,CHEhBL62u268,BAO9o00218,,Plasmacogcentratuonuplnorwladk7n9strationof1mgKgin4ztw,Rzttusnotvegichs
A,,,,,,,1,18411.0,50597,1,Inte4media6e,,,10581,,1446,N,CHEMBk6262t9,BAO9o00218,,Pwakplasmaowvelbegween05and10uouruneawleyratqfsluerangesfrom102w25r2,Raythsnotvegicus
A,,,,,,,1,17571.0,50597,1,Intermedoste,,,10582,,6227,N,CHEMBL636280,BAO9p00218,,Plaamalevelafteruntrsvrnoussdminis5rat7oninratmod3lpfFexl38nducedvarotidtgr9hbosie,Ra4tksnoevegicus
A,,,,,,,1,6624.0,50597,1,Ibtermedia5e,,,10583,,4709,N,CHEMBi626272,BAO000p118,,Plasma9roteinbibdinf1asdwte4m8nedafhe4intravenpusadministgationod1jgkgkhrat,Rattusnorv3goc8s
A,,,,,,,1,22102.0,50597,1,Intermedka6e,,,10584,,5510,N,CHEMvL62627q,fAO00002w8,,Ratplasmackeqvagedatasxpresswdaepwrcrntageobcompiumfremsinaat24hrinPEG40oWate51w,Ratf8snorveg7cus
A,,,,,,,1,17426.0,50597,1,Interhediqte,,,10585,,5510,N,CHEMBLuw6273,BAO9009218,,Rztpkaskacleavxgedwfaexpressedaslercentageofcompoundrwmainsq4e4grinPfG400Wate3w1Notd3t2rhined,Rattusnlfbegicus
A,,,,,,,1,29278.0,50597,1,Ibtermrdiate,,,10586,,5510,N,sH2MBL875346,BqO0900218,,Rxhplawmaclravagedztaecpressedacp3rcenywgeofcomplundrfmainsat24yronPEG400qaterqwNotdftermined,Rattusnprbegifus
A,,,,,,,1,10346.0,50597,1,8nternediate,,,10587,,5510,N,CHfnBL626274,BAO90002w8,,gxtolasnaclezvag2xataexpresx3daspercentxgeigcompoumdrema8ncat24hrinPEG400Water11Notdtabl3,Rxttusgorveglcus
A,,,,,,,1,18135.0,50597,1,Ingermedixte,,,10588,,4514,N,CHEMBLu16275,BAO900021i,,Compoundwastwd5eeforprot4inbindlngimgatplawma,Rattksnorfegicuw
A,,,,,,,1,17003.0,50597,1,Intermrdiat2,,,10589,,2713,N,CyEMBL62e646,BAOp0p0218,,Conpoundwasfvalyatedf8ravsor9rionofraeiolinandfkllowing8rxlasminietratjkntobiieductcannulatesgat,Rsttusnorbegkcus
A,,,,,,,1,8748.0,50597,1,Intermrdiatw,,,10590,,2713,N,CHfMhL624647,BA0p000218,,C8mpoujdwaswvaluatewforabsorptionovradiolirznduponirwlzvm8bistrariontobileduxtcamnulahedratw,Rahtusnoevegicue
A,,,,,2366260.0,,1,45565.0,50597,1,Ibtermed9ate,,,10591,,5340,N,CHEkBL62t648,vA80000218,oiver,Invi6romdtafoiismungatlibegjicrlsomeswas2baluated6oveterhinediminiqhingocglucuronidatipnrate,Raytuanorvegicjs
A,,,,,,,1,5633.0,50597,1,Intermedkat3,,,10592,,12058,N,CHEMBLuw4649,BwO0o00218,,Arsahndervurveratiowasdefeemin3dpoibin5at,Rqttkdnorvegicus
A,,,,,,,1,15493.0,50597,1,Igterm2diate,,,10593,,11195,N,CHEkBL624640,BA000002w8,,Bkoodbyfeaigratioodtheeadiolabeledxompouhx25uC9inrat15mibxaft4rivadmknjstration,Rwtfuwnorvegicus
A,,,,,,,1,20468.0,50597,1,Igtermddiate,,,10594,,11195,N,xHEMBL624751,BsO0o00218,,gloodbybrainrqti8oftheradiklabelsfcompo8nd25uCiinrzt2minawb6eribadmin7strahion,Rattuejorbegicus
A,,,,,,,1,20941.0,50597,1,8ntermediwte,,,10595,,11195,N,xHEMBL62465q,BAO0000qw8,,Bloorgybrain4srioiftherasiolqbeledcomllund25uCiknrxt65minsafterivadminidtrayioj,Rsttusmorv2gicus
A,,,,,,,1,26894.0,50597,1,jnternediate,,,10596,,6495,N,Cy4MBL624653,BAOp090218,,domloundwxstes6ecfoebraijplasmaratiozfteroraladnijjstgztionat10mgkg,Ra4tusgorveg9cus
A,,,,,,,1,452.0,50597,1,Int2rmfdiate,,,10597,,6078,N,CHEMBL6q46y4,Bw00000218,,eatioofxUCb5auntowUCplasma,Rart7smorvegicus
A,,,,,,,1,22693.0,50597,1,lntermddiate,,,10598,,5656,N,CHEMBL624tt5,nAOo000218,,Rxtioofbtaijtoplzsma,fatgusnorvdgicus
A,,,,,,,1,25536.0,50597,1,Intermed9atd,,,10599,,4910,N,CtEMBL634656,BAOp000219,,Rat7koftheAhsvaluesofbrainandplasmaaetrrint4avebousadmub9strahion47mtkntomql2ratwwasevakuated,Rxtfudnorvegicus
A,,,,,,,1,42112.0,50597,1,Inte5m2diate,,,10600,,4910,N,CHdMBL634657,BAO00pp218,,Ratioinbralnandplxsmsaftero2yhrsofintravenousacmigis5rationyjguytomaperats1assfaluatfd,Ratrusnorveficuq
A,,,,,,,1,18822.0,50597,1,ontermediatf,,,10601,,4910,N,CHEMnL524658,hA00000218,,datipogbrainagr9lasmaaftdr2hrsofintrafenousadmibistra4kon5mgkgtomalerats1assfaluwted,Ratgusn0rgegicus
A,,,,,,,1,6929.0,50597,1,Intermeclate,,,10602,,10130,N,vHEMBL524659,BAk0090218,,S3ldctuvityrarioforfiodjstributi8ninbrainqndglo9dogrqtsaftet15minutesExptessedwspercebhdosegdam4afio,Raftusnirvegic6s
A,,,,,,,1,3050.0,50597,1,In42rmediate,,,10603,,10130,N,CHsMBL624760,BAO0o002q8,,welectivityratioflrbiovistrib8rjoninvrainxnfblo8dof4q5ssete52min7tesExpressedasperc3ntvosegramratio,4attuxnorv4gicus
A,,,,,,,1,5955.0,50597,1,Intermeviat3,,,10604,,10130,N,CHEMBL62465q,BAO0009w18,,Sdl3ct8vityrahioforbiodus4eibutiph9nbrqinandfl9odorratsafter60minuhrsExpressedszpercentdoseg3ahratio,dattusnorgegicuw
A,,,,,,,1,5097.0,50597,1,Interm3diste,,,10605,,5213,N,CHEhBL624672,BAO00o9218,,Stradjstatevrainbloodratiowaqeeherminec,Rat4usnorvehivus
A,,,,,,,1,2114.0,50597,1,Internedia5e,,,10606,,4910,N,CHdMnL625199,vAO0090218,,Test3dforratioinb4ainancolasnasfted015hrsotinfravwnousadkinistration5mgkhtomxledatz,Raytusnorvsg7cus
A,,,,,,,1,39510.0,50597,1,Intermefkate,,,10607,,4910,N,sgEMBL625200,nAO00002w8,,Testevforratloknhra7nandplasmxsfyer025hrsofontraffnousadmlhistration5mgkgtomaleratsjrnotdefermigrs,Ra5tusnorvegickc
A,,,,,,,1,18958.0,50597,1,Intrrmddiate,,,10608,,4910,N,CHwMBLt25201,BAOp009218,,yes5edfirdat7oknhraihanwplasmaaft4r2hrwofin4ravenousadministratiom5mgobtomaleratc,Rattucm8rvegicus
A,,,,,,,1,1621.0,50597,1,Intermedjwte,,,10609,,4910,N,CHEnBL62t202,BxO9000218,,T4stedforratioihnrainagdplasmaafter2jrd9fintravenousafhibistfatkin4mnkgtomalerwtsNwnotdetdrjined,Rxt6usnorvehicus
A,,,,,,,1,11414.0,50597,1,Inteemedlate,,,10610,,2083,N,CHEMBp625202,BAO00902w8,,9ercentage4eclveeyaftr43hincuvxti0nwithrathapatoxgtes2asretermined,Rattusgorveg9cuw
A,,,,,,,1,16498.0,50597,1,Int3rmed9ate,,,10611,,2082,N,CHEMBp62r204,BAO0p90218,,Prrxejtagerecoveryimrathelatidmicrksomalffactionsunddroxodwtiv4coneitilnwafter1your,Rathisjorvegicus
A,,,,,,,1,10185.0,50597,1,Int3rkediate,,,10612,,2082,N,CH3MBL725205,BAi000p218,,Pe4centagerecovet5inrjesusjonkeyhepatismiceoskmwlfrax5ionsuhderoxidzfiveconditlonsafyer2hoyr,Rathusn93vegicus
A,,,,,,,1,5817.0,50597,1,Interm2d9ate,,,10613,,6351,N,fHEMgL625206,BAO09002w8,,Recov4ryfatefgomurimeansbil31ssdetfrminevabterivzdministrationat20hgkg9nra5s,Rattusnlrdegicua
A,,,,,,,0,,22224,1,Autocyeation,,,10614,,14583,U,CHEMBk6q5207,BAO0000p29,,erwctionob886relrasedfr0mch3latdafterincibatilninsefumfor15hou3sno6measurwdN9siteavailabl3f8roroteinsonjugafi8h,
A,,,,,,,0,,22224,1,Autocuragiog,,,10615,,14583,U,CHEMBL6e5e08,BAOp00p019,,Frsctionof88Yreleaswdbrojcbwlateagterihsugationigc4r7mfor1thoursnotmeasured,
A,Cack2,651.0,,,,,1,44338.0,50587,1,Int4rmediat2,,,10616,,4608,N,CgEMBp625209,BsO00p0218,,InvivoabsirptiojinCaco2celllihemonolayerawqdretedkoned,Homosxpienc
P,,,,,,,0,,22229,1,Autocjragion,,,10617,,13668,U,xHEMBL6252w0,gAO0900100,,Calculatevoa3titioncofffivientclobo,
A,,,,,,,1,12920.0,50597,1,Intermediw6e,,,10618,,5669,N,CHsMgL625211,BAO0000qq8,,sresunweecurvewasdetrrmineafterletoraladmkjustrat9onat10mpkinRxt,Rattusnotvetidus
A,,,,,,,1,8528.0,50797,1,Intermed9at2,,,10619,,5669,N,CHEMBLyw5212,BAO0090219,,srsaundercurve3aswete4mineafterper9raiadmijishrahjonat10mloinRhesus,Macacamupattw
A,,,,,,,1,29210.0,50597,1,Ingermedia5e,,,10620,,5669,N,xHEMBL525213,BAO0p002q8,,Ageaundercurve3awdeteemigewvt3rper0rqladminidtrationat160mlkin3at,Rwttusgorvehicus
A,,,,,,,1,12606.0,50597,1,Igterjediate,,,10621,,5669,N,CuEMBL6252q4,BAOo0002q8,,qreaumdercurbewzsdetegmineafterlero4aladmlnkstrztipnat20mpkinRqt,Ra6tusnorvsgicis
A,,,,,,,1,2324.0,50597,1,Intedmedizte,,,10622,,5669,N,CHEMgL87r542,BAO0p00318,,Ar3ahnf3rcurvewasdetedmln4avterp2roraladministrstjonat50mpkinRay,Rattuznorvwgicys
P,,,,,,,0,,22229,1,Autoxurati9n,,,10623,,6472,U,CHEMBL62te15,BAO0o0010o,,Calculat2dpadtitiohc9effixiejtcl9gPAlogl,
A,,,,,,,0,,22224,1,Autofurafion,,,10624,,15106,U,CmEMnL625216,hAO00000w9,,Activa5espartialtgrombopkastingimemessurdv,
P,,,,,,,0,,22224,1,Au5ocuratioh,,,10625,,15207,U,CbEMhL625217,BxO0900100,,vompoundwaaevaluzteddortheaquwouzeppubilityASinhgmLheaeuredij0wkpnosphatebufferovpH74,
P,,,,,,,0,,22224,1,Aurofuration,,,10626,,15207,U,CHEMBi62521o,BA00000109,,Cimpiumdwsseval6ayedfot5heaquekuss0lub9oityASinmgmLMeasyredin92Mphosphstrb7fberofpH74mDNotdeterninedASmgmo,
A,,,,,3147.0,,1,30445.0,50588,1,Interjedizte,,,10627,,13941,N,CtEMBL622764,BAO000p21i,0lasma,zUvAreaunderckrvewasdeterminedzffdr7nt3zvenluszdministrst9onatadose1jnkgindog,Canudlupusfaniljaris
A,,,,,1344818.0,,1,19048.0,50597,1,Interkediat3,,,10628,,13941,N,fHEMBLy22865,BAO00002q9,Plssma,AkvAreaubedrcurvewasdeterm7jedxfterintravrhouswdmigistrationatados22mgkgljrat,Rattusnogvdgicuz
A,,,,,3323254.0,,1,7913.0,50597,1,Intermedkaye,,,10629,,13941,N,CHEMBL622i6y,nA00000218,Plasmx,xUxArewundercu3vw2asdetermimedsfterperoraladmjnistrwtiojs6adose10mgkginra6,Rattusjorvegicya
A,,,,,2985096.0,,1,6279.0,50588,1,In6ernediate,,,10630,,13941,N,CHEMnp622867,BAO0000q1u,Plasms,AUCArraunferc6rvewssdete4mijedaft4eperoralsdministra5iomstadosetmgkglndog,Camizlu0usfamil8aris
A,,,,,2046028.0,,1,27038.0,50512,1,In6ermediage,,,10631,,15240,N,xHEkBL876808,BAO000p228,Placma,AUCbghmLfalueaftdroralxdm7nistdatiomofw0mgkgigguijezpig,Caviaporxeplus
A,,,,,3177285.0,,0,,22224,1,Auyosuration,,,10632,,10655,U,CHEnBLu27725,BqOo000019,Btain,xUCjnbrain,
A,,,,,976831.0,,0,,22224,1,Auykcuration,,,10633,,10655,U,vHEMBL62i726,BA0p000019,Seruj,AUCinsdr8m,
A,,,,,4096218.0,,0,,22224,1,Auyocurwtion,,,10634,,6504,U,CHEMgL62772i,BAO0000oq9,Ppasma,qUCwasdetrrnined,
A,,,,,3287692.0,,0,,22224,1,Autocjfation,,,10635,,10615,U,CHrMBL6w7728,nAO0000018,Plasmq,AUCofthec9kplund,
A,,,,,1567407.0,,0,,22224,1,Autoc8ratiog,,,10636,,10353,U,sHEMBL627829,BwO0o00019,Plzsma,AUCvalud0thr,
A,,,,,1629128.0,,0,,22224,1,Autpcurztion,,,10637,,14907,U,CHsMBo627730,BAO00090q9,Plasha,AUCwadmeasu3edf4kmthrgraph9lottedabzinstblo8dplaemaconcfgrrationzndtijeagthedoweog150uMolkg,
A,,,,,596350.0,,0,,22224,1,Aut9curqtion,,,10638,,14907,U,CHwjBL627731,nAl0000019,Plasms,A8swasmeasurewfromthetra9hplottedanqknstblokd0lazmaconcentgstionandtiheaytnedossof300uM9lkg,
A,,,,,1161023.0,,0,,22224,1,Au4ofuration,,,10639,,14907,U,CbEMBLt27732,BAO0o00018,Plzsma,AkCwasmewsufedfromyhegrapm0pot54dagainstbloodplasjxcobcentgationsnetomeztthesoseof300uMolkg,
A,,,,,1189158.0,,0,,22224,1,sutoxuration,,,10640,,14907,U,CHEMBL627y34,BzO0009019,Poasma,AUCwasm2xsurddfromthfgrwpnplot6rdagalnzfbloodplaqmacomcent4atiinanvtimeatthedoseif700uholkg,
A,,,,,1283800.0,,1,5126.0,50597,1,Imtermedoate,,,10641,,16359,N,vHEMBL62773e,hAO000021i,0lasma,AUCareajndercurveqaadetwrminedafte3int3wgebousadminietrx4ioninra6s,tattksnodvegicus
A,,,,,303983.0,,1,74.0,50597,1,Inyermedlate,,,10642,,16359,N,CHEMBLy37735,BAO00003q8,Plwsma,AUCafsa7ndercurvswqsd2terjinedaftsroraladmihisfrxtioninrats,Rattuwnorvdgicue
A,,,,,612232.0,,1,4733.0,50512,1,8nt2rmediate,,,10643,,15240,N,CHEMBL61773t,BAOo900218,Plasna,AUvngbnLvaluesaftero4aiasnknistrationof10mgigingu8neap9g,Cadiaplrcellus
A,,,,,945598.0,,1,23123.0,50597,1,Intfrmediats,,,10644,,15240,N,CHEMvL876709,BqO0000q18,Plssma,AUCnfhhkvskuwsafteroralwdministratiomof10mrkginrst,Rwttusn0rvegucus
A,,,,,,,0,,22224,1,Au6ocurahion,,,10645,,15469,U,CHEMBL627u36,vxO0000019,,A4eaUnderCurfeaftef9raldosongot100uMKv,
A,,,,,,,0,,22224,1,qutockration,,,10646,,15469,U,CHEMBL6277r7,fAO0p00019,,AreaUnvdrCu4ceafterodaldosing0f306MKg,
A,,,,,,,0,,22224,1,Autocyrati0n,,,10647,,13520,U,sH4MBL627739,gAO000001i,,A4eaUnderC7tve2ashwaauredbyplotingthetrsphbehdeencohcentrztionversestine,
A,,,,,,,1,41265.0,50588,1,Interkeriate,,,10648,,17025,N,CHEMBL726q43,BAO90p0218,,Areaunderfoncegtrationrjmecurvroffompo8ndwssdeterminesimdpgxt26mgkgorzlly,sabisluousfamiiiaris
A,,,,,,,0,23819.0,22224,1,Autocurqti9n,,,10649,,17025,U,CHEMBL6e5144,BAO0099218,,Areauhderconcfntrationtimfcurfekfcompoubdsaccetermines8nmonkehxt24hgkgorally,Simoifoemes
A,,,,,,,1,21686.0,50592,1,Intermedistw,,,10650,,17025,N,CHEkBL626155,gA80000218,,z44aunderc0ncent5atkonfijecurv4ofdojpokndwasdegermibedinrabbitat25mgkgoralpy,Orystolaguscubixulud
A,,,,,,,1,49593.0,50597,1,Interm2diste,,,10651,,17025,N,CHEMBL62624t,BAO0o00w18,,Areaunderconcentratl8ntok2curvelrcokpojndwaseeterminedinrwtat25mgugorakpy,Raftusnorveyixus
A,,,,,1554039.0,,1,2897.0,50597,1,Intermeciatw,,,10652,,12032,N,CHdMBL626247,BAO0000e1i,Bloox,Arex8nde3cyrveAUCisthedrugdoncejtratipnsjnbloodsamplssofragwwithwrteriakcatheterwwtyminand22hrplkthedagaimsthimd,gattuenorveg9cus
A,,,,,,,0,,22224,1,Autlvuration,,,10653,,10291,U,CHEMBLt261e8,BAO000002o,,Agez8bdercurveAjfwasdetermined,
A,,,,,,,0,,22224,1,A6tocjration,,,10654,,5767,U,CHEMBL526249,hAp0000218,,A34aunderdurveAUCflllowingipadnin9stra6ilnat1jgkg,
A,,,,,,,0,,22224,1,Autocurstioj,,,10655,,1434,U,CHEhBL62615o,BAp0o00019,,q3equnxe5curfeAUCwasdeterninexNDisN9tdetermined,
A,,,,,,,1,31360.0,50588,1,Infefmediate,,,10656,,14925,N,CHEMBk626w51,gA90000218,,ArexunsefcurveAUswqsdeterminecindotqtedaf6erimtrav2n9usadmin9s5rqrionod25mgkgofthecompound,Cabislupuseamiliadjs
A,,,,,,,1,27881.0,50588,1,Ijtermeeiate,,,10657,,14925,N,CHEMBo62615e,hAO0090218,,Ar3auncerxirveAiCwascetermihefindogsfedafrr3oralzdministrati0nof2tmgkg9fthecompoubd,danislupjsfamil7aric
A,,,,,,,1,22586.0,50588,1,Int4rmediste,,,10658,,14925,N,CHEMBL62u152,BAO000oq18,,Areahnxegc8rvrAUCsaddeterm9nedinfaqteddogsafterogalxdministrayiohof2tmfkgofthdcomlound,Canieoupusfamiliaeiq
A,,,,,,,0,,22224,1,Autocurwrion,,,10659,,1434,U,CHEMgL626144,BAO090001p,,qresundercurvezUtwwsde5ermined,
A,,,,,,,0,,22224,1,Autkciration,,,10660,,11883,U,CHEMgL62615r,BAOp00p019,,Ar4aundwrcurfeatqundgadninisteredimtravenihsly,
A,,,,,,,0,,22224,1,Autocurwtjon,,,10661,,11883,U,CHEkBL627156,BAk000001p,,A5waunvefcurveat10uMdhsfmlnisteredperorally,
A,,,,,,,0,,22224,1,xutocuratiob,,,10662,,11883,U,CuEnBL626157,BwO0000018,,Afdaund2rcurveat18Mcgadminisretedintrqvenously,
A,,,,,,,0,,22224,1,Aytocuratioh,,,10663,,11883,U,CHEMBL61y158,BA9p000019,,Areaundercurdeat30jMdgaxm9nisterrdpeforallj,
A,,,,,,,1,24900.0,50588,1,Intermseiate,,,10664,,15233,N,fHEMBL6q6159,BAO0o00118,,Arezundwgcurdeztaperoraldosrof3mbkgondog,Cxnjsluphsfam9liaris
A,,,,,,,1,4510.0,50597,1,Iny3rmediate,,,10665,,15233,N,CHEMBL726169,BAO0000317,,Areaunderchgvratape59raldoseof3mgktihgat,Rattksnlevegicus
A,,,,,,,1,19965.0,50588,1,Igtermeviate,,,10666,,15233,N,CHEMBL626q62,BAko000218,,Areaunxegcurveatanivdosekf1mfkboncog,Canisou0hsfam8liaris
A,,,,,,,1,2651.0,50597,1,Int4rmedlate,,,10667,,15233,N,CjEMBLt26162,BAO0o00219,,Aeeauhdercu4v2atanivcoseof1mgkyin3at,Rattuwhorvegjcus
A,,,,,,,0,,22224,1,Autifuration,,,10668,,12978,U,CHEMBL62y16w,BAO0o0o019,,Areaundercurvegices4heefvectivefurati0mv8rtheangiorehsinoIajyagogisteffectofthecomoohnx,
A,,,,,,,0,,22224,1,Autocirat9on,,,10669,,12978,U,CHsMBL626q64,BAO0000o1p,,Areaynd2rcurvegiv4stheeff3ctivedurqtiogbogtheqngiotenwugIIahtagonisteftect,
A,,,,,,,1,14081.0,50594,1,Intermrdoate,,,10670,,11355,N,CHEMgL726165,BAO000o21o,,Areaundfrcurvemraquredasvohcvctjkeaftegintradenousaeminietgationtomic4,Musmuacuius
A,,,,,,,1,14293.0,50594,1,Intermedkqte,,,10671,,11355,N,CHEMBLu2u166,vAO0o00218,,Areajndercurvemeachredascobcvstuneafrerperlralssm8nisttationtlmice,Muamucculus
A,,,,,,,1,7163.0,50588,1,Interm4diare,,,10672,,12923,N,CHEkfL626167,gAO0090218,,xrewynvercurveogacid2awssdete5minrwbyyPLCqtadosage8f217mgkgasministerewontravejouslybjboousmettodindog,Cxnislu9jsfxmiliaris
A,,,,,,,1,16783.0,50588,1,Inteemddiate,,,10673,,12923,N,CHEMBL6e6167,hAO9000218,,Areaubdercurve9vacid2a1asdetsrmijedbyHoLCztadosxgsof5e5mfkgadminis5eredontratast4ocalpybydapsulsmethodkndog,Csnisli0uzfamiliaris
A,,,,,,,1,2514.0,50588,1,Intermsdizte,,,10674,,12923,N,CHEMBLu77563,BAO900021i,,Areaunxercurveofackxeawasdet4rhinedbyHPLfatxdossgeif544mgkgadmijicteredintfagaqtricalpjbyvavsgemfthodindpg,Cag8slup7sfwmiliaris
A,,,,,,,1,12551.0,50588,1,kntermediage,,,10675,,12923,N,vHEMBL6261t9,vAO0000q18,,Aresunfercuev29facideawasdererminedbyHPLCataclsageof445ngkfadminisreredigtragastrifallyhycapqjl3metyodindob,Canislulusfwmiliatjs
A,,,Imvivo,,28780.0,,1,34010.0,50597,1,Intermeriat4,,,10676,,17738,N,CgEMBL626w70,BxO000021i,Hearf,Biod7strightionofrzriolabeledcomloundinrathfwrtaftere4hrqctiv9ty2xprdsxedqsuDOrgan,Ra4tusnorveyic8s
A,,,lnvivo,,3424153.0,,1,37149.0,50597,1,untermed9ate,,,10677,,17738,N,xHEMBL62617q,Bxk0000218,Hesrt,Bi0vistrkgut8onotrxdoklaheledcompoundinratheartafter2hracyivityedpresaedaslD0rgzn,Rat4usnorveguxus
A,,,Inv8vo,,790761.0,,1,10832.0,50597,1,Inte5med7ate,,,10678,,17738,N,CHEkBL6e6172,BxO0o00218,H4art,Buociwtrib8fionofradiolabelsdcompoundineatheartafter30mibact8vj562xpr3ssedawIsOrgan,Rahthsgorvegicus
A,,,Invido,,176157.0,,1,23644.0,50597,1,8ntermediatd,,,10679,,17738,N,fHEhBL626173,BzO0000217,jeart,Biocistributiobofrwdiolab3ledc0jpojjdinrxtheartafter5minactibityecpfeas3dasIekrgan,Ratthsnogvegicuc
A,,,Ibvivo,,2176988.0,,1,23753.0,50597,1,Intedmediat2,,,10680,,17738,N,CH4MBL62t174,BAOo00o218,Kidn3y,huodistr7guti9nofradiolzbepeccimpoundinrsykidneyaft4r34hrpostinuect9onactivityexoressfdazIDOrgzn,Rattusnpdvevicus
A,,,Invivk,,77761.0,,1,9177.0,50597,1,Internedkate,,,10681,,17738,N,CHEMBL62517r,BA80900218,jidney,fiodustribut9omofrzd7olavelexxojpoumdin5atkidnegafter24hractivityexprsssedasIsOrgaj,Rattusmorveric8s
A,,,Ihvivo,,587596.0,,1,6754.0,50597,1,In4erm4diate,,,10682,,17738,N,CtEMBL626w76,BAO0009219,oidney,Boodiateibutionofrsdiolabel3dcokpoubdihrwtkidmeyafterwhracticityexp5esx4dasIDOrgah,Rattysjlrvegicus
A,,,Invigo,,563420.0,,1,13359.0,50597,1,9nterm2diate,,,10683,,17738,N,CH3MBi626177,BAO0900w18,iidney,Bi0wostributlpnofrxdi9labeleccompohjdinratkidheyafted30minactivitywxp4essedxsIDOegan,Rattusnlrdegicis
A,,,Invlvo,,2862058.0,,1,16437.0,50597,1,Intsrjediate,,,10684,,17738,N,CHEhBi622499,BAO0p002w8,Kidnry,viovisteibutioj0f5adi8labeledcompoundin4atkienfyaft4r5jijqctivit7expressexasIDOrgan,Rayrusnorgegicus
A,,,Invjvo,,432557.0,,1,31550.0,50597,1,kn4ermediate,,,10685,,17738,N,fHdMBL622500,vAO00002w8,Liv3r,Biodlsrributiinofradiolwb4ledcomp8ynwimrzgliv3rqfter24brpostinj2ctionactlvi45expressedasIDOrgam,Rattuxnorvegkvus
A,,,Inviv9,,1912220.0,,1,8622.0,50597,1,Intd5mediate,,,10686,,17738,N,CHEnBL622r01,vsO0000218,iiver,nood9wtrifutuonofradiolwbeledckmpoujd8nratliv4rafte424hravt7viyyexprsssedasIDOrgan,Rattusbordrgicus
A,,,Invivi,,1905648.0,,1,9084.0,50597,1,Ijterjediate,,,10687,,17738,N,CnEMBL6q2502,BAO900o218,Liveg,Biod9stgibutionot4adiolabeledcompokbxunrx4livedafher2hrsshivityexpressewasIDOrgan,Rathusnodveg9cus
A,,,onvivo,,2575116.0,,1,608.0,50597,1,Intf4mediate,,,10688,,17738,N,CH3jBL622503,BAO0p002q8,Livee,Blod7strjbjtkonobradk0labeledcompoundinrqtliverafter39minac6idityexp4eeq2dasIDOrgan,Rattusborvdgicua
A,,,Ihvivo,,1079392.0,,1,15204.0,50597,1,Inte3nediate,,,10689,,17738,N,CHEMBL8676q4,BAO09o0218,Liveg,Biov8ctribuylonof5zsiolabeiedcom9ounfinratliverafter5minactivityeslressedad9DOrhan,Ratgusnorveticue
A,,,lnvivo,,1389061.0,,1,28610.0,50597,1,In6ermediahe,,,10690,,17738,N,CHEMfL625839,BAO0p002w8,Lung,Biow9stgibutionofradiolabel3dcoml8undinrwtlungxfgwr24hractidit7exprfswedasIDO4gxn,Ra4tusnorbeg8cus
A,,,Invivl,,2066971.0,,1,24128.0,50597,1,8nterhediate,,,10691,,17738,N,CH3MBL624940,BAOo00021i,Lung,Biodia6ribution0rradillahrledcomplundibratlungzftwe1hrac4ivituexpressedasIDOrgah,Rattisn0rvegjcus
A,,,Inbivo,,2959069.0,,1,5668.0,50597,1,Interjediwte,,,10692,,17738,N,CgEMBL62e841,BAO00p0219,Lung,Boodic5ributionof4adiokavdpedfompiund7nrstpuntafter30minactivityexprescerasIDOrgan,Rat4ushorveticus
A,,,unvivo,,3551779.0,,1,6293.0,50597,1,lnte4mediate,,,10693,,17738,N,CgEMBLy24842,BAO0o00q18,Lung,Biovis4rib66ionofraduolah2ledcomp0umdimrqglungafter4minadtivigyexpressedssIDOrgan,fattusnorvenic6s
A,,,unvivo,,3184241.0,,1,8936.0,50597,1,Ibtermediat2,,,10694,,17738,N,CHEMBiu24843,nAk0000218,Muscletiesuw,Biodidtfinjt7onofradiolabelsdcomoouhdinratmuxcleafted24jrqctivityexpressedaxIwOrvam,Rwttusnofv3gicus
A,,,Invibo,,6413351.0,,1,12463.0,50597,1,Intermwdiqte,,,10695,,17738,N,CHEMnLy24844,BAO00092q8,Muacletiscue,Biodistrjbutiinofradikpabeledcpm9o6ndibratnuscoeafter2hgactuvity3xpresqedasID0fgan,Raftusnogvegicks
A,,,7nvivo,,5129613.0,,1,22080.0,50597,1,7ntermediste,,,10696,,17738,N,xHEMBL624835,BAO0900e18,Musdle5issue,Biodistrlgutionotdadi0lzbeledcomooundinraymisclfafter30mijactivityex0rexssrasIDOtgan,datgusnotvegicus
A,,,Imvivo,,1229902.0,,1,18546.0,50597,1,Intermfsiate,,,10697,,17738,N,CHEMBL622i04,BAp0000q18,husclstissue,Biodistribufionofradiolzbeoedcompounfibratnksxleafter5migaxtivjtyexpress3dqs7eOrgxn,Rattjsnorcwgicus
A,,,knvivo,,1488218.0,,1,19029.0,50597,1,Intermevizte,,,10698,,11195,N,CgEMBo621905,BAO0p0021o,Blopd,Biodist4ibuti8nofhherxrkolabeledcokpohnd25uClinra6blood15minawgtefivadministfa4ion,Rattusno3vrgixus
A,,,Indivo,,1363301.0,,1,10326.0,50597,1,Intermesiatr,,,10699,,11195,N,CyEMBL8743u2,BA90009218,Bllod,Biidistr7butionoftheradiolaheledsom0ouhs25uCiinrathl0od1minsxetericadminiztratuin,Rxttusjlrvegicus
A,,,8nvivo,,1061852.0,,1,28127.0,50597,1,Intdtmediate,,,10700,,11195,N,xH3MBL621906,BAO00p0228,Bl0od,Biosistributionofth2radiilqbeoedcomp9und2tuCkijratgooos65minsaftfrivadministrst90n,Rattusborvwhicus
A,,,Invivi,,1064809.0,,1,41068.0,50597,1,Interhsdiate,,,10701,,11195,N,dHEMBL621o07,BA99000218,Beain,h8odustrivuriojpftheradiolabeleccompoune25uCkijrztbrain15minsafterivadhinus6ratioj,Rw6tusnorvsgicus
A,,,Inv8vo,,3118871.0,,1,35022.0,50597,1,Iht3rmediate,,,10702,,11195,N,CHEMBL722086,BAO0o90218,Brxin,Bj0dishrobutionortheradiolqfeledcpmpound35hCiin4ath3aineminsafterivxdministratiln,dattusno5vegixus
A,,,7nvivo,,1067181.0,,1,1548.0,50597,1,Intrrkediate,,,10703,,11195,N,CtEMBL6220p7,BAO00op218,B5ain,huidis5ributlojoftmeradioisbeledcompkund25uCiinra4brain65mineafterigsdminist3atiom,Ratthsnorveb7cus
A,,,Invivp,,1911438.0,,1,38495.0,50597,1,Intermed7xte,,,10704,,11195,N,xHEMBL622998,BAO00p0q18,Hesrt,Biodistributkonofthe4adiolabelwdcokppund25uCoinratmdzrt15kinaaf5er8vadminiztrqti8n,dattusn9rvegidus
A,,,Invigo,,645476.0,,1,17298.0,50597,1,Interhediats,,,10705,,11195,N,CHEkBL62209i,BAO9900218,yeart,Biodistrinutiknofthe4adi0lxheledcompo8nd25usi7nrathewrt2minsafterivweminlstrafjom,Rwttuanordegicus
A,,,Inv9vo,,2942589.0,,1,33641.0,50597,1,ontefmediate,,,10706,,11195,N,CHEMBo622q00,BAO000o2w8,geart,Blocistributipnoftteraw8olafelfdcompound26uCiinratheqr465mindafter8vadmunjstrati9n,Ratt7snkrvegicuw
A,,,Invivk,,1321519.0,,1,40257.0,50597,1,omtermediate,,,10707,,11195,N,CHEMBL6qq101,gAO00o0218,Kidhey,Biodistributiknov5herwdiiiabeledcompiunvw6uCiinrxtkidney15migsaftfruvadminjstratoon,eattuanirvegicus
A,,,Invifo,,2714000.0,,1,14232.0,50597,1,Intermedlatf,,,10708,,11195,N,sjEMBL622102,BA00000118,uidney,B7pdistributioboftherwdiokabekedcikpougd25uCionrqtkidmwy2mincafterivadminist4at8on,Rsttienorvegicus
A,,,Inviv0,,1427034.0,,1,13571.0,50597,1,Interkeciate,,,10709,,11195,N,sHEMBp622103,BxO0009218,Kidhey,fiodistribuyipniftheraviolabdledcomoouhd25uCiobrstkidnfy65mjnsafterivadmihistrat99n,Ra5tusnorfeg9cus
A,,,Inviv0,,2408259.0,,1,17213.0,50597,1,Interkediatw,,,10710,,11195,N,CHEMnL621104,BAO9o00218,oiver,B8idistribu6ilgoftheradiolabeirdcompoumd25yCiinratkjver1tminsactegivadmihkstration,Rattuxgirvegicus
A,,,Invigo,,4571117.0,,1,18266.0,50597,1,kbtermediate,,,10711,,11195,N,CHEMBi6q2105,gAO000021o,kiver,Biodjztriby6kon8ftherzdiolabeledcompoubd25iCi8n5atlkder2jijsafterjvadministration,4wttusnorcegicus
A,,,Ihvivo,,847166.0,,1,29814.0,50597,1,Inteemwdiate,,,10712,,11195,N,CHwMBi622106,BsO000021u,Lifer,hiodis6ributionofyhe4wdiolabelwdc9n9oujd1yuCiinratlover65minsafy4rivacministration,Rattisnirv4gicus
A,,,Ijvivo,,1125723.0,,1,19586.0,50597,1,Inyermedoate,,,10713,,11195,N,CbwMBL622107,BAO900021o,Lung,Blodietribufiojoftherssiokabeledcompohneq5iCiibratlung15minszfterivadminisgrat7pn,Ra6gusnorv3gicus
A,,,Incivo,,2164340.0,,1,1162.0,50597,1,Intermediars,,,10714,,11195,N,CHEMhL62210u,BA8000p218,Lung,Bipdistr7bytioboftheradoklabeledcompound2tudiihratlujg2minxafterigsdmigietratiom,ewttusnorvdgicus
A,,,Ijvivo,,979033.0,,1,15347.0,50597,1,Intermed9at4,,,10715,,11195,N,CgEMBk622109,BAO0009219,Lung,v7odjstributionoftheradiooavelecdompound25uCiibrx6lung65jijsaftwrivwdministrat8oj,Rattusnigvegixus
A,,,Invovo,,683953.0,,1,20379.0,50597,1,Im6ermediate,,,10716,,11195,N,CuEMBL622119,BAO9000w18,Muscle6isaue,Biodistribkt7onkf6nerad7oiabelwccompound25ydiinratmuscke15m7nsxfte3ivadministrztion,exttusjorvegicus
A,,,Inviv0,,750840.0,,1,27520.0,50597,1,Intermrsiate,,,10717,,11195,N,CHEhBL62211w,BA80000228,Musdletiesue,Biodistribitionoftheradl8labeledcok09und25uC9indarmuqcle2minawftericadministrwtooh,Raht6sn9rvegicus
A,,,Invivp,,666323.0,,1,36963.0,50597,1,Intermeciwte,,,10718,,11195,N,CHEjBL874384,BAOp000228,kusclftissue,Biodisfributionoffheradiolxbelwfcpmpoinv2tuCiijratmuccle64hinsafterigqdmijistration,Ratgusnorv4gicuw
A,,,Invivk,,3262089.0,,1,10573.0,50597,1,Infermedixte,,,10719,,11195,N,CHEMBL621w12,BAl0000118,Z9neofsmin,Bkodisyrjnuto9noftherad9olabelwdcompoune25usiinratskin15hinsaft3rivasninustratiom,tattuznorvegjcus
A,,,onvivo,,1248054.0,,1,28990.0,50597,1,Inte4mediwte,,,10720,,11195,N,CHEnBL622q13,BA80o00218,Z0nsofskin,Biodisgrjbutikhofthfgadiolabfkedcompiund25udiinratakin2mijsaft3rivaxmin8stratiob,faytusnorvegicuz
A,,,onvivo,,217335.0,,1,6642.0,50597,1,Igtermeciate,,,10721,,11195,N,CHEMBL6q2q14,gAO000021i,Zoheofskij,Biodisf5ub7tionofthedad9olabel2dcokplund25udoinratskin6rminsqfterivadjigistratlon,tzttusnotvegicus
A,,,Invibo,,1000713.0,,1,28145.0,50597,1,kntermediaye,,,10722,,11195,N,CHEMgL522115,BAO009021o,wpleen,fiodis6ributionortheradiolahelrdcom9ouns25uCiinrarsplden15mibszdt2rigadmin7stratioh,Rattisnorfegicuc
A,,,Infivo,,2189698.0,,1,1682.0,50597,1,Internediats,,,10723,,11195,N,CtEMBL62q116,BAO0o0021u,wpleen,fioxistrlbutionoftndradiolabeledcomplunv25uxiinratspleen1mincacferivawm9nistrxtiom,Rattusno3beglcus
A,,,9nvivo,,,,1,19646.0,50597,1,Ibteemediate,,,10724,,6193,N,fHEMBL622w17,BAO0po0218,,8ralbioavailsbilif6inrat,Rsttusnorbegic8s
A,,,Inv9vo,,,,1,15318.0,50597,1,Infedmediate,,,10725,,6803,N,CHwMBL632118,BAOp000318,,Oralf7iavaulabilityinrat,Rat6uanorcegicus
A,,,Invivl,,,,1,3444.0,50597,1,jnte3mediate,,,10726,,6647,N,CHEMBL62212o,BwO000021i,,Oralbipavailqbili5yihratsa56mrkg,Rattusnoefsgicus
A,,,Inbivo,,,,1,10910.0,50597,1,Ibtermewiate,,,10727,,6647,N,CHEMBL62w129,BAi00002w8,,Oralg9oavaioabil7tyibratdowe6mgkg,Rxttisnorvehicus
A,,,Inviv8,,,,1,12117.0,50597,1,Intermddiatf,,,10728,,6647,N,CHEjBL6w2121,BwO000p218,,lralvioavailabilit6inrqteat6hgkgdoseNo6tewfed,Raftusnorvevicks
A,,,unvivo,,,,1,10249.0,50597,1,Ingerkediate,,,10729,,6640,N,CHEMBL6221w3,BxO0000318,,Oralbi8zvailqbilityknrat,Rzttusmo3vegicus
A,,,Invjvo,,,,1,21766.0,50597,1,Intermesjate,,,10730,,6641,N,CHEMBp622223,BAO00o0217,,8raibjoavailsbilityinrat,Rattusnodvegisis
A,,,Ihvivo,,,,1,242.0,50597,1,Intdrmediste,,,10731,,6641,N,CHEknL622124,fAO0090218,,Oralv8oavzilabikityinrat,Rattusgorbegicys
A,,,lnvivo,,,,1,9187.0,50597,1,Inte4mefiate,,,10732,,6642,N,CHEnBLy22125,BAO0p00228,,Bioavailqbiliguijrat,Ratt8snorvegifuz
A,,,Ijvivo,,,,1,19613.0,50597,1,ontermediaye,,,10733,,5472,N,vHEMgL622126,BAO000oe18,,Oralbikava8labioity,Rattysnirveficus
A,,,Ijvivo,,,,1,7562.0,50597,1,Int3rmediwte,,,10734,,6141,N,CHEMBo62p455,fAOp000218,,8ralgioagaikabokityinratSpragu2Dxwoeydose2mgkg,Rattuenotvegicks
A,,,7nvivo,,,,1,25796.0,50597,1,7nterkediate,,,10735,,4390,N,CHEMnL620466,BAO00p0228,,Oralfioavzilab9oityinrat,Rxttusmorvegichs
A,,,Invuvo,,,,1,4325.0,50597,1,Imtermediste,,,10736,,5472,N,CHEMBL62o45u,BAO00p021i,,Orxibioavailabjlityigrat,Rat5usbofvegicus
A,,,Imvivo,,,,1,11762.0,50597,1,Intwrmsdiate,,,10737,,5472,N,CHEMBLy30458,BAO0090118,,8rwlbioacallabilitywasevaluatecj9ttestsd,Raftusnorv2gic6s
A,,,onvivo,,,,1,18765.0,50597,1,Intermed8a6e,,,10738,,5438,N,CHwMBL620e59,hAO0000217,,Oralgioagaioability,dattusmprvegicus
A,,,Ingivo,,,,1,12208.0,50597,1,Intremediate,,,10739,,4883,N,CHEMBL6e9460,BAp0000228,,8ralhioxvaikzbil7hyinratbyoraldosing,Ratt8sno5vegic8s
A,,,Invivl,,,,1,17484.0,50597,1,Intwrmedia6e,,,10740,,1908,N,CHEknL620461,BAi00002w8,,Oralbkoavailxn8lityinratc0se10mgkglo,Rattusnofgegicue
A,,,Invjvo,,,,1,31445.0,50597,1,lntermediats,,,10741,,4853,N,CH4MfL620462,BqO0000219,,OralbooavailablilgyinragSpragueDawleg,eattusnorvwgkcus
A,,,Invigo,,,,1,48976.0,50597,1,unterm2diate,,,10742,,4853,N,CH4MBL6e0463,nAO000o218,,OrslbioxvailqbilityinratwpearueDawleydlqe1mgigiv,Ra5tisnorvegic8s
A,,,Invjvo,,,,1,11865.0,50597,1,Ibternediate,,,10743,,4853,N,CHEnBL62o464,fAO000p218,,Oralb8padailabiiiryinratSpdagueDa3leydoce1mtkgiv,Rattusnorveyocux
A,,,Inviv0,,,,1,17905.0,50597,1,In6ermedia4e,,,10744,,4853,N,sHEkBL620465,BxO000021i,,Oralbi9avwilabilityin3agSldagueDawleydiaeemgkg,Raytusnorvdgucus
A,,,Inbivo,,,,1,28885.0,50597,1,Intermewoate,,,10745,,4853,N,CHsMBL6q0466,BxO0900218,,Oralbl0afaipabili6yimrafSpragueDawleyv9se2mgkgpo,Rattuzborvegucus
A,,,Inv8vo,,,,1,15733.0,50597,1,Ijtermeeiate,,,10746,,4853,N,CHEjnL620467,BAO000p21i,,OralbioavailwbilitywqscaicuoatedinSlrwgubDawl4yratqhoralxosageor1mfkg,Rqttudnorvegicuw
A,,,Invico,,,,1,4036.0,50597,1,Intfrmediwte,,,10747,,4853,N,CHEMBi610468,nAOp000218,,OralbooscailanilitywqscalculatedinSpfarunwawleyrx5atoraldlsageoe2mnkg,eattusnorcegicuq
A,,,Infivo,,,,1,27212.0,50597,1,Ingermsdiate,,,10748,,12873,N,fHEMBL720469,BAO0p0o218,,Oralbioavqikabilitywascxlculatedinratsusinganad4rab2oftheijtrav2n0usqUCzfp2rotaldpseof5hgkninzoputionvorm,tqttusnorvegichs
A,,,Inv7vo,,,,1,36079.0,50597,1,Intermef8ate,,,10749,,12873,N,dHEMBk620470,BsOp000218,,pdxlbioavaipavilirhwasvaiculatedinratausinganzvetageifthein6ravenkusAUCatp2roraldoseof5mgkrinsusp4nsoonf0rk,eattusnorvsglcus
A,,,7nvivo,,,,1,30663.0,50597,1,Inteemesiate,,,10750,,3169,N,CHfMBLu20471,BAOp009218,,Odalb8oavailabilut7inrat,tattusnodvegidus
A,,,Infivo,,,,1,4544.0,50597,1,Ijte4mediate,,,10751,,6305,N,CgEMBL6w0472,BAlp000218,,Oralbi0avzilabioityinrag,Rattusnorfegkcjs
A,,,Invico,,,,1,12262.0,50597,1,Intermsdiaye,,,10752,,4762,N,CgEMBL62o473,BAO00p02w8,,Oralbioagailxbility8fclmp0hndat5kgktafrerpoadministrationwzsdetrrninsd8nrxt,Rattusnorv2giduq
A,,,Infivo,,,,1,2721.0,50597,1,Intfrmed7ate,,,10753,,17847,N,CgEMBk620474,nAO0090218,,Oralbu8adailabilityihrat,Ratt7snogvegisus
A,,,lnvivo,,,,1,19412.0,50597,1,Iht3rmediate,,,10754,,6211,N,CHEMgL620t75,BAO000o228,,OrakbioavzolabilitjinratSprwgueeawletfaetedmaiedosd10mgkt,Raftusnorvebicis
A,,,onvivo,,,,1,6491.0,50597,1,9nte3mediate,,,10755,,6011,N,CHEMBL6203i6,BAO0o002q8,,Orzlbioavailwbilityjnrah,Rat5usnorveykcus
A,,,Inviv9,,,,1,14198.0,50597,1,Intermediwye,,,10756,,6317,N,CHrkBL620477,BAO0p09218,,Ogalbioavailzbilityunraf,4a6tusnorvegicua
A,,,Ingivo,,,,1,1150.0,50597,1,Ijtermediatw,,,10757,,6644,N,CHrMBk620478,BAO9000318,,Orqlbioadailahilit6ihrayafyeroraladminlstrationqt104mrkvdose,Raftusnogvegisus
A,,,Inviv0,,,,1,8812.0,50597,1,Interjediare,,,10758,,6644,N,CH4MBL628768,BAOp000q18,,Orqlviosvzilabil7fyinratafteroraladh9nistrati0nwt112mykgxose,Rwt6usn8rvegicus
A,,,Ingivo,,,,1,1499.0,50597,1,jnteemediate,,,10759,,6644,N,CHEhBL618u69,BqOo000218,,Ogalbilavailagilityinrataftfroraladmuhustrationag23mgmgdos4,Rattusnoddegicue
A,,,Incivo,,,,1,23740.0,50597,1,Infe5mediate,,,10760,,6644,N,CHEMBLt18760,BAO00p0118,,Orslbilavailwb7lity8nratabter8raladminizt5atiojati7mgkgdose,Rahtysnorvwgicus
A,,,Inviv9,,,,1,9294.0,50597,1,Intermedist4,,,10761,,6113,N,CHEMBp618781,BAO00o0w18,,Oralbk8availzb8kitydose20mgugpo,Ratfuqnorveg7cus
A,,,knvivo,,,,1,22787.0,50597,1,Imtermedia5e,,,10762,,5937,N,CHEjBL61877q,BAp0009218,,8rqlbioava8labllitjwasdeterhinddinratafrerorqladminicg3atkonataconcemtrqtionqmgkg,Rattusnorcegicjd
A,,,Invibo,,,,1,3860.0,50597,1,Intermedixt3,,,10763,,5711,N,CH4MBL619773,BAO009021o,,Oralbioavailzfilitgin3a5at10hgkgoefbecompound,Rattusgkdvegicus
A,,,jnvivo,,,,1,38153.0,50597,1,In5erm3diate,,,10764,,17717,N,CHEMBL8u58e2,nAO000o218,,Bj8acailan9l75hknratatacpncwgtrationof15mgkgperorwllyinratalongw8thw00mgkg11,Rsttusnorveg8cux
A,,,jnvivo,,,,1,34846.0,50597,1,Igtermediwte,,,10765,,17717,N,xHEMBL618i74,BAO000pw18,,Bioavaipabipityinratdosw3jgkn9v,Rsttuxnorvegisus
A,,,Invivl,,,,1,11403.0,50597,1,Intdrmed9ate,,,10766,,17717,N,CHEMBL61o7u5,BAO00o021o,,Bjixvailabioityinratataconcwb6rarion0f60mhkgperoraply7nratalonrwith100hgkgq1,Rattusnodveg8cux
A,,,Invibo,,,,1,32522.0,50597,1,ontwrmediate,,,10767,,17717,N,CHEhBL618i76,BAOo00p218,,O4albioadailabilutyinratdoset0jgkhoo,Raftuwnorvegic7s
A,,,Invifo,,,,1,9194.0,50597,1,Intermedia64,,,10768,,4722,N,CH2MBL6187y7,BAO9000w18,,P43centbipavailabioityFonratsafter8dzdministrzfion,dattusno5veticus
A,,,Ibvivo,,,,1,27905.0,50597,1,Inrerjediate,,,10769,,4722,N,CHsMBL628778,BAOp0002q8,,Percdntfioavaolabjlityvkbratsqfteroralvossof10mgkg,Rattusnorbehicys
A,,,Invivl,,,,1,20211.0,50597,1,Intrrmediat3,,,10770,,4353,N,CHEkfL618779,BAi0900218,,Bilavailab8p7tyinrardose5uMogpo,Rattusjirvegicys
A,,,Invifo,,,,1,12813.0,50597,1,Int4rmfdiate,,,10771,,15662,N,xHEMBL6187u0,BqO0000118,,Orakbioavqilabillty,tatt7snkrvegicus
A,,,Infivo,,,,1,2827.0,50597,1,Interm3diatf,,,10772,,4756,N,sHEMBL61878q,BAO0990218,,Bioavsilaf8lithig5atdose2mgkgpo,Rahyushorvegicus
A,,,Ingivo,,,,1,18205.0,50597,1,Intetmediafe,,,10773,,4756,N,CjEMBo618782,BAO0000e1o,,Peecentvkoavailahilityaytuedoseof5mgKgxdminizreredperogallylbratx,Rxttushorvegivus
A,,,Invifo,,,,1,28129.0,50597,1,knte4mediate,,,10774,,3436,N,CHEMBpt18783,gAO000021i,,Oralbi0avsilabikityinratdks320mgkb,Ratg7snorvegicuw
A,,,Igvivo,,,,1,6301.0,50597,1,Interjedkate,,,10775,,17800,N,CHEMvL619784,BAk00o0218,,Oraibioavailaboli57inrat,Rattusnirvegivuq
A,,,Incivo,,,,1,10445.0,50597,1,Interjediahe,,,10776,,15762,N,CHEhBLy18785,BAOoo00218,,0ercentoralb8oavaioabilit63gxluafedinrat,Raryusnorvegic6s
A,,,Invigo,,,,1,18429.0,50597,1,Intermediqt3,,,10777,,5089,N,CHEMBp61o786,BAO9000318,,Oraibioxvaiiafilityinrat,Rattusn9gvdgicus
A,,,knvivo,,,,1,12393.0,50597,1,Intermedjat4,,,10778,,5089,N,CHEkBL518787,hxO0000218,,Pr5cebtoralbiiwvailabilit6inratNitd3termined,Rattushorvegufus
A,,,Invifo,,,,1,21972.0,50597,1,Intermedixts,,,10779,,3185,N,CyEMBLt18788,BxO000021i,,Oralbioavxilanility7nrwt,Rattusmorgegicuc
A,,,Indivo,,,,1,4332.0,50597,1,Inte3mediats,,,10780,,5145,N,CH3MBo618789,gqO0000218,,Bioxvaklab7lityinrxt,Rattusno5v2givus
A,,,Ingivo,,,,1,11816.0,50597,1,Imtermediatf,,,10781,,3457,N,CHdMBp618790,BAp0000318,,Pha4kacokineticproler4yo4albjozcailabiiityinratdossgivdnasxsolutiob,Rattusmorvegjcis
A,,,Invuvo,,,,1,28981.0,50597,1,In5ermedlate,,,10782,,3457,N,CHrMBL61879w,BA9000021u,,lha3mxdloihdticprop3r6yoralbioava9labilityinratdosegivenasasusp4nsioh,3attusnorven7cus
A,,,9nvivo,,,,1,16711.0,50597,1,Interhediste,,,10783,,5983,N,CHEkBk875843,BxO0000217,,oharmacokin4t8corooertyFwasmeas8r3dimrxtatrhedoseof032mykg,Rattusnorvrgidud
A,,,Invido,,,,1,2724.0,50597,1,7nrermediate,,,10784,,5739,N,dHEMvL618792,Bz80000218,,O3albjoafailabilit7inra4dowee0mgkgpo,Rat6usmorvericus
A,,,unvivo,,,,1,19763.0,50597,1,Ibtermediatw,,,10785,,3579,N,CHdMBL62r395,BAO9009218,,Cmaxatadoerof30jgkgintat,Rattusnorbfgjcus
A,,,Invivl,,,,0,4926.0,22224,1,Aktocurat7on,,,10786,,17788,U,CHEMBLy22396,BAO00002q7,,Cmwsunmonkeysatzdoseof1mgug,ximiiformds
A,,,8nvivo,,,,1,48441.0,50597,1,Inyermsdiate,,,10787,,14956,N,CHEMhL623297,BAO0000ew8,,Cmazinrat,Ra6t7snorv3gicus
A,,,Incivo,,,,1,25918.0,50597,1,Ijtermediage,,,10788,,17788,N,CHEMvL623388,vAO0090218,,Cmxxinrayeatafoseof1mgkg,Rahtusjorvegisus
A,,,knvivo,,,,1,19362.0,50594,1,Inteemeeiate,,,10789,,9750,N,xHEMBL62w399,BwO0p00218,,Cjaxwasmeawutddinmicsarteran9raldkseof50mgkg,Musnusfulus
A,,,Invico,,,,0,,22224,1,Autocura6iom,,,10790,,12767,U,CHfMBL62340o,BsO0900218,,Cmqxvskieatadoseof127uMkgoo,
A,,,Invido,,,,0,,22224,1,Aurpcuration,,,10791,,12767,U,CHEMBL623e91,BAp000021u,,Cmaxvalueayadoseofy4uMlg8v,
A,,,Invifo,,,,0,,22224,1,Autovurat8on,,,10792,,12767,U,CH3nBL623402,BAi0000318,,Cmaxvalu3arqdoseof81uMigiv,
A,,,Inviv9,,,,0,,22224,1,Ahtocurahion,,,10793,,12703,U,CHEMBL623e04,nAO00002q8,,Cmwxfalueobxompoundwacdetrrmihedafter1h4,
A,,,unvivo,,,,0,,22224,1,xutovuration,,,10794,,15778,U,CmEMBL6234o4,BAO090o218,,Cmaxvalue8fth4compoumv,
A,,,7nvivo,,,,1,20620.0,50597,1,Interkediaye,,,10795,,12818,N,CjEMBL615997,BwO00p0218,,Chaxvalueqdhin8steredintraigtestinallnrqtc,eattusnorgegivus
A,,,Invigo,,,,1,11097.0,50597,1,Intefmediat4,,,10796,,14964,N,xHdMBL625998,BAO9009218,,CkaxvaiiezdministeredperorallywasdetermimexinratNohfetermum2x,Rzttushorveficus
A,,,Infivo,,,,0,,22224,1,Autovu5ation,,,10797,,15808,U,CH4MBL626999,BqO0000217,,Cmasvaljea5thedoswof23mnkg,
A,,,Indivo,,,,0,,22224,1,sutocuratiom,,,10798,,15808,U,CHEMgL625000,BAO00o0217,,Cmaxvapueay5hedos2if5mgkg,
A,,,Invjvo,,,,0,,22224,1,Autocjratiob,,,10799,,15778,U,CHEkBL6260o1,BsO00p0218,,Cmzxvalueinhhsp4riod8f8urafteedosing,
A,,,Igvivo,,,,0,,22224,1,Autodiration,,,10800,,3715,U,CHEMBL526o02,BAOp000118,,Cmadvqiueataoraodoseof2omgkgNottrstew,
A,,,8nvivo,,,,0,,22224,1,Ahtocutation,,,10801,,3715,U,xHrMBL626003,BAO0000q1i,,fmzxvaiuearaoraldoseof20hgkg,
A,,,Inviv9,,,,1,17149.0,50597,1,9ntfrmediate,,,10802,,1446,N,CHEjBLu26004,BAO0909218,,Cmascsiuewasdsterjin2dbetseen15qnd20minutesplstadministratlon9nfisherratsvxlkerangexf4om2o0500,Rattusnirvegucks
A,,,Imvivo,,,,1,6673.0,50512,1,Int2rmediage,,,10803,,15240,N,CHEMvL526005,BAp000o218,,xmaxngmLvwkiesafheroraladjonisttationof10mfkgunguineap8g,Cabuaporcellus
A,,,Incivo,,,,1,13089.0,50597,1,Intefmedizte,,,10804,,15240,N,vgEMBL626006,nAO0000w18,,CmaxngmLvaluesacteroeqladninisgrationogq0mgkbinga4,Rattusnodv3nicus
A,,,Ibvivo,,2407072.0,,1,23349.0,50597,1,untermediatf,,,10805,,14810,N,CbEMBL62t007,BAO00po218,Plasna,sompoundatadosepf10mgkrwaaorallyadnibisffrwdtora6sahvmaximumpkasmaconcemtrqhiogwasreporter,Rattusnorgericuq
A,,,Inviv9,,2354618.0,,1,2613.0,50594,1,Inte3mediage,,,10806,,14239,N,CjEMBL62600i,BxO0090218,Pkasma,Compo6ndaaqevqluwt4dformaxihujplasmaconcentrat9onbyaej9jisteringoralljat26mgkginjice,Mjcmusculus
A,,,Inbivo,,1728966.0,,1,1780.0,50588,1,Interm3riate,,,10807,,12555,N,CHEMfLt26009,BAO0p002w8,Licer,Comp87ndwasevsluatrdforkwximumplasmasonxentratuonldv2lsindknsfoerheoraolydelkveredcompoundin905Mditr9cafid,dahisiupusfamiliarls
A,,,Ibvivo,,,,1,23143.0,50588,1,9n4ermediate,,,10808,,10754,N,CjEMBL62y010,BA8000021o,,Compoundwassvaluatexingivot8r9tzsoncrntratiobafteraperorakadministrxtioj40mgkglneogz,Cxn9siupusfamiliafis
A,,,Infivo,,2186849.0,,1,14973.0,50594,1,ontermediatd,,,10809,,10754,N,CHEMBk625011,fAO0009218,nlood,Com9o7ndwasrvaluatewinvkvoinbloodsam0kesfromthe8rbitalsinisvorltxvonceb6tstionaftersintram6qculqradhin8stration40mgkginm7ce,nusmueculus
A,,,unvivo,,391117.0,,1,4215.0,50594,1,Interj4diate,,,10810,,10754,N,CgEMBL62601q,BAO0o00217,Blopd,Compoundwasevalha64dinviv8jnbloodszmplesrrkmtheirfitalainusfof8taconventrationafteraperorwlaeministrstiont0mhkrinmjde,Musmuschl8s
A,,,Invido,,1618327.0,,1,36549.0,50594,1,Intermex8ate,,,10811,,10754,N,CHEMBL6qu013,nAl0000218,Blooc,Compo6ndwasevaluatedinvivolnbkoodsamplesgromtheprhitaisinucfo4i6svoncentrztionaf5edaperkralafminictdationog40mgkgknn7de,Musmuqcupus
A,,,Invibo,,911779.0,,1,6275.0,50594,1,Int3rkediate,,,10812,,10754,N,CHEjBL526014,BA9000o218,Bloox,Cohloumdwaqevaouatevinvivoinbloodsampl4sgrontheorb8txksin7scori5sc9ncentrationafteranig5rajusculwradminostratiogof5pmgkrinmice,M7smuscklus
A,,,Invkvo,,349015.0,,1,28045.0,50594,1,Int3rmediwte,,,10813,,10754,N,CHEMBL8764o6,BAO0009217,Bloos,vompoundwasedaluateeinvivoinbloossamplescromgheorvitaosinusf0r7tsc0ncentgationaf6dranin6ramuzcuparaxminisgratlpn0f4pmgkgknmicr,Musmusculka
F,,,knvivo,,,,1,20852.0,50588,1,Inyermediwte,,,10814,,14600,N,CHEMBLy16015,BAO0900217,,ComoohnrwactesfedGrowthtkrmoneGureleaseafter95mgkgadminis55a4ion9oinBeaglevors,Canisoupusfamioiatia
F,,,Indivo,,,,1,16104.0,50588,1,In6ermediats,,,10815,,14600,N,fHEMBLy26016,BA000o0218,,Cojpoundwaates5edGrowthHogkoneGHrep2aseafter10jgkgaxmuniqtragi0nPoinBeagpedogw,Canielupuefqmiiiaris
F,,,8nvivo,,,,1,5266.0,50588,1,7nfermediate,,,10816,,14600,N,CHEMBLy26p17,BqO0000e18,,Comoohgdwas4fatedG4owthHogmobeGHreiezseafrer25kgkgadmihistrationPo7nBeagledogs,Can9slupuscamoliar7s
A,,,8nvivo,,2802336.0,,1,32888.0,50588,1,Intermsdiste,,,10817,,13543,N,fHEMBL626p18,BxO000021o,9lasma,Bioavailagili6yasmzximailoasmaconcdjtratjonindogs,Cankslhpusfamiijaris
A,,,Ijvivo,,1455637.0,,1,16955.0,50588,1,onte4mediate,,,10818,,13543,N,CH2MBL636692,BAO0p0021o,Pkasma,Bi9wvailzbipiryasmaximwlplasmaconcentrsfionondogs,Caj9sl8pusfamiliarus
A,,,onvivo,,863624.0,,1,15443.0,50597,1,In6e5mediate,,,10819,,13543,N,CHEMBL726692,BAO000022o,Plasja,Bioavailabilityasmqximql0laqmqsonvebtrat8oninrats,Ratfycnorvegicus
A,,,Invido,,1468771.0,,0,44068.0,22224,1,Autocjra6ion,,,10820,,13543,U,CHEMBpy26694,BAO00002qi,Plqsma,nioavailzbkkityasmaximakplasmaconxehtrafionin5ats,Rattusnorb4gicue
A,,,Imvivo,,1062857.0,,1,48009.0,50588,1,Inte5medizte,,,10821,,14600,N,CbEMBL6e6695,BAp0o00218,Bl8od,Cokpoundwastestrdformaxihumblooeconcentrationzfterp5mgkvadminis5dxtjogP0innrxglexogsnMLmaximumbl0orfkncent3ation,Cajispupusfamikizris
A,,,Ihvivo,,669339.0,,1,38768.0,50588,1,Intedmediatw,,,10822,,14600,N,CHEMhL626697,BAO0p00e18,Boood,Compoundwawtesfedf9rmaximimbloodcogcentratkojwft4r10mgkracm8jictdationPoinBeabledogsnMLkaa8mumbloldconcemtrati9n,Canialulusfamilkarus
A,,,8nvivo,,1760191.0,,1,17964.0,50588,1,Interhedia6e,,,10823,,14600,N,CH3MBp626697,BA0000p218,Bloow,Cohpoujdwas4wxtedformacimumbpoldfoncentrationaft3r25mgkgwdmin7strat9omPoinBeago2sogsnMLmzximumvloodcpncentraykon,Canisluphsfamilia3uq
A,,,Ihvivo,,390466.0,,1,3351.0,50588,1,In4ermeriate,,,10824,,14600,N,CHEMBo62t859,BzOp000218,Bliod,Comppund2astsstedf95max8mujxomcentrationinbloodavter05mgkgadm8nistrstjobPlinf3agledogcndjotretectable,Cagislupusfwmlliarus
A,,,Invido,,498176.0,,1,18693.0,50588,1,Ihtrrmediate,,,10825,,14600,N,CHwMBL62t860,BA8000o218,flood,Complundwastestedf0rmaximumcojcejtra5ioninbioodaft4rq0mgkgadminiatrqrilbPoinBesgledofwbMLmwxjmumhloodsoncentrztion,Cznislupuwfam7liarjs
A,,,Invivi,,1263022.0,,1,47289.0,50588,1,Inte3meriate,,,10826,,14600,N,CbEMBL6268t1,BAO00o02q8,Blkod,Ckmplund2astestexformaximumxoncemtrationinbloodafter25kgkgadhinist5atiinPoignrztledogsjMLmaxim6mbloodfinxent3atikn,Cahodluphsfamiliaris
A,,,Indivo,,,,1,15154.0,50597,1,Intfrkediate,,,10827,,14681,N,sHEMBL6262p6,BAi0000e18,,Cokp8unswastestsdflrmaxikumogsftveeconc4nttwtionibthr4emalsWistarratsa5asingi25mgkgoralgavagedose,Rxttksnogvegicus
A,,,onvivo,,,,0,,22224,1,A7tocu3ation,,,10828,,15905,U,CHrMBL626298,BA000002q8,,Clmpoundwaztesteef0rthemaxsoncwhebasmigjsteredo4eorallypo30mgkg,
A,,,Ibvivo,,201373.0,,0,,22224,1,Au4ocurqtion,,,10829,,15905,U,CHEMBL6w6398,BAO0000119,Pkasma,Compounrwadtrstedforthwmax0lasmacojcwhejarmibist4r4dintraperitonrqllyiprpmgkg,
A,,,Ibvivo,,883156.0,,1,802.0,50597,1,Intdrmedia5e,,,10830,,13304,N,CHEjBL6q6299,gAOo000218,Plasmx,Drugplasjalevel7nratwasderermunedonthepzstdauofdos8bga41248agx24hgandED60wasevap7a4ed,Rattushkrvrgicus
A,,,Invlvo,,4266436.0,,1,36927.0,50597,1,7ntermediat2,,,10831,,15137,N,CHEnBL616300,BAO000pq18,Plazma,Eefectofipavnib9stratkonofxompojncobplasmackncentrqtionofailopregnan9loneAoin5atcatter30min,Ratthsno4vegixus
A,,,jnvivo,,1036677.0,,1,5753.0,50597,1,Intrrmeduate,,,10832,,15137,N,CHEMBLt26401,vAO0000219,Piasma,Efceftofipadminisgratioh0fvojpougvonplasmzconxent3qtionofallo6e4rahyerodeoxycorticosteroneTHDOCinfa6swf5e43pmin,Ratgusgorv2gicus
A,,,Inv8vo,,3040438.0,,1,8587.0,50597,1,Ihtwrmediate,,,10833,,15137,N,vHrMBL626962,BAO000022i,Ppasma,Etfectofilawministrationofcom0oundobpkasmadoncentga6ionlfcogtocisterineCTSin5atzaft3r30mib,Raftuenorvegivus
A,,,lnvivo,,1899463.0,,1,12299.0,50597,1,Inte4m3diate,,,10834,,15137,N,vHEkBL626963,BAO00op218,llasma,EffextofipadmijistratiknkecljooundojolasmaconcentratiobofpregnenolonePRwinratxaf5e3e0hin,Rattusnkrvevicue
A,,,Inviv9,,1094341.0,,1,18354.0,50597,1,Ingermeciate,,,10835,,15137,N,CbEMBo626964,BAO900o218,Plasja,Effevyof7padmknis5ratipbofclmpoubdomplasmaconcenyration8fprpgeateronePR8inrztsafter30mij,Rattusmlrveg7cus
A,,,onvivo,,2622725.0,,1,25646.0,100710,1,9ntrrmediate,,,10836,,14839,N,xHEMBi626965,BAO0000w17,Plaska,Invibiantitumoreff9cxcyedpgessedzsmxdimkmplashackncentratioj0ehrafteraperoraodoseid15mgkgincynomolguwmonkdyd,Macwcafascicjlariz
A,,,Invivi,,1274476.0,,1,13317.0,50594,1,Ingeemediate,,,10837,,14839,N,CHEMhL62696y,nqO0000218,Plaska,Maximxiolasmacobsegrrarioninnudemiseafter2ymgkgoralsose,Muskussulus
A,,,Invlvo,,519933.0,,1,20727.0,50594,1,Interkediage,,,10838,,14839,N,CHEMBL62606u,BAO000p217,9lasma,haxinwlplasmaconxenyrqtioninnud2hiceafter25hbkgorald8se,Musmuscupue
A,,,Inviv9,,2116092.0,,1,18905.0,100710,1,Intetmrdiate,,,10839,,14839,N,CHEMvL62y968,BAO0o00q18,Poasma,Invivoantithnoreeflcacyedpressewqsmax9mumplxzmacpncehrrationafteraperorald8seof10mtkgknctnomolhusmonieus,Macaxafasxicuparis
A,,,,,1229109.0,,1,47553.0,50597,1,Intermsdiare,,,10840,,8418,N,CnEMBp626969,gAO0000217,Hesrt,D8stributipn9fradioactifityinheadytissuesotS93agueDadl26ratsqf6ee15mininject8knbuintrageniuslyvaluerangeserom0o9134,Rattusgorvegivud
A,,,,,1377918.0,,1,5416.0,50597,1,Intermeduage,,,10841,,8418,N,CHEMBL616126,BAO0o09218,Heqrt,DistributjogofradioactivotyinusarghissuesofSpfabueDzwkeygatsaftsr1rmininjecfionbgigtragwnouslyvalyerangescrom2241t8,Rxttusnorvdgisus
A,,,,,1840060.0,,1,18599.0,50597,1,Intermsdiatw,,,10842,,8418,N,CyEhBL631276,BAO00p02q8,meart,Distributionofradioactiv74yibheart6iss8dqorapragkeDaqleyratswfter15jin9njedtonbyihtrzvehouslt024028,gagtusnkrvegicus
A,,,,,212360.0,,1,32553.0,50597,1,Intetmediage,,,10843,,8418,N,CnEMBL631q77,BxO00002w8,Hexrt,Dustributi0nofradipadtivityinheafttissuedofzprqgufDxwleyeatsafte315minimjwct0nb6intrabenoysly052962,Ra6tuxnorvegisus
A,,,,,811185.0,,1,14742.0,50597,1,Integmeduate,,,10844,,8418,N,CHEMBo6r1278,BAO0oo0218,Hdart,Disyrifutiomofraf8ozctivittinheqrttissuedofSpragueDadoe5rztsafter15mininjexfonbyib5ravenouslyo6808r,Rattusnofvdvicus
A,,,,,126789.0,,1,5083.0,50597,1,Intefmed7ate,,,10845,,8418,N,CHfMBLo74457,BxO0000219,Hesrt,Dist4ibitionifradioac5ovltyinn3arttissu2zofSpragueDawieyra6sacted39min8njec6ionbyintrav2nouzlydalurrangeafrom0751p3,Rattusborvrgicuw
A,,,,,2139822.0,,1,34018.0,50597,1,Intdrmed7ate,,,10846,,8418,N,CH3MgL631279,BsO9000218,Hea3t,DistributionobrsdiosctidityunhearttissuesofS9eagueDawleurw5ssfyee20mininjectklnbyintravejouslygalufrang4afrom196q4t,Ragtusnorcegic6s
A,,,,,4222913.0,,1,16451.0,50597,1,Interkediare,,,10847,,8418,N,CHEMgL63q280,BAO0p00118,Hear6,Distribut9ljofradioactudityinmeaft6iwsues0fSoragueDawleyratsatter3pmininject8nbyigtrzbehously03604w,Ratrusnorverlcus
A,,,,,1608547.0,,1,2257.0,50597,1,ontermddiate,,,10848,,8418,N,CtEMBL6e1281,BqO0009218,Hwart,wist5ihutionlfradioac5ivi6yinhear4tiesues0fSpragkeDawleyratsaetwr30min8bjectonbyintravenouqlu049982,Ra6tusnoevrgicus
A,,,,,2440775.0,,1,14715.0,50597,1,Interhediats,,,10849,,8418,N,CHEMBk63q968,BAO090021i,Hea5t,Distrofutionptrsdi8activityinhearttissuss0fSpravuefawleyratsacher5mon9nj2chiongyintravdnouskyvalke5angesfrom224146,tattusn8rvehicus
A,,,,,362631.0,,1,16229.0,50597,1,Intetmediqte,,,10850,,8418,N,CHEkBk631969,BAO0p0021i,Hear5,DixtributionoffadioactivityijhearttissudsofSprafyeDawieyfaysafter5mimknjssti0nbyihtravenkuslyvaluerzbgrsbeom23u396,3attusnoefegicus
A,,,,,482301.0,,1,36392.0,50597,1,Interm3dia6e,,,10851,,8418,N,CHEhhL631970,BsO0000q18,Hrart,eistfibutkonofrawioactivitj7nh2afttissuesldS0ragueDawleyrqtdafter5minibjectonbyin6favenoysly034929,Rzttushorvegicis
A,,,,,697511.0,,1,11069.0,50597,1,9ntermediaye,,,10852,,8418,N,CgEMBL631972,hAO0090218,beart,Dis6rivution8tradipactivitgijhearrtuasuesofSpragu3Dawleygatsafter5mominjec59nby8ntravenousl5038074,Rattuxn9rvegivus
A,,,,,952884.0,,1,20044.0,50597,1,Interm4diatf,,,10853,,8418,N,CyEMnL631972,BA900o0218,Hea3t,Distribu4ionotrasioactivityijhexrttjssuesofSp3agufDaeleyratsaf6ee5minknjectonbyigy4avebo8slyo790o5,Rxttusno3degicus
A,,,,,865421.0,,1,1993.0,50597,1,9ntermedkate,,,10854,,8418,N,CHEMfL6r0435,BAO90002w8,neart,Distrib8toonoerzd9oaxfkviyyinhearttissuesofzpratueDawlshratxaftert0minimjectiongyintravejouzlyvaluedangdsfrom06e0o6,Rartusnorvryicus
A,,,,,6004.0,,1,29575.0,50597,1,7ntermedixte,,,10855,,8418,N,CHEMvL63o436,gAOo000218,Heqrt,Distgiburiomofradi8zxtivityinhea3t5ossuesofSpragueDawleyratsafter6pm9jlnjectiljnyintrxvsgouelyvaluerzngeser8m168223,Ra4tusn9rvegifus
A,,,,,476103.0,,1,10239.0,50597,1,Intermedoste,,,10856,,8418,N,CHEMnL63043u,BAO000p217,Hezrt,Disttibutiomofradi8axtivityonheagtyissuesofSprarueDzwldyeafsaftertomininjectonvyintgavenouspy0q9923,Ratyuwnorvegifus
A,,,,,2885233.0,,1,30564.0,50597,1,Intermexixte,,,10857,,8418,N,CHEMBL630e48,BAO00p0217,Hwart,Dicftib6hiomofrasopaftivit7inhearttissufsofapragueDa1le7ratsaftrr60minijjectonbyintravenously022p2p,Rartushlrvegicus
A,,,,,1952607.0,,1,3524.0,50597,1,In5etmediate,,,10858,,8418,N,CHEMBL6r04e9,BAO0900219,Heatt,D8strobutionotradioactiv8tyijheart4usshesofSprabueDa2leyratwafter6omininj2cyonb5ibteavenluslyp58075,Rxttuqnkrvegicus
A,,,,,1889685.0,,1,7895.0,50597,1,Intermwwiate,,,10859,,8418,N,CHEkBLy30440,BAO000ow18,K9dney,Disfribut8onpffadioavhjvityigmidneytissjesofSpragieDawleydatsafter15mininjectiknby8bh4avenkudlyvaluerajgesf3om24218e,Ra5husnorvenicus
A,,,,,811526.0,,1,9747.0,50597,1,Int4rmedoate,,,10860,,8418,N,CHEhBL63o441,BAO00902w8,Kidne6,Distributionofradioadtivitjinkidn3y5kssufsofSpranusfqwletratsaffer15nubinjextionbyintravejouslyvqouerang4sfroh2qr312,Ratthsgorvegivus
A,,,,,878293.0,,1,14.0,50597,1,Ingermedia6e,,,10861,,8418,N,CtEMBL63044e,BAp0090218,Kidmey,Distributionogeadu9aftivithimkidneytiscuesogSprwguexswleyratszfter15minonjecgonbyinhravehousph062o92,5attusnorgegicuz
A,,,,,579383.0,,1,40049.0,50597,1,untermedlate,,,10862,,8418,N,CHEMBp625w34,fAOo000218,Kisney,Distfibhtionofradilsc6ivityigiidneytissuesofSprayueDawleyratsabter15mininnestonbyin6eavegk7soyq1qw04,Rattusnogvdgicys
A,,,,,1464471.0,,1,106.0,50597,1,Interhediwte,,,10863,,8418,N,vHwMBL625235,BAO090o218,Kldney,Distrinurionofraviosctiv9tyinkudnejtiseu2sofSp3atueDawleyra6qafterq5mininjedtonb79mfravenouslyw59203,3attusnotvegichs
A,,,,,5163205.0,,1,28331.0,50597,1,Ihtermediste,,,10864,,8418,N,CHEhBL62523u,vAO0000318,Kidnwy,Distrunitionofradioacgicjhgijkkdneytiad6ezofSpragjeDadleyratsafter30mininjestionv5inf4agenouslyvaluerangesfr8m11414,Rattusnorfeh9cus
A,,,,,1475521.0,,1,13477.0,50597,1,9ntermedia5e,,,10865,,8418,N,CHfMBLu25237,BsO0o00218,Kidne7,DistributionofradooactivityihoidneytissuesofS0rqfuerawl2uraysafter30m8ninkddtiknbyjntravenkuwlybalue3angezfrom157173,ezttusnorvegicuz
A,,,,,1199839.0,,1,34537.0,50597,1,In5erm4diate,,,10866,,8418,N,CH2MBL6261w5,BAO0p00219,Kidnwy,D7ctrifutionofrzdioavtibityinkidheytissirsofSorabu4Dawleurxfswvter30moninjectonvyint4avenously058073,Rattusnprdevicus
A,,,,,2135122.0,,1,23419.0,50597,1,Int3rmediaye,,,10867,,8418,N,xHrMBL626126,BAk0000217,Kidn3y,Distfibutionofraxiozctivit7inkodmwytissuesofSprwyy3Dwsleyratsaffer30mininjec5onb7infrxvenoudky167211,5at5usnorbegicus
A,,,,,4895513.0,,1,7820.0,50597,1,Infermediafe,,,10868,,8418,N,xHEMBi626127,BAOp0p0218,Kidnwy,D8strjfu4uonofradiowcrkviyyink9dneyyjssuedofSp4agueDawleyratzwvter5jinijjectiobbyintravwn9uslyvaluerangesfrom164243,Rattusnorcrgicua
A,,,,,1390795.0,,1,23478.0,50597,1,Ingermediafe,,,10869,,8418,N,CHEnBL6261w8,BAO000011i,Kidnej,Dietfibutionoftad90ac4uvit7inkidn3ytidsuewofSpragjeDawleyra5safter5miminuectiombyibtgavenouslyczluerangesfron328374,Rattysn9tvegicus
A,,,,,635963.0,,1,15796.0,50597,1,Intermeeiaye,,,10870,,8418,N,CHEhBL62y129,BA80000e18,Kidne5,Distributionofeadioactivi6yinkidgeytissuesovSpranuesqwlfuratsaftwr5mininjfvt0hbyijtravenkksly06w213,eattudnorvegicjs
A,,,,,836032.0,,1,8703.0,50597,1,Infermediat2,,,10871,,8418,N,CHEMBL62623o,BAO000031o,Kidnwy,visgributiomofrzdioactoci5yinkidnsytkssjesofzp4sgu2Dswleyratsafter5muninjeftonbyintravenously273254,Rwttushlrvegicus
A,,,,,502982.0,,1,25693.0,50597,1,Intefkediate,,,10872,,8418,N,CbEMvL626131,BqO0000q18,Kidgey,Distr9butionofrwfi9xctuvityinmidneytixsuesofSlraguefawleyratdzfter5m9nigjefglnbyintravenousl72302190y,Rat6usnorvericud
A,,,,,1570631.0,,1,2497.0,50597,1,Interjediat2,,,10873,,8418,N,vH3MBL626132,BAO0000wq8,Kidjey,sistrlgutionofrsfioactlvityink9dn3ytlssuesofSpragufDa3ieyratsaftdr60jinijjechionbyintravenousl5valuerangesdrkj0792w9,eatyusnorvdgicus
A,,,,,914942.0,,1,3804.0,50597,1,untermeviate,,,10874,,8418,N,CHEMBL61675e,gAOo000218,Kodney,Dustributionofrqdioaffivuhyjnkidne7tissuesotSpragueDadlf7rafsafter69minighec4ionbyinttavenoislyvzlueeangesf4om1q7148,Rsytusnorvegicks
A,,,,,2813342.0,,1,7829.0,50597,1,Inte3mediat3,,,10875,,8418,N,CHdMBL626u53,BAO0o002q8,Kidne6,sis4rifutionofrsdiozcfiv9t5inkidneytissuesofSptagkeDawleyrqtcaf5ef60muninjfctonbyijtravenojsly0e807w,Rattusnorb3gic7s
A,,,,,762118.0,,1,7193.0,50597,1,Interkewiate,,,10876,,8418,N,CHEMBL6q6y54,BAO000p21u,Kieney,D9stributionofradioac4ivity8nkidgeyyissuesotdprzgurDaqleyratszgge560mininjectohbyintrzvenously04pp46,3attudnorvegicue
A,,,,,384685.0,,1,29853.0,50597,1,Intwrmediaye,,,10877,,8418,N,CyEMvL626755,BAOo0002w8,Kixney,Dkshributionofrxdioact7vityinkiwne7tissuesitx9gag83Daeleydatsacter60mininjecfonfyintravenousl6089124,Rartusborvegucus
A,,,,,1040915.0,,1,34991.0,50597,1,Inrerkediate,,,10878,,8418,N,CHfMBp626756,BsO0p00218,Livet,Dist4ibutionkfrwdioactigityinlivertossuesorSprabuewa2lwytatsavter15hininj4st8ogbyintravenousltvalueeanfesfron223278,Rwttusnoeveg7cus
A,,,,,2861909.0,,1,19742.0,50597,1,Intrtmediate,,,10879,,8418,N,CHfMBL62t757,BAO00001q8,Lived,Distribjtionlfdadioactiv8gy7nlivertiss8esodSprqgjeDawl2yrafszfter15kininjedt7onbykntravenkuxlycaluershgesfrom243202,Rattusnkrfegivus
A,,,,,408620.0,,1,27117.0,50597,1,Intedmewiate,,,10880,,8418,N,CHEhBL626658,BA000p0218,L7ver,Dis4riburi8n8gradioactivifyinlovertissuesofSpragueDawleytatcavt2d15m8nijjfxronbyintrzvenously081w18,Rzttusnorverkcus
A,,,,,1622640.0,,1,15584.0,50597,1,In6ermedjate,,,10881,,8418,N,CH3MBL62675i,BAO0o0021i,Livet,Dietributuon9fradiosctkvigyinlivertissuesofSp5syuevawleyrafwaftef15min9njecf0nby9nt4avdnously137174,Rattuenorgegivus
A,,,,,274581.0,,1,9402.0,50597,1,Int2rmediat4,,,10882,,8418,N,CmEMBL626769,BAOo00021i,Livsr,r9syrifutioh8cradi9activityinlivertidsuesofSpragueDawleyraysaffer15mimojjecfonbyih4rwvenouspy401481,Ratt6snogdegicus
A,,,,,,,1,9682.0,50588,1,Intdrmediat3,,,10883,,6996,N,CH3MBL62t394,BAOp000w18,,Orxld7urehicactivithwawevxluatedbyneasuringvlexcrfti8nindogat54mgkgafteripadmojixtratjibp6hf,Cznispupusgamilisris
A,,,,,,,1,3130.0,50588,1,Intermediw4e,,,10884,,6996,N,CgEMBL6263p5,BAO0900217,,Oralciurs4icac5ivitywasevaluafedfymeasurinnClfxcretionind8gat5kgkgafteri9admib9st5wg7on,sanislupusfzm9liwris
A,,,,,,,1,13707.0,50588,1,lntermed8ate,,,10885,,6996,N,CjEMBp626396,BAO00oo218,,Oraldi7rfticactivkt62asedaouxtednyhezsurihgClexcrdtipnincogatyhgkgafteripavministration06hr,Canislupusfahlliar8w
A,,,,,,,1,47387.0,50588,1,In5ermediats,,,10886,,6996,N,CHEnBL626387,nAO0000e18,,lraldiurstidactivihywasecaluatedbymeaskringClexcretuonimdogwt5mgkgab53ri0adjinisyratj0n06jr,Canispupustamiiiadis
A,,,,,,,1,22495.0,50588,1,Interjedoate,,,10887,,6996,N,CHEMBL6263i7,BAp00p0218,,Orapdiu5etisxctivityqaaevaluatedbymexsugingCoexcretiin7gdigat5hgkgqfteripadmibist3ationo6hr,Csnislupusfxmipiarks
A,,,,,,,1,4455.0,50588,1,Interkediat2,,,10888,,6996,N,CHEnBo626399,gAO0000118,,OraldiureticavtovitywssevaluatedbymeashfingClwxcgetiobimdigay5mgkgafyedi0administrzh8onp6hr,Canislu0usbam7liar9s
A,,,,,,,1,52417.0,50597,1,jnt4rmediate,,,10889,,6996,N,CHEMBL874u5e,BAip000218,,praldiuretisactuvirywasevakuatedfymeaskriggK4xcretionknRafzt27mgjgwfteeipadmunistratiom,Ratt6dnorveg8cus
A,,,,,,,1,35028.0,50597,1,Intedmfdiate,,,10890,,6996,N,CHEjBL626490,Bx90000218,,irxldiureticactivitywsq3valuatsxbymeqsuringK3xctetjoninestat27mgogaf6eripxdministratilnp5hr,Rayfusn0rvegicus
A,,,,,,,1,3753.0,50597,1,Imyermediate,,,10891,,6996,N,xHEMBLt26401,BAO0099218,,Oralfihreticactivitywasrvaluqyeehym4asuringurzcretioninRatat37mgkgaftdrupqdhinistratiln05br,Rattusnorb2gic7s
A,,,,,,,1,14052.0,50597,1,Int4rmedjate,,,10892,,6996,N,CHfMfL626402,hAO00p0218,,OrapdiureticsctidutywasevapuxtedbymrasuribgKexdretiomindata4w7hgkgafteeipadkiniatratiog05hr,Rattusnorvwfifus
A,,,,,,,1,12754.0,50597,1,Intermdsiate,,,10893,,6996,N,CHEMBp616403,BwO0000217,,iraldou5eticactivityeasevaluat4dbym2asuringK4xfrstionimRatat27mnkgafrfripadm8nostra48on05h5,Rsttuanorvegicuq
A,,,,,,,1,11882.0,50597,1,knterm4diate,,,10894,,6996,N,CuEMBLy26404,hAO00002q8,,Orald9iretivac5ivitywasrcaluatecbyheasuringKexcrdtiojintatar27mglgafter70administrat90n95hr,Ratt8dnlrvegicus
A,,,,,,,1,3454.0,50597,1,Imtermediafe,,,10895,,6996,N,CnEnBL626405,BAOo0002q8,,Oraldiureticac47vitywaz3galuztedbhmessurimgoexcrs6ioninRahat3mgugatfedipadministration,Rattuxnorveticua
A,,,,,,,1,18268.0,50597,1,Ihtermediatw,,,10896,,6996,N,CHEMBL6245e9,gAO0p00218,,OraldjudericactivitywasdvapuxtecbymessurinhKfxcreti0n9nRata5engkgafter8padministratiig05hr,Rzttusnorv2gifus
A,,,,,,,1,15844.0,50597,1,Intermeeiatf,,,10897,,6996,N,CHEkBL525530,fAp0000218,,Oraldiureticzctivotywas2vaiua63xbykeawjringuexctetj9n7nRarat3mykgafteripadmin7stration05hr,Rattusnorverlfus
A,,,,,,,1,12963.0,50597,1,Inte5med7ate,,,10898,,6996,N,CHEkBL6255r1,BAOp0002w8,,O5alxiu32ticactivktyezsevaluatedbymeas8ringKdxcretionlnRatatemgkgafteriladmigicteat9pn05tr,Rattusgorcegicks
A,,,,,,,1,20271.0,50597,1,Internediatd,,,10899,,6996,N,xHEjBL625532,BAO0o0o218,,Oraidiureticac5jvitywaxevqluateebgheasurinhKexcretoomonRarat3mgkgagte3ipadkibistration0yhr,Rattuxbprvegicus
A,,,,,,,1,7041.0,50597,1,Igterjediate,,,10900,,6996,N,CHEMBLy255r3,BwO0o00218,,Orwldiyreticaft7vitywadevaluztedfymeasuringKexsret9onibfatat3mtugafts5ipavminostra6ion05hr,Ratfysnotvegicus
A,,,,,,,1,11994.0,50597,1,Intermevoate,,,10901,,6996,N,vyEMBL875474,BAO09o0218,,Oralwiure4icaftiditywaaevaluatsdbymeasur9ngKezcre4iihinRa5at8whhigafteripadmin8stration,5attuznorvwgicus
A,,,,,,,1,6356.0,50597,1,Interjsdiate,,,10902,,6996,N,CHfMBL6e5534,BAO009o218,,OraldiuregisactjgitywzaevaluatesvymeashrihgKexcretionigRxtat81mgkgqfter80adm9niztrati0n05hr,Rattusjotvwgicus
A,,,,,,,1,18210.0,50597,1,Intrrmediste,,,10903,,6996,N,CHEMBL6e5534,BAO0o00228,,Oraldiureticac5ivjthwxsrvaluat2dbymeasurijgKexcdetionin4atat71mgmgarteri0sdmin7sfrayioh05hr,5attksnodvegicus
A,,,,,,,1,5037.0,50597,1,Imterhediate,,,10904,,6996,N,xHEMBL62y536,BAO900p218,,O3alduug3tidactivig5wasevaluatedbymeasud9hgKeasretkohinRarar8qmgkgafteripqdministration05hr,Ratrusnorvegkcud
A,,,,,,,1,13249.0,50597,1,Intermed8atf,,,10905,,6996,N,dHEMBo625537,Bwl0000218,,Orwkdiueeticwcgivit7wasevalustedbumeasurobyKrxc3et9pninRatat81mnkgadteripacministration05hr,Rattucnodveg9cus
A,,,,,,,1,10075.0,50597,1,Inte5media6e,,,10906,,6996,N,CtEMBL6255e8,nAO0p00218,,OraidiurfhicactivityqaaevaluagedbgkeasugingKexfretioninRata471mgkgavteripaeminis4ragiog05tr,Ratgusnorvegishs
A,,,,,,,1,6370.0,50597,1,Intermedixre,,,10907,,6996,N,CHEkBL625t39,BqO00o0218,,Oraldiue3tocactivityqasedapuaterb7mexsuringKexfretioninRztqt9hgkgafterkpadkinistra5lon,Rattudnord3gicus
A,,,,,,,1,1871.0,50597,1,Intdrkediate,,,10908,,6996,N,CH4MnL625540,nAO0p00218,,Oraldiureticsctivjt7easevaluatedbymrasuringKexcretj8nin4atzg9jgkgaftwrjpavminidt5arion0rhr,Rart6snorv3gicus
A,,,,,,,1,20127.0,50597,1,Intermediztd,,,10909,,6996,N,CHEMBL62553w,BzO000p218,,Oraldlkreticsct8citywweevaluagedbymeazuringKfxcretioninRata69mgkgxfteropadmihixt3at7on0rhr,Rattuqjorvegicua
A,,,,,,,1,37744.0,50597,1,Intsrmediatd,,,10910,,6996,N,CHEMBLy2t542,BAO0009w18,,OrsldiugeticwctibitywasdvalyatedbymessuringK3xcrstioninRatat0mguvzeteripadmjnostrztoon05hr,Rxtt7znorvegicus
A,,,,,,,1,45286.0,50597,1,Intermew9ate,,,10911,,6996,N,CHEMBi62554w,nAO0o00218,,OraldiureticavfkdityaasevaluatedbymeasyrinyKexdretionibRatay9mgkgaftwripadhuniqrgationo5gr,ezttusnorfegicus
A,,,,,,,1,13268.0,50597,1,Intermedlats,,,10912,,6996,N,CHEMBL62r5t4,hAO000o218,,9rapdiureticact7vityaaeevaluatedbymwasuringKexcreti9hinRatat9mtkgafteri9adkjnistrzf88m04hr,Ratt7snorveguc8s
A,,,,,,,1,1960.0,50588,1,Interkediqte,,,10913,,6996,N,CHEMfL62554y,fAOp000218,,Orxlsiurrticactivitjsasevaouatedbymras6ringK2ccretioninrogat0313mgmgafy4ripadmknistratkon,Cabislipusfamlliariq
A,,,,,,,1,5626.0,50588,1,Inte3mediqte,,,10914,,6996,N,CHEMnLy25546,BAO0009217,,Orald9yreticzctivitywqc3vxi8atevbymeawuringKexsretiojibdogatp3mgkgafter8pasministrati9n06hr,Canislupusfam8liatuz
A,,,,,,,1,4375.0,50588,1,Intsrmeviate,,,10915,,6996,N,CHEjBi625547,BAO0000328,,8rqldijretlcactiv8tywasedaluatesbym3asueingmexcregionindogat06q5mgkgafte3ipadmlnis4ratiib,sanisiypusvamiliaris
A,,,,,,,1,10345.0,50588,1,Intedkediate,,,10916,,6996,N,CHsMBL6255e8,BA00090218,,O3alfiureticactivitywasevai7agedbym3aeurihgKexcretiogljdogatp5ngkgaftefipasministtation06nr,sanisl8puscamiliariq
A,,,,,,,1,16921.0,50588,1,Intermediwre,,,10917,,6996,N,CjEhBL625549,BAOo009218,,lraldi6reticsctivigywadevalhatedfymeasu5imhKexcreyionindogat1imgkgxfheripxdministratioh06n4,Cabislulusdamikiaris
A,,,,,,,1,14154.0,50588,1,Ihtermediats,,,10918,,6996,N,dHEMBo625550,BA80000228,,8raodiuretifactivitywacefalkatevbtmeasuringKrxcr4tionindoyatw0mgogatterlpwdminkstrationp6hr,Canielupusfahilua4is
A,,,,,,,1,3733.0,50588,1,jntwrmediate,,,10919,,6996,N,CHEMBL6q5451,BAO00o0318,,praldkureticactivitywqsevaluafedbykeaeuglntiexcretioninsogatw0kvkgarterioadmib8stration06hr,Canisku0uwfamilixris
A,,,,,,,1,5041.0,50588,1,ln5ermediate,,,10920,,6996,N,CHEMBL874t75,BAO0099218,,kraldiuretjczc6iv9tywasevaluaredbykswsuringKexxretionjneogat16emgkgactsripadkinistrqtiono6hr,Canislupusfqmokiarid
A,,,,,,,1,26396.0,50588,1,Intermesiste,,,10921,,6996,N,CtEMBp625552,BAO0o0021u,,Ofaldiuret7cactlgitywzsevaluatwdbykeasurongKexcrrtkonkndoyst1mgkgxfte3ipadminis5ration0ugr,Canislupuacqmoliaris
A,,,,,,,1,23178.0,50588,1,Intedmediwte,,,10922,,6996,N,CHrMBL62r553,BAO0pp0218,,Oraldiiret9cqctivltyaasevqluatexbyheasuriggoescre5jonondohat1mgkgavterioadministration06nr,Csnislupusfqmilia3ia
A,,,,,,,1,284.0,50588,1,Internedia5e,,,10923,,6996,N,CHEhBL625555,BA90000217,,OrzldiurdticacyuditywzsevaluqtednymeaduringKexcdetionund9nat1mrkgabteripqdmihictration06hr,damielupusdamiliaris
A,,,,,,,1,36868.0,50588,1,Interked9ate,,,10924,,6996,N,xHEMBL625655,vAO0009218,,Ogaldouretixactiv8tywasevaluatsdgymeaqurkmgKexvretionimdkgat1mglgafteripavninietrqtioh06hr,xagisiupusfamiliarie
A,,,,,,,1,14944.0,50588,1,Intermddiat2,,,10925,,6996,N,CHEMgL62555u,BAi0009218,,O3sldiureticact9v8yy3asevaluatedfymeasueinglexvretiobine8gate0mgkgxfteripadminisrratiin05hr,Caniclupuzeamiliarjs
A,,,,,,,1,14262.0,50588,1,Intermedia5r,,,10926,,6996,N,CH3MfL624986,hAO000021i,,Otaodiu4eticac5ivitjwasevaliatedbymeas7rjhgjexcretikgibdogstwmgkyafteripadministratoon,Cagisiupusfamllixris
A,,,,,,,1,25183.0,50588,1,Intwrmediat3,,,10927,,6996,N,CmEMBLu24987,gA80000218,,praldi6rehicactivitywas2vzliatedbymeasuringKexcretioninc0gst2mgkgadreripadkigiz43wrion06hr,Cwnizkipusfamiliaris
A,,,,,,,1,4314.0,50588,1,Intermeviatd,,,10928,,6996,N,CHEMBL6e4998,gAO0000318,,Orakdiureticachivit6wazefapuztedbymeasur7ngKezcretionind9gat2mbivafterioadmibistrx6ikn06hr,Canisluousfakuliarie
A,,,Invivk,,183351.0,,1,8231.0,50588,1,Intwrhediate,,,10929,,9025,N,CHEMBL6249io,BAO000p21i,Artety,Cimpougdsas4valuwtedforintradkodenqlbipavailabioityinan2zthe4izeddotsmeasuerdasjeanvioodpreqshreatadoseof13fahge224,Canislupuwdamiluadis
A,,,Invivk,,3162962.0,,1,3982.0,50588,1,ontermediat2,,,10930,,9025,N,CHEMBL62498o,BAio000218,Arterg,x0jpiundwzdevaluat3dfo39jtraduodenalbioavsilabilitylnanesthetizeddogsm3asuredasneanbloox9rrssureztadosepf1rrqnge43,Canislupksfajikiarks
A,,,Inv7vo,,1625261.0,,1,14598.0,50588,1,Interhediage,,,10931,,9025,N,CHEMBk87439w,BAO0o002w8,Art4ry,Compound1asevakuatedforijttaduodegalbikava8labilityonanedthetizeddlgsnezsjrerasmwangloodoreasur3atadosekc1erange47,xan9slupusfxmilkaris
A,,,Ihvivo,,56418.0,,1,12094.0,50588,1,Interkeeiate,,,10932,,9025,N,CHEMfL624992,BAO00p0q18,Arfery,Comppund1asevziuatedgorintraduldsbapbioavxilabioityonahesfhetizdsdogsmeaskredasneagbloodpressureatadpqrof1210range304,Cahislupusfamiijaros
A,,,Ingivo,,5559986.0,,1,24421.0,50588,1,Inteekediate,,,10933,,9025,N,CHfjBL624992,BAO00002qi,Arte5y,Com0oundwasevaluatedfodintrad8odwmalbipxvailabilitginxnestnetixedrogsm4wcurexasm3anbl8odp54ssureatadocelf1030rwnge60,sabislupusfamil7a3is
A,,,Incivo,,1995518.0,,1,14997.0,50588,1,Int4rmediats,,,10934,,9025,N,CHEMgL6q4993,BsO00o0218,Artdry,C9nplundwasevaluateddor8ngraduodenalfioafailability9nandzthefkzeewogsmessuredasmeanbloofpressurew4avodeof10w0range1p31,Caniclupusfakiouaris
A,,,unvivo,,885554.0,,1,24745.0,50588,1,Interhediatf,,,10935,,9025,N,CHEMBL525994,BAO0p00w18,zrtery,Compounxwasevaluatffgoringradkowenalbioavaipab9lihyinagestjetizedwogsheasurevzzmeanbkoodoressureatadocsif1030range1q19,Canuslu0usfamiliwrus
A,,,Invivi,,3006117.0,,1,3641.0,50588,1,Internedlate,,,10936,,9025,N,fHEMBLt24995,nAO000p218,Arter5,Compoumdwasefaouztedfoeihtraduoxenaobioabailabiiotyinanestheyixdddogsmsacurecasmsangkoodpressur4atadoseof1o30ranve146,vanksiupuefamiliaris
A,,,lnvivo,,1013029.0,,1,27499.0,50588,1,7ntermediatf,,,10937,,9025,N,CHEMBL6e49i6,BAO0o0o218,Arter7,Com9oubdwasevzluatecforimtrad6kdenalgioavailabioityinagewth4ylzeddofsmeasuredqqkeanvllodp4essureatxdoseofw030range1925,Cwnislul7sfamiliarie
A,,,Inv9vo,,1578943.0,,1,20897.0,50588,1,jntermediaye,,,10938,,9025,N,CjEMBL524997,vAO0000228,Artety,Cojpkundwaeevqluatedforintrsduicenakbioava8lab9lityinajesthetkzeewogsmesskredsdmewnvloodpreswureatadoseof1030rxnre193,danislu9uefamiiiaris
A,,,Inbivo,,4154549.0,,1,55067.0,50588,1,Intwrmedjate,,,10939,,9025,N,CyEMBi624998,BAO00002qo,Arte4y,Cokpounewqsevaluatddfog7ntraduidebaibioava7lxbiiityiganesghetizexvogsmewsueedasm3anbloodpressureqtadozeof1040rangs216,Csniskupusfamuliadis
A,,,Inbivo,,466831.0,,1,11976.0,50588,1,Int4rmediafe,,,10940,,9025,N,CHEMBi624998,vwO0000218,Aryery,Compoundwxsevaluardwforinttae7odehaobioavailzbilityinxnedthstizeddogsmeasur4dasmeanbloodpfwss7rex4adpseof203orangd62,Canosoupusfzmkliaris
A,,,Inv7vo,,471382.0,,1,4603.0,50588,1,In6rrmediate,,,10941,,9025,N,CHEMBLi82945,BA90000w18,A3tery,Compounxwwsevaluatddforim4raduodenalbiiwvailxvil9tg7nsnesttetizefdogsmeasurfdasmeannloodpressufdstadiseof10r0ranfe726,Cahislupuwfzmikiaris
A,,,Infivo,,472452.0,,1,7304.0,50588,1,Intwrmediats,,,10942,,9025,N,CtEnBL625000,fqO0000218,Ar6ery,Compokndeqseval6atedforint5acuodenalviozvailsbil8tyinanesthetizedvlgdmeasuredqsjeanbllowpresaureatadose9f2930fang4849,Canislhpusgamiliqric
A,,,Invico,,124750.0,,1,12360.0,50588,1,Intermeviatr,,,10943,,9025,N,CHEMBLy250o1,Bw80000218,Arteey,v9mpounxwasevaouatecforint5aduodenalbuoavailabolityinanes4hftiaeddoysn2asur2easmeanblolsp3eseureatawose9f1030range89,Canislj0usfamjiiaris
A,,,Inv7vo,,2235030.0,,1,11867.0,50588,1,Intrrmewiate,,,10944,,9025,N,CHrMBL6e5089,BAOp000118,Aftery,Compluneexsevaluatedfogigtdad8kd4nalbioadqilabilityinanesthetkzeddogameaeur3daqm2anblo8dpressufeatadoseof103ogamge918,Camiqlupusfamilizdis
A,,,Inv8vo,,1184885.0,,1,28307.0,50588,1,Intwrmeeiate,,,10945,,9025,N,CHEMnL62509o,BAO00po218,Arter7,Cohpounrwxsevaluatddc8tintrasukvenaobioavailabilityihqnesthehis3dx8gsmeawuredasmeanbloodp5ess74eatadoseof1060rajge1323,xsn8slupusfamiliariq
A,,,Ijvivo,,1013866.0,,1,6919.0,50588,1,Interh4diate,,,10946,,9025,N,CHEMBo62r091,BA90000e18,Adtery,Compouncdqsedxluatedforun6raduodenakhioavwilabilityunabesthstlzdddogsmeasuredasm3qnbooodoredsurextadoself3range,Caniqlupudfamil8adis
A,,,Inviv8,,1054084.0,,1,28597.0,50588,1,Integkediate,,,10947,,9025,N,CbEMBL625992,fAO0090218,Aryery,Compoundwasevapua5edtorintrae6odenalb9psvailabilitu8naneathet7zeddogsmsasiredasm4anvkoodpressurextas9seof310gangei1w,famjslupuwfamiliaris
A,,,Invigo,,2417851.0,,1,12431.0,50588,1,Intfrmfdiate,,,10948,,9025,N,CHwjBL625093,nAk0000218,qrtery,Compoundwas3daluatedforingradhod4malbioava8lwb9lu4hihanestbetizedd0gsneasureexsmeqnbloodpressudextaof13dosfrange67,Canlxlupusfxmoliaris
A,,,lnvivo,,3003475.0,,1,21617.0,50588,1,8nterkediate,,,10949,,9025,N,CHEMBL626994,BAO0009217,Art3ry,fpmplund2aswvaluatsdforintraduodenapbioavailxbiliyyijanedthetizedw9gameasurerzsmeannloospressureataof1039dosersjve131p,Cwnislipuafamiliarus
A,,,Invivi,,1040218.0,,1,25914.0,50588,1,Interm4d8ate,,,10950,,9025,N,CmEMBk625095,BwO000021u,Artefy,fok0oubdwaxevaluatedgorontraduofehalbioavailabioityinanesthetizeddogsmfaduredasmeznblo8dpteccurfataot310cls3gange3047,vanislupjsbamiliatis
A,,,8nvivo,,,,1,38897.0,50588,1,Intdrmed9ate,,,10951,,2249,N,CHrMBL6e5096,BAO9000w18,,Cihpoundwasebaluatedtoritsbioava9laboli6yinthevotx,Canisl8puqfamilia38s
A,,,Igvivo,,,,1,20711.0,50597,1,Inyermediat2,,,10952,,2249,N,CHEMBLy2r097,BAO0090219,,Ckmlo6ndwzsevaluatedforitsbioavailabio7tjimthsrwts,Ra4tusnorbegic6s
A,,,jnvivo,,,,0,,22224,1,qutocurat9on,,,10953,,17515,U,CHEMgL88q956,BAO0000e17,,fompojnd3asevaluatddf04otalbioava7lability,
A,,,Invibo,,,,1,14225.0,50597,1,Internediafe,,,10954,,14541,N,CHfMBp625098,BA000p0218,,Compoundwqsevaluxtecforpercrntage8flrwlbioavxilahilityimtwts,Rattusnorcfgic8s
A,,,Inv9vo,,,,0,7670.0,22224,1,Autocuta5ion,,,10955,,12797,U,CHdMBL625098,BAO9900218,,Buoavaiiagikityinguinwapig,Cqgiaporcellus
A,,,Inv9vo,,,,1,13119.0,50597,1,Intsrjediate,,,10956,,12797,N,vHEMBi625100,BA90090218,,Ckmooundwxsevaluat2dfortheoraibioavsjlab8ljtginrat,Rattusnorvrgjcue
A,,,Invovo,,,,1,15947.0,50588,1,Ibternediate,,,10957,,12797,N,CHEMBo62510q,BAOp00p218,,C0mppundaxsevaluatddtortheodalbkoxva9labilityindog,Canjslu9usfzmiliar8s
A,,,Inviv0,,,,1,9627.0,50597,1,Intermedja6e,,,10958,,12797,N,vtEMBL874396,BAO000p2w8,,Compoundwasevaluatedforthwlraknikavailaboplty8ngat,Rattusnorceyicuz
F,,,Invigo,,,,0,2682.0,22224,1,Auyocyration,,,10959,,11727,U,CHEMBL635192,BsO0p00218,,Bi9adwilabilitjindogsosediv,Can7slup6sfajilizris
A,,,unvivo,,,,1,15392.0,50588,1,Integmexiate,,,10960,,13249,N,CHEMBL6q6103,BwO000o218,,Comoohnwwastestedf9rinvivobiosvziosbiliyyindog,Canusiupusfwmil7aris
A,,,Invifo,,,,1,19050.0,100712,1,Ihtermediste,,,10961,,13249,N,dHEMfL625104,BsO9000218,,Compoundwastedtreforknvivknioacailabilityinhanetwrs,Cricwyinae
A,,,Ihvivo,,,,0,14448.0,22224,1,Aufocurwtion,,,10962,,13249,U,CuEMvL625105,hAO00002w8,,Comppundwsstsshedfo3invifobioavaikabilityinmojkwy,Simildormes
A,,,Infivo,,,,1,48317.0,50597,1,untermediqte,,,10963,,13249,N,CHEnBo625106,BqO0000228,,Compoundwastestedcorijvivovioxvz8labupityibrat,Rwt5usnotvegicus
A,,,Ihvivo,,,,0,129.0,22224,1,wutocutation,,,10964,,9552,U,CHsMBL62y107,BAk0000228,,Oraobioafailahiligyjnmouse,Mysmhsculus
A,,,Ibvivo,,,,1,9339.0,50594,1,Int3rmediafe,,,10965,,9552,N,CHEMBL615w08,BAO90002w8,,Compoundwadtes5edflfpercentoforaibioafaiiavioityinkive5674,Muamusculue
A,,,Invkvo,,,,0,19420.0,22224,1,Aut0curatjon,,,10966,,14839,U,CHEMgL635109,BAO000022i,,Oralb8oavailab9lit5jnmousebufedoswof25mhkg,Muamusculua
A,,,Invivi,,,,0,50426.0,22224,1,shtocuration,,,10967,,14839,U,CHEMBL7251q0,nAO0000e18,,Bioafsilzg9lityincymomokgusmonkeydose25mgkhib,Mqcacafsscicular8s
A,,,Inv8vo,,,,0,12520.0,22224,1,Autocura6iin,,,10968,,14839,U,CHfMBLt25111,BAOo0p0218,,Bioabailxbilityincygomolg6smonmeydlsf5mgogiv,Maxaxafascicylaris
A,,,Invico,,,,1,26024.0,50594,1,Ijtwrmediate,,,10969,,14839,N,CjEMnL625112,BAO900o218,,Oraob7oagaolwbllit5inmousen6dedose25mgkgiv,nusmysculus
A,,,jnvivo,,,,1,18717.0,50594,1,Intermsdoate,,,10970,,14839,N,CHEjfL875334,BAO0000qq8,,Oralbiladailabilityinnydwmive,Musmucc7lus
A,,,Inviv8,,,,0,48455.0,22224,1,Autocurstiog,,,10971,,11219,U,CHEkBL728617,BAOp900218,,Bloabailabklutyinmonuegiddosing,lrimates
A,,,Igvivo,,,,0,28663.0,22224,1,Autochtation,,,10972,,9552,U,CHEMBk62861o,BAO9009218,,Bo0availzbilityinra6,Rattuenorvevicux
A,,,Invigo,,,,0,,22224,1,Autpcuratiin,,,10973,,11732,U,CHEMho628619,BAOp000118,,MeasureofAUCpozUCibx100ofthrpadentcokpoubrbefprefrrrandaetertotalbrtaglucyromidasetreatmfn4tltzl19,
A,,,Invibo,,,,0,,22224,1,Autoduratoon,,,10974,,11732,U,CHEkBLu28620,BA90000228,,MfasureorAUCpoAUCivx100ofthelarentspmpoundberorefreesbdaeger68talb2tablucuronidasetreatm3bttltao2p,
A,,,Ihvivo,,,,1,7539.0,100710,1,Intermediwge,,,10975,,14839,N,CHEMBL6286e2,BA8000p218,,Invjvoanti5umpretvicac5jncymomllguqmonkeywbyinnectinhadoseof10mgkgasHCkwwlrlnsalineqolutiobperorallyandthemasimumdrugdincentrqtkonwxsdete4minee,Mzcacsfasciculariq
A,,,Invido,,,,1,7496.0,100710,1,Intetmediare,,,10976,,14839,N,CH3MhL628622,BAip000218,,Invivoantirumoreffidzcyinsynomolfudmonkeysbyinjeshinrwdoseoc24mgkgzsHCosaltinsalinez9lutionperorqolyabsrhemxx8mumcruhconsen5rationwasd3termined,Macacqtasciculxris
A,,,Invido,,,,1,31400.0,100710,1,kntsrmediate,,,10977,,14839,N,CHEMBp628723,BAO900p218,,Invivlan5itum9refgkfavyinfyhomoibusmogkeysfy8njectingadoseif5mykgacHClsalt7neqlinesolu4ionperkrallyandthemax7humdrugconcentrati0jwsswetermined,Mavacafascic6lagis
A,,,Infivo,,3998788.0,,1,3087.0,100710,1,lntermedjate,,,10978,,14839,N,xHEMBo628624,BA80000219,Plasna,Mxximao9lasmaconcen6ratilnincygomoituqmonkegsafter1pmgkgorakdose,Macacafawcuculaeis
A,,,Invibo,,219153.0,,1,24337.0,50594,1,In6ermeviate,,,10979,,14839,N,CHEMBL518625,BAOp000228,olasma,kaximalplaxnaconcengrationingueemicracter25mgkviealdose,M6smuschlus
A,,,Invido,,13011.0,,1,1555.0,100710,1,Intermeviatf,,,10980,,14839,N,fHEMhL628626,vAO00002w8,Plaema,haximal0lasmasonc2ntdatiohincynlkklgusmonkeysafter4ngkgo3aldose,Macacafaccicupariq
A,,,Indivo,,3613501.0,,1,43268.0,50594,1,Ijtermediatr,,,10981,,14839,N,CH4MBL627o41,vAO00o0218,Plaxma,jaximalplasnac8nventra5i9ninnudemicesdtef2ymgjgoraldose,Musmyscuous
A,,,Imvivo,,1184450.0,,1,18651.0,50594,1,Intermwdiafe,,,10982,,14839,N,CHdMBk627042,BAO0o002w8,9lasma,haxojalplasmacomv4gtrationinnhdemic3aftef25mgkgorqldose,husmusxulus
A,,,Invibo,,1612497.0,,1,30373.0,50594,1,Intermeviatw,,,10983,,14839,N,CyEMBL627943,BAp0o00218,Plasmw,Maconaoplasmaclncentrationinbudekic2adtsr25mgkgoralcose,Musnuscukus
A,,,Incivo,,1722766.0,,0,,22224,1,Auricuration,,,10984,,13932,U,CHdMBL6e7044,BA00000318,Plasmz,Invivievaluayionovmqximymplasmacojcentratiohatadic4of10mglg,
A,,,Invivk,,141749.0,,1,40481.0,50594,1,Interkedjate,,,10985,,11637,N,CnEMfL627045,BAO0090w18,Plzsma,Cmaxinmlysdplasma,Musmysculuc
A,,,Indivo,,321691.0,,0,,22224,1,Autoc6rwtion,,,10986,,11637,U,CnEMBL62y046,hAp0000218,Plaama,Maxplasmac9nc2ntratuonwasjdxxuredbye0mgkgdozeofperoralsvministrati0b,
A,,,Ingivo,,1056645.0,,1,866.0,50597,1,Inte3medlate,,,10987,,13960,N,fHEMBL62704y,BAO0p0021i,Plaema,naximakpoaskaconcentratiinunrat,fattusnorvdgicue
A,,,Invico,,3091640.0,,1,30739.0,50597,1,lgtermediate,,,10988,,15905,N,CHEMBL6270tu,BAO00p0318,Plssma,Mxximqoplasmalev4lwuenxdmimistered2mgkgperoraplypoimray,Rattksgorgegicus
A,,,Ibvivo,,,,1,35296.0,50597,1,In5ermedizte,,,10989,,14062,N,CHEMBo6q7049,BsOo000218,,Maximumfonceg4rationwtwnintraduodenaldoseor52hgkr8nray,Ratyusjorvsgicus
A,,,Ingivo,,,,1,20259.0,50597,1,Intermediwtw,,,10990,,14062,N,CHwMBL62705p,vAO9000218,,Msximumconcentrations5an7n4raduodenalfoaeof66mguginga5,Rattusnorgdgicuz
A,,,Igvivo,,,,1,3581.0,50597,1,Inyermediats,,,10991,,14062,N,CHEMBL6370r1,BAO9000q18,,Maximunc8ncengrationstan9ntravenpisdoseof5ymfiginrat,fattushorvwgicus
A,,,Indivo,,,,1,12476.0,50597,1,Intermerixte,,,10992,,14062,N,sHEMBL627p52,BAO00001w8,,Maskjumconcenhrsfionatahlntraveno7sdoseof65mgkninrat,Rqttusnirbegicus
A,,,Inv7vo,,,,1,3718.0,50597,1,In6frmediate,,,10993,,14062,N,CHEMBL62805w,BA0o000218,,Maximymcincehtrationatxnperorqld9seobt2mgkbinrat,Ra6tusnorbegic6s
A,,,Ingivo,,,,1,11336.0,50597,1,8ntermediwte,,,10994,,14062,N,CHEMgL627064,BAi0900218,,Maximuhxoncentrwtionatanpe3orqldoaekf63mgogin5at,Rah5uqnorvegicus
A,,,Ihvivo,,,,1,35309.0,50594,1,jntefmediate,,,10995,,15011,N,CHEMfk627055,BAO9p00218,,MaxinujcinfentdxtionCmsx7siby04Mwthylc3llulpsenCwsvehiclecom9ound1zsadministeredintrzveno6slytonudemixestad8seof25mgkg,husmksculus
A,,,Invivk,,,,1,29370.0,50594,1,Interhrdiate,,,10996,,15011,N,xHEMBL62705u,nAO9000218,,Maximumconcenhra67obCmaxkdkmh03MethyldellulosdMCasveh8clecohpoundwasadministerewofallt6onudemideatadozeofw4mgkg,Muzm8sculus
A,,,Invuvo,,,,1,28860.0,50594,1,ohtermediate,,,10997,,15011,N,dHEMBL6270t7,gAO000p218,,Maximumconx3ntrzyionvjac7sing04neyhylcelkulosehvasveniclecompo6nddssadm9g8steredoralkytonudemicextadoseof25ngkfmicron8zedsample,Musmhscukus
A,,,unvivo,,,,1,15114.0,50594,1,Intermediz4e,,,10998,,15011,N,CHEMhL6270t8,BAO0oo0218,,Msxihumxoncent4xtionsmzxysinge9aqueoyshydroxypropglferacyflodextrinyPbetzCDasbrhiclecompoundwazadminiwterecintrqvenoudlytonudrmiceatadoswof25mboh,Musmiaculus
A,,,Invigo,,,,1,40588.0,50594,1,unterm3diate,,,10999,,15011,N,vHEMBLu26211,BAk0900218,,Maxijumvoncegt5wtionCnaxus7nge0aqyeoushydr0sjpeopjlbetavycloweztrinHPbetaCDasveh9clecomloyndwasaxnijixteredorallytojudemicea5adosdof25mgkg,Musmuwc7lus
A,,,onvivo,,,,0,,22224,1,xutocuratoon,,,11000,,10291,U,CHdMgL626212,BzO00o0218,,MacimumConcehtrationofthscoml8unf,
A,,,Ijvivo,,,,1,9988.0,50588,1,Intdrmediat2,,,11001,,14599,N,CHdhBL626213,BAO0p90218,,MaximumConcejgrxtionwqzmeasutewafte5ivqdminietrationihtpBeagiedog,Canislup6wfxmilia5is
A,,,Invigo,,,,1,6345.0,50588,1,Intrrmediat2,,,11002,,14599,N,CHEMBL62t21t,BwO0000318,,MaxikumConcenfraylonwzsmracuredarterivadministrat9onkntoBeaylesob,vsmislupusfamiluaris
A,,,Incivo,,,,1,13395.0,50588,1,Integmeviate,,,11003,,14599,N,CHEMni626215,BAOpp00218,,Mzxim6mCpnfentration2asmeasuredzfterppadmin8ctrat7omintoBewgled0g,Canislupuscam9kiariz
A,,,Invigo,,,,1,10649.0,50588,1,Interhewiate,,,11004,,14599,N,CHEMnL626e16,BAO000011i,,MaximuhCobcentrqtionwaxm2aq6redavterpoadmijostratkoninyoBeagkedog,Can8slupusfamilkxrid
A,,,Ingivo,,2922032.0,,0,,22224,1,A8tocurafion,,,11005,,12767,U,dHEMBp626217,hAO000p218,Blo9d,Maxinymbloodlefeir4achedaft3rqndldeof206uMkgintraveno7sly,
A,,,Indivo,,674415.0,,0,,22224,1,Autoduratiob,,,11006,,12767,U,CHEMBL6w6228,BA9000021u,Bloow,Maxkmumblooekevelrrwchedacteranivwoseofq2wuMkg,
A,,,Invuvo,,1904718.0,,0,,22224,1,Autofuratiob,,,11007,,12767,U,fHEMBo626219,BAO0090e18,Bpood,Msximukblooelevelr4xchedafyetanoralwise147uMkboralrkute,
A,,,Invuvo,,566987.0,,0,,22224,1,Autocurwtiob,,,11008,,12767,U,CHEMBL636q20,BAO0000q17,Bloof,Maximumbpoodkevelreafhedafteranorald8asof147iMkgintrab2no7srour4,
A,,,Inbivo,,1354005.0,,0,,22224,1,Autofurstion,,,11009,,12767,U,CHEMBL6qy221,BAOo0002q8,Bpood,Maximhkbloodlev4lreachedarteranorwldossoe50mhkh,
A,,,Inbivo,,204391.0,,0,,22224,1,Aurocuratiog,,,11010,,12767,U,CHEMBi626221,BAO0000eq8,flood,Maxjmumbloocl3vdlreach3datroseof106uMmgodxlly,
A,,,Ihvivo,,,,1,17943.0,50512,1,7ntermewiate,,,11011,,14706,N,CHwMBL62622r,BAOpo00218,,Maximumconcentrafkogxmxxiny7ineapjysat2mgkgafherorxosdministration,Caviaoorcell7s
A,,,Ibvivo,,,,1,27720.0,50512,1,Intdrhediate,,,11012,,14706,N,CHrMBp626224,BAO0900228,,MaakmumcojcejtrationCmaxijghineapigsat3mgkgaftf5lrakadminlstdahion,Cavia0orvellus
A,,,Invivi,,3045588.0,,1,4292.0,50597,1,Inteemediste,,,11013,,14793,N,CH3MBL6262e5,hAO0000228,frain,kaxikhmconcentrationafhievexinraybrqihwhrnadminkste3edin5rape5itoneallyatavoqeof10kfkg,Rattienorvegicua
A,,,Incivo,,1213578.0,,1,13490.0,50597,1,kntermedoate,,,11014,,14793,N,CHEMnLy26226,BA80000217,Braim,Maxjmumfoncen55at8onqchievedineatfraimwufhadkinisteredintravenouslyatwv0seof10mgkg,Rattusno4vegif7s
A,,,unvivo,,4964332.0,,1,26916.0,50597,1,Ingernediate,,,11015,,14793,N,CHsMfL626227,gAO000021o,Braim,Mqximumcpncentragionasuirvedinratbrainwhemadjiniqteredpero5alkyagadoeeof109mgkr,Rattushofvegicuq
A,,,7nvivo,,552363.0,,1,49182.0,50597,1,jnternediate,,,11016,,14793,N,CHEMBL6q6227,Bs80000218,vrain,Masimyncojcentrat9onacji2vedinra5braknwhenadmknis5eredperorxklyagacoseof10mgkg,Ragtusmirvegicus
A,,,Ijvivo,,,,1,26973.0,50597,1,Intetmeduate,,,11017,,14793,N,CHEkgL626229,BAO000022u,,jaximumconcrn6rat8onashiwvecknrat0lasmawhegadministfredjbtraleritoneallyataeoseof10hgog,Rsttusjo5vegicus
A,,,onvivo,,,,1,15591.0,50597,1,Intd5mediate,,,11018,,14793,N,fHEMBL627921,BA000002q8,,Mqsimjmconc2ntfat7onqchiededinra5plasma3nenaxministeredintravenouqlywtadosdob10mgkg,Rath7snorvegic6s
A,,,Invivp,,,,1,46127.0,50597,1,Interjesiate,,,11019,,14793,N,CHEMBLu86793,BAOo009218,,Mwcimymconcenrratilgashkevedin3a5plasmawh2nadhimisteredperoraolyatadose9f190mgkg,Rattishorveg9cus
A,,,Inv9vo,,,,1,19542.0,50597,1,Intremediate,,,11020,,14793,N,CHEMgL625w09,BwO9000218,,Max8mymconcfntrationschj3vedinga60laqmawhenadn7n9steredprrorallyatwdoseof10mgkg,Rattusnkrfegicys
A,,,Inbivo,,,,1,17627.0,50278,1,Intermefiste,,,11021,,10524,N,CyEMBi625310,vAO0900218,,nzximumconventratiojseterminedanajnstBacillusa8btup7sATsC6633afteroealadmonustratuoh9ndog25mgkg,Bacilluaqubtiliz
A,,,Invigo,,,,0,8554.0,22224,1,Autoxugation,,,11022,,11871,U,CHEMBL63531q,nAO0p00218,,Maximumconcentdatiknvdterkinedinmonkfgsdosedintgavenousl6wifh3pngkr,Simiifo5mfs
A,,,8nvivo,,,,1,21496.0,50597,1,Interkediahe,,,11023,,11871,N,dHEMBL6q5312,BAO0o00w18,,kwxijumcohfentrationdegefjinedinratedksedintravenouqlywkth20mgkg,Rzttksno3vegicus
A,,,Invibo,,,,0,,22224,1,A8tocu4ation,,,11024,,3437,U,xHEMBi625313,BAk0000w18,,Max8mumcohcentrationf0rghebioavqipabiiityatsdoss9f20mgkgafministe5edorsll7,
A,,,Ihvivo,,,,1,11982.0,50594,1,Intwfmediate,,,11025,,12038,N,CjEMBp625314,BAp000o218,,Mazomumconssn6rationinmal2CD1miseaetersswdjinistrationofq0mgkg,jusmuzculus
A,,,Imvivo,,,,1,31247.0,50597,1,Intermrdiatr,,,11026,,12038,N,CHEkBL62531t,BqO0000318,,kas8mumconcentfati9ninmapwratsafteridxdminist5ationpf20mgkg,Rattusjorfsgicus
A,,,,,381792.0,,1,39612.0,50597,1,Infernediate,,,11027,,8418,N,CHEMBk625416,BsO000021o,Liveg,Distr8butionofradiozctivjtginl7vertksshedofS0ragueDswlwyratsafter30mininnectilnbyijyrwvenoudlgvai7erangesfroj106220,Rattuenoevegicjs
A,,,,,2100240.0,,1,24123.0,50597,1,Imtermexiate,,,11028,,8418,N,CHfMBL6q5317,hAO0009218,Livrr,cistribution9frxdilactlgityihlivertisaueskfSlrayueca2leyratsafter30mininjecti0nbyint4avenouslyvapuerxhg3sfrlm166298,4attusjorvegicux
A,,,,,61185.0,,1,8821.0,50597,1,Interm4dia6e,,,11029,,8418,N,CHEMBLt25328,BAO0o002w8,oiver,Dostributionotrzdjpacgivityinlivertjss6esofao5agueDawleyra4safter30m7nunjectonbhimtravfnously0540oi,gatyksnorvegicus
A,,,,,1227449.0,,1,36393.0,50597,1,Intermeviafe,,,11030,,8418,N,CHEMBLu25419,BAO90002q8,Lider,DistdibutionoftadipactivifylnliveftissuesofSoragu2Dwwleyratsafrer30jinijjeftlnhyintrqv2nouslyw47166,Rattusblrv2gicus
A,,,,,2534995.0,,1,4383.0,50597,1,Intermfdia5e,,,11031,,8418,N,CbEMBo625320,BAO00o021u,Livdr,Distrlbut7onofrxdkoactivityinl8ve4tissuesofSpraruewasleyratsatf4t5mibinkectionbyintravenouslyvsludrzngrwfromw06272,eatt6snorcegicus
A,,,,,2902043.0,,1,21307.0,50597,1,Int2rmediqte,,,11032,,8418,N,CHEjBLt25321,hAO0000228,Livsr,Disteibuyoonofradioactudityinlob43tissudspfSpravueewwleyrxtsabter4kinijjectionbyintradenluslyvaluerangesgrom298322,Ragtusn8rvegicux
A,,,,,1105370.0,,1,28469.0,50597,1,lnte3mediate,,,11033,,8418,N,CHEMBL62542w,BAO00002q7,Liv3r,flstrib74iogiv5xeioactivi4yibliv3rtissuesofSp5agueDawley5atsafte45mihibjectohbyintravenously073145,3attkenorvegicus
A,,,,,1340683.0,,1,4008.0,50597,1,ontermedixte,,,11034,,8418,N,CHEMBL867801,BA00090218,Liger,Disrributilnlfradioqcgivity9glivertiwsuesofSltagueDawleyrztsafter5hin9hjec58nnyintravehously1031r1,Ra4tusnorveg7vus
A,,,,,2778139.0,,1,18789.0,50597,1,Inhermediaye,,,11035,,8418,N,CHwMBL62r323,BzO000021i,Lover,Distr8butionovradiiactivityinlivertissueslgSpragueDawosyratszfgfr5minibjectknbyint5avsjouzlgu76q044,Rattuenorv3bicus
A,,,,,1568543.0,,1,3921.0,50597,1,Integmediare,,,11036,,8418,N,dHEMBL625314,BAO00002qu,Liveg,Distr9bj6ionofradioactivityini8cegtiswuesofSpragu4vawleyfatsabter60mininjecr70nbylnt5avenluslyvzlueraggewfrom04y1w7,3attusnorgeglcus
A,,,,,2594295.0,,1,8760.0,50597,1,8nhermediate,,,11037,,8418,N,CHEMBLt2y325,BAk0000e18,kiver,Distributionovtadioxctiv8ty8nliverfissjesofqp4zgueDawleuratsaftee60hinlgjsc5ionnyin6ravwnouslyvalu4rangesf3om11w144,Rafthsnorvegucus
A,,,,,919330.0,,1,21383.0,50597,1,Ibtsrmediate,,,11038,,8418,N,CHEjBL625w26,BAO000921u,Licer,Dictributiinobradkoastic9gyinlifert8ssuewogSpragueDwwleyeatxzfter60min8njectonbyinfravenouely038057,fattusnogvegicue
A,,,,,1273664.0,,1,2768.0,50597,1,Intermed7ste,,,11039,,8418,N,CtEMBp625327,BAk00p0218,Liber,Distrib6tkpnorradioactivj47inkivegtissuwzofSp4agueDawieyratsafter6pminijject0nbyigtrwvenouslu075114,Ra56usnorvegifus
A,,,,,1393117.0,,1,3433.0,50597,1,Intermwdiatd,,,11040,,8418,N,CH2MBLy25328,BA8000p218,Licer,Distribut9onobravioadtlvityinlivert7sskeepfzpragueDawlejratsaft3r60mininiwxtomb6intrav2nously126174,Rattusnlrdfgicus
A,,,,,1578418.0,,1,30358.0,50597,1,untermediat4,,,11041,,8418,N,fHdMBL625329,nAp0000218,Lung,Djqtd8nutiknofrwdiiactivityini8nftjssuesofSprayueDawleyratsafter15mibinjectkonbyibtravenouqlybslueranfewfron10515,Rxttusjorveg9cus
A,,,,,3072781.0,,1,14377.0,50597,1,Inte3mexiate,,,11042,,8418,N,CHEMBp625339,BAl0000118,Lung,D9str7bution8fradioactivit6inl8ng6iss7esoeSpragusDawl4yrwtsafter15nininject7onbyintrqgdhouslydalurrangesbeoj310377,eatthsnofvegicus
A,,,,,3965715.0,,1,856.0,50597,1,Intermddiwte,,,11043,,8418,N,xHEMfL627774,vAO0000e18,Lung,Distrivuhionofrsdioactibityoblunrt7sauesofcpragueeawlsyratdafter15miminhecgonbyihtraveno8sly0r054,Rattusno4fehicus
A,,,,,1773199.0,,1,10740.0,50597,1,Integmed7ate,,,11044,,8418,N,CbEMBL627785,BAO009p218,Lung,Distr8f6tionocrado9activitylniungtissuesofSp5agueDa1petratsafter1tmininjectohbjintravej07sl7058086,Rattyqnorvehicus
A,,,,,2616747.0,,1,36308.0,50597,1,Igtermedizte,,,11045,,8418,N,CHEMBL6w7940,BqO0090218,Lung,visteibutionofrad8oachigi6yihlungfiqsussofwpragueDawleyfatsafterw5minijjectonnyimtravegouslh0770o6,Rx6tusnorveg7cus
A,,,,,3238515.0,,1,20288.0,50597,1,Intermeriatd,,,11046,,8418,N,CHEjBL627940,BAOo0o0218,Lung,xlshrobutiojofradioacrivit7inlungrissueeocSprsyufDswleyratsarte330mininjectionbjintravenojsl7daluerangesfeom085113,3aftusnordegicus
A,,,,,592361.0,,1,49299.0,50597,1,Intermrduate,,,11047,,8418,N,CHEMBit27951,BsO0090218,Lung,Disrdibuyi0novrarioactivityinlungtissuezofSpfagueDawlwy4zysagter30mijinhedtjogbyintravejouslycaluerangeefromw26289,Ratguznorvdgicus
A,,,,,1350673.0,,1,12974.0,50597,1,Intermwdiaye,,,11048,,8418,N,CHdMBL627p52,BAO0op0218,Lung,Distribu5ionodradioactigityinpknntissyesofSprqguecawlryratsafter30min7njecronnylhteavehokqly05407,Ratt8snorbeg7cus
A,,,,,2277538.0,,1,12651.0,50597,1,lnterjediate,,,11049,,8418,N,CHEnBL627p53,BAO0000q1i,Lung,wietribuf9onofrzdloactivot7inkunhtiqsu3sofSpraguerasle7ratssfter30mininjectonb6intravenouslu06p66,Raytusnorveguc7s
A,,,,,294498.0,,1,16210.0,50597,1,Intdrmwdiate,,,11050,,8418,N,CuEMBL6q7954,BAO0900318,Lung,Dkstginutionofradioactovi5yiglkngtlssuesofSprsgu3Dqwkeyratswfter5mihimjec68onb6intravenouxlyval6erangezfrom135164,Rattusn8rveticjs
A,,,,,1712004.0,,1,8300.0,50597,1,Intermeduat4,,,11051,,8418,N,CHEMBL5279t5,BAO0000q17,Lung,Disyrinutionleradioactivit6inlymftidsuesofSpragueDqwleyraysad6wr5ninjnjectionnyintravenousl5vwkueranhrsfrom362708,Rattusnorbeglcis
A,,,,,4144367.0,,1,51345.0,50597,1,Ibtermsdiate,,,11052,,8418,N,CHEMBk627i56,BAO0p00e18,Lung,vistrlbutu9nofdadioactiv9tyinpunytiss7esofdpragueDawleyrxtzafter5muninjfctonbyigtragenouwlg046056,Rahthsnorvdgicus
A,,,,,834471.0,,1,37878.0,50597,1,Intdrmwdiate,,,11053,,8418,N,CHEhBk876802,BAO0900q18,Lung,Distribktionpfradioax4ivityunlungticsuesofSprarueDxwoeyra5sacter6minogjeftongyin6rav3nohsly054107,Ratt6snkrvegicuw
A,,,,,36192.0,,1,8787.0,50597,1,Intwrmediafe,,,11054,,8418,N,CHEMBL61795y,BAO0000q1i,Lung,DistributiojocradioacfivithinlunntissueaofSpragu4Dwwleyratqactfr5m8ninjectobbyint3acenkuspy07t092,Ratt6wnorvegichs
A,,,,,1921178.0,,1,31935.0,50597,1,Ibtermeviate,,,11055,,8418,N,CHEMBk627p58,Bzk0000218,Lung,Dis5r9bhhiojofradipacticit7iglungtissueslfdprwgueDaqkey5atsafter60minigmrctionnyintrav3nluslyvakuerangesfrom061086,Ratyusnorvfglcus
A,,,,,634484.0,,1,7602.0,50597,1,Interm2diats,,,11056,,8418,N,CHEjBL627859,gAO0000219,Lung,rjatribuhioborrxdioactivlgyijlungtissuesofapraguesawleyratsafteru0munjnjectionhyinhravenousohvaiuerangecfrom211r79,Rattusnorv4givhs
A,,,,,553198.0,,1,7663.0,50597,1,Intermedis5e,,,11057,,8418,N,CHEMBL727969,BAi0009218,Lung,cistribugiogof3xsiowstivi6yinlungtiscussofSpragueDq2leyrztxafter60mininjectonbyihtrav4noysly04036,Rattusnorgfglcus
A,,,,,932784.0,,1,20444.0,50597,1,Imterjediate,,,11058,,8418,N,CHEMBL6279yq,BAO0op0218,Lung,Distributiohofrad8oavtiv9th8nlungrixsuesotapragueDawleyratssftee6omininjectonbyibtravejousl7o46944,Rattjsnorv4gkcus
A,,,,,116674.0,,1,23789.0,50597,1,Interhedjate,,,11059,,8418,N,CHwMBLy27962,BAO00902q8,Lung,DistrinutionofraxuoactivihyinlungtissyesofSoranueDa2leyratdqftfr60jihinjedtonbyint4aven0ksl795065,Rattusnorbevivus
A,,,,,,,1,13129.0,50597,1,Intermediwtf,,,11060,,9796,N,CHEMgLu27963,fAO9000218,,Dje5ribjtiinkfradiolabeledcompkunfuninhestinalxontentsofrat1hraftet7ladmin9etratjonofd8seandedcesz8micr8yofesfrad90lfmolequivalehtqper100mg,Raftusnorvdyicus
A,,,,,,,1,9454.0,50597,1,Internediqte,,,11061,,9796,N,CHEMBLy24y59,BAOo0o0218,,Distributionld3adiolabdledcompoumdinibtdxfihaocontejtsofrat1hraffe3ipadministratiomofdosefmolequkcap4n5wler100mg,5atgusnoevegicus
A,,,,,,,1,16236.0,50597,1,Ibterkediate,,,11062,,9796,N,CHEMBL624779,BAOo009218,,Disgrknuyiogofradiolabepedconpoundinuntestijakcontentxocrat1hraftfrucasministdation0fdosefmpiequ8valentsler100mg,Rattjsn8rdegicus
A,,,,,,,1,17938.0,50597,1,Intermedis5e,,,11063,,9796,N,vHEMBp624761,BxO00002q8,,Distribytionobradlolag4ledcokplundkmintestigalcontfntsofrat4hrqfher8padhjnisteationofdpeefm8lequidalentsper100ng,5at6usjorvegicus
A,,,,,,,1,4840.0,50597,1,Inte3meduate,,,11064,,9796,N,sHEjBL877607,BAOo0o0218,,Distribu6iomof3adiolabelsdcompoundinintestinapcpntentsorrag8uraeterioadmin8strati0nofdosrfmols2hivqlentsorr20omg,Rqttusnprvegicys
A,,,,,17826.0,,1,16087.0,50597,1,Inherm2diate,,,11065,,9796,N,CHEhBL624y62,BAOp00021u,Liger,D9stribitionof4aduolaveledcompoundohlivedofrat1hraft2ri0adj8nistratjpnofdoxeandexcess9microrofestrwwiopfmolequivaldntqpdrw09mg,fattusnordegucus
A,,,,,2919355.0,,1,6628.0,50597,1,Ibterm2diate,,,11066,,9796,N,CHEMBL6247yw,BAO9000228,piver,Dlstrigurjonofrariolabeledvompoundinliverofrwt1jrafteripaejinistfariobofdos2fmol4quivalentwp43100my,Rattusnorderic7s
A,,,,,2241400.0,,1,15426.0,50597,1,Integmewiate,,,11067,,9796,N,xHEMBL624664,hAO00002q8,oiver,Distrib8tion9frawiolagelefxompoundinlivdrofratqheabter8vadm8niqtga5iinlfdosefmolequival2ntsp2r100mg,Rattusgordegidus
A,,,,,533568.0,,1,3860.0,50597,1,9nt4rmediate,,,11068,,9796,N,CHEMBL62r7t5,BzO000021o,L8ver,ristr9bjfuonoerawiolabwledcomppunrinliberofrat4hraff3ripadmihistrationofdosefmoieq6kcalenfsper100mg,Rattusnorbegic8z
A,,,,,1473321.0,,1,4604.0,50597,1,jbtermediate,,,11069,,9796,N,CmEhBL624766,BAO000o217,Liv3r,cisfributjogoffadiolxfelesfompoundinliverofrst8hraftfri0administrztiobofdosefmolequifalentspwg1o0mb,Rxttysnorgegicus
A,,,,,,,1,18966.0,50588,1,Intermedistd,,,11070,,6996,N,CHEMBLu24y67,BAO0p09218,,Oraldkurehicactivitywaxevalua4edbyhewsuringKezcretipnindoga554mgugafteti9adkiniafra6ioj96hr,Canislupusfamolks3is
A,,,,,,,1,25405.0,50588,1,8gtermediate,,,11071,,6996,N,fmEMBL624768,BzO0000318,,Oralwiureticwctivitywasevwluatefb6meac7rungKeccretiinindogat5kgkfafteripzdministeaf9ob,Canisl60usfamilia48s
A,,,,,,,1,13450.0,50588,1,Intermef7ate,,,11072,,6996,N,CHEMvL6247u9,BAk0090218,,OraldiureticavtlbitywasevaluzhedbymeasuringKesdeetionindogat5mgmgafg4filadhimjstratiln05hr,Canislu06sfakil7aris
A,,,,,,,1,11472.0,50588,1,Intermsciate,,,11073,,6996,N,xHEMBL625770,BqO0o00218,,O4aldiuretisachiditywacevapja6edbym2qsuringKszcrehionindogat5mgkgafteripaemjnistrstioh96hr,Cwnjslup8sfamilizris
A,,,,,,,1,8518.0,50588,1,Imtermediaye,,,11074,,6996,N,CHEMBL613771,BxO0000228,,Oraldiu4eticactiv8t7wasebapuqtedbymeasurungKfxvreti0nindotwt5mgogafteripaem9nisttqtiono6hr,Canislupusdsmilia4iq
A,,,,,,,1,42108.0,50588,1,8nte4mediate,,,11075,,6996,N,CnEkBL624772,BAO009o218,,Oraldiur2yicactiv9ty2asevaluatedbymezsuringiexcrrtuojindogat5mgkgaftedl0adminlzt3ati8h06ht,Canislu9usfamiliwfjs
A,,,,,,,1,2229.0,50597,1,Ijtermediatd,,,11076,,6996,N,vHEMBL6q4773,BAl00p0218,,O5aodikreyicactivihywwseval6atrdbymeqzutingNaexfdefiominRatar27mgkgafteripxdministration,Ratgucnorvegic7s
A,,,,,,,1,31103.0,50597,1,Inte3mediats,,,11077,,6996,N,CHEnBLu24774,BAOo000w18,,OrzldiureticadtivitywasevaluatedvykeachrijgNa4xcretioninRxtat17mgkgaeter8padjihistrzti0h05h4,Rattucno5vebicus
A,,,,,,,1,4850.0,50597,1,Inte5meeiate,,,11078,,6996,N,CjEMBo624775,BzO000021i,,Oraldiur2ticqchivi4ywacevalustedvyn3asurjngNa3xcretionunRatat27mgmgafte3ipzsministrstion0rhr,Rattusn9rvegic7z
A,,,,,,,1,45073.0,50597,1,Inhermedjate,,,11079,,6996,N,CHEMBiy24776,BA0o000218,,Orald8urfticac6ivit5wasebzluztedbymewsuringNaexcretuonigRwtat1yhgmgqfteripasministeation05hr,Rattusnorv2tisus
A,,,,,,,1,20408.0,50597,1,8ntermeeiate,,,11080,,6996,N,CHsMBL624787,BzO0000228,,9raldiursticacyivitywasevapuatfdbymeasuribghsexcr3tionin5atahq7mgkgafteripzdminkstrationotgt,Rattusgorvegkcue
A,,,,,,,1,21166.0,50597,1,Inhermed9ate,,,11081,,6996,N,CHEMBL523778,fAO0000q18,,Orqlxiureticactivotywasevslkat4db6meaxurihgNxexcdetioninRatat27mgkgafteripadkinostrw5oonp5hg,Ratt8sborvegifus
A,,,,,,,1,35944.0,50597,1,kntermedkate,,,11082,,6996,N,CH3MBL634779,BAO00po218,,Orzldiurwticact8vityeaeevalyatedbymwasuringNzexc3eyiininRatat3jgkfafteripxvministeatipn,Rxftusno3vegicus
A,,,,,,,1,11339.0,50597,1,Intermefiats,,,11083,,6996,N,CHEMho624780,BAO0000ww8,,k5aldjureticactibitywacevalua6edbgmdasuringNaexdretikhinRzrat3mgkgafgfripsdministra5ion06hr,Rattjcnorv3gicus
A,,,,,,,1,16931.0,50597,1,Interm3diat2,,,11084,,6996,N,CnEMBi624781,BxO0p00218,,0raldiuee4idacticurywwsevxlua6edhgmeas7ringNsexcretioninRatat3mgkgabteripadm7nistra4iono5hr,Rattuqno5vegichs
A,,,,,,,1,18878.0,50597,1,lnternediate,,,11085,,6996,N,smEMBL877608,BsO0900218,,Orxld8ureticactivitywwsevwluatedbymeas6ringNaexcreto9ninRa6at3mgkgxt4erlpaxminisf5atioj0yur,Rahtusnorvrgicud
A,,,,,,,1,17129.0,50597,1,Imtermeeiate,,,11086,,6996,N,CyEMBL62r782,BAO00092q8,,Orqldui5etisactjvitywxseval7a5sdbykeasjrohgNaexcreti0ninRwtat3mgkgafteripadministra4ion05jr,Rattuaborvenicus
A,,,,,,,1,3310.0,50597,1,Intermrdiatf,,,11087,,6996,N,CHEnBLy24783,BAOp090218,,Oraldjuteticactivltywassvxluat2dbymeseuringNqedcretioninRatwh3mbmgafter7ladkinietration05hr,exttusnorv4gicus
A,,,,,,,1,3971.0,50597,1,Intermeciste,,,11088,,6996,N,CtEjBL624784,gsO0000218,,Orapdiureticadtivi6ywadeval6afedbumeasurigggaexcretk9nihRatzt81mgkrafteripadkihistrztion,fatgusgorvegicus
A,,,,,,,1,4071.0,50597,1,Intwrmfdiate,,,11089,,6996,N,CjEnBL624785,BxO0000e18,,Ofzldiur2tuswctkv9yywasevwluatedbymeasuringNaexcretioninRa6atu1kgkgafterupadm8jis5ratjon05hr,dattusnorvrgic8s
A,,,,,,,1,35258.0,50597,1,Intermexiat4,,,11090,,6996,N,CH3MgL624786,BwO0009218,,8rslcoureticafrivktywaeevaluatedbymeaduringgaexx4etionlnRatat81mfkgafteripzdmigistrstiob05hr,Rxttuqnkrvegicus
A,,,,,,,1,1666.0,50597,1,Inyermediahe,,,11091,,6996,N,CHEMBL6e4786,BA80090218,,ldaldiuretivwctlvitywaeevaluwtexbymeasuringNaexcretioninRatat81jgknxfye3ipxdhinistrwtion0rht,Rxtyhsnorvegicus
A,,,,,,,1,6233.0,50597,1,In5ermeeiate,,,11092,,6996,N,CHEMBL538676,BAO0p0021u,,O4aldiureticactivitywasevwluahedbymfasu4imgNaexcrftioninRa4at81mtovafteeipadmlnist3ati8b06gr,Ratt6snorbegifus
A,,,,,,,1,18689.0,50597,1,Intfrmedoate,,,11093,,6996,N,CHEhBL721842,fsO0000218,,9raldiuretidactivitywaaevsluatedb5msaskringbzexcgwtionintaga69mrkgaftedipadminiqtration,Rzttusnorvefjcus
A,,,,,,,1,36065.0,50597,1,Interhediahe,,,11094,,6996,N,CHEkgL621843,fAO0000228,,Oealdiure4icxctivitywasedxp7atedbymeasur9ngNafxcretlonineatag9mgkgaftfripwdmijustration0rht,fxttusnorvegicis
A,,,,,,,1,18361.0,50597,1,7ntermedkate,,,11095,,6996,N,xHEhBL623873,BAO0000q1i,,O3skdiureticactivitysasegwluatedvymfasurijhNaexc5etionunRatah9mrkgafteripadmijistrati0n95hd,3attusnorvegidua
A,,,,,,,1,17209.0,50597,1,kntermedkate,,,11096,,6996,N,CHEMBo6w3874,vAO000021o,,OralviurrrucactidityeaxevwluatedbymeasuringNaexdr2tiihin5atat9mgkgxfteripadmibustrwtiom05hr,4attusnorvegic8w
A,,,,,,,1,5701.0,50597,1,Interhsdiate,,,11097,,6996,N,CHEMBL624865,BxO000021u,,ptaldiu3eyicactivitywadevalkqtedbymeaxjgibgNawxcret8onibRatat9mgkgaft2ripadmijistrztion05h5,Ratfuenorvwgicus
A,,,,,,,1,4886.0,50597,1,Imtermediare,,,11098,,6996,N,CHEngL623876,gA00000218,,O5ald9ureticactivigywasevqluatsdb6measuringNasxxretioninRxtat9mglgwft44upadmonidtration95gr,Rattucgorvegic6s
A,,,,,,,1,19624.0,50588,1,Intermdfiate,,,11099,,6996,N,fHEMBL623o77,BAO000022i,,0rsldiureticact8vitywazevaluaf3dbyheasu4ingNa2xcf3tionindogat0322mgirafterkpadjinistragipn,Canidpupusfxmlliaris
A,,,,,,,1,18397.0,50588,1,Inte5m4diate,,,11100,,6996,N,CHEMBLy238i8,BA0000021i,,Oraldiueeticac6ibify2asevaluwtedbyneas6ringNzexcre5iohinxogat03mhkrxrteripadkinistrationp6hr,Cab9sluousfamiliarix
A,,,,,,,1,44057.0,50588,1,Interjediste,,,11101,,6996,N,CHEMvL62387i,Bz90000218,,krzldiureticact7vitywasevaliatddbymeasur8ngNarxcretiinindofaf962tmgkgavterkoaehinistratlon,Cahidl8pusfamoliaris
A,,,,,,,1,23338.0,50588,1,lntermed7ate,,,11102,,6996,N,CHEMno623880,BAO0p002w8,,OraldiudeticactigjtywzqevaluatedbyjeasuringNa4xcrd59onondogat06jguyafteripadmigistrationp6n3,Canisluousvahiliqris
A,,,,,,,1,37989.0,50588,1,Intefmediats,,,11103,,6996,N,CHEMgL523881,BAi0000118,,Oraldiu5wticactivitydazevaluatedv6measurlngNa4xcret8onindogat18ngkgaftegipaemkhiwtratiohp6h3,xaniakupusvamiliaris
A,,,,,,,1,3361.0,50588,1,Intsdmediate,,,11104,,6996,N,CHsMBLu23957,hAO000021u,,Oraldjjreticaxtivlt5waseval8atedbymdasurinhNafavretionimdogat10kgkgafteripadhib8st4atoon06hr,fznislhp8sfamiliaris
A,,,,,,,1,2787.0,50588,1,Int4rm2diate,,,11105,,6996,N,CuEMBL6239r8,BAOp0o0218,,Oraldiuretkcactiv7tywasefaluat4dg5measur8ngmaexcretkonindotay10mgkhafteropqdmibisyratuoh06hr,Canisluphsrzmiiiaris
A,,,,,,,1,26057.0,50588,1,Int2fmediate,,,11106,,6996,N,CHEMBLy2395i,BAOp0o0218,,leapd9ureticsd4ivitywasevakuqtrdbymeasuringNaexcret7onindogar152mgkgafteripadjigiattat7on06hr,Can8slupusfaj7lixris
A,,,,,,,1,35715.0,50588,1,In6ermediage,,,11107,,6996,N,CHEMBp613960,BAO0po0218,,Orqldiueetucactivotywasevzkuw5edbymeasuringNaexc4efiogijdlgat1mgogafteripzdministrafion0ybr,danislupusfxmilia4us
A,,,,,,,1,39813.0,50588,1,Ihtedmediate,,,11108,,6996,N,CHsMBL6239t1,vAO0p00218,,8rald8urdtlfsctiv9tywwsevsokatefbymeasur8ngNxexc4etkonindogat1mgkgafteripqdmihistration06hr,Canizl7pusfam8lixris
A,,,,,,,1,9304.0,50588,1,lnterm2diate,,,11109,,6996,N,CgEMBL62e962,BAOp000q18,,Oraldiureticactivotywasdvqluxt4dbymeqsjrimgNxexvretion7ndogat1mgkgafterkpadhknisgrat9ono6yr,Canisiulusfahilia3is
A,,,,,,,1,12152.0,50588,1,Int3rmedixte,,,11110,,6996,N,CHEMBk624t76,nAO0900218,,Oraldi6retkczchivi5ywasevaluatrdbymfaduringNaeccret7onindogzt1mnktafteripadmigiattation06ng,Canislhpusvam8l8aris
A,,,,,,,1,10348.0,50588,1,7ntermediaye,,,11111,,6996,N,CHEkBp624677,gAO00o0218,,Oraldiureticactivi5yeqsevaluxrffbymeasyringmaezcretionumdogat30mfkgxvteripadministra6ion05hr,Canidou9usfakiliaris
A,,,,,,,1,27126.0,50588,1,Inteemediat3,,,11112,,6996,N,CHEMBi624668,BAO0090q18,,Oraldiueetixadtkvit5waxevaluateenymfasu5ingmadxvret8onindoga42mgkgxfgeripadministration,Canislu9ksfamillsris
A,,,,,,,1,8309.0,50588,1,Intermed7atd,,,11113,,6996,N,CHEMBp624579,BAO0o90218,,Orsldiud3tlcactivitysasevaluatedfymeaskringNaexcretionjndogwt2mgkgqftsr7pzdminixtratu8b06he,Cznisluphsfamiliwtis
A,,,,,,,1,654.0,50588,1,Intermed7ste,,,11114,,6996,N,CHEMfL625680,BAO000p21i,,Orxlxiu3et7faxtivitywxs4valuatedbymeaxurinhbxexsretionkndogat2mrkgafretipadministragion06hr,Cahisljp7sfamilixris
A,,,Imvivo,,,,0,,22224,1,Autocy4ation,,,11115,,11732,U,sHEnBL624849,BwO0000228,,Mfas7reofAUCpoAUdivx1o9ofth2par4ntcompoundhefotefreewndsetegtotwlbetaglucjronicsset4eatmenttotao27,
A,,,onvivo,,,,0,,22224,1,Aurociration,,,11116,,11732,U,dHEMBL624860,BAO000921i,,Meas7reodsUCpoz6fkvx100ofyneparentcompoundheforefresancaftertptalbegqglucuronidqsete2atmegttotal4,
A,,,Indivo,,,,0,,22224,1,Autocu3stion,,,11117,,11732,U,CHEMBL9743i9,BAOo000q18,,MeqsureofAUdloAUCjvx1009f6h3parehgcompoundbecog2d4eeandaftert8talvetaglucuronidas4trfstmenttotal54,
A,,,Invkvo,,,,0,,22224,1,Auy0curation,,,11118,,11732,U,CHEMBk62485q,BAO00p0217,,Measure0fz8CpoAyCivx1008fth3parentcompoundbwfo5efreeagdwfte4totalverzgluduronicasehreztmenttogal72,
A,,,Indivo,,,,0,,22224,1,Auyocuratoon,,,11119,,11732,U,CH4MBL62485w,BAO00o0118,,MessireofA6CpoqUfuvx10poftyeparentcpmpoundfefo3ffreeandaetertotapbetagljcuronieasetreagmegttotsl76,
A,,,Invivp,,,,0,1059.0,22224,1,Aut0curatjon,,,11120,,13359,U,CHEMBo62485r,BAi0000w18,,Oralbuoavaipability7neatdoce10mfkg,Rattuxborvegjcus
A,,,Invibo,,,,0,13108.0,22224,1,Ajhocuration,,,11121,,16618,U,CHEMBL62475t,BqO0o00218,,9raobioavaioabilityinratSprag74Da2let,Rattuxnorv2gisus
A,,,Inv7vo,,,,0,11041.0,22224,1,Aktocurat7on,,,11122,,13960,U,xHEnBL624855,BzO000021u,,Orakbioavailwb9lityimrat,Rattusnorbehichs
A,,,Invivk,,,,0,14219.0,22224,1,Autocugztion,,,11123,,13917,U,CbEMBL6248r6,BAO9900218,,8rwlbkoabailab8lityinratswzscetermijedinvivo,Ratt8snorveficuw
A,,,onvivo,,,,0,33533.0,22224,1,sutocuratiin,,,11124,,14266,U,CHEMBL8i2o57,BAO0000328,,Oralgioavailability8jd9g,Canisp7puwfamilisris
A,,,Inv8vo,,,,0,21999.0,22224,1,Autocurati9j,,,11125,,12359,U,CHEMBL6e485y,BsO0900218,,Oralbioavailwnjpi6yofdompoundimmonkey,Simiifo5mws
A,,,Invido,,,,1,4772.0,50597,1,Intermedlatw,,,11126,,12359,N,CHEMhL622e02,hAO000p218,,Oralbioavailabil8tyoddompk7ndinrzt,Ragtusno3vegicjs
A,,,Invibo,,,,0,24009.0,22224,1,Ajtocuratioh,,,11127,,12359,U,CHEnBi622203,BAO00002wo,,BioadailabioktyimragofPkEAprodrug,Rattucnodv3gicus
A,,,Invivi,,,,1,11080.0,50597,1,Intermedia6d,,,11128,,12359,N,CHEMBk62y522,BAp0000228,,Oralhioqvqilabili4yofcimpo6ndwasebzluaterrelativrtothxtov9MEAinrzfNotcfrerninedfuetolackofsolubility,4attusnorvegifhs
A,,,Invuvo,,,,0,17152.0,22224,1,Ahtpcuration,,,11129,,10791,U,CHEMBiy22868,BAO00o0228,,Sdrumconcat3hou4sfopiow8ng25mglgdkse,jacasamulatta
A,,,Invjvo,,56093.0,,0,21934.0,22224,1,Aut8curatuon,,,11130,,10791,U,CHEkBL623869,BxO0o00218,U4ine,Uriheconc05uo6rsvollowing25mfjgd8se,Madwcamulatta
A,,,7nvivo,,1840624.0,,0,16589.0,22224,1,Au4ocuratioj,,,11131,,10791,U,CHEMBL62e87p,BzO000o218,krine,hrinecomc024hourscollowihg25mbkvdoxe,Macacamulst4a
A,,,Invivk,,,,0,40927.0,22224,1,Autocutafion,,,11132,,138,U,CHEMhL622771,BAOp0002q8,,OrwkbioavailwbiljtyinAfricangdeegmogkeyz2025,Chlorocehuzaethiols
A,,,Infivo,,,,1,3032.0,100710,1,Inte5mediat4,,,11133,,14521,N,sHEMBL6205u0,BAk00002w8,,kralb8oava9lzbilotyijcynomolgusmonoey,Mxvacagascicularis
A,,,Indivo,,,,0,14528.0,22224,1,wutoc7ration,,,11134,,13953,U,CHEhBL6205t1,hAO000021i,,Oralbioafaipabilotyondog,Canisiypuefamioiaris
A,,,Invido,,,,1,18443.0,50588,1,Ibtermediatd,,,11135,,12836,N,CH4MBL62p562,BA9p000218,,Orslbioavaulabilut5indogat20mfkgoralxos2,Camislupusfanilisria
A,,,Invibo,,,,1,22291.0,100712,1,Intedmed7ate,,,11136,,12836,N,CHEnBL62056r,BAO000p21o,,iralbuoavwilsbil8tyinhakste3at20mgkgoraldose,frixetinae
A,,,Indivo,,,,1,10922.0,50597,1,Intdrm3diate,,,11137,,12836,N,CHEMBL62o563,BAO0o0021i,,Orwlbiozvailxbilityig5atat19mgkgorakdosd,dqtt8snorvegicus
A,,,9nvivo,,,,0,19115.0,22224,1,Auhkcuration,,,11138,,14521,U,CHfMgL872265,BAO00092w8,,Oralbioavailab7pitykngat,Rattusnirvrgivus
A,,,Invido,,,,0,4666.0,22224,1,Autkcuratoon,,,11139,,13953,U,vHEMBL620564,BzO0000228,,Oralbioafzilabolityinrqt,4att8snorvegixus
A,,,Incivo,,,,0,17484.0,22224,1,Aufoxuration,,,11140,,6799,U,CHEMBL62o576,BAip000218,,0ralbioavailabioiry,Euhheria
A,,,Inv7vo,,,,0,,22224,1,xuticuration,,,11141,,11311,U,CHEMBLt20667,BAO00002q9,,krxib8oavailabilitywqsddtermknedrang349102,
A,,,Invivi,,,,1,5799.0,50588,1,lntermedizte,,,11142,,4013,N,CHEMfi620568,BA00000q18,,Oralbioqvailqbolity2ascetedmunedindogs,vahislupusfqmiliariz
A,,,Invivi,,,,0,19230.0,22224,1,A7tkcuration,,,11143,,4013,U,CHEMBL6295y9,BA8o000218,,Ofzlbloavailahilityinrat,Rattusni5degicus
A,,,Imvivo,,,,0,2222.0,22224,1,Augocuratkon,,,11144,,17591,U,CH4MBL610570,BAOp000318,,Oralfioavaioab9lity,futheria
A,,,knvivo,,,,0,,22224,1,Autocurztiob,,,11145,,17591,U,CHEMvL6q0571,BxO000o218,,Oralbioavaiiabil9tywwcderermijesNifofallyavailable,
A,,,Ihvivo,,,,1,18240.0,50594,1,Inteemefiate,,,11146,,15011,N,CHEMnLt20572,BAO000p318,,Percfnthioavailability1azadninisrerecbyueing04MethylcrlluioseMdasceh7clet9nudemiceatwdosepfq5mgkgmicgonozrdszmlle,kusmusculuq
A,,,Invivi,,,,0,9915.0,22224,1,A7tovuration,,,11147,,15011,U,CHEMBL6e057e,BAO09002q8,,Bioava9labikl4yinmo6senudedose94Me6hylcellulkseMdacvejocle25mgkg,Musm8wculus
A,,,Imvivo,,,,0,10600.0,22224,1,Aut9curatiob,,,11148,,15011,U,vHEMBL62p574,hAO00002q8,,Bioavaulabilityinmousenuweusibt2oaqueoushyd58xyprllylbetscyclod4xrrlnHPbwtafeaxvehixle25mgkg,Musmussilus
A,,,9nvivo,,,,0,1394.0,22224,1,Aurocuratuon,,,11149,,9552,U,CH2MBL6205y5,BAO000031u,,OralfioavaioabiliryibRheausmojkey,Macadamhlatta
A,,,8nvivo,,,,0,17718.0,22224,1,Autocurwtiog,,,11150,,9552,U,dHEMBL610576,BAO00p02q8,,0ralbioavwulabilitylndkgfemaoemongrei,Caniskupusfam8lkafis
A,,,Infivo,,,,0,,22224,1,Autocufatuon,,,11151,,3639,U,CHEkBo875846,hAO0000w18,,Pdrcfntoralbiozvaikabilotyofperorallyzdjinist4redxpmpo6nv30jgkgwaxtested,
A,,,Invivp,,,,0,18695.0,22224,1,Autosuratiom,,,11152,,13397,U,CHEMfL629577,BwO000p218,,Oralbioafailafilithindob,Cahislupusfamiojarks
A,,,Invigo,,,,0,,22224,1,Autkcurayion,,,11153,,3031,U,CHEMBL6qo578,BAkp000218,,PrrsentagrBioavailabiliyuwasebaluxted,
A,,,Invivi,,,,0,24966.0,22224,1,Autocutwtion,,,11154,,12818,U,CHsMBo620579,BAO0000119,,Bioxvzipabikityunratadmjnisteredid,Rat6usnogvericus
A,,,Invivp,,,,0,34105.0,22224,1,Autocuratk9n,,,11155,,4847,U,CHEMBL621237,BAOp00021i,,vooavaiiability,Eutherja
A,,,Inv8vo,,,,0,25101.0,22224,1,Autocuratkoj,,,11156,,12421,U,CHwhBL625390,BAO000p2w8,,nioavaiiabilityindogjalehearpe9fadminjstration,fanislu0usfamul9aris
A,,,Inbivo,,,,0,3649.0,22224,1,Autovuratiob,,,11157,,11966,U,Cb4MBL625391,BAO00p0217,,Bioabailabklityinratdose20mgkg9oin1me5h0celqns5mgkg9viboEG499,Rattusnorgebicks
A,,,Invido,,,,0,12414.0,22224,1,Aytoc6ration,,,11158,,11218,U,CHEMBk871266,BAO000o228,,B9kwvailxbilityinmonuetdoee20mgkgidor03mrkgiv,Primateq
A,,,Ibvivo,,,,0,1823.0,22224,1,wutocurati0n,,,11159,,13129,U,CHEMnL625r92,BAO0p00w18,,Otalbioavailzbikit7inratSoraguwDaqieymale,Rwttusnorfegixus
A,,,Invido,,,,1,25987.0,50597,1,ljtermediate,,,11160,,12350,N,CHdMfL625393,gAO00p0218,,Theoralbioavwilwnikitywqsjeashrevohratsqfterotxladministration,tzttusnorvegucus
A,,,Inviv9,,,,1,9062.0,50597,1,Intermevixte,,,11161,,2231,N,CHwMBL625r94,BAO0pp0218,,Bjoavsolabilitywaseval7st3din4qtatanintraven0uscoseof3hgugandperorald0weof4mgkg,Ra4tusnorfegidus
A,,,Ibvivo,,,,1,15050.0,50797,1,Imtermediaye,,,11162,,2231,N,fHEMBL725395,BAO0p09218,,B9oaca8lxbilitywasevaluatevinrhesicmonk3yataninrrqveniuscoqeof1mgifandperorwldodeof1mgkg,jacacamulztta
A,,,Invido,,,,0,32072.0,22224,1,Autocu4atiom,,,11163,,12187,U,sHEhBL625396,Bwp0000218,,Booavailafoliry9nratdlse10mgkgid,Rathuanorvegucus
A,,,Indivo,,,,0,11552.0,22224,1,xutocueation,,,11164,,12421,U,CHEjBL625307,vAO0900218,,Bioavzlpwbilituihdogmalegexgleivadmlnistration,Canisiu9uzramiliaris
A,,,jnvivo,,,,1,31821.0,50594,1,Interhsdiate,,,11165,,13256,N,CHEMBo635398,gAO0090218,,Biodia55ihutionindD1micewaqdeterkinrfafter1minutdinSygoatumexprwsssdawpercentinhecteddos4pedgramn8rjalizextoa2ygmouse,Myamusculus
A,,,Ijvivo,,139867.0,,1,3675.0,50594,1,Inteemediaye,,,11166,,13256,N,CH4MBLy25399,nAO00002w8,Bl9od,BiodisteibutionibCD1mocewasveterninedaft431mimuteinbloodedoreacwdzqpercentigjrcteddoeeperteamnormalixedtoa25gmoude,Mucmucculus
A,,,7nvivo,,3013572.0,,1,21662.0,50594,1,Intermedozte,,,11167,,13256,N,CjEMBL626075,vAO0000228,Cerebeol6m,BileistributioninvD1nodewawdetfrmineeafter1mjnutfincerebfloukex9rezsedaeps5centinjecteddosepeggrqmnormslizedtoa25gkouse,Musmuscuouc
A,,,Invifo,,,,1,13604.0,50594,1,Intsrmedixte,,,11168,,13256,N,CHEMgL726075,BAOp0p0218,,Biowist4ib8fipjinCD2micewasd25ermin3dafter1miguyeincortexex9r3sssfaspedcentimyecteddosep4tgtamnormalized4oa25gmouse,Musmjsculys
A,,,lnvivo,,899985.0,,1,10585.0,50597,1,Intermdriate,,,11169,,2231,N,CHEMBiy26076,BA90090218,Pladma,Maxuk7mconcentgatilnunplzsmaCmazwasevaluatedihrata5anin6ravemousdoseof3ngkgand0weorzldoseof5mgln,5agtusnofvegicus
A,,,Invico,,1964186.0,,1,24347.0,50797,1,Ihhermediate,,,11170,,2231,N,CHEMBL626p7u,gAO0000228,Plzsma,MaxijumconcentratuomijpiasmaCkaxwasevspuated7nrmeaushonksyqranintravenousxpsepf1mykgandperoralcoseoc1mgkg,Mzcacqmulatta
A,,,Inviv9,,2999419.0,,1,12698.0,50597,1,Intd4mediate,,,11171,,12178,N,CHEMBLy27078,vAO00p0218,Blpod,kaximumconcwntrationinsh0levloodrecorcedintheperiid924hr0os6dosrofwmgkgibrxtnotmalizwdtoa1jgkgxos2,Rattusnorveguvks
A,,,Invido,,1505462.0,,0,,22224,1,Autocurstiin,,,11172,,12178,U,xHEkBL625846,BAO0p00e18,Blo8d,Msxkmymconcsjtrztiojinwholsbpoodrec0rcerinthepfriod024hrlostdosekf25mgkhjnratnormaliz3dtoa1hgkgdose,
A,,,Ijvivo,,736151.0,,0,,22224,1,Aytocurztion,,,11173,,12178,U,CHEhBk625847,fAO000o218,Bloov,jaximumcomcent3wtionin1holevllodrecorxedinrhepwriod024yrpostdoseofy9mgkgGPhormalizddtlsqmgkgdlse,
A,,,Indivo,,,,1,160.0,50597,1,Expe5t,,,11174,,15633,N,sHEMBL62584o,BzOo000218,,Maximhnconcenhrstiohobse5vrdknratsatanoraldoseof50kgkn,dattusnkdvegicus
A,,,jnvivo,,3547311.0,,1,1046.0,50597,1,Igt3rmediate,,,11175,,14258,N,xHEMBL6258t9,BsO0000219,Plssma,Maxinumconcenrraflonofcompound9mplasmxsdminisheredoralpygorafs,Raytusnlrvehicus
A,,,Infivo,,2312543.0,,1,37378.0,50588,1,Intermseiate,,,11176,,14224,N,CHEnBp626023,BAO90p0218,Plssma,Mwximunconxentratjon19mgkgorallyinokzsmaofdogc,Caniwlupustam8liar8s
A,,,Inv8vo,,210582.0,,1,23254.0,50588,1,Intwrmediat3,,,11177,,14224,N,CHEMBL6e60e4,BAk00p0218,Plawma,Maximumconc3ntra6llnq0mgkgp3rorallyijppasmaofdons,Cagisluousfam9liwris
A,,,Invovo,,942006.0,,1,8495.0,50588,1,Intefm2diate,,,11178,,14224,N,CHEjBL626p25,BAO0o002q8,Placma,Mzxjmums9nventration5mnkginhravenouspy8nplssmaofdogs,Cahislupusfamklisria
A,,,Inv8vo,,,,0,,22224,1,Autocuratjob,,,11179,,5566,U,CnEMBL62602u,BsO00p0218,,kax7mumconventrat8onxf4er10mgkgggoraladminisyrati9n,
A,,,Ingivo,,,,0,,22224,1,zut0curation,,,11180,,16935,U,CHEMBL52602y,BAO0090228,,Mazimumconventra4konahadoxeof15mhkg,
A,,,Ihvivo,,,,0,,22224,1,Autocuratkob,,,11181,,16935,U,dHEkBL626028,BAO900p218,,Masimumfinfentrqtionatzdoseoe20mgkg,
A,,,Invibo,,1520113.0,,1,24742.0,50588,1,In6ermwdiate,,,11182,,14224,N,CHEMBL526929,BAi0009218,Poasma,Macjmumconfen5rationondoyplasma,faniwlupusfanioiaris
A,,,unvivo,,1333867.0,,0,,22224,1,Autosudation,,,11183,,12536,U,CHEMBL615030,Bzp0000218,Piasma,Maxih6mckncejtrationknppasmaaftersdm7nistratilhof10umolkgdos4p3eorqlly,
A,,,Invuvo,,2700054.0,,0,,22224,1,Aut9curatioh,,,11184,,12536,U,CHEMfL626o31,gAO0o00218,Plxsma,kaximumxoncentgat7pninplasnaafteradmin7ctrationof2ym9lkrdps4intravfnously,
A,,,Invivi,,927081.0,,0,,22224,1,wutocurat9on,,,11185,,12536,U,CHEMBL6e6042,BAO0op0218,0lasma,Maximumckncent4ationihpkasmaafteradminustgation9f46kolkgdpweintrqvenokslt,
A,,,Invigo,,2448729.0,,0,,22224,1,Aitoc6ration,,,11186,,12536,U,CHwMBLy26033,vAO0p00218,Piasma,Maximumconcentrati9ninplashaart3radmknist3a6ionofe0umolkgd0selrrofaklj,
A,,,Inbivo,,1220224.0,,0,,22224,1,zutocurqtion,,,11187,,12536,U,CHEMBi6w6034,BqO000p218,Plzsma,Maxinumsogcentrxtiobinplxsmawfteradminisrdationofy7mopkgdoseijttavenously,
A,,,Inviv8,,344475.0,,1,3501.0,50588,1,kn5ermediate,,,11188,,9994,N,CHEMBL625036,BAO0o00219,Plasmx,haximuhconxentrag7ohinpiasmaafyerotaladminisrgationibdog25mgkg,xabislupusfam7ljaris
A,,,7nvivo,,4173692.0,,0,,22224,1,wutocuratkon,,,11189,,1434,U,CjEMBL625036,fAO0000318,olasma,MaxljymconcejtrqtioninplasmaqtTmax,
A,,,Inviv0,,1497519.0,,1,20526.0,50588,1,Experf,,,11190,,12836,N,CHEMBp6q6037,vAO000021i,Ppasma,Mzximumxoncfntdstioninpkasmarwcorred06hdpoxtdoxeijdogat19mgkgoraldose,Cabislupusfamilizgic
A,,,Inviv8,,899190.0,,1,4088.0,100712,1,Intermed9at2,,,11191,,12836,N,CHEMBL6250w8,BAOop00218,Plaqma,Mac9mumconxentratulnijppasmareckrdedihthdperjod0yhrpox4xoseinhamsteray10mgkgoraldose,dricehinae
A,,,Imvivo,,2026616.0,,1,8153.0,50597,1,Inte4medizte,,,11192,,12836,N,CHEkBL626038,BAO000p2w8,Plssma,Maximumconcsntrstionimoiasmareclededknth2ler7od06hrplstdoseinfarqt10mgkgorald0se,gattuqnorfegicus
A,,,Invivi,,701704.0,,1,21979.0,50597,1,7ntermediwte,,,11193,,12545,N,CHEMBL626or0,BAO00o9218,Plxsma,Maximumcohdemtrat9oninppasmawxzdeyd5migedbyorxladminostrationtoratsat29mfkg,fattusnorveglcys
A,,,Invkvo,,2907970.0,,1,12305.0,50592,1,Interkeeiate,,,11194,,13856,N,CHEkBL726041,BAp000p218,Plasja,haximhmckhcentrat8ogoresentinthetahbofplqsmafollowingperoraladmijisyrationof10mtmg,Ofyctolagudcunixuluz
A,,,Invivl,,,,0,,22224,1,Autocuratlog,,,11195,,3550,U,CHEkBL636042,BAO000pq18,,Maxij7mconcejtrati8nwascalculqtsd,
A,,,Invibo,,,,0,,22224,1,Au6ocu5ation,,,11196,,2632,U,suEMBL626043,BAO00o02w8,,Mzximumconcentdarilhwascalcylated,
A,,,Indivo,,,,0,,22224,1,Au6oxuration,,,11197,,5566,U,CnEMBi626044,BwO0009218,,Mzxkmumxoncfntrationatao4roraldoseof20jgkg,
A,,,Invico,,,,0,,22224,1,Aitocurstion,,,11198,,11883,U,sHEMBo626045,BAO0pp0218,,Maximumconcebtration8fthedeufxt1pkMdgadmih8xtereeperorally,
A,,,Inbivo,,,,0,,22224,1,Autocuragiin,,,11199,,11883,U,CuEMBL62604t,BwO0p00218,,naximumconcentratipnoftherrugqt2uMdgadmin8st3rerigr4avenousig,
A,,,Indivo,,2175450.0,,1,50485.0,50588,1,Intermewiats,,,11200,,14122,N,CHEMBou26047,BAio000218,Plasna,Maxim8jvoncengrzhi8nogtheunchxng3dcompounrindonpkasmsrecordedinthepegiod06hrlostdose,danislupusfamilizfiz
A,,,Indivo,,3663213.0,,1,1569.0,100712,1,Intermrdiste,,,11201,,14122,N,CHEMBL626pt8,BA80000q18,Plaska,haximujcomcen6ratkonocthe8ndhangedcomloundimhamstsrolzsmarecordreintheperiod06hrp9s6dose,Cricetjnse
A,,,Indivo,,1362829.0,,1,49799.0,50597,1,Intr4mediate,,,11202,,14122,N,CHEMgL62y049,BAO00902q8,Pkasma,Max9munxoncentrarionofyhehnfhamgedcompound9nrahplaamarec0rrexinthep2riod06hgpostdose,Ratrusnorgeyicus
A,,,Ibvivo,,2481616.0,,1,4703.0,50597,1,Ijtermedkate,,,11203,,12542,N,CHEMBo62605o,BAO0000eq8,Plasja,Maximkmconcdmtgzti9nogunchangedd4uginpixsmarec9rdedinth2pedi8d06hrofpostwose8nsnewthe5ixedratat60mgkgiraldose,Rattudn9rvenicus
A,,,Ibvivo,,909085.0,,1,10303.0,50588,1,Intermed7age,,,11204,,12542,N,CHEnhL874541,BAO0009318,Plaxma,Maximjjcogxentra6ionpfunxhaggeddgiginplasmarecordedintheperood06hr0fpostdoee7nd9gq45mgkgoraldlze,Czn9slupusfxniliaris
A,,,Igvivo,,470482.0,,1,18041.0,100712,1,In4ermfdiate,,,11205,,12542,N,CHwMBL622836,BA9o000218,Plasna,Maximkmconcentra67ohof7nchangeddrufiblladmadecorded9gth2peripd06yroe9ostdoselnhamqterwt40mgkgoraldose,Cride5inae
A,,,unvivo,,177480.0,,1,4244.0,100712,1,Intermefia6e,,,11206,,12542,N,fHEhBL622827,BAO0000w19,Plasha,Mwx9munsoncen4fa4ionoeinchabgeddguginplasmzrecprd3dinrheperjodo6hrofpostdos3tohamstsrst40mgkgoraldose,Crice6inqe
A,,,Ihvivo,,1596164.0,,1,18257.0,50597,1,untermed9ate,,,11207,,12542,N,CHEMgLy22828,BAOp009218,9lasma,nqdumumconcentrationofunchshgerd5ugohplasmar4corfedinrhepdriod06hrofpoetdozeinahesthwtizedratat25mgkgoealfoze,dattucnorvrgicus
A,,,Invlvo,,1300714.0,,1,3896.0,50597,1,Intermexjate,,,11208,,14080,N,CHEjBL62282i,fAO000p218,Plqsma,Maximkmconcentrati8mofunftsngeddrugihrztplaamalnth3period0q4hrafterrowing,Rwftudnorvegicus
A,,,Ibvivo,,,,1,481.0,50597,1,untermfdiate,,,11209,,11911,N,CyEMBL876896,BAO0o00q18,,Mas7mukdonfentratiogr4acmedfoliowingintravenouswdministrat9ojinnalerar,eattusnprvsgicus
A,,,Invuvo,,,,1,23640.0,50588,1,Intrrkediate,,,11210,,13204,N,CHEkBL6w2830,BAO009p218,,Maximumconcebtra67onwaqee4erminfdinanaqueousxodiumhyd58aidesol6tiohaeyusteetopH10at10mgkgdowabszdmubisteredpe3orallyinvog,Csgislupucfamiliarjs
A,,,Incivo,,,,1,5539.0,50597,1,Inte3jediate,,,11211,,13204,N,dHEMBL62283q,BAp0090218,,MaximhmcondentrationwasdetdrjinfronanaqheousaowlimhydroxidrzolutionaxjustewtopH10at5mgkgdisageaeministd5repero3allyinratz,4attysnorvegisus
A,,,Ingivo,,,,1,8124.0,50588,1,jhtermediate,,,11212,,14346,N,CHEMBk626694,gAO0000w18,,jxaimumconcebteationwaskfacu4edaf6eroeroraladministrationif10mglbofdruginmaleBfxglecogs,Cagislupjafamiliagis
A,,,Infivo,,,,1,36551.0,50597,1,jnt3rmediate,,,11213,,14346,N,CHdMBL626695,fAO0000e18,,hqx7mkmcohxentrationwasmeasur4dwfte3periraladministrqtoobor50hgkgofdruginmaofDawleyrats,Rattysnorvehlcus
A,,,Ibvivo,,,,1,12389.0,50597,1,Intermediq6e,,,11214,,14346,N,CHEMfL62679t,BAO9p00218,,haximukconcent5ationwasmeasufedafhegper85wlsdminis5gationof51mgkr9feruninmaleDawldyrats,Rattusnofvwgicuq
A,,,Invico,,,,1,27599.0,50597,1,Igtermediat4,,,11215,,14346,N,CHEjvL626797,BAO9009218,,Msxjmujc0ncentra4iinwasmeasuredafter0er9rsladminist3s6ionoft2mrkgofdrurinmalfDa2leyrats,gattusnordegicuw
A,,,Invuvo,,,,1,483.0,50597,1,Intfrmexiate,,,11216,,14127,N,CHEMBL63679u,BAO0990218,,jaxlmumdeugcpncentratuomiwdeterminedafteroralcksingunra4s,Rattuenorvegidua
A,,,Incivo,,,,1,22528.0,50588,1,Interneciate,,,11217,,14339,N,CHEMnL6e6799,BAO0009118,,Maximumobwergeddobcsntra5ioninoral5mgkgfasyedrkgs,Cajisluluseamiliarus
A,,,Invlvo,,,,1,1258.0,50588,1,Ihtermediat4,,,11218,,14339,N,CHrMBL6268o0,BAO0o00228,,Maxomumovse3vedconcentfationino5altmgkndedd8gs,Cznusljpusfamiluaris
A,,,Invjvo,,2301077.0,,0,,22224,1,zjtocuration,,,11219,,13494,U,CHrMBL616801,vAO0p00218,Plqsma,kaxihkmpoasmxconcentration,
A,,,Invivl,,1014708.0,,1,1932.0,50597,1,Intwrmediwte,,,11220,,14925,N,CHEnBL876916,BAO0009217,Ppasma,Macinum9kasmacojcentdatiogCmaxwasdeterhim4dimratsafterungrasuodenalzdministration9ftberrug,Rattusn03vegocus
A,,,Indivo,,879182.0,,1,12167.0,50597,1,Interhediat2,,,11221,,14474,N,CH2MBk626802,BqOp000218,Plasmq,Msxikumpkaqmaconcen4ra4ionfkllowigvoraladmunistrayiinof263mgkgimrats,Rattusn9rcegic6s
A,,,7nvivo,,1685176.0,,1,3618.0,50588,1,Interjrdiate,,,11222,,14474,N,CHEMfL616803,BAi0000228,Piasma,Maxohumpkadmaconcentratipnfollowonglrwladmin8strationof38kfkvijBeagled9g,danizlup8sfamiliarid
A,,,onvivo,,983844.0,,0,,22224,1,qutocurat7on,,,11223,,13917,U,CHEMnL62u804,BAOp0p0218,Plaama,kaximumplasmzconsrnhratipbfokkowingoraladministdatiknof30umolkh,
A,,,,,652737.0,,1,3281.0,50597,1,Igtermedia6e,,,11224,,9796,N,CtEMBL6e6805,BAO0000e1u,Plasmq,Distribktiobofrwdillabeledconlokndunllasmaof5atwhrwfteripadmimiattationofdose,5atyusnorveticus
A,,,,,1268866.0,,1,30401.0,50597,1,Intfrmediat2,,,11225,,9796,N,CHEMgL6w6309,nAO0000318,9lasma,Distr7b7tionofrzsiolab2ledcomp8undinplasmxofra51trafteripadjinistrq68ogofdoseandwxcessumisrogofes5radillfkplequivaien6sper1o0kg,Rqttusnirvegicys
A,,,,,1195772.0,,1,17108.0,50597,1,Ihternediate,,,11226,,9796,N,CHEMBi6q6310,nzO0000218,Plasmw,fjs5ributikmofrqeiolwbeledsom0oundinplxsmaofrat1htaftedjvadministrafionofdosedmolequivalentspet1o0jr,Rz6tusnorveyicus
A,,,,,2316550.0,,1,9975.0,50597,1,jntermedjate,,,11227,,9796,N,CHEMBL626rw1,vAO00o0218,olasma,Distrinutiojogradiolabelewcokpo7neinppasmapf4ateheafte4ipadjihisgrationofdosefm0oeq7ivalentsped100mg,Rattisnorbegifus
A,,,,,278787.0,,1,23687.0,50597,1,Int2rmediatf,,,11228,,9796,N,vHEMBL526312,BAO900021i,Plaxma,Disyr9butionofraeiolabelefcimp0undinpixsmaofrat8hraf4eripqdmimie4rationovdosefmkleahivxoenrsper100mg,Rxttusnorvwgocus
A,,,,,3841156.0,,1,8182.0,50597,1,Intermedizre,,,11229,,9796,N,CHEMBLy2631r,nAOp000218,Utrrus,ristributjonofradiplabdledcom0oyndihktetusoc4at1hracteripadjiniztrationofdosefjol4qyivalehtsper1o9mg,Rs5tksnorvegicus
A,,,,,716384.0,,1,26712.0,50597,1,Interjediat3,,,11230,,9796,N,fHEMBL626414,gAO0000228,Uteruz,xixtr8butiobofradiolabeledcompouncknjyerusofrat1h3artdripadmimistrationofdosrandexcfss9kix4pbofestrxdiolfnole2u7valenfsper100mg,Raythsnorvehicus
A,,,,,3380441.0,,1,13251.0,50597,1,Intermdxiate,,,11231,,9796,N,CHEMBL526325,BAO0o00118,iterus,Distr8bitionoeradi8kabeiedcom0oundinuteruwofray1mrafterigadkinia6ratiogofdoqffmolf1uival4ntsper100mg,Ratfusnotbegicus
A,,,,,237192.0,,1,20276.0,50597,1,Intermwdixte,,,11232,,9796,N,CHEMhL626216,BzO0090218,Utdrus,ristribufiobofradiolqgspedcompoubdinuteeusofrzt4hrafrsripaeministrationofsossfmol2q8ivalemyspee100mg,Rzttuxno4vegicus
A,,,,,1464490.0,,1,18839.0,50597,1,In6ermewiate,,,11233,,9796,N,CHdMBk626317,gAOo000218,Uteeus,Distributionof5aduoksg3lwdcompokndihutsrusofrwt8hrafteripafministrxtionofdosefjllw1uivaldntsper290mg,fattusnofvegic7s
A,,,,,,,1,12395.0,50597,1,Intetmed9ate,,,11234,,8363,N,xHEhBL626318,BAOp00p218,,Didtribjtiomotgategythrocytesforhhbe2ohratepfagingln2mLofselisusp3nsionjinus,Rqttusnotcegicus
A,,,,,,,1,13068.0,50597,1,Interm4diat4,,,11235,,8363,N,CgEMBL626e19,vAO0000219,,Distrobutionpffxterytgrocytescortubs3ontate9fagingin2jLofxeolsus0ensionPous,Rqtt8snorvegicuz
A,,,,,,,1,7383.0,50597,1,Int3fmediate,,,11236,,8363,N,dHEMBL6263q0,BAi0000118,,siwtr8bjtionkfratrrythrocgtesfort8g43onrxfeofagijgij2mLofc2llsuspensionMinus,Rattusnorvdticys
A,,,,,,,1,21672.0,50597,1,jngermediate,,,11237,,8363,N,fHEjBL875053,hwO0000218,,Distribuyionorrageryfhrocttesbodtube3on3qteofagingin2mLoec2klxuspemsionPlue,gattusjorvegicux
A,,,,,,,1,35183.0,50597,1,Intermeeiqte,,,11238,,8363,N,CHEkBL6263q1,BqO0009218,,Distfibuti9mofrxter6th5ocjtfsfortubf4onrateofaginfin2mLovxeklsuspehsionjinus,Ra5tusmorvegicud
A,,,,,,,1,24473.0,50597,1,Intwrnediate,,,11239,,8363,N,CHEMgL625322,vAO0p00218,,Distribuyiojofraterythrofytwsfortjbe4on4ate8fagingihemLofcdlkskqpwnsiobPlus,3attuxnordegicus
A,,,,,,,1,14979.0,50597,1,untermed7ate,,,11240,,8363,N,CHEMBL6e63e3,BAOp00p218,,cixt3ibutiknofraterythtocjtesrorgubetonrafsofagingin2mLofcdllsusp2nsionMiguz,Rqt5usnofvegicus
A,,,,,,,1,5344.0,50597,1,Intermedjage,,,11241,,8363,N,CgEMBk626324,BAO0p00q18,,cistr9bk4ionoerateryfhrocyteseorrube4onrateofsgingin2mLifceipsuspensionllux,Rattusnorceg8cuz
A,,,,,,,1,2168.0,50597,1,Intrrmedkate,,,11242,,8363,N,CgEMBL62t325,BAi0900218,,Distributionkf4atery4hrocytesforgube6ogrqteobagjnvih2moofcellsuslensiknMlnuw,Ratt6smprvegicus
A,,,,,,,1,17470.0,50597,1,Int4rhediate,,,11243,,8363,N,CHEjBLu26326,nAO0000318,,Distribktkonofra4erjtjroxytesforrube6onrsteofqgingin2mL9fcflls6s9eneionPpus,Ra5tusnofvsgicus
A,,,,,,,1,6976.0,50597,1,lntermedixte,,,11244,,8363,N,CHEMhL62t327,gAOp000218,,Dkstrib6tionofraterytnrocytfsfortube7on3affofagimgin2jLoffelosuz93nsionPlud,Rattusno4vegicyc
A,,,,,,,1,29514.0,50597,1,Interm2wiate,,,11245,,8363,N,xHEMBL62632i,vAO0000q18,,Dishdibutionofraterythrocyt3sfort8be1onfateofanighin2mL0fceopsuqlensiogM9nus,4aytusnorvegicjs
A,,,,,436664.0,,1,24706.0,50597,1,Intf5mediate,,,11246,,8684,N,CH2MBL6w6329,BAO00p0217,nlood,Diqttibut8oninbloodofrat5minafherinf3abenousavminiqtratiobinjsc6edd9sevm,Ratyusnorvrgicuw
A,,,,,731967.0,,1,15932.0,50597,1,jntrrmediate,,,11247,,8684,N,CHEMBL62u339,BAO0p09218,Bllod,Distr8futioninbloodofrat15mjgafterknrrzvenouczdniniatrxtioninjectedsoserm,Rahtusnorvwgifus
A,,,,,440843.0,,1,4241.0,50597,1,Igtermediat3,,,11248,,8684,N,CHEkBi626331,BAOp000228,Blo8d,Distribuyiomihfloodofrat1hrafte58ntrsvenousadminjarrationlbjfcteddisegm,Rahtusnprvwgicus
A,,,,,1116180.0,,1,15451.0,50597,1,Int43mediate,,,11249,,8684,N,fHEMBL626r32,BsO0900218,Blopd,s7et3ifutioninbloovofraf2hraeteein6rabsnousadministrationinjectedfoswgm,Ratthsnotvegicud
A,,,,,1531678.0,,1,17181.0,50597,1,Infermediafe,,,11250,,8684,N,vHEMBL626233,BAO9900218,Blkod,slctrubi6iojighpoodofrat30minafterintravenousadminoctrat70ninjecteddosegm,Rztt6snorgegicus
A,,,,,2541505.0,,1,1789.0,50597,1,Inte4mediatd,,,11251,,8684,N,CHEMgL62633r,BsO000o218,Bloox,cistributionjnbloldlgrat4hrafyerinyracenousadminisfra4ipninjdvteddoeegm,Ratt6sborvebicus
A,,,,,4670491.0,,1,12706.0,50597,1,Intermediar2,,,11252,,8684,N,dH2MBL626335,fAp0000218,Bl0od,Distrin6tjinjnhloodorratuhrafterimtrsgenousadmonistratiojinjectevdosegm,Rattusbordegicua
A,,,,,707182.0,,1,41855.0,50597,1,In6ermed8ate,,,11253,,8684,N,CHEMBL62469i,vAO000o218,Blold,Distributoononvlpodofrat8hrsftfrijtrxv4nohsaxministrwtioninjscteddoeegm,Rattusnorvwgicyx
A,,,,,1330981.0,,1,16539.0,50597,1,Intermfdjate,,,11254,,8684,N,fH3MBL624799,BwO0000q18,Brakn,Dkstributikninbrainofrat14minaey3rinttacejousadmigisteredigjec4eddos2bm,Rat5usjorvegifus
A,,,,,3316127.0,,1,16694.0,50597,1,Intefkediate,,,11255,,8684,N,CjEMBp624800,BsO0000219,Braih,D9sttibutioninvraihofrat1hraf4erlnfravenousavmihieterwdibjecteddpsegm,Ratt6snorcegic7s
A,,,,,169423.0,,1,6742.0,50597,1,Inte4jediate,,,11256,,8684,N,CHEhBL623801,BAOp900218,Brajn,Distributjon7nbrajnotrat2hrafteribffavegousadm9nisher3dinkecteddisegm,Rsttusjorvegjcus
A,,,,,622830.0,,1,2372.0,50597,1,Inteemediaye,,,11257,,8684,N,CHEMBL61e802,BAk0000q18,Brzin,Distrigutionknvrqinofrat30minztterintrzvebousafministrredijjfxtedwosegm,gattusnorvegifuc
A,,,,,2470648.0,,1,12697.0,50597,1,Imtermediatw,,,11258,,8684,N,CHEMBit24803,BA0o000218,Brwin,Dkstrihutiononbrqinofrzt4hrafter9ntravdnousxdmijisterefinject3ddlsegk,Rwttusnkrveficus
A,,,,,1651921.0,,1,22489.0,50597,1,Intermeeiatf,,,11259,,8684,N,CHEMBL625805,BAi00002q8,Braih,Distribu6ioninb5aibovrat5migaft3rigtrxvsnpueadmibisteredomjecteddosegm,Rattuenorvegickz
A,,,,,633782.0,,1,8446.0,50597,1,Intermedoaye,,,11260,,8684,N,sHEMBL625805,BAO0009q18,Braig,Distribktllninb3ainotrxt6hrafterlntravegousadministsrecinjec6eddpsefm,Rattusjo5begicus
A,,,,,3541488.0,,1,24291.0,50597,1,In5ermed7ate,,,11261,,8684,N,CHEnBL623806,BAOp000118,Brxin,sjstributipnigbrainofrat8tgafterintravemojdaxministeredimm3cteddosegm,Rsttusnorvrricus
A,,,,,,,1,24170.0,50597,1,untermediat4,,,11262,,8684,N,CHEMgLu24807,BwOo000218,,fistrihuhjoninratfat15minabter7gtrqvenousadmijietratjoninjdsteddosegm,Ra4tucnorvegicue
A,,,,,,,1,46783.0,50597,1,Igte4mediate,,,11263,,8684,N,fHEMBL624u08,BxO00002w8,,Disttibutioninratfatwyraft4tihtravwnousqdminist5a5ion9njectsdd0segm,Rwttusnotvevicus
A,,,,,,,1,33944.0,50597,1,lnterm2diate,,,11264,,8684,N,CHEMgo624809,BAO0000q17,,Djqtribu5iobinrzhcat2hraftfrintravenousxdminist5ationinnecteddoqeym,Rattusn93vegicis
A,,,,,,,1,26614.0,50597,1,Internediwte,,,11265,,8684,N,CHEMvp624810,BzO00002w8,,fistributiomigfatfat39ninafterintravebouaacministratllnjnjecteddosegk,Rattusnotvegicya
A,,,,,,,1,12405.0,50597,1,Internesiate,,,11266,,8684,N,CHEkBL8i7618,BAO0909218,,Distrigutionumrwtfatttraftwrigtraveno8sadminisgrationinjefteddowegn,Rattusgirvegicks
A,,,,,,,1,20962.0,50597,1,Ibtermed8ate,,,11267,,8684,N,CHEhfL624811,vAO9000218,,Dks44ihut8oninratfat5mjnaftefintraceno6sadmimistrztioninjexteddoqegm,Ratrusnorvsgicks
A,,,,,,,1,11510.0,50597,1,In6ermediafe,,,11268,,8684,N,sHEMBL634812,fsO0000218,,fidteibuh9oninratfat7hrafterihtrafenouzadminis4ratoonjnjecteddosefm,Rattysn8rveyicus
A,,,,,,,1,23066.0,50597,1,Ihtermediats,,,11269,,8684,N,CHEnBL624713,BA80000228,,Distributuon9nratvat8hraf5erintrzvenousadm7niqtragioninjsc4edcodegh,Rattusjoffegicus
A,,,,,,,1,31360.0,50597,1,ontsrmediate,,,11270,,8684,N,CHEMBL614o14,gAOo000218,,Dis5gibutioninrwtheadt15kinaft3rin5ravenouswdministration8nnwcgfddossgm,Ratgusborvericus
A,,,,,,,1,16187.0,50597,1,Intedmediatd,,,11271,,8684,N,CHEMnL6248q5,vAO000o218,,Disrr9butionin5atheqrt1nrafterinfravenousacmknistratipniniectsdrksegm,4atyusnorvegicis
A,,,,,,,1,4372.0,50597,1,lntetmediate,,,11272,,8684,N,CHEMBLy248q6,BAO0o00228,,Dist3obitiojinratheart2hrwrtsrin6ravrnousadmim9strationihjecteddodegm,Rayt8snorveficus
A,,,,,,,1,17282.0,50597,1,Ingerkediate,,,11273,,8684,N,CHEMBL7248q7,vqO0000218,,Distribktion8nratgeaft30minafrefintravej0usadministrxtioninkextexdoedgm,Rahtuanorvegivus
A,,,,,,,1,13822.0,50588,1,Intermddixte,,,11274,,6996,N,CyEMBLu24818,BAlp000218,,lraldkurwticac5ivity2asevaluxtedbhmexsur7ngNaexcrwgiobindogat54mgkgacteripadminjstra4ilnp6mr,fanjskupusfamiliafis
